PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HIRSCH, SR; ZASTROW, JE				HIRSCH, SR; ZASTROW, JE			BASOPHIL DEGRANULATION - NEW METHOD OF OBSERVATION AND ITS CORRELATION WITH SKIN TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ACKERMAN GA, 1963, ANN NY ACAD SCI, V103, P376, DOI 10.1111/j.1749-6632.1963.tb53710.x; BOBITT JR, 1964, P SOC EXP BIOL MED, V117, P608; FRIEDLAENDER S, 1964, J ALLERGY, V35, P361, DOI 10.1016/0021-8707(64)90100-5; HAYE KR, 1968, BRIT J DERMATOL, V80, P811, DOI 10.1111/j.1365-2133.1968.tb11951.x; HEATH ID, 1961, NATURE, V191, P1370, DOI 10.1038/1911370a0; ISHIZAKA T, 1971, J IMMUNOL, V106, P705; JUHLIN L, 1966, J HISTOCHEM CYTOCHEM, V14, P525, DOI 10.1177/14.7.525; KIRSHBAUM BA, 1967, AM J MED SCI, V253, P473; LEVIN RA, 1967, AM J CLIN PATHOL, V48, P150, DOI 10.1093/ajcp/48.1_ts.150; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1967, J ALLERGY, V40, P160, DOI 10.1016/0021-8707(67)90005-6; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; PRUZANSKY JJ, 1966, J ALLERGY, V38, P315, DOI 10.1016/0021-8707(66)90028-1; REYNOLDS RD, 1967, ANN ALLERGY, V25, P318; SHELLEY WB, 1961, NATURE, V191, P1056, DOI 10.1038/1911056a0; SHELLEY WB, 1963, ANN NY ACAD SCI, V103, P427, DOI 10.1111/j.1749-6632.1963.tb53713.x; SHELLEY WB, 1962, NATURE, V195, P1181, DOI 10.1038/1951181a0; VANARSDEL PP, 1965, J AMER MED ASSOC, V191, P238, DOI 10.1001/jama.1965.03080030082012	18	36	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	6					338	&		10.1016/0091-6749(72)90037-1	http://dx.doi.org/10.1016/0091-6749(72)90037-1			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O2043	4634960				2022-12-18	WOS:A1972O204300003
J	YUNGINGER, JW; GLEICH, GJ				YUNGINGER, JW; GLEICH, GJ			COMPARISON OF PROTEIN-BINDING CAPACITIES OF CYANOGEN BROMIDE-ACTIVATED POLYSACCHARIDES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; PORATH J, 1967, NATURE, V215, P1491, DOI 10.1038/2151491a0; REJNEK J, 1969, J IMMUNOL, V102, P638; WIDE L, 1967, LANCET, V2, P1105; WIDE L, 1967, IMMUNOCHEMISTRY, V4, P381, DOI 10.1016/0019-2791(67)90097-3; WIDE L, 1969, ACTA ENDOCRINOL-COP, VS 63, P207; YUNGINGER JW, TO BE PUBLISHED	12	36	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	2					109	+		10.1016/0091-6749(72)90006-1	http://dx.doi.org/10.1016/0091-6749(72)90006-1			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N1795	4114292	Bronze			2022-12-18	WOS:A1972N179500006
J	Delmonte, OM; Bergerson, JRE; Burbelo, PD; Durkee-Shock, JR; Dobbs, K; Bosticardo, M; Keller, MD; McDermott, DH; Rao, VK; Dimitrova, D; Quiros-Roldan, E; Imberti, L; Ferre, EMN; Schmitt, M; Lafeer, C; Pfister, J; Shaw, D; Draper, D; Truong, M; Ulrick, J; DiMaggio, T; Urban, A; Holland, SM; Lionakis, MS; Cohen, JI; Ricotta, EE; Notarangelo, LD; Freeman, AF				Delmonte, Ottavia M.; Bergerson, Jenna R. E.; Burbelo, Peter D.; Durkee-Shock, Jessica R.; Dobbs, Kerry; Bosticardo, Marita; Keller, Michael D.; McDermott, David H.; Rao, V. Koneti; Dimitrova, Dimana; Quiros-Roldan, Eugenia; Imberti, Luisa; Ferre, Elise M. N.; Schmitt, Monica; Lafeer, Christine; Pfister, Justina; Shaw, Dawn; Draper, Deborah; Truong, Meng; Ulrick, Jean; DiMaggio, Tom; Urban, Amanda; Holland, Steven M.; Lionakis, Michail S.; Cohen, Jeffrey I.; Ricotta, Emily E.; Notarangelo, Luigi D.; Freeman, Alexandra F.			Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SARS-CoV-2; antibody response; COVID-19; inborn errors of immunity; immunomodulators; immune suppressants; JAK inhibitors; adverse events	COVID-19	Background: SARS-CoV-2 vaccination is recommended in patients with inborn errors of immunity (IEIs); however, little is known about immunogenicity and safety in these patients. Objective: We sought to evaluate the impact of genetic diagnosis, age, and treatment on antibody response to COVID-19 vaccine and related adverse events in a cohort of patients with IEIs. Methods: Plasma was collected from 22 health care worker controls, 81 patients with IEIs, and 2 patients with thymoma; the plasma was collected before immunization, 1 to 6 days before the second dose of mRNA vaccine, and at a median of 30 days after completion of the immunization schedule with either mRNA vaccine or a single dose of Johnson & Johnson's Janssen vaccine. Anti-spike (anti-S) and anti-nucleocapsid antibody titers were measured by using a luciferase immunoprecipitation systems method. Information on T-and B-cell counts and use of immunosuppressive drugs was extracted from medical records, and information on vaccine-associated adverse events was collected after each dose. Results: Anti-S antibodies were detected in 27 of 46 patients (58.7%) after 1 dose of mRNA vaccine and in 63 of 74 fully immunized patients (85.1%). A lower rate of seroconversion (7 of 11 [63.6%]) was observed in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Previous use of rituximab and baseline counts of less than 1000 CD3(+) T cells/mL and less than 100 CD19(+) B cells/mL were associated with lower anti-S IgG levels. No significant adverse events were reported. Conclusion: Vaccinating patients with IEIs is safe, but immunogenicity is affected by certain therapies and gene defects. These data may guide the counseling of patients with IEIs regarding prevention of SARS-CoV-2 infection and the need for subsequent boosts.	[Delmonte, Ottavia M.; Bergerson, Jenna R. E.; Dobbs, Kerry; Bosticardo, Marita; Rao, V. Koneti; Ferre, Elise M. N.; Schmitt, Monica; Lafeer, Christine; Pfister, Justina; Shaw, Dawn; Draper, Deborah; Truong, Meng; Ulrick, Jean; DiMaggio, Tom; Urban, Amanda; Holland, Steven M.; Lionakis, Michail S.; Ricotta, Emily E.; Notarangelo, Luigi D.; Freeman, Alexandra F.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [McDermott, David H.] NIAID, Lab Mol Immunol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Cohen, Jeffrey I.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; [Burbelo, Peter D.] NCI, Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA; [Dimitrova, Dimana] NCI, Expt Transplantat & Immunotherapy Branch, NIH, Bethesda, MD 20892 USA; [Durkee-Shock, Jessica R.; Keller, Michael D.] Childrens Natl Hosp, Ctr Canc & Immunol Res, Washington, DC USA; [Durkee-Shock, Jessica R.; Keller, Michael D.] Childrens Natl Hosp, Div Allergy & Immunol, Washington, DC USA; [Quiros-Roldan, Eugenia] Univ Brescia, Dept Infect & Trop Dis, Brescia, Italy; [Quiros-Roldan, Eugenia] ASST Spedali Civili Brescia, Brescia, Italy; [Quiros-Roldan, Eugenia; Imberti, Luisa] ASST Spedali Civili Brescia, Diagnost Lab, CREA Lab, Brescia, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's National Health System; Children's National Health System; University of Brescia; Hospital Spedali Civili Brescia; Hospital Spedali Civili Brescia	Freeman, AF (corresponding author), NIH, Bldg 10,Room 12C103,10 Ctr Dr, Bethesda, MD 20892 USA.; Notarangelo, LD (corresponding author), NIH, Bldg 10,Room 5-3950,10 Ctr Dr, Bethesda, MD 20892 USA.	luigi.notarangelo2@nih.gov; freemal@mail.nih.gov	Lionakis, Michail/J-8840-2017; Ricotta, Emily/AGX-9953-2022; Quiros roldan, Eugenia/GYQ-7450-2022	Lionakis, Michail/0000-0003-4994-9500; Ricotta, Emily/0000-0001-9928-8275; Imberti, Luisa/0000-0002-2075-8391; Durkee-Shock, Jessica/0000-0003-0984-6881; Bergerson, Jenna/0000-0001-9122-4998	Intramural Research programs of the National Institute of Dental and Craniofacial Research; National Institute of Allergy and Infectious Diseases, National Institutes of Health [1 ZIA AI001270-01]; Regione Lombardia	Intramural Research programs of the National Institute of Dental and Craniofacial Research; National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Regione Lombardia(Regione Lombardia)	Supported by the Intramural Research programs of the National Institute of Dental and Craniofacial Research and the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant 1 ZIA AI001270-01 [to L.D.N.] ) and Regione Lombardia (the project Risposta immune in pazienti con COVID-19 e co-morbidita?) .	Aksoy S, 2007, LEUKEMIA LYMPHOMA, V48, P1307, DOI 10.1080/10428190701411441; Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; Azzi Y, 2021, TRANSPLANTATION, V105, P37, DOI 10.1097/TP.0000000000003523; Bastard P, 2021, J EXP MED, V218, DOI 10.1084/jem.20210554; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Burbelo PD, 2020, J INFECT DIS, V222, P206, DOI 10.1093/infdis/jiaa273; Castano-Jaramillo LM, 2021, J CLIN IMMUNOL, V41, P1463, DOI 10.1007/s10875-021-01077-5; Delmonte OM, 2021, BLOOD, V138, P1019, DOI 10.1182/blood.2020008629; Diefenbach Catherine, 2021, medRxiv, DOI 10.1101/2021.06.02.21257804; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Goudouris ES, 2021, J CLIN IMMUNOL, V41, P1479, DOI 10.1007/s10875-021-01066-8; Hagin D, 2021, J ALLERGY CLIN IMMUN, V148, P739, DOI 10.1016/j.jaci.2021.05.029; Ho HE, 2021, J ALLER CL IMM-PRACT, V9, DOI 10.1016/j.jaip.2020.09.052; Majumdar S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010003; Mc Guire PJ, 2010, CLIN IMMUNOL, V135, P412, DOI 10.1016/j.clim.2010.02.006; Meyts I, 2021, J ALLERGY CLIN IMMUN, V147, P520, DOI 10.1016/j.jaci.2020.09.010; Milito C, 2021, J ALLER CL IMM-PRACT, V9, P2904, DOI 10.1016/j.jaip.2021.04.017; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Shields AM, 2021, J ALLERGY CLIN IMMUN, V147, P870, DOI 10.1016/j.jaci.2020.12.620; Squire Jacqueline, 2021, Ann Allergy Asthma Immunol, V127, P383, DOI 10.1016/j.anai.2021.05.015; Vijenthira A, 2020, BLOOD, V136, P2881, DOI 10.1182/blood.2020008824; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570	25	35	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2021	148	5					1192	1197		10.1016/j.jaci.2021.08.016	http://dx.doi.org/10.1016/j.jaci.2021.08.016		NOV 2021	6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WV7LX	34492260	Bronze, Green Published			2022-12-18	WOS:000717415000018
J	Patel, DD; Bussel, JB				Patel, Dhavalkumar D.; Bussel, James B.			Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Immunoglobulin; IgG; IgG lowering; autoimmune disease; FcRn inhibitors; plasma exchange; echovirus; half-life; IVIg	INTRAVENOUS GAMMA-GLOBULIN; FAMILIAL HYPERCATABOLIC HYPOPROTEINEMIA; I-RELATED RECEPTOR; IMMUNOGLOBULIN-G; PLASMA-EXCHANGE; AMERICAN SOCIETY; FCGRT GENE; MOUSE FCRN; IGG; ANTIBODY	The humoral immune response provides specific, long-lived protection against invading pathogens, via immunoglobulin production and other memory functions. IgG, the most abundant immunoglobulin isotype, has the longest half-life and protects against bacterial and viral infections. The neonatal Fc receptor (FcRn) transports IgG across barriers, for example, the placenta, enhancing fetal humoral immunity to levels similar to their mothers'. Importantly, FcRn, by protecting IgG from intracellular degradation, results in an approximately 21-day circulating IgG half-life and high plasma levels; similarly, FcRn recycles albumin and is the portal of entry for enteric cytopathic human orphan (echo) virus infection. Dysregulated immune responses may lead to antibodies against self-antigens (autoantibodies), resulting in organ-specific or systemic autoimmune diseases. Autoantibody-mediated diseases have been treated by nonspecific immunoglobulin-lowering/modulating therapies, including immunoadsorption, plasma exchange, and high-dose intravenous immunoglobulin. However, targeting FcRn with specific inhibitors results in reduction in only IgG levels. The effectiveness of FcRn inhibitors in autoimmune diseases, including myasthenia gravis and immune thrombocytopenia, provides further evidence that IgG is a primary driver in these autoantibody-mediated diseases. We describe the role of FcRn in human biology, including insights that clinical testing of FcRn inhibitors have provided into FcRn biology and autoimmune disease mechanisms, allowing fact-based speculation on their therapeutic potential.	[Patel, Dhavalkumar D.] UCB Pharma, Allee Rech 60, B-1070 Brussels, Belgium; [Patel, Dhavalkumar D.] Univ N Carolina, Chapel Hill, NC 27515 USA; [Bussel, James B.] Weill Cornell Med, New York, NY USA	UCB Pharma SA; University of North Carolina; University of North Carolina Chapel Hill; Cornell University	Patel, DD (corresponding author), UCB Pharma, Allee Rech 60, B-1070 Brussels, Belgium.	Dhaval.Patel@ucb.com			UCBPharma; Good Publications Practice (GPP3) guidelines	UCBPharma(UCB Pharma SA); Good Publications Practice (GPP3) guidelines	This article was written by the authors with editorial support provided by Laura Griffin, PhD, of iMed Comms, an Ashfield Company, part of UDG Healthcare plc, funded by UCBPharma in accordance with Good Publications Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).The article was reviewed and approved for publication by all authors and the sponsor. The authors acknowledge Linda Feighery, PhD, CMPP, and Veronica Porkess, PhD, CMPP, of UCB Pharma for publication and editorial support.	Akilesh S, 2008, P NATL ACAD SCI USA, V105, P967, DOI 10.1073/pnas.0711515105; Baker K, 2014, FRONT IMMUNOL, V5, DOI [10.3389/fimmu.2014.00408, 10.3389/fimmu.2014.00664]; Afonso AFB, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010015; Billiet T, 2016, AM J GASTROENTEROL, V111, P1438, DOI 10.1038/ajg.2016.306; Blumberg LJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax9586; BRAMBELL FW, 1964, NATURE, V203, P1352, DOI 10.1038/2031352a0; BRAMBELL FWR, 1958, BIOL REV, V33, P488, DOI 10.1111/j.1469-185X.1958.tb01412.x; Bril V, 2019, NEUROLOGY; Brimberg L, 2015, TRENDS IMMUNOL, V36, P709, DOI 10.1016/j.it.2015.09.008; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; BUSSEL J, 1986, J CLIN IMMUNOL, V6, P50, DOI 10.1007/BF00915364; BUSSEL JB, 1983, BLOOD, V62, P480; Cacoub P, 2015, AM J MED, V128, P950, DOI 10.1016/j.amjmed.2015.02.017; Caulet M, 2016, CLIN PHARMACOKINET, V55, P1381, DOI 10.1007/s40262-016-0406-3; Challa DK, 2013, MABS-AUSTIN, V5, P655, DOI 10.4161/mabs.25439; Chaudhury C, 2006, BIOCHEMISTRY-US, V45, P4983, DOI 10.1021/bi052628y; Chaudhury C, 2003, J EXP MED, V197, P315, DOI 10.1084/jem.20021829; Cines DB, 2020, BLOOD, V135, P2085, DOI 10.1182/blood.2019001133; ClinicalTrials.gov, US NAT LIB MED; Collins J, 2019, NEUROLOGY, V92; Cooper PR, 2013, BRAIN RES, V1534, P13, DOI 10.1016/j.brainres.2013.08.035; Dau PC, 1995, J CLIN APHERESIS, V10, P210, DOI 10.1002/jca.2920100410; de Taeye SW, 2019, ANTIBODIES, V8, DOI 10.3390/antib8020030; Dickinson BL, 1999, J CLIN INVEST, V104, P903, DOI 10.1172/JCI6968; Elkon K, 2008, NAT CLIN PRACT RHEUM, V4, P491, DOI 10.1038/ncprheum0895; European Medicines Agency, EU CLIN TRIALS REG; Firan M, 2001, INT IMMUNOL, V13, P993, DOI 10.1093/intimm/13.8.993; Fokkink WJR, 2016, ANN CLIN TRANSL NEUR, V3, P547, DOI 10.1002/acn3.307; FRANK MM, 1977, ANN INTERN MED, V87, P210, DOI 10.7326/0003-4819-87-2-210; Gouilleux-Gruart V, 2013, CLIN EXP IMMUNOL, V171, P186, DOI 10.1111/cei.12002; Greco A, 2015, AUTOIMMUN REV, V14, P246, DOI 10.1016/j.autrev.2014.11.006; GUNNAR S, 1967, ACTA PAEDIATR SCAND, V56, P572, DOI 10.1111/j.1651-2227.1967.tb15982.x; Guptill JT, 2016, AUTOIMMUNITY, V49, P472, DOI 10.1080/08916934.2016.1214823; Hahn BH, 1998, NEW ENGL J MED, V338, P1359, DOI 10.1056/NEJM199805073381906; Hartung HP, 2008, J NEUROL, V255, P3, DOI 10.1007/s00415-008-3002-0; Haston JC, 2015, PEDIATR ANN, V44, pE103, DOI 10.3928/00904481-20150512-09; Haymann JP, 2000, J AM SOC NEPHROL, V11, P632, DOI 10.1681/ASN.V114632; Hillyer CD., 2006, BLOOD BANKING TRANSF; Hornby PJ, 2014, PHARM RES-DORDR, V31, P908, DOI 10.1007/s11095-013-1212-3; Howard JF, 2019, NEUROLOGY, V92, pE2661, DOI 10.1212/WNL.0000000000007600; Hubbard JJ, 2020, J EXP MED, V217; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; Huijbers MG, 2019, EXP NEUROL, V317, P133, DOI 10.1016/j.expneurol.2019.03.001; Huijbers MG, 2018, ANN NY ACAD SCI, V1413, P92, DOI 10.1111/nyas.13561; IMBACH P, 1981, LANCET, V1, P1228; Ipe TS, 2018, J CLIN APHERESIS, V33, P78, DOI 10.1002/jca.21562; Israel EJ, 1997, IMMUNOLOGY, V92, P69, DOI 10.1046/j.1365-2567.1997.00326.x; Janeway CA, 2001, IMMUNOBIOLOGY IMMUNE; Jolles S, 2005, CLIN EXP IMMUNOL, V142, P1, DOI 10.1111/j.1365-2249.2005.02834.X; Juel VC, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-44; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kaplan AA, 2008, AM J KIDNEY DIS, V52, P1180, DOI 10.1053/j.ajkd.2008.02.360; Kasprick A, 2020, BRIT J PHARMACOL, V177, P2381, DOI 10.1111/bph.14986; Kiessling P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan1208; Kobayashi N, 2002, AM J PHYSIOL-RENAL, V282, pF358, DOI 10.1152/ajprenal.0164.2001; Latvala S, 2017, J HISTOCHEM CYTOCHEM, V65, P321, DOI 10.1369/0022155417705095; Leach JL, 1996, J IMMUNOL, V157, P3317; Lehmann HC, 2006, ARCH NEUROL-CHICAGO, V63, P930, DOI 10.1001/archneur.63.7.930; Ling LE, 2019, CLIN PHARMACOL THER, V105, P1031, DOI 10.1002/cpt.1276; Liu LM, 2007, J IMMUNOL, V178, P5390, DOI 10.4049/jimmunol.178.8.5390; Lozano NA, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.12972; MCMILLAN R, 1981, NEW ENGL J MED, V304, P1135, DOI 10.1056/NEJM198105073041904; Morosky S, 2019, P NATL ACAD SCI USA, V116, P3758, DOI 10.1073/pnas.1817341116; Neuber T, 2014, MABS-AUSTIN, V6, P928, DOI 10.4161/mabs.28744; Newland AC, 2020, AM J HEMATOL, V95, P178, DOI 10.1002/ajh.25680; Norfolk D., 2013, TRANSFUSION HDB, V5th; Ober RJ, 2004, J IMMUNOL, V172, P2021, DOI 10.4049/jimmunol.172.4.2021; Oganesyan V, 2014, J BIOL CHEM, V289, P7812, DOI 10.1074/jbc.M113.537563; Olaru F, 2014, J AM SOC NEPHROL, V25, P918, DOI 10.1681/ASN.2013050498; Pabst O, 2020, MUCOSAL IMMUNOL, V13, P12, DOI 10.1038/s41385-019-0227-4; Padmanabhan A, 2019, J CLIN APHERESIS, V34, P171, DOI 10.1002/jca.21705; Passot C, 2013, MABS-AUSTIN, V5, P614, DOI 10.4161/mabs.24815; Patel DA, 2011, J IMMUNOL, V187, P1015, DOI 10.4049/jimmunol.1003780; Perez EE, 2017, J ALLERGY CLIN IMMUN, V139, pS1, DOI 10.1016/j.jaci.2016.09.023; Peter HH, 2020, J ALLERGY CLIN IMMUN, V146, P479, DOI 10.1016/j.jaci.2020.07.016; Pyzik M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01540; Qiao SW, 2008, P NATL ACAD SCI USA, V105, P9337, DOI 10.1073/pnas.0801717105; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; Robak T, 2020, BLOOD ADV; RODEWALD R, 1984, J CELL BIOL, V99, pS159, DOI 10.1083/jcb.99.1.159s; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155; Roopenian DC, 2010, J CLIN IMMUNOL, V30, P790, DOI 10.1007/s10875-010-9458-6; Roy S, 2019, AM J OBSTET GYNECOL, V220, pe1; Sachs UJH, 2006, IMMUNOLOGY, V119, P83, DOI 10.1111/j.1365-2567.2006.02408.x; Salimonu L S, 1978, Int J Gynaecol Obstet, V16, P119; Sanchez LM, 1999, BIOCHEMISTRY-US, V38, P9471, DOI 10.1021/bi9907330; Sand KMK, 2015, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00682; Schlachetzki F, 2002, J NEUROCHEM, V81, P203, DOI 10.1046/j.1471-4159.2002.00840.x; Schuck P, 1999, MOL IMMUNOL, V36, P1117, DOI 10.1016/S0161-5890(99)00093-0; Shock A, 2020, J ALLERGY CLIN IMMUN, V146, P492, DOI 10.1016/j.jaci.2020.06.036; SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718; Simister NE, 1996, EUR J IMMUNOL, V26, P1527, DOI 10.1002/eji.1830260718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Sinico RA, 2016, CLIN EXP IMMUNOL, V183, P157, DOI 10.1111/cei.12729; Smith B, 2019, INT IMMUNOPHARMACOL, V66, P362, DOI 10.1016/j.intimp.2018.11.040; Smith B, 2018, MABS-AUSTIN, V10, P1111, DOI 10.1080/19420862.2018.1505464; Sokolove J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035296; Spiekermann GM, 2002, J EXP MED, V196, P303, DOI 10.1084/jem.20020400; Stapleton NM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1608; STIEHM ER, 1966, PEDIATRICS, V37, P715; Tebruegge M, 2009, SEMIN FETAL NEONAT M, V14, P222, DOI 10.1016/j.siny.2009.02.002; Tenten V, 2013, J AM SOC NEPHROL, V24, P1966, DOI 10.1681/ASN.2013010018; Tholpady A, 2016, TEX HEART I J, V43, P363, DOI 10.14503/THIJ-15-5672; Trampert DC, 2018, BBA-MOL BASIS DIS, V1864, P1401, DOI 10.1016/j.bbadis.2017.07.038; Ulrichts P, 2018, J CLIN INVEST, V128, P4372, DOI 10.1172/JCI97911; Vaughn DE, 1998, STRUCTURE, V6, P63, DOI 10.1016/S0969-2126(98)00008-2; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; WALDMANN TA, 1990, J CLIN INVEST, V86, P2093, DOI 10.1172/JCI114947; WALDMANN TA, 1969, PROG ALLERGY, V13, P1, DOI 10.1159/000287491; Wani MA, 2006, P NATL ACAD SCI USA, V103, P5084, DOI 10.1073/pnas.0600548103; Ward ES, 2003, INT IMMUNOL, V15, P187, DOI 10.1093/intimm/dxg018; Werth VP, 2018, J INVEST DERMATOL, V138, pS92, DOI 10.1016/j.jid.2018.03.546; Winters JL, 2012, HEMATOL-AM SOC HEMAT, P7, DOI 10.1182/asheducation-2012.1.7; Zhang Y, 2001, J NEUROCHEM, V76, P1597, DOI 10.1046/j.1471-4159.2001.00222.x; Zhao X, 2019, CELL, V177, P1553, DOI 10.1016/j.cell.2019.04.035; Zhou XJ, 2009, CLIN EXP RHEUMATOL, V27, P609; Zhu XP, 2001, J IMMUNOL, V166, P3266, DOI 10.4049/jimmunol.166.5.3266	118	35	36	3	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2020	146	3					467	478		10.1016/j.jaci.2020.07.015	http://dx.doi.org/10.1016/j.jaci.2020.07.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NO0HS	32896307	hybrid			2022-12-18	WOS:000569168900001
J	Humblet-Baron, S; Franckaert, D; Dooley, J; Ailal, F; Bousfiha, A; Deswarte, C; Oleaga-Quintas, C; Casanova, JL; Bustamante, J; Liston, A				Humblet-Baron, Stephanie; Franckaert, Dean; Dooley, James; Ailal, Fatima; Bousfiha, Aziz; Deswarte, Caroline; Oleaga-Quintas, Carmen; Casanova, Jean-Laurent; Bustamante, Jacinta; Liston, Adrian			IFN-gamma and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IFN-gamma; CD25; CD8(+) T-cell hyperactivation; hemophagocytic lymphohistiocytosis	CD8(+) T-CELLS; INTERFERON-GAMMA; MICE; ANEMIA; INFECTION; PERFORIN; DISEASE; VIRUS; HLH	Background: Inflammatory activation of CD8(+) T cells can, when left unchecked, drive severe immunopathology. Hyperstimulation of CD8(+) T cells through a broad set of triggering signals can precipitate hemophagocytic lymphohistiocytosis (HLH), a life-threatening systemic inflammatory disorder. Objective: The mechanism linking CD8(+) T-cell hyperactivation to pathology is controversial, with excessive production of IFN-gamma and, more recently, excessive consumption of IL-2, which are proposed as competing hypotheses. We formally tested the proximal mechanistic events of each pathway in a mouse model of HLH. Methods: In addition to reporting a complete autosomal recessive IFN-gamma receptor 1-deficient patient with multiple aspects of HLH pathology, we used the mouse model of perforin (Prf1)(KO) mice infected with lymphocytic choriomeningitis virus to genetically eliminate either IFN-gamma production or CD25 expression and assess the immunologic, hematologic, and physiologic disease measurement. Results: We found a striking dichotomy between the mechanistic basis of the hematologic and inflammatory components of CD8(+) T cell-mediated pathology. The hematologic features of HLH were completely dependent on IFN-gamma production, with complete correction after loss of IFN-gamma production without any role for CD8(+) T cell-mediated IL-2 consumption. By contrast, the mechanistic contribution of the immunologic features was reversed, with no role for IFN-gamma production but substantial correction after reduction of IL-2 consumption by hyperactivated CD8(+) T cells. These results were complemented by the characterization of an IFN-gamma receptor 1-deficient patients with HLH-like disease, in whom multiple aspects of HLH pathology were observed in the absence of IFN-gamma signaling. Conclusion: These results synthesize the competing mechanistic models of HLH pathology into a dichotomous pathogenesis driven through discrete pathways. A holistic model provides a new paradigm for understanding HLH and, more broadly, the consequences of CD8(+) T-cell hyperactivation, thereby paving the way for clinical intervention based on the features of HLH in individual patients.	[Humblet-Baron, Stephanie; Franckaert, Dean; Dooley, James; Liston, Adrian] VIB Ctr Brain & Dis Res, Leuven, Belgium; [Humblet-Baron, Stephanie; Franckaert, Dean; Dooley, James; Liston, Adrian] KU Leuven Univ Leuven, Dept Microbiol & Immunol, Herestr 49, B-3000 Leuven, Belgium; [Ailal, Fatima; Bousfiha, Aziz] Hassan II Univ, Med Sch, Ibn Rochd Lab LICIA Immunol Clin Inflammat & Alle, Clin Immunol Unit,Casablanca Childrens Hosp, Casablanca, Morocco; [Deswarte, Caroline; Oleaga-Quintas, Carmen; Casanova, Jean-Laurent; Bustamante, Jacinta] Necker Hosp Sick Children, Imagine Inst, INSERM U1163, Lab Human Genet Infect Dis,Necker Branch, Paris, France; [Deswarte, Caroline; Oleaga-Quintas, Carmen; Casanova, Jean-Laurent; Bustamante, Jacinta] Paris Descartes Univ, Paris, France; [Casanova, Jean-Laurent; Bustamante, Jacinta] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, 1230 York Ave, New York, NY 10021 USA; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA; [Casanova, Jean-Laurent] Necker Hosp Sick Children, AP HP, Pediat Hematol Immunol Unit, Paris, France; [Bustamante, Jacinta] Necker Hosp Sick Children, AP HP, Ctr Study Primary Immunodeficiencies, Paris, France	Flanders Institute for Biotechnology (VIB); KU Leuven; Hassan II University of Casablanca; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Rockefeller University; Howard Hughes Medical Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Liston, A (corresponding author), KU Leuven Univ Leuven, Dept Microbiol & Immunol, Herestr 49, B-3000 Leuven, Belgium.; Liston, A (corresponding author), VIB, Autoimmune Genet Lab, Leuven, Belgium.	adrian.liston@gmail.com	Quintas, Carmen Oleaga/AAS-3884-2020; Bustamante, Jacinta/H-7877-2017; Oleaga-Quintas, Carmen/H-8038-2017	Bustamante, Jacinta/0000-0002-3439-2482; Humblet-Baron, Stephanie/0000-0003-4684-069X; Oleaga-Quintas, Carmen/0000-0002-6057-0959	VIB Grand Challenges; FWO; IUAP (T-TIME); FWO postdoctoral fellowship; St. Giles Foundation; Jeffrey Modell Foundation; Rockefeller University Center for Clinical and Translational Science; National Center for Research Resources [8UL1TR000043]; National Center for Advancing Sciences (NCATS); National Institutes of Health; National Institute of Allergy and Infectious Diseases [5R01AI089970-02]; Rockefeller University; European Research Council (ERC); Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence [ANR-10-LABX-62-IBEID]; French National Research Agency (ANR) under the "Investments for the future'' program [ANR-10-IAHU-01]; French National Research Agency (ANR) under the "Investments for the future'' program (ANR-GENMSMD) [ANR-16-CE17-0005-01]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI095983] Funding Source: NIH RePORTER; BBSRC [BBS/E/B/000C0427, BBS/E/B/000C0428] Funding Source: UKRI	VIB Grand Challenges; FWO(FWO); IUAP (T-TIME); FWO postdoctoral fellowship(FWO); St. Giles Foundation; Jeffrey Modell Foundation; Rockefeller University Center for Clinical and Translational Science; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Sciences (NCATS); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Rockefeller University; European Research Council (ERC)(European Research Council (ERC)); Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence; French National Research Agency (ANR) under the "Investments for the future'' program(French National Research Agency (ANR)); French National Research Agency (ANR) under the "Investments for the future'' program (ANR-GENMSMD)(French National Research Agency (ANR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Supported by the VIB Grand Challenges, FWO, and IUAP (T-TIME). S.H-B. was supported by an FWO postdoctoral fellowship. The Laboratory of Human Genetics of Infectious Diseases is supported by grants from the St. Giles Foundation, the Jeffrey Modell Foundation, the Rockefeller University Center for Clinical and Translational Science, grant no. 8UL1TR000043 from the National Center for Research Resources and the National Center for Advancing Sciences (NCATS), the National Institutes of Health, the National Institute of Allergy and Infectious Diseases (grant no. 5R01AI089970-02), the Rockefeller University, the European Research Council (ERC), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), and the French National Research Agency (ANR) under the "Investments for the future'' program (grant no. ANR-10-IAHU-01 and ANR-GENMSMD (ANR-16-CE17-0005-01).	Allen CE, 2015, HEMATOL-AM SOC HEMAT, P177, DOI 10.1182/asheducation-2015.1.177; Avau A, 2014, ARTHRITIS RHEUMATOL, V66, P1340, DOI 10.1002/art.38359; Badovinac VP, 2003, IMMUNITY, V18, P463, DOI 10.1016/S1074-7613(03)00079-7; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Bergsten E, 2017, BLOOD, V130, P2728, DOI 10.1182/blood-2017-06-788349; Binder D, 1997, J EXP MED, V185, P517, DOI 10.1084/jem.185.3.517; Binder D, 1998, J EXP MED, V187, P1903, DOI 10.1084/jem.187.11.1903; Brayton CF, 2012, VET PATHOL, V49, P85, DOI 10.1177/0300985811430696; Bustamante J, 2014, SEMIN IMMUNOL, V26, P454, DOI 10.1016/j.smim.2014.09.008; Canna SW, 2013, ARTHRITIS RHEUM-US, V65, P1764, DOI 10.1002/art.37958; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Das R, 2016, BLOOD, V127, P1666, DOI 10.1182/blood-2015-12-684399; de Saint Basile Genevieve, 2015, F1000Res, V4, P930, DOI 10.12688/f1000research.6754.1; Goedhart M, 2018, STEM CELLS DEV, V27, P579, DOI 10.1089/scd.2017.0196; Humblet-Baron S, 2016, J ALLERGY CLIN IMMUN, V138, P200, DOI 10.1016/j.jaci.2015.12.1314; Janka GE, 2014, BLOOD REV, V28, P135, DOI 10.1016/j.blre.2014.03.002; Janka GE, 2013, HEMATOL-AM SOC HEMAT, P605, DOI 10.1182/asheducation-2013.1.605; Jenkins MR, 2015, J EXP MED, V212, P307, DOI 10.1084/jem.20140964; Jordan MB, 2004, BLOOD, V104, P735, DOI 10.1182/blood-2003-10-3413; Jordan M, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.LBA-3.LBA-3; Jordan MB, 2011, BLOOD, V118, P4041, DOI 10.1182/blood-2011-03-278127; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kong XF, 2010, HUM MOL GENET, V19, P434, DOI 10.1093/hmg/ddp507; Libregts SF, 2011, BLOOD, V118, P2578, DOI 10.1182/blood-2010-10-315218; Maekawa Y, 2008, NAT IMMUNOL, V9, P1140, DOI 10.1038/ni.1649; Maschalidi S, 2016, BLOOD, V128, P60, DOI 10.1182/blood-2016-02-700013; Muriel-Vizcaino R, 2016, J CLIN IMMUNOL, V36, P420, DOI 10.1007/s10875-016-0292-3; Nikiforow S, 2015, HEMATOL-AM SOC HEMAT, P183, DOI 10.1182/asheducation-2015.1.183; Oldenhove G, 2009, IMMUNITY, V31, P772, DOI 10.1016/j.immuni.2009.10.001; Oleaga-Quintas C, 2019, HUM MOL GENET, V28, P524, DOI 10.1093/hmg/ddy357; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Schmid JP, 2009, EMBO MOL MED, V1, P112, DOI 10.1002/emmm.200900009; Shackelford C, 2002, TOXICOL PATHOL, V30, P93, DOI 10.1080/01926230252824761; Srivastava S, 2014, J EXP MED, V211, P961, DOI 10.1084/jem.20131556; Sumegi J, 2011, BLOOD, V117, pE151, DOI 10.1182/blood-2010-08-300046; Staines-Boone AT, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00075; Tesi B, 2015, J ALLERGY CLIN IMMUN, V135, P1638, DOI 10.1016/j.jaci.2014.11.030; Trottestam H, 2011, BLOOD, V118, P4577, DOI 10.1182/blood-2011-06-356261; Utzschneider DT, 2013, NAT IMMUNOL, V14, P603, DOI 10.1038/ni.2606; Zoller EE, 2011, J EXP MED, V208, P1203, DOI 10.1084/jem.20102538	40	35	37	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2215	+		10.1016/j.jaci.2018.10.068	http://dx.doi.org/10.1016/j.jaci.2018.10.068			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30578871	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000470113200025
J	Thomas, DC; Charbonnier, LM; Schejtman, A; Aldhekri, H; Coomber, EL; Dufficy, ER; Beenken, AE; Lee, JC; Clare, S; Speak, AO; Thrasher, AJ; Santilli, G; Al-Mousa, H; Alkuraya, FS; Chatila, TA; Smith, KGC				Thomas, David C.; Charbonnier, Louis-Marie; Schejtman, Andrea; Aldhekri, Hasan; Coomber, Eve L.; Dufficy, Elizabeth R.; Beenken, Anne E.; Lee, James C.; Clare, Simon; Speak, Anneliese O.; Thrasher, Adrian J.; Santilli, Giorgia; Al-Mousa, Hamoud; Alkuraya, Fowzan S.; Chatila, Talal A.; Smith, Kenneth G. C.			EROS/CYBC1 mutations: Decreased NADPH oxidase function and chronic granulomatous disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Thomas, David C.; Dufficy, Elizabeth R.; Beenken, Anne E.; Lee, James C.; Smith, Kenneth G. C.] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England; [Charbonnier, Louis-Marie; Chatila, Talal A.] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Charbonnier, Louis-Marie; Chatila, Talal A.] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Schejtman, Andrea; Thrasher, Adrian J.; Santilli, Giorgia] UCL Great Ormond St Inst Child Hlth, Mol Immunol Unit, London, England; [Aldhekri, Hasan; Al-Mousa, Hamoud] King Faisal Specialist Hosp & Res Ctr, Dept Paediat, Riyadh, Saudi Arabia; [Coomber, Eve L.; Clare, Simon; Speak, Anneliese O.] Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton, Cambs, England; [Al-Mousa, Hamoud] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia; [Alkuraya, Fowzan S.] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Riyadh, Saudi Arabia; [Alkuraya, Fowzan S.] Alfaisal Univ, Dept Anat & Cell Biol, Coll Med, Riyadh, Saudi Arabia; [Alkuraya, Fowzan S.] King Abdulaziz City Sci & Technol, Saudi Human Genome Programme, Riyadh, Saudi Arabia	University of Cambridge; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; University of London; University College London; King Faisal Specialist Hospital & Research Center; Wellcome Trust Sanger Institute; Alfaisal University; King Faisal Specialist Hospital & Research Center; Alfaisal University; King Abdulaziz City for Science & Technology	Thomas, DC (corresponding author), Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England.	tdct2@cam.ac.uk; kgcs2@cam.ac.uk	Al-Mousa, Hamoud/AAS-4477-2020; Lee, James/ABD-5920-2020	Lee, James/0000-0001-5711-9385; Thomas, David/0000-0002-9738-2329; Chatila, Talal/0000-0001-7439-2762; Thrasher, Adrian/0000-0002-6097-6115; Charbonnier, Louis-Marie/0000-0002-4594-7893; Smith, Kenneth/0000-0003-3829-4326	MRC [MR/L019027/1] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI085090] Funding Source: NIH RePORTER; Medical Research Council [MR/L019027/1] Funding Source: Medline; NIAID NIH HHS [R01 AI085090] Funding Source: Medline; Wellcome Trust [098051, 104807/Z/14/Z] Funding Source: Medline; Department of Health Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome Trust); Department of Health		Conti F, 2016, J ALLERGY CLIN IMMUN, V138, P241, DOI 10.1016/j.jaci.2015.11.041; Monies D, 2017, HUM GENET, V136, P921, DOI 10.1007/s00439-017-1821-8; Parekh C, 2011, PEDIATR BLOOD CANCER, V56, P460, DOI 10.1002/pbc.22830; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Thomas DC, 2017, J EXP MED, V214, P1111, DOI 10.1084/jem.20161382; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234	6	35	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					782	+		10.1016/j.jaci.2018.09.019	http://dx.doi.org/10.1016/j.jaci.2018.09.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30312704	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000457718700040
J	Altunbulakli, C; Reiger, M; Neumann, AU; Garzorz-Stark, N; Fleming, M; Huelpuesch, C; Castro-Giner, F; Eyerich, K; Akdis, CA; Traidl-Hoffmann, C				Altunbulakli, Can; Reiger, Matthias; Neumann, Avidan U.; Garzorz-Stark, Natalie; Fleming, Megan; Huelpuesch, Claudia; Castro-Giner, Francesc; Eyerich, Kilian; Akdis, Cezmi A.; Traidl-Hoffmann, Claudia			Relations between epidermal barrier dysregulation and Staphylococcus species-dominated microbiome dysbiosis in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; US POPULATION; MECHANISMS; INSIGHTS; IMMUNE; ECZEMA		[Altunbulakli, Can; Neumann, Avidan U.; Castro-Giner, Francesc; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Reiger, Matthias; Neumann, Avidan U.; Fleming, Megan; Huelpuesch, Claudia; Traidl-Hoffmann, Claudia] Tech Univ Munich, UNIKA T, Inst Environm Med, Augsburg, Germany; [Reiger, Matthias; Neumann, Avidan U.; Fleming, Megan; Huelpuesch, Claudia; Traidl-Hoffmann, Claudia] Helmholtz Zentrum Munchen, Augsburg, Germany; [Altunbulakli, Can; Reiger, Matthias; Neumann, Avidan U.; Fleming, Megan; Huelpuesch, Claudia; Akdis, Cezmi A.; Traidl-Hoffmann, Claudia] CK CARE, Davos, Switzerland; [Reiger, Matthias; Fleming, Megan; Huelpuesch, Claudia; Traidl-Hoffmann, Claudia] ZIEL Inst Food & Hlth, Freising Weihenstephan, Germany; [Neumann, Avidan U.] Helmholtz Zentrum Munchen, ICB, Augsburg, Germany; [Garzorz-Stark, Natalie; Eyerich, Kilian] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Castro-Giner, Francesc] Swiss Fed Inst Technol, Funct Genom Ctr Zurich, Zurich, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Traidl-Hoffmann, C (corresponding author), Tech Univ Munich, UNIKA T, Inst Environm Med, Augsburg, Germany.; Traidl-Hoffmann, C (corresponding author), Helmholtz Zentrum Munchen, Augsburg, Germany.; Traidl-Hoffmann, C (corresponding author), CK CARE, Davos, Switzerland.; Traidl-Hoffmann, C (corresponding author), ZIEL Inst Food & Hlth, Freising Weihenstephan, Germany.	claudia.traidl-hoffmann@tum.de	Castro-Giner, Francesc/D-7992-2014; Akdis, Cezmi/AAV-4844-2020	Castro-Giner, Francesc/0000-0001-6111-0754; Akdis, Cezmi/0000-0001-8020-019X; Altunbulakli, Can/0000-0003-2264-7377	Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland; Swiss National Science Foundation [310030-156823, 320030-140772]	Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	Supported by the Christine Kuhne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland, and Swiss National Science Foundation Grants 310030-156823 and 320030-140772.	Barr DB, 2005, ENVIRON HEALTH PERSP, V113, P192, DOI 10.1289/ehp.7337; Brown SJ, 2017, J PATHOL, V241, P140, DOI 10.1002/path.4810; CDC (Centers for Disease Control and Prevention), 2009, 4 REP HUM EXP ENV CH; Clark RT, 2009, CLIN VACCINE IMMUNOL, V16, P397, DOI 10.1128/CVI.00210-08; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Gong JQ, 2006, BRIT J DERMATOL, V155, P680, DOI 10.1111/j.1365-2133.2006.07410.x; Grainger J, 2006, ENVIRON RES, V100, P394, DOI 10.1016/j.envres.2005.06.004; Li Z, 2008, ENVIRON RES, V107, P320, DOI 10.1016/j.envres.2008.01.013; Perzanowski MS, 2013, J ALLERGY CLIN IMMUN, V131, P886, DOI 10.1016/j.jaci.2012.12.666; Peters KO, 2017, J EXPO SCI ENV EPID, V27, P290, DOI 10.1038/jes.2016.57; Scinicariello F, 2014, ENVIRON HEALTH PERSP, V122, P299, DOI 10.1289/ehp.1307234; Spergel JM, 2010, IMMUNOL ALLERGY CLIN, V30, P269, DOI 10.1016/j.iac.2010.06.003; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Williams MR, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0567-4	16	35	35	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1643	+		10.1016/j.jaci.2018.07.005	http://dx.doi.org/10.1016/j.jaci.2018.07.005			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30048670	Bronze			2022-12-18	WOS:000449429800030
J	Hemmer, W; Altmann, F; Holzweber, F; Gruber, C; Wantke, F; Wohrl, S				Hemmer, Wolfgang; Altmann, Friedrich; Holzweber, Friedrich; Gruber, Clemens; Wantke, Felix; Woehrl, Stefan			ImmunoCAP cellulose displays cross-reactive carbohydrate determinant (CCD) epitopes and can cause false-positive test results in patients with high anti-CCD IgE antibody levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CCDs; cellulose; component-resolved diagnosis; cross-reactive carbohydrate determinants; in vitro diagnosis; IgE measurement; ImmunoCAP; N-glycans	COMPONENT-RESOLVED DIAGNOSIS; ALLERGEN-SPECIFIC IGE; HYMENOPTERA VENOM; CLINICAL-RELEVANCE; IMMUNOGLOBULIN-E; MAJOR ALLERGENS; BINDING; GLYCANS; POLLEN; LATEX	BACKGROUND: Cross-reactive carbohydrate determinants (CCDs) in plants and insect venoms are a common cause of irrelevant positive test results during in vitro allergy diagnosis. We observed that some CCD-positive sera show nonspecific IgE binding even with CCD-free recombinant allergens when using the Phadia ImmunoCAP platform. OBJECTIVE: We investigated whether cellulose used as an allergen carrier in ImmunoCAP harbors residual N-glycans, causing nonspecific background binding in CCD-positive sera. METHODS: IgE binding to 6 samples of blank ImmunoCAPs coupled to either streptavidin (SA-CAP-1 or 2) or nonallergenic maltose-binding protein (MBP; MBP-CAP-1 to 4) and binding to a panel of 4 recombinant allergens were compared in CCD-positive sera before and after inhibition with a CCD inhibitor (MUXF3-human serum albumin). RESULTS: Of 52 CCD-positive sera (bromelain, 1.01-59.6 kilounits of antigen per liter [kU(A)/L]) tested on SA-CAP-1, 35 (67%) showed IgE binding of greater than 0.35 kU(A)/L (0.41-4.22 kU(A)/L). Among those with anti-CCD IgE levels of greater than 7.0 kU(A)/L, 90% (26/29) were positive. IgE binding to SA-CAP-1 correlated with IgE binding to bromelain (r = 0.68) and was completely abolished by serum preincubation with the CCD inhibitor (n = 15). Binding scores with SA-CAP-2 and MBP-CAP-1 to MBP-CAP-4 were generally lower but strongly correlated with those of SA-CAP-1 and bromelain. IgE reactivity of 10 CCD-positive sera (14.0-52.5 kU(A)/L) with the recombinant allergens rPhl p 12, rFel d 1, rAra h 2, and rPru p 3 was positive to at least 1 allergen in 8 of 10 (0.36-1.63 kU(A)/L) and borderline in 2 of 10 (0.21-0.25 kU(A)/L). Binding correlated with antibody binding to bromelain (r = 0.61) and to all blank ImmunoCAPs (r > 0.90) and could be completely blocked by the CCD inhibitor. Overall, mean background binding to cellulose CCDs corresponded to 2% to 3% of the reactivity seen with bromelain. CONCLUSIONS: Cellulose used as a solid-phase allergen carrier can contain varying amounts of CCDs sufficient to cause false-positive test results up to 2 kU(A)/L with nonglycosylated recombinant allergens in patients with high levels of anti-CCD IgE antibodies.	[Hemmer, Wolfgang; Wantke, Felix; Woehrl, Stefan] FAZ Floridsdorf Allergy Ctr, Vienna, Austria; [Altmann, Friedrich; Gruber, Clemens] Univ Nat Resources & Life Sci, Dept Chem, Vienna, Austria; [Holzweber, Friedrich] Das Lab, Villach, Austria	University of Natural Resources & Life Sciences, Vienna	Hemmer, W (corresponding author), Floridsdorf Allergy Ctr, Franz Jonas Pl 8-6, A-1210 Vienna, Austria.	hemmer@faz.at	Wöhrl, Stefan/B-6954-2013	Wöhrl, Stefan/0000-0002-6324-0007; Altmann, Friedrich/0000-0002-0112-7877; Grunwald-Gruber, Clemens/0000-0002-6097-8348	Thermo Fisher; Austrian Science Fund; Austrian Research Promotion Agency	Thermo Fisher; Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Research Promotion Agency	W. Hemmer personally received payment for lectures from Thermo Fisher. F. Altmann is employed by the University of Natural Resources and Life Sciences, Vienna, Austria; has grants from the Austrian Science Fund and the Austrian Research Promotion Agency for other works; and has patents filed in Germany (has yet to receive royalties). C. Gruber is employed by the University of Natural Resources and Life Sciences, Vienna. S. Wohrl is member of the ISAC Advisory Board and received payments for lectures from Thermo Fisher. The rest of the authors declare that they have no relevant conflicts of interest.	AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Altmann F, 2016, ALLERGO J, V25, P18, DOI 10.1007/s40629-016-0112-6; Collot M, 2011, BIOORGAN MED CHEM, V19, P1306, DOI 10.1016/j.bmc.2010.12.001; Coutinho V, 2008, ANN ALLERG ASTHMA IM, V101, P394, DOI 10.1016/S1081-1206(10)60316-X; Datema MR, 2015, J ALLERGY CLIN IMMUN, V136, P382, DOI 10.1016/j.jaci.2014.12.1949; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; Ebo DG, 2010, CLIN EXP ALLERGY, V40, P348, DOI 10.1111/j.1365-2222.2009.03370.x; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; Guilloux L, 2009, INT ARCH ALLERGY IMM, V149, P91, DOI 10.1159/000189190; Hagihara S, 1992, Rinsho Byori, V40, P1217; HAMILTON RG, 1985, J IMMUNOL METHODS, V77, P95, DOI 10.1016/0022-1759(85)90187-5; Hamilton RG, 2010, J ALLERGY CLIN IMMUN, V126, P33, DOI 10.1016/j.jaci.2010.03.014; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Hemmer W., 2012, ANTICARBOHYDRATE ANT, P181; Holzweber F, 2013, ALLERGY, V68, P1269, DOI 10.1111/all.12229; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Kleine-Tebbe J, 2016, IMMUNOL ALLERGY CLIN, V36, P191, DOI 10.1016/j.iac.2015.08.012; Kochuyt AM, 2005, CLIN EXP ALLERGY, V35, P441, DOI 10.1111/j.1365-2222.2005.02217.x; Kohler J, 2014, J ALLERGY CLIN IMMUN, V133, P1383, DOI 10.1016/j.jaci.2013.10.060; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; Lannoo N, 2015, PLANT SCI, V239, P67, DOI 10.1016/j.plantsci.2015.06.023; Mari A, 2002, INT ARCH ALLERGY IMM, V129, P286, DOI 10.1159/000067591; Mari A, 2008, ALLERGY, V63, P891, DOI 10.1111/j.1398-9995.2008.01703.x; Michel J, 2016, ALLERGY, V71, P651, DOI 10.1111/all.12850; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Nolte H, 1997, ANN ALLERG ASTHMA IM, V79, P27, DOI 10.1016/S1081-1206(10)63080-3; Ollert M, 2005, CLIN CHEM, V51, P1241, DOI 10.1373/clinchem.2004.046565; ONEIL CE, 1986, DIAGN CLIN IMMUNOL, V4, P253; Pabst M, 2007, ANAL CHEM, V79, P5051, DOI 10.1021/ac070363i; Reuter A, 2006, CLIN EXP ALLERGY, V36, P815, DOI 10.1111/j.1365-2222.2006.2492.x; Sander I, 2005, INT ARCH ALLERGY IMM, V136, P39, DOI 10.1159/000082583; Schwarz M, 2003, GLYCOBIOLOGY, V13, P749, DOI 10.1093/glycob/cwg091; Seismann H, 2010, MOL IMMUNOL, V47, P799, DOI 10.1016/j.molimm.2009.10.005; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VANTOORENENBERGEN AW, 1987, INT ARCH ALLER A IMM, V83, P436, DOI 10.1159/000234382; Villalta D, 2013, CLIN CHEM LAB MED, V51, P1991, DOI 10.1515/cclm-2013-0027; von Gunten S, 2009, J ALLERGY CLIN IMMUN, V123, P1268, DOI 10.1016/j.jaci.2009.03.013	38	35	37	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					372	+		10.1016/j.jaci.2017.04.028	http://dx.doi.org/10.1016/j.jaci.2017.04.028			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28506851	Bronze			2022-12-18	WOS:000419312200042
J	Lotfi-Emran, S; Ward, BR; Le, QT; Pozez, AL; Manjili, MH; Woodfolk, JA; Schwartz, LB				Lotfi-Emran, Sahar; Ward, Brant R.; Le, Quang T.; Pozez, Andrea L.; Manjili, Masoud H.; Woodfolk, Judith A.; Schwartz, Lawrence B.			Human mast cells present antigen to autologous CD4(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; HLA class II; HLA-DM; CD80; antigen presentation; structured illumination microscopy; tryptase; superantigen; cytomegalovirus antigen	DENDRITIC CELLS; CO-STIMULATION; UP-REGULATION; IFN-GAMMA; CD80; ACTIVATION; RECEPTOR; COSTIMULATION; EXPRESSION; TOLERANCE	Background: Mast cells (MCs), the primary effector cell of the atopic response, participate in immune defense at host/environment interfaces, yet the mechanisms by which they interact with CD4(+) T cells has been controversial. Objective: We used in situ matured primary human MCs and matched CD4(+) T cells to diligently assess the ability of MCs to act as antigen-presenting cells. Methods: We examined mature human skin-derived MCs using flow cytometry for expression of antigen-presenting molecules, for their ability to stimulate CD4(+) T cells to express CD25 and proliferate when exposed to superantigen or to cytomegalovirus (CMV) antigen using matched T cells and MCs from CMV-seropositive or CMV-seronegative donors, and for antigen uptake. Subcellular localization of antigen, HLA molecules, and tryptase was analyzed by using structured illumination microscopy. Results: Our data show that IFN-gamma induces HLA class II, HLA-DM, CD80, and CD40 expression on MCs, whereas MCs take up soluble and particulate antigens in an IFN-gamma independent manner. IFN-gamma primed MCs guide activation of T cells by Staphylococcus aureus superantigen and, when preincubated with CMV antigens, induce a recall CD4(+) T(H)1 proliferation response only in CMV-seropositive donors. MCs co-opt their secretory granules for antigen processing and presentation. Consequently, MC degranulation increases surface delivery of HLA class II/peptide, further enhancing stimulation of T-cell proliferation. Conclusions: IFN-gamma primes human MCs to activate T cells through superantigen and to present CMV antigen to T(H)1 cells, co-opting MC secretory granules for antigen processing and presentation and creating a feed-forward loop of T-cell MC cross-activation.	[Lotfi-Emran, Sahar; Manjili, Masoud H.] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA; [Ward, Brant R.; Le, Quang T.; Schwartz, Lawrence B.] Virginia Commonwealth Univ, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA; [Pozez, Andrea L.] Virginia Commonwealth Univ, Div Plast & Reconstruct Surg, Richmond, VA 23298 USA; [Manjili, Masoud H.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA; [Woodfolk, Judith A.] Univ Virginia, Div Asthma Allergy & Immunol, Charlottesville, VA USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of Virginia	Schwartz, LB (corresponding author), Virginia Commonwealth Univ, POB 980263, Richmond, VA 23298 USA.	lawrence.schwartz@vcuhealth.org	Lotfi-Emran, Sahar/AGY-2353-2022	Lotfi-Emran, Sahar/0000-0002-8650-6779	National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center Core Support Grant [P30 CA016059]; VCU Department of Pathology; Massey Cancer Center; NIH/National Institute of Neurological Disorders and Stroke (NINDS) Center Core Grant [5 P30 NS047463]; NIH/NCI Cancer Center Support Grant [P30 CA016059]; NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center Core Support Grant; VCU Department of Pathology; Massey Cancer Center; NIH/National Institute of Neurological Disorders and Stroke (NINDS) Center Core Grant; NIH/NCI Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Human tissues and patient consent forms were provided by the Virginia Commonwealth University (VCU) Tissue and Data Acquisition and Analysis Core Facility, supported by funding from National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center Core Support Grant P30 CA016059, the VCU Department of Pathology, and Massey Cancer Center. Other tissue samples were provided by the Cooperative Human Tissue Network, a National Cancer Institute supported resource. Microscopy was performed at the VCU Department of Anatomy and Neurobiology Microscopy Facility, which is supported by funding from the NIH/National Institute of Neurological Disorders and Stroke (NINDS) Center Core Grant 5 P30 NS047463 and from NIH/NCI Cancer Center Support Grant P30 CA016059.	Andersson MK, 2009, INT IMMUNOL, V21, P95, DOI 10.1093/intimm/dxn128; Arndt SO, 2000, EMBO J, V19, P1241, DOI 10.1093/emboj/19.6.1241; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Birkholz K, 2010, BLOOD, V116, P2277, DOI 10.1182/blood-2010-02-268425; Boesteanu AC, 2009, SEMIN IMMUNOL, V21, P69, DOI 10.1016/j.smim.2009.02.005; Bozzacco L, 2007, P NATL ACAD SCI USA, V104, P1289, DOI 10.1073/pnas.0610383104; Cao LX, 2015, P NATL ACAD SCI USA, V112, P7237, DOI 10.1073/pnas.1505924112; de Vries VC, 2009, AM J TRANSPLANT, V9, P2270, DOI 10.1111/j.1600-6143.2009.02755.x; Ebert S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004100; Emi-Sugie M, 2016, J ALLERGY CLIN IMMUN, V137, pAB76, DOI 10.1016/j.jaci.2015.12.259; Frossi B, 2011, EUR J IMMUNOL, V41, P1872, DOI 10.1002/eji.201041300; Fuse S, 2011, CELL IMMUNOL, V266, P130, DOI 10.1016/j.cellimm.2010.09.008; Garidou L, 2009, J VIROL, V83, P8905, DOI 10.1128/JVI.00027-09; Gaudenzio N, 2013, J ALLERGY CLIN IMMUN, V131, P1400, DOI 10.1016/j.jaci.2013.01.029; Gaudenzio N, 2009, BLOOD, V114, P4979, DOI 10.1182/blood-2009-02-202648; Grewal IS, 1996, IMMUNOL REV, V153, P85, DOI 10.1111/j.1600-065X.1996.tb00921.x; Haanstra KG, 2009, CLIN EXP IMMUNOL, V158, P91, DOI 10.1111/j.1365-2249.2009.03994.x; Haile ST, 2013, J IMMUNOL, V191, P2829, DOI 10.4049/jimmunol.1202777; Hwang JY, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00258; JANICKA M, 1994, EXP CELL RES, V215, P17, DOI 10.1006/excr.1994.1308; Kambayashi T, 2014, NAT REV IMMUNOL, V14, P719, DOI 10.1038/nri3754; Kambayashi T, 2009, J IMMUNOL, V182, P4686, DOI 10.4049/jimmunol.0803180; Kambe N, 2001, BLOOD, V97, P2045, DOI 10.1182/blood.V97.7.2045; Kitajima T, 1996, J IMMUNOL, V157, P2340; Lahoud MH, 2012, P NATL ACAD SCI USA, V109, P16270, DOI 10.1073/pnas.1208796109; Lang TJ, 2002, J IMMUNOL, V168, P3786, DOI 10.4049/jimmunol.168.8.3786; LANIER LL, 1995, J IMMUNOL, V154, P97; Le QT, 2011, J IMMUNOL, V187, P1912, DOI 10.4049/jimmunol.1001806; Leveson-Gower DB, 2013, BLOOD, V122, P3659, DOI 10.1182/blood-2013-08-519157; Lu LF, 2006, NATURE, V442, P997, DOI 10.1038/nature05010; Lutz MB, 1996, EUR J IMMUNOL, V26, P586, DOI 10.1002/eji.1830260313; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Makida R, 1996, MOL IMMUNOL, V33, P891, DOI 10.1016/0161-5890(96)84615-3; Manzotti CN, 2006, EUR J IMMUNOL, V36, P1413, DOI 10.1002/eji.200535170; Manzotti CN, 2002, EUR J IMMUNOL, V32, P2888, DOI 10.1002/1521-4141(2002010)32:10<2888::AID-IMMU2888>3.0.CO;2-F; McAdam AJ, 1998, IMMUNOL REV, V165, P231; McAlpine SM, 2012, FASEB J, V26, P1280, DOI 10.1096/fj.11-188979; Ndejembi MP, 2006, J IMMUNOL, V177, P7698, DOI 10.4049/jimmunol.177.11.7698; Nickel T, 2009, ATHEROSCLEROSIS, V205, P442, DOI 10.1016/j.atherosclerosis.2009.01.002; Okayama Y, 2000, J IMMUNOL, V164, P4332, DOI 10.4049/jimmunol.164.8.4332; Park JJ, 2010, BLOOD, V116, P1291, DOI 10.1182/blood-2010-01-265975; Pawelec G, 2011, VIRUS RES, V157, P175, DOI 10.1016/j.virusres.2010.09.010; Perez N, 2008, J IMMUNOL, V180, P6566, DOI 10.4049/jimmunol.180.10.6566; Raundhal M, 2015, J CLIN INVEST, V125, P3037, DOI 10.1172/JCI80911; Rodewald HR, 2012, IMMUNITY, V37, P13, DOI 10.1016/j.immuni.2012.07.007; Sadegh-Nasseri S, 2015, MOL IMMUNOL, V68, P81, DOI 10.1016/j.molimm.2015.07.018; Sansom DM, 2003, TRENDS IMMUNOL, V24, P314, DOI 10.1016/S1471-4906(03)00111-X; Schubert N, 2015, ARTHRITIS RHEUMATOL, V67, P903, DOI 10.1002/art.38996; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; Suurmond J, 2013, EUR J IMMUNOL, V43, P1758, DOI 10.1002/eji.201243058; Tel J, 2011, EUR J IMMUNOL, V41, P1014, DOI 10.1002/eji.201040790; Thorpe M, 2012, INT IMMUNOL, V24, P771, DOI 10.1093/intimm/dxs081; Valitutti Salvatore, 2010, Self Nonself, V1, P114; VanGool SW, 1996, IMMUNOL REV, V153, P47; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690; Wertheimer AM, 2014, J IMMUNOL, V192, P2143, DOI 10.4049/jimmunol.1301721; WISKOCIL R, 1985, J IMMUNOL, V134, P1599; Yu M, 2011, J CLIN INVEST, V121, P3133, DOI 10.1172/JCI43598; Zhao W, 2012, J CLIN IMMUNOL, V32, P150, DOI 10.1007/s10875-011-9605-8	59	35	35	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					311	+		10.1016/j.jaci.2017.02.048	http://dx.doi.org/10.1016/j.jaci.2017.02.048			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28624612	Bronze			2022-12-18	WOS:000419312200036
J	Lieberman, PL; Jones, I; Rajwanshi, R; Rosen, K; Umetsu, DT				Lieberman, Phillip L.; Jones, Ilisten; Rajwanshi, Richa; Rosen, Karin; Umetsu, Dale T.			Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA		[Lieberman, Phillip L.] Univ Tennessee, Coll Med, Div Allergy & Immunol, Dept Internal Med, Memphis, TN 38163 USA; [Lieberman, Phillip L.] Univ Tennessee, Coll Med, Div Allergy & Immunol, Dept Pediat, Memphis, TN 38163 USA; [Jones, Ilisten; Umetsu, Dale T.] Univ Calif San Francisco, Dept Pediat, Div Allergy & Immunol, San Francisco, CA USA; [Rajwanshi, Richa; Rosen, Karin; Umetsu, Dale T.] Genentech Inc, San Francisco, CA 94080 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of California System; University of California San Francisco; Roche Holding; Genentech	Lieberman, PL (corresponding author), Univ Tennessee, Coll Med, Div Allergy & Immunol, Dept Internal Med, Memphis, TN 38163 USA.; Lieberman, PL (corresponding author), Univ Tennessee, Coll Med, Div Allergy & Immunol, Dept Pediat, Memphis, TN 38163 USA.	phillieberman@hotmail.com			Genentech, Inc, South San Francisco, Calif; Novartis Pharma AG, Basel, Switzerland; Genentech, Inc; Novartis Pharmaceuticals Corporation	Genentech, Inc, South San Francisco, Calif(Roche HoldingGenentech); Novartis Pharma AG, Basel, Switzerland; Genentech, Inc(Roche HoldingGenentech); Novartis Pharmaceuticals Corporation(Novartis)	This study was designed and funded by Genentech, Inc, South San Francisco, Calif and Novartis Pharma AG, Basel, Switzerland. Third-party writing assistance was provided by Charlotte Kenreigh, PharmD, of Envision Pharma Group (Excel Scientific Solutions, Inc), and funded by Genentech, Inc and Novartis Pharmaceuticals Corporation.	[Anonymous], 2016, CINQ PRESCR INF; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; GlaxoSmithKline, 2017, NUC PRESCR INF; Gonzalez-Perez A, 2010, J ALLERGY CLIN IMMUN, V125, P1098, DOI 10.1016/j.jaci.2010.02.009; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; Khan DA, 2016, ANN ALLERG ASTHMA IM, V117, P115, DOI 10.1016/j.anai.2016.05.013; Lieberman PL, 2016, J ALLERGY CLIN IMMUN, V138, P913, DOI 10.1016/j.jaci.2016.03.030; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; Mullins RJ, 2003, CLIN EXP ALLERGY, V33, P1033, DOI 10.1046/j.1365-2222.2003.01671.x	9	35	36	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1734	+		10.1016/j.jaci.2017.07.013	http://dx.doi.org/10.1016/j.jaci.2017.07.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28797731	hybrid			2022-12-18	WOS:000417206000038
J	Liu, X; Pichulik, T; Wolz, OO; Dang, TM; Stutz, A; Dillen, C; Garcia, MD; Kraus, H; Dickhofer, S; Daiber, E; Munzenmayer, L; Wahl, S; Rieber, N; Kummerle-Deschner, J; Yazdi, A; Franz-Wachtel, M; Macek, B; Radsak, M; Vogel, S; Schulte, B; Walz, JS; Hartl, D; Latz, E; Stilgenbauer, S; Grimbacher, B; Miller, L; Brunner, C; Wolz, C; Weber, ANR				Liu, Xiao; Pichulik, Tica; Wolz, Olaf-Oliver; Dang, Truong-Minh; Stutz, Andrea; Dillen, Carly; Garcia, Magno Delmiro; Kraus, Helene; Dickhofer, Sabine; Daiber, Ellen; Munzenmayer, Lisa; Wahl, Silke; Rieber, Nikolaus; Kummerle-Deschner, Jasmin; Yazdi, Amir; Franz-Wachtel, Mirita; Macek, Boris; Radsak, Markus; Vogel, Sebastian; Schulte, Berit; Walz, Juliane Sarah; Hartl, Dominik; Latz, Eicke; Stilgenbauer, Stephan; Grimbacher, Bodo; Miller, Lloyd; Brunner, Cornelia; Wolz, Christiane; Weber, Alexander N. R.			Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-1; ibrutinib; Bruton tyrosine kinase; NLRP3; inflammasome; macrophage; X-linked agammaglobulinemia; Staphylococcus aureus; Muckle-Wells syndrome; inflammation	CHRONIC LYMPHOCYTIC-LEUKEMIA; X-LINKED AGAMMAGLOBULINEMIA; MASS-SPECTROMETRY; B-CELL; NALP3 INFLAMMASOME; IN-VIVO; BTK; ACTIVATION; IMMUNITY; EXPRESSION	Background: The Nod-like receptor NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) and Bruton tyrosine kinase (BTK) are protagonists in innate and adaptive immunity, respectively. NLRP3 senses exogenous and endogenous insults, leading to inflammasome activation, which occurs spontaneously in patients with Muckle-Wells syndrome; BTK mutations cause the genetic immunodeficiency X-linked agammaglobulinemia (XLA). However, to date, few proteins that regulate NLRP3 inflammasome activity in human primary immune cells have been identified, and clinically promising pharmacologic targeting strategies remain elusive. Objective: We sought to identify novel regulators of the NLRP3 inflammasome in human cells with a view to exploring interference with inflammasome activity at the level of such regulators. Methods: After proteome-wide phosphoproteomics, the identified novel regulator BTK was studied in human and murine cells by using pharmacologic and genetic BTK ablation. Results: Here we show that BTK is a critical regulator of NLRP3 inflammasome activation: pharmacologic (using the US Food and Drug Administration-approved inhibitor ibrutinib) and genetic (in patients with XLA and Btk knockout mice) BTK ablation in primary immune cells led to reduced IL-1 beta processing and secretion in response to nigericin and the Staphylococcus aureus toxin leukocidin AB (LukAB). BTK affected apoptosis-associated speck-like protein containing a CARD (ASC) speck formation and caspase-1 cleavage and interacted with NLRP3 and ASC. S aureus infection control in vivo and IL-1 beta release from cells of patients with Muckle-Wells syndrome were impaired by ibrutinib. Notably, IL-1 beta processing and release from immune cells isolated from patients with cancer receiving ibrutinib therapy were reduced. Conclusion: Our data suggest that XLA might result in part from genetic inflammasome deficiency and that NLRP3 inflammasome-linked inflammation could potentially be targeted pharmacologically through BTK.	[Liu, Xiao; Pichulik, Tica; Wolz, Olaf-Oliver; Dang, Truong-Minh; Garcia, Magno Delmiro; Dickhofer, Sabine; Weber, Alexander N. R.] Univ Tubingen, Interfac Inst Cell Biol, Dept Immunol, Morgenstelle 15, D-72076 Tubingen, Germany; [Daiber, Ellen; Munzenmayer, Lisa; Schulte, Berit; Wolz, Christiane] Univ Tubingen, Interfac Inst Microbiol & Infect Med, Tubingen, Germany; [Wahl, Silke; Franz-Wachtel, Mirita; Macek, Boris] Univ Tubingen, Proteome Ctr Tubingen, Tubingen, Germany; [Stutz, Andrea; Latz, Eicke] Univ Hosp Bonn, Inst Innate Immun, Bonn, Germany; [Dillen, Carly; Miller, Lloyd] Johns Hopkins Univ, Dept Dermatol, Baltimore, MD 21218 USA; [Kraus, Helene; Grimbacher, Bodo] Univ Hosp Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Rieber, Nikolaus; Kummerle-Deschner, Jasmin] Univ Hosp Tubingen, Dept Pediat 1, Tubingen, Germany; [Yazdi, Amir] Univ Hosp Tubingen, Dept Dermatol, Tubingen, Germany; [Vogel, Sebastian] Univ Hosp Tubingen, Dept Cardiol & Cardiovasc Dis, Tubingen, Germany; [Walz, Juliane Sarah] Univ Hosp Tubingen, Med Hosp 2, Dept Hematol & Oncol, Tubingen, Germany; [Radsak, Markus] Univ Hosp Mainz, Med Hosp 3, Mainz, Germany; [Latz, Eicke] Univ Massachusetts, Div Infect Dis & Immunol, Worcester, MA 01605 USA; [Stilgenbauer, Stephan] Ulm Univ Hosp, Dept Internal Med 3, Ulm, Germany; [Brunner, Cornelia] Univ Ulm, Med Ctr, Dept Otorhinolaryngol, Ulm, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; University of Bonn; Johns Hopkins University; University of Freiburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University Hospital Mainz; University of Massachusetts System; University of Massachusetts Worcester; Ulm University; Ulm University	Weber, ANR (corresponding author), Univ Tubingen, Interfac Inst Cell Biol, Dept Immunol, Morgenstelle 15, D-72076 Tubingen, Germany.	alexander.weber@uni.tuebingen.de	Macek, Boris/N-1442-2015; Radsak, Markus P/L-3651-2013; Brunner, Cornelia/H-8893-2018; Stilgenbauer, Stephan/ABE-6609-2020; Walz, Juliane/ABE-1748-2021; Latz, Eicke/H-3951-2014	Macek, Boris/0000-0002-1206-2458; Radsak, Markus P/0000-0002-3991-5721; Brunner, Cornelia/0000-0002-6456-5508; Walz, Juliane/0000-0001-6404-7391; Latz, Eicke/0000-0003-1488-5666; Weber, Alexander/0000-0002-8627-7056; Vogel, Sebastian/0000-0002-3284-0464; Wolz, Christiane/0000-0003-3909-5281	Else-Kroner-Fresenius Stiftung; University of Tubingen; University Hospital Tubingen [2310-0-0]	Else-Kroner-Fresenius Stiftung; University of Tubingen; University Hospital Tubingen	Supported by the Else-Kroner-Fresenius Stiftung (to A.N.R.W.), the University of Tubingen, and the University Hospital Tubingen (Fortune Grant 2310-0-0 to X.L. and A.N.R.W.).	Bartok E, 2013, NAT METHODS, V10, P147, DOI [10.1038/nmeth.2327, 10.1038/NMETH.2327]; Block H, 2012, INT REV IMMUNOL, V31, P104, DOI 10.3109/08830185.2012.668982; Broderick L, 2015, ANNU REV PATHOL-MECH, V10, P395, DOI 10.1146/annurev-pathol-012414-040431; Brunner C, 2005, HISTOL HISTOPATHOL, V20, P945, DOI 10.14670/HH-20.945; BRUTON OC, 1952, PEDIATRICS, V9, P722; Burger JA, 2014, LANCET ONCOL, V15, P1090, DOI 10.1016/S1470-2045(14)70335-3; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Cho JS, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003047; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; de Almeida L, 2015, IMMUNITY, V43, P264, DOI 10.1016/j.immuni.2015.07.018; Di Paolo JA, 2011, NAT CHEM BIOL, V7, P41, DOI 10.1038/NCHEMBIO.481; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Elias JE, 2007, NAT METHODS, V4, P207, DOI 10.1038/nmeth1019; Fiedler K, 2011, BLOOD, V117, P1329, DOI 10.1182/blood-2010-04-281170; Franklin BS, 2014, NAT IMMUNOL, V15, P727, DOI 10.1038/ni.2913; Gaidt MM, 2016, IMMUNITY, V44, P833, DOI 10.1016/j.immuni.2016.01.012; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hendriks RW, 2011, EXPERT OPIN THER TAR, V15, P1003, DOI 10.1517/14728222.2011.585971; Hendriks RW, 2011, NAT CHEM BIOL, V7, P4, DOI 10.1038/nchembio.502; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Holzinger D, 2012, J LEUKOCYTE BIOL, V92, P1069, DOI 10.1189/jlb.0112014; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Ito M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8360; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Katsnelson MA, 2015, J IMMUNOL, V194, P3937, DOI 10.4049/jimmunol.1402658; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Khan WN, 2012, J IMMUNOL, V188, P2933, DOI 10.4049/jimmunol.1200490; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Koch A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001588; McGettrick AF, 2013, DIABETES OBES METAB, V15, P19, DOI 10.1111/dom.12169; Melehani JH, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004970; Miller LS, 2007, J IMMUNOL, V179, P6933, DOI 10.4049/jimmunol.179.10.6933; Miller LS, 2011, NAT REV IMMUNOL, V11, P505, DOI 10.1038/nri3010; Murthy P, 2017, BIOCHEM BIOPH RES CO, V483, P230, DOI 10.1016/j.bbrc.2016.12.161; Olsen Jesper V., 2009, V492, P131, DOI 10.1007/978-1-59745-493-3_7; Peschel A, 2012, NAT MED, V18, P1336, DOI 10.1038/nm.2918; Pimienta Genaro, 2009, V527, P107, DOI 10.1007/978-1-60327-834-8_9; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rieber N, 2015, CLIN IMMUNOL, V157, P56, DOI 10.1016/j.clim.2015.01.003; Schroeder MJ, 2004, ANAL CHEM, V76, P3590, DOI 10.1021/ac0497104; Stutz Andrea, 2013, Methods Mol Biol, V1040, P91, DOI 10.1007/978-1-62703-523-1_8; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Teocchi MA, 2015, IMMUN INFLAMM DIS, V3, P171, DOI 10.1002/iid3.57; Thurlow LR, 2011, J IMMUNOL, V186, P6585, DOI 10.4049/jimmunol.1002794; Tomlinson MG, 2004, MOL CELL BIOL, V24, P2455, DOI 10.1128/MCB.24.6.2455-2466.2004; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Verreck FAW, 2004, P NATL ACAD SCI USA, V101, P4560, DOI 10.1073/pnas.0400983101; Wang H, 2015, HEPATOLOGY, V62, P1375, DOI 10.1002/hep.28105	52	35	35	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1054	+		10.1016/j.jaci.2017.01.017	http://dx.doi.org/10.1016/j.jaci.2017.01.017			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28216434	Bronze			2022-12-18	WOS:000412172900017
J	Papadopoulos, NG; Megremis, S; Kitsioulis, NA; Vangelatou, O; West, P; Xepapadaki, P				Papadopoulos, Nikolaos G.; Megremis, Spyridon; Kitsioulis, Nikolaos A.; Vangelatou, Olympia; West, Peter; Xepapadaki, Paraskevi			Promising approaches for the treatment and prevention of viral respiratory illnesses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Influenza; bronchiolitis; common cold; respiratory syncytial virus; rhinovirus; vaccine; monoclonal; antiviral; natural products; public health	SYNCYTIAL VIRUS-INFECTION; EXPERIMENTAL RHINOVIRUS INFECTION; BRONCHIAL EPITHELIAL-CELLS; F NANOPARTICLE VACCINE; INFLUENZA VACCINE; IN-VITRO; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; NEURAMINIDASE INHIBITORS; ASTHMA EXACERBATIONS	Viral respiratory tract infections are the most common human ailments, leading to enormous health and economic burden. Hundreds of viral species and subtypes have been associated with these conditions, with influenza viruses, respiratory syncytial virus, and rhinoviruses being the most frequent and with the highest burden. When considering prevention or treatment of viral respiratory tract infections, potential targets include the causative pathogens themselves but also the immune response, disease transmission, or even just the symptoms. Strategies targeting all these aspects are developing concurrently, and several novel and promising approaches are emerging. In this perspective we overview the entire range of options and highlight some of the most promising approaches, including new antiviral agents, symptomatic or immunomodulatory drugs, the re-emergence of natural remedies, and vaccines and public health policies toward prevention. Wide-scale prevention through immunization appears to be within reach for respiratory syncytial virus and promising for influenza virus, whereas additional effort is needed in regard to rhinovirus, as well as other respiratory tract viruses.	[Papadopoulos, Nikolaos G.; Megremis, Spyridon; West, Peter] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Papadopoulos, Nikolaos G.; Kitsioulis, Nikolaos A.; Xepapadaki, Paraskevi] Natl & Kapodistrian Univ Athens, Allergy Dept, Pediat Clin 2, Athens, Greece; [Vangelatou, Olympia] Agr Univ Athens, Dept Nutr Physiol & Feeding, Athens, Greece	University of Manchester; National & Kapodistrian University of Athens; Agricultural University of Athens	Papadopoulos, NG (corresponding author), Univ Athens, Dept Pediat 2, 41 Fidippidou, Athens 11527, Greece.	ngp@allergy.gr	N.G., Papadopoulos/L-8670-2013	N.G., Papadopoulos/0000-0002-4448-3468; West, Peter/0000-0002-0097-5006	Abbvie; Novartis; MEDA; MSD; Omega Pharma; Danone	Abbvie(AbbVie); Novartis(Novartis); MEDA; MSD; Omega Pharma; Danone(Danone Nutricia)	N. G. Papadopoulos serves on advisory boards for Novartis, Faes Farma, Biomay, HAL, and Nutricia Research; serves as a consultant for Menarini, Novartis, and MEDA; and receives payments for lectures from Abbvie, Novartis, MEDA, MSD, Omega Pharma, and Danone. The rest of the authors declare that they have no relevant conflicts of interest.	Allan GM, 2014, CAN MED ASSOC J, V186, P190, DOI 10.1503/cmaj.121442; Amber R, 2017, J PHARM PHARMACOL, V69, P109, DOI 10.1111/jphp.12669; Antrobus RD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048322; Atsmon J, 2014, VACCINE, V32, P5816, DOI 10.1016/j.vaccine.2014.08.031; Atsmon J, 2012, J CLIN IMMUNOL, V32, P595, DOI 10.1007/s10875-011-9632-5; Bacharier LB, 2015, JAMA-J AM MED ASSOC, V314, P2034, DOI 10.1001/jama.2015.13896; Barrett B, 2012, ANN FAM MED, V10, P337, DOI 10.1370/afm.1376; Bedke N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044580; Berry M, 2015, VIRUSES-BASEL, V7, P996, DOI 10.3390/v7030996; Blaas D, 2016, WIEN MED WOCHENSCHR, V166, P211, DOI 10.1007/s10354-016-0461-2; Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006; Boivin G, 2013, INFLUENZA OTHER RESP, V7, P18, DOI 10.1111/irv.12176; Both L, 2013, VACCINE, V31, P1553, DOI 10.1016/j.vaccine.2013.01.025; Boukhvalova M, 2016, BONE MARROW TRANSPL, V51, P119, DOI 10.1038/bmt.2015.212; Bozzetto S, 2017, PHARMACOL RES, V115, P162, DOI 10.1016/j.phrs.2016.11.007; Carbonell-Estrany X, 2010, PEDIATRICS, V125, pE35, DOI 10.1542/peds.2008-1036; Chada KE, 2017, VACCINE, V35, P3162, DOI 10.1016/j.vaccine.2017.04.029; Combret Y, 2017, MINERVA ANESTESIOL, V83, P624, DOI 10.23736/S0375-9393.17.11708-6; Corti D, 2017, CURR OPIN VIROL, V24, P60, DOI 10.1016/j.coviro.2017.03.002; Coulombe F, 2014, IMMUNITY, V40, P554, DOI 10.1016/j.immuni.2014.02.013; Cox RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131652; Cutts FT, 2007, B WORLD HEALTH ORGAN, V85, P719, DOI 10.2471/BLT.06.038414; Dang AT, 2017, SCI REP-UK, V7, DOI 10.1038/srep43844; Dao TT, 2010, J NAT PROD, V73, P1636, DOI 10.1021/np1002753; Darwish I, 2011, EXPERT REV ANTI-INFE, V9, P807, DOI [10.1586/eri.11.56, 10.1586/ERI.11.56]; Dash M, 2011, PROG POLYM SCI, V36, P981, DOI 10.1016/j.progpolymsci.2011.02.001; De Palma AM, 2008, MED RES REV, V28, P823, DOI 10.1002/med.20125; DeVincenzo JP, 2016, NEW ENGL J MED, V374, P1391, DOI 10.1056/NEJMc1516110; DeVincenzo JP, 2012, ANTIVIR THER, V17, P213, DOI 10.3851/IMP2064; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Ermler ME, 2017, J VIROL, V91, DOI 10.1128/JVI.00286-17; Eroglu E, 2016, ADV VIROL, V2016, DOI 10.1155/2016/7971847; Esposito S, 2014, VACCINE, V32, P2546, DOI 10.1016/j.vaccine.2014.03.055; Ferrario Beatrice E, 2015, Clin Mol Allergy, V13, P8, DOI 10.1186/s12948-015-0012-1; Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007; Fries L, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0090-7; Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015; Gerald LB, 2012, J ALLERGY CLIN IMMUN, V130, P1317, DOI 10.1016/j.jaci.2012.08.031; Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809; Glanville N, 2015, CURR OPIN VIROL, V11, P83, DOI 10.1016/j.coviro.2015.03.004; Glenn GM, 2016, J INFECT DIS, V213, P411, DOI 10.1093/infdis/jiv406; Glenn GM, 2013, VACCINE, V31, P524, DOI 10.1016/j.vaccine.2012.11.009; Gomes AC, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5010006; Gomez M, 2009, PEDIATR INFECT DIS J, V28, P655, DOI 10.1097/INF.0b013e318199c3b1; Gonzales-van Horn SR, 2015, J LEUKOCYTE BIOL, V98, P185, DOI 10.1189/jlb.3RU0315-099R; Grandea AG, 2010, P NATL ACAD SCI USA, V107, P12658, DOI 10.1073/pnas.0911806107; Grienke U, 2012, NAT PROD REP, V29, P11, DOI 10.1039/c1np00053e; Griffiths C, 2017, CLIN MICROBIOL REV, V30, P277, DOI 10.1128/CMR.00010-16; Groppelli E, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006197; Gulraiz F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095134; Gupta P, 2016, MABS-AUSTIN, V8, P991, DOI 10.1080/19420862.2016.1167294; Haidari M, 2009, PHYTOMEDICINE, V16, P1127, DOI 10.1016/j.phymed.2009.06.002; Hao QK, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006895.pub3; Harrison SC, 2015, VIROLOGY, V479, P498, DOI 10.1016/j.virol.2015.03.043; Harutyunyan S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003270; Hayden FG, 2013, INFLUENZA OTHER RESP, V7, P36, DOI 10.1111/irv.12173; He WQ, 2016, P NATL ACAD SCI USA, V113, P11931, DOI 10.1073/pnas.1609316113; Heath MD, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2329-5; Helmstadter A, 2014, DRUG DISCOV TODAY, V19, P4, DOI 10.1016/j.drudis.2013.07.016; Herfst S, 2017, CURR OPIN VIROL, V22, P22, DOI 10.1016/j.coviro.2016.11.006; Herzog C, 2009, VACCINE, V27, P4381, DOI 10.1016/j.vaccine.2009.05.029; Hwang HS, 2014, ANTIVIR RES, V110, P115, DOI 10.1016/j.antiviral.2014.07.016; Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4; Jiang Di, 2016, J Clin Cell Immunol, V7, DOI 10.4172/2155-9899.1000475; Jorquera PA, 2015, VACCINES-BASEL, V3, P829, DOI 10.3390/vaccines3040829; Jund R, 2015, ACTA OTO-LARYNGOL, V135, P42, DOI 10.3109/00016489.2014.952047; Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202; Kantor DB, 2016, AM J RESP CRIT CARE, V194, P1552; Karsch-Volk M, 2015, JAMA-J AM MED ASSOC, V313, P618, DOI 10.1001/jama.2014.17145; Kepreotes E, 2017, LANCET, V389, P930, DOI 10.1016/S0140-6736(17)30061-2; Koatz AM, 2016, LUNG, V194, P687, DOI 10.1007/s00408-016-9880-5; Kohlmann R, 2009, J VIROL, V83, P12601, DOI 10.1128/JVI.01036-09; Koltsida O, 2011, EMBO MOL MED, V3, P348, DOI 10.1002/emmm.201100142; Krammer F, 2013, J VIROL, V87, P6542, DOI [10.1128/JVI.00641-13, 10.1128/JVI.03183-13]; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Kuster SP, 2013, EMERG INFECT DIS, V19, P606, DOI 10.3201/eid1904.111812; Laborda P, 2016, MOLECULES, V21, DOI 10.3390/molecules21111513; Laccourreye O, 2015, EUR ANN OTORHINOLARY, V132, P31, DOI 10.1016/j.anorl.2014.11.001; Lambour J, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.97; Lee CH, 2003, ARCH PHARM RES, V26, P367, DOI 10.1007/BF02976693; Lee JS, 2014, VACCINE, V32, P5866, DOI 10.1016/j.vaccine.2014.08.045; LEE S, 2016, NAT COMMUN, V7; Leitner WW, 1999, VACCINE, V18, P765, DOI 10.1016/S0264-410X(99)00271-6; Leonov A, 2015, MOLECULES, V20, P6544, DOI 10.3390/molecules20046544; Lillie P., PHASE 2A STUDY ASSES; Little P, 2015, LANCET, V386, P1631, DOI 10.1016/S0140-6736(15)60127-1; Liu AL, 2008, BIOORGAN MED CHEM, V16, P7141, DOI 10.1016/j.bmc.2008.06.049; Liu H, 2016, VACCINE, V34, P5845, DOI 10.1016/j.vaccine.2016.10.040; Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74; Lou ZY, 2014, TRENDS PHARMACOL SCI, V35, P86, DOI 10.1016/j.tips.2013.11.006; Lowell GH, 2017, VACCINE, V35, P713, DOI 10.1016/j.vaccine.2016.12.063; Lowry JA, 2015, PEDIATR REV, V36, P286, DOI 10.1542/pir.36-7-286; Lu YM, 2015, PHARMACOLOGY, V95, P139, DOI 10.1159/000377683; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15; Lundstrom K, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040039; Ma SC, 2001, CHEM PHARM BULL, V49, P1471, DOI 10.1248/cpb.49.1471; Mameli C, 2015, PHARMACOL RES, V97, P79, DOI 10.1016/j.phrs.2015.04.007; Marasco WA, 2007, NAT BIOTECHNOL, V25, DOI 10.1038/nbt1363; Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583; Matias G, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4177-z; Mazur N, 2015, LANCET RESP MED, V3, P888, DOI 10.1016/S2213-2600(15)00255-6; Menzel M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28698; MITCHISON D A, 1965, Br Med J, V1, P1344; Morice A, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2016-000137; Namazova-Baranova LS, 2014, INT J IMMUNOPATH PH, V27, P413, DOI 10.1177/039463201402700311; Niespodziana K, 2012, FASEB J, V26, P1001, DOI 10.1096/fj.11-193557; O'Brien KL, 2015, LANCET INFECT DIS, V15, P1398, DOI 10.1016/S1473-3099(15)00247-9; Oldstone MBA, 2013, VIROLOGY, V435, P92, DOI 10.1016/j.virol.2012.09.039; Palomo C, 2016, ANTIMICROB AGENTS CH, V60, P6498, DOI 10.1128/AAC.00842-16; Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x; Papadopoulos NG, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02294-2016; Petrova NV, 2017, ANTIVIR RES, V142, P185, DOI 10.1016/j.antiviral.2017.03.017; Pleguezuelos O, 2015, CLIN VACCINE IMMUNOL, V22, P828, DOI 10.1128/CVI.00098-15; Pleguezuelos O, 2012, VACCINE, V30, P4655, DOI 10.1016/j.vaccine.2012.04.089; Pleschka S, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-197; Porter JD, 2016, J ANTIMICROB CHEMOTH, V71, P2767, DOI 10.1093/jac/dkw222; Qiao L, 2016, ANTIVIR RES, V131, P131, DOI 10.1016/j.antiviral.2016.05.001; Ramos EL, 2015, J INFECT DIS, V211, P1038, DOI 10.1093/infdis/jiu539; Reichert JM, 2017, MABS-AUSTIN, V9, P167, DOI 10.1080/19420862.2016.1269580; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Ritchie AI, 2015, ANN AM THORAC SOC S2, V12, pS115, DOI DOI 10.1513/ANNALSATS.201503-151AW; Rumzhum NN, 2016, CLIN EXP ALLERGY, V46, P397, DOI 10.1111/cea.12697; Sayes CM, 2007, TOXICOL SCI, V97, P163, DOI 10.1093/toxsci/kfm018; Schapowal A, 2015, ADV THER, V32, P187, DOI 10.1007/s12325-015-0194-4; Serhan CN, 2015, SEMIN IMMUNOL, V27, P200, DOI 10.1016/j.smim.2015.03.004; Shirey KA, 2016, MUCOSAL IMMUNOL, V9, P1173, DOI 10.1038/mi.2015.141; Shirey KA, 2014, MUCOSAL IMMUNOL, V7, P549, DOI 10.1038/mi.2013.71; Shirey KA, 2013, NATURE, V497, P498, DOI 10.1038/nature12118; Simoes EAF, 2015, J INFECT DIS, V211, pS1, DOI 10.1093/infdis/jiu828; Smith TRF, 2017, VACCINE, V35, P2840, DOI 10.1016/j.vaccine.2017.04.008; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; Suess T, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-26; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Tang JW, 2017, LANCET INFECT DIS; Tao WQ, 2017, ANTIVIR RES, V141, P62, DOI 10.1016/j.antiviral.2017.01.021; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Telcian AG, 2017, ANTIVIR RES, V137, P93, DOI 10.1016/j.antiviral.2016.11.004; Ternette N, 2007, VACCINE, V25, P7271, DOI 10.1016/j.vaccine.2007.07.025; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Toussaint M, 2017, NAT MED, V23, P681, DOI 10.1038/nm.4332; Turley CB, 2011, VACCINE, V29, P5145, DOI 10.1016/j.vaccine.2011.05.041; Turner RB, 2017, BENEF MICROBES, V8, P207, DOI 10.3920/BM2016.0160; Turner RB, 1999, JAMA-J AM MED ASSOC, V281, P1797, DOI 10.1001/jama.281.19.1797; U.S. Food and Drug Administration (FDA), FDA EL RISK EV MIT S; van der Linden L, 2015, VIRUSES-BASEL, V7, P4529, DOI 10.3390/v7082832; van Doorn E, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2341-9; van Doorn E, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006339, 10.1097/md.0000000000006339]; Van Epps HL, 2006, J EXP MED, V203, P803, DOI 10.1084/jem.2034fta; Wasserman R, 2016, J CLIN IMMUNOL, V36, P590, DOI 10.1007/s10875-016-0308-z; Wilkinson K, 2017, VACCINE, V35, P2775, DOI 10.1016/j.vaccine.2017.03.092; Willmott M, 2016, ARCH DIS CHILD, V101, P42, DOI 10.1136/archdischild-2015-308875; Wollacott AM, 2016, EBIOMEDICINE, V5, P147, DOI 10.1016/j.ebiom.2016.02.021; Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352; Wu HZ, 2009, VIRUS RES, V145, P39, DOI 10.1016/j.virusres.2009.06.012; Xie GC, 2016, BIOMED ENVIRON SCI, V29, P137, DOI 10.3967/bes2016.015; Yang CF, 2013, VACCINE, V31, P2822, DOI 10.1016/j.vaccine.2013.04.006; Yang K, 2014, CURR OPIN VIROL, V6, P78, DOI 10.1016/j.coviro.2014.03.009; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927; Yingsakmongkon S, 2008, BIOL PHARM BULL, V31, P511, DOI 10.1248/bpb.31.511; Younan P, 2017, MBIO, V8, DOI [10.1128/mbio.00226-17, 10.1128/mBio.00226-17]; Yuan S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.367; Zaraket Hassan, 2016, Curr Treat Options Infect Dis, V8, P311, DOI 10.1007/s40506-016-0085-5; Zdrenghea MT, 2017, REV MED VIROL, V27, DOI 10.1002/rmv.1909; Zheng BJ, 2008, P NATL ACAD SCI USA, V105, P8091, DOI 10.1073/pnas.0711942105; Zhu Q, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj1928	169	35	36	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					921	932		10.1016/j.jaci.2017.07.001	http://dx.doi.org/10.1016/j.jaci.2017.07.001			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28739285	Green Submitted, Green Published, Bronze			2022-12-18	WOS:000412172900003
J	Nyenhuis, SM; Krishnan, JA; Berry, A; Calhoun, WJ; Chinchilli, VM; Engle, L; Grossman, N; Holguin, F; Israel, E; Kittles, RA; Kraft, M; Lazarus, SC; Lehman, EB; Mauger, DT; Moy, JN; Peters, SP; Phipatanakul, W; Smith, LJ; Sumino, K; Szefler, SJ; Wechsler, ME; Wenzel, S; White, SR; Ackerman, SJ				Nyenhuis, Sharmilee M.; Krishnan, Jerry A.; Berry, Alalia; Calhoun, William J.; Chinchilli, Vernon M.; Engle, Linda; Grossman, Nicole; Holguin, Fernando; Israel, Elliot; Kittles, Rick A.; Kraft, Monica; Lazarus, Stephen C.; Lehman, Erik B.; Mauger, David T.; Moy, James N.; Peters, Stephen P.; Phipatanakul, Wanda; Smith, Lewis J.; Sumino, Kaharu; Szefler, Stanley J.; Wechsler, Michael E.; Wenzel, Sally; White, Steven R.; Ackerman, Steven J.			Race is associated with differences in airway inflammation in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; race; eosinophil; airway inflammation; African American; body mass index; corticosteroid; induced sputum; clinical trial	GLUCOCORTICOID-RECEPTOR-BETA; RANDOMIZED CONTROLLED-TRIAL; CLINICAL-RESEARCH NETWORK; BODY-MASS INDEX; INDUCED SPUTUM; INHALED CORTICOSTEROIDS; PERSISTENT ASTHMA; EOSINOPHILIC INFLAMMATION; TIOTROPIUM BROMIDE; RACIAL DISPARITIES	Background: African American subjects have a greater burden from asthma compared with white subjects. Whether the pattern of airway inflammation differs between African American and white subjects is unclear. Objective: We sought to compare sputum airway inflammatory phenotypes of African American and white subjects treated or not with inhaled corticosteroids (ICSs; ICS+ and ICS-, respectively). Methods: We performed a secondary analysis of self-identified African American and white subjects with asthma enrolled in clinical trials conducted by the National Heart, Lung, and Blood Institute-sponsored Asthma Clinical Research Network and AsthmaNet. Demographics, clinical characteristics, and sputum cytology after sputum induction were examined. We used a sputum eosinophil 2% cut point to define subjects with either an eosinophilic (>= 2%) or noneosinophilic (<2%) inflammatory phenotype. Results: Among 1018 participants, African American subjects (n = 264) had a lower FEV1 percent predicted (80% vs 85%, P <.01), greater total IgE levels (197 vs 120 IU/mL, P <.01), and a greater proportion with uncontrolled asthma (43% vs 28%, P <.01) compared with white subjects (n = 754). There were 922 subjects in the ICS+ group (248 African American and 674 white subjects) and 298 subjects in the ICS- group (49 African American and 249 white subjects). Eosinophilic airway inflammation was not significantly different between African American and white subjects in either group (percentage with eosinophilic phenotype: ICS+ group: 19% vs 16%, P = .28; ICS- group: 39% vs 35%, P = .65; respectively). However, when adjusted for confounding factors, African American subjects were more likely to exhibit eosinophilic airway inflammation than white subjects in the ICS+ group (odds ratio, 1.58; 95% CI, 1.01-2.48; P = .046) but not in the ICS- group (P = .984). Conclusion: African American subjects exhibit greater eosinophilic airway inflammation, which might explain the greater asthma burden in this population.	[Nyenhuis, Sharmilee M.; Krishnan, Jerry A.; Ackerman, Steven J.] Univ Illinois, Dept Med, Chicago, IL USA; [Nyenhuis, Sharmilee M.; Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA; [Berry, Alalia] Univ Wisconsin, Dept Med, Div Allergy Pulm & Crit Care, Sch Med & Publ Hlth, Madison, WI USA; [Calhoun, William J.] Univ Texas Med Branch, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Galveston, TX 77555 USA; [Chinchilli, Vernon M.; Engle, Linda; Lehman, Erik B.; Mauger, David T.] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Grossman, Nicole; Israel, Elliot; Wechsler, Michael E.] Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Holguin, Fernando; Wenzel, Sally] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; [Kittles, Rick A.; Kraft, Monica] Univ Arizona, Coll Med, Tucson, AZ USA; [Lazarus, Stephen C.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, San Francisco, CA USA; [Moy, James N.] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA; [Peters, Stephen P.] Wake Forest Sch Med, Dept Med, Div Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC USA; [Phipatanakul, Wanda] Boston Childrens Hosp, Dept Pediat, Div Allergy & Immunol, Boston, MA USA; [Smith, Lewis J.] Northwestern Univ, Dept Med, Div Pulm & Crit Care, Chicago, IL USA; [Sumino, Kaharu] Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Dept Pediat, Div Pulm Med, Aurora, CO USA; [Wechsler, Michael E.] Natl Jewish Hlth, Dept Med, Div Pulm Crit Care & Sleep Med, Denver, CO USA; [White, Steven R.] Univ Chicago, Dept Med, Div Pulm Crit Care, 5841 S Maryland Ave, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Medical Branch Galveston; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Brigham & Women's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Arizona; University of California System; University of California San Francisco; John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Wake Forest University; Harvard University; Boston Children's Hospital; Northwestern University; Washington University (WUSTL); Children's Hospital Colorado; National Jewish Health; University of Chicago	Nyenhuis, SM (corresponding author), 920N CSB MC 719,840 S Wood St, Chicago, IL 60612 USA.	snyenhui@uic.edu	Wechsler, Michael/AAC-5506-2019; Sumino, Kaharu/AAA-2028-2021	Smith, Lewis J/0000-0002-4728-1562; Wenzel, Sally/0000-0002-4242-0164; Sumino, Kaharu/0000-0002-6214-2966; Calhoun, William/0000-0001-7075-712X; Szefler, Stanley/0000-0002-6911-3199	National Institutes of Health/National Heart, Lung, and Blood Institute Chicago Metropolitan AsthmaNet Consortium (CMAC) [U10HL098096]; American Academy of Allergy, Asthma, & Immunology/Association of Specialty Professors T. Franklin Williams Scholar; University of Illinois at Chicago (UIC) Center for Clinical and Translational Science (CCTS); National Center for Advancing Translational Sciences [KL2RR029878, UL1TR000050];  [U10 HL074225];  [U10 HLA074227];  [U10 HLA074231];  [U10 HLA074204];  [U10 HLA074212];  [U10 HLA074073];  [U10 HLA074206];  [U10 HLA074208];  [U10 HLA074218];  [R21 HL118588-01]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001422, UL1TR000050] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR029878] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL118588, U10HL074208, U10HL098096, U10HL074225, U10HL074227, U10HL074073, U10HL074206, U10HL098103, U10HL074204, U10HL074212, U10HL098102, U10HL098090, U10HL074231, U10HL098107, U10HL074218, U10HL098075, U10HL098098] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute Chicago Metropolitan AsthmaNet Consortium (CMAC); American Academy of Allergy, Asthma, & Immunology/Association of Specialty Professors T. Franklin Williams Scholar; University of Illinois at Chicago (UIC) Center for Clinical and Translational Science (CCTS); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); ; ; ; ; ; ; ; ; ; ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grant U10HL098096 from the National Institutes of Health/National Heart, Lung, and Blood Institute Chicago Metropolitan AsthmaNet Consortium (CMAC) and U10 HL074225, U10 HLA074227, U10 HLA074231, U10 HLA074204, U10 HLA074212, U10 HLA074073, U10 HLA074206, U10 HLA074208, U10 HLA074218, and R21 HL118588-01 (to S.J.A.). Also supported by the American Academy of Allergy, Asthma, & Immunology/Association of Specialty Professors T. Franklin Williams Scholar (to S.M.N.), the University of Illinois at Chicago (UIC) Center for Clinical and Translational Science (CCTS), award nos. KL2RR029878 (to S.M.N.) and UL1TR000050 (to J.A.K.) from the National Center for Advancing Translational Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Akinbami LJ, 2014, J ALLERGY CLIN IMMUN, V134, P547, DOI 10.1016/j.jaci.2014.05.037; [Anonymous], ASTHMA PREVALENCE HL; Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; Boudreaux ED, 2003, PEDIATRICS, V111, pE615, DOI 10.1542/peds.111.5.e615; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Calhoun WJ, 2012, JAMA-J AM MED ASSOC, V308, P987, DOI 10.1001/2012.jama.10893; Camargo CA, 2010, J ASTHMA, V47, P76, DOI 10.3109/02770900903338494; Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Deykin A, 2007, AM J RESP CRIT CARE, V175, P228, DOI 10.1164/rccm.200601-112OC; Dixon Anne E, 2010, Proc Am Thorac Soc, V7, P325, DOI 10.1513/pats.200903-013ST; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Federico MJ, 2005, CHEST, V127, P571, DOI 10.1378/chest.127.2.571; Ford JG, 2006, CLIN CHEST MED, V27, P423, DOI 10.1016/j.ccm.2006.05.001; Gershman NH, 1996, EUR RESPIR J, V9, P2448, DOI 10.1183/09031936.96.09122448; Goleva E, 2006, AM J RESP CRIT CARE, V173, P607, DOI 10.1164/rccm.200507-1046OC; Goleva E, 2009, AM J RESP CELL MOL, V40, P223, DOI 10.1165/rcmb.2007-0327OC; Grant EN, 2000, AM J PUBLIC HEALTH, V90, P1923, DOI 10.2105/AJPH.90.12.1923; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Haselkorn T, 2008, ANN ALLERG ASTHMA IM, V101, P256, DOI 10.1016/S1081-1206(10)60490-5; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Iwamoto H, 2008, EUR RESPIR J, V31, P1379, DOI 10.1183/09031936.00014108; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Korevaar DA, 2015, LANCET RESP MED, V3, P290, DOI 10.1016/S2213-2600(15)00050-8; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Li LB, 2010, AM J RESP CRIT CARE, V182, P877, DOI 10.1164/rccm.201001-0015OC; Malka J, 2014, J ALLERGY CLIN IMMUN, V134, P483, DOI 10.1016/j.jaci.2014.03.039; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; Martin RJ, 2001, CONTROL CLIN TRIALS, V22, p207S, DOI 10.1016/S0197-2456(01)00164-7; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Minoguchi K, 2002, CHEST, V121, P732, DOI 10.1378/chest.121.3.732; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Naqvi M, 2007, J ALLERGY CLIN IMMUN, V120, P137, DOI 10.1016/j.jaci.2007.02.045; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, EPR3 NAT HEART LUNG; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; Nyenhuis SM, 2015, J ALLERGY CLIN IMMUN, V135, pAB86, DOI 10.1016/j.jaci.2014.12.1213; Ortega VE, 2014, J ALLERGY CLIN IMMUN, V133, P16, DOI 10.1016/j.jaci.2013.10.040; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; Schatz M, 2015, J ALLER CL IMM-PRACT, V3, P560, DOI 10.1016/j.jaip.2015.03.017; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; Spanevello A, 2000, AM J RESP CRIT CARE, V162, P1172, DOI 10.1164/ajrccm.162.3.9908057; Stewart KA, 2010, ARCH PEDIAT ADOL MED, V164, P720, DOI 10.1001/archpediatrics.2010.100; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Sutherland ER, 2014, J ALLERGY CLIN IMMUN, V133, P34, DOI 10.1016/j.jaci.2013.10.025; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Thakur N, 2013, AM J RESP CRIT CARE, V188, P1202, DOI 10.1164/rccm.201306-1016OC; Tran TN, 2014, ANN ALLERG ASTHMA IM, V113, P19, DOI 10.1016/j.anai.2014.04.011; Wagener AH, 2015, THORAX, V70, P115, DOI 10.1136/thoraxjnl-2014-205634; Wechsler ME, 2011, AM J RESP CRIT CARE, V184, P1247, DOI 10.1164/rccm.201103-0514OC; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Woodruff PG, 2001, J ALLERGY CLIN IMMUN, V108, P753, DOI 10.1067/mai.2001.119411; Zoratti EM, 1998, AM J RESP CRIT CARE, V158, P371, DOI 10.1164/ajrccm.158.2.9608039	63	35	35	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					257	+		10.1016/j.jaci.2016.10.024	http://dx.doi.org/10.1016/j.jaci.2016.10.024			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28069248	Green Accepted, Bronze			2022-12-18	WOS:000404542000026
J	Vigo, T; Procaccini, C; Ferrara, G; Baranzini, S; Oksenberg, JR; Matarese, G; Diaspro, A; de Rosbo, NK; Uccelli, A				Vigo, Tiziana; Procaccini, Claudio; Ferrara, Giovanni; Baranzini, Sergio; Oksenberg, Jorge R.; Matarese, Giuseppe; Diaspro, Alberto; de Rosbo, Nicole Kerlero; Uccelli, Antonio			IFN-gamma orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IFN-gamma; immunomodulation; T cells; mesenchymal stem cells; mammalian target of rapamycin; signal transducer and activator of transcription 1; signal transducer and activator of transcription 3	INTERFERON-GAMMA; STROMAL CELLS; MOLECULAR-BASIS; SELF-RENEWAL; TGF-BETA; MTOR; DISEASE; EXPRESSION; STAT3; IMMUNOSUPPRESSION	Background: Mesenchymal stem cells (MSCs) display a therapeutic plasticity because of their ability to modulate immunity, foster tissue repair, and differentiate into mesodermal cells. IFN-gamma has been described to differently affect human mesenchymal stem cell (hMSC) and mouse mesenchymal stem cell (mMSC) immunomodulation and differentiation, depending on the inflammatory milieu. Objective: We aimed at dissecting the relevant intracellular pathways through which IFN-gamma affects MSC plasticity and the consequence of their manipulation on MSC functions. Methods: Modification of relevant IFN-gamma-dependent pathways in mMSCs was carried out in vitro through gene silencing or chemical inhibition of key components. Functional outcomes were assessed by means of Western blotting, real-time PCR, differentiation, and proliferation assays on MSCs. The effect on T cells was addressed by T-cell proliferation assays; the effect of mammalian target of rapamycin (mTOR) manipulation in MSCs was studied in vivo in a mouse model of delayed-type hypersensitivity assay. To address whether similar mechanisms are involved also in hMSCs on IFN-gamma stimulation, the effect of chemical inhibition on the same intracellular pathways was assessed by means of Western blotting, and the final outcome on immunomodulatory properties was evaluated based on real-time PCR and T-cell proliferation. Results: We revealed that in mMSCs IFN-gamma-induced immunoregulation is mediated by early phosphorylation of signal transducer and activator of transcription (STAT) 1 and STAT3, which is significantly enhanced by an extracellular signal-regulated kinase 1/2-dependent mTOR inhibition, thereby promoting pSTAT1 nuclear translocation. Accordingly, after intracellular mTOR inhibition, MSCs augmented their ability to inhibit T-cell proliferation and control delayed-type hypersensitivity in vivo. Similarly, on mTOR blockade, hMSCs also enhanced their immunoregulatory features. A sustained exposure to IFN-gamma led to inhibition of STAT3 activity, which in mMSCs resulted in an impaired proliferation and differentiation. Conclusion: These results provide new insights about MSC intracellular pathways affected by IFN-gamma, demonstrating that pharmacologic or genetic manipulation of MSCs can enhance their immunomodulatory functions, which could be translated into novel therapeutic approaches.	[Vigo, Tiziana; Ferrara, Giovanni; de Rosbo, Nicole Kerlero; Uccelli, Antonio] Univ Genoa, Dipartimento Neurosci Riabilitaz Oftalmol Genet &, Fac Med & Chirurg, Genoa, Italy; [Vigo, Tiziana; Ferrara, Giovanni; de Rosbo, Nicole Kerlero; Uccelli, Antonio] Ctr Excellence Biomed Res, Genoa, Italy; [Procaccini, Claudio; Matarese, Giuseppe] Univ Napoli Federico II, Lab Immunol, Ist Endocrinol & Oncol Sperimentale, CNR,Dipartimento Med Mol & Biotecnol Med, Naples, Italy; [Baranzini, Sergio; Oksenberg, Jorge R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Matarese, Giuseppe] Univ Napoli Federico II, Dipartimento Med Mol & Biotecnol Med, Naples, Italy; [Diaspro, Alberto] Ist Italiano Tecnol, Nanophysics, Genoa, Italy; [Uccelli, Antonio] IRCCS AOU San Martino IST, Genoa, Italy	University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of California System; University of California San Francisco; University of Naples Federico II; Istituto Italiano di Tecnologia - IIT; University of Genoa; IRCCS AOU San Martino IST	Uccelli, A (corresponding author), Largo Daneo 3, I-16132 Genoa, Italy.	auccelli@neurologia.unige.it	Procaccini, Claudio/AAB-3696-2019; Diaspro, Alberto/E-7833-2010; Ferrara, Giovanni/D-8550-2015; Matarese, Giuseppe/AAO-4077-2021; UCCELLI, Antonio/E-7343-2012; Vigo, Tiziana/AAA-6498-2021	Diaspro, Alberto/0000-0002-4916-5928; Ferrara, Giovanni/0000-0002-4442-8864; Matarese, Giuseppe/0000-0001-9429-0616; UCCELLI, Antonio/0000-0002-2008-6038; Baranzini, Sergio/0000-0003-0067-194X	Italian Foundation for Multiple Sclerosis [MESEMS-FISM 2012/S/4]; Italian Ministry of Health [1221276]; Italian Ministry of University and Scientific Research [2009JN7SCN_003]; Merck Serono (project MS-Run); European Union IDEAS Programme European Research Council Starting Grant [310496]; Fondazione Italiana Sclerosi Multipla (FISM) [2012/R/11]; ASI (Italian Space Agency) [2014-033-R.O]	Italian Foundation for Multiple Sclerosis; Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of University and Scientific Research(Ministry of Education, Universities and Research (MIUR)); Merck Serono (project MS-Run); European Union IDEAS Programme European Research Council Starting Grant; Fondazione Italiana Sclerosi Multipla (FISM)(Fondazione Italiana Sclerosi Multipla (FISM)); ASI (Italian Space Agency)(Agenzia Spaziale Italiana (ASI))	Supported by grants to A.U. from the Italian Foundation for Multiple Sclerosis (grant MESEMS-FISM 2012/S/4), the Italian Ministry of Health (grant no. 1221276), the Italian Ministry of University and Scientific Research (grant no. 2009JN7SCN_003), and Merck Serono (project MS-Run) and by grants to G.M. from the European Union IDEAS Programme European Research Council Starting Grant "menTORing Tregs" (no. 310496), the Fondazione Italiana Sclerosi Multipla (FISM; no. 2012/R/11), and the ASI (Italian Space Agency; no. 2014-033-R.O).	Bai L, 2012, NAT NEUROSCI, V15, P862, DOI 10.1038/nn.3109; Bonneau A, 2012, MOL BIOL REP, V39, P2129, DOI 10.1007/s11033-011-0960-6; Chan JL, 2006, BLOOD, V107, P4817, DOI 10.1182/blood-2006-01-0057; Chow S, 2006, EXP HEMATOL, V34, P1183, DOI 10.1016/j.exphem.2006.05.002; Croitoru-Lamoury J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014698; DASILVA ML, 2006, J CELL SCI, V119, P2204, DOI DOI 10.1242/JCS.02932; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Dorronsoro A, 2014, EUR J IMMUNOL, V44, P480, DOI 10.1002/eji.201343668; Duque G, 2009, STEM CELLS, V27, P550, DOI 10.1634/stemcells.2008-0886; Fang P, 2006, EXP CELL RES, V312, P1229, DOI 10.1016/j.yexcr.2005.12.011; Fielhaber JA, 2009, J BIOL CHEM, V284, P24341, DOI 10.1074/jbc.M109.033530; Galvin-Burgess KE, 2013, STEM CELLS, V31, P48, DOI 10.1002/stem.1252; Hu XY, 2009, IMMUNITY, V31, P539, DOI 10.1016/j.immuni.2009.09.002; Huang GY, 2015, CELL MOL LIFE SCI, V72, P1741, DOI 10.1007/s00018-015-1833-2; Krampera M, 2006, STEM CELLS, V24, P386, DOI 10.1634/stemcells.2005-0008; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Liu Y, 2013, J BIOL CHEM, V288, P30708, DOI 10.1074/jbc.M113.478685; Mounayar M, 2015, STEM CELLS, V33, P1892, DOI 10.1002/stem.1986; Norata GD, 2015, IMMUNITY, V43, P421, DOI 10.1016/j.immuni.2015.08.023; Novick D, 2013, SEMIN IMMUNOL, V25, P439, DOI 10.1016/j.smim.2013.10.014; Procaccini C, 2010, IMMUNITY, V33, P929, DOI 10.1016/j.immuni.2010.11.024; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Romieu-Mourez R, 2007, J IMMUNOL, V179, P1549, DOI 10.4049/jimmunol.179.3.1549; Sheng HM, 2008, CELL RES, V18, P846, DOI 10.1038/cr.2008.80; Stagg J, 2006, BLOOD, V107, P2570, DOI 10.1182/blood-2005-07-2793; Stegmann KA, 2015, EUR J IMMUNOL, V45, P3431, DOI 10.1002/eji.201546018; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Uccelli A, 2007, TRENDS IMMUNOL, V28, P219, DOI 10.1016/j.it.2007.03.001; Vidal C, 2012, STEM CELLS, V30, P1042, DOI 10.1002/stem.1063; Wang L, 2013, STEM CELLS, V31, P1383, DOI 10.1002/stem.1388; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496	34	35	36	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1667	1676		10.1016/j.jaci.2016.09.004	http://dx.doi.org/10.1016/j.jaci.2016.09.004			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27670240	Green Submitted			2022-12-18	WOS:000400465300027
J	Gillis, CM; Jonsson, F; Mancardi, DA; Tu, NX; Beutier, H; Van Rooijen, N; Macdonald, LE; Murphy, AJ; Bruhns, P				Gillis, Caitlin M.; Jonsson, Friederike; Mancardi, David A.; Tu, Naxin; Beutier, Heloise; Van Rooijen, Nico; Macdonald, Lynn E.; Murphy, Andrew J.; Bruhns, Pierre			Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; IgG; knock-in mouse model; basophil; neutrophil; monocyte; macrophage; human Fc gamma R; platelet-activating factor; histamine	PLATELET-ACTIVATING-FACTOR; FC-GAMMA RECEPTORS; MAST-CELL TRYPTASE; SYSTEMIC-ANAPHYLAXIS; MEDIATED ANAPHYLAXIS; TRANSGENIC MICE; MOUSE MODEL; B-CELLS; ANTIBODIES; SPECIFICITY	Background: Anaphylaxis can proceed through distinct IgE- or IgG-dependent pathways, which have been investigated in various mouse models. We developed a novel mouse strain in which the human low-affinity IgG receptor locus, comprising both activating (hFc gamma RIIA, hFc gamma RIIIA, and hFc gamma RIIIB) and inhibitory (hFc gamma RIIB) hFc gamma R genes, has been inserted into the equivalent murine locus, corresponding to a locus swap. Objective: We sought to determine the capabilities of hFc gamma Rs to induce systemic anaphylaxis and identify the cell types and mediators involved. Methods: hFc gamma R expression on mouse and human cells was compared to validate the model. Passive systemic anaphylaxis was induced by injection of heat-aggregated human intravenous immunoglobulin and active systemic anaphylaxis after immunization and challenge. Anaphylaxis severity was evaluated based on hypothermia and mortality. The contribution of receptors, mediators, or cell types was assessed based on receptor blockade or depletion. Results: The human-to-mouse low-affinity Fc gamma R locus swap engendered hFc gamma RIIA/IIB/IIIA/IIIB expression in mice comparable with that seen in human subjects. Knock-in mice were susceptible to passive and active anaphylaxis, accompanied by downregulation of both activating and inhibitory hFc gamma R expression on specific myeloid cells. The contribution of hFc gamma RIIA was predominant. Depletion of neutrophils protected against hypothermia and mortality. Basophils contributed to a lesser extent. Anaphylaxis was inhibited by platelet-activating factor receptor or histamine receptor 1 blockade. Conclusion: Low-affinity Fc gamma R locus-switched mice represent an unprecedented model of cognate hFc gamma R expression. Importantly, IgG-related anaphylaxis proceeds within a native context of activating and inhibitory hFc gamma Rs, indicating that, despite robust hFc gamma RIIB expression, activating signals can dominate to initiate a severe anaphylactic reaction.	[Gillis, Caitlin M.; Jonsson, Friederike; Mancardi, David A.; Beutier, Heloise; Bruhns, Pierre] Inst Pasteur, Dept Immunol, Unit Antibodies Therapy & Pathol, 25 Rue Docteur Roux, F-75015 Paris, France; [Gillis, Caitlin M.; Jonsson, Friederike; Mancardi, David A.; Beutier, Heloise; Bruhns, Pierre] INSERM, U1222, Paris, France; [Gillis, Caitlin M.; Beutier, Heloise] Univ Paris 06, Paris, France; [Van Rooijen, Nico] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol, Amsterdam, Netherlands; [Tu, Naxin; Macdonald, Lynn E.; Murphy, Andrew J.] Regeneron Pharmaceut, Tarrytown, NY USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Regeneron	Gillis, CM; Bruhns, P (corresponding author), Inst Pasteur, Dept Immunol, Unit Antibodies Therapy & Pathol, 25 Rue Docteur Roux, F-75015 Paris, France.	caitlin.gillis@pasteur.fr; bruhns@pasteur.fr	Van Rooijen, Nico/Z-1578-2019; Bruhns, Pierre/F-5567-2013; Jönsson, Friederike/H-7525-2014; Gillis, Caitlin/AAJ-8475-2020	Bruhns, Pierre/0000-0002-4709-8936; Jönsson, Friederike/0000-0002-1667-8065; Gillis, Caitlin/0000-0001-9892-206X; Murphy, Andrew/0000-0003-4152-4081	European Research Council (ERC) [ERC-2013-CoG 616050]; Institut Pasteur and the Institut National de la Sante et de la Recherche Medicale (INSERM); Pasteur-Paris University (PPU) International PhD program; Institut Carnot Pasteur Maladies Infectieuses; Balsan company; University Pierre et Marie Curie	European Research Council (ERC)(European Research Council (ERC)); Institut Pasteur and the Institut National de la Sante et de la Recherche Medicale (INSERM); Pasteur-Paris University (PPU) International PhD program; Institut Carnot Pasteur Maladies Infectieuses; Balsan company; University Pierre et Marie Curie	This work was supported by the European Research Council (ERC)-Seventh Framework Program (ERC-2013-CoG 616050). Additional support was provided by the Institut Pasteur and the Institut National de la Sante et de la Recherche Medicale (INSERM). C.M.G. was supported partly by a stipend from the Pasteur-Paris University (PPU) International PhD program and by the Institut Carnot Pasteur Maladies Infectieuses and partly by the Balsan company. F.J. is an employee of the Centre National de La Recherche Scientifique (CNRS). H.B. is supported by a fellowship from the University Pierre et Marie Curie.	Auerbach W, 2000, BIOTECHNIQUES, V29, P1024, DOI 10.2144/00295st04; Beutier H, 2017, J ALLERGY CLIN IMMUN, V139, P269, DOI 10.1016/j.jaci.2016.03.028; Borges L, 2000, CYTOKINE GROWTH F R, V11, P209, DOI 10.1016/S1359-6101(00)00007-1; Boulaftali Y, 2014, CIRC RES, V114, P1174, DOI 10.1161/CIRCRESAHA.114.301611; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Bruhns P, 2015, IMMUNOL REV, V268, P25, DOI 10.1111/imr.12350; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016/S0002-9270(03)00231-4; Chen K, 2012, BLOOD, V120, P4421, DOI 10.1182/blood-2011-12-401133; Dybendal T, 2003, ACTA ANAESTH SCAND, V47, P1211, DOI 10.1046/j.1399-6576.2003.00237.x; Fisher MM, 1998, BRIT J ANAESTH, V80, P26, DOI 10.1093/bja/80.1.26; Gill P, 2015, J ALLERGY CLIN IMMUN, V135, P1424, DOI 10.1016/j.jaci.2015.04.019; Gillis C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00254; Golden David B K, 2004, Novartis Found Symp, V257, P101; Heijnen IAFM, 1996, J CLIN INVEST, V97, P331, DOI 10.1172/JCI118420; Hoh RA, 2016, J ALLERGY CLIN IMMUN, V137, P157, DOI 10.1016/j.jaci.2015.05.029; IFF ET, 1966, INT ARCH ALLER A IMM, V30, P313, DOI 10.1159/000229815; Jonsson F, 2013, J LEUKOCYTE BIOL, V94, P643, DOI 10.1189/jlb.1212623; Jonsson F, 2012, BLOOD, V119, P2533, DOI 10.1182/blood-2011-07-367334; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; JOUVINMARCHE E, 1984, J IMMUNOL, V133, P892; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V132, P1375, DOI 10.1016/j.jaci.2013.09.008; Khodoun MV, 2011, P NATL ACAD SCI USA, V108, P12413, DOI 10.1073/pnas.1105695108; Langlet C, 2012, J IMMUNOL, V188, P1751, DOI 10.4049/jimmunol.1102744; Laroche D, 2014, ANESTHESIOLOGY, V121, P272, DOI 10.1097/ALN.0000000000000276; Lee JK, 2011, CLIN EXP ALLERGY, V41, P923, DOI 10.1111/j.1365-2222.2011.03779.x; Li FB, 2011, SCIENCE, V333, P1030, DOI 10.1126/science.1206954; Li M, 1996, J EXP MED, V183, P1259, DOI 10.1084/jem.183.3.1259; Macdonald LE, 2014, P NATL ACAD SCI USA, V111, P5147, DOI 10.1073/pnas.1323896111; Mancardi DA, 2008, J CLIN INVEST, V118, P3738, DOI 10.1172/JCI36452; Mancardi DA, 2013, BLOOD, V121, P1563, DOI 10.1182/blood-2012-07-442541; Mancardi DA, 2011, J IMMUNOL, V186, P1899, DOI 10.4049/jimmunol.1003642; McKenzie SE, 1999, J IMMUNOL, V162, P4311; Mertes PM, 2011, J ALLERGY CLIN IMMUN, V128, P366, DOI 10.1016/j.jaci.2011.03.003; Meyer T, 2015, BLOOD, V126, P2230, DOI 10.1182/blood-2015-04-638684; Million M, 1997, EUR J PHARMACOL, V334, P67, DOI 10.1016/S0014-2999(97)01142-4; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Mullins RJ, 2015, J ALLERGY CLIN IMMUN, V136, P367, DOI 10.1016/j.jaci.2015.05.009; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; Nocerino R, 2015, J ALLERGY CLIN IMMUN, V135, P833, DOI 10.1016/j.jaci.2014.12.1912; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Patil SU, 2015, J ALLERGY CLIN IMMUN, V136, P125, DOI 10.1016/j.jaci.2015.03.026; Poueymirou WT, 2007, NAT BIOTECHNOL, V25, P91, DOI 10.1038/nbt1263; Reber LL, 2013, J ALLERGY CLIN IMMUN, V132, P881, DOI 10.1016/j.jaci.2013.06.008; Rispens T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055566; Smith KGC, 2010, NAT REV IMMUNOL, V10, P328, DOI 10.1038/nri2762; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Tsuboi N, 2008, IMMUNITY, V28, P833, DOI 10.1016/j.immuni.2008.04.013; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Tutt AL, 2015, J IMMUNOL, V195, P5503, DOI 10.4049/jimmunol.1402988; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Veri MC, 2007, IMMUNOLOGY, V121, P392, DOI 10.1111/j.1365-2567.2007.02588.x; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19; Zarbock A, 2008, J EXP MED, V205, P2339, DOI 10.1084/jem.20072660	64	35	36	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1253	+		10.1016/j.jaci.2016.06.058	http://dx.doi.org/10.1016/j.jaci.2016.06.058			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27568081	Green Submitted, Bronze			2022-12-18	WOS:000398771800020
J	Sokolowska, M; Chen, LY; Liu, YQ; Martinez-Anton, A; Logun, C; Alsaaty, S; Cuento, RA; Cai, RM; Sun, JF; Quehenberger, O; Armando, AM; Dennis, EA; Levine, SJ; Shelhamer, JH				Sokolowska, Milena; Chen, Li-Yuan; Liu, Yueqin; Martinez-Anton, Asuncion; Logun, Carolea; Alsaaty, Sara; Cuento, Rosemarie A.; Cai, Rongman; Sun, Junfeng; Quehenberger, Oswald; Armando, Aaron M.; Dennis, Edward A.; Levine, Stewart J.; Shelhamer, James H.			Dysregulation of lipidomic profile and antiviral immunity in response to hyaluronan in patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MACROPHAGES; INDUCTION; BLOOD		[Sokolowska, Milena; Chen, Li-Yuan; Liu, Yueqin; Martinez-Anton, Asuncion; Logun, Carolea; Alsaaty, Sara; Cai, Rongman; Sun, Junfeng; Shelhamer, James H.] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA; [Cuento, Rosemarie A.; Levine, Stewart J.] NHLBI, Lab Asthma & Lung Inflammat, Cardiovasc & Pulm Branch, NIH, Bldg 10, Bethesda, MD 20892 USA; [Quehenberger, Oswald] Univ Calif San Diego, Dept Pharmacol, Dept Med, La Jolla, CA 92093 USA; [Armando, Aaron M.; Dennis, Edward A.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Sokolowska, Milena] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Sokolowska, Milena] CK CARE, Davos, Switzerland	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California San Diego; University of California System; University of California San Diego; Swiss Institute of Allergy & Asthma Research; University of Zurich	Shelhamer, JH (corresponding author), NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA.	jshelhamer@cc.nih.gov	Dennis, Edward A./M-5554-2019; Martinez Anton, Asuncion/A-5806-2017; Chen, Liyuan/AAF-3864-2020	Dennis, Edward A./0000-0003-3738-3140; Martinez Anton, Asuncion/0000-0001-9758-5911; Sokolowska, Milena/0000-0001-9710-6685	National Institutes of Health Intramural Program (Critical Care Medicine Department, Clinical Center and Division of Intramural Research, National Heart, Lung, and Blood Institute); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006197] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL000182] Funding Source: NIH RePORTER	National Institutes of Health Intramural Program (Critical Care Medicine Department, Clinical Center and Division of Intramural Research, National Heart, Lung, and Blood Institute); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CLINICAL CENTER	Supported by the National Institutes of Health Intramural Program (Critical Care Medicine Department, Clinical Center and Division of Intramural Research, National Heart, Lung, and Blood Institute).	Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Coulombe F, 2014, IMMUNITY, V40, P554, DOI 10.1016/j.immuni.2014.02.013; Feltens R, 2015, J CHROMATOGR SEP TEC, V6, P290, DOI DOI 10.4172/2157-7064.1000290; Gielen V, 2015, J ALLERGY CLIN IMMUN, V136, P177, DOI 10.1016/j.jaci.2014.11.039; Jarjour NN, 2012, AM J RESP CRIT CARE, V185, P356, DOI 10.1164/rccm.201107-1317PP; Lauer ME, 2015, J BIOL CHEM, V290, P23124, DOI 10.1074/jbc.M115.663823; Liang JR, 2011, J ALLERGY CLIN IMMUN, V128, P403, DOI 10.1016/j.jaci.2011.04.006; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Remane D, 2015, J CHROMATOGR B, V998, P40, DOI 10.1016/j.jchromb.2015.06.021; Sokolowska M, 2014, J BIOL CHEM, V289, P4470, DOI 10.1074/jbc.M113.515106; Sokolowska M, 2010, J ALLERGY CLIN IMMUN, V125, P1393, DOI 10.1016/j.jaci.2010.02.016; Tam VC, 2013, CELL, V154, P213, DOI 10.1016/j.cell.2013.05.052; Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361	13	35	36	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1379	1383		10.1016/j.jaci.2016.09.031	http://dx.doi.org/10.1016/j.jaci.2016.09.031			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27826094	Bronze, Green Accepted, Green Submitted			2022-12-18	WOS:000398771800035
J	Gupta, J; Johansson, E; Bernstein, JA; Chakraborty, R; Hershey, GKK; Rothenberg, ME; Mersha, TB				Gupta, Jayanta; Johansson, Elisabet; Bernstein, Jonathan A.; Chakraborty, Ranajit; Hershey, Gurjit K. Khurana; Rothenberg, Marc E.; Mersha, Tesfaye B.			Resolving the etiology of atopic disorders by using genetic analysis of racial ancestry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic march; food allergy; atopic dermatitis; allergic rhinitis; asthma; racial ancestry; admixture mapping; phenotyping; gene-environment interaction; -omics	GENOME-WIDE ASSOCIATION; SERUM IGE LEVELS; ENVIRONMENTAL TOBACCO-SMOKE; OF-FUNCTION VARIANTS; AFRICAN-AMERICAN CHILDREN; CHILDHOOD FOOD ALLERGY; LUNG-FUNCTION; DNA METHYLATION; PEANUT ALLERGY; HAY-FEVER	Atopic dermatitis (AD), food allergy, allergic rhinitis, and asthma are common atopic disorders of complex etiology. The frequently observed atopic march from early AD to asthma, allergic rhinitis, or both later in life and the extensive comorbidity of atopic disorders suggest common causal mechanisms in addition to distinct ones. Indeed, both disease-specific and shared genomic regions exist for atopic disorders. Their prevalence also varies among races; for example, AD and asthma have a higher prevalence in African Americans when compared with European Americans. Whether this disparity stems from true genetic or race-specific environmental risk factors or both is unknown. Thus far, the majority of the genetic studies on atopic diseases have used populations of European ancestry, limiting their generalizability. Large-cohort initiatives and new analytic methods, such as admixture mapping, are currently being used to address this knowledge gap. Here we discuss the unique and shared genetic risk factors for atopic disorders in the context of ancestry variations and the promise of high-throughput "-omics''-based systems biology approach in providing greater insight to deconstruct their genetic and nongenetic etiologies. Future research will also focus on deep phenotyping and genotyping of diverse racial ancestry, gene-environment, and gene-gene interactions.	[Gupta, Jayanta; Johansson, Elisabet; Hershey, Gurjit K. Khurana; Mersha, Tesfaye B.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Asthma Res, Cincinnati, OH 45229 USA; [Rothenberg, Marc E.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Bernstein, Jonathan A.] Univ Cincinnati, Dept Internal Med, Div Immunol, Allergy Sect, Cincinnati, OH 45267 USA; [Chakraborty, Ranajit] Univ North Texas Hlth Sci Ctr, Ctr Computat Genom, Inst Appl Genet, Dept Mol & Med Genet, Ft Worth, TX USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Mersha, TB (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	tesfaye.mersha@cchmc.org		Bernstein, Jonathan/0000-0002-3476-1196	National Institutes of Health [K01 HL103165, U19 AI066738, U19 AI070235, R01 DK076893, R01 HL132344, R37 A1045898]; Diversity and Health Disparities Award of the Cincinnati Children's Research Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL103165, R01HL132344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235, R37AI045898, U19AI066738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076893] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Diversity and Health Disparities Award of the Cincinnati Children's Research Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health grants K01 HL103165, U19 AI066738, U19 AI070235, R01 DK076893, R01 HL132344, and R37 A1045898 and the Diversity and Health Disparities Award of the Cincinnati Children's Research Foundation.	Agache I, 2012, ALLERGY, V67, P835, DOI 10.1111/j.1398-9995.2012.02832.x; Akdis CA, 2006, CURR OPIN IMMUNOL, V18, P718, DOI 10.1016/j.coi.2006.09.016; Akinbami LJ, 2014, J ALLERGY CLIN IMMUN, V134, P547, DOI 10.1016/j.jaci.2014.05.037; Akinbami Lara J, 2012, NCHS Data Brief, P1; Al-Hammadi S, 2011, ASIAN PAC J ALLERGY, V29, P313; Aldrich MC, 2013, AM J PUBLIC HEALTH, V103, pE73, DOI 10.2105/AJPH.2013.301370; Alduraywish SA, 2016, ALLERGY, V71, P77, DOI 10.1111/all.12784; Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Amato R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007927; Andiappan AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019719; Asai Y, 2013, J ALLERGY CLIN IMMUN, V132, P239, DOI 10.1016/j.jaci.2013.03.043; Aschard H, 2012, HUM GENET, V131, P1591, DOI 10.1007/s00439-012-1192-0; Auer PL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0138-2; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Barnes Kathleen C, 2011, Proc Am Thorac Soc, V8, P143, DOI 10.1513/pats.201103-030MS; Barnes KC, 2010, CURR OPIN ALLERGY CL, V10, P427, DOI 10.1097/ACI.0b013e32833de6ee; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16; Basehore MJ, 2004, J ALLERGY CLIN IMMUN, V114, P80, DOI 10.1016/j.jaci.2004.05.035; Battle NC, 2007, AM J RESP CRIT CARE, V175, P881, DOI 10.1164/rccm.200607-992OC; Baye TM, 2010, PHARMACOGENOMICS J, V10, P465, DOI 10.1038/tpj.2010.71; Baye TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016522; Baye TM, 2010, J ALLERGY CLIN IMMUN, V126, P425, DOI 10.1016/j.jaci.2010.05.025; Ben-Gashir MA, 2002, BRIT J DERMATOL, V147, P920, DOI 10.1046/j.1365-2133.2002.04965.x; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188, DOI 10.1093/oxfordjournals.epirev.a017925; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Bernstein JA, 2013, AM J RHINOL ALLERGY, V27, P457, DOI 10.2500/ajra.2013.27.3983; Bernstein JA, 2012, ANN ALLERG ASTHMA IM, V109, P173, DOI 10.1016/j.anai.2012.06.013; Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049; Bjorksten B, 2008, PEDIAT ALLERG IMM-UK, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x; Blake K, 2013, PULM PHARMACOL THER, V26, P342, DOI 10.1016/j.pupt.2013.01.009; Bonner R, 2013, AM J RESP CRIT CARE, V188, P515, DOI 10.1164/rccm.201212-2208LE; Bourgon R, 2010, P NATL ACAD SCI USA, V107, P9546, DOI 10.1073/pnas.0914005107; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brasier AR, 2008, J ALLERGY CLIN IMMUN, V121, P30, DOI 10.1016/j.jaci.2007.10.015; Brooks C, 2013, CURR OPIN ALLERGY CL, V13, P70, DOI 10.1097/ACI.0b013e32835ad0d2; Brown P, 2012, EUR FOOD RES TECHNOL, V235, P971, DOI 10.1007/s00217-012-1827-3; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Bunyavanich S, 2015, J ALLERGY CLIN IMMUN, V135, P31, DOI 10.1016/j.jaci.2014.10.015; Bunyavanich S, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-48; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; Bussmann C, 2011, J DTSCH DERMATOL GES, V9, P670, DOI 10.1111/j.1610-0387.2011.07656.x; Caggana M, 1999, GENET MED, V1, P267; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Carlson CS, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001661; Carroll CL, 2005, PEDIATR DERMATOL, V22, P192, DOI 10.1111/j.1525-1470.2005.22303.x; Casto AM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001266; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; Chen E, 2009, THORAX, V64, P38, DOI 10.1136/thx.2007.095091; Chen JT, 2002, ENVIRON HEALTH PERSP, V110, P211, DOI 10.1289/ehp.02110s2211; Chen TK, 2012, J FORMOS MED ASSOC, V111, P686, DOI 10.1016/j.jfma.2011.11.027; Choudhry S, 2005, AM J RESP CRIT CARE, V172, P173, DOI 10.1164/rccm.200409-1232OC; Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7; Chung KF, 2015, CURR OPIN ALLERGY CL, V15, P56, DOI 10.1097/ACI.0000000000000134; Chung Kian Fan, 2013, Ann Am Thorac Soc, V10 Suppl, pS109, DOI 10.1513/AnnalsATS.201304-087AW; Clarke R, 2008, NAT REV CANCER, V8, P37, DOI 10.1038/nrc2294; Coca AF, 1923, J IMMUNOL, V8, P163; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Corona E, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003447; Correa P, 2012, GUT LIVER, V6, P21, DOI 10.5009/gnl.2012.6.1.21; Curtiss FR, 2007, J MANAGE CARE PHARM, V13, P810, DOI 10.18553/jmcp.2007.13.9.810; Dai JY, 2012, BIOMETRIKA, V99, P929, DOI 10.1093/biomet/ass044; Darlenski R, 2014, CLIN DERMATOL, V32, P409, DOI 10.1016/j.clindermatol.2013.11.007; Davila I, 2009, J INVEST ALLERG CLIN, V19, P25; Deo RC, 2007, PLOS GENET, V3, P2200, DOI 10.1371/journal.pgen.0030196; DiGiulio DB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003056; Dillon ST, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-239; Dogan MV, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-151; Dries DL, 2009, CIRC-CARDIOVASC GENE, V2, P540, DOI 10.1161/CIRCGENETICS.109.922898; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Duncan LE, 2011, AM J PSYCHIAT, V168, P1041, DOI 10.1176/appi.ajp.2011.11020191; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Elbahlawan L, 2006, PEDIATR CRIT CARE ME, V7, P15, DOI 10.1097/01.PCC.0000194010.63115.A2; Febbo PG, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-461; Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142; Feinberg AP, 2015, JAMA-J AM MED ASSOC, V314, P1129, DOI 10.1001/jama.2015.10414; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P544, DOI 10.1016/j.jaci.2007.05.025; Flores C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026807; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Forno E, 2009, CURR OPIN ALLERGY CL, V9, P154, DOI 10.1097/ACI.0b013e3283292207; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Freedman ML, 2006, P NATL ACAD SCI USA, V103, P14068, DOI 10.1073/pnas.0605832103; Fumagalli M, 2009, J EXP MED, V206, P1395, DOI 10.1084/jem.20082779; Galanter JM, 2014, J ALLERGY CLIN IMMUN, V134, P295, DOI 10.1016/j.jaci.2013.08.055; Gamble C, 2010, J ALLERGY CLIN IMMUN, V126, P1149, DOI 10.1016/j.jaci.2010.08.049; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507; Gauderman WJ, 2010, AM J EPIDEMIOL, V172, P116, DOI 10.1093/aje/kwq097; Genuneit J, 2013, PEDIAT ALLERG IMM-UK, V24, P293, DOI 10.1111/pai.12053; Gharib SA, 2011, J ALLERGY CLIN IMMUN, V128, P1176, DOI 10.1016/j.jaci.2011.07.053; Gosalbes MJ, 2013, CLIN EXP ALLERGY, V43, P198, DOI 10.1111/cea.12063; Gravlee CC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006821; Greene CS, 2014, J CELL PHYSIOL, V229, P1896, DOI 10.1002/jcp.24662; Greenhawt M, 2013, J ALLER CL IMM-PRACT, V1, P378, DOI 10.1016/j.jaip.2013.04.009; Grice EA, 2012, ANNU REV GENOM HUM G, V13, P151, DOI 10.1146/annurev-genom-090711-163814; Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; Gunther T, 2013, GENETICS, V195, P205, DOI 10.1534/genetics.113.152462; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Gutierrez-Arcelus M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004958; Halapi E, 2004, CURR OPIN PULM MED, V10, P22, DOI 10.1097/00063198-200401000-00005; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Heederik D, 2012, J ALLERGY CLIN IMMUN, V130, P44, DOI 10.1016/j.jaci.2012.01.067; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Heyn H, 2013, GENOME RES, V23, P1363, DOI 10.1101/gr.154187.112; Hill DJ, 2008, CLIN EXP ALLERGY, V38, P161, DOI 10.1111/j.1365-2222.2007.02861.x; Himes BE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134057; Hong XM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7304; Hong XM, 2012, SEMIN IMMUNOPATHOL, V34, P655, DOI 10.1007/s00281-012-0323-y; Hong XM, 2009, CURR OPIN PEDIATR, V21, P770, DOI 10.1097/MOP.0b013e32833252dc; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Hu D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063858; Hu YH, 2003, J PROTEOME RES, V2, P405, DOI 10.1021/pr0340227; Huang YJ, 2013, AM J RESP CRIT CARE, V187, P1382, DOI 10.1164/rccm.201303-0488WS; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Hussein YM, 2013, CELL IMMUNOL, V285, P31, DOI 10.1016/j.cellimm.2013.08.001; Hwang S, 2008, J THEOR BIOL, V252, P722, DOI 10.1016/j.jtbi.2008.02.011; Igartua C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6965; Indra AK, 2013, EXPERT REV PROTEOMIC, V10, P309, DOI 10.1586/14789450.2013.814881; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Jackson KD, 1997, NCHS DATA BRIEF, V2013, P1; Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026; Jiang XY, 2011, MOL CELL BIOCHEM, V353, P35, DOI 10.1007/s11010-011-0771-z; Jimenez E, 2008, RES MICROBIOL, V159, P187, DOI 10.1016/j.resmic.2007.12.007; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Kabesch M, 2007, ALLERGY, V62, P423, DOI 10.1111/j.1398-9995.2006.01300.x; Kabesch M, 2014, CURR OPIN ALLERGY CL, V14, P62, DOI 10.1097/ACI.0000000000000025; Kaminsky DA, 2014, CURR OPIN PULM MED, V20, P17, DOI 10.1097/MCP.0000000000000004; Kauffmann F, 2012, J ALLERGY CLIN IMMUN, V130, P1229, DOI 10.1016/j.jaci.2012.10.038; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Keet CA, 2014, ANN ALLERG ASTHMA IM, V112, P222, DOI 10.1016/j.anai.2013.12.007; Kelso John M, 2014, Pediatrics, V134 Suppl 3, pS172, DOI 10.1542/peds.2014-1817OOO; Khianey R, 2011, CURR OPIN ALLERGY CL, V11, P345, DOI 10.1097/ACI.0b013e328348a82e; Kijima A, 2013, ALLERGOL INT, V62, P105, DOI 10.2332/allergolint.12-OA-0468; Kim H, 2013, J ALLERGY CLIN IMMUN, V131, pAB1; Kim H, 2013, J ALLERGY CLIN IMMUN, V131, p1A; Koplin JJ, 2014, ALLERGY, V69, P1639, DOI 10.1111/all.12487; Kottyan LC, 2015, J ALLERGY CLIN IMMUN, V135, P43, DOI 10.1016/j.jaci.2014.10.041; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Kovacic MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023714; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Kumar R, 2011, PEDIATRICS, V128, pE821, DOI 10.1542/peds.2011-0691; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; Le Souef PN, 2006, EUR RESPIR J, V28, P1258, DOI 10.1183/09031936.06.00088006; Lee S, 2014, AM J HUM GENET, V95, P5, DOI 10.1016/j.ajhg.2014.06.009; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Leong AB, 2012, CLIN REV ALLERG IMMU, V43, P156, DOI 10.1007/s12016-011-8263-1; Levin AM, 2014, AM J RESP CRIT CARE, V190, P266, DOI 10.1164/rccm.201402-0204OC; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Li YF, 2008, RESP MED, V102, P984, DOI 10.1016/j.rmed.2008.02.008; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097, DOI 10.1164/ajrccm.162.6.2004178; Li YR, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0091-5; Liang Y, 2015, CLIN REV ALLERGY IMM; Libes JM, 2014, J AM COLL SURGEONS, V218, P707, DOI 10.1016/j.jamcollsurg.2013.12.044; Litonjua AA, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-52; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Liu AH, 2015, J ALLERGY CLIN IMMUN, V136, P860, DOI 10.1016/j.jaci.2015.08.012; Liu CT, 2014, HUM MOL GENET, V23, P4738, DOI 10.1093/hmg/ddu183; Liu X, 2009, CLIN EXP ALLERGY, V39, P991, DOI 10.1111/j.1365-2222.2009.03228.x; Lovinsky-Desir S, 2012, CURR ALLERGY ASTHM R, V12, P211, DOI 10.1007/s11882-012-0257-4; Lu TX, 2013, J ALLERGY CLIN IMMUN, V132, P3, DOI 10.1016/j.jaci.2013.04.039; Lum S, 2015, EUR RESPIR J, V46, P1662, DOI 10.1183/13993003.00415-2015; LUOMA R, 1983, ALLERGY, V38, P339, DOI 10.1111/j.1398-9995.1983.tb04128.x; Luoni G, 2001, GENES IMMUN, V2, P411, DOI 10.1038/sj.gene.6363797; Magnusson LL, 2005, CLIN EXP ALLERGY, V35, P1550, DOI 10.1111/j.1365-2222.2005.02374.x; Mar A, 1999, J AM ACAD DERMATOL, V40, P597, DOI 10.1016/S0190-9622(99)70443-3; Maranville JC, 2013, PHARMACOGENOMICS J, V13, P121, DOI 10.1038/tpj.2011.55; Margolis DJ, 2014, JAMA DERMATOL, V150, P254, DOI 10.1001/jamadermatol.2013.7954; Margolis DJ, 2014, J ALLERGY CLIN IMMUN, V133, P784, DOI 10.1016/j.jaci.2013.09.015; Marth GT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r84; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; Martino D, 2014, EPIGENETICS-US, V9, P998, DOI 10.4161/epi.28945; Mathias RA, 2014, ADV EXP MED BIOL, V795, P125, DOI 10.1007/978-1-4614-8603-9_9; Mc Mahon SS, 2014, SEMIN CELL DEV BIOL, V35, P98, DOI 10.1016/j.semcdb.2014.06.011; McLeish S, 2007, ARCH DIS CHILD, V92, P1032, DOI 10.1136/adc.2006.112185; Mersha TB, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00292; Mersha TB, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-014-0023-x; Meyers DA, 2005, J ALLERGY CLIN IMMUN, V115, P1169, DOI 10.1016/j.jaci.2005.01.070; Mikhaylova L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070387; Milenkovic O, 2010, IEEE T INFORM THEORY, V56, P649, DOI 10.1109/TIT.2009.2036971; Minton K, 2008, NAT REV IMMUNOL, V8, P662, DOI 10.1038/nri2401; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore JH, 2009, AM J HUM GENET, V85, P309, DOI 10.1016/j.ajhg.2009.08.006; Moore MM, 2004, PEDIATRICS, V113, P468, DOI 10.1542/peds.113.3.468; Moorman Jeanne E, 2012, Vital Health Stat 3, P1; Moreno-Estrada A, 2014, SCIENCE, V344, P1280, DOI 10.1126/science.1251688; Moshammer H, 2006, AM J RESP CRIT CARE, V173, P1255, DOI 10.1164/rccm.200510-1552OC; Murcray CE, 2011, GENET EPIDEMIOL, V35, P201, DOI 10.1002/gepi.20569; Murcray CE, 2009, AM J EPIDEMIOL, V169, P219, DOI 10.1093/aje/kwn353; Myers JMB, 2014, J ALLERGY CLIN IMMUN, V134, P891, DOI 10.1016/j.jaci.2014.03.037; Myers JMB, 2010, J INVEST DERMATOL, V130, P430, DOI 10.1038/jid.2009.300; Nguyen EA, 2012, PEDIAT ALLER IMM PUL, V25, P128, DOI 10.1089/ped.2012.0173; Obeng BB, 2008, CURR OPIN ALLERGY CL, V8, P391, DOI 10.1097/ACI.0b013e32830ebb70; Ober C, 2000, AM J RESP CRIT CARE, V161, pA600; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Okada H, 2010, CLIN EXP IMMUNOL, V160, P1, DOI 10.1111/j.1365-2249.2010.04139.x; Ono JG, 2014, PEDIATR RES, V75, P165, DOI 10.1038/pr.2013.186; Ortega VE, 2014, J ALLERGY CLIN IMMUN, V133, P16, DOI 10.1016/j.jaci.2013.10.040; Ortiz RA, 2015, IMMUNOL ALLERGY CLIN, V35, P19, DOI 10.1016/j.iac.2014.09.014; Ostblom E, 2008, CLIN EXP ALLERGY, V38, P1325, DOI 10.1111/j.1365-2222.2008.03010.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Patterson N, 2004, AM J HUM GENET, V74, P979, DOI 10.1086/420871; Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Pinart M, 2014, LANCET RESP MED, V2, P131, DOI 10.1016/S2213-2600(13)70277-7; Prescott S, 2011, PEDIAT ALLERG IMM-UK, V22, P155, DOI 10.1111/j.1399-3038.2011.01145.x; Prince BT, 2015, PEDIATR CLIN N AM, V62, P1479, DOI 10.1016/j.pcl.2015.07.007; Puig C, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-47; Punekar YS, 2009, CLIN EXP ALLERGY, V39, P1889, DOI 10.1111/j.1365-2222.2009.03366.x; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Raherison C, 2007, RESP MED, V101, P107, DOI 10.1016/j.rmed.2006.04.010; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Rava M, 2015, CURR OPIN ALLERGY CL, V15, P70, DOI 10.1097/ACI.0000000000000131; Rebane A, 2014, J ALLERGY CLIN IMMUN, V134, P836, DOI 10.1016/j.jaci.2014.05.022; Rebane A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0424-x; Rebane A, 2013, J ALLERGY CLIN IMMUN, V132, P15, DOI 10.1016/j.jaci.2013.04.011; Reich D, 2005, NAT GENET, V37, P1113, DOI 10.1038/ng1646; Reich D, 2007, AM J HUM GENET, V80, P716, DOI 10.1086/513206; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008; Rockman MV, 2003, CURR BIOL, V13, P2118, DOI 10.1016/j.cub.2003.11.025; Rodriguez E, 2014, J INVEST DERMATOL, V134, P1873, DOI 10.1038/jid.2014.87; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Rosser FJ, 2014, AM J RESP CRIT CARE, V189, P1316, DOI 10.1164/rccm.201401-0186PP; Rumpel JA, 2012, J ALLERGY CLIN IMMUN, V130, P1302, DOI 10.1016/j.jaci.2012.09.001; Sadee W, 2014, HUM GENET, V133, P1199, DOI 10.1007/s00439-014-1476-7; Salari K, 2005, GENET EPIDEMIOL, V29, P76, DOI 10.1002/gepi.20079; Scadding GK, 2015, ARCH DIS CHILD, V100, P576, DOI 10.1136/archdischild-2014-306300; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; Scirica CV, 2007, CHEST, V132, p770S, DOI 10.1378/chest.07-1905; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Shen Y, 2014, HUM IMMUNOL, V75, P991, DOI 10.1016/j.humimm.2014.07.004; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Sitaraman R, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00578; Sittka A, 2013, PEDIATR RES, V73, P543, DOI 10.1038/pr.2013.8; Smit LAM, 2009, AM J RESP CRIT CARE, V179, P363, DOI 10.1164/rccm.200810-1533OC; Smith AM, 2008, J PEDIATR-US, V152, P709, DOI 10.1016/j.jpeds.2007.10.011; Soderhall C, 2007, PLOS BIOL, V5, P1952, DOI 10.1371/journal.pbio.0050242; Spergel JM, 2005, CURR OPIN ALLERGY CL, V5, P17, DOI 10.1097/00130832-200502000-00005; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Stevenson MD, 2007, J PEDIATR-US, V151, P187, DOI 10.1016/j.jpeds.2007.03.001; Stocks J, 2014, EXPERT REV RESP MED, V8, P527, DOI 10.1586/17476348.2014.927317; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Takatsu K, 2008, CURR OPIN IMMUNOL, V20, P288, DOI 10.1016/j.coi.2008.04.001; Tamari M, 2014, J DERMATOL, V41, P213, DOI 10.1111/1346-8138.12321; Tan THT, 2012, CLIN EXP ALLERGY, V42, P20, DOI 10.1111/j.1365-2222.2011.03823.x; Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200; Tang L, 2014, GENET MOL RES, V13, P1383, DOI 10.4238/2014.February.28.11; Taylor-Black S, 2012, ANN ALLERG ASTHMA IM, V109, P431, DOI 10.1016/j.anai.2012.09.012; Taylor-Black SA, 2014, ANN ALLERG ASTHMA IM, V112, P554, DOI 10.1016/j.anai.2014.03.020; Tennessen JA, 2012, SCIENCE, V337, P64, DOI 10.1126/science.1219240; Terracciano R, 2015, PROTEOM CLIN APPL, V9, P203, DOI 10.1002/prca.201400099; Thawer-Esmail F, 2014, J ALLERGY CLIN IMMUN, V133, P280, DOI 10.1016/j.jaci.2013.09.053; Thomas DC, 2012, AM J EPIDEMIOL, V175, P203, DOI 10.1093/aje/kwr365; Thomson G, 2001, ADV GENET, V42, P475, DOI 10.1016/S0065-2660(01)42037-2; Thyssen JP, 2014, EVOL BIOL, V41, P388, DOI 10.1007/s11692-014-9282-7; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P622, DOI 10.1016/j.jaci.2012.03.045; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P76, DOI 10.1016/j.jaci.2012.02.040; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tsai HJ, 2009, CLIN EXP ALLERGY, V39, P101, DOI 10.1111/j.1365-2222.2008.03111.x; TURKELTAUB PC, 1991, ANN ALLERGY, V67, P147; Turner SW, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-107; Uhm TG, 2012, ALLERGY ASTHMA IMMUN, V4, P68, DOI 10.4168/aair.2012.4.2.68; Vachiramon V, 2012, PEDIATR DERMATOL, V29, P395, DOI 10.1111/j.1525-1470.2012.01740.x; Vafa M, 2007, MICROBES INFECT, V9, P1043, DOI 10.1016/j.micinf.2007.04.011; van Beijsterveldt CEM, 2007, EUR RESPIR J, V29, P516, DOI 10.1183/09031936.00065706; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Vercelli D, 2010, J ALLERGY CLIN IMMUN, V125, P347, DOI 10.1016/j.jaci.2009.12.976; Vergara C, 2013, GENET EPIDEMIOL, V37, P393, DOI 10.1002/gepi.21702; Vergara C, 2009, HUM GENET, V125, P565, DOI 10.1007/s00439-009-0649-2; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; Wang IJ, 2013, CLIN EXP ALLERGY, V43, P535, DOI 10.1111/cea.12108; Wechsler ME, 2011, AM J RESP CRIT CARE, V184, P1247, DOI 10.1164/rccm.201103-0514OC; Wegienka G, 2013, CURR ALLERGY ASTHM R, V13, P255, DOI 10.1007/s11882-013-0343-2; Wegienka G, 2012, ALLERGY ASTHMA PROC, V33, P493, DOI 10.2500/aap.2012.33.3600; Wei P, 2015, EUR ARCH OTO-RHINO-L, V272, P889, DOI 10.1007/s00405-014-3145-9; Wheelock CE, 2013, EUR RESPIR J, V42, P802, DOI 10.1183/09031936.00078812; Williams LK, 2008, ANN ALLERG ASTHMA IM, V100, P128, DOI 10.1016/S1081-1206(10)60421-8; Williams LK, 2006, J ALLERGY CLIN IMMUN, V118, P851, DOI 10.1016/j.jaci.2006.07.007; Williams MR, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0567-4; Willis-Owen Saffron A. G., 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000282; Winge MCG, 2011, BRIT J DERMATOL, V165, P1074, DOI 10.1111/j.1365-2133.2011.10475.x; Wolf R, 2012, CLIN DERMATOL, V30, P329, DOI 10.1016/j.clindermatol.2011.08.023; Yick CY, 2013, EUR RESPIR J, V42, P662, DOI 10.1183/09031936.00115412; Yu SQ, 2011, AM J RHINOL ALLERGY, V25, pE242, DOI 10.2500/ajra.2011.25.3682; Zhang DD, 2010, AM J HUM GENET, V86, P411, DOI 10.1016/j.ajhg.2010.02.005; Zheng T, 2011, ALLERGY ASTHMA IMMUN, V3, P67, DOI 10.4168/aair.2011.3.2.67; Zhou GQ, 2004, MOL BIOL EVOL, V21, P29, DOI 10.1093/molbev/msg231; Zhu XF, 2005, NAT GENET, V37, P177, DOI 10.1038/ng1510	312	35	38	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					676	699		10.1016/j.jaci.2016.02.045	http://dx.doi.org/10.1016/j.jaci.2016.02.045			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27297995	Green Accepted, Bronze			2022-12-18	WOS:000385496000004
J	Roux, M; Devillier, P; Yang, WH; Montagut, A; Abiteboul, K; Viatte, A; Zeldin, RK				Roux, Michel; Devillier, Philippe; Yang, William H.; Montagut, Armelle; Abiteboul, Kathy; Viatte, Agnes; Zeldin, Robert K.			Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen immunotherapy; allergic rhinitis; house dust mite; sublingual immunotherapy tablet; double-blind placebo-controlled trial; environmental exposure chamber; dose-ranging	VISUAL ANALOG SCALE; CHALLENGE CHAMBER; RHINITIS; ASTHMA; IMMUNOTHERAPY; SYMPTOMS; TRIAL	Background: In a natural field study, sublingual tablets of house dust mite (HDM) allergen extracts (STG320) were efficacious in treating HDM-associated allergic rhinitis. Objectives: We sought to assess the efficacy and safety of 3 doses of STG320 in an environmental exposure chamber. Methods: In this randomized, double-blind study, adults with HDM-associated allergic rhinitis were given a daily sublingual tablet containing placebo or STG320 at a dose of 500IR, 300IR, or 100IR (IR, index of reactivity) for 6 months. Participants recorded their rhinitis symptoms during 4-hour HDM EEC challenges at randomization and months 1, 2, 4, and 6. The primary efficacy end point was the change from baseline to end of treatment in the area under the curve of the rhinitis total symptom score (Ch(BL)AUC(RTSS 0-4h)). Differences from the placebo group were analyzed by analysis of covariance. Adverse events (AEs) and routine safety parameters were recorded. Results: A total of 355 subjects were randomized to 1 of 4 groups: 500IR(n=93), 300IR(n=86), 100IR(n=89), or placebo (n=87). The least squaresmean differences fromplacebo inCh(BL)AUC(RTSS 0-4h) for the 500IR, 300IR, and 100IR groups indicated a dosedependent effect, with reductions in symptomscores of 33%, 29%, and 20%, respectively. The most frequent AEs were throat irritation and oral pruritus. There were no reports of anaphylaxis or reports consistent with severe laryngopharyngeal disorders and no use of epinephrine. AEs leading to premature discontinuations were more common in the 500IR group. Conclusions: A dose-dependent effect of sublingual HDM immunotherapy was demonstrated in this environmental exposure chamber study, supporting further development of this treatment.	[Roux, Michel; Montagut, Armelle; Abiteboul, Kathy; Viatte, Agnes; Zeldin, Robert K.] Stallergenes SA, Antony, France; [Devillier, Philippe] Foch Hosp, Clin Res Unit, UPRES EA 220, Suresnes, France; [Yang, William H.] Allergy & Asthma Res Ctr, Ottawa, ON, Canada	Stallergenes Greer; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay	Zeldin, RK (corresponding author), Stallergenes SA, Global Clin Dev Dept, 6 Rue Alexis Tocqueville, F-92183 Antony, France.	rzeldin@stallergenes.com			Stallergenes S.A., France	Stallergenes S.A., France	This study was funded by Stallergenes S.A., France.	Baron-Bodo V, 2012, CLIN EXP ALLERGY, V42, P1510, DOI 10.1111/j.1365-2222.2012.04044.x; Bergmann KC, 2014, J ALLERGY CLIN IMMUN, V133, P1608, DOI 10.1016/j.jaci.2013.11.012; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet PJ, 2009, J ALLERGY CLIN IMMUN, V123, P1349, DOI 10.1016/j.jaci.2009.02.033; Compalati E, 2009, ALLERGY, V64, P1570, DOI 10.1111/j.1398-9995.2009.02129.x; Demoly P, 2013, CLIN EXP ALLERGY, V43, P881, DOI 10.1111/cea.12121; Devillier P, 2011, ALLERGY, V66, P163, DOI 10.1111/j.1398-9995.2010.02473.x; European Medicines Agency, 2008, CHMPEWP185042006 EUR; Food and Drug Administration, 2000, GUID IND AL IN PRESS; Gaffin JM, 2009, CURR OPIN ALLERGY CL, V9, P128, DOI 10.1097/ACI.0b013e32832678b0; Gotzsche PC, 2008, ALLERGY, V63, P646, DOI 10.1111/j.1398-9995.2008.01690.x; Horak F, 1998, ALLERGY, V53, P68, DOI 10.1111/j.1398-9995.1998.tb03775.x; Horak F, 2009, J ALLERGY CLIN IMMUN, V124, P471, DOI 10.1016/j.jaci.2009.06.006; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Nolte H, 2015, J ALLERGY CLIN IMMUN, V135; Nurmatov U, 2012, ALLERGY, V67, P158, DOI 10.1111/j.1398-9995.2011.02752.x; Patel D, 2011, J ALLERGY CLIN IMMUN, V127, pAB20, DOI 10.1016/j.jaci.2010.12.091; Rosner-Friese K, 2015, J ALLERGY CLIN IMMUN, V135, P636, DOI 10.1016/j.jaci.2014.10.045; Rolla G, 2007, CHEST, V131, P1345, DOI 10.1378/chest.06-2618; Ronborg SM, 1997, ALLERGY, V52, P821, DOI 10.1111/j.1398-9995.1997.tb02153.x; Sheikh A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001563.pub3; Stubner P, 2004, CURR MED RES OPIN, V20, P891, DOI 10.1185/030079904125003700; Thomas WR, 2012, HUM VACC IMMUNOTHER, V8, P1469, DOI 10.4161/hv.20812	23	35	36	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					451	+		10.1016/j.jaci.2016.03.039	http://dx.doi.org/10.1016/j.jaci.2016.03.039			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27289490	Bronze			2022-12-18	WOS:000380835800015
J	Dupin, I; Allard, B; Ozier, A; Maurat, E; Ousova, O; Delbrel, E; Trian, T; Bui, HN; Dromer, C; Guisset, O; Blanchard, E; Hilbert, G; Vargas, F; Thumerel, M; Marthan, R; Girodet, PO; Berger, P				Dupin, Isabelle; Allard, Benoit; Ozier, Annaig; Maurat, Elise; Ousova, Olga; Delbrel, Eva; Trian, Thomas; Hoang-Nam Bui; Dromer, Claire; Guisset, Olivier; Blanchard, Elodie; Hilbert, Gilles; Vargas, Frederic; Thumerel, Matthieu; Marthan, Roger; Girodet, Pierre-Olivier; Berger, Patrick			Blood fibrocytes are recruited during acute exacerbations of chronic obstructive pulmonary disease through a CXCR4-dependent pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic obstructive pulmonary disease; fibrocyte; mortality; lung function; chemotaxis	CIRCULATING FIBROCYTES; ACUTE ASTHMA; CELLS; IDENTIFICATION; INFECTION; PROGNOSIS; MORTALITY; RISK	Background: Chronic obstructive pulmonary disease (COPD) is characterized by peribronchial fibrosis. The chronic course of COPD is worsened by recurrent acute exacerbations. Objective: The aim of the study was to evaluate the recruitment of blood fibrocytes in patients with COPD during exacerbations and, subsequently, to identify potential mechanisms implicated in such recruitment. Methods: Using flow cytometry, we quantified circulating fibrocytes and characterized their chemokine receptor expression in 54 patients with COPD examined during an acute exacerbation (V1) and 2 months afterward (V2) and in 40 control subjects. The role of the chemokines CXCL12 and CCL11 in fibrocyte migration was investigated by using a chemotaxis assay. Patients were followed for up to 3 years after V1. Results: We demonstrated a significantly increased number of circulating fibrocytes at V1 compared with control subjects. The number of circulating fibrocytes decreased at V2. A high percentage of circulating fibrocytes during exacerbation was associated with increased risk of death. The percentage of fibrocytes at V2 was negatively correlated with FEV1, forced vital capacity, FEV1/forced vital capacity ratio, transfer lung capacity of carbon monoxide, and PaO2. Fibrocytes highly expressed CXCR4 and CCR3, the chemokine receptors for CXCL12 and CCL11, respectively. Fibrocytes collected from patients with COPD at V1 had increased chemotactic migration in response to CXCL12 but not to CCL11 compared with those from control subjects. Plerixafor, a CXCR4 antagonist, decreased fibrocyte migration to plasma from patients with exacerbating COPD. Conclusion: Blood fibrocytes are recruited during COPD exacerbations and related to mortality and low lung function. The CXCL12/CXCR4 axis is involved in such fibrocyte recruitment (Firebrob study; ClinicalTrials NCT01196832).	[Dupin, Isabelle; Allard, Benoit; Ozier, Annaig; Maurat, Elise; Ousova, Olga; Delbrel, Eva; Trian, Thomas; Thumerel, Matthieu; Marthan, Roger; Girodet, Pierre-Olivier; Berger, Patrick] Univ Bordeaux, 146 Rue Leo Saignat, F-33076 Bordeaux, France; [Dupin, Isabelle; Allard, Benoit; Ozier, Annaig; Maurat, Elise; Ousova, Olga; Delbrel, Eva; Trian, Thomas; Thumerel, Matthieu; Marthan, Roger; Girodet, Pierre-Olivier; Berger, Patrick] INSERM, U1045, Ctr Rech Cardiothorac Bordeaux, Dept Pharmacol, Bordeaux, France; [Ozier, Annaig; Hoang-Nam Bui; Dromer, Claire; Guisset, Olivier; Blanchard, Elodie; Hilbert, Gilles; Vargas, Frederic; Thumerel, Matthieu; Marthan, Roger; Girodet, Pierre-Olivier; Berger, Patrick] CHU Bordeaux, Serv Explorat Fonct Resp, Serv Pneumol, Serv Reanimat Med,Serv Chirurg Thorac, Pessac, France	UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux	Dupin, I (corresponding author), Univ Bordeaux, INSERM, U1045, Ctr Rech Cardiothorac Bordeaux, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	isabelle.dupin@u-bordeaux.fr; patrick.berger@u-bordeaux.fr	Berger, Patrick/D-8779-2012; Dupin, Isabelle/ABE-7780-2020	Berger, Patrick/0000-0003-4702-0343; Dupin, Isabelle/0000-0002-4992-9625; Girodet, Pierre-Olivier/0000-0002-9298-9711; Marthan, Roger/0000-0001-5412-5712; Blanchard, Elodie/0000-0001-5445-9122; thumerel, matthieu/0000-0003-4673-8433; Allard, Benoit/0000-0002-7093-5851; HILBERT, Gilles/0000-0003-3547-1753; trian, thomas/0000-0002-2567-4867	Bordeaux University Hospital (ie, CHU de Bordeaux); Nycomed; Takeda; Fondation du Souffle-Fonds de dotation Recherche en Sante Respiratoire [SR2013-021]	Bordeaux University Hospital (ie, CHU de Bordeaux); Nycomed; Takeda(Takeda Pharmaceutical Company Ltd); Fondation du Souffle-Fonds de dotation Recherche en Sante Respiratoire	Sponsored by Bordeaux University Hospital (ie, CHU de Bordeaux) and supported by 3 grants from Nycomed, Takeda, and Fondation du Souffle-Fonds de dotation Recherche en Sante Respiratoire (grant no. SR2013-021).	Bara I, 2012, AM J RESP CRIT CARE, V185, P715, DOI 10.1164/rccm.201105-0915OC; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Celli BR, 2012, AM J RESP CRIT CARE, V185, P1065, DOI 10.1164/rccm.201110-1792OC; De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134; Dournes G, 2015, AM J RESP CRIT CARE, V191, P63, DOI 10.1164/rccm.201408-1423OC; Gao P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057678; George SN, 2014, EUR RESPIR J, V44, P87, DOI 10.1183/09031936.00223113; GOLD, GLOB STRAT DIAGN MAN; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mehrad B, 2007, BIOCHEM BIOPH RES CO, V353, P104, DOI 10.1016/j.bbrc.2006.11.149; Moeller A, 2009, AM J RESP CRIT CARE, V179, P588, DOI 10.1164/rccm.200810-1534OC; Piquet J, 2013, EUR RESPIR J, V42, P946, DOI 10.1183/09031936.00180312; Reilkoff RA, 2011, NAT REV IMMUNOL, V11, P427, DOI 10.1038/nri2990; Schmidt M, 2003, J IMMUNOL, V171, P380, DOI 10.4049/jimmunol.171.1.380; Sehmi R, 2003, IMMUNOLOGY, V109, P536, DOI 10.1046/j.1365-2567.2003.01686.x; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; Trimble A, 2014, AM J RESP CRIT CARE, V190, P1395, DOI 10.1164/rccm.201407-1287OC; Wang CH, 2008, AM J RESP CRIT CARE, V178, P583, DOI 10.1164/rccm.200710-1557OC; Wang CH, 2015, J ALLERGY CLIN IMMUN, V135, P1154, DOI 10.1016/j.jaci.2014.09.011; Wark PAB, 2013, RESPIROLOGY, V18, P996, DOI 10.1111/resp.12099; Wedzicha JA, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-181; White JR, 2000, J BIOL CHEM, V275, P36626, DOI 10.1074/jbc.M006613200; Wysoczynski M, 2005, BLOOD, V105, P40, DOI 10.1182/blood-2004-04-1430; Yeager ME, 2012, EUR RESPIR J, V39, P104, DOI 10.1183/09031936.00072311	27	35	39	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1036	+		10.1016/j.jaci.2015.08.043	http://dx.doi.org/10.1016/j.jaci.2015.08.043			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26602164	Bronze			2022-12-18	WOS:000373351200009
J	Hoffman, SM; Chapman, DG; Lahue, KG; Cahoon, JM; Rattu, GK; Daphtary, N; Aliyeva, M; Fortner, KA; Erzurum, SC; Comhair, SAA; Woodruff, PG; Bhakta, N; Dixon, AE; Irvin, CG; Janssen-Heininger, YMW; Poynter, ME; Anathy, V				Hoffman, Sidra M.; Chapman, David G.; Lahue, Karolyn G.; Cahoon, Jonathon M.; Rattu, Gurkiranjit K.; Daphtary, Nirav; Aliyeva, Minara; Fortner, Karen A.; Erzurum, Serpil C.; Comhair, Suzy A. A.; Woodruff, Prescott G.; Bhakta, Nirav; Dixon, Anne E.; Irvin, Charles G.; Janssen-Heininger, Yvonne M. W.; Poynter, Matthew E.; Anathy, Vikas			Protein disulfide isomerase-endoplasmic reticulum resident protein 57 regulates allergen-induced airways inflammation, fibrosis, and hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Unfolded protein response; endoplasmic reticulum stress; asthma; house dust mite; protein disulfide isomerase; endoplasmic reticulum protein 57; recombination-activating gene 1; epithelium; airways hyperresponsiveness	HOUSE-DUST MITE; KAPPA-B ACTIVATION; EPITHELIAL-CELLS; ER STRESS; ASTHMA; DISEASE; APOPTOSIS; PATHOGENESIS; MICE; LUNG	Background: Evidence for association between asthma and the unfolded protein response is emerging. Endoplasmic reticulum resident protein 57 (ERp57) is an endoplasmic reticulum-localized redox chaperone involved in folding and secretion of glycoproteins. We have previously demonstrated that ERp57 is upregulated in allergen-challenged human and murine lung epithelial cells. However, the role of ERp57 in asthma pathophysiology is unknown. Objectives: Here we sought to examine the contribution of airway epithelium-specific ERp57 in the pathogenesis of allergic asthma. Methods: We examined the expression of ERp57 in human asthmatic airway epithelium and used murine models of allergic asthma to evaluate the relevance of epithelium-specific ERp57. Results: Lung biopsy specimens from asthmatic and nonasthmatic patients revealed a predominant increase in ERp57 levels in epithelium of asthmatic patients. Deletion of ERp57 resulted in a significant decrease in inflammatory cell counts and airways resistance in a murine model of allergic asthma. Furthermore, we observed that disulfide bridges in eotaxin, epidermal growth factor, and periostin were also decreased in the lungs of house dust mite-challenged ERp57-deleted mice. Fibrotic markers, such as collagen and alpha smooth muscle actin, were also significantly decreased in the lungs of ERp57-deleted mice. Furthermore, adaptive immune responses were dispensable for house dust mite-induced endoplasmic reticulum stress and airways fibrosis. Conclusions: Here we show that ERp57 levels are increased in the airway epithelium of asthmatic patients and in mice with allergic airways disease. The ERp57 level increase is associated with redox modification of proinflammatory, apoptotic, and fibrotic mediators and contributes to airways hyperresponsiveness. The strategies to inhibit ERp57 specifically within the airways epithelium might provide an opportunity to alleviate the allergic asthma phenotype.	[Hoffman, Sidra M.; Lahue, Karolyn G.; Janssen-Heininger, Yvonne M. W.; Anathy, Vikas] Univ Vermont, Coll Med, Dept Pathol & Lab Med, HSRF 218,149 Beaumont Ave, Burlington, VT 05405 USA; [Chapman, David G.; Daphtary, Nirav; Aliyeva, Minara; Fortner, Karen A.; Dixon, Anne E.; Irvin, Charles G.; Poynter, Matthew E.] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA; [Cahoon, Jonathon M.; Rattu, Gurkiranjit K.] Univ Vermont, Dept Biol, Burlington, VT 05405 USA; [Erzurum, Serpil C.; Comhair, Suzy A. A.] Cleveland Clin, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44106 USA; [Woodruff, Prescott G.; Bhakta, Nirav] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Chapman, David G.] Univ Sydney, Sydney Med Sch, Woolcock Inst Med Res, Sydney, NSW 2006, Australia	University of Vermont; University of Vermont; University of Vermont; Cleveland Clinic Foundation; University of California System; University of California San Francisco; University of Sydney; Woolcock Institute of Medical Research	Anathy, V (corresponding author), Univ Vermont, Coll Med, Dept Pathol & Lab Med, HSRF 218,149 Beaumont Ave, Burlington, VT 05405 USA.	Vikas.anathy@med.uvm.edu		Poynter, Matthew/0000-0002-7578-4570; Chapman, David/0000-0002-8211-1817	National Institutes of Health (NIH) [R01HL122383]; Parker B. Francis Fellowship; American Thoracic Society; AAFA-Sheldon C. Siegel award; UVM-College of Medicine; NIH [R01HL079331, HL103453, HL081064]; national Health and Medical Research Council of Australia [1053790]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL116657, P01HL103453, R01HL122383, R01HL060014, R01HL085464, U10HL109250, P01HL081064, R01HL079331, R24HL123767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103532, P20GM103496] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parker B. Francis Fellowship; American Thoracic Society; AAFA-Sheldon C. Siegel award; UVM-College of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); national Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health (NIH) grant R01HL122383, a Parker B. Francis Fellowship, and American Thoracic Society unrestricted grant, the AAFA-Sheldon C. Siegel award, the UVM-College of Medicine Internal Grant Program to V.A. and NIH grant R01HL079331 to Y.M.W.J.-H. D.G.C. is a recipient of a CJ Martin Fellowship from the national Health and Medical Research Council of Australia (1053790). S.C.E. and S.A.A.C. are supported by NIH grants HL103453 and HL081064.	Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Ather JL, 2011, AM J RESP CELL MOL, V44, P631, DOI 10.1165/rcmb.2010-0106OC; Bates JHT, 2008, AM J RESP CRIT CARE, V177, P261, DOI 10.1164/rccm.200706-832OC; Bentley JK, 2014, J ALLERGY CLIN IMMUN, V134, P1433, DOI 10.1016/j.jaci.2014.05.029; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Chen G, 2009, J CLIN INVEST, V119, P2914, DOI 10.1172/JCI39731; Davies Donna E, 2009, Proc Am Thorac Soc, V6, P678, DOI 10.1513/pats.200907-067DP; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Garbi N, 2006, NAT IMMUNOL, V7, P93, DOI 10.1038/ni1288; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Grillo C, 2006, FREE RADICAL BIO MED, V41, P1113, DOI 10.1016/j.freeradbiomed.2006.06.016; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Hoffman SM, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-141; Hoffstrom BG, 2010, NAT CHEM BIOL, V6, P900, DOI 10.1038/NCHEMBIO.467; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P37; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate Stephen T, 2009, Proc Am Thorac Soc, V6, P655, DOI 10.1513/pats.200907-072DP; Holtzman MJ, 2014, NAT REV IMMUNOL, V14, P686, DOI 10.1038/nri3739; James AL, 2012, AM J RESP CRIT CARE, V185, P1058, DOI 10.1164/rccm.201110-1849OC; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Korfei M, 2008, AM J RESP CRIT CARE, V178, P838, DOI 10.1164/rccm.200802-313OC; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lan RS, 2002, PHARMACOL THERAPEUT, V95, P239, DOI 10.1016/S0163-7258(02)00237-1; Lawson WE, 2011, P NATL ACAD SCI USA, V108, P10562, DOI 10.1073/pnas.1107559108; Le Cras TD, 2011, AM J PHYSIOL-LUNG C, V300, pL414, DOI 10.1152/ajplung.00346.2010; Lundblad LKA, 2007, AM J RESP CRIT CARE, V175, P768, DOI 10.1164/rccm.200610-1410OC; Martino MB, 2013, MUCOSAL IMMUNOL, V6, P639, DOI 10.1038/mi.2012.105; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Noble PB, 2012, J ALLERGY CAIRO, V2012; Ono Y, 2013, BIOCHEM BIOPH RES CO, V434, P904, DOI 10.1016/j.bbrc.2013.04.055; Oyeniran C, 2015, J ALLERGY CLIN IMMUN, V136, P1035, DOI 10.1016/j.jaci.2015.02.031; Park SW, 2009, P NATL ACAD SCI USA, V106, P6950, DOI 10.1073/pnas.0808722106; Perl AKT, 2005, AM J RESP CELL MOL, V33, P455, DOI 10.1165/rcmb.2005-0180OC; Perl AK, 2009, AM J RESP CELL MOL, V40, P1, DOI 10.1165/rcmb.2008-0011ED; Poynter ME, 2004, J IMMUNOL, V173, P7003, DOI 10.4049/jimmunol.173.11.7003; Rate A, 2009, J IMMUNOL, V182, P72, DOI 10.4049/jimmunol.182.1.72; Ryu JH, 2013, J ALLERGY CLIN IMMUN, V131, P549, DOI 10.1016/j.jaci.2012.07.050; Schatz DG, 2011, NAT REV IMMUNOL, V11, P251, DOI 10.1038/nri2941; Schroeder BW, 2012, AM J RESP CELL MOL, V47, P178, DOI 10.1165/rcmb.2011-0421OC; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Turano C, 2011, CELL MOL BIOL LETT, V16, P539, DOI 10.2478/s11658-011-0022-z; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhao GP, 2015, J BIOL CHEM, V290, P8949, DOI 10.1074/jbc.M114.619353	48	35	36	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					822	+		10.1016/j.jaci.2015.08.018	http://dx.doi.org/10.1016/j.jaci.2015.08.018			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26435004	Green Accepted, Bronze			2022-12-18	WOS:000371897500026
J	Shipe, R; Burdick, MD; Strieter, BA; Liu, L; Shim, YM; Sung, SS; Teague, WG; Mehrad, B; Strieter, RM; Rose, CE				Shipe, Ryan; Burdick, Marie D.; Strieter, Brett A.; Liu, Ling; Shim, Yun Michael; Sung, Sun-sang; Teague, W. Gerald; Mehrad, Borna; Strieter, Robert M.; Rose, C. Edward, Jr.			Number, activation, and differentiation of circulating fibrocytes correlate with asthma severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma severity; fibrocytes; peripheral blood; biomarker	AIR-FLOW OBSTRUCTION; PULMONARY-FIBROSIS; PERIPHERAL-BLOOD; REFERENCE VALUES; GROWTH; CELLS; INVOLVEMENT; POPULATION; EXPRESSION; PROGNOSIS	Background: A biomarker that predicts poor asthma control would be clinically useful. Fibrocytes are bone marrow-derived circulating progenitor cells that have been implicated in tissue fibrosis and T(H)2 responses in asthmatic patients. Objective: We sought to test the hypothesis that the concentration and activation state of peripheral blood fibrocytes correlates with asthma severity. Methods: By using fluorescence-activated cell sorting analysis, fibrocytes (CD45(+) and collagen(+) [Col1](+)) were enumerated and characterized in the buffy coats of fresh peripheral blood samples from+5 control subjects and 40 asthmatic patients. Results: Concentrations of peripheral blood total (CD45(+)Col1(+)), activated (the TGF-beta transducing protein phosphorylated SMAD2/3 [p-SMAD2/3](+) or phosphorylated AKT [p-AKT]1), and differentiated (alpha-smooth muscle actin [alpha-SMA](+)) fibrocytes were increased in asthmatic patients compared with control subjects. The increase in total and CD45(+)Col1(+)CXCR4(+) fibrocytes was primarily seen in patients with severe asthma (Global Initiative for Asthma steps 4-5) as opposed to those with milder asthma (Global Initiative for Asthma steps 1-3). In addition, numbers of circulating alpha-SMA(+) and alpha-SMA(+)CXCR4(+) fibrocytes were increased in asthmatic patients experiencing an asthma exacerbation in the preceding 12 months. Asignificant correlation (P <. 05) was observed between CD45(+)Col1(+) CXCR4(+) fibrocytes and the activation phenotypes CD45(+)Col1(+)p-SMAD2/3(+) and CD45(+)Col1(+)p-AKT(+). Conclusion: There was correlation between circulating fibrocyte subsets and asthma severity, and there was an increased number of activated/differentiated fibrocytes in circulating blood of asthmatic patients experiencing an exacerbation in the preceding+2 months.	[Shipe, Ryan; Burdick, Marie D.; Strieter, Brett A.; Liu, Ling; Shim, Yun Michael; Sung, Sun-sang; Mehrad, Borna; Strieter, Robert M.; Rose, C. Edward, Jr.] Univ Virginia, Sch Med, Dept Med, Div Pulm & Crit Care Med, Charlottesville, VA 22908 USA; [Teague, W. Gerald] Univ Virginia, Sch Med, Dept Pediat, Div Pulm, Charlottesville, VA 22908 USA; [Strieter, Robert M.] Novartis Inst Biomed Res, Cambridge, MA USA	University of Virginia; University of Virginia; Novartis	Rose, CE (corresponding author), Univ Virginia Hlth Syst, Div Pulm & Crit Care Med, Box 800546, Charlottesville, VA 22908 USA.	cer@virginia.edu	Mehrad, Borna/AAC-9876-2019; Mehrad, Borna/D-9363-2015; Mehrad, Borna/G-2659-2010; Shim, Yun Michael/N-2049-2017	Mehrad, Borna/0000-0001-5198-065X; Mehrad, Borna/0000-0001-5198-065X; Shim, Yun Michael/0000-0002-3780-3371	Novartis Institute for Biomedical Research; National Institutes of Health [HL098526, HL098329, IA117397]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL098329, R01HL132287, R01HL132177, R01HL098526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI117397] Funding Source: NIH RePORTER	Novartis Institute for Biomedical Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from Novartis Institute for Biomedical Research and National Institutes of Health grants HL098526 ( to R. M. S., B. M., and C. E. R.), HL098329 ( to B. M.), and IA117397 ( to B.M.).	Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; Aiba S, 1997, J CUTAN PATHOL, V24, P65; [Anonymous], 2015, GLOB STRAT ASTHM MAN; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bellini A, 2012, MUCOSAL IMMUNOL, V5, P140, DOI 10.1038/mi.2011.60; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; Chae EJ, 2011, ALLERGY ASTHMA IMMUN, V3, P111, DOI 10.4168/aair.2011.3.2.111; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Curran-Everett D, 2000, AM J PHYSIOL-REG I, V279, pR1, DOI 10.1152/ajpregu.2000.279.1.R1; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Grinnan D, 2006, J ALLERGY CLIN IMMUN, V118, P1234, DOI 10.1016/j.jaci.2006.07.036; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hong KM, 2007, J BIOL CHEM, V282, P22910, DOI 10.1074/jbc.M703597200; Hung C, 2013, AM J RESP CRIT CARE, V188, P820, DOI 10.1164/rccm.201212-2297OC; Isgro M, 2013, BIOCHEM BIOPH RES CO, V437, P446, DOI 10.1016/j.bbrc.2013.06.099; Lo CY, 2015, J ALLERGY CLIN IMMUN, V135, P1186, DOI 10.1016/j.jaci.2014.10.031; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Moeller A, 2009, AM J RESP CRIT CARE, V179, P588, DOI 10.1164/rccm.200810-1534OC; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Peng SB, 2005, MOL CANCER RES, V3, P227; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Quan TE, 2004, INT J BIOCHEM CELL B, V36, P598, DOI 10.1016/j.biocel.2003.10.005; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; *SAS I, 1987, SAS STAT GUID PERS C; Saunders R, 2009, J ALLERGY CLIN IMMUN, V123, P376, DOI 10.1016/j.jaci.2008.10.048; Schmidt M, 2003, J IMMUNOL, V171, P380, DOI 10.4049/jimmunol.171.1.380; Song N, 2009, CANCER RES, V69, P6057, DOI 10.1158/0008-5472.CAN-08-2007; Trimble A, 2014, AM J RESP CRIT CARE, V190, P1395, DOI 10.1164/rccm.201407-1287OC; U.S. Department of Health & Human Services - Centers for Disease Control and Prevention: National Surveillance of Asthma: United States, 2001, DHSS PUBL, V2013-1419; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; Wang CH, 2008, AM J RESP CRIT CARE, V178, P583, DOI 10.1164/rccm.200710-1557OC; Wang CH, 2012, J ALLERGY CLIN IMMUN, V129, P1367, DOI 10.1016/j.jaci.2012.01.038; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8	37	35	37	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					750	+		10.1016/j.jaci.2015.07.037	http://dx.doi.org/10.1016/j.jaci.2015.07.037			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26371837	Green Accepted, Bronze			2022-12-18	WOS:000371897500017
J	Chaker, AM; Shamji, MH; Dumitru, FA; Calderon, MA; Scadding, GW; Makatsori, M; Jones, I; He, QA; Subramanian, KK; Arm, JP; Durham, SR; Schmidt-Weber, CB				Chaker, Adam M.; Shamji, Mohamed H.; Dumitru, Florentina A.; Calderon, Moises A.; Scadding, Guy W.; Makatsori, Melina; Jones, Ieuan; He, Qiuling A.; Subramanian, Kulandayan K.; Arm, Jonathan P.; Durham, Stephen R.; Schmidt-Weber, Carsten B.			Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; subcutaneous allergen immunotherapy; anti-IL-4; FluoroSpot; intradermal late-phase response	T-CELL CLONES; ALLERGIC DISEASE; B-CELLS; RESPONSES; INDUCTION; INTERLEUKIN-4; EXPRESSION; ASTHMA; IL-10; IGE	Background: Allergen immunotherapy is currently the only disease-modifying treatment available for allergic rhinitis and allergic asthma. Objectives: We sought to evaluate the induction of sustained tolerance to allergen when anti-IL-4 was combined with a suboptimal course of grass pollen subcutaneous immunotherapy (SCIT) using the allergen-induced skin late-phase response (LPR) and exploratory immune monitoring as surrogate markers of therapeutic response. Methods: In this randomized, double-blind, 3-group parallel design trial, 37 participants with seasonal allergic rhinitis received suboptimal SCIT (30,000 standardized quality units) in combination with anti-IL-4 (VAK694) and suboptimal SCIT (30,000 standardized quality units) plus placebo antibody or double placebo (placebo SCIT and placebo antibody) restricted to 13 weeks before the grass pollen season. The primary end point was the size of the LPR at 12 months. Exploratory end points included measures of the immunomodulatory activity of treatment by using IL-4 and IL-10 FluoroSpot assays, flow cytometry of T cells, and measurement of IgE, IgG(4), and facilitated antigen binding. Results: Both active treatment arms led to a substantial and sustained reduction of the LPR with no additional suppression with addition of anti-IL-4. Treatment with anti-IL-4 and SCIT compared with SCIT alone led to a sustained reduction in allergen-specific IL-4-producing cell counts (P<.01). Both active treatment arms led to induction of dual IL-4/IL-10-producing cells during the pollen season. Conclusion: The combination of anti-IL-4 with SCIT provided no additional benefit over SCIT alone in suppressing the allergen-induced skin LPR. A larger trial is needed to assess whether the observed ex vivo downregulation of T(H)2 responses might translate into clinical benefit.	[Chaker, Adam M.; Shamji, Mohamed H.; Dumitru, Florentina A.; Calderon, Moises A.; Scadding, Guy W.; Makatsori, Melina; Durham, Stephen R.; Schmidt-Weber, Carsten B.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Allergy & Clin Immunol, London SW7 2AZ, England; [Shamji, Mohamed H.; Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Immunomodulat & Tolerance Grp, Allergy & Clin Immunol, London SW7 2AZ, England; [Jones, Ieuan; He, Qiuling A.; Subramanian, Kulandayan K.; Arm, Jonathan P.] Novartis Inst Biomed Res, Cambridge, MA USA; [Jones, Ieuan; He, Qiuling A.; Subramanian, Kulandayan K.; Arm, Jonathan P.] Novartis Inst Biomed Res, Basel, Switzerland; [Chaker, Adam M.; Schmidt-Weber, Carsten B.] Tech Univ Munich, Ctr Allergy & Environm ZAUM, D-80802 Munich, Germany; [Chaker, Adam M.; Schmidt-Weber, Carsten B.] Helmholtz Ctr Munich, D-80802 Munich, Germany; [Chaker, Adam M.] Tech Univ Munich, Klinikum Rechts Isar, Dept Otolaryngol, Allergy Sect, D-80802 Munich, Germany	Imperial College London; Imperial College London; Novartis; Novartis; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Schmidt-Weber, CB (corresponding author), Tech Univ Munich, Ctr Allergy & Environm ZAUM, D-80802 Munich, Germany.; Schmidt-Weber, CB (corresponding author), Helmholtz Ctr Munich, D-80802 Munich, Germany.	csweber@tum.de	Schmidt-Weber, Carsten B./AAU-1621-2021; Shamji, Mohamed/AAD-1788-2019; Shamji, Mohamed/AAU-8811-2020	Schmidt-Weber, Carsten B./0000-0002-3203-8084; Shamji, Mohamed/0000-0003-3425-3463; Chaker, Adam/0000-0002-5117-4073	Novartis [CVAK694 A2205]	Novartis(Novartis)	Supported by Novartis (CVAK694 A2205).	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Burgler S, 2010, J IMMUNOL, V184, P6161, DOI 10.4049/jimmunol.0903243; Burgler S, 2009, J ALLERGY CLIN IMMUN, V123, P588, DOI 10.1016/j.jaci.2008.12.017; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Crawley AM, 2010, EUR J IMMUNOL, V40, P1396, DOI 10.1002/eji.200940093; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Faustino L, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/721817; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kanno Y, 2012, ANNU REV IMMUNOL, V30, P707, DOI 10.1146/annurev-immunol-020711-075058; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Mantel PY, 2006, J IMMUNOL, V176, P3593, DOI 10.4049/jimmunol.176.6.3593; Mantel PY, 2007, PLOS BIOL, V5, P2847, DOI 10.1371/journal.pbio.0050329; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Ouaked N, 2009, J IMMUNOL, V182, P1041, DOI 10.4049/jimmunol.182.2.1041; Quapp R, 2007, BIOCHEM BIOPH RES CO, V363, P948, DOI 10.1016/j.bbrc.2007.09.076; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Stott B, 2013, J ALLERGY CLIN IMMUN, V132, P446, DOI 10.1016/j.jaci.2013.03.050; Strombeck A, 2014, CLIN EXP ALLERGY, V44, P940, DOI 10.1111/cea.12290; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Wachholz PA, 2003, CLIN EXP ALLERGY, V33, P1171, DOI 10.1046/j.1365-2222.2003.01765.x; Wambre E, 2014, J ALLERGY CLIN IMMUN, V133, P872, DOI 10.1016/j.jaci.2013.10.054	39	35	37	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					452	+		10.1016/j.jaci.2015.08.046	http://dx.doi.org/10.1016/j.jaci.2015.08.046			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26531865	Bronze			2022-12-18	WOS:000369235500014
J	Mueller, GA; Pedersen, LC; Glesner, J; Edwards, LL; Zakzuk, J; London, RE; Arruda, LK; Chapman, MD; Caraballo, L; Pomes, A				Mueller, Geoffrey A.; Pedersen, Lars C.; Glesner, Jill; Edwards, Lori L.; Zakzuk, Josefina; London, Robert E.; Arruda, L. Karla; Chapman, Martin D.; Caraballo, Luis; Pomes, Anna			Analysis of glutathione S-transferase allergen cross-reactivity in a North American population: Relevance for molecular diagnosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cockroach; house dust mite; helminth; glutathione S-transferases (GST); cross-reactivity; diagnosis	HOUSE-DUST-MITE; IGE ANTIBODY-RESPONSES; GERMAN-COCKROACH; DERMATOPHAGOIDES-PTERONYSSINUS; ASCARIS-LUMBRICOIDES; BLOMIA-TROPICALIS; ASTHMA; IDENTIFICATION; SENSITIZATION; EXPOSURE	Background: It is not clear whether cross-reactivity or cosensitization to glutathione S-transferases (GSTs) occurs in tropical and subtropical environments. In the United States, Bla g 5 is the most important GST allergen and lack of coexposure to GSTs from certain species allows a better assessment of cross-reactivity. Objectives: To examine the molecular structure of GST allergens from cockroach (Bla g 5), dust mites (Der p 8 and Blo t 8), and helminth (Asc s 13) for potential cross-reactive sites, and to assess the IgE cross-reactivity of sensitized patients from a temperate climate for these allergens for molecular diagnostic purposes. Methods: Four crystal structures were determined. Sera from patients allergic to cockroach and mite were tested for IgE reactivity to these GSTs. A panel of 6 murine anti-Bla g 5 mAb was assessed for cross-reactivity with the other 3 GSTs using antibody binding assays. Results: Comparisons of the allergen structures, formed by 2-domain monomers that dimerize, revealed few contiguous regions of similar exposed residues, rendering cross-reactivity unlikely. Accordingly, anti-Bla g 5 or anti-Der p 8 IgE from North American patients did not recognize Der p 8 or Bla g 5, respectively, and neither showed binding to Blo t 8 or Asc s 13. A weaker binding of anti-Bla g 5 IgE to Der p 8 versus Bla g 5 (similar to 100-fold) was observed by inhibition assays, similar to a weak recognition of Der p 8 by anti-Bla g 5 mAb. Patients from tropical Colombia had IgE to all 4 GSTs. Conclusions: The lack of significant IgE cross-reactivity among the 4 GSTs is in agreement with the low shared amino acid identity at the molecular surface. Each GST is needed for accurate molecular diagnosis in different geographic areas.	[Mueller, Geoffrey A.; Pedersen, Lars C.; Edwards, Lori L.; London, Robert E.] NIEHS, Genome Integr & Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; [Glesner, Jill; Chapman, Martin D.; Pomes, Anna] Indoor Biotechnol Inc, Charlottesville, VA 22903 USA; [Zakzuk, Josefina; Caraballo, Luis] Univ Cartagena, Inst Immunol Res, Cartagena, Colombia; [Zakzuk, Josefina; Caraballo, Luis] Fdn Dev Med & Biol Sci, Cartagena, Colombia; [Arruda, L. Karla] Univ Sao Paulo, Ribeirao Preto Med Sch, Sao Paulo, Brazil	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); INDOOR Biotechnologies; Universidad de Cartagena; Universidade de Sao Paulo	Pomes, A (corresponding author), Indoor Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA.	apomes@inbio.com	Pedersen, Lars/C-6173-2019; Mueller, Geoffrey A/I-2909-2017; Pomés, Anna/H-7010-2019; London, Robert E/F-7990-2019; Arruda, L. Karla/D-5845-2013	Pedersen, Lars/0000-0002-4488-4077; Mueller, Geoffrey A/0000-0001-8361-5323; Pomés, Anna/0000-0002-8729-1829; London, Robert E/0000-0001-9108-8463; Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632; Zakzuk, Josefina/0000-0002-6007-5376	National Institute of Environmental Health Sciences, National Institutes of Health [Z01- ES102885-01, ZIA- ES102645]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI077653]; US Department of Energy, Office of Science, Office of Basic Energy Sciences [W-31-109-Eng-38]; Administrative Department of Science, Technology and Innovation (Colciencias) (Colombia) [406-2011, 201-2015]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES102645, ZIAES102906] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); US Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); Administrative Department of Science, Technology and Innovation (Colciencias) (Colombia); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health (Research Project nos. Z01- ES102885-01 to R.E.L. and ZIA- ES102645 to L.C.P.), and in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (under Award no. R01AI077653 to A.P. and M.D.C.). Use of the Advance Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences (contract no. W-31-109-Eng-38). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research was also supported by the Administrative Department of Science, Technology and Innovation (Colciencias) Contract 406-2011 and 201-2015 (Colombia).	Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Aalberse Rob C, 2007, Clin Mol Allergy, V5, P2, DOI 10.1186/1476-7961-5-2; Acevedo N, 2011, PARASITE IMMUNOL, V33, P309, DOI 10.1111/j.1365-3024.2011.01288.x; Acevedo N, 2009, ALLERGY, V64, P1635, DOI 10.1111/j.1398-9995.2009.02084.x; Acevedo N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078353; Agianian B, 2003, J MOL BIOL, V326, P151, DOI 10.1016/S0022-2836(02)01327-X; Arruda LK, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0428-6; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1997, AM J RESP CRIT CARE, V155, P343, DOI 10.1164/ajrccm.155.1.9001334; BUTLER JE, 1992, J IMMUNOL METHODS, V150, P77, DOI 10.1016/0022-1759(92)90066-3; Chew FT, 1999, CLIN EXP ALLERGY, V29, P982, DOI 10.1046/j.1365-2222.1999.00543.x; Chruszcz M, 2012, J BIOL CHEM, V287, P7388, DOI 10.1074/jbc.M111.311159; Chruszcz M, 2009, J MOL BIOL, V386, P520, DOI 10.1016/j.jmb.2008.12.049; Cooper PJ, 2009, CURR OPIN ALLERGY CL, V9, P29, DOI 10.1097/ACI.0b013e32831f44a6; Ghosh D, 2014, J BIOL CHEM, V289, P21374, DOI 10.1074/jbc.M114.559971; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hales BJ, 2006, J ALLERGY CLIN IMMUN, V118, P361, DOI 10.1016/j.jaci.2006.04.001; Hasegawa H, 2009, CURR OPIN STRUC BIOL, V19, P341, DOI 10.1016/j.sbi.2009.04.003; Huang CH, 2006, CLIN EXP ALLERGY, V36, P369, DOI 10.1111/j.1365-2222.2006.02447.x; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Jeong KY, 2009, INT ARCH ALLERGY IMM, V148, P59, DOI 10.1159/000151506; Kuo IC, 2003, J ALLERGY CLIN IMMUN, V111, P603, DOI 10.1067/mai.2003.167; Liao EC, 2013, CLIN VACCINE IMMUNOL, V20, P506, DOI 10.1128/CVI.00633-12; Liebau E, 1997, BIOCHEM J, V324, P659, DOI 10.1042/bj3240659; ONEILL GM, 1994, BBA-GENE STRUCT EXPR, V1219, P521, DOI 10.1016/0167-4781(94)90080-9; Oseroff C, 2012, J IMMUNOL, V189, P679, DOI 10.4049/jimmunol.1200694; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Santiago HC, 2012, J ALLERGY CLIN IMMUN, V130, P248, DOI 10.1016/j.jaci.2012.02.045; Santiago HC, 2011, J ALLERGY CLIN IMMUN, V127, P479, DOI 10.1016/j.jaci.2010.11.007; Santos ABR, 2008, J ALLERGY CLIN IMMUN, V121, P1040, DOI 10.1016/j.jaci.2007.12.1147; Satinover SM, 2005, J ALLERGY CLIN IMMUN, V115, P803, DOI 10.1016/j.jaci.2005.01.018; Simpson A, 2003, ALLERGY, V58, P53, DOI 10.1034/j.1398-9995.2003.23354.x; Slater JE, 2007, CLIN EXP ALLERGY, V37, P1033, DOI 10.1111/j.1365-2222.2007.02751.x; Weghofer M, 2008, EUR J CLIN INVEST, V38, P959, DOI 10.1111/j.1365-2362.2008.02048.x	37	35	35	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1369	1377		10.1016/j.jaci.2015.03.015	http://dx.doi.org/10.1016/j.jaci.2015.03.015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	25930195	Bronze, Green Accepted			2022-12-18	WOS:000364787200027
J	Wollmann, E; Lupinek, C; Kundi, M; Selb, R; Niederberger, V; Valenta, R				Wollmann, Eva; Lupinek, Christian; Kundi, Michael; Selb, Regina; Niederberger, Verena; Valenta, Rudolf			Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RHINOCONJUNCTIVITIS; VACCINATION; TRIAL		[Wollmann, Eva; Lupinek, Christian; Valenta, Rudolf] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol, Vienna, Austria; [Kundi, Michael] Med Univ Vienna, Ctr Publ Hlth, Inst Environm Hlth, Vienna, Austria; [Selb, Regina; Niederberger, Verena] Med Univ Vienna, Dept Ear Nose & Throat Dis, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Wollmann, E (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol, Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Lupinek, Christian/I-3311-2019	Lupinek, Christian/0000-0002-8612-8245; Valenta, Rudolf/0000-0001-5944-3365; Rigler, Eva/0000-0002-3596-3937; Selb, Regina/0000-0001-5531-5198	Austrian Science Fund FWF [F 4613, F 4605] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Dreborg S, 2012, INT ARCH ALLERGY IMM, V158, P63, DOI 10.1159/000330649; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Mahler V, 2004, CLIN EXP ALLERGY, V34, P115, DOI 10.1111/j.1365-2222.2004.01857.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004	10	35	36	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					806	809		10.1016/j.jaci.2015.02.034	http://dx.doi.org/10.1016/j.jaci.2015.02.034			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25913196	Green Published, hybrid			2022-12-18	WOS:000360913300036
J	Jackson, DJ; Trujillo-Torralbo, MB; del-Rosario, J; Bartlett, NW; Edwards, MR; Mallia, P; Walton, RP; Johnston, SL				Jackson, David J.; Trujillo-Torralbo, Maria-Belen; del-Rosario, Jerico; Bartlett, Nathan W.; Edwards, Michael R.; Mallia, Patrick; Walton, Ross P.; Johnston, Sebastian L.			The influence of asthma control on the severity of virus-induced asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IFN-BETA		[Jackson, David J.; Trujillo-Torralbo, Maria-Belen; del-Rosario, Jerico; Bartlett, Nathan W.; Edwards, Michael R.; Mallia, Patrick; Walton, Ross P.; Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Infect Sect, London, England; [Jackson, David J.; Trujillo-Torralbo, Maria-Belen; del-Rosario, Jerico; Bartlett, Nathan W.; Edwards, Michael R.; Mallia, Patrick; Walton, Ross P.; Johnston, Sebastian L.] MRC, London, England; [Jackson, David J.; Trujillo-Torralbo, Maria-Belen; del-Rosario, Jerico; Bartlett, Nathan W.; Edwards, Michael R.; Mallia, Patrick; Walton, Ross P.; Johnston, Sebastian L.] Asthma UK Ctr Allerg Mech Asthma, London, England; [Jackson, David J.; Trujillo-Torralbo, Maria-Belen; del-Rosario, Jerico; Mallia, Patrick; Johnston, Sebastian L.] Imperial Coll Healthcare NHS Trust, London, England	Imperial College London; University of London; King's College London; Imperial College London	Jackson, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Infect Sect, London, England.	d.jackson@imperial.ac.uk	Jackson, David/AAG-8818-2020; Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200; Bartlett, Nathan/0000-0002-2715-5163	National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish; Asthma UK [RF07/04, MRC-Asthma UK Centre, CH11SJ] Funding Source: researchfish; Medical Research Council [G1000758B, G1000758] Funding Source: Medline; Department of Health [NF-SI-0508-10212] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health		Bateman ED, 2008, ALLERGY, V63, P932, DOI 10.1111/j.1398-9995.2008.01724.x; Bateman ED, 2010, J ALLERGY CLIN IMMUN, V125, P600, DOI 10.1016/j.jaci.2009.11.033; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Global Initiative for Asthma, 2011, GLOB STRAT ASTHM MAN; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Slejko JF, 2014, J ALLERGY CLIN IMMUN, V133, P1579, DOI 10.1016/j.jaci.2013.10.028; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044	11	35	36	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					497	+		10.1016/j.jaci.2015.01.028	http://dx.doi.org/10.1016/j.jaci.2015.01.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25772596	Green Submitted			2022-12-18	WOS:000359004900038
J	Wang, CH; Punde, TH; Huang, CD; Chou, PC; Huang, TT; Wu, WH; Liu, CH; Chung, KF; Kuo, HP				Wang, Chun-Hua; Punde, Tushar Harishchandra; Huang, Chien-Da; Chou, Pai-Chien; Huang, Tzu-Ting; Wu, Wen-Hao; Liu, Cheng-Hsien; Chung, Kian Fan; Kuo, Han-Pin			Fibrocyte trafficking in patients with chronic obstructive asthma and during an acute asthma exacerbation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; fibrocytes; chemokines; chemokine receptors; S100A9	PERIPHERAL-BLOOD FIBROCYTES; AIRWAY SMOOTH-MUSCLE; CIRCULATING FIBROCYTES; MIGRATION; CELLS; DIFFERENTIATION; IDENTIFICATION; ACTIVATION; CXCR4	Background: Fibrocytes express several chemokine receptors (CCR7 and CXCR4) that regulate their recruitment and trafficking into tissue-damage sites in response to specific chemokine gradients (CCL19 and CXCL12). Objective: We investigated whether these chemoattractants and S100A9, through the receptor for advanced glycation endproducts (RAGE; ie, its receptor), are involved in fibrocyte trafficking in patients with chronic obstructive asthma (COA) and during an acute exacerbation (AE) in patients without airflow obstruction (Asthma AE group). Methods: We collected peripheral blood from 14 asthmatic patients with normal pulmonary function, 14 patients with COA, 11 patients in the Asthma AE group, and 14 healthy subjects. Isolated circulating fibrocytes were used for migration assay. Expression of CCR7, CXCR4, S100A9, and RAGE in fibrocytes was measured by using flow cytometry. CCL19 and CXCL12 expression in bronchial tissues was determined by using immunohistochemistry and RT-PCR. Results: There were higher numbers of circulating fibrocytes in patients in the Asthma AE group and patients with COA. The expression of CXCL12 in bronchial tissues and CXCR4 in circulating fibrocytes was higher in the Asthma AE group and, to a lesser extent, in patients with COA. The expression of CCL19 in bronchial tissues and CCR7 in fibrocytes was higher in patients with COA. CXCL12/CXCR4 and CCL19/CCR7 enhanced fibrocyte transmigration in the Asthma AE group and in patients with COA, respectively. The upregulated expression of S100A9 and RAGE in fibrocytes of patients in the Asthma AE group and those with COA contributes to the enhanced basal migratory motility of fibrocytes. Conclusion: TheCXCR4/CXCL12 axis contributes to chemotaxis of fibrocytes in patients in the Asthma AE group, whereas the CCR7/CCL19 axis plays an important role in patients with COA. S100A9 enhances the basal migratory motility of fibrocytes from patients in the Asthma AE group and patients with COA.	[Wang, Chun-Hua; Huang, Chien-Da; Chou, Pai-Chien; Huang, Tzu-Ting; Kuo, Han-Pin] Chang Gung Mem Hosp, Dept Thorac Med, Taipei 10591, Taiwan; [Wang, Chun-Hua; Chou, Pai-Chien; Kuo, Han-Pin] Chang Gung Univ, Dept Med, Taoyuan, Taiwan; [Punde, Tushar Harishchandra] Natl Tsing Hua Univ, Inst NanoEngn & MicroSyst, Hsinchu, Taiwan; [Wu, Wen-Hao; Liu, Cheng-Hsien] Natl Tsing Hua Univ, Dept Power Mech Engn, Hsinchu, Taiwan; [Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England	Chang Gung Memorial Hospital; Chang Gung University; National Tsing Hua University; National Tsing Hua University; Imperial College London	Kuo, HP (corresponding author), Chang Gung Mem Hosp, Dept Thorac Med, 199 Tung Hwa N Rd, Taipei 10591, Taiwan.	q8828@ms11.hinet.net	Wang, Chun-Hua/V-9861-2019; Huang, Chien-Da/AAY-3771-2021; Wang, Chun-Hua/C-1488-2016; Chung, Kian Fan/B-1872-2012	Wang, Chun-Hua/0000-0002-3514-9353; Chung, Kian Fan/0000-0001-7101-1426; Huang, Chien-Da/0000-0002-4999-6019; Liu, Cheng-Hsien/0000-0003-1882-3892	Taiwan National Science Council [NSC-96-2628-B-182-22-my3, NSC-99-2314-B-182-043-my3, NSC-102-2314-B-182A-057-my2]; Chang Gung Research Project [CMRPG 371091, CMRPG3A0701, CMRPG390041]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U19ES019536] Funding Source: NIH RePORTER; Medical Research Council [G1001362] Funding Source: researchfish	Taiwan National Science Council(Ministry of Science and Technology, Taiwan); Chang Gung Research Project; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by Taiwan National Science Council grants NSC-96-2628-B-182-22-my3, NSC-99-2314-B-182-043-my3, and NSC-102-2314-B-182A-057-my2 and Chang Gung Research Project grants (CMRPG 371091, CMRPG3A0701, and CMRPG390041).	Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bargagli E, 2008, INFLAMMATION, V31, P351, DOI 10.1007/s10753-008-9085-z; Bellini A, 2007, LAB INVEST, V87, P858, DOI 10.1038/labinvest.3700654; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; Ehrchen JM, 2009, J LEUKOCYTE BIOL, V86, P557, DOI 10.1189/jlb.1008647; Feng PH, 2012, AM J RESP CRIT CARE, V186, P1025, DOI 10.1164/rccm.201204-0636OC; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302; Kaur D, 2006, AM J RESP CRIT CARE, V174, P1179, DOI 10.1164/rccm.200603-394OC; Ko YS, 2004, CIRCULATION, V109, P1172, DOI 10.1161/01.CIR.0000117233.57190.BD; Kwon CH, 2013, MOL CELLS, V35, P226, DOI 10.1007/s10059-013-2269-x; Lo YL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027769; Lominadze G, 2005, J IMMUNOL, V174, P7257, DOI 10.4049/jimmunol.174.11.7257; Mehrad B, 2009, INT J BIOCHEM CELL B, V41, P1708, DOI 10.1016/j.biocel.2009.02.020; Mendez-Enriquez E, 2014, INT IMMUNOPHARMACOL, V20, P1, DOI 10.1016/j.intimp.2014.01.032; Murdoch C, 2000, IMMUNOL REV, V177, P175, DOI 10.1034/j.1600-065X.2000.17715.x; Nihlberg K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-50; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Quan TE, 2004, INT J BIOCHEM CELL B, V36, P598, DOI 10.1016/j.biocel.2003.10.005; Sakai N, 2006, P NATL ACAD SCI USA, V103, P14098, DOI 10.1073/pnas.0511200103; Saunders R, 2009, J ALLERGY CLIN IMMUN, V123, P376, DOI 10.1016/j.jaci.2008.10.048; Schmidt M, 2003, J IMMUNOL, V171, P380, DOI 10.4049/jimmunol.171.1.380; Singh SR, 2014, ALLERGY, V69, P1189, DOI 10.1111/all.12444; Vogl T, 2004, BLOOD, V104, P4260, DOI 10.1182/blood-2004-02-0446; Wang CH, 2008, AM J RESP CRIT CARE, V178, P583, DOI 10.1164/rccm.200710-1557OC; Wang CH, 2012, J ALLERGY CLIN IMMUN, V129, P1367, DOI 10.1016/j.jaci.2012.01.038; Weng CM, 2013, AM J RESP CRIT CARE, V188, P298, DOI 10.1164/rccm.201301-0132OC; Yang LJ, 2002, LAB INVEST, V82, P1183, DOI 10.1097/01.LAB.0000027841.50269.61	30	35	37	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1154	U524		10.1016/j.jaci.2014.09.011	http://dx.doi.org/10.1016/j.jaci.2014.09.011			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25441632				2022-12-18	WOS:000353980700007
J	Eltonsy, S; Forget, A; Beauchesne, MF; Blais, L				Eltonsy, Sherif; Forget, Amelie; Beauchesne, Marie-France; Blais, Lucie			Risk of congenital malformations for asthmatic pregnant women using a long-acting beta(2)-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; pregnancy; congenital malformations; inhaled corticosteroid; long-acting beta(2)-agonist; combination therapy; high-dose inhaled corticosteroid; cohort study; comparative safety study; administrative health databases	1ST TRIMESTER; ADMINISTRATIVE DATABASES; PERINATAL OUTCOMES; RURAL RESIDENCE; BIRTH-DEFECTS; HEART-DEFECTS; MANAGEMENT; EXPOSURE; QUEBEC; FETAL	Background: Current recommendations for managing persistent asthma during pregnancy when low-dose inhaled corticosteroids (ICSs) are insufficient include adding a long-acting beta(2)-agonist (LABA) or increasing the ICS dose. However, there are no data to help clinicians evaluate the safest regimen during pregnancy. Objective: We sought to compare the risk of major congenital malformations in asthmatic women exposed to a LABA plus ICS combination and those exposed to ICS monotherapy at higher doses during the first trimester. Methods: A cohort of asthmatic pregnant women exposed to ICSs during the first trimester who delivered between January 1990 and March 2009 was established. The primary outcome was major malformation recorded at birth or during the first year of life. Two subcohorts were established as follows: (1) users of a LABA plus low-dose ICS combination or users of a medium-dose ICS and (2) users of a LABA plus medium-dose ICS combination or users of a high-dose ICS. Generalized estimating equations were used to compare the risk of major malformations between the groups. Results: In one subcohort there were 643 women who used a LABA plus low-dose ICS and 305 who used a medium-dose ICS; the other subcohort included 198 users of a LABA plus medium-dose ICS and 156 users of a high-dose ICS. The prevalence of major malformations was 6.9% and 7.2%, respectively. The adjusted odds ratio for major malformations was 1.1 (95% CI, 0.6-1.9) when a LABA plus low-dose ICS was used compared with a medium-dose ICS and 1.2 (95% CI, 0.5-2.7) when a LABA plus medium-dose ICS was used compared with a high-dose ICS. Conclusion: The risk of major malformations was similar with a LABA plus ICS combination and ICS monotherapy at higher doses, suggesting that both therapeutic options can be considered during pregnancy.	[Eltonsy, Sherif; Forget, Amelie; Beauchesne, Marie-France; Blais, Lucie] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada; [Eltonsy, Sherif; Forget, Amelie; Blais, Lucie] Hop Sacre Coeur Montreal, Sherbrooke, PQ, Canada; [Beauchesne, Marie-France] Univ Sherbrooke, Ctr Hosp, Dept Pharm, Sherbrooke, PQ J1K 2R1, Canada	Universite de Montreal; Universite de Montreal; University of Sherbrooke	Blais, L (corresponding author), Univ Montreal, Fac Pharm, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	lucie.blais@umontreal.ca	Eltonsy, Sherif/AAQ-7952-2020	Eltonsy, Sherif/0000-0002-0520-5406	Canadian Institutes of Health Research [MOP97731]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Supported by a research grant received from the Canadian Institutes of Health Research (grant MOP97731).	Andrade SE, 2006, PHARMACOEPIDEM DR S, V15, P546, DOI 10.1002/pds.1235; Beckmann CA, 2002, MCN-AM J MATERN-CHIL, V27, P98; Blais L, 2006, PHARMACOEPIDEM DR S, V15, P245, DOI 10.1002/pds.1202; Blais L, 2008, J ALLERGY CLIN IMMUN, V121, P1379, DOI 10.1016/j.jaci.2008.02.038; Blais L, 2007, THORAX, V62, P320, DOI 10.1136/thx.2006.062950; Blais L, 2013, PHARMACOEPIDEM DR S, V22, P881, DOI 10.1002/pds.3446; Blais L, 2009, J ALLERGY CLIN IMMUN, V124, P1229, DOI 10.1016/j.jaci.2009.09.025; Brent R L, 2001, Pediatr Rev, V22, P153, DOI 10.1542/pir.22-5-153; Breton MC, 2008, RESP MED, V102, P862, DOI 10.1016/j.rmed.2008.01.008; Briggs GG., 2017, DRUGS PREGNANCY LACT; Chambers Karen, 2003, Case Manager, V14, P58, DOI 10.1016/j.casemgr.2003.09.003; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Eltonsy S, 2014, RESP MED, V108, P9, DOI 10.1016/j.rmed.2013.07.009; Eltonsy S, 2011, BIRTH DEFECTS RES A, V91, P937, DOI 10.1002/bdra.22850; Gill SK, 2012, BIRTH DEFECTS RES A, V94, P1010, DOI 10.1002/bdra.23049; Gitau R, 1998, LANCET, V352, P707, DOI 10.1016/S0140-6736(05)60824-0; Global Initiative for Asthma (GINA), 2012, GLOB STRAT ASTHM MAN; Guo JJ, 2011, ANN ALLERG ASTHMA IM, V106, P214, DOI 10.1016/j.anai.2010.12.008; Gur C, 2004, REPROD TOXICOL, V18, P93, DOI 10.1016/j.reprotox.2003.10.007; Hintze J., 2007, NCSS PASS AND GESS; Kips JC, 2001, AM J RESP CRIT CARE, V164, P923, DOI 10.1164/ajrccm.164.6.2010107; Koren G, 1998, NEW ENGL J MED, V338, P1128, DOI 10.1056/NEJM199804163381607; Langlois PH, 2009, BIRTH DEFECTS RES A, V85, P764, DOI 10.1002/bdra.20586; Lemiere Catherine, 2004, Can Respir J, V11 Suppl A, p9A; Lim A, 2011, ANN PHARMACOTHER, V45, P931, DOI 10.1345/aph.1P764; Liu SL, 2013, CIRCULATION, V128, P583, DOI 10.1161/CIRCULATIONAHA.112.001054; Lougheed MD, 2010, CAN RESPIR J, V17, P15, DOI 10.1155/2010/827281; Martel MJ, 2005, BMJ-BRIT MED J, V330, P230, DOI 10.1136/bmj.38313.624352.8F; Maselli DJ, 2013, THER ADV RESPIR DIS, V7, P87, DOI 10.1177/1753465812464287; McCallister JW, 2013, CURR OPIN PULM MED, V19, P13, DOI 10.1097/MCP.0b013e32835a5bf3; Messer LC, 2010, ANN EPIDEMIOL, V20, P32, DOI 10.1016/j.annepidem.2009.09.006; Mok CC, 2001, POSTGRAD MED J, V77, P157, DOI 10.1136/pmj.77.905.157; Murphy VE, 2013, BJOG-INT J OBSTET GY, V120, P812, DOI 10.1111/1471-0528.12224; National Asthma Education and Prevention Program (National Heart Lung and Blood Institute) Working Group on Asthma and Pregnancy, 2005, WORK GROUP ASTHM PRE, p[ix, 57]; Olesen C, 1999, EUR J CLIN PHARMACOL, V55, P139, DOI 10.1007/s002280050608; Powell H, 2011, J ASTHMA, V48, P1032, DOI 10.3109/02770903.2011.631239; ROWLAND JM, 1983, ADV VET SCI COMP MED, V27, P99; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; SCHARDEIN JL, 2000, CHEM INDUCED BIRTH D, P1109; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; Schatz M, 2009, NEW ENGL J MED, V360, P1862, DOI 10.1056/NEJMcp0809942; Seckl JR, 2004, EUR J ENDOCRINOL, V151, pU49, DOI 10.1530/eje.0.151u049; Shapiro S., 1977, BIRTH DEFECTS DRUGS, P516; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; Tegethoff M, 2009, ENDOCR REV, V30, P753, DOI 10.1210/er.2008-0014; Vilain A, 2008, PHARMACOEPIDEM DR S, V17, P345, DOI 10.1002/pds.1558; Yang J, 2008, AM J EPIDEMIOL, V167, P145, DOI 10.1093/aje/kwm283; Yawn B, 2007, J AM BOARD FAM MED, V20, P289, DOI 10.3122/jabfm.2007.03.060144; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	49	35	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					123	U198		10.1016/j.jaci.2014.07.051	http://dx.doi.org/10.1016/j.jaci.2014.07.051			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25226849				2022-12-18	WOS:000347298200014
J	Moghaddam, AE; Hillson, WR; Noti, M; Gartlan, KH; Johnson, S; Thomas, B; Artis, D; Sattentau, QJ				Moghaddam, Amin E.; Hillson, William R.; Noti, Mario; Gartlan, Kate H.; Johnson, Steven; Thomas, Benjamin; Artis, David; Sattentau, Quentin J.			Dry roasting enhances peanut-induced allergic sensitization across mucosal and cutaneous routes in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GLYCATION END-PRODUCTS; RECEPTOR		[Moghaddam, Amin E.; Hillson, William R.; Gartlan, Kate H.; Johnson, Steven; Thomas, Benjamin; Sattentau, Quentin J.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Noti, Mario; Artis, David] Univ Penn, Perelman Sch Med, Inst Immunol, Dept Microbiol, Philadelphia, PA 19104 USA	University of Oxford; University of Pennsylvania; Pennsylvania Medicine	Moghaddam, AE (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	amin.moghaddam@path.ox.ac.uk	Gartlan, Kate/C-5315-2009; Noti, Mario/I-6581-2019; Gartlan, Kate/S-7187-2019; Moghaddam, Amin/N-2300-2014; Johnson, Steven J/F-9182-2016; Gartlan, Kate H/B-7279-2012	Gartlan, Kate/0000-0002-0343-1274; Noti, Mario/0000-0001-9386-1245; Moghaddam, Amin/0000-0001-8668-1609; Johnson, Steven J/0000-0002-7877-3543; Artis, David/0000-0002-1753-4100	Medical Research Council [G0000635, G0900888] Funding Source: Medline; NIAID NIH HHS [R01 AI095466, R01 AI074878, AI097333, AI09560, R01 AI061570, AI095466, R01 AI097333, R01 AI102942, U01 AI095608] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI095466, R01AI097333, R01AI102942, R01AI074878, U01AI095608, R01AI061570] Funding Source: NIH RePORTER; MRC [G0000635] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Hebling CM, 2013, J AGR FOOD CHEM, V61, P5638, DOI 10.1021/jf303554t; Ilchmann A, 2010, J ALLERGY CLIN IMMUN, V125, P175, DOI 10.1016/j.jaci.2009.08.013; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Lee AJ, 2013, ASIA PAC ALLERGY, V3, P3, DOI 10.5415/apallergy.2013.3.1.3; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Moghaddam AE, 2011, J IMMUNOL, V187, P1626, DOI 10.4049/jimmunol.1003906; Mueller GA, 2013, ALLERGY, V68, P1546, DOI 10.1111/all.12261; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Prusak AM, 2014, ACTA SCI POLON-TECHN, V13, P321, DOI 10.17306/J.AFS.2014.3.10	10	35	37	2	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1453	1456		10.1016/j.jaci.2014.07.032	http://dx.doi.org/10.1016/j.jaci.2014.07.032			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25253515	Green Accepted, Bronze			2022-12-18	WOS:000346075400032
J	Verstegen, RHJ; Driessen, GJ; Bartol, SJW; Van Noesel, CJM; Boon, L; van der Burg, M; van Dongen, JJM; de Vries, E; van Zelm, MC				Verstegen, Ruud H. J.; Driessen, Gertjan J.; Bartol, Sophinus J. W.; Van Noesel, Carel J. M.; Boon, Louis; van der Burg, Mirjam; van Dongen, Jacques J. M.; de Vries, Esther; van Zelm, Menno C.			Defective B-cell memory in patients with Down syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Down syndrome; common variable immunodeficiency antibody; B cell; selection; somatic hypermutation; IgM; IgA; plasma cell	COMMON VARIABLE IMMUNODEFICIENCY; SOMATIC HYPERMUTATION; LYMPHOCYTE SUBPOPULATIONS; STATISTICAL-ANALYSIS; REPLICATION HISTORY; ANTIBODY-RESPONSE; INTRINSIC DEFECT; ANTIGEN RECEPTOR; IMMUNOGLOBULIN; SELECTION	Background: Patients with Down syndrome carry immunologic defects, as evidenced by the increased risks for autoimmune diseases, hematologic malignancies, and respiratory tract infections. Moreover, the low numbers of circulating B cells suggest impaired humoral immunity. Objective: We sought to study how immunodeficiency in patients with Down syndrome results from immunologic defects in the B-cell compartment. Methods: We studied blood B-cell subset composition, replication history, somatic hypermutation status, and classswitch recombination in 17 children with Down syndrome. Germinal centers and plasma cells were studied in tonsils from 4 additional children with Down syndrome. Results: Blood transitional B-cell numbers were normal, but naive mature and memory B-cell numbers were reduced despite slightly increased serum B cell-activating factor levels. Germinal centers and plasma cells in tonsils appeared normal, as were serum immunoglobulin levels. CD27(+) IgD(+) IgM(+) "natural effector'' B cells showed reduced proliferation and somatic hypermutation levels, whereas these were normal in CD27(+) IgD(-) memory B cells. Furthermore, IgM(+) and IgA(+), but not IgG(+), memory B cells showed impaired molecular signs for antigen selection. The B-cell pattern was highly similar to that of patients with common variable immunodeficiency and a defect in B-cell activation and proliferation. Conclusion: Children with Down syndrome seem capable of normal germinal center and plasma cell formation. Still, blood memory B-cell numbers were reduced and showed impaired molecular maturation of IgA and IgM, which are important for mucosal immunity. The observed molecular defects in circulating IgA and IgM B-cell memory could reflect impaired local responses, which underlie the increased susceptibility to respiratory tract infections of patients with Down syndrome.	[Verstegen, Ruud H. J.] Jeroen Bosch Hosp, Dept Pediat, NL-5200 ME Shertogenbosch, Netherlands; [Driessen, Gertjan J.] Univ Med Ctr Rotterdam, Dept Pediat Infect Dis & Immunol, Rotterdam, Netherlands; [Driessen, Gertjan J.; Bartol, Sophinus J. W.; van der Burg, Mirjam; van Dongen, Jacques J. M.; van Zelm, Menno C.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Van Noesel, Carel J. M.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Boon, Louis] Bioceros BV, Utrecht, Netherlands	Jeroen Bosch Ziekenhuis; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Bioceros B.V.	de Vries, E (corresponding author), Jeroen Bosch Hosp, Dept Pediat, POB 90153, NL-5200 ME Shertogenbosch, Netherlands.	e.d.vries@jbz.nl	Verstegen, Ruud/N-5964-2019; van Zelm, Menno C/O-4404-2015; Verstegen, Ruud/R-8613-2018; van Dongen, Jacques J.M./F-8537-2015; Boon, Laurence/HCI-3629-2022; Driessen, Gertjan/AAI-9711-2020	Verstegen, Ruud/0000-0001-6638-8405; van Zelm, Menno C/0000-0003-4161-1919; Verstegen, Ruud/0000-0001-6638-8405; van Dongen, Jacques J.M./0000-0001-7686-0021; Boon, Louis/0000-0002-0937-9171; de Vries, Esther/0000-0003-4311-3550; van Dongen, Jacques J.M./0000-0002-3650-7087	Peribosch Foundation and a grant from the Erasmus University Rotterdam (EUR-Fellowship)	Peribosch Foundation and a grant from the Erasmus University Rotterdam (EUR-Fellowship)	Supported by the Peribosch Foundation and a grant from the Erasmus University Rotterdam (EUR-Fellowship; to M.C.v.Z.).	Akinci O, 2010, ENVIRON MOL MUTAGEN, V51, P57, DOI 10.1002/em.20511; Andersen P, 2005, BLOOD, V105, P511, DOI 10.1182/blood-2003-12-4359; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Bloemers BLP, 2007, PEDIATRICS, V120, pE1076, DOI 10.1542/peds.2007-0788; Bloemers BLP, 2010, J PEDIATR-US, V156, P804, DOI 10.1016/j.jpeds.2009.12.006; Bloemers BL, 2010, J PEDIAT, V156, pe1; Bose B, 2005, IMMUNOLOGY, V116, P172, DOI 10.1111/j.1365-2567.2005.02208.x; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Costa-Carvalho BT, 2006, BRAZ J MED BIOL RES, V39, P1587, DOI 10.1590/S0100-879X2006005000047; de Vries E, 2000, Ned Tijdschr Geneeskd, V144, P2197; Driessen GJ, 2013, J ALLERGY CLIN IMMUN, V131, P1367, DOI 10.1016/j.jaci.2013.01.053; Driessen GJ, 2011, BLOOD, V118, P6814, DOI 10.1182/blood-2011-06-361881; Dunn-Walters DK, 1998, IMMUNOLOGY, V95, P339; Elsayed Solaf M, 2009, Immun Ageing, V6, P2, DOI 10.1186/1742-4933-6-2; Garrison MM, 2005, J PEDIATR-US, V147, P748, DOI 10.1016/j.jpeds.2005.06.032; Gemen EFA, 2012, PEDIATR BLOOD CANCER, V59, P1310, DOI 10.1002/pbc.24246; Goldacre MJ, 2004, ARCH DIS CHILD, V89, P1014, DOI 10.1136/adc.2003.046219; Hilton JM, 1999, J PAEDIATR CHILD H, V35, P383, DOI 10.1046/j.1440-1754.1999.00386.x; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Joshi AY, 2011, VACCINE, V29, P5040, DOI 10.1016/j.vaccine.2011.04.060; Kreuzaler M, 2012, J IMMUNOL, V188, P497, DOI 10.4049/jimmunol.1102321; Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020; Kusters MAA, 2013, VACCINE, V31, P6261, DOI 10.1016/j.vaccine.2013.09.070; Kusters MAA, 2009, CLIN EXP IMMUNOL, V156, P189, DOI 10.1111/j.1365-2249.2009.03890.x; Kusters MA, 2011, PEDIATR INFECT DIS J, V30, P357, DOI 10.1097/INF.0b013e3181ff85a8; Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838; Longo NS, 2008, J IMMUNOL, V181, P1299, DOI 10.4049/jimmunol.181.2.1299; Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X; PASCUAL V, 1991, J IMMUNOL, V146, P4385; Piatosa B, 2012, CYTOM PART A, V81A, P835, DOI 10.1002/cyto.a.22108; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; Pugh-Bernard AE, 2001, J CLIN INVEST, V108, P1061, DOI 10.1172/JCI200112462; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; Roizen NJ, 2003, LANCET, V361, P1281, DOI 10.1016/S0140-6736(03)12987-X; Sapoznikov A, 2008, NAT IMMUNOL, V9, P388, DOI 10.1038/ni1571; Shott SR, 2006, AM J MED GENET C, V142C, P131, DOI 10.1002/ajmg.c.30095; Uduman M, 2011, NUCLEIC ACIDS RES, V39, pW499, DOI 10.1093/nar/gkr413; van der Burg M, 2010, BLOOD, V115, P4770, DOI 10.1182/blood-2009-10-250514; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964; van Zelm MC, 2014, J ALLERGY CLIN IMMUN, V134, P135, DOI 10.1016/j.jaci.2013.11.015; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Verstegen RHJ, 2010, PEDIATR RES, V67, P563, DOI 10.1203/PDR.0b013e3181d4ecc1; von Bernuth H, 2012, EUR J IMMUNOL, V42, P3126, DOI 10.1002/eji.201242683; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Wehr C, 2004, CLIN IMMUNOL, V113, P161, DOI 10.1016/j.clim.2004.05.010; Weller S, 2012, BLOOD, V120, P4992, DOI 10.1182/blood-2012-07-440776; Wu YC, 2010, BLOOD, V116, P1070, DOI 10.1182/blood-2010-03-275859; Yaari G, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks457; Yamato F, 2009, PEDIATR INT, V51, P474, DOI 10.1111/j.1442-200X.2008.02761.x	52	35	36	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1346	+		10.1016/j.jaci.2014.07.015	http://dx.doi.org/10.1016/j.jaci.2014.07.015			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25159464	Bronze			2022-12-18	WOS:000346075400017
J	Nachshon, L; Goldberg, MR; Schwartz, N; Sinai, T; Amitzur-Levy, R; Elizur, A; Eisenberg, E; Katz, Y				Nachshon, Liat; Goldberg, Michael R.; Schwartz, Naama; Sinai, Tali; Amitzur-Levy, Roni; Elizur, Arnon; Eisenberg, Eli; Katz, Yitzhak			Decreased bone mineral density in young adult IgE-mediated cow's milk-allergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bone mineral density; cow's milk allergy; osteoporosis	ORAL IMMUNOTHERAPY; FOOD ALLERGY; EGG ALLERGY; CHILDREN; ADOLESCENTS; FRACTURES; TOLERANCE; HEALTH; WOMEN; DAIRY	Background: IgE-mediated cow's milk-allergic (IgE-CMA) patients provide a valuable model for studying the relationship between dairy intake and bone mineral density (BMD) because they are unable to consume even minor amounts of dairy foods. Objective: To determine the effects of dairy restriction on BMD in young adult IgE-CMA patients. Methods: A prospective observational study was conducted from July 2012 to June 2013 at the Allergy unit of the Assaf-Harofeh Medical Center. Densitometric measurements of postpubertal patients diagnosed with IgE-CMA (group I, n = 33) were compared with those of volunteers matched for age and sex without IgE-CMA (control group II, n = 24). In a second analysis, group I and II patients were compared with IgE-CMA patients who after desensitization consumed milk for 12 to 39 months before analysis (group III, n = 12). Results: Densitometric measurements (average T scores and Z scores) of the hip, femoral neck, and lumbar spine of IgE-CMA patients were significantly lower than of those in the control group (P < .0001). A T score below -2.5 SD, identifying a risk for osteoporosis, was found in 27% of IgE-CMA patients but in none of the controls (P < .0071). Calcium intake was severely reduced in allergic patients than in controls (P < .0001). BMD measurements in group III were significantly greater than in group I (P < .0001) and unchanged from the control group. Conclusions: Patients with IgE-CMA have a significant risk of reduced BMD and early osteoporosis, which appears to be reversible on milk desensitization. Adequate calcium intake is not achieved while on a nondairy diet, requiring investigation into optimal nutritional protocols for these patients.	[Nachshon, Liat; Goldberg, Michael R.; Amitzur-Levy, Roni; Elizur, Arnon; Katz, Yitzhak] Assaf Harofeh Med Ctr, Inst Allergy & Immunol, IL-70300 Zerifin, Israel; [Schwartz, Naama] Univ Haifa, Sch Publ Hlth, IL-31999 Haifa, Israel; [Sinai, Tali; Amitzur-Levy, Roni] Hebrew Univ Jerusalem, Sch Nutr Sci, IL-76100 Rehovot, Israel; [Elizur, Arnon; Katz, Yitzhak] Tel Aviv Univ, Sackler Fac Med, Dept Pediat, IL-69978 Tel Aviv, Israel; [Eisenberg, Eli] Tel Aviv Univ, Raymond & Beverly Sackler Sch Phys & Astron, IL-69978 Tel Aviv, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; University of Haifa; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University	Katz, Y (corresponding author), Assaf Harofeh Med Ctr, Inst Allergy & Immunol, IL-70300 Zerifin, Israel.	ykatz49@gmail.com	Eisenberg, Eli/D-2587-2009	Eisenberg, Eli/0000-0001-8681-3202; Sinai, Tali/0000-0003-1252-4701; Elizur, Arnon/0000-0001-8157-8143	Ministry of Health, Israel [3-000009365]; Allergists for Israel Association	Ministry of Health, Israel; Allergists for Israel Association	This study was supported in part by the Ministry of Health, Israel (grant no. 3-000009365). M. R. G. is funded by a Kamea grant from the Ministry of Health, Israel. Supported in part by a grant to L. N. from the Allergists for Israel Association.	Alwis G, 2010, ACTA PAEDIATR, V99, P1091, DOI 10.1111/j.1651-2227.2010.01713.x; Binkley TL, 2008, REV ENDOCR METAB DIS, V9, P95, DOI 10.1007/s11154-008-9073-5; Bischoff-Ferrari HA, 2011, J BONE MINER RES, V26, P833, DOI 10.1002/jbmr.279; Black RE, 2002, AM J CLIN NUTR, V76, P675, DOI 10.1093/ajcn/76.3.675; Burge R, 2007, J BONE MINER RES, V22, P337; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Cadogan J, 1997, BMJ-BRIT MED J, V315, P1255, DOI 10.1136/bmj.315.7118.1255; Esterle L, 2009, OSTEOPOROSIS INT, V20, P567, DOI 10.1007/s00198-008-0708-x; Feskanich D, 2014, JAMA PEDIATR, V168, P54, DOI 10.1001/jamapediatrics.2013.3821; Goulding A, 2005, J BONE MINER RES, V20, P2090, DOI 10.1359/JBMR.050820; Greer FR, 2006, PEDIATRICS, V117, P578, DOI 10.1542/peds.2005-2822; Heaney RP, 2009, J AM COLL NUTR, V28, p82S, DOI 10.1080/07315724.2009.10719808; HEANEY RP, 1988, AM J CLIN NUTR, V47, P707, DOI 10.1093/ajcn/47.4.707; HENDERSON RC, 1994, BONE MINER, V27, P1, DOI 10.1016/S0169-6009(08)80181-X; Hidvegi E, 2003, J PEDIATR GASTR NUTR, V36, P44, DOI 10.1097/00005176-200301000-00010; Jamal SA, 2012, CLIN J AM SOC NEPHRO, V7, P1877, DOI 10.2215/CJN.04880512; Jensen VB, 2004, PEDIAT ALLERG IMM-UK, V15, P562, DOI 10.1111/j.1399-3038.2004.00191.x; Kalkwarf HJ, 2003, AM J CLIN NUTR, V77, P257, DOI 10.1093/ajcn/77.1.257; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Konstantynowicz J, 2007, OSTEOPOROSIS INT, V18, P1601, DOI 10.1007/s00198-007-0397-x; Konstantynowicz J, 1998, Pol Merkur Lekarski, V5, P203; Levy MB, 2014, ANN ALLERG ASTHMA IM, V112, P58, DOI 10.1016/j.anai.2013.10.001; Levy MB, 2012, ISR MED ASSOC J, V14, P29; Ludwig DS, 2013, JAMA PEDIATR, V167, P788, DOI 10.1001/jamapediatrics.2013.2408; Manias K, 2006, BONE, V39, P652, DOI 10.1016/j.bone.2006.03.018; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; Mesias M, 2011, CRIT REV FOOD SCI, V51, P195, DOI 10.1080/10408390903502872; Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6; Nachshon L, 2013, J ALLERGY CLIN IMMUN, V131, pAB98, DOI 10.1016/j.jaci.2012.12.1019; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Papandreou D, 2010, INT J ENDOCRINOL, V2010, DOI 10.1155/2010/472173; Robbins K, 2014, J ALLERGY CLIN IMMUN, V133, pAB234, DOI 10.1016/j.jaci.2013.12.832; Shahar D, 2003, EUR J EPIDEMIOL, V18, P855, DOI 10.1023/A:1025634020718; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Teegarden D, 1999, AM J CLIN NUTR, V69, P1014; Uenishi K, 2010, ASIA PAC J CLIN NUTR, V19, P432; Ward K, 2014, J CLIN ENDOCRINOL ME; Weaver CM, 2010, PHYSIOL BEHAV, V100, P63, DOI 10.1016/j.physbeh.2010.01.020; 2001, JAMA, V285, P785	41	35	36	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1108	+		10.1016/j.jaci.2014.06.026	http://dx.doi.org/10.1016/j.jaci.2014.06.026			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25091435				2022-12-18	WOS:000344938900016
J	Turner, PJ; Mehr, S; Sayers, R; Wong, M; Shamji, MH; Campbell, DE; Mills, ENC				Turner, Paul J.; Mehr, Sam; Sayers, Rebekah; Wong, Melanie; Shamji, Mohamed H.; Campbell, Dianne E.; Mills, E. N. Clare			Loss of allergenic proteins during boiling explains tolerance to boiled peanut in peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Turner, Paul J.] Univ London Imperial Coll Sci Technol & Med, Sect Paediat Allergy & Infect Dis, London, England; [Turner, Paul J.] Univ London Imperial Coll Sci Technol & Med, MRC, London, England; [Turner, Paul J.] Univ London Imperial Coll Sci Technol & Med, Asthma UK Ctr Allerg Mech Asthma, London, England; [Turner, Paul J.; Campbell, Dianne E.] Univ Sydney, Div Paediat & Child Hlth, Sydney, NSW 2006, Australia; [Mehr, Sam; Wong, Melanie; Campbell, Dianne E.] Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia; [Sayers, Rebekah; Mills, E. N. Clare] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester Inst Biotechnol, Inst Inflammat & Repair, Manchester, Lancs, England; [Shamji, Mohamed H.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London, England; [Shamji, Mohamed H.] Univ London Imperial Coll Sci Technol & Med, MRC, London, England; [Campbell, Dianne E.] Univ London Imperial Coll Sci Technol & Med, Asthma UK Ctr Allerg Mech Asthma, London, England	Imperial College London; Imperial College London; Imperial College London; University of London; King's College London; University of Sydney; University of Sydney; University of Manchester; Imperial College London; Imperial College London; Imperial College London; University of London; King's College London	Turner, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Paediat Allergy & Infect Dis, London, England.	paulyt@doctors.org.uk	Shamji, Mohamed/AAD-1788-2019; Shamji, Mohamed/AAU-8811-2020	Shamji, Mohamed/0000-0003-3425-3463; Mehr, Sam/0000-0003-2483-917X; Turner, Paul/0000-0001-9862-5161; Campbell, Dianne/0000-0002-0907-6963	National Institute for Health Research [CL-2009-18-009] Funding Source: researchfish; MRC [MR/K010468/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/F/00041800] Funding Source: Medline; Medical Research Council [MR/K010468/1] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Blanc F, 2011, MOL NUTR FOOD RES, V55, P1887, DOI 10.1002/mnfr.201100251; Marsh J, 2008, MOL NUTR FOOD RES, V52, pS272, DOI 10.1002/mnfr.200700524; Martos G, 2011, J ALLERGY CLIN IMMUN, V127, P990, DOI 10.1016/j.jaci.2011.01.057; Mondoulet L, 2005, J AGR FOOD CHEM, V53, P4547, DOI 10.1021/jf050091p; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Shek LPC, 2010, J ALLERGY CLIN IMMUN, V126, P324, DOI 10.1016/j.jaci.2010.06.003; Turner PJ, 2013, J ALLERGY CLIN IMMUN, V131, P920, DOI 10.1016/j.jaci.2012.11.016; Vissers YM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023998	9	35	36	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					751	753		10.1016/j.jaci.2014.06.016	http://dx.doi.org/10.1016/j.jaci.2014.06.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	25065723				2022-12-18	WOS:000341372400038
J	Nagasaki, T; Matsumoto, H; Kanemitsu, Y; Izuhara, K; Tohda, Y; Kita, H; Horiguchi, T; Kuwabara, K; Tomii, K; Otsuka, K; Fujimura, M; Ohkura, N; Tomita, K; Yokoyama, A; Ohnishi, H; Nakano, Y; Oguma, T; Hozawa, S; Ito, I; Oguma, T; Inoue, H; Tajiri, T; Iwata, T; Izuhara, Y; Ono, J; Ohta, S; Yokoyama, T; Niimi, A; Mishima, M				Nagasaki, Tadao; Matsumoto, Hisako; Kanemitsu, Yoshihiro; Izuhara, Kenji; Tohda, Yuji; Kita, Hideo; Horiguchi, Takahiko; Kuwabara, Kazunobu; Tomii, Keisuke; Otsuka, Kojiro; Fujimura, Masaki; Ohkura, Noriyuki; Tomita, Katsuyuki; Yokoyama, Akihito; Ohnishi, Hiroshi; Nakano, Yasutaka; Oguma, Tetsuya; Hozawa, Soichiro; Ito, Isao; Oguma, Tsuyoshi; Inoue, Hideki; Tajiri, Tomoko; Iwata, Toshiyuki; Izuhara, Yumi; Ono, Junya; Ohta, Shoichiro; Yokoyama, Tetsuji; Niimi, Akio; Mishima, Michiaki			Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CLUSTER-ANALYSIS		[Nagasaki, Tadao; Matsumoto, Hisako; Kanemitsu, Yoshihiro; Otsuka, Kojiro; Ito, Isao; Oguma, Tsuyoshi; Inoue, Hideki; Tajiri, Tomoko; Iwata, Toshiyuki; Izuhara, Yumi; Niimi, Akio; Mishima, Michiaki] Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto, Japan; [Matsumoto, Hisako; Kanemitsu, Yoshihiro; Tohda, Yuji; Kita, Hideo; Horiguchi, Takahiko; Kuwabara, Kazunobu; Tomii, Keisuke; Otsuka, Kojiro; Fujimura, Masaki; Ohkura, Noriyuki; Tomita, Katsuyuki; Yokoyama, Akihito; Ohnishi, Hiroshi; Nakano, Yasutaka; Oguma, Tetsuya; Hozawa, Soichiro; Niimi, Akio; Mishima, Michiaki] Kinki Hokuriku Airway Dis Conf, Osaka, Japan; [Izuhara, Kenji] Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga, Japan; [Tohda, Yuji; Tomita, Katsuyuki] Kinki Univ, Fac Med, Dept Resp Med & Allergol, Osaka, Japan; [Kita, Hideo] Takatsuki Red Cross Hosp, Dept Resp Med, Osaka, Japan; [Horiguchi, Takahiko; Kuwabara, Kazunobu] Fujita Hlth Univ, Educ Hosp 2, Dept Resp Internal Med, Toyoake, Aichi, Japan; [Tomii, Keisuke; Otsuka, Kojiro] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan; [Fujimura, Masaki; Ohkura, Noriyuki] Kanazawa Univ, Grad Sch Med, Dept Resp Med, Kanazawa, Ishikawa, Japan; [Yokoyama, Akihito; Ohnishi, Hiroshi] Kochi Univ, Dept Haematol & Resp Med, Kochi 780, Japan; [Nakano, Yasutaka; Oguma, Tetsuya] Shiga Univ Med Sci, Dept Internal Med, Div Resp Med, Otsu, Shiga, Japan; [Hozawa, Soichiro] Hiroshima Allergy & Resp Clin, Hiroshima, Japan; [Ohta, Shoichiro] Saga Med Sch, Dept Lab Med, Saga, Japan; [Yokoyama, Tetsuji] Natl Inst Publ Hlth, Dept Hlth Promot, Wako, Saitama 3510197, Japan; [Niimi, Akio] Nagoya City Univ, Sch Med Sci, Dept Med Oncol & Immunol, Nagoya, Aichi, Japan	Kyoto University; Saga University; Kindai University (Kinki University); Fujita Health University; Kobe City Medical Center General Hospital; Kanazawa University; Kochi University; Shiga University of Medical Science; Saga University; National Institute of Public Health - Japan; Nagoya City University	Nagasaki, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto, Japan.	hmatsumo@kuhp.kyoto-u.ac.jp		Ito, Isao/0000-0003-3109-898X; Ohnishi, Hiroshi/0000-0002-7863-4519; Inoue, Hideki/0000-0002-8624-6524	Grants-in-Aid for Scientific Research [24591466] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Amelink M, 2013, ALLERGY, V68, P674, DOI 10.1111/all.12136; Amelink M, 2013, J ALLERGY CLIN IMMUN, V132, P336, DOI 10.1016/j.jaci.2013.04.052; Boudier A, 2013, AM J RESP CRIT CARE, V188, P550, DOI 10.1164/rccm.201301-0156OC; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Kanemitsu Y, 2013, J ALLERGY CLIN IMMUN, V132, P305, DOI 10.1016/j.jaci.2013.04.050; Kim TB, 2013, EUR RESPIR J, V41, P1308, DOI 10.1183/09031936.00100811; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nadif R, 2009, THORAX, V64, P374, DOI 10.1136/thx.2008.103069; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Wood LG, 2012, CHEST, V142, P86, DOI 10.1378/chest.11-1838	10	35	35	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1474	U406		10.1016/j.jaci.2013.12.1084	http://dx.doi.org/10.1016/j.jaci.2013.12.1084			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24582168				2022-12-18	WOS:000335450700035
J	Griffith, LM; Cowan, MJ; Notarangelo, LD; Kohn, DB; Puck, JM; Pai, SY; Ballard, B; Bauer, SC; Bleesing, JJH; Boyle, M; Brower, A; Buckley, RH; van der Burg, M; Burroughs, LM; Candotti, F; Cant, AJ; Chatila, T; Cunningham-Rundles, C; Dinauer, MC; Dvorak, CC; Filipovich, AH; Fleisher, TA; Gaspar, HB; Gungor, T; Haddad, E; Hovermale, E; Huang, F; Hurley, A; Hurley, M; Iyengar, S; Kang, EM; Logan, BR; Long-Boyle, JR; Malech, HL; McGhee, SA; Modell, F; Modell, V; Ochs, HD; O'Reilly, RJ; Parkman, R; Rawlings, DJ; Routes, JM; Shearer, WT; Small, TN; Smith, H; Sullivan, KE; Szabolcs, P; Thrasher, A; Torgerson, TR; Veys, P; Weinberg, K; Zuniga-Pflucker, JC				Griffith, Linda M.; Cowan, Morton J.; Notarangelo, Luigi D.; Kohn, Donald B.; Puck, Jennifer M.; Pai, Sung-Yun; Ballard, Barbara; Bauer, Sarah C.; Bleesing, Jack J. H.; Boyle, Marcia; Brower, Amy; Buckley, Rebecca H.; van der Burg, Mirjam; Burroughs, Lauri M.; Candotti, Fabio; Cant, Andrew J.; Chatila, Talal; Cunningham-Rundles, Charlotte; Dinauer, Mary C.; Dvorak, Christopher C.; Filipovich, Alexandra H.; Fleisher, Thomas A.; Gaspar, Hubert Bobby; Gungor, Tayfun; Haddad, Elie; Hovermale, Emily; Huang, Faith; Hurley, Alan; Hurley, Mary; Iyengar, Sumathi; Kang, Elizabeth M.; Logan, Brent R.; Long-Boyle, Janel R.; Malech, Harry L.; McGhee, Sean A.; Modell, Fred; Modell, Vicki; Ochs, Hans D.; O'Reilly, Richard J.; Parkman, Robertson; Rawlings, David J.; Routes, John M.; Shearer, William T.; Small, Trudy N.; Smith, Heather; Sullivan, Kathleen E.; Szabolcs, Paul; Thrasher, Adrian; Torgerson, Troy R.; Veys, Paul; Weinberg, Kenneth; Zuniga-Pflucker, Juan Carlos		Workshop Participants	Primary Immune Deficiency Treatment Consortium (PIDTC) report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allogeneic hematopoietic cell transplantation; gene therapy; primary immunodeficiency; clinical trial	STEM-CELL TRANSPLANTATION; SEVERE COMBINED IMMUNODEFICIENCY; UMBILICAL-CORD BLOOD; CHRONIC GRANULOMATOUS-DISEASE; WISKOTT-ALDRICH-SYNDROME; BONE-MARROW-TRANSPLANTATION; LONG-TERM SURVIVAL; GENE-THERAPY; UNRELATED DONOR; SINGLE-CENTER	The Primary Immune Deficiency Treatment Consortium (PIDTC) is a network of 33 centers in North America that study the treatment of rare and severe primary immunodeficiency diseases. Current protocols address the natural history of patients treated for severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome, and chronic granulomatous disease through retrospective, prospective, and cross-sectional studies. The PIDTC additionally seeks to encourage training of junior investigators, establish partnerships with European and other International colleagues, work with patient advocacy groups to promote community awareness, and conduct pilot demonstration projects. Future goals include the conduct of prospective treatment studies to determine optimal therapies for primary immunodeficiency diseases. To date, the PIDTC has funded 2 pilot projects: newborn screening for SCID in Navajo Native Americans and B-cell reconstitution in patients with SCID after hematopoietic stem cell transplantation. Ten junior investigators have received grant awards. The PIDTC Annual Scientific Workshop has brought together consortium members, outside speakers, patient advocacy groups, and young investigators and trainees to report progress of the protocols and discuss common interests and goals, including new scientific developments and future directions of clinical research. Here we report the progress of the PIDTC to date, highlights of the first 2 PIDTC workshops, and consideration of future consortium objectives.	[Griffith, Linda M.] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Cowan, Morton J.; Puck, Jennifer M.; Dvorak, Christopher C.] Univ Calif San Francisco, Div Allergy Immunol & Blood & Marrow Transplantat, Dept Pediat, San Francisco, CA 94143 USA; [Cowan, Morton J.; Puck, Jennifer M.; Dvorak, Christopher C.] Univ Calif San Francisco, UCSF Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Notarangelo, Luigi D.] Childrens Hosp, Div Immunol, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA; [Notarangelo, Luigi D.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA USA; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Microbiol, Los Angeles, CA 90024 USA; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Immunol, Los Angeles, CA USA; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Mol Genet, Los Angeles, CA USA; [Puck, Jennifer M.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA; [Pai, Sung-Yun; Chatila, Talal] Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA; [Ballard, Barbara; Boyle, Marcia; Hovermale, Emily] Immune Deficiency Fdn, Towson, MD USA; [Bauer, Sarah C.] Lurie Childrens Hosp Chicago, Northwestern Feinberg Sch Med, Chicago, IL USA; [Bleesing, Jack J. H.; Rawlings, David J.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Brower, Amy] Amer Coll Med Genet & Genom, Newborn Screening Translat Res Network, Bethesda, MD USA; [Buckley, Rebecca H.] Duke Univ, Sch Med, Durham, NC 27706 USA; [van der Burg, Mirjam] Erasmus MC, Rotterdam, Netherlands; [Burroughs, Lauri M.] Univ Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Seattle, WA 98195 USA; [Candotti, Fabio] NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; [Cant, Andrew J.] Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, New York, NY USA; [Dinauer, Mary C.] Washington Univ, Sch Med, St Louis, MO 63130 USA; [Filipovich, Alexandra H.] Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA; [Fleisher, Thomas A.] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA; [Gaspar, Hubert Bobby] UCL, Great Ormond St Hosp, Inst Child Hlth, Ctr Immunodeficiency, London WC1E 6BT, England; [Gungor, Tayfun] Univ Zurich, Childrens Hosp Zurich, CH-8006 Zurich, Switzerland; [Haddad, Elie] Mother & Child Ste Justine Hosp, Montreal, PQ, Canada; [Huang, Faith] Mt Sinai Med Ctr, New York, NY 10029 USA; [Hurley, Alan; Hurley, Mary] Chron Granulomatous Dis Assoc, San Marino, CA USA; [Iyengar, Sumathi] Wiskott Aldrich Fdn, Smyrna, GA USA; [Kang, Elizabeth M.; Malech, Harry L.] NIAID, Lab Host Defenses, NIH, Bethesda, MD 20892 USA; [Logan, Brent R.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA; [Logan, Brent R.] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA; [Long-Boyle, Janel R.] Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA; [McGhee, Sean A.] Stanford Univ, Med Ctr, Lucile Packard Childrens Hosp, Stanford, CA 94305 USA; [Modell, Fred; Modell, Vicki] Jeffrey Modell Fdn, New York, NY USA; [Ochs, Hans D.] Univ Washington, Sch Med, Ctr Immun & Immunotherapy, Seattle Childrens Hosp Res Inst, Seattle, WA USA; [O'Reilly, Richard J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Parkman, Robertson] Childrens Hosp Los Angeles, Div Res Immunol BMT, Los Angeles, CA 90027 USA; [Rawlings, David J.; Torgerson, Troy R.] Univ Washington, Sch Med, Seattle Childrens Res Inst, Seattle, WA USA; [Routes, John M.] Med Coll Wisconsin, Childrens Hosp Wisconsin, Milwaukee, WI 53226 USA; [Shearer, William T.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; [Small, Trudy N.] Mem Sloan Kettering Canc Ctr, Pediat Bone Marrow Transplant Serv, New York, NY 10021 USA; [Smith, Heather] SCID Angels Life Fdn, Lakeland, FL USA; [Sullivan, Kathleen E.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Philadelphia, PA 19104 USA; [Szabolcs, Paul] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; [Thrasher, Adrian] UCL, Great Ormond St Hosp, Inst Child Hlth, Ctr Immunodeficiency, London WC1E 6BT, England; [Veys, Paul] Great Ormond St Hosp Sick Children, Inst Child Hlth, London, England; [Weinberg, Kenneth] Stanford Univ, Sch Med, Lucile Packard Childrens Hosp, Stanford, CA 94305 USA; [Zuniga-Pflucker, Juan Carlos] Univ Toronto, Toronto, ON M5S 1A1, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; Harvard University; Boston Children's Hospital; Harvard Medical School; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Cincinnati Children's Hospital Medical Center; Duke University; Erasmus University Rotterdam; Erasmus MC; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Newcastle General Hospital; Icahn School of Medicine at Mount Sinai; Washington University (WUSTL); Cincinnati Children's Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University Children's Hospital Zurich; University of Zurich; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Center for International Blood & Marrow Transplant Research; Medical College of Wisconsin; Medical College of Wisconsin; University of California System; University of California San Francisco; Lucile Packard Children's Hospital (LPCH); Stanford University; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Memorial Sloan Kettering Cancer Center; Children's Hospital Los Angeles; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Children's Hospital of Wisconsin; Medical College of Wisconsin; Baylor College of Medicine; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Lucile Packard Children's Hospital (LPCH); Stanford University; University of Toronto	Griffith, LM (corresponding author), NIAID, Div Allergy Immunol & Transplantat, NIH, 6610 Rockledge Dr,Rm 6716, Bethesda, MD 20892 USA.	LGriffith@niaid.nih.gov	Zuniga-Pflucker, Juan C/H-1295-2012; Kohn, Donald/N-5085-2016; Volpi, Stefano/O-3717-2014; Routes, john/AAA-4833-2021; Haddad, Elie/AAQ-4971-2020; Rawlings, David/CAI-4751-2022; Güngör, Tayfun/ABF-4256-2020; Dvorak, Christopher C/AAX-1630-2020; Notarangelo, Luigi D/F-9718-2016; Pai, Sung-Yun/AAH-7762-2019	Kohn, Donald/0000-0003-1840-6087; Volpi, Stefano/0000-0002-7129-868X; Routes, john/0000-0001-8378-3773; Güngör, Tayfun/0000-0002-3261-1186; Dvorak, Christopher C/0000-0002-6146-3952; Notarangelo, Luigi D/0000-0002-8335-0262; Pai, Sung-Yun/0000-0002-0158-8147; Shearer, William/0000-0002-2483-2130; Chatila, Talal/0000-0001-7439-2762; Candotti, Fabio/0000-0001-6399-6042; Malech, Harry/0000-0001-5874-5775; Haddad, Elie/0000-0003-2446-6879; , Jacob/0000-0003-4036-2105; Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178	Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases; National Human Genome Research Institute; National Institute of Allergy and Infectious Diseases; Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Md [U54-AI082973, U54-NS064808, R13-AI094943]; Immune Deficiency Foundation, Towson, Md; Jeffrey Modell Foundation, New York, NY; Robert A. Good Immunology Society, St Petersburg, Fla; Manton Center for Orphan Disease Research; Children's Hospital Translational Research Program, Children's Hospital, Boston, Mass; Baxter International, Deerfield, Ill; CSL Behring, King of Prussia, Pa; Sigma-Tau Pharmaceuticals, Gaithersburg, Md; Talecris Biotherapeutics, Research Triangle Park, NC; National Institute for Health Research [NF-SI-0611-10001] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [V1259, V1223, V1242, V0904] Funding Source: researchfish; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD068322] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI045008, P01AI097100, R18AI048693, R13AI094943, ZIAAI000988, ZIAAI000989, ZIAAI000991, ZIAAI000992, ZIAAI000645, U54AI082973, ZIAAI000644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS064808] Funding Source: NIH RePORTER	Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Md; Immune Deficiency Foundation, Towson, Md; Jeffrey Modell Foundation, New York, NY; Robert A. Good Immunology Society, St Petersburg, Fla; Manton Center for Orphan Disease Research; Children's Hospital Translational Research Program, Children's Hospital, Boston, Mass; Baxter International, Deerfield, Ill; CSL Behring, King of Prussia, Pa; Sigma-Tau Pharmaceuticals, Gaithersburg, Md; Talecris Biotherapeutics, Research Triangle Park, NC; National Institute for Health Research(National Institute for Health Research (NIHR)); Great Ormond Street Hospital Childrens Charity; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases; the Intramural Research Programs of the National Human Genome Research Institute and the National Institute of Allergy and Infectious Diseases; and the Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Md; U54-AI082973 (primary investigator: M. J. Cowan); U54-NS064808 (primary investigator: J. P. Krischer); R13-AI094943 (primary investigators: M. J. Cowan and L. D. Notarangelo). Workshops in April 2011 (San Francisco, Calif) and April 2012 (Boston, Mass) were also supported in part by the Immune Deficiency Foundation, Towson, Md; the Jeffrey Modell Foundation, New York, NY; the Robert A. Good Immunology Society, St Petersburg, Fla; the Manton Center for Orphan Disease Research and the Children's Hospital Translational Research Program, Children's Hospital, Boston, Mass; Baxter International, Deerfield, Ill; CSL Behring, King of Prussia, Pa; Sigma-Tau Pharmaceuticals, Gaithersburg, Md; and Talecris Biotherapeutics, Research Triangle Park, NC.	Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151; Aiuti A, 2012, CURR OPIN IMMUNOL, V24, P585, DOI 10.1016/j.coi.2012.07.012; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Bhattacharya A, 2005, BONE MARROW TRANSPL, V36, P295, DOI 10.1038/sj.bmt.1705054; BIASCO L, 2012, MOL THER S1, V20, pS86; Borte S, 2013, CURR OPIN HEMATOL, V20, P48, DOI 10.1097/MOH.0b013e32835a9130; Boztug K, 2010, NEW ENGL J MED, V363, P1918, DOI 10.1056/NEJMoa1003548; Brown L, 2011, BLOOD, V117, P3243, DOI 10.1182/blood-2010-08-300384; Buckley RH, 2013, J CLIN IMMUNOL, V33, P96, DOI 10.1007/s10875-012-9797-6; Candotti F, 2012, BLOOD, V120, P3635, DOI 10.1182/blood-2012-02-400937; Cavazzana-Calvo M, 2013, BRIT J HAEMATOL, V160, P146, DOI 10.1111/bjh.12119; Cavazzana-Calvo M, 2012, CURR OPIN IMMUNOL, V24, P580, DOI 10.1016/j.coi.2012.08.008; Chen J, 2006, BLOOD, V107, P3764, DOI 10.1182/blood-2005-09-3593; Chen Y, 2012, BLOOD, V119, P1130, DOI 10.1182/blood-2011-09-380436; Chiesa R, 2012, EXPERT REV CLIN IMMU, V8, P255, DOI [10.1586/ECI.12.9, 10.1586/eci.12.9]; Czechowicz A, 2010, IMMUNOL ALLERGY CLIN, V30, P159, DOI 10.1016/j.iac.2010.03.003; DiNardo L, 2012, PEDIATR TRANSPLANT, V16, P63, DOI 10.1111/j.1399-3046.2011.01606.x; Dvorak CC, 2008, BIOL BLOOD MARROW TR, V14, P1125, DOI 10.1016/j.bbmt.2008.07.008; Dvorak CC, 2013, J CLIN IMMUNOL, V33, P1156, DOI 10.1007/s10875-013-9917-y; Dvorak CC, 2010, IMMUNOL ALLERGY CLIN, V30, P125, DOI 10.1016/j.iac.2009.10.004; Eapen M, 2012, BIOL BLOOD MARROW TR, V18, P1438, DOI 10.1016/j.bbmt.2012.03.003; Eapen M, 2010, HEMATOL-AM SOC HEMAT, P43, DOI 10.1182/asheducation-2010.1.43; Eapen M, 2011, LANCET ONCOL, V12, P1214, DOI 10.1016/S1470-2045(11)70260-1; Fernandes JF, 2012, BLOOD, V119, P2949, DOI 10.1182/blood-2011-06-363572; Filipovich AH, 2001, BLOOD, V97, P1598, DOI 10.1182/blood.V97.6.1598; Fischer A, 2010, NAT IMMUNOL, V11, P457, DOI 10.1038/ni0610-457; Frangoul H, 2010, BONE MARROW TRANSPL, V45, P283, DOI 10.1038/bmt.2009.137; Friedrich W, 2009, IMMUNOL RES, V44, P18, DOI 10.1007/s12026-008-8063-8; Gaspar HB, 2012, BLOOD, V120, P3628, DOI 10.1182/blood-2012-08-446559; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Griffith LM, 2009, J ALLERGY CLIN IMMUN, V124, P1152, DOI 10.1016/j.jaci.2009.10.022; Griffith LM, 2008, J ALLERGY CLIN IMMUN, V122, P1087, DOI 10.1016/j.jaci.2008.09.045; Gungor T, 2005, TRANSPLANTATION, V79, P1596, DOI 10.1097/01.TP.0000163466.73485.5E; Hacein-Bey-Abina S, 2010, NEW ENGL J MED, V363, P355, DOI 10.1056/NEJMoa1000164; Haddad E, 2013, J ALLERGY CLIN IMMUN, V131, P994, DOI 10.1016/j.jaci.2013.01.047; Hassan A, 2012, BLOOD, V120, P3615, DOI 10.1182/blood-2011-12-396879; Iguchi A, 2011, BONE MARROW TRANSPL, V46, P1526, DOI 10.1038/bmt.2010.338; Kang EM, 2012, METHOD ENZYMOL, V507, P125, DOI 10.1016/B978-0-12-386509-0.00007-7; Kang EM, 2011, J ALLERGY CLIN IMMUN, V127, P1319, DOI 10.1016/j.jaci.2011.03.028; Kang EM, 2010, BLOOD, V115, P783, DOI 10.1182/blood-2009-05-222760; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Keerthikumar S, 2009, NUCLEIC ACIDS RES, V37, pD863, DOI 10.1093/nar/gkn682; Kim H, 2011, BIOL BLOOD MARROW TR, V17, P1289, DOI 10.1016/j.bbmt.2010.12.715; Kim YJ, 2011, CRIT REV ONCOL HEMAT, V79, P112, DOI 10.1016/j.critrevonc.2010.07.009; Kohn DB, 2013, BIOL BLOOD MARROW TR, V19, pS64, DOI 10.1016/j.bbmt.2012.09.021; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Kwan A, 2013, J ALLERGY CLIN IMMUN, V132, P140, DOI 10.1016/j.jaci.2013.04.024; Law J, 2012, BIOL BLOOD MARROW TR, V18, P1656, DOI 10.1016/j.bbmt.2012.05.006; Modell V, 2011, IMMUNOL RES, V51, P61, DOI 10.1007/s12026-011-8241-y; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182/blood-2010-11-319376; Morio T, 2011, BRIT J HAEMATOL, V154, P363, DOI 10.1111/j.1365-2141.2011.08735.x; Ozsahin H, 2008, BLOOD, V111, P439, DOI 10.1182/blood-2007-03-076679; Pai SY, 2011, BLOOD, V118, P80, DOI 10.1182/blood.V118.21.164.164; Parikh S, 2012, BIOL BLOOD MARROW TR, V18, pS53, DOI 10.1016/j.bbmt.2011.10.013; Paruzynski A, 2012, MOL THER, V20, pS212; Puck JM, 2012, J ALLERGY CLIN IMMUN, V129, P607, DOI 10.1016/j.jaci.2012.01.032; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; Rao K, 2005, BLOOD, V105, P879, DOI 10.1182/blood-2004-03-0960; Santilli G, 2011, MOL THER, V19, P122, DOI 10.1038/mt.2010.226; Sarzotti-Kelsoe M, 2009, BLOOD, V114, P1445, DOI 10.1182/blood-2009-01-199323; Sato T, 2007, PEDIATR INT, V49, P795, DOI 10.1111/j.1442-200X.2007.02468.x; Scaramuzza S, 2012, MOL THER, V20, pS211; Schuetz C, 2009, IMMUNOL RES, V44, P35, DOI 10.1007/s12026-008-8068-3; Schulz AS, 2011, BLOOD, V117, P4642, DOI 10.1182/blood-2010-06-284349; Segal BH, 2011, BIOL BLOOD MARROW TR, V17, pS123, DOI 10.1016/j.bbmt.2010.09.008; Shin CR, 2012, BONE MARROW TRANSPL, V47, P1428, DOI 10.1038/bmt.2012.31; Slatter MA, 2011, BLOOD, V117, P4367, DOI 10.1182/blood-2010-10-312082; Soncini E, 2009, BRIT J HAEMATOL, V145, P73, DOI 10.1111/j.1365-2141.2009.07614.x; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088; Straathof KC, 2009, LANCET, V374, P912, DOI 10.1016/S0140-6736(09)60945-4; Szabolcs P, 2010, SEMIN HEMATOL, V47, P22, DOI 10.1053/j.seminhematol.2009.10.009; Teigland CL, 2013, BONE MARROW TRANSPL, V48, P1050, DOI 10.1038/bmt.2013.6; Tewari P, 2012, BIOL BLOOD MARROW TR, V18, P1368, DOI 10.1016/j.bbmt.2012.02.002; Veys P, 2009, HEMATOPOIETIC STEM C, P153; Woolfrey A, 2010, BIOL BLOOD MARROW TR, V16, P1382, DOI 10.1016/j.bbmt.2010.03.024; Yu GP, 2011, PEDIATR TRANSPLANT, V15, P733, DOI 10.1111/j.1399-3046.2011.01563.x; Zychlinski D, 2008, MOL THER, V16, P718, DOI 10.1038/mt.2008.5	78	35	36	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					335	+		10.1016/j.jaci.2013.07.052	http://dx.doi.org/10.1016/j.jaci.2013.07.052			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24139498	Green Accepted			2022-12-18	WOS:000332397100005
J	Sicherer, SH; Leung, DYM				Sicherer, Scott H.; Leung, Donald Y. M.			Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2013	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dermatology; skin disease; urticaria; atopic dermatitis; anaphylaxis; allergy; hypersensitivity disorders; food; drug; insect venom	ARA H 2; PEANUT ORAL IMMUNOTHERAPY; IGE CROSS-REACTIVITY; QUALITY-OF-LIFE; MAL D 1; ATOPIC-DERMATITIS; MAST-CELL; HIGH-RISK; T-CELLS; EOSINOPHILIC ESOPHAGITIS	This review highlights some of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects; and allergic skin diseases that were reported in the Journal in 2013. Studies on food allergy suggest that (1) 7.6% of the US population is affected, (2) a "healthy" early diet might prevent food allergy, (3) the skin might be an important route of sensitization, (4) allergen component testing might aid diagnosis, (5) the prognosis of milk allergy might be predictable through early testing, (6) oral or sublingual immunotherapy show promise but also have caveats, and (7) preclinical studies show promising alternative modes of immunotherapy and desensitization. Studies on eosinophilic esophagitis show a relationship to connective tissue disorders and that dietary management is an effective treatment for adults. Markers of anaphylaxis severity have been determined and might inform potential diagnostics and therapeutic targets. Insights on serum tests for drug and insect sting allergy might result in improved diagnostics. Genetic and immune-mediated defects in skin epithelial differentiation contribute to the severity of atopic dermatitis. Novel management approaches to treatment of chronic urticaria, including use of omalizumab, are being identified.	[Sicherer, Scott H.] Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy & Immunol, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Div Pediat Allergy Immunol, Dept Pediat, Denver, CO USA	Icahn School of Medicine at Mount Sinai; National Jewish Health	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,One Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			Food Allergy Research and Education (FARE); Novartis; National Institute of Allergy and Infectious Diseases; FARE	Food Allergy Research and Education (FARE); Novartis(Novartis); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FARE	S. H. Sicherer is a member of the American Board of Allergy and Immunology, has received consultancy fees from Food Allergy Research and Education (FARE) and Novartis, has received research support from the National Institute of Allergy and Infectious Diseases and FARE, and has received royalties from UpToDate. D. Y. M. Leung declares that he has no relevant conflicts of interest.	Abonia JP, 2013, J ALLERGY CLIN IMMUN, V132, P378, DOI 10.1016/j.jaci.2013.02.030; Allen KJ, 2013, J ALLERGY CLIN IMMUN, V131, P1109, DOI 10.1016/j.jaci.2013.01.017; Allen KJ, 2013, J ALLERGY CLIN IMMUN; Amoah AS, 2013, J ALLERGY CLIN IMMUN, V132, P639, DOI 10.1016/j.jaci.2013.04.023; Armentia A, 2013, J ALLERGY CLIN IMMUN, V131, DOI 10.1016/j.jaci.2012.09.012; Asai Y, 2013, J ALLERGY CLIN IMMUN, V132, P239, DOI 10.1016/j.jaci.2013.03.043; Asero R, 2013, J ALLERGY CLIN IMMUN, V132, P983, DOI 10.1016/j.jaci.2013.04.037; Bae JM, 2013, J ALLERGY CLIN IMMUN, V132, P110, DOI 10.1016/j.jaci.2013.02.044; Bartnikas LM, 2013, J ALLER CL IMM-PRACT, V1, P354, DOI 10.1016/j.jaip.2013.04.002; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Ben-Shoshan M, 2013, J ALLERGY CLIN IMMUN, V132, P739, DOI 10.1016/j.jaci.2013.06.016; Bergmann MM, 2013, J ALLER CL IMM-PRACT, V1, P22, DOI 10.1016/j.jaip.2012.11.005; Berin MC, 2013, J ALLERGY CLIN IMMUN, V131, P14, DOI 10.1016/j.jaci.2012.10.058; Berroth A, 2013, J ALLERGY CLIN IMMUN, V131, P1547, DOI 10.1016/j.jaci.2013.02.029; Bertelsen R. J., 2013, J ALLERGY CLIN IMMUN; Blank S, 2013, J ALLERGY CLIN IMMUN, V131, P1239, DOI 10.1016/j.jaci.2012.10.047; Blom WM, 2013, J ALLERGY CLIN IMMUN, V131, P172, DOI 10.1016/j.jaci.2012.10.034; Boguniewicz M, 2013, J ALLERGY CLIN IMMUN, V132, P511, DOI 10.1016/j.jaci.2013.06.030; Bonadonna P, 2013, J ALLER CL IMM-PRACT, V1, P474, DOI 10.1016/j.jaip.2013.06.014; Brauweiler AM, 2013, J ALLERGY CLIN IMMUN, V131, P421, DOI 10.1016/j.jaci.2012.10.030; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P630, DOI 10.1016/j.jaci.2013.02.034; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P623, DOI 10.1016/j.jaci.2013.02.035; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Bublin M, 2013, J ALLERGY CLIN IMMUN, V132, P118, DOI 10.1016/j.jaci.2013.01.022; Caiado J, 2013, J ALLER CL IMM-PRACT, V1, P494, DOI 10.1016/j.jaip.2013.06.002; Camargo CA, 2013, J ALLER CL IMM-PRACT, V1, P266, DOI 10.1016/j.jaip.2013.02.004; Caponetto P, 2013, J ALLER CL IMM-PRACT, V1, P302, DOI 10.1016/j.jaip.2013.01.007; Caubet JC, 2013, J ALLERGY CLIN IMMUN, V131, P222, DOI 10.1016/j.jaci.2012.06.049; Cui H, 2013, J ALLERGY CLIN IMMUN, V132, P1205, DOI 10.1016/j.jaci.2013.07.026; Desjardins M, 2013, J ALLER CL IMM-PRACT, V1, P289, DOI 10.1016/j.jaip.2013.03.006; Dhingra N, 2013, J ALLERGY CLIN IMMUN, V132, P498, DOI 10.1016/j.jaci.2013.04.043; Dinwiddie DL, 2013, J ALLERGY CLIN IMMUN, V131, P594, DOI 10.1016/j.jaci.2012.10.062; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; DunnGalvin A, 2013, J ALLERGY CLIN IMMUN, V131, P230, DOI 10.1016/j.jaci.2012.08.051; Ebisawa M, 2013, J ALLERGY CLIN IMMUN, V132, P976, DOI 10.1016/j.jaci.2013.04.028; Esparza-Gordillo J, 2013, J ALLERGY CLIN IMMUN, V132, P371, DOI 10.1016/j.jaci.2013.01.057; Farrell J, 2013, J ALLERGY CLIN IMMUN, V132, P493, DOI 10.1016/j.jaci.2013.02.045; Felix R, 2013, J ALLERGY CLIN IMMUN, V131, P1423, DOI 10.1016/j.jaci.2012.10.007; Fischer J, 2013, J ALLERGY CLIN IMMUN, V132, P489, DOI 10.1016/j.jaci.2013.03.010; Fleischer DM, 2013, J ALLER CL IMM-PRACT, V1, P29, DOI 10.1016/j.jaip.2012.09.003; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Flohr C, 2013, J ALLERGY CLIN IMMUN, V132, P774, DOI 10.1016/j.jaci.2013.03.016; Foetisch K, 2013, J ALLERGY CLIN IMMUN, V131, P1711, DOI 10.1016/j.jaci.2012.12.1577; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Friedlander JL, 2013, J ALLER CL IMM-PRACT, V1, P479, DOI 10.1016/j.jaip.2013.06.007; Gao ZS, 2013, J ALLERGY CLIN IMMUN, V131, P224, DOI 10.1016/j.jaci.2012.07.015; Garn H, 2013, J ALLERGY CLIN IMMUN, V131, P1465, DOI 10.1016/j.jaci.2013.04.031; Geroldinger-Simic M, 2013, J ALLERGY CLIN IMMUN, V131, P94, DOI 10.1016/j.jaci.2012.06.039; Gittler JK, 2013, J ALLERGY CLIN IMMUN, V131, P300, DOI 10.1016/j.jaci.2012.06.048; Greenhawt M, 2013, J ALLER CL IMM-PRACT, V1, P332, DOI 10.1016/j.jaip.2013.05.009; Greenhawt M, 2013, J ALLER CL IMM-PRACT, V1, P186, DOI 10.1016/j.jaip.2013.01.002; Greenhawt M, 2013, J ALLER CL IMM-PRACT, V1, P378, DOI 10.1016/j.jaip.2013.04.009; Grimshaw KE, 2013, J ALLERGY CLIN IMMUN; Groetch M, 2013, J ALLER CL IMM-PRACT, V1, P323, DOI 10.1016/j.jaip.2013.05.002; Gupta R, 2013, JAMA PEDIATR, V167, P1026, DOI 10.1001/jamapediatrics.2013.2376; Gupta RS, 2013, J ALLERGY CLIN IMMUN, V131, P150, DOI 10.1016/j.jaci.2012.07.016; Hamsten C, 2013, ALLERGY, V68, P549, DOI 10.1111/all.12128; Hiragun T, 2013, J ALLERGY CLIN IMMUN, V132, P608, DOI 10.1016/j.jaci.2013.03.047; Hofmann C, 2013, J ALLERGY CLIN IMMUN, V131, P1384, DOI 10.1016/j.jaci.2012.10.037; Holbrook T, 2013, J ALLERGY CLIN IMMUN, V132, P1219, DOI 10.1016/j.jaci.2013.06.021; Jarvinen KM, 2013, J ALLER CL IMM-PRACT, V1, P317, DOI 10.1016/j.jaip.2013.04.004; Johansson SGO, 2013, J ALLERGY CLIN IMMUN, V132, P235, DOI 10.1016/j.jaci.2012.11.017; Jones SM, 2013, J ALLERGY CLIN IMMUN, V131, P3, DOI 10.1016/j.jaci.2012.11.012; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Keet CA, 2013, J ALLER CL IMM-PRACT, V1, P101, DOI 10.1016/j.jaip.2012.08.007; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Kelso JM, 2013, ANN ALLERG ASTHMA IM, V111, P301, DOI 10.1016/j.anai.2013.07.030; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V131, P1555, DOI 10.1016/j.jaci.2013.02.043; Kim EH, 2013, J ALLERGY CLIN IMMUN, V132, P476, DOI 10.1016/j.jaci.2013.02.017; Kim J, 2013, J ALLERGY CLIN IMMUN, V132, P495, DOI 10.1016/j.jaci.2013.04.019; Klemans RJB, 2013, J ALLERGY CLIN IMMUN, V131, P157, DOI 10.1016/j.jaci.2012.08.010; Kollmann D, 2013, J ALLERGY CLIN IMMUN, V132, P1008, DOI 10.1016/j.jaci.2013.05.030; Krause K, 2013, J ALLERGY CLIN IMMUN, V132, P751, DOI 10.1016/j.jaci.2013.04.008; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Landheer J, 2013, J ALLERGY CLIN IMMUN, V132, P1252, DOI 10.1016/j.jaci.2013.07.051; Le TM, 2013, J ALLERGY CLIN IMMUN, V131, P164, DOI 10.1016/j.jaci.2012.09.009; Lee S, 2013, J ALLERGY CLIN IMMUN, V131, P1103, DOI 10.1016/j.jaci.2013.01.011; Leisten S, 2013, J ALLERGY CLIN IMMUN, V131, P1247, DOI 10.1016/j.jaci.2012.12.1576; Leung J, 2013, J ALLERGY CLIN IMMUN, V132, P1215, DOI 10.1016/j.jaci.2013.08.017; Li JN, 2013, J ALLERGY CLIN IMMUN, V131, P442, DOI 10.1016/j.jaci.2012.10.011; Lieberman JA, 2013, J ALLER CL IMM-PRACT, V1, P75, DOI 10.1016/j.jaip.2012.11.002; Liu Y, 2013, J ALLERGY CLIN IMMUN, V131, P213, DOI 10.1016/j.jaci.2012.10.018; de Oliveira LCL, 2013, J ALLER CL IMM-PRACT, V1, P394, DOI 10.1016/j.jaip.2013.05.010; Lucendo AJ, 2013, J ALLERGY CLIN IMMUN, V131, P797, DOI 10.1016/j.jaci.2012.12.664; Ma SK, 2013, J ALLERGY CLIN IMMUN, V132, P764, DOI 10.1016/j.jaci.2013.04.017; Macy E, 2013, J ALLER CL IMM-PRACT, V1, P258, DOI 10.1016/j.jaip.2013.02.002; Masthoff LJN, 2013, J ALLERGY CLIN IMMUN, V132, P393, DOI 10.1016/j.jaci.2013.02.024; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; McGowan EC, 2013, J ALLERGY CLIN IMMUN, V131, P55; Morita H, 2013, J ALLERGY CLIN IMMUN, V131, P590, DOI 10.1016/j.jaci.2012.09.005; Nakamura R, 2013, J ALLERGY CLIN IMMUN, V132, P1436, DOI 10.1016/j.jaci.2013.07.017; Nwaru BI, 2013, J ALLERGY CLIN IMMUN, V131, P78, DOI 10.1016/j.jaci.2012.10.028; Otani IM, 2013, J ALLERGY CLIN IMMUN, V131, P1576, DOI 10.1016/j.jaci.2013.02.042; Pahr S, 2013, J ALLERGY CLIN IMMUN, V132, P1000, DOI 10.1016/j.jaci.2013.05.016; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Pelucchi C, 2013, J ALLERGY CLIN IMMUN, V132, P616, DOI 10.1016/j.jaci.2013.04.009; Penders J, 2013, J ALLERGY CLIN IMMUN, V132, P601, DOI 10.1016/j.jaci.2013.05.043; Peters RL, 2013, J ALLERGY CLIN IMMUN, V132, P874, DOI 10.1016/j.jaci.2013.05.038; Pfefferle PI, 2013, J ALLERGY CLIN IMMUN, V131, P1453, DOI 10.1016/j.jaci.2013.03.020; Picard M, 2013, J ALLER CL IMM-PRACT, V1, P252, DOI 10.1016/j.jaip.2013.01.006; Pinczower GD, 2013, J ALLERGY CLIN IMMUN, V131, P238, DOI 10.1016/j.jaci.2012.09.038; Posthumus J, 2013, J ALLERGY CLIN IMMUN, V131, P923, DOI 10.1016/j.jaci.2012.12.665; Rachid O, 2013, J ALLERGY CLIN IMMUN, V131, P236, DOI 10.1016/j.jaci.2012.10.016; Raedler D, 2013, J ALLERGY CLIN IMMUN, V131, P789, DOI 10.1016/j.jaci.2012.08.008; Reber LL, 2013, J ALLERGY CLIN IMMUN, V132, P881, DOI 10.1016/j.jaci.2013.06.008; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Rouzaire P, 2013, J ALLER CL IMM-PRACT, V1, P273, DOI 10.1016/j.jaip.2013.02.007; Ruffner MA, 2013, J ALLER CL IMM-PRACT, V1, P343, DOI 10.1016/j.jaip.2013.05.011; Saffari H, 2013, J ALLERGY CLIN IMMUN; Saito N, 2013, J ALLERGY CLIN IMMUN, V131, P434, DOI 10.1016/j.jaci.2012.09.014; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Sasaki T, 2013, J ALLERGY CLIN IMMUN, V132, P1111, DOI 10.1016/j.jaci.2013.08.027; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Schindewolf M, 2013, J ALLERGY CLIN IMMUN, V132, P131, DOI 10.1016/j.jaci.2013.02.047; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Schnyder B, 2013, J ALLERGY CLIN IMMUN, V132, P756, DOI 10.1016/j.jaci.2013.04.013; Shemer A, 2013, J ALLERGY CLIN IMMUN, V131, P577, DOI 10.1016/j.jaci.2012.11.010; Sicherer SH, 2013, J ALLER CL IMM-PRACT, V1, P1, DOI 10.1016/j.jaip.2012.10.004; Sicherer SH, 2013, J ALLERGY CLIN IMMUN, V131, P55, DOI 10.1016/j.jaci.2012.11.007; Simons E, 2013, J ALLER CL IMM-PRACT, V1, P309, DOI 10.1016/j.jaip.2013.02.001; Sprecher E, 2013, J ALLERGY CLIN IMMUN, V132, P1130, DOI 10.1016/j.jaci.2013.09.026; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Teraki Y, 2013, J ALLERGY CLIN IMMUN, V132, P971, DOI 10.1016/j.jaci.2013.07.029; Turner PJ, 2013, J ALLERGY CLIN IMMUN, V131, P920, DOI 10.1016/j.jaci.2012.11.016; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; van Anrooij B, 2013, J ALLERGY CLIN IMMUN, V132, P125, DOI 10.1016/j.jaci.2012.12.1578; Varga EM, 2013, J ALLERGY CLIN IMMUN, V131, P1419, DOI 10.1016/j.jaci.2012.08.037; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; Vidal C, 2013, J ALLERGY CLIN IMMUN, V132, P989, DOI 10.1016/j.jaci.2013.04.045; von Berg A, 2013, J ALLERGY CLIN IMMUN, V131, P1565, DOI 10.1016/j.jaci.2013.01.006; Vos B, 2013, J ALLERGY CLIN IMMUN, V131, P1225, DOI 10.1016/j.jaci.2012.07.041; Wood RA, 2013, J ALLERGY CLIN IMMUN; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060; Yaghmaie P, 2013, J ALLERGY CLIN IMMUN, V131, P428, DOI 10.1016/j.jaci.2012.10.041; Yoon SY, 2013, J ALLERGY CLIN IMMUN, V132, P981, DOI 10.1016/j.jaci.2013.04.038; Zurzolo GA, 2013, J ALLER CL IMM-PRACT, V1, P401, DOI 10.1016/j.jaip.2013.03.002	138	35	37	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					324	334		10.1016/j.jaci.2013.11.013	http://dx.doi.org/10.1016/j.jaci.2013.11.013			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24373349	Bronze			2022-12-18	WOS:000332397100004
J	Wei, Y; Xia, WT; Ye, XL; Fan, YP; Shi, JB; Wen, WP; Yang, PC; Li, HB				Wei, Yi; Xia, Wentong; Ye, Xingling; Fan, Yunping; Shi, Jianbo; Wen, Weiping; Yang, Pingchang; Li, Huabin		Nasal Hlth Grp China NHGC	The antimicrobial protein short palate, lung, and nasal epithelium clone 1 (SPLUNC1) is differentially modulated in eosinophilic and noneosinophilic chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Short palate, lung, and nasal epithelium clone 1; nasal polyps; chronic rhinosinusitis; Toll-like receptor; cytokine; eosinophil; submucosal gland; glucocorticoid	EXPRESSION; PLUNC; INFLAMMATION; INFECTION; FEATURES; DEFENSE	Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a highly heterogeneous disease with aberrant host defense responses. However, whether innate immunity is similarly impaired in patients with eosinophilic and those with noneosinophilic CRSwNP remains unclear. Objectives: We sought to evaluate the expression and possible modulation of short palate, lung, and nasal epithelium clone 1 (SPLUNC1), an innate immune molecule, in the 2 CRSwNP subsets. Methods: Polyp tissue and uncinate processes were collected from 40 patients with CRSwNP, 27 patients with chronic rhinosinusitis without nasal polyps (CRSsNP), and 22 control subjects. Expression of SPLUNC1; Toll-like receptor (TLR) 2, TLR3, and TLR4; and the proinflammatory cytokines IL-1 alpha, IL-4, IL-13, IL-17A, and IFN-gamma was examined in nasal tissues. Additionally, SPLUNC1 expression in response to specific inflammatory stimulation was measured in cultured polyp epithelial cells and A549 cells. Results: Polyp tissues exhibited significantly decreased expression of SPLUNC1 and other innate immune molecules compared with uncinate process tissues from patients with CRSwNP (P<.05), patients with CRSsNP, and healthy control subjects. Moreover, the eosinophilic CRSwNP subset exhibited significantly decreased SPLUNC1 expression and numbers of submucosal glands, as well as significantly increased IL-4 and IL-13 mRNA levels, compared with the noneosinophilic subset (P<.05). Accordingly, SPLUNC1 expression in polyp epithelial cells was significantly inhibited by IL-4 and IL-13 stimulation in vitro but was significantly upregulated after stimulation with TLR agonists and glucocorticoids (P<.05). Conclusion: Differential SPLUNC1 suppression between the eosinophilic and noneosinophilic CRSwNP subsets suggests that they possess distinct pathogenic mechanisms. This finding might benefit the design of appropriate therapeutic interventions targeted to each subset.	[Wei, Yi; Xia, Wentong; Ye, Xingling; Shi, Jianbo; Wen, Weiping; Li, Huabin] Sun Yat Sen Univ, Affiliated Hosp 1, Otorhinolaryngol Hosp, Allergy & Canc Ctr, Guangzhou 510080, Guangdong, Peoples R China; [Wei, Yi; Xia, Wentong; Ye, Xingling; Shi, Jianbo; Wen, Weiping; Li, Huabin] Sun Yat Sen Univ, Otorhinolaryngol Inst, Guangzhou 510080, Guangdong, Peoples R China; [Fan, Yunping] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Otolaryngol, Zhuhai, Peoples R China; [Yang, Pingchang] Shenzhen Univ, Hlth Sci Ctr, Shenzhen, Peoples R China; [Li, Huabin] Shanghai Jiao Tong Univ, Dept Otolaryngol Head & Neck Surg, Xinhua Hosp, Sch Med, Shanghai 200030, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Shenzhen University; Shanghai Jiao Tong University	Li, HB (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Otorhinolaryngol Hosp, Allergy & Canc Ctr, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	allergyli@163.com	Yang, Ping-Chang/K-4669-2019; 温, 家琦/GYV-3177-2022		National Natural Science Grant of China [81070771, 81070772, 81271054]; Ministry of Hygiene [201202005]; Guangdong Province Natural Science Grant [S2011010004634, S2011020002295]; Program for New Century Excellent Talents in University [NCET-10-0851]	National Natural Science Grant of China(National Natural Science Foundation of China (NSFC)); Ministry of Hygiene; Guangdong Province Natural Science Grant; Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET))	Supported by grants from the National Natural Science Grant of China (nos. 81070771, 81070772, and 81271054), the Ministry of Hygiene (no. 201202005), Guangdong Province Natural Science Grant (nos. S2011010004634 and S2011020002295), and the Program for New Century Excellent Talents in University (no. NCET-10-0851).	Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Bartlett J, 2011, BIOCHEM SOC T, V39, P1012, DOI 10.1042/BST0391012; Berger G, 2002, LARYNGOSCOPE, V112, P738, DOI 10.1097/00005537-200204000-00026; Bingle L, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-79; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Chin D, 2013, CURR OPIN OTOLARYNGO, V21, P23, DOI 10.1097/MOO.0b013e32835bc3f9; Chu HW, 2007, J IMMUNOL, V179, P3995, DOI 10.4049/jimmunol.179.6.3995; Chu HW, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-155; Claeys S, 2005, CLIN EXP ALLERGY, V35, P467, DOI 10.1111/j.1365-2222.2005.02215.x; Di YP, 2011, BIOCHEM SOC T, V39, P1051, DOI 10.1042/BST0391051; Fan Y, 2011, J ALLERGY CLIN IMMUN, V127, P520; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gally F, 2011, AM J PATHOL, V178, P2159, DOI 10.1016/j.ajpath.2011.01.026; Garcia-Caballero A, 2009, P NATL ACAD SCI USA, V106, P11412, DOI 10.1073/pnas.0903609106; Ghafouri B, 2004, BBA-PROTEINS PROTEOM, V1699, P57, DOI 10.1016/j.bbapap.2004.01.001; Hsu J, 2011, AM J RHINOL ALLERGY, V25, P285, DOI 10.2500/ajra.2011.25.3680; Ishitoya Junichi, 2010, Allergol Int, V59, P239, DOI 10.2332/allergolint.10-RAI-0231; Kim JW, 2007, OTOLARYNG HEAD NECK, V137, P925, DOI 10.1016/j.otohns.2007.07.036; Lane AP, 2006, AM J RHINOL, V20, P117, DOI 10.1177/194589240602000122; Liu YF, 2013, STAT INTERFACE, V6, P1; Lukinskiene L, 2011, J IMMUNOL, V187, P382, DOI 10.4049/jimmunol.1001769; Luo Q, 2011, ORL-J OTO-RHIN-LARYN, V73, P206, DOI 10.1159/000328342; Payne SC, 2011, LARYNGOSCOPE, V121, P2262, DOI 10.1002/lary.21969; Payne SC, 2011, J ALLERGY CLIN IMMUN, V128, P710, DOI 10.1016/j.jaci.2011.05.022; Ramanathan M, 2007, AM J RHINOL, V21, P110, DOI 10.2500/ajr.2007.21.2997; Ramanathan M, 2008, AM J RHINOL, V22, P115, DOI 10.2500/ajr.2008.22.3136; Sakuma Y, 2011, AURIS NASUS LARYNX, V38, P583, DOI 10.1016/j.anl.2011.01.007; Schleimer Robert P, 2004, Proc Am Thorac Soc, V1, P222, DOI 10.1513/pats.200402-018MS; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; Shi LL, 2013, ALLERGY, V68, P101, DOI 10.1111/all.12064; Thaikoottathil JV, 2012, AM J RESP CELL MOL, V47, P253, DOI 10.1165/rcmb.2012-0064OC; Tieu DD, 2009, J ALLERGY CLIN IMMUN, V124, P37, DOI 10.1016/j.jaci.2009.04.045; Tsou YA, 2013, LARYNGOSCOPE, V123, P845, DOI 10.1002/lary.23871; Wang HT, 2013, EUR ARCH OTO-RHINO-L, V270, P1867, DOI 10.1007/s00405-012-2295-x; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zhang N, 2007, J IMMUNOL, V179, P578, DOI 10.4049/jimmunol.179.1.578	38	35	37	0	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					420	+		10.1016/j.jaci.2013.09.052	http://dx.doi.org/10.1016/j.jaci.2013.09.052			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24342548				2022-12-18	WOS:000332397100017
J	Lighaam, LC; Vermeulen, E; den Bleker, T; Meijlink, KJ; Aalberse, RC; Barnes, E; Culver, EL; van Ham, SM; Rispens, T				Lighaam, Laura C.; Vermeulen, Ellen; den Bleker, Tamara; Meijlink, Kimberley J.; Aalberse, Rob C.; Barnes, Eleanor; Culver, Emma L.; van Ham, S. Marieke; Rispens, Theo			Phenotypic differences between IgG(4)(+) and IgG(1)(+) B cells point to distinct regulation of the IgG(4) response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOGLOBULIN G4		[Lighaam, Laura C.; Vermeulen, Ellen; den Bleker, Tamara; Meijlink, Kimberley J.; Aalberse, Rob C.; van Ham, S. Marieke; Rispens, Theo] Sanquin Blood Supply, Div Res, Amsterdam, Netherlands; [Lighaam, Laura C.; Vermeulen, Ellen; den Bleker, Tamara; Meijlink, Kimberley J.; Aalberse, Rob C.; van Ham, S. Marieke; Rispens, Theo] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands; [Barnes, Eleanor; Culver, Emma L.] Univ Oxford, Nuffield Dept Med, Oxford, England	University of Amsterdam; Academic Medical Center Amsterdam; University of Oxford	Lighaam, LC (corresponding author), Sanquin Blood Supply, Div Res, Amsterdam, Netherlands.	t.rispens@sanquin.nl		Culver, Emma/0000-0001-9644-8392; Barnes, Eleanor/0000-0002-0860-0831; Meijlink, Kimberley/0000-0001-5373-7784	Medical Research Council [MR/K010239/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [MR/K010239/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Acharya M, 2010, CLIN EXP IMMUNOL, V162, P12, DOI 10.1111/j.1365-2249.2010.04210.x; Adjobimey T, 2010, ANN TROP MED PARASIT, V104, P455, DOI 10.1179/136485910X12786389891407; Barrington RA, 2009, P NATL ACAD SCI USA, V106, P14490, DOI 10.1073/pnas.0903477106; Jeannin P, 1998, J IMMUNOL, V160, P3555; Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014	8	35	39	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					267	270		10.1016/j.jaci.2013.07.044	http://dx.doi.org/10.1016/j.jaci.2013.07.044			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24074895				2022-12-18	WOS:000329105700039
J	Hwang, SL; Li, X; Lu, Y; Jin, Y; Jeong, YT; Kim, YD; Lee, IK; Taketomi, Y; Sato, H; Cho, YS; Murakami, M; Chang, HW				Hwang, Seung-Lark; Li, Xian; Lu, Yue; Jin, Ye; Jeong, Yong-Tae; Kim, Yong Deuk; Lee, In-Kyu; Taketomi, Yoshitaka; Sato, Hiroyasu; Cho, You Sook; Murakami, Makoto; Chang, Hyeun Wook			AMP-activated protein kinase negatively regulates Fc epsilon RI-mediated mast cell signaling and anaphylaxis in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; AMP-activated protein kinase; liver kinase B1; Fyn; anaphylaxis	AFFINITY IGE RECEPTOR; SYK; DEGRANULATION; INFLAMMATION; RESPONSES; STRESS; GROWTH; LOCALIZATION; SUBUNIT; PATHWAY	Background: Aggregation of Fc epsilon RI activates a cascade of signaling events leading to mast cell activation, followed by inhibitory signals that turn off the activating signals. However, the overall view of negative signals in mast cells is still incomplete. Although AMP-activated protein kinase (AMPK), which is generally known as a regulator of energy metabolism, is also associated with anti-inflammation, little is known about the role of AMPK in mast cells. Objectives: We investigated the role of AMPK and its regulatory mechanism in mast cells. Method: The roles of AMPK in Fc epsilon RI-dependent activation of bone marrow-derived mast cells (BMMCs) were evaluated by using chemical agents, small interfering RNAs (siRNAs), or adenovirus that modulated the activity or expression of AMPK signaling components. In addition, AMPK alpha 2(-/-) mice were used to verify the role of AMPK in anaphylactic models. Results: Fc epsilon RI signaling and associated effector functions in BMMCs were suppressed by the AMPK activator 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) and were conversely augmented by siRNA knockdown of AMPK alpha 2 or liver kinase B1 (LKB1), an upstream kinase of AMPK. Furthermore, AMPK alpha 2 deficiency led to increased Fc epsilon RI-mediated BMMC activation and anaphylaxis that were insensitive to AICAR, whereas enforced expression of AMPK alpha 2 in AMPK alpha 2(-/-) BMMCs reversed the hypersensitive Fc epsilon RI signaling to normal levels. Pharmacologic inhibition or siRNA knockdown of Fyn mimicked AMPK activation, suggesting that Fyn counterregulates the LKB1-AMPK axis. Mechanistically, Fyn controlled AMPK activity by regulating LKB1 localization. Conclusions: The Fyn-regulated LKB1-AMPK axis acts as a novel inhibitory module for mast cell activation, which points to AMPK activators as therapeutic drugs for allergic diseases.	[Hwang, Seung-Lark; Li, Xian; Lu, Yue; Jin, Ye; Jeong, Yong-Tae; Chang, Hyeun Wook] Yeungnam Univ, Coll Pharm, Gyongsan 712749, South Korea; [Hwang, Seung-Lark; Kim, Yong Deuk; Lee, In-Kyu] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Res Inst Aging & Metab,WCU Program, Taegu, South Korea; [Taketomi, Yoshitaka; Sato, Hiroyasu; Murakami, Makoto] Tokyo Metropolitan Inst Med Sci, Lipid Metab Project, Tokyo 1568506, Japan; [Cho, You Sook] Univ Ulsan, Coll Med, Dept Allergy & Clin Immunol, Asan Med Ctr, Seoul, South Korea	Yeungnam University; Kyungpook National University; Tokyo Metropolitan Institute of Medical Science; University of Ulsan	Chang, HW (corresponding author), Yeungnam Univ, Coll Pharm, Gyongsan 712749, South Korea.	murakami-mk@igakuken.or.jp; hwchang@yu.ac.kr	Lee, In-Kyu/AAR-6374-2021; Lu, Yue/AAD-5889-2020		National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [NRF-2012R1A2A2A01013681]; Korea Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A111345]; National Research Foundation of Korea [NRF-2010-616-E00011]; Ministry of Education, Culture, Sports, Science and Technology of Japan [22116005, 24117724]; JSPS-NRF Bilateral Joint Project [FY2010]; Grants-in-Aid for Scientific Research [22116005] Funding Source: KAKEN	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korea Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea; National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS-NRF Bilateral Joint Project(National Research Foundation of Korea); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	X.L., Y.L., Y.J., and H.W.C. were supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2012R1A2A2A01013681). S.-L.H., Y.-T.J., Y.D.K., I.-K.L. and H.W.C. were supported in part by the Korea Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111345). S.-L.H., X.L., Y.L., and H.W.C. were supported in part by a National Research Foundation of Korea grant (NRF-2010-616-E00011). Y.T., H.S., and M.M. were supported by a grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (22116005 and 24117724). M. M. and H.W.C. were supported by the JSPS-NRF Bilateral Joint Project FY2010.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Barbu EA, 2010, J BIOL CHEM, V285, P15761, DOI 10.1074/jbc.M110.109413; Bastie CC, 2007, CELL METAB, V5, P371, DOI 10.1016/j.cmet.2007.04.005; BERGREN DR, 1991, J ALLERGY CLIN IMMUN, V88, P604, DOI 10.1016/0091-6749(91)90154-G; Bess E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020848; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Costello PS, 1996, ONCOGENE, V13, P2595; Dong YZ, 2010, CIRCULATION, V121, P792, DOI 10.1161/CIRCULATIONAHA.109.900928; Galic S, 2011, J CLIN INVEST, V121, P4903, DOI 10.1172/JCI58577; Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x; Gomez G, 2005, J IMMUNOL, V175, P7602, DOI 10.4049/jimmunol.175.11.7602; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Lu Y, 2012, MOL CELL BIOCHEM, V365, P333, DOI 10.1007/s11010-012-1273-3; Lu Y, 2011, BIOCHEM PHARMACOL, V82, P1700, DOI 10.1016/j.bcp.2011.08.022; MacIver NJ, 2011, J IMMUNOL, V187, P4187, DOI 10.4049/jimmunol.1100367; MARQUARDT DL, 1986, BIOCHEM PHARMACOL, V35, P4415, DOI 10.1016/0006-2952(86)90757-4; Mayer A, 2008, EUR J IMMUNOL, V38, P948, DOI 10.1002/eji.200738045; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Molfetta R, 2007, ARCH IMMUNOL THER EX, V55, P219, DOI 10.1007/s00005-007-0028-4; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Poderycki M, 2010, J IMMUNOL, V184, P84, DOI 10.4049/jimmunol.0901590; Randriamboavonjy V, 2010, BLOOD, V116, P2134, DOI 10.1182/blood-2010-04-279612; Sag D, 2008, J IMMUNOL, V181, P8633, DOI 10.4049/jimmunol.181.12.8633; Salminen A, 2011, J MOL MED, V89, P667, DOI 10.1007/s00109-011-0748-0; Saltiel AR, 2003, TRAFFIC, V4, P711, DOI 10.1034/j.1600-0854.2003.00119.x; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Sherman MH, 2010, MOL CELL, V39, P873, DOI 10.1016/j.molcel.2010.08.019; Siraganian RP, 2003, CURR OPIN IMMUNOL, V15, P639, DOI 10.1016/j.coi.2003.09.010; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; Taketomi Y, 2007, J IMMUNOL, V178, P7042, DOI 10.4049/jimmunol.178.11.7042; Tamas P, 2006, J EXP MED, V203, P1665, DOI 10.1084/jem.20052469; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, P1163, DOI 10.1016/j.jaci.2008.12.1126; Xiao WB, 2005, J IMMUNOL, V175, P6885, DOI 10.4049/jimmunol.175.10.6885; Yamada E, 2010, CELL METAB, V11, P113, DOI 10.1016/j.cmet.2009.12.010; Yang ZG, 2010, J BIOL CHEM, V285, P19051, DOI 10.1074/jbc.M110.123620; Yu M, 2006, J IMMUNOL, V176, P2421, DOI 10.4049/jimmunol.176.4.2421; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	45	35	35	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					729	+		10.1016/j.jaci.2013.02.018	http://dx.doi.org/10.1016/j.jaci.2013.02.018			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23587332	hybrid			2022-12-18	WOS:000323612000026
J	Figueiredo, CA; Amorim, LD; Alcantara-Neves, NM; Matos, SMA; Cooper, PJ; Rodrigues, LC; Barreto, ML				Figueiredo, Camila Alexandrina; Amorim, Leila D.; Alcantara-Neves, Neuza M.; Matos, Sheila M. A.; Cooper, Philip J.; Rodrigues, Laura C.; Barreto, Mauricio L.			Environmental conditions, immunologic phenotypes, atopy, and asthma: New evidence of how the hygiene hypothesis operates in Latin America	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LCA; environment; infections; immune phenotypes; children; hygiene hypothesis; SCAALA	CYTOKINE PRODUCTION; RISK-FACTORS; INFECTIONS; HEALTH; CHILDREN; POVERTY; DISEASE; BRAZIL	Background: It has been proposed that improved hygiene and reduced experience of infections in childhood influences the development of allergic diseases. The mechanisms by which the hygiene operates are not well established but are underpinned by two apparently incompatible immunologic paradigms, the balance of T(H)1 versus T(H)2 cytokines and IL-10-mediated regulation of T(H)2 cytokines. Objective: This study defined immunologic phenotypes with the use of latent class analysis and investigated their associations with environmental factors, markers of allergy and asthma, in a Latin American population. Methods: We studied 1127 children living in urban Brazil. Data on wheeze and environmental exposures were collected with standardized questionnaires. Atopy was measured by specific IgE in serum and skin prick test reactivity to aeroallergens. Cytokines were measured in culture after the stimulation of peripheral blood leukocytes with mitogen. Infections with pathogens were assessed by serology and stool examinations. Children were classified as having high or low burden of infection. Latent class analysis was used to identify immune phenotypes on the basis of cytokine production. Logistic regression was used to evaluate the adjusted effects of environment and burden of infection on the immunologic phenotypes and the effect of the phenotypes on atopy and asthma. Results: Three phenotypes were identified, labeled underresponsive, intermediate, and responsive. Children of more educated mothers, living in improved environmental conditions, and with a low burden of infection were significantly more likely to have the responsive phenotype. The responsive phenotype was significantly associated with an increased prevalence of atopy but not asthma. Conclusion: Our findings contribute to a better understanding of the immune mechanisms by which the hygiene hypothesis operates in urban Latin America. (J Allergy Clin Immunol 2013; 131:1064-8.)	[Figueiredo, Camila Alexandrina; Alcantara-Neves, Neuza M.] Univ Fed Bahia, Inst Ciencias Saude, BR-41110040 Salvador, BA, Brazil; [Amorim, Leila D.] Univ Fed Bahia, Inst Matemat, BR-41110040 Salvador, BA, Brazil; [Matos, Sheila M. A.; Barreto, Mauricio L.] Univ Fed Bahia, Inst Saude Colet, BR-41110040 Salvador, BA, Brazil; [Cooper, Philip J.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Cooper, Philip J.] Univ San Francisco Quito, Colegio Ciencias Salud, Quito, Ecuador; [Rodrigues, Laura C.] London Sch Hyg & Trop Med, London WC1, England	Universidade Federal da Bahia; Universidade Federal da Bahia; Universidade Federal da Bahia; Liverpool School of Tropical Medicine; University of Liverpool; University of London; London School of Hygiene & Tropical Medicine	Barreto, ML (corresponding author), Univ Fed Bahia, Inst Saude Colet, Rua Basilio da Gama S-N, BR-41110040 Salvador, BA, Brazil.	mauricio@ufba.br	RODRIGUES, LAURA CUNHA/AAO-4130-2021; Barreto, Mauricio L/B-1752-2008; Amorim, Leila/ABG-9480-2021; Amorim, Leila/B-4508-2015; Figueiredo, Camila Alexandrina/H-3525-2015	Barreto, Mauricio L/0000-0002-0215-4930; Amorim, Leila/0000-0002-1112-2332; Amorim, Leila/0000-0002-1112-2332; Figueiredo, Camila Alexandrina/0000-0003-1356-6188	Wellcome Trust, UK, HCPC Latin America Excellence Centre Programme [072405/Z/03/Z]; National Institutes of Science and Technology Program (MCT-CNPq, Brazil) [57386/2008-9]; Wellcome Trust	Wellcome Trust, UK, HCPC Latin America Excellence Centre Programme; National Institutes of Science and Technology Program (MCT-CNPq, Brazil); Wellcome Trust(Wellcome TrustEuropean Commission)	Supported by The Wellcome Trust, UK, HCPC Latin America Excellence Centre Programme (Ref 072405/Z/03/Z), and the National Institutes of Science and Technology Program (MCT-CNPq, Brazil; contract no. 57386/2008-9).; Disclosure of potential conflict of interest: P. J. Cooper has received grants from the Wellcome Trust. The rest of the authors declare that they have no relevant conflicts of interest.	Alcantara-Neves NM, 2012, J ALLERGY CLIN IMMUN, V129, P359, DOI 10.1016/j.jaci.2011.09.015; Barreto Mauricio L, 2006, BMC Pulm Med, V6, P15, DOI 10.1186/1471-2466-6-15; Barreto ML, 2007, LANCET, V370, P1622, DOI 10.1016/S0140-6736(07)61638-9; Barreto ML, 2011, LANCET, V377, P1877, DOI 10.1016/S0140-6736(11)60202-X; Barreto ML, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-167; Dattoli VCC, 2010, HELICOBACTER, V15, P273, DOI 10.1111/j.1523-5378.2010.00766.x; Collins L. M., 2010, LATENT CLASS LATENT, DOI DOI 10.1002/9780470567333; Cooper PJ, 2009, ALLERGY, V64, P5, DOI 10.1111/j.1398-9995.2008.01902.x; Cooper PJ, 2012, CURR OPIN ALLERGY CL, V12, P171, DOI 10.1097/ACI.0b013e3283510967; Croudace TJ, 2003, AM J EPIDEMIOL, V157, P834, DOI 10.1093/aje/kwg049; da Cunha SS, 2010, REV PANAM SALUD PUBL, V28, P405, DOI 10.1590/S1020-49892010001200001; Dunn KM, 2006, AM J EPIDEMIOL, V163, P754, DOI 10.1093/aje/kwj100; Figueiredo CA, 2011, CLIN IMMUNOL, V139, P57, DOI 10.1016/j.clim.2010.12.019; Figueiredo CA, 2010, INFECT IMMUN, V78, P3160, DOI 10.1128/IAI.01228-09; Figueiredo CA, 2009, ENVIRON HEALTH PERSP, V117, P845, DOI 10.1289/ehp.0800366; Guarner F, 2006, DIGESTION, V73, P5, DOI 10.1159/000089775; Guarner F, 2006, NAT CLIN PRACT GASTR, V3, P275, DOI 10.1038/ncpgasthep0471; Moncayo AL, 2010, THORAX, V65, P409, DOI 10.1136/thx.2009.126490; Muthen L, 2007, MUTH N MUTH N; Rodrigues LC, 2008, CLIN EXP ALLERGY, V38, P1769, DOI 10.1111/j.1365-2222.2008.03027.x; Rook GAW, 2007, T ROY SOC TROP MED H, V101, P1072, DOI 10.1016/j.trstmh.2007.05.014; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; World Health Organization, 2012, PROGR DRINK WAT SAN; Worldwide variation in prevalence of symptoms of asthma allergic rhinoconjunctivitis and atopic eczema: ISAAC, 1998, LANCET, V351, P1225, DOI DOI 10.1016/S0140-6736(97)07302-9; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Ziegelbauer K, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001162	27	35	37	0	47	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1064	+		10.1016/j.jaci.2013.01.016	http://dx.doi.org/10.1016/j.jaci.2013.01.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23414599	Green Accepted, Green Published			2022-12-18	WOS:000317187200014
J	Schnyder, B; Pichler, WJ				Schnyder, Benno; Pichler, Werner J.			Allergy to sulfonamides	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; CROSS-REACTIVITY; DRUG HYPERSENSITIVITY; ANTIBIOTICS		[Schnyder, Benno; Pichler, Werner J.] Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergol, Div Allergol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Pichler, WJ (corresponding author), Univ Bern, Inselspital, Clin Rheumatol Clin Immunol & Allergol, CH-3010 Bern, Switzerland.	Werner.pichler@insel.ch		Pichler, Werner J./0000-0002-8117-359X				Adam J, 2011, BRIT J CLIN PHARMACO, V71, P701, DOI 10.1111/j.1365-2125.2010.03764.x; Borras-Blasco J, 2008, J ANTIMICROB CHEMOTH, V62, P879, DOI 10.1093/jac/dkn292; Depta JPH, 2004, J ALLERGY CLIN IMMUN, V113, P519, DOI 10.1016/j.jaci.2003.11.030; Empedrad R, 2003, J ALLERGY CLIN IMMUN, V112, P629, DOI 10.1067/mai.2003.1690; Johnson KK, 2005, ANN PHARMACOTHER, V39, P290, DOI 10.1345/aph.1E350; Kohli-Pamnani A, 2006, ANN ALLERG ASTHMA IM, V96, P620, DOI 10.1016/S1081-1206(10)63559-4; Lin D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005646.pub2; Naisbitt DJ, 2003, J ALLERGY CLIN IMMUN, V111, P1393, DOI 10.1067/mai.2003.1507; Naisbitt DJ, 2003, MOL PHARMACOL, V63, P732, DOI 10.1124/mol.63.3.732; Pichler WJ, 2011, J DERMATOL, V38, P216, DOI 10.1111/j.1346-8138.2010.01142.x; Pichler WJ, 2004, ALLERGY, V59, P809, DOI 10.1111/j.1398-9995.2004.00547.x; Romano Antonino, 2008, Allergy Asthma Clin Immunol, V4, P66, DOI 10.1186/1710-1492-4-2-66; Shiohara Tetsuo, 2006, Allergol Int, V55, P1, DOI 10.2332/allergolint.55.1; Strom BL, 2003, NEW ENGL J MED, V349, P1628, DOI 10.1056/NEJMoa022963; Zawodniak A, 2010, INT ARCH ALLERGY IMM, V153, P152, DOI 10.1159/000312632	15	35	35	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					256	U380		10.1016/j.jaci.2012.10.003	http://dx.doi.org/10.1016/j.jaci.2012.10.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23265699				2022-12-18	WOS:000312961200051
J	Javaloyes, G; Goikoetxea, MJ; Nunez, IG; Aranda, A; Sanz, ML; Blanca, M; Perales, AD; da Souza, J; Esparza, I; del Pozo, V; Blazquez, AB; Scheurer, S; Vieths, S; Ferrer, M				Javaloyes, Gracia; Goikoetxea, Maria J.; Garcia Nunez, Ignacio; Aranda, Ana; Sanz, Maria L.; Blanca, Miguel; Diaz Perales, Araceli; da Souza, Juliana; Esparza, Irene; del Pozo, Victoria; Blazquez, Ana B.; Scheurer, Stephan; Vieths, Stefan; Ferrer, Marta			Pru p 3 acts as a strong sensitizer for peanut allergy in Spain	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LIPID TRANSFER PROTEINS; CROSS-REACTIVITY; MAJOR ALLERGENS; PEACH		[Javaloyes, Gracia; Goikoetxea, Maria J.; Sanz, Maria L.; Ferrer, Marta] Univ Navarra Clin, Dept Allergy & Clin Immunol, Pamplona, Spain; [Garcia Nunez, Ignacio; Aranda, Ana; Blanca, Miguel; Blazquez, Ana B.] Carlos Haya Hosp, Fdn IMABIS, Allerg Dis Res Lab, Malaga, Spain; [Diaz Perales, Araceli; da Souza, Juliana] Univ Politecn Madrid, Dept Biotecnol, ETSI Montes, Madrid, Spain; [Esparza, Irene] Univ Navarra, Dept Pharm & Pharmaceut Technol, Adjuvant Unit, E-31080 Pamplona, Spain; [Esparza, Irene] Univ Navarra, Dept Microbiol, E-31080 Pamplona, Spain; [del Pozo, Victoria] IIS Fdn Jimenez Diaz, Dept Immunol, Madrid, Spain; [del Pozo, Victoria] CIBER Enfermedades Resp CIBERES, Madrid, Spain; [Scheurer, Stephan; Vieths, Stefan] Paul Ehrlich Inst, Fed Inst Vaccines & Biomed, Div Allergol, D-6070 Langen, Germany	University of Navarra; FIMABIS; Hospital Carlos Haya; Universidad Politecnica de Madrid; University of Navarra; University of Navarra; Fundacion Jimenez Diaz; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Paul Ehrlich Institute	Javaloyes, G (corresponding author), Univ Navarra Clin, Dept Allergy & Clin Immunol, Pamplona, Spain.	mferrerp@unav.es	Goikoetxea, Maria Jose/AAJ-9054-2021; Díaz-Perales, Araceli/D-8433-2016; Ferrer, Marta/C-4319-2016; Esparza, Irene/GOK-2265-2022; Scheurer, Stephan/A-6509-2019; de Souza Rebouças, Juliana/AAJ-7879-2020	Goikoetxea, Maria Jose/0000-0003-2213-6999; Díaz-Perales, Araceli/0000-0002-1093-3627; Ferrer, Marta/0000-0001-8495-1302; Esparza, Irene/0000-0002-3208-4195; Scheurer, Stephan/0000-0002-2859-562X; de Souza Rebouças, Juliana/0000-0003-1886-1602				Asero R, 2002, ALLERGY, V57, P900, DOI 10.1034/j.1398-9995.2002.t01-1-23541.x; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V112, P1002, DOI 10.1016/j.jaci.2003.07.006; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P87, DOI 10.1046/j.0022-0477.2001.01257.x; Hartz C, 2010, INT ARCH ALLERGY IMM, V153, P335, DOI 10.1159/000316344; Krause S, 2009, J ALLERGY CLIN IMMUN, V124, P771, DOI 10.1016/j.jaci.2009.06.008; Lauer I, 2009, CLIN EXP ALLERGY, V39, P1427, DOI 10.1111/j.1365-2222.2009.03312.x; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010	8	35	35	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1432	1434		10.1016/j.jaci.2012.08.038	http://dx.doi.org/10.1016/j.jaci.2012.08.038			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23069486	Green Accepted			2022-12-18	WOS:000311641100032
J	Bime, C; Wei, CY; Holbrook, JT; Sockrider, MM; Revicki, DA; Wise, RA				Bime, Christian; Wei, Christine Y.; Holbrook, Janet T.; Sockrider, Marianna M.; Revicki, Dennis A.; Wise, Robert A.			Asthma Symptom Utility Index: Reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma Symptom Utility Index; reliability; validity; responsiveness; minimal important difference	QUALITY-OF-LIFE; OUTCOMES; QUESTIONNAIRE; VALIDATION	Background: The evaluation of asthma symptoms is a core outcome measure in asthma clinical research. The Asthma Symptom Utility Index (ASUI) was developed to assess the frequency and severity of asthma symptoms. The psychometric properties of the ASUI are not well characterized, and a minimal important difference (MID) is not established. Objectives: We assessed the reliability, validity, and responsiveness to change of the ASUI in a population of adult asthmatic patients. We also sought to determine the MID for the ASUI. Methods: Adult asthmatic patients (n = 1648) from 2 previously completed multicenter randomized trials were included. Demographic information, spirometric results, ASUI scores, and other asthma questionnaire scores were obtained at baseline and during follow-up visits. Participants also kept a daily asthma diary. Results: The internal consistency reliability of the ASUI was 0.74 (Cronbach a). Test-retest reliability was 0.76 (intraclass correlation). Construct validity was demonstrated by significant correlations between ASUI scores and Asthma Control Questionnaire scores (Spearman correlation r = -20.79; 95% CI, -0.85 to -0.75; P < .001) and Mini Asthma Quality of Life Questionnaire scores (r = 0.59; 95% CI, 0.51-0.61; P < .001). Responsiveness to change was demonstrated, with significant differences between mean changes in ASUI scores across groups of participants differing by 10% in percent predicted FEV1 (P < .001) and by 0.5 points in Asthma Control Questionnaire scores (P < .001). Anchor-based and statistical methods support an MID for the ASUI of 0.09 points. Conclusions: The ASUI is reliable, valid, and responsive to changes in asthma control over time. The MID of the ASUI (range of scores, 0-1) is 0.09. (J Allergy Clin Immunol 2012;130:1078-84.)	[Bime, Christian; Wise, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Wei, Christine Y.; Holbrook, Janet T.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Sockrider, Marianna M.] Baylor Coll Med, Houston, TX 77030 USA; [Revicki, Dennis A.] United BioSource Corp, Bethesda, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Baylor College of Medicine; United Biosource Corporation	Wise, RA (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Pulm & Crit Care Med, 4B72,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	rwise@jhmi.edu		Bime, Christian/0000-0003-4787-2685; Wise, Robert/0000-0002-8353-2349	National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) [5U01HL072968]; American Lung Association; American Lung Association of Alabama; American Lung Association of Central Florida; American Lung Association of Colorado; American Lung Association of Delaware; American Lung Association of Eastern Missouri; American Lung Association of Finger Lakes (New York); American Lung Association of Georgia; American Lung Association of Gulfcoast Florida; American Lung Association of Hudson Valley (New York); American Lung Association of Illinois; American Lung Association of Indiana; American Lung Association of Louisiana; American Lung Association of Maine; American Lung Association of Metropolitan Chicago; American Lung Association of Michigan; American Lung Association of Mid-Ohio; American Lung Association of Minnesota; American Lung Association of Nashua-Suffolk (New York); American Lung Association of New Hampshire; American Lung Association of New York City; American Lung Association of North Carolina; American Lung Association of Northeast Florida; American Lung Association of Ohio; American Lung Association of Oklahoma; American Lung Association of Pennsylvania; American Lung Association of South Florida; American Lung Association of Southeast Florida; American Lung Association of Texas; American Lung Association of Vermont; American Lung Association of Western Missouri; American Lung Association of Wisconsin; American Lung Association of Greater Norfolk County (Massachusetts); American Lung Association of Hawaii; American Lung Association of Middlesex County (Massachusetts); American Lung Association of New York State; American Lung Association of Northern Rockies; American Lung Association of Queens (New York); American Lung Association of Western Massachusetts; American Lung Association of Virginia; Baylor College of Medicine; Thalheim Family; Duke University; Ernest N. Morial Asthma, Allergy, and Respiratory Disease Center; Merck Foundation; GlaxoSmithKline; National Heart, Lung, and Blood Institute; BIPI; Merck; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072968, T32HL007534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI091274] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Lung Association; American Lung Association of Alabama; American Lung Association of Central Florida; American Lung Association of Colorado; American Lung Association of Delaware; American Lung Association of Eastern Missouri; American Lung Association of Finger Lakes (New York); American Lung Association of Georgia; American Lung Association of Gulfcoast Florida; American Lung Association of Hudson Valley (New York); American Lung Association of Illinois; American Lung Association of Indiana; American Lung Association of Louisiana; American Lung Association of Maine; American Lung Association of Metropolitan Chicago; American Lung Association of Michigan; American Lung Association of Mid-Ohio; American Lung Association of Minnesota; American Lung Association of Nashua-Suffolk (New York); American Lung Association of New Hampshire; American Lung Association of New York City; American Lung Association of North Carolina; American Lung Association of Northeast Florida; American Lung Association of Ohio; American Lung Association of Oklahoma; American Lung Association of Pennsylvania; American Lung Association of South Florida; American Lung Association of Southeast Florida; American Lung Association of Texas; American Lung Association of Vermont; American Lung Association of Western Missouri; American Lung Association of Wisconsin; American Lung Association of Greater Norfolk County (Massachusetts); American Lung Association of Hawaii; American Lung Association of Middlesex County (Massachusetts); American Lung Association of New York State; American Lung Association of Northern Rockies; American Lung Association of Queens (New York); American Lung Association of Western Massachusetts; American Lung Association of Virginia; Baylor College of Medicine; Thalheim Family; Duke University; Ernest N. Morial Asthma, Allergy, and Respiratory Disease Center; Merck Foundation(Merck & Company); GlaxoSmithKline(GlaxoSmithKline); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BIPI; Merck(Merck & Company); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Study of Acid Reflux and Asthma was supported by the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI; 5U01HL072968) and the American Lung Association and is registered at ClinicalTrials.Gov as NCT00069823. The Safety of Inactivated Influenza Vaccine in Asthma trial was supported by grants from the American Lung Associations of Alabama, Central Florida, Colorado, Delaware, Eastern Missouri, Finger Lakes (New York), Georgia, Gulfcoast Florida, Hudson Valley (New York), Illinois, Indiana, Louisiana, Maine, Metropolitan Chicago, Michigan, Mid-Ohio, Minnesota, Nashua-Suffolk (New York), New Hampshire, New York City, North Carolina, Northeast Florida, Ohio, Oklahoma, Pennsylvania, South Florida, Southeast Florida, Texas, Vermont, Western Missouri, Wisconsin, Greater Norfolk County (Massachusetts), Hawaii, Middlesex County (Massachusetts), New York State, Northern Rockies, Queens (New York), Western Massachusetts, and Virginia; Baylor College of Medicine; the Thalheim Family; Duke University; the Ernest N. Morial Asthma, Allergy, and Respiratory Disease Center; the Merck Foundation; and GlaxoSmithKline.; Disclosure of potential conflict of interest: C. Bime has received support for travel from the American Lung Association. J. T. Holbrook has been supported by one or more grants from and has received support for travel from the American Lung Association and has received one or more payments for lecturing from or is on the speakers' bureau for ARVO and the American Thoracic Society. M. M. Sockrider has received grants and support for travel from the American Lung Association and has received one or more grants from or has one or more grants pending with the National Heart, Lung, and Blood Institute. R. A. Wise is a member of the Clinical Endpoint Committee for GlaxoSmithKline, the Data and Safety Monitoring Board (SC) for BIPI, the Mortality Review Committee for Mylan, the Scientific Advisory Board for AstraZeneca, the Steering Committee for Spiration, and the Scientific Advisory Board for Sunovion and has received one or more grants from or has one or more grants pending with BIPI, Merck, and GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2007, J ALLERGY CLIN IM S1, V120, pS94; Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961; Cazzola M, 2008, EUR RESPIR J, V31, P416, DOI 10.1183/09031936.00099306; Flood EM, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-51; Hanania NA, 2009, NEW ENGL J MED, V360, P1487, DOI 10.1056/NEJMoa0806290; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, pS124, DOI 10.1016/j.jaci.2011.12.981; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; McCoy K, 2006, J ALLERGY CLIN IMMUN, V118, P1226, DOI 10.1016/j.jaci.2006.09.006; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; *NIH, 1991, NIH PUBL; Peters SP, 2011, NEW ENGL J MED, V364, P578; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2003, J ALLERGY CLIN IMMUN, V112, P283, DOI 10.1067/mai.2003.1516; Schatz M, 2011, J ALLERGY CLIN IMMUN, V128, P44, DOI 10.1016/j.jaci.2010.12.1112; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	22	35	35	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1078	1084		10.1016/j.jaci.2012.07.058	http://dx.doi.org/10.1016/j.jaci.2012.07.058			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	23026499	Green Accepted			2022-12-18	WOS:000310571400006
J	Goleva, E; Jackson, LP; Gleason, M; Leung, DYM				Goleva, Elena; Jackson, Leisa P.; Gleason, Melanie; Leung, Donald Y. M.			Usefulness of PBMCs to predict clinical response to corticosteroids in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; corticosteroids; glucocorticoid receptor	GLUCOCORTICOID-RECEPTOR-BETA; STEROID-RESISTANT ASTHMA; INSENSITIVE ASTHMA; T-CELLS; EXPRESSION; PHOSPHATASE-1; DEXAMETHASONE; MACROPHAGES; SENSITIVITY; INHIBITION	Background: Blood tests are needed to identify steroid-resistant (SR) asthmatic patients early so that they can be managed with alternative anti-inflammatory therapy. Objective: We sought to assess the usefulness of peripheral blood to predict steroid response in asthmatic patients. Methods: Nineteen asthmatic patients with FEV1 of less than 80% of predicted value were classified as SR or steroid sensitive (SS) based on change in lung FEV1 percentage after 7 days of oral prednisone. Blood was collected at baseline (visit 1) and 30 days after prednisone administration (visit 3). PBMCs were cultured for 4 hours with or without 10(-7) mol/L dexamethasone, and cellular response to dexamethasone was determined by using real-time PCR based on expression analysis of steroid-regulated genes. Suppression of PHA-induced T-cell proliferation by dexamethasone was assessed. Results: Prednisone significantly improved FEV1 percentages in SS asthmatic patients (mean +/- SE: 17.5% +/- 2.4%) but not SR asthmatic patients (0.8% +/- 2.0%, P < .001). Before prednisone treatment, mitogen-induced kinase phosphatase 1 (P = .01) and IL-8 mRNA (P < .05) levels were significantly higher in PBMCs from SR asthmatic patients. TNF-alpha (P < .05) and IL-8 fold suppression by dexamethasone (P < .05) were significantly reduced in PBMCs from SR asthmatic patients. The expression of glucocorticoid receptor (GCR) beta, but not GCR-alpha, was significantly increased in PBMCs of SR asthmatic patients (P = .01). The dexamethasone inhibitory concentration of 50% for PBMC proliferation was significantly higher for SR asthmatic patients (P < .05). These markers no longer differed between groups in PBMCs 30 days after prednisone administration. The composite score of assays at baseline before prednisone was significantly different between SR and SS asthmatic patients (P < .001). Conclusions: PBMCs from SR asthmatic patients have higher baseline mitogen-induced kinase phosphatase 1, IL-8, and GCR-beta mRNA levels; have a lower GCR-alpha/GCR-beta mRNA ratio; are less responsive to suppression of TNF-alpha and IL-8 by dexamethasone; and require more dexamethasone to suppress T-cell proliferation compared with SS asthmatic patients. (J Allergy Clin Immunol 2012; 129: 687-93.)	[Goleva, Elena; Jackson, Leisa P.; Gleason, Melanie; Leung, Donald Y. M.] Natl Jewish Hlth, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; [Leung, Donald Y. M.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA	National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Leung, DYM (corresponding author), Natl Jewish Hlth, Div Pediat Allergy & Immunol, 1400 Jackson St,K926I, Denver, CO 80206 USA.	leungd@njhealth.org			Genentech, Inc; National Institutes of Health [AI070140, HL37260]; Genentech; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL037260, R01HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070140, R56AI070140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	Genentech, Inc(Roche HoldingGenentech); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genentech(Roche HoldingGenentech); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported in part by Genentech, Inc, and National Institutes of Health grants AI070140 and HL37260.; M. Gleason has served on an advisory panel for Dey Pharmaceutical. D. Y. M. Leung has received research support from the National Institutes of Health and Genentech. The rest of the authors declare that they have no relevant conflicts of interest.	Abraham SM, 2006, J EXP MED, V203, P1883, DOI 10.1084/jem.20060336; Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Chrousos George P, 2005, Sci STKE, V2005, ppe48, DOI 10.1126/stke.3042005pe48; Donn R, 2007, FASEB J, V21, P402, DOI 10.1096/fj.06-7236com; Federico MJ, 2005, CHEST, V127, P571, DOI 10.1378/chest.127.2.571; Global Initiative for Asthma, 2009, GLOB STRAT ASTHM MAN; Goleva E, 2006, AM J RESP CRIT CARE, V173, P607, DOI 10.1164/rccm.200507-1046OC; Goleva E, 2008, J ALLERGY CLIN IMMUN, V122, P550, DOI 10.1016/j.jaci.2008.07.007; Goleva E, 2007, J ALLERGY CLIN IMMUN, V120, P1065, DOI 10.1016/j.jaci.2007.07.042; Goleva E, 2009, AM J RESP CELL MOL, V40, P223, DOI 10.1165/rcmb.2007-0327OC; Good PI, 2005, PERMUTATION PARAMETR; Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Hauk PJ, 2002, AM J RESP CELL MOL, V27, P361, DOI 10.1165/rcmb.4861; HILL MR, 1990, CLIN PHARMACOL THER, V48, P390, DOI 10.1038/clpt.1990.167; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Lewis-Tuffin LJ, 2007, MOL CELL BIOL, V27, P2266, DOI 10.1128/MCB.01439-06; Li LB, 2007, BLOOD, V110, P1570, DOI 10.1182/blood-2007-01-070755; Li LB, 2010, AM J RESP CRIT CARE, V182, P877, DOI 10.1164/rccm.201001-0015OC; Li LB, 2006, J LEUKOCYTE BIOL, V79, P818, DOI 10.1189/jlb.0805466; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; National Heart Lung and Blood Institute, 2007, NIH PUBL; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yudt MR, 2003, MOL CELL BIOL, V23, P4319, DOI 10.1128/MCB.23.12.4319-4330.2003; 1987, AM REV RESP DIS, V136, P225	32	35	37	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					687	U137		10.1016/j.jaci.2011.12.001	http://dx.doi.org/10.1016/j.jaci.2011.12.001			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22236730	Green Accepted			2022-12-18	WOS:000301189300012
J	Kitamura, N; Yokoyama, H; Yashiro, T; Nakano, N; Nishiyama, M; Kanada, S; Fukai, T; Hara, M; Ikeda, S; Ogawa, H; Okumura, K; Nishiyama, C				Kitamura, Nao; Yokoyama, Hokuto; Yashiro, Takuya; Nakano, Nobuhiro; Nishiyama, Makoto; Kanada, Shunsuke; Fukai, Tatsuo; Hara, Mutsuko; Ikeda, Shigaku; Ogawa, Hideoki; Okumura, Ko; Nishiyama, Chiharu			Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PU.1; class II transactivator; dendritic cells; MHC class II	EPSILON-RI-BETA; CHAIN GENE-EXPRESSION; MAST-CELLS; T-CELLS; CIITA; ACTIVATION; DIFFERENTIATION; OVERPRODUCTION; MECHANISM; SURVIVAL	Background: PU.1 is a hematopoietic cell-specific transcription factor belonging to the Ets family. We hypothesized that PU.1 is involved in MHC class II expression in dendritic cells (DCs). Objective: The role of PU.1 in MHC class II expression in DCs was analyzed. Methods: Transcriptional regulation of the DC-specific pI promoter of the class II transactivator (CIITA) gene and subsequent MHC class II expression was investigated by using PU.1 small interfering RNA (siRNA) and reporter, chromatin immunoprecipitation, and electrophoretic mobility shift assays. Results: PU.1 siRNA introduction suppressed MHC class II expression, allogeneic and syngeneic T-cell activation activities of bone marrow-derived DCs (BMDCs) with reduction of CIITA mRNA driven by the DC-specific promoter pI, and MHC class II mRNA. The chromatin immunoprecipitation assay showed constitutive binding of PU.1 to the pI region in BMDCs, whereas acetylation of histone H3 on pI was suppressed by LPS stimulation in parallel with shutdown of CIITA transcription. PU.1 transactivated the pI promoter through cis-elements at -47/-44 and -30/-27 in a reporter assay and to which PU.1 directly bound in an electrophoretic mobility shift assay. Acetylation of histones H3 and H4 on pI was reduced in PU.1 siRNA-introduced BMDCs. Knockdown of interferon regulatory factor 4 or 8, which is a heterodimer partner of PU.1, by siRNA did not affect pI-driven CIITA transcription or MHC class II expression. Conclusion: PU.1 basally transactivates the CIITA pI promoter in DCs by functioning as a monomeric transcription factor and by affecting histone modification, resulting in the subsequent expression and function of MHC class II. (J Allergy Clin Immunol 2012;129:814-24.)	[Kitamura, Nao; Yokoyama, Hokuto; Yashiro, Takuya; Nakano, Nobuhiro; Kanada, Shunsuke; Fukai, Tatsuo; Hara, Mutsuko; Ogawa, Hideoki; Okumura, Ko; Nishiyama, Chiharu] Juntendo Univ, Sch Med, Atopy Res Ctr, Tokyo 1138421, Japan; [Kitamura, Nao; Fukai, Tatsuo; Ikeda, Shigaku] Juntendo Univ, Sch Med, Dept Dermatol, Tokyo 1138421, Japan; [Yokoyama, Hokuto; Nishiyama, Makoto] Univ Tokyo, Biotechnol Res Ctr, Tokyo, Japan	Juntendo University; Juntendo University; University of Tokyo	Nishiyama, C (corresponding author), Juntendo Univ, Atopy Allergy Res Ctr, Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	chinishi@juntendo.ac.jp	yashiro, takuya/Y-1543-2019; yashiro, takuya/I-8210-2012; Nishiyama, Chiharu/GPW-9372-2022	yashiro, takuya/0000-0002-9319-3467; Nishiyama, Makoto/0000-0001-8143-8052; Nakano, Nobuhiro/0000-0002-5317-5950; Fukai, Tatsuo/0000-0002-7884-5201	Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [22791091] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by the Funding Program for Next Generation World-Leading Researchers from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to C.N.).	Anderson KL, 2000, J IMMUNOL, V164, P1855, DOI 10.4049/jimmunol.164.4.1855; Carotta S, 2010, IMMUNITY, V32, P628, DOI 10.1016/j.immuni.2010.05.005; Chang HC, 2010, NAT IMMUNOL, V11, P527, DOI 10.1038/ni.1867; Dakic A, 2007, TRENDS IMMUNOL, V28, P108, DOI 10.1016/j.it.2007.01.006; Escalante CR, 2002, MOL CELL, V10, P1097, DOI 10.1016/S1097-2765(02)00703-7; Green MR, 2006, J IMMUNOL, V177, P3865, DOI 10.4049/jimmunol.177.6.3865; Guerriero A, 2000, BLOOD, V95, P879, DOI 10.1182/blood.V95.3.879.003k13_879_885; Hamdorf M, 2011, STEM CELLS, V29, P297, DOI 10.1002/stem.564; Holling TM, 2002, J IMMUNOL, V168, P763, DOI 10.4049/jimmunol.168.2.763; Ito T, 2005, J IMMUNOL, V174, P376, DOI 10.4049/jimmunol.174.1.376; Ito T, 2009, INT IMMUNOL, V21, P803, DOI 10.1093/intimm/dxp048; Kanada S, 2008, J IMMUNOL, V180, P8204, DOI 10.4049/jimmunol.180.12.8204; Kanada S, 2011, BLOOD, V117, P2211, DOI 10.1182/blood-2010-06-291898; Landmann S, 2001, J EXP MED, V194, P379, DOI 10.1084/jem.194.4.379; LeibundGut-Landmann S, 2004, NAT IMMUNOL, V5, P899, DOI 10.1038/ni1109; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Maeda K, 2003, J IMMUNOL, V170, P334, DOI 10.4049/jimmunol.170.1.334; Maeda K, 2006, BLOOD, V108, P262, DOI 10.1182/blood-2005-07-2878; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nakano N, 2007, BLOOD, V109, P4846, DOI 10.1182/blood-2006-09-045641; Nakano N, 2009, J ALLERGY CLIN IMMUN, V123, P74, DOI 10.1016/j.jaci.2008.10.040; Nishiyama C, 1999, J IMMUNOL, V163, P623; Nishiyama C, 2004, J IMMUNOL, V173, P6458, DOI 10.4049/jimmunol.173.10.6458; Nishiyama C, 2004, BIOCHEM BIOPH RES CO, V313, P516, DOI 10.1016/j.bbrc.2003.11.145; Nishiyama C, 2002, J IMMUNOL, V168, P4546, DOI 10.4049/jimmunol.168.9.4546; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Pai RK, 2002, J IMMUNOL, V169, P1326, DOI 10.4049/jimmunol.169.3.1326; Reith W, 2005, NAT REV IMMUNOL, V5, P793, DOI 10.1038/nri1708; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Smith MA, 2011, J BIOL CHEM, V286, P7893, DOI 10.1074/jbc.M110.165431; van der Stoep N, 2004, BLOOD, V104, P2849, DOI 10.1182/blood-2004-03-0790; Walseng E, 2010, J BIOL CHEM, V285, P41749, DOI 10.1074/jbc.M110.157586; Yoon H, 2010, J IMMUNOL, V184, P5018, DOI 10.4049/jimmunol.1000079	36	35	36	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					814	U319		10.1016/j.jaci.2011.10.019	http://dx.doi.org/10.1016/j.jaci.2011.10.019			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22112519				2022-12-18	WOS:000301189300030
J	Hasdenteufel, F; Waton, J; Cordebar, V; Studer, M; Collignon, O; Luyasu, S; Beaudouin, E; Renaudin, JM; Morisset, M; Kanny, G; Barbaud, A				Hasdenteufel, Frederic; Waton, Julie; Cordebar, Vanina; Studer, Myriam; Collignon, Olivier; Luyasu, Samuel; Beaudouin, Etienne; Renaudin, Jean-Marie; Morisset, Martine; Kanny, Gisele; Barbaud, Annick			Delayed hypersensitivity reactions caused by iodixanol: An assessment of cross-reactivity in 22 patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IODINATED CONTRAST-MEDIA; SKIN		[Hasdenteufel, Frederic; Cordebar, Vanina; Luyasu, Samuel; Beaudouin, Etienne; Renaudin, Jean-Marie; Morisset, Martine; Kanny, Gisele] Univ Hosp Nancy, EA Allergy Dis Diag & Therapeut 3999, Dept Internal Med Clin Immunol & Allergol, Nancy, France; [Waton, Julie; Studer, Myriam; Barbaud, Annick] Univ Hosp Nancy, Dept Dermatol, Nancy, France; [Collignon, Olivier] Genclis SAS, Vandoeuvre Les Nancy, France	CHU de Nancy; Universite de Lorraine; CHU de Nancy; Universite de Lorraine	Hasdenteufel, F (corresponding author), Univ Hosp Nancy, EA Allergy Dis Diag & Therapeut 3999, Dept Internal Med Clin Immunol & Allergol, Nancy, France.	f.hasdenteufel@orange.fr	, barbaud/AAZ-7250-2021; Kanny, Gisèle/AHA-8910-2022; Morisset, Martine/A-3084-2017	Morisset, Martine/0000-0002-4028-703X				Brockow K, 2002, ALLERGY, V57, P45; Brockow K, 2009, ALLERGY, V64, P234, DOI 10.1111/j.1398-9995.2008.01832.x; Christiansen C, 2005, TOXICOLOGY, V209, P185, DOI 10.1016/j.tox.2004.12.020; Delgado-Jimenez Y, 2006, CONTACT DERMATITIS, V55, P348, DOI 10.1111/j.1600-0536.2006.00957.x; Haussler MD, 2010, ACTA RADIOL, V51, P924, DOI 10.3109/02841851.2010.504739; Kanny G, 2005, J ALLERGY CLIN IMMUN, V115, P179, DOI 10.1016/j.jaci.2004.09.012; Lerch M, 2007, J ALLERGY CLIN IMMUN, V119, P1529, DOI 10.1016/j.jaci.2007.02.007; Vernassiere C, 2004, CONTACT DERMATITIS, V50, P359, DOI 10.1111/j.0105-1873.2004.00367.x	8	35	35	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1356	1357		10.1016/j.jaci.2011.05.034	http://dx.doi.org/10.1016/j.jaci.2011.05.034			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21782229	Bronze			2022-12-18	WOS:000298342700031
J	Lambiase, A; Leonardi, A; Sacchetti, M; Deligianni, V; Sposato, S; Bonini, S				Lambiase, Alessandro; Leonardi, Andrea; Sacchetti, Marta; Deligianni, Velika; Sposato, Sabrina; Bonini, Stefano			Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONJUNCTIVITIS		[Lambiase, Alessandro; Sacchetti, Marta; Sposato, Sabrina; Bonini, Stefano] Univ Rome Campus Biomed, Dept Ophthalmol, Rome, Italy; [Leonardi, Andrea; Deligianni, Velika] Univ Padua, Dept Ophthalmol, Padua, Italy	University Campus Bio-Medico - Rome Italy; University of Padua	Lambiase, A (corresponding author), Univ Rome Campus Biomed, Dept Ophthalmol, Rome, Italy.	s.bonini@unicampus.it	Lambiase, Alessandro/K-3902-2016; Bonini, Stefano/A-2250-2012; Bonini, Sergio/T-6594-2019; Sacchetti, Marta/AAB-8616-2021	Lambiase, Alessandro/0000-0002-8974-991X; Bonini, Stefano/0000-0002-7787-2144; Bonini, Sergio/0000-0003-0079-3031; sacchetti, marta/0000-0001-5569-778X				BONINI S, 1992, J ALLERGY CLIN IMMUN, V89, P103, DOI 10.1016/S0091-6749(05)80046-6; Bonini S, 2000, OPHTHALMOLOGY, V107, P1157, DOI 10.1016/S0161-6420(00)00092-0; Cameron JA, 1997, J PEDIAT OPHTH STRAB, V34, P261; Ebihara N, 2009, J OCUL PHARMACOL TH, V25, P365, DOI 10.1089/jop.2008.0103; Fraunfelder FW, 2006, CORNEA, V25, P1133, DOI 10.1097/01.ico.0000240084.27663.fd; Kosrirukvongs Panida, 2004, Journal of the Medical Association of Thailand, V87, P190; Leonardi A, 2002, PROG RETIN EYE RES, V21, P319, DOI 10.1016/S1350-9462(02)00006-X; Sacchetti M, 2010, OPHTHALMOLOGY, V117, P1294, DOI 10.1016/j.ophtha.2009.11.043; Tabbara KF, 1999, CAN J OPHTHALMOL, V34, P88	9	35	36	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					896	+		10.1016/j.jaci.2011.07.004	http://dx.doi.org/10.1016/j.jaci.2011.07.004			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21868078				2022-12-18	WOS:000296538100032
J	Rothers, J; Halonen, M; Stern, DA; Lohman, IC; Mobley, S; Spangenberg, A; Anderson, D; Wright, AL				Rothers, Janet; Halonen, Marilyn; Stern, Debra A.; Lohman, I. Carla; Mobley, Sara; Spangenberg, Amber; Anderson, Dayna; Wright, Anne L.			Adaptive cytokine production in early life differentially predicts total IgE levels and asthma through age 5 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; IgE; cytokines; IL-4; IL-5; IL-13; IFN-gamma; children	INTERFERON-GAMMA PRODUCTION; BLOOD MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; SUBSEQUENT DEVELOPMENT; CHILDHOOD ASTHMA; IL-13 PRODUCTION; ATOPIC DISEASE; BIRTH COHORT; SERUM IGE; 1ST YEAR	Background: Although it has been postulated that allergic disease is associated with a predominance of T(H)2 cells, whether IgE levels and asthma might differ in their relation to early-life cytokine production is not known. Objective: We sought to assess the relationship between first-year adaptive immune cytokine production with asthma and total IgE levels through age 5 years in a nonselected birth cohort. Methods: Mitogen (concanavalin A/phorbol 12-myristate 13-acetate)-stimulated IL-4, IL-5, IL-13, and IFN-gamma levels were measured in supernatants from cord blood mononuclear cells and PBMCs at birth, 3 months, and 12 months. Total serum IgE levels and physician-diagnosed active asthma were assessed at 1, 2, 3, and 5 years. Longitudinal models that adjust for both T(H)1 and T(H)2 cytokine production were used to determine relations of outcomes. Results: Relations of cytokines to total IgE levels and asthma were strikingly different. Total IgE levels through age 5 years were positively associated with 12-month IL-4 (P < .001), IL-5 (P < .001), and IL-13 (P = .02) levels when adjusted for IFN-gamma levels and inversely associated with 12-month IFN-gamma levels after IL-4 adjustment (P = .01). Active asthma through age 5 years was positively associated with 3-month IL-13 levels adjusted for IFN-gamma (odds ratio, 2.6; P < .001) and inversely associated with 3-month IFN-gamma levels adjusted for IL-13 (odds ratio, 0.5; P = .001). These relations were strongest for nonatopic asthma. Conclusion: Total IgE levels and active asthma through age 5 years are associated with adaptive cytokine production in early life, although relations vary temporally and with regard to the relative importance of individual cytokines. (J Allergy Clin Immunol 2011;128:397-402.)	[Rothers, Janet; Halonen, Marilyn; Stern, Debra A.; Lohman, I. Carla; Mobley, Sara; Spangenberg, Amber; Anderson, Dayna; Wright, Anne L.] Univ Arizona HSC, Arizona Resp Ctr, Coll Med, Tucson, AZ 85724 USA; [Rothers, Janet] Univ Arizona HSC, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ 85724 USA; [Halonen, Marilyn] Univ Arizona HSC, Dept Pharmacol, Coll Med, Tucson, AZ 85724 USA; [Wright, Anne L.] Univ Arizona HSC, Dept Pediat, Coll Med, Tucson, AZ 85724 USA	University of Arizona; University of Arizona; University of Arizona; University of Arizona	Wright, AL (corresponding author), Univ Arizona HSC, Arizona Resp Ctr, Coll Med, Tucson, AZ 85724 USA.	awright@arc.arizona.edu		Halonen, Marilyn/0000-0001-9606-935X	National Institutes of Health [AI 42268, AI 61811]; National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061811, R01AI042268] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI 42268 and AI 61811.; J. Rothers, D. A. Stern, I. C. Lohman, S. Mobley, A. Spangenberg, D. Anderson, and A. L. Wright receive research support from the National Institutes of Health. M. Halonen receives research support from the National Institute of Allergy and Infectious Diseases.	BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Crestani E, 2007, J ALLERGY CLIN IMMUN, V120, P820, DOI 10.1016/j.jaci.2007.05.033; Duramad P, 2006, ENVIRON HEALTH PERSP, V114, P1916, DOI 10.1289/ehp.9306; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Gabrielsson S, 2001, CLIN EXP IMMUNOL, V126, P390, DOI 10.1046/j.1365-2249.2001.01703.x; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; Halonen M, 1999, AM J RESP CRIT CARE, V160, P564, DOI 10.1164/ajrccm.160.2.9809038; Halonen M, 2009, J IMMUNOL, V182, P3285, DOI 10.4049/jimmunol.0711996; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Hoekstra MO, 1997, CLIN EXP ALLERGY, V27, P1254; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Jutel M, 2011, CURR ALLERGY ASTHM R, V11, P139, DOI 10.1007/s11882-011-0178-7; Kim JH, 2008, J ASTHMA, V45, P948, DOI 10.1080/02770900802419676; KRONMAL RA, 1993, J ROY STAT SOC A STA, V156, P379, DOI 10.2307/2983064; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Nurse B, 1997, J ALLERGY CLIN IMMUN, V100, P662, DOI 10.1016/S0091-6749(97)70171-4; Ohshima Y, 2002, PEDIATR RES, V51, P195, DOI 10.1203/00006450-200202000-00012; Paludan SR, 1998, SCAND J IMMUNOL, V48, P459; Poulsen LK, 2007, ANN MED, V39, P440, DOI 10.1080/07853890701449354; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; ROBINSON DS, 1993, THORAX, V48, P845, DOI 10.1136/thx.48.8.845; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; Su Y, 2010, CLIN EXP ALLERGY, V40, P1222, DOI 10.1111/j.1365-2222.2010.03539.x; Tadaki H, 2009, PEDIAT ALLERG IMM-UK, V20, P227, DOI 10.1111/j.1399-3038.2008.00783.x; TANG MLK, 1995, CLIN EXP ALLERGY, V25, P515, DOI 10.1111/j.1365-2222.1995.tb01088.x; Uekert SJ, 2006, J ALLERGY CLIN IMMUN, V118, P1375, DOI 10.1016/j.jaci.2006.09.008; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; Vercelli D, 2002, CURR OPIN ALLERGY CL, V2, P389, DOI 10.1097/00130832-200210000-00004; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; Williams TJ, 2000, J ALLERGY CLIN IMMUN, V105, P951, DOI 10.1067/mai.2000.106211; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	37	35	36	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					397	U422		10.1016/j.jaci.2011.04.044	http://dx.doi.org/10.1016/j.jaci.2011.04.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21683432	Green Accepted			2022-12-18	WOS:000293280800022
J	Raymond, M; Van, VQ; Wakahara, K; Rubio, M; Sarfati, M				Raymond, Marianne; Vu Quang Van; Wakahara, Keiko; Rubio, Manuel; Sarfati, Marika			Lung dendritic cells induce T(H)17 cells that produce T(H)2 cytokines, express GATA-3, and promote airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)17; T(H)2; dendritic cells; airway inflammation; signal regulatory protein alpha	MEMORY T-CELLS; IMMUNE-RESPONSES; TH17 CELLS; DIFFERENTIATION; INTERLEUKIN-17; TH2; HYPERRESPONSIVENESS; ACTIVATION; GENERATION; MIGRATION	Background: Dendritic cells (DCs) are crucial to shape the adaptive immune response. Extensive in vitro manipulation reprograms T(H)2 and T(H)17 cell lines into T(H)1 cells, leading to the concept of CD4(+) T-H cell subset plasticity. The conversion of memory T(H)17 cells into T(H)2 cells or vice versa remains to be clarified. Objective: We examined the localization of T(H)17/T(H)2 cells in vivo, their cellular origin (T(H)2 vs T(H)17), and the underlying mechanisms that drive the generation of these double T-H producers. Methods: Antigen-loaded bone marrow-derived DCs (ovalbumin-DCs) were repeatedly administered locally (intratracheally) or systemically (intravenously) to naive mice to elicit chronic airway inflammation. Inflamed lungs and mediastinal lymph nodes were examined for the presence of IL-17(+) IL-13(+) IL-4(+) CD4(+) T cells that coexpressed retinoic acid receptor-related orphan receptor gamma t and GATA-3 (T(H)17/T(H)2). Results: We show that repetitive administration of inflammatory ovalbumin-DCs, locally or systemically, promoted the development of antigen-specific T(H)17/T(H)2 cells in lungs and mediastinal lymph nodes. Immunized mice had IgE-independent and steroid-resistant airway inflammation with a mixed neutrophil and eosinophil infiltration of the bronchoalveolar lavage fluid. Airway inflammatory signal regulatory protein alpha-positive DCs reprogrammed in vitro-generated T(H)17 but not T(H)2 cells, as well as lung effector T-H cells, into T(H)17/T(H)2 cells. Conclusion: We demonstrate the existence of T(H)17/T(H)2 cells that express GATA-3 in inflamed tissues and their T(H)17 origin. We further propose that repeated immunization with inflammatory DCs prevails on the route of DC administration to drive T(H)17/T(H)2-associated chronic lung inflammation. (J Allergy Clin Immunol 2011; 128: 192-201.)	[Raymond, Marianne; Vu Quang Van; Wakahara, Keiko; Rubio, Manuel; Sarfati, Marika] Ctr Hosp Univ Montreal, Notre Dame Hop, Immunoregulat Lab, Res Ctr CRCHUM, Montreal, PQ H2L 4M1, Canada	Universite de Montreal	Sarfati, M (corresponding author), Ctr Hosp Univ Montreal, Hop Notre Dame, Immunoregulat Lab, Res Ctr CRCHUM, Pavillon Mailloux,M4211K,1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.	m.sarfati@umontreal.ca	WAKAHARA, Keiko/I-7324-2014		Canadian Institute for Health and Research (CIHR) [MOP-53152]	Canadian Institute for Health and Research (CIHR)(Canadian Institutes of Health Research (CIHR))	Supported by the Canadian Institute for Health and Research (CIHR grant MOP-53152).	Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018; Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Belyakov IM, 2004, J CLIN INVEST, V113, P998, DOI 10.1172/JCI200420261; Bluestone JA, 2009, NAT REV IMMUNOL, V9, P811, DOI 10.1038/nri2654; Bonasio R, 2006, CURR OPIN IMMUNOL, V18, P503, DOI 10.1016/j.coi.2006.05.011; Cavanagh LL, 2005, NAT IMMUNOL, V6, P1029, DOI 10.1038/ni1249; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Feuerer M, 2009, NAT IMMUNOL, V10, P689, DOI 10.1038/ni.1760; Fortin G, 2009, J EXP MED, V206, P1995, DOI 10.1084/jem.20082805; GeurtsvanKessel CH, 2009, J EXP MED, V206, P2339, DOI 10.1084/jem.20090410; Gill N, 2010, NAT IMMUNOL, V11, P558, DOI 10.1038/ni0710-558; Guo LY, 2009, P NATL ACAD SCI USA, V106, P13463, DOI 10.1073/pnas.0906988106; He R, 2009, J ALLERGY CLIN IMMUN, V124, P761, DOI 10.1016/j.jaci.2009.07.040; Hegazy AN, 2010, IMMUNITY, V32, P116, DOI 10.1016/j.immuni.2009.12.004; Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993; Holgate ST, 2009, IMMUNITY, V31, P362, DOI 10.1016/j.immuni.2009.08.013; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Kuipers H, 2009, J LEUKOCYTE BIOL, V85, P64, DOI 10.1189/jlb.0807519; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lexberg MH, 2008, EUR J IMMUNOL, V38, P2654, DOI 10.1002/eji.200838541; Liang SC, 2007, J IMMUNOL, V179, P7791, DOI 10.4049/jimmunol.179.11.7791; Martin-Fontecha A, 2008, J EXP MED, V205, P2561, DOI 10.1084/jem.20081212; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Mills KHG, 2008, EUR J IMMUNOL, V38, P2636, DOI 10.1002/eji.200838535; O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097; Oboki Keisuke, 2008, Allergol Int, V57, P121, DOI 10.2332/allergolint.R-07-160; Page K, 2011, J INNATE IMMUN, V3, P167, DOI 10.1159/000320718; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Pepper M, 2010, NAT IMMUNOL, V11, P83, DOI 10.1038/ni.1826; Peters M, 2010, IMMUNOL CELL BIOL, V88, P537, DOI 10.1038/icb.2010.3; Raymond M, 2009, J ALLERGY CLIN IMMUN, V124, P1333, DOI 10.1016/j.jaci.2009.07.021; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Shan M, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranlsmed.3000154; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774; Zhou XY, 2009, CURR OPIN IMMUNOL, V21, P281, DOI 10.1016/j.coi.2009.05.007; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	47	35	36	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					192	U313		10.1016/j.jaci.2011.04.029	http://dx.doi.org/10.1016/j.jaci.2011.04.029			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21601259				2022-12-18	WOS:000292245600025
J	Twaroch, TE; Focke, M; Civaj, V; Weber, M; Balic, N; Mari, A; Ferrara, R; Quirce, S; Spitzauer, S; Swoboda, I; Valenta, R				Twaroch, Teresa E.; Focke, Margit; Civaj, Vera; Weber, Milena; Balic, Nadja; Mari, Adriano; Ferrara, Rosetta; Quirce, Santiago; Spitzauer, Susanne; Swoboda, Ines; Valenta, Rudolf			Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Olive pollen allergy; Ole e 1; specific immunotherapy; peptides; epitopes	BASOPHIL HISTAMINE-RELEASE; MAJOR ALLERGEN; CROSS-REACTIVITY; IMMUNOGLOBULIN-E; E-I; IGG ANTIBODIES; CELL EPITOPES; DOUBLE-BLIND; TREE POLLEN; B-CELLS	Background: Trees of the family Oleaceae (olive and ash) are important allergen sources in Mediterranean countries, Northern and Central Europe, and North America. The major olive pollen allergen Ole e 1 represents the majority of allergenic epitopes in olive pollen and cross-reacts with Fra e 1, the major ash pollen allergen. Objective: We sought to develop a safe vaccine for the treatment of Oleaceae pollen allergy. Methods: We synthesized 5 peptides ranging from 32 to 36 amino acids, which covered the whole sequence of Ole e 1. The IgE and T-cell reactivity of the peptides was compared with that of Ole e 1 by means of dot blot experiments, as well as ELISA, and in proliferation assays. Rabbits were immunized with non-IgE-reactive, keyhole limpet hemocyanin-coupled peptides or Ole e 1. The reactivity of the IgG antibodies with Ole e 1 and their ability to inhibit IgE binding to nOle e 1 was evaluated by means of ELISA. Results: Only the C-terminal Ole e 1 peptide showed IgE binding, whereas the other peptides were nonallergenic. Immunization of rabbits with Ole e 1-derived peptides bound to the carrier molecule keyhole limpet hemocyanin induced in rabbits the production of Ole e 1-specific IgG antibodies, which cross-reacted with Fra e 1, and inhibited olive and ash pollen-sensitized patients' IgE binding to Ole e 1. Conclusion: Two non-IgE-binding peptides with low T-cell reactivity from the N-terminus of Ole e 1 were identified that might represent safe vaccine candidates for immunotherapy of Oleaceae pollen allergy. (J Allergy Clin Immunol 2011; 128: 178-84.)	[Twaroch, Teresa E.; Focke, Margit; Civaj, Vera; Weber, Milena; Swoboda, Ines; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res,Div Immunopathol, A-1090 Vienna, Austria; [Balic, Nadja; Spitzauer, Susanne] Med Univ Vienna, Clin Inst Lab Diagnost, Clin Dept Med & Chem Lab Diagnost, A-1090 Vienna, Austria; [Quirce, Santiago] Hosp La Paz, Dept Allergy, Madrid, Spain; [Mari, Adriano; Ferrara, Rosetta] IDI IRCCS, Ctr Mol Allergol, Rome, Italy	Medical University of Vienna; Medical University of Vienna; Hospital Universitario La Paz; IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Swoboda, I (corresponding author), Med Univ Vienna, Christian Doppler Lab Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res,Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	ines.swoboda@meduniwien.ac.at	s, q/AAD-7171-2020	Swoboda, Ines/0000-0002-9164-1721; Valenta, Rudolf/0000-0001-5944-3365	Christian Doppler Association; Biomay (Vienna, Austria); FWF Austrian Science Fund; Phadia (Uppsala, Sweden)	Christian Doppler Association; Biomay (Vienna, Austria); FWF Austrian Science Fund(Austrian Science Fund (FWF)); Phadia (Uppsala, Sweden)	Supported by a research grant from the Christian Doppler Association and Biomay (Vienna, Austria).; Disclosure of potential conflict of interest: R. Valenta has received research support from the FWF Austrian Science Fund, the Christian Doppler Association, Biomay (Vienna, Austria), and Phadia (Uppsala, Sweden) and is a consultant for Biomay regarding allergy therapy and for Phadia regarding allergy diagnosis. The rest of the authors have declared that they have no conflict of interest.	ARNON R, 1992, FASEB J, V6, P3265, DOI 10.1096/fasebj.6.14.1385242; Barderas R, 2005, J ALLERGY CLIN IMMUN, V115, P351, DOI 10.1016/j.jaci.2004.10.001; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; Cardaba B, 1998, CLIN EXP ALLERGY, V28, P413; Castro AJ, 2007, J INVEST ALLERG CLIN, V17, P41; Chen KW, 2008, MOL IMMUNOL, V45, P2486, DOI 10.1016/j.molimm.2008.01.006; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Demoly P, 2002, CLIN EXP ALLERGY, V32, P1071, DOI 10.1046/j.1365-2222.2002.01392.x; Edlmayr J, 2009, J IMMUNOL, V182, P6298, DOI 10.4049/jimmunol.0713622; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gonzalez EM, 2006, MOL IMMUNOL, V43, P570, DOI 10.1016/j.molimm.2005.04.015; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larche M, 2005, NAT MED, V11, pS69, DOI 10.1038/nm1226; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; LOMBARDERO M, 1992, J ALLERGY CLIN IMMUN, V89, P884, DOI 10.1016/0091-6749(92)90445-8; Lombardero M, 2002, ALLERGY, V57, P29, DOI 10.1034/j.1398-9995.2002.057s71029.x; Marazuela EG, 2007, CLIN EXP ALLERGY, V37, P251, DOI 10.1111/j.1365-2222.2006.02632.x; Marazuela EG, 2008, MOL IMMUNOL, V45, P438, DOI 10.1016/j.molimm.2007.05.030; MARTINOROZCO E, 1994, INT ARCH ALLERGY IMM, V104, P160, DOI 10.1159/000236725; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 2002, CLIN EXP ALLERGY, V32, P933, DOI 10.1046/j.1365-2222.2002.01369.x; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Pajaron MJ, 1997, ALLERGY, V52, P829, DOI 10.1111/j.1398-9995.1997.tb02154.x; Palomares O, 2006, INT ARCH ALLERGY IMM, V141, P110, DOI 10.1159/000094713; PAUL WE, 1970, J EXP MED, V132, P283, DOI 10.1084/jem.132.2.283; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pree I, 2010, CLIN EXP ALLERGY, V40, P1346, DOI 10.1111/j.1365-2222.2010.03548.x; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; SISKIND GW, 1966, J EXP MED, V123, P673, DOI 10.1084/jem.123.4.673; Uermosi C, 2010, J ALLERGY CLIN IMMUN, V126, P375, DOI 10.1016/j.jaci.2010.05.040; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; van Neerven RJJ, 2004, CLIN EXP ALLERGY, V34, P420, DOI 10.1111/j.1365-2222.2004.01899.x; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; Vrtala S, 1998, J IMMUNOL, V160, P6137; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; WHEELER AW, 1992, CLIN EXP ALLERGY, V22, P1052, DOI 10.1111/j.1365-2222.1992.tb00129.x; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425, DOI 10.1016/S1081-1206(10)61509-8; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x	48	35	37	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					178	U283		10.1016/j.jaci.2011.03.011	http://dx.doi.org/10.1016/j.jaci.2011.03.011			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21513971				2022-12-18	WOS:000292245600023
J	Pessach, IM; Ordovas-Montanes, J; Zhang, SY; Casanova, JL; Giliani, S; Gennery, AR; Al-Herz, W; Manos, PD; Schlaeger, TM; Park, IH; Rucci, F; Agarwal, S; Mostoslavsky, G; Daley, GQ; Notarangelo, LD				Pessach, Itai M.; Ordovas-Montanes, Jose; Zhang, Shen-Ying; Casanova, Jean-Laurent; Giliani, Silvia; Gennery, Andrew R.; Al-Herz, Waleed; Manos, Philip D.; Schlaeger, Thorsten M.; Park, In-Hyun; Rucci, Francesca; Agarwal, Suneet; Mostoslavsky, Gustavo; Daley, George Q.; Notarangelo, Luigi D.			Induced pluripotent stem cells: A novel frontier in the study of human primary immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; induced pluripotent stem cells; reprogramming	IPS CELLS; EFFICIENT GENERATION; DOPAMINERGIC-NEURONS; IN-VITRO; HUMAN ES; DIFFERENTIATION; DEFICIENCY; DERIVATION; CARDIOMYOCYTES; PATHOGENESIS	Background: The novel ability to epigenetically reprogram somatic cells into induced pluripotent stem cells (iPSCs) through the exogenous expression of transcription promises to revolutionize the study of human diseases. Objective: Here we report on the generation of 25 iPSC lines from 6 patients with various forms of primary immunodeficiencies (PIDs) affecting adaptive immunity, innate immunity, or both. Methods: Patients' dermal fibroblasts were reprogrammed by expression of 4 transcription factors, octamer-binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2), Krueppel-like factor 4 (KLF4), and cellular myelomonocytosis proto-oncogene (cMYC), by using a single excisable polycistronic lentiviral vector. Results: iPSCs derived from patients with PIDs show a stemness profile that is comparable with that observed in human embryonic stem cells. After in vitro differentiation into embryoid bodies, pluripotency of the patient-derived iPSC lines was demonstrated by expression of genes characteristic of each of the 3 embryonic layers. We have confirmed the patient-specific origin of the iPSC lines and ascertained maintenance of karyotypic integrity. Conclusion: By providing a limitless source of diseased stem cells that can be differentiated into various cell types in vitro, the repository of iPSC lines from patients with PIDs represents a unique resource to investigate the pathophysiology of hematopoietic and extrahematopoietic manifestations of these diseases and might assist in the development of novel therapeutic approaches based on gene correction. (J Allergy Clin Immunol 2011;127:1400-7.)	[Pessach, Itai M.; Ordovas-Montanes, Jose; Rucci, Francesca; Notarangelo, Luigi D.] Harvard Univ, Sch Med, Div Immunol, Childrens Hosp Boston, Boston, MA 02115 USA; [Pessach, Itai M.] Safra Childrens Hosp, Talpiot Med Leadership Program, Sheba Med Ctr, Tel Hashomer, Israel; [Ordovas-Montanes, Jose] Tufts Univ, Dept Biol, Medford, MA 02155 USA; [Zhang, Shen-Ying; Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, New York, NY 10021 USA; [Casanova, Jean-Laurent] Univ Paris 05, Lab Human Genet Infect Dis, Necker Branch, Paris, France; [Casanova, Jean-Laurent] Necker Med Sch, INSERM U980, Paris, France; [Giliani, Silvia] Univ Brescia, Dept Pediat, Angelo Nocivelli Inst Mol Med, Brescia, Italy; [Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Al-Herz, Waleed] Al Sabah Hosp, Dept Pediat, Allergy & Clin Immunol Unit, Kuwait, Kuwait; [Manos, Philip D.; Schlaeger, Thorsten M.; Park, In-Hyun; Agarwal, Suneet; Daley, George Q.] Childrens Hosp Boston, Div Pediat Hematol Oncol, Boston, MA USA; [Manos, Philip D.; Schlaeger, Thorsten M.; Park, In-Hyun; Agarwal, Suneet; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Manos, Philip D.; Schlaeger, Thorsten M.; Park, In-Hyun; Daley, George Q.] Childrens Hosp Boston, Stem Cell Program, Boston, MA USA; [Schlaeger, Thorsten M.; Agarwal, Suneet; Daley, George Q.] Harvard Stem Cell Inst, Cambridge, England; [Park, In-Hyun] Yale Univ, Sch Med, Yale Stem Cell Ctr, Dept Genet, New Haven, CT 06520 USA; [Agarwal, Suneet; Daley, George Q.; Notarangelo, Luigi D.] Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA; [Mostoslavsky, Gustavo] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Mostoslavsky, Gustavo] Boston Univ, Sch Med, Ctr Regenerat Med CReM, Boston, MA 02118 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Chaim Sheba Medical Center; Tufts University; Rockefeller University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Brescia; Newcastle University - UK; Al Sabah Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Yale University; Harvard University; Boston Children's Hospital; Boston University; Boston University	Notarangelo, LD (corresponding author), Harvard Univ, Sch Med, Div Immunol, Childrens Hosp Boston, Karp Bldg,Rm 9210,1 Blackfan Circle, Boston, MA 02115 USA.	luigi.notarangelo@childrens.harvard.edu	Giliani, Silvia/AAX-8843-2020; Zhang, Shen-Ying/I-2685-2017; Notarangelo, Luigi D/F-9718-2016; Casanova, Jean-Laurent/I-3418-2017	Giliani, Silvia/0000-0001-8137-4642; Zhang, Shen-Ying/0000-0002-9449-3672; Notarangelo, Luigi D/0000-0002-8335-0262; Ordovas-Montanes, Jose/0000-0001-5444-5601; Mostoslavsky, Gustavo/0000-0002-0784-2169; Schlaeger, Thorsten/0000-0002-1599-9908; Casanova, Jean-Laurent/0000-0002-7782-4169	National Institutes of Health [1R03AI088352-01, 1R21AI0898-10-01]; March of Dimes [6-FY10-282]; Translation Research Program; Harvard Catalyst Grant; Manton Foundation; Fondazione "Angelo Nocivelli"; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL089150, U01HL100001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI089810, R03AI088352, Z01AI000898] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes(March of Dimes); Translation Research Program; Harvard Catalyst Grant; Manton Foundation; Fondazione "Angelo Nocivelli"; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants 1R03AI088352-01 and 1R21AI0898-10-01, March of Dimes grant 6-FY10-282, the Translation Research Program (all to L.D.N.), and a Harvard Catalyst Grant (to G.Q.D.). Also supported by the Manton Foundation (to L.D.N. and G.Q.D.) and by Fondazione "Angelo Nocivelli" (to S.G.).	Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189; Buzzard JJ, 2004, NAT BIOTECHNOL, V22, P381, DOI 10.1038/nbt0404-381; Cai JL, 2010, STEM CELLS DEV, V19, P1017, DOI 10.1089/scd.2009.0319; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Cassani B, 2010, J ALLERGY CLIN IMMUN, V125, P209, DOI 10.1016/j.jaci.2009.10.023; Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529; Chan EM, 2009, NAT BIOTECHNOL, V27, P1033, DOI 10.1038/nbt.1580; Chapgier A, 2006, J IMMUNOL, V176, P5078, DOI 10.4049/jimmunol.176.8.5078; Choi KD, 2009, STEM CELLS, V27, P559, DOI 10.1634/stemcells.2008-0922; de Diego RP, 2010, IMMUNITY, V33, P400, DOI 10.1016/j.immuni.2010.08.014; Dervovic D, 2010, SEMIN IMMUNOL, V22, P276, DOI 10.1016/j.smim.2010.04.014; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Freund C, 2010, NETH HEART J, V18, P51; Gai H, 2010, DIFFERENTIATION, V79, P171, DOI 10.1016/j.diff.2010.01.002; Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092; Hanson EP, 2008, J ALLERGY CLIN IMMUN, V122, P1169, DOI 10.1016/j.jaci.2008.08.018; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107; INAMI Y, 2010, IMMUNOL CELL BIOL; Karner E, 2009, J CELL PHYSIOL, V218, P323, DOI 10.1002/jcp.21605; Kiskinis E, 2010, J CLIN INVEST, V120, P51, DOI 10.1172/JCI40553; Lee G, 2010, NAT PROTOC, V5, P688, DOI 10.1038/nprot.2010.35; Lee G, 2009, NATURE, V461, P402, DOI 10.1038/nature08320; Lei FY, 2009, CELL IMMUNOL, V260, P1, DOI 10.1016/j.cellimm.2009.09.005; Lengerke C, 2009, ANN NY ACAD SCI, V1176, P219, DOI 10.1111/j.1749-6632.2009.04606.x; Lerou PH, 2008, NAT PROTOC, V3, P923, DOI 10.1038/nprot.2008.60; Li F, 2010, J CELL BIOCHEM, V109, P643, DOI 10.1002/jcb.22440; Li WQ, 2010, J CELL PHYSIOL, V222, P492, DOI 10.1002/jcp.22000; Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Mizuno Y, 2010, FASEB J, V24, P2245, DOI 10.1096/fj.09-137174; Mohtashami M, 2010, J IMMUNOL, V185, P867, DOI 10.4049/jimmunol.1000782; Morizane R, 2009, BIOCHEM BIOPH RES CO, V390, P1334, DOI 10.1016/j.bbrc.2009.10.148; Mostoslavsky G, 2006, P NATL ACAD SCI USA, V103, P16406, DOI 10.1073/pnas.0608130103; Nishikawa S, 2008, NAT REV MOL CELL BIO, V9, P725, DOI 10.1038/nrm2466; Nizzardo M, 2010, CELL MOL LIFE SCI, V67, P3837, DOI 10.1007/s00018-010-0463-y; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; Notarangelo LD, 2008, CURR OPIN ALLERGY CL, V8, P534, DOI 10.1097/ACI.0b013e328310fe7d; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Park IH, 2008, NAT PROTOC, V3, P1180, DOI 10.1038/nprot.2008.92; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Pessach I, 2009, PEDIATR RES, V65, p3R, DOI 10.1203/PDR.0b013e31819dbe1e; Rolletschek A, 2009, BIOL CHEM, V390, P845, DOI 10.1515/BC.2009.103; Sauer AV, 2009, CURR OPIN ALLERGY CL, V9, P496, DOI 10.1097/ACI.0b013e3283327da5; Slatter MA, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001419; Somers A, 2010, STEM CELLS, V28, P1728, DOI 10.1002/stem.495; Sommer CA, 2010, STEM CELLS, V28, P64, DOI 10.1002/stem.255; Sommer CA, 2009, STEM CELLS, V27, P543, DOI 10.1634/stemcells.2008-1075; Song ZH, 2009, CELL RES, V19, P1233, DOI 10.1038/cr.2009.107; Staerk J, 2010, CELL STEM CELL, V7, P20, DOI 10.1016/j.stem.2010.06.002; Sullivan KE, 2008, IMMUNOL ALLERGY CLIN, V28, P353, DOI 10.1016/j.iac.2008.01.003; Sultana DA, 2010, SEMIN IMMUNOL, V22, P254, DOI 10.1016/j.smim.2010.04.011; Swistowski A, 2010, STEM CELLS, V28, P1893, DOI 10.1002/stem.499; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Ueda T, 2010, BIOCHEM BIOPH RES CO, V391, P38, DOI 10.1016/j.bbrc.2009.10.157; Xu D, 2009, P NATL ACAD SCI USA, V106, P808, DOI 10.1073/pnas.0812090106; Zhang JH, 2009, CIRC RES, V104, pE30, DOI 10.1161/CIRCRESAHA.108.192237; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522; Zwi L, 2009, CIRCULATION, V120, P1513, DOI 10.1161/CIRCULATIONAHA.109.868885	61	35	36	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1400	U140		10.1016/j.jaci.2010.11.008	http://dx.doi.org/10.1016/j.jaci.2010.11.008			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21185069	Bronze, Green Accepted			2022-12-18	WOS:000291048500011
J	Eckl-Dorna, J; Klein, B; Reichenauer, TG; Niederberger, V; Valenta, R				Eckl-Dorna, Julia; Klein, Brigitte; Reichenauer, Thomas G.; Niederberger, Verena; Valenta, Rudolf			Exposure of rye (Secale cereale) cultivars to elevated ozone levels increases the allergen content in pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							POLLUTANTS; IGE		[Eckl-Dorna, Julia; Niederberger, Verena] Med Univ Vienna, Dept Otorhinolaryngol, Seibersdorf, Austria; [Klein, Brigitte; Valenta, Rudolf] Med Univ Vienna, Div Immunopathol, Ctr Pathophysiol Infectiol & Immunol, Seibersdorf, Austria; [Reichenauer, Thomas G.] Austrian Inst Technol GmbH, Seibersdorf, Austria	Medical University of Vienna; Medical University of Vienna; Austrian Institute of Technology (AIT)	Eckl-Dorna, J (corresponding author), Med Univ Vienna, Dept Otorhinolaryngol, Seibersdorf, Austria.	thomas.reichenauer@ait.ac.at; rudolf.valenta@meduniwien.ac.at	Eckl-Dorna, Julia/AAY-6371-2020	Valenta, Rudolf/0000-0001-5944-3365; Eckl-Dorna, Julia/0000-0001-5981-1607	Austrian Science Fund FWF [F 4613] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; Masuch G, 1997, ALLERGY, V52, P874, DOI 10.1111/j.1398-9995.1997.tb02163.x; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Parnia S, 2002, ALLERGY, V57, P1111, DOI 10.1034/j.1398-9995.2002.02167.x; Rogerieux F, 2007, INT ARCH ALLERGY IMM, V143, P127, DOI 10.1159/000099079; Rogers CA, 2006, ENVIRON HEALTH PERSP, V114, P865, DOI 10.1289/ehp.8549; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985	8	35	36	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1315	1317		10.1016/j.jaci.2010.06.012	http://dx.doi.org/10.1016/j.jaci.2010.06.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20674963				2022-12-18	WOS:000284947800037
J	Lee, JJ; Jabara, HH; Garibyan, L; Rauter, I; Sannikova, T; Dillon, SR; Bram, R; Geha, RS				Lee, John J.; Jabara, Haifa H.; Garibyan, Lilit; Rauter, Ingrid; Sannikova, Tatyana; Dillon, Stacey R.; Bram, Richard; Geha, Raif S.			The C104R mutant impairs the function of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) through haploinsufficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI); common variable immunodeficiency; a proliferation-inducing ligand (APRIL); haploinsufficiency; murine model	COMMON VARIABLE IMMUNODEFICIENCY; MUTATIONS; RECEPTOR; APRIL; BLYS; VARIANTS; BAFF	Background: TNFRSF13B, which encodes transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), is mutated in 10% of patients with common variable immunodeficiency. One of the 2 most common TACI mutations in common variable immunodeficiency, C104R, abolishes ligand binding and is found predominantly in the heterozygous state. The murine TACI mutant C76R is the equivalent of the human TACI mutant C104R. Objective: We sought to define the consequence of the C76R mutation on TACI function in mice that express both wild-type TACI and the murine C76R mutant. Methods: Transgenic mice that express murine TACI C76R, the counterpart of human TACI C104R, on the TACI(+/-) B6/129 background (C76R/TACI(+/-) mice) were constructed. Serum immunoglobulins and antibody responses to the type II T-independent antigen trinitrophenylated (TNP)-Ficoll were determined by means of ELISA. B-cell proliferation in response to a proliferation-inducing ligand was determined based on tritiated thymidine incorporation into DNA. IgG1 secretion by B cells in response to a proliferation-inducing ligand plus IL-4 was determined by means of ELISA. Results: C76R/TACI(+/-) mice had significantly impaired antibody responses to the type II T-independent antigen TNP-Ficoll compared with TACI(+/+) B6/129 control animals, and their B cells were impaired in their capacity to proliferate and secrete IgG1 in response to TACI ligation. Unexpectedly, TACI(+/-) mice had similarly impaired B-cell function as C76R/TACI(+/-) littermates. Impaired TACI function caused by haploinsufficiency was confirmed in TACI(+/-) mice on the C57BL/6 background. Conclusion: These results suggest that the human TACI mutant C104R might impair TACI function in heterozygotes through haploinsufficiency. (J Allergy Clin Immunol 2010;126:1234-41.)	[Lee, John J.; Jabara, Haifa H.; Garibyan, Lilit; Rauter, Ingrid; Sannikova, Tatyana; Geha, Raif S.] Childrens Hosp Boston, Div Immunol, Boston, MA 02115 USA; [Lee, John J.; Jabara, Haifa H.; Garibyan, Lilit; Rauter, Ingrid; Sannikova, Tatyana; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Dillon, Stacey R.] Zymogenet Inc, Preclin Res & Dev, Seattle, WA 98105 USA; [Bram, Richard] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Zymogenet Inc.; Mayo Clinic	Geha, RS (corresponding author), Childrens Hosp Boston, Div Immunol, 1 Blackfan Circle,Karp 10, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Garibyan, Lilit/AAR-1638-2020		National Institute of Health [AI-031541, T32-AI-007512]; American Academy of Allergy, Asthma Immunology GSK; Austrian Science Fund [J2744-B12]; St Jude Children's Hospital; ZymoGenetics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031541, P01AI031541, P01AI076210, U01AI031541, T32AI007512] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy, Asthma Immunology GSK; Austrian Science Fund(Austrian Science Fund (FWF)); St Jude Children's Hospital; ZymoGenetics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institute of Health grants AI-031541 and T32-AI-007512; the American Academy of Allergy, Asthma & Immunology GSK Award (J.J.L.); and the Austrian Science Fund J2744-B12 (I.R.).; Disclosure of potential conflict of interest: S. R. Dillon is an employee and stockholder of ZymoGenetics, Inc. R. Bram has received payment from St Jude Children's Hospital and ZymoGenetics for patents related to the TACI gene. R. S. Geha has received research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	[Anonymous], 1999, CLIN EXP IMMUNOL, V118, P1; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Castigli E, 2007, J ALLERGY CLIN IMMUN, V120, P885, DOI 10.1016/j.jaci.2007.06.012; Castigli E, 2007, NAT GENET, V39, P430, DOI 10.1038/ng0407-430; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Cunningham-Rundles C, 2006, J IMMUNOL, V176, P1978, DOI 10.4049/jimmunol.176.3.1978; Di Renzo M, 2004, CLIN EXP MED, V3, P211, DOI 10.1007/s10238-004-0027-2; Dillon SR, 2006, NAT REV DRUG DISCOV, V5, P235, DOI 10.1038/nrd1982; Garibyan L, 2007, J CLIN INVEST, V117, P1550, DOI 10.1172/JCI31023; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Lee JJ, 2009, BLOOD, V114, P2254, DOI 10.1182/blood-2008-11-189720; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; Ozcan E, 2009, J ALLERGY CLIN IMMUN, V123, pS94, DOI 10.1016/j.jaci.2008.12.335; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2009, BLOOD, V113, P1967, DOI 10.1182/blood-2008-02-141937; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Shaw AC, 1999, J EXP MED, V189, P123, DOI 10.1084/jem.189.1.123; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Yan MH, 2000, NAT IMMUNOL, V1, P37, DOI 10.1038/76889; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790; Yu JE, 2009, J ALLERGY CLIN IMMUN, V124, P349, DOI 10.1016/j.jaci.2009.05.019; Zhang L, 2007, J ALLERGY CLIN IMMUN, V120, P1178, DOI 10.1016/j.jaci.2007.10.001	27	35	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1234	U253		10.1016/j.jaci.2010.08.017	http://dx.doi.org/10.1016/j.jaci.2010.08.017			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20889194	Green Accepted			2022-12-18	WOS:000284947800023
J	Campana, R; Vrtala, S; Maderegger, B; Jertschin, P; Stegfellner, G; Swoboda, I; Focke-Tejkl, M; Blatt, K; Gieras, A; Zafred, D; Neubauer, A; Valent, P; Keller, W; Spitzauer, S; Valenta, R				Campana, Raffaela; Vrtala, Susanne; Maderegger, Bernhard; Jertschin, Peter; Stegfellner, Gottfried; Swoboda, Ines; Focke-Tejkl, Margarete; Blatt, Katharina; Gieras, Anna; Zafred, Domen; Neubauer, Angela; Valent, Peter; Keller, Walter; Spitzauer, Susanne; Valenta, Rudolf			Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Birch pollen allergy; immunotherapy; rBet v 1; recombinant hypoallergenic derivative molecules	T-CELL EPITOPE; QUANTITATIVE IGE INHIBITION; RECOMBINANT ALLERGENS; WILD-TYPE; IMMUNOTHERAPY; PROFILIN; BET-V-1; VACCINE; EXPRESSION; REACTIVITY	Background: At least 100 million patients suffer from birch pollen allergy. Objective: Rational design of recombinant derivatives of the major birch pollen allergen, Bet v 1, characterized by reduced IgE reactivity, preservation of sequences relevant for the induction of allergen-specific blocking IgG, and maintenance of T-cell epitopes for immunotherapy of birch pollen allergy. Methods: Three recombinant mosaic proteins derived from Bet v 1 were generated by reassembly of codon-optimized genes coding for Bet v 1 fragments containing the elements for the induction of allergen-specific blocking IgG antibodies and the major T-cell epitopes. The proteins were expressed in Escherichia coli as recombinant mosaic molecules and compared with the Bet v 1 wild-type protein by chemical and structural methods, regarding IgE-binding and IgG-binding capacity, in basophil activation assays and tested for the in vivo induction of IgG responses. Results: Three recombinant Bet v 1 (rBet v 1) mosaic proteins with strongly reduced IgE reactivity and allergenic activity were expressed and purified. Immunization with the recombinant hypoallergens induced IgG antibodies that inhibited IgE reactivity of patients with allergy to Bet v 1 comparable to those induced with the rBet v 1 wild-type allergen. Conclusion: We report the generation and preclinical characterization of 3 hypoallergenic rBet v 1 derivatives with suitable properties for immunotherapy of birch pollen allergy. (J Allergy Clin Immunol 2010;126:1024-31.)	[Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Christian Doppler Lab Allergy Res, Dept Pathophysiol,Div Immunopathol, A-1090 Vienna, Austria; [Blatt, Katharina; Valent, Peter] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, A-1090 Vienna, Austria; [Spitzauer, Susanne] Med Univ Vienna, Vienna Gen Hosp AKH, Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria; [Maderegger, Bernhard; Jertschin, Peter; Stegfellner, Gottfried; Neubauer, Angela] Karl Franzens Univ Graz, Vienna Competence Ctr, Biomay AG, Graz, Austria; [Zafred, Domen; Keller, Walter] Karl Franzens Univ Graz, Inst Chem, Div Struct Biol, Graz, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; University of Graz; University of Graz	Valenta, R (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Christian Doppler Lab Allergy Res, Dept Pathophysiol,Div Immunopathol, AKH 3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Gamperl, Susi/V-2715-2019; Keller, Walter/AAW-1501-2021; Valent, Peter/B-8533-2016; Test, PV/U-9451-2019; Gieras, Anna/S-8345-2019; Test, Test/Y-7921-2019; Zafred, Domen/Q-6244-2018	Gamperl, Susi/0000-0003-0456-5095; Keller, Walter/0000-0002-2261-958X; Valent, Peter/0000-0003-0456-5095; Zafred, Domen/0000-0002-2029-4902; Gieras, Anna/0000-0002-5147-2281; Campana, Raffaela/0000-0001-9309-9908; Swoboda, Ines/0000-0002-9164-1721; Vrtala, Susanne/0000-0003-4250-8243; Valenta, Rudolf/0000-0001-5944-3365	Austrian Science Fund (FWF) [F1803, F1804, F1815, F1809, L214-B13]; Biomay, Vienna, Austria; Austrian Science Fund; Christian Doppler Research Association; Biomay; Phadia	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Biomay, Vienna, Austria; Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Association; Biomay; Phadia(Phadia)	Supported by grants F1803, F1804, F1815, F1809, and L214-B13 of the Austrian Science Fund (FWF) and by a research grant from Biomay, Vienna, Austria.; R. Valenta receives research support from the Austrian Science Fund, the Christian Doppler Research Association, Biomay, and Phadia and has provided legal consultation services/expert witness testimony in cases related to allergy diagnostics and allergy therapeutics. D. Zafred receives research support from the Austrian Science Fund. W. Keller receives research support from the Austrian Science Fund. The rest of the authors have declared that they have no conflict of interest.	Ball T, 2009, ALLERGY, V64, P569, DOI 10.1111/j.1398-9995.2008.01910.x; Baranyi U, 2008, J IMMUNOL, V180, P8168, DOI 10.4049/jimmunol.180.12.8168; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; Hauswirth AW, 2002, J ALLERGY CLIN IMMUN, V110, P102, DOI 10.1067/mai.2002.125257; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Kahlert H, 2008, INT ARCH ALLERGY IMM, V145, P193, DOI 10.1159/000109288; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; KLIMEK L, 2005, ALLERGY CLIN IMMUN S, V1, P15; Laffer S, 1996, J IMMUNOL, V157, P4953; Linhart B, 2005, CURR OPIN IMMUNOL, V17, P646, DOI 10.1016/j.coi.2005.09.010; Mothes N, 2004, INT ARCH ALLERGY IMM, V135, P357, DOI 10.1159/000082332; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Mothes-Luksch N, 2008, J IMMUNOL, V181, P4864, DOI 10.4049/jimmunol.181.7.4864; Moverare R, 2002, INT ARCH ALLERGY IMM, V128, P325, DOI 10.1159/000063855; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Nopp A, 2000, J ALLERGY CLIN IMMUN, V106, P101, DOI 10.1067/mai.2000.106924; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; RAK S, 2009, C EUR AC ALL CLIN IM; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969, DOI 10.1016/S0091-6749(99)70077-1; Vrtala S, 2000, J IMMUNOL, V165, P6653, DOI 10.4049/jimmunol.165.11.6653; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Wallner M, 2007, J ALLERGY CLIN IMMUN, V120, P374, DOI 10.1016/j.jaci.2007.05.021; Weiss Richard, 2006, V127, P253; Westritschnig K, 2007, J IMMUNOL, V179, P7624, DOI 10.4049/jimmunol.179.11.7624; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pD593, DOI 10.1093/nar/gkh077; Wiedemann P, 1996, J BIOL CHEM, V271, P29915, DOI 10.1074/jbc.271.47.29915; Wiedermann Ursula, 2005, Current Drug Targets - Inflammation and Allergy, V4, P577, DOI 10.2174/156801005774322207	38	35	35	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					1024	U200		10.1016/j.jaci.2010.05.023	http://dx.doi.org/10.1016/j.jaci.2010.05.023			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20638112				2022-12-18	WOS:000283727100020
J	Pochard, P; Vickery, B; Berin, MC; Grishin, A; Sampson, HA; Caplan, M; Bottomly, K				Pochard, Pierre; Vickery, Brian; Berin, M. Cecilia; Grishin, Alexander; Sampson, Hugh A.; Caplan, Michael; Bottomly, Kim			Targeting Toll-like receptors on dendritic cells modifies the T(H)2 response to peanut allergens in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; EMP-123; dendritic cell; Toll-like receptor; MyD88; IL-12	MURINE MODEL; ANAPHYLACTIC REACTIONS; IGE BINDING; IMMUNOTHERAPY; PROTEINS; INFLAMMATION; EXPRESSION; CHILDREN; AGONIST; CANCER	Background: Delivery of allergens with bacterial adjuvants has been shown to be a successful immunotherapeutic strategy for food allergy treatment in animal models. How microbial signals, acting through the innate immune system, reshape ongoing allergic responses is poorly understood. Objective: To investigate the contribution of Toll-like receptors (TLRs) in the response to bacterial adjuvants, we designed an in vitro system to characterize the effect of heat-killed Escherichia coli vector (HKE) on peanut-induced responses of dendritic cells (DCs) and T cells. Methods: Wild-type or TLR signaling deficient bone marrow derived DCs were pulsed with crude peanut extract (CPE) alone (50 mu g/mL) in the presence of HKE (10(6)/mL). DC maturation was analyzed by means of flow cytometry. Treated DCs were cocultured with carboxyfluorescein succinimidyl ester (CFSE)-labeled CD4(+) T cells from sensitized mice. Cytokine production from DCs and T cells was measured by using Bioplex assays. Results: Peanut-pulsed DCs induced the production of IL-4, IL-5, and IL-13, as well as IL-17 and IFN-gamma, from primed T cells. Adding HKE to CPE-pulsed DCs resulted in a significant decrease in T(H)2 cytokine production associated with an increase in IFN-gamma levels and profound attenuation of T-cell proliferation. These effects were linked to HKE-induced TLR-dependent changes in DC reactivity to CPE, especially the production of polarizing cytokines, such as IL-12. Conclusions: TLR signals modulate peanut-induced DC maturation in vitro, leading to changes in the T-cell response to peanut. These TLR effects must be confirmed in vivo and might constitute another alternative for allergen immunotherapies. (J Allergy Clin Inununol 2010;126:92-7.)	[Pochard, Pierre; Vickery, Brian; Bottomly, Kim] Yale Univ, Sch Med, Dept Immunol, New Haven, CT USA; [Pochard, Pierre; Vickery, Brian; Caplan, Michael] Yale Univ, Sch Med, Dept Physiol, New Haven, CT USA; [Berin, M. Cecilia; Grishin, Alexander; Sampson, Hugh A.] Mt Sinai Sch Med, Div Allergy & Immunol, Dept Pediat, New York, NY USA	Yale University; Yale University; Icahn School of Medicine at Mount Sinai	Vickery, B (corresponding author), Duke Univ, Med Ctr, Box 2644, Durham, NC 27710 USA.	brian.vickery@duke.edu		Vickery, Brian/0000-0002-7243-5543; berin, cecilia/0000-0002-9051-9249; Pochard, Pierre/0000-0002-5608-7286	National Institutes of Health/National Institute of Allergy and Infectious Diseases [U19AI066738]; National Institutes of Health; Environmental Protection Agency; Food Allergy Initiative; Allertein Therapeutics, LLC; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066738] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Environmental Protection Agency(United States Environmental Protection Agency); Food Allergy Initiative; Allertein Therapeutics, LLC; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases grant U19AI066738.; M. C. Berin receives research support from the National Institutes of Health, the Environmental Protection Agency, and the Food Allergy Initiative. A. Grishin receives research support from Allertein Therapeutics, LLC. H. A. Sampson is a consultant for and 4% shareholder in Allertein Pharmaceuticals, LLC; receives research support from the Food Allergy Initiative and the National Institutes of Health/National Institute of Allergy and Infectious Diseases; is a consultant and scientific advisor for the Food Allergy Initiative; has served as President of the American Academy of Allergy, Asthma & Immunology; and is 45% owner of Herbal Springs, LLC. M. Caplan is a consultant for Allertein Pharmaceuticals. K. Bottomly is a shareholder in Allertein Therapeutics, LLC, and has provided legal consultation/expert witness testimony in cases related to allergy. The rest of the authors have declared that they have no conflict of interest.	Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Berin MC, 2006, ALLERGY, V61, P64, DOI 10.1111/j.1398-9995.2006.01012.x; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026; Gringhuis SI, 2007, IMMUNITY, V26, P605, DOI 10.1016/j.immuni.2007.03.012; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Lee SY, 2001, CLIN IMMUNOL, V101, P220, DOI 10.1006/clim.2001.5122; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Naugler WE, 2008, TRENDS MOL MED, V14, P109, DOI 10.1016/j.molmed.2007.12.007; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Powlesland AS, 2006, J BIOL CHEM, V281, P20440, DOI 10.1074/jbc.M601925200; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Ternblay JN, 2007, J ALLERGY CLIN IMMUN, V120, P659, DOI 10.1016/j.jaci.2007.04.044; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Zhu FG, 2007, J ALLERGY CLIN IMMUN, V120, P631, DOI 10.1016/j.jaci.2007.05.015	28	35	40	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					92	97		10.1016/j.jaci.2010.04.003	http://dx.doi.org/10.1016/j.jaci.2010.04.003			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20538332	Green Accepted			2022-12-18	WOS:000280061800016
J	Rank, MA; Wollan, P; Kita, H; Yawn, BP				Rank, Matthew A.; Wollan, Peter; Kita, Hirohito; Yawn, Barbara P.			Acute exacerbations of chronic rhinosinusitis occur in a distinct seasonal pattern	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISEASE		[Rank, Matthew A.; Kita, Hirohito] Mayo Clin, Div Allerg Dis, Rochester, MN 55905 USA; [Wollan, Peter; Yawn, Barbara P.] Olmsted Med Ctr, Dept Res, Rochester, MN USA	Mayo Clinic; Olmsted Medical Center	Rank, MA (corresponding author), Mayo Clin, Div Allerg Dis, Rochester, MN 55905 USA.	rank.matthew@mayo.edu			NIAMS NIH HHS [R01 AR030582, R01 AR30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Chen Y, 2003, LARYNGOSCOPE, V113, P1199, DOI 10.1097/00005537-200307000-00016; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Min YG, 1996, EUR ARCH OTO-RHINO-L, V253, P435; Pleis John R, 2002, Vital Health Stat 10, P1; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	6	35	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					168	169		10.1016/j.jaci.2010.03.041	http://dx.doi.org/10.1016/j.jaci.2010.03.041			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20641152	Green Accepted			2022-12-18	WOS:000280061800032
J	Hochwallner, H; Schulmeister, U; Swoboda, I; Focke-Tejkl, M; Civaj, V; Balic, N; Nystrand, M; Harlin, A; Thalhamer, J; Scheiblhofer, S; Keller, W; Paykov, T; Zafred, D; Niggemann, B; Quirce, S; Mari, A; Pauli, G; Ebner, C; Papadopoulos, NG; Herz, U; van Tol, EAF; Valenta, R; Spitzauer, S				Hochwallner, Heidrun; Schulmeister, Ulrike; Swoboda, Ines; Focke-Tejkl, Margit; Civaj, Vera; Balic, Nadja; Nystrand, Mats; Harlin, Annika; Thalhamer, Josef; Scheiblhofer, Sandra; Keller, Walter; Paykov, Tea; Zafred, Domen; Niggemann, Bodo; Quirce, Santiago; Mari, Adriano; Pauli, Gabrielle; Ebner, Christof; Papadopoulos, Nikolaos G.; Herz, Udo; van Tol, Eric A. F.; Valenta, Rudolf; Spitzauer, Susanne			Visualization of clustered IgE epitopes on alpha-lactalbumin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; food allergy; milk allergy; recombinant allergen; IgE epitope	GRASS-POLLEN ALLERGEN; IMMUNOGLOBULIN-E LEVELS; COWS MILK ALLERGY; BOVINE BETA-LACTOGLOBULIN; CROSS-REACTIVITY; SYNTHETIC PEPTIDES; BINDING; PROTEIN; DETERMINANTS; EXPRESSION	Background: alpha-Lactalbumin (alpha-La) is a major cow's milk (CM) allergen responsible for allergic reactions in infants. Objective: We performed molecular, structural, and immunologic characterization of alpha-La. Methods: Recombinant alpha-lactalbumin (r alpha-La) was expressed in Escherichia coli, purified to homogeneity, and characterized by means of mass spectrometry and circular dichroism, and its allergenic activity was studied by using microarray technology, as well as in a basophil histamine release assay. IgE epitope mapping was performed with synthetic peptides. Results: According to circular dichroism analysis, rot-La represented a folded protein with a high thermal stability and refolding capacity. r alpha-La reacted with IgE antibodies from 57.6% of patients with CM allergy (n = 66) and induced the strongest basophil degranulation with sera from patients with CM allergy who had exhibited gastrointestinal symptoms or severe systemic reactions on CM exposure. r alpha-La contained sequential and conformational IgE epitopes. Superposition of IgE-reactive peptides onto the 3-dimensional structure of alpha-La revealed a close vicinity of the N- and C-terminal peptides within a surface-exposed patch. Conclusions: r alpha-La can be used for the diagnosis of patients with severe allergic reactions to CM and serves as a paradigmatic tool for the development of therapeutic strategies for CM allergy. (J Allergy Clin Immunol 2010;125:1279-85.)	[Swoboda, Ines; Focke-Tejkl, Margit; Civaj, Vera; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol,Ctr Pathophysiol Infect & Immun, A-1090 Vienna, Austria; [Hochwallner, Heidrun; Schulmeister, Ulrike; Balic, Nadja; Spitzauer, Susanne] Med Univ Vienna, Dept Med & Chem Lab Diagnost, A-1090 Vienna, Austria; [Nystrand, Mats; Harlin, Annika] Phadia AB, Uppsala, Sweden; [Thalhamer, Josef; Scheiblhofer, Sandra] Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, Dept Mol Biol, A-5020 Salzburg, Austria; [Keller, Walter; Paykov, Tea; Zafred, Domen] Graz Univ, Inst Mol Biosci, A-8010 Graz, Austria; [Niggemann, Bodo] German Red Cross Hosp, Berlin, Germany; [Quirce, Santiago] Hosp La Paz, Dept Allergy, Madrid, Spain; [Mari, Adriano] IRCCS, IDI, Ctr Clin & Expt Allergol, Rome, Italy; [Pauli, Gabrielle] Hop Univ, Serv Pneumol, Strasbourg, France; [Ebner, Christof] Allergy Clin Reumannpl, Vienna, Austria; [Papadopoulos, Nikolaos G.] Univ Athens, Dept Allergy, Pediat Clin 2, GR-10679 Athens, Greece; [Herz, Udo; van Tol, Eric A. F.] Mead Johnson Nutr, Evansville, IN USA	Medical University of Vienna; Medical University of Vienna; Thermo Fisher Scientific; Phadia; Salzburg University; University of Graz; Hospital Universitario La Paz; IRCCS Istituto Dermopatico dell'Immacolata (IDI); CHU Strasbourg; National & Kapodistrian University of Athens	Valenta, R (corresponding author), Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol,Ctr Pathophysiol Infect & Immun, 3Q,Waehringer Guertel 8-20, A-1090 Vienna, Austria.	Rudolf.valenta@meduniwien.ac.at	Thalhamer, Josef/E-5787-2011; N.G., Papadopoulos/L-8670-2013; Papadopoulos, Nikolaos/ABE-1774-2021; Keller, Walter/AAW-1501-2021; Pavkov-Keller, Tea/K-9234-2015; Zafred, Domen/Q-6244-2018; s, q/AAD-7171-2020	Thalhamer, Josef/0000-0003-2285-6400; N.G., Papadopoulos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-4448-3468; Keller, Walter/0000-0002-2261-958X; Pavkov-Keller, Tea/0000-0001-7871-6680; Zafred, Domen/0000-0002-2029-4902; Papadopoulos, Nikolaos/0000-0002-2508-3872; Valenta, Rudolf/0000-0001-5944-3365; Scheiblhofer, Sandra/0000-0003-2867-9054; Swoboda, Ines/0000-0002-9164-1721	Austrian Science Foundation [F01804, F01805, F01815]; Biomay, Vienna, Austria; Mead Johnson Nutrition, Evansville, Ind.; Christian Doppler Forschungsgesellschaft; Austrian Science Fund; Phadia; Biomay AG	Austrian Science Foundation(Austrian Science Fund (FWF)); Biomay, Vienna, Austria; Mead Johnson Nutrition, Evansville, Ind.; Christian Doppler Forschungsgesellschaft; Austrian Science Fund(Austrian Science Fund (FWF)); Phadia(Phadia); Biomay AG	Supported by research Grants F01804, F01805, and F01815 from the Austrian Science Foundation and by research grants from Biomay, Vienna, Austria, and Mead Johnson Nutrition, Evansville, Ind.; Disclosure of potential conflict of interest: J. Thalhamer has consultant arrangements with Biomay AG and receives research support from Biomay AG, Christian Doppler Forschungsgesellschaft, and the Austrian Science Fund. S. Scheiblhofer, W. Keller. T. Pavkov, and D. Zafred receive research support from the Austrian Science Fund. G. Pauli has consultant arrangements with Stallergenes. N. G. Papadopoulos is on advisory boards for Merck and GlaxoSmithKline and receives honoraria for talks from Novards. Eric A. F. van Tol is employed by and receives research support from Mead Johnson Nutrition. R. Valenta has consultant arrangements with Biomay and Phadia and receives research support from Biomay and Phadia. The rest of the authors have declared that they have no conflict of interest.	ADAMS SL, 1991, IMMUNOL CELL BIOL, V69, P191, DOI 10.1038/icb.1991.28; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDO BA, 1984, AUST J DAIRY TECHNOL, V39, P120; BALL T, 1994, J BIOL CHEM, V269, P28323; Bernard H, 1999, FOOD AGR IMMUNOL, V11, P101, DOI 10.1080/09540109999960; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Chrysina ED, 2000, J BIOL CHEM, V275, P37021, DOI 10.1074/jbc.M004752200; de Wit JN, 1998, J DAIRY SCI, V81, P597, DOI 10.3168/jds.S0022-0302(98)75613-9; Docena GH, 1996, ALLERGY, V51, P412, DOI 10.1111/j.1398-9995.1996.tb04639.x; Edlmayr J, 2009, J IMMUNOL, V182, P6298, DOI 10.4049/jimmunol.0713622; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Flicker S, 2006, J ALLERGY CLIN IMMUN, V117, P1336, DOI 10.1016/j.jaci.2006.02.012; Flicker S, 2000, J IMMUNOL, V165, P3849, DOI 10.4049/jimmunol.165.7.3849; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Garcia-Ara MC, 2004, CLIN EXP ALLERGY, V34, P866, DOI 10.1111/j.1365-2222.2004.01976.x; GJESING B, 1986, ALLERGY, V41, P51, DOI 10.1111/j.1398-9995.1986.tb00275.x; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; Host A, 2002, ANN ALLERG ASTHMA IM, V89, P33, DOI 10.1016/S1081-1206(10)62120-5; HOST A, 1992, ALLERGY, V47, P218, DOI 10.1111/j.1398-9995.1992.tb00654.x; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; Kaul S, 2007, CLIN EXP ALLERGY, V37, P141, DOI 10.1111/j.1365-2222.2006.02618.x; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Mari A, 2002, INT ARCH ALLERGY IMM, V129, P286, DOI 10.1159/000067591; Maynard F, 1997, INT ARCH ALLERGY IMM, V113, P478, DOI 10.1159/000237625; Maynard F, 1999, FOOD AGR IMMUNOL, V11, P179, DOI 10.1080/09540109999852; Moreno FJ, 2005, J AGR FOOD CHEM, V53, P9810, DOI 10.1021/jf0515227; Niemi M, 2007, STRUCTURE, V15, P1413, DOI 10.1016/j.str.2007.09.012; Padavattan S, 2009, J IMMUNOL, V182, P2141, DOI 10.4049/jimmunol.0803018; Permyakov EA, 2000, FEBS LETT, V473, P269, DOI 10.1016/S0014-5793(00)01546-5; Purohit A, 2005, CLIN EXP ALLERGY, V35, P186, DOI 10.1111/j.1365-2222.2005.02156.x; Saff EB, 1997, MATH INTELL, V19, P5, DOI 10.1007/BF03024331; Schulmeister U, 2008, CLIN EXP ALLERGY, V38, P60, DOI 10.1111/j.1365-2222.2007.02860.x; Schulmeister U, 2009, J IMMUNOL, V182, P7019, DOI 10.4049/jimmunol.0712366; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; Selo I, 1999, CLIN EXP ALLERGY, V29, P1055, DOI 10.1046/j.1365-2222.1999.00612.x; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; Slangen CJ, 1999, J AGR FOOD CHEM, V47, P4549, DOI 10.1021/jf990212j; Swoboda I, 2002, J IMMUNOL, V168, P4576, DOI 10.4049/jimmunol.168.9.4576; Swoboda I, 2007, J IMMUNOL, V178, P6290, DOI 10.4049/jimmunol.178.10.6290; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJI NM, 1993, IMMUNOL LETT, V37, P215, DOI 10.1016/0165-2478(93)90033-X; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; Vassilopoulou E, 2008, INT ARCH ALLERGY IMM, V146, P156, DOI 10.1159/000113519; WAL JM, 1995, ADV EXP MED BIOL, V371, P879; Werfel T, 2008, J DTSCH DERMATOL GES, V6, P573, DOI 10.1111/j.1610-0387.2008.06778.x; Westritschnig K, 2008, EUR J CLIN INVEST, V38, P260, DOI 10.1111/j.1365-2362.2008.01938.x; Westritschnig K, 2004, J IMMUNOL, V172, P5684, DOI 10.4049/jimmunol.172.9.5684; Whitehead A, 2004, ATLA-ALTERN LAB ANIM, V32, P73, DOI 10.1177/026119290403202s15	50	35	38	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1279	1285		10.1016/j.jaci.2010.03.007	http://dx.doi.org/10.1016/j.jaci.2010.03.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20466413				2022-12-18	WOS:000278831000015
J	Saghafian-Hedengren, S; Sverremark-Ekstrom, E; Linde, A; Lilja, G; Nilsson, C				Saghafian-Hedengren, Shanie; Sverremark-Ekstrom, Eva; Linde, Annika; Lilja, Gunnar; Nilsson, Caroline			Early-life EBV infection protects against persistent IgE sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epstein-Barr virus; seronegative; seropositive; age-dependent dual roles of infection; polyclonal stimulatory effect; persistent IgE sensitization	EPSTEIN-BARR-VIRUS; ALLERGIC DISEASE; CAPSID ANTIGEN; ASTHMA; ANTIBODIES; CYTOMEGALOVIRUS; PREVALENCE; CHILDHOOD; ATOPY; WHEEZE	Background: Infection with EBV has previously been implicated in influencing allergic disorders, but its precise role remains contradictor),. The timing of primary infection may contribute to the discrepancies. Objective: This study aimed at investigating whether the time-point of primary EBV infection during childhood could be of importance in modulating the risk of developing IgE, sensitization. Methods: A total of 219 Swedish infants were followed prospectively to 5 years of age with clinical examinations, skin prick testing, specific IgE analyses, and determination of serostatus against EBV. Results: After analysis of the children's EBV serostatus,we found that 5-year-olds who were infected with EBV before the age of 2 years were at a significantly lower risk of being persistently IgE-sensitized-that is, sensitized at both 2 and 5 years of age (adjusted odds ratio, 0.34; 95% CI, 0.12-0.94). In contrast, contraction of EBV after 2 years of age was highly associated with late-onset IgE sensitization (adjusted odds ratio, 4.64; 95% CI, 1.57-13.69). Persistently sensitized 5-year-olds had higher specific-IgE levels than children with late-onset IgE sensitization (P <.01). Conclusion: Our data support the value of early-life microbial exposure for protection against the development of IgE sensitization and underscore the proximate postnatal years as ail important period (luring which EBV could contribute to ail allergo-protective immune profile. (J Allergy Clin Immunol 2010;125:433-8.)	[Saghafian-Hedengren, Shanie; Sverremark-Ekstrom, Eva] Stockholm Univ, Wenner Gren Inst, Dept Immunol, S-10691 Stockholm, Sweden; [Linde, Annika] Swedish Inst Infect Dis Control, Dept Epidemiol, Solna, Sweden; [Lilja, Gunnar; Nilsson, Caroline] Karolinska Inst, Dept Clin Sci & Educ, Soder Sjukhuset, Stockholm, Sweden; [Lilja, Gunnar; Nilsson, Caroline] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden	Stockholm University; Swedish Institute for Infectious Disease Control; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet	Saghafian-Hedengren, S (corresponding author), Stockholm Univ, Wenner Gren Inst, Dept Immunol, SvanteArrheniusvag 16-18, S-10691 Stockholm, Sweden.	shanie@imun.su.se	Nilsson, Caroline/AFK-2402-2022; Nilsson, Caroline/AAF-9663-2022; Sverremark-Ekström, Eva/A-2305-2016	Sverremark-Ekström, Eva/0000-0001-6271-8681	Swedish Research Council [57X-15160-05-2]; Swedish Asthma and Allergy Association; Kousul Th C Berg Foundation; Samariten Foundation; Mjolkdroppen Foundation; Vardal Foundation; Heart and Lung Foundation; Hesselman Foundation; Golden Jubilee Memorial Foundation; HIM Lovisa/Axel Tielman Foundation; Golje Foundation; GlaxoSmithKline; Brio AB; Karolinska Institute	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Asthma and Allergy Association; Kousul Th C Berg Foundation; Samariten Foundation; Mjolkdroppen Foundation; Vardal Foundation; Heart and Lung Foundation(Swedish Heart-Lung Foundation); Hesselman Foundation; Golden Jubilee Memorial Foundation; HIM Lovisa/Axel Tielman Foundation; Golje Foundation; GlaxoSmithKline(GlaxoSmithKline); Brio AB; Karolinska Institute(Karolinska Institutet)	Supported by the Swedish Research Council (grant no. 57X-15160-05-2), the Swedish Asthma and Allergy Association, the Kousul Th C Berg Foundation. the Samariten Foundation, the Mjolkdroppen Foundation, the Vardal Foundation, the Heart and Lung Foundation, the Hesselman Foundation. the Golden Jubilee Memorial Foundation, the HIM Lovisa/Axel Tielman Foundation, the Golje Foundation. GlaxoSmithKline. Brio AB, and the Karolinska Institute. Phadia AB supplied reagents for plasma IgE analyses.	Calvani M, 1997, PEDIATR ALLERGY IMMU, V8, P91, DOI 10.1111/j.1399-3038.1997.tb00150.x; Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707; Garn H, 2007, IMMUNOBIOLOGY, V212, P441, DOI 10.1016/j.imbio.2007.03.006; Holt PG, 2007, CURR OPIN ALLERGY CL, V7, P547, DOI 10.1097/ACI.0b013e3282f14a17; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Isolauri E, 2008, J CLIN GASTROENTEROL, V42, pS91, DOI 10.1097/MCG.0b013e3181639a98; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kurukulaaratchy RJ, 2006, ANN ALLERG ASTHMA IM, V97, P84, DOI 10.1016/S1081-1206(10)61375-0; LINDE A, 1987, J MED VIROL, V21, P109, DOI 10.1002/jmv.1890210203; LINDE A, 1990, J INFECT DIS, V161, P903, DOI 10.1093/infdis/161.5.903; Linde A, 2007, MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED, P1564; Message SD, 2002, BRIT MED BULL, V61, P29, DOI 10.1093/bmb/61.1.29; Musharrafieh U, 2009, J ASTHMA, V46, P382, DOI 10.1080/02770900902777775; Nilsson C, 2005, J ALLERGY CLIN IMMUN, V116, P438, DOI 10.1016/j.jaci.2005.04.027; Nilsson C, 2009, CLIN EXP ALLERGY, V39, P509, DOI 10.1111/j.1365-2222.2008.03147.x; Okudaira H, 1999, INT ARCH ALLERGY IMM, V120, P177, DOI 10.1159/000024265; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; RYSTEDT I, 1984, INT ARCH ALLER A IMM, V75, P179, DOI 10.1159/000233610; Saghafian-Hedengren S, 2009, J IMMUNOL, V182, P2511, DOI 10.4049/jimmunol.0801699; Sidorchuk A, 2004, J ALLERGY CLIN IMMUN, V114, P1434, DOI 10.1016/j.jaci.2004.08.009; Sidorchuk A, 2003, PEDIATR INFECT DIS J, V22, P642, DOI 10.1097/00006454-200307000-00014; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; STAGNO S, 1994, P NATL ACAD SCI USA, V91, P2384, DOI 10.1073/pnas.91.7.2384; STRANNEGARD IL, 1981, INT ARCH ALLER A IMM, V64, P314, DOI 10.1159/000232709; SUNDQVIST VA, 1981, J VIROL METHODS, V2, P301, DOI 10.1016/0166-0934(81)90029-X; Takeuchi K, 2006, PATHOL INT, V56, P112, DOI 10.1111/j.1440-1827.2006.01936.x; von Mutius E, 2001, EUR RESPIR J, V18, P872, DOI 10.1183/09031936.01.00268401; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; Votava M, 1996, ACTA VIROL, V40, P99; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	31	35	36	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					433	438		10.1016/j.jaci.2009.09.033	http://dx.doi.org/10.1016/j.jaci.2009.09.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	19963258	Green Submitted			2022-12-18	WOS:000274764000023
J	Komarow, HD; Hu, ZH; Brittain, E; Uzzaman, A; Gaskins, D; Metcalfe, DD				Komarow, Hirsh D.; Hu, Zonghui; Brittain, Erica; Uzzaman, Ashraf; Gaskins, Donna; Metcalfe, Dean D.			Serum tryptase levels in atopic and nonatopic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANAPHYLAXIS; DEFICIENCY		[Komarow, Hirsh D.; Uzzaman, Ashraf; Gaskins, Donna; Metcalfe, Dean D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Hu, Zonghui; Brittain, Erica] NIAID, Biostat Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Komarow, HD (corresponding author), NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	komarowh@niaid.nih.gov			Intramural NIH HHS [NIH0010049406, Z01 AI000951-03, ZIA AI000951-06] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000951, ZIAAI000249] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Knight AK, 2005, CLIN EXP IMMUNOL, V141, P333, DOI 10.1111/j.1365-2249.2005.02837.x; Laske N, 2004, PEDIAT ALLERG IMM-UK, V15, P86, DOI 10.1046/j.0905-6157.2003.00106.x; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; Soto D, 2002, CLIN EXP ALLERGY, V32, P1000, DOI 10.1046/j.1365-2222.2002.01416.x; van Toorenenbergen AW, 2005, J ALLERGY CLIN IMMUN, V116, P1159, DOI 10.1016/j.jaci.2005.07.023	8	35	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					845	848		10.1016/j.jaci.2009.06.040	http://dx.doi.org/10.1016/j.jaci.2009.06.040			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19665778	Green Accepted			2022-12-18	WOS:000270802800034
J	Somech, R; Simon, AJ; Lev, A; Dalal, I; Spirer, Z; Goldstein, I; Nagar, M; Amariglio, N; Rechavi, G; Roifman, CM				Somech, Raz; Simon, Amos J.; Lev, Atar; Dalal, Ilan; Spirer, Zvi; Goldstein, Itamar; Nagar, Meital; Amariglio, Ninette; Rechavi, Gideon; Roifman, Chaim M.			Reduced central tolerance in Omenn syndrome leads to immature self-reactive oligoclonal T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Omenn syndrome; autoimmunity; immunodeficiency; SCID; AIRE; tolerance; Foxp3; Treg; oligoclones; TREC	SEVERE COMBINED IMMUNODEFICIENCY; AIRE DEFICIENCY; RAG2 GENES; MUTATIONS; EXPRESSION; TRANSPLANTATION; LYMPHOCYTES; ENTEROPATHY	Background: Omenn syndrome (OS) is characterized by a peculiar severe T-cell immune deficiency associated with autoimmunelike manifestations. Dysregulations of the central and peripheral immune tolerance, mediated by the protein autoimmune regulator (AIRE) and regulatory T cells, respectively, were proposed as possible mechanisms of this aberrant inflammatory process. Objective: We studied mechanisms of central and peripheral tolerance in patients with OS and also examined the gene expression profile associated with OS features. Methods: T-cell receptor diversity, DNA rearrangement, and the expression of AIRE and forkhead box P3 mRNA as well as the expression of regulatory T cells in cells obtained from patients with OS were studied. Characterization of gene expression in these cells was carried out by using the TaqMan Low-Density Array. Results: Transcript expression of peripheral blood AIRE but not forkhead box P3 was reduced in patients with OS. The expression of natural killer T and regulatory T cells was normal, although the latter showed an abnormal CD4-negative population. Patients with OS have oligoclonal T cells with limited DNA recombination activity, including the presence of early but not late T-cell maturation events, regardless of the genetic defect underlying the syndrome. The transcriptional profile associated with OS features reveals significant changes in 25.5% of the tested genes compared with normal control. Conclusion: Our findings suggest that T-cell oligoclonal expansion in OS emanates from an incomplete block before the maturation stage of negative selection, which may explain escape of autoreactive T cells from the thymus. Dysregulated genes in patients with OS are closely involved with self-tolerance and autoimmunity. (J Allergy Clin Immunol 2009;124:793-800.)	[Somech, Raz] Tel Aviv Univ, Sackler Sch Med, Safra Childrens Hosp, Sheba Med Ctr,Canc Res Ctr, Tel Hashomer, Israel; [Somech, Raz; Spirer, Zvi] Safra Childrens Hosp, Pediat Immunol Serv, Tel Hashomer, Israel; [Somech, Raz; Dalal, Ilan; Spirer, Zvi] Sackler Sch Med, Tel Aviv, Israel; [Dalal, Ilan] Wolfson Med Ctr, Pediat Emergency Med Unit, Holon, Israel; [Roifman, Chaim M.] Univ Toronto, Toronto, ON, Canada; [Roifman, Chaim M.] Hosp Sick Children, Div Immunol & Allergy, Dept Pediat, Canadian Ctr Primary Immunodeficiency,Jeffrey Mod, Toronto, ON M5G 1X8, Canada	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Somech, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Safra Childrens Hosp, Sheba Med Ctr,Canc Res Ctr, Tel Hashomer, Israel.	rsomech@hotmail.com		Goldstein, Itamar/0000-0001-5393-186X				Aleman K, 2001, EUR J PEDIATR, V160, P718, DOI 10.1007/s004310100816; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Cavadini P, 2005, J CLIN INVEST, V115, P728, DOI 10.1172/JCI200523087; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; Delves PJ, 2000, NEW ENGL J MED, V343, P37, DOI 10.1056/NEJM200007063430107; Dik WA, 2005, J EXP MED, V201, P1715, DOI 10.1084/jem.20042524; Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; Giliani S, 2006, J PEDIATR-US, V148, P272, DOI 10.1016/j.jpeds.2005.10.004; Grunebaum E, 2008, J ALLERGY CLIN IMMUN, V122, P1219, DOI 10.1016/j.jaci.2008.08.031; Kato Masahiko, 2006, Allergol Int, V55, P115, DOI 10.2332/allergolint.55.115; Khiong K, 2007, J CLIN INVEST, V117, P1270, DOI 10.1172/JCI30513; Kisand K, 2008, BLOOD, V112, P2657, DOI 10.1182/blood-2008-03-144634; Notarangelo LD, 2006, ADV IMMUNOL, V89, P321, DOI 10.1016/S0065-2776(05)89008-X; Peterson P, 2008, NAT REV IMMUNOL, V8, P948, DOI 10.1038/nri2450; Pollard KM, 2004, J IMMUNOL, V173, P5880, DOI 10.4049/jimmunol.173.9.5880; Roifman CM, 2008, BONE MARROW TRANSPL, V41, P947, DOI 10.1038/bmt.2008.11; Roifman CM, 2008, J ALLERGY CLIN IMMUN, V121, P1056, DOI 10.1016/j.jaci.2007.12.1148; Roifman CM, 2006, J ALLERGY CLIN IMMUN, V117, P897, DOI 10.1016/j.jaci.2006.01.003; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Signorini S, 1999, BLOOD, V94, P3468, DOI 10.1182/blood.V94.10.3468.422k34_3468_3478; Suzuki E, 2008, AUTOIMMUNITY, V41, P133, DOI 10.1080/08916930701773941; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Villa A, 1999, J CLIN IMMUNOL, V19, P87, DOI 10.1023/A:1020550432126; Villa A, 2008, J ALLERGY CLIN IMMUN, V122, P1082, DOI 10.1016/j.jaci.2008.09.037; Vincenti F, 2008, J ALLERGY CLIN IMMUN, V121, P299, DOI 10.1016/j.jaci.2008.01.002; Wada T, 2008, BLOOD, V112, P1872, DOI 10.1182/blood-2008-04-149708; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wong SY, 2007, J CLIN INVEST, V117, P1213, DOI 10.1172/JCI32214	30	35	35	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					793	800		10.1016/j.jaci.2009.06.048	http://dx.doi.org/10.1016/j.jaci.2009.06.048			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767069	Bronze			2022-12-18	WOS:000270802800026
J	Allakhverdi, Z; Comeau, MR; Jessup, HK; Delespesse, G				Allakhverdi, Zoulfia; Comeau, Michael R.; Jessup, Heidi K.; Delespesse, Guy			Thymic stromal lymphopoietin as a mediator of crosstalk between bronchial smooth muscles and mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLAMMATION; EXPRESSION; ASTHMA		[Allakhverdi, Zoulfia; Delespesse, Guy] Univ Montreal, Notre Dame Hosp, CHUM Res Ctr, Lab Allergy, Montreal, PQ H3C 3J7, Canada; [Comeau, Michael R.; Jessup, Heidi K.] Amgen Inc, Inflammat Res, Seattle, WA USA	Universite de Montreal; Amgen	Allakhverdi, Z (corresponding author), Univ Montreal, Notre Dame Hosp, CHUM Res Ctr, Lab Allergy, Montreal, PQ H3C 3J7, Canada.	comeaumr@amgen.com; guy.delespesse@sympatico.ca	Allakhverdi, Zoulfia/AAG-1379-2019					Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; Sukkar MB, 2006, J ALLERGY CLIN IMMUN, V118, P641, DOI 10.1016/j.jaci.2006.05.013; Theoharides TC, 2006, ANN NY ACAD SCI, V1088, P78, DOI 10.1196/annals.1366.025; Woodman L, 2008, J IMMUNOL, V181, P5001, DOI 10.4049/jimmunol.181.7.5001; Zhang KQ, 2007, AM J PHYSIOL-LUNG C, V293, pL375, DOI 10.1152/ajplung.00045.2007	9	35	37	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					958	960		10.1016/j.jaci.2009.01.059	http://dx.doi.org/10.1016/j.jaci.2009.01.059			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19348931				2022-12-18	WOS:000265058600027
J	Hortobagyi, L; Kierstein, S; Krytska, K; Zhu, XP; Das, AM; Poulain, F; Haczku, A				Hortobagyi, Laszlo; Kierstein, Sonja; Krytska, Kateryna; Zhu, Xiaoping; Das, Anuk M.; Poulain, Francis; Haczku, Angela			Surfactant protein D inhibits TNF-alpha production by macrophages and dendritic cells in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TNF; SP-D; dendritic cell; mouse model; airway inflammation	RESPIRATORY SYNCYTIAL VIRUS; INDUCED AIRWAY INFLAMMATION; INFLUENZA-A VIRUS; PULMONARY COLLECTINS; DEFICIENT MICE; IN-VIVO; MOUSE MODEL; LUNG; CLEARANCE; RESPONSES	Background: Surfactant protein (SP) D shares target cells with the proinflammatory cytokine TNF-alpha, an important autocrine stimulator of dendritic cells and macrophages in the airways. Objective: We sought to study the mechanisms by which TNF-alpha and SP-D can affect cellular components of the pulmonary innate immune system. Methods: Cytokine and SP-D protein and mRNA expression was assessed by means of ELISA, Western blotting, and real-time PCR, respectively, by using in vivo models of allergic airway sensitization. Macrophage and dendritic cell phenotypes were analyzed by means or FACS analysis. Maturation of bone marrow-derived dendritic cells was investigated in vitro. Results: TNF-alpha, elicited either by allergen exposure or pulmonary overexpression, induced SP-D, IL-13, and mononuclear cell influx in the lung. Recombinant IL-13 by its-elf was also capable of enhancing SP-D in vivo and in vitro, and the SP-D response to allergen challenge was impaired in IL-13-deficient mice. Allergen-induced increase of SP-D in the airways coincided with resolution of TNF-alpha release and cell influx. SPD-deficient mice had constitutively high numbers of alveolar mononuclear cells expressing TNF-alpha, MHC class II, CD86, and CD11b, characteristics of proinflammatory, myeloid dendritic cells. Recombinant SP-D significantly suppressed all of these molecules in bone marrow-derived dendritic cell cultures. Conclusions: TNF-alpha can contribute to enhanced SP-D production in the lung indirectly through inducing IL-13. SP-D, on the other hand, can antagonize the proinflammatory effects of TNF-a on macrophages and dendritic cells, at least partly, by inhibiting production of this cytokine.	[Haczku, Angela] Univ Penn, Dept Med, Translat Res Labs, Allergy & Crit Care Div, Philadelphia, PA 19104 USA; [Das, Anuk M.] Centocor Inc, King Of Prussia, PA USA; [Poulain, Francis] Univ Calif Davis, Dept Pediat, Davis, CA 95616 USA	University of Pennsylvania; Pennsylvania Medicine; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; University of California System; University of California Davis	Haczku, A (corresponding author), Univ Penn, Dept Med, Translat Res Labs, Allergy & Crit Care Div, 125 S 31st St, Philadelphia, PA 19104 USA.	haczku@mail.med.upenn.edu	HACZKU, ANGELA/A-8486-2013	HACZKU, ANGELA/0000-0002-1301-4941	Centocor;  [R01-A1055593-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055593] Funding Source: NIH RePORTER	Centocor; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grant R01-A1055593-01 and Centocor.	ANTAL JM, 1992, INFECT IMMUN, V60, P1114, DOI 10.1128/IAI.60.3.1114-1121.1992; Arias-Diaz J, 2000, SHOCK, V14, P300, DOI 10.1097/00024382-200014030-00010; Atochina EN, 2004, INFECT IMMUN, V72, P6002, DOI 10.1128/IAI.72.10.6002-6011.2004; Barr FE, 2000, AM J RESP CELL MOL, V23, P586, DOI 10.1165/ajrcmb.23.5.3771; Borron P, 2000, AM J PHYSIOL-LUNG C, V278, pL840, DOI 10.1152/ajplung.2000.278.4.L840; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Brinker KG, 2003, AM J PHYSIOL-LUNG C, V284, pL232, DOI 10.1152/ajplung.00187.2002; Brinker KG, 2001, AM J PHYSIOL-LUNG C, V281, pL1453, DOI 10.1152/ajplung.2001.281.6.L1453; Cao Y, 2004, J ALLERGY CLIN IMMUN, V113, P439, DOI 10.1016/j.jaci.2003.11.031; Chabot S, 2003, AM J RESP CELL MOL, V28, P347, DOI 10.1165/rcmb.4883; Choi IW, 2004, INT IMMUNOPHARMACOL, V4, P1817, DOI 10.1016/j.intimp.2004.07.030; Crouch E C, 2000, Respir Res, V1, P93; Fujita M, 2005, CYTOKINE, V31, P25, DOI 10.1016/j.cyto.2005.02.006; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Grayson MH, 2007, J IMMUNOL, V179, P1438, DOI 10.4049/jimmunol.179.3.1438; Haczku A, 2006, PHARMACOL THERAPEUT, V110, P14, DOI 10.1016/j.pharmthera.2005.08.008; Haczku A, 2002, AM J PHYSIOL-LUNG C, V283, pL755, DOI 10.1152/ajplung.00062.2002; Haczku A, 2006, J IMMUNOL, V176, P3557, DOI 10.4049/jimmunol.176.6.3557; Hansen S, 2007, AM J RESP CELL MOL, V36, P94, DOI 10.1165/rcmb.2006-0195OC; Hartshorn KL, 2002, INFECT IMMUN, V70, P6129, DOI 10.1128/IAI.70.11.6129-6139.2002; Hawgood S, 2002, AM J PHYSIOL-LUNG C, V283, pL1002, DOI 10.1152/ajplung.00118.2002; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; Hu B, 2004, AM J RESP CELL MOL, V30, P687, DOI 10.1165/rcmb.2003-0255OC; Kierstein S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-85; Kohl J, 2007, MOL IMMUNOL, V44, P44, DOI 10.1016/j.molimm.2006.06.016; Korfhagen TR, 2001, AM J RESP CELL MOL, V25, P668, DOI 10.1165/ajrcmb.25.6.f221; Kremlev SG, 1997, AM J PHYSIOL-LUNG C, V272, pL1070, DOI 10.1152/ajplung.1997.272.6.L1070; Kumarathasan P, 2005, INT J TOXICOL, V24, P59, DOI 10.1080/10915810590921379; Kuroki Y, 2007, CELL MICROBIOL, V9, P1871, DOI 10.1111/j.1462-5822.2007.00953.x; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Lekkala M, 2006, INFECT IMMUN, V74, P4549, DOI 10.1128/IAI.00243-06; LeVine AM, 2004, AM J RESP CELL MOL, V31, P193, DOI 10.1165/rcmb.2003-0107OC; LeVine AM, 2001, MICROBES INFECT, V3, P161, DOI 10.1016/S1286-4579(00)01363-0; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; Li G, 2002, AM J RESP CELL MOL, V26, P277, DOI 10.1165/ajrcmb.26.3.4584; McIntosh JC, 1996, AM J PHYSIOL-LUNG C, V271, pL310, DOI 10.1152/ajplung.1996.271.2.L310; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; MIYAZAKI Y, 1995, J CLIN INVEST, V96, P250, DOI 10.1172/JCI118029; Morelli AE, 2003, BLOOD, V101, P611, DOI 10.1182/blood-2002-06-1769; Mukhopadhyay S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-125; Nakae S, 2007, J ALLERGY CLIN IMMUN, V119, P680, DOI 10.1016/j.jaci.2006.11.701; Palaniyar N, 2005, J IMMUNOL, V174, P7352, DOI 10.4049/jimmunol.174.11.7352; Pastva Amy M, 2007, Proc Am Thorac Soc, V4, P252, DOI 10.1513/pats.200701-018AW; Sano H, 1999, J IMMUNOL, V163, P387; Scanlon ST, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-97; Schaub B, 2004, CLIN EXP ALLERGY, V34, P1819, DOI 10.1111/j.1365-2222.2004.02068.x; Senft AP, 2007, AM J PHYSIOL-LUNG C, V292, pL469, DOI 10.1152/ajplung.00297.2006; Vermaelen KY, 2003, J IMMUNOL, V171, P1016, DOI 10.4049/jimmunol.171.2.1016; Wang JY, 2007, IMMUNOBIOLOGY, V212, P417, DOI 10.1016/j.imbio.2007.01.002; Weikert LF, 2000, AM J PHYSIOL-LUNG C, V279, pL216, DOI 10.1152/ajplung.2000.279.2.L216; Wills-Karp Marsha, 2007, Proc Am Thorac Soc, V4, P247, DOI 10.1513/pats.200704-046AW; Wu L, 2007, IMMUNITY, V26, P741, DOI 10.1016/j.immuni.2007.06.006; Yoshida M, 2006, RESPIROLOGY, V11, pS37, DOI 10.1111/j.1440-1843.2006.00806.x	55	35	38	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					521	528		10.1016/j.jaci.2008.05.002	http://dx.doi.org/10.1016/j.jaci.2008.05.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18554706	Green Accepted, Bronze			2022-12-18	WOS:000259234000012
J	Davis, CM; Shearer, WT				Davis, Carla M.; Shearer, William T.			Diagnosis and management of HIV drug hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 23-27, 2007	San Diego, CA	Amer Acad Allergy, Asthma & Immunol		human immunodeficiency virus; drug hypersensitivity; trimethoprim-sulfamethoxazole; antiretroviral agents; protease inhibitor; fusion inhibitor; integrase inhibitor	PNEUMOCYSTIS-CARINII-PNEUMONIA; REVERSE-TRANSCRIPTASE INHIBITOR; NEVIRAPINE-ASSOCIATED RASH; PLACEBO-CONTROLLED TRIAL; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON SYNDROME; RISK-FACTOR-ANALYSIS; TRIMETHOPRIM-SULFAMETHOXAZOLE; FUSION INHIBITOR	Drug hypersensitivity reactions are an important cause of morbidity in HIV-infected patients who take complex medication regimens. Correct diagnosis and management of these reactions are essential in the clinical care of HIV disease. Trimethoprim-sulfamethoxazole, abacavir, nevirapine, atazanavir, and enfuvirtide can all cause hypersensitivity rashes. In this review, we discuss the evidence for immunologic mechanisms of hypersensitivity reactions to HIV medications, the clinical characteristics of these reactions, and guidelines that currently exist for their identification and management.	[Davis, Carla M.] Baylor Coll Med, Dept Pediat, Div Allergy & Immunol, Houston, TX 77030 USA	Baylor College of Medicine	Davis, CM (corresponding author), Baylor Coll Med, Dept Pediat, Div Allergy & Immunol, 6621 Fannin St,MC FC 330-01, Houston, TX 77030 USA.	cmdavis@texaschildrenshospital.org		Shearer, William/0000-0002-2483-2130	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD041983] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027551, P30AI036211] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0188] Funding Source: Medline; NHLBI NIH HHS [HL72705] Funding Source: Medline; NIAID NIH HHS [AI27551, AI36211] Funding Source: Medline; NICHD NIH HHS [HD79533, HD78522, HD41983] Funding Source: Medline; PHS HHS [A169441] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bacot BK, 1997, J ALLERGY CLIN IMMUN, V100, P707, DOI 10.1016/S0091-6749(97)70177-5; Ball RA, 2003, J AM ACAD DERMATOL, V49, P826, DOI 10.1016/S0190-9622(03)02099-1; CARR A, 1993, J INFECT DIS, V167, P180, DOI 10.1093/infdis/167.1.180; CARR A, 1993, AIDS, V7, P65, DOI 10.1097/00002030-199301000-00010; CARR A, 1994, AIDS, V8, P333, DOI 10.1097/00002030-199403000-00006; Claes Petra, 2004, Eur J Intern Med, V15, P255, DOI 10.1016/j.ejim.2004.04.007; Clotet B, 2004, AIDS, V18, P1137, DOI 10.1097/00002030-200405210-00007; Cutrell AG, 2004, ANN PHARMACOTHER, V38, P2171, DOI 10.1345/aph.1E202; DeSimone JA, 2004, CLIN INFECT DIS, V39, pE110, DOI 10.1086/425502; *DHHS, 2006, DHHS PAN ANT GUID AD; Drummond NS, 2006, ANTIVIR THER, V11, P393; Easterbrook P J, 2003, HIV Med, V4, P321, DOI 10.1046/j.1468-1293.2003.00166.x; Escaut L, 1999, AIDS, V13, P1419, DOI 10.1097/00002030-199907300-00026; Fontaine C, 2005, AIDS, V19, P1927, DOI 10.1097/01.aids.0000189861.44311.ed; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2; HENNESSY S, 1995, J GEN INTERN MED, V10, P380, DOI 10.1007/BF02599836; Hervey PS, 2000, DRUGS, V60, P447, DOI 10.2165/00003495-200060020-00015; Herzmann C, 2005, HIV MED, V6, P379, DOI 10.1111/j.1468-1293.2005.00329.x; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Hetherington S, 2001, CLIN THER, V23, P1603, DOI 10.1016/S0149-2918(01)80132-6; Ho TTY, 1998, AIDS, V12, P2082, DOI 10.1097/00002030-199815000-00026; Joint Task Force on Practice Parameters tAAoA Asthma and Immunology the American Academy of Allergy Asthma and Immunology and the Joint Council of Allergy Asthma and Immunology, 1999, ANN ALLERG ASTHMA IM, V83, P665, DOI DOI 10.1016/S1081-1206(10)62890-6; Knobel H, 2004, JAIDS-J ACQ IMM DEF, V37, P1276, DOI 10.1097/01.qai.0000137372.18814.34; Knobel H, 2001, J ACQ IMMUN DEF SYND, V28, P14, DOI 10.1097/00042560-200109010-00003; Koopmans PP, 1998, PHARM WORLD SCI, V20, P253, DOI 10.1023/A:1008617019897; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Martin AM, 2005, AIDS, V19, P97, DOI 10.1097/00002030-200501030-00014; Montaner JSG, 2003, JAIDS-J ACQ IMM DEF, V33, P41, DOI 10.1097/00126334-200305010-00007; Murphy RL, 2003, JAIDS-J ACQ IMM DEF, V34, pS15, DOI 10.1097/00126334-200309011-00004; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Neuman MG, 2002, THER DRUG MONIT, V24, P728, DOI 10.1097/00007691-200212000-00008; Ogedegbe Anthony O, 2003, Clin Liver Dis, V7, P475, DOI 10.1016/S1089-3261(03)00023-0; Ouagari Z, 2006, AIDS, V20, P1207, DOI 10.1097/01.aids.0000226965.17966.3c; Phan T G, 1999, Australas J Dermatol, V40, P153, DOI 10.1046/j.1440-0960.1999.00347.x; Phillips EJ, 2006, CLIN INFECT DIS, V43, P103, DOI 10.1086/504878; Phillips EJ, 2005, AIDS, V19, P979, DOI 10.1097/01.aids.0000171414.99409.fb; Phillips EJ, 2002, AIDS, V16, P2223, DOI 10.1097/00002030-200211080-00017; Pirmohamed M, 2001, CURR OPIN ALLERGY CL, V1, P311, DOI 10.1097/00130832-200108000-00006; Pitche P, 2005, Med Trop (Mars), V65, P359; Pollard RB, 1998, CLIN THER, V20, P1071, DOI 10.1016/S0149-2918(98)80105-7; PORTEOUS DM, 1991, ARCH DERMATOL, V127, P740, DOI 10.1001/archderm.127.5.740; Rauch A, 2006, CLIN INFECT DIS, V43, P99, DOI 10.1086/504874; Reilly TP, 2002, CURR OPIN ALLERGY CL, V2, P307, DOI 10.1097/00130832-200208000-00004; Rotunda A, 2003, ACTA DERM-VENEREOL, V83, P1, DOI 10.1080/00015550310002611; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; RZANY B, 1993, ARCH DERMATOL, V129, P1059, DOI 10.1001/archderm.129.8.1059; SHAFER RW, 1989, J ACQ IMMUN DEF SYND, V2, P389; Shahar E, 2005, AIDS, V19, P451, DOI 10.1097/01.aids.0000161779.23191.e5; Symonds W, 2002, CLIN THER, V24, P565, DOI 10.1016/S0149-2918(02)85132-3; Thurmond LM, 2000, ANTIRETROVIR THER S5, V5, P53; Vilar F Javier, 2003, J HIV Ther, V8, P42; WALMSLEY S, 1995, J ACQ IMMUN DEF SYND, V8, P348; Warren KJ, 1998, LANCET, V351, P567, DOI 10.1016/S0140-6736(98)24008-6; Wit FWNM, 2001, AIDS, V15, P2423, DOI 10.1097/00002030-200112070-00010; Yee D, 2003, AM J RESP CRIT CARE, V167, P1472, DOI 10.1164/rccm.200206-626OC; 2000, MORBID MORTAL WKLY R, V49, P1153	59	35	38	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					826	832		10.1016/j.jaci.2007.10.021	http://dx.doi.org/10.1016/j.jaci.2007.10.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	286YY	18190954				2022-12-18	WOS:000254884000003
J	Saffar, AS; Dragon, S; Ezzati, P; Shan, L; Gounni, AS				Saffar, Arash S.; Dragon, Stephane; Ezzati, Peyman; Shan, Lianyu; Gounni, Abdelilah Soussi			Phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase regulate induction of Mcl-1 and survival in glucocorticoid-treated human neutrophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; neutrophil; apoptosis; signal transduction inflammation; asthma	COLONY-STIMULATING FACTOR; INDUCED APOPTOSIS; DEXAMETHASONE; INHIBITION; EXPRESSION; CELLS; PHOSPHORYLATION; RECEPTOR; PATHWAYS; BCL-2	Background: Glucocorticoids have been shown to inhibit human neutrophil apoptosis, with implications that this might help accentuate neutrophilic inflammation. Objective: The aim of this study was to investigate the molecular mechanisms involved in glucocorticoid-mediated inhibition of primary human neutrophil apoptosis. Methods: Primary human neutrophils were isolated from peripheral blood of healthy volunteers and cultured in vitro with dexamethasone. Results: Here we confirm that dexamethasone, a classical glucocorticoid, significantly inhibited apoptosis of primary human neutrophils. This inhibition was not dependent on transrepression of proapoptotic molecules but was associated with induction of antiapoptotic Mcl-1. Remarkably, glucocorticoid-mediated enhancement of Mcl-1 and survival were significantly suppressed by pharmacologic inhibition of p38 mitogen-activated protein kinase or phosphatidylinositol 3-kinase. Inhibition of the above kinases also blocked glucocorticoid-induced maintenance of mitochondrial transmembrane potential and suppression of caspases. Conclusion: Phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase are protein kinases that regulate the prosurvival effect of glucocorticoids on human neutrophils.	[Saffar, Arash S.; Dragon, Stephane; Ezzati, Peyman; Shan, Lianyu; Gounni, Abdelilah Soussi] Univ Manitoba, Fac Med, Dept Immunol, Natl Training Program Allergy & Asthma, Winnipeg, MB, Canada	University of Manitoba	Gounni, AS (corresponding author), 730 William Ave, Winnipeg, MB R3E 0W3, Canada.	gounm@cc.umanitoba.ca	Gounni, Abdelilah Soussi/AAH-3456-2020	DRAGON, Stephane/0000-0002-4999-5307; Gounni, Abdelilah/0000-0003-1265-6560; Soussi Gounni, Abdelilah/0000-0002-7282-0388				Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Alvarado-Kristensson M, 2001, FASEB J, V15, P129, DOI 10.1096/fj.01-0817fje; Arndt PG, 2004, J BIOL CHEM, V279, P10883, DOI 10.1074/jbc.M309901200; Bailly-Maitre B, 2001, CELL DEATH DIFFER, V8, P279, DOI 10.1038/sj.cdd.4400815; Baumann S, 2005, BLOOD, V106, P617, DOI 10.1182/blood-2004-11-4390; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; Bruno A, 2005, J IMMUNOL, V174, P8090, DOI 10.4049/jimmunol.174.12.8090; COX G, 1995, J IMMUNOL, V154, P4719; Cox G, 1997, J LEUKOCYTE BIOL, V61, P224, DOI 10.1002/jlb.61.2.224; DAVIES HR, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003134; De Bosscher K, 2005, P NATL ACAD SCI USA, V102, P15827, DOI 10.1073/pnas.0505554102; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Edwards SW, 2004, BIOCHEM SOC T, V32, P489, DOI 10.1042/BST0320489; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Francois S, 2005, J IMMUNOL, V174, P3633, DOI 10.4049/jimmunol.174.6.3633; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Hasegawa T, 2003, BLOOD, V101, P1164, DOI 10.1182/blood-2002-05-1505; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; in't Veen JCCM, 1999, AM J RESP CRIT CARE, V160, P93; Kato T, 1995, NAT IMMUN, V14, P198; Kilpatrick LE, 2006, J LEUKOCYTE BIOL, V80, P1512, DOI 10.1189/jlb.0406284; Klein JB, 2001, CELL SIGNAL, V13, P335, DOI 10.1016/S0898-6568(01)00151-6; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; LILES WC, 1995, BLOOD, V86, P3181; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Lindemans CA, 2004, BIOCHEM SOC T, V32, P480, DOI 10.1042/BST0320480; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liu CY, 2004, J BIOMED SCI, V11, P214, DOI 10.1159/000076034; Lu JH, 2006, FEBS LETT, V580, P3539, DOI 10.1016/j.febslet.2006.05.031; Maianski NA, 2004, CELL DEATH DIFFER, V11, P143, DOI 10.1038/sj.cdd.4401320; Martinez D, 2006, J IMMUNOL, V176, P1163, DOI 10.4049/jimmunol.176.2.1163; Mendoza-Milla C, 2005, FEBS LETT, V579, P3947, DOI 10.1016/j.febslet.2005.05.081; Messmer UK, 2001, BRIT J PHARMACOL, V133, P467, DOI 10.1038/sj.bjp.0704093; Miller AL, 2005, MOL ENDOCRINOL, V19, P1569, DOI 10.1210/me.2004-0528; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Moulding DA, 2001, J LEUKOCYTE BIOL, V70, P783; Nguyen LT, 2005, RESP MED, V99, P200, DOI 10.1016/j.rmed.2004.06.007; Petrin D, 2006, CELL SIGNAL, V18, P479, DOI 10.1016/j.cellsig.2005.05.021; Sakamoto C, 2003, INT J HEMATOL, V77, P60, DOI 10.1007/BF02982604; Sasson R, 2003, BIOCHEM BIOPH RES CO, V311, P1047, DOI 10.1016/j.bbrc.2003.10.097; Schorr K, 2000, CANCER RES, V60, P5950; Stellato Cristiana, 2004, Proc Am Thorac Soc, V1, P255, DOI 10.1513/pats.200402-015MS; WALKER RI, 1980, REV INFECT DIS, V2, P282; Wang KQ, 2003, J IMMUNOL, V171, P1035, DOI 10.4049/jimmunol.171.2.1035; Ward C, 2005, EUR J IMMUNOL, V35, P2728, DOI 10.1002/eji.200425561; Yamamoto M, 1998, HEPATOLOGY, V27, P959, DOI 10.1002/hep.510270410; Zainudin B, 1997, Respirology, V2, P17, DOI 10.1111/j.1440-1843.1997.tb00051.x	50	35	38	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					492	498		10.1016/j.jaci.2007.10.003	http://dx.doi.org/10.1016/j.jaci.2007.10.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18036649				2022-12-18	WOS:000253337800032
J	Lorenz, Y; Enrique, E; LeQuynh, L; Fotisch, K; Retzek, M; Biemelt, S; Sonnewald, U; Vieths, S; Scheurer, S				Lorenz, Yvonne; Enrique, Ernesto; LeQuynh, Lien; Fotisch, Kay; Retzek, Mechthild; Biemelt, Sophia; Sonnewald, Uwe; Vieths, Stefan; Scheurer, Stephan			Skin prick tests reveal stable and heritable reduction of allergenic potency of gene-silenced tomato fruits	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						gene silencing; RNA interference; food allergy; tomato; Lyc e 3; allergenic potency; hypoallergenic; genetically modified food	LIPID TRANSFER PROTEIN; MAJOR APPLE ALLERGEN; PEACH PRUNUS-PERSICA; RECOMBINANT ALLERGENS; CHERRY ALLERGY; FOOD ALLERGY; IGE; IDENTIFICATION; DIAGNOSIS; COMPONENT	Background: Today, for patients with food allergy, the only possibility to prevent allergic reactions is avoidance of the allergenic food. Genetic engineering of hypoallergenic plants by means of RNA interference (RNAi) could be an approach to improve the quality of life of subjects with food allergy. Objectives: We sought to achieve stable inhibition of expression of the allergenic nonspecific lipid transfer protein Lyc e 3 in tomato and to analyze the reduction of allergenicity in vitro by using histamine release assays and in vivo by using skin prick tests with transgenic tomato fruits. Methods: Gene silencing was performed by means of RNAi and monitored by using Western blotting with nonspecific lipid transfer protein-specific antibodies and sera from patients with tomato allergy. Dose-dependent basophil histamine release assays, prick-to-prick skin testing, and determination of endogenous histamine content were performed with fruits harvested from plants of the first and second generation to assess the allergenic potency compared with that of wild-type fruits. Results: We demonstrated that silencing of Lyc e 3 by means of RNAi contributes to reduced skin reactivity and is passed on to the next generation of fruits. A significant reduction of allergenic potency was determined in vitro and confirmed by using skin prick tests. Conclusion: Taken together, these results indicate that RNAi technology is an effective tool to generate foods with,reduced allergenicity. Clinical implications: Allergen-reduced plant foods might allow reduction of dietary restrictions for patients allergic to panallergen families.	Paul Ehrlich Inst, D-63225 Langen, Germany; Hosp Gen Castellon, Castellon de La Plana, Spain; Univ Erlangen Nurnberg, Erlangen, Germany	Paul Ehrlich Institute; University of Erlangen Nuremberg	Scheurer, S (corresponding author), Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	schst@pei.de	Sonnewald, Uwe/J-7875-2012; Scheurer, Stephan/A-6509-2019	Sonnewald, Uwe/0000-0003-1835-5339; Scheurer, Stephan/0000-0002-2859-562X				Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Bolhaar STHP, 2005, CLIN EXP ALLERGY, V35, P1638, DOI 10.1111/j.1365-2222.2005.02390.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chardin H, 2003, INT ARCH ALLERGY IMM, V131, P85, DOI 10.1159/000070923; Dodo H, 2005, CURR ALLERGY ASTHM R, V5, P67, DOI 10.1007/s11882-005-0058-0; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; *EUR AC ALL CLIN I, 1993, IMMUNOTHERAPY S, V48, P7; Fernandez-Rivas M, 2003, J ALLERGY CLIN IMMUN, V112, P789, DOI 10.1016/S0091-6749(03)02016-5; Foetisch K, 2001, EUR FOOD RES TECHNOL, V213, P259, DOI 10.1007/s002170100343; Gilissen LJWJ, 2005, J ALLERGY CLIN IMMUN, V115, P364, DOI 10.1016/j.jaci.2004.10.014; Herman EM, 2003, PLANT PHYSIOL, V132, P36, DOI 10.1104/pp.103.021865; Kondo Y, 2001, INT ARCH ALLERGY IMM, V126, P294, DOI 10.1159/000049526; Kubo S, 2003, J IMMUNOL, V170, P775, DOI 10.4049/jimmunol.170.2.775; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAJAGER WB, 2002, NAHRUNGSMITTELALLERG; LEQUYNH L, 2006, PLANT BIOTECH, V4, P231; LLEONART R, 1992, ANN ALLERGY, V69, P128; Marion D., 2003, PLANT FOOD ALLERGENS, P57; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; Pastorello EA, 2004, MOL NUTR FOOD RES, V48, P356, DOI 10.1002/mnfr.200400047; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Scheurer S, 2001, J ALLERGY CLIN IMMUN, V107, P724, DOI 10.1067/mai.2001.113864; Tada Y, 1996, FEBS LETT, V391, P341, DOI 10.1016/0014-5793(96)00773-9; Westphal S, 2003, EUR J BIOCHEM, V270, P1327, DOI 10.1046/j.1432-1033.2003.03503.x; Westphal S, 2004, ALLERGY, V59, P526, DOI 10.1046/j.1398-9995.2003.00413.x	25	35	36	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					711	718		10.1016/j.jaci.2006.05.014	http://dx.doi.org/10.1016/j.jaci.2006.05.014			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950292				2022-12-18	WOS:000240649000026
J	Nassenstein, C; Dawbarn, D; Pollock, K; Allen, SJ; Erpenbeck, VJ; Spies, E; Krug, N; Braun, A				Nassenstein, Christina; Dawbarn, David; Pollock, Kenneth; Allen, Shelley Jane; Erpenbeck, Veit Johannes; Spies, Emma; Krug, Norbert; Braun, Armin			Pulmonary distribution, regulation, and functional role of Trk receptors in a murine model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sensory nerves; airway hyperreactivity; airway inflammation; reflex bronchospasm; capsaicin	NERVE GROWTH-FACTOR; RAT SENSORY NEURONS; AIRWAY INFLAMMATION; NEUROTROPHIN RECEPTORS; SUBSTANCE-P; CAPSAICIN; EXPRESSION; P75; HYPERRESPONSIVENESS; EOSINOPHILS	Background: Neurotrophins have been implicated in the pathogenesis of asthma because of their ability to promote hyperreactivity of sensory neurons and to induce airway inflammation. Hyperreactivity of sensory nerves is one key mechanism of airway hyperreactivity that is defined as an abnormal reactivity of the airways to unspecific stimuli, such as cold air and cigarette smoke. Neurotrophins use a dual-receptor system consisting of Trk receptor tyrosine kinases and the structurally unrelated p75 neurotrophin receptor. Objective: The aim of this study was to characterize the distribution, allergen-dependent regulation, and functional relevance of the Trk receptors in allergic asthma. Methods: BALB/c mice were sensitized to ovalbumin. After provocation with ovalbumin or vehicle aerosol, respectively, Trk receptor expression was analyzed in lung tissue by means of fluorescence microscopy and quantitative RT-PCR. To assess the functional relevance of Trk receptors in asthma, we tested the effects of the intranasally administered pan-Trk receptor decoy REN1826. Allergic airway inflammation was quantified and lung function was measured by using head-out body plethysmography. Results: Trk receptors were expressed in neurons, airway smooth muscle cells, and cells of the inflammatory infiltrate surrounding the bronchi and upregulated after allergen challenge. Local application of REN1826 reduced IL-4 and IL-5 cytokine levels but had no effect on IL-13 levels or the cellular composition of bronchoalveolar lavage fluid cells. Furthermore, REN1826 decreased broncho-obstruction in response to sensory stimuli, indicating a diminished hyperreactivity of sensory nerves, but did not influence airway smooth muscle hyperreactivity in response to methacholine. Conclusion: These results emphasize the important role of Trk receptor signaling in the development of asthma. Clinical implications: Our data indicate that blocking of Trk receptor signaling might reduce asthma symptoms.	Fraunhofer Inst Toxicol & Expt Med, D-30625 Hannover, Germany; Univ Bristol, Henry Wellcome Labs, Bristol BS8 1TH, Avon, England; ReNeuron Ltd, Guildford, Surrey, England	Fraunhofer Gesellschaft; University of Bristol	Braun, A (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Nikolai Fuchs Str 1, D-30625 Hannover, Germany.	braun@item.fraunhofer.de	Braun, Armin/B-8750-2009	Braun, Armin/0000-0002-1142-1463; Allen, Shelley/0000-0001-7870-740X	Alzheimers Research UK [ART-PG2002-3] Funding Source: researchfish	Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK))		Bachar O, 2004, CLIN EXP ALLERGY, V34, P1137, DOI 10.1111/j.1365-2222.2004.1868.x; BARNES PJ, 1992, BRIT MED BULL, V48, P149, DOI 10.1093/oxfordjournals.bmb.a072531; Barnes PJ, 2001, RESP PHYSIOL, V125, P145, DOI 10.1016/S0034-5687(00)00210-3; BARNES PJ, 1986, LANCET, V1, P242; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BONNINGTON JK, 2003, J PHYSL S, V551, pS433; Braun A, 2004, BRIT J PHARMACOL, V141, P431, DOI 10.1038/sj.bjp.0705638; Braun A, 1998, EUR J IMMUNOL, V28, P3240, DOI 10.1002/(SICI)1521-4141(199810)28:10<3240::AID-IMMU3240>3.0.CO;2-U; Braun A, 2001, INT ARCH ALLERGY IMM, V124, P205, DOI 10.1159/000053711; Caroleo MC, 2001, J NEUROIMMUNOL, V113, P193, DOI 10.1016/S0165-5728(00)00441-0; de Vries A, 1999, AM J RESP CRIT CARE, V159, P1541, DOI 10.1164/ajrccm.159.5.9808058; Dechant G, 2001, CELL TISSUE RES, V305, P229, DOI 10.1007/s004410100378; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Fischer A, 1996, J CLIN INVEST, V98, P2284, DOI 10.1172/JCI119039; FULLER RW, 1985, J APPL PHYSIOL, V58, P1080, DOI 10.1152/jappl.1985.58.4.1080; GOEDERT M, 1981, P NATL ACAD SCI-BIOL, V78, P5895, DOI 10.1073/pnas.78.9.5895; HAHN HL, 1986, B EUR PHYSIOPATH RES, V22, P112; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Hunter DD, 2000, AM J RESP CRIT CARE, V161, P1985, DOI 10.1164/ajrccm.161.6.9908051; Joos GF, 2000, ALLERGY, V55, P321, DOI 10.1034/j.1398-9995.2000.00112.x; Kerzel S, 2003, AM J RESP CELL MOL, V28, P170, DOI 10.1165/rcmb.4811; LEE KF, 1994, DEVELOPMENT, V120, P1027; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; LUNDBERG JM, 1983, ACTA PHYSIOL SCAND, V119, P49, DOI 10.1111/j.1748-1716.1983.tb07304.x; Malm-Erjefalt M, 2001, AM J RESP CELL MOL, V24, P352, DOI 10.1165/ajrcmb.24.3.4357; Mazzone SB, 2002, AM J PHYSIOL-REG I, V283, pR86, DOI 10.1152/ajpregu.00007.2002; Nassenstein C, 2003, J EXP MED, V198, P455, DOI 10.1084/jem.20010897; Nassenstein C, 2004, PROG BRAIN RES, V146, P347; Path G, 2002, AM J RESP CRIT CARE, V166, P818, DOI 10.1164/rccm.200202-134OC; Quarcoo D, 2004, CLIN EXP ALLERGY, V34, P1146, DOI 10.1111/j.1365-2222.2004.01993.x; Ricci A, 2004, AM J RESP CELL MOL, V30, P12, DOI 10.1165/rcmb.2002-0110OC; SARIA A, 1984, EUR J PHARMACOL, V106, P207, DOI 10.1016/0014-2999(84)90699-X; Shu XQ, 1999, NEUROSCI LETT, V274, P159, DOI 10.1016/S0304-3940(99)00701-6; Suh YG, 2005, CURR PHARM DESIGN, V11, P2687, DOI 10.2174/1381612054546789; Szallasi A, 1999, PHARMACOL REV, V51, P159; SZOLCSANYI J, 1982, NEUROSCI LETT, V34, P247, DOI 10.1016/0304-3940(82)90183-5; Zhang YH, 2004, NEUROSCI LETT, V366, P187, DOI 10.1016/j.neulet.2004.05.042; [No title captured]	38	35	37	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					597	605		10.1016/j.jaci.2006.04.052	http://dx.doi.org/10.1016/j.jaci.2006.04.052			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950277				2022-12-18	WOS:000240649000011
J	Bauer, R; Scheiblhofer, S; Kern, K; Gruber, C; Stepanoska, T; Thalhamer, T; Hauser-Kronberger, C; Alinger, B; Zoegg, T; Gabler, M; Ferreira, F; Hard, A; Thalhamer, J; Weiss, R				Bauer, Roman; Scheiblhofer, Sandra; Kern, Kerstin; Gruber, Christina; Stepanoska, Tatjana; Thalhamer, Theresa; Hauser-Kronberger, Cornelia; Alinger, Beate; Zoegg, Thomas; Gabler, Maximilian; Ferreira, Fatima; Hard, Arnulf; Thalhamer, Josef; Weiss, Richard			Generation of hypoallergenic DNA vaccines by forced ubiquitination: Preventive and therapeutic effects in a mouse model of allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						type I allergy; DNA vaccine; genetic immunization; gene therapy; ubiquitin; IgE; bronchoalveolar lavage; eosinophils; lung pathology	BIRCH-POLLEN ALLERGEN; T-CELL EPITOPE; MHC CLASS-II; IGE ANTIBODY-FORMATION; BET V 1; GENETIC IMMUNIZATION; MURINE MODEL; AIRWAY HYPERRESPONSIVENESS; IMMUNE-RESPONSES; MAJOR ALLERGEN	Background: Hypoallergenic immunotherapy of type I allergies aims at inducing T-cell immunity while avoiding cross-linking of pre-existing IgE. DNA-based immunotherapy depends on the recruitment of antigen-specific THI cells and therefore has to provide the whole repertoire of T-cell epitopes. Ubiquitination offers a general approach for the production of hypoallergenic DNA vaccines. Objective: A DNA-based vaccine encoding the major birch pollen allergen Bet v I stably linked to ubiquitin was evaluated for its antiallergic potential in a BALB/c mouse model of allergy. Methods: Plasmid DNA was applied to mice before (preventive) or after (therapeutic) sensitization with recombinant Bet v 1. In the preventive setting, mice were exposed to aerosolized allergen in addition. Cytokine production was monitored via ELISPOT and Luminex. IgG(1), IgG(2a), and IgE subclass antibody titers were determined by ELISA. In vitro antigen-specific cross-linking of IgE was measured in a degranulation assay. Bronchoalveolar lavages were analyzed for leukocyte subsets as well as for IFN-gamma and IL-5, and paraffin sections of lungs were examined for mucus production and endothelial damage. Results: Prevaccination with ubiquitinated Bet v I-stimulated T(H)1-biased immune responses with concomitant suppression of functional IgE, reduction of eosinophil counts in bronchoalveolar lavages, and alleviation of lung pathology, and could also suppress an ongoing IgE response in a therapeutic setting. Conclusion: The data clearly demonstrate that hypoallergenic DNA vaccines encoding ubiquitin fusion constructs induce effective antiallergic immune responses. Clinical implications: Ubiquitination of allergen gene vaccines eliminates the risk of IgE cross-linking, thereby meeting the safety requirements for clinical applications.	Salzburg Univ, Dept Mol Biol, Div Allergy & Immunol, A-5020 Salzburg, Austria; Paracelsus Private Med Univ, Dept Pathol, Salzburg, Austria; Christian Doppler Lab Allergy Diagnost & Therapy, Salzburg, Austria; Paracelsus Private Med Univ, Inst Physiol & Pathophysiol, Salzburg, Austria	Salzburg University; Paracelsus Private Medical University; Paracelsus Private Medical University	Thalhamer, J (corresponding author), Salzburg Univ, Dept Mol Biol, Div Allergy & Immunol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	Josef.Thalhamer@sbg.ac.at	Zögg, Thomas/AAU-1851-2021; Weiss, Richard/N-7279-2013; Gabler, Maximilian/ABG-3105-2020; Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019; Thalhamer, Josef/E-5787-2011	Zögg, Thomas/0000-0003-0454-4227; Weiss, Richard/0000-0003-3185-7253; Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Thalhamer, Josef/0000-0003-2285-6400; Scheiblhofer, Sandra/0000-0003-2867-9054; Gabler, Maximilian/0000-0002-8860-9675; Guttmann-Gruber, Christina/0000-0001-8232-5068; Hartl, Arnulf/0000-0001-9626-6425				Adel-Patient K, 2001, INT ARCH ALLERGY IMM, V126, P59, DOI 10.1159/000049495; Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Bonifaz LC, 1999, EUR J IMMUNOL, V29, P119, DOI 10.1002/(SICI)1521-4141(199901)29:01<119::AID-IMMU119>3.0.CO;2-O; Bousquet J, 2004, ALLERGY, V59, P1, DOI 10.1111/j.1398-9995.2004.00425.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Delogu G, 2000, INFECT IMMUN, V68, P3097, DOI 10.1128/IAI.68.6.3097-3102.2000; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Fu TM, 1998, VACCINE, V16, P1711, DOI 10.1016/S0264-410X(98)00134-0; Hartl A, 2004, METHODS, V32, P328, DOI 10.1016/j.ymeth.2003.08.014; Hartl A, 1999, J ALLERGY CLIN IMMUN, V103, P107, DOI 10.1016/S0091-6749(99)70533-6; Hartl A, 2004, ALLERGY, V59, P65, DOI 10.1046/j.1398-9995.2003.00335.x; Hartl A, 1999, INT ARCH ALLERGY IMM, V120, P17, DOI 10.1159/000024216; Hochreiter R, 2003, EUR J IMMUNOL, V33, P1667, DOI 10.1002/eji.200323377; Holtzman MJ, 2003, CHEST, V123, p377S, DOI 10.1378/chest.123.3_suppl.377S-a; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Janssen EM, 2000, J IMMUNOL, V164, P580, DOI 10.4049/jimmunol.164.2.580; Jarman ER, 2004, IMMUNOLOGY, V112, P631, DOI 10.1111/j.1365-2567.2004.01927.x; Jilek S, 2001, J IMMUNOL, V166, P3612, DOI 10.4049/jimmunol.166.5.3612; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; Leachman SA, 2002, J VIROL, V76, P7616, DOI 10.1128/JVI.76.15.7616-7624.2002; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lich JD, 2000, J EXP MED, V191, P1513, DOI 10.1084/jem.191.9.1513; Liu YC, 2005, NAT REV IMMUNOL, V5, P941, DOI 10.1038/nri1731; Maecker HT, 2001, J IMMUNOL, V166, P959, DOI 10.4049/jimmunol.166.2.959; Mukherjee P, 2001, J IMMUNOL, V167, P2632, DOI 10.4049/jimmunol.167.5.2632; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; O'Sullivan Siobhan M, 2005, Proc Am Thorac Soc, V2, P162, DOI 10.1513/pats.200502-016AW; Peng HJ, 2002, VACCINE, V20, P1761, DOI 10.1016/S0264-410X(02)00029-4; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Rodriguez F, 1997, J VIROL, V71, P8497, DOI 10.1128/JVI.71.11.8497-8503.1997; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; Smith AM, 1998, J ALLERGY CLIN IMMUN, V101, P423, DOI 10.1016/S0091-6749(98)70259-3; Sudowe S, 2002, GENE THER, V9, P147, DOI 10.1038/sj.gt.3301625; VAILES LD, 1994, J ALLERGY CLIN IMMUN, V93, P22, DOI 10.1016/0091-6749(94)90229-1; Valenta R, 2002, CL ALLER IM, V16, P495; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969, DOI 10.1016/S0091-6749(99)70077-1; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Vrtala S, 2000, J IMMUNOL, V165, P6653, DOI 10.4049/jimmunol.165.11.6653; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Wiedermann U, 2001, INT ARCH ALLERGY IMM, V124, P391, DOI 10.1159/000053767; Wu YQ, 1997, J IMMUNOL, V159, P6037; Zhang M, 2005, GENE THER, V12, P1049, DOI 10.1038/sj.gt.3302490	47	35	41	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					269	276		10.1016/j.jaci.2006.03.033	http://dx.doi.org/10.1016/j.jaci.2006.03.033			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815165				2022-12-18	WOS:000239184800033
J	Johnston, SL				Johnston, SL			Macrolide antibiotics and asthma treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma exacerbation; macrolide; atypical; bacterial infection; Chlamydophila pneumoniae; Mycoplasma pneumoniae	VIRUS-INDUCED ASTHMA; CHLAMYDIA-PNEUMONIAE; MYCOPLASMA-PNEUMONIAE; INFECTION; SEVERITY; CHILDREN; EXACERBATIONS; RHINOVIRUS; FREQUENCY; DISEASE	Treatment for acute asthma exacerbations is a major need not adequately met by current therapies. Although virus infections are the major cause of acute exacerbations, other factors can increase the risk/severity of exacerbations. Increasing evidence suggests atypical bacterial infections contribute to, exacerbation severity, as well as stable asthma, particularly severe asthma. Macrolide antibiotics and the new ketolide antibiotic telithromycin are active against atypical bacteria and also have anti-inflammatory activity. A recent study has shown telithromycin to be effective in the treatment of acute exacerbations of asthma, although the mechanism or mechanisms of action were not determined. Controlled studies report small improvements in lung function with macrolide treatment of stable asthma. Further studies are urgently required to assess the role of such therapies in acute exacerbations and in severe stable asthma, in which the risk/benefit ratios are likely to be most in favor of therapy demonstrated to be effective.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Med, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Wright Fleming Inst Infect & Immun, London W2 1PG, England	Imperial College London; Imperial College London	Johnston, SL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Med, Norfolk Pl, London W2 1PG, England.	s.johnston@imperial.ac.uk	Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200				Biscione GL, 2004, EUR RESPIR J, V24, P745, DOI 10.1183/09031936.04.00049004; Black PN, 2001, AM J RESP CRIT CARE, V164, P536, DOI 10.1164/ajrccm.164.4.2011040; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Cunningham AF, 1998, EUR RESPIR J, V11, P345, DOI 10.1183/09031936.98.11020345; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Johnston SL, 2005, AM J RESP CRIT CARE, V172, P1078, DOI 10.1164/rccm.200412-1743PP; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563; MURRAY CS, 2005, THORAX          1229; RICHELDI L, 2003, MACROLIDES CHRONIC A; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wark PAB, 2002, EUR RESPIR J, V20, P834, DOI 10.1183/09031936.02.00192002	17	35	41	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1233	1236		10.1016/j.jaci.2006.03.035	http://dx.doi.org/10.1016/j.jaci.2006.03.035			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750980				2022-12-18	WOS:000238332300005
J	Ng, N; Lam, D; Paulus, P; Batzer, G; Horner, AA				Ng, Nicholas; Lam, Diane; Paulus, Petra; Batzer, Glenda; Horner, Anthony A.			House dust extracts have both T(H)2 adjuvant and tolerogenic activities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hygiene; hypothesis; toll-like receptor; house dust; allergy; asthma; tolerance; innate immunity	ACTIVATED PROTEIN-KINASE; TOLL-LIKE RECEPTOR-2; SCHOOL-AGE-CHILDREN; IMMUNOSTIMULATORY DNA; DENDRITIC CELLS; ENDOTOXIN TOLERANCE; HYGIENE HYPOTHESIS; TH2 RESPONSES; AIR-POLLUTION; C-FOS	Background: Although mechanisms remain a subject of controversy, there is general agreement that living environments influence allergic risk during the first years of life. We reasoned that sterile house dust extracts (HDEs) would have immunologic activities reflective of their environments of origin and therefore would be useful surrogates for investigations of how ambient exposures influence immune homeostasis. Objective: These experiments determined how airway HDE exposures influence adaptive responses to a coadministered antigen and subsequent airway hypersensitivity responses to antigen challenge. Methods: Mice received intranasal ovalbumin (OVA) vaccinations on a weekly basis. Select groups of mice also received intranasal HDE weekly with OVA; daily at one seventh the weekly dose, beginning 7 days before the first OVA sensitization; or both. Results: Weekly intranasal vaccinations with,OVA and HDE primed mice for the development of T(H)2-biased immune and airway hypersensitivity responses. In contrast, daily low-dose intranasal FIDE exposures protected against the immunologic and pathologic outcomes associated with weekly intranasal OVA/HDE vaccinations. The T(H)2 adjuvant activities of HDEs were found to be dependant on MyD88, a molecule critical for signaling through a majority of Toll-like receptors. Moreover, the tolerogenic activity associated with daily intranasal HDE exposures could be replicated with LPS. Conclusion: These investigations demonstrate that in addition to allergens, living environments contain immunomodulatory materials with both T(H)2 adjuvant and tolerogenic activities. Clinical implications: As the contents of HDEs are ubiquitous, these experiments might recapitulate and help explain clinically relevant immunologic events involved in the maintenance of aeroallergen tolerance and the dysregulated responses that lead to allergic respiratory diseases.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Aging, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Horner, AA (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ahorner@ucsd.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI040682, R01AI061772] Funding Source: NIH RePORTER; NIAID NIH HHS [AI61772, AI40682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Alexis NE, 2004, CLIN IMMUNOL, V111, P126, DOI 10.1016/j.clim.2003.12.002; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; Boasen J, 2005, J ALLERGY CLIN IMMUN, V116, P185, DOI 10.1016/j.jaci.2005.03.015; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Dillon S, 2004, J IMMUNOL, V172, P4733, DOI 10.4049/jimmunol.172.8.4733; Du CG, 1998, J LEUKOCYTE BIOL, V64, P92, DOI 10.1002/jlb.64.1.92; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; FRANKENBERGER M, 1995, J INFLAMM, V45, P56; Frew AJ, 2005, J ALLERGY CLIN IMMUN, V115, P1197, DOI 10.1016/j.jaci.2005.03.006; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Horner AA, 2003, CURR OPIN IMMUNOL, V15, P614, DOI 10.1016/j.coi.2003.09.021; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; MARTINEZ FD, 1999, LANCET S2, V354, P2; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Platts-Mills TAE, 2004, SPRINGER SEMIN IMMUN, V25, P271, DOI 10.1007/s00281-003-0149-8; Rabinovitch N, 2005, J ALLERGY CLIN IMMUN, V116, P1053, DOI 10.1016/j.jaci.2005.08.045; Reid GSD, 2005, BLOOD, V105, P3641, DOI 10.1182/blood-2004-06-2468; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Sly LM, 2004, IMMUNITY, V21, P227, DOI 10.1016/j.immuni.2004.07.010; Takabayashi K, 2003, J IMMUNOL, V170, P3898, DOI 10.4049/jimmunol.170.7.3898; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579	34	35	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1074	1081		10.1016/j.jaci.2006.03.025	http://dx.doi.org/10.1016/j.jaci.2006.03.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675335				2022-12-18	WOS:000237436300015
J	Keller, AC; Mucida, D; Gomes, E; Faquim-Mauro, E; Faria, AMC; Rodriguez, D; Russo, M				Keller, AC; Mucida, D; Gomes, E; Faquim-Mauro, E; Faria, AMC; Rodriguez, D; Russo, M			Hierarchical suppression of asthma-like responses by mucosal tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tolerance; asthma; anaphylactic antibodies; AHR	LUNG EOSINOPHILIC INFLAMMATION; DELTA T-CELLS; ORAL TOLERANCE; INHALED ANTIGEN; IGE RESPONSES; IGG1 ANTIBODIES; DENDRITIC CELLS; CUTTING EDGE; MOUSE; EXPOSURE	Background: Mucosal tolerance can be induced by oral or nasal administration of soluble proteins and results in the suppression of cellular and/or humoral immune responses to the specific antigen. Objective: To compare the effect of oral or nasal ovalbumin administration before, during or after immunization on the development of cellular and humoral immune responses by using a murine asthma model. Methods: To induce lung allergic inflammation, animals were immunized twice with ovalbumin/aluminum hydroxide gel and challenged twice with ovalbumin. To induce tolerance, BALB/c mice received ovalbumin by the oral or nasal routes for 3 consecutive days. The ovalbumin administration was initiated before (day -7), during (day 0), or after immunization (day 7). Results: Airway eosinophilia, airway hyperreactivity, mucus hypersecretion, and cytokine production were suppressed when oral or nasal ovalbumin administration was initiated before immunization. Oral but not nasal ovalbumin exposure suppressed ovalbumin-specific nonanaphylactic IgG(1) antibodies, whereas both routes suppressed the production of anaphylactic IgG(1) and IgE antibodies. Mucosal ovalbumin administration at day 0 inhibited all T(H)2-mediated allergic parameters but not nonanaphylactic IgG(1) antibodies. Finally, ovalbumin exposure 7 days after immunization was still effective in suppressing lung allergy but not ovalbumin-specific anaphylactic IgG(1) and IgE antibodies. Conclusion: We show that the effectiveness of mucosal tolerance depends on route and time and presents a hierarchical pattern of suppression in the following order: lung allergic responses > anaphylactic antibodies > ovalbumin-specific IgG(1).	Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, BR-05508900 Sao Paulo, SP, Brazil; Butantan Inst, Immunopathol Lab, Sao Paulo, Brazil; Univ Fed Minas Gerais, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil	Universidade de Sao Paulo; Instituto Butantan; Universidade Federal de Minas Gerais	Russo, M (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Av Prof Lineu Prestes-1730, BR-05508900 Sao Paulo, SP, Brazil.	momrusso@icb.usp.br	Faquim-Mauro, Eliana/M-2489-2017; Faquim-Mauro, Eliana L/C-9636-2012; Keller, Alexandre C/E-4621-2012; Rodriguez Soto, Dunia Del Carmen/J-4305-2014; Faria, Ana Maria/AAK-8688-2021	Faquim-Mauro, Eliana/0000-0001-8083-4272; Keller, Alexandre C/0000-0002-7827-0292; Rodriguez Soto, Dunia Del Carmen/0000-0001-9779-1280; Mucida, Daniel/0000-0002-0000-0452; Faria, Ana Maria/0000-0002-0604-8510				Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; de Sousa Mucida Daniel, 2003, Current Drug Targets - Inflammation and Allergy, V2, P187; Faquim-Mauro EL, 1999, J IMMUNOL, V163, P3572; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Faria AMC, 2003, J AUTOIMMUN, V20, P135, DOI 10.1016/S0896-8411(02)00112-9; HOLT PG, 1981, IMMUNOLOGY, V42, P409; Macedo-Soares MF, 2004, J ALLERGY CLIN IMMUN, V114, P97, DOI 10.1016/j.jaci.2004.03.033; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MCMENAMIN C, 1995, J IMMUNOL, V154, P4390; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; OVARY Z, 1958, J IMMUNOL, V81, P355; Rodriguez D, 2003, J IMMUNOL, V171, P1001, DOI 10.4049/jimmunol.171.2.1001; Russo M, 2001, AM J RESP CELL MOL, V24, P518, DOI 10.1165/ajrcmb.24.5.4320; Russo M, 1998, IMMUNOL LETT, V61, P15, DOI 10.1016/S0165-2478(97)00155-7; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Schaerli P, 2005, IMMUNOL RES, V31, P57, DOI 10.1385/IR:31:1:57; Schaerli P, 2001, J IMMUNOL, V167, P6082, DOI 10.4049/jimmunol.167.11.6082; Weiner HL, 2001, NAT IMMUNOL, V2, P671, DOI 10.1038/90604; Yssel H, 2000, INT ARCH ALLERGY IMM, V121, P10, DOI 10.1159/000024292	21	35	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					283	290		10.1016/j.jaci.2005.10.019	http://dx.doi.org/10.1016/j.jaci.2005.10.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461128				2022-12-18	WOS:000235687300009
J	Amlie-Lefond, C; Paz, DA; Connelly, MP; Huffnagle, GB; Dunn, KS; Whelan, NT; Whelan, HT				Amlie-Lefond, C; Paz, DA; Connelly, MP; Huffnagle, GB; Dunn, KS; Whelan, NT; Whelan, HT			Innate immunity for biodefense: A strategy whose time has come	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						biodefense; immunomodulation; innate immunity; Toll-like receptors	CPG OLIGODEOXYNUCLEOTIDES; DENDRITIC CELLS; IMMUNOMODULATORY OLIGONUCLEOTIDES; MICE; AGONISTS; RESISTANCE; IMIQUIMOD; BACTERIAL	Defense against biothreat agents requires a broad-spectrum approach. Modulation of the innate immune system might fulfill this requirement. Hackett's previous review of innate immune activation as a broad-spectrum biodefense strategy identified several unresolved questions. The current article is a systematic approach to answering those questions with the focused participation of research groups developing this technology. Our team of academic and industry participants reviewed the promising agents and came to the following conclusions. It is feasible to construct a biodefense platform combining synergistic agents that activate the innate immune system against a broad range of pathogens on the basis of conserved microbial components by using a nasal spray for immune activation in the respiratory and gastrointestinal tracts because these are the most likely routes of attack. It might also be possible to include agents that inhibit molecular events leading to septic shock. Innate immune-activating agents designed to activate Toll-like and other receptors will probably provide protection against the biothreat pathogen spectrum for periods ranging from 2 to 14 days for IFNs up to 26 weeks for immunomodulatory oligonucleotides. Initial treatment is proposed on the first index case or biosensor alert. Boost doses would be required. Harmful inflammation is possible, but thus far, only transient fever has been observed. Autoimmune reaction and retroviral activation have not been seen thus far in preclinical and human trials of many of these compounds. Toll-like receptor agonists caused cytokine production in all subjects tested, but genetic polymorphism reduced the response to IFN in African American subjects.	Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; Univ Michigan, Dept Internal Med & Microbiol & Immunol, Ann Arbor, MI 48109 USA; Natl Def Univ, Ctr Technol & Natl Secur Policy, Washington, DC 20319 USA	Medical College of Wisconsin; University of Michigan System; University of Michigan; National Defense University - USA	Whelan, HT (corresponding author), Med Coll Wisconsin, Dept Neurol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	hwhelan@mcw.edu	Huffnagle, Gary B./ABF-1323-2020					Arevalo I, 2001, CLIN INFECT DIS, V33, P1847, DOI 10.1086/324161; Billich Andreas, 2002, Curr Opin Investig Drugs, V3, P698; Charoenvit Y, 2004, ANTIMICROB AGENTS CH, V48, P2455, DOI 10.1128/AAC.48.7.2455-2463.2004; Cluff CW, 2005, INFECT IMMUN, V73, P3044, DOI 10.1128/IAI.73.5.3044-3052.2005; Cox JT, 2004, J WOMENS HEALTH, V13, P265, DOI 10.1089/154099904323016428; ERLANDSSON H, 2004, EUR J IMMUNOL, V34, P103; Grajkowski A, 2005, NUCLEIC ACIDS RES, V33, P3550, DOI 10.1093/nar/gki657; Gursel M, 2002, EUR J IMMUNOL, V32, P2617, DOI 10.1002/1521-4141(200209)32:9<2617::AID-IMMU2617>3.0.CO;2-F; Hackett CJ, 2003, J ALLERGY CLIN IMMUN, V112, P686, DOI 10.1016/S0091-6749(03)02025-6; Hahm B, 2005, IMMUNITY, V22, P247, DOI 10.1016/j.immuni.2005.01.005; HAYDEN FG, 1985, ANTIVIR RES, P229; Kandimalla ER, 2005, P NATL ACAD SCI USA, V102, P6925, DOI 10.1073/pnas.0501729102; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Leifer CA, 2003, J IMMUNOTHER, V26, P313, DOI 10.1097/00002371-200307000-00003; Liu G, 2004, FEMS IMMUNOL MED MIC, V40, P201, DOI 10.1016/S0928-8244(03)00358-4; Matthews SJ, 2004, CLIN THER, V26, P991, DOI 10.1016/S0149-2918(04)90173-7; Nishiwaki T, 2004, AM J PATHOL, V165, P631, DOI 10.1016/S0002-9440(10)63327-5; Obermeier F, 2002, EUR J IMMUNOL, V32, P2084, DOI 10.1002/1521-4141(200207)32:7<2084::AID-IMMU2084>3.0.CO;2-Q; Padalko E, 2004, ANTIMICROB AGENTS CH, V48, P267, DOI 10.1128/AAC.48.1.267-274.2004; Romani L, 2004, BLOOD, V103, P4232, DOI 10.1182/blood-2003-11-4036; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; Simbirtsev Andrey, 2003, Russ J Immunol, V8, P11; SPERBER SJ, 1987, CLIN LAB MED, V7, P869, DOI 10.1016/S0272-2712(18)30721-2; Stover AG, 2004, J BIOL CHEM, V279, P4440, DOI 10.1074/jbc.M310760200; Theos AU, 2004, CUTIS, V74, P134; Verthelyi D, 2003, J IMMUNOL, V170, P4717, DOI 10.4049/jimmunol.170.9.4717; Vollmer J, 2004, EUR J IMMUNOL, V34, P251, DOI 10.1002/eji.200324032; Wang DQ, 2005, VACCINE, V23, P2614, DOI 10.1016/j.vaccine.2004.11.028; Webster JI, 2004, J ENDOCRINOL, V181, P207, DOI 10.1677/joe.0.1810207; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100	31	35	37	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1334	1342		10.1016/j.jaci.2005.08.048	http://dx.doi.org/10.1016/j.jaci.2005.08.048			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337468	Green Published, Bronze			2022-12-18	WOS:000235687000027
J	Morgan, AJ; Symon, FA; Berry, MA; Pavord, ID; Corrigan, CJ; Wardlaw, AJ				Morgan, AJ; Symon, FA; Berry, MA; Pavord, ID; Corrigan, CJ; Wardlaw, AJ			IL-4-expressing bronchoalveolar T cells from asthmatic and healthy subjects preferentially express CCR3 and CCR4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lung; human; T(H)1/T(H)2 cells; T cells; chemokines	CHEMOKINE RECEPTORS; LYMPHOCYTES; SUBSETS; TH1	Background: The concept of the polarization of chemokine receptor expression by T(H)1 and T(H)2 cells provides an attractive mechanism for their differential recruitment to tissue, which could be subject to disease-specific therapeutic intervention. The paradigm that T(H)1 cells preferentially express CXCR3 and CCR5 and T(H)2 cells preferentially express CCR3, CCR4, and CCR8 has been well established in the setting of in vitro polarized cell lines; however, the situation in vivo appears less clear-cut. Objective: We sought to investigate whether this pattern of polarization can be demonstrated in human lung tissue. Methods: We used single-cell analysis to investigate the relationship between chemokine receptor expression and cytokine production on peripheral blood and bronchoalveolar lavage fluid T cells in patients with asthma, a putative T(H)2 disease, as well as in healthy control subjects. Results: We have found in both asthmatic and control subjects that IL-4-expressing blood and bronchoalveolar lavage fluid T cells are significantly more likely to express the T(H)2 type 2 chemokine receptors CCR3 and CCR4, with 10-fold and 2-fold differences in expression, respectively, compared with IFN-gamma-expressing cells. Conclusion: We have provided evidence that polarization of T(H)2-type chemokine receptors on IL-4-expressing cells can be demonstrated in an in vivo setting and therefore that these cells might indeed be susceptible to differential patterns of recruitment as a result of expression of the relevant chemokines at inflammatory sites.	Univ Leicester, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England; Guys Hosp, GKT Sch Med, Dept Asthma Allergy & Resp Serv, London SE1 9RT, England	University of Leicester; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Wardlaw, AJ (corresponding author), Univ Leicester, Glenfield Hosp, Inst Lung Hlth, Groby Rd, Leicester LE3 9QP, Leics, England.	Aw24@le.ac.uk		Pavord, Ian/0000-0002-4288-5973; Wardlaw, Andrew/0000-0001-6583-0791; Corrigan, Chris/0000-0002-0706-6534				Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; *BRIT THOR SOC, 2003, THORAX S1, V58; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; Kim CH, 2001, J CLIN INVEST, V107, P595, DOI 10.1172/JCI11902; Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI200113543; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; Kunkel EJ, 2000, J EXP MED, V192, P761, DOI 10.1084/jem.192.5.761; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; TOMORI Z, 1993, EUR RESPIR J, V6, P53; Wallin A, 1999, AM J RESP CRIT CARE, V159, P79, DOI 10.1164/ajrccm.159.1.9801007	23	35	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					594	600		10.1016/j.jaci.2005.03.052	http://dx.doi.org/10.1016/j.jaci.2005.03.052			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159629				2022-12-18	WOS:000235686500019
J	Elliott, L; Heederik, D; Marshall, S; Peden, D; Loomis, D				Elliott, L; Heederik, D; Marshall, S; Peden, D; Loomis, D			Progression of self-reported symptoms in laboratory animal allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; laboratory animal allergy; symptom progression; incidence; animal workers; occupational asthma	SENSITIZATION; EXPOSURE; WORKERS; ATOPY	Background: Laboratory animal allergy is a common illness among workers exposed to laboratory animals and can progress to symptoms of asthma. Objectives: This study evaluates the continuum of disease from allergy symptoms to asthma symptoms in a dynamic cohort of workers exposed to animals in a pharmaceutical company. Methods: Data arose from annual questionnaires administered to workers in a surveillance program established to monitor exposure to animals and the development of allergy. The life-table method was used to compare asthma-free survival between workers with and without symptoms of allergy. A Cox proportional hazards model was used to examine the effects of covariates on the development of asthma. Results: A total of 603 workers contributed 2527.4 person-years to the study over the 12.3-year period. The probabilities of experiencing asthma symptoms by the 11th year of follow-up were 0.367 for workers with allergy symptoms and 0.052 for those without allergy symptoms. The hazard ratio for asthma symptoms when comparing workers with and without allergy symptoms was 7.39 (95% CI, 3.29-16.60) after adjustment for sex and family history of allergy. Female subjects developed asthma at a rate 3.4 times that of male subjects. Conclusions: This study supports the hypothesis that laboratory animal allergy symptoms are a major risk factor for the development of asthma. It also suggests a heightened risk of asthma for women who work with laboratory animals, a finding that has not been previously reported.	Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; Ctr Asthma & Lung Biol, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; Utrecht University	Elliott, L (corresponding author), Univ N Carolina, Dept Epidemiol, CB-7435, Chapel Hill, NC 27599 USA.	Leslie.Elliott@unc.edu	Loomis, Dana/AAE-3988-2019	Peden, David/0000-0003-4526-4627; Loomis, Dana/0000-0003-3297-5200; Heederik, Dick/0000-0002-4550-1437; Marshall, Stephen/0000-0002-2664-9233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062624] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62624] Funding Source: Medline; ODCDC CDC HHS [T42/CCT422952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ODCDC CDC HHS		AGRUP G, 1986, BRIT J IND MED, V43, P192; AOYAMA K, 1992, BRIT J IND MED, V49, P41; BLAND SM, 1986, J OCCUP ENVIRON MED, V28, P1151; BOTHAM PA, 1995, OCCUP ENVIRON MED, V52, P129, DOI 10.1136/oem.52.2.129; Bousquet J, 2003, ALLERGY, V58, P691, DOI 10.1034/j.1398-9995.2003.00105.x; Bush R K, 2001, ILAR J, V42, P4; Bush RK, 2003, ILAR J, V44, P28, DOI 10.1093/ilar.44.1.28; Caracta CF, 2003, MT SINAI J MED, V70, P215; COCKCROFT A, 1981, LANCET, V1, P827; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; Fisher R, 1998, J OCCUP ENVIRON MED, V40, P609, DOI 10.1097/00043764-199807000-00005; FUORTES LJ, 1996, AM J IND MED, V29, P676; Goodno LE, 2002, J OCCUP ENVIRON MED, V44, P1143, DOI 10.1097/00043764-200212000-00008; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; Seward J P, 2001, ILAR J, V42, P47; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; VENABLES KM, 1988, BRIT J IND MED, V45, P660; Wood R A, 2001, ILAR J, V42, P12	18	35	35	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					127	132		10.1016/j.jaci.2005.03.038	http://dx.doi.org/10.1016/j.jaci.2005.03.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990785	Green Published			2022-12-18	WOS:000235686300020
J	O'Connor, GT				O'Connor, GT			Allergen avoidance in asthma: What do we do now?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergen avoidance; environmental control measures; dust mites; cockroach allergen; pet allergen	HOUSE-DUST MITE; PLACEBO-CONTROLLED TRIAL; INNER-CITY HOMES; COCKROACH ALLERGEN; ENVIRONMENTAL INTERVENTION; PRIMARY PREVENTION; EXPOSURE; CHILDREN; CHILDHOOD; REDUCTION	Although allergen exposure can clearly aggravate the condition of sensitized patients with asthma, there is uncertainty and controversy about exactly which allergen avoidance interventions should be recommended to patients with asthma. Interventions that appear logical may fail to be clinically efficacious for several reasons. Although narrow interventions, such as allergen-impermeable mattress covers to reduce exposure to dust mite allergens, may offer little benefit if used alone, recent evidence suggests that a multifaceted, home-based environmental intervention focusing on multiple exposures may provide clinical benefits to patients with asthma. The role of allergen avoidance in infancy in the primary prevention of asthma is a subject of active investigation, but data remain too preliminary to make public health recommendations in this regard.	Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA	Boston University	O'Connor, GT (corresponding author), Boston Univ, Sch Med, Ctr Pulm, Dept Med, 715 Albany St,Room R304, Boston, MA 02118 USA.	goconnor@bu.edu		O'Connor, George/0000-0002-6476-3926	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050516, U01AI039769] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-50516, AI-39769] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Arshad SH, 2002, CLIN EXP ALLERGY, V32, P843, DOI 10.1046/j.1365-2222.2002.01378.x; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Custovic A, 2002, ANN ALLERG ASTHMA IM, V88, P432, DOI 10.1016/S1081-1206(10)62378-2; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; Eggleston P. A., 2004, Journal of Allergy and Clinical Immunology, V113, pS179, DOI 10.1016/j.jaci.2004.01.081; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842, DOI 10.1016/S0091-6749(99)70296-4; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gotzsche PC, 1998, BRIT MED J, V317, P1105, DOI 10.1136/bmj.317.7166.1105; Grootendorst DC, 2001, CLIN EXP ALLERGY, V31, P400, DOI 10.1046/j.1365-2222.2001.01022.x; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; KRIEGER J, IN PRESS AM J PUBLIC; McDonald E, 2002, CHEST, V122, P1535, DOI 10.1378/chest.122.5.1535; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; *NAT ASTHM ED PREV, 1997, NIH PUBL; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Platts-Mills TAE, 2004, J ALLERGY CLIN IMMUN, V113, P388, DOI 10.1016/j.jaci.2003.12.027; PLATTSMILLS TAE, 1982, LANCET, V2, P675; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; van der Heide S, 1999, J ALLERGY CLIN IMMUN, V104, P447, DOI 10.1016/S0091-6749(99)70391-X; VANLEEUEWN SW, 1925, ALLERGIC DIS TREATME; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; [No title captured]	28	35	37	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					26	30		10.1016/j.jaci.2005.02.013	http://dx.doi.org/10.1016/j.jaci.2005.02.013			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990768				2022-12-18	WOS:000235686300003
J	Litonjua, AA; Belanger, K; Celedon, JC; Milton, DK; Bracken, MB; Kraft, P; Triche, EW; Sredl, DL; Weiss, ST; Leaderer, BP; Gold, DR				Litonjua, AA; Belanger, K; Celedon, JC; Milton, DK; Bracken, MB; Kraft, P; Triche, EW; Sredl, DL; Weiss, ST; Leaderer, BP; Gold, DR			Polymorphisms in the 5 ' region of the CD14 gene are associated with eczema in young children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema; polymorphism; genetic; IgE	PROMOTER POLYMORPHISM; SOLUBLE CD14; GENOME BROWSER; 1ST YEAR; ASTHMA; ATOPY; IGE; ENDOTOXIN; ALLERGY; LIFE	Background: Variants in the CD14 gene (CD14) are hypothesized to be associated with atopic disorders. However, most studies have only investigated one polymorphism in this gene. Objective: We sought to study the association of 5 single nucleotide polymorphisms (SNPs) in the 5' flanking region of CD14 with eczema and serum IgE levels in young children. Methods: We genotyped SNPs in an approximately 6.5-kb region in the 5' region of CD14 in 344 2-year-old white children from 2 birth cohorts in the northeastern United States. We examined the relation of both single SNPs and haplotypes in CD14 with the atopic outcomes. Results: Two SNPs were significantly associated with eczema. In dominant models adjusted for potential confounders, SNP rs2569193 was associated with significantly decreased risk for eczema (odds ratio [OR] for CT/TT vs CC, 0.5; 95% CI, 0.3-0.8), whereas SNP rs2569190 (also reported as the C-159T) was associated with significantly increased risk for eczema (OR for CT/TT vs CC, 2.3; 95% CI, 1.4-3.8). The CT/TT genotypes of SNP rs2569190 also had higher geometric means of serum IgE than the CC genotype (24.6 vs 15 IU/mL, P = .025). Haplotype analyses provided results similar to those of the single SNP analyses. Conclusions: Our results contradict previous reports that have found a protective effect of the T allele of SNP rs2569190 (C-159T) against atopic disorders. Nevertheless, these results confirm the importance of polymorphisms in CD14 in the development of atopy, and future studies of this gene region will need to account for linkage disequilibrium and environmental exposures unique to the study population.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Pulm & Crit Care Med Sect, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Yale Univ, Sch Med, Ctr Perinatal Pediat & Environm Epidemiol, Dept Epidemiol & Publ Hlth, New Haven, CT USA; Harvard Partners Ctr Genet & Genom, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System; Harvard University; Harvard Medical School; Yale University; Harvard University	Litonjua, AA (corresponding author), 181 Longwood Ave, Boston, MA 02115 USA.	augusto.litonjua@channing.harvard.edu	Milton, Donald K/G-3286-2010; Triche, Elizabeth/I-4986-2014	Milton, Donald K/0000-0002-0550-7834; Litonjua, Augusto/0000-0003-0422-5875	NIAID NIH HHS [AI 35786] Funding Source: Medline; NIEHS NIH HHS [ES11013, ES05410, ES07456] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786, R56AI035786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011013, R01ES007456] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Benjamini Y, 1999, DISTRIBUTION FREE MU; Buckova D, 2003, ALLERGY, V58, P1023, DOI 10.1034/j.1398-9995.2003.00271.x; CELEDON JC, 2000, AM J RESP CRIT CARE, V161, pA927; Eggleston PA, 1999, ENVIRON HEALTH PERSP, V107, P439, DOI 10.1289/ehp.99107s3439; Gao PS, 1999, CLIN GENET, V56, P164; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Harris JM, 2001, BRIT J DERMATOL, V144, P795, DOI 10.1046/j.1365-2133.2001.04135.x; Heesen M, 2001, INTENS CARE MED, V27, P1770, DOI 10.1007/s001340101106; Heinzmann A, 2003, EUR J IMMUNOGENET, V30, P345, DOI 10.1046/j.1365-2370.2003.00414.x; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Kusunoki T, 2002, AM J RESP CRIT CARE, V165, P551, DOI 10.1164/ajrccm.165.4.correspondenceib; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Leung TF, 2003, PEDIAT ALLERG IMM-UK, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; O'Donnell AR, 2004, AM J RESP CRIT CARE, V169, P615, DOI 10.1164/rccm.200302-278OC; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; *US CENS BUR, 1997, AM HOUS SURV 1997 NA; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Vercelli D, 2001, J ENDOTOXIN RES, V7, P45, DOI 10.1179/096805101101532521; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634	31	35	35	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1056	1062		10.1016/j.jaci.2005.02.006	http://dx.doi.org/10.1016/j.jaci.2005.02.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867866				2022-12-18	WOS:000229055100024
J	Burgess, JK; Blake, AE; Boustany, S; Johnson, PRA; Armour, CL; Black, JL; Hunt, NH; Hughes, JM				Burgess, JK; Blake, AE; Boustany, S; Johnson, PRA; Armour, CL; Black, JL; Hunt, NH; Hughes, JM			CD40 and OX40 ligand are increased on stimulated asthmatic airway smooth muscle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inflammation; CD40; OX40 ligand; TNF; IL-1 beta; prostaglandin E-2; human airway smooth muscle cells	NECROSIS-FACTOR-ALPHA; CELL-ADHESION MOLECULE-1; HUMAN ENDOTHELIAL-CELLS; MAST-CELL; INTERFERON-GAMMA; EXPRESSION; CYTOKINES; CYCLO-OXYGENASE-2; PROLIFERATION; INDUCTION	Background: Severe, persistent asthma is characterized by airway smooth muscle hyperplasia, inflammatory cell infiltration into the smooth muscle, and increased expression of many cytokines, including IL-4, IL-13, IL-1beta, and TNF-alpha. These cytokines have the potential to alter the expression of surface receptors such as CD40 and OX40 ligand on the airway smooth muscle cell. Objective: To examine whether cytokines alter expression of CD40 and OX40 ligand on airway smooth muscle cells and identify any differences in response between asthmatic and nonasthmatic airway smooth muscle cells. Methods: We used How cytometry and immunohistochemistry to detect CD40 and OX40 ligand on airway smooth muscle cells cultured in the presence of TNF-alpha, IL-1beta, IL-4, or IL-13. Prostaglandin E-2 levels were assessed by ELISA. Results: TNF-alpha increased expression of both CD40 and OX40 ligand on both asthmatic and nonasthmatic airway smooth muscle cells. The level of expression was significantly greater on the asthmatic cells. IL-1beta alone had no effect, but it attenuated the TNF-induced expression of both CD40 and OX40 ligand. The mechanism of inhibition was COX-dependent for CD40 and was COX-independent but cyclic AMP-dependent for OX40 ligand. IL-4 and IL-13 had no effect. Conclusion: Our study has demonstrated that TNF-alpha and IL-1beta have the potential to modulate differentially the interactions between cells present in the inflamed airways of a patient with asthma and therefore to contribute to the regulation of airway inflammation and remodeling.	Univ Sydney, Dept Pharmacol, Resp Res Grp, Sydney, NSW 2006, Australia; Woolcock Inst Med Res, Sydney, NSW, Australia; Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; Woolcock Institute of Medical Research; University of Sydney; University of Sydney	Burgess, JK (corresponding author), Univ Sydney, Dept Pharmacol, Resp Res Grp, Bosch Bldg,D05, Sydney, NSW 2006, Australia.	janette@pharmacol.usyd.edu.au	Burgess, Janette K/A-3597-2010; Hunt, Nick H/A-3636-2011; Black, Judith L/C-6559-2008; Burgess, Janette/M-7117-2019	Armour, Carol/0000-0002-2930-2227; Burgess, Janette/0000-0001-9868-9966				ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; Ammit AJ, 1997, AM J RESP CRIT CARE, V155, P1123, DOI 10.1164/ajrccm.155.3.9116997; Belvisi MG, 1998, BRIT J PHARMACOL, V125, P1102, DOI 10.1038/sj.bjp.0702104; Belvisi MG, 1997, BRIT J PHARMACOL, V120, P910, DOI 10.1038/sj.bjp.0700963; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Burgess JK, 1998, BLOOD, V92, P2366, DOI 10.1182/blood.V92.7.2366.2366_2366_2373; Burgess JK, 2004, J ALLERGY CLIN IMMUN, V113, P683, DOI 10.1016/j.jaci.2003.12.311; Burgess JK, 2003, AM J RESP CRIT CARE, V167, P71, DOI 10.1164/rccm.200205-416OC; Burgess JK, 2004, J ALLERGY CLIN IMMUN, V113, P876, DOI 10.1016/j.jaci.2004.02.029; CARLOS T, 1991, BLOOD, V77, P2266; CARLOS TM, 1990, BLOOD, V76, P965; Chambers LS, 2003, AM J PHYSIOL-LUNG C, V285, pL619, DOI 10.1152/ajplung.00416.2002; DURANDARCZYNSKA W, 1993, HISTOCHEMISTRY, V100, P465, DOI 10.1007/BF00267827; Faffe DS, 2003, AM J PHYSIOL-LUNG C, V285, pL907, DOI 10.1152/ajplung.00120.2003; Hawker KM, 1998, AM J PHYSIOL-LUNG C, V275, pL469, DOI 10.1152/ajplung.1998.275.3.L469; Hughes JM, 2000, MEDIAT INFLAMM, V9, P93, DOI 10.1080/096293500411550; Johnson PRA, 2004, J ALLERGY CLIN IMMUN, V113, P690, DOI 10.1016/j.jaci.2003.12.312; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; JOHNSON PRA, 1995, AM J PHYSIOL, V269, P514; Lazaar AL, 1998, J IMMUNOL, V161, P3120; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Nguyen VT, 2002, J BIOL CHEM, V277, P13796, DOI 10.1074/jbc.M111906200; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Romagnani S, 2002, MOL IMMUNOL, V38, P881, DOI 10.1016/S0161-5890(02)00013-5; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Stewart AG, 1999, MOL PHARMACOL, V56, P1079, DOI 10.1124/mol.56.5.1079; Sukkar MB, 2000, MEDIAT INFLAMM, V9, P161, DOI 10.1080/09629350020008673; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; Vancheri C, 2001, AM J RESP CELL MOL, V25, P592, DOI 10.1165/ajrcmb.25.5.4609; Zhu YK, 2001, J ALLERGY CLIN IMMUN, V108, P989, DOI 10.1067/mai.2001.120193; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	33	35	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					302	308		10.1016/j.jaci.2004.11.004	http://dx.doi.org/10.1016/j.jaci.2004.11.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696085				2022-12-18	WOS:000227043600014
J	van den Bemt, L; van Knapen, L; de Vries, MP; Jansen, M; Cloosterman, S; van Schayck, CP				van den Bemt, L; van Knapen, L; de Vries, MP; Jansen, M; Cloosterman, S; van Schayck, CP			Clinical effectiveness of a mite allergen-impermeable bed-covering system in asthmatic mite-sensitive patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; house dust mite; allergen avoidance; peak expiratory flow	HOUSE-DUST-MITE; WORKING PARTY STANDARDIZATION; TESTS EUROPEAN-COMMUNITY; OFFICIAL STATEMENT; AVOIDANCE MEASURES; CHILDREN; REDUCTION; SEVERITY; EXPOSURE; BEDROOMS	Background: Exposure to allergens plays a role in the development of bronchial hyperresponsiveness and in the chronic inflammatory response seen in asthmatic patients. House dust mites (HDMs) are an important source of allergen. Reduction of these allergens might lead to better lung function and reduction of asthma symptoms. Objective: The effect of HDM-impermeable covers on HDM allergen levels, peak flow values, and asthma symptoms were measured. Therefore a randomized clinical trial was carried out. Methods: Fifty-two allergic asthmatic patients were randomly allocated to use the HDM-impermeable or placebo covers. During the study period, daily peak flow and asthma symptom scores were recorded. Dust samples were taken from the mattresses. Results: We observed a significant reduction in HDM allergen levels on the mattresses after encasing them with HDM-impermeable covers (reduction of 87% of Der p 1 in micrograms per gram of dust; P < .001). Baseline symptoms were so low that no improvement could be established. Morning peak expiratory flow is significantly higher in the intervention group compared with that seen in the placebo group during the study period (beta = 20.2; P < .01). Conclusions: HDM-impermeable covers significantly decreased the level of HDM allergens. Furthermore, morning peak flow was significantly increased during the intervention period. This study indicates that HDM allergen-avoidance measures might have beneficial effects on allergen reduction and asthma outcome.	Univ Limburg, Dept Gen Practice, Res Inst Caphri, NL-6200 MD Maastricht, Netherlands; Univ Nijmegen, Med Ctr, Dept Gen Practice, Nijmegen, Netherlands	Hasselt University; Maastricht University; Radboud University Nijmegen	van den Bemt, L (corresponding author), Univ Limburg, Dept Gen Practice, Res Inst Caphri, POB 616, NL-6200 MD Maastricht, Netherlands.	L.vandenbemt@hag.umcn.nl	Bemt, Lisette van den van den/L-4193-2015	Bemt, Lisette van den van den/0000-0002-3771-8273				[Anonymous], CLIN EXPT ALLERGY; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Cloosterman S. G. M., 1995, European Respiratory Journal, V8, p499S; Cloosterman SGM, 1997, J ALLERGY CLIN IMMUN, V100, P313, DOI 10.1016/S0091-6749(97)70243-4; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; DENMAN AM, 1990, LANCET, V335, P1038, DOI 10.1016/0140-6736(90)91103-H; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Garrett MH, 1998, ALLERGY, V53, P1060, DOI 10.1111/j.1398-9995.1998.tb03815.x; GILLIES DRN, 1987, CLIN ALLERGY, V17, P105, DOI 10.1111/j.1365-2222.1987.tb02327.x; Gotzsche PC, 1998, BRIT MED J, V317, P1105, DOI 10.1136/bmj.317.7166.1105; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; Halken S., 1997, Journal of Allergy and Clinical Immunology, V99, pS320; HEGARTY JM, 1993, ALLERGY, V48, P108; MARKS GB, 1995, CLIN EXP ALLERGY, V25, P114, DOI 10.1111/j.1365-2222.1995.tb01015.x; MARKS GB, 1995, J ALLERGY CLIN IMMUN, V96, P441, DOI 10.1016/S0091-6749(95)70285-7; MURRAY AB, 1983, PEDIATRICS, V71, P418; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442, DOI 10.1164/ajrccm.149.6.8004296; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1982, LANCET, V2, P675; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Quanjer PH, 1997, EUR RESPIR J, V10, pS2; Rijssenbeek-Nouwens LHM, 2002, THORAX, V57, P784, DOI 10.1136/thorax.57.9.784; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; Sporik R, 1998, J ALLERGY CLIN IMMUN, V101, P451, DOI 10.1016/S0091-6749(98)70352-5; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; WALSHAW MJ, 1986, Q J MED, V58, P199	29	35	37	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					858	862		10.1016/j.jaci.2004.05.069	http://dx.doi.org/10.1016/j.jaci.2004.05.069			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480327				2022-12-18	WOS:000224439100021
J	Todd, DC; Davis, BE; Hurst, TS; Cockcroft, DW				Todd, DC; Davis, BE; Hurst, TS; Cockcroft, DW			Dosimeter methacholine challenge: Comparison of maximal versus submaximal inhalations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						methacholine challenge; nebulizer; dosimeter; deep inhalation	DEEP INSPIRATION; HYPERRESPONSIVENESS; ASTHMA	Background: Deep inhalation has bronchodilating and bronchoprotective effects, particularly in subjects who are normal or have mild airway hyperresponsiveness (AHR). We have anecdotally observed that the 5 breath to total lung capacity (TLC) dosimeter method reduced the response to methacholine in some subjects with mild AHR. Objective: To compare prospectively submaximal inhalations with TLC inhalations during the dosimeter methacholine challenge. Methods: Sixteen subjects with asthma and a methacholine PC20 < 8 mg/mL performed 2 methacholine challenges in random order; the standard dosimeter method was compared with a modified dosimeter challenge in which methacholine inhalations were performed to approximately 50% to 60% below TLC. Results: The standard methacholine challenge PC20 was almost twice that obtained with the modified submaximal inhalation method (geometric mean PC20, 5.2 mg/mL vs 2.8 mg/mL, respectively; P = 0.0216). In the 5 subjects with the mildest AHR, there was a 2.5-fold to 14-fold difference in PC20 between methods. The standard (full TLC) PC20S were falsely negative (> 16 mg/mL) in these 5 subjects with current asthma, 4 of whom required inhaled corticosteroids. Conclusion: A submaximal inhalation dosimeter methacholine challenge results in a significantly lower PC20 compared with the standard 5-breath dosimeter method. This effect is limited to the mildly responsive group, probably because of the bronchoprotective effect of the deep inhalation during the standard method, and results in false-negative tests in some subjects.	Univ Saskatchewan, Royal Univ Hosp, Dept Med, Div Resp Med, Saskatoon, SK, Canada	University of Saskatchewan	Cockcroft, DW (corresponding author), Univ Saskatchewan, Div Resp Med, Ellis Hall,Rm 551,5th Floor, Saskatoon, SK S7N 0W8, Canada.	cockcroft@sask.usask.ca						Brown RH, 2000, AM J RESP CRIT CARE, V161, P1256, DOI 10.1164/ajrccm.161.4.9806051; Brusasco V, 2001, ALLERGY, V56, P1114, DOI 10.1034/j.1398-9995.2001.00148.x; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; COCKCROFT DW, 2004, IN PRESS CHEST; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Fredberg JJ, 2001, RESPIR RES, V2, P273, DOI 10.1186/rr68; Jokic R, 1998, CHEST, V114, P1796, DOI 10.1378/chest.114.6.1796-a; Kapsali T, 2000, J APPL PHYSIOL, V89, P711, DOI 10.1152/jappl.2000.89.2.711; Moore BJ, 1997, AM J RESP CRIT CARE, V156, P1278, DOI 10.1164/ajrccm.156.4.96-11082; Scichilone N, 2001, INT ARCH ALLERGY IMM, V124, P262, DOI 10.1159/000053728; Scichilone N, 2001, AM J RESP CRIT CARE, V163, P413, DOI 10.1164/ajrccm.163.2.2003119; SIMARD B, 2003, AM J RESP CRIT CARE, V167, pA182; TODD DC, 2004, IN PRESS ANN ALLERGY	14	35	35	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					517	519		10.1016/j.jaci.2004.06.016	http://dx.doi.org/10.1016/j.jaci.2004.06.016			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356550				2022-12-18	WOS:000223799600007
J	Deruaz, U; Leimgruber, A; Berney, M; Pradervand, E; Spertini, F				Deruaz, U; Leimgruber, A; Berney, M; Pradervand, E; Spertini, F			Levocetirizine better protects than desloratadine in a nasal provocation with allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						levocetirizine; desloratadine; nasal provocation test; acoustic rhinometry; antihistamine; nasal lavage; early allergic phase; late allergic phase	HEALTHY ADULT VOLUNTEERS; ACOUSTIC RHINOMETRY; LAVAGE FLUID; ANTIGEN CHALLENGE; MEDIATOR RELEASE; GRASS-POLLEN; ANTIALLERGIC ACTIVITY; H-1 ANTAGONISTS; AIR-FLOW; RHINITIS	Background: Direct comparisons of antihistamines are rare but very much needed. Newly available antihistamine preparations, levocetirizine, the R-enantiomer of racemate cetirizine, and desloratadine, an active metabolite of loratadine, have been recently released for allergic rhinitis. Objective: We sought to compare levocetirizine and desloratadine in a nasal provocation test (NPT) with grass pollen. Methods: Twenty-four volunteers with grass pollen allergy and a history of rhinitis were enrolled in a double-blind, placebo-controlled, crossover study. Three NPTs were performed in a dose-escalating manner during the out-of-season period 4 hours after a single dose of levocetirizine (5 mg), desloratadine (5 mg), or placebo. Results: Differences in the mean allergen dose level (primary end point) necessary to reach the NPT threshold indicated improved protection provided by levocetirizine compared with that provided by desloratadine (P = .02). Sneezing and rhinorrhea were better inhibited by levocetirizine than desloratadine. Nasal congestion, as assessed by using objective methods, was not limited by either active substances or placebo. In nasal lavage fluid, IL-5, IL-8, eotaxin, and eosinophil cationic protein levels increased at 24 hours, without differences between the groups. In contrast, levocetirizine, but not desloratadine, significantly limited albumin extravasation into nasal lavage fluid in the early-phase response. Conclusions: This study demonstrates a better overall protection of a single dose of levocetirizine compared with desloratadine in an NPT with grass pollen allergen. In contrast to late-phase inflammatory markers, which were unaffected, extravascular leakage of the early-phase marker albumin was significantly limited by levocetirizine.	CHU Vaudois, Div Allergy & Immunol, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Spertini, F (corresponding author), CHU Vaudois, Div Allergy & Immunol, Rue Bugnon, CH-1011 Lausanne, Switzerland.	Francois.Spertini@chuv.hospvd.ch						Allocco FT, 2002, ANN ALLERG ASTHMA IM, V89, P578, DOI 10.1016/S1081-1206(10)62105-9; Bachert C, 2001, ALLERGY, V56, P14, DOI 10.1034/j.1398-9995.2001.00102.x; Baroody FM, 1996, ARCH OTOLARYNGOL, V122, P309; Bensch GW, 2002, ANN ALLERG ASTHMA IM, V88, P457, DOI 10.1016/S1081-1206(10)62382-4; Bousquet J, 1998, ALLERGY, V53, P579, DOI 10.1111/j.1398-9995.1998.tb03933.x; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; Ciprandi G, 1997, CLIN EXP ALLERGY, V27, P1175; Ciprandi G, 1996, J ALLERGY CLIN IMMUN, V98, P1088, DOI 10.1016/S0091-6749(96)80196-5; Ciprandi G, 1997, CLIN EXP ALLERGY, V27, P1160; Denham KJ, 2003, INFLAMM RES, V52, P424, DOI 10.1007/s00011-003-1193-5; Devalia JL, 2001, ALLERGY, V56, P50, DOI 10.1034/j.1398-9995.2001.00726.x; Ganslmayer M, 1999, ALLERGY, V54, P974, DOI 10.1034/j.1398-9995.1999.00160.x; Gillard M, 2003, INFLAMM RES, V52, pS49, DOI 10.1007/s000110300050; Gillard M, 2002, MOL PHARMACOL, V61, P391, DOI 10.1124/mol.61.2.391; Greiff L, 2002, ANN ALLERG ASTHMA IM, V89, P413, DOI 10.1016/S1081-1206(10)62044-3; Henz BM, 2001, ALLERGY, V56, P7, DOI 10.1034/j.1398-9995.2001.00101.x; HILBERG O, 1995, ALLERGY, V50, P166; HILBERG O, 1995, ALLERGY, V50, P683, DOI 10.1111/j.1398-9995.1995.tb02586.x; Horak F, 1998, ALLERGY, V53, P68, DOI 10.1111/j.1398-9995.1998.tb03775.x; Horak F, 2003, ALLERGY, V58, P481, DOI 10.1034/j.1398-9995.2003.00148.x; Horak F, 2002, CLIN DRUG INVEST, V22, P13, DOI 10.2165/00044011-200222002-00002; Horak F, 2002, J ALLERGY CLIN IMMUN, V109, P956, DOI 10.1067/mai.2002.124657; Horak F, 2001, INT ARCH ALLERGY IMM, V125, P73, DOI 10.1159/000053799; Jacobi HH, 1998, INT ARCH ALLERGY IMM, V116, P53, DOI 10.1159/000023925; Jacobi HH, 1999, J ALLERGY CLIN IMMUN, V103, P768, DOI 10.1016/S0091-6749(99)70418-5; Jacobi HH, 1998, CLIN EXP ALLERGY, V28, P83; JANKOWSKI R, 1993, INT ARCH ALLERGY IMM, V101, P311, DOI 10.1159/000236469; KLEMENTSSON H, 1990, J ALLERGY CLIN IMMUN, V86, P466, DOI 10.1016/S0091-6749(05)80201-5; Kosa L., 2002, Allergy (Copenhagen), V57, P63; Kumar NS, 1996, ALLERGY ASTHMA PROC, V17, P93, DOI 10.2500/108854196778645047; Larsson C, 2001, AM J RHINOL, V15, P403, DOI 10.1177/194589240101500609; Leynadier F, 2001, Acta Otorhinolaryngol Belg, V55, P305; LIM MC, 1995, AM J RESP CRIT CARE, V151, P136, DOI 10.1164/ajrccm.151.1.7812543; Malling HJ., 2003, ALLERGY, V48, P55; Miadonna A, 1999, CLIN EXP ALLERGY, V29, P941; MONROE EW, 1997, J ALLERGY CLIN IMMUN, V99, P798; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1993, ANN ALLERGY, V71, P292; OSTERBALLE O, 1982, ALLERGY, V37, P169, DOI 10.1111/j.1398-9995.1982.tb01893.x; Persi L, 1999, J ALLERGY CLIN IMMUN, V103, P591, DOI 10.1016/S0091-6749(99)70229-0; Purohit A, 2003, BRIT J CLIN PHARMACO, V56, P388, DOI 10.1046/j.1365-2125.2003.01897.x; SIM TC, 1994, AM J RESP CRIT CARE, V149, P339, DOI 10.1164/ajrccm.149.2.8306027; Simons FER, 1997, ANN ALLERG ASTHMA IM, V79, P530, DOI 10.1016/S1081-1206(10)63061-X; Simons FER, 1999, CLIN EXP ALLERGY, V29, P125, DOI 10.1046/j.1365-2222.1999.0290s3125.x; SULMUN LM, 2002, BMC FAM PRACT, V3, P14; Terada N, 2001, AM J RESP CRIT CARE, V164, P575, DOI 10.1164/ajrccm.164.4.2009046; Terrien MH, 1999, J ALLERGY CLIN IMMUN, V103, P1025, DOI 10.1016/S0091-6749(99)70174-0; TILLEMENT JP, 1995, ALLERGY, V50, P12, DOI 10.1111/j.1398-9995.1995.tb04258.x; WAGENMANN M, 1994, J ALLERGY CLIN IMMUN, V93, P594, DOI 10.1016/S0091-6749(94)70071-0; Walsh GM, 2001, DRUGS, V61, P207, DOI 10.2165/00003495-200161020-00006; Walsh GM, 2000, ALLERGY, V55, P53, DOI 10.1034/j.1398-9995.2000.00009.x; Wang DY, 2001, ALLERGY, V56, P339, DOI 10.1034/j.1398-9995.2001.00775.x; White P, 1998, CLIN EXP ALLERGY, V28, P266; YOULTEN LFJ, 1983, ARB P EHRLICH I, V78, P111; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P624, DOI 10.1016/S0091-6749(97)70166-0	55	35	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					669	676		10.1016/j.jaci.2004.01.773	http://dx.doi.org/10.1016/j.jaci.2004.01.773			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100671				2022-12-18	WOS:000220956600013
J	Terr, AI				Terr, AI			Are indoor molds causing a new disease?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fungi; toxic molds; Stachybotrys species; litigation; controversies	STACHYBOTRYS-CHARTARUM; HOME DAMPNESS; HYPERSENSITIVITY PNEUMONITIS; FUNGAL CONTAMINATION; PULMONARY HEMORRHAGE; TOXIGENIC FUNGI; EXPOSURE; HEALTH; CHILDREN; INFANTS	Three mechanisms for disease caused by mold-infection, allergy, and toxicity-are established and well recognized by clinicians. In each case the corresponding diseases are specific to a particular fungus. The mechanisms involved include a recognized inflammatory pathology that leads to objective clinical evidence of disease. Recent widespread litigation has arisen out of an unproved assertion that exposure to indoor molds causes an ill-defined illness. This illness is characterized by the absence of objective evidence of disease and by the lack of a defined pathology. There is usually no specificity for the involved fungus purported to cause the illness. Those publications that claim such an illness are reviewed. They are found to lack scientific validity, often on the basis of faulty methodology and insufficient information. There is no coherent clinical description for the presumed illness. Recommendations are offered for published reports and studies to address this problem.	Terr Med Corp, San Francisco, CA 94108 USA		Terr, AI (corresponding author), Terr Med Corp, 450 Sutter St,Suite 2534, San Francisco, CA 94108 USA.							AUGER PL, 1994, AM J IND MED, V25, P41, DOI 10.1002/ajim.4700250110; BERNTON HS, 1942, J ALLERGY, V16, P85; Blackley CH., 1873, EXPT RES CAUSES NATU; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363, DOI 10.1164/ajrccm/140.5.1363; BURGE HA, 1985, CLIN REV ALLERG, V3, P319, DOI 10.1007/BF02992998; *CDCP, 2000, JAMA-J AM MED ASSOC, V283, P1951; Cooley JD, 1998, OCCUP ENVIRON MED, V55, P579, DOI 10.1136/oem.55.9.579; CROFT WA, 1986, ATMOS ENVIRON, V20, P549, DOI 10.1016/0004-6981(86)90096-X; Dales R, 1998, ARCH ENVIRON HEALTH, V53, P190, DOI 10.1080/00039899809605694; Dales RE, 1997, INT J EPIDEMIOL, V26, P120, DOI 10.1093/ije/26.1.120; Dearborn DG, 1999, ENVIRON HEALTH PERSP, V107, P495, DOI 10.1289/ehp.99107s3495; DeShazo RD, 1997, NEW ENGL J MED, V337, P254, DOI 10.1056/NEJM199707243370407; DOULL J, 1986, CASARETT DOULLS TOXI, P3; Etzel RA, 1998, ARCH PEDIAT ADOL MED, V152, P757; Etzel RA, 1998, PEDIATRICS, V101, P712, DOI 10.1542/peds.101.4.712; Fung Frederick, 2003, Appl Occup Environ Hyg, V18, P535, DOI 10.1080/10473220301451; GUTMANN L, 1975, NEUROLOGY, V25, P922, DOI 10.1212/WNL.25.10.922; Hodgson MJ, 1998, J OCCUP ENVIRON MED, V40, P241, DOI 10.1097/00043764-199803000-00006; HYNDMAN SJ, 1990, SOC SCI MED, V30, P131, DOI 10.1016/0277-9536(90)90336-Q; Jarvis BB, 1998, APPL ENVIRON MICROB, V64, P3620; JOFFE AZ, 1977, FUSARIUM POAE F SPOR, V18, P93; Johanning E, 1996, INT ARCH OCC ENV HEA, V68, P207; Johanning E, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.1289/ehp.99107s3489; JOHANNING E, 1993, P INDOOR AIR 93, V1, P225; KOZAK PP, 1979, ANN ALLERGY, V43, P88; KOZAK PP, 1980, ANN ALLERGY, V45, P549; Kuhn DM, 2003, CLIN MICROBIOL REV, V16, P144, DOI 10.1128/CMR.16.1.144-172.2003; Li CS, 1996, ARCH ENVIRON HEALTH, V51, P42, DOI 10.1080/00039896.1996.9935992; Ostry V, 1999, Cas Lek Cesk, V138, P515; Patel AM, 2001, J ALLERGY CLIN IMMUN, V108, P661; PLATT SD, 1990, BRIT MED J, V298, P1675; Rao CY, 1996, J AIR WASTE MANAGE, V46, P899, DOI 10.1080/10473289.1996.10467526; SAFIRSTEIN BH, 1976, CHEST, V70, P788, DOI 10.1378/chest.70.6.788; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; Santilli J, 2003, ANN ALLERG ASTHMA IM, V90, P203, DOI 10.1016/S1081-1206(10)62142-4; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P395, DOI 10.1016/S0091-6749(98)70126-5; STRACHAN DP, 1990, THORAX, V45, P382, DOI 10.1136/thx.45.5.382; van Leeuwen W S, 1924, Proc R Soc Med, V17, P19; Vesper SJ, 1999, APPL ENVIRON MICROB, V65, P3175; Wild LG, 2001, J INVEST ALLERG CLIN, V11, P3	40	35	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					221	226		10.1016/j.jaci.2003.11.014	http://dx.doi.org/10.1016/j.jaci.2003.11.014			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14722497				2022-12-18	WOS:000188885700006
J	Magnusson, J; Lin, XP; Dahlman-Hoglund, A; Hanson, LA; Telemo, E; Magnusson, O; Bengtsson, U; Ahlstedt, S				Magnusson, J; Lin, XP; Dahlman-Hoglund, A; Hanson, LA; Telemo, E; Magnusson, O; Bengtsson, U; Ahlstedt, S			Seasonal intestinal inflammation in patients with birch pollen allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						birch pollen allergy; Bet v 1; duodenal mucosa; eosinophils; eosinophil major basic protein; immunoglobulin E; T-lymphocytes	MESSENGER-RNA EXPRESSION; NONASTHMATIC PATIENTS; ORAL IMMUNOTHERAPY; NASAL-MUCOSA; MAST-CELLS; FOOD; IGE; CHILDREN; RHINITIS; IMMUNOREACTIVITY	Background: The pathophysiologic interactions of inflammatory reactions between the mucosa of the respiratory tract and that of the gastrointestinal tract in individuals with allergy are poorly studied, despite the fact that allergic symptoms in the airways and the gastrointestinal tract might arise in the same patient. Objective: The objective of this study was to examine the inflammatory response histologically by enumerating eosinophils, IgE+ cells, and T cells in duodenal biopsy specimens in adult patients with IgE-mediated birch pollen allergy during the birch pollen season and off-season. Methods: Nine patients with birch pollen allergy verified by skin prick test and serum IgE antibodies were investigated toward the end of the birch pollen season and again 6 months later (off-season). Duodenal biopsy specimens were obtained and studied by immunostaining for the eosinophil major basic protein (MBP), IgE, and CD3+ T cells. Results: Oral allergy syndrome to birch-associated foods was present in all patients as indicated by questionnaire. Duodenal increases of MBP+ eosinophils and IgE-bearing cells were found in the patients during the birch pollen season as compared with off-season. No seasonal differences in the T-cell numbers in these patients were seen. Off-season, there was no significant difference between the patients and the control subjects regarding the intestinal frequencies of MBP+ eosinophils, mucosal IgE+ cells, and T cells. Conclusion: Birch pollen exposure triggered a local inflammation with an increase in duodenal eosinophils and IgE-carrying mast cells in patients with allergy. Our study gives evidence for the interplay between immunologically active cells in the airways and the gut.	Sahlgrens Univ Hosp, Dept Resp Med & Allergy, Asthma & Allergy Res Grp, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Clin Immunol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Rheumatol & Inflammat Res, S-41345 Gothenburg, Sweden; Frolunda Specialist Hosp, Dept Surg, Gothenburg, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital; Karolinska Institutet	Magnusson, J (corresponding author), Sahlgrens Univ Hosp, Dept Resp Med & Allergy, Asthma & Allergy Res Grp, S-41345 Gothenburg, Sweden.							AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; Bacharier LB, 2000, J ALLERGY CLIN IMMUN, V105, pS547, DOI 10.1016/S0091-6749(00)90059-9; BENGTSSON U, 1991, INT ARCH ALLER A IMM, V95, P86, DOI 10.1159/000235459; Bischoff SC, 1997, GUT, V40, P745, DOI 10.1136/gut.40.6.745; Bischoff SC, 1997, INT ARCH ALLERGY IMM, V113, P348, DOI 10.1159/000237598; BJORKSTEN B, 1986, ALLERGY, V41, P290, DOI 10.1111/j.1398-9995.1986.tb02031.x; Bolos AM, 2000, J ALLERGY CLIN IMMUN, V105, pS259, DOI 10.1016/S0091-6749(00)91198-9; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DahlmanHoglund A, 1996, CLIN EXP IMMUNOL, V106, P534, DOI 10.1046/j.1365-2249.1996.d01-875.x; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128, DOI 10.1159/000237525; Durham SR, 2000, AM J RHINOL, V14, P305, DOI 10.2500/105065800781329492; EINARSSON R, 1988, ALLERGY, V43, P469, DOI 10.1111/j.1398-9995.1988.tb00921.x; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Hellgren J, 1997, CLIN OTOLARYNGOL, V22, P536, DOI 10.1046/j.1365-2273.1997.00073.x; KNUTSON TW, 1993, J ALLERGY CLIN IMMUN, V91, P553, DOI 10.1016/0091-6749(93)90261-D; Knutson TW, 1996, J ALLERGY CLIN IMMUN, V97, P1225, DOI 10.1016/S0091-6749(96)70189-6; Lin XP, 2002, J ALLERGY CLIN IMMUN, V109, P879, DOI 10.1067/mai.2002.123238; MARCUCCI F, 1985, CLIN ALLERGY, V15, P345, DOI 10.1111/j.1365-2222.1985.tb03002.x; Marcucci F, 2001, ALLERGY, V56, P231; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; MAYER JH, 2001, 20 C EUR AC ALL CLIN; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; MOLLER C, 1986, ALLERGY, V41, P280, DOI 10.1111/j.1398-9995.1986.tb02029.x; MOSBECH H, 1987, ALLERGY, V42, P451, DOI 10.1111/j.1398-9995.1987.tb00362.x; O'Sullivan M, 2000, NEUROGASTROENT MOTIL, V12, P449; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Romagnani P, 2000, IMMUNOL TODAY, V21, P416, DOI 10.1016/S0167-5699(00)01670-4; Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X; Rothenberg ME, 2001, ALLERGY, V56, P21, DOI 10.1034/j.1398-9995.2001.00905.x; TALLEY NJ, 1995, AM J GASTROENTEROL, V90, P2115; Thaminy A, 2000, EUR RESPIR J, V16, P1091, DOI 10.1034/j.1399-3003.2000.16f12.x; Thompson WG, 1999, GUT, V45, P43; Vandezande LM, 1999, CLIN EXP ALLERGY, V29, P652, DOI [10.1046/j.1365-2222.1999.00514.x, 10.1046/j.1365-2222.1999.00511.x]; WALLAERT B, 1995, J EXP MED, V182, P1897, DOI 10.1084/jem.182.6.1897; Wallaert B, 2002, ALLERGY, V57, P405, DOI 10.1034/j.1398-9995.2002.13527.x; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Yazar A, 2001, AM J GASTROENTEROL, V96, P1511, DOI 10.1111/j.1572-0241.2001.03748.x	41	35	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					45	51		10.1067/mai.2003.1604	http://dx.doi.org/10.1067/mai.2003.1604			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847478				2022-12-18	WOS:000184010600008
J	Stadtmauer, G; Beyer, K; Bardina, L; Sicherer, SH				Stadtmauer, G; Beyer, K; Bardina, L; Sicherer, SH			Anaphylaxis to ingestion of hempseed (Cannabis sativa)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGENS		Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY USA	Icahn School of Medicine at Mount Sinai	Stadtmauer, G (corresponding author), 115 E 61 St, New York, NY 10021 USA.							Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P154, DOI 10.1067/mai.2002.125487; LISKOW B, 1971, ANN INTERN MED, V75, P571, DOI 10.7326/0003-4819-75-4-571; Perez JA, 2000, J EMERG MED, V18, P260, DOI 10.1016/S0736-4679(99)00209-7; VFIDAL C, 1991, ALLERGY, V46, P647; West D. P., HEMP MARIJUANA MYTHS	6	35	35	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					216	217		10.1067/mai.2003.1591	http://dx.doi.org/10.1067/mai.2003.1591			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847507				2022-12-18	WOS:000184010600038
J	Djukanovic, R				Djukanovic, R			Airway inflammation in asthma and its consequences: Implications for treatment in children and adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway inflammation; eosinophilia; airway remodeling; asthma	BRONCHOALVEOLAR LAVAGE FLUID; EPIDERMAL GROWTH-FACTOR; MAST-CELL TRYPTASE; GLUCOCORTICOID-DEPENDENT ASTHMA; ALLERGIC ASTHMATICS; BRONCHIAL-MUCOSA; FACTOR RECEPTOR; EPITHELIAL REPAIR; ANTIGEN CHALLENGE; LUNG FIBROBLASTS	The development and wide availability of novel research techniques such as bronchoscopy and induced sputum have enhanced our understanding of the pathophysiology of asthma. The appreciation of the inflammatory nature of asthma and the remodeling associated with chronic disease have undoubtedly led to improved disease management and a better understanding of how anti-asthma drugs work. Although extensive data about inflammation and its sequelae in children are lacking, both chronic inflammation and airway remodeling are more than likely to be involved in the development and progression of asthma in this young population. Indeed, evidence suggests that airway restructuring occurs early. The implications for treatment in any differences of inflammation and remodeling between children and adults, then, are likely to be important. Although corticosteroids are considered as first-line anti-inflammatory treatment, especially in chronic asthma, for many patients neither inhaled nor oral corticosteroid therapy can control inflammation adequately. In children, neither the addition of long-acting beta(2)-agonist therapy nor doubling of the corticosteroid dose has produced the same benefits seen in adults. A clearer understanding of the pathophysiologic mechanisms of asthma in adults and pediatric patients should provide new insights into different asthma phenotypes. Therefore, the development and application of relatively simple and safe methods for assessing markers of inflammation and alterations in the airways are vital, especially for children.	Univ Southampton, Southampton SO9 5NH, Hants, England	University of Southampton	Djukanovic, R (corresponding author), Southampton Gen Hosp, Div Infect Inflammat & Repair, Level D,Ctr Block, Southampton SO16 6YD, Hants, England.			Djukanovic, Ratko/0000-0001-6039-5612				Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907, DOI 10.1164/ajrccm.157.6.9609040; BARROW RE, 1993, LUNG, V171, P335, DOI 10.1007/BF00165699; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Cai Y, 1998, EUR RESPIR J, V11, P848, DOI 10.1183/09031936.98.11040848; Cairns JA, 1997, J CLIN INVEST, V99, P1313, DOI 10.1172/JCI119290; Cairns JA, 1996, J IMMUNOL, V156, P275; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; Compton SJ, 1998, J IMMUNOL, V161, P1939; COOKSON WOCM, 1987, BRIT J CLIN PHARMACO, V24, P120, DOI 10.1111/j.1365-2125.1987.tb03150.x; de Longueville M, 2000, PEDIAT ALLERG IMM-UK, V11, P41, DOI 10.1034/j.1399-3038.2000.00510.x; DEMOLY P, 1994, AM J RESP CRIT CARE, V150, P214, DOI 10.1164/ajrccm.150.1.7912988; DENT G, 2001, AM J RESP CRIT CARE, V163, pA600; Djukanovic R, 1997, AM J RESP CRIT CARE, V155, P826, DOI 10.1164/ajrccm.155.3.9117012; Djukanovic R, 1996, THORAX, V51, P575, DOI 10.1136/thx.51.6.575; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Djukanovic R, 2000, J ALLERGY CLIN IMMUN, V105, pS522, DOI 10.1016/S0091-6749(00)90055-1; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Edwards A, 2001, THORAX, V56, P331, DOI 10.1136/thorax.56.4.331; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; Gibson PG, 1999, PEDIATR PULM, V28, P261, DOI 10.1002/(SICI)1099-0496(199910)28:4<261::AID-PPUL5>3.0.CO;2-I; Gibson PG, 2000, EUR RESPIR J, V16, P1008; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Heaney LG, 1998, CLIN EXP ALLERGY, V28, P196; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate ST, 2001, AM J RESP CRIT CARE, V164, P1997, DOI 10.1164/ajrccm.164.10.correspondence_a; JARJOUR NN, 1991, AM REV RESPIR DIS, V144, P83, DOI 10.1164/ajrccm/144.1.83; KALENDERIAN R, 1988, CHEST, V94, P119, DOI 10.1378/chest.94.1.119; KAWIEC ME, 2001, AM J RESP CRIT CARE, V163, P1338; KELLEY J, 1991, AM J PHYSIOL, V260, pL123, DOI 10.1152/ajplung.1991.260.2.L123; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; KRISHNA MT, 1998, AM J RESP CRIT CARE, V157, pA456; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAWRENCE WT, 1994, CLIN DERMATOL, V12, P157, DOI 10.1016/0738-081X(94)90266-6; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; Louis E, 1999, CLIN EXP ALLERGY, V29, P660; Louis R, 1997, AM J RESP CRIT CARE, V155, P466, DOI 10.1164/ajrccm.155.2.9032180; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Milanese M, 2001, J APPL PHYSIOL, V91, P1035, DOI 10.1152/jappl.2001.91.3.1035; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; MONTEFORT S, 1992, THORAX, V47, P499, DOI 10.1136/thx.47.7.499; MONTEFORT S, 1993, CLIN EXP ALLERGY, V23, P185, DOI 10.1111/j.1365-2222.1993.tb00880.x; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NANNEY LB, 1986, J INVEST DERMATOL, V86, P260, DOI 10.1111/1523-1747.ep12285389; NOGRADY SG, 1981, THORAX, V36, P268, DOI 10.1136/thx.36.4.268; O'Byrne PM, 2001, J ALLERGY CLIN IMMUN, V108, P503, DOI 10.1067/mai.2001.119149; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; Roberts JA, 1999, EUR RESPIR J, V14, P275, DOI 10.1034/j.1399-3003.1999.14b07.x; RUSCH V, 1993, CANCER RES, V53, P2379; SCHLEIMER RP, 1983, CLIN REV ALLERG, V1, P327; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; Stanciu LA, 1996, J IMMUNOL METHODS, V189, P107, DOI 10.1016/0022-1759(95)00240-5; TAYTARD A, 1987, BRIT J CLIN PHARMACO, V24, P743, DOI 10.1111/j.1365-2125.1987.tb03240.x; THOMSON NC, 1980, THORAX, V35, P428, DOI 10.1136/thx.35.6.428; Verberne AAPH, 1998, AM J RESP CRIT CARE, V158, P213, DOI 10.1164/ajrccm.158.1.9706048; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Vignola AM, 1996, CLIN EXP IMMUNOL, V106, P114, DOI 10.1046/j.1365-2249.1996.d01-811.x; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; Vrugt B, 1999, EUR RESPIR J, V13, P1245, DOI 10.1183/09031936.99.13612539; WALLS AF, 1991, CLIN SCI, V81, P183, DOI 10.1042/cs0810183; WALLS AF, 1998, MAST CELL PROTEASES; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Wardlaw AJ, 2000, BRIT MED BULL, V56, P985, DOI 10.1258/0007142001903490; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; WHITE JP, 1987, BRIT J DIS CHEST, V81, P155, DOI 10.1016/0007-0971(87)90134-3; WILSON JW, 1992, AM REV RESPIR DIS, V145, P958, DOI 10.1164/ajrccm/145.4_Pt_1.958; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Zhang SL, 1999, LAB INVEST, V79, P395	80	35	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6		S			S539	S548		10.1067/mai.2002.124568	http://dx.doi.org/10.1067/mai.2002.124568			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	568JU	12063510				2022-12-18	WOS:000176539300005
J	Perez, C; Sanchez-Borges, M; Capriles, E				Perez, C; Sanchez-Borges, M; Capriles, E			Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Minist Hlth, Inst Oncol & Hematol, Caracas, Venezuela; Cent Univ Venezuela, Fac Med, Caracas, Venezuela; Ctr Medicodocente Trinidad, Caracas, Venezuela	University of Central Venezuela	Perez, C (corresponding author), Minist Hlth, Inst Oncol & Hematol, Caracas, Venezuela.							BERNSTEIN JA, 1991, J ALLERGY CLIN IMMUN, V87, P93, DOI 10.1016/0091-6749(91)90217-C; Capriles-Behrens E, 2000, J INVEST ALLERG CLIN, V10, P277; Ellis MH, 1998, J ALLERGY CLIN IMMUN, V102, P876, DOI 10.1016/S0091-6749(98)70032-6; Nettis E, 2001, ARCH DERMATOL, V137, P99; Sanchez-Borges M, 2001, J ALLERGY CLIN IMMUN, V107, pS134; Sanchez-Borges N, 2000, ANN ALLERG ASTHMA IM, V84, P101, DOI 10.1016/S1081-1206(10)62748-2; Stevenson DD, 2000, J ALLERGY CLIN IMMUN, V105, pS367, DOI 10.1016/S0091-6749(00)91503-3; STEVENSON DD, 1992, ALLERGY; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; Szczeklik A, 1997, ALLERGY, V52, P613, DOI 10.1111/j.1398-9995.1997.tb01039.x	10	35	35	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					1060	1061		10.1067/mai.2001.120275	http://dx.doi.org/10.1067/mai.2001.120275			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742290				2022-12-18	WOS:000172938400028
J	Hoffman, DR; El-Choufani, SE; Smith, MM; de Groot, H				Hoffman, DR; El-Choufani, SE; Smith, MM; de Groot, H			Occupational allergy to bumblebees: Allergens of Bombus terrestris	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bumblebee; venom; phospholipase; protease; occupational allergy; epitope; honeybee	CROSS-REACTIVITY; HYMENOPTERA VENOM; STRUCTURAL BASIS; HONEYBEE VENOM; BEE-VENOM; ANAPHYLAXIS	Background: With the increase in commercial vegetable production in greenhouses, occupational sensitization to bumble-bee venom is becoming more common. Studies using sera from subjects thus sensitized allow evaluation of the allergenic specificity of bumblebee sensitization. Objective: The purposes of this study were to determine the degree of species group specificity of bumblebee venom allergens in sera of allergic patients and to investigate the structural basis of this specificity. Methods: Allergens were purified from bumblebee venom, studied serologically by direct binding and inhibition techniques, and characterized by enzyme analysis and amino acid sequencing. Three-dimensional models of the phospholipases were constructed and analyzed. Results: Bombus terrestris venom contains phospholipase A(2), venom protease, hyaluronidase, and acid phosphatase allergens. The protease and phospholipase A(2) allergens contain IgE-reactive epitopes that are different from those seen in Bombus pennsylvanicus, a North American species. Bumblebee phospholipase A(2) is only 53% identical to honeybee phospholipase A(2),. The results of 3-dimensional modeling are consistent with the immunologic observations. Conclusions: Patients with primary bumblebee sensitization should be diagnosed and treated with venom from the appropriate species group of bumblebees. Bumblebee venom phospholipase A(2) and protease are antigenically distinct from honeybee venom proteins. There are significant species group-specific epitopes on bumblebee venom proteins.	E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, Greenville, NC 27858 USA; Univ Rotterdam Hosp, Dept Allergol, Rotterdam, Netherlands	University of North Carolina; East Carolina University; Erasmus University Rotterdam; Erasmus MC	Hoffman, DR (corresponding author), E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, Greenville, NC 27858 USA.							de Jong NW, 1999, ALLERGY, V54, P980, DOI 10.1034/j.1398-9995.1999.00158.x; DEGROOT H, 1995, ALLERGY, V50, P581, DOI 10.1111/j.1398-9995.1995.tb01203.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; Hoffman DR, 1996, J ALLERGY CLIN IMMUN, V97, P812, DOI 10.1016/S0091-6749(96)80159-X; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; JACOBSON RS, 1992, J ALLERGY CLIN IMMUN, V89, P292; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; KOCHUYT AM, 1993, CLIN EXP ALLERGY, V23, P190, DOI 10.1111/j.1365-2222.1993.tb00881.x; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; McNairy MM, 2000, J ALLERGY CLIN IMMUN, V105, pS57, DOI 10.1016/S0091-6749(00)90602-X; Peitsch MC, 1997, ELECTROPHORESIS, V18, P498, DOI 10.1002/elps.1150180326; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Stapel SO, 1998, ALLERGY, V53, P769, DOI 10.1111/j.1398-9995.1998.tb03973.x; Stern A, 2000, ALLERGY, V55, P88, DOI 10.1034/j.1398-9995.2000.00202.x; Winningham KM, 2001, J ALLERGY CLIN IMMUN, V107, pS221	17	35	41	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					855	860		10.1067/mai.2001.119029	http://dx.doi.org/10.1067/mai.2001.119029			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692115				2022-12-18	WOS:000172523800030
J	Nagase, H; Kudo, K; Izumi, S; Ohta, K; Kobayashi, N; Yamaguchi, M; Matsushima, K; Morita, Y; Yamamoto, K; Hirai, K				Nagase, H; Kudo, K; Izumi, S; Ohta, K; Kobayashi, N; Yamaguchi, M; Matsushima, K; Morita, Y; Yamamoto, K; Hirai, K			Chemokine receptor expression profile of eosinophils at inflamed tissue sites: Decreased CCR3 and increased CXCR4 expression by lung eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; CXCR4; CCR3; stromal cell-derived factor 1 alpha; CXCL12; eotaxin; CCL11; chemotaxis; bronchoalveolar lavage; eosinophilic pneumonia	EOTAXIN RECEPTOR; SELECTIVE RECRUITMENT; MOLECULAR-CLONING; RANTES; CELLS	Background: To date, most studies dealing with eosinophil chemokine receptors have used eosinophils isolated from peripheral blood. During the movement of eosinophils from the peripheral blood to inflamed tissue sites, microenvironmental signals might alter their expression of chemokine receptors, However, little is known about the profile of expression of chemokine receptors by eosinophils at inflame tissue sites in human beings. Objective: The purpose of this study was to determine whether eosinophils that have migrated into inflamed tissues exhibit expression that is qualitatively profile of chemokine receptor ex and/or quantitatively different from that of eosinophils in peripheral locations. Methods: We studied simultaneously the expression and function of chemokine receptors in eosinophils in both bronchoalveolar lavage fluid (BALF) and peripheral blood specimens of 7 patients with eosinophilic lung diseases. Results: De novo expression of CCR2, CCR4, and CCR5 was not detected at either the protein or the mRNA level. However, surface expression of CCR3 was decreased and CXCR4 was conversely increased with statistical significance in BALF eosinophils. Moreover, the changes in CCR3 and CXCR4 expression were reflected in the altered migratory response to their ligands. On the other hand, the levels of CXCR1, CXCR2, CXCR3, and CCR1 were virtually unchanged in BALF eosinophils, and these receptors did not have functional significance. Conclusion: Eosinophils at inflamed tissue sites exhibited an expression profile qualitatively similar to that in peripheral locations, except for decreased CCR3 and increased CXCR4 expression. Our results suggest that CCR3 is primarily and CXCR4 is cooperatively involved in eosinophil accumulation at inflamed tissue sites.	Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Resp Med, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, CREST, Tokyo 1138655, Japan; Int Med Ctr Japan, Dept Pulmonol, Tokyo, Japan; Teikyo Univ, Sch Med, Dept Internal Med, Tokyo 173, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; National Center for Global Health & Medicine - Japan; Teikyo University	Hirai, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Nagase, Hiroyuki/Y-4367-2019; Yamamoto, Kazuhiko/N-5096-2015	Nagase, Hiroyuki/0000-0002-0296-5901; 				ALAM R, 1993, J IMMUNOL, V150, P3442; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; El-Shazly A, 1998, INT ARCH ALLERGY IMM, V117, P55, DOI 10.1159/000053573; FLEISHER TA, 1991, CURRENT PROTOCOLS IM; Fujisawa T, 2000, J ALLERGY CLIN IMMUN, V106, P507; Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Loetscher P, 2001, J BIOL CHEM, V276, P2986, DOI 10.1074/jbc.M005652200; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Nagase H, 1999, ALLERGY, V54, P944, DOI 10.1034/j.1398-9995.1999.00184.x; Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935; Petering H, 1999, BLOOD, V93, P694, DOI 10.1182/blood.V93.2.694.402k31_694_702; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POST TW, 1995, J IMMUNOL, V155, P5299; Sabroe I, 1999, J IMMUNOL, V162, P2946; Sato K, 1999, BLOOD, V93, P34, DOI 10.1182/blood.V93.1.34.424k27_34_42; SCHWEIZER RC, 1994, BLOOD, V83, P3697; Tan JQ, 2000, J IMMUNOL, V165, P1548, DOI 10.4049/jimmunol.165.3.1548; Ulfman LH, 2001, J IMMUNOL, V166, P588, DOI 10.4049/jimmunol.166.1.588	22	35	36	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					563	569		10.1067/mai.2001.118292	http://dx.doi.org/10.1067/mai.2001.118292			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590382				2022-12-18	WOS:000171760300015
J	Dibildox, J				Dibildox, J			Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beclomethasone dipropionate; cosyntropin; hypothalamic pituitary axis; mometasone furoate	BECLOMETHASONE DIPROPIONATE; NASONEX	Intranasal mometasone furoate (NIF) has been extensively studied in adults and has been found to be safe and effective therapy for the treatment of allergic rhinitis. Several studies have now been conducted on pediatric patients. In all, 990 pediatric patients given mometasone furoate nasal spray (MFNS) have been studied in phase I, II, and III clinical trials. In a dose-ranging study, 5 doses of nasal spray (25, 100, and 200 mug MFNS daily and 168 mug beclomethasone dipropionate daily) were compared with placebo. The 100- and 200-mug daily doses of MFNS NN ere found to be more effective than 168 mug beclomethasone dipropionate or 25 mug MFNS given daily. MFNS (100 mug once daily) was chosen as the appropriate dose. In clinical efficacy and safety trials, MFNS was given to 381 patients 3 to 11 years of age for 4 weeks (357 patients received 100 mug MFNS daily for 6 months) and was found to decrease symptom scores from baseline significantly better than placebo. The long-term safety of MFNS was also studied in 166 patients treated for one year; no significant changes in intraocular pressure were detected. Cosyntropin stimulation showed no decreases in cortisol. In adults, nasal mucosa showed improvement in appearance of epithelium and reduction of inflammatory infiltrates, and there were no signs of nasal atrophy.	Ctr Med Potosi, San Luis Potosi 78200, Mexico		Dibildox, J (corresponding author), Ctr Med Potosi, Antonio Aguilar 155,Col Burocratos Estados, San Luis Potosi 78200, Mexico.							Agertoft L, 1993, Pediatr Allergy Immunol, V4, P152, DOI 10.1111/j.1399-3038.1993.tb00084.x; Brannan MD, 1997, CLIN THER, V19, P1330, DOI 10.1016/S0149-2918(97)80008-2; Brannan MD, 1996, J ALLERGY CLIN IMMUN, V97, P62; Bronsky EA, 1997, ANN ALLERG ASTHMA IM, V79, P51, DOI 10.1016/S1081-1206(10)63084-0; Davies RJ, 1997, CLIN THER, V19, P27; Drouin M, 1996, ANN ALLERG ASTHMA IM, V77, P153, DOI 10.1016/S1081-1206(10)63502-8; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Hebert JR, 1996, ALLERGY, V51, P569; Mandl M, 1997, ANN ALLERG ASTHMA IM, V79, P370, DOI 10.1016/S1081-1206(10)63030-X; Meltzer EO, 1998, CLIN PEDIATR, V37, P1, DOI 10.1177/000992289803700101; Meltzer EO, 1999, J ALLERGY CLIN IMMUN, V104, P107, DOI 10.1016/S0091-6749(99)70121-1; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1016/S0194-5998(98)70235-9; Onrust SV, 1998, DRUGS, V56, P725, DOI 10.2165/00003495-199856040-00018; Schenkel EJ, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e22; TARLO SM, 1977, J ALLERGY CLIN IMMUN, V59, P232, DOI 10.1016/0091-6749(77)90155-5; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x	16	35	43	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1		S			S54	S58		10.1067/mai.2001.115567	http://dx.doi.org/10.1067/mai.2001.115567			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	459BU	11449207				2022-12-18	WOS:000170230600009
J	Martinez, FD				Martinez, FD			Links between pediatric and adult asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway obstruction; asthma birth cohorts; atopy; longitudinal studies; pediatric asthma; persistent wheezers	RESPIRATORY SYNCYTIAL VIRUS; INTERFERON REGULATORY FACTOR-1; MATERNAL SMOKING; LUNG-FUNCTION; EARLY-LIFE; CHILDHOOD ASTHMA; RISK-FACTORS; 1ST YEAR; ILLNESS; BRONCHIOLITIS	Connections between events occurring in early life with adult asthma suggest that both the altered regulation of airway caliber and tone and the changes in airway structure present in many asthma cases may have their roots in developmental patterns established during infancy and childhood. The Melbourne epidemiologic study, the British 1958 birth cohort, and the Tasmanian asthma survey all provide important information on the outcomes of childhood asthma in later life, Among the findings, these studies showed that in a large proportion of asthmatic children, asthma remits in early adulthood, and the severity of asthma tracks significantly with age, Newer longitudinal studies have measured lung function shortly after birth, before any respiratory symptoms have occurred. Several lines of evidence suggest that those children who will go on to have more severe and persistent asthma symptoms already have immune responses skewed toward the T-helper type 2 (T(H)2) at the time of the very first episodes of airway obstruction in infancy. In most children whose asthma is triggered mainly by respiratory infections, asthma symptoms appear to remit by the adolescent years, Congenital and acquired deficits in lung function, however, may lead to recurrence of these symptoms during adult life and after long periods of remission, especially among active smokers.	Univ Arizona, Resp Sci Ctr, Tucson, AZ USA	University of Arizona	Martinez, FD (corresponding author), POB 245030,1501 N Campbell Ave,Room 2349, Tucson, AZ 85724 USA.				NHLBI NIH HHS [HL66447, HL64307, HL56177] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064307, R01HL056177, R01HL066447] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; Bont L, 2000, AM J RESP CRIT CARE, V161, P1518, DOI 10.1164/ajrccm.161.5.9904078; BURROWS B, 1988, AM REV RESPIR DIS, V138, P829, DOI 10.1164/ajrccm/138.4.829; CAMILLI AE, 1993, PEDIATR PULM, V16, P275, DOI 10.1002/ppul.1950160502; Castro-Rodriguez JA, 1999, AM J RESP CRIT CARE, V159, P1891, DOI 10.1164/ajrccm.159.6.9811035; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403, DOI 10.1164/ajrccm.159.2.9712029; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830, DOI 10.1164/ajrccm.160.6.9812100; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129, DOI 10.1164/ajrccm/145.5.1129; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Koller DY, 1997, J ALLERGY CLIN IMMUN, V99, P752, DOI 10.1016/S0091-6749(97)80007-3; Larsen GL, 1999, J PEDIATR-US, V135, pS21; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Martinez FD, 1998, J ALLERGY CLIN IMMUN, V102, P915, DOI 10.1016/S0091-6749(98)70328-8; MATINEZ FD, 1995, NEW ENGL J MED, V332, P133; *NAT ASTHM ED PREV, 1997, NIH PUBL; OSWALD H, 1994, BRIT MED J, V309, P95, DOI 10.1136/bmj.309.6947.95; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; PANUSKA JR, 1995, J CLIN INVEST, V96, P2445, DOI 10.1172/JCI118302; Pedersen S, 1998, EUR RESPIR J, V12, p1S; PHELAN PD, 1995, CLIN PEDIATR, P307; PULLAN C, 1982, BRIT MED J, V5, P1665; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; SIGURS N, 1995, PEDIATRICS, V95, P500; Silverman M, 1997, THORAX, V52, P936, DOI 10.1136/thx.52.11.936; SIMS DG, 1981, BRIT MED J, V282, P2086, DOI 10.1136/bmj.282.6282.2086; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Strachan DP, 1996, BRIT MED J, V312, P1195; Takeuchi R, 1998, J VIROL, V72, P837, DOI 10.1128/JVI.72.1.837-840.1998; Takeuchi R, 1998, J VIROL, V72, P4498, DOI 10.1128/JVI.72.5.4498-4502.1998; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; Terrazzano G, 2000, TISSUE ANTIGENS, V55, P326, DOI 10.1034/j.1399-0039.2000.550406.x; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243; Young S, 2000, PEDIATR PULM, V29, P331, DOI 10.1002/(SICI)1099-0496(200005)29:5<331::AID-PPUL1>3.0.CO;2-A; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	41	35	35	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5		S			S449	S455		10.1067/mai.2001.114993	http://dx.doi.org/10.1067/mai.2001.114993			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	435RD	11344374				2022-12-18	WOS:000168894200003
J	Schroeder, JT; Lichtenstein, LM; Roche, EM; Xiao, HQ; Liu, MC				Schroeder, JT; Lichtenstein, LM; Roche, EM; Xiao, HQ; Liu, MC			IL-4 production by human basophils found in the lung following segmental allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; cytokine; histamine; IgE; late phase; lung	MESSENGER-RNA; LATE-PHASE; PERIPHERAL-BLOOD; MAST-CELLS; INTERLEUKIN-3 IL-3; ANTIGEN CHALLENGE; HISTAMINE-RELEASE; HUMAN EOSINOPHILS; IGE SYNTHESIS; T-CELLS	Background: Human blood basophils secrete high levels of IL-4 following activation with specific allergen, yet their role as cytokine-producing cells in allergic lesions has not been described. Objective: Our objective was to investigate whether and under what conditions basophils infiltrating allergic lesions in the lung secrete IL-4 in vitro. Methods: Bronchoalveolar lavage (BAL) cells were recovered 20 hours after segmental allergen challenge, Basophils were enriched with Percoll using a protocol commonly used for blood basophils, IL-4 and histamine were measured in culture supernatants following activation with a variety of stimuli. Two-color flow cytometry was performed to detect intracellular IL-4, Results: IL-4 protein was detected in all basophil culture supernatants following a 4- to 5-hour incubation in medium alone; the levels obtained did not significantly increase with the addition of anti-IgE, BAL basophils failed to release histamine in response to specific allergen but showed nearly 60% histamine release with N-formyl-methionyl-leucyl-phenylalanine, suggesting that they were desensitized to IgE-mediated stimuli as a result of their activation in vivo. Using these same conditions, IL-4 was not detected in BAL cell fractions enriched for lymphocytes and eosinophils, Ionomycin induced IL-4 secretion by BAL basophils, and this response was reduced with the addition of phorbol myristate acetate, In contrast, phorbol myristate acetate promoted the secretion of IL-4 by BAL cells enriched for lymphocytes; both findings are identical to those reported for basophils and lymphocytes purified from blood. Flow cytometry confirmed the secretion of IL-4 by BAL basophils, Conclusions: These data suggest that basophils migrating to the lung following allergen challenge represent a major source of IL-4.	Johns Hopkins Asthma & Allergy Ctr, Unit Off 2, Dept Med, Div Clin Immunol, Baltimore, MD 21224 USA; Johns Hopkins Asthma & Allergy Ctr, Dept Med, Div Pulmonol, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Schroeder, JT (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Unit Off 2, Dept Med, Div Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NHLBI NIH HHS [HL62204] Funding Source: Medline; NIAID NIH HHS [AI42221, AI07290] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI042221, R21AI042221, R01AI042221] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BOCHNER BS, 1989, J IMMUNOL METHODS, V125, P265, DOI 10.1016/0022-1759(89)90102-6; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; Corry DB, 1999, NATURE, V402, pB18; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GILBERT HS, 1975, BLOOD, V46, P279; GOLDSTEIN RA, 1985, J ALLERGY CLIN IMMUN, V76, P145; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MACGLASHAN DW, 1981, J IMMUNOL, V127, P2410; Moller GM, 1996, AM J RESP CELL MOL, V14, P439; MOQBEL R, 1995, J IMMUNOL, V155, P4939; Nakajima H, 1996, J IMMUNOL, V156, P4859; OCHENSBERGER B, 1995, BLOOD, V86, P4039, DOI 10.1182/blood.V86.11.4039.bloodjournal86114039; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; Schroeder JT, 1998, ASTHMA AND ALLERGIC DISEASES, P75, DOI 10.1016/B978-012473340-4/50009-6; Schroeder JT, 1998, J LEUKOCYTE BIOL, V63, P692, DOI 10.1002/jlb.63.6.692; Ying S, 1997, J IMMUNOL, V158, P3539	29	35	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					265	271		10.1067/mai.2001.112846	http://dx.doi.org/10.1067/mai.2001.112846			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174192				2022-12-18	WOS:000167071400012
J	Phipatanakul, W; Eggleston, PA; Conover-Walker, MK; Kesavanathan, J; Sweitzer, D; Wood, RA				Phipatanakul, W; Eggleston, PA; Conover-Walker, MK; Kesavanathan, J; Sweitzer, D; Wood, RA			A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						zafirlukast; acoustic rhinometry; cat challenge; cat allergen	INDUCED BRONCHOCONSTRICTION; LEUKOTRIENE-ANTAGONIST; RECEPTOR ANTAGONIST; ALLERGEN; ICI-204,219; SYMPTOMS; ANTIGEN; ASTHMA	Background: Zafirlukast, a leukotriene antagonist, has been shown to have protective effects against a variety of asthma triggers. Objective: Our purpose was to evaluate zafirlukast's effects on upper and lower airway responses to cat allergen exposure with use of a well-characterized cat exposure model. Methods: In a double-blind, placebo-controlled, cross-over trial 18 subjects with cat-induced asthma were randomly assigned to receive 1 week each of zafirlukast or placebo followed by a 1-hour cat challenge. Upper and loner respiratory symptoms mere rated and spirometry and acoustic rhinometry were performed. Challenges were stopped early if the subject was too uncomfortable or had a >50% decrease in FEV1. Results: Overall changes in FEV1 were significantly different with zafirlukast treatment (P =.02). Significant differences in FEV1 change were detected at 15 and 30 minutes (P =.027 and .05, respectively) but not at 45 and 60 minutes. Changes in acoustic rhinometry mere also significantly different at 15 and 30 minutes (P = .05 and .0005, respectively) but not at 45 and 60 minutes. Challenge length was significantly longer with zafirlukast versus placebo after adjustment For differences in allergen exposure (P = .022). Respiratory symptom scores were significantly different (lower respiratory, P < .001; upper respiratory, P = .038) through the first 30 minutes of the challenge after adjustment for allergen exposure. Conclusions: Zafirlukast was significantly more effective than placebo in preserving pulmonary function and nasal anatomy and extending challenge length when cat-sensitive asthmatic subjects were exposed to high levels of cat allergen.	Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Div Environm Hlth Engn, Baltimore, MD 21205 USA; AstraZeneca, Wilmington, DE USA	Johns Hopkins University; Johns Hopkins University; AstraZeneca	Phipatanakul, W (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.				NIAID NIH HHS [AI07007] Funding Source: Medline; NIEHS NIH HHS [R01ES07527] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007527] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Corren J, 1999, J ALLERGY CLIN IMMUN, V103, pS134; DAHLEN B, 1994, EUR RESPIR J, V7, P324, DOI 10.1183/09031936.94.07020324; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; FINDLAY SR, 1992, J ALLERGY CLIN IMMUN, V89, P1040, DOI 10.1016/0091-6749(92)90227-S; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; HILBERG O, 1989, J APPL PHYSIOL, V66, P295, DOI 10.1152/jappl.1989.66.1.295; Kemp JP, 1996, TODAY THER TRENDS, V14, P89; LAZARUS SC, 1995, AM J RESP CRIT CAR S, V151, pA42; Phipatanakul W, 1998, J ALLERGY CLIN IMMUN, V102, P896, DOI 10.1016/S0091-6749(98)70325-2; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x	14	35	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					704	710		10.1067/mai.2000.105123	http://dx.doi.org/10.1067/mai.2000.105123			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756219				2022-12-18	WOS:000086604100007
J	Kimura, M; Tsuruta, S; Yoshida, T				Kimura, M; Tsuruta, S; Yoshida, T			IL-4 production by PBMCs on stimulation with mite allergen is correlated with the level of serum IgE antibody against mite in children with bronchial asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial asthma; house dust mite; Candida albicans; IL-4; IFN-gamma; IL-13; IgE synthesis	INTERFERON-GAMMA PRODUCTION; MESSENGER-RNA EXPRESSION; T-CELL CLONES; DERMATOPHAGOIDES-FARINAE; ATOPIC-DERMATITIS; B-CELLS; CYTOKINE PRODUCTION; PERIPHERAL-BLOOD; IFN-GAMMA; INTERLEUKIN-4	Background: Although IL-4, IL-13, and IFN-gamma are known to affect IgE synthesis, it remains unclear which one plays the most important role in in vivo IgE synthesis in atopic patients. Objective: The aim of this study is to clarify the difference in importance among these cytokines in up-regulation of IgE synthesis in atopic patients. Methods: We measured IL-4, IL-13, and IFN-gamma production by PBMCs on stimulation with house dust mite (HDM) in 23 children, 3 to 15 years old, with bronchial asthma (BA) and analyzed the correlation with HDM-specific IgE antibody levels expressed as HDM IgE radioallergosorbent test (RAST) results. Results: The production of IL-4 and IL-13 by PBMCs on stimulation with HDM was significantly higher in children with BA than in nonatopic control subjects (IL-4, 752.9 +/- 365.9 vs 312.3 +/- 230.0 fg/mL, P < .001; IL-13, 21.9 pg/ml [<12.0-77.6] vs <12.0, P < .01). IL-4 production showed a close positive correlation with HDM IgE RAST (r = 0.71, P < .001), which was distinctly stronger than that between IL-13 production and HDM IgE RAST (r = 0.46, P < .05), IFN-gamma production was neither different between children with BA and nonatopic control subjects (7.24 [1.54-33.90] pg/mL vs 11.2 [1.66-75.9] pg/mL) nor correlated with HDM IgE RAST levels. Essentially the same result was obtained by stimulation of PBMCs with a purified HDM major allergen Der f 1. Conclusion: IL-4 is likely to be the most important cytokine in up-regulation of in vivo IgE synthesis against HDM in children with BA.	Shizuoka Childrens Hosp, Dept Allergy & Clin Immunol, Shizuoka 4208660, Japan		Kimura, M (corresponding author), Shizuoka Childrens Hosp, Dept Allergy & Clin Immunol, Urushiyama 860, Shizuoka 4208660, Japan.							Bellinghausen I, 1999, J ALLERGY CLIN IMMUN, V103, P298, DOI 10.1016/S0091-6749(99)70505-1; COFFMAN RL, 1986, J IMMUNOL, V136, P949; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; HAIDA M, 1985, J ALLERGY CLIN IMMUN, V75, P686, DOI 10.1016/0091-6749(85)90094-6; HIRATANI M, 1981, J ALLERGY CLIN IMMUN, V68, P205, DOI 10.1016/0091-6749(81)90185-8; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; JUNG T, 1995, J ALLERGY CLIN IMMUN, V96, P515, DOI 10.1016/S0091-6749(95)70296-2; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Kimura M, 1998, J ALLERGY CLIN IMMUN, V101, P84, DOI 10.1016/S0091-6749(98)70197-6; Kimura M, 1998, J ALLERGY CLIN IMMUN, V102, P238, DOI 10.1016/S0091-6749(98)70092-2; Koning H, 1997, CYTOKINE, V9, P416, DOI 10.1006/cyto.1996.0184; Levy F, 1997, INT ARCH ALLERGY IMM, V112, P49, DOI 10.1159/000237431; MALEFYT RD, 1995, INT IMMUNOL, V7, P1405, DOI 10.1093/intimm/7.9.1405; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Noguchi E, 1996, INT ARCH ALLERGY IMM, V110, P380, DOI 10.1159/000237331; Park CS, 1996, J ALLERGY CLIN IMMUN, V97, P1121, DOI 10.1016/S0091-6749(96)70267-1; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; ROITT I, 1994, ESSENTIAL IMMUNOLOGY, P312; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; TANG MLK, 1995, PEDIATR ALLERGY IMMU, V6, P11, DOI 10.1111/j.1399-3038.1995.tb00251.x; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137	31	35	37	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				327	332		10.1016/S0091-6749(00)90083-6	http://dx.doi.org/10.1016/S0091-6749(00)90083-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669854				2022-12-18	WOS:000085402200018
J	Smith, SJ; Ying, S; Meng, Q; Sullivan, MHF; Barkans, J; Kon, OM; Sihra, B; Larche, M; Levi-Schaffer, F; Kay, AB				Smith, SJ; Ying, S; Meng, Q; Sullivan, MHF; Barkans, J; Kon, OM; Sihra, B; Larche, M; Levi-Schaffer, F; Kay, AB			Blood eosinophils from atopic donors express messenger RNA for the alpha, beta, and gamma subunits of the high-affinity IgE receptor (Fc epsilon RI) and intracellular, but not cell surface, alpha subunit protein	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; high-affinity IgE receptor (Fc epsilon RI); allergy; atopy	NONATOPIC SUBJECTS; MAST-CELLS; CHAIN; MACROPHAGES; BASOPHILS; ASTHMA	Background: Blood eosinophils from hypereosinophilic donors were previously reported to possess the functional high-affinity IgE receptor (Fc epsilon RI), so providing a potential mechanism to account for eosinophil degranulation in atopic allergic disease. Furthermore, tissue eosinophils from allergic tissue reactions were shown to be mRNA(+) for the alpha, beta, and gamma subunits of Fc epsilon RI and gave positive immunostaining with an anti-Fc epsilon RI-alpha antibody. Recent studies, however, revealed negative surface staining on peripheral blood eosinophils, but intracellular Fc epsilon RT-alpha protein was identified by Western blot analysis. Objective: Our purpose was to examine on peripheral blood eosinophils from atopic subjects (1) surface expression and mRNA for Fc epsilon RI-alpha, (2) up-regulation of Fc epsilon RI-alpha by allergy-associated tissue factors, and (3) Fc epsilon RI-alpha-dependent release of eosinophil peroxidase (EPO). Methods: We measured (1) Fc epsilon RI mRNA expression by in situ hybridization, (2) Fc epsilon RI-alpha by flow cytometry and immunocytochemistry (with use of nonpermeabilized and permeabilized cells), and (3) Fc epsilon RI-alpha-dependent release of EPO. Results: Eosinophils from atopic donors had negligible surface expression of Fc epsilon RI-alpha, which was not enhanced by culture with IgE, IL-3, IL-4, IL-5, GM-CSF, or fibronectin or coculture with fibroblasts. Permeabilization, however, revealed appreciable intracellular staining for Fc epsilon RI-alpha. The majority of eosinophils were mRNA(+) for the alpha, beta, and gamma subunits of Fc epsilon RI. Small but significant (P = .03) increases in a chain mRNA expression were observed after coculture of eosinophils with fibroblasts but not with IgE, IL-4, or fibronectin. Cross-linking of FceRI on the surface of eosinophils from atopic donors did not lead to detectable EPO release. Conclusion: Human blood eosinophils express negligible, non-functional membrane Fc epsilon RI-alpha but have intracellular Fc epsilon RI-alpha protein and mRNA expression for the alpha, beta, and gamma subunits.	Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Allergy & Clin Immunol, London SW3 6LY, England; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, Sch Pharm, IL-91010 Jerusalem, Israel	Imperial College London; Hebrew University of Jerusalem	Kay, AB (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Allergy & Clin Immunol, Dovehouse St, London SW3 6LY, England.		Larche, Mark/B-4326-2010	Larche, Mark/0000-0002-1439-7593; Levi-Schaffer, Francesca/0000-0003-0620-2810; Kon, Onn Min/0000-0003-2647-4688				Barata LT, 1997, EUR J IMMUNOL, V27, P1236, DOI 10.1002/eji.1830270527; BORGHI H, 1994, HISTOCHEM J, V26, P252; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Kita H, 1999, J IMMUNOL, V162, P6901; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; Kon OM, 1998, ALLERGY, V53, P891, DOI 10.1111/j.1398-9995.1998.tb03997.x; Rajakulasingam K, 1998, AM J RESP CRIT CARE, V158, P233, DOI 10.1164/ajrccm.158.1.9708106; Rajakulasingam K, 1997, J ALLERGY CLIN IMMUN, V100, P78, DOI 10.1016/S0091-6749(97)70198-2; Saini SS, 1999, J IMMUNOL, V162, P5624; Seminario MC, 1999, J IMMUNOL, V162, P6893; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; SPIEGEL MR, 1988, SCHAUMS OUTLINE SERI; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; WHITE SR, 1991, J IMMUNOL METHODS, V144, P257, DOI 10.1016/0022-1759(91)90094-V; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Ying S, 1996, EUR J IMMUNOL, V26, P70, DOI 10.1002/eji.1830260111; Ying S, 1998, IMMUNOLOGY, V93, P281, DOI 10.1046/j.1365-2567.1998.00418.x	20	35	36	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				309	317		10.1016/S0091-6749(00)90081-2	http://dx.doi.org/10.1016/S0091-6749(00)90081-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669852				2022-12-18	WOS:000085402200016
J	Vignola, AM; Chanez, P; Bonsignore, G; Godard, P; Bousquet, J				Vignola, AM; Chanez, P; Bonsignore, G; Godard, P; Bousquet, J			Structural consequences of airway inflammation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic inflammation; tissue remodeling; asthma	OBSTRUCTIVE PULMONARY-DISEASE; CHARCOT-LEYDEN CRYSTALS; LONG-TERM TREATMENT; LUNG-FUNCTION; BRONCHIAL-ASTHMA; FATAL ASTHMA; INHALED CORTICOSTEROIDS; SUBEPITHELIAL FIBROSIS; CHILDHOOD ASTHMA; MUCOSAL BIOPSIES	Asthma represents a chronic inflammatory process of the airways followed by healing, the end-result of which is an altered structure referred to as a remodeling of the airways. Repair usually involves 2 distinct processes: regeneration (which is the replacement of injured tissue by parenchymal cells of the same type) and replacement by connective tissue and its eventual maturation into scar tissue. In many instances both processes contribute to the healing response and inflammation. In asthma the processes of cell dedifferentiation, migration, differentiation, and maturation and connective tissue deposition can be followed either by complete or altered restitution of airway structure and function, the latter often seen as fibrosis and increase in smooth muscle and mucus gland mass. These features result in an increased resistance to airflow, particularly when there is bronchial contraction and bronchial hyperresponsiveness. The effect on airflow is compounded by the presence of increased mucous secretion and inflammatory exudate, which not only blocks the airway passages but also causes an increased surface tension that favors airway closure.	CHU Montpellier, Clin Malad Resp, Hosp Arnaud Villenueve, F-34295 Montpellier 5, France; Ist Fisiopatol Resp, Palermo, Italy	Universite de Montpellier; CHU de Montpellier	Bousquet, J (corresponding author), CHU Montpellier, Clin Malad Resp, Hosp Arnaud Villenueve, F-34295 Montpellier 5, France.		Bousquet, Jean/O-4221-2019	chanez, pascal/0000-0003-4059-0917				ACKERMAN SJ, 1982, J EXP MED, V155, P1597, DOI 10.1084/jem.155.6.1597; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Altraja A, 1996, AM J RESP CELL MOL, V15, P482, DOI 10.1165/ajrcmb.15.4.8879182; BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BLACKHALL MI, 1970, ARCH DIS CHILD, V45, P363, DOI 10.1136/adc.45.241.363; BLANC PD, 1993, CHEST, V104, P1371, DOI 10.1378/chest.104.5.1371; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BOUSQUET J, 1987, HIGHLIGHTS ASTHMOLOG, P394; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; CADE JF, 1973, AUST NZ J MED, V3, P545, DOI 10.1111/j.1445-5994.1973.tb04293.x; Cardell BS, 1959, THORAX, V14, P341; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Connolly M J, 1988, Pulm Pharmacol, V1, P53, DOI 10.1016/0952-0600(88)90011-7; COTRAN RS, 1989, ROBBINS PATHOLOGIC B, P39; Curschmann H., 1882, DTSCH ARCH KLIN MED, V32, P1; DAIL D, 1988, PULMONARY PATHOLOGY, P359; DOMPELING E, 1992, EUR RESPIR J, V5, P945; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; FERGUSON AC, 1988, J ALLERGY CLIN IMMUN, V82, P19, DOI 10.1016/0091-6749(88)90045-0; FREEDMAN BJ, 1972, B PHYSIO-PATHOL RESP, V8, P545; GREENOUGH A, 1987, THORAX, V42, P500, DOI 10.1136/thx.42.7.500; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HOLLOWAY L, 1995, ASTHMA RHINITIS, P109; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; KERSTJENS HAM, 1993, EUR RESPIR J, V6, P868; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V97, P153, DOI 10.1016/S0091-6749(96)80215-6; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MESSER JW, 1960, DIS CHEST, V38, P616, DOI 10.1378/chest.38.6.616; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; NEELD DA, 1990, AM REV RESPIR DIS, V142, P1200, DOI 10.1164/ajrccm/142.5.1200; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084, DOI 10.1164/ajrccm/146.4.1084; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918, DOI 10.1164/ajrccm/145.4_Pt_1.918; RAMSDALE EH, 1985, THORAX, V40, P422, DOI 10.1136/thx.40.6.422; REID LM, 1987, J ALLERGY CLIN IMMUN, V80, P415, DOI 10.1016/0091-6749(87)90064-9; ROCHE WR, 1989, LANCET, V1, P520; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169, DOI 10.1164/ajrccm/145.1.169; SAETTA M, 1995, AM J RESP CRIT CARE, V151, P489, DOI 10.1164/ajrccm.151.2.7842211; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; SOBONYA RE, 1984, AM REV RESPIR DIS, V130, P289; STEPHENS NL, 1977, CAN J PHYSIOL PHARM, V55, P833, DOI 10.1139/y77-112; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VANSCHAYCK CP, 1991, AM REV RESPIR DIS, V144, P1297, DOI 10.1164/ajrccm/144.6.1297; Vergnenegre A, 1992, Allergol Immunopathol (Madr), V20, P190; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Vignola AM, 1996, CLIN EXP IMMUNOL, V106, P114, DOI 10.1046/j.1365-2249.1996.d01-811.x; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WANG JH, 1994, J ALLERGY CLIN IMMUN, V94, P1025, DOI 10.1016/0091-6749(94)90121-X; WELLER PF, 1980, P NATL ACAD SCI-BIOL, V77, P7440, DOI 10.1073/pnas.77.12.7440; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849, DOI 10.1152/jappl.1990.69.3.849; YAN K, 1985, AM REV RESPIR DIS, V132, P25	63	35	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S514	S517		10.1016/S0091-6749(00)90053-8	http://dx.doi.org/10.1016/S0091-6749(00)90053-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669534				2022-12-18	WOS:000085439600011
J	Xu, BZ; Jarvelin, MR; Pekkanen, J				Xu, BZ; Jarvelin, MR; Pekkanen, J			Body build and atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; body mass index; body build; birth cohort			Natl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio, Finland; Univ Oulu, Dept Publ Hlth & Gen Practice, Oulu, Finland; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Epidemiol & Publ Hlth, London, England	Finland National Institute for Health & Welfare; University of Oulu; Imperial College London	Xu, BZ (corresponding author), Natl Publ Hlth Inst, Environm Epidemiol Unit, POB 95, Kuopio, Finland.			Jarvelin, Marjo-Riitta/0000-0002-2149-0630				Chen Y, 1999, AM J EPIDEMIOL, V150, P255, DOI 10.1093/oxfordjournals.aje.a009996; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323, DOI 10.1046/j.1365-2222.1999.00455.x; RANTAKALLIO P, 1969, ACTA PAEDIAT SC S193, V0193; Shaheen SO, 1999, THORAX, V54, P396, DOI 10.1136/thx.54.5.396; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368	5	35	36	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				393	394		10.1016/S0091-6749(00)90095-2	http://dx.doi.org/10.1016/S0091-6749(00)90095-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669865				2022-12-18	WOS:000085402200030
J	Martinez, FD				Martinez, FD			Present and future treatment of asthma in infants and young children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	54th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-18, 1998	WASHINGTON, D.C.	Amer Acad Allergy Asthma & Immunol		asthma; pediatric; inhaled corticosteroids; inflammation; lung function; wheeze	BECLOMETHASONE DIPROPIONATE; INHALED BUDESONIDE; CHILDHOOD ASTHMA; WHEEZY INFANTS; LUNG-FUNCTION; RESPONSIVENESS; ATOPY; LIFE; AGE	Asthma is a chronic inflammatory disease of the airways characterized by the local production of inflammatory mediators and an increase in recruitment of inflammatory cells (predominantly eosinophils and mast cells), It has been proposed that the chronic nature of this inflammatory response may be responsible for long-term pulmonary changes including bronchial hyperresponsiveness, airway remodeling, and irreversible airflow obstruction. Much of the information available on the pathogenesis of asthma is based on studies performed in young adults. Because of numerous complications, studies in infants and young children are often difficult to conduct; therefore information on this age group is lacking, Although studies are limited, data suggest that an asthma-like inflammation is present at a very early age, with increases in inflammatory cells and thickening of the lung basement membrane detected in infants and young children, In addition, lung function of children with persistent wheezing was significantly lower by 6 years of age compared with children who had no wheezing episodes during the same period; differences between groups were not apparent at 6 months of age. These data suggest that airway inflammation in young children with asthma is associated with nonreversible impairment of lung function. Recent National Asthma Education and Prevention Guidelines stress the importance of anti-inflammatory agents, particularly inhaled corticosteroids, in the treatment of young children with persistent asthma, Given data supporting the presence of an inflammatory response early in the disease course, early intervention with anti-inflammatory agents may be indicated at the onset of symptoms to prevent long-term, irreversible, impairment of lung function. Although several studies have shown that inhaled corticosteroids may be effective in the treatment of recurrent wheezing in infancy, tools need to be developed to distinguish infants with early-onset asthma from those with transient wheezing.	Univ Arizona, Ctr Sci Res, Dept Pediat, Tucson, AZ 85724 USA	University of Arizona	Martinez, FD (corresponding author), Univ Arizona, Ctr Sci Res, Dept Pediat, Tucson, AZ 85724 USA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Awadh N, 1998, THORAX, V53, P248, DOI 10.1136/thx.53.4.248; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENSON V, 1998, VITAL HLTH STAT, V10, P77; BISGAARD H, 1990, LANCET, V336, P649, DOI 10.1016/0140-6736(90)92147-A; Busse WW, 1998, J ALLERGY CLIN IMMUN, V102, pS17, DOI 10.1016/S0091-6749(98)70002-8; DUFF AL, 1993, PEDIATRICS, V92, P535; Hogg JC, 1997, APMIS, V105, P735, DOI 10.1111/j.1699-0463.1997.tb05079.x; KELLY WJW, 1990, J ALLERGY CLIN IMMUN, V85, P548, DOI 10.1016/0091-6749(90)90092-I; Kraemer R, 1997, RESPIRATION, V64, P342; LORBER DB, 1978, AM REV RESPIR DIS, V118, P855; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1998, EUR RESPIR J, V12, p3S; *NAT ASTHM ED PREV, 1997, NIH NATL HEART LUNG; NOBLE V, 1992, ARCH DIS CHILD, V67, P285, DOI 10.1136/adc.67.3.285; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Pare PD, 1997, CIBA F SYMP, V206, P71; Pohunek P., 1997, European Respiratory Journal Supplement, V10, p160S; Reijonen T, 1996, ARCH PEDIAT ADOL MED, V150, P512, DOI 10.1001/archpedi.1996.02170300066013; Richter H, 1998, J PEDIATR-US, V132, P849, DOI 10.1016/S0022-3476(98)70316-6; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946; Stevenson EC, 1997, CLIN EXP ALLERGY, V27, P1027, DOI 10.1111/j.1365-2222.1997.tb01254.x; STICK SM, 1995, ARCH DIS CHILD, V73, P327, DOI 10.1136/adc.73.4.327; WILSON N, 1995, ARCH DIS CHILD, V72, P317, DOI 10.1136/adc.72.4.317; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	25	35	35	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	2				S169	S174		10.1016/S0091-6749(99)70058-8	http://dx.doi.org/10.1016/S0091-6749(99)70058-8			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	249RH	10518843				2022-12-18	WOS:000083345700003
J	Christodoulopoulos, P; Wright, E; Frenkiel, S; Luster, A; Hamid, Q				Christodoulopoulos, P; Wright, E; Frenkiel, S; Luster, A; Hamid, Q			Monocyte chemotactic proteins in allergen-induced inflammation in the nasal mucosa: Effect of topical corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; chemokines; monocyte chemotactic proteins; eosinophils; topical corticosteroids	CYTOKINE MESSENGER-RNA; INDUCED RHINITIS; TISSUE EOSINOPHILIA; CHEMOATTRACTANT PROTEIN-1; FLUTICASONE PROPIONATE; CC-CHEMOKINES; T-LYMPHOCYTES; EXPRESSION; CELLS; EOTAXIN	Background: Human allergen-induced rhinitis is associated with the recruitment and activation of inflammatory cells, particularly eosinophils and CD4(+) T cells, in the nasal mucosa. Chemokines are inflammatory mediators capable of attracting specific inflammatory cell populations. Monocyte chemotactic proteins (MCPs), a subfamily of CC chemokines, have been shown to induce chemotactic activity particularly in eosinophils, T cells, and monocytes under in vitro assay conditions. Objective: To assess the contribution of MCPs in the recruitment of inflammatory cells in vivo, we investigated the allergen-induced late response in subjects with allergic rhinitis. Methods: Patients were randomized to receive a 6-week treatment with either topical corticosteroid (n = 6) or a matched placebo (n = 6), Nasal inferior turbinate biopsy specimens were obtained from all subjects before and during allergen-induced late responses. By using immunocytochemistry, tissue sections were examined for the presence of MCP-1, MCP-3, and MCP-4 and for the phenotype of infiltrating cells within the nasal mucosa In addition, double sequential immunocytochemistry was used to confirm the phenotype of MCP-immunoreactive positive cells, Furthermore, the effect of topical corticosteroids on the expression of MCPs and on the cellular infiltrate was also examined. Results: MCP-1, MCP-3, and MCP-4 were expressed in all the baseline samples, with prominent staining observed within the nasal epitheliun. Biopsy specimens taken after challenge exhibited significant upregulation in the expression of MCP-3 and MCP-4 (P < .001). On the other hand, this increase in response to allergen was reduced in patients pretreated with topical corticosteroids. Colocalization experiments revealed that the majority of MCP+ cells in the subepithelium were macrophages, followed by T cells and eosinophils. Conclusion: Our results demonstrate that allergen-induced rhinitis is associated with an increased expression of MCP-3 and MCP-1, which may be closely related to the influx of inflammatory cells and may thus contribute to the pathogenesis of allergic rhinitis.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; SMBD Jewish Gen Hosp, Dept Otolaryngol Head & Neck Surg, Montreal, PQ, Canada; McGill Univ, McGill Nasal Res Grp, Montreal, PQ, Canada; Massachusetts Gen Hosp, Div Infect Dis, Charlestown, MA USA	McGill University; McGill University; Harvard University; Massachusetts General Hospital	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912				ANTONY VB, 1993, J IMMUNOL, V151, P7216; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; DURHAM SR, 1992, J IMMUNOL, V148, P2390; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Godiska R, 1997, J LEUKOCYTE BIOL, V61, P353, DOI 10.1002/jlb.61.3.353; Izumi S, 1997, EUR J IMMUNOL, V27, P816, DOI 10.1002/eji.1830270404; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; MOQBEL R, 1995, J IMMUNOL, V155, P4939; NOSO N, 1994, BIOCHEM BIOPH RES CO, V200, P1470, DOI 10.1006/bbrc.1994.1616; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Rajakulasingam K, 1997, AM J RESP CRIT CARE, V155, P696, DOI 10.1164/ajrccm.155.2.9032215; RAK S, 1994, CLIN EXP ALLERGY, V24, P930, DOI 10.1111/j.1365-2222.1994.tb02724.x; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; VANDAMME J, 1994, J IMMUNOL, V152, P5495; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; Wright ED, 1998, J OTOLARYNGOL, V27, P281; YING S, 1994, IMMUNOLOGY, V82, P200; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252	28	35	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1036	1044		10.1016/S0091-6749(99)70176-4	http://dx.doi.org/10.1016/S0091-6749(99)70176-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359883				2022-12-18	WOS:000080929500010
J	Cockcroft, DW; Davis, BE; Swystun, VA; Marciniuk, DD				Cockcroft, DW; Davis, BE; Swystun, VA; Marciniuk, DD			Tolerance to the bronchoprotective effect of beta(2)-agonists: Comparison of the enantiomers of salbutamol with racemic salbutamol and placebo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchoprotection; salbutamol enantiomers; tolerance; bronchodilation	EXERCISE-INDUCED BRONCHOCONSTRICTION; AIRWAY RESPONSIVENESS; INHALED ALBUTEROL; SALMETEROL; ALLERGEN; METHACHOLINE; ASTHMA; HYPERRESPONSIVENESS; AGONIST	Background: Regular use of racemic salbutamol results in the partial loss of its bronchoprotective effect. The 2 enantiomers of salbutamol, the bronchodilator R-salbutamol and nonbronchodilator S-salbutamol, are now available. Objective: We sought to compare the effect of regular use of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the bronchoprotective effect of a single dose of racemic salbutamol against methacholine-induced bronchoconstriction. Methods: Eleven of 13 well-controlled beta(2)-agonist-free asthmatic subjects completed a double-blind, randomized study comparing racemic salbutamol 2.5 mg, S-salbutamoI 1.25 mg, R-salbutamol 1.25 mg, and dilueut placebo nebulized and inhaled 3 times daily for 6 days (greater than or equal to 6-day washout period). Ten to 12 hours after the last dose, the subjects performed measurement of FEV1, methacholine PC20, and a repeat methacholine PC20 done 1 hour after the first methacholine test and 10 minutes after 2 puffs (200 mu g) of racemic salbutamol administered from a metered-dose inhaler. The primary endpoint was the methacholine PC20 dose shift (Delta log PC20 divided by log 2) from before to after administration of 200 mu g of racemic salbutamol. Results: The methacholine dose shift was 3.2 doubling doses (9-fold increase in methacholine PC20 after 200 mu g of racemic salbutamol) during the placebo treatment and was unaltered (3.2) after administration of S-salbutamoI. The dose shift was significantly lower after both the R-salbutamol and racemic salbutamol treatments (2.2 and 2.6 doubling doses, respectively); there was no significant difference between R-salbutamol and racemic salbutamol. There was no treatment effect on baseline FEV1, baseline methacholine PC20, or bronchodilation. Conclusion: Regular treatment with racemic salbutamol or R-salbutamol, but not S-salbutamol, results in a partial loss of bronchoprotection, without loss of bronchodilation, compared with placebo.	Univ Saskatchewan, Royal Univ Hosp, Dept Med, Div Resp Med, Saskatoon, SK S7N 0W8, Canada	University of Saskatchewan	Cockcroft, DW (corresponding author), Univ Saskatchewan, Royal Univ Hosp, Dept Med, Div Resp Med, 103 Hosp Dr,Ellis Hall, Saskatoon, SK S7N 0W8, Canada.							BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COCKCROFT DW, 1995, AM J RESP CRIT CARE, V152, P1485, DOI 10.1164/ajrccm.152.5.7582281; COCKCROFT DW, 1995, J ALLERGY CLIN IMMUN, V96, P44, DOI 10.1016/S0091-6749(95)70031-5; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; Cockcroft DW, 1996, THORAX, V51, P1051, DOI 10.1136/thx.51.10.1051; Cockcroft DW, 1997, THORAX, V52, P845, DOI 10.1136/thx.52.10.845; Cockcroft DW, 1996, CHEST, V110, P579, DOI 10.1378/chest.110.2.579-a; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Giannini D, 1996, CHEST, V110, P1452, DOI 10.1378/chest.110.6.1452; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; Jokic R, 1998, CHEST, V114, P1796, DOI 10.1378/chest.114.6.1796-a; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; Lipworth BJ, 1997, THORAX, V52, P849, DOI 10.1136/thx.52.10.849; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; SANJAR S, 1988, LANCET, V2, P160; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655	21	35	35	1	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1049	1053		10.1016/S0091-6749(99)70178-8	http://dx.doi.org/10.1016/S0091-6749(99)70178-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359885				2022-12-18	WOS:000080929500012
J	deShazo, RD; O'Brien, MM; Justice, WK; Pitcock, J				deShazo, RD; O'Brien, MM; Justice, WK; Pitcock, J			Diagnostic criteria for sarcoidosis of the sinuses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sinusitis; sarcoidosis	FUNGAL SINUSITIS	Background: Although newer technologies facilitate its diagnosis and treatment, little is known about sarcoidosis of the paranasal sinuses. Objectives: We sought to better characterize sarcoidosis of the sinuses and establish criteria for diagnosis. Methods: Case-finding criteria were established, and over 50 reports of sarcoidosis of the sinuses in the medical literature were reviewed. Nine case reports of patients fulfilling the case-finding criteria were identified, as were 6 additional patients from our clinics. Results: Nasal obstruction and chronic sinusitis were the usual initial complaints from patients and were associated with mucosal crusting, studding, plaque-like changes, or polyps in the nose in 5 of 6 of our patients, The most consistent finding in nose and sinuses was an ergthematous, edematous, friable, hypertrophied mucosa, Like 5 of 6 of our patients, most patients had extra-pulmonary sarcoidosis involving multiple organs, but some had isolated upper respiratory disease. Radiologic studies shelved extensive and often complete opacification of the sinuses and nose similar to that seen in diffuse polyposis associated with chronic bacterial and fungal sinusitis. No specific histopathologic findings distinguished sinus disease from those reported with pulmonary involvement. Pharyngeal involvement was present in 2 case reports and caused the apparent asphyxiation of 1 of our patients. Conclusion: Sarcoidosis of the sinuses should be considered in the differential diagnosis of sinusitis, especially in association with nasal polyposis, even when the sarcoidosis has not been otherwise diagnosed. On the basis of this experience, we propose diagnostic criteria for sarcoidosis of the sinuses. These include (1) radiologic evidence of sinusitis, (2) histopathologic confirmation of noncaseating granuloma in the sinus tissue supported by negative stains for fungus and acid-fast bacilli, (3) negative serologic test results for syphilis and antineutrophil cytoplasmic antibodies, and (4) no clinical evidence of other disease processes associated with granulomatous nasal and sinus inflammation. These criteria will provide the basis for further studies to assess both the natural history and the effectiveness of treatment in sarcoidosis of the sinuses.	Univ Mississippi, Med Ctr, Dept Med, Div Clin Immunol & Allergy, Jackson, MS 39216 USA; Univ S Alabama, Dept Pathol, Mobile, AL 36688 USA; Premier Otolaryngol Grp, Mobile, AL USA	University of Mississippi; University of Mississippi Medical Center; University of South Alabama	deShazo, RD (corresponding author), Univ Mississippi, Med Ctr, Dept Med, Div Clin Immunol & Allergy, 2500 N State St, Jackson, MS 39216 USA.							Bordley JE, 1942, ARCHIV OTOLARYNGOL, V36, P740; Brinker H., 1994, SARCOIDOSIS OTHER GR, P69; BRONSON LJ, 1976, ARCH OPHTHALMOL-CHIC, V94, P243; COUP AJ, 1980, HISTOPATHOLOGY, V4, P293, DOI 10.1111/j.1365-2559.1980.tb02923.x; deShazo RD, 1997, ARCH OTOLARYNGOL, V123, P1181, DOI 10.1001/archotol.1997.01900110031005; DeShazo RD, 1997, NEW ENGL J MED, V337, P254, DOI 10.1056/NEJM199707243370407; JAMES DG, 1982, J LARYNGOL OTOL, V96, P711, DOI 10.1017/S0022215100093026; James DG, 1994, SARCOIDOSIS OTHER GR, P417; KATZENSTEIN AA, 1997, KATZENSTEIN ASKINS S, P178; KRESPI YP, 1995, OTOLARYNG HEAD NECK, V112, P221, DOI 10.1016/S0194-5998(95)70240-7; LINDSAY JR, 1951, ANN OTO RHINOL LARYN, V60, P549, DOI 10.1177/000348945106000224; Livas I, 1996, ANN ALLERG ASTHMA IM, V76, P405, DOI 10.1016/S1081-1206(10)63454-0; LIVINGSTONE G, 1956, J Laryngol Otol, V70, P426, DOI 10.1017/S0022215100053135; Lynch Joseph P. Iii, 1997, Comprehensive Therapy, V23, P197; MAILLARD AAJ, 1978, ARCH OTOLARYNGOL, V104, P197; NEVILLE E, 1976, THORAX, V31, P660, DOI 10.1136/thx.31.6.660; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; Novy F G, 1936, Cal West Med, V45, P41; Page J R, 1969, J Laryngol Otol, V83, P1005, DOI 10.1017/S0022215100071255; ROBINSON B, 1950, Med J Aust, V2, P568; Sheffield EA, 1997, CLIN CHEST MED, V18, P741, DOI 10.1016/S0272-5231(05)70416-0; STAMMBERGER H, 1984, ANN OTO RHINOL LARYN, V93, P251, DOI 10.1177/000348948409300313; TAY HL, 1994, J LARYNGOL OTOL, V108, P682, DOI 10.1017/S0022215100127823; WEISS JACK ALLAN, 1960, LARYNGOSCOPE, V70, P1351	24	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				789	795		10.1016/S0091-6749(99)70421-5	http://dx.doi.org/10.1016/S0091-6749(99)70421-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329811	Bronze			2022-12-18	WOS:000080470200012
J	Sorkness, CA				Sorkness, CA			Establishing a therapeutic index for the inhaled corticosteroids: Part II - Comparisons of systemic activity and safety among different inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inhaled glucocorticoids; safety; growth; clinical cataracts; bone effects; pituitary-adrenal function tests	GLUCOCORTICOID-INDUCED OSTEOPOROSIS; BONE-MINERAL DENSITY; ASTHMATIC-CHILDREN; CHILDHOOD ASTHMA; LONG-TERM; BECLOMETHASONE DIPROPIONATE; FLUTICASONE PROPIONATE; LINEAR GROWTH; MILD ASTHMA; BUDESONIDE	The systemic activity and safety of inhaled corticosteroids are best studied in randomized, controlled, long-term trials with clinically relevant doses in subjects. These studies require large numbers of enrolled subjects and are difficult to conduct, Potential confounders to safety analyses must be controlled. The occurrence and magnitude of adrenal suppression has been the most extensively evaluated systemic effect of inhaled corticosteroids. The significance of these findings in relation to relevant clinical outcomes must be evaluated. At low to medium inhaled corticosteroid dosages, the hypothalamic-pituitary-adrenal axis is minimally and only partially suppressed. Statistically significant changes occur at high inhaled corticosteroid dosages; the magnitude of this effect is less than with prednisone, greater than or equal to 10 mg/day, Standards for the design of growth studies in children with asthma have been recommended and recently implemented. Four randomized, controlled, clinical trials have reported reductions in growth rates of greater than or equal to 1 cm/yr with beclomethasone less than or equal to 400 mu g/day. By comparison, 2 randomized controlled clinical trials with fluticasone, 50 to 100 mu g twice daily via dry powder inhaler, could not detect differences in height velocity in prepubertal children treated with cromolyn sodium or placebo. Trials with low to medium doses of beclomethasone, fluticasone, and budesonide document little to no effect on bone mineral density and bone metabolism. Population-based and limited randomized controlled trials suggest that low to medium doses of inhaled corticosteroids do not cause cataracts or glaucoma. Patients requiring high-dose inhaled corticosteroids should be monitored for adverse effects, with appropriate lifestyle changes and pharmacologic strategies implemented.	Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Sorkness, CA (corresponding author), Univ Wisconsin Hosp, 600 Highland Ave,H6-367, Madison, WI 53792 USA.							ABUEKTEISH F, 1995, THORAX, V50, P674, DOI 10.1136/thx.50.6.674; ADAMSONS I, 1991, ARCH OPHTHALMOL-CHIC, V109, P993, DOI 10.1001/archopht.1991.01080070105046; Agertoft L, 1997, EUR RESPIR J, V10, P1507, DOI 10.1183/09031936.97.10071507; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Agertoft L, 1998, AM J RESP CRIT CARE, V157, P178, DOI 10.1164/ajrccm.157.1.9707072; Agertoft Lone, 1996, European Respiratory Journal Supplement, V9, p294S; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; Allen DB, 1998, J PEDIATR-US, V132, P472, DOI 10.1016/S0022-3476(98)70023-X; ALLEN DB, 1997, ACTA PAEDIATR, V86, P1; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Bootsma GP, 1996, AM J RESP CRIT CARE, V153, P924, DOI 10.1164/ajrccm.153.3.8630574; BROWN DCP, 1989, ANN ALLERGY, V63, P47; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; DEMPSTER DW, 1989, J BONE MINER RES, V4, P137; Dluhy RG, 1998, J ALLERGY CLIN IMMUN, V101, pS447, DOI 10.1016/S0091-6749(98)70157-5; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; FORD LB, 1997, AM J RESP CRIT CARE, V155, pA354; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; *GLOB IN ASTHM, 1995, NIH NAT HEART LUNG B; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HOSKING DJ, 1993, RESP MED, V87, P15, DOI 10.1016/S0954-6111(05)80252-5; HUGHES J, 1996, THORAX S3, V51, pA72; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; KARLBERG J, 1994, ACTA PAEDIATR, V83, P777, DOI 10.1111/j.1651-2227.1994.tb13138.x; KARLBERG J, 1993, ACTA PAEDIATR, V82, P631, DOI 10.1111/j.1651-2227.1993.tb18029.x; Kelly HW, 1998, ANN PHARMACOTHER, V32, P220, DOI 10.1345/aph.17014; Lemanske RF, 1997, AM J RESP CRIT CARE, V156, P685, DOI 10.1164/ajrccm.156.3.ed-13; Luengo M, 1997, EUR RESPIR J, V10, P2110, DOI 10.1183/09031936.97.10092110; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MACADAMS MR, 1986, ANN INTERN MED, V104, P648, DOI 10.7326/0003-4819-104-5-648; MACKENZIE CA, 1993, EUR RESPIR REV, V3, P321; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; Martinati LC, 1996, AM J RESP CRIT CARE, V153, P232, DOI 10.1164/ajrccm.153.1.8542121; MEDICI TG, 1998, AM J RESP CRIT CARE, V157, pA407; MERKUS PJFM, 1993, PEDIATRICS, V91, P1121; *NAT ASTHM ED PREV, 1997, NIH NAT HEART LUNG B; NINAN TK, 1992, ARCH DIS CHILD, V67, P703, DOI 10.1136/adc.67.6.703; OPATOWSKY I, 1995, OPHTHALMOLOGY, V102, P177; OSUR S, 1998, AM J RESP CRITICA S3, V157, pA405; Pauwels RA, 1998, AM J RESP CRIT CARE, V157, P827, DOI 10.1164/ajrccm.157.3.9610009; Picado C, 1996, DRUG SAFETY, V15, P347, DOI 10.2165/00002018-199615050-00005; PREECE MA, 1993, EUR RESPIR REV, V3, P317; Price JF, 1997, PEDIATR PULM, V24, P178; Price JF, 1997, PEDIATR PULM, P40; PRICE JF, 1993, EUR RESPIR REV, V3, P338; PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem-72-2-382; REID DM, 1993, RESP MED, V87, P9, DOI 10.1016/S0954-6111(05)80251-3; SHOHAT M, 1987, ARCH DIS CHILD, V62, P63, DOI 10.1136/adc.62.1.63; Silverstein MD, 1997, J ALLERGY CLIN IMMUN, V99, P466, DOI 10.1016/S0091-6749(97)70072-1; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SIMONS FER, 1993, LANCET, V342, P776, DOI 10.1016/0140-6736(93)91541-S; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; TATTERSFIELD AE, 1998, AM J RESP CRIT CARE, V157, pA408; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; Toogood J H, 1994, Int J Risk Saf Med, V5, P1, DOI 10.3233/JRS-1994-5102; VARSANO I, 1990, J ALLERGY CLIN IMMUN, V85, P914, DOI 10.1016/0091-6749(90)90077-H; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305; WALES JKH, 1987, ARCH DIS CHILD, V62, P166, DOI 10.1136/adc.62.2.166; Wisniewski AF, 1997, THORAX, V52, P853, DOI 10.1136/thx.52.10.853; Wolthers OD, 1996, EUR RESPIR J, V9, P821, DOI 10.1183/09031936.96.09040821; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163; WOLTHERS OD, 1990, BRIT MED J, V301, P145, DOI 10.1136/bmj.301.6744.145; WONG J, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415-a; Woodcock A, 1998, J ALLERGY CLIN IMMUN, V101, pS456, DOI 10.1016/S0091-6749(98)70159-9	67	35	37	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	2				S52	S64		10.1016/S0091-6749(98)70005-3	http://dx.doi.org/10.1016/S0091-6749(98)70005-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	133CT	9798723				2022-12-18	WOS:000076669400007
J	Goldberg, A; Confino-Cohen, R; Waisel, Y				Goldberg, A; Confino-Cohen, R; Waisel, Y			Allergic responses to pollen of ornamental plants: High incidence in the general atopic population and especially among flower growers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ornamental plants; pollen; flowers; flower growers; atopy	OCCUPATIONAL ALLERGY; SUNFLOWER POLLEN; FICUS-BENJAMINA; REACTIVITY	Background: The incidence of allergy to pollen of ornamental plants has not been deeply investigated, and its extent has remained obscure. Most of such studies have concentrated only on pollen of ornamental plants from the Asteraceae family (Compositae). In this study an attempt was made to clarify whether various other ornamental plants may also cause skin responses and allergic symptoms among allergic urban dwellers and among rural flower growers. Methods: Two hundred ninety-two patients mere referred for allergic evaluation by their primary physicians; 75 flower growers and 44 university students were evaluated. For all participants, a detailed health record was obtained, and skin prick tests (SPTs) were performed. Extracts for SPTs included commercial common airborne allergens and autochthonous pollen extracts of 11 species of plants belonging to the Asteraceae, Ranunculaceae, Liliaceae, Scrophulariaceae, and Genetianaceae families. Results: Fifty-one of the 292 patients (17%) referred for allergic evaluation had positive SPT responses to pollen of various ornamental plants. A similar incidence was found among the students (23%). However, the incidence among flower growers was significantly higher, reaching 52%. Higher incidence (83%) of positive SPT responses to ornamental plants was found among flower growers also sensitive to the common allergens. All the tested plants, not only those belonging to the Asteraceae family, provoked positive SPT responses in all 3 groups of participants. None of the participants from the general population or the group of students reported exacerbation of allergic symptoms on exposure to the tested plants. In contrast, almost half of the flower growers (45%) described nasal, ocular, or respiratory symptoms associated with occupational exposure to the tested plants. Some 15% of the growers were eventually compelled to change their profession. Conclusions: The incidence of positive SPT responses to ornamental plants was 17% to 23% among the general public but 52% among flower growers, Thus the effects of ornamental plant pollen on atopic patients should be seriously contemplated.	Meir Gen Hosp, Sapir Med Ctr, Allergy & Clin Immunol Unit, IL-44281 Kfar Saba, Israel; Tel Aviv Univ, Dept Plant Sci, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University	Goldberg, A (corresponding author), Meir Gen Hosp, Sapir Med Ctr, Allergy & Clin Immunol Unit, IL-44281 Kfar Saba, Israel.							AXELSSON IGK, 1991, ALLERGY, V46, P92, DOI 10.1111/j.1398-9995.1991.tb00550.x; BIRCHER AJ, 1995, CLIN EXP ALLERGY, V25, P228, DOI 10.1111/j.1365-2222.1995.tb01033.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V75, P70, DOI 10.1016/0091-6749(85)90015-6; HAUSEN BM, 1991, CONTACT DERMATITIS, V24, P274, DOI 10.1111/j.1600-0536.1991.tb01722.x; JIMENEZ A, 1994, INT ARCH ALLERGY IMM, V105, P297, DOI 10.1159/000236772; Kumar S, 1993, Indian J Med Sci, V47, P280; OLIVER F, 1991, CLIN EXP DERMATOL, V16, P1, DOI 10.1111/j.1365-2230.1991.tb00282.x; PIIRILA P, 1994, INT ARCH OCC ENV HEA, V66, P131, DOI 10.1007/BF00383369; SRIRAMARAO P, 1993, INT ARCH ALLERGY IMM, V100, P79, DOI 10.1159/000236391; SUZUKI S, 1975, INT ARCH ALLER A IMM, V48, P800, DOI 10.1159/000231368; UEDA A, 1992, J ALLERGY CLIN IMMUN, V90, P742, DOI 10.1016/0091-6749(92)90097-L; WAHL R, 1983, ANAL BIOCHEM, V134, P189, DOI 10.1016/0003-2697(83)90282-8; Waisel Y, 1996, ALLERGY, V51, P819, DOI 10.1111/j.1398-9995.1996.tb00028.x	13	35	38	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					210	214		10.1016/S0091-6749(98)70088-0	http://dx.doi.org/10.1016/S0091-6749(98)70088-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723663	Bronze			2022-12-18	WOS:000075537100010
J	Kimura, M; Tsuruta, S; Yoshida, T				Kimura, M; Tsuruta, S; Yoshida, T			Unique profile of IL-4 and IFN-gamma production by peripheral blood mononuclear cells in infants with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; infants; IL-4; IFN-gamma; lymphocyte proliferation; house dust mite; egg white; IgE	INTERFERON-GAMMA; DERMATOPHAGOIDES-FARINAE; ALLERGIC DISEASES; IGE PRODUCTION; T-CELLS; INTERLEUKIN-4; LYMPHOCYTES; RESPONSES; SUBSETS; HELPER	Although the level of house dust mite (HDM)-specific lymphocyte proliferation is high in infants with atopic dermatitis (AD), the level of HDM-specific IgE antibody (HDM-IgE-RAST) is usually very low or negative. To elucidate the cause of the deficient HDM-specific IgE antibody formation in infants with AD, we examined the profile of IL-4 and IFN-gamma production by HDM-stimulated PBMCs. The amount of IL-4 production was higher in infants with AD and in children with AD (3 to 15 years) than in the nonatopic control subjects. Although the amount of INF-gamma production in children with AD was lower than that found in nonatopic children, it was higher in infants with AD than in nonatopic infants. This result suggests that HDM-specific helper T lymphocytes in infants with AD have not get differentiated into T-H2 but rather stayed at the stage of T-H0. The level of IgE-RAST for egg white (EW) is already elevated in infants with AD. The amount of IL-4 produced by EW-stimulated PBMCs was comparable to that produced by HDM-stimulated PBMCs in infants with AD. However, the amount of IFN-gamma produced by EW-stimulated PBMCs was distinctly lower than that produced by HDM-stimulated PBMCs in infants with AD. Although there was no correlation between the amount of IL-4 production by HDM-stimulated PBMCs and the level of HDM-IgE-RAST in infants with AD, the amount of IL-4 production by EW-stimulated PBMCs was closely correlated with the level of EW-IgE-RAST. These results suggest that it is not the lack of IL-4 but rather a relative increase in IFN-gamma production by HDM-specific helper T lymphocytes that causes the deficiency of HDM-specific IgE-antibody synthesis in infants with AD.	Shizuoka Childrens Hosp, Dept Allergy & Clin Immunol, Shizuoka 4208660, Japan		Kimura, M (corresponding author), Shizuoka Childrens Hosp, Dept Allergy & Clin Immunol, Urushiyama 860, Shizuoka 4208660, Japan.							COFFMAN RL, 1986, J IMMUNOL, V136, P949; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; HAIDA M, 1985, J ALLERGY CLIN IMMUN, V75, P686, DOI 10.1016/0091-6749(85)90094-6; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; HIRATANI M, 1981, J ALLERGY CLIN IMMUN, V68, P205, DOI 10.1016/0091-6749(81)90185-8; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; KAGI MK, 1994, INT ARCH ALLERGY IMM, V103, P332, DOI 10.1159/000236651; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Kimura M, 1998, J ALLERGY CLIN IMMUN, V101, P84, DOI 10.1016/S0091-6749(98)70197-6; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; MITCHELL EB, 1982, LANCET, V1, P127; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SLY RM, 1996, NELSON TXB PEDIAT, P641; TANG MLK, 1995, PEDIATR ALLERGY IMMU, V6, P11, DOI 10.1111/j.1399-3038.1995.tb00251.x; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137	26	35	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					238	244		10.1016/S0091-6749(98)70092-2	http://dx.doi.org/10.1016/S0091-6749(98)70092-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723667	Bronze			2022-12-18	WOS:000075537100015
J	Dluhy, RG				Dluhy, RG			Clinical relevance of inhaled corticosteroids and HPA axis suppression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inhaled corticosteroids; hypothalamic-pituitary-adrenal axis suppression; adrenal function tests	ASTHMA; THERAPY	Although hypothalamic-pituitary-adrenal (HPA) asis suppression has traditionally been viewed as an adverse event after long-term administration of corticosteroids, this effect can also be used to compare the potency of different inhaled corticosteroids. However, various factors such as the dose, frequency of administration, treatment duration, study population (patients with asthma versus normal volunteers), and prior systemic steroid therapy influence adrenal suppression with inhaled corticosteroids. The different adrenal function tests available and the results produced with these tests also must be considered along with the clinical relevance of such results. Whereas low doses of inhaled corticosteroids are likely to cause minimal or no HPA asis suppression, longterm high-dose inhaled corticosteroid use may result in significant suppression by effectively replacing endogenous steroid production. The risk of acute adrenal insufficiency in patients taking low/medium-dose inhaled corticosteroids is minimal, but patients receiving long-term high-dose treatment may require supplementary systemic steroids during stress challenges, especially if they have previously received long-term systemic steroid treatment.	Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Dluhy, RG (corresponding author), Brigham & Womens Hosp, 221 Longwood Ave, Boston, MA 02115 USA.							BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BROWN PH, 1991, RESP MED, V85, P501, DOI 10.1016/S0954-6111(06)80268-4; BROWN PH, 1992, RESP MED, V86, P495, DOI 10.1016/S0954-6111(96)80009-6; GRAHNEN A, 1994, BRIT J CLIN PHARMACO, V38, P521, DOI 10.1111/j.1365-2125.1994.tb04393.x; KEHLET H, 1973, BRIT J ANAESTH, V45, P1043, DOI 10.1093/bja/45.10.1043; PADFIELD PL, 1993, EUR RESPIR REV, V3, P494; TOOGOOD JH, 1984, EUR J RESPIR DIS, V65, P321; TORDJMAN K, 1995, J CLIN ENDOCR METAB, V80, P1301, DOI 10.1210/jc.80.4.1301; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1731	9	35	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	2	S			S447	S450		10.1016/S0091-6749(98)70157-5	http://dx.doi.org/10.1016/S0091-6749(98)70157-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZK101	9563370	Bronze			2022-12-18	WOS:000073285000004
J	Sporik, R; Hill, DJ; Thompson, PJ; Stewart, GA; Carlin, JB; Nolan, TM; Kemp, AS; Hosking, CS				Sporik, R; Hill, DJ; Thompson, PJ; Stewart, GA; Carlin, JB; Nolan, TM; Kemp, AS; Hosking, CS			The Melbourne House Dust Mite Study: Long-term efficacy of house dust mite reduction strategies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mite; allergen; Der p 1; asthma treatment; humidity; long-term study	ALLERGEN AVOIDANCE; P-I; BRONCHIAL HYPERREACTIVITY; CONTROLLED TRIAL; EXPOSURE; ASTHMA; CHILDREN; CHILDHOOD; ANTIGEN; RISK	Background: Asthma severity among mite-sensitized individuals appears to be related to the degree of mite allergen exposure. Objectives: The objective of this study was to assess the longterm effectiveness of mite avoidance measures in the homes of asthmatic children in Melbourne, Australia. Methods: The concentration of house dust mite allergen (Der p 1) was measured on the child's mattress surfaces and bedroom floors in 85 homes on 10 occasions over a 16-month period. After the first three visits, all mattresses were covered with a semipermeable encasement, and carpeted bedroom floors were randomly allocated to regular applications of a placebo or an "anti-mite" shampoo. Results: The concentration of Der p 1 recovered was initially high in the carpeted bedrooms (n = 66) (41.1, 95% confidence interval, 30.7 to 55.0 mu g Der p 1 per gm) and mattresses (n = 85) (39.6, 27.2 to 57.7). During the initial observation period the concentration of mite allergen fell in the treatment, placebo, and parental control groups. During the seven treatment periods, no differences were seen between the Der p 1 concentrations in the groups using the "anti-mite" shampoo, placebo shampoo, or the parental control group (e.g., at visit 4; 12.6, 8.2 to 19.5; 14.8, 8.6 to 25.1; and 12.0, 8.1 to 17.7 mu g/gm, respectively). In contrast, the concentration of Der p 1 in samples from uncarpeted floors and mattress encasements was low (4.1, 2.1 to 8.0 mu g/gm and 4.2, 2.6 to 6.5 mu g/gm, respectively) and insufficient dust for analysis was frequently obtained from these sites. Conclusions: There was no additional benefit from the use of an "anti-mite" shampoo. The absence of carpets and the use of mattress encasements was a useful long-term strategy for mite allergen avoidance.	Royal Childrens Hosp, Dept Allergy, Melbourne, Vic 3051, Australia; QEII Med Ctr, Univ Dept Med, Nedlands, WA, Australia; Univ W Australia, Dept Microbiol, Nedlands, WA, Australia; Royal Childrens Hosp, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia; Royal Childrens Hosp, Dept Clin Immunol, Melbourne, Vic, Australia; John Hunters Childrens Hosp, Newcastle, NSW, Australia	Royal Children's Hospital Melbourne; University of Western Australia; University of Western Australia; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne	Hill, DJ (corresponding author), Royal Childrens Hosp, Dept Allergy, 151 Flemington Rd, Melbourne, Vic 3051, Australia.		Carlin, John/AAG-4332-2020; Carlin, John B/B-3492-2012; Nolan, Terry/A-2236-2008	Carlin, John/0000-0002-2694-9463; Carlin, John B/0000-0002-2694-9463; Nolan, Terry/0000-0001-6018-3863				ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; COLLOFF MJ, 1994, CLIN EXP ALLERGY, V24, P94, DOI 10.1111/j.1365-2222.1994.tb00202.x; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; CUSTOVIC A, 1995, CLIN EXP ALLERGY, V25, P312, DOI 10.1111/j.1365-2222.1995.tb01048.x; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; HARVING H, 1994, ALLERGY, V49, P866, DOI 10.1111/j.1398-9995.1994.tb00789.x; Hill DJ, 1997, J ALLERGY CLIN IMMUN, V99, P323, DOI 10.1016/S0091-6749(97)70049-6; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MAELZER D, 1993, MITES ASTHMA DOMESTI, P9; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; *NAEPP NHLBI, 1997, PUBL NAEPP NHLBI; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1995, J ALLERGY CLIN IMMUN, V96, P435, DOI 10.1016/S0091-6749(95)70284-9; PLATTSMILLS TAE, 1982, LANCET, V2, P675; SPIEKSMA FT, 1971, BMJ-BRIT MED J, V1, P82, DOI 10.1136/bmj.1.5740.82; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; TOVEY E, 1993, LANCET, V342, P126, DOI 10.1016/0140-6736(93)91334-I; Tovey ER, 1997, J ALLERGY CLIN IMMUN, V100, P464, DOI 10.1016/S0091-6749(97)70136-2; TOVEY ER, 1992, CLIN EXP ALLERGY, V22, P67, DOI 10.1111/j.1365-2222.1992.tb00116.x; VALLETTA EA, 1995, ALLERGY, V50, P366, DOI 10.1111/j.1398-9995.1995.tb01162.x	25	35	38	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				451	456		10.1016/S0091-6749(98)70352-5	http://dx.doi.org/10.1016/S0091-6749(98)70352-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564796	Bronze			2022-12-18	WOS:000073113500004
J	Vallverdu, A; Asturias, JA; Arilla, MC; Gomez-Bayon, N; Martinez, A; Martinez, J; Palacios, R				Vallverdu, A; Asturias, JA; Arilla, MC; Gomez-Bayon, N; Martinez, A; Martinez, J; Palacios, R			Characterization of recombinant Mercurialis annua major allergen Mer a 1 (profilin)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cDNA cloning; euphorbiacea; Ricinus communis; cross-reactivity; latex; olive tree pollen; sequencing; polymerase; chain reaction; recombinant allergen; expression	HIGH-LEVEL EXPRESSION; IGE-BINDING CAPACITY; ESCHERICHIA-COLI; BIRCH PROFILIN; CDNA CLONING; POLLEN; IDENTIFICATION; SENSITIZATION; PURIFICATION; POLYMERASE	Background: Two major allergens (Mer a 1A and Mer a 1B), tentatively identified as profilin, have been described in the euphorbiacea, Mercurialis annua. Objectives: We sought to clone and characterize these major allergens from M. annua pollen and to obtain the immunologically active and soluble recombinant allergen, which could then be used for diagnostic procedures and therapy. Methods: Isolation of cDNA clones was performed by polymerase chain reaction amplification with degenerate primers. Expression in Escherichia coli BL21 (DE3) was carried out with a vector based in the T7 expression system, and the recombinant allergen was isolated by affinity chromatography on poly-(L-proline)-Sepharose. Electrophoretic (sodium dodecylsulfate-polyacrylamide gel electrophoresis, isoelectric focusing, and 2-dimensional polyacrylamide gel electrophoresis) and immunochemical methods (Western blot and ELISA) mere used for the characterization of the recombinant allergen. Results: Two cDNA inserts coding for M. annua pollen profilin (Mer a 1) were cloned and sequenced. Full-length Mer a 1 cDNA was expressed in E. coli as nonfusion protein. The final yield of recombinant Mer a 1 from the culture media after a single purification step on poly-(L-proline)-Sepharose was as much as 5 mg per liter. The reactivity of recombinant Mer a 1 with IgE antibodies present in sera from patients allergic to M. annua, Olea europaea, and Ricinus communis pollens was comparable to that of the natural counterparts, but latex profilin had no cross-reactivity with M. annua profilin. Recombinant Mer a 1 was shown to share B-epitopes with sunflower profilin. Conclusion: This approach is suitable for the production of defined and purified recombinant allergens, which could allow more detailed immunologic characterization of these proteins and the development of much more accurate diagnostic measures and specific anti-allergic treatments.	IFIDESA, ARISTEGUI, Dept Res & Dev, Bilbao 48008, Spain		Asturias, JA (corresponding author), IFIDESA, ARISTEGUI, Dept Res & Dev, Alameda Urquijo 27, Bilbao 48008, Spain.			MARTINEZ, JORGE/0000-0001-7002-0056; Asturias, Juan/0000-0001-9570-522X				ARIANO R, 1993, ANN ALLERGY, V70, P249; Arilla M C, 1997, Allergol Immunopathol (Madr), V25, P145; Asturias JA, 1997, J ALLERGY CLIN IMMUN, V100, P365, DOI 10.1016/S0091-6749(97)70250-1; Baatout S, 1996, EUR J CLIN CHEM CLIN, V34, P575; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; DeCorte V, 1997, FEBS LETT, V401, P191, DOI 10.1016/S0014-5793(96)01471-8; Elfman L, 1997, INT ARCH ALLERGY IMM, V113, P249, DOI 10.1159/000237561; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; GARCIAORTEGA P, 1992, J ALLERGY CLIN IMMUN, V89, P987, DOI 10.1016/0091-6749(92)90221-M; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; JIMENEZ A, 1994, INT ARCH ALLERGY IMM, V105, P297, DOI 10.1159/000236772; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; METZLER WJ, 1994, J BIOL CHEM, V269, P4620; MITTERMANN I, 1995, PLANT MOL BIOL, V27, P137, DOI 10.1007/BF00019185; MIYAMOTO T, 1991, ADV ALLERGOLOGY CLIN, P343; Nieto A., 1997, Journal of Allergy and Clinical Immunology, V99, pS157; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Petersen A, 1997, ELECTROPHORESIS, V18, P819, DOI 10.1002/elps.1150180528; RIHS HP, 1994, INT ARCH ALLERGY IMM, V105, P190, DOI 10.1159/000236824; Sambrook J, 1989, MOL CLONING LAB MANU; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Thorn KS, 1997, STRUCTURE, V5, P19, DOI 10.1016/S0969-2126(97)00163-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1992, INT ARCH ALLERGY IMM, V99, P271, DOI 10.1159/000236263; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332, DOI 10.1111/j.1365-2222.1995.tb01051.x; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; Vallverdu A, 1997, INT ARCH ALLERGY IMM, V112, P356, DOI 10.1159/000237480; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; Vrtala S, 1996, BIOCHEM BIOPH RES CO, V226, P42, DOI 10.1006/bbrc.1996.1309; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; Wiedemann P, 1996, J BIOL CHEM, V271, P29915, DOI 10.1074/jbc.271.47.29915	42	35	41	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					363	370		10.1016/S0091-6749(98)70249-0	http://dx.doi.org/10.1016/S0091-6749(98)70249-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525453				2022-12-18	WOS:000072593900014
J	Anibarro, B; Fontela, JL; De la Hoz, F				Anibarro, B; Fontela, JL; De la Hoz, F			Occupational asthma induced by garlic dust	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; garlic; onion; grass pollen; allergens	INHALATION	Background: Garlic dust has not been a frequently encountered cause of IgE-mediated disease. Objective: We report on 12 patients (all of them garlic workers) with the clinical criteria for occupational asthma. Methods: Skin prick tests and serum-specific IgE determinations were performed with common inhalants, garlic, and other members of the Liliaceae family (onion, leek, and asparagus). Bronchial challenge test with garlic powder was performed in all patients. Garlic and onion extract proteins were separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis. Immunoblot and IgE immunoblot inhibition analyses were performed with patients' sera on extracts of garlic, onion, and pollens of Phleum pratense and Chenopodium album. Results: Garlic sensitization was demonstrated by bronchial challenge test in seven patients (group 1) and ruled out in the remaining five (group 2). Clinical data were similar in both groups. The patients with garlic allergy had a mean age of 27 years, and all of them had pollen allergy; sensitization to other members of the Liliaceae family was also common. Electrophoresis of garlic extract revealed two major protein bands at approximately 12 and 54 kd. During IgE immunoblotting, the pool of sera reacted with garlic proteins mainly at 54 kd. Preincubation with onion, Phleum and Chenopodium partially abolished the IgE binding to several allergens of garlic. Conclusion: We report on seven patients in whom an occupational garlic allergy vias demonstrated. Garlic allergy is relatively rare but seems to affect young subjects with pollen allergy, and sensitization to other members of the Liliaceae family is common. The results of this study confirm the presence of some structurally similar allergens in garlic, onion, and certain pollens.	Hosp Virgen de la Luz, Cuenca, Spain; Abello SA, Alergia & Inmunol, Madrid, Spain		Anibarro, B (corresponding author), C Arzobispo Morcillo 42 9C, E-28029 Madrid, Spain.							COUTURIER P, 1982, J ALLERGY CLIN IMMUN, V70, P145, DOI 10.1016/0091-6749(82)90246-9; CROPP GJA, 1980, AM THORACIC SOC NEWS, V6, P11; FALLERONI AE, 1981, J ALLERGY CLIN IMMUN, V68, P156, DOI 10.1016/0091-6749(81)90173-1; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; HENSON G. E., 1940, JOUR FLORIDA MED ASSOC, V27, P86; Hjorth N, 1976, Contact Dermatitis, V2, P28, DOI 10.1111/j.1600-0536.1976.tb02975.x; LYBARGER JA, 1982, J ALLERGY CLIN IMMUN, V69, P448, DOI 10.1016/0091-6749(82)90120-8; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; SEURI M, 1993, CLIN EXP ALLERGY, V23, P1011, DOI 10.1111/j.1365-2222.1993.tb00292.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALDIVIESO R, 1994, J ALLERGY CLIN IMMUN, V94, P928, DOI 10.1016/0091-6749(94)90161-9	11	35	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				734	738		10.1016/S0091-6749(97)70266-5	http://dx.doi.org/10.1016/S0091-6749(97)70266-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438479	Bronze			2022-12-18	WOS:000071353600003
J	Bochner, BS				Bochner, BS			Cellular adhesion and its antagonism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							L-SELECTIN; INTEGRIN				Bochner, BS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21224, USA.							BECK LA, 1997, ADHESION MOL ALLERGI, P339; BOCHNER BS, 1997, ALLERGY, P251; BRISKIN M, 1997, ADHESION MOL ALLERGI, P105; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Fryer AD, 1997, J CLIN INVEST, V99, P2036, DOI 10.1172/JCI119372; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; HUNT SW, 1997, CELL ADHESION MOL AL, P73; LOBB RR, 1997, ADHESION MOL ALLERGI, P396; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Mannion BA, 1996, J IMMUNOL, V157, P2039; Matsumoto K, 1997, J ALLERGY CLIN IMMUN, V99, P648, DOI 10.1016/S0091-6749(97)70027-7; MONTEFORT S, 1997, ADHESION MOL ALLERGI, P315; POLITO AJ, 1997, CELL ADHESION MOL AL, P43; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VLIAGOFTIS H, 1997, ADHESION MOL ALLERGI, P151; WALSH GM, 1997, ADHESION MOL ALLERGI, P187; WARNER JA, 1997, ADHESION MOL ALLERGI, P139; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939	20	35	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					581	585		10.1016/S0091-6749(97)70158-1	http://dx.doi.org/10.1016/S0091-6749(97)70158-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389284				2022-12-18	WOS:A1997YG20200001
J	Baroody, FM; Suh, SH; Naclerio, RM				Baroody, FM; Suh, SH; Naclerio, RM			Total IgE serum levels correlate with sinus mucosal thickness on computerized tomography scans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sinusitis; total IgE; CT scans; mucosal thickening	AIRWAY RESPONSIVENESS; ASTHMA; EOSINOPHILIA; CHILDREN; ATOPY	Background: Sinusitis involves an inflammatory response with similarities to asthma. Objective: We sought to determine whether a correlation exists between total IgE and the sinus mucosal thickening as assessed by computed tomography (CT) scans. Methods: We screened the charts of 300 otolaryngology patients who had total and specific serum IgE determinations in 1994 and from this group selected all patients who had also undergone a sinus CT scan close to the time of serum evaluation (n = 86), Severity of disease on CT scan was graded by two investigators blinded to IgE levels. Results: There was a significant positive correlation between severity of disease on CT scans and IgE (r(s) = 0.37, p = 0.0007). Furthermore, patients with a more advanced disease stage had higher IgE levels. There was also a positive correlation between severity of disease and the sum of specific IgE grades (r(s) = 0.29, p = 0.007), Conclusion: The data suggest that IgE levels or a linked genetic parameter may contribute to the mucosal inflammation in the paranasal sinuses.			Baroody, FM (corresponding author), UNIV CHICAGO,SECT OTOLARYNGOL HEAD & NECK SURG,PRITZKER SCH MED,5841 S MARYLAND AVE MC1035,CHICAGO,IL 60637, USA.				NIDCD NIH HHS [DC02714] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002714] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		APRIL MM, 1993, LARYNGOSCOPE, V103, P985; BAROODY FM, 1995, ARCH OTOLARYNGOL, V121, P1396; BUCKLEY RH, 1993, ALLERGY PRINCIPLES P, P1007; FRIEDMAN WH, 1990, LARYNGOSCOPE, V100, P1161; GLICKLICH RE, 1994, AM J RHINOL, V8, P291; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; KALINER MA, 1996, CLIN IMMUNOLOGY PRIN, V1, P909; Kennedy D W, 1992, Laryngoscope, V102, P1; LEVINE H, 1993, RHINOLOGY SINUSOLOGY, P261; LOURY MC, 1991, SMELL TASTE HLTH DIS, P517; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; MANNING SC, 1993, LARYNGOSCOPE, V103, P717, DOI 10.1288/00005537-199307000-00002; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SMALL CB, 1993, J INFECT DIS, V167, P283, DOI 10.1093/infdis/167.2.283; STANTON AG, 1987, PRIMER BIOSTATISTICS, P191; SUNYER J, 1995, J ALLERGY CLIN IMMUN, V95, P699, DOI 10.1016/S0091-6749(95)70175-3; ZINREICH SJ, 1987, RADIOLOGY, V163, P769, DOI 10.1148/radiology.163.3.3575731	22	35	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					563	568		10.1016/S0091-6749(97)70151-9	http://dx.doi.org/10.1016/S0091-6749(97)70151-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338553				2022-12-18	WOS:A1997YA52900022
J	Anderson, SD; Rodwell, LT; Daviskas, E; Spring, JF; duToit, J				Anderson, SD; Rodwell, LT; Daviskas, E; Spring, JF; duToit, J			The protective effect of nedocromil sodium and other drugs on airway narrowing provoked by hyperosmolar stimuli: A role for the airway epithelium?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; aerosols; hyperosmolar saline; exercise; hyperventilation; nedocromil sodium; cromolyn sodium; diuretics; indomethacin; steroids	EXERCISE-INDUCED ASTHMA; ULTRASONICALLY NEBULIZED SOLUTIONS; PRESSURIZED AEROSOL; INDUCED BRONCHOCONSTRICTION; CROMOLYN SODIUM; ION-TRANSPORT; DRY AIR; CROMOGLYCATE; SALINE; DURATION	The airways of persons with asthma are sensitive to acute changes in airway osmolarity and to dehydration. In reviewing the literature it is clear that airway narrowing provoked by these stimuli is blocked acutely by inhaling aerosols of nedocromil sodium cromolyn sodium, frusemide, bumetanide, and antihistamines and by chronic use of aerosol corticosteroids. The responses are unaffected by inhalation of amiloride and verapamil. We have previously proposed that increases in the osmolarity of airway surface liquid (ASL) occur as a result of the water lost by evaporation during hyperpnea with dry air. An increase or decrease in osmolarity of the ASL will also occur with deposition of hyperosmolar and hypoosmolar droplets. Changes in osmolarity of the ASL result in the movement of water out of (shrinkage) and into (swelling) the epithelial cell, and this necessitates regulatory volume increase or decrease by the cell. We propose that nedocromil sodium and cromolyn sodium can affect wafer transport into and out of the epithelial cell by an action on chloride ion channels. A unifying hypothesis to explain the protective affect of these drugs may be their capacity to affect regulatory volume increase of decrease in a variety of cell types.	PRINCE CHARLES HOSP,DEPT THORAC MED,CHERMSIDE,AUSTRALIA	Prince Charles Hospital	Anderson, SD (corresponding author), ROYAL PRINCE ALFRED HOSP,DEPT RESP MED,PCP9,MISSENDEN RD,CAMPERDOWN,NSW 2050,AUSTRALIA.							ALBAZZAZ MK, 1992, EUR RESPIR J, V5, P967; ANDERSON SD, 1994, CHEST, V105, P673, DOI 10.1378/chest.105.3.673; ANDERSON SD, 1989, ALLERGY PROC, V10, P215, DOI 10.2500/108854189778960054; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; ANDERSON SD, 1992, THORAX, V47, P748, DOI 10.1136/thx.47.9.748; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; ANDERSON SD, 1991, NEW ENGL J MED, V324, P131; Anderson SD, 1995, PROVOCATION CHALLENG, P249; BEL EH, 1991, AM REV RESPIR DIS, V143, P109, DOI 10.1164/ajrccm/143.1.109; BONER AL, 1989, ANN ALLERGY, V62, P38; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; CHUDRY N, 1987, ARCH DIS CHILD, V62, P412, DOI 10.1136/adc.62.4.412; COMIS A, 1993, EUR RESPIR J, V6, P523; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Daviskas E, 1996, EUR RESPIR J, V9, P716, DOI 10.1183/09031936.96.09040716; DAVISKAS E, 1990, J APPL PHYSIOL, V69, P362, DOI 10.1152/jappl.1990.69.1.362; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; JACKSON DM, 1992, EUR J PHARMACOL, V221, P172; JENKINS C, 1992, P ANN SCI M THOR SOC; JUNIPER EF, 1987, CLIN ALLERGY, V17, P523, DOI 10.1111/j.1365-2222.1987.tb02048.x; KONIG P, 1987, J ALLERGY CLIN IMMUN, V79, P64, DOI 10.1016/S0091-6749(87)80018-0; MIHALYKA MS, 1987, AUST NZ J MED, V17, pS524; MORTON AR, 1992, ANN ALLERGY, V68, P143; Novembre E, 1994, Pediatr Allergy Immunol, V5, P107, DOI 10.1111/j.1399-3038.1994.tb00226.x; PHIPPS P, 1987, EUR J NUCL MED, V13, P183, DOI 10.1007/BF00256488; PHIPPS PR, 1990, CHEST, V97, P1327, DOI 10.1378/chest.97.6.1327; RECHKEMMER GR, 1988, AM REV RESPIR DIS, V38, P57; ROBERTS JA, 1985, CLIN ALLERGY, V15, P377, DOI 10.1111/j.1365-2222.1985.tb03006.x; ROBUSCHI M, 1987, CLIN ALLERGY, V17, P69, DOI 10.1111/j.1365-2222.1987.tb02321.x; RODWELL LT, 1992, EUR RESPIR J, V5, P953; RODWELL LT, 1993, THORAX, V48, P208, DOI 10.1136/thx.48.3.208; RODWELL LT, 1993, EUR RESPIR J, V6, P855; RODWELL LT, 1991, EUR RESPIR J, V4, P1126; RODWELL LT, 1992, AM REV RESPIR DIS, V146, P1149, DOI 10.1164/ajrccm/146.5_Pt_1.1149; RODWELL LT, 1994, THESIS U SYDNEY SYDN; RODWELL LT, 1994, AUST NZ J MED, V24, P459; RODWELL LT, IN PRESS THORAX; ROMANIN C, 1991, EMBO J, V10, P3603, DOI 10.1002/j.1460-2075.1991.tb04926.x; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SCHOEFFEL RE, 1983, AUST NZ J MED, V13, P157, DOI 10.1111/j.1445-5994.1983.tb02672.x; SELTZER M, 1988, J AEROSOL MED, V1, P147; SMITH CM, 1990, EUR RESPIR J, V3, P144; SMITH CM, 1989, J ALLERGY CLIN IMMUN, V84, P781, DOI 10.1016/0091-6749(89)90309-6; SMITH CM, 1987, P 10 INT C PHARM AUG; VILSVIK J, 1988, ANN ALLERGY, V61, P367	47	35	35	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	2	S			S124	S134		10.1016/S0091-6749(96)80140-0	http://dx.doi.org/10.1016/S0091-6749(96)80140-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VW140	8939188				2022-12-18	WOS:A1996VW14000028
J	Boxer, M				Boxer, M			Accupril- and Cozaar-induced angioedema in the same patient	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter																		*MED EC CO, 1996, PHYS DESK REF, P1628; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967	2	35	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					471	471		10.1016/S0091-6749(96)70176-8	http://dx.doi.org/10.1016/S0091-6749(96)70176-8			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757229				2022-12-18	WOS:A1996VC99500031
J	GeaBanacloche, JC; Metcalfe, DD				GeaBanacloche, JC; Metcalfe, DD			Ciprofloxacin desensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ANAPHYLACTOID REACTIONS		UNIV AUTONOMA MADRID,CLIN PUERTA HIERRO,SERV MED INTERNA 1,MADRID,SPAIN	Autonomous University of Madrid; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	GeaBanacloche, JC (corresponding author), NIAID,LAB ALLERG DIS,NIH,BLDG 10,ROOM 11S231,10 CTR DR,MSC 1888,BETHESDA,MD 20892, USA.							ASSOUAD M, 1995, ANN INTERN MED, V122, P396, DOI 10.7326/0003-4819-122-5-199503010-00026; DAVILA I, 1993, ALLERGY, V48, P388, DOI 10.1111/j.1398-9995.1993.tb02413.x; DAVIS H, 1989, ANN INTERN MED, V111, P1041, DOI 10.7326/0003-4819-111-12-1041; SOETIKNO RM, 1993, ANN PHARMACOTHER, V27, P1404, DOI 10.1177/106002809302701118; VIDAL C, 1995, POSTGRAD MED J, V71, P318, DOI 10.1136/pgmj.71.835.318-a	5	35	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1426	1427		10.1016/S0091-6749(96)70218-X	http://dx.doi.org/10.1016/S0091-6749(96)70218-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648046	Bronze			2022-12-18	WOS:A1996VD60700038
J	vanHalteren, HK; vanderLinden, PWG; Burgers, SA; Bartelink, AKM				vanHalteren, HK; vanderLinden, PWG; Burgers, SA; Bartelink, AKM			Hymenoptera sting challenge of 348 patients: Relation to subsequent field stings	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sting challenge; Hymenoptera; immunotherapy; anaphylaxis	VENOM IMMUNOTHERAPY; NATURAL-HISTORY; WASP VENOM; INSECT; ALLERGY; ANAPHYLAXIS; BEE	Background: Patients with a history of a serious anaphylactic reaction after a Hymenoptera sting are usually given venom immunotherapy. Because the natural history of Hymenoptera sting anaphylaxis is often of a declining severity, there is a chance of overtreatment. Objective: identification of patients at risk for a future anaphylactic reaction may reduce the number of patients who need venom immunotherapy. Methods: We investigated the relation between the grade of hypersensitivity to an in-hospital sting challenge and the reaction to a subsequent accidental field sting. From 1982 through 1992, 348 patients with mild or no symptoms after a sting challenge were not given venom immunotherapy. All patients were asked by letter whether they had experienced a subsequent field sting. In case of a sting, the severity of the reaction was further evaluated. Results: Information could be obtained from 327 patients: 129 had been re-stung, and 110 of them had only had a local reaction. Thirteen patients had experienced mild systemic symptoms, and six patients had experienced serious manifestations. In two of the latter group hypotension was observed. Conclusion: In 95% of patients with a previous anaphylactic reaction, the result of the in-hospital sting challenge provided a good prediction of tolerance to a subsequent Hymenoptera field sting.	EEMLAND HOSP,DEPT INTERNAL MED,3800 ED AMERSFOORT,NETHERLANDS; KENNEMER GASTHUIS,DEPT INTERNAL MED,HAARLEM,NETHERLANDS; ACAD HOSP,DEPT PULMONOL,UTRECHT,NETHERLANDS	Spaarne Hospital								Aalberse R C, 1979, Monogr Allergy, V14, P29; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; CHARPIN D, 1992, J ALLERGY CLIN IMMUN, V90, P331, DOI 10.1016/S0091-6749(05)80011-9; ENGEL T, 1988, ALLERGY, V43, P289, DOI 10.1111/j.1398-9995.1988.tb00902.x; FRANKEN HH, 1994, J ALLERGY CLIN IMMUN, V93, P431, DOI 10.1016/0091-6749(94)90351-4; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; LICHTENSTEIN LM, 1994, J ALLERGY CLIN IMMUN, V94, P137, DOI 10.1016/0091-6749(94)90030-2; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; MILLER SD, 1994, ALLERGY PROC, V15, P65, DOI 10.2500/108854194778702973; MULLER HL, 1966, J ASTHMA RES, V3, P331; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P618; PRZYBILLA B, 1991, NEW TRENDS ALLERGY, P335; REISMAN RE, 1994, NEW ENGL J MED, V331, P523, DOI 10.1056/NEJM199408253310808; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1994, J ALLERGY CLIN IMMUN, V94, P651, DOI 10.1016/0091-6749(94)90167-8; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; TAMIR R, 1992, ALLERGY, V47, P260, DOI 10.1111/j.1398-9995.1992.tb00660.x; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329	25	35	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1058	1063		10.1016/S0091-6749(96)70258-0	http://dx.doi.org/10.1016/S0091-6749(96)70258-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626982				2022-12-18	WOS:A1996UL26100005
J	SPECTOR, SL; NICKLAS, RA; BERNSTEIN, IL; BLESSINGMOORE, J; STRUNK, RC; GUTMAN, AA; PEARLMAN, DS; LEE, RE; FINEMAN, S; GREEN, R; HENDELES, L; LOWENTHAL, M; SAAVEDRADELGADO, AM				SPECTOR, SL; NICKLAS, RA; BERNSTEIN, IL; BLESSINGMOORE, J; STRUNK, RC; GUTMAN, AA; PEARLMAN, DS; LEE, RE; FINEMAN, S; GREEN, R; HENDELES, L; LOWENTHAL, M; SAAVEDRADELGADO, AM			PRACTICE PARAMETERS FOR THE DIAGNOSIS AND TREATMENT OF ASTHMA - PREFACE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							EXERCISE-INDUCED ASTHMA; HOUSE-DUST MITE; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; STEROID-DEPENDENT ASTHMA; PEAK EXPIRATORY FLOW; ACUTE BRONCHIAL-ASTHMA; SKIN-TEST REACTIVITY; SLOW-RELEASE THEOPHYLLINE; BETA-ADRENERGIC AGONIST; OBSTRUCTIVE AIRWAYS DISEASE											AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; ABRAHAM WM, 1986, EUR J RESPIR DIS, V69, P192; ABRAMOWITZ PW, 1980, J ALLERGY CLIN IMMUN, V66, P123, DOI 10.1016/0091-6749(80)90059-7; ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ACHUH S, 1994, PEDIATR RES, V35, pA873; ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; ADINOFF AD, 1987, SEMIN RESPIR MED, V8, P308, DOI 10.1055/s-2007-1012669; ADINOFF AD, 1983, PEDIATR RES, V17, P264; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; AHMED T, 1981, J ALLERGY CLIN IMMUN, V67, P135, DOI 10.1016/0091-6749(81)90009-9; AHRENS RC, 1987, J ALLERGY CLIN IMMUN, V79, P876, DOI 10.1016/0091-6749(87)90235-1; ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ALLIOTT RJ, 1972, BMJ-BRIT MED J, V1, P539, DOI 10.1136/bmj.1.5799.539; ALLON M, 1989, ANN INTERN MED, V110, P426, DOI 10.7326/0003-4819-110-6-426; ALTOUNYAN REC, 1980, CLIN ALLERGY, V10, P481, DOI 10.1111/j.1365-2222.1980.tb02162.x; AMBROSINO DM, 1988, J ALLERGY CLIN IMMUN, V81, P1175, DOI 10.1016/0091-6749(88)90887-1; AMIRAV I, 1994, ARCH PEDIAT ADOL MED, V148, P1339, DOI 10.1001/archpedi.1994.02170120101019; ANDERSEN LI, 1986, CHEST, V90, P358, DOI 10.1378/chest.90.3.358; ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; ANDERSON SD, 1993, ALLERGY PRINCIPLES P, P1343; ANDERSON SD, 1989, USE NONISOTONIC INHA, P227; [Anonymous], 1990, LANCET, V335, P693; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1990, BRIT MED J, V301, P651; ARLIAN LG, 1978, J MED ENTOMOL, V14, P484; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; ARMENIO L, 1993, ARCH DIS CHILD, V68, P193, DOI 10.1136/adc.68.2.193; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; AU WYW, 1985, CLIN PHARMACOL THER, V37, P472, DOI 10.1038/clpt.1985.74; AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; AUBIER M, 1986, J ALLERGY CLIN IMMUN, V78, P787, DOI 10.1016/0091-6749(86)90062-X; AYD FJ, 1974, JAMA-J AM MED ASSOC, V230, P263, DOI 10.1001/jama.230.2.263; AYRES JG, 1987, BRIT J CLIN PRACT, V41, P971; BADIER M, 1988, J ALLERGY CLIN IMMUN, V81, P437, DOI 10.1016/0091-6749(88)90913-X; BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BAKER GJ, 1981, MED J AUSTRALIA, V2, P614, DOI 10.5694/j.1326-5377.1981.tb113018.x; BAKER JR, 1988, J ALLERGY CLIN IMMUN, V81, P664, DOI 10.1016/0091-6749(88)91036-6; BAKER MD, 1986, J PEDIATR-US, V109, P538, DOI 10.1016/S0022-3476(86)80140-8; BANNER AS, 1979, ARCH INTERN MED, V139, P434, DOI 10.1001/archinte.139.4.434; BANNER AS, 1976, JAMA-J AM MED ASSOC, V235, P1337, DOI 10.1001/jama.235.13.1337; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BARDIN PG, 1992, CLIN EXP ALLERGY, V22, P809, DOI 10.1111/j.1365-2222.1992.tb02825.x; BARISH CF, 1985, ARCH INTERN MED, V145, P1882, DOI 10.1001/archinte.145.10.1882; BARNES DW, 1987, CHEST, V91, P246, DOI 10.1378/chest.91.2.246; BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BARNES PJ, 1990, IMMUNOL ALLERGY CLIN, V10, P241; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; BARNES PJ, 1985, AM J MED, V79, P5, DOI 10.1016/0002-9343(85)90080-4; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BARNES PJ, 1988, AM J MED, V85, P64, DOI 10.1016/0002-9343(88)90245-8; BART KJ, 1987, J ALLERGY CLIN IMMUN, V79, P296, DOI 10.1016/0091-6749(87)90144-8; BASCOM R, 1986, AM REV RESPIR DIS, V134, P248; BATEMAN JRM, 1978, CLIN SCI MOL MED, V55, P523, DOI 10.1042/cs0550523; BATES DV, 1983, CAN J PUBLIC HEALTH, V74, P117; BATES DV, 1987, ENVIRON RES, V43, P317, DOI 10.1016/S0013-9351(87)80032-4; BCK KC, 1994, AM REV RESPIR CRIT C, V149, P352; BEASLEY CRW, 1987, BRIT MED J, V294, P1197, DOI 10.1136/bmj.294.6581.1197-a; BEASLEY R, 1991, AUST NZ J MED, V21, P753, DOI 10.1111/j.1445-5994.1991.tb01385.x; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BEASLEY R, 1987, AM REV RESPIR DIS, V136, P1140, DOI 10.1164/ajrccm/136.5.1140; BECKER A, 1994, CHEST, V106, pS231, DOI 10.1378/chest.106.4_Supplement.231S; BECKER AB, 1983, J PEDIATR-US, V102, P465, DOI 10.1016/S0022-3476(83)80679-9; Becker M H, 1980, J Community Health, V6, P113, DOI 10.1007/BF01318980; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; BELLIA V, 1985, CHEST, V88, P89, DOI 10.1378/chest.88.1.89; BELLIA V, 1988, CHEST, V94, P108, DOI 10.1378/chest.94.1.108; BENDER B, 1992, JAMA-J AM MED ASSOC, V267, P2621; BENDER BG, 1991, ANN ALLERGY, V66, P414; BENDOV I, 1983, AM REV RESPIR DIS, V127, P113, DOI 10.1164/arrd.1983.127.1.113; BENDOV I, 1986, AM REV RESPIR DIS, V133, P116, DOI 10.1164/arrd.1986.133.1.116; BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BENTUR L, 1992, PEDIATRICS, V89, P133; BENTUR L, 1990, ANN ALLERGY, V65, P122; BERGER M, 1987, J PEDIATR-US, V110, P325, DOI 10.1016/S0022-3476(87)80182-8; BERLOW BA, 1991, J ALLERGY CLIN IMMUN, V87, P710, DOI 10.1016/0091-6749(91)90393-3; BERMAN SZ, 1975, J ALLERGY CLIN IMMUN, V56, P206, DOI 10.1016/0091-6749(75)90091-3; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BERNSTEIN DI, 1988, J ALLERGY CLIN IMMUN, V81, P6, DOI 10.1016/0091-6749(88)90213-8; BERNSTEIN DI, 1989, J ALLERGY CLIN IMMUN, V84, P820, DOI 10.1016/0091-6749(89)90345-X; BERNSTEIN IL, 1981, CLIN CHEST MED, V2, P255; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V50, P235, DOI 10.1016/0091-6749(72)90017-6; BERNSTEIN IL, 1964, DIS CHEST, V46, P469, DOI 10.1378/chest.46.4.469; BERNSTEIN IL, 1985, ALLERGY, P1; BERNSTEIN IL, 1980, 4TH P FDA S WASH, P258; BERNSTEIN IL, 1983, ALLERGY PRINCIPLES P, P901; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BEYNON HLC, 1988, LANCET, V2, P370; BIAGINI RE, 1985, J ALLERGY CLIN IMMUN, V76, P794, DOI 10.1016/0091-6749(85)90750-X; BIANCO S, 1988, LANCET, V2, P252; BIELLO DR, 1979, AM J ROENTGENOL, V133, P1033, DOI 10.2214/ajr.133.6.1033; BIERMAN CW, 1988, NEW ENGL REG ALLERGY, V9, P193; BIERMAN CW, 1977, PEDIATRICS, V60, P845; BIRKHEAD G, 1989, J ALLERGY CLIN IMMUN, V84, P484, DOI 10.1016/0091-6749(89)90361-8; BJORNSDOTTIR US, 1992, MED CLIN N AM, V76, P895; BLAKE KV, 1988, ANN EMERG MED, V17, P1024, DOI 10.1016/S0196-0644(88)80439-6; BLESSINGMOORE J, 1994, J ASTHMA, V31, P415, DOI 10.3109/02770909409089482; BLESSINGMOORE J, 1987, CLIN REV ALLERG, V5, P191; BLESSINGMOORE J, 1994, PEDIATRIC RESPIRATOR; BLUMENTHAL MN, 1988, J ALLERGY CLIN IMMUN, V81, P681, DOI 10.1016/0091-6749(88)91038-X; BOAT TF, 1990, NEW ENGL J MED, V323, P1700, DOI 10.1056/NEJM199012133232410; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BONER AL, 1987, EUR J PEDIATR, V146, P408, DOI 10.1007/BF00444950; BONHAM GS, 1981, AM J PUBLIC HEALTH, V71, P290, DOI 10.2105/AJPH.71.3.290; BOONSAWAT W, 1992, AM REV RESPIR DIS, V146, P565, DOI 10.1164/ajrccm/146.3.565; BOOTH H, 1993, THORAX, V48, P1121, DOI 10.1136/thx.48.11.1121; BOUDINOT FD, 1986, J PHARMACOKINET BIOP, V14, P469, DOI 10.1007/BF01059656; BOUSHEY HA, 1987, POSTGRAD MED J, V63, P69; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P1, DOI 10.1016/0091-6749(94)90064-7; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; BRAUDE AC, 1983, LANCET, V2, P995; BRENNER BE, 1983, AM J MED, V74, P1005, DOI 10.1016/0002-9343(83)90802-1; BRENNER M, 1988, CLIN ALLERGY, V18, P143, DOI 10.1111/j.1365-2222.1988.tb02853.x; BRENNER M, 1990, IMMUNOL ALLERGY CLIN, V11, P92; BRITTAIN RT, 1990, LUNG, V168, P111, DOI 10.1007/BF02718122; BROGDEN RN, 1991, DRUGS, V42, P895, DOI 10.2165/00003495-199142050-00010; BROGDEN RN, 1993, DRUGS, V45, P693, DOI 10.2165/00003495-199345050-00007; BROOK I, 1981, JAMA-J AM MED ASSOC, V246, P967, DOI 10.1001/jama.246.9.967; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BROWN HM, 1991, ANN ALLERGY, V67, P25; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; BRUNETTE MG, 1988, PEDIATRICS, V81, P624; BUCKNALL CE, 1988, LANCET, V1, P748; BUDA AJ, 1979, NEW ENGL J MED, V301, P453, DOI 10.1056/NEJM197908303010901; BUFFINGTON GA, 1976, JAMA-J AM MED ASSOC, V236, P1958, DOI 10.1001/jama.236.17.1958; BUNDGAARD A, 1986, EUR J RESPIR DIS, V68, P41; BUNDGAARD A, 1983, BRIT J DIS CHEST, V77, P147, DOI 10.1016/0007-0971(83)90020-7; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BUSINCO L, 1981, INT J PEDIATR OTORHI, V3, P287, DOI 10.1016/0165-5876(81)90053-7; BUSSE WW, 1988, CHEST, V93, P1076, DOI 10.1378/chest.93.5.1076; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; BUSSE WW, 1985, AM J MED, V79, P62, DOI 10.1016/0002-9343(85)90091-9; BUSSE WW, 1988, INSIGHTS ALLERGY, V3, P1; CABANES LR, 1989, NEW ENGL J MED, V320, P1317, DOI 10.1056/NEJM198905183202005; CABLE HR, 1981, J LARYNGOL OTOL, V95, P775, DOI 10.1017/S0022215100091428; CALABRESE EJ, 1978, METHODOLOGIC APPROAC; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CAMPBELL M, 1994, CHEST, V106, pS274, DOI 10.1378/chest.106.4_Supplement.274S; CANNY GJ, 1990, ANN ALLERGY, V64, P406; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; CARSTAIRS JR, 1985, AM REV RESPIR DIS, V132, P541; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; CARTLAND JDC, 1992, PEDIATRICS, V89, P183; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P64; CENTOR RM, 1984, NEW ENGL J MED, V310, P577, DOI 10.1056/NEJM198403013100907; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHALEB JA, 1974, CURR MED RES OPIN, V2, P275; CHAN CS, 1988, AM REV RESPIR DIS, V137, P1502, DOI 10.1164/ajrccm/137.6.1502; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; CHANDELER E, 1980, AM REV RESPIR DIS, V121, P621; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; CHANYEUNG M, 1986, AM REV RESPIR DIS, V133, P666; CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; CHAPMAN KR, 1984, CLIN PHARMACOL THER, V35, P762, DOI 10.1038/clpt.1984.108; CHAPMAN M, 1986, J ALLERGY CLIN IMMUN, V77, P204; CHAROUS BL, 1990, ANN ALLERGY, V65, P53; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; CHARPIN D, 1990, Journal of Allergy and Clinical Immunology, V85, P185; CHARPIN D, 1988, CHEST, V93, P758, DOI 10.1378/chest.93.4.758; CHEN WY, 1982, CHEST, V81, P675, DOI 10.1378/chest.81.6.675; CHERNIACK RM, 1992, PULMONARY FUNCTION T, P221; CHERVINSKY P, 1986, AM J MED, V81, P67, DOI 10.1016/0002-9343(86)90465-1; CHESTNUT DH, 1989, ANESTHIOLOGY, V71, pA481; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; CHRISTOPHER KL, 1983, NEW ENGL J MED, V308, P1566, DOI 10.1056/NEJM198306303082605; CHUDRY N, 1987, ARCH DIS CHILD, V62, P412, DOI 10.1136/adc.62.4.412; CHUR V, 1989, J ALLERGY CLIN IMMUN, V83, P198; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; CLARK JG, 1989, ANN INTERN MED, V111, P368, DOI 10.7326/0003-4819-111-5-368; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CLARK NM, 1989, CHEST, V95, P1110, DOI 10.1378/chest.95.5.1110; CLARK TJH, 1985, J ALLERGY CLIN IMMUN, V76, P330, DOI 10.1016/0091-6749(85)90649-9; CLARK TJH, 1971, BR J DIS CHEST, V71, P87; CLIFTON GD, 1990, AM REV RESPIR DIS, V141, P575, DOI 10.1164/ajrccm/141.3.575; CLOUTIER MM, 1981, PEDIATRICS, V67, P6; CNATTINGIUS S, 1988, BMJ-BRIT MED J, V297, P258, DOI 10.1136/bmj.297.6643.258; COCHRANE GM, 1975, THORAX, V30, P300, DOI 10.1136/thx.30.3.300; COCKCROFT A, 1981, LANCET, V1, P827; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COLEMAN JJ, 1986, CHEST, V90, P45, DOI 10.1378/chest.90.1.45; COLLINS JV, 1975, Q J MED, V44, P259; COMSTOCK GW, 1975, AM REV RESPIR DIS, V111, P573; CONNOLLY CK, 1979, BRIT J DIS CHEST, V73, P357, DOI 10.1016/S0007-0971(79)80173-4; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; Cooke RA, 1932, AM J MED SCI, V183, P309; COOPER JA, 1982, P INT C RESIDENTIAL; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CORSSEN G, 1972, ANESTH ANAL CURR RES, V51, P588; Cox J S, 1970, Adv Drug Res, V5, P115; CRAMER JA, 1990, ARCH INTERN MED, V150, P1509, DOI 10.1001/archinte.150.7.1509; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; CRANE J, 1989, THORAX, V44, P136, DOI 10.1136/thx.44.2.136; CRAWFORD JS, 1980, ANAESTHESIA, V35, P397, DOI 10.1111/j.1365-2044.1980.tb05138.x; CREER TL, 1985, NIH842364 NAT HEART; CRIMI E, 1989, J ALLERGY CLIN IMMUN, V83, P985, DOI 10.1016/0091-6749(89)90116-4; CRIMI N, 1988, CLIN ALLERGY, V18, P367, DOI 10.1111/j.1365-2222.1988.tb02884.x; CRIMI N, 1989, ANN ALLERGY, V62, P26; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; CROPP GJA, 1980, AM THORACIC SOC NEWS, V67, P11; CUMMINGS NP, 1983, PEDIATR RES, V17, P373; CURRAN WS, 1961, ANN INTERN MED, V55, P777, DOI 10.7326/0003-4819-55-5-777; CYPCAR D, 1993, IMMUNOL ALLERGY CLIN, V13, P745; DAHL R, 1989, J ALLERGY CLIN IMMUN, V83, P811, DOI 10.1016/0091-6749(89)90019-5; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; DAVE NK, 1990, J ALLERGY CLIN IMMUN, V86, P147, DOI 10.1016/S0091-6749(05)80059-4; DAVIES R, 1987, REV ESP ALLERGO IMMU, V2, P79; DAVIES RJ, 1976, AM REV RESPIR DIS, V114, P1011; DAVIS RS, 1983, J ALLERGY CLIN IMMUN, V72, P393, DOI 10.1016/0091-6749(83)90505-5; DEAN NC, 1988, POSTGRAD MED, V84, P103; DEBELIC M, 1988, ANN ALLERGY, V61, P25; DEBLAQUIERE P, 1989, AM REV RESPIR DIS, V140, P910, DOI 10.1164/ajrccm/140.4.910; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DEES SC, 1974, N C MED J, V35, P230; DELANEY MD, 1986, HDB PULMONARY EMERGE; DEMONCHY JGR, 1985, AGENTS ACTIONS, V16, P252; DEROM E, 1990, American Review of Respiratory Disease, V141, pA469; DESTEFANO G, 1990, ANN ALLERGY, V65, P260; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DICKSON W, 1979, MAST CELL ITS ROLE H, P343; DIETEMANN A, 1989, J ALLERGY CLIN IMMUN, V83, P263; DIXON CMS, 1990, BRIT J CLIN PHARMACO, V30, P371, DOI 10.1111/j.1365-2125.1990.tb03786.x; DOAN T, 1993, J ALLERGY CLIN IMMUN, V91, P319; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; DOCKERY DW, 1989, CLIN EPIDEMIOLOGY CH, V43, P201; DODGE R, 1986, AM REV RESPIR DIS, V133, P981; DOLOVICH J, 1983, ASTHMA, P132; DOWELL SF, 1993, PEDIATRICS, V92, P223; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; DRUCE HM, 1992, J ALLERGY CLIN IMMUN, V90, P436, DOI 10.1016/0091-6749(92)90165-X; DRUCE HM, 1991, J ALLERGY CLIN IMMUN, V88, P675, DOI 10.1016/0091-6749(91)90161-G; DRY J, 1985, J INT MED RES, V13, P289, DOI 10.1177/030006058501300508; DUSDIEKER L, 1982, J PEDIATR-US, V101, P281; DYSON D, 1991, J ALLERGY CLIN IMMUN, V85, P258; EASTON RE, 1967, ARCH ENVIRON HEALTH, V15, P160, DOI 10.1080/00039896.1967.10664897; EATON ML, 1980, ANN INTERN MED, V92, P758, DOI 10.7326/0003-4819-92-6-758; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; EIGEN H, 1987, J ALLERGY CLIN IMMUN, V80, P612, DOI 10.1016/0091-6749(87)90016-9; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; ELIASSON A, 1992, CHEST, V102, P2; ELLIS EF, 1993, ALLERGY PRINCIPLES P, P1225; ELLIS EF, 1988, ALLERGY PRINCIPLES P, P1037; ELLULMICALLEF R, 1975, LANCET, V2, P1269; EMETSU DT, 1993, PEDIATRIC RESPIRATOR, P703; ENGSTROM I, 1977, SCAND J RESPIR DIS, P49; EPLER GR, 1983, CHEST, V83, P161, DOI 10.1378/chest.83.2.161; ERAKER SA, 1984, ANN INTERN MED, V100, P258, DOI 10.7326/0003-4819-100-2-258; Erikson E.H., 1963, CHILDHOOD SOC; ERNST P, 1993, AM REV RESPIR DIS, V148, P75, DOI 10.1164/ajrccm/148.1.75; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V130, P363; ESTRADA DE LA RIVA G, 1958, South Med J, V51, P865; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; EVANS WE, 1985, J RHEUMATOL, V12, P15; EZURUM SC, 1991, ANN INTERN MED, V114, P353; FAIRFAX AJ, 1982, PROSTA LEUKOTR MED, V8, P239, DOI 10.1016/0262-1746(82)90046-4; FAIRFAX AJ, 1980, THORAX, V35, P526, DOI 10.1136/thx.35.7.526; FALLIERS CJ, 1966, J ALLERGY, V38, P183, DOI 10.1016/0021-8707(66)90041-4; FANTA CH, 1986, AM J MED, V80, P5, DOI 10.1016/0002-9343(86)90041-0; FANTA CH, 1982, AM J MED, V72, P416, DOI 10.1016/0002-9343(82)90498-3; FANTA CH, 1983, AM J MED, V75, P781; FANUNK D, 1991, INT PEDITR, V2, P269; FELDMAN CH, 1987, CLIN REV ALLERG, V5, P195; FERGUSON AC, 1988, J ALLERGY CLIN IMMUN, V82, P19, DOI 10.1016/0091-6749(88)90045-0; FIEL SB, 1983, AM J MED, V75, P259, DOI 10.1016/0002-9343(83)91202-0; FINDLAY SR, 1983, AM REV RESPIR DIS, V128, P1008; FINNERTY JP, 1988, J ALLERGY CLIN IMMUN, V81, P240, DOI 10.1016/0091-6749(88)90524-6; FIREMAN P, 1992, J ALLERGY CLIN IMMUN, V90, P433, DOI 10.1016/0091-6749(92)90164-W; Firket J, 1936, T FARADAY SOC, V32, P1192, DOI 10.1039/tf9363201192; Firket J., 1931, 1930 B ACAD ROYAL ME, V11, P683; FISCHL MA, 1981, NEW ENGL J MED, V305, P783, DOI 10.1056/NEJM198110013051402; FISH JE, 1980, J ALLERGY CLIN IMMUN, V65, P154, DOI 10.1016/0091-6749(80)90201-8; FISHBURNE JI, 1972, OBSTET GYNECOL, V39, P892; FITZPATRICK MF, 1990, BRIT MED J, V301, P1365, DOI 10.1136/bmj.301.6765.1365; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; FLETCHER EC, 1983, J APPL PHYSIOL, V54, P632, DOI 10.1152/jappl.1983.54.3.632; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FLOYER J, 1986, TREATISE ASTHMA; FORASTIERE F, 1994, AM J RESP CRIT CARE, V149, P365, DOI 10.1164/ajrccm.149.2.8306031; FORD AW, 1989, CLIN EXP ALLERGY, V19, P183, DOI 10.1111/j.1365-2222.1989.tb02362.x; FORESI A, 1986, J ALLERGY CLIN IMMUN, V78, P1130, DOI 10.1016/0091-6749(86)90262-9; FOULDS RA, 1993, J ALLERGY CLIN IMMUN, V92, P202, DOI 10.1016/0091-6749(93)90109-S; FOWLES J, 1990, Journal of Allergy and Clinical Immunology, V85, P195; FOX JL, 1961, PENN MED J, V64, P634; FRANK NR, 1962, J APPL PHYSIOL, V17, P252, DOI 10.1152/jappl.1962.17.2.252; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; FREUDENBERG N, 1980, J SCHOOL HEALTH, V50, P522, DOI 10.1111/j.1746-1561.1980.tb02079.x; FREY FJ, 1988, CLIN PHARMACOL THER, V44, P510, DOI 10.1038/clpt.1988.188; FRIDAY GA, 1988, CLIN CHEST MED, V9, P557; FURUKAWA CT, 1984, LANCET, V1, P621; FURUKAWA CT, 1988, J ALLERGY CLIN IMMUN, V81, P83, DOI 10.1016/0091-6749(88)90224-2; FURUKAWA CT, 1992, PEDIATRICS, V90, P639; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; GAL TJ, 1981, ANESTH ANALG, V60, P85; GALVEZ RA, 1987, J ALLERGY CLIN IMMUN, V79, P331, DOI 10.1016/0091-6749(87)90150-3; GEARHART JM, 1988, EXP LUNG RES, V14, P587, DOI 10.3109/01902148809087831; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GERBLICH AA, 1986, J ALLERGY CLIN IMMUN, V77, P676, DOI 10.1016/0091-6749(86)90408-2; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GLEZEN WP, 1989, AM REV RESPIR DIS, V140, P873, DOI 10.1164/ajrccm/140.4.873; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GODFREY S, 1984, J ALLERGY CLIN IMMUN, V73, P630, DOI 10.1016/0091-6749(84)90295-1; GODRREY S, 1977, MUSCULAR EXERCISE LU, P247; GOLD WM, 1985, CHEST, V87, pS30, DOI 10.1378/chest.87.1.30S; GOLDMAN J, 1991, THORAX, V46, P401, DOI 10.1136/thx.46.6.401; GOLDMAN J, 1988, LANCET, V2, P493, DOI 10.1016/S0140-6736(88)90132-8; GONZALEZ ER, 1988, AM FAM PHYSICIAN, V37, P169; GONZALEZ JP, 1987, DRUGS, V34, P560, DOI 10.2165/00003495-198734050-00004; GORDON EH, 1987, J ASTHMA, V24, P261, DOI 10.3109/02770908709070950; GRADMAN AH, 1990, J SPIR DIS, V11, P68; GRAMMER LC, 1989, J ALLERGY CLIN IMMUN, V84, P805, DOI 10.1016/0091-6749(89)90343-6; GRANDORDY BM, 1988, EUR RESPIR J, V1, P531; GRAVELYN TR, 1988, AM REV RESPIR DIS, V137, P641, DOI 10.1164/ajrccm/137.3.641; GREEN M, 1971, LANCET, V1, P1159; GREEN WF, 1986, AUST NZ J MED, V16, P639, DOI 10.1111/j.1445-5994.1986.tb00002.x; GREEN WF, 1989, CLIN EXP ALLERGY, V19, P203, DOI 10.1111/j.1365-2222.1989.tb02365.x; GREENBERG MA, 1988, J PEDIATR-US, V113, P504, DOI 10.1016/S0022-3476(88)80639-5; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P645, DOI 10.1016/0091-6749(84)90223-9; GREENBERGER PA, 1988, J ALLERGY CLIN IMMUN, V81, P646, DOI 10.1016/0091-6749(88)91034-2; GREENBERGER PA, 1983, ANN INTERN MED, V98, P478, DOI 10.7326/0003-4819-98-4-478; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; GREENBERGER PA, 1984, ANN ALLERGY, V55, P444; GREOS LS, 1991, AM REV RESPIR DIS, V144, P586, DOI 10.1164/ajrccm/144.3_Pt_1.586; GROGGINS RC, 1979, BRIT J DIS CHEST, V73, P297, DOI 10.1016/0007-0971(79)90056-1; GROSS NJ, 1987, POSTGRAD MED J, V63, P29; GROSS NJ, 1987, CHEST, V91, pS52; GROSSMAN J, 1988, AM J MED, V85, P11, DOI 10.1016/0002-9343(88)90234-3; GRUNDBACHER FJ, 1975, J ALLERGY CLIN IMMUN, V56, P104, DOI 10.1016/0091-6749(75)90114-1; GUILL MF, 1987, ANN ALLERGY, V59, P367; GUNNISON AF, 1987, CRIT REV TOXICOL, V17, P185, DOI 10.3109/10408448709071208; GUTSTADT LB, 1989, AM J DIS CHILD, V143, P471, DOI 10.1001/archpedi.1989.02150160101020; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HABY MM, 1994, PEDIATR PULM, V18, P323, DOI 10.1002/ppul.1950180510; HADDI E, 1989, J ALLERGY CLIN IMMUN, V83, P198; HAGERDAL M, 1983, ANESTHESIOLOGY, V59, P425; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; HALKEN S, 1991, ALLERGY, V46, P507, DOI 10.1111/j.1398-9995.1991.tb00613.x; HALTOM JR, 1986, ANNU REV MED, V37, P143; HAMBLETON G, 1977, LANCET, V1, P381; HAMILTON RG, 1992, IMMUNOL CLIN PRACT, V15, P96; HAMMERSCHLAG MR, 1992, J RESPIR DIS, V13, P1385; HARGREAVE FE, 1990, IMMUNOL ALLERGY CLIN, V10, P439; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HARNSBERGER JK, 1983, J PEDIATR-US, V102, P505, DOI 10.1016/S0022-3476(83)80174-7; HARPER PC, 1987, ARCH INTERN MED, V147, P56, DOI 10.1001/archinte.147.1.56; HARRIES MG, 1981, LANCET, V1, P5; HARRIES MG, 1979, CLIN ALLERGY, V9, P437, DOI 10.1111/j.1365-2222.1979.tb02506.x; HARRIS JB, 1987, J PEDIATR-US, V110, P627, DOI 10.1016/S0022-3476(87)80567-X; HARRIS JC, 1986, J AM ACAD CHILD PSY, V25, P120, DOI 10.1016/S0002-7138(09)60608-7; HART BJ, 1990, CLIN EXP ALLERGY, V20, P203, DOI 10.1111/j.1365-2222.1990.tb02669.x; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; HARVING H, 1990, ANN ALLERGY, V65, P25; HASKELL RJ, 1983, ARCH INTERN MED, V143, P1324, DOI 10.1001/archinte.143.7.1324; HAVARD JG, 1975, DIS ABS INT, V35, P69; HAYDEN ML, 1992, J ALLERGY CLIN IMMUN, V89, P536, DOI 10.1016/0091-6749(92)90320-2; HAYNES RB, 1976, COMPLIANCE THERAPEUT; HAZZARD A, 1986, J ASTHMA, V23, P61, DOI 10.3109/02770908609077476; HEINER DC, 1970, J ALLERGY, V45, P30, DOI 10.1016/0021-8707(70)90014-6; HEMEON WCL, 1955, ARCH IND HLTH, V41, P29; HENDELES L, 1992, J PEDIATR-US, V120, P177, DOI 10.1016/S0022-3476(05)80423-8; HENDELES L, 1980, J ALLERGY CLIN IMMUN, V66, P177, DOI 10.1016/0091-6749(80)90035-4; HENDELES L, 1984, CLIN PHARMACOKINET, V9, P95, DOI 10.2165/00003088-198409020-00001; HENDELES L, 1986, J ALLERGY CLIN IMMUN, V78, P743, DOI 10.1016/0091-6749(86)90055-2; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; HENDELES L, 1978, AM REV RESPIR DIS, V118, P97; Hendeles L, 1986, APPLIED PHARMACOKINE, P1105; HENDERSON WR, 1987, J ALLERGY CLIN IMMUN, V79, P543, DOI 10.1016/S0091-6749(87)80146-X; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; HERMAN JJ, 1983, J PEDIATR-US, V102, P196, DOI 10.1016/S0022-3476(83)80519-8; HERXHEIMER H, 1949, BMJ-BRIT MED J, V2, P901, DOI 10.1136/bmj.2.4633.901; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; HETZEL MR, 1979, THORAX, V34, P749, DOI 10.1136/thx.34.6.749; HIGGINS RM, 1988, CHEST, V94, P718, DOI 10.1378/chest.94.4.718; HIGGINS RM, 1987, LANCET, V2, P863; HILL M, 1988, J ALLERGY CLIN IMMUN, V82, P30, DOI 10.1016/0091-6749(88)90047-4; HILL NS, 1988, ARCH INTERN MED, V148, P2579, DOI 10.1001/archinte.148.12.2579; HILMAN B, 1994, CLIN MANIFESTATIONS, P661; HIRSHMAN CA, 1979, BRIT J ANAESTH, V51, P713, DOI 10.1093/bja/51.8.713; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; HOLBREICH M, 1990, J RESPIRATORY DISEAS, V11, P366; HOLGATE ST, 1977, LANCET, V2, P375; HOLGATE ST, 1988, Q J MED, V66, P5; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; HOLGATE ST, 1985, J ALLERGY CLIN IMMUN, V76, P375, DOI 10.1016/0091-6749(85)90657-8; HOLMA B, 1977, ARCH ENVIRON HEALTH, V32, P216; HONICKY RE, 1985, PEDIATRICS, V75, P587; HOPP RJ, 1993, PEDIATRIC RESPIRATOR, P131; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; HUANG D, 1993, ANN INTERN MED, V119, P1155, DOI 10.7326/0003-4819-119-12-199312150-00001; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; HUDSON LD, 1977, CHEST, V72, P401; HUHTI E, 1986, RESPIRATION, V50, P298, DOI 10.1159/000195150; IRWIN RS, 1981, AM REV RESPIR DIS, V123, P413; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; JACOBS RL, 1982, JAMA-J AM MED ASSOC, V247, P40, DOI 10.1001/jama.247.1.40; JANSON C, 1994, AM J RESP CRIT CARE, V149, P930, DOI 10.1164/ajrccm.149.4.8143058; JENKINS PF, 1981, THORAX, V36, P835, DOI 10.1136/thx.36.11.835; JENNE JW, 1986, AM REV RESPIR DIS, V134, P708; JENNE JW, 1993, PHARMACOTHERAPY, V13, P595; JICK H, 1975, DRUG THER, P85; JOAD JP, 1986, J ALLERGY CLIN IMMUN, V78, P1147, DOI 10.1016/0091-6749(86)90264-2; JOAD JP, 1987, J ALLERGY CLIN IMMUN, V79, P78, DOI 10.1016/S0091-6749(87)80020-9; JOHNSON D, 1991, J ASTHMA, V28, P85, DOI 10.3109/02770909109082732; JONES G, 1991, AM REV RESPIR DIS, V143, P179, DOI 10.1164/ajrccm/143.1.179; JONKMAN JHG, 1984, CLIN PHARMACOKINET, V9, P309, DOI 10.2165/00003088-198409040-00002; JOSEPHSON GW, 1980, CHEST, V78, P429, DOI 10.1378/chest.78.3.429; JOUBERT JR, 1985, ALLERGY, V40, P202, DOI 10.1111/j.1398-9995.1985.tb00217.x; JUNIPER EF, 1987, CLIN ALLERGY, V17, P523, DOI 10.1111/j.1365-2222.1987.tb02048.x; JUSKO WJ, 1979, J PHARM SCI, V68, P1358, DOI 10.1002/jps.2600681106; KALINER MA, 1990, AM FAM PHYSICIAN, V42, P1609; KALINER MA, 1992, J ALLERGY CLIN IMMUN, V90, P424, DOI 10.1016/0091-6749(92)90162-U; KALLENBACH JM, 1993, AM J MED, V95, P265, DOI 10.1016/0002-9343(93)90278-W; KALLIEL JN, 1989, CHEST, V96, P1336, DOI 10.1378/chest.96.6.1336; KAMBUROFF PL, 1980, EUR J RESPIR DIS, V61, P65; KAMM RD, 1992, AM REV RESPIR DIS, V145, P1249, DOI 10.1164/ajrccm/145.6.1249; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG B, 1989, ANN ALLERGY, V62, P30; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P802, DOI 10.1016/0091-6749(93)90057-M; KAPLAN MA, 1959, ANTIBIOTICS ANN 1958, P273; KAREM, 1993, J PEDIATR, V123, P313; KARETZKY MS, 1980, ANN ALLERGY, V44, P12; KARPEL JP, 1986, AM REV RESPIR DIS, V133, P727; KASENBERG DF, 1987, PEDIATR ASTHMA ALLER, V1, P165; KASPER WJ, 1990, PEDIATR INFECT DIS J, V9, P729, DOI 10.1097/00006454-199010000-00009; KATZ RM, 1986, MED SCI SPORT EXER, V18, P331, DOI 10.1249/00005768-198606000-00014; KATZ U, 1988, PEDIATR ASTHMA ALLER, V2, P309; KAWA T, 1987, J RESPIR DIS S, V150, P1; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; KELLY HW, 1985, ANN ALLERGY, V54, P405; KELSEN SG, 1978, AM J MED, V64, P622, DOI 10.1016/0002-9343(78)90582-X; KEMP JP, 1984, J ALLERGY CLIN IMMUN, V73, P32, DOI 10.1016/0091-6749(84)90481-0; KEMP JP, 1994, AM J RESP CRIT CARE, V150, P1612, DOI 10.1164/ajrccm.150.6.7952623; KEMP JP, 1992, ANN ALLERGY, V69, P276; KEMP JP, 1986, J ALLERGY CLIN IMMUN, V77, P509, DOI 10.1016/0091-6749(86)90187-9; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; KENDALL MJ, 1982, J CLIN HOSP PHARM, V7, P31, DOI 10.1111/j.1365-2710.1982.tb00905.x; KEREM E, 1993, J PEDIATR-US, V123, P313, DOI 10.1016/S0022-3476(05)81710-X; KERR HD, 1973, ARCH ENVIRON HEALTH, V26, P144, DOI 10.1080/00039896.1973.10666242; KERREBIJN KF, 1985, J ALLERGY CLIN IMMUN, V76, P628; KERSTEN W, 1989, J ALLERGY CLIN IMMUN, V83, P263; KIDNEY JC, 1993, AM REV RESPIR DIS, V147, pA772; KINNEY EL, 1978, JAMA-J AM MED ASSOC, V240, P2247, DOI 10.1001/jama.1978.03290210029010; Kirscht J P, 1977, J Community Health, V3, P115, DOI 10.1007/BF01674233; KLEIN JJ, 1983, AM REV RESPIR DIS, V127, P413, DOI 10.1164/arrd.1983.127.4.413; KLINGER KW, 1993, PEDIATRIC RESPIRATOR, P652; KNIEST FM, 1991, CLIN EXP ALLERGY, V21, P39, DOI 10.1111/j.1365-2222.1991.tb00802.x; KOENIG JQ, 1985, INHAL TOXICOL, P85; KOH YY, 1993, CLIN EXP ALLERGY, V23, P696, DOI 10.1111/j.1365-2222.1993.tb01796.x; ROBERTSON WO, 1994, PEDIATRICS, V93, P119; 1985, CHEST, V87, pS107; 1979, 79387 NAT I HLTH PUB, P7; 1991, FDA MED B        DEC, P3; 1991, J ALLERGY CLIN IMMUN, V88, P425; 1993, PARAMETERS OPERATION; 1987, BR J DIS CHEST, V81, P30; 1993, J ALLERGY CLIN IMMUN, V91, P1234; 1988, J ALLERGY CLIN IMMUN, V82, P487; 1989, PROVOCATIVE CHALLENG, P316; 1991, AM REV RESPIR DIS, V142, P487; 1994, CONSORTIUM CHILDRENS; 1992, 923091 NAT HEART LUN; 1988, FDA DRUG B, V18, P32; 1995, SUMMER CAMPS CHILDRE; 1993, J ALLERGY CLIN IMMUN, V92, P223; 1976, PEDIATRICS, V57, P272; 1991, J ALLERGY CLIN IMMUN, V88, P506; 1991, ANN ALLERGY, V88, P506; 1992, PEDIATR ASTHMA ALLER, V6, P115; 1984, PEDIATRICS, V74, P155; 1989, MMWR-MORBID MORTAL W, V38, P205; 1992, PATIENT INFORMATION; 1988, US FOOD DRUG ADM DRU, V18, P32; 1989, J ALLERGY CLIN IMMUN, V84, P129; 1991, J ALLERGY CLIN IMMUN, V88, P477; 1988, HDB PARENTS SPECIAL; 1989, MINNESOTA MULTIPHASI; KOENIG JQ, 1987, J ALLERGY CLIN IMMUN, V79, P54, DOI 10.1016/S0091-6749(87)80016-7; KOENIG JQ, 1988, J ALLERGY CLIN IMMUN, V81, P897, DOI 10.1016/0091-6749(88)90947-5; KOENIG JQ, 1989, NEW ENGL J MED, V321, P1426; KOENIG JQ, 1988, PEDIATR ASTHMA ALLER, V2, P199; KOEPKE JW, 1984, JAMA-J AM MED ASSOC, V251, P2982, DOI 10.1001/jama.251.22.2982; KOEPKE JW, 1983, J ALLERGY CLIN IMMUN, V72, P504, DOI 10.1016/0091-6749(83)90588-2; KONIG P, 1984, J ALLERGY CLIN IMMUN, V73, P686, DOI 10.1016/0091-6749(84)90306-3; KONIG P, 1982, ANN ALLERGY, V49, P86; KONIG P, 1993, J PEDIATR-US, V122, P219, DOI 10.1016/S0022-3476(06)80116-2; KOPFERSCHMITTKUBLER MC, 1987, J ALLERGY CLIN IMMUN, V80, P730, DOI 10.1016/0091-6749(87)90295-8; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; KOTSES H, 1995, J ALLERGY CLIN IMMUN, V95, P529, DOI 10.1016/S0091-6749(95)70315-2; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; KRAEMER R, 1983, J PEDIATR-US, V102, P347, DOI 10.1016/S0022-3476(83)80646-5; KRAVIS LP, 1985, AM J DIS CHILD, V139, P558, DOI 10.1001/archpedi.1985.02140080028026; KREIT JW, 1989, J APPL PHYSIOL, V66, P217, DOI 10.1152/jappl.1989.66.1.217; KRYGER M, 1976, AM J MED, V61, P85, DOI 10.1016/0002-9343(76)90048-6; KUNITOH H, 1992, ANN ALLERGY, V69, P111; KURLAND G, 1979, J ALLERGY CLIN IMMUN, V63, P407, DOI 10.1016/0091-6749(79)90214-8; LABOVITZ E, 1982, JAMA-J AM MED ASSOC, V247, P786, DOI 10.1001/jama.247.6.786; LABRALCO J M, 1984, Journal of Allergy and Clinical Immunology, V73, P124; LAI CKW, 1989, AM REV RESPIR DIS, V140, P917, DOI 10.1164/ajrccm/140.4.917; LAL S, 1986, EUR J RESPIR DIS, V69, P136; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; LAO TT, 1990, EUR J OBSTET GYN R B, V35, P183, DOI 10.1016/0028-2243(90)90160-3; LAPIN CD, 1995, J ASTHMA, V32, P5, DOI 10.3109/02770909509089495; LARSSON K, 1992, CHEST, V101, P953, DOI 10.1378/chest.101.4.953; LATIMER KM, 1983, AM REV RESPIR DIS, V128, P440, DOI 10.1164/arrd.1983.128.3.440; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LAU S, 1989, J ALLERGY CLIN IMMUN, V83, P263; LAWFORD P, 1978, BRIT MED J, V1, P84, DOI 10.1136/bmj.1.6105.84; LEAHY BC, 1983, BRIT J DIS CHEST, V77, P159, DOI 10.1016/0007-0971(83)90022-0; LEE ML, 1982, J ALLERGY CLIN IMMUN, V69, P331, DOI 10.1016/S0091-6749(82)80012-2; LEE TH, 1984, J ALLERGY CLIN IMMUN, V73, P634, DOI 10.1016/0091-6749(84)90296-3; LEE TH, 1992, AM REV RESPIR DIS, V145, pS1, DOI 10.1164/ajrccm/145.2_Pt_2.S1; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V88, P895, DOI 10.1016/0091-6749(91)90246-K; LEMANSKE RF, 1988, J CLIN IMMUNOL, V8, P1, DOI 10.1007/BF00915151; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LEMANSKE RF, 1989, J CLIN INVEST, V11, P378; LEMAO J, 1989, J ALLERGY CLIN IMMUN, V83, P926, DOI 10.1016/0091-6749(89)90107-3; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; LEMEN RJ, 1993, KENDIGS DISORDERS RE, P147; LENNEY W, 1978, ARCH DIS CHILD, V53, P532, DOI 10.1136/adc.53.7.532; LEUNG KBP, 1988, THORAX, V43, P756, DOI 10.1136/thx.43.10.756; LEUNG KBP, 1986, AGENTS ACTIONS, V18, P110, DOI 10.1007/BF01987997; LEVY L, 1947, J ALLERGY, V18, P244, DOI 10.1016/0021-8707(47)90048-8; LEWIS CE, 1984, PEDIATRICS, V74, P478; LI JTC, 1985, AM J MED, V79, P10, DOI 10.1016/0002-9343(85)90081-6; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1985, CECIL TXB MED, V2, P1870; LIN RY, 1993, ANN EMERG MED, V22, P1847, DOI 10.1016/S0196-0644(05)80412-3; LIND P, 1987, J ALLERGY CLIN IMMUN, V80, P541, DOI 10.1016/0091-6749(87)90005-4; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; LINDGREN S, 1992, NEW ENGL J MED, V327, P926, DOI 10.1056/NEJM199209243271305; LINNA O, 1983, ALLERGY, V38, P513, DOI 10.1111/j.1398-9995.1983.tb02360.x; LINVIA O, 1983, ALLERGY, V38, P513; LIPWORTH BJ, 1989, AM REV RESPIR DIS, V140, P586, DOI 10.1164/ajrccm/140.3.586; LIPWORTH BJ, 1992, DRUG SAFETY, V7, P54, DOI 10.2165/00002018-199207010-00007; LITTENBERG B, 1988, JAMA-J AM MED ASSOC, V259, P1678, DOI 10.1001/jama.259.11.1678; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; LUDWICK SK, 1986, J PEDIATR-US, V109, P446, DOI 10.1016/S0022-3476(86)80115-9; LULICH KM, 1986, MED TOXICOL ADV DRUG, V1, P286, DOI 10.1007/BF03259844; LULLA S, 1980, J PEDIATR-US, V97, P346, DOI 10.1016/S0022-3476(80)80179-X; LUSHNIAK B D, 1990, Journal of Allergy and Clinical Immunology, V85, P251; LUSK RP, 1989, PEDIATR CLIN N AM, V36, P1411; LUTSKY II, 1975, ANN ALLERGY, V35, P201; LYON EM, 1986, ANN ALLERGY, V57, P135; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; MACDONALD NE, 1985, J RESPIR DIS, V6, P11; MACHADO L, 1985, ALLERGY, V40, P580, DOI 10.1111/j.1398-9995.1985.tb00886.x; MADONINI E, 1987, J ALLERGY CLIN IMMUN, V79, P358, DOI 10.1016/0091-6749(87)90156-4; MAGNUSSEN H, 1988, J ALLERGY CLIN IMMUN, V81, P518, DOI 10.1016/0091-6749(88)90190-X; MAGNUSSEN H, 1988, CHEST, V93, P937, DOI 10.1378/chest.93.5.937; MAGUIRE JF, 1991, PEDIATRICS, V88, P1180; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MALISH DM, 1985, IMMUNOL ALLERGY PRAC, V7, P31; MALLING HJ, 1993, ALLERGY, V48, P9; MALLING HJ, 1986, ALLERGY, V41, P57, DOI 10.1111/j.1398-9995.1986.tb00276.x; MALO JL, 1992, J ALLERGY CLIN IMMUN, V89, P567, DOI 10.1016/0091-6749(92)90324-U; MALO JL, 1990, J ALLERGY CLIN IMMUN, V85, P729, DOI 10.1016/0091-6749(90)90191-6; MALO JL, 1990, J ALLERGY CLIN IMMUN, V56, P323; MALVEAUX FJ, 1993, J ASTHMA, V30, P431, DOI 10.3109/02770909309056751; MANSFIELD LE, 1981, ANN ALLERGY, V47, P431; MANSMANN HC, 1991, PEDIATRIC ASTHMA ALL, V5, P273; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MARTIN J, 1980, AM REV RESPIR DIS, V121, P441, DOI 10.1164/arrd.1980.121.3.441; MARTIN RJ, 1989, AM REV RESPIR DIS, V139, P475, DOI 10.1164/ajrccm/139.2.475; MARTIN TG, 1982, ANN EMERG MED, V11, P466, DOI 10.1016/S0196-0644(82)80063-2; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MASSANARI M, 1985, J PEDIATR-US, V106, P348, DOI 10.1016/S0022-3476(85)80332-2; MASSANARI M, 1985, DRUG INTEL CLIN PHAR, V19, P462; MASSANARI M, 1992, J ALLERGY CLIN IMMUN, V89, P154; MASSANARI MJ, 1986, DRUG INTEL CLIN PHAR, V20, P471; MASSEY KL, 1988, EUR J CLIN PHARMACOL, V34, P555, DOI 10.1007/BF00615217; MATHISON DA, 1988, ALLERGY PRINCIPLES P, P1063; MATT B, 1994, RESPIRATORY DISEASE, P551; MATTHYS H, 1985, RESPIRATION, V48, P269, DOI 10.1159/000194839; MATUS I, 1981, AM J ORTHOPSYCHIAT, V51, P327, DOI 10.1111/j.1939-0025.1981.tb01378.x; MAWHINNEY H, 1991, ANN ALLERGY, V66, P294; MAWHINNEY H, 1986, DRUGS, V32, P178, DOI 10.2165/00003495-198632020-00005; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; MCCANN DP, 1990, WESTERN J MED, V153, P44; MCCARTHY TP, 1992, BRIT J GEN PRACT, V42, P429; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V95, P641, DOI 10.1016/S0091-6749(95)70166-4; MCFADDEN ER, 1968, NEW ENGL J MED, V278, P1027, DOI 10.1056/NEJM196805092781901; MCFADDEN ER, 1984, J ALLERGY CLIN IMMUN, V73, P413, DOI 10.1016/0091-6749(84)90347-6; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V78, P1, DOI 10.1016/0091-6749(86)90106-5; MCFADDEN ER, 1979, NEW ENGL J MED, V301, P763; MCFADDEN ER, 1978, ALLERGY PRINCIPLES P, V2, P687; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MEETHAM AR, 1964, ATMOSPHERIC POLLUTIO, P231; MELIA RJW, 1977, BRIT MED J, V2, P149, DOI 10.1136/bmj.2.6080.149; MELLINS RB, 1989, J RESPIR DIS S, V10, pS47; MELTZER EO, 1982, PEDIATRICS, V69, P340; MELZER E, 1980, AM REV RESPIR DIS, V121, P17; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P646, DOI 10.1016/0091-6749(85)90088-0; MENDOZA J, 1970, ANN ALLERGY, V28, P159; MENITOVE SM, 1983, AM J MED, V74, P898, DOI 10.1016/0002-9343(83)91082-3; MENON P, 1991, ANN ALLERGY, V67, P573; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; METZGER WJ, 1983, N ENGL REGIONAL ALLE, V3, P270; MILAVETZ G, 1989, ANN ALLERGY, V62, P453; MILAVETZ G, 1987, J ALLERGY CLIN IMMUN, V80, P723, DOI 10.1016/0091-6749(87)90294-6; MILAVETZ G, 1986, J PEDIATR-US, V109, P351, DOI 10.1016/S0022-3476(86)80403-6; MILLER BD, 1989, AM J DIS CHILD, V143, P1294, DOI 10.1001/archpedi.1989.02150230052022; MILLER J, 1988, ANN ALLERGY, V60, P154; MILLER TP, 1992, CHEST, V102, P515, DOI 10.1378/chest.102.2.515; MILLMAN M, 1983, ANN ALLERGY, V50, P85; MILNER AD, 1987, POSTGRAD MED J, V63, P53; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MISIERES J, 1987, ALLERGY IMMUNOL, V19, P18; MISZKIEL KA, 1988, BRIT J CLIN PHARMACO, V26, P295, DOI 10.1111/j.1365-2125.1988.tb05280.x; MITHOEFER JC, 1965, NEW ENGL J MED, V272, P1200, DOI 10.1056/NEJM196506102722303; MOLER FW, 1988, J ALLERGY CLIN IMMUN, V81, P1101, DOI 10.1016/0091-6749(88)90876-7; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; MORGAN MA, 1984, AM J CLIN PATHOL, V82, P597, DOI 10.1093/ajcp/82.5.597; MORGAN MDL, 1982, BRIT MED J, V285, P849, DOI 10.1136/bmj.285.6345.849; MORGAN WJ, 1992, PEDIATR CLIN N AM, V39, P1185; MORRIS HG, 1985, J ALLERGY CLIN IMMUN, V75, P1, DOI 10.1016/0091-6749(85)90002-8; MORRIS HG, 1986, AM J MED, V81, P36, DOI 10.1016/0002-9343(86)90460-2; MORRIS K, 1990, AM J DIS CHILD, V144, P105, DOI 10.1001/archpedi.1990.02150250117047; MORTON AR, 1989, J ALLERGY CLIN IMMUN, V83, P55, DOI 10.1016/0091-6749(89)90477-6; MORTON AR, 1979, ANN ALLERGY, V42, P257; MOSBECH H, 1991, CLIN EXP ALLERGY, V21, P351, DOI 10.1111/j.1365-2222.1991.tb01667.x; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; MURANAKA M, 1978, ANN ALLERGY, V40, P132; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P350, DOI 10.1016/0091-6749(81)90079-8; MURPHY DMF, 1976, CHEST, V69, P372, DOI 10.1378/chest.69.3.372; MURPHY KR, 1985, J PEDIATR-US, V106, P931, DOI 10.1016/S0022-3476(85)80241-9; MURPHY TM, 1991, BASIC MECHANISMS PED, P221; MURRAY AB, 1988, CHEST, V94, P701, DOI 10.1378/chest.94.4.701; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; MURRAY AB, 1983, PEDIATRICS, V71, P418; MYERS DJ, 1985, CLIN RES, V33, pA107; NASSIF EG, 1981, J PEDIATR-US, V98, P158; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; NAUMANN BD, 1985, TOXICOLOGIST, V5, P180; NEIJENS HJ, 1985, J PEDIATR-US, V107, P811, DOI 10.1016/S0022-3476(85)80426-1; NELSON E, 1982, NEW LETTERS, V49, P73; NELSON HS, 1983, ANN ALLERGY, V51, P411; NELSON HS, 1986, J ALLERGY CLIN IMMUN, V77, P771, DOI 10.1016/0091-6749(86)90372-6; NELSON LA, 1987, PEDIATR ASTHMA ALLER, V1, P175; NEUVONEN PJ, 1983, EUR J CLIN PHARMACOL, V24, P557, DOI 10.1007/BF00609903; NEVILLE E, 1982, BRIT MED J, V285, P796, DOI 10.1136/bmj.285.6344.796; NEWHOUSE MT, 1993, PEDIATR PULM, V15, P271, DOI 10.1002/ppul.1950150502; NEWHOUSE MT, 1987, CHEST, V9, P585; NEWMAN SP, 1984, THORAX, V39, P935, DOI 10.1136/thx.39.12.935; NEWMANTAYLOR AJ, 1979, CLIN ALLERGY, V9, P213; NEWTH CJL, 1991, AM REV RESPIR DIS, V143, P766, DOI 10.1164/ajrccm/143.4_Pt_1.766; NGUYEN B, 1992, NOV ANN M AM COLL AL; NICKERSON BG, 1980, PEDIATRICS, V65, P1140; NICKLAS RA, 1984, J ALLERGY CLIN IMMUN, V73, P20, DOI 10.1016/0091-6749(84)90479-2; NICKLAS RA, 1990, J ALLERGY CLIN IMMUN, V85, P959, DOI 10.1016/0091-6749(90)90084-H; NOGRADY SG, 1978, THORAX, V33, P700, DOI 10.1136/thx.33.6.700; NORMAN PS, 1990, J ALLERGY CLIN IMMUN, V85, P522, DOI 10.1016/0091-6749(90)90165-Z; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; NOVEMBRE E, 1988, J ALLERGY CLIN IMMUN, V81, P1059, DOI 10.1016/0091-6749(88)90181-9; NOWAK RM, 1983, JAMA-J AM MED ASSOC, V249, P2043, DOI 10.1001/jama.249.15.2043; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; ODRISCOLL BR, 1989, LANCET, V1, P1418; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; OHOLLAREN MT, 1988, J ALLERGY CLIN IMMUN, V81, P246, DOI 10.1016/0091-6749(88)90547-7; OHOLLAREN MT, 1986, J ALLERGY CLIN IMMUN, V77, P199; OLLERENSHAW SL, 1992, AM REV RESPIR DIS, V145, P922, DOI 10.1164/ajrccm/145.4_Pt_1.922; OLSON KR, 1985, AM J EMERG MED, V3, P386, DOI 10.1016/0735-6757(85)90195-0; ONEIL SL, 1985, J SCHOOL HEALTH, V55, P237, DOI 10.1111/j.1746-1561.1985.tb04129.x; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; OREFICE U, 1992, RESPIRATION, V59, P97; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; ORENSTEIN SR, 1988, J PEDIATR-US, V112, P847, DOI 10.1016/S0022-3476(88)80204-X; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OSTERBALLE O, 1979, ALLERGY, V34, P125, DOI 10.1111/j.1398-9995.1979.tb01373.x; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; OWNBY DR, 1984, AM J DIS CHILD, V138, P1062, DOI 10.1001/archpedi.1984.02140490062015; OWNBY DR, 1994, J ALLERGY CLIN IMMUN, V94, P662, DOI 10.1016/0091-6749(94)90171-6; PAGE CP, 1991, LANCET, V337, P717, DOI 10.1016/0140-6736(91)90289-2; PAGGIARO P, 1987, AM REV RESPIR DIS, V136, P1237, DOI 10.1164/ajrccm/136.5.1237; PAGGIARO PL, 1987, CLIN ALLERGY, V17, P333, DOI 10.1111/j.1365-2222.1987.tb02023.x; PALEY A, 1973, GERIATRICS, V28, P54; PANG LM, 1977, CHEST, V72, P469, DOI 10.1378/chest.72.4.469; PARCEL GS, 1979, PEDIATRICS, V64, P878; PARK GD, 1983, CLIN PHARMACOL THER, V34, P663, DOI 10.1038/clpt.1983.229; PARK GD, 1983, AM J MED, V74, P961, DOI 10.1016/0002-9343(83)90790-8; PARKER G, 1979, J PSYCHOSOM RES, V23, P295, DOI 10.1016/0022-3999(79)90034-5; PARKER SR, 1989, AM REV RESPIR DIS, V140, P848, DOI 10.1164/ajrccm/140.3.848; PARRISH RH, 1980, AM PHARM, V20, P37, DOI 10.1016/S0160-3450(16)31004-2; PARTRIDGE MR, 1979, THORAX, V34, P771, DOI 10.1136/thx.34.6.771; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PATEL KR, 1986, EUR J RESPIR DIS, V69, P256; PATEL KR, 1981, CLIN ALLERGY, V11, P429, DOI 10.1111/j.1365-2222.1981.tb01615.x; PATEL KR, 1986, BRIT J CLIN PHARMACO, V21, P231, DOI 10.1111/j.1365-2125.1986.tb05181.x; PATEL KR, 1987, J ALLERGY CLIN IMMUN, V79, P355, DOI 10.1016/0091-6749(87)90155-2; PATEL KR, 1988, AM REV RESPIR DIS, V138, P54, DOI 10.1164/ajrccm/138.1.54; PATTERSMORE PK, 1992, ALLERGY, V11, P325; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PATTERSON R, 1983, ANN INTERN MED, V99, P18, DOI 10.7326/0003-4819-99-1-18; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PAUWELS R, 1987, CHEST, V92, pS32, DOI 10.1378/chest.92.1_Supplement.32S; PEARLMAN DS, 1984, AM J DIS CHILD, V138, P459, DOI 10.1001/archpedi.1984.02140430037010; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; PEDERSEN S, 1993, AM REV RESPIR DIS, V147, pA265; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; PERRIN JM, 1986, PEDIATRICS, V77, P587; PERSSON K, 1991, ASTHMA PATHOLOGY TRE; PETHERAM IS, 1979, POSTGRAD MED J, V55, P877, DOI 10.1136/pgmj.55.650.877; PETHERAM IS, 1981, THORAX, V36, P308, DOI 10.1136/thx.36.4.308; PETTY TL, 1990, CHEST, V97, P75, DOI 10.1378/chest.97.1.75; PHANUPHAK P, 1980, AM J MED, V68, P479, DOI 10.1016/0002-9343(80)90285-5; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; PHILLIPS MJ, 1984, THORAX, V39, P345, DOI 10.1136/thx.39.5.345; PIERSON WE, 1988, PEDIATR CLIN N AM, V35, P1031; PIERSON WE, 1984, J ALLERGY CLIN IMMUN, V73, P717, DOI 10.1016/0091-6749(84)90313-0; PIERSON WE, 1989, WESTERN J MED, V151, P339; PIERSON WE, 1992, J ALLERGY CLIN IMMUN, V90, P557, DOI 10.1016/0091-6749(92)90128-O; PIERSON WE, 1983, ASTHMATIC CHILD PLAY, P187; PIERSON WE, 1987, J ALLERGY CLIN IMMUN, V79, P96; PIZOV R, 1994, ANESTHESIOLOGY, V81, pA1471; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; PLATTSMILLS TAE, 1982, LANCET, P765; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V15, P21; PLATTSMILLS TAE, 1989, J RESP DIS, V10, P53; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V81, P242, DOI 10.1016/0091-6749(88)90531-3; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLOCK J, 1977, PEDIATRICS, V60, P840; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; POZANSKI EO, 1984, J AM ACAD CHILD PSY, V23, P191; PRAHL P, 1987, ALLERGY, V42, P541, DOI 10.1111/j.1398-9995.1987.tb00379.x; PRATTER MR, 1983, CHEST, V84, P42, DOI 10.1378/chest.84.1.42; PRENNER BM, 1976, ANN ALLERGY, V37, P180; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RACHELEFSKY GS, 1978, CHEST, V73, P1017; RACHELEFSKY GS, 1986, PEDIATRICS, V78, P1133; RACHELEFSKY GS, 1987, J ALLERGY CLIN IMMUN, V80, P506, DOI 10.1016/0091-6749(87)90087-X; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; RAMSDELL JW, 1982, AM REV RESPIR DIS, V126, P829; RANDOLPH C, 1993, AM J ASTHMA ALLERGY, V6, P129; RAPPAPORT L, 1989, AM J DIS CHILD, V143, P368, DOI 10.1001/archpedi.1989.02150150126032; RATTO D, 1988, JAMA-J AM MED ASSOC, V260, P527, DOI 10.1001/jama.260.4.527; RAWLS DJ, 1971, J CONSULT CLIN PSYCH, V36, P260, DOI 10.1037/h0030762; RAYBURN WF, 1989, AM J OBSTET GYNECOL, V160, P529, DOI 10.1016/S0002-9378(89)80020-1; RAYNER RJ, 1987, ARCH DIS CHILD, V62, P840, DOI 10.1136/adc.62.8.840; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; REBUCK AS, 1973, NEW ENGL J MED, V288, P66, DOI 10.1056/NEJM197301112880203; REBUCK AS, 1987, AM J MED, V82, P59, DOI 10.1016/0002-9343(87)90378-0; REBUCK AS, 1971, AM J MED, V51, P788, DOI 10.1016/0002-9343(71)90307-X; REED CE, 1985, J ALLERGY CLIN IMMUN, V76, P335, DOI 10.1016/0091-6749(85)90650-5; REED CE, 1991, IMMUNOL ALLERGY CLIN, V11, P1; REED CE, 1988, AM J MED, V85, P14, DOI 10.1016/0002-9343(88)90235-5; REICHES NA, 1993, PEDIATRICS, V22, P223; REID LM, 1987, J ALLERGY CLIN IMMUN, V80, P415, DOI 10.1016/0091-6749(87)90064-9; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; REINER A, 1978, ACTA OTO-LARYNGOL, V355, P1; REISMAN J, 1988, J ALLERGY CLIN IMMUN, V81, P16, DOI 10.1016/0091-6749(88)90214-X; REPSHER LM, 1983, TODAYS THERAPEUTIC T, V1, P77; RICHTER JE, 1982, ANN INTERN MED, V97, P93, DOI 10.7326/0003-4819-97-1-93; ROBBERECHT P, 1983, MOL PHARMACOL, V24, P169; ROBERTSON CF, 1985, J PEDIATR-US, V106, P672, DOI 10.1016/S0022-3476(85)80101-3; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROBINSON D, 1994, AM RESPIR CRIT CARE, V148, P401; ROBINSON LD, 1985, CHEST, V87, pS105, DOI 10.1378/chest.87.1.105S; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROGERS RM, 1973, CHEST, V63, P986, DOI 10.1378/chest.63.6.986; ROHR AS, 1987, ANN ALLERGY, V59, P107; ROSE CC, 1984, NEW ENGL J MED, V310, P573, DOI 10.1056/NEJM198403013100906; ROSENTHAL RR, 1979, CHEST, V75, P228, DOI 10.1378/chest.75.2.228; ROSS RN, 1988, CLIN THER, V10, P188; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; RUBIN RP, 1991, J BIOL MED, V9, P4; RUBINSTEIN I, 1987, NEW ENGL J MED, V317, P482, DOI 10.1056/NEJM198708203170805; RUBINSTEIN S, 1984, ANN ALLERGY, V53, P311; RUDNITSKY GS, 1993, ANN EMERG MED, V22, P1842, DOI 10.1016/S0196-0644(05)80411-1; RUTLAND J, 1990, NEW ENGL J MED, V323, P1681, DOI 10.1056/NEJM199012133232406; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; Sackett D L, 1978, Patient Couns Health Educ, V1, P18; SALZMAN GA, 1989, CHEST, V95, P1017, DOI 10.1378/chest.95.5.1017; SAMET JM, 1987, AM REV RESPIR DIS, V136, P1486, DOI 10.1164/ajrccm/136.6.1486; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SANJAR S, 1990, BRIT J PHARMACOL, V99, P679, DOI 10.1111/j.1476-5381.1990.tb12989.x; SANTO M, 1980, S AFR MED J, V58, P394; SARSFIELD JK, 1976, ARCH DIS CHILD, V51, P186, DOI 10.1136/adc.51.3.186; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P771; SBARBARO JA, 1991, ANN ALLERGY, V66, P273; SCHACHTER EN, 1981, ANN ALLERGY, V46, P12; SCHATZ M, 1992, ANN ALLERGY, V68, P123; SCHATZ M, 1988, Journal of Allergy and Clinical Immunology, V81, P509, DOI 10.1016/0091-6749(88)90187-X; SCHATZ M, 1976, ANN INTERN MED, V84, P261, DOI 10.7326/0003-4819-84-3-261; SCHATZ M, 1988, ALLERGY PRINCIPLES P, P1097; SCHECKER MH, 1993, J ALLERGY CLIN IMMUN, V92, P783, DOI 10.1016/0091-6749(93)90054-J; Schiffer C. G, 1963, CHILDRENS BUREAU PUB, V405; SCHILD HO, 1951, LANCET, V261, P376; SCHINDLBECK N, 1980, JAMA-J AM MED ASSOC, V260, P3156; SCHLESINGER RB, 1983, J TOXICOL ENV HEALTH, V12, P441, DOI 10.1080/15287398309530440; SCHLESINGER RB, 1984, TOXICOL LETT, V22, P249, DOI 10.1016/0378-4274(84)90074-2; SCHLOSBERG M, 1993, IMMUNOL ALLERGY CLIN, V13, P721; SCHLUETER DP, 1986, AM J MED, V81, P55, DOI 10.1016/0002-9343(86)90463-8; SCHOEFFEL RE, 1983, AUST NZ J MED, V13, P157, DOI 10.1111/j.1445-5994.1983.tb02672.x; SCHROECKENSTEIN DC, 1988, J ALLERGY CLIN IMMUN, V82, P115, DOI 10.1016/0091-6749(88)90060-7; SCHUH S, 1990, PEDIATRICS, V86, P509; SCHUH S, 1989, PEDIATRICS, V83, P513; SCHULLER DE, 1983, J ALLERGY CLIN IMMUN, V71, P147, DOI 10.1016/0091-6749(83)90359-7; SCHWARTZ HJ, 1985, J ALLERGY CLIN IMMUN, V75, P525, DOI 10.1016/S0091-6749(85)80027-0; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SCHWARTZ S, 1980, CHEST, V78, P100, DOI 10.1378/chest.78.1.100; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P319, DOI 10.1016/0091-6749(87)90038-8; SESSLER CN, 1990, AM J MED, V88, P567, DOI 10.1016/0002-9343(90)90519-J; SETTIPANE GA, 1987, NEW ENGL REG ALLERGY, V8, P323; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V49, P348, DOI 10.1016/0091-6749(72)90133-9; SETTIPANE GA, 1979, JAMA-J AM MED ASSOC, V241, P811, DOI 10.1001/jama.241.8.811; SHAPIRO GG, 1992, J ALLERGY CLIN IMMUN, V90, P417, DOI 10.1016/0091-6749(92)90160-4; SHAPIRO GG, 1974, PEDIATRICS, V53, P867; SHAW RJ, 1985, BRIT J DIS CHEST, V79, P385, DOI 10.1016/0007-0971(85)90073-7; SHEEHY AF, 1972, ARCH INTERN MED, V130, P37, DOI 10.1001/archinte.130.1.37; SHEPHERD GL, 1981, BRIT J DIS CHEST, V75, P215, DOI 10.1016/0007-0971(81)90057-7; SHIM C, 1980, AM J MED, V69, P891, DOI 10.1016/S0002-9343(80)80016-7; SHIM CS, 1983, ARCH INTERN MED, V143, P890, DOI 10.1001/archinte.143.5.890; SHIM CS, 1980, AM J MED, V68, P11, DOI 10.1016/0002-9343(80)90155-2; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P82; SHOVLIN CL, 1990, LANCET, V336, P1258, DOI 10.1016/0140-6736(90)92878-L; SHRENK HH, 1948, PUBLIC HLTH B, V306; SHRIDHARANI M, 1982, ANN ALLERGY, V49, P156; SHULANER FA, 1970, PEDIATRICS, V45, P465; SIEGAL S, 1964, J ALLERGY, V35, P252, DOI 10.1016/0021-8707(64)90007-3; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; SIEGEL SC, 1985, J ALLERGY CLIN IMMUN, V76, P1, DOI 10.1016/0091-6749(85)90795-X; SIEGEL SC, 1983, ALLERGY PRINCIPLES P, P863; SILVER RB, 1984, CLIN PEDIATR, V23, P81, DOI 10.1177/000992288402300203; SIMON RA, 1986, ANN ALLERGY, V56, P281; SIMONS FER, 1988, LANCET, V2, P624; SINTEK C, 1979, J PEDIATR-US, V94, P314, DOI 10.1016/S0022-3476(79)80856-2; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P379, DOI 10.1016/0091-6749(80)90117-7; SLAVIN RG, 1992, J ALLERGY CLIN IMMUN, V90, P534, DOI 10.1016/0091-6749(92)90180-A; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; SLAVIN RG, 1984, J ALLERGY CLIN IMMUN, V73, P712, DOI 10.1016/0091-6749(84)90312-9; SLAVIN RG, 1988, ALLERGY PRINCIPLES P; SLOTT RI, 1974, J ALLERGY CLIN IMMUN, V54, P229, DOI 10.1016/0091-6749(74)90065-7; SLY PD, 1985, AM J DIS CHILD, V139, P479, DOI 10.1001/archpedi.1985.02140070053032; SLY RM, 1988, ANN ALLERGY, V60, P433; SLY RM, 1994, ANN ALLERGY, V73, P439; SLY RM, 1985, J ALLERGY CLIN IMMUN, V75, P443; SLY RM, 1989, J ALLERGY CLIN IMMUN, V84, P131, DOI 10.1016/0091-6749(89)90187-5; SLY RM, 1992, ANN ALLERGY, V69, P81; SLY RM, 1992, NELSON TXB PEDIATRIC, P587; SLY RM, 1982, DRUG THER, V12, P102; SLY RM, 1982, DRUG THER, V12, P95; SMITH AB, 1989, J ALLERGY CLIN IMMUN, V84, P794, DOI 10.1016/0091-6749(89)90342-4; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; SMITH DW, 1991, NEW ENGL J MED, V325, P24, DOI 10.1056/NEJM199107043250105; SMITH JA, 1980, CHEST, V78, P816, DOI 10.1378/chest.78.6.816; SMITH JM, 1988, ALLERGY PRINCIPLES P, P897; SMITH L, 1993, CURR PROBL PEDIATR, P271; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SMITH PR, 1977, CHEST, V71, P129, DOI 10.1378/chest.71.2.129; SMITH TF, 1984, J PEDIATR-US, V105, P896, DOI 10.1016/S0022-3476(84)80073-6; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SMOLENSKY MH, 1986, J ASTHMA, V23, P321, DOI 10.3109/02770908609073179; SNJOAQUIN VH, 1982, CLIN PEDIATR, V12, P724; SOBONYA R, 1977, HUM PATHOL, V8, P293, DOI 10.1016/S0046-8177(77)80026-9; Solomon W.R., 1978, ALLERGY PRINCIPLES P, P312; SOLOMON WR, 1978, ALLERGY PRINCIPLES P, P899; SONDHEIMER JM, 1988, PEDIATR CLIN N AM, V35, P103; SORRI M, 1980, Rhinology (Utrecht), V18, P83; SOSIN A, 1991, Pediatric Asthma Allergy and Immunology, V5, P39, DOI 10.1089/pai.1991.5.39; SOUTAR CA, 1977, THORAX, V32, P677, DOI 10.1136/thx.32.6.677; SOUZA LM, 1981, CLIN ALLERGY, V11, P506, DOI 10.1111/j.1365-2222.1981.tb01627.x; SPAGNOLO SV, 1986, HDB PULMONARY EMERGE; SPECTOR S, 1976, AM REV RESPIR DIS, V113, P43; SPECTOR S, 1985, BRONCHIAL ASTHMA MEC, P360; SPECTOR SL, 1985, ANN ALLERGY, V55, P552; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; SPECTOR SL, 1983, ANN ALLERGY, V51, P173; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V78, P529, DOI 10.1016/0091-6749(86)90100-4; SPECTOR SL, 1985, J ALLERGY CLIN IMMUN, V76, P302, DOI 10.1016/0091-6749(85)90646-3; SPECTOR SL, 1991, DM-DIS MON, V37, P1; SPECTOR SL, 1989, PROVOCATIVE CHALLENG, P293; SPECTOR SS, 1986, CHEST, V90, P623, DOI 10.1378/chest.90.4.623-b; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; SPIEKSMA FTM, 1991, CLIN EXP ALLERGY, V21, P655, DOI 10.1111/j.1365-2222.1991.tb03192.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SPORIK R, 1993, J ALLERGY CLIN IMMUN, V91, P307; SQUILLACE SP, 1993, J ALLERGY CLIN IMMUN, V91, P308; STALCUP SA, 1977, NEW ENGL J MED, V297, P592, DOI 10.1056/NEJM197709152971107; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; STARR SE, 1992, PEDIATR INFECT DIS J, V11, P419; STENIUSAARNIALA B, 1988, THORAX, V43, P12, DOI 10.1136/thx.43.1.12; STERK PJ, 1991, AM REV RESPIR DIS, V143, P1433, DOI 10.1164/ajrccm/143.6.1433; STEVENS WJ, 1980, EUR J RESPIR DIS, V61, P203; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1986, NEW ENGL REG ALLERGY, V7, P101; STORMS WW, 1986, AM J MED, V81, P61, DOI 10.1016/0002-9343(86)90464-X; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; STRUNK RC, 1987, J ALLERGY CLIN IMMUN, V80, P455, DOI 10.1016/0091-6749(87)90073-X; SUESS WM, 1986, J ASTHMA, V23, P291, DOI 10.3109/02770908609073175; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; Sullivan TJ, 1988, CURRENT THERAPY ALLE, P91; SUR S, 1994, MAYO CLIN PROC, V69, P495, DOI 10.1016/S0025-6196(12)61651-6; SVENDSEN UG, 1991, EUR RESPIR J, V4, P992; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; SZCZEKLIK A, 1991, ALLERGY, V46, P312, DOI 10.1111/j.1398-9995.1991.tb00590.x; SZEFLER S J, 1991, Pediatric Asthma Allergy and Immunology, V5, P227, DOI 10.1089/pai.1991.5.227; SZEFLER SJ, 1991, J ALLERGY CLIN IMMUN, V88, P147, DOI 10.1016/0091-6749(91)90323-G; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; SZEFLER SJ, 1986, EUR J CLIN PHARMACOL, V30, P323, DOI 10.1007/BF00541537; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; SZEFLER SJ, 1982, J ALLERGY CLIN IMMUN, V69, P455, DOI 10.1016/0091-6749(82)90121-X; TAGER IB, 1989, CHEST, V96, P1161, DOI 10.1378/chest.96.5.1161; TAI E, 1975, BR J DIS CHEST, V69, P125; TAITEL MS, 1995, J ALLERGY CLIN IMMUN, V95, P672, DOI 10.1016/S0091-6749(95)70171-0; TAN WC, 1987, ALLERGY, V42, P315, DOI 10.1111/j.1398-9995.1987.tb02215.x; TANAKA RM, 1982, CHEST, V82, P438, DOI 10.1378/chest.82.4.438; TASHKIN DP, 1987, ANN ALLERGY, V59, P49; TATTERSFIELD AE, 1992, ASTHMA BASIC MECHANI, P527; TAUSSIG LM, 1981, PEDIATRICS, V67, P1; TAYLOR WR, 1992, PEDIATRICS, V90, P657; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TEPPER R, 1995, AM J RESP CRIT CARE, V151, pS19, DOI 10.1164/ajrccm/151.2_Pt_2.S19; TEPPER RS, 1986, AM REV RESPIR DIS, V134, P513; THOMPSON RA, 1989, LANCET, V1, P259; THOMSON NC, 1978, THORAX, V33, P694, DOI 10.1136/thx.33.6.694; THOMSON NC, 1980, THORAX, V35, P428, DOI 10.1136/thx.35.6.428; THORPE JE, 1987, CHEST, V91, P21, DOI 10.1378/chest.91.1.21; TINKELMAN D, 1994, J ASTHMA, V31, P419, DOI 10.3109/02770909409089483; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TINKELMAN DG, 1983, ANN ALLERGY, V50, P398; TINKELMAN DG, 1980, ANN ALLERGY, V44, P283; Tinstman T C, 1981, Nebr Med J, V66, P261; TOFT P, 1991, INTENS CARE MED, V17, P465, DOI 10.1007/BF01690768; TOMINACK RL, 1969, LANCET, V2, P1026; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V83, P528, DOI 10.1016/0091-6749(89)90034-1; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TOOGOOD JH, 1991, ANN ALLERGY, V67, P87; TOVEY ER, 1992, CLIN EXP ALLERGY, V22, P67, DOI 10.1111/j.1365-2222.1992.tb00116.x; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOWERS C V, 1991, American Journal of Obstetrics and Gynecology, V164, P295; TOWNLEY RG, 1989, ANN ALLERGY, V63, P455; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TRASK CH, 1962, NEW ENGL J MED, V266, P639, DOI 10.1056/NEJM196203292661303; TRUDEAU W, 1989, J ALLERGY CLIN IMMUN, V83, P264; TSE CST, 1982, HOSP FORMUL, V17, P1625; TULLETT WM, 1985, THORAX, V40, P41, DOI 10.1136/thx.40.1.41; TURNERWARWICK M, 1988, AM J MED, V85, P6, DOI 10.1016/0002-9343(88)90231-8; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9; TWAROG FJ, 1982, JAMA-J AM MED ASSOC, V248, P2030, DOI 10.1001/jama.248.16.2030; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; UDEN DL, 1985, ANN EMERG MED, V14, P229, DOI 10.1016/S0196-0644(85)80445-5; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; URDAL KNUT, 1949, ACTA OTO LARYNGOL [STOCKHOLM], V37, P20, DOI 10.3109/00016484909120210; POLGAR G, 1979, AM REV RESPIR DIS, V120, P625; UTELL MJ, 1985, ENVIRON HEALTH PERSP, V63, P39, DOI 10.2307/3430027; UTELL MJ, 1983, AM REV RESPIR DIS, V128, P444, DOI 10.1164/arrd.1983.128.3.444; UTELL MJ, 1983, J AEROSOL SCI, V14, P202, DOI 10.1016/0021-8502(83)90029-0; VANAS A, 1986, EUR J RESPIR DIS, V69, P143; VANASPEREN PP, 1990, J ALLERGY CLIN IMMUN, V85, P790, DOI 10.1016/0091-6749(90)90200-N; VANBEVER HP, 1992, DRUGS, V44, P36, DOI 10.2165/00003495-199244010-00003; VANBEVER HP, 1989, CLIN EXP ALLERGY, V19, P399, DOI 10.1111/j.1365-2222.1989.tb02405.x; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; VANMETRE TE, 1989, J ALLERGY CLIN IMMUN, V83, P888, DOI 10.1016/0091-6749(89)90102-4; VANMETRE TE, 1988, ALLERGY PRINCIPLES P, P1327; VANRENTERGHEM D, 1987, ANN ALLERGY, V59, P313; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; VANTO T, 1983, ANN ALLERGY, V50, P340; VATHENEN AS, 1988, LANCET, V1, P554; VENABLES KM, 1990, J ALLERGY CLIN IMMUN, V85, P55, DOI 10.1016/0091-6749(90)90221-O; VERTINSKY PA, 1976, INT J HEALTH EDUC, V19, P16; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; VESTAL RE, 1987, J PHARMACOL EXP THER, V241, P488; VETER IZ, 1988, AM REV RESPIR DIS, V137, P302; VICHYANOND P, 1989, J ALLERGY CLIN IMMUN, V84, P867, DOI 10.1016/0091-6749(89)90381-3; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; WADE TA, 1988, J ALLERGY CLIN IMMUN, V872, P1012; WAGENMANN M, 1992, J ALLERGY CLIN IMMUN, V90, P419, DOI 10.1016/0091-6749(92)90161-T; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; WAHEDNA I, 1991, THORAX, V46, pP770; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; WALD JA, 1986, J ALLERGY CLIN IMMUN, V78, P36, DOI 10.1016/0091-6749(86)90112-0; WALKER FB, 1987, CHEST, V91, P49, DOI 10.1378/chest.91.1.49; WALL MA, 1984, PEDIATR CLIN N AM, V31, P773; WALLER RE, 1963, INT J AIR WATER POLL, V7, P773; WALSHAW MJ, 1986, Q J MED, V58, P199; WANG JLF, 1979, J PEDIATR-US, V94, P376, DOI 10.1016/S0022-3476(79)80574-0; WARD AJM, 1993, AM REV RESPIR DIS, V147, P518, DOI 10.1164/ajrccm/147.3.518; WARDLAW AJ, 1993, BRONCHIAL ASTHMA MEC, P258; WARNER JO, 1978, LANCET, V2, P912; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1990, CLIN EXP ALLERGY, V20, P15, DOI 10.1111/j.1365-2222.1990.tb02465.x; WASSERFALLEN JB, 1990, AM REV RESPIR DIS, V142, P108, DOI 10.1164/ajrccm/142.1.108; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WEBB AK, 1979, POSTGRAD MED J, V55, P161, DOI 10.1136/pgmj.55.641.161; WEBSTER JR, 1966, NEW ENGL J MED, V274, P931, DOI 10.1056/NEJM196604282741703; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1984, J ALLERGY CLIN IMMUN, V73, P525, DOI 10.1016/0091-6749(84)90505-0; WEINBERGER M, 1978, J PEDIATR-US, V92, P1, DOI 10.1016/S0022-3476(78)80058-4; WEINBERGER MM, 1993, PHARMACOTHERAPY, V13, P598; WEINBERGER MW, 1976, JAMA-J AM MED ASSOC, V235, P2110, DOI 10.1001/jama.235.19.2110; WEINER P, 1988, AM REV RESPIR DIS, V137, P1309, DOI 10.1164/ajrccm/137.6.1309; WEINGER M, 1989, ADVERSE REACTIONS DR, P273; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WELCH MJ, 1994, J ALLERGY CLIN IMMUN, V93, P198; WELLIVER RC, 1989, IMMUNOL ALLERGY PRAC, V11, P378; WESTERMAN DE, 1979, AM J MED, V66, P565, DOI 10.1016/0002-9343(79)91165-3; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577; WILLIAMS MH, 1980, ARCH INTERN MED, V140, P1604, DOI 10.1001/archinte.140.12.1604; WILLIAMS SJ, 1981, THORAX, V36, P629, DOI 10.1136/thx.36.8.629; WILSON JW, 1994, AM J RESP CRIT CARE, V149, P86, DOI 10.1164/ajrccm.149.1.8111605; WILSON NM, 1994, CLIN EXP ALLERGY, V24, P522, DOI 10.1111/j.1365-2222.1994.tb00949.x; WILSONPESSANO SR, 1987, J ALLERGY CLIN IMMUN, V80, P487, DOI 10.1016/0091-6749(87)90081-9; WILSONPESSANO SR, 1985, PREV MED, V14, P670, DOI 10.1016/0091-7435(85)90066-0; WINDOM HH, 1990, CLIN PHARMACOL THER, V48, P296, DOI 10.1038/clpt.1990.152; WINTHER B, 1990, OTOLARYNG HEAD NECK, V103, P876, DOI 10.1177/01945998901030S507; WISSOW LS, 1988, AM J DIS CHILD, V142, P748, DOI 10.1001/archpedi.1988.02150070062026; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6; WOLF SI, 1988, ANN ALLERGY, V61, P357; WONG CS, 1990, LANCET, V336, P1396, DOI 10.1016/0140-6736(90)93099-B; WOO OF, 1984, J TOXICOL-CLIN TOXIC, V22, P411, DOI 10.3109/15563658408992572; WOOD RA, 1992, J ALLERGY CLIN IMMUN, V89, P126, DOI 10.1016/S0091-6749(05)80049-1; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; WOOD RE, 1988, J PEDIATR-US, V112, P1, DOI 10.1016/S0022-3476(88)80109-4; WOOLCOCK AJ, 1977, AM REV RESPIR DIS, V115, P191; WOOLCOCK AJ, 1989, J ALLERGY CLIN IMMUN, V84, P975, DOI 10.1016/0091-6749(89)90397-7; WRENN K, 1991, ANN INTERN MED, V115, P241, DOI 10.7326/0003-4819-115-4-241; XANG BC, 1992, ANN ALLERGY, V68, P237; YELLOWLEES PM, 1990, CHEST, V97, P628, DOI 10.1378/chest.97.3.628; YURCHAK AM, 1976, PEDIATRICS, V57, P518; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T; ZINREICH SJ, 1992, J ALLERGY CLIN IMMUN, V90, P445, DOI 10.1016/0091-6749(92)90167-Z; ZINREICH SJ, 1987, RADIOLOGY, V163, P769, DOI 10.1148/radiology.163.3.3575731	1088	35	36	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	2				707	870						164	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	TG530					2022-12-18	WOS:A1995TG53000001
J	TAMAOKI, J; TAGAYA, E; SAKAI, A; KONNO, K				TAMAOKI, J; TAGAYA, E; SAKAI, A; KONNO, K			EFFECTS OF MACROLIDE ANTIBIOTICS ON NEURALLY-MEDIATED CONTRACTION OF HUMAN ISOLATED BRONCHUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AIRWAY SMOOTH MUSCLE; BRONCHIAL HYPERREACTIVITY; ERYTHROMYCIN; ACETYLCHOLINE; VAGAL NERVE; ASTHMA	SMOOTH-MUSCLE; DEPENDENT ASTHMA; HUMAN AIRWAYS; NERVE; TROLEANDOMYCIN; INVITRO; HYPERRESPONSIVENESS; NEUROTRANSMISSION; INHIBITION; EFFICACY	Background: Long-term administration of macrolide antibiotic substances is an alternative therapy used in the treatment of asthma and airway hyperresponsiveness, but neither its mechanism of action nor whether this substance exerts an immediate action in the airways is known. Methods: Contractile responses of human isolated bronchial strips to electrical field stimulation (EFS) and acetylcholine were assessed under isometric conditions in the absence and presence of erythromycin, roxithromycin, or clarithromycin. Results: Incubation of tissues with erythromycin (3 X 10(-5) mol/L) attenuated the contractile responses to EFS so that the stimulus frequency required to produce 50% of the maximal contraction increased form 4.1 +/- 0.5 to 10.1 +/- 0.7 Hz (mean +/- SE; p < 0.001). In contrast, contractile responses to acetylcholine were not changed. Erythromycin reduced the EFS-induced contraction in a concentration-dependent fashion; the maximal decrease from the baseline response was 92.8% +/- 3.6% (p < 0.001). This inhibitory effect was not altered by propranolol, indomethacin, ouabain, charybdotoxin, or mechanical removal of the epithelium. Roxithromycin and clarithromycin likewise inhibited neurally mediated contraction. Conclusions: These results suggest that macrolides may inhibit cholinergic neuroeffector transmission in the human airway smooth muscle, probably by reducing exocytotic release of acetylcholine from the nerve terminals.	TOKYO WOMENS MED COLL,DEPT MED,TOKYO 162,JAPAN	Tokyo Women's Medical University								ANDERSON R, 1984, J ANTIMICROB CHEMOTH, V14, P41, DOI 10.1093/jac/14.1.41; ATCHISON WD, 1988, J PHARMACOL EXP THER, V245, P394; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; COTT GR, 1988, NEW ENGL J MED, V318, P634, DOI 10.1056/NEJM198803103181010; ELLIS JL, 1992, AM REV RESPIR DIS, V147, P1543; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3239; GOLD WM, 1972, J APPL PHYSIOL, V33, P719, DOI 10.1152/jappl.1972.33.6.719; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; JOHNSON JD, 1980, J LAB CLIN MED, V95, P429; KAMADA AK, 1993, J ALLERGY CLIN IMMUN, V91, P873, DOI 10.1016/0091-6749(93)90345-G; LAFORCE CF, 1983, J ALLERGY CLIN IMMUN, V72, P34, DOI 10.1016/0091-6749(83)90049-0; LEES GM, 1981, BRIT J PHARMACOL, V73, P535, DOI 10.1111/j.1476-5381.1981.tb10453.x; MINOCHA A, 1991, J PHARMACOL EXP THER, V257, P1248; MITCHELL RW, 1986, J PHARMACOL EXP THER, V236, P803; MIURA M, 1992, AM REV RESPIR DIS, V146, P132, DOI 10.1164/ajrccm/146.1.132; MIYACHI Y, 1986, J INVEST DERMATOL, V86, P449, DOI 10.1111/1523-1747.ep12285793; MIYATAKE H, 1991, CHEST, V99, P670, DOI 10.1378/chest.99.3.670; NELSON S, 1987, AM REV RESPIR DIS, V136, P1207, DOI 10.1164/ajrccm/136.5.1207; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; RHODEN KJ, 1988, J APPL PHYSIOL, V65, P700, DOI 10.1152/jappl.1988.65.2.700; SEGAL IH, 1976, BIOCH CALCULATIONS, P246; SINGH YN, 1978, ANESTHESIOLOGY, V48, P418, DOI 10.1097/00000542-197806000-00008; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; TAMAOKI J, 1993, J APPL PHYSIOL, V74, P297; THOMAS RC, 1972, PHYSIOL REV, V52, P563, DOI 10.1152/physrev.1972.52.3.563; WALTERS EH, 1984, J APPL PHYSIOL, V57, P129, DOI 10.1152/jappl.1984.57.1.129; ZAROWITZ BJM, 1981, CLIN PHARMACOL THER, V29, P601, DOI 10.1038/clpt.1981.84; ZEIGER RS, 1980, J ALLERGY CLIN IMMUN, V66, P438, DOI 10.1016/0091-6749(80)90003-2	29	35	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					853	859		10.1016/S0091-6749(95)70129-X	http://dx.doi.org/10.1016/S0091-6749(95)70129-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722166				2022-12-18	WOS:A1995QT46800011
J	SCHNEIDER, T; LANG, AB; CARBALLIDO, JM; BABI, LFS; DUDLER, T; KAGI, MK; BLASER, K; SUTER, M				SCHNEIDER, T; LANG, AB; CARBALLIDO, JM; BABI, LFS; DUDLER, T; KAGI, MK; BLASER, K; SUTER, M			HUMAN MONOCLONAL OR POLYCLONAL ANTIBODIES RECOGNIZE PREDOMINANTLY DISCONTINUOUS EPITOPES ON BEE VENOM PHOSPHOLIPASE A(2)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BEE VENOM PHOSPHOLIPASE A(2); BEE VENOM ALLERGY; EPITOPE MAPPING; HUMAN MONOCLONAL ANTIBODY; IGE; IGG(4)	SYNTHETIC PEPTIDES; CYTOCHROME-C; PROTEINS; ANTIGEN; LYSOZYME; COMPLEX	Background: Two hybridomas, which secrete human monoclonal antibodies of IgG(4) isotype specific for the main bee venom antigen/allergen phospholipase A(2) were generated. The antigenic determinants recognized by these antibodies were mapped and compared with the binding sites of murine monoclonal and human polyclonal antibodies raised against the same antigen. Methods: Two hybridomas were developed by fusing heteromyelomas to Epstein-Barr virus immortalized B cells obtained from beekeepers. The cloned hybridomas were stable and secreted up to 40 mg/L of antibody into the culture supernatant. Phospholipase A(2) specificity of the human monoclonal antibodies was confirmed by binding and inhibition ELISA and by Western blot analysis. Epitope mapping on phospholipase A(2) was done with the PEPSCAN method and ELISA techniques. Results: The epitopes recognized by the human monoclonal antibodies were shown to be discontinuous and did not contain the sugar residue. Similar results were obtained with polyclonal antibodies of IgG(4) isotype (from beekeepers) specific for phospholipase A(2), which could also inhibit the binding of the human monoclonal antibodies to phospholipase A(2). In contrast, antigen binding of the human monoclonal antibodies could not be inhibited by murine monoclonal antibodies against bee venom phospholipase A(2). Conclusions: The data indicate that the human monoclonal antibodies obtained are representative of a part of the polyclonal immune response to phospholipase A(2) from beekeepers and may allow a more precise analysis of the humoral immune response to phospholipase A(2) that is associated with protection.	SWISS INST ALLERGY & ASTHMA RES,CH-7270 DAVOS,SWITZERLAND; SWISS SERUM & VACCINE INST,CH-3001 BERN,SWITZERLAND; UNIV ZURICH HOSP,DEPT DERMATOL,ALLERGY UNIT,CH-8091 ZURICH,SWITZERLAND	Swiss Institute of Allergy & Asthma Research; University of Zurich; University Zurich Hospital				Santamaria Babi, Luis F/0000-0002-1674-6654				ARNON R, 1992, FASEB J, V6, P3265, DOI 10.1096/fasebj.6.14.1385242; BARAKAT S, 1991, CLIN EXP IMMUNOL, V86, P71; BOYD JE, 1992, CLIN EXP IMMUNOL, V88, P189, DOI 10.1111/j.1365-2249.1992.tb03061.x; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GRETCH DR, 1987, ANAL BIOCHEM, V163, P270, DOI 10.1016/0003-2697(87)90123-0; HELD W, 1989, SCAND J IMMUNOL, V29, P203, DOI 10.1111/j.1365-3083.1989.tb01117.x; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; LANG AB, 1991, J IMMUNOL, V146, P3160; LANG AB, 1992, J IMMUNOL METHODS, V154, P21, DOI 10.1016/0022-1759(92)90208-B; Muller UR., 1990, INSECT STING ALLERGY; MULLER WD, 1993, INT ARCH ALLERGY IMM, V101, P153, DOI 10.1159/000236513; OERTLE M, 1989, EUR J BIOCHEM, V182, P699, DOI 10.1111/j.1432-1033.1989.tb14881.x; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; REISMAN RE, 1989, INT ARCH ALLER A IMM, V89, P67, DOI 10.1159/000234925; SAVOCA R, 1991, J IMMUNOL METHODS, V141, P245, DOI 10.1016/0022-1759(91)90151-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWAB C, 1993, PROTEIN SCI, V2, P175; SCIBIENS.RJ, 1973, J IMMUNOL, V111, P114; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHARMA S, 1991, P NATL ACAD SCI USA, V88, P4877, DOI 10.1073/pnas.88.11.4877; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; SMITHGILL SJ, 1982, J IMMUNOL, V128, P314; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STILES BG, 1991, J PROTEIN CHEM, V10, P193, DOI 10.1007/BF01024784; SUTER M, 1982, J IMMUNOL METHODS, V53, P103, DOI 10.1016/0022-1759(82)90244-7; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; WETTERWALD A, 1985, INT ARCH ALLER A IMM, V77, P195, DOI 10.1159/000233784; YUAN J, 1992, ANAL BIOCHEM, V205, P179, DOI 10.1016/0003-2697(92)90596-Y; YUAN W, 1990, BIOCHEMISTRY-US, V29, P6082, DOI 10.1021/bi00477a028	32	35	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					61	70		10.1016/0091-6749(94)90072-8	http://dx.doi.org/10.1016/0091-6749(94)90072-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	7517969				2022-12-18	WOS:A1994NX39300009
J	DESHAZO, RD; BANKS, WA				DESHAZO, RD; BANKS, WA			MEDICAL CONSEQUENCES OF MULTIPLE FIRE ANT STINGS OCCURRING INDOORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMPORTED FIRE ANTS; INSECT REACTIONS; STINGING INSECTS; CEREBROVASCULAR ACCIDENTS; RESIDENTIAL INSECT INFESTATION	PLATELET-ACTIVATING-FACTOR; SOLENOPSIS-INVICTA; HYMENOPTERA VENOM; ANAPHYLAXIS; ALLERGENS; SKIN	Stings by the imported fire ant almost always lead to dermal wheal and pare reactions followed by sterile pustules at sting sites. Less commonly, large local dermal reactions, pyoderma, anaphylaris, or neuropathy may occur. Such reactions have previously been associated with contact with the insects out of doors. We present two previously unreported cases of indoor attacks on individuals by imported fire ants. One patient experienced a cerebrovascular accident in association with the attack, whereas the second patient had no obvious sequelae. With these two reports, a total of four such indoor massive sting episodes have appeared in the recent medical literature. Physicians and other individuals living in areas indigenous to the fire ant should be aware that infestation of buildings with fire ants may be associated with attacks on human beings indoors. Individuals with cognitive dysfunction seem to be especially at risk for attacks by fire ants.	USDA ARS,MOBILE,AL	United States Department of Agriculture (USDA)	DESHAZO, RD (corresponding author), UNIV SO ALABAMA,COLL MED,DEPT INTERNAL MED,2451 FILLINGIM ST,MOBILE,AL 36617, USA.							ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; AWAI LE, 1984, ANN ALLERGY, V53, P48; CARO MR, 1957, ARCH DERMATOL, V75, P475, DOI 10.1001/archderm.1957.01550160001001; DAY JM, 1962, ARCH NEUROL-CHICAGO, V7, P184, DOI 10.1001/archneur.1962.04210030022003; DESHAZO RD, 1984, J ALLERGY CLIN IMMUN, V74, P841, DOI 10.1016/0091-6749(84)90188-X; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DIAZ JD, 1989, SOUTH MED J, V82, P775, DOI 10.1097/00007611-198906000-00026; FOX RW, 1982, J ALLERGY CLIN IMMUN, V70, P120, DOI 10.1016/0091-6749(82)90239-1; HANNAN CJ, 1986, J ALLERGY CLIN IMMUN, V78, P331, DOI 10.1016/S0091-6749(86)80085-9; HARDWICK WE, 1992, PEDIATRICS, V90, P622; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P300, DOI 10.1016/0091-6749(87)90035-2; JAVORS MA, IN PRESS LIFE SCI; JONES TH, 1982, TETRAHEDRON, V38, P1949, DOI 10.1016/0040-4020(82)80044-6; LINDSBERG PJ, 1991, ANN NEUROL, V30, P117, DOI 10.1002/ana.410300202; Lofgren C.S., 1986, P36; LOFGREN CS, 1975, ANNU REV ENTOMOL, V20, P1, DOI 10.1146/annurev.en.20.010175.000245; PORTER SD, 1990, ECOLOGY, V71, P2095, DOI 10.2307/1938623; RHOADES RB, 1909, J ALLERGY CLIN IMMUN, V84, P159; SMITH JD, 1971, ARCH DERMATOL, V103, P438, DOI 10.1001/archderm.103.4.438; STAFFORD CT, 1989, SOUTHERN MED J, V82, P1520, DOI 10.1097/00007611-198912000-00015; VALONE FH, 1989, J IMMUNOL, P71; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857	24	35	37	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					847	850		10.1016/0091-6749(94)90376-X	http://dx.doi.org/10.1016/0091-6749(94)90376-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182226	Bronze			2022-12-18	WOS:A1994NL91900007
J	MATRICARDI, PM; NISINI, R; BISELLI, R; DAMELIO, R				MATRICARDI, PM; NISINI, R; BISELLI, R; DAMELIO, R			EVALUATION OF THE OVERALL DEGREE OF SENSITIZATION TO AIRBORNE ALLERGENS BY A SINGLE SEROLOGIC TEST - IMPLICATIONS FOR EPIDEMIOLOGIC STUDIES OF ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY; IGE; EPIDEMIOLOGY; CAP-PHADIATOP; SCREENING	SKIN-TEST REACTIVITY; INHALANT ALLERGIES; BRONCHIAL HYPERREACTIVITY; SCREENING-TEST; SERUM IGE; PHADIATOP; ASTHMA; RAST; PREVALENCE; RHINITIS	In most epidemiologic studies of respiratory allery, the overall degree of sensitization is usually measured by indices based on skin prick test reactions to a panel of relevant airborne allergens. In the present study we used a single assay (CAP-Phadiatop, Pharmacia, Uppsala, Sweden), which is based on the reaction between serum-specific IgE and a mixture of locally relevant inhalant allergens to measure the degree of sensitization to inhalants in the sera of 1815 young Italian men, in whom a complete diagnostic workup for respiratory allergy was performed in parallel. The intensity of reaction in the CAP-Phadiatop assay was highly correlated with: (1) an allergy index (p < 0.005), based on skin prick test reactivity to seven relevant inhalant allergens (Dermatophagoides pteronyssinus, mixed grass pollens, cat epithelium, Parietaria judaica, Olea europaea, Artemisia vulgaris, Alternaria tenuis); (2) the concentration of specific IgE to the same allergens, measured by CRP-RAST(p < 0.001), in both monosensitized and polysensitized subjects; (3) the rate of respiratory allergic diseases (p < 0.0001). Therefore CAP-Phadiatop intensity of reaction is a reliable indicator of the overall degree of sensitization to inhalant allergens. Furthermore, as demonstrated by relative operating characteristic analysis, it has an acceptable detectability power in identifying subjects with symptomatic expression of the atopy status [P(A) = 0.948]. The evaluation of the degree of sensitization to inhalants by a single and semiautomated assay represents a step forward in the standardization of procedures for epidemiologic studies of inhalant allergic diseases and for mass screening programs, which are aimed at identifying predictive markers of disease susceptibility.	UNIV REGGIO CALABRIA, DEPT EXPT & CLIN MED, CATANZARO, ITALY	Universita Mediterranea di Reggio Calabria	MATRICARDI, PM (corresponding author), ITALIAN AIR FORCE DASRS, IMMUNOL LAB, AEROPORTO PRATICA MARE, I-00040 ROME, ITALY.		Nisini, Roberto/M-4363-2015	Nisini, Roberto/0000-0003-1077-423X				[Anonymous], 1989, ALLERGY S10, V10, P1; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CORBO GM, 1987, ALLERGY, V42, P230, DOI 10.1111/j.1398-9995.1987.tb02204.x; DREBORG S, 1991, CLIN EXP ALLERGY, V21, P529, DOI 10.1111/j.1365-2222.1991.tb00841.x; ERDREICH LS, 1981, AM J EPIDEMIOL, V114, P649, DOI 10.1093/oxfordjournals.aje.a113236; ERIKSSON NE, 1990, ALLERGY, V45, P285, DOI 10.1111/j.1398-9995.1990.tb00497.x; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; FREIDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274, DOI 10.1016/0091-6749(83)90032-5; GREGG I, 1986, CLIN ALLERGY, V16, P17, DOI 10.1111/j.1365-2222.1986.tb01949.x; GUSTAFSSON D, 1988, ALLERGY, V43, P105, DOI 10.1111/j.1398-9995.1988.tb00402.x; HEROLD DA, 1987, ALLERGOLOGIE, V10, P300; KLINK M, 1990, J ALLERGY CLIN IMMUN, V85, P440, DOI 10.1016/0091-6749(90)90153-U; KRAUSE RM, 1986, J ALLERGY CLIN IMMUN, V78, P953, DOI 10.1016/0091-6749(86)90283-6; MATRICARDI PM, 1990, CLIN EXP ALLERGY, V20, P151, DOI 10.1111/j.1365-2222.1990.tb02660.x; MENSINGA TT, 1990, J ALLERGY CLIN IMMUN, V86, P99, DOI 10.1016/S0091-6749(05)80129-0; MERRETT J, 1978, CLIN ALLERGY, V8, P235, DOI 10.1111/j.1365-2222.1978.tb03219.x; MERRETT J, 1987, CLIN ALLERGY, V17, P409, DOI 10.1111/j.1365-2222.1987.tb02034.x; OWNBY DR, 1990, J ALLERGY CLIN IMMUN, V86, P279, DOI 10.1016/S0091-6749(05)80088-0; OWNBY DR, 1984, J ALLERGY CLIN IMMUN, V73, P466, DOI 10.1016/0091-6749(84)90356-7; VERDIANI P, 1990, J ALLERGY CLIN IMMUN, V86, P576, DOI 10.1016/S0091-6749(05)80215-5; WEVER AMJ, 1990, ALLERGY, V45, P92, DOI 10.1111/j.1398-9995.1990.tb00464.x	23	35	35	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				68	79		10.1016/0091-6749(94)90234-8	http://dx.doi.org/10.1016/0091-6749(94)90234-8			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	8308184				2022-12-18	WOS:A1994MT78100008
J	BENINATI, W; DERDAK, S; DIXON, PF; GRIDER, DJ; STROLLO, DC; HENSLEY, RE; LUCEY, DR				BENINATI, W; DERDAK, S; DIXON, PF; GRIDER, DJ; STROLLO, DC; HENSLEY, RE; LUCEY, DR			PULMONARY EOSINOPHILS EXPRESS HLA-DR IN CHRONIC EOSINOPHILIC PNEUMONIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PULMONARY EOSINOPHILIA; EOSINOPHILS; HLA-DR ANTIGEN; BRONCHOALVEOLAR LAVAGE FLUID; ASTHMA	PERFUSED RAT LUNGS; MEDIATED INJURY; INFLAMMATION; FIBROSIS; INCREASE; ASTHMA; CELLS	Background: Chronic eosinophilic pneumonia is a rare idiopathic disorder. What role the eosinophil plays in the pathogenesis of this disease is unknown. The recent finding that mature eosinophils can express the class II major histocompatibility complex molecule HLA-DR suggests an immunologic role, perhaps through antigen presentation. The purpose of this research was to determine whether lung-derived eosinophils exhibit in vivo expression of HLA-DR. Methods: Eosinophils were obtained simultaneously from bronchoalveolar lavage and peripheral blood from a 59-year-old woman with asthma and chronic eosinophilic pneumonia. Eosinophil-enriched aliquots of peripheral blood were cocultured with human lung fibroblasts (with or without additional granulocyte-macrophage colony-stimulating factor). The percentage of cells expressing HLA-DR was quantitated by flow cytometric analysis. Results: Eosinophils derived from bronchoalveolar lavage displayed in vivo expression of HLA-DR (86%) in contrast to those from peripheral blood (7%), suggesting compartmentalization of eosinophil activation within the lung. Peripheral blood eosinophils retained the capacity for HLA-DR expression when coincubated with lung fibroblasts (83%) with augmentation by granulocyte-macrophage colony-stimulating factor (93%). Conclusion: These data demonstrate that lung eosinophil HLA-DR expression occurs in vivo; it may contribute to the pathogenesis of inflammatory lung injury.	WILFORD HALL USAF MED CTR,DEPT PULM DIS,CLIN INVEST DIRECTORATE,SAN ANTONIO,TX; WILFORD HALL USAF MED CTR,DEPT PATHOL,SAN ANTONIO,TX; WILFORD HALL USAF MED CTR,DEPT RADIOL,SAN ANTONIO,TX; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	United States Department of Defense; United States Air Force; United States Department of Defense; United States Air Force; United States Department of Defense; United States Air Force; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Grider, Douglas/0000-0002-6346-094X				AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BARTTER T, 1989, ARCH INTERN MED, V149, P272; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; COOK RM, 1987, INT ARCH ALLER A IMM, V83, P428, DOI 10.1159/000234380; DAVIS WB, 1984, J CLIN INVEST, V74, P269, DOI 10.1172/JCI111411; DERDAK S, 1991, LANCET, V337, P374, DOI 10.1016/0140-6736(91)91015-M; DVORAK AM, 1991, BLOOD CELL BIOCH MEG, P237; FORD RM, 1966, AM REV RESPIR DIS, V93, P797; FUJIMOTO K, 1990, AM REV RESPIR DIS, V142, P1414, DOI 10.1164/ajrccm/142.6_Pt_1.1414; GAENSLER EA, 1977, AM J ROENTGENOL, V128, P1; HANSEL TT, 1992, J IMMUNOL, V149, P2130; HANSEL TT, 1991, CLIN EXP IMMUNOL, V86, P271; HOIDAL JR, 1990, AM REV RESPIR DIS, V142, P1245, DOI 10.1164/ajrccm/142.6_Pt_1.1245; HOLGATE ST, 1992, AM REV RESPIR DIS, V145, pS2, DOI 10.1164/ajrccm/145.2_Pt_2.S2; JEDERLINIC PJ, 1988, MEDICINE, V67, P154, DOI 10.1097/00005792-198805000-00002; JOHNSON HM, 1992, SCI AM, V266, P92, DOI 10.1038/scientificamerican0492-92; Johnson HM, 1992, SCI AM, V266, P98; KATZENSTEIN AL, 1990, SURG PATHOLOGY NONNE, P182; LIEBOW AA, 1969, MEDICINE, V48, P251, DOI 10.1097/00005792-196907000-00001; LOPEZ M, 1991, IMMUNOLOGICALLY MEDI, P413; LUCEY DR, 1991, J ACQ IMMUN DEF SYND, V4, P24; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1348, DOI 10.1073/pnas.86.4.1348; LUCEY DR, 1989, J EXP MED, V169, P327, DOI 10.1084/jem.169.1.327; MAWHORTER SD, 1992, CLIN RES, V40, pA269; MAYO JR, 1989, AM J ROENTGENOL, V153, P727; NISHIKAWA K, 1992, J ALLERGY CLIN IMMUN, V90, P169, DOI 10.1016/0091-6749(92)90068-D; OHNO I, 1991, AM J RESP CELL MOL, V5, P505, DOI 10.1165/ajrcmb/5.6.505; PETERSON MW, 1987, CHEST, V92, P51, DOI 10.1378/chest.92.1.51; PINCUS SH, 1987, BLOOD, V70, P572; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; ROWEN JL, 1990, AM REV RESPIR DIS, V142, P215, DOI 10.1164/ajrccm/142.1.215; WATTERS LC, 1987, AM REV RESPIR DIS, V135, P696; WELLER PF, 1992, CLIN IMMUNOL IMMUNOP, V62, pS55, DOI 10.1016/0090-1229(92)90041-L; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; YAZDANBAKHSH M, 1987, IMMUNOLOGY, V60, P123	36	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					442	449		10.1016/0091-6749(93)90123-W	http://dx.doi.org/10.1016/0091-6749(93)90123-W			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360395	Bronze			2022-12-18	WOS:A1993LX30900010
J	AICHANE, A; CAMPBELL, AM; CHANAL, I; RICHARD, MC; ARNAUD, B; MICHEL, FB; BOUSQUET, J				AICHANE, A; CAMPBELL, AM; CHANAL, I; RICHARD, MC; ARNAUD, B; MICHEL, FB; BOUSQUET, J			PRECISION OF CONJUNCTIVAL PROVOCATION TESTS IN RIGHT AND LEFT EYES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CONJUNCTIVAL CHALLENGE; ALLERGEN; HISTAMINE; PGD(2); LTC(4)	POLLEN-ALLERGIC CHILDREN; TEAR FLUID; RADIOIMMUNOASSAY; LEVOCABASTINE; CHALLENGE; PLACEBO; RELEASE; HUMANS	Background: Conjunctival provocation tests (CPTs) are used for assessing the efficacy of antiallergic treatments, but their reproducibility is not well characterized. A study was carried out to assess the reproducibility of CPTs and the release of mediators during CPTs. Methods: Both eyes of 30 grass-pollen-allergic patients were challenged with threefold increasing concentrations of a standardized orchard grass pollen extract. The positivity of the CPT was assessed by a cumulative symptom score. The release of mediators was examined by means of histamine (radioimmunoassay), prostaglandin D2 and leukotrienes C4 and D4 (enzyme immunoassay). Results: There was a significant correlation between the concentrations of allergen inducing a positive CPT in both eyes (p < 0.0001, Spearman). All but one patient had a significant release of at least one mediator. After allergen CPT there was a significant release in both eyes in 13 of 20 patients for prostaglandin D2, 11 of 19 for leukotrienes C4 and D4 and 15 of 18 for histamine. The correlations between the levels of mediators released during diluent and allergen challenges in both eyes were significant for prostaglandin D2 (diluent and allergen challenges) and leukotrienes C4 and D4 (allergen challenge). Conclusion: Considering the whole group of patients, CPT is reproducible in both eyes, but the results are less satisfactory when patients are examined individually.	HOP ARNAUD DE VILLENEUVE,MALAD RESP CLIN,F-34059 MONTPELLIER 1,FRANCE; HOP ARNAUD DE VILLENEUVE,INSERM,CJF 92-10,MONTPELLIER,FRANCE; HOP GUI DE CHAULIAC,SERV OPHTALMOL,MONTPELLIER,FRANCE; LE MILLENAIRE,LAB CHAUVIN,MONTPELLIER,FRANCE	Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier			Bousquet, Jean/O-4221-2019					ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P84, DOI 10.1001/archopht.1990.01070030090035; BISGAARD H, 1984, PROSTAGLANDINS, V27, P369, DOI 10.1016/0090-6980(84)90196-5; BONINI S, 1988, J ALLERGY CLIN IMMUN, V82, P462, DOI 10.1016/0091-6749(88)90020-6; BONINI S, 1989, INT ARCH ALLER A IMM, V88, P144, DOI 10.1159/000234769; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1990, RECENT TRENDS CLIN P, P139; CIPRANDI G, 1991, INT ARCH ALLER A IMM, V96, P344, DOI 10.1159/000235519; FRIEDLAENDER MH, 1988, INT OPHTHALMOL CLIN, V28, P338, DOI 10.1097/00004397-198802840-00018; KJAERGAARD SK, 1990, INT ARCH OCC ENV HEA, V62, P133, DOI 10.1007/BF00383590; KJELLMAN NIM, 1986, CLIN ALLERGY, V16, P441, DOI 10.1111/j.1365-2222.1986.tb01979.x; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; MACLOUF J, 1986, PROSTAGLANDINS, V31, P123, DOI 10.1016/0090-6980(86)90230-3; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; MOSBECH H, 1987, ALLERGY, V42, P451, DOI 10.1111/j.1398-9995.1987.tb00362.x; PIPKORN U, 1988, ALLERGY, V43, P81, DOI 10.1111/j.1398-9995.1988.tb00398.x; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; PROUD D, 1990, J ALLERGY CLIN IMMUN, V85, P896, DOI 10.1016/0091-6749(90)90075-F; RIMAS M, 1990, ALLERGY, V45, P18, DOI 10.1111/j.1398-9995.1990.tb01079.x; SCHOENEICH M, 1990, CLIN EXP ALLERGY, V20, P171, DOI 10.1111/j.1365-2222.1990.tb02663.x; TREDE NS, 1989, ALLERGY, V44, P272, DOI 10.1111/j.1398-9995.1989.tb01069.x; TUFT SJ, 1989, ACTA OPHTHALMOL, V67, P301, DOI 10.1111/j.1755-3768.1989.tb01875.x; ZUBER P, 1988, J ALLERGY CLIN IMMUN, V82, P590, DOI 10.1016/0091-6749(88)90969-4; 1980, GUIDELINES REGISTRAT	24	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				49	55		10.1016/0091-6749(93)90036-F	http://dx.doi.org/10.1016/0091-6749(93)90036-F			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	8335854				2022-12-18	WOS:A1993LQ35300008
J	BRAND, PLP; KERSTJENS, HAM; JANSEN, HM; KAUFFMAN, HF; DEMONCHY, JGR; KERREBIJN, KF; QUANJER, H; SLUITER, HJ; POUW, EM; SCHOONBROOD, DFME; ROOS, CM; DEGOOYER, A; POSTMA, DS; VANDERMARK, W; SLUITER, HJ; KOETER, GH; DEJONG, PM; STERK, PJ; WEVER, AMJ; DIJKMAN, JH; DEKHUIJZEN, PNR; FOLGERING, HTM; VANHERWAARDEN, CLA; OVERBEEK, SE; BOGAARD, JM; HILVERING, C; GANS, SJ; MENGELERS, HJJ; VANDERBRUGGEN, B; KREUKNIET, J; VANESSENZANDVLIET, EEM; KERREBIJN, KF; DUIVERMAN, EJ; KOUWENBERG, JM; PRINSEN, JE; WAALKENS, HJ; GERRITSEN, J; KNOL, K; KAPTEIN, AA; DEKKER, FW; MERKUS, PJFM; QUANJER, PH; POCOCK, SJ; HUGHES, MD; BLEECKER, ER; MEYERS, DA				BRAND, PLP; KERSTJENS, HAM; JANSEN, HM; KAUFFMAN, HF; DEMONCHY, JGR; KERREBIJN, KF; QUANJER, H; SLUITER, HJ; POUW, EM; SCHOONBROOD, DFME; ROOS, CM; DEGOOYER, A; POSTMA, DS; VANDERMARK, W; SLUITER, HJ; KOETER, GH; DEJONG, PM; STERK, PJ; WEVER, AMJ; DIJKMAN, JH; DEKHUIJZEN, PNR; FOLGERING, HTM; VANHERWAARDEN, CLA; OVERBEEK, SE; BOGAARD, JM; HILVERING, C; GANS, SJ; MENGELERS, HJJ; VANDERBRUGGEN, B; KREUKNIET, J; VANESSENZANDVLIET, EEM; KERREBIJN, KF; DUIVERMAN, EJ; KOUWENBERG, JM; PRINSEN, JE; WAALKENS, HJ; GERRITSEN, J; KNOL, K; KAPTEIN, AA; DEKKER, FW; MERKUS, PJFM; QUANJER, PH; POCOCK, SJ; HUGHES, MD; BLEECKER, ER; MEYERS, DA			INTERPRETATION OF SKIN-TESTS TO HOUSE DUST MITE AND RELATIONSHIP TO OTHER ALLERGY PARAMETERS IN PATIENTS WITH ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INTRADERMAL TESTS; ALLERGY; RESPIRATORY HYPERSENSITIVITY; ASTHMA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE	COMMUNITY POPULATION-SAMPLE; SERUM IMMUNOGLOBULIN-E; TEST REACTIVITY; PRICK TEST; IGE LEVELS; HAY-FEVER; DIAGNOSIS; EOSINOPHILIA; HISTAMINE; AGE	Background: The relationships between allergic symptoms after exposure to house dust, allergy parameters (skin test to house dust mite [HDM], total IgE, HDM-specific IgE, and blood eosinophil counts), and several confounding variables (age, sex, smoking habits, and airway hyperresponsiveness) were evaluated in 235 patients with asthma and chronic obstructive pulmonary disease (COPD). Results: Skin tests had higher diagnostic value (sensitivity plus specificity) for symptomatic allergy than specific IgE (1.45 versus 1.36) or total IgE (1.16). The other allergy parameters gave no additional information on symptoms once the skin test was known. Expressing the skin test relative to the histamine control proved slightly better than uncorrected wheal size, but this probably has limited clinical value. The best cutoff level for a positive skin test was 0.7 when the histamine wheal size was accounted for by division, -6 mm when subtraction was used, and 7 mm for absolute wheal size. These cutoff levels proved equally applicable in various subgroups of patients with asthma and COPD. Only the skin test and female sex were independent predictors of allergic symptoms. Conclusion: We conclude that skin tests to HDM are better predictors for clinical allergy than total or specific IgE levels and eosinophil count, and that they are applicable in most patients with asthma and with COPD.	UNIV GRONINGEN HOSP,DEPT ALLERGOL,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT PULM,9713 EZ GRONINGEN,NETHERLANDS; UNIV AMSTERDAM HOSP,DEPT PULM,AMSTERDAM,NETHERLANDS; SOPHIA CHILDRENS UNIV HOSP,DEPT PEDIAT PULM,ROTTERDAM,NETHERLANDS; JULIANA CHILDRENS HOSP,DEPT PEDIAT PULM,THE HAGUE,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT PEDIAT PULM,9713 EZ GRONINGEN,NETHERLANDS; LEIDEN UNIV,DEPT GEN PRACTICE,2300 RA LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT PHYSIOL,2300 RA LEIDEN,NETHERLANDS	University of Groningen; University of Groningen; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; University of Groningen; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC			Dekker, Friedo W/B-6452-2011; Kerstjens, Huib/N-4754-2017; Sterk, P.J./AAK-8175-2020; Merkus, P.J.F.M./L-4523-2015; Brand, Paul/ABB-3693-2021; Dekhuijzen, P NR/H-8024-2014	Dekker, Friedo W/0000-0002-2433-2494; Kerstjens, Huib/0000-0001-7705-7927; Dekhuijzen, P NR/0000-0003-1365-900X				AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; AHLSTEDT S, 1974, CLIN ALLERGY, V4, P131, DOI 10.1111/j.1365-2222.1974.tb01370.x; ARMITAGE P, 1987, STATISTICAL METHODS, P473; BACKMAN A, 1991, ALLERGY, V46, P81, DOI 10.1111/j.1398-9995.1991.tb00548.x; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BERG TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209, DOI 10.1016/0091-6749(74)90063-3; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; BRAND P L P, 1990, Clinical and Experimental Allergy, V20, P16; BRAND PLP, 1992, EUR RESPIR J, V5, P21; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; COLLINSWILLIAMS C, 1976, ANN ALLERGY, V36, P161; DREBORG S, 1987, CLIN ALLERGY, V17, P537, DOI 10.1111/j.1365-2222.1987.tb02050.x; DREBORG S, 1987, ALLERGY, V42, P117, DOI 10.1111/j.1398-9995.1987.tb02369.x; EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844; FERGUSON AC, 1986, CAN MED ASSOC J, V134, P1365; FINNERTY JP, 1989, CLIN EXP ALLERGY, V19, P51, DOI 10.1111/j.1365-2222.1989.tb02343.x; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; HALONEN M, 1982, J ALLERGY CLIN IMMUN, V69, P221, DOI 10.1016/0091-6749(82)90103-8; Hosmer D.W., 1989, APPL LOGISTIC REGRES, P1; KAUFFMANN F, 1989, BRONCHITIS 4, P60; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; LOPEZ LR, 1988, J ALLERGY CLIN IMMUN, V81, P1143, DOI 10.1016/0091-6749(88)90882-2; MENSINGA TT, 1990, J ALLERGY CLIN IMMUN, V86, P99, DOI 10.1016/S0091-6749(05)80129-0; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P21, DOI 10.1016/0091-6749(83)90542-0; NEIJENS HJ, 1979, J ALLERGY CLIN IMMUN, V64, P507, DOI 10.1016/0091-6749(79)90060-5; NIEMEIJER NR, IN PRESS ALLERGY; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; PEPYS J, 1969, CLIN ASPECTS IMMUNOL, P189; PETERSSON G, 1986, ALLERGY, V41, P398, DOI 10.1111/j.1398-9995.1986.tb00319.x; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; SOX HC, 1988, MED DECIS MAKING, P77; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P776, DOI 10.1164/ajrccm/144.4.776; VANARSDEL PP, 1989, ANN INTERN MED, V110, P304, DOI 10.7326/0003-4819-110-4-304; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VERVLOET D, 1991, CLIN EXP ALLERGY, V21, P733, DOI 10.1111/j.1365-2222.1991.tb03203.x; VOHLONEN I, 1989, ALLERGY, V44, P525, DOI 10.1111/j.1398-9995.1989.tb04196.x; 1987, AM REV RESPIR DIS, V136, P225; 1991, HARRISONS PRINCIPLES	45	35	36	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					560	570		10.1016/0091-6749(93)90262-E	http://dx.doi.org/10.1016/0091-6749(93)90262-E			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	8436772				2022-12-18	WOS:A1993KN54800004
J	MAJCHEL, AM; PROUD, D; FRIEDHOFF, L; CRETICOS, PS; NORMAN, PS; NACLERIO, RM				MAJCHEL, AM; PROUD, D; FRIEDHOFF, L; CRETICOS, PS; NORMAN, PS; NACLERIO, RM			THE NASAL RESPONSE TO HISTAMINE CHALLENGE - EFFECT OF THE POLLEN SEASON AND IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RAGWEED; HISTAMINE; ALLERGY; IMMUNOTHERAPY; RHINITIS; NASAL MUCOSA; HYPERRESPONSIVENESS	ALLERGIC RHINITIS; RAGWEED-POLLEN; MUCOSA; SENSITIVITY; POLLINOSIS; RESPONSIVENESS; SECRETIONS; EXPOSURE	To evaluate changes in the nasal response to histamine, we challenged 19 subjects with allergic rhinitis caused by ragweed (RW) before, during, and after the RW season with increasing doses of histamine diphosphate. We compared their response, as measured by symptoms and the levels of TAME-esterase activity and albumin recovered in the nasal lavage fluid, with response of two groups with allergic rhinitis undergoing immunotherapy with moderate-dose (N = 16) and high-dose (N = 11) RW (2 and 24-mu-g of antigen E [Amb a I] as maintenance dose, respectively). Four challenges with histamine were performed in each group: before, at the peak of, near the end of, and 2 weeks after the RW season. The three groups of subjects had similar skin sensitivity to antigen and levels of TAME-esterase activity and albumin recovered from nasal lavages after histamine challenge performed before seasonal exposure. Symptom diaries obtained throughout the season revealed a significant reduction only in the high-dose immunotherapy-treated group. At the peak of the season, the untreated group had more symptoms in response to the challenge compared with the challenges before and after the season (p = 0.04 for both groups). The saline challenge occurring before challenging with histamine also demonstrated a significant increase at the peak of the season compared with increases before the season (p = 0.02). This observation was also true for the levels of albumin and TAME-esterase activity. If the response after saline challenge was subtracted from each response after histamine challenge, no difference was found in the results between any of the visits. No changes occurred for the net albumin and TAME-esterase activity scores through the season. The saline challenges for the two immunotherapy-treated groups did not reveal a significant change, nor did the overall challenge vary during the season. We speculate that the increased responsiveness of the nasal mucosa during the allergen season may represent an increase in the baseline reactivity of the mucosa and not an increased responsiveness to histamine. Immunotherapy prevents this change in baseline reactivity.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21224 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI 31335, AI 04866, AI 20136] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI020136, R01AI031335, R01AI004866, R37AI004866] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON M, 1989, ACTA OTO-LARYNGOL, V107, P270, DOI 10.3109/00016488909127508; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; JULIUSSON S, 1988, CLIN ALLERGY, V18, P615, DOI 10.1111/j.1365-2222.1988.tb02913.x; KONNO A, 1981, ARCH OTO-RHINO-LARYN, V232, P253, DOI 10.1007/BF00457450; LICHTENSTEIN LM, 1985, J CLIN INVEST, V76, P2247; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; WALDEN SM, 1991, AM REV RESPIR DIS, V144, P642, DOI 10.1164/ajrccm/144.3_Pt_1.642	17	35	36	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					85	91		10.1016/S0091-6749(06)80014-X	http://dx.doi.org/10.1016/S0091-6749(06)80014-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JE255	1629510				2022-12-18	WOS:A1992JE25500010
J	MAGNUSSEN, H; BOERGER, S; TEMPLIN, K; BAUNACK, AR				MAGNUSSEN, H; BOERGER, S; TEMPLIN, K; BAUNACK, AR			EFFECTS OF A THROMBOXANE-RECEPTOR ANTAGONIST, BAY U 3405, ON PROSTAGLANDIN-D2-INDUCED AND EXERCISE-INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BAY U 3405; THROMBOXANE-RECEPTOR ANTAGONIST; PGD2 CHALLENGE; EXERCISE CHALLENGE; PATIENTS WITH ASTHMA	NEUTROPHIL CHEMOTACTIC FACTOR; INDUCED ASTHMA; WATER-LOSS; HEAT; HISTAMINE; AIRWAYS; MEDIATORS; CHALLENGE; RELEASE; REST	In the pathogenesis of exercise-induced bronchoconstriction (EIB), prostaglandin D2 (PGD2) may play a role as a newly generated, mast cell-derived mediator. As the bronchoconstrictor effects of PGD2 are predominantly mediated via stimulation of thromboxane receptors in the lung, we studied a novel, orally effective, thromboxane-receptor antagonist, BAY u 3405, on EIB in 12 male subjects with mild asthma. On 4 study days, we determined, in a randomized, double-blind, placebo-controlled, crossover fashion, the effects of 20 mg of BAY u 3405 administered orally 1 hour before PGD, and exercise challenges, respectively. Increasing dosages of PGD2 were inhaled to establish dose-response curves that allowed determination of the provocative concentration necessary to decrease FEV1 by at least 20% (PC20) and to increase specific airway resistance (SR(aw)) by 100% (PC100). EIB was measured as a maximal fall/increase in postexertional FEV1/SR(aw) after bicycle exercise and cold-air breathing. Prechallenge lung-function values were similar on all four occasions. BAY u 3405 did not elicit any effect on resting bronchial tone. After placebo, the geometric means (SD) of PC20 and PC100 were 0.0380 (2.6) and 0.0266 (2.4) mg/ml, increasing to 0.554 (5.9) and 0.143 (8.1) mg/ml after BAY u 3405 (p = 0.0002). Mean (SD) maximal postexertional decrease in FEV1 and increase in SR(aw) after placebo was 29.4% (16.4%) and 280% (135%), and after BAY u 3405, 31.4% (18.1%) and 379% (281%) (not significant). No clinically relevant BAY u 3405-related side effects were observed. From these results we conclude that RAY u 3405 is highly effective in attenuating PGD2-induced bronchoconstriction. However, BAY u 3405 does not modulate EIB, suggesting that the mast cell-derived mediator, PGD2, does not play an important role in the pathogenesis of exercise-induced asthma.	LANDESVERSICHERUNGSANSTALT,KRANKENHAUS GROSSHANSDORF,CTR PNEUMOL & THORAC SURG,HAMBURG,GERMANY; BAYER AG,INST CLIN RES D,W-5600 WUPPERTAL 1,GERMANY	Bayer AG								ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; ANDERSON SD, 1985, J ALLERGY CLIN IMMUN, V76, P763, DOI 10.1016/0091-6749(85)90745-6; BEASLEY RCW, 1989, J APPL PHYSIOL, V66, P1685, DOI 10.1152/jappl.1989.66.4.1685; BOBERG M, 1991, DRUG FUTURE, V16, P701; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHEN WY, 1977, RESPIRATION, V34, P305, DOI 10.1159/000193842; DANTZKER DR, 1987, AM REV RESPIR DIS, V136, P225; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; FEATHERSTONE RL, 1990, N-S ARCH PHARMACOL, V341, P439; FINNERTY JP, 1991, THORAX, V46, P190, DOI 10.1136/thx.46.3.190; GILBERT IA, 1987, J APPL PHYSIOL, V63, P1681, DOI 10.1152/jappl.1987.63.4.1681; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; IIKURA Y, 1988, J ALLERGY CLIN IMMUN, V81, P1050, DOI 10.1016/0091-6749(88)90179-0; KAY AB, 1982, J ALLERGY CLIN IMMUN, V70, P317, DOI 10.1016/0091-6749(82)90019-7; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; MIADONNA A, 1990, J ALLERGY CLIN IMMUN, V85, P906, DOI 10.1016/0091-6749(90)90076-G; PHILLIPS GD, 1989, J APPL PHYSIOL, V66, P304, DOI 10.1152/jappl.1989.66.1.304; PLISS LB, 1990, AM REV RESPIR DIS, V142, P73, DOI 10.1164/ajrccm/142.1.73; QUANJER PLH, 1983, B EUROP PHYSIOPAT S5, V19, P7; ROSENTRETER U, 1989, ARZNEIMITTEL-FORSCH, V39-2, P1519; SLY RM, 1974, ANN ALLERGY, V33, P138; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; WHITE MV, 1991, ASTHMA ITS PATHOLOGY, P409; ZEHR BB, 1989, CHEST, V95, P1059, DOI 10.1378/chest.95.5.1059	30	35	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1119	1126		10.1016/0091-6749(92)90295-D	http://dx.doi.org/10.1016/0091-6749(92)90295-D			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1535083				2022-12-18	WOS:A1992HZ74800006
J	BIELORY, L; FROHMAN, LP				BIELORY, L; FROHMAN, LP			ALLERGIC AND IMMUNOLOGICAL DISORDERS OF THE EYE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							GIANT-CELL ARTERITIS; SYSTEMIC LUPUS-ERYTHEMATOSUS; ERYTHROCYTE SEDIMENTATION-RATE; CORNEAL ALLOGRAFT-REJECTION; MAJOR BASIC-PROTEIN; TEMPORAL ARTERITIS; VERNAL CONJUNCTIVITIS; COGANS SYNDROME; PAPILLARY CONJUNCTIVITIS; WEGENERS GRANULOMATOSIS		UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT OPHTHALMOL,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT NEUROSCI,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	BIELORY, L (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MED,DIV PHYS BIOCHEM,185 S ORANGE AVE,NEWARK,NJ 07103, USA.							ABELSON MB, 1983, ARCH OPHTHALMOL-CHIC, V101, P555; ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P520, DOI 10.1001/archopht.1990.01070060068051; ABELSON MB, 1983, AM J OPHTHALMOL, V95, P502, DOI 10.1016/0002-9394(83)90272-6; ABELSON MB, 1991, INVEST OPHTH VIS SCI, V32, P683; ALLANSMITH M, 1982, EYE IMMUNOLOGY, P66; ALLANSMITH MR, 1988, CLIN ALLERGY, V18, P1, DOI 10.1111/j.1365-2222.1988.tb02837.x; ALLANSMITH MR, 1987, ALLERGY INFLAMMATION, V20, P307; ALLANSMITH MR, 1981, AM J OPHTHALMOL, V9, P71; ARONSON AJ, 1979, ARCH INTERN MED, V139, P1312, DOI 10.1001/archinte.139.11.1312; ATKINS CJ, 1972, ANN INTERN MED, V76, P65, DOI 10.7326/0003-4819-76-1-65; BALLOW M, 1980, J ALLERGY CLIN IMMUN, V66, P112, DOI 10.1016/0091-6749(80)90057-3; BALLOW M, 1983, AM J OPHTHALMOL, V95, P161, DOI 10.1016/0002-9394(83)90009-0; Beetham WP, 1940, ARCH OPHTHALMOL-CHIC, V24, P21; BENEZRA D, 1986, AM J OPHTHALMOL, V101, P278, DOI 10.1016/0002-9394(86)90819-6; BENSON JL, 1990, INVEST OPHTH VIS SCI, V31, P2123; BETTMAN IW, 1968, AMA ARCH OPHTHAL CHI, V80, P189; BIELORY L, 1988, MEDICINE, V67, P40, DOI 10.1097/00005792-198801000-00003; BIELORY L, 1990, J ALLERGY CLIN IMMUN, V85, P808, DOI 10.1016/0091-6749(90)90203-G; BIELORY L, 1989, AM J MED, V86, P707, DOI 10.1016/0002-9343(89)90450-6; BIELORY L, 1988, TRANSPLANT P, V20, P144; BIELORY L, 1991, J ALLERGY CLIN IMMUN, V87, P819; BIRKHEAD NC, 1957, JAMA-J AM MED ASSOC, V163, P821, DOI 10.1001/jama.1957.02970450023007; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BROWN AL, 1925, AM J OPHTHALMOL, V8, P614; BROWN SI, 1976, AM J OPHTHALMOL, V82, P825; BUCKLEY RJ, 1988, INT OPHTHALMOL CLIN, V28, P303, DOI 10.1097/00004397-198802840-00009; BULLEN CL, 1983, OPHTHALMOLOGY, V90, P279; BURNS JC, 1985, PEDIATR INFECT DIS J, V4, P258, DOI 10.1097/00006454-198505000-00010; BUTRUS SI, 1991, INVEST OPHTH VIS SCI, V32, P740; CARLOW TJ, 1974, JAMA-J AM MED ASSOC, V228, P197, DOI 10.1001/jama.228.2.197; CHAN LS, 1990, ARCH DERMATOL, V126, P1466, DOI 10.1001/archderm.126.11.1466; CHENG KH, 1990, INVEST OPHTH VIS SCI, V31, P2244; CHESON BD, 1976, AM J MED, V60, P549, DOI 10.1016/0002-9343(76)90722-1; COBO LM, 1984, OPHTHALMOLOGY, V91, P903; COGAN DG, 1964, ARCH OPHTHALMOL-CHIC, V71, P172, DOI 10.1001/archopht.1964.00970010188005; COLVARD DM, 1977, ARCH OPHTHALMOL-CHIC, V95, P1813; COYLE PK, 1989, INVEST OPHTH VIS SCI, V30, P1872; DINNING WJ, 1990, EYE SYSTEMIC DIS, P279; DINNING WJ, 1979, BEHCETS SYNDROME, P177; DONNELLY JJ, 1990, INVEST OPHTH VIS SCI, V31, P1315; DONSHIK PC, 1983, AM J OPHTHALMOL, V96, P460, DOI 10.1016/S0002-9394(14)77909-7; EASTY DL, 1987, ALLERGY INT TXB, P513; EISENSTEIN B, 1958, NEW ENGL J MED, V258, P1074, DOI 10.1056/NEJM195805292582202; FAUCI AS, 1983, J ALLERGY CLIN IMMUN, V72, P211, DOI 10.1016/0091-6749(83)90021-0; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; Faure J P, 1980, Curr Top Eye Res, V2, P215; FOSTER CS, 1990, OPHTHALMOLOGY, V97, P992; FOSTER CS, 1980, AM J OPHTHALMOL, V90, P175, DOI 10.1016/S0002-9394(14)74850-0; FRAUNFELDER FT, 1989, DRUG INDUCED OCULAR, P321; FRIEDLAENDER MH, 1984, ARCH OPHTHALMOL-CHIC, V102, P1198; FRIEDLAENDER MH, 1987, JAMA-J AM MED ASSOC, V258, P2916; FRITH PA, 1989, BRIT J OPHTHALMOL, V73, P52, DOI 10.1136/bjo.73.1.52; FUJIKAWA LS, 1989, OPHTHALMOLOGY, V96, P1115; GELFAND ML, 1972, B NEW YORK ACAD MED, V48, P647; GEPHARDT BM, 1990, INVEST OPHTHALMOL VI, V31, P2254; GERSONY WM, 1991, JAMA-J AM MED ASSOC, V265, P2699, DOI 10.1001/jama.265.20.2699; GERY I, 1986, INVEST OPHTH VIS SCI, V27, P1296; GOLD DH, 1972, BRIT J OPHTHALMOL, V56, P800, DOI 10.1136/bjo.56.11.800; GOODMAN BW, 1979, AM J MED, V67, P839, DOI 10.1016/0002-9343(79)90744-7; GOOGE JM, 1985, ARCH OPHTHALMOL-CHIC, V103, P81; GRAHAM AM, 1980, NEUROOPHTHALMOLOGY, V1, P73; GRAHAM E, 1981, BRIT MED J, V282, P269, DOI 10.1136/bmj.282.6260.269; HAYNES BF, 1981, ARTHRITIS RHEUM, V24, P501, DOI 10.1002/art.1780240308; HOANGXUAN T, 1989, OPHTHALMOLOGY, V96, P1110; Horton BM., 1932, PROC STAFF MEET MAYO, V7, P700; HULL RG, 1984, ANN RHEUM DIS, V43, P746, DOI 10.1136/ard.43.5.746; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; HUNTER DG, 1991, INVEST OPHTH VIS SCI, V32, P681; Hutchinson J., 1890, ARCH SURG-CHICAGO, V1, P323; IRANI AMA, 1990, J ALLERGY CLIN IMMUN, V86, P34, DOI 10.1016/S0091-6749(05)80120-4; JABS DA, 1986, ARCH OPHTHALMOL-CHIC, V104, P558; JACOBSON DM, 1987, ARCH OPHTHALMOL-CHIC, V105, P965; JOHNSTON AC, 1973, CAN J OPHTHALMOL, V8, P38; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V85, P606, DOI 10.1016/0091-6749(90)90100-I; KALBIAN V V, 1970, American Journal of Medicine, V49, P823, DOI 10.1016/S0002-9343(70)80064-X; KRAY KT, 1985, J ALLERGY CLIN IMMUN, V76, P623, DOI 10.1016/0091-6749(85)90785-7; KYLE V, 1989, ANN RHEUM DIS, V48, P667, DOI 10.1136/ard.48.8.667; KYLE V, 1990, BRIT MED J, V300, P344, DOI 10.1136/bmj.300.6721.344; LAUVER JW, 1978, BRIT J RADIOL, V52, P582; LEONARDI A, 1991, INVEST OPHTH VIS SCI, V32, P737; MASHETER HC, 1959, P ROY SOC MED, V52, P1039; MCCULLEY JP, 1982, OPHTHALMOLOGY, V89, P1173; MCDONNELL PJ, 1986, OPHTHALMOLOGY, V93, P518; MCINTOSH RM, 1974, ANN INTERN MED, V81, P111, DOI 10.7326/0003-4819-81-1-111; MEISLER DM, 1981, AM J OPHTHALMOL, V92, P368, DOI 10.1016/0002-9394(81)90526-2; MEISLER DM, 1980, AM J OPHTHALMOL, V89, P66, DOI 10.1016/0002-9394(80)90231-7; MICHELSON JB, 1982, SURV OPHTHALMOL, V26, P190, DOI 10.1016/0039-6257(82)90079-0; MILLER DH, 1987, NEURORADIOLOGY, V29, P226, DOI 10.1007/BF00451758; MILLER GR, 1966, AM J OPHTHALMOL, V62, P103, DOI 10.1016/0002-9394(66)91685-0; MONDINO BJ, 1978, OPHTHALMOLOGY, V85, P801; NEUMANN E, 1959, AM J OPHTHALMOL, V47, P166, DOI 10.1016/S0002-9394(14)76417-7; O'Connor G. R., 1986, OCULAR IMMUNOLOGY; OBENAUF CD, 1978, AM J OPHTHALMOL, V86, P648, DOI 10.1016/0002-9394(78)90184-8; PAMIR MN, 1981, ARCH NEUROL-CHICAGO, V38, P643, DOI 10.1001/archneur.1981.00510100071012; Parelhoff E S, 1985, J Pediatr Ophthalmol Strabismus, V22, P100; PULIDO JS, 1990, ARCH OPHTHALMOL-CHIC, V108, P845, DOI 10.1001/archopht.1990.01070080087041; RAHI AHS, 1976, IMMUNOPATHOLOGY EYE; ROITT IM, 1989, IMMUNOLOGY, P216; ROSENBAUM JT, 1990, SEMIN ARTHRITIS RHEU, V19, P248, DOI 10.1016/0049-0172(90)90004-Y; ROSENFELD SI, 1986, AM J MED, V80, P143, DOI 10.1016/0002-9343(86)90066-5; SACKS RD, 1991, AM J OPHTHALMOL, V111, P430, DOI 10.1016/S0002-9394(14)72376-1; SALINASCARMONA MC, 1982, EUR J IMMUNOL, V12, P480, DOI 10.1002/eji.1830120606; SAPSE AT, 1969, ARCH OPHTHALMOL-CHIC, V81, P815, DOI 10.1001/archopht.1969.00990010817012; SAVAGE COS, 1987, LANCET, V1, P1389; SAVESODERBERGH J, 1986, JAMA-J AM MED ASSOC, V255, P493, DOI 10.1001/jama.255.4.493; SCULLY RE, 1988, NEW ENGL J MED, V318, P760; SETTIPANE GA, 1965, J ALLERGY, V36, P92, DOI 10.1016/0021-8707(65)90036-5; SMITH L, 1988, RES STAFF PHYS, V34, P48; SOX HC, 1986, ANN INTERN MED, V104, P515, DOI 10.7326/0003-4819-104-4-515; STEGMAN R, 1975, ARCH OPHTHALMOL-CHIC, V93, P1354; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; TERVAERT JWC, 1990, LANCET, V336, P709; THEODORE RH, 1939, ARCH OPHTHALMOL-CHIC, V21, P828; TROCME SD, 1989, AM J OPHTHALMOL, V108, P57, DOI 10.1016/S0002-9394(14)73261-1; UDELL IJ, 1981, AM J OPHTHALMOL, V92, P824, DOI 10.1016/S0002-9394(14)75637-5; VANDERWOUDE FJ, 1985, LANCET, V1, P425; VANDERWOUDE FJ, 1989, CLIN EXP IMMUNOL, V78, P143; WACKER WB, 1977, J IMMUNOL, V119, P1949; WOLF SM, 1965, ARCH NEUROL-CHICAGO, V12, P315, DOI 10.1001/archneur.1965.00460270091012; WOLFF D, 1965, ANN OTO RHINOL LARYN, V74, P507, DOI 10.1177/000348946507400219; WONG RL, 1986, AM J MED, V80, P959, DOI 10.1016/0002-9343(86)90645-5; YOUNG E, 1985, INVEST OPHTH VIS SCI, V26, P571	122	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				1	18		10.1016/S0091-6749(05)80033-8	http://dx.doi.org/10.1016/S0091-6749(05)80033-8			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1730829	Bronze			2022-12-18	WOS:A1992GZ90800001
J	KEMENY, DM; PRICE, JF; RICHARDSON, V; RICHARDS, D; LESSOF, MH				KEMENY, DM; PRICE, JF; RICHARDSON, V; RICHARDS, D; LESSOF, MH			THE IGE AND IGG SUBCLASS ANTIBODY-RESPONSE TO FOODS IN BABIES DURING THE 1ST YEAR OF LIFE AND THEIR RELATIONSHIP TO FEEDING REGIMEN AND THE DEVELOPMENT OF FOOD ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IMMUNOSORBENT-ASSAY ELISA; BEE-VENOM IMMUNOTHERAPY; COWS MILK; CLINICAL SYMPTOMS; ATOPIC DISEASE; FULL-TERM; SUB-CLASS; INFANTS; QUANTITATION; AVOIDANCE	This follow-up study of 191 babies investigated the development of food allergy in an unselected population and its relationship to total and antigen-specific IgE and IgG subclass levels. Sensitization to egg, as indicated by a positive skin test or RAST, was found in 5% of 1-year-old babies, but none of the babies in this series fulfilled the clinical criteria for immediate-type milk allergy. For both bovine casein (CAS) and egg albumin, the IgG response was largely restricted to IgGl in contrast to the predominant IgG4 response to these antigens that is found in adults. The level of IgG4, but not IgG1, antibody to CAS and ovalbumin (OV) was lower in some of the babies compared with that of their mothers (N = 166; p < 0.05, Student's paired t test). However, there was no difference in the total serum IgG subclass levels between mothers and babies. These results demonstrate that, in the population of babies studied, (1) type I hypersensitivity to egg occurred in 5% of 1-year-old babies, (2) the predominant IgG subclass of antibodies to CAS and OV in babies is IgG1, and (3) in the 22% of babies, there was substantially (> 1000-fold) less IgG4 antibody to CAS and OV than in their mothers, suggesting specific exclusion of some IgG4 antibodies.			KEMENY, DM (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT ALLERGY & ALLIED RESP DISORDERS,DIV MED,LONDON SE1 9RT,ENGLAND.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; BIELORY L, 1989, J ALLERGY CLIN IMMUN, V85, P573; BJORKSTEN F, 1978, LANCET, V2, P624; BLACK CM, 1988, J IMMUNOL METHODS, V106, P71, DOI 10.1016/0022-1759(88)90273-6; CATTY D, 1977, EUR J PEDIATR, V125, P89, DOI 10.1007/BF00489982; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; DEVEY ME, 1989, J ALLERGY CLIN IMMUN, V84, P326, DOI 10.1016/0091-6749(89)90416-8; DEVEY ME, UNPUB J ALLERGY CLIN; EASTHAM EJ, 1978, J PEDIATR-US, V93, P561, DOI 10.1016/S0022-3476(78)80888-9; FALLSTROM SP, 1978, INT ARCH ALLER A IMM, V56, P97, DOI 10.1159/000232011; FALTHMAGNUSSON K, 1988, J ALLERGY CLIN IMMUN, V81, P743, DOI 10.1016/0091-6749(88)91048-2; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; HAMILTON RG, 1980, J IMMUNOL, V124, P2966; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; HATTEVIG G, 1990, J ALLERGY CLIN IMMUN, V85, P108, DOI 10.1016/0091-6749(90)90231-R; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; HAY FC, 1971, CLIN EXP IMMUNOL, V9, P355; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; KEMENY DM, 1987, J IMMUNOL METHODS, V96, P47, DOI 10.1016/0022-1759(87)90366-8; KEMENY DM, 1987, INT ARCH ALLER A IMM, V83, P113, DOI 10.1159/000234343; KEMENY DM, 1988, J IMMUNOL METHODS, V108, P105, DOI 10.1016/0022-1759(88)90408-5; KEMENY DM, 1989, J IMMUNOL METHODS, V120, P251, DOI 10.1016/0022-1759(89)90249-4; KEMENY DM, 1986, CLIN ALLERGY, V16, P571, DOI 10.1111/j.1365-2222.1986.tb01996.x; KEMENY DM, 1989, CLIN EXP ALLERGY, V19, P545, DOI 10.1111/j.1365-2222.1989.tb02431.x; KEMENY DM, 1987, IMMUNOLOGICAL TECHNI, P47; KEMENY DM, 1981, J IMMUNOL METHODS, V49, P89; KILSHAW PJ, 1984, INT ARCH ALLER A IMM, V74, P8; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; MATTHEW DJ, 1977, LANCET, V1, P321; MORRELL A, 1971, VOX SANG, V21, P481; PITCHERWILMOTT RW, 1980, CLIN EXP IMMUNOL, V41, P303; PRICE JF, 1989, ALLERGY INT TXB, P423; ROUNDTRESS S, 1985, ARCH DIS CHILD, V60, P727; SCHUR PH, 1973, CLIN IMMUNOL IMMUNOP, V2, P62, DOI 10.1016/0090-1229(73)90036-6; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	36	35	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1991	87	5					920	929		10.1016/0091-6749(91)90413-I	http://dx.doi.org/10.1016/0091-6749(91)90413-I			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FM095	2026845				2022-12-18	WOS:A1991FM09500003
J	SCHROECKENSTEIN, DC; MEIERDAVIS, S; BUSH, RK				SCHROECKENSTEIN, DC; MEIERDAVIS, S; BUSH, RK			OCCUPATIONAL SENSITIVITY TO TENEBRIO-MOLITOR LINNAEUS (YELLOW MEALWORM)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILLIAM S MIDDLETON MEM VET ADM MED CTR,ALLERGY SECT,2500 OVERLOOK TERRACE,MADISON,WI 53705; UNIV WISCONSIN,DEPT MED,ALLERGY CLIN IMMUNOL SECT,MADISON,WI 53706	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison								BERNSTEIN DI, 1983, J ALLERGY CLIN IMMUN, V72, P475, DOI 10.1016/0091-6749(83)90584-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FRANKLAND AW, 1965, BRIT J IND MED, V22, P157; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GOLD BL, 1985, AM REV RESPIR DIS, V131, P949; KROUTIL LA, 1987, J ALLERGY CLIN IMMUN, V80, P170, DOI 10.1016/0091-6749(87)90126-6; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OKUMURA GT, 1967, VECTOR VIEWS, V14, P19; PERLMAN F, 1961, J ALLERGY, V32, P93, DOI 10.1016/0021-8707(61)90061-2; PERLMAN F, 1958, J ALLERGY, V29, P302, DOI 10.1016/0021-8707(58)90037-6; PETRY RW, 1985, J ALLERGY CLIN IMMUN, V75, P268, DOI 10.1016/0091-6749(85)90056-9; PHILLIPS JK, 1984, INSECT MANAGEMENT FO, P279; SCHROECKENSTEIN DC, 1988, J ALLERGY CLIN IMMUN, V82, P1081, DOI 10.1016/0091-6749(88)90147-9; SHELDON JM, 1941, J ALLERGY, V13, P493; STEVENSON DD, 1967, J ALLERGY, V39, P274, DOI 10.1016/0021-8707(67)90091-3; TSCHINKEL WR, 1975, J INSECT PHYSIOL, V21, P753, DOI 10.1016/0022-1910(75)90008-6; WIDE L, 1967, LANCET, V2, P1105; Wirtz R.A., 1980, Bulletin of the Entomological Society of America, V26, P356; WITTICH F. W., 1940, JOUR ALLERGY, V12, P42, DOI 10.1016/S0021-8707(40)90390-2; 1986, USDA AGR HDB, V500, P34	20	35	37	0	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					182	188		10.1016/S0091-6749(05)80064-8	http://dx.doi.org/10.1016/S0091-6749(05)80064-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2384648				2022-12-18	WOS:A1990DV31600007
J	SHALIT, M; SCHWARTZ, LB; VONALLMEN, C; ATKINS, PC; LAVKER, RM; ZWEIMAN, B				SHALIT, M; SCHWARTZ, LB; VONALLMEN, C; ATKINS, PC; LAVKER, RM; ZWEIMAN, B			RELEASE OF HISTAMINE AND TRYPTASE DURING CONTINUOUS AND INTERRUPTED CUTANEOUS CHALLENGE WITH ALLERGEN IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN, SCH MED, ALLERGY & IMMUNOL SECT, 512 JOHNSON PAVILL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, RICHMOND, VA 23298 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Virginia Commonwealth University					NIAMS NIH HHS [P01-AR39674-01] Funding Source: Medline; PHS HHS [R01-14332] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039674] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; ATKINS PC, 1987, J IMMUNOL, V139, P2744; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BENYON RC, 1987, J IMMUNOL, V138, P861; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CHARLESWORTH EN, 1988, J ALLERGY CLIN IMMUN, V81, P212, DOI 10.1016/0091-6749(88)90412-5; CRAIG SS, 1988, LAB INVEST, V58, P682; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; SHALIT M, 1987, J ALLERGY CLIN IMMUN, V80, P87, DOI 10.1016/S0091-6749(87)80196-3; SHALIT M, 1988, J IMMUNOL, V141, P821; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; THARP MD, 1987, J ALLERGY CLIN IMMUN, V79, P646, DOI 10.1016/S0091-6749(87)80162-8; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2	23	35	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					117	125		10.1016/S0091-6749(05)80131-9	http://dx.doi.org/10.1016/S0091-6749(05)80131-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	1695232				2022-12-18	WOS:A1990DQ68800017
J	LI, JTC; YUNGINGER, JW; REED, CE; JAFFE, HS; NELSON, DR; GLEICH, GJ				LI, JTC; YUNGINGER, JW; REED, CE; JAFFE, HS; NELSON, DR; GLEICH, GJ			LACK OF SUPPRESSION OF IGE PRODUCTION BY RECOMBINANT INTERFERON-GAMMA - A CONTROLLED TRIAL IN PATIENTS WITH ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT IMMUNOL,ROCHESTER,MN 55905; GENENTECH INC,SAN FRANCISCO,CA 94080	Mayo Clinic; Mayo Clinic; Mayo Clinic; Roche Holding; Genentech								Adolphson C. R., 1986, MANUAL CLIN LABORATO, P652; COFFMAN RL, 1986, J IMMUNOL, V136, P949; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELPRETE G, 1988, J IMMUNOL, V140, P4193; ERON LJ, 1986, NEW ENGL J MED, V315, P1059, DOI 10.1056/NEJM198610233151704; EZEKOWITZ RAB, 1988, NEW ENGL J MED, V319, P146, DOI 10.1056/NEJM198807213190305; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; HERNANDEZASENSIO M, 1979, J IMMUNOL, V122, P1601; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; KURZROCK R, 1985, CANCER RES, V45, P2866; LETTBROWN MA, 1981, J CLIN INVEST, V67, P547, DOI 10.1172/JCI110065; NATHAN CF, 1986, NEW ENGL J MED, V315, P6, DOI 10.1056/NEJM198607033150102; Ogden EC, 1974, MANUAL SAMPLING AIRB; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; QUESADA JR, 1984, NEW ENGL J MED, V310, P15, DOI 10.1056/NEJM198401053100104; SKURKOVICH S, 1983, ANN ALLERGY, V53, P305; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; THOMPSON JA, 1987, CANCER IMMUNOL IMMUN, V25, P47; VADHANRAJ S, 1986, J CLIN ONCOL, V4, P137, DOI 10.1200/JCO.1986.4.2.137	20	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					934	940		10.1016/0091-6749(90)90080-N	http://dx.doi.org/10.1016/0091-6749(90)90080-N			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2110199	Bronze			2022-12-18	WOS:A1990DD95900018
J	OHMAN, JL; MALKIEL, S; LEWIS, S; LORUSSO, JR				OHMAN, JL; MALKIEL, S; LEWIS, S; LORUSSO, JR			ALLERGY TO HUMAN SEMINAL FLUID - CHARACTERIZATION OF THE ALLERGEN AND EXPERIENCE WITH IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM OUTPATIENT CLIN,ALLERGY RES LAB,BOSTON,MA 02108; TUFTS UNIV,SCH MED,BOSTON,MA 02111; UNIV MASSACHUSETTS,SCH MED,WORCESTER,MA 01605	Tufts University; University of Massachusetts System; University of Massachusetts Worcester								BERGER H, 1975, NEW YORK STATE J MED, V75, P1072; BERNSTEIN IL, 1985, ANN ALLERGY, V55, P335; BERNSTEIN IL, 1981, ANN INTERN MED, V94, P459, DOI 10.7326/0003-4819-94-4-459; BLAIR H, 1985, CLIN ALLERGY, V15, P117, DOI 10.1111/j.1365-2222.1985.tb02263.x; CHANG TW, 1976, AM J OBSTET GYNECOL, V126, P442, DOI 10.1016/0002-9378(76)90634-7; FRANKLAND AW, 1974, CLIN ALLERGY, V4, P249, DOI 10.1111/j.1365-2222.1974.tb01382.x; FREIDMAN SA, 1984, JAMA-J AM MED ASSOC, V251, P2684; HALPERN BN, 1967, IMMUNOLOGY, V12, P247; KOOISTRA JB, 1980, J ALLERGY CLIN IMMUN, V66, P148, DOI 10.1016/0091-6749(80)90062-7; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LEVINE BB, 1973, NEW ENGL J MED, V288, P894, DOI 10.1056/NEJM197304262881707; LORUSSO JR, 1986, J ALLERGY CLIN IMMUN, V78, P928, DOI 10.1016/0091-6749(86)90242-3; MATHIAS CGT, 1980, ARCH DERMATOL, V116, P209, DOI 10.1001/archderm.116.2.209; MATTHIAS CG, 1979, J ALLERGY CLIN IMMUN, V63, P173; MIKKELSEN EJ, 1975, ANN ALLERGY, V34, P239; MUMFORD DM, 1978, ANN ALLERGY, V40, P40; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; REUNALA T, 1977, FERTIL STERIL, V28, P832; SCHULZ KH, 1974, NEW ENGL J MED, V290, P916; SIRAGANIAN RP, 1975, CLIN IMMUNOL IMMUNOP, V4, P59, DOI 10.1016/0090-1229(75)90040-9; WEIRS DM, 1978, HDB EXPT IMMUNOLOGY, V1, P6	21	35	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				103	107		10.1016/0091-6749(90)90230-2	http://dx.doi.org/10.1016/0091-6749(90)90230-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299095				2022-12-18	WOS:A1990CM37800018
J	GELFAND, EW				GELFAND, EW			THE USE OF INTRAVENOUS IMMUNE GLOBULIN IN COLLAGEN VASCULAR DISORDERS - A POTENTIALLY NEW MODALITY OF THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GELFAND, EW (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,DENVER,CO 80206, USA.							GROOTHOFF JW, 1988, BRIT MED J, V296, P1362, DOI 10.1136/bmj.296.6633.1362; HELEWA A, 1981, J CHRON DIS, V34, P353, DOI 10.1016/0021-9681(81)90073-4; ROIFMAN CM, 1988, CLIN RES, V36, pA446; ROIFMAN CM, 1987, JAMA-J AM MED ASSOC, V258, P513, DOI 10.1001/jama.1987.03400040111034; 1943, AID INVESTIGATION PE	5	35	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	2	S			613	616		10.1016/0091-6749(89)90199-1	http://dx.doi.org/10.1016/0091-6749(89)90199-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ398	2794302				2022-12-18	WOS:A1989AZ39800008
J	RAFFERTY, P; HOLGATE, ST				RAFFERTY, P; HOLGATE, ST			HISTAMINE AND ITS ANTAGONISTS IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, MED 1-LEVEL D-CTR BLOCK, TREMONA RD, SOUTHAMPTON S09 4XY, ENGLAND	University of Southampton								ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; ATKINS PC, 1980, J ALLERGY CLIN IMMUN, V66, P478, DOI 10.1016/0091-6749(80)90009-3; AUSTEN KF, 1976, METHODS IMMUNOLOGY I, V5, P126; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BEER DJ, 1984, J ALLERGY CLIN IMMUN, V73, P439, DOI 10.1016/0091-6749(84)90353-1; BERMAN JS, 1984, J IMMUNOL, V133, P1495; BERNSTEIN T B, 1947, Ill Med J, V92, P90; Best CH, 1927, J PHYSIOL-LONDON, V52, P397; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BOE J, 1980, RESPIRATION, V40, P117, DOI 10.1159/000194261; BOOIJNOO.H, 1970, J ALLERGY, V46, P1, DOI 10.1016/0021-8707(70)90055-9; BRAUDE S, 1984, LANCET, V2, P372; BROHERGER H, 1986, CLIN ALLERGY, V16, P119; BRYANT DH, 1976, CLIN ALLERGY, V6, P523, DOI 10.1111/j.1365-2222.1976.tb01937.x; BUSSE W, 1988, J ALLERGY CLIN IMMUN, V81, P212; CASTERLINE CL, 1977, J ALLERGY CLIN IMMUN, V59, P420, DOI 10.1016/0091-6749(77)90004-5; CHAN TB, 1987, BRIT J DIS CHEST, V81, P260, DOI 10.1016/0007-0971(87)90159-8; CHAND N, 1986, ALLERGY, V41, P473, DOI 10.1111/j.1398-9995.1986.tb00331.x; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; CHAND N, 1985, INT ARCH ALLER A IMM, V77, P451, DOI 10.1159/000233825; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CHURCH MK, 1980, BRIT J PHARMACOL, V69, P663, DOI 10.1111/j.1476-5381.1980.tb07919.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; CRAPS L, 1978, CLIN ALLERGY, V8, P373, DOI 10.1111/j.1365-2222.1978.tb00472.x; CURRY JJ, 1946, J CLIN INVEST, V25, P792, DOI 10.1172/JCI101765; Dale HH, 1910, J PHYSIOL-LONDON, V41, P318; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DEGARA PF, 1951, J ALLERGY, V22, P429, DOI 10.1016/0021-8707(51)90146-3; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; DEVOS C, 1985, ANN ALLERGY, V55, P392; Diamantis W., 1981, PHARMACOLOGIST, V23, P149; DORWARD AJ, 1982, CLIN ALLERGY, V12, P355, DOI 10.1111/j.1365-2222.1982.tb02539.x; DUNLOP LS, 1977, BRIT J PHARMACOL, V59, pP475; EISER NM, 1980, CLIN SCI, V58, P537, DOI 10.1042/cs0580537; EISER NM, 1981, CLIN SCI, V60, P363, DOI 10.1042/cs0600363; EISER NM, 1982, B EUR PHYSIOPATH RES, V18, P449; EYERMANN CH, 1946, J ALLERGY, V17, P210, DOI 10.1016/0021-8707(46)90146-3; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FIELDS DAS, 1984, J ALLERGY CLIN IMMUN, V73, P400, DOI 10.1016/0091-6749(84)90415-9; Fourneau E, 1933, ARCH INT PHARMACOD T, V46, P178; GAROVOY MR, 1983, J IMMUNOL, V130, P357; GRAFFLONNEVIG V, 1985, J ALLERGY CLIN IMMUN, V76, P59, DOI 10.1016/0091-6749(85)90805-X; GROGGINS RC, 1979, BRIT J DIS CHEST, V73, P297, DOI 10.1016/0007-0971(79)90056-1; HARTLEY JPR, 1980, THORAX, V35, P675, DOI 10.1136/thx.35.9.675; HARTLEY JPR, 1981, CLIN SCI, V61, P151, DOI 10.1042/cs0610151; HENRY RL, 1983, ARCH DIS CHILD, V58, P304, DOI 10.1136/adc.58.4.304; HERXHEIMER H, 1949, BMJ-BRIT MED J, V2, P901, DOI 10.1136/bmj.2.4633.901; HONDA M, 1982, ALLERGY, V37, P41, DOI 10.1111/j.1398-9995.1982.tb04115.x; HOWARTH PH, 1985, J ALLERGY CLIN IMMUN, V75, P166, DOI 10.1016/0091-6749(85)90383-5; HOWARTH PH, 1987, J ALLERGY CLIN IMMUN, V80, P703, DOI 10.1016/0091-6749(87)90291-0; HOWARTH PH, 1984, THORAX, V39, P668, DOI 10.1136/thx.39.9.668; ISHIZAKA T, 1981, J ALLERGY CLIN IMMUN, V67, P90, DOI 10.1016/0091-6749(81)90002-6; ITKIN IH, 1970, J ALLERGY, V45, P178, DOI 10.1016/0021-8707(70)90126-7; KAILSHE GA, 1945, P STAFF M MAYO CLIN, V30, P436; KALINER M, 1978, AM REV RESPIR DIS, V118, P1015; Katz G, 1941, J AMER MED ASSOC, V117, P1782, DOI 10.1001/jama.1941.02820470030008; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; KENNEDY JD, 1980, BRIT MED J, V281, P1458, DOI 10.1136/bmj.281.6253.1458; LANE DJ, 1980, CLIN ALLERGY, V10, P519, DOI 10.1111/j.1365-2222.1980.tb02132.x; LEVY L, 1947, J ALLERGY, V18, P244, DOI 10.1016/0021-8707(47)90048-8; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LILJA G, 1983, ALLERGY, V38, P31, DOI 10.1111/j.1398-9995.1983.tb00853.x; LITTLE MM, IN PRESS J ALLERGY C; MACONOCHIE JG, 1979, BRIT J CLIN PHARMACO, V7, P231, DOI 10.1111/j.1365-2125.1979.tb00927.x; MARTIN M, 1975, ALLERGOL IMMUNOPAT S, V5, P5; MARTIN U, 1978, ARZNEIMITTELFORSCH, V28-1, P770; MARTIN U, 1978, TRIANGLE, V17, P141; MORGAN DJR, 1985, CLIN SCI, V69, P63, DOI 10.1042/cs0690063; MORLEY J, 1986, ANN ALLERGY, V56, P335; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; NATHAN RA, 1979, AM REV RESPIR DIS, V120, P1251; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V13, P199, DOI 10.1111/j.1365-2125.1982.tb01356.x; NOAH JW, 1954, J ALLERGY, V25, P210, DOI 10.1016/0021-8707(54)90180-X; NORGRADY SG, 1981, THORAX, V36, P268; NORGRADY SG, 1978, THORAX, V33, P700; PAGE CP, 1985, AGENTS ACTIONS, V16, P33, DOI 10.1007/BF01999637; PARTRIDGE MR, 1979, THORAX, V34, P771, DOI 10.1136/thx.34.6.771; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PATERSON JW, 1983, EUR J CLIN PHARMACOL, V25, P187, DOI 10.1007/BF00543789; PETERS S P, 1982, Journal of Allergy and Clinical Immunology, V69, P150; PETHERAM IS, 1981, THORAX, V36, P308, DOI 10.1136/thx.36.4.308; PHILLIPS MJ, 1984, THORAX, V39, P345, DOI 10.1136/thx.39.5.345; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; POPA VT, 1980, CHEST, V78, P442, DOI 10.1378/chest.78.3.442; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAFFERTY P, 1988, THORAX, V43, pP220; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; RAFFERTY P, 1987, ALLERGOL IMMUNOL CLI, V2, P188; RAFFERTY P, 1988, AM REV RESPIR DIS, V137, pA286; RANDOLPH THERON G., 1941, JOUR ALLERGY, V12, P450, DOI 10.1016/S0021-8707(41)90221-6; RIHOUX JP, 1985, ANN ALLERGY, V55, P392; RILEY JF, 1953, J PHYSIOL-LONDON, V120, P528, DOI 10.1113/jphysiol.1953.sp004915; ROCKLIN RE, 1977, J IMMUNOL, V118, P1734; ROCKLIN RE, 1978, CELL IMMUNOL, V37, P162, DOI 10.1016/0008-8749(78)90184-3; ROSS WJ, 1979, J MED CHEM, V22, P412, DOI 10.1021/jm00190a011; SAMSON SR, 1979, J PHYSIOL-LONDON, V287, P509; SCHILD HO, 1951, LANCET, V261, P376; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0; THOMSON NC, 1979, CLIN SCI, V56, P235, DOI 10.1042/cs0560235; THOMSON NC, 1980, THORAX, V35, P428, DOI 10.1136/thx.35.6.428; TINKELMAN DG, 1986, ANN ALLERGY, V56, P213; Tomioka H, 1979, Monogr Allergy, V14, P313; TUCKER A, 1975, AM J PHYSIOL, V229, P1008, DOI 10.1152/ajplegacy.1975.229.4.1008; UVNAS B, 1970, ACTA PHYSIOL SCAND, V78, P1; Weiss S, 1932, ARCH INTERN MED, V49, P360, DOI 10.1001/archinte.1932.00150100017002; Windaus A, 1907, BER DTSCH CHEM GES, V40, P3691, DOI 10.1002/cber.190704003164; ZECHEL HJ, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1184	112	35	35	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					144	151		10.1016/0091-6749(89)90317-5	http://dx.doi.org/10.1016/0091-6749(89)90317-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2474591				2022-12-18	WOS:A1989AL83600002
J	CRIMI, E; BRUSASCO, V; CRIMI, P				CRIMI, E; BRUSASCO, V; CRIMI, P			EFFECT OF NEDOCROMIL SODIUM ON THE LATE ASTHMATIC REACTION TO BRONCHIAL ANTIGEN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV GENOA,CATTEDRA MED COMUNITA,IST IGIENE & MED PREVENT,I-16132 GENOA,ITALY	University of Genoa	CRIMI, E (corresponding author), UNIV GENOA,CATTEDRA ALLEGOL RESP,IST MED SPORT,VIALE BENEDETTO 15 10,I-16132 GENOA,ITALY.							BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; CAIRNS H, 1985, J MED CHEM, V28, P1832, DOI 10.1021/jm00150a014; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; COCHRAN WG, 1957, EXPT DESIGNS, P376; COCKCROFT DW, 1985, ANN ALLERGY, V55, P857; COCKCROFT DW, 1987, ANN ALLERGY, V59, P405; CRIMI E, 1986, J ALLERGY CLIN IMMUN, V78, P908, DOI 10.1016/0091-6749(86)90239-3; CROMWELL O, 1986, J ALLERGY CLIN IMMUN, V77, P184; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DORWARD AJ, 1986, CLIN ALLERGY, V16, P309, DOI 10.1111/j.1365-2222.1986.tb01962.x; EADY RP, 1985, BRIT J PHARMACOL, V85, P323, DOI 10.1111/j.1476-5381.1985.tb08864.x; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; HEGARDT B, 1981, ALLERGY, V36, P115, DOI 10.1111/j.1398-9995.1981.tb04105.x; HUTSON PA, 1988, BRIT J PHARMACOL, V94, P6, DOI 10.1111/j.1476-5381.1988.tb11493.x; JOSEPH M, 1988, American Review of Respiratory Disease, V137, P29; LAL S, 1984, THORAX, V39, P809, DOI 10.1136/thx.39.11.809; MATTOLI S, 1987, J ALLERGY CLIN IMMUN, V79, P747, DOI 10.1016/0091-6749(87)90206-5; METZGER WJ, 1985, CHEST, V87, pS155, DOI 10.1378/chest.87.5_Supplement.155S; ORR TSC, 1986, ASTHMA CLIN PHARM TH, P265; QUANJER PLH, 1983, B EUROP PHYSIOPAT S5, V19, P7; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SHAW RJ, 1985, BRIT J DIS CHEST, V79, P385, DOI 10.1016/0007-0971(85)90073-7; WELLS E, 1986, J IMMUNOL, V137, P3941; WELLS E, 1983, BIOCHEM PHARMACOL, V32, P837, DOI 10.1016/0006-2952(83)90585-3; YOUNGCHAIYUD P, 1986, CLIN ALLERGY, V16, P129, DOI 10.1111/j.1365-2222.1986.tb00756.x	27	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					985	990		10.1016/0091-6749(89)90116-4	http://dx.doi.org/10.1016/0091-6749(89)90116-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2541193				2022-12-18	WOS:A1989U716100022
J	CASALE, TB				CASALE, TB			THE INTERACTION OF AZELASTINE WITH HUMAN-LUNG HISTAMINE-H1, BETA, AND MUSCARINIC RECEPTOR-BINDING SITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,COLL MED,IOWA CITY,IA 52242; VET ADM MED CTR,DEPT INTERNAL MED,IOWA CITY,IA 52240	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; CASALE TB, 1985, BIOCHEM PHARMACOL, V34, P3285, DOI 10.1016/0006-2952(85)90347-8; CASALE TB, 1987, BIOCHEM PHARMACOL, V36, P2557, DOI 10.1016/0006-2952(87)90530-2; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CHAND N, 1986, AGENTS ACTIONS, V19, P164, DOI 10.1007/BF01966201; CHAND N, 1980, J APPL PHYSIOL, V49, P729, DOI 10.1152/jappl.1980.49.4.729; Dale HH, 1910, J PHYSIOL-LONDON, V41, P318; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DRAZEN JM, 1978, J CLIN INVEST, V61, P1441, DOI 10.1172/JCI109063; EISER NM, 1980, CLIN SCI, V58, P537, DOI 10.1042/cs0580537; JOAD JP, 1988, BIOCHEM PHARMACOL, V37, P973, DOI 10.1016/0006-2952(88)90193-1; JOAD JP, 1987, LIFE SCI, V41, P1577, DOI 10.1016/0024-3205(87)90724-7; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; LITTLE M, 1988, J ALLERGY CLIN IMMUN, V81, P278, DOI 10.1016/0091-6749(88)90676-8; LITTLE M M, 1987, American Review of Respiratory Disease, V135, pA317; LITTLE MM, 1987, J ALLERGY CLIN IMMUN, V79, P204; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGNUSSEN H, 1987, CHEST, V91, P855, DOI 10.1378/chest.91.6.855; MOTOJIMA S, 1985, ASIAN PAC J ALLERGY, V3, P174; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLLIER S, 1986, J ALLERGY CLIN IMMUN, V78, P358, DOI 10.1016/S0091-6749(86)80090-2; PIETRA GG, 1978, FED PROC, V37, P2466; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; SELLICK H, 1971, J APPL PHYSIOL, V31, P15, DOI 10.1152/jappl.1971.31.1.15; SPECTOR SL, 1987, J ALLERGY CLIN IMMUN, V80, P75, DOI 10.1016/S0091-6749(87)80194-X; STEEL L, 1979, J ALLERGY CLIN IMMUN, V64, P287, DOI 10.1016/0091-6749(79)90146-5; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0; ZECHEL HJ, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1184	28	35	38	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					771	776		10.1016/0091-6749(89)90013-4	http://dx.doi.org/10.1016/0091-6749(89)90013-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2540229				2022-12-18	WOS:A1989U342000010
J	DAHL, R; PEDERSEN, B; HAGGLOF, B				DAHL, R; PEDERSEN, B; HAGGLOF, B			NOCTURNAL ASTHMA - EFFECT OF TREATMENT WITH ORAL SUSTAINED-RELEASE TERBUTALINE, INHALED BUDESONIDE, AND THE 2 IN COMBINATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									AB DRACO,DEPT EXPLORATORY CLIN RES,S-22101 LUND,SWEDEN		DAHL, R (corresponding author), AARHUS UNIV,DEPT RESP DIS,DK-8000 AARHUS C,DENMARK.		Dahl, Ronahl/F-8170-2013					BARNES PJ, 1984, BRIT MED J, V288, P1397, DOI 10.1136/bmj.288.6428.1397; BARNES PJ, 1985, AM J MED, V79, P5, DOI 10.1016/0002-9343(85)90080-4; COCHRANE GM, 1975, THORAX, V30, P300, DOI 10.1136/thx.30.3.300; DAHL R, 1982, EUR J RESPIR DIS, V63, P132; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; HARTLEY JPR, 1984, GLUCOCORTICOSTEROIDS, P10; HENRIKSEN JM, 1983, AM REV RESPIR DIS, V128, P993; HORN CR, 1984, LANCET, V1, P1143; KERR HD, 1973, ARCH ENVIRON HEALTH, V26, P144, DOI 10.1080/00039896.1973.10666242; KOETER GH, 1984, EUR J CLIN PHARMACOL, V26, P435, DOI 10.1007/BF00542137; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LEWINSOHN HC, 1960, BRIT MED J, V1, P462, DOI 10.1136/bmj.1.5171.462; RYAN G, 1982, THORAX, V37, P432; TURNERWARWICK M, 1984, NOCTURNAL ASTHMA, P3; WESTERMANN CJJ, 1986, ALLERGY, V41, P308, DOI 10.1111/j.1398-9995.1986.tb02034.x	16	35	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					811	815		10.1016/0091-6749(89)90019-5	http://dx.doi.org/10.1016/0091-6749(89)90019-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2651509	Bronze			2022-12-18	WOS:A1989U342000016
J	BUTCHER, BT; ONEIL, CE; REED, MA; ALTMAN, LC; LOPEZ, M; LEHRER, SB				BUTCHER, BT; ONEIL, CE; REED, MA; ALTMAN, LC; LOPEZ, M; LEHRER, SB			BASIDIOMYCETE ALLERGY - MEASUREMENT OF SPORE-SPECIFIC IGE ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,MED CTR,DEPT MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70118	Tulane University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL032621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020331] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32621] Funding Source: Medline; NIAID NIH HHS [AI 20331] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFIFI AA, 1979, STATISTICAL ANAL COM, P97; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; GIANNINI EH, 1975, ANN ALLERGY, V35, P372; GREGORY PH, 1957, J GEN MICROBIOL, V17, P135, DOI 10.1099/00221287-17-1-135; HYDE H. A., 1960, ACTA ALLERGOL, V15, P159; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; LEHRER SB, 1984, MOLD ALLERGY WORKSHO, P81; LOPEZ M, 1976, J ALLERGY CLIN IMMUN, V57, P480, DOI 10.1016/0091-6749(76)90064-6; LOPEZ M, 1985, INT ARCH ALLER A IMM, V77, P169, DOI 10.1159/000233775; ONEIL CE, IN PRESS INT ARCH AL; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SANTILLI J, 1985, ANN ALLERGY, V55, P469; SPRENGER JD, 1986, J ALLERGY CLIN IMMUN, V77, P200; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5	16	35	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					803	809		10.1016/S0091-6749(87)80269-5	http://dx.doi.org/10.1016/S0091-6749(87)80269-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	3693758				2022-12-18	WOS:A1987L502000006
J	DOLOVICH, J; KENNEDY, L; VICKERSON, F; KAZIM, F				DOLOVICH, J; KENNEDY, L; VICKERSON, F; KAZIM, F			CONTROL OF THE HYPERSECRETION OF VASOMOTOR RHINITIS BY TOPICAL IPRATROPIUM BROMIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DOLOVICH, J (corresponding author), MCMASTER UNIV,MED CTR,DEPT PEDIAT,ROOM 3V41,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.							ANGGARD A, 1977, ACTA OTO-LARYNGOL, V83, P22, DOI 10.3109/00016487709128806; BORUM P, 1978, Rhinology (Utrecht), V16, P225; BORUM P, 1981, AM REV RESPIR DIS, V123, P416; BORUM P, 1979, ACTA OTOLARYNGOL S S, V360, P35; CONNELL JT, 1983, ANN ALLERGY, V50, P227; GROTH S, 1983, EUR J RESPIR DIS, V64, P490; JOKINEN K, 1983, RHINOLOGY, V21, P331; MALMBERG H, 1983, CLIN OTOLARYNGOL, V8, P273, DOI 10.1111/j.1365-2273.1983.tb01441.x; MYGIND N, 1983, EUR J RESPIR DIS, V64, P167; MYGIND N, 1978, NASAL ALLERGY, P282; MYGIND N, 1978, NASAL ALLERGY, P232; POPPIUS H, 1973, BMJ-BRIT MED J, V4, P134, DOI 10.1136/bmj.4.5885.134; VONHAACKE NP, 1983, BRIT MED J, V287, P1258, DOI 10.1136/bmj.287.6401.1258-a	13	35	38	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				274	278		10.1016/0091-6749(87)90031-5	http://dx.doi.org/10.1016/0091-6749(87)90031-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	2957416				2022-12-18	WOS:A1987K103600007
J	SEARS, MR; REA, HH; BEAGLEHOLE, R				SEARS, MR; REA, HH; BEAGLEHOLE, R			ASTHMA MORTALITY - A REVIEW OF RECENT EXPERIENCE IN NEW-ZEALAND	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GREEN LANE HOSP,AUCKLAND 3,NEW ZEALAND; UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH & GEN PRACTICE,AUCKLAND,NEW ZEALAND	University of Auckland	SEARS, MR (corresponding author), UNIV OTAGO,SCH MED,DUNEDIN,NEW ZEALAND.							[Anonymous], 1984, Thorax, V39, P505; ASHER MI, 1986, AM REV RESPIR DIS, V133, pA58; BARCLAY J, 1981, LANCET, V2, P369; BEAGLEHOLE R, 1981, LANCET, V2, P38; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; BURNEY PGJ, 1986, LANCET, V2, P323; COCHRANE GM, 1975, THORAX, V30, P300, DOI 10.1136/thx.30.3.300; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; GRANT IWB, 1983, BR MED J, V286, P364; HARRISON AC, 1986, AM REV RESPIR DIS, V133, pA176; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; JONES DT, IN PRESS BR J DIS CH; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; MITCHELL EA, 1984, NEW ZEAL MED J, V97, P67; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1986, BRIT MED J, V293, P1342, DOI 10.1136/bmj.293.6558.1342; SEARS MR, 1985, NEW ZEAL MED J, V98, P271; SEARS MR, 1985, NEW ZEAL MED J, V98, P765; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; SLY RM, 1984, ANN ALLERGY, V53, P20; SMITH J M, 1971, Clinical Allergy, V1, P57, DOI 10.1111/j.1365-2222.1971.tb02447.x; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STEWART CJ, 1985, BRIT J DIS CHEST, V79, P229, DOI 10.1016/S0007-0971(85)80023-1; STOLLEY PD, 1978, PREV MED, V7, P519, DOI 10.1016/0091-7435(78)90265-7; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; SUTHERLAND DC, 1984, NEW ZEAL MED J, V97, P845; THORNLEY PE, 1983, BRIT MED J, V286, P890; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; WEINBERGER M, 1981, LANCET, V2, P370; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; WILSON JD, 1981, LANCET, V1, P1235; WOOLCOCK AJ, 1983, EUR J RESPIR DIS, V64, P571; 1970, VITAL STATISTICS DIS; DHEW PUBLICATION PHS; 1982, BR MED J, V285, P1251; HOSPITAL MORBIDITY; MORTALITY DEMOGRAPHI; 1977, MANUAL INT STATISTIC, V1	43	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				319	325		10.1016/0091-6749(87)90038-8	http://dx.doi.org/10.1016/0091-6749(87)90038-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	3624683				2022-12-18	WOS:A1987K103600014
J	BUSSE, WW; SWENSON, CA; SHARPE, G; KOSCHAT, M				BUSSE, WW; SWENSON, CA; SHARPE, G; KOSCHAT, M			ENHANCED BASOPHIL HISTAMINE-RELEASE TO CONCANAVALIN-A IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	BUSSE, WW (corresponding author), UNIV WISCONSIN HOSP,H6-360,600 HIGHLAND AVE,MADISON,WI 53792, USA.		Koschat, Martin A./AGY-2264-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015685, P50AI010404] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15685, AI 10404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASSEM ESK, 1981, CLIN ALLERGY, V11, P367, DOI 10.1111/j.1365-2222.1981.tb01607.x; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUTLER JM, 1983, J ALLERGY CLIN IMMUN, V71, P490, DOI 10.1016/0091-6749(83)90467-0; CONROY MC, 1977, J IMMUNOL, V118, P1317; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FOREMAN JC, 1979, J IMMUNOL, V123, P153; FOREMAN JC, 1973, NATURE, V245, P249, DOI 10.1038/245249a0; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1692; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P295; SIRAGANIAN PA, 1974, J IMMUNOL, V112, P2117; SIRAGANIAN RP, 1975, J IMMUNOL, V114, P886; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SOBOTKA AK, 1978, IMMUNOL REV, V41, P171, DOI 10.1111/j.1600-065X.1978.tb01464.x; THUESON DO, 1979, J IMMUNOL, V123, P633; THUESON DO, 1979, J IMMUNOL, V123, P626; TUNG R, 1982, J IMMUNOL, V128, P2067	18	35	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				90	97		10.1016/0091-6749(86)90119-3	http://dx.doi.org/10.1016/0091-6749(86)90119-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	2424961	Bronze			2022-12-18	WOS:A1986D299600014
J	MAY, CD				MAY, CD			ARE CONFUSION AND CONTROVERSY ABOUT FOOD HYPERSENSITIVITY REALLY NECESSARY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material																		AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ANDERSON JA, ADVERSE REACTIONS FO; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BOCK SA, 1983, ALLERGY PRINCIPLES P, V2, P1415; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; GRAHAM DT, 1950, J ALLERGY, V21, P478, DOI 10.1016/0021-8707(50)90095-5; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; HANNUKSELA M, 1977, CONTACT DERMATITIS, V3, P79, DOI 10.1111/j.1600-0536.1977.tb03603.x; LOWENSTEIN H, 1983, ALLERGY, V38, P577, DOI 10.1111/j.1398-9995.1983.tb04143.x; MAY CD, 1982, J ALLERGY CLIN IMMUN, V69, P255, DOI 10.1016/S0091-6749(82)80001-8; PARK LC, 1965, ARCH GEN PSYCHIAT, V12, P336; PEARSON DJ, 1983, LANCET, V1, P1259; RIX KJB, 1984, BRIT J PSYCHIAT, V145, P121, DOI 10.1192/bjp.145.2.121; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; Tuft Louis, 1944, JOUR ALLERGY, V15, P346, DOI 10.1016/S0021-8707(44)90144-9; Tuft Louis, 1942, JOUR ALLERGY, V13, P574, DOI 10.1016/S0021-8707(42)90070-4; WOLF S, 1959, P RES NERV MENT DIS, V35, P147	23	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	3					329	333		10.1016/0091-6749(85)90067-3	http://dx.doi.org/10.1016/0091-6749(85)90067-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AEB46	3973307				2022-12-18	WOS:A1985AEB4600001
J	GRAFT, DF; SCHUBERTH, KC; KAGEYSOBOTKA, A; KWITEROVICH, KA; NIV, Y; LICHTENSTEIN, LM; VALENTINE, MD				GRAFT, DF; SCHUBERTH, KC; KAGEYSOBOTKA, A; KWITEROVICH, KA; NIV, Y; LICHTENSTEIN, LM; VALENTINE, MD			THE DEVELOPMENT OF NEGATIVE SKIN-TESTS IN CHILDREN TREATED WITH VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,BALTIMORE,MD 21239; JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21239	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015443] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARDE SH, 1983, J ALLERGY CLIN IMMUN, V71, P141, DOI 10.1016/0091-6749(83)90333-0; CHIPPS BE, 1980, J PEDIATR-US, V97, P177, DOI 10.1016/S0022-3476(80)80470-7; FRIEDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P57; GRAFT D F, 1982, Journal of Allergy and Clinical Immunology, V69, P124; GRAFT DF, PED CLIN N AM; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KING TP, 1978, BIOCHEMISTRY, V17, P5156; LEVY DA, 1967, J IMMUNOL, V99, P1068; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; MARSH DG, 1977, IMMUNOGENETICS, V5, P235, DOI 10.1007/BF01570479; NORMAN PS, 1982, PROG ALLERGY, V32, P318; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; REISMAN RE, 1979, J ALLERGY CLIN IMMUN, V64, P3, DOI 10.1016/0091-6749(79)90074-5; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V64, P1, DOI 10.1016/0091-6749(79)90073-3; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	25	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					61	68		10.1016/0091-6749(84)90485-8	http://dx.doi.org/10.1016/0091-6749(84)90485-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6693669	Bronze			2022-12-18	WOS:A1984SB99000009
J	ROSENTHAL, RR				ROSENTHAL, RR			SIMPLIFIED EUCAPNIC VOLUNTARY HYPERVENTILATION CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ROSENTHAL, RR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV ALLERGY & CLIN IMMUNOL,BALTIMORE,MD 21205, USA.							CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; MENKES HA, 1980, AM REV RESPIR DIS, V121, P619; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; PHILLIPS YY, 1983, J ALLERGY CLIN IMMUN, V71, P107, DOI 10.1016/0091-6749(83)90198-7; ROSENTHAL R R, 1984, Journal of Allergy and Clinical Immunology, V73, P179; STERLING GM, 1968, CLIN SCI, V34, P277	8	35	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					676	679		10.1016/0091-6749(84)90304-X	http://dx.doi.org/10.1016/0091-6749(84)90304-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6425390				2022-12-18	WOS:A1984SS04600011
J	CICARDI, M; BERGAMASCHINI, L; TUCCI, A; AGOSTONI, A; TORNAGHI, G; COGGI, G; COLOMBI, R; VIALE, G				CICARDI, M; BERGAMASCHINI, L; TUCCI, A; AGOSTONI, A; TORNAGHI, G; COGGI, G; COLOMBI, R; VIALE, G			MORPHOLOGIC EVALUATION OF THE LIVER IN HEREDITARY ANGIOEDEMA PATIENTS ON LONG-TERM TREATMENT WITH ANDROGEN DERIVATIVES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MILAN,DEPT CLIN MED,I-20133 MILAN,ITALY; UNIV MILAN,DEPT PATHOL,I-20133 MILAN,ITALY	University of Milan; University of Milan			cicardi, marco/K-9219-2016; Viale, Giuseppe/AAE-8921-2019; BERGAMASCHINI, LUIGI CESARE/T-6367-2017	cicardi, marco/0000-0003-1251-225X; BERGAMASCHINI, LUIGI CESARE/0000-0002-5103-0942				AGOSTONI A, 1980, J ALLERGY CLIN IMMUN, V65, P75, DOI 10.1016/0091-6749(80)90181-5; AGOSTONI A, 1977, B I SIEROTER MILAN, V56, P1; CHOPRA S, 1978, JAMA-J AM MED ASSOC, V240, P1153, DOI 10.1001/jama.240.11.1153; CICARDI M, 1982, AM J MED SCI, V284, P48; DAVIS PJ, 1974, JOHNS HOPKINS MED J, V135, P391; FALK H, 1979, LANCET, V2, P1120; FARRELL GC, 1975, LANCET, V1, P430; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GOODMAN MA, 1977, MED J AUSTRALIA, V1, P220, DOI 10.5694/j.1326-5377.1977.tb130636.x; HOSEA SW, 1980, ANN INTERN MED, V93, P809, DOI 10.7326/0003-4819-93-6-809; HUANG S, 1981, DIAGNOSTIC IMMUNOCYT, P325; LACHMANN PJ, 1973, HDB EXPT IMMUNOLOGY, P1; LEONARDJOHNSON FR, 1972, LANCET, V2, P1273; NADELL J, 1977, ARCH PATHOL LAB MED, V101, P405; PARADINAS FJ, 1977, HISTOPATHOLOGY, V1, P225, DOI 10.1111/j.1365-2559.1977.tb01663.x; PEARSON K, 1980, LANCET, V1, P645; PITTS JS, 1978, J LAB CLIN MED, V92, P501; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; SALE GE, 1977, ARCH PATHOL LAB MED, V101, P600; SHEFFER AL, 1981, J ALLERGY CLIN IMMUN, V68, P181, DOI 10.1016/0091-6749(81)90181-0; SHEFFER AL, 1977, ANN INTERN MED, V86, P306, DOI 10.7326/0003-4819-86-3-306; SHEFFER AL, 1979, J ALLERGY CLIN IMMUN, V64, P275, DOI 10.1016/0091-6749(79)90144-1; SPAULDING WB, 1960, ANN INTERN MED, V86, P306; SWEENEY EC, 1976, J CLIN PATHOL, V29, P626, DOI 10.1136/jcp.29.7.626; WESTABY D, 1977, LANCET, V2, P261	25	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	3					294	298		10.1016/0091-6749(83)90034-9	http://dx.doi.org/10.1016/0091-6749(83)90034-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RH938	6886261	Bronze			2022-12-18	WOS:A1983RH93800010
J	HOFFMAN, DR; WOOD, CL; HUDSON, P				HOFFMAN, DR; WOOD, CL; HUDSON, P			DEMONSTRATION OF IGE AND IGG ANTIBODIES AGAINST VENOMS IN THE BLOOD OF VICTIMS OF FATAL STING ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DEPT HUMAN RESOURCES STATE N CAROLINA,CHAPEL HILL,NC		HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL & LAB MED,GREENVILLE,NC 27834, USA.							BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; ENNIK F, 1980, WESTERN J MED, V133, P463; GOLDEN D B K, 1982, Journal of Allergy and Clinical Immunology, V69, P124; HERBERT FA, 1982, ANN ALLERGY, V48, P12; Hoffman D R, 1981, Methods Enzymol, V73, P656; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; PARRISH HM, 1963, AM J MED SCI, V245, P129; PETERS GA, 1978, ANN ALLERGY, V41, P268; SCHMIDT CC, 1852, JB PRACT MED, V76, P311; TORSNEY PJ, 1973, J ALLERGY CLIN IMMUN, V52, P303, DOI 10.1016/0091-6749(73)90049-3	11	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	2					193	196		10.1016/0091-6749(83)90099-4	http://dx.doi.org/10.1016/0091-6749(83)90099-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC188	6822695				2022-12-18	WOS:A1983QC18800004
J	KRILIS, S; BALDO, BA; RAISON, RL; CALLARD, RE; BASTEN, A				KRILIS, S; BALDO, BA; RAISON, RL; CALLARD, RE; BASTEN, A			STANDARDIZATION OF ANTIGEN-E IN RAGWEED POLLEN EXTRACTS USING A MONOCLONAL-ANTIBODY BASED ENZYME-IMMUNOASSAY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SYDNEY,DEPT MED,IMMUNOL UNIT,SYDNEY,NSW 2006,AUSTRALIA; CSIRO,WHEAT RES UNIT,RYDE,NSW,AUSTRALIA	University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Callard, Robin E/C-5682-2008					AAS K, 1975, INT ARCH ALLER A IMM, V49, P44, DOI 10.1159/000231375; ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; ARBESMAN CE, 1977, INT ARCH ALLER A IMM, V53, P310, DOI 10.1159/000231767; AVRAMEAS S, 1978, SCAND J IMMUNOL   S7, V8, P7; AWDEH ZL, 1968, NATURE, V219, P66, DOI 10.1038/219066a0; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BALDO BA, 1977, LANCET, V1, P802; BALDO BA, 1980, MED J AUSTRALIA, V2, P651, DOI 10.5694/j.1326-5377.1980.tb131962.x; BALDO BA, 1980, CONT TOPICS MOL IMMU, V8, P41; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; CENTER GJ, 1976, J ALLERGY CLIN IMMUN, V54, P56; EKINS R, 1980, NATURE, V284, P14; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GRIFFITHS BW, 1971, CAN J BIOCHEM CELL B, V49, P396, DOI 10.1139/o71-058; HARRIS CC, 1979, P NATL ACAD SCI USA, V76, P5336, DOI 10.1073/pnas.76.10.5336; KATELARIS C, 1982, ALLERGY, V37, P21, DOI 10.1111/j.1398-9995.1982.tb04113.x; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KRILIS S, 1981, INT ARCH ALLER A IMM, V66, P252, DOI 10.1159/000232912; KRILIS S, 1981, MONOCLONAL ANTIBODIE; LEE YS, 1979, J ALLERGY CLIN IMMUN, V63, P336, DOI 10.1016/0091-6749(79)90128-3; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; LICHTENSTEIN LM, 1976, NEW ENGL J MED, V295, P1195, DOI 10.1056/NEJM197611182952113; MARSH DG, 1975, ANTIGENS, V3, P271; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X	27	35	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	3					261	265		10.1016/0091-6749(83)90079-9	http://dx.doi.org/10.1016/0091-6749(83)90079-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH188	6338088				2022-12-18	WOS:A1983QH18800001
J	STROM, GB; BOSWELL, RN; JACOBS, RL				STROM, GB; BOSWELL, RN; JACOBS, RL			INVIVO AND INVITRO COMPARISON OF FIRE ANT VENOM AND FIRE ANT WHOLE-BODY EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											STROM, GB (corresponding author), WILFORD HALL USAF MED CTR,DEPT MED,ALLERGY IMMUNOL SECT,LACKLAND AFB,TX 78236, USA.							ANDERSON MC, 1982, J ALLERGY CLIN IMMUN, V69, P3, DOI 10.1016/0091-6749(82)90080-X; BAER H, 1979, TOXICON, V17, P397, DOI 10.1016/0041-0101(79)90267-8; BEAVEN MA, 1971, J PHARMACOL EXP THER, V176, P52; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BLUM MS, 1958, SCIENCE, V128, P306, DOI 10.1126/science.128.3319.306-a; BLUM MS, 1973, ANN ENTOMOL SOC AM, V66, P702, DOI 10.1093/aesa/66.3.702; BRAND JM, 1972, TOXICON, V10, P259, DOI 10.1016/0041-0101(72)90011-6; BUFFKIN DC, 1972, TOXICON, V10, P526; CARO MR, 1957, ARCH DERMATOL, V75, P475, DOI 10.1001/archderm.1957.01550160001001; CUATRECASAS P, 1971, ANNU REV BIOCHEM, V40, P259, DOI 10.1146/annurev.bi.40.070171.001355; GREEN AW, 1980, J ALLERGY CLIN IMMUN, V66, P186, DOI 10.1016/0091-6749(80)90037-8; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JAMES FK, 1976, J ALLERGY CLIN IMMUN, V58, P110, DOI 10.1016/0091-6749(76)90112-3; JAMES FK, 1976, J ASTHMA RES, V13, P179, DOI 10.3109/02770907609104174; Langone J J, 1980, Methods Enzymol, V70, P221; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LOCKEY RF, 1974, J ALLERGY CLIN IMMUN, V54, P132, DOI 10.1016/0091-6749(74)90050-5; MACCONNELL JG, 1971, TETRAHEDRON, V26, P1129; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; RHOADES RB, 1978, ANN ALLERGY, V40, P100; RHOADES RB, 1975, J ALLERGY CLIN IMMUN, V56, P84, DOI 10.1016/0091-6749(75)90112-8; RHOADES RB, 1977, MED ASPECTS IMPORTED, P3; RHOADES RB, 1977, MED ASPECTS IMPORTED, P57; RHOADES RB, 1977, MED ASPECTS IMPORTED, P58; Smith K O, 1980, Methods Enzymol, V70, P388; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; VALENTINE MD, 1976, J ALLERGY CLIN IMMUN, V57, P247; Yeager W, 1978, J Med Assoc Ga, V67, P101	28	35	35	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	1					46	53		10.1016/0091-6749(83)90051-9	http://dx.doi.org/10.1016/0091-6749(83)90051-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QZ198	6189879				2022-12-18	WOS:A1983QZ19800006
J	TING, S; REIMANN, BEF; RAULS, DO; MANSFIELD, LE				TING, S; REIMANN, BEF; RAULS, DO; MANSFIELD, LE			NONFAMILIAL, VIBRATION-INDUCED ANGIOEDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILLIAM BEAUMONT ARMY MED CTR, DEPT CLIN INVEST, EL PASO, TX 79920 USA; WILLIAM BEAUMONT ARMY MED CTR, DEPT PATHOL, EL PASO, TX 79920 USA	William Beaumont Army Medical Center; William Beaumont Army Medical Center	TING, S (corresponding author), WILLIAM BEAUMONT ARMY MED CTR, DEPT MED, ALLERGY & IMMUNOL SERV, EL PASO, TX 79920 USA.							CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; EBKEN RK, 1968, J ALLERGY, V41, P338, DOI 10.1016/0021-8707(68)90076-2; HUNTER JAA, 1974, BRIT J DERMATOL, V90, P491, DOI 10.1111/j.1365-2133.1974.tb06443.x; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; METZGER WJ, 1976, J ALLERGY CLIN IMMUN, V57, P605, DOI 10.1016/0091-6749(76)90012-9; NAYLOR PFD, 1955, BRIT J DERMATOL, V67, P239, DOI 10.1111/j.1365-2133.1955.tb12729.x; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V50, P174, DOI 10.1016/0091-6749(72)90048-6; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Ryan T, 1977, Bibl Anat, P180; SMITH J A, 1982, Journal of Allergy and Clinical Immunology, V69, P138; SOLOMON LM, 1966, ARCH DERMATOL, V94, P156, DOI 10.1001/archderm.94.2.156; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STUTTGEN G, 1978, ARCH DERMATOL RES, V263, P139, DOI 10.1007/BF00446435; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; WATSON ML, 1958, J BIOPHYS BIOCHEM CY, V4, P475, DOI 10.1083/jcb.4.4.475	17	35	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	6					546	551		10.1016/0091-6749(83)90435-9	http://dx.doi.org/10.1016/0091-6749(83)90435-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QV139	6189876				2022-12-18	WOS:A1983QV13900005
J	BROWN, LA; GOLDBERG, ND; SHEARER, WT				BROWN, LA; GOLDBERG, ND; SHEARER, WT			LONG-TERM TICARCILLIN DESENSITIZATION BY THE CONTINUOUS ORAL-ADMINISTRATION OF PENICILLIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BAYLOR COLL MED,DEPT PEDIAT,ALLERGY & IMMUNOL SECT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MICROBIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT IMMUNOL,HOUSTON,TX 77030; TEXAS CHILDRENS HOSP,ALLERGY & IMMUNOL SERV,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine				Shearer, William/0000-0002-2483-2130				CHIPPS BE, 1980, J ALLERGY CLIN IMMUN, V65, P61, DOI 10.1016/0091-6749(80)90178-5; FINKE SR, 1965, AM J MED, V38, P71, DOI 10.1016/0002-9343(65)90161-0; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; GREEN GR, 1967, ANN INTERN MED, V67, P235, DOI 10.7326/0003-4819-67-2-235; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1969, INT ARCH ALLER A IMM, V35, P445, DOI 10.1159/000230197; LEVINE BB, 1973, J INFECT DIS, V128, P364; MCCRACKEN GH, 1978, PEDIATRICS, V62, P738; NORMAN PS, 1974, DRUGS CHOICE 1974 75; PARKER CW, 1975, NEW ENGL J MED, V292, P957, DOI 10.1056/NEJM197505012921806; PARKER CW, 1975, NEW ENGL J MED, V292, P511, DOI 10.1056/NEJM197503062921006; PARKER CW, 1975, NEW ENGL J MED, V292, P732, DOI 10.1056/NEJM197504032921407; PARRY MF, 1977, J PEDIATR-US, V90, P144, DOI 10.1016/S0022-3476(77)80790-7; PORTER J, 1977, LANCET, V1, P587; SMITH JW, 1966, NEW ENGL J MED, V274, P998, DOI 10.1056/NEJM196605052741804; SULLIVAN TJ, 1980, J ALLERGY CLIN IMMUN, V65, P195; VANARSDEL PP, 1978, ALLERGY PRINCIPLES P, V2, P1133; WEINSTEIN L, 1980, PHARM BASIS THERAPEU; 1980, DRUG THER B, V18, P11; 1977, MED LETT DRUGS THER, V19, P17	21	35	37	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	1					51	54		10.1016/0091-6749(82)90087-2	http://dx.doi.org/10.1016/0091-6749(82)90087-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ377	6798088	Bronze			2022-12-18	WOS:A1982MZ37700009
J	SCHWARTZ, HJ; LOCKEY, RF; SHEFFER, AL; PARRINO, J; BUSSE, WW; YUNGINGER, JW				SCHWARTZ, HJ; LOCKEY, RF; SHEFFER, AL; PARRINO, J; BUSSE, WW; YUNGINGER, JW			A MULTI-CENTER STUDY ON SKIN-TEST REACTIVITY OF HUMAN VOLUNTEERS TO VENOM AS COMPARED WITH WHOLE-BODY HYMENOPTERA ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CASE WESTERN RESERVE UNIV,SCH MED,DEPT INTERNAL MED,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH 44106; UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED,TAMPA,FL 33620; VET ADM HOSP,TAMPA,FL 33612; HARVARD UNIV,SCH MED,DEPT INTERNAL MED,BOSTON,MA 02115; NEW ENGLAND DEACONESS HOSP,BOSTON,MA 02215; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901	Case Western Reserve University; University Hospitals of Cleveland; State University System of Florida; University of South Florida; Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI-11483, AI-00107] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENSON RL, 1930, J ALLERGY, V1, P105; BERNTON HS, 1966, J ALLERGY, V36, P315; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, pCH77; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; REISMAN RE, 1979, CLIN ALLERGY, V9, P303, DOI 10.1111/j.1365-2222.1979.tb01557.x; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703	8	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	1					81	85		10.1016/0091-6749(81)90051-8	http://dx.doi.org/10.1016/0091-6749(81)90051-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KZ173	7451775	Bronze			2022-12-18	WOS:A1981KZ17300016
J	STOY, PJ; ROITMANJOHNSON, B; WALSH, G; GLEICH, GJ; MENDELL, N; YUNIS, E; BLUMENTHAL, MN				STOY, PJ; ROITMANJOHNSON, B; WALSH, G; GLEICH, GJ; MENDELL, N; YUNIS, E; BLUMENTHAL, MN			AGING AND SERUM IMMUNOGLOBULIN-E LEVELS, IMMEDIATE SKIN-TESTS, AND RAST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO MEM,BOX 434,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455; MAYO MED SCH,DEPT MED,ROCHESTER,MN 55901; SUNY STONY BROOK,DEPT COMMUNITY HLTH & PREVENT MED,STONY BROOK,NY 11794; HARVARD UNIV,DEPT IMMUNOGENET,BOSTON,MA 02215	Mayo Clinic; Mayo Clinic; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University					NHLBI NIH HHS [HL 23631] Funding Source: Medline; NIAID NIH HHS [AI 11483] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; BLUMENTHAL MN, 1979, RECENT ADV GERONTOLO; BUCKLEY C, 1974, FED P, V33, P2435; BUCKLEY CE, 1970, J IMMUNOL, V105, P964; DELESPESSE G, 1977, CLIN ALLERGY, V7, P155, DOI 10.1111/j.1365-2222.1977.tb01436.x; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HANNEUSE Y, 1978, CLIN ALLERGY, V8, P165, DOI 10.1111/j.1365-2222.1978.tb00461.x; JOHANSSON SG, 1968, INT ARCH ALLER A IMM, V34, P1; KAY MMB, 1976, CLIN IMMUNOL IMMUNOP, V6, P394, DOI 10.1016/0090-1229(76)90093-3; KING TP, 1972, BIOCHEMISTRY-US, V11, P367, DOI 10.1021/bi00753a010; KISHIMOTO S, 1978, J IMMUNOL, V121, P1773; LANGE C, 1977, PROGR CLIN PATHOLOGY, V8; LAPKOFF CB, 1974, INT ARCH ALLER A IMM, V46, P215, DOI 10.1159/000231125; NIE NH, 1975, STATISTICAL PACKAGE, pCH14; NIE NH, 1980, NEW PROCEDURES FACIL, P62; Nye L, 1975, Clin Allergy, V5, P13; ORREN A, 1975, INT ARCH ALLER A IMM, V48, P824, DOI 10.1159/000231370; PHAIR JP, 1978, J INFECT DIS, V138, P67, DOI 10.1093/infdis/138.1.67; PUPIL P, 1976, ANN ANESTHESIOL, V27, P199; RODL J, 1975, CLIN EXP IMMUNOL, V22, P84; SIEGEL S, 1956, NONPARAMETRIC STAT, P184; SMITH JM, 1978, ALLERGY PRINCIPLES P; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031; WIDE L, 1967, LANCET, V2, P1105	25	35	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	6					421	426		10.1016/0091-6749(81)90195-0	http://dx.doi.org/10.1016/0091-6749(81)90195-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MU790	6171585	Bronze			2022-12-18	WOS:A1981MU79000003
J	ANDERSON, CJ; CRAIG, S; BARDANA, EJ				ANDERSON, CJ; CRAIG, S; BARDANA, EJ			ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS AND BILATERAL FUNGAL BALLS TERMINATING IN DISSEMINATED ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ANDERSON, CJ (corresponding author), UNIV OREGON,HLTH SCI CTR,DIV IMMUNOL ALLERGY & RHEUMATOL,PORTLAND,OR 97201, USA.							BARDANA EJ, 1975, AM J DIS CHILD, V129, P1164, DOI 10.1001/archpedi.1975.02120470020005; BARDANA EJ, 1972, J ALLERGY CLIN IMMUN, V50, P222, DOI 10.1016/0091-6749(72)90016-4; BARDANA EJ, 1972, J ALLERGY CLIN IMMUN, V50, P208, DOI 10.1016/0091-6749(72)90015-2; Degott C, 1973, Ann Med Interne (Paris), V124, P135; HENDERSON AH, 1968, THORAX, V23, P501, DOI 10.1136/thx.23.5.501; HILTON AM, 1975, POSTGRAD MED J, V51, P98; HUSEBYE KO, 1967, DIS CHEST, V51, P327, DOI 10.1378/chest.51.3.327; KATZENSTEIN AL, 1975, AM REV RESPIR DIS, V111, P497; KENNEDY WPU, 1972, THORAX, V27, P604, DOI 10.1136/thx.27.5.604; LEGGAT P O, 1968, British Journal of Diseases of the Chest, V62, P147, DOI 10.1016/S0007-0971(68)80005-1; LIBSHITZ HI, 1974, AM J ROENTGENOL, V120, P883, DOI 10.2214/ajr.120.4.883; McCarthy D S, 1973, Clin Allergy, V3, P57, DOI 10.1111/j.1365-2222.1973.tb01310.x; MERKOW LP, 1971, AM J PATHOL, V62, P57; ORIE NGM, 1960, AM REV RESPIR DIS, V82, P649; RILEY DJ, 1975, AM REV RESPIR DIS, V111, P232; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P940; SIDRANSKY H, 1965, ARCH PATHOL, V79, P299; SIDRANSKY H, 1962, LAB INVEST, V11, P1172; SIDRANSKY HERSCHEL, 1959, AMER JOUR PATHOL, V35, P169; TURNERWARWICK M, 1973, CLIN ALLERGY       S, V3, P53; WALMER HW, 1963, ANN INTERN MED, V58, P472; YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002	23	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	2					140	144		10.1016/0091-6749(80)90199-2	http://dx.doi.org/10.1016/0091-6749(80)90199-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JF199	7351446				2022-12-18	WOS:A1980JF19900010
J	OLENCHOCK, SA; MULL, JC; MAJOR, PC; PEACH, MJ; GLADISH, ME; TAYLOR, G				OLENCHOCK, SA; MULL, JC; MAJOR, PC; PEACH, MJ; GLADISH, ME; TAYLOR, G			INVITRO ACTIVATION OF ALTERNATIVE PATHWAY OF COMPLEMENT BY SETTLED GRAIN DUST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											OLENCHOCK, SA (corresponding author), CTR DIS CONTROL, APPALACHIAN LAB OCCUPAT SAFETY & HLTH, DIV RESP DIS STUDIES, IMMUNOL SECT, MORGANTOWN, WV 26505 USA.							BRUNSON KW, 1976, INFECT IMMUN, V14, P1256, DOI 10.1128/IAI.14.5.1256-1258.1976; DESPREZ RM, 1975, INFECT IMMUN, V11, P1235, DOI 10.1128/IAI.11.6.1235-1243.1975; DIERICH MP, 1973, IMMUNOLOGY, V24, P721; DOPICO GA, 1977, AM REV RESPIR DIS, V115, P915; ELIN RJ, 1976, J IMMUNOL, V117, P1238; ELLMAN L, 1971, J EXP MED, V134, P162, DOI 10.1084/jem.134.1.162; FINE DP, 1972, J IMMUNOL, V109, P807; Finney D. J., 1971, PROBIT ANAL, P1; FRANK MM, 1971, J EXP MED, V134, P176, DOI 10.1084/jem.134.1.176; GEWURZ H, 1968, J EXP MED, V128, P1049, DOI 10.1084/jem.128.5.1049; Gewurz H., 1976, MANUAL CLIN IMMUNOLO, P36; HUDSON AR, 1977, AM REV RESPIR DIS, V115, P89; JACOBSON M, 1961, EXPLOSIBILITY AGRICU; KOTANI S, 1977, BIKEN J, V20, P5; MARCUS RL, 1971, P NATL ACAD SCI USA, V68, P1351, DOI 10.1073/pnas.68.6.1351; Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133; MORRISON DC, 1977, J IMMUNOL, V118, P362; OLENCHOCK SA, 1978, CLIN ALLERGY, V8, P125, DOI 10.1111/j.1365-2222.1978.tb00457.x; OLENCHOCK SA, AIRBORNE GRAIN DUST; OSLER AG, 1973, PROG ALLERGY, V17, P51, DOI 10.1159/000313290; Selzer G B, 1970, Bull Parenter Drug Assoc, V24, P153; TSE KS, 1973, ARCH ENVIRON HEALTH, V27, P74, DOI 10.1080/00039896.1973.10666321; WARREN P, 1974, J ALLERGY CLIN IMMUN, V53, P139, DOI 10.1016/0091-6749(74)90002-5; WILSON MR, 1977, J ALLERGY CLIN IMMUN, V60, P218, DOI 10.1016/0091-6749(77)90133-6; WINKELSTEIN JA, 1978, J IMMUNOL, V120, P174; 1967, HDB IND LOSS PREVENT	26	35	35	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	5					295	300		10.1016/0091-6749(78)90161-6	http://dx.doi.org/10.1016/0091-6749(78)90161-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FW432	701665				2022-12-18	WOS:A1978FW43200007
J	KAMMERMEYER, JK; RAJTORA, DW; ANURAS, J; RICHERSON, HB				KAMMERMEYER, JK; RAJTORA, DW; ANURAS, J; RICHERSON, HB			CLINICAL EVALUATION OF INTRANASAL TOPICAL FLUNISOLIDE THERAPY IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,HOSP & CLIN,DEPT INTERNAL MED,ALLERGY IMMUNOL SECT,IOWA CITY,IA 52242	University of Iowa								AARON TH, 1964, ANN ALLERGY, V22, P155; AARON TH, 1965, ANN ALLERGY, V23, P100; ANDERSON JACK R., 1956, ANN ALLERGY, V14, P44; BAGRATUNI L., 1960, ANN ALLERGY, V18, P859; BROSTOFF J, 1969, J ALLERGY, V44, P77, DOI 10.1016/0021-8707(69)90003-3; BURGER JH, 1955, ANN NY ACAD SCI, V61, P566, DOI 10.1111/j.1749-6632.1955.tb42508.x; CHAMPION PK, 1974, ARCH INTERN MED, V134, P750, DOI 10.1001/archinte.134.4.750; CHERVINSKY P, 1966, ANN ALLERGY, V24, P150; CREPEA SB, 1974, MONOGRAPH CLINICAL I; CZARNY D, 1968, LANCET, V2, P188; Fishman A E, 1970, Pa Med, V73, P54; FOULDS WS, 1955, LANCET, V1, P234; GODFREY MP, 1957, LANCET, V1, P767; HERXHEIMER H, 1956, LANCET, V1, P537; LAKE CF, 1957, P STAFF M MAYO CLIN, V32, P641; LEOPOLD HC, 1968, ANN ALLERGY, V26, P248; MCALLEN MK, 1969, LANCET, V1, P968; MICHELS MI, 1967, ANN ALLERGY, V25, P569; MORRISOWEN RM, 1958, BRIT MED J, V1, P969, DOI 10.1136/bmj.1.5077.969; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; NORMAN PS, 1967, J ALLERGY, V40, P57, DOI 10.1016/0021-8707(67)90060-3; NORMAN PS, 1965, J ALLERGY, V36, P284, DOI 10.1016/0021-8707(65)90087-0; NORMAN PS, 1966, J ALLERGY, V38, P93, DOI 10.1016/0021-8707(66)90048-7; PENNYPACKER CS, 1954, J ALLERGY, V25, P513, DOI 10.1016/S0021-8707(54)90032-5; ROHEN MORTIMER B., 1955, ANN ALLERGY, V13, P109; SMITH JM, 1975, BRIT MED J, V2, P255, DOI 10.1136/bmj.2.5965.255; SMITH RE, 1965, ANN ALLERGY, V23, P273; SMITH TT, 1954, AMA ARCH OTOLARYNGOL, V60, P24; TAUB SJ, 1965, EYE EAR NOSE THROAT, V44, P106; TAUB SJ, 1968, EYE EAR NOSE THROAT, V47, P80; TUFT H S, 1954, Ann Allergy, V12, P687; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	32	35	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	4					287	293		10.1016/0091-6749(77)90049-5	http://dx.doi.org/10.1016/0091-6749(77)90049-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DB886	14982				2022-12-18	WOS:A1977DB88600003
J	SLY, RM; BADIEI, B; FACIANE, J				SLY, RM; BADIEI, B; FACIANE, J			COMPARISON OF SUBCUTANEOUS TERBUTALINE WITH EPINEPHRINE IN TREATMENT OF ASTHMA IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LOUISIANA STATE UNIV, MED CTR, DEPT PEDIAT, NEW ORLEANS, LA 70112 USA	Louisiana State University System								ARNER B, 1970, ACTA MED SCAND, P45; ARNER B, 1970, ACTA MED SCAND, P25; BERGMAN J, 1969, EXPERIENTIA, V25, P899, DOI 10.1007/BF01898049; DACOSTA JL, 1973, MED J AUSTRALIA, V2, P588; FORMGREN H, 1970, SCAND J RESPIR DIS, V51, P203; FORMGREN H, 1970, SCAND J RESPIR DIS, V51, P195; GLASS P, 1973, CURR THER RES CLIN E, V15, P141; GRIZZLE JE, 1965, BIOMETRICS, V21, P467, DOI 10.2307/2528104; HOLTEN K, 1974, BRIT J DIS CHEST, V68, P111, DOI 10.1016/0007-0971(74)90023-0; LINDQUIST EF, 1953, DESIGN ANALYSIS EXPT; NOU E, 1971, SCAND J RESPIR DIS, V52, P192; PERSSON H, 1970, ACTA MED SCAND, P11; PERSSON H, 1970, ACTA MED SCAND, P21; SACKNER MA, 1975, CHEST, V68, P616, DOI 10.1378/chest.68.5.616; SACKNER MA, 1974, CLIN PHARMACOL THER, V16, P499	15	35	35	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					128	135		10.1016/0091-6749(77)90214-7	http://dx.doi.org/10.1016/0091-6749(77)90214-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	319140	Bronze			2022-12-18	WOS:A1977CV62200006
J	CHMELIK, F; DOPICO, G; REED, CE; DICKIE, H				CHMELIK, F; DOPICO, G; REED, CE; DICKIE, H			FARMERS LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,MED SCH,DEPT PREVENT MED,MADISON,WI; UNIV WISCONSIN,MED SCH,DEPT INTERN MED,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								BARBEE RA, 1968, AM REV RESPIR DIS, V97, P223; BARBEE RA, 1965, P SOC EXP BIOL MED, V118, P546, DOI 10.3181/00379727-118-29901; BARBORIAK JJ, 1972, J ALLERGY CLIN IMMUN, V49, P81, DOI 10.1016/0091-6749(72)90059-0; CAMPBELL JM, 1932, BRIT MED J, V2, P1143; CROSS T, 1968, J GEN MICROBIOL, V50, P35; EMANUEL DA, 1964, AM J MED, V37, P392, DOI 10.1016/0002-9343(64)90195-0; GRANT IWB, 1972, BRIT MED J, V1, P530, DOI 10.1136/bmj.1.5799.530; GREGORY PH, 1963, J GEN MICROBIOL, V33, P147, DOI 10.1099/00221287-33-1-147; HAPKE EJ, 1968, THORAX, V23, P451, DOI 10.1136/thx.23.5.451; KOBAYASHI M, 1963, P SOC EXP BIOL MED, V113, P472, DOI 10.3181/00379727-113-28400; MIECHE H, 1930, ARB DTSCH LANDEU GES, V196, P1; NICHOLSON DP, 1972, AM J MED, V53, P131, DOI 10.1016/0002-9343(72)90123-4; PEPYS J, 1963, LANCET, V2, P607; Pepys J, 1969, HYPERSENSITIVITY DIS; REED CE, 1972, POSTGRAD MED, V51, P120, DOI 10.1080/00325481.1972.11698134; ROBERTS RC, 1973, J ALLERGY CLIN IMMUN, V52, P297, DOI 10.1016/0091-6749(73)90048-1; ROSE B, 1967, ARCH ENVIRON HEALTH, V14, P97, DOI 10.1080/00039896.1967.10664701; SALVAGGIO J, 1973, CHEST              S, V63, P515; SEAL RME, 1968, THORAX, V23, P469, DOI 10.1136/thx.23.5.469; TSIKLINSKY P, 1899, DEL I PASTEUR, V13, P500; WEIR DM, 1973, HDB EXPTL IMMUNOLOGY; WENZEL FJ, 1974, AM REV RESPIR DIS, V109, P464; WENZEL FJ, 1964, ANN ALLERGY, V22, P533; WENZEL FJ, 1971, J ALLERGY CLIN IMMUN, V48, P224, DOI 10.1016/0091-6749(71)90069-8; WENZEL FJ, 1967, AM REV RESPIR DIS, V95, P652	25	35	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	3					180	188		10.1016/0091-6749(74)90055-4	http://dx.doi.org/10.1016/0091-6749(74)90055-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U0308	4604472				2022-12-18	WOS:A1974U030800007
J	SALVAGGIO, J; LOPEZ, M; ARQUEMBOURG, P; WALDMAN, R; SLY, M				SALVAGGIO, J; LOPEZ, M; ARQUEMBOURG, P; WALDMAN, R; SLY, M			SALIVARY, NASAL WASH, AND SPUTUM LGA CONCENTRATIONS IN ATOPIC AND NONATOPIC INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA, J HILLIS MILLER HLTH CTR, GAINESVILLE, FL 32601 USA; LOUISIANA STATE UNIV, MED CTR, NEW ORLEANS, LA 70112 USA	State University System of Florida; University of Florida; Louisiana State University System								AMANN AJ, 1969, NEW ENGL J MED, V281, P469; AMMANN A J, 1970, Clinical and Experimental Immunology, V7, P833; ARBESMAN CE, 1970, J ALLERGY, V45, P106; BISHOP ON, 1967, STATISTICS BIOLOGY P; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; CASSIDY JT, 1969, NEW ENGL J MED, V280, P275; CLAMAN HN, 1967, J ALLERGY, V40, P151, DOI 10.1016/0021-8707(67)90004-4; COHEN AB, 1970, CLIN EXP IMMUNOL, V6, P753; DOUGLAS RG, 1967, J IMMUNOL, V99, P297; HUNTLEY CC, 1963, AM J DIS CHILD, V106, P545, DOI 10.1001/archpedi.1963.02080050547003; HYSLOP NE, 1970, CLIN RES, V18, P426; JOHANSSON SG, 1970, CLIN EXP IMMUNOL, V6, P43; KASEL JA, 1969, J IMMUNOL, V102, P555; KAUFMAN HS, 1970, LANCET, V2, P1061; KOHLER PF, 1967, J ALLERGY, V39, P311, DOI 10.1016/0021-8707(67)90095-0; KUMAR L, 1971, J ALLERGY, V47, P86; LEVINE BB, 1971, J IMMUNOL, V106, P29; MESTECKY J, 1971, SCIENCE, V171, P1163, DOI 10.1126/science.171.3976.1163; MOMMA K, 1965, ACTA PAEDIATR JAPON, V7, P1; NEWCOMB RW, 1968, J IMMUNOL, V101, P905; ODALY JA, 1971, BIOCHEMISTRY-US, V10, P3843, DOI 10.1021/bi00797a007; ROSSEN RD, 1965, P SOC EXP BIOL MED, V119, P1169; SALVAGGIO J, 1969, J ALLERGY, V44, P344, DOI 10.1016/0021-8707(69)90026-4; SALVAGGIO J, 1966, J ALLERGY, V38, P31, DOI 10.1016/0021-8707(66)90070-0; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SALVAGGIO JE, 1970, J ALLERGY, V46, P326, DOI 10.1016/0021-8707(70)90083-3; SCHWARTZ DP, 1971, NEW ENGL J MED, V284, P513, DOI 10.1056/NEJM197103112841002; SMITH CB, 1967, J IMMUNOL, V99, P133; TOMASI TB, 1965, J EXP MED, V121, P101, DOI 10.1084/jem.121.1.101; TURK A, 1970, IMMUNOLOGY, V19, P85; WALDMAN RH, 1968, J IMMUNOL, V100, P80; WIGLEY FM, 1970, NEW ENGL J MED, V283, P1250, DOI 10.1056/NEJM197012032832303; YUNGINGER JW, 1971, J ALLERGY, V47, P87	33	35	35	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	6					335	343		10.1016/0091-6749(73)90072-9	http://dx.doi.org/10.1016/0091-6749(73)90072-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8319	4197394	Bronze			2022-12-18	WOS:A1973P831900003
J	TUCHINDA, M; CHAI, H				TUCHINDA, M; CHAI, H			EFFECT OF IMMUNOTHERAPY IN CHRONIC ASTHMATIC CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS ASTHMA RES INST & HOSP,DENVER,CO 80204									AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; CHAI H, 1972, EXCERPTA MEDICA  232; CITRON K M, 1958, Thorax, V13, P229, DOI 10.1136/thx.13.3.229; FONTANA VJ, 1966, J AMER MED ASSOC, V195, P985, DOI 10.1001/jama.195.12.985; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MCALLEN MK, 1967, BMJ-BRIT MED J, V1, P22, DOI 10.1136/bmj.1.5531.22; McALLEN MONICA K., 1961, THORAX, V16, P30, DOI 10.1136/thx.16.1.30; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201	12	35	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	3					131	138		10.1016/0091-6749(73)90018-3	http://dx.doi.org/10.1016/0091-6749(73)90018-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0896	4734568				2022-12-18	WOS:A1973P089600001
J	VARGA, JM; CESKA, M				VARGA, JM; CESKA, M			CHARACTERIZATION OF ALLERGEN EXTRACTS BY GEL ISOELECTROFOCUSING AND RADIOIMMUNOSORBENT ALLERGEN ASSAY - ALLERGENS IN TIMOTHY POLLEN (PHLEUM PRATENSE) EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CESKA M, 1971, INT J APPL RADIAT IS, V22, P311, DOI 10.1016/0020-708X(71)90006-8; CESKA M, 1970, ACTA ENDOCRINOL-COP, V64, P111, DOI 10.1530/acta.0.0640111; CESKA M, 1971, BIOCHEM J, V121, P139, DOI 10.1042/bj1210139; FIREMAN P, 1967, J ALLERGY, V40, P259, DOI 10.1016/0021-8707(67)90073-1; HELMKAMP RW, 1967, INT J APPL RADIAT IS, V18, P737, DOI 10.1016/0020-708X(67)90011-7; MALLEY A, 1962, J ALLERGY, V33, P84, DOI 10.1016/0021-8707(62)90067-9; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; REID RT, 1966, J EXP MED, V123, P845, DOI 10.1084/jem.123.5.845; SVENSSON H, 1961, ACTA CHEM SCAND, V15, P325, DOI 10.3891/acta.chem.scand.15-0325; VARGA JM, 1970, ANNUAL M SWEDISH MED, P424; WRIGLEY C, 1968, Science Tools, V15, P17	13	35	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	5					274	&		10.1016/0091-6749(72)90095-4	http://dx.doi.org/10.1016/0091-6749(72)90095-4			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M4215	5019945				2022-12-18	WOS:A1972M421500003
J	Gonsalves, NP; Aceves, SS				Gonsalves, Nirmala P.; Aceves, Seema S.			Diagnosis and treatment of eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Eosinophil; dysphagia; stricture; fibrosis; corticosteroid; diet; remodeling	6-FOOD ELIMINATION DIET; CONSENSUS RECOMMENDATIONS; GASTROESOPHAGEAL-REFLUX; HISTOLOGIC REMISSION; ADULTS; CHILDREN; EFFICACY; FEATURES; THERAPY; PLACEBO	Eosinophilic esophagitis (EoE) is an eosinophil-rich, T(H)2 antigen-mediated disease of increasing pediatric and adult worldwide prevalence. Diagnosis requires greater than or equal to 15 eosinophils per high-power field on light microscopy. Symptoms reflect esophageal dysfunction, and typical endoscopic features include linear furrows, white plaques, and concentric rings. Progressive disease leads to pathologic tissue remodeling, with ensuing esophageal rigidity and loss of luminal diameter caused by strictures. Therapies include proton pump inhibitors, elimination diets, and topical corticosteroids. Effective treatment can reverse tissue fibrosis in some patients, as well as decrease the rate of food impactions. Esophageal dilation might be required to increase luminal patency. The chronic nature of EoE necessitates long-term therapy to avoid disease recurrence and complications. This review serves the function of providing the current state-of-the-art diagnostic criteria and disease management for adult and pediatric EoE.	[Gonsalves, Nirmala P.] Northwestern Univ, Dept Med, Div Gastroenterol, Chicago, IL 60611 USA; [Aceves, Seema S.] Univ Calif San Diego, Dept Pediat, Div Allergy Immunol, San Diego, CA 92103 USA; [Aceves, Seema S.] Univ Calif San Diego, Dept Med, Div Allergy Immunol, San Diego, CA 92103 USA	Northwestern University; University of California System; University of California San Diego; University of California System; University of California San Diego	Aceves, SS (corresponding author), Dept Pediat, 9500 Gilman Dr,MC 0760, La Jolla, CA 92093 USA.; Aceves, SS (corresponding author), Dept Med, 9500 Gilman Dr,MC 0760, La Jolla, CA 92093 USA.; Gonsalves, NP (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, 676 N St Claire,Suite 1400, Chicago, IL 60611 USA.	n-gonsalves@northwestern.edu; saceves@ucsd.edu			National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI092135, AI135034]	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grants AI092135 and AI135034 (to S.S.A.).	Aceves SS, 2018, J ALLERGY CLIN IMMUN, V142, P130, DOI 10.1016/j.jaci.2018.05.014; Aceves SS, 2014, CLIN GASTROENTEROL H, V12, P1216, DOI 10.1016/j.cgh.2013.09.007; Aceves SS, 2011, J ALLERGY CLIN IMMUN, V128, P1047, DOI 10.1016/j.jaci.2011.09.026; Akei HS, 2005, GASTROENTEROLOGY, V129, P985, DOI 10.1053/j.gastro.2005.06.027; Arias A, 2014, GASTROENTEROLOGY, V146, P1639, DOI 10.1053/j.gastro.2014.02.006; Armentia A, 2018, ALLERGOL IMMUNOPATH, V46, P181, DOI 10.1016/j.aller.2017.11.001; Barbi E, 2004, ALLERGY, V59, P668, DOI 10.1111/j.1398-9995.2004.00398.x; Carlson DA, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2017.47; Cheng E, 2013, GUT, V62, P824, DOI 10.1136/gutjnl-2012-302250; Cohen MS, 2007, CLIN GASTROENTEROL H, V5, P1149, DOI 10.1016/j.cgh.2007.05.017; Collins CA, 2019, J ALLERGY CLIN IMMUN, V144, P1050, DOI 10.1016/j.jaci.2019.06.015; Collins MH, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12470; Dellon ES, 2018, GASTROENTEROLOGY, V155, P1022, DOI 10.1053/j.gastro.2018.07.009; Dellon ES, 2019, CLIN GASTROENTEROL H, V17, P666, DOI 10.1016/j.cgh.2018.05.051; Dellon ES, 2017, GASTROENTEROLOGY, V152, P776, DOI 10.1053/j.gastro.2016.11.021; Dellon ES, 2014, GASTROINTEST ENDOSC, V79, P577, DOI 10.1016/j.gie.2013.10.027; Dellon ES, 2013, AM J GASTROENTEROL, V108, P679, DOI 10.1038/ajg.2013.71; Doerfler B, 2015, DIS ESOPHAGUS, V28, P42, DOI 10.1111/dote.12175; Dohil R, 2012, DIGEST DIS SCI, V57, P1413, DOI 10.1007/s10620-011-1991-5; Eluri S, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2017.27; Eluri S, 2016, GASTROINTEST ENDOSC, V83, P1142, DOI 10.1016/j.gie.2015.11.019; Fahey LM, 2018, CLIN TRANSL GASTROEN, V9, DOI 10.1038/s41424-018-0003-x; Fillon SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042938; Fox VL, 2003, GASTROINTEST ENDOSC, V57, P30, DOI 10.1067/mge.2003.33; Franciosi JP, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-126; Friedlander JA, 2016, GASTROINTEST ENDOSC, V83, P299, DOI 10.1016/j.gie.2015.05.044; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Furuta GT, 2013, GUT, V62, P1395, DOI 10.1136/gutjnl-2012-303171; Gonsalves N, 2006, GASTROINTEST ENDOSC, V64, P313, DOI 10.1016/j.gie.2006.04.037; Gonsalves N, 2014, GASTROENTEROL CLIN N, V43, P375, DOI 10.1016/j.gtc.2014.02.011; Gonsalves N, 2014, DIGEST DIS, V32, P89, DOI 10.1159/000357078; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Greuter T, 2019, CLIN GASTROENTEROL H, V17, P419, DOI 10.1016/j.cgh.2018.05.045; Hassan M, 2019, J PEDIATR GASTR NUTR, V68, P559, DOI 10.1097/MPG.0000000000002202; Hirano I, 2013, GUT, V62, P489, DOI 10.1136/gutjnl-2011-301817; Jensen ET, 2019, J PEDIATR GASTR NUTR, V68, P50, DOI 10.1097/MPG.0000000000002114; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kagalwalla AF, 2017, CLIN GASTROENTEROL H, V15, P1698, DOI 10.1016/j.cgh.2017.05.048; Katzka DA, 2015, CLIN GASTROENTEROL H, V13, P77, DOI 10.1016/j.cgh.2014.06.026; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Kuchen T, 2014, ALLERGY, V69, P1248, DOI 10.1111/all.12455; Kwiatek MA, 2011, GASTROENTEROLOGY, V140, P82, DOI 10.1053/j.gastro.2010.09.037; Leung J, 2013, J ALLERGY CLIN IMMUN, V132, P1215, DOI 10.1016/j.jaci.2013.08.017; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Loizou D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0113483; Lucendo AJ, 2019, GASTROENTEROLOGY, V157, P74, DOI 10.1053/j.gastro.2019.03.025; Lucendo AJ, 2013, J ALLERGY CLIN IMMUN, V131, P797, DOI 10.1016/j.jaci.2012.12.664; Martin LJ, 2015, J ALLERGY CLIN IMMUN, V135, P1519, DOI 10.1016/j.jaci.2015.03.004; Menard-Katcher C, 2017, AM J GASTROENTEROL, V112, P1466, DOI 10.1038/ajg.2017.131; Miehlke S, 2016, GUT, V65, P390, DOI 10.1136/gutjnl-2014-308815; Molina-Infante J, 2015, AM J GASTROENTEROL, V110, P1567, DOI 10.1038/ajg.2015.314; Molina-Infante J, 2014, J ALLERGY CLIN IMMUN, V134, P1093, DOI 10.1016/j.jaci.2014.07.023; Molina-Infante J, 2012, DIGESTION, V85, P210, DOI 10.1159/000335932; Murali AR, 2016, J GASTROEN HEPATOL, V31, P1111, DOI 10.1111/jgh.13281; Nhu QM, 2018, ANN ALLERG ASTHMA IM, V121, P156, DOI 10.1016/j.anai.2018.05.006; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Peterson KA, 2013, AM J GASTROENTEROL, V108, P759, DOI 10.1038/ajg.2012.468; Philpott H, 2016, J GASTROEN HEPATOL, V31, P590, DOI 10.1111/jgh.13173; Protheroe C, 2009, CLIN GASTROENTEROL H, V7, P749, DOI 10.1016/j.cgh.2009.03.022; Rajan J, 2016, J ALLERGY CLIN IMMUN, V137, P147, DOI 10.1016/j.jaci.2015.05.045; Ram G, 2015, ANN ALLERG ASTHMA IM, V115, P224, DOI 10.1016/j.anai.2015.07.004; Ramirez RM, 2013, J ALLERGY CLIN IMMUN, V132, P503, DOI 10.1016/j.jaci.2013.04.053; Rawla P, 2018, DRUGS R&D, V18, P259, DOI 10.1007/s40268-018-0253-9; Rawson R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144651; Rodriguez-Sanchez J, 2014, ALLERGY, V69, P936, DOI 10.1111/all.12420; Safroneeva E, 2016, GASTROENTEROLOGY, V150, P581, DOI 10.1053/j.gastro.2015.11.004; Schoepfer AM, 2014, GASTROENTEROLOGY, V147, P1255, DOI 10.1053/j.gastro.2014.08.028; Schoepfer AM, 2013, GASTROENTEROLOGY, V145, P1230, DOI 10.1053/j.gastro.2013.08.015; Schoepfer AM, 2010, AM J GASTROENTEROL, V105, P1062, DOI 10.1038/ajg.2009.657; Sgouros SN, 2006, EUR J GASTROEN HEPAT, V18, P211, DOI 10.1097/00042737-200602000-00015; Shoda T, 2018, LANCET GASTROENTEROL, V3, P477, DOI 10.1016/S2468-1253(18)30096-7; Spergel J, 2018, J ALLERGY CLIN IMMUN, V142, P1, DOI 10.1016/j.jaci.2018.05.001; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; Straumann A, 2012, ALLERGY, V67, P477, DOI 10.1111/j.1398-9995.2012.02787.x; Straumann A, 2011, CLIN GASTROENTEROL H, V9, P400, DOI 10.1016/j.cgh.2011.01.017; Tabatabaei N, 2014, BIOMED OPT EXPRESS, V5, P197, DOI 10.1364/BOE.5.000197; van Rhijn BD, 2013, ALLERGY, V68, P1475, DOI 10.1111/all.12257; Warners MJ, 2018, AM J GASTROENTEROL, V113, P836, DOI 10.1038/s41395-018-0052-5; Warners MJ, 2018, GASTROENTEROLOGY, V154, P57, DOI 10.1053/j.gastro.2017.08.062; Wechsler JB, 2018, CLIN GASTROENTEROL H, V16, P1056, DOI 10.1016/j.cgh.2017.12.019; Wen T, 2019, J CLIN INVEST, V129, P2014, DOI 10.1172/JCI125917; Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Zhang X, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0035700, 10.1371/journal.pone.0035991]	86	34	34	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					1	7		10.1016/j.jaci.2019.11.011	http://dx.doi.org/10.1016/j.jaci.2019.11.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31910983	Green Accepted, Bronze			2022-12-18	WOS:000505590800001
J	Soriano, VX; Peters, RL; Ponsonby, AL; Dharmage, SC; Perrett, KP; Field, MJ; Knox, A; Tey, D; Odoi, S; Gell, G; Perez, BC; Allen, KJ; Gurrin, LC; Koplin, JJ				Soriano, Victoria X.; Peters, Rachel L.; Ponsonby, Anne-Louise; Dharmage, Shyamali C.; Perrett, Kirsten P.; Field, Michael J.; Knox, Andrew; Tey, Dean; Odoi, Sasha; Gell, Grace; Perez, Beatriz Camesella; Allen, Katrina J.; Gurrin, Lyle C.; Koplin, Jennifer J.			Earlier ingestion of peanut after changes to infant feeding guidelines: The EarlyNuts study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Infant feeding; early introduction; peanut; egg; food allergy; guidelines; timing of introduction; weaning; infants; observational	FOOD ALLERGY; RISK; PREVENTION; PREVALENCE; HEALTHNUTS; ANAPHYLAXIS; HISTORY; TRENDS	Background: Randomized controlled trials demonstrate that timely introduction of peanut to infants reduces the risk of peanut allergy. However, much debate remains regarding how to best achieve earlier peanut introduction at the population level. Our previous study in 2007-2011 (HealthNuts, n = 5300) indicated that few infants were consuming peanut in the first year. Australian infant feeding guidelines were updated in 2016 to recommend introducing peanut before 12 months for all infants. There were no data available on the subsequent effect on peanut introduction or peanut reactions. Objective: We sought to assess the consequences of a nonscreening approach to allergenic food introduction in a population-based sample of infants in their first year of life. Methods: EarlyNuts is a population-based, cross-sectional study of 12-month-old infants in Melbourne, Australia, recruited by using an identical sampling frame and methods to HealthNuts (72% response rate vs 73% response rate in HealthNuts). We report here on the first 860 participants recruited between November 2016 and October 2018. Results: Most infants (88.6%; 95% CI, 86.1% to 90.7%) had introduced peanut by 12 months (median age, 6 months), an increase from 28.4% (95% CI, 27.2% to 29.7%) in the HealthNuts study. By 12 months, the majority of these (76.4%) had consumed peanut more than 4 times, and 28% were eating peanut more than once per week. Preliminary results on parentreported reactions show that 4.0% of those consuming peanut by 12 months had possible IgE-mediated reactions. Conclusions: There has been a striking shift toward earlier peanut introduction, with a 3-fold increase in peanut introduction by age 1 year in 2018 compared with 2007-2011.	[Soriano, Victoria X.; Peters, Rachel L.; Perrett, Kirsten P.; Field, Michael J.; Knox, Andrew; Tey, Dean; Odoi, Sasha; Gell, Grace; Perez, Beatriz Camesella; Allen, Katrina J.; Gurrin, Lyle C.; Koplin, Jennifer J.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Soriano, Victoria X.; Peters, Rachel L.; Tey, Dean; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Ponsonby, Anne-Louise; Dharmage, Shyamali C.; Perrett, Kirsten P.; Gurrin, Lyle C.; Koplin, Jennifer J.] Univ Melbourne, Sch Populat & Global Hlth, Parkville, Vic, Australia; [Perrett, Kirsten P.; Tey, Dean; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic, Australia; [Tey, Dean] Royal Childrens Hosp, Melbourne Allergy Ctr & Childrens Specialists MAC, Parkville, Vic, Australia; [Ponsonby, Anne-Louise] Florey Inst Neurosci & Mental Hlth, Neuroepidemiol Res Grp, Parkville, Vic, Australia	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; Florey Institute of Neuroscience & Mental Health	Koplin, JJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	jennifer.koplin@mcri.edu.au	Perrett, Kirsten/P-8813-2019	Perrett, Kirsten/0000-0002-5683-996X; Peters, Rachel/0000-0002-2411-6628; Koplin, Jennifer/0000-0002-7576-5142; Ponsonby, Anne-Louise/0000-0002-6581-3657; Soriano, Victoria Ximena/0000-0002-8412-5657	National Health and Medical Research Council of Australia (NHMRC); Murdoch Children's Research Institute; Victorian Government's Operational Infrastructure Program; NHMRC-funded Centre for Food and Allergy Research (CFAR)	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Murdoch Children's Research Institute; Victorian Government's Operational Infrastructure Program; NHMRC-funded Centre for Food and Allergy Research (CFAR)	This work was supported by funding from the National Health and Medical Research Council of Australia (NHMRC) and the Murdoch Children's Research Institute. Research at the Murdoch Children's Research Institute is supported by the Victorian Government's Operational Infrastructure Program. V.X.S. is supported by a PhD scholarship from the NHMRC-funded Centre for Food and Allergy Research (CFAR).	Australasian Society of Clinical Immunology and Allergy, 2016, ASCIA GUID INF FEED; Australasian Society of Clinical Immunology and Allergy (ASCIA), 2018, ASCIA PCC INTR SOL F; Department of Health & Human Services, 2016, VICT MOTH BAB CHILDR; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fewtrell M, 2017, J PEDIATR GASTR NUTR, V64, P119, DOI 10.1097/MPG.0000000000001454; Fisher HR, 2019, J ALLER CL IMM-PRACT, V7, P367, DOI 10.1016/j.jaip.2018.11.005; Fleischer DM, 2016, PEDIATR DERMATOL, V33, P102, DOI 10.1111/pde.12685; Grant J., 2017, NATL STANDARDS PRACT; Greenhawt MJ, 2016, J ALLER CL IMM-PRACT, V4, P221, DOI 10.1016/j.jaip.2015.12.016; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Ierodiakonou D, 2016, JAMA-J AM MED ASSOC, V316, P1181, DOI 10.1001/jama.2016.12623; Koplin JJ, 2014, ALLERGY, V69, P1639, DOI 10.1111/all.12487; Koplin JJ, 2013, CLIN EXP ALLERGY, V43, P826, DOI 10.1111/cea.12090; Koplin JJ, 2012, ALLERGY, V67, P1415, DOI 10.1111/all.12015; Koplin JJ, 2016, J ALLERGY CLIN IMMUN, V138, P1131, DOI 10.1016/j.jaci.2016.04.011; Koplin JJ, 2015, INT J EPIDEMIOL, V44, P1161, DOI 10.1093/ije/dyu261; Koplin JJ, 2013, INT J ENV RES PUB HE, V10, P5364, DOI 10.3390/ijerph10115364; Landsberger HA, 1958, HAWTHORNE REVISITED, P119; McKean M, 2015, CLIN PEDIATR, V54, P745, DOI 10.1177/0009922815584927; Mullins RJ, 2015, J ALLERGY CLIN IMMUN, V136, P367, DOI 10.1016/j.jaci.2015.05.009; National Health and Medical Research Council (NHMRC), 2012, INF FEED GUID INF HL; Netting MJ, 2017, J ALLER CL IMM-PRACT, V5, P1617, DOI 10.1016/j.jaip.2017.03.013; Netting MJ, 2017, J PAEDIATR CHILD H, V53, P870, DOI 10.1111/jpc.13594; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Peters RL, 2017, J ALLERGY CLIN IMMUN, V140, P145, DOI 10.1016/j.jaci.2017.02.019; Pratt AL, 2019, ANN ALLERG ASTHMA IM, V122, P207, DOI 10.1016/j.anai.2018.11.010; Rudders SA, 2014, J ALLERGY CLIN IMMUN, V134, P960, DOI 10.1016/j.jaci.2014.06.018; Shaker M, 2018, ALLERGY, V73, P1707, DOI 10.1111/all.13446; Shaker M, 2018, ALLERGY, V73, P2214, DOI 10.1111/all.13565; State Government of Victoria, 2018, MAT CHILD HLTH SERV; Tang MLK, 2018, J ALLER CL IMM-PRACT, V6, P408, DOI 10.1016/j.jaip.2017.08.011; Tey D, 2014, J ALLERGY CLIN IMMUN, V133, P476, DOI 10.1016/j.jaci.2013.11.019; Togias A, 2017, WORLD ALLERGY ORGAN, V10, DOI 10.1186/s40413-016-0137-9; WHO, 2015, GUID SUG INT AD CHIL, V57, P1716	35	34	34	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1327	+		10.1016/j.jaci.2019.07.032	http://dx.doi.org/10.1016/j.jaci.2019.07.032			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31401287	Bronze			2022-12-18	WOS:000495004700023
J	Tanno, LK; Chalmers, R; Bierrenbach, AL; Simons, FER; Martin, B; Molinari, N; Annesi-Maesano, I; Worm, M; Cardona, V; Papadopoulos, NG; Sanchez-Borges, M; Rosenwasser, LJ; Ansontegui, I; Ebisawa, M; Sisul, JC; Jares, E; Gomez, M; Agache, L; Hellings, P; Muraro, A; Thien, F; Pawankar, R; Sublett, JL; Casale, T; Demoly, P				Tanno, Luciana Kase; Chalmers, Robert; Bierrenbach, Ana Luiza; Simons, F. Estelle R.; Martin, Bryan; Molinari, Nicolas; Annesi-Maesano, Isabella; Worm, Margitta; Cardona, Victoria; Papadopoulos, Nikolaos G.; Sanchez-Borges, Mario; Rosenwasser, Lanny J.; Ansontegui, Ignacio; Ebisawa, Motohiro; Sisul, Juan Carlos; Jares, Edgardo; Gomez, Maximiliano; Agache, Loana; Hellings, Peter; Muraro, Antonella; Thien, Francis; Pawankar, Ruby; Sublett, James L.; Casale, Thomas; Demoly, Pascal		Joint Allergy Academies	Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases-11	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; big data; classification; International Classification of Diseases; mortality; World Health Organization	HYPERSENSITIVITY CONDITIONS SECTION; FATAL ANAPHYLAXIS; FRANCE ANALYSIS; ALLERGY; DEATHS; UNDERNOTIFICATION; REVISION; ICD-11; BRAZIL; TERMS	We review the history of the classification and coding changes for anaphylaxis and provide current and perspective information in the field. In 2012, an analysis of Brazilian data demonstrated undernotification of anaphylaxis-related deaths because of the difficulties of coding using the International Classification of Diseases, 10th Revision. This work triggered strategic international actions supported by the Joint Allergy Academies and the International Classification of Diseases World Health Organization (WHO) leadership to update the classification of allergic disorders for the International Classification of Diseases, 11th Revision (ICD-11), which resulted in construction of the pioneer "Allergic and hypersensitivity conditions'' chapter. The usability of the new framework has been tested by evaluating the same data published in 2012 from the ICD-11 perspective. Coding accuracy was much improved, reaching 95% for definite anaphylaxis. As the results were provided to the WHO Mortality Reference Group, coding rules have been changed, allowing anaphylaxis to be recorded as an underlying cause of death in official mortality statistics. The mandatory use of ICD-11 from January 2022 for documenting cause of death could have 2 immediate consequences: (1) the reported number of anaphylaxis-related deaths might increase because of more appropriate coding and (2) the cross-sectional and longitudinal mortality data generated might ultimately lead to a better understanding of anaphylaxis epidemiology and improved health policies directed at reducing anaphylaxis-related mortality.	[Tanno, Luciana Kase; Bierrenbach, Ana Luiza] Hosp Sirio Libanes, Sao Paulo, Brazil; [Tanno, Luciana Kase; Demoly, Pascal] Univ Hosp Montpellier, Montpellier, France; [Tanno, Luciana Kase; Annesi-Maesano, Isabella; Demoly, Pascal] Sorbonne Univ, INSERM, UMRS 1136, Paris, France; [Tanno, Luciana Kase] WHO, Collaborating Ctr Sci Classificat Support, Montpellier, France; [Chalmers, Robert] WHO, ICD 11 Med & Sci Advisory Comm, Geneva, Switzerland; [Chalmers, Robert] Univ Manchester, Ctr Dermatol, Manchester, Lancs, England; [Bierrenbach, Ana Luiza] Hosp Sirio Libanes, Sans Epidemiol & Res & Teaching Res Inst IEP, Sao Paulo, Brazil; [Simons, F. Estelle R.] Univ Manitoba, Dept Pediat & Child Hlth, Sect Allergy & Clin Immunol, Winnipeg, MB, Canada; [Martin, Bryan] Ohio State Univ, Med & Pediat, Columbus, OH 43210 USA; [Molinari, Nicolas] CHRU Montpellier, DIM, IMAG, UMR 5149, Montpellier, France; [Worm, Margitta] Charite Univ Med Berlin, Dept Dermatol & Allergy, Div Allergy & Immunol, Berlin, Germany; [Cardona, Victoria] Hosp Valle De Hebron, Allergy Sect, Internal Med Dept, Barcelona, Spain; [Papadopoulos, Nikolaos G.] Univ Manchester, Inst Human Dev, Ctr Paediat & Child Hlth, Manchester, Lancs, England; [Papadopoulos, Nikolaos G.] Univ Athens, Pediat Clin 2, Dept Allergy, Athens, Greece; [Sanchez-Borges, Mario] Ctr Med Docente Trinidad, Allergy & Clin Immunol Dept, Caracas, Venezuela; [Rosenwasser, Lanny J.] Childrens Mercy Hosp & Clin, Div Immunol Res, Dept Pediat, Kansas City, MO USA; [Ansontegui, Ignacio] Hosp Quironsalud Bizkaia Erandio, Dept Allergy & Immunol, Bilbao, Spain; [Ebisawa, Motohiro] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan; [Sisul, Juan Carlos] Latinamer Soc Allergy Asthma & Immunol, Asuncion, Paraguay; [Jares, Edgardo] LIBRA Fdn, Buenos Aires, DF, Argentina; [Jares, Edgardo] CMP SA Buenos Aires, Buenos Aires, DF, Argentina; [Gomez, Maximiliano] Catholic Univ Salta, Hosp San Bernardo, Allergy & Asthma Unit, Res & Educ Fdn Ayre, Salta, Argentina; [Agache, Loana] Transylvania Univ, Brasov, Romania; [Hellings, Peter] Univ Hosp Leuven, ENT Clin Dept, Leuven, Belgium; [Hellings, Peter] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Clin Immunol, Leuven, Belgium; [Muraro, Antonella] Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy; [Thien, Francis] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Thien, Francis] Eastern Hlth, Dept Resp Med, Boxhill, Australia; [Pawankar, Ruby] Nippon Med Sch, Tokyo, Japan; [Sublett, James L.] Univ Louisville, Sch Med, Dept Pediat, Family Allergy & Asthma & Sec Allergy & Immunol, Louisville, KY 40292 USA; [Casale, Thomas] Univ South Carolina, Morsani Coll Med, Tampa, FL USA	Hospital Sirio Libanes; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; World Health Organization; World Health Organization; University of Manchester; Hospital Sirio Libanes; University of Manitoba; University System of Ohio; Ohio State University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Mathematical Sciences (INSMI); Universite de Montpellier; CHU de Montpellier; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hospital Universitari Vall d'Hebron; University of Manchester; National & Kapodistrian University of Athens; Children's Mercy Hospital; quironsalud Group; Transylvania University of Brasov; KU Leuven; University Hospital Leuven; KU Leuven; University of Padua; Azienda Ospedaliera - Universita di Padova; Monash University; Nippon Medical School; University of Louisville	Tanno, LK (corresponding author), Univ Hosp Montpellier, Hop Arnaud Villeneuve, Dept Pulmonol, Div Allergy, 371 Av Doyen Gaston Giraud, F-34295 Montpellier 5, France.	luciana.tanno@gmail.com	Demoly, Pascal/Y-9938-2019; Tanno, Luciana Kase/J-9981-2014; N.G., Papadopoulos/L-8670-2013; Cardona, Victoria/GRX-4196-2022; Bierrenbach, Ana L/F-3185-2014	Demoly, Pascal/0000-0001-7827-7964; Tanno, Luciana Kase/0000-0003-3236-1225; N.G., Papadopoulos/0000-0002-4448-3468; Bierrenbach, Ana L/0000-0002-6837-0636; Cardona, Victoria/0000-0003-2197-9767; Worm, Margitta/0000-0002-3449-1245; Ebisawa, Motohiro/0000-0003-4117-558X	MEDA/Mylan Pharma grant through CHRUM administration; Novartis grant through CHRUM administration	MEDA/Mylan Pharma grant through CHRUM administration; Novartis grant through CHRUM administration	P.D. and L.K.T. received unrestricted Novartis and MEDA/Mylan Pharma grants through CHRUM administration.	Ansotegui IJ, 2016, CURR TREAT OPTIONS A, V3, P205, DOI DOI 10.1007/S40521-016-0094-0; Brown SGA, 2006, MED J AUSTRALIA, V185, P283, DOI 10.5694/j.1326-5377.2006.tb00563.x; Demoly P, 2014, ALLERGY, V69, P559, DOI 10.1111/all.12386; Demoly P., 2018, J INVESTIG ALLERGOL; Hynes M, MORTALITY ITS RISK F; Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018; Kivisto JE, 2016, J ALLERGY CLIN IMMUN, V138, P630, DOI 10.1016/j.jaci.2016.05.015; KNIBBS GEORGE H., 1929, MED JOUR AUSTRALIA, V1, P2; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Moriyama IM, 2011, HIST STAT CLASSIFICA; Mullins RJ, 2016, CLIN EXP ALLERGY, V46, P1099, DOI 10.1111/cea.12748; Muraro A, 2014, ALLERGY, V69, P1026, DOI 10.1111/all.12437; Pouessel G, 2018, PEDIAT ALLERG IMM-UK, V29, P101, DOI 10.1111/pai.12828; Pouessel G, 2017, J ALLERGY CLIN IMMUN, V140, P610, DOI 10.1016/j.jaci.2017.02.014; Pulteney R., 1805, GEN VIEW WRITINGS LI; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Simons FER, 2011, WORLD ALLERGY ORGAN, V4, P13, DOI 10.1097/WOX.0b013e318211496c; Simons FER, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-9; Tanno LK, 2017, REV FR ALLERGOL, V57, P583, DOI 10.1016/j.reval.2017.06.004; Tanno LK, 2017, CLIN EXP ALLERGY, V47, P1108, DOI 10.1111/cea.12973; Tanno LK, 2017, ALLERGY, V72, P120, DOI 10.1111/all.13006; Tanno LK, 2016, ALLERGY, V71, P1235, DOI 10.1111/all.12945; Tanno LK, 2016, ALLERGY, V71, P671, DOI 10.1111/all.12834; Tanno LK, 2015, ALLERGY, V70, P609, DOI 10.1111/all.12604; Tanno LK, 2012, ALLERGY, V67, P783, DOI 10.1111/j.1398-9995.2012.02829.x; Tanno LK, 2017, ALLERGY ASTHMA PROC, V38, pE54; Tanno LK, 2016, ALLERGY ASTHMA IMMUN, V8, P383, DOI 10.4168/aair.2016.8.4.383; Tanno LK, 2018, CURR OPIN ALLERGY CL, V18, P365, DOI 10.1097/ACI.0000000000000467; Tanno LK, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0234-0; Tanno LK, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-016-0554-4; Tanno LK, 2016, J ALLER CL IMM-PRACT, V4, P1265, DOI 10.1016/j.jaip.2016.06.024; Tanno LK, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0115-2; Tanno LK, 2016, ASIA PAC ALLERGY, V6, P149, DOI 10.5415/apallergy.2016.6.3.149; Tanno LK, 2016, J ALLER CL IMM-PRACT, V4, P650, DOI 10.1016/j.jaip.2016.01.015; Tanno LK, 2016, J ALLER CL IMM-PRACT, V4, P643, DOI 10.1016/j.jaip.2015.12.022; Tanno LK, 2015, ASIA PAC ALLERGY, V5, P193, DOI 10.5415/apallergy.2015.5.4.193; Tanno LK, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0063-x; Tanno LK, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-42; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; WHO Web site, WHO COLL CTR; World Health Organization, INT CLASS DIS WEB SI; World Health Organization, ICD 11 BET DRAFT WEB; Xu YS, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-38	43	34	35	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					627	633		10.1016/j.jaci.2019.05.013	http://dx.doi.org/10.1016/j.jaci.2019.05.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	31229269	Bronze, Green Published			2022-12-18	WOS:000485222300001
J	Ferrua, F; Galimberti, S; Courteille, V; Slatter, MA; Booth, C; Moshous, D; Neven, B; Blanche, S; Cavazzana, M; Laberko, A; Shcherbina, A; Balashov, D; Soncini, E; Porta, F; Al-Mousa, H; Al-Saud, B; Al-Dhekri, H; Arnaout, R; Formankova, R; Bertrand, Y; Lange, A; Smart, J; Wolska-Kusnierz, B; Aquino, VM; Dvorak, CC; Fasth, A; Fouyssac, F; Heilmann, C; Hoenig, M; Schuetz, C; Kelecic, J; Bredius, RGM; Lankester, AC; Lindemans, CA; Suarez, F; Sullivan, KE; Albert, MH; Kalwak, K; Barlogis, V; Bhatia, M; Bordon, V; Czogala, W; Alonso, L; Dogu, F; Gozdzik, J; Ikinciogullari, A; Krivan, G; Ljungman, P; Meyts, I; Mustillo, P; Smith, AR; Speckmann, C; Sundin, M; Keogh, SJ; Shaw, PJ; Boelens, JJ; Schulz, AS; Sedlacek, P; Veys, P; Mahlaoui, N; Janda, A; Davies, EG; Fischer, A; Cowan, MJ; Gennery, AR				Ferrua, Francesca; Galimberti, Stefania; Courteille, Virginie; Slatter, Mary Anne; Booth, Claire; Moshous, Despina; Neven, Benedicte; Blanche, Stephane; Cavazzana, Marina; Laberko, Alexandra; Shcherbina, Anna; Balashov, Dmitry; Soncini, Elena; Porta, Fulvio; Al-Mousa, Hamoud; Al-Saud, Bandar; Al-Dhekri, Hasan; Arnaout, Rand; Formankova, Renata; Bertrand, Yves; Lange, Andrzej; Smart, Joanne; Wolska-Kusnierz, Beata; Aquino, Victor M.; Dvorak, Christopher C.; Fasth, Anders; Fouyssac, Fanny; Heilmann, Carsten; Hoenig, Manfred; Schuetz, Catharina; Kelecic, Jadranka; Bredius, Robbert G. M.; Lankester, Arjan C.; Lindemans, Caroline A.; Suarez, Felipe; Sullivan, Kathleen E.; Albert, Michael H.; Kalwak, Krzysztof; Barlogis, Vincent; Bhatia, Monica; Bordon, Victoria; Czogala, Wojciech; Alonso, Laura; Dogu, Figen; Gozdzik, Jolanta; Ikinciogullari, Aydan; Krivan, Gergely; Ljungman, Per; Meyts, Isabelle; Mustillo, Peter; Smith, Angela R.; Speckmann, Carsten; Sundin, Mikael; Keogh, Steven John; Shaw, Peter John; Boelens, Jaap Jan; Schulz, Ansgar S.; Sedlacek, Petr; Veys, Paul; Mahlaoui, Nizar; Janda, Ales; Davies, E. Graham; Fischer, Alain; Cowan, Morton J.; Gennery, Andrew Richard		SCETIDE; PIDTC; EBMT; ESID IEWP	Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD40 ligand; hematopoietic stem cell transplantation; X-linked hyper-IgM syndrome; primary immunodeficiency	BONE-MARROW-TRANSPLANTATION; HYPER-IGM SYNDROME; X-LINKED IMMUNODEFICIENCY; IMMUNOGLOBULIN-M SYNDROME; DEFECTIVE EXPRESSION; CLINICAL-FEATURES; T-CELLS; CHILDREN; EXPERIENCE; MUTATIONS	Background: CD40 ligand (CD40L) deficiency, an X-linked primary immunodeficiency, causes recurrent sinopulmonary, Pneumocystis and Cryptosporidium species infections. Long-term survival with supportive therapy is poor. Currently, the only curative treatment is hematopoietic stem cell transplantation (HSCT). Objective: We performed an international collaborative study to improve patients' management, aiming to individualize risk factors and determine optimal HSCT characteristics. Methods: We retrospectively collected data on 130 patients who underwent HSCT for CD40L deficiency between 1993-2015. We analyzed outcome and variables' relevance with respect to survival and cure. Results: Overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were 78.2%, 58.1%, and 72.3% 5 years after HSCT. Results were better in transplantations performed in 2000 or later and in children less than 10 years old at the time of HSCT. Pre-existing organ damage negatively influenced outcome. Sclerosing cholangitis was the most important risk factor. After 2000, superior OS was achieved with matched donors. Use of myeloablative regimens and HSCT at 2 years or less from diagnosis associated with higher OS and DFS. EFS was best with matched sibling donors, myeloablative conditioning (MAC), and bone marrow-derived stem cells. Most rejections occurred after reduced-intensity or nonmyeloablative conditioning, which associated with poor donor cell engraftment. Mortality occurred mainly early after HSCT, predominantly from infections. Among survivors who ceased immunoglobulin replacement, T-lymphocyte chimerism was 50% or greater donor in 85.2%. Conclusion: HSCT is curative in patients with CD40L deficiency, with improved outcome if performed before organ damage development. MAC is associated with better OS, EFS, and DFS. Prospective studies are required to compare the risks of HSCT with those of lifelong supportive therapy.	[Ferrua, Francesca; Slatter, Mary Anne; Gennery, Andrew Richard] Great North Childrens Hosp, Dept Pediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Ferrua, Francesca; Slatter, Mary Anne; Gennery, Andrew Richard] Great North Childrens Hosp, HSCT, Newcastle Upon Tyne, Tyne & Wear, England; [Ferrua, Francesca] Ist Sci San Raffaele, Pediat Immunohematol & Bone Marrow Transplantat U, San Raffaele Telethon Inst Gene Therapy SR Tiget, Via Olgettina 60, I-20132 Milan, Italy; [Ferrua, Francesca] Univ Vita Salute San Raffaele, Milan, Italy; [Galimberti, Stefania] Univ Milano Bicocca, Sch Med Surg, Ctr Biostat Clin Epidemiol, Monza, Italy; [Courteille, Virginie; Moshous, Despina; Neven, Benedicte; Blanche, Stephane; Cavazzana, Marina; Mahlaoui, Nizar; Fischer, Alain] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, Paris, France; [Slatter, Mary Anne; Gennery, Andrew Richard] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Booth, Claire; Davies, E. Graham] Great Ormond St Hosp Sick Children, Dept Pediat Immunol, London, England; [Moshous, Despina; Neven, Benedicte; Blanche, Stephane; Mahlaoui, Nizar; Fischer, Alain] Necker Enfants Malades Hosp, AP HP, Pediat Hematol Immunol & Rheumatol Unit, Paris, France; [Cavazzana, Marina] Necker Childrens Hosp, AP HP, Biotherapy Dept, Paris, France; [Cavazzana, Marina] Grp Hosp Univ Ouest, AP HP, INSERM, Biotherapy Clin Invest Ctr, Paris, France; [Cavazzana, Marina] Lab Human Lymphohematopoiesis, INSERM UMR 1163, Paris, France; [Laberko, Alexandra; Shcherbina, Anna; Balashov, Dmitry] Dmitry Rogachev Fed Res Ctr Pediat Hematol Oncol, Moscow, Russia; [Soncini, Elena; Porta, Fulvio] Spedali Civili Brescia, Pediat Oncol Hematol & BMT Unit, Brescia, Italy; [Al-Mousa, Hamoud; Al-Saud, Bandar; Al-Dhekri, Hasan; Arnaout, Rand] King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh, Saudi Arabia; [Formankova, Renata; Sedlacek, Petr] Univ Hosp Motol Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Bertrand, Yves] Hosp Civils Lyon, Inst Hematol & Oncol Pediat, Lyon, France; [Lange, Andrzej] Polish Acad Sci, L Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland; [Lange, Andrzej] Lower Silesian Ctr Cellular Transplantat, Wroclaw, Poland; [Lange, Andrzej] Natl Bone Marrow Donor Registry, Wroclaw, Poland; [Smart, Joanne] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Wolska-Kusnierz, Beata] Childrens Mem Hlth Inst, Immunol Dept, Warsaw, Poland; [Aquino, Victor M.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA; [Dvorak, Christopher C.; Cowan, Morton J.] Univ Calif San Francisco, Div Pediat Allergy Immunol & Bone Marrow Transpla, San Francisco, CA 94143 USA; [Fasth, Anders] Univ Gothenburg, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden; [Fasth, Anders] Queen Silvia Childrens Hosp, Gothenburg, Sweden; [Fouyssac, Fanny] Univ Hosp Nancy, Children Hosp, Pediat Oncol & Hematol Unit, Van Doeuvre Les Nancy, France; [Heilmann, Carsten] Rigshosp, Pediat Clin, Copenhagen, Denmark; [Hoenig, Manfred; Schuetz, Catharina; Schulz, Ansgar S.] Univ Med Ctr Ulm, Dept Pediat, Ulm, Germany; [Kelecic, Jadranka] Univ Hosp Ctr Zagreb, Dept Pediat, Div Allergol Clin Immunol Resp Dis & Rheumatol, Zagreb, Croatia; [Bredius, Robbert G. M.; Lankester, Arjan C.] Leiden Univ, Med Ctr, Willem Alexander Childrens Hosp, Dept Pediat, Leiden, Netherlands; [Lindemans, Caroline A.; Boelens, Jaap Jan] Univ Utrecht, Univ Med Ctr Utrecht, Dept Pediat, Utrecht, Netherlands; [Lindemans, Caroline A.; Boelens, Jaap Jan] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [Suarez, Felipe] Hop Necker Enfants Malad, AP HP, Hematol Adulte, Paris, France; [Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Dept Pediat, Div Allergy Immunol, Philadelphia, PA 19104 USA; [Albert, Michael H.] Dr von Hauner Univ Childrens Hosp, Pediat Hematol Oncol, Munich, Germany; [Kalwak, Krzysztof] Wroclaw Med Univ, Dept Pediat Hematol & Oncol, Wroclaw, Poland; [Barlogis, Vincent] Hop Timone Enfants, Serv Dhematol Pediat, Marseille, France; [Bhatia, Monica] Columbia Univ, Coll Phys & Surg, Pediat Stem Cell Transplantat, New York, NY USA; [Bordon, Victoria] Ghent Univ Hosp, Pediat Hematol Oncol & Stem Cell Transplantat, Ghent, Belgium; [Czogala, Wojciech] Univ Childrens Hosp Cracow, Krakow, Poland; [Alonso, Laura] Hosp Univ MatemoInfantil Vall dHebron, Pediat Hematol & Oncol Dept, Barcelona, Spain; [Dogu, Figen] Ankara Univ, Dept Pediat Immunol & Allergy, Sch Med, Ankara, Turkey; [Gozdzik, Jolanta] Jagiellonian Univ, Univ Childrens Hosp, Transplantat Ctr, Dept Clin Immunol & Transplantol,Med Coll, Krakow, Poland; [Ikinciogullari, Aydan] Ankara Univ, Med Sch, Dept Pediat Immunol Allergy, Ankara, Turkey; [Ikinciogullari, Aydan] Ankara Univ, Med Sch, BMT Unit, Ankara, Turkey; [Krivan, Gergely] United St Istvan & St Laszlo Hosp, Dept Pediat Hematol & Stem Cell Transplantat, Budapest, Hungary; [Ljungman, Per] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden; [Meyts, Isabelle] Katholieke Univ Leuven, Dept Immunol & Microbiol, Univ Hosp Leuven, Dept Pediat,Div Pediat Immunol, Leuven, Belgium; [Mustillo, Peter] Nationwide Childrens Hosp, Columbus, OH USA; [Smith, Angela R.] Univ Minnesota, Pediat Blood & Marrow Transplant, Minneapolis, MN USA; [Speckmann, Carsten] Univ Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Speckmann, Carsten] Univ Freiburg, Div Pediat Hematol & Oncol, Dept Pediat & Adolescent Med, Fac Med, Freiburg, Germany; [Sundin, Mikael] Karolinska Inst, CLINTTEC, Div Pediat, Stockholm, Sweden; [Sundin, Mikael] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Pediat Blood Disorders Immunodeficiency & SCT, Stockholm, Sweden; [Keogh, Steven John; Shaw, Peter John] Childrens Hosp Westmead, Canc Ctr Children, Sydney, NSW, Australia; [Shaw, Peter John] Univ Sydney, Med Program, Sydney, NSW, Australia; [Boelens, Jaap Jan] Mem Sloan Kettering Canc Ctr, Dept Pediat, BMT & Cell Therapies Program, 1275 York Ave, New York, NY 10021 USA; [Boelens, Jaap Jan] Univ Med Ctr, Lab Translat Immunol, Tumor Immunol, Utrecht, Netherlands; [Veys, Paul] Great Ormond St Hosp Sick Children, Dept BMT, London, England; [Courteille, Virginie; Moshous, Despina; Neven, Benedicte; Blanche, Stephane; Fouyssac, Fanny; Suarez, Felipe; Barlogis, Vincent; Mahlaoui, Nizar; Fischer, Alain] Necker Enfants Malades Univ Hosp, AP HP, French Natl Reference Ctr Primary Immune Deficien, Paris, France; [Mahlaoui, Nizar] INSERM UMR 1163, Lab Human Genet Infect Dis, Necker Branch, Paris, France; [Janda, Ales] Univ Freiburg, Med Ctr, Ctr Pediat, Freiburg, Germany; [Janda, Ales] Univ Freiburg, Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Fischer, Alain] Coll France, Paris, France; [Czogala, Wojciech] Ul Lubostron 33-43, PL-30383 Krakow, Poland	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; University of Milano-Bicocca; UDICE-French Research Universities; Universite Paris Cite; Newcastle University - UK; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology & Immunology; Hospital Spedali Civili Brescia; King Faisal Specialist Hospital & Research Center; Motol University Hospital; CHU Lyon; Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences; Royal Children's Hospital Melbourne; Children's Memorial Health Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of Gothenburg; Queen Silvia Children's Hospital; CHU de Nancy; Universite de Lorraine; Rigshospitalet; University of Copenhagen; Ulm University; University of Zagreb; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; Utrecht University Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Munich; Wroclaw Medical University; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Columbia University; Ghent University; Ghent University Hospital; Ankara University; Jagiellonian University; Collegium Medicum Jagiellonian University; Ankara University; Ankara University; Szent Laszlo Hospital; Karolinska Institutet; Karolinska University Hospital; KU Leuven; University Hospital Leuven; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Freiburg; University of Freiburg; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Sydney; University of Sydney; Memorial Sloan Kettering Cancer Center; Utrecht University; Utrecht University Medical Center; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Freiburg; University of Freiburg; UDICE-French Research Universities; PSL Research University Paris; College de France	Ferrua, F (corresponding author), Ist Sci San Raffaele, Pediat Immunohematol & Bone Marrow Transplantat U, San Raffaele Telethon Inst Gene Therapy SR Tiget, Via Olgettina 60, I-20132 Milan, Italy.	ferrua.francesca@hsr.it	Meyts, Isabelle/Z-3295-2019; Sedlacek, Petr/V-4703-2019; Kalwak, Krzysztof/U-1724-2019; Fasth, Anders/I-1109-2019; İkinciogullari, Aydan/AAQ-3841-2020; Ferrua, Francesca/K-4340-2016; MAHLAOUI, Nizar/AAH-6103-2020; Moshous, Despina/B-7507-2017; Al-Mousa, Hamoud/AAS-4477-2020; Dvorak, Christopher C/AAX-1630-2020; Dogu, Figen/AAI-1316-2020; shaw, peter John/D-8255-2011; Balashov, Dmitry/AAW-8132-2020; Lange, Andrzej/AAR-3247-2021; Bordon, Victoria/AAJ-7451-2020; Bredius, Robbert/AAF-2592-2019; galimberti, stefania/H-2594-2012; Booth, Claire/I-3667-2016; Sundin, Mikael/E-5942-2013	Kalwak, Krzysztof/0000-0003-1174-5799; İkinciogullari, Aydan/0000-0003-1145-0843; Ferrua, Francesca/0000-0002-5695-4490; MAHLAOUI, Nizar/0000-0002-0030-8094; Moshous, Despina/0000-0001-6719-3693; Dvorak, Christopher C/0000-0002-6146-3952; Dogu, Figen/0000-0002-7869-4941; shaw, peter John/0000-0003-0101-4482; Lange, Andrzej/0000-0003-3544-1853; Speckmann, Carsten/0000-0002-6217-1556; Booth, Claire/0000-0002-2626-5037; Sundin, Mikael/0000-0002-9871-0961; Cavazzana, Marina/0000-0002-0264-0891; Fasth, Anders/0000-0002-0033-740X; GALIMBERTI, STEFANIA/0000-0003-1504-7242; Bredius, Robbert/0000-0001-8151-1539	ESID Medium Term Fellowship; Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, Maryland [U54-AI082973, R13-AI094943]; CEREDIH; French Ministry of Health; National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre based at Newcastle Hospitals NHS Foundation Trust; Newcastle University	ESID Medium Term Fellowship; Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, Maryland; CEREDIH; French Ministry of Health; National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre based at Newcastle Hospitals NHS Foundation Trust; Newcastle University	F. F. received an ESID Medium Term Fellowship. M. J. Cowan, C. C. Dvorak, and K. E. Sullivan are supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), and the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, Maryland (Public Health Service grant/cooperative agreements U54-AI082973 and R13-AI094943). The SCETIDE registry is funded by CEREDIH and the French Ministry of Health. Research was supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre based at Newcastle Hospitals NHS Foundation Trust and Newcastle University. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.	Al-Saud B, 2015, PEDIATR TRANSPLANT, V19, P634, DOI 10.1111/petr.12538; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; Allewelt H, 2015, PEDIATR BLOOD CANCER, V62, P2216, DOI 10.1002/pbc.25711; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Aschermann Z, 2007, ARCH NEUROL, V64; Bacigalupo A, 2009, BIOL BLOOD MARROW TR, V15, P1628, DOI 10.1016/j.bbmt.2009.07.004; Balashov D, 2015, BIOL BLOOD MARROW TR, V21, P1955, DOI 10.1016/j.bbmt.2015.07.008; Bordigoni P, 1998, BONE MARROW TRANSPL, V22, P1111, DOI 10.1038/sj.bmt.1701497; Cabral-Marques O, 2018, J ALLERGY CLIN IMMUN, V142, P1571, DOI 10.1016/j.jaci.2018.02.026; Cabral-Marques O, 2017, J ALLERGY CLIN IMMUN, V139, P900, DOI 10.1016/j.jaci.2016.07.018; Cunningham CK, 1999, J PEDIATR-US, V134, P584, DOI 10.1016/S0022-3476(99)70245-3; de la Morena MT, 2017, J ALLERGY CLIN IMMUN, V139, P1282, DOI 10.1016/j.jaci.2016.07.039; Dimicoli S, 2003, BONE MARROW TRANSPL, V32, P733, DOI 10.1038/sj.bmt.1704211; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Dogu F, 2011, EXP CLIN TRANSPLANT, V9, P349; Duplantier JE, 2001, CLIN IMMUNOL, V98, P313, DOI 10.1006/clim.2000.4994; Dvorak CC, 2009, J PEDIAT HEMATOL ONC, V31, P300, DOI 10.1097/MPH.0b013e3181914a81; EBMT/ESID, 2011, EBMT ESID GUIDELINES; Etzioni A, 2004, PEDIATR RES, V56, P519, DOI 10.1203/01.PDR.0000139318.65842.4A; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; Gennery AR, 2000, J PEDIATR-US, V137, P290, DOI 10.1067/mpd.2000.106445; Gennery AR, 2004, BLOOD, V103, P1152, DOI 10.1182/blood-2003-06-2014; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; HADZIC N, N ENGL J MED, V342, P320; Hasegawa S, 2014, J NEUROL SCI, V340, P86, DOI 10.1016/j.jns.2014.02.033; Hayward AR, 1997, J IMMUNOL, V158, P977; Hongeng S, 2005, ACTA HAEMATOL-BASEL, V114, P174, DOI 10.1159/000087895; Hubbard N, 2016, BLOOD, V127, P2513, DOI 10.1182/blood-2015-11-683235; Jacobsohn DA, 2004, PEDIATRICS, V113, P122, DOI 10.1542/peds.113.2.e122; Janda A, 2012, ALERGIE, V14, P34; Jasinska A, 2013, PEDIATR TRANSPLANT, V17, pE37, DOI 10.1111/j.1399-3046.2012.01786.x; Kato T, 1999, BONE MARROW TRANSPL, V23, P1081, DOI 10.1038/sj.bmt.1701753; Khawaja K, 2001, ARCH DIS CHILD, V84, P508, DOI 10.1136/adc.84.6.508; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; Law J, 2012, BIOL BLOOD MARROW TR, V18, P1656, DOI 10.1016/j.bbmt.2012.05.006; Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9; Mitsui-Sekinaka K, 2015, J ALLERGY CLIN IMMUN, V136, P1018, DOI 10.1016/j.jaci.2015.02.020; Notarangelo LD, 1996, IMMUNOL TODAY, V17, P511, DOI 10.1016/0167-5699(96)30059-5; Petrovic A, 2009, IMMUNOL RES, V44, P169, DOI 10.1007/s12026-009-8111-z; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Rezaei N, 2013, PEDIATR TRANSPLANT, V17, P1, DOI 10.1111/petr.12012; Scholl PR, 1998, BONE MARROW TRANSPL, V22, P1215, DOI 10.1038/sj.bmt.1701512; Slatter MA, 2011, BLOOD, V117, P4367, DOI 10.1182/blood-2010-10-312082; THOMAS C, 1995, NEW ENGL J MED, V333, P426, DOI 10.1056/NEJM199508173330705; Tomizawa D, 2004, AM J HEMATOL, V76, P33, DOI 10.1002/ajh.20044; Toniati P, 2008, CLIN EXP IMMUNOL, V154, P121; Tsuji Y, 2007, HAEMATOLOGICA, V92, P1727, DOI 10.3324/haematol.11531; Urban C, 2004, EUR J HAEMATOL, V72, P444, DOI 10.1111/j.1600-0609.2004.00256.x; Van Hoeyveld E, 2007, IMMUNOLOGY, V120, P497, DOI 10.1111/j.1365-2567.2006.02520.x; Wolska-Kusnierz B, 2007, J PEDIATR GASTR NUTR, V45, P458, DOI 10.1097/MPG.0b013e318054b09b; Ziegner UHM, 2001, J PEDIATR-US, V138, P570, DOI 10.1067/mpd.2001.112511	52	34	37	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2238	2253		10.1016/j.jaci.2018.12.1010	http://dx.doi.org/10.1016/j.jaci.2018.12.1010			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30660643	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000470113200027
J	Tian, B; Hosoki, K; Liu, ZQ; Yang, J; Zhao, YX; Sun, H; Zhou, J; Rytting, E; Kaphalia, L; Calhoun, WJ; Sur, S; Brasier, AR				Tian, Bing; Hosoki, Koa; Liu, Zhiqing; Yang, Jun; Zhao, Yingxin; Sun, Hong; Zhou, Jia; Rytting, Erik; Kaphalia, Lata; Calhoun, William J.; Sur, Sanjiv; Brasier, Allan R.			Mucosal bromodomain-containing protein 4 mediates aeroallergen-induced inflammation and remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bromodomain-containing protein 4; epigenetics; myofibroblast; airway remodeling; aeroallergen; nuclear factor kappa B; histone acetyltransferase activity	EPITHELIAL-MESENCHYMAL TRANSITION; ALLERGIC AIRWAY INFLAMMATION; PULMONARY-FIBROSIS; TRANSCRIPTIONAL ELONGATION; CELLS; ASTHMA; SENSITIZATION; ACTIVATION; INNATE; BRD4	Background: Frequent exacerbations of allergic asthma lead to airway remodeling and a decrease in pulmonary function, producing morbidity. Cat dander is an aeroallergen associated with asthma risk. Objective: We sought to elucidate the mechanism of cat dander-induced inflammation-remodeling. Methods: We identified remodeling in mucosal samples from allergic asthma by using quantitative RT-PCR. We developed a model of aeroallergen-induced experimental asthma using repetitive cat dander extract exposure. We measured airway inflammation using immunofluorescence, leukocyte recruitment, and quantitative RT-PCR. Airway remodeling was measured by using histology, collagen content, myofibroblast numbers, and selected reaction monitoring. Inducible nuclear factor kappa B (NF-kappa B)-BRD4 interaction was measured by using a proximity ligation assay in situ. Results: Enhanced mesenchymal signatures are observed in bronchial biopsy specimens from patients with allergic asthma. Cat dander induces innate inflammation through NF-kappa B signaling, followed by production of a profibrogenic mesenchymal transition in primary humansmall airway epithelial cells. The I kappa B kinase-NF kappa B signaling pathway is required for mucosal inflammation-coupled airway remodeling and myofibroblast expansion in the mouse model of aeroallergen exposure. Cat dander induces NF-kappa B/RelA to complex with and activate BRD4, resulting in modifying the chromatin environment of inflammatory and fibrogenic genes through its atypical histone acetyltransferase activity. A novel small-molecule BRD4 inhibitor (ZL0454) disrupts BRD4 binding to the NF-kappa B-RNA polymerase II complex and inhibits its histone acetyltransferase activity. ZL0454 prevents epithelial mesenchymal transition, myofibroblast expansion, IgE sensitization, and fibrosis in airways of naive mice exposed to cat dander. Conclusions: NF-kappa B-inducible BRD4 activity mediates cat dander-induced inflammation and remodeling. Therapeutic modulation of the NF-kappa B-BRD4 pathway affects allergen-induced inflammation, epithelial cell-state changes, extracellular matrix production, and expansion of the subepithelial myofibroblast population.	[Tian, Bing; Hosoki, Koa; Yang, Jun; Zhao, Yingxin; Sun, Hong; Kaphalia, Lata; Calhoun, William J.; Sur, Sanjiv] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA; [Tian, Bing; Yang, Jun; Zhao, Yingxin; Zhou, Jia; Calhoun, William J.; Sur, Sanjiv] Univ Texas Med Branch, Sealy Ctr Mol Med, Galveston, TX 77555 USA; [Liu, Zhiqing; Zhou, Jia] Univ Texas Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; [Yang, Jun; Zhao, Yingxin; Zhou, Jia; Calhoun, William J.; Sur, Sanjiv] Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77555 USA; [Rytting, Erik] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA; [Brasier, Allan R.] Univ Wisconsin, Sch Med & Publ Hlth, Inst Clin & Translat Res, Madison, WI USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Wisconsin System; University of Wisconsin Madison	Brasier, AR (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Hlth Sci Learning Ctr 4246, 750 Highland Ave, Madison, WI 53705 USA.	abrasier@wisc.edu		Calhoun, William/0000-0001-7075-712X; Hosoki, Koa/0000-0003-4228-2176; Liu, Zhiqing/0000-0003-0266-6677	National Institutes of Health/National Institute of Allergy and Infectious Diseases [AI062885]; NIH/National Center for Advancing Translational Science (NCATS) [UL1TR001439]; National Science Foundation (NSF) [DMS-1361411/DMS-1361318]; University of Texas Medical Branch (UTMB) Technology Commercialization Program; Sanofi Innovation Awards (iAwards); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001439, UL1TR002373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI133454, P01AI062885] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Center for Advancing Translational Science (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Science Foundation (NSF)(National Science Foundation (NSF)); University of Texas Medical Branch (UTMB) Technology Commercialization Program; Sanofi Innovation Awards (iAwards); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by National Institutes of Health/National Institute of Allergy and Infectious Diseases AI062885 (to A.R.B.), NIH/National Center for Advancing Translational Science (NCATS) UL1TR001439 (to A.R.B.), National Science Foundation (NSF) grant DMS-1361411/DMS-1361318 (to A.R.B.), University of Texas Medical Branch (UTMB) Technology Commercialization Program and Sanofi Innovation Awards (iAwards; to A.R.B., J.Z., B.T., and E.R.). Core laboratory support was provided by the UTMB Histopathology Core and Optical Imaging Core.	Al-Muhsen S, 2011, J ALLERGY CLIN IMMUN, V128, P451, DOI 10.1016/j.jaci.2011.04.047; Amara N, 2010, THORAX, V65, P733, DOI 10.1136/thx.2009.113456; Arizmendi NG, 2011, J IMMUNOL, V186, P3164, DOI 10.4049/jimmunol.0903812; Ather JL, 2011, AM J RESP CELL MOL, V44, P631, DOI 10.1165/rcmb.2010-0106OC; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bentley JK, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-127; Bergeron C, 2010, CAN RESPIR J, V17, pE85, DOI 10.1155/2010/318029; Boser SR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182378; Brasier AR, 2011, J VIROL, V85, P11752, DOI 10.1128/JVI.05360-11; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; Brown JD, 2014, MOL CELL, V56, P219, DOI 10.1016/j.molcel.2014.08.024; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Carroll NG, 2000, AM J RESP CRIT CARE, V161, P244, DOI 10.1164/ajrccm.161.1.9805005; Chang HY, 2016, NUCLEIC ACIDS RES, V44, P2514, DOI 10.1093/nar/gkw126; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Dahl R, 2004, RESP MED, V98, P398, DOI 10.1016/j.rmed.2003.11.015; Devaiah BN, 2016, NAT STRUCT MOL BIOL, V23, P540, DOI 10.1038/nsmb.3228; Devaiah BN, 2012, P NATL ACAD SCI USA, V109, P6927, DOI 10.1073/pnas.1120422109; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Hackett TL, 2012, CURR OPIN ALLERGY CL, V12, P53, DOI 10.1097/ACI.0b013e32834ec6eb; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammond M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040405; Hiraga R, 2013, ANTICANCER RES, V33, P4431; Holgate Stephen T, 2004, Proc Am Thorac Soc, V1, P93, DOI 10.1513/pats.2306034; Hosoki K, 2017, J ALLERGY CLIN IMMUN, V140, P1436, DOI 10.1016/j.jaci.2017.04.044; Hosoki K, 2016, J ALLERGY CLIN IMMUN, V137, P1506, DOI 10.1016/j.jaci.2015.09.036; Hosoki K, 2016, AM J RESP CELL MOL, V54, P81, DOI 10.1165/rcmb.2015-0044OC; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Ijaz T, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.434; Ijaz T, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-13; Kale SL, 2017, SCI REP-UK, V7, DOI 10.1038/srep42341; Kalita M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/505864; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kelly LA, 2012, CURR OPIN PULM MED, V18, P29, DOI 10.1097/MCP.0b013e32834db10d; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Liu ZQ, 2018, EUR J MED CHEM, V151, P450, DOI 10.1016/j.ejmech.2018.04.006; Liu ZQ, 2017, J MED CHEM, V60, P4533, DOI 10.1021/acs.jmedchem.6b01761; Noble PW, 2012, J CLIN INVEST, V122, P2756, DOI 10.1172/JCI60323; Pawankar R, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-12; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Prakash YS, 2017, AM J RESP CRIT CARE, V195, P247, DOI 10.1164/rccm.201611-2248ST; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Ray S, 2013, J INVEST DERMATOL, V133, P1212, DOI 10.1038/jid.2012.499; Rock JR, 2011, P NATL ACAD SCI USA, V108, pE1475, DOI 10.1073/pnas.1117988108; Sagara H, 2002, J ALLERGY CLIN IMMUN, V110, P249, DOI 10.1067/mai.2002.126078; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Tian B., 2017, J VIROL, P91; Tian B, 2019, AM J RESP CELL MOL, V60, P68, DOI 10.1165/rcmb.2017-0445OC; Tian B, 2018, CELL REP, V23, P1138, DOI 10.1016/j.celrep.2018.03.106; Tian B, 2017, AM J RESP CELL MOL, V56, P506, DOI 10.1165/rcmb.2016-0259OC; Tian B, 2016, AM J PHYSIOL-LUNG C, V311, pL1183, DOI 10.1152/ajplung.00224.2016; Tian B, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1707-x; Tian B, 2013, J VIROL, V87, P7075, DOI 10.1128/JVI.03399-12; Tully JE, 2013, J IMMUNOL, V191, P5811, DOI 10.4049/jimmunol.1301329; Wu RF, 2010, MOL CELL BIOL, V30, P3553, DOI 10.1128/MCB.01445-09; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304; Zhang YQ, 2017, J PROTEOME RES, V16, P3068, DOI 10.1021/acs.jproteome.7b00432; Zhao YX, 2017, J IMMUNOL, V198, P3345, DOI 10.4049/jimmunol.1601291; Zhao YX, 2016, J PROTEOMICS, V148, P126, DOI 10.1016/j.jprot.2016.07.014; Zhao YX, 2013, METHODS, V61, P313, DOI 10.1016/j.ymeth.2013.02.001	64	34	35	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1380	+		10.1016/j.jaci.2018.09.029	http://dx.doi.org/10.1016/j.jaci.2018.09.029			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30321559	Bronze, Green Accepted			2022-12-18	WOS:000463348900015
J	Matricardi, PM; Dramburg, S; Potapova, E; Skevaki, C; Renz, H				Matricardi, Paolo Maria; Dramburg, Stephanie; Potapova, Ekaterina; Skevaki, Chrysanthi; Renz, Harald			Molecular diagnosis for allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; allergen immunotherapy; allergic rhinitis; asthma; biomarker; component-resolved diagnostics; diagnostic algorithm; IgE; IgE tests; molecular allergology; molecular spreading	COMPONENT-RESOLVED DIAGNOSIS; DE-NOVO SENSITIZATION; GRASS-POLLEN ALLERGY; PRECISION MEDICINE; IGE SENSITIZATION; PHLEUM-PRATENSE; EARLY-CHILDHOOD; SUBLINGUAL IMMUNOTHERAPY; POLYSENSITIZED PATIENTS; EAACI GUIDELINES	The extensive use of allergen molecules in birth cohort studies revealed that atopic sensitization is a sequential IgE response to distinct non-cross-reacting molecules from the same allergenic source (ie, molecular spreading), starting with an initiator molecule. This phenomenon reaches different degrees of progression (monomolecular, oligomolecular, and polymolecular) according to the individual atopic propensity and allergen exposure, thus producing an extreme heterogeneity of IgE sensitization profiles in patient populations. In patients with allergic rhinitis, the broader the IgE molecular sensitization profile, the greater is the risk of asthma and other allergic comorbidities, such as oral allergy syndrome. Hence it has been proposed to anticipate immunologic intervention at disease onset (early allergen immunotherapy) or even earlier during the preclinical sensitization stage (allergen immunoprophylaxis). Diagnostic algorithms based on singleplex or multiplex molecular IgE tests allow the discrimination of genuine from cross-reacting sensitization and the selection of the right extracts for allergen immunotherapy composition. Patients with extreme molecular poly-sensitization and greater risk of asthma or other IgE-mediated comorbidities, can be easily identified by means of allergen microarray or macroarray procedures and might benefit from anti-IgE treatment. IgE molecular tests have opened the era of precision allergology, and their routine use should aim at cost-effectiveness, according to the principles of the Choosing Wisely initiative.	[Matricardi, Paolo Maria; Dramburg, Stephanie; Potapova, Ekaterina] Charite Univ Med Berlin, Dept Pediat Pulmonol Immunol & Intens Care Med, Augustenburger Pl 1, D-13353 Berlin, Germany; [Skevaki, Chrysanthi; Renz, Harald] Philipps Univ Marburg, Inst Lab Med, UGMLC, German Ctr Lung Res DZL, Marburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Philipps University Marburg	Matricardi, PM (corresponding author), Charite Univ Med Berlin, Dept Pediat Pulmonol Immunol & Intens Care Med, Augustenburger Pl 1, D-13353 Berlin, Germany.	paolo.matricardi@charite.de	Dramburg, Stephanie/AAM-8340-2020	Dramburg, Stephanie/0000-0002-9303-3260; Potapova, Ekaterina/0000-0003-4427-6335	Charite Medical University; Universities of Giessen and Marburg Lung Center (UGMLC); German Center for Lung Research (DZL) [82DZL00502/A2]; Deutsche Forschungsgemeinschaft (DFG) [SFB 1021]	Charite Medical University; Universities of Giessen and Marburg Lung Center (UGMLC); German Center for Lung Research (DZL); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	Supported by the Charite Medical University (P.M.M., S.D., and E.P.) and the Universities of Giessen and Marburg Lung Center (UGMLC; to H.R. and C.S.), the German Center for Lung Research (DZL; 82DZL00502/A2; to H.R. and C.S.), and the Deutsche Forschungsgemeinschaft (DFG)-funded SFB 1021 (C04, to H.R. and C.S.).	AALBERSE RC, 1991, EUR RESPIR J, V4, pS78; Alessandri C, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0158-7; Anto JM, 2017, J ALLERGY CLIN IMMUN, V139, P388, DOI 10.1016/j.jaci.2016.12.940; Arasi S, 2018, ITAL J PEDIATR, V44, DOI 10.1186/s13052-018-0519-4; Asarnoj A, 2017, J ALLERGY CLIN IMMUN, V140, P587, DOI 10.1016/j.jaci.2016.12.973; Asarnoj A, 2016, J ALLERGY CLIN IMMUN, V137, P813, DOI 10.1016/j.jaci.2015.09.052; Asero R, 2006, J INVEST ALLERG CLIN, V16, P253; Asero R, 2005, INT ARCH ALLERGY IMM, V137, P62, DOI 10.1159/000085105; Bahceciler NN, 2013, IMMUNOTHERAPY-UK, V5, P183, DOI [10.2217/IMT.12.161, 10.2217/imt.12.161]; Becker S, 2016, INT ARCH ALLERGY IMM, V170, P132, DOI 10.1159/000447694; Brunetto B, 2010, ALLERGY, V65, P184, DOI 10.1111/j.1398-9995.2009.02150.x; Calderon M, 2012, ALLERGY, V67, P462, DOI 10.1111/j.1398-9995.2012.02785.x; Calderon MA, 2012, J ALLERGY CLIN IMMUN, V129, P929, DOI 10.1016/j.jaci.2011.11.019; Canonica GW, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0079-7; Canonica GW, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-17; Casset A, 2012, INT ARCH ALLERGY IMM, V159, P253, DOI 10.1159/000337654; Chapman MD, 2008, J ALLERGY CLIN IMMUN, V122, P882, DOI 10.1016/j.jaci.2008.07.030; Chen KW, 2019, J ALLERGY CLIN IMMUN, V143, P1248, DOI 10.1016/j.jaci.2018.10.048; Ciprandi G, 2012, ANN ALLERG ASTHMA IM, V109, P392, DOI 10.1016/j.anai.2012.09.006; Cipriani F, 2018, ALLERGY, V73, P673, DOI 10.1111/all.13338; Cromwell O, 2011, J ALLERGY CLIN IMMUN, V127, P865, DOI 10.1016/j.jaci.2011.01.047; Cromwell Oliver, 2009, Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess, V96, P210; Curin M, 2017, ANN ALLERG ASTHMA IM, V119, P201, DOI 10.1016/j.anai.2016.11.022; Custovic A, 2015, J ALLERGY CLIN IMMUN, V136, P1645, DOI 10.1016/j.jaci.2015.03.041; Darsow U, 2014, CLIN EXP ALLERGY, V44, P778, DOI 10.1111/cea.12303; DiFraia M, 2018, CLIN EXP ALLERGY, P1; Douladiris N, 2013, INT ARCH ALLERGY IMM, V162, P65, DOI 10.1159/000353113; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; European Directorate for the Quality of Medicines (EDQM), 2010, EUR PHARM S6, P679; Focke M, 2008, CLIN EXP ALLERGY, V38, P1400, DOI 10.1111/j.1365-2222.2008.03031.x; Focke M, 2009, EUR J CLIN INVEST, V39, P429, DOI 10.1111/j.1365-2362.2009.02109.x; Gadermaier E, 2011, ALLERGY, V66, P1174, DOI 10.1111/j.1398-9995.2011.02592.x; Galli SJ, 2016, J ALLERGY CLIN IMMUN, V137, P1289, DOI 10.1016/j.jaci.2016.03.006; Hamilton RG, 2015, J ALLERGY CLIN IMMUN, V136, P811, DOI 10.1016/j.jaci.2015.03.002; Hatzler L, 2014, PEDIAT ALLERG IMM-UK, V25, P366, DOI 10.1111/pai.12248; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Heffler E, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-018-0186-3; Hofmaier S, 2015, J ALLERGY CLIN IMMUN, V135, P1367, DOI 10.1016/j.jaci.2014.09.048; Holt PG, 2013, J ALLERGY CLIN IMMUN, V132, P991, DOI 10.1016/j.jaci.2013.04.049; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; Huang X, 2018, ALLERGY, V73, P421, DOI 10.1111/all.13269; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; Jensen-Jarolim E, 2017, WORLD ALLERGY ORGAN, V10, DOI 10.1186/s40413-017-0162-3; Jung K, 2013, ALLERGO J, V22, P586, DOI 10.1007/s15007-013-0455-y; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300; Kack U, 2018, J ALLERGY CLIN IMMUN, V142, P1113, DOI 10.1016/j.jaci.2018.05.012; Kaul S, 2011, ALLERGY, V66, P753, DOI 10.1111/j.1398-9995.2011.02552.x; Kleine-Tebbe J, 2015, ALLERGO J, V24, P33, DOI 10.1007/s40629-015-0067-z; Kleine-Tebbe J, 2016, IMMUNOL ALLERGY CLIN, V36, P191, DOI 10.1016/j.iac.2015.08.012; Klimek L, 2015, ALLERGY, V70, P1329, DOI 10.1111/all.12676; Kohler J, 2014, J ALLERGY CLIN IMMUN, V133, P1383, DOI 10.1016/j.jaci.2013.10.060; Kristiansen M, 2017, PEDIAT ALLERG IMM-UK, V28, P18, DOI 10.1111/pai.12661; Lee JE, 2011, ANN ALLERG ASTHMA IM, V107, P79, DOI 10.1016/j.anai.2011.03.012; Lockey RF, 2017, ANN ALLERG ASTHMA IM, V118, P2, DOI 10.1016/j.anai.2016.03.032; Lowenstein H, 2014, CHEM IMMUNOL ALLERGY, V100, P323, DOI 10.1159/000359989; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Lyons JJ, 2018, J EXP MED, V215, P1009, DOI 10.1084/jem.20172306; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; Mari A, 2011, CURR OPIN ALLERGY CL, V11, P438, DOI 10.1097/ACI.0b013e32834a41dd; Mastrorilli C, 2016, ALLERGY, V71, P1181, DOI 10.1111/all.12888; Matricardi PM, 2016, PEDIAT ALLERG IMM-UK, V27, P1, DOI 10.1111/pai.12563; Matricardi PM, 2016, CLIN EXP ALLERGY, V46, P664, DOI 10.1111/cea.12679; Matricardi PM, 2014, PEDIAT ALLERG IMM-UK, V25, P15, DOI 10.1111/pai.12200; Melioli G, 2012, PEDIAT ALLERG IMM-UK, V23, P433, DOI 10.1111/j.1399-3038.2011.01228.x; Morden NE, 2014, NEW ENGL J MED, V370, P589, DOI 10.1056/NEJMp1314965; Moreno C, 2014, ALLERGY, V69, P1357, DOI 10.1111/all.12474; Mothes-Luksch N, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-018-0199-y; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Muraro A, 2018, ALLERGY, V73, P739, DOI 10.1111/all.13420; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Noon L, 1911, LANCET, V1, P1572; Pajno GB, 2018, ALLERGY, V73, P799, DOI 10.1111/all.13319; Papadopoulos NG, 2019, PEDIAT ALLERG IMM-UK, V30, P7, DOI 10.1111/pai.12990; Patelis A, 2016, CLIN EXP ALLERGY, V46, P730, DOI 10.1111/cea.12607; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Pifferi M, 2002, ALLERGY, V57, P785, DOI 10.1034/j.1398-9995.2002.23498.x; Posa D, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0697-y; Posa D, 2017, J ALLERGY CLIN IMMUN, V139, P541, DOI 10.1016/j.jaci.2016.08.014; Rossi RE, 2007, VACCINE, V25, P957, DOI 10.1016/j.vaccine.2006.08.040; Saltabayeva U, 2017, INT ARCH ALLERGY IMM, V173, P93, DOI 10.1159/000477442; Sastre J, 2015, ALLERGY, V70, P598, DOI 10.1111/all.12575; Sastre J, 2012, ALLERGY, V67, P709, DOI 10.1111/j.1398-9995.2012.02808.x; Scala E, 2010, CLIN EXP ALLERGY, V40, P911, DOI 10.1111/j.1365-2222.2010.03470.x; Schwarz A, 2016, J ALLERGY CLIN IMMUN, V138, P1426, DOI 10.1016/j.jaci.2016.01.057; Shamji MH, 2017, ALLERGY, V72, P1156, DOI 10.1111/all.13138; Siroux V, 2018, ALLERGY, V73, P1447, DOI 10.1111/all.13410; Skrindo I, 2015, PEDIAT ALLERG IMM-UK, V26, P239, DOI 10.1111/pai.12366; Stringari G, 2014, J ALLERGY CLIN IMMUN, V134, P75, DOI 10.1016/j.jaci.2014.01.042; Szepfalusi Z, 2014, PEDIAT ALLERG IMM-UK, V25, P788, DOI 10.1111/pai.12310; Tripodi S, 2012, J ALLERGY CLIN IMMUN, V129, P834, DOI 10.1016/j.jaci.2011.10.045; Tuppo L, 2013, CLIN EXP ALLERGY, V43, P128, DOI 10.1111/cea.12028; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2007, J INVESTIG ALLERG S1, V17, P88; Valenta R, 2018, ADV IMMUNOL, V138, P195, DOI 10.1016/bs.ai.2018.03.002; van Hage M, 2017, J ALLERGY CLIN IMMUN, V140, P974, DOI 10.1016/j.jaci.2017.05.008; Vieths S, 2012, Pharmeur Bio Sci Notes, V2012, P118; Weghofer M, 2008, EUR J CLIN INVEST, V38, P959, DOI 10.1111/j.1365-2362.2008.02048.x; Weghofer M, 2013, J IMMUNOL, V190, P3059, DOI 10.4049/jimmunol.1202288; Westman M, 2017, SEMIN IMMUNOL, V30, P61, DOI 10.1016/j.smim.2017.07.005; Wickman M, 2017, EBIOMEDICINE, V26, P91, DOI 10.1016/j.ebiom.2017.11.009; WIDE L, 1967, LANCET, V2, P1105; Wojtalewicz N, 2017, ALLERGO J, V26, P20, DOI 10.1007/s40629-016-0005-8; Zolkipli Z, 2015, J ALLERGY CLIN IMMUN, V136, P1541, DOI 10.1016/j.jaci.2015.04.045	105	34	36	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					831	843		10.1016/j.jaci.2018.12.1021	http://dx.doi.org/10.1016/j.jaci.2018.12.1021			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30850070	Bronze			2022-12-18	WOS:000460272900002
J	Togias, A; Gergen, PJ; Hu, JW; Babineau, DC; Wood, RA; Cohen, RT; Makhija, MM; Hershey, GKK; Kercsmar, CM; Gruchalla, RS; Liu, AH; Wang, E; Kim, H; Lamm, CI; Bacharier, LB; Pillai, D; Sigelman, SM; Gern, JE; Busse, WW				Togias, Alkis; Gergen, Peter J.; Hu, Jack W.; Babineau, Denise C.; Wood, Robert A.; Cohen, Robyn T.; Makhija, Melanie M.; Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.; Gruchalla, Rebecca S.; Liu, Andrew H.; Wang, Emily; Kim, Haejin; Lamm, Carin I.; Bacharier, Leonard B.; Pillai, Dinesh; Sigelman, Steve M.; Gern, James E.; Busse, William W.			Rhinitis in children and adolescents with asthma: Ubiquitous, difficult to control, and associated with asthma outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinitis prevalence; rhinitis phenotypes; rhinitis management; rhinoconjunctivitis; asthma	ALLERGIC RHINITIS; FLUTICASONE PROPIONATE; RISK-FACTORS; COEXISTENCE; BURDEN	Background: Rhinitis and asthma are linked, but substantial knowledge gaps in this relationship exist. Objective: We sought to determine the prevalence of rhinitis and its phenotypes in children and adolescents with asthma, assess symptom severity and medication requirements for rhinitis control, and investigate associations between rhinitis and asthma. Methods: Seven hundred forty-nine children with asthma participating in the Asthma Phenotypes in the Inner-City study received baseline evaluations and were managed for 1 year with algorithm-based treatments for rhinitis and asthma. Rhinitis was diagnosed by using a questionnaire focusing on individual symptoms, and predefined phenotypes were determined by combining symptom patterns with skin tests and measurement of serum specific IgE levels. Results: Analyses were done on 619 children with asthma who completed at least 4 of 6 visits. Rhinitis was present in 93.5%, and phenotypes identified at baseline were confirmed during the observation/management year. Perennial allergic rhinitis with seasonal exacerbations was most common (34.2%) and severe. Nonallergic rhinitis was least common (11.3%) and least severe. The majority of children remained symptomatic despite use of nasal corticosteroids with or without oral antihistamines. Rhinitis was worse in patients with difficult-to-control versus easy-to-control asthma, and its seasonal patterns partially corresponded to those of difficult-to-control asthma. Conclusion: Rhinitis is almost ubiquitous in urban children with asthma, and its activity tracks that of lower airway disease. Perennial allergic rhinitis with seasonal exacerbations is the most severe phenotype and most likely to be associated with difficult-to-control asthma. This study offers strong support to the concept that rhinitis and asthma represent the manifestations of 1 disease in 2 parts of the airways.	[Togias, Alkis; Gergen, Peter J.; Sigelman, Steve M.] NIAID, Div Allergy Immunol & Transplantat, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Hu, Jack W.; Babineau, Denise C.] Rho Fed Syst Div, 6330 Quadrangle Dr, Chapel Hill, NC 27517 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Div Allergy & Immunol, Baltimore, MD USA; [Cohen, Robyn T.] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02215 USA; [Makhija, Melanie M.] Ann & Robert H Lurie Childrens Hosp Chicago, Div Allergy & Immunol, Chicago, IL 60611 USA; [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Div Asthma Res, Cincinnati, OH USA; [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Div Pulm Med, Cincinnati, OH USA; [Gruchalla, Rebecca S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Liu, Andrew H.] Natl Jewish Hlth, Div Allergy & Immunol, Denver, CO USA; [Liu, Andrew H.] Childrens Hosp Colorado, Dept Allergy & Immunol, Aurora, CO USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA; [Wang, Emily; Kim, Haejin] Henry Ford Hlth Syst, Div Allergy & Immunol, Detroit, MI USA; [Lamm, Carin I.] Coll Phys & Surg, Dept Pediat, New York, NY USA; [Bacharier, Leonard B.] St Louis Childrens Hosp, Div Allergy Immunol & Pulm Med, St Louis, MO 63178 USA; [Pillai, Dinesh] Childrens Natl Hlth Syst, Dept Pulm Med, Washington, DC USA; [Gern, James E.; Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Div Allergy & Immunol, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Boston University; Ann & Robert H. Lurie Children's Hospital of Chicago; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Henry Ford Health System; Henry Ford Hospital; St. Louis Children's Hospital; Washington University (WUSTL); Children's National Health System; University of Wisconsin System; University of Wisconsin Madison	Hu, JW (corresponding author), Rho Fed Syst Div, 6330 Quadrangle Dr, Chapel Hill, NC 27517 USA.	jack_hu@rhoworld.com		Bacharier, Leonard/0000-0003-0432-2704	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [HHSN272200900052C, HHSN272201000052I]; National Center for Research Resources [NCRR/NIH UL1TR001079, UL1TR000451, UL1TR001105, 1UL1RR025780, UL1TR000075, NCATS/NIH UL1TR000150, UL1TR000077-04, UL1 TR000154, UL1TR001082, UL1TR000040]; National Center for Advancing Translational Sciences [NCRR/NIH UL1TR001079, UL1TR000451, UL1TR001105, 1UL1RR025780, UL1TR000075, NCATS/NIH UL1TR000150, UL1TR000077-04, UL1 TR000154, UL1TR001082, UL1TR000040]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001422, UL1TR000040, UL1TR001079, UL1TR000077, UL1TR000451, UL1TR001105, UL1TR001082, UL1TR000150, UL1TR000154, UL1TR000075] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM2AI117870, UM1AI114271] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, under contract nos. HHSN272200900052C and HHSN272201000052I. Additional support was provided by the National Center for Research Resources and National Center for Advancing Translational Sciences under grants NCRR/NIH UL1TR001079, UL1TR000451, UL1TR001105, 1UL1RR025780, UL1TR000075, NCATS/NIH UL1TR000150, UL1TR000077-04, UL1 TR000154, UL1TR001082, and UL1TR000040. GlaxoSmithKline provided Ventolin HFA, Flonase, Flovent, Advair under a clinical trial agreement with the NIH/NIAID.	[Anonymous], 2007, J ALLERGY CLIN IMMUN, V120, pS94, DOI 10.1016/j.jaci.2007.09.029; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P723, DOI 10.1111/j.1365-2222.2005.02251.x; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Celedon JC, 2001, AM J RESP CRIT CARE, V163, P1108, DOI 10.1164/ajrccm.163.5.2005086; Ciprandi G, 2004, ANN ALLERG ASTHMA IM, V93, P575, DOI 10.1016/S1081-1206(10)61266-5; Cruz AA, 2007, ALLERGY, V62, P1, DOI 10.1111/j.1398-9995.2007.01551.x; Durham SR, 2016, J ALLERGY CLIN IMMUN, V138, P1081, DOI 10.1016/j.jaci.2016.04.061; Gaugris S, 2006, J ASTHMA, V43, P1, DOI 10.1080/02770900500446823; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P185, DOI 10.2500/108854198778557836; Jacobs R, 2009, ALLERGY ASTHMA PROC, V30, P120, DOI 10.2500/aap.2009.30.3206; Kapsali T, 1997, J ALLERGY CLIN IMMUN, V99, P556; Kocabas CN, 2005, PEDIATR PULM, V40, P235, DOI 10.1002/ppul.20247; Leynaert N, 2004, J ALLERGY CLIN IMMUN, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Liu AH, 2016, J ALLERGY CLIN IMMUN, V138, P1042, DOI 10.1016/j.jaci.2016.06.060; Masuda S, 2008, PEDIAT ALLERG IMM-UK, V19, P517, DOI 10.1111/j.1399-3038.2007.00675.x; Meltzer EO, 2012, ALLERGY ASTHMA PROC, V33, P324, DOI 10.2500/aap.2012.33.3587; Oka A, 2017, J ALLER CL IMM-PRACT, V5, P160, DOI 10.1016/j.jaip.2016.08.002; Pongracic JA, 2016, J ALLERGY CLIN IMMUN, V138, P1030, DOI 10.1016/j.jaci.2016.06.059; Ponte EV, 2008, ALLERGY, V63, P564, DOI 10.1111/j.1398-9995.2007.01624.x; Revicki DA, 1998, QUAL LIFE RES, V7, P693, DOI 10.1023/A:1008860113818; Rondon C, 2012, J ALLERGY CLIN IMMUN, V129, P1460, DOI 10.1016/j.jaci.2012.02.032; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V135, P1465, DOI 10.1016/j.jaci.2014.12.1942; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Togias A, 2000, J ALLERGY CLIN IMMUN, V105, pS599, DOI 10.1067/mai.2000.106885; Webb DR, 2002, ANN ALLERG ASTHMA IM, V88, P385, DOI 10.1016/S1081-1206(10)62369-1; White P, 1998, CLIN EXP ALLERGY, V28, P266; Zoratti EM, 2016, J ALLERGY CLIN IMMUN, V138, P1016, DOI 10.1016/j.jaci.2016.06.061	27	34	36	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1003	+		10.1016/j.jaci.2018.07.041	http://dx.doi.org/10.1016/j.jaci.2018.07.041			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30213627	Bronze, Green Accepted			2022-12-18	WOS:000460272900020
J	Kack, U; Asarnoj, A; Gronlund, H; Borres, MP; van Hage, M; Lilja, G; Konradsen, JR				Kack, Ulrika; Asarnoj, Anna; Gronlund, Hans; Borres, Magnus P.; van Hage, Marianne; Lilja, Gunnar; Konradsen, Jon R.			Molecular allergy diagnostics refine characterization of children sensitized to dog dander	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; Can f 1; Can f 2; Can f 3; Can f 4; Can f 5; Can f 6; children; dog; IgE; molecular allergology; nasal provocation test; sensitization	SEVERE CHILDHOOD ASTHMA; FEL D 4; LIPOCALIN ALLERGEN; FURRY ANIMALS; IMMUNOLOGICAL CHARACTERIZATION; CROSS-REACTIVITY; NORTHERN SWEDEN; CAT; SCHOOLCHILDREN; POPULATION	Background: Sensitization to dog dander is an important risk factor for rhinoconjunctivitis and asthma but is not sufficient for diagnosing dog allergy. Molecular allergy diagnostics offer new opportunities for refined characterization. Objectives: We sought to study the association between sensitization to all presently known dog allergen components and clinical symptoms of dog allergy in children evaluated by using nasal provocation tests (NPTs). Methods: Sixty children (age, 10-18 years) sensitized to dog dander extract underwent NPTs with dog dander extract. Measurement of IgE levels to dog dander and to Can f 1, Can f 2, Can f 3, and Can f 5 was performed with ImmunoCAP, and measurement of IgE levels to Can f 4 and Can f 6 was performed with streptavidin ImmunoCAP. An IgE level of 0.1 kU(A)/L or greater was considered positive. Results: There was an association between sensitization to an increasing number of dog allergen components and a positive nasal challenge result (P = .01). Sensitization to lipocalins (odds ratio [OR], 6.0; 95% CI, 1.04-34.5), in particular Can f 4 (OR, 6.80; 95% CI 1.84-25.2) and Can f 6 (OR, 5.69; 95% CI, 1.59-20.8), was associated with a positive NPT result. Monosensitization to Can f 5 was related to a negative NPT result (OR, 5.78; 95% CI, 1.01-33.0). Conclusion: Sensitization to an increasing number of dog allergen components and to lipocalins is associated with dog allergy. Monosensitization to Can f 5 should not be regarded primarily as a marker for dog allergy.	[Kack, Ulrika; Lilja, Gunnar] Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, S1,Sjukhusbacken 10, S-11883 Stockholm, Sweden; [Asarnoj, Anna; Konradsen, Jon R.] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Gronlund, Hans] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Asarnoj, Anna; van Hage, Marianne; Konradsen, Jon R.] Karolinska Inst, Dept Med, Solna Immunol & Allergy Unit, Stockholm, Sweden; [Asarnoj, Anna; van Hage, Marianne; Konradsen, Jon R.] Karolinska Univ Hosp, Stockholm, Sweden; [Borres, Magnus P.] Thermo Fisher Sci, Uppsala, Sweden; [Borres, Magnus P.] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden	Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Thermo Fisher Scientific; Uppsala University	Kack, U (corresponding author), Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, S1,Sjukhusbacken 10, S-11883 Stockholm, Sweden.	ulrika.kack@sll.se	Konradsen, Jon/AAD-5620-2021; van Hage, Marianne/A-9678-2017; Asarnoj, Anna/ABC-4112-2020	Konradsen, Jon/0000-0001-7745-8624; van Hage, Marianne/0000-0003-3091-1596; Asarnoj, Anna/0000-0002-0797-2369	Swedish Asthma and Allergy Association's Research Foundation; Stockholm County Council (ALF project); Swedish Research Council; Swedish Heart-Lung Foundation; Swedish Cancer; Allergy Foundation; Hesselman foundation; Konsul Th C Bergh foundation; Karolinska Institutet; Stockholm County Council (post-doc)	Swedish Asthma and Allergy Association's Research Foundation; Stockholm County Council (ALF project)(Stockholm County Council); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Cancer; Allergy Foundation; Hesselman foundation; Konsul Th C Bergh foundation; Karolinska Institutet(Karolinska Institutet); Stockholm County Council (post-doc)(Stockholm County Council)	Supported by the Swedish Asthma and Allergy Association's Research Foundation, the Stockholm County Council (ALF project and clinical post-doc), the Swedish Research Council, the Swedish Heart-Lung Foundation, the Swedish Cancer and Allergy Foundation, the Hesselman foundation, the Konsul Th C Bergh foundation, and the Karolinska Institutet.	Agache I, 2015, ALLERGY, V70, P355, DOI 10.1111/all.12586; Asarnoj A, 2016, J ALLERGY CLIN IMMUN, V137, P813, DOI 10.1016/j.jaci.2015.09.052; Bjerg A, 2015, PEDIAT ALLERG IMM-UK, V26, P557, DOI 10.1111/pai.12422; Borres MP, 2011, PEDIAT ALLERG IMM-UK, V22, P454, DOI 10.1111/j.1399-3038.2011.01197.x; Carlsen KCL, 2006, ALLERGY, V61, P454, DOI 10.1111/j.1398-9995.2005.00938.x; Curin M, 2011, INT ARCH ALLERGY IMM, V154, P258, DOI 10.1159/000321113; de Blay F, 2015, ANN ALLERG ASTHMA IM, V115, P385, DOI 10.1016/j.anai.2015.07.014; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; Dordal MT, 2011, J INVEST ALLERG CLIN, V21, P1; Hilger C, 2012, J ALLERGY CLIN IMMUN, V129, P1149, DOI 10.1016/j.jaci.2011.10.017; Khurana T, 2016, ANN ALLERG ASTHMA IM, V116, P440, DOI 10.1016/j.anai.2016.02.006; Konradsen JR, 2015, J ALLERGY CLIN IMMUN, V135, P616, DOI 10.1016/j.jaci.2014.08.026; Konradsen JR, 2014, PEDIAT ALLERG IMM-UK, V25, P187, DOI 10.1111/pai.12198; Lebecque S, 1997, J ALLERGY CLIN IMMUN, V99, P374, DOI 10.1016/S0091-6749(97)70056-3; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; Liccardi G, 2011, CURR ALLERGY ASTHM R, V11, P421, DOI 10.1007/s11882-011-0214-7; Madhurantakam C, 2010, J MOL BIOL, V401, P68, DOI 10.1016/j.jmb.2010.05.043; Mattsson L, 2010, CLIN EXP ALLERGY, V40, P1276, DOI 10.1111/j.1365-2222.2010.03533.x; Mattsson L, 2009, J ALLERGY CLIN IMMUN, V123, P362, DOI 10.1016/j.jaci.2008.11.021; Nagao Mizuho, 2017, Clin Mol Allergy, V15, P4, DOI 10.1186/s12948-017-0061-8; Nilsson OB, 2012, ALLERGY, V67, P751, DOI 10.1111/j.1398-9995.2012.02826.x; Nilsson OB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111041; Nilsson OB, 2014, METHODS, V66, P86, DOI 10.1016/j.ymeth.2013.09.002; Nordlund B, 2012, ALLERGY, V67, P661, DOI 10.1111/j.1398-9995.2012.02797.x; Pepper AN, 2018, J ALLERGY CLIN IMMUN, V141, P1570, DOI 10.1016/j.jaci.2017.11.066; Perzanowski MS, 2016, J ALLERGY CLIN IMMUN, V138, P1582, DOI 10.1016/j.jaci.2016.05.017; Polovic N, 2013, ALLERGY, V68, P585, DOI 10.1111/all.12130; Ronmark E, 2009, J ALLERGY CLIN IMMUN, V124, P357, DOI 10.1016/j.jaci.2009.05.011; Rytkonen-Nissinen M, 2015, ALLERGY ASTHMA IMMUN, V7, P384, DOI 10.4168/aair.2015.7.4.384; Schoos AMM, 2016, J ALLERGY CLIN IMMUN, V137, P1277, DOI 10.1016/j.jaci.2015.09.035; Schoos AMM, 2017, J ALLER CL IMM-PRACT, V5, P1754, DOI 10.1016/j.jaip.2017.03.028; Spitzauer S, 1995, J ALLERGY CLIN IMMUN, V96, P951, DOI 10.1016/S0091-6749(95)70233-4; Uriarte SA, 2016, ALLERGY, V71, P1066, DOI 10.1111/all.12917; ZWEIG MH, 1993, CLIN CHEM, V39, P561	34	34	35	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1113	+		10.1016/j.jaci.2018.05.012	http://dx.doi.org/10.1016/j.jaci.2018.05.012			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29852259	Bronze			2022-12-18	WOS:000446327300012
J	Tost, J				Tost, Jorg			A translational perspective on epigenetics in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Epigenetics; DNA methylation; microRNA; biomarker; allergy; asthma; forkhead protein 3; epigenetic editing; antagomirs; antisense molecules; oligonucleotide therapy	REGULATORY T-CELLS; EPIGENOME-WIDE ASSOCIATION; DNA METHYLATION; FOOD ALLERGY; HISTONE DEACETYLASES; AIRWAY INFLAMMATION; MICRORNA EXPRESSION; MILK ALLERGY; FATTY-ACIDS; ASTHMA	The analysis of epigenetic modifications in allergic diseases has recently attracted substantial interest because epigenetic modifications can mediate the effects of the environment on the development of or protection from allergic diseases. Furthermore, recent research has provided evidence for an altered epigenomic landscape in disease-relevant cell populations. Although still in the early phase, epigenetic modifications, particularly DNA methylation and microRNAs, might have potential for assisting in the stratification of patients for treatment and complement or replace in the future biochemical or clinical tests. The first epigenetic biomarkers correlating with the successful outcome of immunotherapy have been reported, and with personalized treatment options being rolled out, epigenetic modifications might well play a role in monitoring or even predicting the response to tailored therapy. However, further studies in larger cohorts with well-defined phenotypes in specific cell populations need to be performed before their implementation. Furthermore, the epigenome provides an interesting target for therapeutic intervention, with microRNA mimics, inhibitors, and antisense oligonucleotides being evaluated in clinical trials in patients with other diseases. Selection or engineering of populations of extracellular vesicles and epigenetic editing represent novel tools for modulation of the cellular phenotype and responses, although further technological improvements are required. Moreover, interactions between the host epigenome and the microbiome are increasingly recognized, and interventions of the microbiome could contribute to modulation of the epigenome with a potential effect on the overall goal of prevention of allergic diseases.	[Tost, Jorg] CEA, Lab Epigenet & Environm, Ctr Natl Rech Genom Humaine, Inst Biol Francois Jacob, Batiment G2,2 Rue Gaston Cremieux, F-91000 Evry, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Tost, J (corresponding author), CEA, Lab Epigenet & Environm, Ctr Natl Rech Genom Humaine, Inst Biol Francois Jacob, Batiment G2,2 Rue Gaston Cremieux, F-91000 Evry, France.	tost@cng.fr	Tost, Joerg/H-7129-2019	Tost, Joerg/0000-0002-2683-0817	DBV Technologies; ANR [ANR-13-EPIG-0003-05, ANR-13-CESA-0011-05]; Aviesan/INSERM [EPIG2014-01, EPlG2014-18]; INCa [PRT-K14-049]; Sirius research award (UCB Pharma S.A.); Passerelle research award (Pfizer); iCARE (MSD Avenir)	DBV Technologies; ANR(French National Research Agency (ANR)); Aviesan/INSERM; INCa(Institut National du Cancer (INCA) France); Sirius research award (UCB Pharma S.A.); Passerelle research award (Pfizer); iCARE (MSD Avenir)	Work on food allergy in the laboratory of J. Tost is partially funded by DBV Technologies, and J. Tost had conference and travel fees covered by DBV Technologies. The work in the laboratory of J. Tost is further supported by the following grants unrelated to the presented work: ANR (ANR-13-EPIG-0003-05 and ANR-13-CESA-0011-05), Aviesan/INSERM (EPIG2014-01 and EPlG2014-18), INCa (PRT-K14-049), a Sirius research award (UCB Pharma S.A.), a Passerelle research award (Pfizer), iCARE (MSD Avenir), and the institutional budget of the CNRGH. Z. K. Ballas (editor) disclosed no relevant financial relationships.	Alhamwe BA, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0259-4; Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59; Amarasekera M, 2014, EPIGENETICS-US, V9, P1570, DOI 10.4161/15592294.2014.983366; Andorf S, 2018, LANCET GASTROENTEROL, V3, P85, DOI 10.1016/S2468-1253(17)30392-8; Arathimos R, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0414-7; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y; Berthon BS, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00180-2017; Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Bisgaard H, 2016, NEW ENGL J MED, V375, P2530, DOI 10.1056/NEJMoa1503734; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Brick T, 2016, J ALLERGY CLIN IMMUN, V137, P1699, DOI 10.1016/j.jaci.2015.10.042; Brook PO, 2015, EPIGENOMICS-UK, V7, P1017, DOI 10.2217/epi.15.53; Brunst KJ, 2013, J ALLERGY CLIN IMMUN, V131, P592, DOI 10.1016/j.jaci.2012.10.042; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V138, P1122, DOI 10.1016/j.jaci.2016.03.041; Canas JA, 2018, CLIN EXP ALLERGY; Choudhuri K, 2014, NATURE, V507, P118, DOI 10.1038/nature12951; Cohen JD, 2017, P NATL ACAD SCI USA, V114, P10202, DOI 10.1073/pnas.1704961114; Colley T, 2016, J ALLERGY CLIN IMMUN, V137, P1595, DOI 10.1016/j.jaci.2015.10.013; Collison A, 2011, J ALLERGY CLIN IMMUN, V128, P160, DOI 10.1016/j.jaci.2011.04.005; Cortese R, 2016, EPIGENETICS-US, V11, P205, DOI 10.1080/15592294.2016.1155011; Dantzer JA, 2018, CLIN EXP ALLERGY, V48, P232, DOI 10.1111/cea.13084; Dong XY, 2016, INT J MOL MED, V38, P446, DOI 10.3892/ijmm.2016.2634; Du Toit G, 2018, J ALLERGY CLIN IMMUN, V141, P30, DOI 10.1016/j.jaci.2017.11.010; Elbehidy RM, 2016, MOL IMMUNOL, V71, P107, DOI 10.1016/j.molimm.2015.12.015; Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Galonska C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02708-5; Gon Y, 2017, CLIN EXP ALLERGY, V47, P1586, DOI 10.1111/cea.13016; Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P72, DOI 10.1016/j.semcdb.2015.02.009; Gruzieva O, 2017, ENVIRON HEALTH PERSP, V125, P104, DOI 10.1289/EHP36; Gupta R, 2013, JAMA PEDIATR, V167, P1026, DOI 10.1001/jamapediatrics.2013.2376; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Harb H, 2017, BIOSCIENCE REP, V37, DOI [10.1042/bsr20160485, 10.1042/BSR20160485]; Heffler E, 2017, AM J RESP CELL MOL, V57, P642, DOI 10.1165/rcmb.2016-0231TR; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Hilton IB, 2015, NAT BIOTECHNOL, V33, P510, DOI 10.1038/nbt.3199; Homburg U, 2015, J ALLERGY CLIN IMMUN, V136, P797, DOI 10.1016/j.jaci.2015.02.018; Hong XM, 2016, J ALLERGY CLIN IMMUN, V138, P908, DOI 10.1016/j.jaci.2016.01.056; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Jang HY, 2016, J ALLERGY CLIN IMMUN, V138, P1452, DOI 10.1016/j.jaci.2016.05.019; Jardim MJ, 2012, AM J RESP CELL MOL, V47, P536, DOI 10.1165/rcmb.2011-0160OC; Joubert BR, 2016, AM J HUM GENET, V98, P680, DOI 10.1016/j.ajhg.2016.02.019; Kearns NA, 2015, NAT METHODS, V12, P401, DOI 10.1038/nmeth.3325; Kit AH, 2012, BIOCHIMIE, V94, P2314, DOI 10.1016/j.biochi.2012.07.014; Kobayashi Y, 2014, CHEST, V145, P305, DOI 10.1378/chest.13-0835; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Kulshreshtha A, 2013, J ALLERGY CLIN IMMUN, V131, P1194, DOI 10.1016/j.jaci.2012.12.1565; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Levanen B, 2013, J ALLERGY CLIN IMMUN, V131, P894, DOI 10.1016/j.jaci.2012.11.039; Liang LM, 2015, NATURE, V520, P670, DOI 10.1038/nature14125; Liu XS, 2016, CELL, V167, P233, DOI 10.1016/j.cell.2016.08.056; Liu YC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6393; Lu TX, 2012, J ALLERGY CLIN IMMUN, V129, P1064, DOI 10.1016/j.jaci.2012.01.060; Luo Y, 2014, CLIN EXP DERMATOL, V39, P48, DOI 10.1111/ced.12206; Maes T, 2016, J ALLERGY CLIN IMMUN, V137, P1433, DOI 10.1016/j.jaci.2016.02.018; Malmhall C, 2014, J ALLERGY CLIN IMMUN, V133, P1429, DOI 10.1016/j.jaci.2013.11.008; Martino D, 2015, J ALLERGY CLIN IMMUN, V135, P1319, DOI 10.1016/j.jaci.2014.12.1933; Martino D, 2014, EPIGENETICS-US, V9, P998, DOI 10.4161/epi.28945; Milger K, 2017, ALLERGY, V72, P1962, DOI 10.1111/all.13205; Mondoulet L, 2018, ALLERGY; Nestor CE, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004059; Nicodemus-Johnson J, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.90151; Obata Y, 2014, NAT IMMUNOL, V15, P571, DOI 10.1038/ni.2886; Oh KS, 2017, IMMUNITY, V47, P298, DOI 10.1016/j.immuni.2017.07.012; Ohno S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020172; Okoye IS, 2014, P NATL ACAD SCI USA, V111, pE3081, DOI 10.1073/pnas.1406322111; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Panganiban RPL, 2012, AM J CLIN EXP IMMUNO, V1, P154; Paparo L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0252-z; Park J, 2015, MUCOSAL IMMUNOL, V8, P80, DOI 10.1038/mi.2014.44; Petrus NCM, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0105-z; Pinkerton M, 2013, J ALLERGY CLIN IMMUN, V132, P217, DOI 10.1016/j.jaci.2013.03.006; Pitt JM, 2016, J CLIN INVEST, V126, P1224, DOI 10.1172/JCI81137; Potaczek DP, 2017, EPIGENOMICS-UK, V9, P539, DOI 10.2217/epi-2016-0162; Potaczek DP, 2016, J ALLERGY CLIN IMMUN, V137, P1334, DOI 10.1016/j.jaci.2015.12.1344; Qin HB, 2012, INFLAMMATION, V35, P1595, DOI 10.1007/s10753-012-9474-1; Renz H, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.98; Robbins PD, 2016, J CLIN INVEST, V126, P1173, DOI 10.1172/JCI81131; Rothenberg Marc E, 2016, Cell, V165, P509, DOI 10.1016/j.cell.2016.04.020; Royce SG, 2014, CURR OPIN ALLERGY CL, V14, P44, DOI 10.1097/ACI.0000000000000029; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Sastre B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00826; Savage JH, 2018, ALLERGY, V73, P145, DOI 10.1111/all.13232; Seumois G, 2014, NAT IMMUNOL, V15, P777, DOI 10.1038/ni.2937; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Solberg OD, 2012, AM J RESP CRIT CARE, V186, P965, DOI 10.1164/rccm.201201-0027OC; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Stefanowicz D, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0371-0; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tay FC, 2015, ADV DRUG DELIVER REV, V81, P117, DOI 10.1016/j.addr.2014.05.010; Thakore PI, 2016, NAT METHODS, V13, P127, DOI [10.1038/NMETH.3733, 10.1038/nmeth.3733]; Thakore PI, 2015, NAT METHODS, V12, P1143, DOI 10.1038/nmeth.3630; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Thio CL, 2018, J ALLERGY CLIN IMMUN; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Thorburn AN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8320; Toker A, 2013, J IMMUNOL, V190, P3180, DOI 10.4049/jimmunol.1203473; Tost J, 2016, EPIGENOMICS-UK, V8, P153, DOI 10.2217/epi.15.112; Tremblay BL, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0345-3; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van den Bosch T, 2017, EPIGENOMICS-UK, V9, P1013, DOI 10.2217/epi-2017-0027; van Zandwijk N, 2017, LANCET ONCOL, V18, P1386, DOI 10.1016/S1470-2045(17)30621-6; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; Wesemann DR, 2016, IMMUNITY, V44, P728, DOI 10.1016/j.immuni.2016.02.002; Woo V, 2017, CURR OPIN IMMUNOL, V44, P52, DOI 10.1016/j.coi.2016.12.001; Wu CJ, 2013, INT ARCH ALLERGY IMM, V160, P356, DOI 10.1159/000343030; Xiao C, 2015, J ALLERGY CLIN IMMUN, V136, P923, DOI 10.1016/j.jaci.2015.01.045; Xie GG, 2018, J ALLERGY CLIN IMMUN, V141, P788, DOI 10.1016/j.jaci.2017.07.040; Xu CJ, 2018, LANCET RESP MED, V6, P379, DOI 10.1016/S2213-2600(18)30052-3; Yamamoto M, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-655; Yang IV, 2017, J ALLERGY CLIN IMMUN, V140, P14, DOI 10.1016/j.jaci.2017.05.011; Yang IV, 2017, J ALLERGY CLIN IMMUN, V139, P1478, DOI 10.1016/j.jaci.2016.07.036; Yang IV, 2017, AM J RESP CRIT CARE, V195, P829, DOI 10.1164/rccm.201608-1558LE; Zhang X, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186150	127	34	37	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					715	726		10.1016/j.jaci.2018.07.009	http://dx.doi.org/10.1016/j.jaci.2018.07.009			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	30195377	Bronze			2022-12-18	WOS:000443726500001
J	Molina-Infante, J; Lucendo, AJ				Molina-Infante, Javier; Lucendo, Alfredo J.			Dietary therapy for eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; diet; food allergy; milk; wheat; egg	6-FOOD ELIMINATION DIET; CAUSATIVE FOODS; ADULT PATIENTS; CHILDREN; EFFICACY; REMISSION; ALLERGY; RECOMMENDATIONS; IDENTIFICATION; INFLAMMATION	Eosinophilic esophagitis is a chronic, immune-mediated esophageal disease triggered predominantly, but not exclusively, by food antigens. Presently, available food allergy tests are suboptimal to predict food triggers for eosinophilic esophagitis, especially in adults. Elemental diets (exclusive feeding with amino acid-based formulas) and empiric 6-food elimination diets (withdrawing milk, wheat, egg, soy, nuts, and fish/seafood for 6 weeks) have consistently shown the best efficacy rates. However, their high level of restriction and need for multiple endoscopies have hampered their implementation in clinical practice. Currently, milk, wheat/gluten, and egg are the most common food triggers in children and adults from the United States, Spain, and Australia. Hence less restrictive empiric schemes, such as a 4-food elimination diet (dairy, gluten-containing cereals, egg, and legumes) or a 2-food elimination diet (dairy and gluten-containing cereals) have been lately developed with good efficacy rates (2-food elimination diet, 43%; 4-food elimination diet in adults, 54%; and 4-food elimination diet in children, 64%). A step-up approach (2-4-6) might result in prompt recognition of a majority of responders with few food triggers, reducing the number of endoscopies and costs and shortening the diagnostic process. Standardization of food reintroduction, novel food allergy testing, and studies evaluating a milk elimination diet in children and the long-term outcomes of dietary interventions are warranted.	[Molina-Infante, Javier] Hosp Univ San Pedro de Alcantara, Dept Gastroenterol, C Pablo Naranjo S-N, Caceres 10003, Spain; [Molina-Infante, Javier; Lucendo, Alfredo J.] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain; [Lucendo, Alfredo J.] Hosp Gen Tomelloso CIBEREHD, Dept Gastroenterol, Tomelloso, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD	Molina-Infante, J (corresponding author), Hosp Univ San Pedro de Alcantara, Dept Gastroenterol, C Pablo Naranjo S-N, Caceres 10003, Spain.	xavi_molina@hotmail.com	Lucendo, Alfredo J/C-1958-2009	Lucendo, Alfredo J/0000-0003-1183-1072				Alcedo J, 2017, J ALLERGY CLIN IMMUN; Arias A, 2014, GASTROENTEROLOGY, V146, P1639, DOI 10.1053/j.gastro.2014.02.006; ATTWOOD SEA, 1993, DIGEST DIS SCI, V38, P109, DOI 10.1007/BF01296781; Clayton F, 2014, GASTROENTEROLOGY, V147, P602, DOI 10.1053/j.gastro.2014.05.036; Delaney AL, 2008, DEV DISABIL RES REV, V14, P105, DOI 10.1002/ddrr.16; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Groetch M, 2017, J ALLER CL IMM-PRACT, V5, P312, DOI 10.1016/j.jaip.2016.12.026; Halmos EP, 2015, GUT, V64, P93, DOI 10.1136/gutjnl-2014-307264; Henderson CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1570, DOI 10.1016/j.jaci.2012.03.023; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kagalwalla AF, 2017, CLIN GASTROENTEROL H, V15, P1698, DOI 10.1016/j.cgh.2017.05.048; Kagalwalla AF, 2012, J PEDIATR GASTR NUTR, V55, P711, DOI 10.1097/MPG.0b013e318268da40; Kagalwalla AF, 2011, J PEDIATR GASTR NUTR, V53, P145, DOI 10.1097/MPG.0b013e31821cf503; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Kliewer KL, 2016, J ALLERGY CLIN IMMUN, V137, P1011, DOI 10.1016/j.jaci.2015.10.040; Kliewer KL, 2017, CLIN REV ALLERGY IMM; Kruszewski PG, 2016, DIS ESOPHAGUS, V29, P377, DOI 10.1111/dote.12339; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2017, UNITED EUR GASTROENT, V5, P335, DOI 10.1177/2050640616689525; Lucendo AJ, 2014, ANN ALLERG ASTHMA IM, V113, P624, DOI 10.1016/j.anai.2014.08.004; Lucendo AJ, 2013, J ALLERGY CLIN IMMUN, V131, P797, DOI 10.1016/j.jaci.2012.12.664; Molina-Infante J, 2017, EXPERT REV GASTROENT, V11, P115, DOI 10.1080/17474124.2017.1271324; Molina-Infante J, 2014, J ALLERGY CLIN IMMUN, V134, P1093, DOI 10.1016/j.jaci.2014.07.023; Molina-Infante J, 2012, J ALLERGY CLIN IMMUN, V130, P1200, DOI 10.1016/j.jaci.2012.06.027; O'Shea KM, 2018, GASTROENTEROLOGY, V154, P333, DOI 10.1053/j.gastro.2017.06.065; Peterson KA, 2013, AM J GASTROENTEROL, V108, P759, DOI 10.1038/ajg.2012.468; Philpott H, 2016, ALIMENT PHARM THER, V44, P223, DOI 10.1111/apt.13676; Philpott H, 2016, ALIMENT PHARM THER, V43, P985, DOI 10.1111/apt.13576; Reed CC, 2017, ALIMENT PHARM THER, V46, P836, DOI 10.1111/apt.14290; Rodriguez-Sanchez J, 2014, ALLERGY, V69, P936, DOI 10.1111/all.12420; Simon D, 2016, ALLERGY, V71, P611, DOI 10.1111/all.12846; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; van Rhijn BD, 2015, J ALLERGY CLIN IMMUN, V136, P1095, DOI 10.1016/j.jaci.2015.02.038; Warners MJ, 2017, ALIMENT PHARM THER, V45, P777, DOI 10.1111/apt.13953; Warners MJ, 2018, GASTROENTEROLOGY, V154, P57, DOI 10.1053/j.gastro.2017.08.062; Wolf WA, 2014, CLIN GASTROENTEROL H, V12, P1272, DOI 10.1016/j.cgh.2013.12.034; Wright BL, 2016, J ALLERGY CLIN IMMUN, V138, P1190, DOI 10.1016/j.jaci.2016.02.024	38	34	33	3	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					41	47		10.1016/j.jaci.2018.02.028	http://dx.doi.org/10.1016/j.jaci.2018.02.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29522850				2022-12-18	WOS:000437837500005
J	Senechal, H; Santrucek, J; Melcova, M; Svoboda, P; Zidkova, J; Charpin, D; Guilloux, L; Shahali, Y; Selva, MA; Couderc, R; Aizawa, T; Poncet, P				Senechal, Helene; Santrucek, Jiri; Melcova, Magdalena; Svoboda, Petr; Zidkova, Jarmila; Charpin, Denis; Guilloux, Laurence; Shahali, Youcef; Selva, Marie-Ange; Couderc, Remy; Aizawa, Tomoyasu; Poncet, Pascal			A new allergen family involved in pollen food-associated syndrome: Snakin/gibberellin-regulated proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							B-CELL; COHESIN; CTCF; REPERTOIRE; FEATURES; COHORT; NIPBL; RAG2		[Senechal, Helene; Selva, Marie-Ange; Couderc, Remy; Poncet, Pascal] Armand Trousseau Children Hosp, AP HP, Allergy & Environm Res Team, Biochem Dept, Paris, France; [Santrucek, Jiri; Melcova, Magdalena; Svoboda, Petr; Zidkova, Jarmila] Univ Chem & Technol, Prague, Czech Republic; [Charpin, Denis] Aix Marseille Univ, North Hosp, Dept Pneumonol & Allergy, Marseille, France; [Charpin, Denis] Aix Marseille Univ, INSERM, UMR 600, Marseille, France; [Guilloux, Laurence] Eurofins Biomnis, Lyon, France; [Shahali, Youcef] Agr Res Educ & Extens Org Karaj, Razi Vaccine & Serum Res Inst, Karaj, Iran; [Aizawa, Tomoyasu] Hokkaido Univ, Grad Sch Life Sci, Sapporo, Hokkaido, Japan; [Aizawa, Tomoyasu] Hokkaido Univ, Global Inst Collaborat Res & Educ, Sapporo, Hokkaido, Japan; [Poncet, Pascal] Pasteur Inst, Ctr Innovat & Technol Res, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Chemistry & Technology, Prague; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Razi Vaccine & Serum Research Institute; Hokkaido University; Hokkaido University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Poncet, P (corresponding author), Armand Trousseau Children Hosp, AP HP, Allergy & Environm Res Team, Biochem Dept, Paris, France.; Poncet, P (corresponding author), Pasteur Inst, Ctr Innovat & Technol Res, Paris, France.	pascal.poncet@pasteur.fr	Shahali, Youcef/Q-6431-2018; Poncet, Pascal/ABD-5096-2020; Svoboda, Petr/B-7865-2014; Aizawa, Tomoyasu/F-5278-2011	Shahali, Youcef/0000-0003-3188-4374; Svoboda, Petr/0000-0001-7297-4208; Aizawa, Tomoyasu/0000-0001-9134-7576	"Partenariat Hubert Curien Barrande" from the French ministry of Foreign Affairs; "Partenariat Hubert Curien Barrande" from the French ministry of National and Higher Education and Research; Czech Ministry of Education, Youth and Sports; Specific University Research by the Czech Ministry of Education, Youth and Sports [20/2016]	"Partenariat Hubert Curien Barrande" from the French ministry of Foreign Affairs; "Partenariat Hubert Curien Barrande" from the French ministry of National and Higher Education and Research; Czech Ministry of Education, Youth and Sports(Ministry of Education, Youth & Sports - Czech Republic); Specific University Research by the Czech Ministry of Education, Youth and Sports	The study was financially supported by the "Partenariat Hubert Curien Barrande" from the French ministries of Foreign Affairs and National and Higher Education and Research and the Czech Ministry of Education, Youth and Sports. This work was also supported by a grant from Specific University Research (grant no. 20/2016) by the Czech Ministry of Education, Youth and Sports.	Borck G, 2007, HUM MUTAT, V28, DOI 10.1002/humu.9478; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Charpin D, 2017, CLIN REV ALLERGY IMM; Degner SC, 2011, P NATL ACAD SCI USA, V108, P9566, DOI 10.1073/pnas.1019391108; Degner SC, 2009, J IMMUNOL, V182, P44, DOI 10.4049/jimmunol.182.1.44; Du LK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002482; Enervald E, 2013, J EXP MED, V210, P2503, DOI 10.1084/jem.20130168; Giudicelli Veronique, 2011, Cold Spring Harb Protoc, V2011, P695, DOI 10.1101/pdb.prot5633; Guo CG, 2011, NATURE, V477, P424, DOI 10.1038/nature10495; Inomata N, 2017, J DERMATOL; Inuo C, 2015, INT ARCH ALLERGY IMM, V167, P137, DOI 10.1159/000437325; Jyonouchi S, 2013, PEDIATRICS, V132, pE484, DOI 10.1542/peds.2012-3815; Kuddus MR, 2016, PROTEIN EXPRES PURIF, V122, P15, DOI 10.1016/j.pep.2016.02.002; Lescale C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10529; Liang HE, 2002, IMMUNITY, V17, P639, DOI 10.1016/S1074-7613(02)00448-X; Liu JL, 2010, ADV EXP MED BIOL, V685, P111; Mahlapuu M, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00194; Martinez S, 2015, 34 EAACI M JUN 6; Mehta GD, 2013, FEBS LETT, V587, P2299, DOI 10.1016/j.febslet.2013.06.035; Nahirnak V, 2012, PLANT SIGNAL BEHAV, V7, P1004, DOI 10.4161/psb.20813; Pie J, 2010, AM J MED GENET A, V152A, P924, DOI 10.1002/ajmg.a.33348; Schoumans J, 2007, EUR J HUM GENET, V15, P143, DOI 10.1038/sj.ejhg.5201737; Shahali Y, 2014, FOLIA BIOL-PRAGUE, V60, P192; Truong van ut C, 2012, REV FR ALLERGOL, V52, P429; Tuppo L, 2013, CLIN EXP ALLERGY, V43, P128, DOI 10.1111/cea.12028; Tuppo L, 2017, J AGR FOOD CHEM, V65, P2702, DOI 10.1021/acs.jafc.7b00092; Werfel T, 2015, ALLERGY, V70, P1079, DOI 10.1111/all.12666; Wu YC, 2010, BLOOD, V116, P1070, DOI 10.1182/blood-2010-03-275859; Yang Y, 2015, ELIFE, V4, DOI 10.7554/eLife.09083	30	34	34	2	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					411	+		10.1016/j.jaci.2017.06.041	http://dx.doi.org/10.1016/j.jaci.2017.06.041			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28782634	Green Submitted, Bronze			2022-12-18	WOS:000419312200049
J	Reddy, VB; Graham, TA; Azimi, E; Lerner, EA				Reddy, Vemuri B.; Graham, Thomas A.; Azimi, Ehsan; Lerner, Ethan A.			A single amino acid in MRGPRX2 necessary for binding and activation by pruritogens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RECEPTOR; LL-37; MRGX2		[Reddy, Vemuri B.; Azimi, Ehsan; Lerner, Ethan A.] Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; [Reddy, Vemuri B.; Azimi, Ehsan; Lerner, Ethan A.] Harvard Med Sch, Charlestown, MA 02129 USA; [Graham, Thomas A.] Carle Fdn Hosp, Urbana, IL USA; [Graham, Thomas A.] Mid Florida Dermatol & Plast Surg, Orlando, FL USA	Harvard University; Massachusetts General Hospital	Lerner, EA (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.; Lerner, EA (corresponding author), Harvard Med Sch, Charlestown, MA 02129 USA.	elerner@mgh.harvard.edu		Lerner, Ethan/0000-0001-5480-4133	National Eczema Association; National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR057744, R21AR067399]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR057744, R21AR067399] Funding Source: NIH RePORTER	National Eczema Association; National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	E.A. is the recipient of a grant from the National Eczema Association. Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant nos. R01AR057744 and R21AR067399 to E.A. L.).	Azimi E, 2017, J ALLERGY CLIN IMMUN; Azimi E, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89362; Kallberg M, 2014, METHODS MOL BIOL, V1137, P17, DOI 10.1007/978-1-4939-0366-5_2; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; Lansu K, 2017, NAT CHEM BIOL, V13, P529, DOI [10.1038/NCHEMBIO.2334, 10.1038/nchembio.2334]; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Robas N, 2003, J BIOL CHEM, V278, P44400, DOI 10.1074/jbc.M302456200; Subramanian H, 2011, J BIOL CHEM, V286, P44739, DOI 10.1074/jbc.M111.277152; Umehara Y, 2015, J INVEST DERMATOL, V135, P2887, DOI 10.1038/jid.2015.243	11	34	34	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1726	1728		10.1016/j.jaci.2017.05.046	http://dx.doi.org/10.1016/j.jaci.2017.05.046			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28689793	Green Accepted, Bronze			2022-12-18	WOS:000417206000035
J	Cunha, C; Goncalves, SM; Duarte-Oliveira, C; Leite, L; Lagrou, K; Marques, AO; Lupianez, CB; Mesquita, I; Gaifem, J; Barbosa, AM; Vaz, CP; Branca, R; Campilho, F; Freitas, F; Ligeiro, D; Lass-Florl, C; Loffler, J; Jurado, M; Saraiva, M; Kurzai, O; Rodrigues, F; Castro, AG; Silvestre, R; Sainz, J; Maertens, JA; Torrado, E; Jacobsen, ID; Lacerda, JF; Campos, A; Carvalho, A				Cunha, Cristina; Goncalves, Samuel M.; Duarte-Oliveira, Claudio; Leite, Luis; Lagrou, Katrien; Marques, Antonio; Lupianez, Carmen B.; Mesquita, Ines; Gaifem, Joana; Barbosa, Ana Margarida; Vaz, Carlos Pinho; Branca, Rosa; Campilho, Fernando; Freitas, Fatima; Ligeiro, Dario; Lass-Floerl, Cornelia; Loffler, Jurgen; Jurado, Manuel; Saraiva, Margarida; Kurzai, Oliver; Rodrigues, Fernando; Castro, Antonio G.; Silvestre, Ricardo; Sainz, Juan; Maertens, Johan A.; Torrado, Egidio; Jacobsen, Ilse D.; Lacerda, Joao F.; Campos, Antonio, Jr.; Carvalho, Agostinho			IL-10 overexpression predisposes to invasive aspergillosis by suppressing antifungal immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IDENTIFICATION; CLINICIAN; DISEASE; GUIDE		[Cunha, Cristina; Goncalves, Samuel M.; Duarte-Oliveira, Claudio; Mesquita, Ines; Gaifem, Joana; Barbosa, Ana Margarida; Rodrigues, Fernando; Castro, Antonio G.; Silvestre, Ricardo; Torrado, Egidio; Carvalho, Agostinho] Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; [Cunha, Cristina; Goncalves, Samuel M.; Duarte-Oliveira, Claudio; Mesquita, Ines; Gaifem, Joana; Barbosa, Ana Margarida; Rodrigues, Fernando; Castro, Antonio G.; Silvestre, Ricardo; Torrado, Egidio; Carvalho, Agostinho] ICVS 3B, PT Govt Associate Lab, Braga, Portugal; [Leite, Luis; Vaz, Carlos Pinho; Branca, Rosa; Campilho, Fernando; Campos, Antonio, Jr.] Inst Portugues Oncol Francisco Gentil, Serv Transplant Medula Ossea, Oporto, Portugal; [Lagrou, Katrien] KU Leuven Univ, Dept Microbiol & Immunol, Leuven, Belgium; [Lagrou, Katrien] Univ Hosp Leuven, Dept Lab Med, Leuven, Belgium; [Lagrou, Katrien] Univ Hosp Leuven, Natl Reference Ctr Med Mycol, Leuven, Belgium; [Maertens, Johan A.] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium; [Marques, Antonio] Hosp Braga, Serv Imunohemoterapia, Braga, Portugal; [Lupianez, Carmen B.; Sainz, Juan] Univ Granada, Andalusian Reg Gov, Pfizer,PTS, Ctr Genom & Oncol Res,GENYO,Genom Oncol Area, Granada, Spain; [Lupianez, Carmen B.; Jurado, Manuel; Sainz, Juan] Virgen de las Nieves Univ Hosp, Hematol Dept, Granada, Spain; [Freitas, Fatima] Inst Portugues Sangue & Transplant, Oporto, Portugal; [Ligeiro, Dario] Inst Portugues Sangue & Transplant, Lisbon, Portugal; [Lass-Floerl, Cornelia] Med Univ Innsbruck, Div Hyg & Med Microbiol, Innsbruck, Austria; [Loffler, Jurgen] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany; [Saraiva, Margarida] Univ Porto, I3S Inst Invest Inovacao Saude, Oporto, Portugal; [Saraiva, Margarida] Univ Porto, IBMC, Oporto, Portugal; [Kurzai, Oliver] Friedrich Schiller Univ, Sept Res Ctr, Jena, Germany; [Jacobsen, Ilse D.] Friedrich Schiller Univ, Res Grp Microbial Immunol, Jena, Germany; [Jacobsen, Ilse D.] Leibniz Inst Nat Prod Res & Infect Biol, Hans Knoll Inst, Jena, Germany; [Lacerda, Joao F.] Inst Med Mol, Fac Med Lisboa, r, Lisbon, Portugal; [Lacerda, Joao F.] Hosp Santa Maria, Serv Hematol & Transplant Medula, s, Lisbon, Portugal	Universidade do Minho; Portuguese Institute of Oncology; KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; Hospital de Braga; Pfizer; University of Granada; Hospital Universitario Virgen de las Nieves; Medical University of Innsbruck; University of Wurzburg; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Hans Knoll Institute (HKI); Universidade de Lisboa; Universidade de Lisboa; Hospital Santa Maria	Carvalho, A (corresponding author), Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal.; Carvalho, A (corresponding author), ICVS 3B, PT Govt Associate Lab, Braga, Portugal.	agostinhocarvalho@med.uminho.pt	Castro, Gil/T-7584-2018; Carvalho, Agostinho/D-2667-2009; Cunha, Cristina/AAH-9951-2021; Lass-Flörl, Cornelia/AAA-8449-2020; Rodrigues, Fernando/T-5299-2018; Jacobsen, Ilse/B-3155-2011; Duarte-Oliveira, Cláudio/F-7119-2017; Cunha, Cristina/D-2687-2009; Saraiva, Margarida/E-8781-2011; Torrado, Egídio/T-5156-2018; Juan, Sainz/Y-6473-2019; Silvestre, Ricardo/C-7243-2011	Castro, Gil/0000-0002-4684-4183; Carvalho, Agostinho/0000-0001-8935-8030; Cunha, Cristina/0000-0002-6002-5782; Rodrigues, Fernando/0000-0001-8436-9398; Jacobsen, Ilse/0000-0002-6033-9984; Duarte-Oliveira, Cláudio/0000-0002-8540-0753; Cunha, Cristina/0000-0002-6002-5782; Saraiva, Margarida/0000-0002-8180-1293; Torrado, Egídio/0000-0002-7462-8234; Juan, Sainz/0000-0002-9355-2423; Silvestre, Ricardo/0000-0002-9270-2717; Ligeiro, Dario/0000-0001-5306-3679; Lacerda, Joao/0000-0003-1351-2809; Gaifem, Joana/0000-0001-7306-7378; Goncalves, Samuel/0000-0001-5056-4718; Lass-Florl, Cornelia/0000-0002-2946-7785	Northern Portugal Regional Operational Programme (NORTE), under the Portugal Partnership Agreement, through the European Regional Development Fund (FEDER) [NORTE-01-0145-FEDER-000013]; Fundacao para a Ciencia e Tecnologia (FCT) [IF/00735/2014, IF/01390/2014, IF/00021/2014, SFRH/BPD/96176/2013]; Conselho de Reitores das Universidades Portuguesas (CRUP), Portugal (Acoes Integradas Luso-Alemas) [A-43/16]; Deutscher Akademischer Austauschdienst (DAAD) [57212690]; Fondo de Investigaciones Sanitarias (Madrid, Spain) [PI12/02688]; ERA-NET PathoGenoMics [0315900A]	Northern Portugal Regional Operational Programme (NORTE), under the Portugal Partnership Agreement, through the European Regional Development Fund (FEDER); Fundacao para a Ciencia e Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); Conselho de Reitores das Universidades Portuguesas (CRUP), Portugal (Acoes Integradas Luso-Alemas); Deutscher Akademischer Austauschdienst (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); Fondo de Investigaciones Sanitarias (Madrid, Spain)(Instituto de Salud Carlos III); ERA-NET PathoGenoMics	Supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER) (NORTE-01-0145-FEDER-000013), the Fundacao para a Ciencia e Tecnologia (FCT) (contracts IF/00735/2014 to A.C., IF/01390/2014 to E.T., IF/00021/2014 to R.S., and SFRH/BPD/96176/2013 to C.C.), the Conselho de Reitores das Universidades Portuguesas (CRUP), Portugal (Acoes Integradas Luso-Alemas A-43/16), the Deutscher Akademischer Austauschdienst (DAAD) (project-ID 57212690), the Fondo de Investigaciones Sanitarias (Madrid, Spain) (grant #PI12/02688) and the ERA-NET PathoGenoMics (grant #0315900A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Cunha C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003434; De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Haslam PL, 1999, EUR RESPIR J, V14, P245, DOI 10.1034/j.1399-3003.1999.14b01.x; Howes A, 2016, J IMMUNOL, V197, P2838, DOI 10.4049/jimmunol.1501923; Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564; Kang XY, 2010, J IMMUNOL, V184, P3718, DOI 10.4049/jimmunol.0903613; Larsson L, 2010, GENES IMMUN, V11, P181, DOI 10.1038/gene.2009.103; Lee JC, 2013, CELL, V155, P57, DOI 10.1016/j.cell.2013.08.034; Oliveira-Coelho A, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00411; Potenza L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074326; Sakurai D, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003870; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Scrucca L, 2007, BONE MARROW TRANSPL, V40, P381, DOI 10.1038/sj.bmt.1705727; Scrucca L, 2010, BONE MARROW TRANSPL, V45, P1388, DOI 10.1038/bmt.2009.359	17	34	34	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					867	+		10.1016/j.jaci.2017.02.034	http://dx.doi.org/10.1016/j.jaci.2017.02.034			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28389392	Bronze			2022-12-18	WOS:000409241500029
J	Czarnowicki, T; Esaki, H; Gonzalez, J; Renert-Yuval, Y; Brunner, P; Oliva, M; Estrada, Y; Xu, H; Zheng, XZ; Talasila, S; Haugh, I; Huynh, T; Lyon, S; Tran, G; Sampson, H; Suarez-Farinas, M; Krueger, JG; Guttman-Yassky, E; Paller, AS				Czarnowicki, Tali; Esaki, Hitokazu; Gonzalez, Juana; Renert-Yuval, Yael; Brunner, Patrick; Oliva, Margeaux; Estrada, Yeriel; Xu, Hui; Zheng, Xiuzhong; Talasila, Sreya; Haugh, Isabel; Thy Huynh; Lyon, Sarah; Tran, Gary; Sampson, Hugh; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma; Paller, Amy S.			Alterations in B-cell subsets in pediatric patients with early atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; B cells; T cells; allergen-specific IgE; atopic march	SYSTEMIC-LUPUS-ERYTHEMATOSUS; FOOD ALLERGY; T-CELLS; PERIPHERAL-BLOOD; HUMAN IGE; REFERENCE VALUES; IMMUNE-RESPONSE; DENDRITIC CELLS; CD40 LIGAND; IFN-GAMMA	Background: B cells undergo maturation and class-switching in response to antigen exposure and T-cell help. Early B-cell differentiation has not been defined in patients with early-onset atopic dermatitis (AD). Objective: We sought to define the frequency of B-cell subsets associated with progressive B-cell maturation and IgE class-switching. Methods: We studied 27 children and 34 adults with moderate-to-severe AD (mean SCORAD score, 55 and 65, respectively) and age-matched control subjects (15 children and 27 adults). IgD/CD27 and CD24/CD38 core gating systems and an 11-color flow cytometric panel were used to determine the frequencies of circulating B-cell subsets. Serum total and allergen-specific IgE (sIgE) levels were measured by using ImmunoCAP. Results: Compared with adults, children showed T-cell predominance in the skin. Circulating CD19(+) CD20(+) B-cell counts were lower in patients with pediatric AD than in control subjects (24% vs 33%, P = .04), whereas CD3(+) T-cell counts were higher (62% vs 52%, P = .05). A decreased B-cell/T-cell lymphocyte ratio with age was observed only in pediatric control subjects (r = -0.48, P = .07). In pediatric patients with AD, a positive correlation was observed between B-cell/T-cell ratio and nonswitched memory B-cell counts (r = 0.42, P = .03). Higher frequencies of positive sIgE levels were seen in pediatric patients with AD (P < .0001). Diverse sIgE levels correlated with SCORAD scores and age of pediatric patients with AD (P < .01). Positive correlations were observed between activated B-cell and memory T-cell counts (P < .02). In patients with AD, IgE sensitization to most allergens clustered with age, T(H)1, T(H)2, total IgE levels, and B-cell memory subsets. Conclusions: Peripheral B and T cells are altered in pediatric patients with early AD, but T cells predominate in skin lesions.	[Czarnowicki, Tali; Esaki, Hitokazu; Brunner, Patrick; Zheng, Xiuzhong; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10065 USA; [Gonzalez, Juana] Rockefeller Univ, Translat Technol Core Lab, 1230 York Ave, New York, NY 10021 USA; [Czarnowicki, Tali; Esaki, Hitokazu; Renert-Yuval, Yael; Oliva, Margeaux; Estrada, Yeriel; Xu, Hui; Suarez-Farinas, Mayte; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Czarnowicki, Tali; Esaki, Hitokazu; Renert-Yuval, Yael; Oliva, Margeaux; Estrada, Yeriel; Xu, Hui; Suarez-Farinas, Mayte; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY 10029 USA; [Sampson, Hugh] Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Talasila, Sreya; Haugh, Isabel; Thy Huynh; Lyon, Sarah; Tran, Gary; Paller, Amy S.] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA; [Talasila, Sreya; Haugh, Isabel; Thy Huynh; Lyon, Sarah; Tran, Gary; Paller, Amy S.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Suarez-Farinas, Mayte] Icahn Inst Genom & Multiscale Biol, Dept Genet & Genom Sci, New York, NY USA	Rockefeller University; Rockefeller University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Czarnowicki, T (corresponding author), Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10065 USA.	tczarnowic01@rockefeller.edu	Haugh, Isabel/AAW-9354-2020; Renert-Yuval, Yael/AAP-5414-2020	Esaki, Hitokazu/0000-0002-3716-520X; Brunner, Patrick/0000-0002-3488-3345; Paller, Amy/0000-0001-6187-6549	LEO Foundation [0266-2572, 13-1310]; Center for Basic and Translational Research on Disorders of the Digestive System through Leona M. and Harry B. Helmsley Charitable Trust; National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program [UL1TR0000]; NCATS/NIH CTSA program [UL1 TR000043]; Northwestern University Skin Disease Research Center [NIAMS P30AR057216]	LEO Foundation(LEO Pharma); Center for Basic and Translational Research on Disorders of the Digestive System through Leona M. and Harry B. Helmsley Charitable Trust; National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCATS/NIH CTSA program; Northwestern University Skin Disease Research Center	Supported by a research grant to E.G-Y. and A.S.P. from the LEO Foundation, research grant no. 0266-2572, GCO no. 13-1310. T.C. was cosponsored by the Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust. J.G. was supported in part by grant no. UL1TR0000 from the National Center for Advancing Translational Sciences (NCATS)/National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. J.K.R. was supported in part by grant no. UL1 TR000043 from the NCATS/NIH CTSA program. Blood acquisition was supported by the Northwestern University Skin Disease Research Center (NIAMS P30AR057216).	Ballardini N, 2014, J ALLERGY CLIN IMMUN, V133, P594, DOI 10.1016/j.jaci.2013.08.054; Bergmann MM, 2013, J ALLER CL IMM-PRACT, V1, P22, DOI 10.1016/j.jaip.2012.11.005; Berin MC, 2013, TRENDS IMMUNOL, V34, P390, DOI 10.1016/j.it.2013.04.003; BRUGNONI D, 1994, EUR J IMMUNOL, V24, P1919, DOI 10.1002/eji.1830240831; Buffa S, 2013, AGE, V35, P2009, DOI 10.1007/s11357-012-9488-5; Carsetti R, 2004, IMMUNOL REV, V197, P179, DOI 10.1111/j.0105-2896.2004.0109.x; Chiu CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102809; Chung JB, 2003, TRENDS IMMUNOL, V24, P343, DOI 10.1016/S1471-4906(03)00119-4; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P118, DOI 10.1016/j.jaci.2015.08.027; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P208, DOI 10.1016/j.jaci.2015.03.032; Duchamp M, 2014, IMMUN INFLAMM DIS, V2, P131, DOI 10.1002/iid3.26; Elliott SR, 2000, HUM IMMUNOL, V61, P378, DOI 10.1016/S0198-8859(99)00189-5; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Fuentes-Duculan J, 2010, J INVEST DERMATOL, V130, P2412, DOI 10.1038/jid.2010.165; Garcia C, 2007, ALLERGOL IMMUNOPATH, V35, P15, DOI 10.1157/13099090; Garcia-Marquez M, 2013, BLOOD, V121, P2367, DOI 10.1182/blood-2012-12-468017; GORDON J, 1987, IMMUNOL TODAY, V8, P339, DOI 10.1016/0167-5699(87)90009-0; GROSJEAN I, 1994, EUR J IMMUNOL, V24, P2982, DOI 10.1002/eji.1830241209; Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717; Ide F, 2004, PEDIATR INT, V46, P337, DOI 10.1111/j.1442-200x.2004.01880.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Jones AL, 2016, J ALLERGY CLIN IMMUN, V137, P1247, DOI 10.1016/j.jaci.2016.01.010; Kaminski Denise A, 2012, Methods Mol Biol, V900, P109, DOI 10.1007/978-1-60761-720-4_6; Kaminski DA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00302; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Kong HH, 2012, J INVEST DERMATOL, V132, P933, DOI 10.1038/jid.2011.417; Kumar S, 2013, GENE DEV, V27, P2439, DOI 10.1101/gad.227165.113; LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P119, DOI 10.1016/1074-7613(95)90164-7; Lee J, 2015, INT J RHEUM DIS, V18, P200, DOI 10.1111/1756-185X.12432; Mages HW, 2000, EUR J IMMUNOL, V30, P1040, DOI 10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6; Martin PE, 2015, CLIN EXP ALLERGY, V45, P255, DOI 10.1111/cea.12406; Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Moghtaderi M, 2012, IRAN J IMMUNOL, V9, P32, DOI IJIv9i1A2; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Morva A, 2012, BLOOD, V119, P106, DOI 10.1182/blood-2011-06-360768; Namork E, 2015, ALLERGY ASTHMA CL IM, V11, DOI 10.1186/s13223-015-0095-8; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1989, INT ARCH ALLER A IMM, V90, P32, DOI 10.1159/000235073; Piatosa B, 2010, CYTOM PART B-CLIN CY, V78B, P372, DOI 10.1002/cyto.b.20536; Pistoia V, 1997, IMMUNOL TODAY, V18, P343, DOI 10.1016/S0167-5699(97)01080-3; Poulsen LK, 2007, ANN MED, V39, P440, DOI 10.1080/07853890701449354; POULSEN LK, 1989, ALLERGY, V44, P173, DOI 10.1111/j.1398-9995.1989.tb02258.x; Reljic R, 1997, EUR J IMMUNOL, V27, P572, DOI 10.1002/eji.1830270232; Riffo-Vasquez Y, 2000, CLIN EXP ALLERGY, V30, P728; Rijkers G, 1998, VACCINE, V16, P1396, DOI 10.1016/S0264-410X(98)00098-X; Rodriguez-Pinto D, 2005, CELL IMMUNOL, V238, P67, DOI 10.1016/j.cellimm.2006.02.005; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Sanz I, 2008, SEMIN IMMUNOL, V20, P67, DOI 10.1016/j.smim.2007.12.006; SARFATI M, 1988, J IMMUNOL, V141, P2195; Saunes M, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-168; Scirica CV, 2007, J ALLERGY CLIN IMMUN, V119, P81, DOI 10.1016/j.jaci.2006.09.002; Shi YH, 2003, CLIN IMMUNOL, V108, P128, DOI 10.1016/S1521-6616(03)00092-5; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Spergel JM, 2015, PEDIATRICS, V136, pE1530, DOI 10.1542/peds.2015-1444; Splawski JB, 1996, J IMMUNOL, V156, P119; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Taneichi M, 2002, J IMMUNOL, V169, P4246, DOI 10.4049/jimmunol.169.8.4246; Tesciuba AG, 2008, J IMMUNOL, V181, P1019, DOI 10.4049/jimmunol.181.2.1019; Thornton CA, 2002, PEDIATR RES, V52, DOI 10.1023/01.PDR.00000023172.89966.50; von Kobyletzki LB, 2012, BMC DERMATOL, V12, DOI 10.1186/1471-5945-12-11; Vos Q, 2000, IMMUNOL REV, V176, P154; Wei C, 2007, J IMMUNOL, V178, P6624, DOI 10.4049/jimmunol.178.10.6624; Wei CW, 2011, CYTOM PART A, V79A, P894, DOI 10.1002/cyto.a.21112; Weiss GE, 2009, J IMMUNOL, V183, P2176, DOI 10.4049/jimmunol.0901297; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; Werfel T, 2004, CURR OPIN ALLERGY CL, V4, P379, DOI 10.1097/00130832-200410000-00009; Wesemann DR, 2011, J EXP MED, V208, P2733, DOI 10.1084/jem.20111155; Wu YCB, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00081; Yurasov S, 2005, ANN NY ACAD SCI, V1062, P165, DOI 10.1196/annals.1358.019; Zheng T., 2014, J CLIN CELLULAR IMMU, V5, P2, DOI [10.4172/2155-9899.1000202, DOI 10.4172/2155-9899.1000202, 4172/2155-9899.1000202]	74	34	38	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					134	+		10.1016/j.jaci.2016.09.060	http://dx.doi.org/10.1016/j.jaci.2016.09.060			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27965110	Bronze			2022-12-18	WOS:000404542000013
J	Siler, U; Romao, S; Tejera, E; Pastukhov, O; Kuzmenko, E; Valencia, RG; Spaccamela, VM; Belohradsky, BH; Speer, O; Schmugge, M; Kohne, E; Hoenig, M; Freihorst, J; Schulz, AS; Reichenbach, J				Siler, Ulrich; Romao, Susana; Tejera, Emilio; Pastukhov, Oleksandr; Kuzmenko, Elena; Valencia, Rocio G.; Spaccamela, Virginia Meda; Belohradsky, Bernd H.; Speer, Oliver; Schmugge, Markus; Kohne, Elisabeth; Hoenig, Manfred; Freihorst, Joachim; Schulz, Ansgar S.; Reichenbach, Janine			Severe glucose-6-phosphate dehydrogenase deficiency leads to susceptibility to infection and absent NETosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Glucose-6-phosphate dehydrogenase deficiency; chronic granulomatous disease; neutrophil extracellular trap forma-tion; innate immunity; immunodeficiency; NADPH	CHRONIC GRANULOMATOUS-DISEASE; NEUTROPHIL EXTRACELLULAR TRAPS; CHRONIC NONSPHEROCYTIC ANEMIA; HEMOLYTIC-ANEMIA; G6PD DEFICIENCY; NADPH OXIDASE; LEUKOCYTE GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; DEHYDROGENASE-DEFICIENCY; GRANULOCYTE DYSFUNCTION; BACTERICIDAL ACTIVITY	Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorderof red blood cells in human subjects, causing hemolytic anemia linked to impaired nicotinamide adenine dinucleotide phosphate (NADPH) production and imbalanced redox homeostasis in erythrocytes. Because G6PD is expressed by a variety of hematologic and nonhematologic cells, a broader clinical phenotype could be postulated in G6PD-deficient patients. We describe 3 brothers with severe G6PD deficiency and susceptibility to bacterial infection. Objective: We sought to study the molecular pathophysiology leading to susceptibility to infection in 3 siblings with severe G6PD deficiency. Methods: Blood samples of 3 patients with severe G6PD deficiency were analyzed for G6PD enzyme activity, cellular oxidized nicotinamide adenine dinucleotide phosphate/NADPH levels, phagocytic reactive oxygen species production, neutrophil extracellular trap (NET) formation, and neutrophil elastase translocation. Results: In these 3 brothers strongly reduced NADPH oxidase function was found in granulocytes, leading to impaired NET formation. Defective NET formation has thus far been only observed in patients with the NADPH oxidase deficiency chronic granulomatous disease, who require antibiotic and antimycotic prophylaxis to prevent life-threatening bacterial and fungal infections. Conclusion: Because severe G6PD deficiency can be a phenocopy of chronic granulomatous disease with regard to the cellular and clinical phenotype, careful evaluation of neutrophil function seems mandatory in these patients to decide on appropriate anti-infective preventive measures. Determining the level of G6PD enzyme activity should be followed by analysis of reactive oxygen species production and NET formation to decide on required antibiotic and antimycotic prophylaxis.	[Siler, Ulrich; Romao, Susana; Tejera, Emilio; Pastukhov, Oleksandr; Kuzmenko, Elena; Valencia, Rocio G.; Spaccamela, Virginia Meda; Reichenbach, Janine] Univ Childrens Hosp, Div Immunol, Zurich, Switzerland; [Speer, Oliver; Schmugge, Markus] Univ Childrens Hosp, Div Hematol, Zurich, Switzerland; [Speer, Oliver; Schmugge, Markus] Childrens Res Ctr, Zurich, Switzerland; [Belohradsky, Bernd H.] Ludwig Maximilians Univ Munchen, Univ Childrens Hosp, Dr von Haunersches Kinderspital, Div Infect Dis & Immunol, Munich, Germany; [Kohne, Elisabeth; Hoenig, Manfred; Schulz, Ansgar S.] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Freihorst, Joachim] Childrens Hosp Ostalbklinikum, Aalen, Germany; [Reichenbach, Janine] Univ Zurich, Zurich Ctr Integrat Human Physiol, CH-8006 Zurich, Switzerland; [Reichenbach, Janine] Univ Zurich, Ctr Appl Biotechnol & Mol Med, CH-8006 Zurich, Switzerland; [Reichenbach, Janine] Univ Zurich, Swiss Ctr Regenerat Med, CH-8006 Zurich, Switzerland	University Children's Hospital Zurich; University Children's Hospital Zurich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Ulm University; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; University of Zurich	Reichenbach, J (corresponding author), Univ Childrens Hosp Zurich, Div Immunol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	janine.reichenbach@kispi.uzh.ch	Reichenbach, Janine/U-2171-2018	Reichenbach, Janine/0000-0002-9008-1312; Schmugge, Markus/0000-0003-4745-8572; Tejera, Emilio/0000-0001-9913-4778; Siler, Ulrich/0000-0002-2458-2629	Gebert Ruf Stiftung, program "Rare Diseases-New Approaches'' [GRS-046/10]; Gottfried und Julia Bangerter-Rhyner-Stiftung; Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie); ZIHP (Zurich Center for Integrative Human Physiology); EU-FP7 CELL-PID [CELL-PID HEALTH-2010-261387]; EU-FP7 NET4CGD; Fondazione Ettore e Valeria Rossi	Gebert Ruf Stiftung, program "Rare Diseases-New Approaches''; Gottfried und Julia Bangerter-Rhyner-Stiftung; Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie); ZIHP (Zurich Center for Integrative Human Physiology); EU-FP7 CELL-PID; EU-FP7 NET4CGD; Fondazione Ettore e Valeria Rossi	J.R. was supported by a research grant from Gebert Ruf Stiftung, program "Rare Diseases-New Approaches'' (grant no. GRS-046/10), the Gottfried und Julia Bangerter-Rhyner-Stiftung, and Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie). J.R. and V.M.S. were supported by ZIHP (Zurich Center for Integrative Human Physiology). J.R. and U.S. were supported by a research grant of EU-FP7 CELL-PID HEALTH-2010-261387, EU-FP7 NET4CGD, and Fondazione Ettore e Valeria Rossi.	ABUOSBA YK, 1989, J PEDIATR-US, V114, P748, DOI 10.1016/S0022-3476(89)80131-3; Akong-Moore K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042984; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; ARESE P, 1990, SEMIN HEMATOL, V27, P1; BAEHNER RL, 1972, J RETICULOENDOTH SOC, V12, P150; Bianchi M, 2011, J ALLERGY CLIN IMMUN, V127, P1243, DOI 10.1016/j.jaci.2011.01.021; Bianchi M, 2009, BLOOD, V114, P2619, DOI 10.1182/blood-2009-05-221606; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; CANEPA L, 1991, BIOCHIM BIOPHYS ACTA, V1074, P101, DOI 10.1016/0304-4165(91)90046-J; Cappellini MD, 2008, LANCET, V371, P64, DOI 10.1016/S0140-6736(08)60073-2; CECH P, 1977, SCHWEIZ MED WSCHR, V107, P1458; Cheng ML, 2013, FREE RADICAL RES, V47, P699, DOI 10.3109/10715762.2013.816420; COOPER MR, 1972, J CLIN INVEST, V51, P769, DOI 10.1172/JCI106871; Costa E, 2002, J PEDIAT HEMATOL ONC, V24, P164, DOI 10.1097/00043426-200202000-00023; Curtius HC, 1974, CLIN BIOCH PRINCIPLE; Dinauer MC, 2001, BLOOD, V97, P3738, DOI 10.1182/blood.V97.12.3738; Douda DN, 2015, P NATL ACAD SCI USA, V112, P2817, DOI 10.1073/pnas.1414055112; GRAY GR, 1973, LANCET, V2, P530; Harthan Aaron A, 2013, J Pediatr Pharmacol Ther, V18, P137, DOI 10.5863/1551-6776-18.2.137; HOLMES B, 1970, NEW ENGL J MED, V283, P217, DOI 10.1056/NEJM197007302830501; Jiang Y, 2012, STEM CELLS, V30, P599, DOI 10.1002/stem.1053; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; LaRue N, 2014, AM J TROP MED HYG, V91, P854, DOI 10.4269/ajtmh.14-0194; Lodha A, 2008, J PERINATOL, V28, P77, DOI 10.1038/sj.jp.7211853; MALLOUH AA, 1987, J PEDIATR-US, V111, P850, DOI 10.1016/S0022-3476(87)80202-0; MAMLOK RJ, 1985, ENZYME, V34, P15, DOI 10.1159/000469354; MAMLOK RJ, 1987, J PEDIATR-US, V111, P852, DOI 10.1016/S0022-3476(87)80203-2; MILLER DR, 1974, BLOOD, V44, P323, DOI 10.1182/blood.V44.3.323.323; Moradkhani K, 2012, AM J HEMATOL, V87, P208, DOI 10.1002/ajh.22218; Nowinski Adam, 2007, Pneumonol Alergol Pol, V75, P283; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Paek DS, 2009, J EMERG MED, V37, P273, DOI 10.1016/j.jemermed.2007.10.049; Pamuk GE, 2009, MED PRIN PRACT, V18, P329, DOI 10.1159/000215733; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Queresby FA, 2000, J ORAL MAXIL SURG, V58, P805, DOI 10.1053/joms.2000.7273; Rada B, 2008, SEMIN IMMUNOPATHOL, V30, P237, DOI 10.1007/s00281-008-0126-3; Rada BK, 2004, BLOOD, V104, P2947, DOI 10.1182/blood-2004-03-1005; RAMOT B, 1959, J CLIN INVEST, V38, P1659, DOI 10.1172/JCI103943; Relling MV, 2014, CLIN PHARMACOL THER, V96, P169, DOI 10.1038/clpt.2014.97; Romao S, 2015, J ALLERGY CLIN IMMUN, V136, P1703, DOI 10.1016/j.jaci.2015.09.007; Roos D, 1999, BLOOD, V94, P2955; SCHILIRO G, 1976, PEDIATR RES, V10, P739, DOI 10.1203/00006450-197610080-00009; Seger RA, 2010, NETH J MED, V68, P334; Spolarics Z, 2001, CRIT CARE MED, V29, P728, DOI 10.1097/00003246-200104000-00005; STIEHM E, 2004, IMMUNOLOGIC DISORDER; van Bruggen R, 2002, BLOOD, V100, P1026, DOI 10.1182/blood.V100.3.1026; Vives CJ, 1982, BLOOD, V59, P428; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; Wolach B, 2004, PEDIATR RES, V55, P807, DOI 10.1203/01.PDR.0000120680.47846.47; Yang CH, 1997, J INFECTION, V35, P316, DOI 10.1016/S0163-4453(97)93574-X	51	34	35	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					212	+		10.1016/j.jaci.2016.04.041	http://dx.doi.org/10.1016/j.jaci.2016.04.041			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27458052	Bronze			2022-12-18	WOS:000393996800023
J	Fujiyama, T; Ito, T; Umayahara, T; Ikeya, S; Tatsuno, K; Funakoshi, A; Hashizume, H; Tokura, Y				Fujiyama, Toshiharu; Ito, Taisuke; Umayahara, Takatsune; Ikeya, Shigeki; Tatsuno, Kazuki; Funakoshi, Atsuko; Hashizume, Hideo; Tokura, Yoshiki			Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of T(H)17 cells and their ex vivo expansion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						psoriasis; IL-17A; Th17; vitamin D; corticosteroid	REGULATORY T-CELLS; DENDRITIC CELLS; TH17 CELLS; BETAMETHASONE DIPROPIONATE; IN-VITRO; 1-ALPHA,25-DIHYDROXYVITAMIN D3; HUMAN KERATINOCYTES; CALCIPOTRIOL; EXPRESSION; DIFFERENTIATION	Background: Topical combination of a vitamin D3 analogue and corticosteroid is widely used for the treatment of psoriasis, a T(H)17-mediated disorder, but the underlying mechanism remains unclear. Objective: We investigated the effect of this topical applicant, focusing on skin-infiltrating T(H)17 cells. Methods: In 10 patients with plaque psoriasis, calcipotriol (Cal), betamethasone dipropionate (Bet), or the calcipotriol and betamethasone dipropionate 2-compound formulation (CB) was applied to 3 different psoriatic plaques with similar severity once a day for 14 days. One nonapplied lesion was used as a control. Four-millimeter biopsy specimens were taken from each site, cut into 2 pieces, and subjected to histologic examination and ex vivo expansion of skin-infiltrating T cells with anti-CD3/CD28 antibodies and IL-2. Results: Clinical, histologic, and IL-17A(+) cell-infiltrate improvement was found in the following order: CB > Cal > Bet > control or CB > Bet > Cal > control. Numbers of ex vivo expanded T cells were decreased by topical application of Bet and CB, and CB exhibited the most suppressive result. Numbers and frequencies of T(H)17 cells were significantly reduced by CB and Cal, suggesting that Cal has a capacity to preferentially suppress T(H)17 cells. When the stocked T cells from control samples were stimulated with anti-CD3 antibodies in the presence of Bet, Cal, or both, Cal downmodulated IL-17 and IFN-gamma production and tended to upregulate IL-4 and IL-6 without apoptosis, but Bet inhibited production of these cytokines with apoptosis. Conclusion: These findings suggest that Cal and Bet have different effects on T cells to normalize psoriatic changes, with decreased T(H)17 cell expansion in the skin lesions.	[Fujiyama, Toshiharu; Ito, Taisuke; Umayahara, Takatsune; Ikeya, Shigeki; Tatsuno, Kazuki; Funakoshi, Atsuko; Tokura, Yoshiki] Hamamatsu Univ, Sch Med, Dept Dermatol, Hamamatsu, Shizuoka, Japan; [Hashizume, Hideo] Shimada Municipal Hosp, Dept Dermatol, Shimada, Japan	Hamamatsu University School of Medicine	Fujiyama, T (corresponding author), Hamamatsu Univ, Sch Med, Dept Dermatol, Hamamatsu, Shizuoka, Japan.	fujiyama@hama-med.ac.jp	Hashizume, Hideo/AAL-9490-2020	Hashizume, Hideo/0000-0002-5809-0040; Fujiyama, Toshiharu/0000-0003-3612-8025	Leo Pharma	Leo Pharma(LEO Pharma)	Supported by Leo Pharma.	Agak GW, 2014, J INVEST DERMATOL, V134, P366, DOI 10.1038/jid.2013.334; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Bakdash G, 2013, HUM VACC IMMUNOTHER, V9, P250, DOI 10.4161/hv.22918; BERTHJONES J, 1992, BRIT J DERMATOL, V126, P356, DOI 10.1111/j.1365-2133.1992.tb00678.x; BINDERUP L, 1988, BIOCHEM PHARMACOL, V37, P889, DOI 10.1016/0006-2952(88)90177-3; Boonstra A, 2001, J IMMUNOL, V167, P4974, DOI 10.4049/jimmunol.167.9.4974; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; Bruce D, 2011, INT IMMUNOL, V23, P519, DOI 10.1093/intimm/dxr045; Chang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012925; Chatterjee M, 2012, J BIOL CHEM, V287, DOI [10.1074/jbc.M112.415067, 10.1074/jbc.M111.272179]; Chu CC, 2012, J EXP MED, V209, P935, DOI 10.1084/jem.20112583; Dyring-Andersen B, 2015, SCAND J IMMUNOL, V82, P84, DOI 10.1111/sji.12304; Ferreira GB, 2015, CELL REP; Harper EG, 2009, J INVEST DERMATOL, V129, P2175, DOI 10.1038/jid.2009.65; HASHIMOTO K, 1990, BRIT J DERMATOL, V123, P93, DOI 10.1111/j.1365-2133.1990.tb01828.x; Hashizume H, 2002, J IMMUNOL, V168, P5359, DOI 10.4049/jimmunol.168.10.5359; Hashizume H, 2010, ACTA DERM-VENEREOL, V90, P468, DOI 10.2340/00015555-0927; Hegyi Z, 2012, J INVEST DERMATOL, V132, P1416, DOI 10.1038/jid.2011.486; Hino R, 2011, J EUR ACAD DERMATOL, V25, P243, DOI 10.1111/j.1468-3083.2010.03714.x; Ikeda U, 2010, IMMUNOL LETT, V134, P7, DOI 10.1016/j.imlet.2010.07.002; Joshi S, 2011, MOL CELL BIOL, V31, P3653, DOI 10.1128/MCB.05020-11; Kaminuma O, 2012, INT ARCH ALLERGY IMM, V158, P30, DOI 10.1159/000337757; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Kragballe K, 1998, BRIT J DERMATOL, V139, P649; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Liddicoat DR, 2014, IMMUNOL CELL BIOL, V92, P825, DOI 10.1038/icb.2014.57; LONG CC, 1991, CLIN EXP DERMATOL, V16, P444, DOI 10.1111/j.1365-2230.1991.tb01232.x; Lovato P, 2016, J DERMATOL SCI, V81, P153, DOI 10.1016/j.jdermsci.2015.12.009; Michel G, 1997, J IMMUNOL, V159, P6291; Midorikawa K, 1999, J DERMATOL SCI, V21, P8, DOI 10.1016/S0923-1811(99)00007-9; MILDE P, 1991, J INVEST DERMATOL, V97, P230, DOI 10.1111/1523-1747.ep12480255; Mirandola P, 2011, LAB INVEST, V91, P1188, DOI 10.1038/labinvest.2011.76; Nanzer AM, 2013, J ALLERGY CLIN IMMUN, V132, P297, DOI 10.1016/j.jaci.2013.03.037; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; Osamu N, 2014, J DERMATOL SCI, V75, P201, DOI 10.1016/j.jdermsci.2014.05.007; Papp KA, 2003, J AM ACAD DERMATOL, V48, P48, DOI 10.1067/mjd.2003.130; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Prietl B, 2014, EUR J NUTR, V53, P751, DOI 10.1007/s00394-013-0579-6; Ramesh R, 2014, J EXP MED, V211, P89, DOI 10.1084/jem.20130301; Sakabe J, 2014, ACTA DERM-VENEREOL, V94, P512, DOI 10.2340/00015555-1775; Schewitz-Bowers LP, 2015, P NATL ACAD SCI USA, V112, P4080, DOI 10.1073/pnas.1418316112; Solt LA, 2011, NATURE, V472, P491, DOI 10.1038/nature10075; Suzuki T, 2014, J DERMATOL SCI, V74, P116, DOI 10.1016/j.jdermsci.2013.12.013; Takahashi H, 2003, J DERMATOL SCI, V31, P21, DOI 10.1016/S0923-1811(02)00136-6; van der Velden HMJ, 2010, J DERMATOL TREAT, V21, P13, DOI 10.3109/09546630903214175; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Vissers WHPM, 2004, EXP DERMATOL, V13, P106, DOI 10.1111/j.0906-6705.2004.00151.x; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yoshiki R, 2014, J INVEST DERMATOL, V134, P1912, DOI 10.1038/jid.2014.98; Zaba LC, 2009, J INVEST DERMATOL, V129, P79, DOI 10.1038/jid.2008.194	51	34	35	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					517	+		10.1016/j.jaci.2016.03.048	http://dx.doi.org/10.1016/j.jaci.2016.03.048			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27315769	Bronze			2022-12-18	WOS:000380835800023
J	Eguiluz-Gracia, I; Bosco, A; Dollner, R; Melum, GR; Lexberg, MH; Jones, AC; Dheyauldeen, SA; Holt, PG; Baekkevold, ES; Jahnsen, FL				Eguiluz-Gracia, Ibon; Bosco, Anthony; Dollner, Ralph; Melum, Guro Reinholt; Lexberg, Maria H.; Jones, Anya C.; Dheyauldeen, Sinan Ahmed; Holt, Patrick G.; Baekkevold, Espen S.; Jahnsen, Frode Lars			Rapid recruitment of CD14(+) monocytes in experimentally induced allergic rhinitis in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD14(+) monocytes; resident macrophages; dendritic cells; human airway allergy; nasal mucosa; T(H)2-associated chemokines	ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; NASAL-MUCOSA; T-CELLS; ASTHMA; DIFFERENTIATION; MACROPHAGES; ACTIVATION; SUBSETS; IMPACT	Background: Activated T(H)2 cells and eosinophils are hallmarks of the allergic inflammation seen in patients with allergic rhinitis (AR). However, which cells activate and attract T cells and eosinophils to the inflammatory lesion has not been determined. Objective: We wanted to assess the role of mucosal mononuclear phagocytes, consisting of monocytes, macrophages, and dendritic cells, in the local allergic inflammatory reaction. Methods: Patients with AR and nonatopic control subjects were challenged with pollen extract, and nasal symptoms were recorded. Mucosal biopsy specimens obtained at different time points before and after challenge were used for immunostaining in situ and flow cytometric cell sorting. Sorted mononuclear phagocytes were subjected to RNA extraction and gene expression profiling. Results: In an in vivo model of AR, we found that CD14(+) monocytes were recruited to the nasal mucosa within hours after local allergen challenge, whereas conventional dendritic cells accumulated after several days of continued provocation. Transcriptomic profiling of mucosal mononuclear phagocytes sorted after 1 week of continued allergen challenge showed an activated phenotype at least partially driven by IL-4 signaling, IL-13 signaling, or both. Importantly, gene expression of several T(H)2-related chemokines was significantly upregulated by the mononuclear phagocyte population concomitant with an increased recruitment of CD4(+) T cells and eosinophils. Conclusion: Our findings suggest that the mononuclear phagocyte population is directly involved in the production of proinflammatory chemokines that attract other immune cells. Rapid recruitment of CD14(+) monocytes to the challenged site indicates that these proinflammatory mononuclear phagocytes have a central role in orchestrating local allergic inflammation.	[Eguiluz-Gracia, Ibon; Melum, Guro Reinholt; Lexberg, Maria H.; Baekkevold, Espen S.; Jahnsen, Frode Lars] Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Pathol, N-0027 Oslo, Norway; [Eguiluz-Gracia, Ibon; Melum, Guro Reinholt; Lexberg, Maria H.; Baekkevold, Espen S.; Jahnsen, Frode Lars] Univ Oslo, Rikshosp, Oslo Univ Hosp, CIR, N-0027 Oslo, Norway; [Dollner, Ralph; Dheyauldeen, Sinan Ahmed] Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, N-0027 Oslo, Norway; Univ Oslo, Oslo, Norway; [Bosco, Anthony; Jones, Anya C.; Holt, Patrick G.] Univ Western Australia, Telethon Kids Inst, Perth, WA 6009, Australia; [Dollner, Ralph] Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo; Telethon Kids Institute; University of Western Australia; Ruprecht Karls University Heidelberg	Jahnsen, FL (corresponding author), Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Pathol, N-0027 Oslo, Norway.; Jahnsen, FL (corresponding author), Univ Oslo, Rikshosp, Oslo Univ Hosp, CIR, N-0027 Oslo, Norway.	frode.lars.jahnsen@rr-research.no	Bosco, Anthony/AAC-6900-2022; Eguiluz, Ibon/AAC-4973-2021; Eguiluz-Gracia, Ibon/S-7881-2016; Jones, Anya/AAE-8029-2021	Eguiluz, Ibon/0000-0002-3774-931X; Jones, Anya/0000-0002-6649-4977; Bosco, Anthony/0000-0002-4335-615X	Research Council of Norway through its Centers of Excellenc [179573]; South Eastern Norway Regional Health Authority [1012105]	Research Council of Norway through its Centers of Excellenc; South Eastern Norway Regional Health Authority	Supported in part by the Research Council of Norway through its Centers of Excellence funding scheme (project no. 179573) and grants from the South Eastern Norway Regional Health Authority (project no. 1012105).	Bain CC, 2014, NAT IMMUNOL, V15, P929, DOI 10.1038/ni.2967; Baumann R, 2013, AM J RHINOL ALLERGY, V27, P266, DOI 10.2500/ajra.2013.27.3913; Boes M, 2009, IMMUNOLOGY, V127, P163, DOI 10.1111/j.1365-2567.2009.03078.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Breton G, 2015, J EXP MED, V212, P401, DOI 10.1084/jem.20141441; Chow A, 2011, NAT REV IMMUNOL, V11, P788, DOI 10.1038/nri3087; Commins SP, 2010, J ALLERGY CLIN IMMUN, V125, pS53, DOI 10.1016/j.jaci.2009.07.008; Danilova E, 2015, MUCOSAL IMMUNOL, V8, P107, DOI 10.1038/mi.2014.46; Deliu M, 2014, ALLERGY, V69, P1515, DOI 10.1111/all.12467; Freue GVC, 2007, BIOINFORMATICS, V23, P3162, DOI 10.1093/bioinformatics/btm487; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Girard JP, 2012, NAT REV IMMUNOL, V12, P762, DOI 10.1038/nri3298; Godthelp T, 1996, CLIN EXP ALLERGY, V26, P677, DOI 10.1046/j.1365-2222.1996.1072451.x; Grailer JJ, 2009, J DERMATOL SCI, V56, P141, DOI 10.1016/j.jdermsci.2009.10.001; Huang HJ, 2011, MUCOSAL IMMUNOL, V4, P519, DOI 10.1038/mi.2011.17; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Islam SA, 2012, NAT MED, V18, P705, DOI 10.1038/nm.2760; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; Jahnsen FL, 2004, AM J RESP CELL MOL, V30, P31, DOI 10.1165/rcmb.2002-0230OC; Lambrecht Bart N, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS236, DOI 10.1513/AnnalsATS.201405-218AW; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Melum GR, 2014, J ALLERGY CLIN IMMUN, V134, P613, DOI 10.1016/j.jaci.2014.05.010; Pease JE, 2006, J ALLERGY CLIN IMMUN, V118, P305, DOI 10.1016/j.jaci.2006.06.010; Piccolo SR, 2013, P NATL ACAD SCI USA, V110, P17778, DOI 10.1073/pnas.1305823110; Pilette C, 2013, ALLERGY, V68, P312, DOI 10.1111/all.12090; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Raki M, 2006, GASTROENTEROLOGY, V131, P428, DOI 10.1053/j.gastro.2006.06.002; Rimaniol AC, 2003, J ALLERGY CLIN IMMUN, V112, P1139, DOI 10.1016/j.jaci.2003.09.041; Rivollier A, 2012, J EXP MED, V209, P139, DOI 10.1084/jem.20101387; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Sieweke MH, 2013, SCIENCE, V342, P946, DOI 10.1126/science.1242974; Skrindo I, 2011, CLIN EXP ALLERGY, V41, P954, DOI 10.1111/j.1365-2222.2011.03710.x; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Strickland DH, 2010, CURR OPIN IMMUNOL, V22, P789, DOI 10.1016/j.coi.2010.10.019; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; van de Ven R, 2011, BLOOD, V118, P2502, DOI 10.1182/blood-2011-03-344838; Venturi GM, 2003, IMMUNITY, V19, P713, DOI 10.1016/S1074-7613(03)00295-4; Watchmaker PB, 2014, NAT IMMUNOL, V15, P98, DOI 10.1038/ni.2768; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006	40	34	35	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1872	+		10.1016/j.jaci.2015.11.025	http://dx.doi.org/10.1016/j.jaci.2015.11.025			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26851967	Green Published			2022-12-18	WOS:000377527200029
J	Altes, TA; Mugler, JP; Ruppert, K; Tustison, NJ; Gersbach, J; Szentpetery, S; Meyer, CH; de Lange, EE; Teague, WG				Altes, Talissa A.; Mugler, John P., III; Ruppert, Kai; Tustison, Nicholas J.; Gersbach, Joanne; Szentpetery, Sylvia; Meyer, Craig H.; de lange, Eduard E.; Teague, W. Gerald			Clinical correlates of lung ventilation defects in asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hyperpolarized; 3 He magnetic resonance imaging; ventilation defects; ventilation heterogeneity; severe asthma; childhood asthma	HYPERPOLARIZED HE-3 MRI; MAGNETIC-RESONANCE; SEGMENTATION; SPIROMETRY; CHILDHOOD; DISEASE; AIRWAYS; CT	Background: Lung ventilation defects identified by using hyperpolarized 3-helium gas (He-3) lung magnetic resonance imaging (MRI) are prevalent in asthmatic patients, but the clinical importance of ventilation defects is poorly understood. Objectives: We sought to correlate the lung defect volume quantified by using He-3 MRI with clinical features in children with mild and severe asthma. Methods: Thirty-one children with asthma (median age, 10 years; age range, 3-17 years) underwent detailed characterization and He-3 lung MRI. Quantification of the He-3 signal defined ventilation defect and hypoventilated, ventilated, and well-ventilated volumes. Results: The ventilation defect to total lung volume fraction ranged from 0.1% to 11.6%. Children with ventilation defect percentages in the upper tercile were more likely to have severe asthma than children in the lower terciles (P = .005). The ventilation defect percentage correlated (P < .05 for all) positively with the inhaled corticosteroid dose, total number of controller medications, and total blood eosinophil counts and negatively with the Asthma Control Test score, FEV1 (percent predicted), FEV1/forced vital capacity ratio (percent predicted), and forced expiratory flow rate from 25% to 75% of expired volume (percent predicted). Conclusion: The lung defect volume percentage measured by using He-3 MRI correlates with several clinical features of asthma, including severity, symptom score, medication requirement, airway physiology, and atopic markers.	[Altes, Talissa A.] Univ Missouri, Sch Med, Dept Radiol, Columbia, MO USA; [Mugler, John P., III; Tustison, Nicholas J.; Gersbach, Joanne; Meyer, Craig H.; de lange, Eduard E.] Univ Virginia, Sch Med, Dept Radiol & Med Imaging, Div Med Imaging Res, Charlottesville, VA 22908 USA; [Szentpetery, Sylvia; Teague, W. Gerald] Univ Virginia, Sch Med, Dept Pediat, Child Hlth Res Ctr, Charlottesville, VA 22908 USA; [Mugler, John P., III; Meyer, Craig H.] Univ Virginia, Dept Biomed Engn, Charlottesville, VA USA; [Ruppert, Kai] Cincinnati Childrens Hosp, Ctr Pulm Imaging Res, Cincinnati, OH USA	University of Missouri System; University of Missouri Columbia; University of Virginia; University of Virginia; University of Virginia; Cincinnati Children's Hospital Medical Center	Teague, WG (corresponding author), Univ Virginia, Sch Med, Dept Pediat, Div Resp Med Allergy & Immunol,Child Hlth Res Ctr, POB 30086, Charlottesville, VA 22908 USA.	wgt2p@virginia.edu	Ruppert, Kai/I-7226-2019; Mugler, John/B-9432-2013	Mugler, John/0000-0002-4140-308X; TUSTISON, NICHOLAS/0000-0001-9418-5103	National Institutes of Health/National Heart, Lung, and Blood Institute [1U01HL109250-1]; Ivy Foundation; Hartwell Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL109250] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Ivy Foundation; Hartwell Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program (SARP), 1U01HL109250-1 (to W.G.T.), the Ivy Foundation (to W.G.T.), and the Hartwell Foundation (to T.A.A.).	Altes TA, 2001, J MAGN RESON IMAGING, V13, P378, DOI 10.1002/jmri.1054; Altes TA, 2006, J MAGN RESON IMAGING, V24, P1277, DOI 10.1002/jmri.20723; [Anonymous], 2007, INVEST RADIOL, V42, P384; Avants BB, 2011, NEUROINFORMATICS, V9, P381, DOI 10.1007/s12021-011-9109-y; Cadman RV, 2013, J ALLERGY CLIN IMMUN, V131, P369, DOI 10.1016/j.jaci.2012.10.032; Castro M, 2013, J ALLERGY CLIN IMMUN, V131, P377, DOI 10.1016/j.jaci.2012.12.669; Castro M, 2011, J ALLERGY CLIN IMMUN, V128, P467, DOI 10.1016/j.jaci.2011.04.051; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Costella S, 2012, RESPIROLOGY, V17, P1237, DOI 10.1111/j.1440-1843.2012.02250.x; de Lange EE, 2006, CHEST, V130, P1055, DOI 10.1378/chest.130.4.1055; de Lange EE, 2009, RADIOLOGY, V250, P567, DOI 10.1148/radiol.2502080188; de Lange EE, 1999, RADIOLOGY, V210, P851, DOI 10.1148/radiology.210.3.r99fe08851; Fain SB, 2008, ACAD RADIOL, V15, P753, DOI 10.1016/j.acra.2007.10.019; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Harris RS, 2006, AM J RESP CRIT CARE, V174, P245, DOI 10.1164/rccm.200510-1634OC; Irvin Charles G, 2009, Proc Am Thorac Soc, V6, P306, DOI 10.1513/pats.200808-091RM; Macleod KA, 2009, THORAX, V64, P33, DOI 10.1136/thx.2007.095018; Miller GW, 2010, MAGN RESON MED, V63, P127, DOI 10.1002/mrm.22181; Narayanan M, 2013, AM J RESP CRIT CARE, V187, P1104, DOI 10.1164/rccm.201210-1850OC; National Asthma Education and Prevention Program, 1997, 3 NIH NAT HEART LUNG; National Institutes of Allergy Asthma and Infectious Diseases, 2012, J ALLERGY CLIN IMM S, V129, pS34; PAPASTAMELOS C, 1995, J APPL PHYSIOL, V78, P179, DOI 10.1152/jappl.1995.78.1.179; Parraga G, 2007, INVEST RADIOL, V42, P384, DOI 10.1097/01.rli.0000262571.81771.66; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Svenningsen S, 2014, THORAX, V69, P63, DOI 10.1136/thoraxjnl-2013-203711; Thomen RP, 2015, RADIOLOGY, V274, P250, DOI 10.1148/radiol.14140080; Thompson BR, 2013, J ALLERGY CLIN IMMUN, V131, P1322, DOI 10.1016/j.jaci.2013.01.054; Tustison NJ, 2011, J MAGN RESON IMAGING, V34, P831, DOI 10.1002/jmri.22738; Tustison NJ, 2010, MAGN RESON MED, V63, P1448, DOI 10.1002/mrm.22390; Venegas JG, 2005, NATURE, V434, P777, DOI 10.1038/nature03490; Warfield SK, 2004, IEEE T MED IMAGING, V23, P903, DOI 10.1109/TMI.2004.828354; Woodhouse N, 2005, J MAGN RESON IMAGING, V21, P365, DOI 10.1002/jmri.20290; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015	34	34	34	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					789	+		10.1016/j.jaci.2015.08.045	http://dx.doi.org/10.1016/j.jaci.2015.08.045			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26521043	Green Accepted, Bronze			2022-12-18	WOS:000371897500022
J	Schoos, AMM; Chawes, BL; Rasmussen, MA; Bloch, J; Bonnelykke, K; Bisgaard, H				Schoos, Ann-Marie Malby; Chawes, Bo Lund; Rasmussen, Morten Arendt; Bloch, Joakim; Bonnelykke, Klaus; Bisgaard, Hans			Atopic endotype in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Endotype; sensitization; skin prick test; specific IgE; eczema; asthma; children	SKIN-PRICK TEST; ALLERGEN-SPECIFIC IGE; YOUNG-CHILDREN; BIRTH COHORT; CLINICAL ALLERGY; NATURAL COURSE; ASTHMA; SENSITIZATION; ASSOCIATION; RISK	Background: The term atopic disorder is an early attempt to define specific endotypes of children with asthma, eczema, or both and increased IgE levels. Objective: We performed a longitudinal analysis of the relevance of the atopic endotype from birth to age 13 years. Methods: Allergic sensitization against 28 inhalant and food allergens was assessed at 1/2, 1 1/2, 4, 6, and 13 years of age in 399 children from the Copenhagen Prospective Study on Asthma in Childhood(2000) birth cohort by using both skin prick test responses and specific IgE levels. Asthma and eczema were diagnosed longitudinally by strictly adhering to predefined algorithms. Associations between allergic sensitization, asthma, and eczema were estimated by means of logistic regression, and a machine learning approach was used to identify temporal phenotype clusters of these traits. Results: Allergic sensitization showed no association with asthma through early childhood (0-6 years) when analyzed as any sensitization (odds ratio[OR] range, 0.78-1.29; P >=.48). However, at 13 years of age, any sensitization was associated with asthma (OR range, 4.02-5.94; all P<.001). In contrast, any sensitization was associated with eczema at 1/2, 1 1/2, and 6 years of age (OR range, 2.06-6.02; P <=.01) and borderline associated at 4 years of age (OR, 1.61 [95% CI, 0.96-2.69]; P=.07) but not at 13 years of age (OR, 1.57 [95% CI, 0.78-3.16]; P=.21). We identified 4 latent patterns of disease development that were either dominated by sensitization (37%), eczema (26%), asthma (14%), or healthy status (24%). Conclusion: We found very little interdependency between asthma, eczema, and allergic sensitization through childhood. The associations between those entities were strongly dependent on age, type of allergens, and method of testing for sensitization. Therefore, atopy in children is unlikely to represent a true endotype.	[Schoos, Ann-Marie Malby; Chawes, Bo Lund; Rasmussen, Morten Arendt; Bloch, Joakim; Bonnelykke, Klaus; Bisgaard, Hans] Copenhagen Prospect Studies Asthma Childhood, Herlev, Denmark; [Schoos, Ann-Marie Malby; Chawes, Bo Lund; Rasmussen, Morten Arendt; Bloch, Joakim; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Gentofte Hosp, Copenhagen, Denmark; [Rasmussen, Morten Arendt] Univ Copenhagen, Fac Sci, Dept Food Sci, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen	Bisgaard, H (corresponding author), Copenhagen Prospect Studies Asthma Childhood, Herlev, Denmark.; Bisgaard, H (corresponding author), Univ Copenhagen, Gentofte Hosp, Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Rasmussen, Morten/AAE-9517-2020; Bisgaard, Hans/N-4761-2016; Arendt, Morten/S-8843-2017; Schoos, Ann-Marie Malby/AAO-7677-2020	Rasmussen, Morten/0000-0001-7431-5206; Bisgaard, Hans/0000-0003-4131-7592; Arendt, Morten/0000-0001-7431-5206; Schoos, Ann-Marie Malby/0000-0002-5827-0885; Bonnelykke, Klaus/0000-0003-2003-1018; Bloch, Joakim/0000-0002-9618-3483; Chawes, Bo/0000-0001-6846-6243	Lundbeck Foundation [R16-A1694]; Danish Ministry of Health [903516]; Danish Council for Strategic Research [0603-00280B]	Lundbeck Foundation(Lundbeckfonden); Danish Ministry of Health; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF))	Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) is funded by private and public research funds, all of which are listed on www.copsac.com. The Lundbeck Foundation (grant no. R16-A1694), the Danish Ministry of Health (grant no. 903516), the Danish Council for Strategic Research (grant no. 0603-00280B), and the Capital Region Research Foundation have provided core support for COPSAC. No pharmaceutical company was involved in the study. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript.	Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Ballardini N, 2006, ALLERGY, V61, P337, DOI 10.1111/j.1398-9995.2005.00936.x; Belgrave DCM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001748; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Bonnelykke K, 2013, NAT GENET, V45, P902, DOI 10.1038/ng.2694; Carlsten C, 2010, PEDIAT ALLERG IMM-UK, V21, pE740, DOI 10.1111/j.1399-3038.2010.01021.x; Chawes BLK, 2010, AM J RESP CRIT CARE, V182, P138, DOI 10.1164/rccm.200909-1377OC; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; de Vos G, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0430-z; Garcia-Marcos L, 2007, PEDIAT ALLERG IMM-UK, V18, P240, DOI 10.1111/j.1399-3038.2006.00508.x; Govaere E, 2009, PEDIAT ALLERG IMM-UK, V20, P448, DOI 10.1111/j.1399-3038.2008.00805.x; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Halkjaer LB, 2006, ARCH DERMATOL, V142, P561, DOI 10.1001/archderm.142.5.561; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kurukulaaratchy RJ, 2005, ALLERGY, V60, P1280, DOI 10.1111/j.1398-9995.2005.00890.x; McHugh BM, 2011, ALLERGY ASTHMA PROC, V32, P372, DOI 10.2500/aap.2011.32.3456; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nissen SP, 2013, PEDIAT ALLERG IMM-UK, V24, P549, DOI 10.1111/pai.12108; Ro AD, 2012, EUR J PEDIATR, V171, P479, DOI 10.1007/s00431-011-1580-9; Schoos AMM, 2015, ALLERGY, V70, P41, DOI 10.1111/all.12523; Shaker M, 2014, CURR OPIN PEDIATR, V26, P516, DOI 10.1097/MOP.0000000000000120; Sinclair D, 2004, J CLIN PATHOL, V57, P956, DOI 10.1136/jcp.2004.017681; Soderstrom L, 2011, ALLERGY, V66, P1058, DOI 10.1111/j.1398-9995.2011.02578.x; Stoltz DJ, 2013, CLIN EXP ALLERGY, V43, P233, DOI 10.1111/cea.12050; Vissing NH, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-160; Wahn U, 2000, ALLERGY, V55, P591, DOI 10.1034/j.1398-9995.2000.00111.x; Warren P, 2006, LANCET, V368, P1416, DOI 10.1016/S0140-6736(06)69596-2; 2006, LANCET, V368, P705	34	34	34	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					844	+		10.1016/j.jaci.2015.10.004	http://dx.doi.org/10.1016/j.jaci.2015.10.004			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26597163	Bronze			2022-12-18	WOS:000371897500028
J	Sousa-Pinto, B; Pinto-Ramos, J; Correia, C; Goncalves-Costa, G; Gomes, L; Gil-Mata, S; Araujo, L; Delgado, L				Sousa-Pinto, Bernardo; Pinto-Ramos, Joao; Correia, Claudia; Goncalves-Costa, Gustavo; Gomes, Lidia; Gil-Mata, Sara; Araujo, Luis; Delgado, Luis			Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Sousa-Pinto, Bernardo; Pinto-Ramos, Joao; Correia, Claudia; Goncalves-Costa, Gustavo; Gomes, Lidia; Gil-Mata, Sara; Araujo, Luis; Delgado, Luis] Univ Porto, Fac Med, Immunol Lab, Basic & Clin Immunol Unit, P-4100 Oporto, Portugal; [Sousa-Pinto, Bernardo; Delgado, Luis] Univ Porto, Fac Med, Ctr Res Hlth Technol & Informat Syst CINTESIS, P-4100 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Sousa-Pinto, B (corresponding author), Univ Porto, Fac Med, Immunol Lab, Basic & Clin Immunol Unit, Rua Campo Alegre 823, P-4100 Oporto, Portugal.	mimed10201@med.up.pt	Delgado, Luis/L-8035-2013; Ramos, João/GSM-7241-2022; Sousa-Pinto, Bernardo/O-2846-2014	Delgado, Luis/0000-0003-2375-9071; Sousa-Pinto, Bernardo/0000-0002-1277-3401; Gomes, Lidia/0000-0002-6363-5463; Costa, Gustavo/0000-0003-3012-7603; Araujo, Luis/0000-0001-8511-2930; Gil-Mata, Sara/0000-0002-9564-3652; Correia, Claudia/0000-0002-4239-6096				Colombo S, 2008, J INFECT DIS, V198, P864, DOI 10.1086/591184; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hughes DA, 2004, PHARMACOGENETICS, V14, P335, DOI 10.1097/00008571-200406000-00002; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Martin AM, 2004, P NATL ACAD SCI USA, V101, P4180, DOI 10.1073/pnas.0307067101; Martin MA, 2013, PHARMACOTHERAPY, V33, P765, DOI 10.1002/phar.1278; Munderi P, 2011, TROP MED INT HEALTH, V16, P200, DOI 10.1111/j.1365-3156.2010.02688.x; Phillips EJ, 2005, AIDS, V19, P979, DOI 10.1097/01.aids.0000171414.99409.fb; Phillips EJ, 2002, AIDS, V16, P2223, DOI 10.1097/00002030-200211080-00017; Phillips EJ, 2011, J ALLERGY CLIN IMMUN, V127, pS60, DOI 10.1016/j.jaci.2010.11.046; Rauch A, 2008, ANTIVIR THER, V13, P1019; Rodriguez-Novoa S, 2007, AIDS RES HUM RETROV, V23, P1374, DOI 10.1089/aid.2006.0244; Saag M, 2008, CLIN INFECT DIS, V46, P1111, DOI 10.1086/529382; Stekler J, 2006, AIDS, V20, P1269, DOI 10.1097/01.aids.0000232234.19006.a2	16	34	35	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1092	+		10.1016/j.jaci.2015.03.019	http://dx.doi.org/10.1016/j.jaci.2015.03.019			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25934581	Bronze			2022-12-18	WOS:000362976300028
J	[Anonymous]				[Anonymous]			Somatic NOD2 mosaicism in Blau syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PEDIATRIC GRANULOMATOUS ARTHRITIS; CARD15 MUTATIONS; COHORT						Magri, Giuliana/K-6552-2014	Magri, Giuliana/0000-0002-0163-3542; YAGUE, JORDI/0000-0001-8210-1929; RUIZ-ORTIZ, ESTIBALIZ/0000-0002-3003-934X; De Inocencio, Jaime/0000-0002-0438-0245; Yague Ribes, Jordi/0000-0002-1935-4488; Gonzalez-Roca, Eva/0000-0002-1126-0321; Arostegui, Juan Ignacio/0000-0003-4757-504X; Mensa-Vilaro, Anna/0000-0001-7541-9672; Cerutti, Andrea/0000-0003-3026-4704	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057653, U01AI095613] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI095613, R01 AI057653] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arostegui JI, 2007, ARTHRITIS RHEUM-US, V56, P3805, DOI 10.1002/art.22966; Biesecker LG, 2013, NAT REV GENET, V14, P307, DOI 10.1038/nrg3424; Kanazawa N, 2005, BLOOD, V105, P1195, DOI 10.1182/blood-2004-07-2972; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Nakagawa K, 2013, ANN RHEUM DIS; Rose CD, 2009, ARTHRITIS RHEUM, V60, P1797, DOI 10.1002/art.24533; Tanaka N, 2011, ARTHRITIS RHEUM-US, V63, P3625, DOI 10.1002/art.30512	8	34	35	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					484	+		10.1016/j.jaci.2014.12.1941	http://dx.doi.org/10.1016/j.jaci.2014.12.1941			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25724124	Green Accepted			2022-12-18	WOS:000359004900033
J	Gomez, JL; Crisafi, GM; Holm, CT; Meyers, DA; Hawkins, GA; Bleecker, ER; Jarjour, N; Cohn, L; Chupp, GL				Gomez, Jose L.; Crisafi, Gina M.; Holm, Carole T.; Meyers, Deborah A.; Hawkins, Gregory A.; Bleecker, Eugene R.; Jarjour, Nizar; Cohn, Lauren; Chupp, Geoffrey L.		Severe Asthma Res Program SARP Inv	Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma severity; severe asthma; genetic association studies; genetic variation; CHI3L1 protein; human; YKL-40 protein; human; airway remodeling	RESEARCH-PROGRAM; LUNG; IDENTIFICATION; POLYMORPHISMS; PROTEIN; ATOPY	Background: Single nucleotide polymorphisms (SNPs) in the chitinase 3-like 1 (CHI3L1) promoter, the gene encoding YKL-40, are associated with circulating YKL-40 levels and asthma prevalence. However, the effects of gene polymorphisms on asthma severity and airway expression of YKL-40 have not been examined. Objective: We sought to determine the effect of genetic variation in CHI3L1 on asthma severity and YKL-40 expression in subjects from the Yale Center for Asthma and Airways Disease and the Severe Asthma Research Program. Methods: SNPs spanning the CHI3L1 gene were genotyped in 259 Yale Center for Asthma and Airways Disease and 919 Severe Asthma Research Program subjects. Association and haplotype analyses were conducted to identify effects on airflow obstruction, YKL-40 levels, and asthma severity. Results: Fifteen SNPs in CHI3L1 were associated with FEV1, serum YKL-40 levels, or both. rs12141494 (intron 6) was the only SNP in subjects of European ancestry in both cohorts that was associated with serum YKL-40 levels and postbronchodilator FEV1. Conditional analysis demonstrated that the effect on lung function was independent of the promoter SNP rs4950928, and haplotype analysis demonstrated that G alleles at rs12141494 and rs4950928 are associated with lower YKL-40 expression and higher FEV1 percent predicted values. In asthmatic subjects the risk allele A at rs12141494 was associated with severe asthma and higher YKL-40 expression in the airway (P <= .05). Conclusion: In contrast to the promoter SNP rs4950928, the intronic SNP rs12141494 in CHI3L1 is associated with asthma severity, lung function, and YKL-40 expression in the blood and airway. These data suggest that SNP rs12141494 modulates YKL-40 expression in the airway and contributes to airway remodeling and asthma severity.	[Gomez, Jose L.; Holm, Carole T.; Cohn, Lauren; Chupp, Geoffrey L.] Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, New Haven, CT 06520 USA; [Gomez, Jose L.; Holm, Carole T.; Cohn, Lauren; Chupp, Geoffrey L.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; [Crisafi, Gina M.; Jarjour, Nizar] Univ Wisconsin, Sch Med, Sect Pulm & Crit Care Med, Madison, WI USA; [Meyers, Deborah A.; Hawkins, Gregory A.; Bleecker, Eugene R.] Wake Forest Sch Med, Ctr Human Genom & Personalized Med, Winston Salem, NC USA	Yale University; Yale University; University of Wisconsin System; University of Wisconsin Madison; Wake Forest University	Chupp, GL (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med, 300 Cedar St S441 TAC, New Haven, CT 06520 USA.	geoffrey.chupp@yale.edu		Gomez, Jose/0000-0002-6521-6318	National Institutes of Health [T32HL007778-18, T15LM007056-26, R01HL095390-03, R01HL069116, GCRC RR03186]; Flight Attendant Medical Research Institute Young Clinical Scientist Award [113393]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007778, R01HL118346, R01HL095390, R01HL069116] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007056] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute Young Clinical Scientist Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	Supported by National Institutes of Health training grants T32HL007778-18 and T15LM007056-26 and R01HL095390-03 (to G.L.C.), R01HL069116, and GCRC RR03186 (to G.M.C. and N.J.) and Flight Attendant Medical Research Institute Young Clinical Scientist Award 113393 (to J.L.G.).	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Bara I, 2012, AM J RESP CRIT CARE, V185, P715, DOI 10.1164/rccm.201105-0915OC; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Benjamini Y., 1995, J ROYAL STAT SOC B, V57, P12; Bojesen SE, 2011, CLIN CHIM ACTA, V412, P709, DOI 10.1016/j.cca.2011.01.022; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; CRAPO RO, 1982, B EUR PHYSIOPATH RES, V18, P893; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Gabriel Stacey, 2009, Curr Protoc Hum Genet, VChapter 2, DOI 10.1002/0471142905.hg0212s60; Lee CG, 2012, AM J RESP CRIT CARE, V185, P692, DOI 10.1164/rccm.201202-0203ED; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Rathcke CN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006106; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sohn MH, 2009, AM J RESP CRIT CARE, V179, P449, DOI 10.1164/rccm.200809-1422OC; Tang H, 2013, J IMMUNOL, V190, P438, DOI 10.4049/jimmunol.1201827; Wu AC, 2010, J ALLERGY CLIN IMMUN, V125, P754, DOI 10.1016/j.jaci.2009.12.995; Yeo G, 2004, J COMPUT BIOL, V11, P377, DOI 10.1089/1066527041410418	19	34	41	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					51	U118		10.1016/j.jaci.2014.11.027	http://dx.doi.org/10.1016/j.jaci.2014.11.027			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25592985	Green Accepted			2022-12-18	WOS:000357542200006
J	Hamann, CR; Bernard, S; Hamann, D; Hansen, R; Thyssen, JP				Hamann, Carsten R.; Bernard, Stewart; Hamann, Dathan; Hansen, Ronald; Thyssen, Jacob P.			Is there a risk using hypoallergenic cosmetic pediatric products in the United States?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERLEUKIN-36-RECEPTOR ANTAGONIST DEFICIENCY; GENERALIZED PUSTULAR PSORIASIS; DELAYED-TYPE HYPERSENSITIVITY; ATOPIC-DERMATITIS REACTIVITY; MUTATION ANALYSIS; IL36RN MUTATION; EARLY-ONSET; DISEASE; VARIANTS; GENE		[Hamann, Carsten R.; Bernard, Stewart] Loma Linda Univ, Sch Med, Loma Linda, CA 92354 USA; [Hamann, Dathan] Ohio State Univ, Dept Internal Med, Div Dermatol, Columbus, OH 43210 USA; [Hansen, Ronald] Phoenix Childrens Hosp, Phoenix, AZ USA; [Thyssen, Jacob P.] Copenhagen Univ Hosp, Natl Allergy Res Ctr, Dept Dermatoallergol, Gentofte, Denmark	Loma Linda University; University System of Ohio; Ohio State University; Phoenix Children's Hospital; University of Copenhagen	Hamann, CR (corresponding author), Loma Linda Univ, Sch Med, Loma Linda, CA 92354 USA.	hamann511@gmail.com	Hamann, Carsten/Q-6098-2016; Thyssen, Jacob/ABD-8517-2020	Hamann, Carsten/0000-0003-2011-7380; Thyssen, Jacob Pontoppidan/0000-0003-3770-1743	Lundbeck Foundation [R139-2012-12679] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden)		Abbas O, 2013, DERMATOLOGY, V226, P28, DOI 10.1159/000346572; Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Castanedo-Tardana MP, 2013, DERMATITIS, V24, P2, DOI 10.1097/DER.0b013e31827edc73; Choi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046688; Farooq M, 2013, HUM MUTAT, V34, P176, DOI 10.1002/humu.22203; Herro Elise M, 2011, J Clin Aesthet Dermatol, V4, P39; Kanazawa N, 2013, J DERMATOL, V40, P749, DOI 10.1111/1346-8138.12227; Korber A, 2013, J INVEST DERMATOL, V133, P2634, DOI 10.1038/jid.2013.214; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Li B, 2009, BIOINFORMATICS, V25, P2744, DOI 10.1093/bioinformatics/btp528; Li M, 2013, BRIT J DERMATOL, V168, P452, DOI 10.1111/j.1365-2133.2012.11195.x; Marrakchi S, 2011, NEW ENGL J MED, V365, P620, DOI 10.1056/NEJMoa1013068; McFadden JP, 2012, BRIT J DERMATOL, V166, P1156, DOI 10.1111/j.1365-2133.2012.10915.x; Newell L, 2013, J INVEST DERMATOL, V133, P2372, DOI 10.1038/jid.2013.148; Onoufriadis A, 2011, AM J HUM GENET, V89, P432, DOI 10.1016/j.ajhg.2011.07.022; Renert-Yuval Y, 2014, INT J DERMATOL, V53, P866, DOI 10.1111/ijd.12525; Rossi-Semerano L, 2013, PEDIATRICS, V132, pE1043, DOI 10.1542/peds.2012-3935; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Setta-Kaffetzi N, 2013, J INVEST DERMATOL, V133, P1366, DOI 10.1038/jid.2012.490; Shaughnessy CN, 2014, J AM ACAD DERMATOL, V70, P704, DOI 10.1016/j.jaad.2013.12.009; Shaughnessy CN, 2014, J AM ACAD DERMATOL, V70, P102, DOI 10.1016/j.jaad.2013.08.046; Song HS, 2014, ANN DERMATOL, V26, P424, DOI 10.5021/ad.2014.26.3.424; Sugiura K, 2014, J EUR ACAD DERMATOL, V9, P1; Sugiura K, 2013, J INVEST DERMATOL, V133, P2514, DOI 10.1038/jid.2013.230; The Nordic Cochrane Centre, 2012, REV MAN REVMAN; Thyssen JP, 2014, ALLERGY, V69, P28, DOI 10.1111/all.12358; Williams FMK, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003095; Wong LP, 2013, AM J HUM GENET, V92, P52, DOI 10.1016/j.ajhg.2012.12.005	29	34	34	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					1070	1071		10.1016/j.jaci.2014.07.066	http://dx.doi.org/10.1016/j.jaci.2014.07.066			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25458001				2022-12-18	WOS:000352238600033
J	Lin, CH; Chen, JK; Ko, TM; Wei, CY; Wu, JY; Chung, WH; Chen, SY; Liao, YD; Hung, SI; Chen, YT				Lin, Chia-Hsien; Chen, Jung-Kuei; Ko, Tai-Ming; Wei, Chun-Yu; Wu, Jer-Yuarn; Chung, Wen-Hung; Chen, Shih-Yang; Liao, You-Di; Hung, Shuen-Iu; Chen, Yuan-Tsong			Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							QUALITY-OF-LIFE; HOSPITAL ANXIETY; DEPRESSION SCALE; ASTHMA CONTROL; HYPERSENSITIVITY		[Lin, Chia-Hsien; Chen, Yuan-Tsong] Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10764, Taiwan; [Lin, Chia-Hsien; Chen, Jung-Kuei; Ko, Tai-Ming; Wei, Chun-Yu; Wu, Jer-Yuarn; Liao, You-Di; Chen, Yuan-Tsong] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Hung, Shuen-Iu] Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei 112, Taiwan; [Hung, Shuen-Iu] Natl Yang Ming Univ, Infect & Immun Res Ctr, Taipei 112, Taiwan; [Chung, Wen-Hung] Chang Gung Mem Hosp, Dept Dermatol, Taipei 10591, Taiwan; [Chen, Shih-Yang] Country Hosp, Ctr Gout, Taipei, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Chang Gung Memorial Hospital	Chen, YT (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10764, Taiwan.	sihung@ym.edu.tw; chen0010@ibms.sinica.edu.tw	Wu, Jer-Yuarn/S-7010-2018; Ko, Tai-Ming/ABB-3384-2020; Hung, Shuen-Iu/ABB-2139-2021; Liao, You-Di/S-7018-2018	Hung, Shuen-Iu/0000-0001-6531-5538; Liao, You-Di/0000-0001-5527-4736				Barzi F, 2004, AM J EPIDEMIOL, V160, P34, DOI 10.1093/aje/kwh175; Bishop GD, 2001, J RES PERS, V35, P353, DOI 10.1006/jrpe.2001.2319; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cohen S, 1988, SOC PSYCHOL HEALTH, V1, P31; DeSalvo KB, 2006, J GEN INTERN MED, V21, P267, DOI 10.1111/j.1525-1497.2005.00291.x; Dreger LC, 2010, J ALLERGY CLIN IMMUN, V125, P116, DOI 10.1016/j.jaci.2009.09.051; Gupta MA, 2004, J EUR ACAD DERMATOL, V18, P560, DOI 10.1111/j.1468-3083.2004.00931.x; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Lai CKW, 2011, RESPIROLOGY, V16, P688, DOI 10.1111/j.1440-1843.2011.01954.x; Matsudaira T, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-42; McCrae, 1992, REVISED NEO PERSONAL; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Ng TP, 2009, RESP MED, V103, P895, DOI 10.1016/j.rmed.2008.12.010; Pallant Julie F, 2005, Health Qual Life Outcomes, V3, P82, DOI 10.1186/1477-7525-3-82; Phillips EJ, 2011, J ALLERGY CLIN IMMUN, V127, pS60, DOI 10.1016/j.jaci.2010.11.046; Terkeltaub R, 2010, NAT REV RHEUMATOL, V6, P30, DOI 10.1038/nrrheum.2009.236; Yun J, 2013, CLIN EXP ALLERGY, V43, P1246, DOI 10.1111/cea.12184; Yun J, 2014, J IMMUNOL, V192, P2984, DOI 10.4049/jimmunol.1302306; Zhang YL, 2012, SCI CHINA LIFE SCI, V55, P818, DOI 10.1007/s11427-012-4374-z; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zollner EW, 2012, PEDIATRICS, V130, pE1512, DOI 10.1542/peds.2012-1147	24	34	35	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					1063	+		10.1016/j.jaci.2014.09.041	http://dx.doi.org/10.1016/j.jaci.2014.09.041			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25458913				2022-12-18	WOS:000352238600030
J	Takeda, K; Shiraishi, Y; Ashino, S; Han, JY; Jia, Y; Wang, MQ; Lee, NA; Lee, JJ; Gelfand, EW				Takeda, Katsuyuki; Shiraishi, Yoshiki; Ashino, Shigeru; Han, Junyan; Jia, Yi; Wang, Meiqin; Lee, Nancy A.; Lee, James J.; Gelfand, Erwin W.			Eosinophils contribute to the resolution of lung-allergic responses following repeated allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophils; resolution of inflammation; IL-10	AIRWAY HYPERRESPONSIVENESS; DENDRITIC CELLS; TGF-BETA; T-CELLS; MOUSE EOSINOPHILS; PULMONARY INFLAMMATION; SPUTUM EOSINOPHILIA; ATOPIC ASTHMATICS; IL-10; MICE	Background: Eosinophils accumulate at the site of allergic inflammation and are critical effector cells in allergic diseases. Recent studies have also suggested a role for eosinophils in the resolution of inflammation. Objective: To determine the role of eosinophils in the resolution phase of the response to repeated allergen challenge. Methods: Eosinophil-deficient (PHIL) and wild-type (WT) littermates were sensitized and challenged to ovalbumin (OVA) 7 or 11 times. Airway inflammation, airway hyperresponsiveness (AHR) to inhaled methacholine, bronchoalveolar lavage (BAL) cytokine levels, and lung histology were monitored. Intracellular cytokine levels in BAL leukocytes were analyzed by flow cytometry. Groups of OVA-sensitized PHIL mice received bone marrow from WT or IL-10(-/-) donors 30 days before the OVA challenge. Results: PHIL and WT mice developed similar levels of AHR and numbers of leukocytes and cytokine levels in BAL fluid after OVA sensitization and 7 airway challenges; no eosinophils were detected in the PHIL mice. Unlike WT mice, sensitized PHIL mice maintained AHR, lung inflammation, and increased levels of IL-4, IL-5, and IL-13 in BAL fluid after 11 challenges whereas IL-10 and TGF-beta levels were decreased. Restoration of eosinophil numbers after injection of bone marrow from WT but not IL-10-deficient mice restored levels of IL-10 and TGF-beta in BAL fluid as well as suppressed AHR and inflammation. Intracellular staining of BAL leukocytes revealed the capacity of eosinophils to produce IL-10. Conclusions: After repeated allergen challenge, eosinophils appeared not essential for the development of AHR and lung inflammation but contributed to the resolution of AHR and inflammation by producing IL-10.	[Takeda, Katsuyuki; Shiraishi, Yoshiki; Ashino, Shigeru; Han, Junyan; Jia, Yi; Wang, Meiqin; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; [Lee, Nancy A.; Lee, James J.] Mayo Clin Arizona, Scottsdale, AZ USA	National Jewish Health; Mayo Clinic; Mayo Clinic Phoenix	Gelfand, EW (corresponding author), Natl Jewish Hlth, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njhealth.org	Shiraishi, Yoshiki/Q-3914-2019	Shiraishi, Yoshiki/0000-0001-5275-6318	National Institutes of Health [HL-58723, HL-065228, AI-77609, HL-36577]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058723, R01HL065228, R56HL058723, P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077609, R56AI077609] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institutes of Health (grant no. HL-58723 to N.A.L., grant no. HL-065228 to J.J.L., and grant nos. AI-77609 and HL-36577 to E.W.G.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.	Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886; Arita M, 2012, J BIOCHEM, V152, P313, DOI 10.1093/jb/mvs092; Ashino S, 2014, J ALLERGY CLIN IMMUN, V133, P1162, DOI 10.1016/j.jaci.2013.10.036; Banchereau J, 2012, NAT IMMUNOL, V13, P925, DOI 10.1038/ni.2406; Borchers MT, 2002, J LEUKOCYTE BIOL, V71, P1033; Botelho FM, 2011, AM J RESP CELL MOL, V45, P753, DOI 10.1165/rcmb.2010-0404OC; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Buttner C, 2003, EUR RESPIR J, V21, P799, DOI 10.1183/09031936.03.00027302; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Colavita AM, 2000, J ALLERGY CLIN IMMUN, V106, P880, DOI 10.1067/mai.2000.110475; Cui ZH, 2003, AM J RESP CRIT CARE, V168, P1324, DOI 10.1164/rccm.200305-634OC.R1; Denzler KL, 2000, J IMMUNOL, V165, P5509, DOI 10.4049/jimmunol.165.10.5509; Denzler KL, 2001, J IMMUNOL, V167, P1672, DOI 10.4049/jimmunol.167.3.1672; Di Franco A, 2003, J ASTHMA, V40, P155, DOI 10.1081/JAS-120017986; Doyle AD, 2013, BLOOD, V122, P781, DOI 10.1182/blood-2013-01-473405; Dyer KD, 2013, METHODS MOL BIOL, V1032, P59, DOI 10.1007/978-1-62703-496-8_5; Fattouh R, 2011, AM J RESP CRIT CARE, V183, P179, DOI 10.1164/rccm.200905-0736OC; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fu CL, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-72; Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934, DOI 10.1164/ajrccm.160.3.9806029; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V120, P8, DOI 10.1159/000024215; Hamelmann E, 1997, AM J RESP CELL MOL, V16, P674, DOI 10.1165/ajrcmb.16.6.9191469; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Hogan SP, 1998, J IMMUNOL, V161, P1501; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Isobe Y, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00270; Jacobsen EA, 2014, ALLERGY, V69, P315, DOI 10.1111/all.12321; Jacobsen EA, 2008, J EXP MED, V205, P699, DOI 10.1084/jem.20071840; Jacobsen EA, 2012, BLOOD, V120, P3882, DOI 10.1182/blood-2012-06-330845; Jacobsen EA, 2011, J IMMUNOL, V187, P6059, DOI 10.4049/jimmunol.1102299; Joetham A, 2007, J IMMUNOL, V178, P1433, DOI 10.4049/jimmunol.178.3.1433; Justice JP, 2003, AM J PHYSIOL-LUNG C, V284, pL169, DOI 10.1152/ajplung.00260.2002; Kallinich T, 2007, EUR RESPIR J, V29, P1246, DOI 10.1183/09031936.00094306; Kayaba H, 2001, J IMMUNOL, V167, P995, DOI 10.4049/jimmunol.167.2.995; Kosaka S, 2011, IMMUNOBIOLOGY, V216, P811, DOI 10.1016/j.imbio.2010.12.003; Koya T, 2006, AM J RESP CRIT CARE, V173, P42, DOI 10.1164/rccm.200505-783OC; Koya T, 2007, J ALLERGY CLIN IMMUN, V119, P1241, DOI 10.1016/j.jaci.2007.01.039; Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020; Leckie Maggie J, 2003, Am J Respir Med, V2, P245; Lee JJ, 2012, J ALLERGY CLIN IMMUN, V130, P572, DOI 10.1016/j.jaci.2012.07.025; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382; Miyata J, 2013, J ALLERGY CLIN IMMUN, V131, P353, DOI 10.1016/j.jaci.2012.07.048; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nakajima H, 1996, J IMMUNOL, V156, P4859; Nayyar A, 2012, J IMMUNOL, V189, P72, DOI 10.4049/jimmunol.1103286; Niimi A, 1998, CLIN EXP ALLERGY, V28, P233; Ochkur SI, 2012, J IMMUNOL METHODS, V375, P138, DOI 10.1016/j.jim.2011.10.002; Ogawa Y, 2008, CURR MOL MED, V8, P437, DOI 10.2174/156652408785160907; Ohtomo T, 2010, INT ARCH ALLERGY IMM, V152, P79, DOI 10.1159/000312130; Phipps S, 2004, J INVEST DERMATOL, V122, P1406, DOI 10.1111/j.0022-202X.2004.22619.x; Rosenberg HF, 2013, NAT REV IMMUNOL, V13, P9, DOI 10.1038/nri3341; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442, DOI 10.1164/ajrccm.155.2.9032176; Shi HZ, 2004, J LEUKOCYTE BIOL, V76, P520, DOI 10.1189/jlb.0404228; Spencer LA, 2009, J LEUKOCYTE BIOL, V85, P117, DOI 10.1189/jlb.0108058; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Takeda K, 2009, J IMMUNOL, V183, P181, DOI 10.4049/jimmunol.0803967; Walsh ER, 2008, J EXP MED, V205, P1285, DOI 10.1084/jem.20071836; Wang MQ, 2013, J ALLERGY CLIN IMMUN, V132, P1174, DOI 10.1016/j.jaci.2013.05.027; Wills-Karp M, 2004, SCIENCE, V305, P1726, DOI 10.1126/science.1104134; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	68	34	36	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					451	U610		10.1016/j.jaci.2014.08.014	http://dx.doi.org/10.1016/j.jaci.2014.08.014			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25312762	Green Accepted			2022-12-18	WOS:000349372300017
J	Frans, G; Moens, L; Schaballie, H; Van Eyck, L; Borgers, H; Wuyts, M; Dillaerts, D; Vermeulen, E; Dooley, J; Grimbacher, B; Cant, A; Declerck, D; Peumans, M; Renard, M; De Boeck, K; Hoffman, I; Francois, I; Liston, A; Claessens, F; Bossuyt, X; Meyts, I				Frans, Glynis; Moens, Leen; Schaballie, Heidi; Van Eyck, Lien; Borgers, Heleen; Wuyts, Margareta; Dillaerts, Doreen; Vermeulen, Edith; Dooley, James; Grimbacher, Bodo; Cant, Andrew; Declerck, Dominique; Peumans, Marleen; Renard, Marleen; De Boeck, Kris; Hoffman, Ilse; Francois, Inge; Liston, Adrian; Claessens, Frank; Bossuyt, Xavier; Meyts, Isabelle			Gain-of-function mutations in signal transducer and activator of transcription 1 (STAT1): Chronic mucocutaneous candidiasis accompanied by enamel defects and delayed dental shedding	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOHISTOCHEMICAL LOCALIZATION; RAT MOLARS; T-CELLS		[Frans, Glynis; Moens, Leen; Schaballie, Heidi; Borgers, Heleen; Wuyts, Margareta; Dillaerts, Doreen; Bossuyt, Xavier; Meyts, Isabelle] Katholieke Univ Leuven, Dept Microbiol & Immunol, Expt Immunol Lab, Leuven, Belgium; [Dooley, James; Liston, Adrian] Vlaams Inst Biotechnol, Lab Genet Autoimmun, Leuven, Belgium; [Vermeulen, Edith] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Clin Bacteriol & Mycol, Leuven, Belgium; [Grimbacher, Bodo] Univ Hosp, Ctr Chron Immunodeficiency, Freiburg, Germany; [Cant, Andrew] Newcastle Univ, Inst Cellular Med, Primary Immunodeficiency Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Cant, Andrew] Great North Childrens Hosp, Pediat Immunol Serv, Newcastle Upon Tyne, Tyne & Wear, England; [Declerck, Dominique; Peumans, Marleen] Katholieke Univ Leuven, Univ Hosp Leuven, Sch Dent, Dept Conservat Dent, Leuven, Belgium; [Schaballie, Heidi; Van Eyck, Lien; Renard, Marleen; De Boeck, Kris; Hoffman, Ilse; Francois, Inge; Meyts, Isabelle] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium; [Claessens, Frank] Katholieke Univ Leuven, Dept Cellular & Mol Med, Mol Endocrinol Lab, Leuven, Belgium	KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University of Freiburg; Newcastle University - UK; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven	Frans, G (corresponding author), Katholieke Univ Leuven, Dept Microbiol & Immunol, Expt Immunol Lab, Leuven, Belgium.	Isabelle.Meyts@uzleuven.be	Meyts, Isabelle/Z-3295-2019; Liston, Adrian/G-8606-2013; Claessens, Frank/M-8565-2016; Bossuyt, Xavier/B-2085-2019	Liston, Adrian/0000-0002-6272-4085; Claessens, Frank/0000-0002-8676-7709; Bossuyt, Xavier/0000-0001-6856-8485; Dooley, James/0000-0003-3154-4708				Borgers H, 2010, CLIN IMMUNOL, V134, P198, DOI 10.1016/j.clim.2009.10.006; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Otsuji W, 1999, ARCH ORAL BIOL, V44, P173, DOI 10.1016/S0003-9969(98)00092-2; Sampaio EP, 2013, J ALLERGY CLIN IMMUN, V131, P1624, DOI 10.1016/j.jaci.2013.01.052; Soltesz B, 2013, J MED GENET, V50, P567, DOI 10.1136/jmedgenet-2013-101570; Takezaki S, 2012, J IMMUNOL, V189, P1521, DOI 10.4049/jimmunol.1200926; Tanase S, 1996, ARCH ORAL BIOL, V41, P925, DOI 10.1016/S0003-9969(96)00048-9; Tsai YG, 2012, LAB INVEST, V92, P1260, DOI 10.1038/labinvest.2012.86; Tsai YG, 2010, PEDIAT ALLERG IMM-UK, V21, pE166, DOI 10.1111/j.1399-3038.2009.00870.x; Uzel G, 2013, J ALLERGY CLIN IMMUN, V131, P1611, DOI 10.1016/j.jaci.2012.11.054; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102	11	34	35	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1209	1213		10.1016/j.jaci.2014.05.044	http://dx.doi.org/10.1016/j.jaci.2014.05.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25042743	Green Published, hybrid			2022-12-18	WOS:000344938900034
J	Antico, A; Fante, R				Antico, Andrea; Fante, Rossella			Esophageal hypereosinophilia induced by grass sublingual immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EOSINOPHILIC ESOPHAGITIS; CHILDREN; ALLERGY; ADULTS; POLLEN		[Antico, Andrea] Osped Civile SRL, Allergy Unit, Volta Mantovana, Italy; [Fante, Rossella] Azienda Osped C Poma, Pathol Unit, Mantua, Italy	Hospital Carlo Poma	Antico, A (corresponding author), Osped Civile SRL, Allergy Unit, Volta Mantovana, Italy.	antico47@gmail.com		Antico, Andrea/0000-0001-7832-517X				Almansa C, 2009, AM J GASTROENTEROL, V104, P828, DOI 10.1038/ajg.2008.169; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Onbasi K, 2005, CLIN EXP ALLERGY, V35, P1423, DOI 10.1111/j.1365-2222.2005.02351.x; Rayapudi M, 2010, J LEUKOCYTE BIOL, V88, P337, DOI 10.1189/jlb.0110025; Ridolo E, 2011, ANN ALLERG ASTHMA IM, V106, P73, DOI 10.1016/j.anai.2010.10.010; Sanchez-Garcia S, 2012, J ALLERGY CLIN IMMUN, V129, P1155, DOI 10.1016/j.jaci.2011.11.042; Simon D, 2013, ALLERGY, V68, P945, DOI 10.1111/all.12157; Sorser SA, 2013, J GASTROENTEROL, V48, P81, DOI 10.1007/s00535-012-0608-x	10	34	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1482	+		10.1016/j.jaci.2014.01.030	http://dx.doi.org/10.1016/j.jaci.2014.01.030			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24636095				2022-12-18	WOS:000335450700038
J	Maggadottir, SM; Hill, DA; Ruymann, K; Brown-Whitehorn, TF; Cianferoni, A; Shuker, M; Wang, ML; Chikwava, K; Verma, R; Liacouras, CA; Spergel, JM				Maggadottir, Solrun Melkorka; Hill, David A.; Ruymann, Kathryn; Brown-Whitehorn, Terri F.; Cianferoni, Antonella; Shuker, Michele; Wang, Mei-Lun; Chikwava, Kudakwashe; Verma, Ritu; Liacouras, Chris A.; Spergel, Jonathan M.			Resolution of acute IgE-mediated allergy with development of eosinophilic esophagitis triggered by the same food	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN		[Maggadottir, Solrun Melkorka; Hill, David A.; Ruymann, Kathryn; Brown-Whitehorn, Terri F.; Cianferoni, Antonella; Shuker, Michele; Spergel, Jonathan M.] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Wang, Mei-Lun; Verma, Ritu; Liacouras, Chris A.] Childrens Hosp Philadelphia, Div Anat Pathol, Philadelphia, PA 19104 USA; [Chikwava, Kudakwashe] Childrens Hosp Philadelphia, Div Gastroenterol & Nutr, Philadelphia, PA 19104 USA; [Cianferoni, Antonella; Wang, Mei-Lun; Verma, Ritu; Liacouras, Chris A.; Spergel, Jonathan M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Maggadottir, SM (corresponding author), Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA.	Spergel@email.chop.edu		Maggadottir, Solrun Melkorka/0000-0001-5704-1995; Spergel, Jonathan/0000-0002-4658-5353; Hill, David/0000-0001-9286-4268				Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Ridolo E, 2011, ANN ALLERG ASTHMA IM, V106, P73, DOI 10.1016/j.anai.2010.10.010; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Sanchez-Garcia S, 2012, J ALLERGY CLIN IMMUN, V129, P1155, DOI 10.1016/j.jaci.2011.11.042; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Spergel JM, 2007, J ALLERGY CLIN IMMUN, V119, P509, DOI 10.1016/j.jaci.2006.11.016; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021	9	34	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1487	+		10.1016/j.jaci.2014.02.004	http://dx.doi.org/10.1016/j.jaci.2014.02.004			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24636092				2022-12-18	WOS:000335450700040
J	Hosking, L; Bleecker, E; Ghosh, S; Yeo, A; Jacques, L; Mosteller, M; Meyers, D				Hosking, Louise; Bleecker, Eugene; Ghosh, Soumitra; Yeo, Astrid; Jacques, Loretta; Mosteller, Michael; Meyers, Deborah			GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMPROVED LUNG-FUNCTION; PHARMACOGENETICS; ASSOCIATION		[Hosking, Louise; Yeo, Astrid] GlaxoSmithKline Res & Dev Ltd, Dept Projects Clin Platforms & Sci, Stevenage, Herts, England; [Bleecker, Eugene; Meyers, Deborah] Wake Forest Sch Med, Ctr Human Genom & Personalized Med, Winston Salem, NC USA; [Ghosh, Soumitra] GlaxoSmithKline Res & Dev Ltd, Dept Projects Clin Platforms & Sci, Philadelphia, PA USA; [Jacques, Loretta] GlaxoSmithKline Res & Dev Ltd, Med Dev Ctr Global Clin, Stockley Pk, England; [Mosteller, Michael] GlaxoSmithKline Res & Dev Ltd, Dept Projects Clin Platforms & Sci, Res Triangle Pk, NC USA	GlaxoSmithKline; Wake Forest University; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Hosking, L (corresponding author), GlaxoSmithKline Res & Dev Ltd, Dept Projects Clin Platforms & Sci, Stevenage, Herts, England.	louise.k.hosking@gsk.com			NHLBI NIH HHS [U01 HL065899, U01 HL65899, RC2 HL101487] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065899, RC2HL101487] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Hawkins GA, 2009, J ALLERGY CLIN IMMUN, V123, P1376, DOI 10.1016/j.jaci.2009.01.049; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Maitland-van der Zee AH, 2012, PHARMACOGENOMICS, V13, P243, DOI [10.2217/pgs.11.177, 10.2217/PGS.11.177]; Pascual RM, 2010, CURR OPIN PHARMACOL, V10, P226, DOI 10.1016/j.coph.2010.05.013; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204	7	34	35	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					587	589		10.1016/j.jaci.2013.08.024	http://dx.doi.org/10.1016/j.jaci.2013.08.024			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24131825	Green Accepted			2022-12-18	WOS:000332397100040
J	Rosas-Salazar, C; Ramratnam, SK; Brehm, JM; Han, YY; Boutaoui, N; Forno, E; Acosta-Perez, E; Alvarez, M; Colon-Semidey, A; Canino, G; Celedon, JC				Rosas-Salazar, Christian; Ramratnam, Sima K.; Brehm, John M.; Han, Yueh-Ying; Boutaoui, Nadia; Forno, Erick; Acosta-Perez, Edna; Alvarez, Maria; Colon-Semidey, Angel; Canino, Glorisa; Celedon, Juan C.			Prematurity, atopy, and childhood asthma in Puerto Ricans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; prematurity; Puerto Rican; atopy	POPULATION-BASED COHORT; CHRONIC LUNG-DISEASE; PRETERM BIRTH; RESPIRATORY SYMPTOMS; ALLERGIC RHINITIS; GESTATIONAL-AGE; CHILDREN; RISK; SENSITIZATION; PREVALENCE	Background: Puerto Rican children share a disproportionate burden of prematurity and asthma in the United States. Little is known about prematurity and childhood asthma in Puerto Rican subjects. Objective: We sought to examine whether prematurity is associated with asthma in Puerto Rican children. Methods: We performed a case-control study of 678 children aged 6 to 14 years with (n = 351) and without (n = 327) asthma living in San Juan, Puerto Rico. Prematurity was defined by parental report for our primary analysis. In a secondary analysis, we only included children whose parents reported prematurity that required admission to the neonatal intensive care unit. Asthma was defined as physician-diagnosed asthma and wheeze in the prior year. We used logistic regression for analysis. All multivariate models were adjusted for age, sex, household income, atopy (>= 1 positive IgE level to common allergens), maternal history of asthma, and early-life exposure to environmental tobacco smoke. Results: In a multivariate analysis there was a significant interaction between prematurity and atopy on asthma (P=.006). In an analysis stratified by atopy, prematurity was associated with a nearly 5-fold increased odds of asthma in atopic children (adjusted odds ratio, 4.7; 95% CI, 1.5-14.3; P=.007). In contrast, there was no significant association between prematurity and asthma in nonatopic children. Similar results were obtained in our analysis of prematurity requiring admission to the neonatal intensive care unit and asthma. Conclusions: Our results suggest that atopy modifies the estimated effect of prematurity on asthma in Puerto Rican children. Prematurity might explain, in part, the high prevalence of atopic asthma in this ethnic group.	[Rosas-Salazar, Christian; Ramratnam, Sima K.; Brehm, John M.; Han, Yueh-Ying; Boutaoui, Nadia; Forno, Erick; Celedon, Juan C.] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Div Pediat Pulm Med Allergy & Immunol, Pittsburgh, PA 15260 USA; [Acosta-Perez, Edna; Alvarez, Maria; Colon-Semidey, Angel; Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA; [Acosta-Perez, Edna; Alvarez, Maria; Colon-Semidey, Angel; Canino, Glorisa] Univ Puerto Rico, Dept Pediat, San Juan, PR 00936 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Celedon, JC (corresponding author), 4401 Penn Ave, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu	Rosas-Salazar, Christian/AAC-8571-2021; Alvarez, Maria/GZH-1345-2022; Pérez, Edna Acosta/AAW-6672-2021; Forno, Erick/I-1476-2019	Rosas-Salazar, Christian/0000-0001-6644-5780; Forno, Erick/0000-0001-6497-9885; acosta, edna/0000-0001-7101-3157	National Institutes of Health (NIH) [HL079966, HD052892]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052892] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079966, R01HL117191] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grant HL079966 from the National Institutes of Health (NIH). J.M.B.'s contribution was supported by grant HD052892 from the NIH.	Akinbami Lara J, 2012, NCHS Data Brief, P1; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; Austin PC, 2011, STAT MED, V30, P1292, DOI 10.1002/sim.4200; Baraldi E, 2007, NEW ENGL J MED, V357, P1946, DOI 10.1056/NEJMra067279; Bird HR, 2006, J AM ACAD CHILD PSY, V45, P1032, DOI 10.1097/01.chi.0000227879.65651.cf; BLUMENTHAL MN, 1995, CLIN EXP ALLERGY, V25, P29, DOI 10.1111/j.1365-2222.1995.tb00416.x; Bolte G, 2004, CLIN EXP ALLERGY, V34, P381, DOI 10.1111/j.1365-2222.2004.01890.x; Boyle EM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e896; Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Celedon JC, 2002, PEDIAT ALLERG IMM-UK, V13, P91, DOI 10.1034/j.1399-3038.2002.00083.x; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; Chang HH, 2013, LANCET, V381, P223, DOI 10.1016/S0140-6736(12)61856-X; Cohen RT, 2007, CHEST, V131, P1331, DOI 10.1378/chest.06-1917; Cutz E, 2008, NEW ENGL J MED, V358; Cutz E, 2008, NEW ENGL J MED, V358, P743, DOI 10.1056/NEJMc073362; Dombkowski KJ, 2008, ANN EPIDEMIOL, V18, P290, DOI 10.1016/j.annepidem.2007.11.012; Fawke J, 2010, AM J RESP CRIT CARE, V182, P237, DOI 10.1164/rccm.200912-1806OC; Forno E, 2009, CURR OPIN ALLERGY CL, V9, P154, DOI 10.1097/ACI.0b013e3283292207; Gessner BD, 2007, THORAX, V62, P231, DOI 10.1136/thx.2005.053363; Getahun D, 2010, ARCH PEDIAT ADOL MED, V164, P187, DOI 10.1001/archpediatrics.2009.238; Goyal NK, 2011, PEDIATRICS, V128, pE830, DOI 10.1542/peds.2011-0809; Grischkan J, 2004, J PEDIATR-US, V144, P321, DOI 10.1016/j.jpeds.2003.11.029; Iams JD, 2008, LANCET, V371, P164, DOI 10.1016/S0140-6736(08)60108-7; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P136, DOI 10.2105/AJPH.94.1.136; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Katz KA, 2003, CLIN EXP ALLERGY, V33, P737, DOI 10.1046/j.1365-2222.2003.01670.x; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; Kindlund K, 2010, THORAX, V65, P146, DOI 10.1136/thx.2009.117101; Kuczmarski R J, 2000, Adv Data, P1; Malveaux FJ, 2009, PEDIATRICS, V123, pS129, DOI 10.1542/peds.2008-2233B; March of Dimes, 2012, 2012 PREM BIRTH REP; Maritz GS, 2005, EARLY HUM DEV, V81, P763, DOI 10.1016/j.earlhumdev.2005.07.002; Martin Joyce A, 2012, Natl Vital Stat Rep, V61, P1; Montealegre F, 2004, CLIN EXP ALLERGY, V34, P51, DOI 10.1111/j.1365-2222.2004.01855.x; Perez-Perdomo R, 2003, J ASTHMA, V40, P465, DOI 10.1081/JAS-120018713; Ramsey CD, 2007, J ALLERGY CLIN IMMUN, V119, P150, DOI 10.1016/j.jaci.2006.09.012; Rasanen M, 2000, THORAX, V55, P25, DOI 10.1136/thorax.55.1.25; RONA RJ, 1993, BMJ-BRIT MED J, V306, P817, DOI 10.1136/bmj.306.6881.817; Sevelsted A, 2012, ALLERGY, V67, P670, DOI 10.1111/j.1398-9995.2012.02805.x; Siltanen M, 2004, PEDIATR PULM, V37, P43, DOI 10.1002/ppul.10402; Siltanen M, 2001, J ALLERGY CLIN IMMUN, V107, P229, DOI 10.1067/mai.2001.112128; Siltanen M, 2011, J ALLERGY CLIN IMMUN, V127, P935, DOI 10.1016/j.jaci.2010.12.1107; Smith LK, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6654; Streiner DL, 2012, CHEST, V142, P1380, DOI 10.1378/chest.12-1920; US Census Bureau, HOUS INC STAT 2008 2; US Census Bureau, 2009, HOUS INC STAT 2008 2; Vogt H, 2011, PEDIATRICS, V127, P1052, DOI 10.1542/peds.2010-3083; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; WEISS ST, 1995, PEDIATR PULM, V19, P153, DOI 10.1002/ppul.1950190302	50	34	35	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					357	+		10.1016/j.jaci.2013.09.003	http://dx.doi.org/10.1016/j.jaci.2013.09.003			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24139607	Green Accepted			2022-12-18	WOS:000332397100007
J	Khodoun, MV; Kucuk, ZY; Strait, RT; Krishnamurthy, D; Janek, K; Lewkowich, I; Morris, SC; Finkelman, FD				Khodoun, Marat V.; Kucuk, Zeynep Yesim; Strait, Richard T.; Krishnamurthy, Durga; Janek, Kevin; Lewkowich, Ian; Morris, Suzanne C.; Finkelman, Fred D.			Rapid polyclonal desensitization with antibodies to IgE and Fc epsilon RI alpha	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; basophils; IgE; Fc epsilon RI; mast cells; mouse; rapid desensitization	STIMULATORY FACTOR-I; MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN-E; MAST-CELLS; HIGH-AFFINITY; ANAPHYLAXIS; BASOPHILS; MICE; RECEPTOR; ACTIVATION	Background: Rapid desensitization, a procedure in which persons allergic to an antigen are treated at short intervals with increasing doses of that antigen until they tolerate a large dose, is an effective, but risky, way to induce temporary tolerance. Objective: We wanted to determine whether this approach can be adapted to suppress all IgE-mediated allergies in mice by injecting serially increasing doses of monoclonal antibodies (mAbs) to IgE or Fc epsilon RI alpha. Methods: Active and passive models of antigen-and anti-IgE mAb-induced IgE-mediated anaphylaxis were used. Mice were desensitized with serially increasing doses of anti-IgE mAb, anti-Fc epsilon RI alpha mAb, or antigen. Development of shock (hypothermia), histamine and mast cell protease release, cytokine secretion, calcium flux, and changes in cell number and Fc epsilon RI and IgE expression were evaluated. Results: Rapid desensitization with anti-IgE mAb suppressed IgE-mediated immediate hypersensitivity; however, some mice developed mild anaphylaxis during desensitization. Rapid desensitization with anti-Fc epsilon RI alpha mAb that only binds Fc epsilon RI that is not occupied by IgE suppressed both active and passive IgE-mediated anaphylaxis without inducing disease. It quickly, but temporarily, suppressed IgE-mediated anaphylaxis by decreasing mast cell signaling through Fc epsilon RI, then slowly induced longer lasting mast cell unresponsiveness by removing membrane Fc epsilon RI. Rapid desensitization with anti-Fc epsilon RI alpha mAb was safer and longer lasting than rapid desensitization with antigen. Conclusion: A rapid desensitization approach with anti-Fc epsilon RI alpha mAb safely desensitizes mice to IgE-mediated anaphylaxis by inducing mast cell anergy and later removing all mast cell IgE. Rapid desensitization with an anti-human Fc epsilon RI alpha mAb may be able to prevent human IgE-mediated anaphylaxis.	[Khodoun, Marat V.; Krishnamurthy, Durga; Morris, Suzanne C.] Cincinnati Vet Affairs Med Ctr, Dept Res, Cincinnati, OH USA; [Khodoun, Marat V.; Krishnamurthy, Durga; Janek, Kevin; Morris, Suzanne C.; Finkelman, Fred D.] Univ Cincinnati, Dept Med, Div Immunol Allergy & Rheumatol, Sch Med, Cincinnati, OH 45267 USA; [Kucuk, Zeynep Yesim] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Strait, Richard T.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Lewkowich, Ian; Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Cellular & Mol Immunol, Cincinnati, OH 45229 USA; [Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Finkelman, FD (corresponding author), Univ Cincinnati, Coll Med, Div Immunol Allergy & Rheumatol, Hlth Profess Bldg,3255 Eden Ave,Ste 350, Cincinnati, OH 45267 USA.	finkelfd@ucmail.uc.edu			US Department of Veterans Affairs; American Academy of Allergy, Asthma Immunology; National Institutes of Health (NIH); Department of Defense; Johnson Johnson; FASEB; NIH; American Association of Immunology; Temple University; Creative Educational Concepts Inc; Children's Hospital; Boston; Cleveland Clinic; University of Chicago; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI103816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971] Funding Source: NIH RePORTER	US Department of Veterans Affairs(US Department of Veterans Affairs); American Academy of Allergy, Asthma Immunology; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); FASEB; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Association of Immunology; Temple University; Creative Educational Concepts Inc; Children's Hospital(Tehran University of Medical Sciences); Boston; Cleveland Clinic; University of Chicago(University of Chicago); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the US Department of Veterans Affairs (merit award to F.D.F.).; Disclosure of potential conflict of interest: F. D. Finkelman has received research support from the American Academy of Allergy, Asthma & Immunology; has consultancy arrangements with Abbott Labs, Amgen, Johnson & Johnson, Quintiles Phase One Services, Inc, and the Eli and Edythe Broad Foundation; is employed by the Journal of Allergy Clinical Immunology; has provided expert testimony for Freud, Freeze, & Arnold, Robinson and Epling, PSC, McKool Smith, and Darby & Gazak, PSC; has received one or more grants from or has one or more grants pending with the National Institutes of Health (NIH), the Department of Defense, and Johnson & Johnson; has received one or more payments for lecturing from or is on the speakers' bureau for Temple University, Creative Educational Concepts Inc, Children's Hospital, Boston, the Cleveland Clinic, and the University of Chicago; has one or more patents (planned, pending, or issued) with Becton-Dickinson and eBioscience; has received royalties from UpToDate and Elsevier; and has received one or more payments for travel/accommodations/meeting expenses from FASEB, the NIH, and the American Association of Immunology. The rest of the authors declare that they have no relevant conflicts of interest.	ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; Bochner BS, 2001, SAMTERS IMMUNOLOGICA, P244; Bouza TR, 2011, ANAPHYLAXIS AND HYPERSENSITIVITY REACTIONS, P313, DOI 10.1007/978-1-60327-951-2_20; Boyce JA, 2001, SAMTERS IMMUNOLOGIC, P253; CONRAD DH, 1987, J IMMUNOL, V139, P2290; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Dreyfus DH, 2006, ANN ALLERG ASTHMA IM, V96, P624, DOI 10.1016/S1081-1206(10)63560-0; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1982, J IMMUNOL, V129, P638; FINKELMAN FD, 1981, J IMMUNOL, V126, P680; Galli SJ, 1999, FUNDAMENTAL IMMUNOLO, P1127; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hubner MP, 2011, CLIN IMMUNOL, V141, P205, DOI 10.1016/j.clim.2011.08.004; Khodoun MV, 2004, J EXP MED, V200, P857, DOI 10.1084/jem.20040598; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MORELL A, 1970, J CLIN INVEST, V49, P673, DOI 10.1172/JCI106279; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; OKADA S, 1991, BLOOD, V78, P1706; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Rubinchik E, 1998, ALLERGY, V53, P14, DOI 10.1111/j.1398-9995.1998.tb03768.x; RUDOLPH AK, 1981, EUR J IMMUNOL, V11, P527, DOI 10.1002/eji.1830110617; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580	35	34	36	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1555	+		10.1016/j.jaci.2013.02.043	http://dx.doi.org/10.1016/j.jaci.2013.02.043			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23632296	Green Accepted			2022-12-18	WOS:000320532800014
J	Blank, S; Neu, C; Hasche, D; Bantleon, FI; Jakob, T; Spillner, E				Blank, Simon; Neu, Charles; Hasche, Daniel; Bantleon, Frank I.; Jakob, Thilo; Spillner, Edzard			Polistes species venom is devoid of carbohydrate-based cross-reactivity and allows interference-free diagnostics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VESPID VENOMS; VESPULA; IMMUNOTHERAPY		[Blank, Simon; Hasche, Daniel; Bantleon, Frank I.; Spillner, Edzard] Univ Hamburg, Inst Biochem & Mol Biol, Hamburg, Germany; [Neu, Charles; Jakob, Thilo] Univ Med Ctr Freiburg, Dept Dermatol, Allergy Res Grp, Freiburg, Germany	University of Hamburg; University of Freiburg	Blank, S (corresponding author), Univ Hamburg, Inst Biochem & Mol Biol, Hamburg, Germany.	blank@chemie.uni-hamburg.de; spillner@chemie.uni-hamburg.de	Hasche, Daniel/ABC-3206-2020; Blank, Simon/M-7708-2013	Hasche, Daniel/0000-0001-9306-3059; spillner, edzard/0000-0003-0999-5254				Caruso B, 2007, ALLERGY, V62, P561, DOI 10.1111/j.1398-9995.2007.01353.x; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V127, P265, DOI 10.1016/j.jaci.2010.06.042; JUAREZ C, 1992, ALLERGY, V47, P299, DOI 10.1111/j.1398-9995.1992.tb02057.x; Korosec P, 2012, J ALLERGY CLIN IMMUN, V129, P1406, DOI 10.1016/j.jaci.2011.12.975; Monsalve RI, 2012, ALLERGY, V67, P528, DOI 10.1111/j.1398-9995.2011.02781.x; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; Seismann H, 2010, MOL IMMUNOL, V47, P799, DOI 10.1016/j.molimm.2009.10.005; Vos B, 2013, J ALLERGY CLIN IMMUN, V131, P1225, DOI 10.1016/j.jaci.2012.07.041	9	34	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1239	1242		10.1016/j.jaci.2012.10.047	http://dx.doi.org/10.1016/j.jaci.2012.10.047			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23228245	Bronze			2022-12-18	WOS:000317187200039
J	Kalliola, S; Pelkonen, AS; Malmberg, LP; Sarna, S; Hamalainen, M; Mononen, I; Makela, MJ				Kalliola, Satu; Pelkonen, Anna S.; Malmberg, L. Pekka; Sarna, Seppo; Hamalainen, Mauri; Mononen, Ilkka; Makela, Mika J.			Maternal smoking affects lung function and airway inflammation in young children with multiple-trigger wheeze	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pediatric asthma; environmental tobacco smoke; exhaled nitric oxide; cotinine; lung function	EXHALED NITRIC-OXIDE; ENVIRONMENTAL TOBACCO-SMOKE; CIGARETTE-SMOKING; PARENTAL SMOKING; PRESCHOOL-CHILDREN; ASTHMA; EXPOSURE; ASSOCIATION; NONSMOKERS; IMPEDANCE	Background: Exposure to tobacco smoke is a well-known risk factor for childhood asthma and reduced lung function, but the effect on airway inflammation in preschool-aged children is unclear. Objective: To examine the effect of parental smoking on lung function and fractional concentration of exhaled nitric oxide (FENO) in relation to both parental reports and children's urine cotinine concentrations in preschool-aged children with multiple-trigger wheeze. Methods: A total of 105 3- to 7-year-old children with multiple-trigger wheeze and lung function abnormalities were recruited. Lung function was assessed by impulse oscillometry, and FENO measurements were performed. Exposure to tobacco smoke was determined by parental reports and measurement of children's urinary cotinine concentrations. Results: Forty-three percent of the children were exposed to environmental tobacco smoke according to parental reports. The FENO level was significantly higher in children with a smoking mother (n = 27) than in children with a nonsmoking mother (23.4 vs 12.5 ppb, P = .006). The FENO level expressed as z score and the cotinine level correlated significantly (P = .03). Respiratory resistance at 5 Hz was higher in children exposed to maternal smoking than in others (0.99 vs 0.88 kPas/L, P = .005). Urinary cotinine concentrations reflected well parental reports on their daily smoking and increased relative to the number of cigarettes smoked in the family (P < .01). Atopy was found in 75% of the children, but it was not associated with the FENO value (P = .65). Conclusion: Maternal smoking was associated with increased FENO value and poorer lung function in steroid-naive preschool children with multiple-trigger wheeze. Larger controlled trials are needed to generalize the results. (J Allergy Clin Immunol 2013;131:730-5.)	[Kalliola, Satu; Pelkonen, Anna S.; Malmberg, L. Pekka; Makela, Mika J.] Univ Helsinki, Dept Allergy, Cent Hosp, FIN-00014 Helsinki, Finland; [Sarna, Seppo] Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland; [Hamalainen, Mauri; Mononen, Ilkka] Univ Turku, Joint Clin Biochem Lab, Cent Hosp, Turku, Finland; [Hamalainen, Mauri; Mononen, Ilkka] Wallac, Turku, Finland; [Hamalainen, Mauri; Mononen, Ilkka] Univ Turku, Dept Clin Chem, Turku, Finland	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Turku; University of Turku	Kalliola, S (corresponding author), Helsinki Univ Hosp, Skin & Allergy Hosp, POB 160, FIN-00029 Helsinki, Hus, Finland.	satu.kalliola@hus.fi	Pelkonen, Anna/D-3153-2018	Pelkonen, Anna/0000-0002-1482-8947; Sarna, Seppo/0000-0003-3458-1627; Makela, Mika/0000-0002-2933-3111	Helsinki University Central Hospital Research Funds; Sigrid Juselius Foundation; Nummela Sanatoriums Stiftelse; OrionPharma; GlaxoSmithKline	Helsinki University Central Hospital Research Funds; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Nummela Sanatoriums Stiftelse; OrionPharma; GlaxoSmithKline(GlaxoSmithKline)	This work was supported by Helsinki University Central Hospital Research Funds, the Sigrid Juselius Foundation, and Nummela Sanatoriums Stiftelse.; S. Kalliola has received research support from Helsinki University Central Hospital Research Funds, the Sigrid Juselius Foundation, and Nummela Sanatoriums Stiftelse. L.P. Malmberg has received lecture fees from OrionPharma and GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Barreto M, 2001, PEDIATR ALLERGY IMMU, V12, P247, DOI 10.1034/j.1399-3038.2001.00041.x; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Carlsen KH, 2008, PAEDIATR RESPIR REV, V9, P11, DOI 10.1016/j.prrv.2007.11.007; Carlsen Kai-Hakon, 2005, Treat Respir Med, V4, P337, DOI 10.2165/00151829-200504050-00005; Carlsen KCL, 1997, EUR RESPIR J, V10, P1774, DOI 10.1183/09031936.97.10081774; Cheraghi M, 2009, EUR J PEDIATR, V168, P897, DOI 10.1007/s00431-009-0967-3; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Comhair SAA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018574; Cook DG, 1998, THORAX, V53, P884, DOI 10.1136/thx.53.10.884; de la Riva-Velasco E, 2012, J ASTHMA, V49, P673, DOI 10.3109/02770903.2012.701363; Dinakar C, 2005, J ASTHMA, V42, P113, DOI 10.1081/JAS-51317; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; Franklin PJ, 2006, EUR RESPIR J, V28, P730, DOI 10.1183/09031936.06.00007206; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69, DOI 10.1164/ajrccm.159.1.9804134; Ino T, 2011, J CLIN LAB ANAL, V25, P354, DOI 10.1002/jcla.20485; Jung JW, 2012, PEDIATR PULM, V47, P338, DOI 10.1002/ppul.21556; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609, DOI 10.1164/ajrccm.152.2.7543345; La Grutta S, 2012, J ALLERGY CAIRO, V2012, P916; Laoudi Y, 2010, ALLERGY, V65, P491, DOI 10.1111/j.1398-9995.2009.02190.x; Linnamaa P, 2012, CLIN EXP ALLERGY, V42, P1472, DOI 10.1111/j.1365-2222.2012.04066.x; Makela MJ, 2012, ANN ALLERG ASTHMA IM, V109, P65, DOI 10.1016/j.anai.2012.05.006; Malmberg LP, 2008, PEDIATR PULM, V43, P538, DOI 10.1002/ppul.20805; Malmberg LP, 2009, PEDIAT ALLERG IMM-UK, V20, P673, DOI 10.1111/j.1399-3038.2009.00858.x; Malmberg LP, 2003, THORAX, V58, P494, DOI 10.1136/thorax.58.6.494; Malmberg LP, 2002, CLIN PHYSIOL FUNCT I, V22, P64, DOI 10.1046/j.1365-2281.2002.00396.x; Matt GE, 2011, TOB CONTROL, V20, DOI 10.1136/tc.2010.037382; McSharry CP, 2005, J ALLERGY CLIN IMMUN, V116, P88, DOI 10.1016/j.jaci.2005.03.025; Perzanowski MS, 2010, J ASTHMA, V47, P1015, DOI 10.3109/02770903.2010.513075; Pijnenburg MWH, 2008, CLIN EXP ALLERGY, V38, P246, DOI 10.1111/j.1365-2222.2007.02897.x; Rabinovitch N, 2011, AM J RESP CRIT CARE, V184, P1350, DOI 10.1164/rccm.201010-1706OC; Salam MT, 2011, ALLERGY, V66, P412, DOI 10.1111/j.1398-9995.2010.02492.x; Savenije OEM, 2012, J ALLERGY CLIN IMMUN, V130, P325, DOI 10.1016/j.jaci.2012.05.007; Song LG, 2005, ANAL CHIM ACTA, V545, P200, DOI 10.1016/j.aca.2005.04.051; Spanier AJ, 2006, J PEDIATR-US, V149, P220, DOI 10.1016/j.jpeds.2006.04.001; Spanier AJ, 2009, PEDIATR PULM, V44, P812, DOI 10.1002/ppul.21071; Statistics Finland, 2009, TOB STAT 2009; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7	38	34	36	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					730	735		10.1016/j.jaci.2013.01.005	http://dx.doi.org/10.1016/j.jaci.2013.01.005			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23380219				2022-12-18	WOS:000315587800014
J	Lev, A; Simon, AJ; Broides, A; Levi, J; Garty, BZ; Rosenthal, E; Amariglio, N; Rechavi, G; Somech, R				Lev, Atar; Simon, Amos J.; Broides, Arnon; Levi, Jacob; Garty, Ben Zion; Rosenthal, Ester; Amariglio, Ninette; Rechavi, Gideon; Somech, Raz			Thymic function in MHC class II-deficient patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MHC class II; immunodeficiency; severe combined immunodeficiency; T-cell receptor excision circle (TREC); T-cell receptor repertoire; neonatal screening	SEVERE COMBINED IMMUNODEFICIENCY; CLINICAL-COURSE; EXPRESSION	Background: MHC class II (MHC-II) molecules play a pivotal role in the development, activation, and homeostasis of CD4(+) T-H cells in the thymus. The absence of MHC-II molecules causes severe T-cell immunodeficiency. Objective: We sought to study thymic function, including T-cell receptor excision circle (TREC) quantification, in patients with MHC-II deficiency. Methods: Eight MHC-II-deficient patients underwent a thorough T-cell immunologic work-up, including thymic activity, which was estimated based on TREC levels and T-cell receptor (TCR) genes, as well as analysis of several sequential human TCR gene rearrangements. Results: In vitro responses to mitogens were normal or only slightly reduced, and flow cytometric evaluations of the TCR-V beta repertoires of total CD3(+) lymphocytes were normal in all patients. However, both the flow cytometric evaluation of the TCR-V beta repertoire on CD4(+) cells and spectratyping evaluation of the TCR-V gamma repertoire on total CD3(+) lymphocytes showed clonal abnormalities. TRECs were present in all patients in both total lymphocytes and sorted CD4(+) cells. Additionally, TRECs were detected in genomic DNA obtained from Guthrie cards with dried blood spots. Quantitative RT-PCR assessment of different TCR gene rearrangement events revealed lower levels in MHC-II-deficient patients compared with levels seen in healthy control subjects. This was irrespective of the total lymphocyte numbers, suggesting a reduced global thymic activity. Conclusions: Our report highlights potential pitfalls in diagnosing MHC-II deficiency and emphasizes the probable importance of MHC-II molecules in the normal thymic maturation process of T cells. Patients with MHC-II deficiency have detectable TRECs and might therefore be missed by a TREC-based newborn screening program. (J Allergy Clin Immunol 2013; 131:831-9.)	[Lev, Atar; Simon, Amos J.; Rosenthal, Ester; Amariglio, Ninette; Rechavi, Gideon; Somech, Raz] Chaim Sheba Med Ctr, Canc Res Ctr, Jeffery Modell Fdn JMF Ctr, Edmond & Lily Safra Childrens Hosp, IL-52621 Tel Hashomer, Israel; [Lev, Atar; Simon, Amos J.; Somech, Raz] Chaim Sheba Med Ctr, Pediat Immunol Serv, Jeffery Modell Fdn JMF Ctr, Edmond & Lily Safra Childrens Hosp, IL-52621 Tel Hashomer, Israel; [Lev, Atar; Simon, Amos J.; Garty, Ben Zion; Somech, Raz] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Broides, Arnon; Levi, Jacob] Soroka Med Ctr, Immunol Clin, IL-84101 Beer Sheva, Israel; [Broides, Arnon; Levi, Jacob] Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel; [Garty, Ben Zion] Schneider Childrens Med Ctr Israel, Dept Pediat B, Petah Tiqwa, Israel; [Garty, Ben Zion] Felsenstein Med Res Ctr, Tel Aviv, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Tel Aviv University	Somech, R (corresponding author), Chaim Sheba Med Ctr, Pediat Immunol Serv, Safra Childrens Hosp, IL-52621 Tel Hashomer, Israel.	raz.somech@sheba.health.gov.il			Jeffery Modell Foundation (JMF); Legacy Heritage Biomedical Science Partnership Program of the Israel Science Foundation; Chief Scientist Office of the Ministry of Health	Jeffery Modell Foundation (JMF); Legacy Heritage Biomedical Science Partnership Program of the Israel Science Foundation; Chief Scientist Office of the Ministry of Health	Supported by the Jeffery Modell Foundation (JMF), the Legacy Heritage Biomedical Science Partnership Program of the Israel Science Foundation, and the Chief Scientist Office of the Ministry of Health (to R.S.)	Al-Mousa H, 2010, BIOL BLOOD MARROW TR, V16, P818, DOI 10.1016/j.bbmt.2010.01.002; Amariglio N, 2011, J CLIN IMMUNOL, V31, P1021, DOI 10.1007/s10875-011-9580-0; Amariglio N, 2010, PEDIATR RES, V67, P211, DOI 10.1203/PDR.0b013e3181c6e554; Buckley RH, 2012, J ALLERGY CLIN IMMUN, V129, P597, DOI 10.1016/j.jaci.2011.12.964; Canioni D, 1997, PEDIATR PATHOL LAB M, V17, P645, DOI 10.1080/107710497174633; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; Henwood J, 1996, J IMMUNOL, V156, P895; KLEIN C, 1995, BLOOD, V85, P580; KLEIN C, 1993, J PEDIATR-US, V123, P921, DOI 10.1016/S0022-3476(05)80388-9; Lev A, 2009, CLIN IMMUNOL, V133, P375, DOI 10.1016/j.clim.2009.08.017; Markert ML, 2004, J ALLERGY CLIN IMMUN, V113, P734, DOI 10.1016/j.jaci.2004.01.766; Masternak K, 2000, Rev Immunogenet, V2, P267; Matheux F, 2004, NEWS PHYSIOL SCI, V19, P154, DOI 10.1152/nips.01462.2003; Morinishi Y, 2009, J PEDIATR-US, V155, P829, DOI 10.1016/j.jpeds.2009.05.026; Ouederni M, 2011, BLOOD, V118, P5108, DOI 10.1182/blood-2011-05-352716; Prod'homme T, 2003, IMMUNOGENETICS, V55, P530, DOI 10.1007/s00251-003-0609-2; Puck JM, 2011, CURR OPIN PEDIATR, V23, P667, DOI 10.1097/MOP.0b013e32834cb9b0; Roifman CM, 2012, J ALLERGY CLIN IMMUN, V130, P177, DOI 10.1016/j.jaci.2012.04.029; Routes JM, 2009, JAMA-J AM MED ASSOC, V302, P2465, DOI 10.1001/jama.2009.1806; Saleem MA, 2000, ARCH DIS CHILD, V83, P356, DOI 10.1136/adc.83.4.356; Somech R, 2011, CURR OPIN ALLERGY CL, V11, P517, DOI 10.1097/ACI.0b013e32834c233a; Somech R, 2009, J ALLERGY CLIN IMMUN, V124, P793, DOI 10.1016/j.jaci.2009.06.048; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Waldburger JM, 2000, IMMUNOL REV, V178, P148, DOI 10.1034/j.1600-065X.2000.17813.x; Yang SJ, 2006, INT IMMUNOL, V18, P729, DOI 10.1093/intimm/dxl010	25	34	35	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					831	839		10.1016/j.jaci.2012.10.040	http://dx.doi.org/10.1016/j.jaci.2012.10.040			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23228244				2022-12-18	WOS:000315587800027
J	Hsu, P; Mehr, S				Hsu, Peter; Mehr, Sam			Egg: A frequent trigger of food protein-induced enterocolitis syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Hsu, Peter; Mehr, Sam] Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia	University of Sydney	Hsu, P (corresponding author), Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia.	samm@chw.edu.au		Mehr, Sam/0000-0003-2483-917X				Caubet JC, 2011, J ALLERGY CLIN IMMUN, V128, P1386, DOI 10.1016/j.jaci.2011.07.011; Fogg MI, 2006, PEDIAT ALLERG IMM-UK, V17, P351, DOI 10.1111/j.1399-3038.2006.00418.x; Hwang JB, 2009, ARCH DIS CHILD, V94, P425, DOI 10.1136/adc.2008.143289; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; MCDONALD PJ, 1984, PEDIATR RES, V18, P751, DOI 10.1203/00006450-198408000-00016; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033	6	34	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					241	242		10.1016/j.jaci.2012.08.045	http://dx.doi.org/10.1016/j.jaci.2012.08.045			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23069493				2022-12-18	WOS:000312961200040
J	Hernandez, ML; Herbst, M; Lay, JC; Alexis, NE; Brickey, WJ; Ting, JPY; Zhou, HB; Peden, DB				Hernandez, Michelle L.; Herbst, Margaret; Lay, John C.; Alexis, Neil E.; Brickey, Willie June; Ting, Jenny P. Y.; Zhou, Haibo; Peden, David B.			Atopic asthmatic patients have reduced airway inflammatory cell recruitment after inhaled endotoxin challenge compared with healthy volunteers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; LPS; induced sputum; inflammasome; innate immunity	SERIOUS PNEUMOCOCCAL DISEASE; TOLL-LIKE RECEPTORS; ALVEOLAR MACROPHAGES; INCREASED RISK; EXPRESSION; LIPOPOLYSACCHARIDE; CYTOKINES; SPUTUM; INFECTIONS; INHALATION	Background: Atopic asthmatic patients are reported to be more sensitive to the effects of environmental endotoxin (LPS) than healthy volunteers (HVs). It is unknown whether this sensitivity is due to dysregulated inflammatory responses after LPS exposure in atopic asthmatic patients. Objective: We sought to test the hypothesis that atopic asthmatic patients respond differentially to inhaled LPS challenge compared with HVs. Methods: Thirteen allergic asthmatic (AA) patients and 18 nonallergic nonasthmatic subjects (healthy volunteers [ HVs]) underwent an inhalation challenge to 20,000 endotoxin units of Clinical Center Reference Endotoxin (LPS). Induced sputum and peripheral blood were obtained at baseline and 6 hours after inhaled LPS challenge. Sputum and blood samples were assayed for changes in inflammatory cell numbers and cytokine and cell-surface marker levels on monocytes and macrophages. Results: The percentage of neutrophils in sputum (%PMN) in induced sputum similarly and significantly increased in both HVs and AA patients after inhaled LPS challenge. However, the absolute numbers of leukocytes and PMNs recruited to the airways were significantly lower in AA patients compared with those seen in HVs with inhaled LPS challenge. Sputum levels of IL-6 and TNF-alpha were significantly increased in both cohorts, but levels of IL-1 beta and IL-18 were only significantly increased in the HV group. Cell-surface expression of Toll-like receptors 4 and 2 were significantly enhanced only in the HV group. Conclusions: The airway inflammatory response to inhaled LPS challenge is blunted in AA patients compared with that seen in HVs and accompanied by reductions in airway neutrophilia and inflammasome-dependent cytokine production. These factors might contribute to increased susceptibility to airway microbial infection or colonization in AA patients. (J Allergy Clin Immunol 2012; 130:869-76.)	[Hernandez, Michelle L.; Herbst, Margaret; Lay, John C.; Alexis, Neil E.; Zhou, Haibo; Peden, David B.] UNC, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27516 USA; [Hernandez, Michelle L.; Herbst, Margaret; Lay, John C.; Alexis, Neil E.; Peden, David B.] UNC, Sch Med, Dept Pediat, Chapel Hill, NC 27516 USA; [Brickey, Willie June; Ting, Jenny P. Y.; Peden, David B.] UNC, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27516 USA; [Zhou, Haibo] UNC, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27516 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Hernandez, ML (corresponding author), UNC, Sch Med, Ctr Environm Med Asthma & Lung Biol, 104 Mason Farm Rd, Chapel Hill, NC 27516 USA.	Michelle_Hernandez@med.unc.edu	ZHOU, Haibo/M-7373-2017	Peden, David/0000-0003-4526-4627	National Institutes of Health grant [KL2RR025746]; National Institute of Allergy and Infectious Diseases grant [U19AI077437]; CTSA [UL1RR025747]; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Environmental Health Sciences; NIH/NIAID; NIH; US Environmental Protection Agency; NIAID; National Center for Research Resources; National Heart, Lung, and Blood Institute; National Institute for Environmental Health Sciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000084] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025747, KL2RR025746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077437] Funding Source: NIH RePORTER	National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases grant; CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Environmental Protection Agency(United States Environmental Protection Agency); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute for Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	M.L.H. is supported by National Institutes of Health grant KL2RR025746. N.E.A., W.J.B., J.P.Y.T., and D.B.P. are supported by National Institute of Allergy and Infectious Diseases grant U19AI077437. This work was also supported by CTSA UL1RR025747.; M.L. Hernandez has received research grants and support for travel expenses from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) and has received research grants from the National Institute of Environmental Health Sciences. M. Herbst has received grants from the NIH/NIAID. J.C. Lay has received research grants from the NIH. N.E. Alexis has received research grants from the NIH. W.J. Brickey has received research grants from the NIH and is employed by the NIH and the University of North Carolina. J.P.Y. Ting has received grants from the NIH, has consulted for GlaxoSmithKline, has served on a National Institutes of Health Advisory Committee, and has received payment for the development of education presentations for the American Association of Immunologists. D.B. Peden has received grants from the US Environmental Protection Agency; the NIAID; the National Center for Research Resources; the National Heart, Lung, and Blood Institute; and the National Institute for Environmental Health Sciences. H. Zhou declares that he has no relevant conflicts of interest.	Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Alexis NE, 2006, J ALLERGY CLIN IMMUN, V117, P1396, DOI 10.1016/j.jaci.2006.02.030; Alexis NE, 2003, J ALLERGY CLIN IMMUN, V112, P353, DOI 10.1067/mai.2003.1651; Alexis NE, 2008, ANN ALLERG ASTHMA IM, V100, P206, DOI 10.1016/S1081-1206(10)60444-9; Alexis NE, 2009, J ALLERGY CLIN IMMUN, V124, P1222, DOI 10.1016/j.jaci.2009.07.036; Amoudruz P, 2009, CLIN EXP IMMUNOL, V155, P387, DOI 10.1111/j.1365-2249.2008.03792.x; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Brickey WJ, 2011, J ALLERGY CLIN IMMUN, V128, P900, DOI 10.1016/j.jaci.2011.08.012; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Essilfie AT, 2012, THORAX; Gern JE, 2002, NAT REV IMMUNOL, V2, P132, DOI 10.1038/nri725; Hernandez ML, 2010, J ALLERGY CLIN IMMUN, V126, P537, DOI 10.1016/j.jaci.2010.06.043; Hernandez ML, 2010, INHAL TOXICOL, V22, P648, DOI 10.3109/08958371003610966; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Juarez E, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-2; Juhn YJ, 2008, J ALLERGY CLIN IMMUN, V122, P719, DOI 10.1016/j.jaci.2008.07.029; Jung JA, 2010, J ALLERGY CLIN IMMUN, V125, P217, DOI 10.1016/j.jaci.2009.10.045; Klemets P, 2010, THORAX, V65, P698, DOI 10.1136/thx.2009.132670; Konno S, 1996, INT ARCH ALLERGY IMM, V109, P73, DOI 10.1159/000237234; Lay JC, 2007, J ALLERGY CLIN IMMUN, V120, P719, DOI 10.1016/j.jaci.2007.05.005; Lay JC, 2011, INHAL TOXICOL, V23, P392, DOI 10.3109/08958378.2011.575568; Lensmar C, 2006, RESP MED, V100, P918, DOI 10.1016/j.rmed.2005.08.014; Lun SWM, 2009, J CLIN IMMUNOL, V29, P330, DOI 10.1007/s10875-008-9269-1; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352, DOI 10.1164/ajrccm/146.2.352; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; Mueller-Anneling L, 2004, ENVIRON HEALTH PERSP, V112, P583, DOI 10.1289/ehp.6552; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Prefontaine D, 2010, CLIN EXP ALLERGY, V40, P1648, DOI 10.1111/j.1365-2222.2010.03570.x; Proschan MA, 2006, STAT BIOL HEALTH, P1; PUJOL JL, 1990, INT ARCH ALLER A IMM, V91, P207, DOI 10.1159/000235117; Sousa AR, 1996, AM J RESP CRIT CARE, V154, P1061, DOI 10.1164/ajrccm.154.4.8887608; Sutherland ER, 2007, CHEST, V132, P1962, DOI 10.1378/chest.06-2415; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; ULICH TR, 1991, AM J PATHOL, V138, P1485; ULICH TR, 1991, AM J PATHOL, V138, P521; Webley WC, 2005, AM J RESP CRIT CARE, V171, P1083, DOI 10.1164/rccm.200407-917OC; Zeldin DC, 2006, ENVIRON HEALTH PERSP, V114, P620, DOI 10.1289/ehp.8379	43	34	35	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					869	+		10.1016/j.jaci.2012.05.026	http://dx.doi.org/10.1016/j.jaci.2012.05.026			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22770265	Green Accepted, Green Published			2022-12-18	WOS:000309594800005
J	Xie, Y; Jiang, HH; Nguyen, H; Jia, SP; Berro, A; Panettieri, RA; Wolff, DW; Abel, PW; Casale, TB; Tu, YP				Xie, Yan; Jiang, Haihong; Hoai Nguyen; Jia, Shuping; Berro, Abdo; Panettieri, Reynold A., Jr.; Wolff, Dennis W.; Abel, Peter W.; Casale, Thomas B.; Tu, Yaping			Regulator of G protein signaling 2 is a key modulator of airway hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway hyperresponsiveness; airway smooth muscle mass; airway smooth muscle contraction; Ca2+ mobilization; extracellular signal-regulated kinase; G protein-coupled receptors; knockout mice; ovalbumin-sensitized/-challenged murine model of asthma; phosphatidylinositol 3-kinase; regulator of G protein signaling 2	SMOOTH-MUSCLE; HYPERTENSIVE PATIENTS; G-PROTEIN-SIGNALING-2 RGS2; ASTHMA; EXPRESSION; RECEPTOR; CELLS; MICE; INFLAMMATION; GENE	Background: Drugs targeting individual G protein-coupled receptors are used as asthma therapies, but this strategy is limited because of G protein-coupled receptor signal redundancy. Regulator of G protein signaling 2 (RGS2), an intracellular selective inhibitor of multiple bronchoconstrictor receptors, may play a central role in the pathophysiology and treatment of asthma. Objective: We defined functions and mechanisms of RGS2 in regulating airway hyperresponsiveness (AHR), the pathophysiologic hallmark of asthma. Methods: Real-time PCR and Western blot were used to determine changes in RGS2 expression in ovalbumin-sensitized/-challenged mice. We also used immunohistochemistry and real-time PCR to compare RGS2 expression between human asthmatic and control subjects. The AHR of RGS2 knockout mice was assessed by using invasive tracheostomy and unrestrained plethysmography. Effects of loss of RGS2 on mouse airway smooth muscle (ASM) remodeling, contraction, intracellular Ca2+, and mitogenic signaling were determined in vivo and in vitro. Results: RGS2 was highly expressed in human and murine bronchial epithelium and ASM and was markedly downregulated in lungs of ovalbumin-sensitized/-challenged mice. Lung tissues and blood monocytes from asthma patients expressed significantly lower RGS2 protein (lung) and mRNA (monocytes) than from nonasthma subjects. The extent of reduction of RGS2 on human monocytes correlated with increased AHR. RGS2 knockout caused spontaneous AHR in mice. Loss of RGS2 augmented Ca2+ mobilization and contraction of ASM cells. Loss of RGS2 also increased ASM mass and stimulated ASM cell growth via extracellular signal-regulated kinase and phosphatidylinositol 3-kinase pathways. Conclusion: We identified RGS2 as a potent modulator of AHR and a potential novel therapeutic target for asthma. (J Allergy Clin Immunol 2012; 130:968-76.)	[Xie, Yan; Jiang, Haihong; Wolff, Dennis W.; Abel, Peter W.; Tu, Yaping] Creighton Univ, Sch Med, Dept Pharmacol, Omaha, NE 68178 USA; [Hoai Nguyen; Jia, Shuping; Berro, Abdo; Casale, Thomas B.] Creighton Univ, Sch Med, Dept Internal Med, Omaha, NE 68178 USA; [Panettieri, Reynold A., Jr.] Univ Penn, Pulm Allergy & Crit Care Div, Airways Biol Initiat, Philadelphia, PA USA	Creighton University; Creighton University; University of Pennsylvania	Tu, YP (corresponding author), Creighton Univ, Sch Med, Dept Pharmacol, 2500 Calif Plaza, Omaha, NE 68178 USA.	Yat6033@creighton.edu	Wolff, Dennis W/E-3013-2015; panettieri, reynold/AAG-9485-2019; Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377; Abel, Peter/0000-0002-6588-1676	American Asthma Foundation Early Excellence Award; State of Nebraska Research Fund [LB595, LB692]; National Institutes of Health grant [R01 CA125661, R01 HL097796, P30 ES013508]; National Institutes of Health National Center for Research Resources grant [G20-RR024001]; Merck; National Institutes of Health; American Asthma Foundation; State of Nebraska Research Fund; NATIONAL CANCER INSTITUTE [R01CA125661] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G20RR024001] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097796, R01HL116849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	American Asthma Foundation Early Excellence Award; State of Nebraska Research Fund; National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health National Center for Research Resources grant; Merck(Merck & Company); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Asthma Foundation; State of Nebraska Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by an American Asthma Foundation Early Excellence Award (to Y.T.), State of Nebraska Research Fund grants LB595 and LB692 (to Y.T. and T. B. C.), National Institutes of Health grant R01 CA125661 (to Y.T.) and grants R01 HL097796 and P30 ES013508 (to R.A.P.), and National Institutes of Health National Center for Research Resources grant G20-RR024001.; R.A. Panettieri, Jr has received research support from Merck and the National Institutes of Health. T.B. Casale has received research support from the American Asthma Foundation and the State of Nebraska Research Fund and is executive vice president of the American Academy of Allergy, Asthma, & Immunology. Y. Tu has received research support from the National Institutes of Health, the American Asthma Foundation, and the State of Nebraska Research Fund. The rest of the authors declare that they have no relevant conflicts of interest.	Ammit AJ, 2001, J APPL PHYSIOL, V91, P1431, DOI 10.1152/jappl.2001.91.3.1431; An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; Barker KS, 2005, J INFECT DIS, V192, P901, DOI 10.1086/432487; Berend N, 2008, RESPIROLOGY, V13, P624, DOI 10.1111/j.1440-1843.2008.01330.x; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Busse WW, 2010, CHEST, V138, p4S, DOI 10.1378/chest.10-0100; Calo LA, 2004, J CLIN ENDOCR METAB, V89, P4153, DOI 10.1210/jc.2004-0498; Campbell DB, 2008, SCHIZOPHR RES, V101, P67, DOI 10.1016/j.schres.2008.01.006; Cao X, 2006, ONCOGENE, V25, P3719, DOI 10.1038/sj.onc.1209408; Damera G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028504; Deshpande DA, 2005, AM J RESP CELL MOL, V32, P149, DOI 10.1165/rcmb.2004-0243OC; Deshpande DA, 2006, CELL SIGNAL, V18, P2105, DOI 10.1016/j.cellsig.2006.04.008; Drazen JM, 1999, CLIN EXP ALLERGY, V29, P37; Druey KM, 2009, IMMUNOL RES, V43, P62, DOI 10.1007/s12026-008-8050-0; Druey KM, 2003, EXPERT OPIN THER TAR, V7, P475, DOI 10.1517/14728222.7.4.475; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Ghavami A, 2004, CELL SIGNAL, V16, P711, DOI 10.1016/j.cellsig.2003.11.006; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327, DOI 10.1165/ajrcmb.23.3.3796; Hanania NA, 2010, CURR OPIN PULM MED, V16, P1, DOI 10.1097/MCP.0b013e328333def8; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Holden NS, 2011, P NATL ACAD SCI USA, V108, P19713, DOI 10.1073/pnas.1110226108; Homme M, 2003, ENDOCRINOLOGY, V144, P2496, DOI 10.1210/en.2002-0160; Jia SP, 2011, AM J RESP CELL MOL, V45, P1084, DOI 10.1165/rcmb.2010-0268OC; Jiang HH, 2010, J PHARMACOL EXP THER, V334, P703, DOI 10.1124/jpet.110.168518; Johnston RA, 2007, AM J RESP CRIT CARE, V176, P650, DOI 10.1164/rccm.200702-323OC; Jude Joseph A, 2008, Proc Am Thorac Soc, V5, P15, DOI 10.1513/pats.200704-047VS; Kumar RK, 2008, CURR DRUG TARGETS, V9, P485, DOI 10.2174/138945008784533561; Kurrasch DM, 2004, METHOD ENZYMOL, V389, P3; Larminie C, 2004, MOL BRAIN RES, V122, P24, DOI 10.1016/j.molbrainres.2003.11.014; Lione AM, 2000, J NEUROCHEM, V75, P934, DOI 10.1046/j.1471-4159.2000.0750934.x; Mehta V, 2009, ANN ALLERG ASTHMA IM, V103, P31, DOI 10.1016/S1081-1206(10)60140-8; Moulton BC, 2011, BRIT J PHARMACOL, V163, P44, DOI 10.1111/j.1476-5381.2010.01190.x; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Plant PJ, 2012, AM J RESP CELL MOL, V46, P532, DOI 10.1165/rcmb.2011-0293OC; Riddle EL, 2006, HYPERTENSION, V47, P415, DOI 10.1161/01.HYP.0000200714.81990.61; Riekenberg S, 2009, FEBS J, V276, P649, DOI 10.1111/j.1742-4658.2008.06813.x; Ross EM, 2010, ANNU REV BIOCHEM, V69, P795; Roux E, 1997, BRIT J PHARMACOL, V120, P1294, DOI 10.1038/sj.bjp.0701061; Saxena H, 2012, BRIT J PHARMACOL, V166, P981, DOI 10.1111/j.1476-5381.2011.01807.x; Semplicini A, 2006, J HYPERTENS, V24, P1115, DOI 10.1097/01.hjh.0000226202.80689.8f; Semplicini A, 2010, J HYPERTENS, V28, P1104, DOI 10.1097/HJH.0b013e328339930f; Shi GX, 2004, J IMMUNOL, V172, P5175, DOI 10.4049/jimmunol.172.9.5175; Shore SA, 2002, ASTHMA COPD BASIC ME, P79; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Wolff DW, 2012, INT J CANCER, V130, P1521, DOI 10.1002/ijc.26138; WU HK, 1995, LEUKEMIA, V9, P1291; Yang J, 2005, J HYPERTENS, V23, P1497, DOI 10.1097/01.hjh.0000174606.41651.ae; Yang Z, 2012, AM J RESP CELL MOL B, DOI [10.1165/rcmb.2011-0110OC, DOI 10.1165/RCMB.2011-01100C]; Yang Z, 2011, J BIOL CHEM, V286, P11444, DOI [10.1074/jbc.M110.212480, 10.1074/jbc.M111.229344]	49	34	34	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					968	+		10.1016/j.jaci.2012.05.004	http://dx.doi.org/10.1016/j.jaci.2012.05.004			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22704538				2022-12-18	WOS:000309594800019
J	Gundavarapu, S; Wilder, JA; Mishra, NC; Rir-sima-ah, J; Langley, RJ; Singh, SP; Saeed, AI; Jaramillo, RJ; Gott, KM; Pena-Philippides, JC; Harrod, KS; McIntosh, JM; Buch, S; Sopori, ML				Gundavarapu, Sravanthi; Wilder, Julie A.; Mishra, Neerad C.; Rir-sima-ah, Jules; Langley, Raymond J.; Singh, Shashi P.; Saeed, Ali Imran; Jaramillo, Richard J.; Gott, Katherine M.; Pena-Philippides, Juan Carlos; Harrod, Kevin S.; McIntosh, J. Michael; Buch, Shilpa; Sopori, Mohan L.			Role of nicotinic receptors and acetylcholine in mucous cell metaplasia, hyperplasia, and airway mucus formation in vitro and in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cigarette smoke; nicotine; nicotinic acetylcholine receptors; gamma-aminobutyric acid receptors; acetylcholine; airway mucus	NONNEURONAL CHOLINERGIC SYSTEM; BRONCHIAL EPITHELIAL-CELLS; CIGARETTE-SMOKE; GOBLET CELL; MUCIN EXPRESSION; IMMUNE-SYSTEM; T-CELLS; ASTHMA; NEURONS; RAT	Background: Airway mucus hypersecretion is a key pathophysiologic feature in a number of lung diseases. Cigarette smoke/nicotine and allergens are strong stimulators of airway mucus; however, the mechanism of mucus modulation is unclear. Objectives: We sought to characterize the pathway by which cigarette smoke/nicotine regulates airway mucus and identify agents that decrease airway mucus. Methods: IL-13 and gamma-aminobutyric acid type A receptors (GABA(A)Rs) are implicated in airway mucus. We examined the role of IL-13 and GABA(A)Rs in nicotine-induced mucus formation in normal human bronchial epithelial (NHBE) and A549 cells and secondhand cigarette smoke-induced, ovalbumin-induced, or both mucus formation in vivo. Results: Nicotine promotes mucus formation in NHBE cells; however, the nicotine-induced mucus formation is independent of IL-13 but sensitive to the GABA(A)R antagonist picrotoxin. Airway epithelial cells express alpha 7-, alpha 9-, and alpha 10-nicotinic acetylcholine receptors (nAChRs), and specific inhibition or knockdown of alpha 7- but not alpha 9/alpha 10-nAChRs abrogates mucus formation in response to nicotine and IL-13. Moreover, addition of acetylcholine or inhibition of its degradation increases mucus in NHBE cells. Nicotinic but not muscarinic receptor antagonists block allergen- or nicotine/cigarette smoke-induced airway mucus formation in NHBE cells, murine airways, or both. Conclusions: Nicotine-induced airway mucus formation is independent of IL-13, and alpha 7-nAChRs are critical in airway mucous cell metaplasia/hyperplasia and mucus production in response to various promucoid agents, including IL-13. In the absence of nicotine, acetylcholine might be the biological ligand for alpha 7-nAChRs to trigger airway mucus formation. alpha 7-nAChRs are downstream of IL-13 but upstream of GABA(A)R alpha 2 in the MUC5AC pathway. Acetylcholine and alpha 7-nAChRs might serve as therapeutic targets to control airway mucus. (J Allergy Clin Immunol 2012;130:770-80.)	[Sopori, Mohan L.] Lovelace Resp Res Inst, Div Immunol, Albuquerque, NM 87108 USA; [Saeed, Ali Imran] Univ New Mexico, Albuquerque, NM 87131 USA; [McIntosh, J. Michael] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [McIntosh, J. Michael] Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; [Buch, Shilpa] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA	Lovelace Respiratory Research Institute; University of New Mexico; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Nebraska System; University of Nebraska Medical Center	Sopori, ML (corresponding author), Lovelace Resp Res Inst, Div Immunol, Albuquerque, NM 87108 USA.	msopori@lrri.org		Buch, Shilpa/0000-0002-3103-6685; Harrod, Kevin/0000-0003-0780-9470	US Army Medical Research and Material Command [GW093005]; National Institutes of Health [R01-DA017003]; Lovelace Respiratory Research Institute (IMMSPT); NATIONAL INSTITUTE ON DRUG ABUSE [R01DA017003] Funding Source: NIH RePORTER	US Army Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lovelace Respiratory Research Institute (IMMSPT); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Supported in part by grants from the US Army Medical Research and Material Command (GW093005), the National Institutes of Health (R01-DA017003), and the Lovelace Respiratory Research Institute (IMMSPT).	Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; Boyd RT, 1997, CRIT REV TOXICOL, V27, P299, DOI 10.3109/10408449709089897; Carneiro Jorge, 2009, V514, P95, DOI 10.1007/978-1-60327-527-9_7; Churg A, 2008, AM J PHYSIOL-LUNG C, V294, pL612, DOI 10.1152/ajplung.00390.2007; Curran DR, 2010, AM J RESP CELL MOL, V42, P268, DOI 10.1165/rcmb.2009-0151TR; Dorion G, 2005, AM J PHYSIOL-LUNG C, V288, pL1139, DOI 10.1152/ajplung.00406.2004; El-Zimaity HMT, 1998, ARCH PATHOL LAB MED, V122, P732; Ellison M, 2006, BIOCHEMISTRY-US, V45, P1511, DOI 10.1021/bi0520129; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; Fu XW, 2011, AM J RESP CELL MOL, V44, P222, DOI 10.1165/rcmb.2010-0109OC; Fucile S, 2005, J PHYSIOL-LONDON, V565, P219, DOI 10.1113/jphysiol.2005.084871; Fujii T, 2008, J PHARMACOL SCI, V106, P186, DOI 10.1254/jphs.FM0070109; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Gundavarapu S, 2011, AM J RESP CRIT CARE, V181, pA5442; HARKEMA JR, 1992, AM J PATHOL, V141, P307; Hovenberg HW, 1996, BIOCHEM J, V318, P319, DOI 10.1042/bj3180319; Izuhara K, 2009, CURR MED CHEM, V16, P2867, DOI 10.2174/092986709788803196; Jones AK, 2004, BIOESSAYS, V26, P39, DOI 10.1002/bies.10377; Jones AK, 2010, ADV EXP MED BIOL, V683, P25; Jospin M, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000265; Knutsen AP, 2012, J ALLERGY CLIN IMMUN, V129, P280, DOI 10.1016/j.jaci.2011.12.970; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lips KS, 2007, LIFE SCI, V80, P2263, DOI 10.1016/j.lfs.2007.01.026; Lips KS, 2006, J MOL NEUROSCI, V30, P15, DOI 10.1385/JMN:30:1:15; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Markewitz BA, 1999, AM J MED SCI, V318, P74, DOI 10.1097/00000441-199908000-00002; McCormick A, 2010, CELL MICROBIOL, V12, P1535, DOI 10.1111/j.1462-5822.2010.01517.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; Mishra NC, 2008, J IMMUNOL, V180, P7655, DOI 10.4049/jimmunol.180.11.7655; Mishra NC, 2010, J IMMUNOL, V185, P588, DOI 10.4049/jimmunol.0902227; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Profita M, 2011, LIFE SCI, V89, P36, DOI 10.1016/j.lfs.2011.04.025; Proskocil BJ, 2004, ENDOCRINOLOGY, V145, P2498, DOI 10.1210/en.2003-1728; Razani-Boroujerdi S, 2007, J IMMUNOL, V179, P2889, DOI 10.4049/jimmunol.179.5.2889; Rehan VK, 2009, LUNG, V187, P281, DOI 10.1007/s00408-009-9158-2; Schuster E A, 1992, Am Nurse, V24, P25; Sgard F, 2002, MOL PHARMACOL, V61, P150, DOI 10.1124/mol.61.1.150; Singh SP, 2011, J IMMUNOL, V187, P4542, DOI 10.4049/jimmunol.1101567; Singh SP, 2009, J IMMUNOL, V183, P2115, DOI 10.4049/jimmunol.0900826; Singh SP, 2000, TOXICOL APPL PHARM, V164, P65, DOI 10.1006/taap.2000.8897; Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803; Tournier JM, 2011, CURR OPIN ONCOL, V23, P83, DOI 10.1097/CCO.0b013e3283412ea1; Turner J, 2009, BIOCHEM SOC T, V37, P877, DOI 10.1042/BST0370877; Verbitsky M, 2000, NEUROPHARMACOLOGY, V39, P2515, DOI 10.1016/S0028-3908(00)00124-6; Vestbo J, 2002, NOVART FDN SYMP, V248, P3; Vestbo J., 2002, NOVART FDN SYMP, V248, P277; Whiteaker P, 2007, BIOCHEMISTRY-US, V46, P6628, DOI 10.1021/bi7004202; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Xiang YY, 2007, NAT MED, V13, P862, DOI 10.1038/nm1604; Zhang JM, 2007, J PHYSIOL-LONDON, V579, P753, DOI 10.1113/jphysiol.2006.124578	50	34	36	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					770	+		10.1016/j.jaci.2012.04.002	http://dx.doi.org/10.1016/j.jaci.2012.04.002			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22578901	Green Accepted			2022-12-18	WOS:000308463500028
J	Luckey, U; Schmidt, T; Pfender, N; Romer, M; Lorenz, N; Martin, SF; Bopp, T; Schmitt, E; Nikolaev, A; Yogev, N; Waisman, A; Jakob, T; Steinbrink, K				Luckey, Ulrike; Schmidt, Talkea; Pfender, Nikolai; Romer, Maike; Lorenz, Nadine; Martin, Stefan F.; Bopp, Tobias; Schmitt, Edgar; Nikolaev, Alexey; Yogev, Nir; Waisman, Ari; Jakob, Thilo; Steinbrink, Kerstin			Crosstalk of regulatory T cells and tolerogenic dendritic cells prevents contact allergy in subjects with low zone tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Tolerance; low zone tolerance; contact hypersensitivity; regulatory T cells; dendritic cells; hapten; IL-10; contact allergen; allergic contact dermatitis	SELF-TOLERANCE; EFFECTOR; CD25(+); INDUCTION; HYPERSENSITIVITY; SENSITIZATION; MECHANISMS; SUBSETS; IL-10; ROLES	Background: Allergic contact dermatitis is one of the most common occupational diseases. A main protective mechanism in those who do not develop allergic contact dermatitis is tolerance induction by repeated exposure to low doses of contact allergen, which is termed low zone tolerance (LZT). The mechanisms that determine the tolerance induction in subjects with LZT are still elusive. Objective: We performed analysis of the role of CD4(+)CD25(+) forkhead box protein 3 (FOXP3)-positive regulatory T (Treg) cells and dendritic cells (DCs) in mice with LZT. Methods: Mechanisms of tolerance induction were analyzed in a murine model of LZT by using FOXP3 and IL-10 reporter mice, as well as mice that allow the selective depletion of Treg cells or DCs. Results: Depletion of CD4(+)CD25(+)FOXP3(+) Treg cells during tolerance induction completely abolishes the development of LZT, resulting in a pronounced contact hypersensitivity response. Adoptive transfer experiments, depletion studies, and use of cell type-specific deficient mice revealed that IL-10 production is critical for the suppressor function of Treg cells in mice with LZT and that tolerogenic CD8(+)CD11c(+) DCs located in the skin-draining lymph nodes are essential for LZT. In the absence of Treg cells, DCs did not develop tolerogenic functions, indicating that activated IL-10(+) Treg cells might imprint the tolerogenic DC phenotype. Cell communication analysis revealed that the education of tolerogenic DCs might involve a direct interaction with Treg cells mediated by gap junctions. Subsequently, induction of tolerogenic CD11c(+) DCs leads to the generation of hapten-specific CD8(+) Treg cells, which protect against contact hypersensitivity. Conclusions: Our data demonstrate critical interactions between CD4(+)CD25(+)FOXP3(+) Treg cells and tolerogenic CD8(+)CD11c(+) DCs during the induction of LZT. (J Allergy Clin Immunol 2012;130:781-97.)	[Luckey, Ulrike; Schmidt, Talkea; Lorenz, Nadine; Steinbrink, Kerstin] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, D-55131 Mainz, Germany; [Pfender, Nikolai; Romer, Maike; Martin, Stefan F.; Jakob, Thilo] Univ Freiburg, Med Ctr, Allergy Res Grp, Dept Dermatol, D-79104 Freiburg, Germany; [Bopp, Tobias; Schmitt, Edgar] Johannes Gutenberg Univ Mainz, Inst Immunol, Univ Med Ctr, D-55131 Mainz, Germany; [Nikolaev, Alexey; Yogev, Nir; Waisman, Ari] Johannes Gutenberg Univ Mainz, Inst Mol Med, Univ Med Ctr, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz; University of Freiburg; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Steinbrink, K (corresponding author), Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.	thilo.jakob@uniklinik-freiburg.de; kerstin.steinbrink@unimedizin-mainz.de	Jakob, Thilo/J-1621-2012; Bopp, Tobias/A-4328-2018; Waisman, Ari/C-7383-2015	Bopp, Tobias/0000-0002-3232-8065; Waisman, Ari/0000-0003-4304-8234; Pfender, Nikolai/0000-0003-3933-7463	German Research Foundation [SFB 548/B6, Transregio 52/A7, STE791/4-5, STE791/5-1]; Foundation Rhineland-Palatinate; University of Mainz; "Forschungsprogramm'' from the Baden-Wurttemberg Stiftung [P-LS-AL2/15]; German Research Council; Landesstifung Baden-Wurttemberg; COLIPA; Birken GmbH; Allergopharma; Phadia/Thermo Ficher	German Research Foundation(German Research Foundation (DFG)); Foundation Rhineland-Palatinate; University of Mainz; "Forschungsprogramm'' from the Baden-Wurttemberg Stiftung; German Research Council(German Research Foundation (DFG)); Landesstifung Baden-Wurttemberg; COLIPA; Birken GmbH; Allergopharma; Phadia/Thermo Ficher	Supported by grants from the German Research Foundation (SFB 548/B6, Transregio 52/A7, STE791/4-5, STE791/5-1), the Foundation Rhineland-Palatinate, and intramural grants of the University of Mainz (to K. S.), and by contract research "Forschungsprogramm'' from the Baden-Wurttemberg Stiftung (P-LS-AL2/15, to T. J.).; T. Jakob receives research support from the German Research Council, Landesstifung Baden-Wurttemberg, COLIPA, Birken GmbH, Allergopharma, and Phadia/Thermo Ficher and is a board member of the European Immunodermatology Society and the German Society of Allergy & Clinical Immunology. K. Steinbrink receives research support from the German Research Foundation and the Foundation of Rhineland-Palatinate. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Belz GT, 2002, J EXP MED, V196, P1099, DOI 10.1084/jem.20020861; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Cavani A, 2000, J INVEST DERMATOL, V114, P295, DOI 10.1046/j.1523-1747.2000.00881.x; Cavani A, 2008, CURR OPIN ALLERGY CL, V8, P294, DOI 10.1097/ACI.0b013e3283079ea4; Comes A, 2006, J IMMUNOL, V176, P1750, DOI 10.4049/jimmunol.176.3.1750; Couper KN, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000004; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627; ELMETS CA, 1983, J EXP MED, V158, P781, DOI 10.1084/jem.158.3.781; Fonseca PC, 2006, CYTOM PART A, V69A, P487, DOI 10.1002/cyto.a.20255; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Ikezawa Y, 2005, J DERMATOL SCI, V39, P105, DOI 10.1016/j.jdermsci.2005.02.002; Kish DD, 2005, J LEUKOCYTE BIOL, V78, P725, DOI 10.1189/jlb.0205069; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Lehmann J, 2002, P NATL ACAD SCI USA, V99, P13031, DOI 10.1073/pnas.192162899; Liu K, 2009, SCIENCE, V324, P392, DOI 10.1126/science.1170540; Luckey U, 2011, J CLIN INVEST, V121, P3860, DOI 10.1172/JCI45963; Lushniak BD, 2003, INT ARCH OCC ENV HEA, V76, P325, DOI 10.1007/s00420-002-0417-2; Madan R, 2009, J IMMUNOL, V183, P2312, DOI 10.4049/jimmunol.0900185; Maeda A, 2008, J IMMUNOL, V181, P5956, DOI 10.4049/jimmunol.181.9.5956; Maurer M, 2003, J CLIN INVEST, V112, P432, DOI 10.1172/JCI200318106; McMurchy AN, 2010, J ALLERGY CLIN IMMUN, V126, P1242, DOI 10.1016/j.jaci.2010.09.001; Misra N, 2004, J IMMUNOL, V172, P4676, DOI 10.4049/jimmunol.172.8.4676; Morelli AE, 2007, NAT REV IMMUNOL, V7, P610, DOI 10.1038/nri2132; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Powrie F, 2004, ANN NY ACAD SCI, V1029, P132, DOI 10.1196/annals.1309.030; Ring S, 2010, J ALLERGY CLIN IMMUN, V125, P237, DOI 10.1016/j.jaci.2009.10.025; Ring S, 2009, J ALLERGY CLIN IMMUN, V123, P1287, DOI 10.1016/j.jaci.2009.03.022; Rolland JM, 2010, CURR OPIN ALLERGY CL, V10, P559, DOI 10.1097/ACI.0b013e32833ff2b2; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Sakaguchi S, 2009, INT IMMUNOL, V21, P1105, DOI 10.1093/intimm/dxp095; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; Schildknecht A, 2010, P NATL ACAD SCI USA, V107, P199, DOI 10.1073/pnas.0910620107; Schneider MA, 2007, J EXP MED, V204, P735, DOI 10.1084/jem.20061405; Seidel-Guyenot W, 2004, EUR J IMMUNOL, V34, P3082, DOI 10.1002/eji.200425402; Seidel-Guyenot W, 2006, J ALLERGY CLIN IMMUN, V117, P1170, DOI 10.1016/j.jaci.2006.01.014; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Shortman K, 2010, IMMUNOL REV, V234, P18, DOI 10.1111/j.0105-2896.2009.00870.x; Steinbrink K, 1996, J INVEST DERMATOL, V107, P243, DOI 10.1111/1523-1747.ep12329721; Steinbrink K, 1996, J EXP MED, V183, P759, DOI 10.1084/jem.183.3.759; Stephens GL, 2007, J IMMUNOL, V178, P6901, DOI 10.4049/jimmunol.178.11.6901; Stephens LA, 2000, J IMMUNOL, V165, P3105, DOI 10.4049/jimmunol.165.6.3105; Sun J, 2009, NAT MED, V15, P277, DOI 10.1038/nm.1929; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; Vocanson M, 2010, J ALLERGY CLIN IMMUN, V126, P280, DOI 10.1016/j.jaci.2010.05.022; Wan YSY, 2005, P NATL ACAD SCI USA, V102, P5126, DOI 10.1073/pnas.0501701102; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001	55	34	37	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					781	+		10.1016/j.jaci.2012.06.022	http://dx.doi.org/10.1016/j.jaci.2012.06.022			28	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22935591				2022-12-18	WOS:000308463500029
J	Crapster-Pregont, M; Yeo, J; Sanchez, RL; Kuperman, DA				Crapster-Pregont, Margaret; Yeo, Janice; Sanchez, Raquel L.; Kuperman, Douglas A.			Dendritic cells and alveolarmacrophages mediate IL-13-induced airway inflammation and chemokine production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway; macrophage; chemokines; inflammation; IL-13; IFN-gamma; CD11b; dendritic cell; macrophage-derived chemokine; thymus and activation-regulated chemokine	TRANSCRIPTION FACTOR 6; IFN-GAMMA; IN-VIVO; ALLERGEN CHALLENGE; SIGNAL TRANSDUCER; T-CELLS; DC-SIGN; ASTHMA; INTERLEUKIN-13; MICE	Background: IL-13 in the airway induces pathologies that are highly characteristic of asthma, including mucus metaplasia, airway hyperreactivity (AHR), and airway inflammation. As such, it is important to identify the IL-13-responding cell types that mediate each of the above pathologies. For example, IL-13' s effects on epithelium contribute to mucus metaplasia and AHR. IL-13' s effects on smooth muscle also contribute to AHR. However, it has been difficult to identify the cell types that mediate IL-13-induced airway inflammation. Objective: We sought to determine which cell types mediate IL-13-induced airway inflammation. Methods: We treated the airways of mice with IL-13 alone or in combination with IFN-gamma. We associated the inhibitory effect of IFN-gamma on IL-13-induced airway inflammation and chemokine production with cell types in the lung that coexpress IL-13 and IFN-gamma receptors. We then evaluated IL-13-induced responses in CD11c promoter-directed diphtheria toxin receptor-expressing mice that were depleted of both dendritic cells and alveolar macrophages and in CD11b promoter-directed diphtheria toxin receptor-expressing mice that were depleted of dendritic cells. Results: Dendritic cell and alveolar macrophage depletion protected mice from IL-13-induced airway inflammation and CCL11, CCL24, CCL22, and CCL17 chemokine production. Preferential depletion of dendritic cells protected mice from IL-13-induced airway inflammation and CCL22 and CCL17 chemokine production but not from IL-13-induced CCL11 and CCL24 chemokine production. In either case mice were not protected from IL-13-induced AHR and mucus metaplasia. Conclusions: Pulmonary dendritic cellsand alveolarmacrophages mediate IL-13-induced airway inflammation and chemokine production. (J Allergy Clin Immunol 2012; 129: 1621-7.)	[Crapster-Pregont, Margaret; Yeo, Janice; Sanchez, Raquel L.; Kuperman, Douglas A.] Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Kuperman, DA (corresponding author), Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, 240 E Huron,Rm M-317, Chicago, IL 60611 USA.	d-kuperman@northwestern.edu			National Institutes of Health/National Institute of Allergy and Infectious Diseases [AI076315, AI083534]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI083534, R01AI076315] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	D.A.K. received grant support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (AI076315 and AI083534).	Alferink J, 2003, J EXP MED, V197, P585, DOI 10.1084/jem.20021859; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P553, DOI 10.1016/j.jaci.2004.04.044; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Coyle AJ, 1996, J IMMUNOL, V156, P2680; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Ford JG, 2001, J IMMUNOL, V167, P1769, DOI 10.4049/jimmunol.167.3.1769; Fulkerson PC, 2006, AM J PATHOL, V169, P2117, DOI 10.2353/ajpath.2006.060617; Ge XN, 2010, J IMMUNOL, V185, P1205, DOI 10.4049/jimmunol.1000039; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Jakubzick C, 2006, J IMMUNOL, V176, P3578, DOI 10.4049/jimmunol.176.6.3578; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kumar RK, 2002, CLIN EXP ALLERGY, V32, P1104, DOI 10.1046/j.1365-2222.2002.01420.x; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuperman DA, 2005, J ALLERGY CLIN IMMUN, V116, P305, DOI 10.1016/j.jaci.2005.03.024; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Kuperman DA, 2008, CURR MOL MED, V8, P384, DOI 10.2174/156652408785161032; Lack G, 1996, J IMMUNOL, V157, P1432; Lindley AR, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/727305; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Medoff BD, 2009, J IMMUNOL, V182, P623, DOI 10.4049/jimmunol.182.1.623; Nomiyama H, 1998, CYTOGENET CELL GENET, V81, P10, DOI 10.1159/000015000; Perkins C, 2011, J EXP MED, V208, P853, DOI 10.1084/jem.20100023; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; Pope SM, 2005, J IMMUNOL, V175, P5341, DOI 10.4049/jimmunol.175.8.5341; Teixeira LK, 2005, MEM I OSWALDO CRUZ, V100, P137, DOI 10.1590/S0074-02762005000900024; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vermaelen K, 2004, CYTOM PART A, V61A, P170, DOI 10.1002/cyto.a.20064; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	31	34	36	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1621	+		10.1016/j.jaci.2012.01.052	http://dx.doi.org/10.1016/j.jaci.2012.01.052			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22365581	Green Accepted			2022-12-18	WOS:000304764600024
J	Howell, MD; Gao, PS; Kim, BE; Lesley, LJ; Streib, JE; Taylor, PA; Zaccaro, DJ; Boguniewicz, M; Beck, LA; Hanifin, JM; Schneider, LC; Hata, TR; Gallo, RL; Kaplan, MH; Barnes, KC; Leung, DYM				Howell, Michael D.; Gao, Peisong; Kim, Byung Eui; Lesley, Leighann J.; Streib, Joanne E.; Taylor, Patricia A.; Zaccaro, Daniel J.; Boguniewicz, Mark; Beck, Lisa A.; Hanifin, Jon M.; Schneider, Lynda C.; Hata, Tissa R.; Gallo, Richard L.; Kaplan, Mark H.; Barnes, Kathleen C.; Leung, Donald Y. M.			The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; STAT6; eczema; virus; infection	IFN-GAMMA; ASSOCIATION; EXPRESSION; ASTHMA; RISK; IL-4; INSIGHTS	Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with increased susceptibility to recurrent skin infections. Objective: We sought to determine why a subset of patients with AD have an increased risk of disseminated viral skin infections. Methods: Human subjects with AD with a history of eczema herpeticum (EH) and various control groups were enrolled. Vaccinia virus (VV) expression was measured by means of PCR and immunofluorescent staining in skin biopsy specimens from each study group after incubation with VV. Transgenic mice with a constitutively active signal transducer and activator of transcription 6 gene (STAT6) were characterized for response to VV skin inoculation. Genotyping for 10 STAT6 single nucleotide polymorphisms (SNPs) was performed in a white patient sample (n = 444). Results: VV gene and protein expression were significantly increased in the skin of patients with EH compared with other subject groups after incubation with VV in vitro. Antibody neutralization of IL-4 and IL-13 resulted in lower VV replication in patients with a history of EH. Mice that expressed a constitutively active STAT6 gene compared with wild-type mice had increased mortality and satellite lesion formation after VV skin inoculation. Significant associations were observed between STAT6 SNPs and EH (rs3024975, rs841718, rs167769, and rs703817) and IFN-gamma production. The strongest association was observed for a 2-SNP haplotype (patients with AD with a history of EH vs patients with AD without a history of EH, 24.9% vs 9.2%; P = 5.17 x 10(-6)). Conclusion: The STAT6 gene increases viral replication in the skin of patients with AD with a history of EH. Further genetic association studies and functional investigations are warranted. (J Allergy Clin Immunol 2011;128:1006-14.)	[Howell, Michael D.; Kim, Byung Eui; Lesley, Leighann J.; Streib, Joanne E.; Taylor, Patricia A.; Boguniewicz, Mark; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Howell, Michael D.; Boguniewicz, Mark; Leung, Donald Y. M.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA; [Gao, Peisong; Barnes, Kathleen C.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Zaccaro, Daniel J.] Rho Fed Syst Div, Chapel Hill, NC USA; [Beck, Lisa A.] Univ Rochester, Med Ctr, Dept Dermatol, Rochester, NY 14627 USA; [Hanifin, Jon M.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; [Schneider, Lynda C.] Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Hata, Tissa R.; Gallo, Richard L.] Univ Calif San Diego, Div Dermatol, La Jolla, CA 92093 USA; [Kaplan, Mark H.] Indiana Univ Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN USA	National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Johns Hopkins University; University of Rochester; Oregon Health & Science University; Harvard University; Boston Children's Hospital; University of California System; University of California San Diego; Indiana University System; Indiana University Bloomington	Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St,Rm K926i, Denver, CO 80206 USA.	leungd@njhealth.org	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Kim, Byung Eui/0000-0003-4923-1814; Kaplan, Mark/0000-0002-2923-8245	National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) [N01 AI40029, N01 AI40030, U19 AI070448, PO1 AI056097]; NCRR/NIH [1 UL1 RR025780]; National Institutes of Health (NIH); Astellas Pharma US; Basilea; Novartis; Shionogi USA; Taisho; Astellas; Sanofi-Aventis; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI056097, U19AI070448, N01AI040029] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Astellas Pharma US(Astellas Pharmaceuticals); Basilea; Novartis(Novartis); Shionogi USA; Taisho; Astellas(Astellas Pharmaceuticals); Sanofi-Aventis(Sanofi-Aventis); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) contracts N01 AI40029 and N01 AI40030. Supported in part by the Colorado Clinical Translational Science Award grant 1 UL1 RR025780 from NCRR/NIH. M. H. K. is supported by NIH/NIAID grants U19 AI070448 and PO1 AI056097.; Disclosure of potential conflict of interest: M. Boguniewicz receives research support from the National Institutes of Health (NIH). L. A. Beck has consultant arrangements with Regeneron and receives research support from the NIH/National Institute of Allergy and Infectious Diseases (NIAID). J. M. Hanifin has consultant arrangements with Johnson & Johnson and Otsuka Pharmaceutical Co, Ltd; receives research support from Astellas Pharma US, Basilea, Novartis, Shionogi USA, and Taisho; and serves on the Board of Directors for the National Eczema Association. L. C. Schneider receives research support from Astellas and Novartis. M. H. Kaplan receives research support from the NIH/NIAID. K. C. Barnes receives research support from the NIH and Sanofi-Aventis. The rest of the authors have declared that they have no conflict of interest.	Albanesi C, 2007, J IMMUNOL, V179, P984, DOI 10.4049/jimmunol.179.2.984; Amoli MM, 2002, GENES IMMUN, V3, P220, DOI 10.1038/sj.gene.6363872; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Bruns HA, 2003, J IMMUNOL, V170, P3478, DOI 10.4049/jimmunol.170.7.3478; Freyschmidt EJ, 2007, J ALLERGY CLIN IMMUN, V119, P671, DOI 10.1016/j.jaci.2006.12.645; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Gao PS, 2004, J MED GENET, V41, P535, DOI 10.1136/jmg.2003.015842; Gauderman WJ, 2002, AM J EPIDEMIOL, V155, P478, DOI 10.1093/aje/155.5.478; Grabenstein JD, 2003, JAMA-J AM MED ASSOC, V289, P3278, DOI 10.1001/jama.289.24.3278; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2007, CURR OPIN ALLERGY CL, V7, P413, DOI 10.1097/ACI.0b013e3282a64343; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; Jackson RJ, 2001, J VIROL, V75, P1205, DOI 10.1128/JVI.75.3.1205-1210.2001; Janetzki Sylvia, 2005, Methods Mol Biol, V302, P51; Kaplan MH, 2007, BLOOD, V110, P4367, DOI 10.1182/blood-2007-06-098244; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P957; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Ohmori Y, 2000, J BIOL CHEM, V275, P38095, DOI 10.1074/jbc.M006227200; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Reynolds MG, 2007, EMERG INFECT DIS, V13, P1332, DOI 10.3201/eid1309.070175; Rotz L D, 2001, MMWR Recomm Rep, V50, P1; Sanderson CM, 2000, J GEN VIROL, V81, P47, DOI 10.1099/0022-1317-81-1-47; Schedel M, 2009, J ALLERGY CLIN IMMUN, V124, P583, DOI 10.1016/j.jaci.2009.06.024; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; van den Broek M, 2000, J IMMUNOL, V164, P371, DOI 10.4049/jimmunol.164.1.371; Vercelli D, 2008, J ALLERGY CLIN IMMUN, V122, P267, DOI 10.1016/j.jaci.2008.06.008; Weidinger S, 2004, J MED GENET, V41, P658, DOI 10.1136/jmg.2004.020263; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; WHO, 1980, WKLY EPIDEMIOL REC, V55, P148	36	34	35	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1006	1014		10.1016/j.jaci.2011.06.003	http://dx.doi.org/10.1016/j.jaci.2011.06.003			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21762972	Green Accepted			2022-12-18	WOS:000296578200013
J	Taylor, DR				Taylor, D. Robin			Using biomarkers in the assessment of airways disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airways disease; asthma; biomarkers; chronic obstructive pulmonary disease; exhaled nitric oxide; induced sputum; performance characteristics; validation	EXHALED NITRIC-OXIDE; RANDOMIZED CONTROLLED-TRIAL; OBSTRUCTIVE PULMONARY-DISEASE; NECROSIS-FACTOR-ALPHA; SURROGATE END-POINTS; C-REACTIVE PROTEIN; CHILDHOOD ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; PERSISTENT ASTHMA; EOSINOPHILIC ASTHMA	A biomarker provides a window on underlying disease activity. This is helpful when the pathology, treatment response, or both are heterogeneous or when trying to interpret nonspecific respiratory symptoms in patients with comorbidities. The successful application of a biomarker result is critically dependent on the specific question being addressed and the performance characteristics of the biomarker in relation to that question in the context of pretest probabilities. Negative prediction might be the best way to use a biomarker, such as a D-dimer, pro-brain natriuretic peptide, and exhaled nitric oxide. In this review the role of biomarkers in airways disease ( notably induced sputum eosinophils and exhaled nitric oxide) is considered in relation to risk stratification, identification of treatment responders, identification of a clinical phenotype, monitoring of disease, and new drug development. (J Allergy Clin Immunol 2011;128:927-34.)	Univ Otago, Dunedin Sch Med, Dunedin, New Zealand	University of Otago	Taylor, DR (corresponding author), Univ Otago, Dunedin Sch Med, POB 913, Dunedin, New Zealand.	robin.taylor@stonebow.otago.ac.nz			Aerocrine AB	Aerocrine AB	Disclosure of potential conflict of interest: D. R. Taylor has received lecture fees from Aerocrine AB.	[Anonymous], 2003, EUR RESP J, V22, P470; [Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Bossley CJ, 2009, EUR RESPIR J, V34, P1052, DOI 10.1183/09031936.00186508; Bradding P, 2010, CURR OPIN ALLERGY CL, V10, P54, DOI 10.1097/ACI.0b013e32833489a9; Brightling C, 2008, J ALLERGY CLIN IMMUN, V121, P5, DOI 10.1016/j.jaci.2007.10.028; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P803, DOI 10.1016/j.jaci.2009.11.048; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Caudri D, 2010, THORAX, V65, P801, DOI 10.1136/thx.2009.126912; Cowan DC, 2010, THORAX, V65, P384, DOI 10.1136/thx.2009.126722; Dahl M, 2001, AM J RESP CRIT CARE, V164, P1008, DOI 10.1164/ajrccm.164.6.2010067; Dahl M, 2007, AM J RESP CRIT CARE, V175, P250, DOI 10.1164/rccm.200605-713OC; de Jongste JC, 2009, AM J RESP CRIT CARE, V179, P93, DOI 10.1164/rccm.200807-1010OC; Debley JS, 2010, J ALLERGY CLIN IMMUN, V125, P1228, DOI 10.1016/j.jaci.2010.03.023; Diamant Z, 2010, PULM PHARMACOL THER, V23, P468, DOI 10.1016/j.pupt.2010.06.006; Donaldson GC, 2007, AM J RESP CRIT CARE, V175, P209, DOI 10.1164/rccm.200610-1565ED; Dummer JF, 2009, AM J RESP CRIT CARE, V180, P846, DOI 10.1164/rccm.200905-0685OC; Dupont LJ, 2003, CHEST, V123, P751, DOI 10.1378/chest.123.3.751; Ekroos H, 2002, RESP MED, V96, P895, DOI 10.1053/rmed.2002.1378; Ferrazzoni S, 2009, CHEST, V136, P155, DOI 10.1378/chest.08-2338; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Franklin PJ, 2008, PAEDIATR RESPIR REV, V9, P122, DOI 10.1016/j.prrv.2007.12.004; Fritsch M, 2006, PEDIATR PULM, V41, P855, DOI 10.1002/ppul.20455; Gautrin D, 2010, CURR ALLERGY ASTHM R, V10, P365, DOI 10.1007/s11882-010-0131-1; Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492; Gibson NS, 2008, CHEST, V134, P789, DOI 10.1378/chest.08-0344; Gibson PG, 2009, CLIN EXP ALLERGY, V39, P478, DOI 10.1111/j.1365-2222.2009.03226.x; *GIN, GLANC ASTHM MAN REF; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hewitt Richard S, 2009, Prim Care Respir J, V18, P320, DOI 10.4104/pcrj.2009.00060; Jackson R, 2000, BMJ-BRIT MED J, V320, P709, DOI 10.1136/bmj.320.7236.709; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; Knuffman JE, 2009, J ALLERGY CLIN IMMUN, V123, P411, DOI 10.1016/j.jaci.2008.11.016; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lesko LJ, 2001, ANNU REV PHARMACOL, V41, P347, DOI 10.1146/annurev.pharmtox.41.1.347; Luskin AT, 2005, J ALLERGY CLIN IMMUN, V115, pS539, DOI 10.1016/j.jaci.2005.01.027; Maestrelli P, 2007, EUR RESPIR J, V29, P831, DOI 10.1183/09031936.00022507; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; O'Byrne PM, 2007, AM J RESP CRIT CARE, V176, P1059, DOI 10.1164/rccm.200708-1264ED; Olin AC, 2007, CHEST, V131, P1852, DOI 10.1378/chest.06-2928; Olin AC, 2006, CHEST, V130, P1319, DOI 10.1378/chest.130.5.1319; Pavord ID, 2008, LANCET, V372, P1017, DOI 10.1016/S0140-6736(08)61421-X; Pedrosa M, 2010, J ASTHMA, V47, P817, DOI 10.3109/02770903.2010.491147; Perez-de-Llano LA, 2010, EUR RESPIR J, V35, P1221, DOI 10.1183/09031936.00118809; PETSKY HL, 2010, THORAX; Pijnenburg MW, 2006, PEDIAT ALLERG IMM-UK, V17, P189, DOI 10.1111/j.1399-3038.2006.00394.x; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Pijnenburg MWH, 2005, CLIN EXP ALLERGY, V35, P920, DOI 10.1111/j.1365-2222.2005.02279.x; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Singer AJ, 2009, ACAD EMERG MED, V16, P488, DOI 10.1111/j.1553-2712.2009.00415.x; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Smith AD, 2009, J ALLERGY CLIN IMMUN, V124, P714, DOI 10.1016/j.jaci.2009.07.020; Stein PD, 2006, AM J MED, V119, P1048, DOI 10.1016/j.amjmed.2006.05.060; Stick S, 2009, AM J RESP CRIT CARE, V179, P87, DOI 10.1164/rccm.200810-1604ED; Suarthana E, 2009, OCCUP ENVIRON MED, V66, P111, DOI 10.1136/oem.2008.041079; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Taylor DR, 2008, POSTGRAD MED J, V84, P628, DOI 10.1136/pgmj.2008.069864; Taylor DR, 2009, THORAX, V64, P261, DOI 10.1136/thx.2008.098640; Tossa P, 2010, AM J RESP CRIT CARE, V182, P738, DOI 10.1164/rccm.200903-0415OC; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953, DOI 10.1164/ajrccm.162.3.9909033; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012; Zhang Z, 2005, CANCER EPIDEM BIOMAR, V14, P2283, DOI 10.1158/1055-9965.EPI-05-0774	77	34	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					927	934		10.1016/j.jaci.2011.03.051	http://dx.doi.org/10.1016/j.jaci.2011.03.051			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21621830				2022-12-18	WOS:000296578200002
J	Elsheikh, A; Castrejon, L; Lavergne, SN; Whitaker, P; Monshi, M; Callan, H; El-Ghaiesh, S; Farrell, J; Pichler, WJ; Peckham, D; Park, BK; Naisbitt, DJ				Elsheikh, Ayman; Castrejon, Luis; Lavergne, Sidonie N.; Whitaker, Paul; Monshi, Manal; Callan, Hayley; El-Ghaiesh, Sabah; Farrell, John; Pichler, Werner J.; Peckham, Daniel; Park, B. Kevin; Naisbitt, Dean J.			Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human; T cells; drug hypersensitivity; drug metabolism; cystic fibrosis	HIV-POSITIVE PATIENTS; TOXIC EPIDERMAL NECROLYSIS; BETA-LACTAM ANTIBIOTICS; T-CELL RESPONSES; REACTIVE METABOLITES; NITROSO SULFAMETHOXAZOLE; REDUCED GLUTATHIONE; GENE POLYMORPHISMS; COVALENT BINDING; HYDROXYLAMINE	Background: Exposure of patients with cystic fibrosis to sulfonamides is associated with a high incidence of hypersensitivity reactions. Objective: To compare mechanisms of antigen presentation and characterize the phenotype and function of T cells from sulfamethoxazole-hypersensitive patients with and without cystic fibrosis. Methods: T cells were cloned from 6 patients and characterized in terms of phenotype and function. Antigen specificity and mechanisms of antigen presentation to specific clones were then explored. Antigen-presenting cell metabolism of sulfamethoxazole was quantified by ELISA. The involvement of metabolism in antigen presentation was evaluated by using enzyme inhibitors. Results: Enzyme inhibitable sulfamethoxazole-derived protein adducts were detected in antigen-presenting cells from patients with and without cystic fibrosis. A significantly higher quantity of adducts were detected with cells from patients with cystic fibrosis. Over 500 CD4(+) or CD8(+) T-cell clones were generated and shown to proliferate and kill target cells. Three patterns of MHC-restricted reactivity (sulfamethoxazole-responsive, sulfamethoxazole metabolite-responsive, and cross-reactive) were observed with clones from patients without cystic fibrosis. From patients with cystic fibrosis, sulfamethoxazole metabolite-responsive and cross-reactive, but not sulfamethoxazole-responsive, clones were observed. The response of the cross-reactive clones to sulfamethoxazole was dependent on adduct formation and was blocked by glutathione and enzyme inhibitors. Antigen-stimulated clones from patients with cystic fibrosis secreted higher levels of IFN-gamma, IL-6, and IL-10, but lower levels of IL-17. Conclusion: Sulfamethoxazole metabolism and protein adduct formation is critical for the stimulation of T cells from patients with cystic fibrosis. T cells from patients with cystic fibrosis secrete high levels of IFN-gamma, IL-6, and IL-10. (J Allergy Clin Immunol 2011;127:1543-51.)	[Elsheikh, Ayman; Castrejon, Luis; Lavergne, Sidonie N.; Monshi, Manal; Callan, Hayley; El-Ghaiesh, Sabah; Farrell, John; Park, B. Kevin; Naisbitt, Dean J.] Univ Liverpool, Dept Pharmacol, MRC Ctr Drug Safety Sci, Liverpool L69 3GE, Merseyside, England; [Lavergne, Sidonie N.] Univ Illinois, Dept Vet Biosci, Urbana, IL 61801 USA; [Elsheikh, Ayman; El-Ghaiesh, Sabah] Tanta Univ, Dept Pharmacol, Tanta, Egypt; [Whitaker, Paul; Peckham, Daniel] St James Hosp, Reg Adult Cyst Fibrosis Unit, Leeds, W Yorkshire, England; [Monshi, Manal] King Fahad Med City, Fac Med, Riyadh, Saudi Arabia; [Pichler, Werner J.] Univ Bern, Inselspital, Div Allergol, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland	University of Liverpool; University of Illinois System; University of Illinois Urbana-Champaign; Egyptian Knowledge Bank (EKB); Tanta University; Saint James's University Hospital; King Fahad Medical City; University of Bern; University Hospital of Bern	Naisbitt, DJ (corresponding author), Univ Liverpool, Dept Pharmacol, MRC Ctr Drug Safety Sci, Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.	dnes@liv.ac.uk	El-Ghaiesh, Sabah H/L-8231-2016	El-Ghaiesh, Sabah H/0000-0001-7032-528X; Pichler, Werner J./0000-0002-8117-359X; Peckham, Daniel/0000-0001-7723-1868; Farrell, John/0000-0002-8726-5997; Naisbitt, Dean/0000-0003-4107-7832; Castrejon, Luis/0000-0002-2808-2808	Egyptian government; Mexican National Council for Science and Technology; Saudi Arabian government; Wellcome Trust [078598/Z/05/Z]; Medical Research Council [G0700654]; Medical Research Council [G0700654B] Funding Source: researchfish; MRC [G0700654] Funding Source: UKRI	Egyptian government; Mexican National Council for Science and Technology(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Saudi Arabian government; Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	A.E. and S.E.-G. are PhD students supported by the Egyptian government. L. C. is a PhD student supported by the Mexican National Council for Science and Technology. M. M. is a PhD student supported by the Saudi Arabian government. This work was supported by a grant from the Wellcome Trust (078598/Z/05/Z) as part of the Centre for Drug Safety Science supported by the Medical Research Council (G0700654).	Alfirevic A, 2003, BRIT J CLIN PHARMACO, V55, P158, DOI 10.1046/j.1365-2125.2003.01754.x; Alfirevic A, 2009, PHARMACOGENOMICS, V10, P531, DOI 10.2217/PGS.09.6; Burkhart C, 2001, BRIT J PHARMACOL, V132, P623, DOI 10.1038/sj.bjp.0703845; Callan HE, 2009, CHEM RES TOXICOL, V22, P937, DOI 10.1021/tx900034r; Carr A, 1995, AIDS Clin Rev, P65; Castrejon JL, 2010, CHEM RES TOXICOL, V23, P184, DOI 10.1021/tx900329b; Castrejon JL, 2010, J ALLERGY CLIN IMMUN, V125, P411, DOI 10.1016/j.jaci.2009.10.031; Chessman D, 2008, IMMUNITY, V28, P822, DOI 10.1016/j.immuni.2008.04.020; CRIBB AE, 1991, DRUG METAB DISPOS, V19, P900; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; CRIBB AE, 1990, DRUG METAB DISPOS, V18, P784; Dubin PJ, 2007, INFLAMM RES, V56, P221, DOI 10.1007/s00011-007-6187-2; Elsheikh A, 2010, J IMMUNOL, V185, P6448, DOI 10.4049/jimmunol.1000889; Farrell J, 2003, J PHARMACOL EXP THER, V306, P229, DOI 10.1124/jpet.103.050112; KOCH C, 1991, REV INFECT DIS, V13, pS608; Lavergne SN, 2009, J PHARMACOL EXP THER, V331, P372, DOI 10.1124/jpet.109.155374; Lavergne SN, 2010, CHEM RES TOXICOL, V23, P1009, DOI 10.1021/tx100151v; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Manchanda T, 2002, MOL PHARMACOL, V62, P1011, DOI 10.1124/mol.62.5.1011; Naisbitt DJ, 1999, BRIT J PHARMACOL, V126, P1393, DOI 10.1038/sj.bjp.0702453; Naisbitt DJ, 2003, MOL PHARMACOL, V63, P732, DOI 10.1124/mol.63.3.732; Naisbitt DJ, 2002, MOL PHARMACOL, V62, P628, DOI 10.1124/mol.62.3.628; Naisbitt DJ, 2001, BRIT J PHARMACOL, V133, P295, DOI 10.1038/sj.bjp.0704074; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Nassif A, 2004, J INVEST DERMATOL, V123, P850, DOI 10.1111/j.0022-202X.2004.23439.x; Nembrini C, 2009, J ALLERGY CLIN IMMUN, V123, P986, DOI 10.1016/j.jaci.2009.03.033; Ntimbane Thierry, 2009, Clin Biochem Rev, V30, P153; Nyfeler B, 1997, CLIN EXP ALLERGY, V27, P175, DOI 10.1111/j.1365-2222.1997.tb00690.x; Pichler Werner J, 2002, Am J Clin Dermatol, V3, P229, DOI 10.2165/00128071-200203040-00001; Pirmohamed M, 2000, PHARMACOGENETICS, V10, P705, DOI 10.1097/00008571-200011000-00005; Pirmohamed M, 2001, CURR OPIN ALLERGY CL, V1, P311, DOI 10.1097/00130832-200108000-00006; PLEASANTS RA, 1994, CHEST, V106, P1124, DOI 10.1378/chest.106.4.1124; Roychowdhury S, 2005, J PHARMACOL EXP THER, V314, P43, DOI 10.1124/jpet.105.086009; Roychowdhury S, 2007, DRUG METAB DISPOS, V35, P676, DOI 10.1124/dmd.106.013680; Rozieres A, 2009, ALLERGY, V64, P534, DOI 10.1111/j.1398-9995.2008.01674.x; Rozieres A, 2009, CURR OPIN ALLERGY CL, V9, P305, DOI 10.1097/ACI.0b013e32832d565c; Sanderson JP, 2007, J IMMUNOL, V178, P5533, DOI 10.4049/jimmunol.178.9.5533; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; Summan M, 2002, CHEM-BIOL INTERACT, V142, P155, DOI 10.1016/S0009-2797(02)00060-1; Wetmore DR, 2010, J BIOL CHEM, V285, P30516, DOI 10.1074/jbc.M110.140806; Wu Y, 2007, J ALLERGY CLIN IMMUN, V119, P973, DOI 10.1016/j.jaci.2006.12.617; Wu Y, 2006, J ALLERGY CLIN IMMUN, V118, P233, DOI 10.1016/j.jaci.2006.03.005; Zanni MP, 1998, J CLIN INVEST, V102, P1591, DOI 10.1172/JCI3544	45	34	37	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1543	U348		10.1016/j.jaci.2010.12.1119	http://dx.doi.org/10.1016/j.jaci.2010.12.1119			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21354601				2022-12-18	WOS:000291048500035
J	Ludvigsson, JF; Hemminki, K; Wahlstrom, J; Almqvist, C				Ludvigsson, Jonas F.; Hemminki, Kari; Wahlstrom, Jan; Almqvist, Catarina			Celiac disease confers a 1.6-fold increased risk of asthma: A nationwide population-based cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Ludvigsson, Jonas F.] Orebro Univ Hosp, Dept Pediat, Orebro, Sweden; [Ludvigsson, Jonas F.] Karolinska Univ Hosp, Clin Epidemiol Unit, Dept Med, Stockholm, Sweden; [Hemminki, Kari] German Canc Res Ctr, Div Mol Genet Epidemiol, D-6900 Heidelberg, Germany; [Hemminki, Kari] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden; [Wahlstrom, Jan] Karolinska Inst, Dept Med Solna, Resp Med Unit, Stockholm, Sweden; [Almqvist, Catarina] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Almqvist, Catarina] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Almqvist, Catarina] Karolinska Inst, Astrid Lindgren Childrens Hosp, Stockholm, Sweden	Orebro University; Karolinska Institutet; Karolinska University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Lund University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Ludvigsson, JF (corresponding author), Orebro Univ Hosp, Dept Pediat, Orebro, Sweden.	jonasludvigsson@yahoo.com	Torres, Maria/GVU-3391-2022; Torres, María José/T-3518-2017; Ludvigsson, Jonas F/A-8560-2012; Mayorga, Cristobalina/D-7167-2018; Mayorga, Lina/FBO-7730-2022	Torres, María José/0000-0001-5228-471X; Ludvigsson, Jonas F/0000-0003-1024-5602; Mayorga, Cristobalina/0000-0001-8852-8077; 				Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Dimeloe S, 2010, J STEROID BIOCHEM, V120, P86, DOI 10.1016/j.jsbmb.2010.02.029; Hallert C, 2002, ALIMENT PHARM THER, V16, P1333, DOI 10.1046/j.1365-2036.2002.01283.x; Kemppainen T, 1999, BONE, V24, P249, DOI 10.1016/S8756-3282(98)00178-1; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y; Ludvigsson JF, 2009, JAMA-J AM MED ASSOC, V302, P1171, DOI 10.1001/jama.2009.1320; Ludvigsson JF, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-19; Robinson DS, 2009, CLIN EXP ALLERGY, V39, P1314, DOI 10.1111/j.1365-2222.2009.03301.x	9	34	36	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4								10.1016/j.jaci.2010.12.1076	http://dx.doi.org/10.1016/j.jaci.2010.12.1076			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21315431	Bronze			2022-12-18	WOS:000289055800035
J	Rondon, C; Blanca-Lopez, N; Aranda, A; Herrera, R; Rodriguez-Bada, JL; Canto, G; Mayorga, C; Torres, MJ; Campo, P; Blanca, M				Rondon, Carmen; Blanca-Lopez, Natalia; Aranda, Ana; Herrera, Rocio; Luis Rodriguez-Bada, Jose; Canto, Gabriela; Mayorga, Cristobalina; Jose Torres, Maria; Campo, Paloma; Blanca, Miguel			Celiac disease confers a 1.6-fold increased risk of asthma: A nationwide population-based cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGIC-RHINITIS; IDIOPATHIC RHINITIS; PROVOCATION TEST; GRASS-POLLEN; IGE; IMMUNOTHERAPY; ABSENCE; IMPACT		[Rondon, Carmen; Jose Torres, Maria; Campo, Paloma; Blanca, Miguel] Carlos Haya Hosp, Allergy Serv, Malaga, Spain; [Blanca-Lopez, Natalia; Canto, Gabriela] Infanta Leonor Hosp, Allergy Serv, Madrid, Spain; [Aranda, Ana; Herrera, Rocio; Luis Rodriguez-Bada, Jose; Mayorga, Cristobalina] Carlos Haya Hosp, Fdn IMABIS, Res Lab, Malaga, Spain	Hospital Carlos Haya; Hospital Universitario Infanta Leonor; FIMABIS; Hospital Carlos Haya	Rondon, C (corresponding author), Carlos Haya Hosp, Allergy Serv, Malaga, Spain.	carmenrs61@gmail.com	Torres, Maria/GVU-3391-2022; Torres, María José/T-3518-2017; Ludvigsson, Jonas F/A-8560-2012; Mayorga, Cristobalina/D-7167-2018; Mayorga, Lina/FBO-7730-2022	Torres, María José/0000-0001-5228-471X; Ludvigsson, Jonas F/0000-0003-1024-5602; Mayorga, Cristobalina/0000-0001-8852-8077; 				Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; Clark J, 2007, ALLERGY, V62, P1023, DOI 10.1111/j.1398-9995.2007.01469.x; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V112, P1002, DOI 10.1016/j.jaci.2003.07.006; *EUR MED AG, 2008, GUID CLIN CLIN DEV P; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Hilberg O, 2000, RHINOLOGY, P3; HUGGINS KG, 1975, LANCET, V2, P148; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Rondon C, 2008, ALLERGY, V63, P1352, DOI 10.1111/j.1398-9995.2008.01695.x; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, pS314, DOI 10.1016/j.jaci.2006.12.601; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Rondon C, 2009, J ALLERGY CLIN IMMUN, V123, P1098, DOI 10.1016/j.jaci.2009.02.018; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Ulanova M, 2001, INFECT IMMUN, V69, P1151, DOI 10.1128/IAI.69.2.1151-1159.2001; Valero A, 2007, J ALLERGY CLIN IMMUN, V120, P359, DOI 10.1016/j.jaci.2007.04.006; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wedback A, 2005, RHINOLOGY, V43, P86	21	34	36	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					1071	U342		10.1016/j.jaci.2010.12.1076	http://dx.doi.org/10.1016/j.jaci.2010.12.1076			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21315431	Bronze			2022-12-18	WOS:000289055800034
J	Custovic, A; Rothers, J; Stern, D; Simpson, A; Woodcock, A; Wright, AL; Nicolaou, NC; Hankinson, J; Halonen, M; Martinez, FD				Custovic, Adnan; Rothers, Janet; Stern, Debbie; Simpson, Angela; Woodcock, Ashley; Wright, Anne L.; Nicolaou, Nicolaos C.; Hankinson, Jenny; Halonen, Marilyn; Martinez, Fernando D.			Effect of day care attendance on sensitization and atopic wheezing differs by Toll-like receptor 2 genotype in 2 population-based birth cohort studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Gene*environment interactions; asthma; allergic sensitization; birth cohorts; TLR2	EARLY-LIFE; LUNG-FUNCTION; RESPIRATORY-INFECTIONS; SCHOOL-AGE; ASTHMA; EXPOSURE; GENE; SYMPTOMS; ALLERGY; RISK	Background: Variation in the Toll-like receptor 2 gene (TLR2/-16934) is associated with allergic diseases among farmers' children but not among children not living on farms. Objective: To test the hypothesis that the same genetic variant conferring protection in the farming environment is associated with reduced risk of developing allergic phenotypes among urban children attending day care in early life. Methods: In 2 population-based birth cohorts (Manchester, United Kingdom, Manchester Asthma and Allergy Study [MAAS]; Tucson, Ariz, Tucson Infant Immune Study [IIS]), participants were recruited prenatally and followed prospectively (MAAS: 3, 5, 8 and 11 years; IIS: 1, 2, 3 and 5 years). We assessed allergic sensitization and atopic wheezing at each follow-up. Results: A total of 727 children participated in Manchester and 263 in Tucson. We found no significant associations between TLR2/-16934 and sensitization and atopic wheeze in either cohort. However, a different pattern emerged when we explored the interaction between TLR2/-16934 and day care attendance on these outcomes. We found a significant interaction between day care and TLR2/-16934 on the development of sensitization in the longitudinal model in MAAS in that children carrying the T allele who attended day care were less likely to be sensitized than those who did not attend day care, whereas among AA homozygotes, the association tended to be in the opposite direction. In a longitudinal model in IIS, we found a significant interaction between day care attendance and TLR2/-16934 on the development atopic wheezing. Significant interactions between TLR2/-16934 and day care were maintained when adjusting for socioeconomic status. Conclusion: The effect of day care on sensitization and atopic wheezing may differ among children with different variants of the TLR2 gene. (J Allergy Clin Immunol 2011;127:390-7.)	[Custovic, Adnan; Simpson, Angela; Woodcock, Ashley; Nicolaou, Nicolaos C.; Hankinson, Jenny] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Univ Hosp S Manchester NHS Fdn Trust, Manchester M23 9LT, Lancs, England; [Rothers, Janet; Stern, Debbie; Wright, Anne L.; Halonen, Marilyn; Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85721 USA; [Rothers, Janet] Univ Arizona, Coll Publ Hlth, Tucson, AZ 85721 USA; [Wright, Anne L.] Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA; [Halonen, Marilyn] Univ Arizona, Dept Pharmacol, Tucson, AZ 85721 USA	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; University of Arizona; University of Arizona; University of Arizona; University of Arizona	Custovic, A (corresponding author), Univ Manchester, Univ Hosp S Manchester NHS Fdn Trust, Educ & Res Ctr, 2nd Floor, Manchester M23 9LT, Lancs, England.	adnan.custovic@manchester.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578; Halonen, Marilyn/0000-0001-9606-935X; Simpson, Angela/0000-0003-2733-6666	Asthma UK [04/014]; Moulton Charitable Trust; MRC [G0601361]; National Institutes of Health [AI 42268, AI61811]; Medical Research Council; National Institutes of Health; Medical Research Council [G0601361] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10249] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061811, R01AI042268] Funding Source: NIH RePORTER	Asthma UK; Moulton Charitable Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Manchester Asthma and Allergy Study was supported by Asthma UK grant no. 04/014 and the Moulton Charitable Trust and is currently supported by MRC grant G0601361. The Tucson Infant Immune Study is supported by the National Institutes of Health (AI 42268 and AI61811).; A. Custovic and A. Woodcock have received research support from the Medical Research Council and the Moulton Charitable Trust. A. L. Wright, M. Halonen, and F. D. Martinez have received research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Brady MT, 2005, AM J INFECT CONTROL, V33, P276, DOI 10.1016/j.ajic.2004.11.007; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; DENNY FW, 1986, REV INFECT DIS, V8, P527; DUFFY DL, 1992, CHEST, V102, P654, DOI 10.1378/chest.102.2.654; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Hagerhed-Engman L, 2006, ALLERGY, V61, P447, DOI 10.1111/j.1398-9995.2006.01031.x; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Infante-Rivard C, 2001, AM J EPIDEMIOL, V153, P653, DOI 10.1093/aje/153.7.653; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; Lombardi E, 1997, AM J RESP CRIT CARE, V156, P1863, DOI 10.1164/ajrccm.156.6.9612066; Lowe L, 2004, ARCH DIS CHILD, V89, P540, DOI 10.1136/adc.2003.038539; Lowe LA, 2004, ARCH PEDIAT ADOL MED, V158, P996, DOI 10.1001/archpedi.158.10.996; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Lu N, 2004, CHILD CARE HLTH DEV, V30, P361, DOI 10.1111/j.1365-2214.2004.00411.x; Murray CS, 2004, PEDIATR PULM, V37, P492, DOI 10.1002/ppul.20019; Nafstad P, 2005, PEDIATRICS, V116, pE255, DOI 10.1542/peds.2004-2785; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Nicolaou NC, 2008, J ALLERGY CLIN IMMUN, V122, P500, DOI 10.1016/j.jaci.2008.06.033; Noguchi E, 2004, CLIN EXP ALLERGY, V34, P177, DOI 10.1111/j.1365-2222.2004.01839.x; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; Rothers J, 2007, J ALLERGY CLIN IMMUN, V120, P1201, DOI 10.1016/j.jaci.2007.07.036; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Smit LAM, 2009, AM J RESP CRIT CARE, V179, P363, DOI 10.1164/rccm.200810-1533OC; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Su Y, 2010, CLIN EXP ALLERGY, V40, P1222, DOI 10.1111/j.1365-2222.2010.03539.x; Valdar W, 2006, GENETICS, V174, P959, DOI 10.1534/genetics.106.060004; Vercelli D, 2006, J ALLERGY CLIN IMMUN, V117, P1303, DOI 10.1016/j.jaci.2006.03.030; von Mutius E, 2007, NEW ENGL J MED, V357, P1545, DOI 10.1056/NEJMe078119	39	34	35	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					390	U1232		10.1016/j.jaci.2010.10.050	http://dx.doi.org/10.1016/j.jaci.2010.10.050			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21281869	Green Accepted			2022-12-18	WOS:000286808000012
J	Jung, K; Tanaka, A; Fujita, H; Matsuda, A; Oida, K; Karasawa, K; Okamoto, N; Ohmori, K; Jee, Y; Shin, T; Matsuda, H				Jung, Kyungsook; Tanaka, Akane; Fujita, Hiroshi; Matsuda, Akira; Oida, Kumiko; Karasawa, Kaoru; Okamoto, Noriko; Ohmori, Keitaro; Jee, Youngheun; Shin, Taekyun; Matsuda, Hiroshi			Peroxisome proliferator-activated receptor gamma-mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC/Tnd mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mouse; atopic dermatitis; dendritic cells; peroxisome proliferator-activated receptor gamma; thymic stromal lymphopoietin; matrix metalloproteinase 9	THYMIC STROMAL LYMPHOPOIETIN; LANGERHANS CELLS; IGE HYPERPRODUCTION; PPAR-GAMMA; T-CELLS; EXPRESSION; ALPHA; INFLAMMATION; MIGRATION; APOPTOSIS	Background: Dendritic cells (DCs) are one of the key regulators for the initiation of allergic responses in patients with atopic dermatitis (AD), being strongly triggered by epithelial cell-derived thymic stromal lymphopoietin (TSLP). Because peroxisome proliferator-activated receptor (PPAR) g acts as a negative regulator in immune cells, suppressive properties of PPAR gamma in allergic responses have been proposed. Objective: Because pieces of evidence must be organized to identify the exact role of PPARg in immune regulation, we explored the suppressive effects of a PPARg agonist on various functions of DCs and the onset of AD in a murine model. Methods: Effects of rosiglitazone (RSG) on DCs that were derived from NC/Tnd mice, a model for human AD, were analyzed. RSG was administered to NC/Tnd mice to evaluate its preventive and therapeutic effects on the development of AD. Results: RSG inhibited TSLP-induced DC maturation through downregulation of costimulatory molecules. TSLP-promoted expressions of chemokines in DCs were also suppressed by RSG treatment. Moreover, we showed the necessity of matrix metalloproteinase 9 in TSLP-promoted DC migration by using DCs derived from matrix metalloproteinase 9-deficient NC/Tnd mice, as well as the suppressive effect of PPARg in the process. Daily oral administration of RSG to NC/Tnd mice before the onset of AD revealed a significant reduction in severity of skin lesions and scratching behavior. In mice treated with RSG, both expression of TSLP in the skin and maturation and migration of DCs were markedly suppressed. Conclusion: PPARg can be provided as an inhibitory regulator of TSLP-stimulated DCs in the onset of allergic reactions. (J Allergy Clin Immunol 2011;127:420-9.)	[Jung, Kyungsook; Tanaka, Akane; Fujita, Hiroshi; Matsuda, Akira; Oida, Kumiko; Karasawa, Kaoru; Okamoto, Noriko; Ohmori, Keitaro; Matsuda, Hiroshi] Tokyo Univ Agr & Technol, Lab Vet Mol Pathol & Therapeut, Div Anim Life Sci, Grad Sch,Inst Agr, Fuchu, Tokyo, Japan; [Jee, Youngheun; Shin, Taekyun] Jeju Natl Univ, Coll Vet Med, Cheju, South Korea; [Jee, Youngheun; Shin, Taekyun] Jeju Natl Univ, Vet Med Res Inst, Cheju, South Korea	Tokyo University of Agriculture & Technology; Jeju National University; Jeju National University	Tanaka, A (corresponding author), Tokyo Univ Agr & Technol, Lab Vet Mol Pathol & Therapeut, Div Anim Life Sci, Grad Sch,Inst Agr, 3-5-8 Saiwaicho, Fuchu, Tokyo, Japan.	akane@cc.tuat.ac.jp; hiro@cc.tuat.ac.jp	Matsuda, Hiroshi/C-8358-2013; OHMORI, Keitaro/G-1143-2013; Tanaka, Akane/G-1158-2013	Matsuda, Hiroshi/0000-0003-3189-6842; OHMORI, Keitaro/0000-0002-0582-4880; Tanaka, Akane/0000-0002-7906-5047; SHIN, Taekyun/0000-0002-9851-4354	Japan Society for the Promotion of Science, Japan; Japan Society for the Promotion of Science	Japan Society for the Promotion of Science, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Supported by a Grant-in-Aid for Scientific Research on Priority Areas A and a Grant-in-Aid for Scientific Research on Priority Areas B provided by the Japan Society for the Promotion of Science, Japan.; A. Tanaka and H. Matsuda have received research support from the Japan Society for the Promotion of Science. The rest of the authors have declared that they have no conflict of interest.	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Behshad R, 2008, ARCH DERMATOL, V144, P84, DOI 10.1001/archdermatol.2007.22; Beltrani VS, 2005, CURR OPIN ALLERGY CL, V5, P413, DOI 10.1097/01.all.0000182544.37724.b5; Bleier JI, 2004, J IMMUNOL, V172, P7408, DOI 10.4049/jimmunol.172.12.7408; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Bright JJ, 2003, J IMMUNOL, V171, P5743, DOI 10.4049/jimmunol.171.11.5743; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; Dahten A, 2008, J INVEST DERMATOL, V128, P2211, DOI 10.1038/jid.2008.84; Darmanin S, 2007, J IMMUNOL, V179, P4616, DOI 10.4049/jimmunol.179.7.4616; Devillers ACA, 2007, CLIN EXP DERMATOL, V32, P311, DOI 10.1111/j.1365-2230.2007.02378.x; Dubrac S, 2010, IMMUNOL CELL BIOL, V88, P400, DOI 10.1038/icb.2010.33; Elentner A, 2009, J CELL MOL MED, V13, P2658, DOI 10.1111/j.1582-4934.2009.00797.x; Fu YC, 2000, J LIPID RES, V41, P2017; Han JH, 2002, J BIOL CHEM, V277, P23582, DOI 10.1074/jbc.M200685200; Henri S, 2010, J EXP MED, V207, P189, DOI 10.1084/jem.20091964; Honda K, 2004, J ALLERGY CLIN IMMUN, V113, P882, DOI 10.1016/j.jaci.2004.02.036; Ishii I, 2008, IEEE T AUTOM SCI ENG, V5, P176, DOI 10.1109/TASE.2007.902868; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jakobsen MA, 2006, SCAND J IMMUNOL, V63, P330, DOI 10.1111/j.1365-3083.2006.01745.x; Jenkins SJ, 2007, J IMMUNOL, V179, P3515, DOI 10.4049/jimmunol.179.6.3515; Kawamoto K, 2000, INT IMMUNOL, V12, P103, DOI 10.1093/intimm/12.1.103; Klotz L, 2007, J IMMUNOL, V178, P2122, DOI 10.4049/jimmunol.178.4.2122; Kouwenhoven M, 2002, J NEUROIMMUNOL, V126, P161, DOI 10.1016/S0165-5728(02)00054-1; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Matsumoto M, 1999, J IMMUNOL, V162, P1056; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; Miyata M, 2008, EUR J IMMUNOL, V38, P1487, DOI 10.1002/eji.200737809; Nencioni A, 2002, J IMMUNOL, V169, P1228, DOI 10.4049/jimmunol.169.3.1228; Novak N, 2005, J AM ACAD DERMATOL, V53, pS171, DOI 10.1016/j.jaad.2005.04.060; Omori M, 2007, J IMMUNOL, V178, P1396, DOI 10.4049/jimmunol.178.3.1396; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; Peyrin-Biroulet L, 2010, P NATL ACAD SCI USA, V107, P8772, DOI 10.1073/pnas.0905745107; Ratzinger G, 2002, J IMMUNOL, V168, P4361, DOI 10.4049/jimmunol.168.9.4361; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SALLE DS, 2008, J ALLERGY CLIN IMMUN, V121, P962; Sallusto F, 1999, J EXP MED, V189, P611, DOI 10.1084/jem.189.4.611; Schlezinger JJ, 2002, J IMMUNOL, V169, P6831, DOI 10.4049/jimmunol.169.12.6831; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Sugiyama H, 2000, EUR J IMMUNOL, V30, P3363, DOI 10.1002/1521-4141(2000012)30:12<3363::AID-IMMU3363>3.0.CO;2-B; Tanaka A, 1999, BLOOD, V94, P2390, DOI 10.1182/blood.V94.7.2390.419k16_2390_2395; Tanaka A, 2007, J INVEST DERMATOL, V127, P855, DOI 10.1038/sj.jid.5700603; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Vermaelen KY, 2003, J IMMUNOL, V171, P1016, DOI 10.4049/jimmunol.171.2.1016; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; Yen JH, 2008, BLOOD, V111, P260, DOI 10.1182/blood-2007-05-090613; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zapata-Gonzalez F, 2007, J IMMUNOL, V178, P6130, DOI 10.4049/jimmunol.178.10.6130; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	57	34	36	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					420	U1471		10.1016/j.jaci.2010.10.043	http://dx.doi.org/10.1016/j.jaci.2010.10.043			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21208653	Bronze			2022-12-18	WOS:000286808000016
J	Marichal, T; Bedoret, D; Mesnil, C; Pichavant, M; Goriely, S; Trottein, F; Cataldo, D; Goldman, M; Lekeux, P; Bureau, F; Desmet, CJ				Marichal, Thomas; Bedoret, Denis; Mesnil, Claire; Pichavant, Muriel; Goriely, Stanislas; Trottein, Francois; Cataldo, Didier; Goldman, Michel; Lekeux, Pierre; Bureau, Fabrice; Desmet, Christophe J.			Interferon response factor 3 is essential for house dust mite-induced airway allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway allergy; interferon response factor 3; interferon response factor 7; dendritic cell; type I interferon	ASTHMA EXACERBATIONS; ENDOTOXIN EXPOSURE; DENDRITIC CELLS; TH2 RESPONSES; IDENTIFICATION; PATHOGENESIS; INFLAMMATION; IRF-3; RISK; TRIF	Background: Pattern-recognition receptors (PRRs) are critically involved in the pathophysiology of airway allergy, yet most of the signaling pathways downstream of PRRs implicated in allergic airway sensitization remain unknown. Objective: We sought to study the effects of genetic depletion of interferon response factor (IRF) 3 and IRF7, important transcription factors downstream of various PRRs, in a murine model of house dust mite (HDM)-induced allergic asthma. Methods: We compared HDM-induced allergic immune responses in IRF3-deficient (IRF3(-/-)), IRF7(-/-), and wild-type mice. Results: Parameters of airway allergy caused by HDM exposure were strongly attenuated in IRF3(-/-), but not IRF7(-/-), mice compared with those in wild-type mice. Indeed, in HDM-exposed IRF3(-/-) mice HDM-specific T(H)2 cell responses did not develop. This correlated with impaired maturation and migration of IRF3(-/-) lung dendritic cells (DCs) on HDM treatment. Furthermore, adoptive transfer of HDM-loaded DCs indicated that IRF3(-/-) DCs had an intrinsic defect rendering them unable to migrate and to prime HDM-specific T(H)2 responses. Intriguingly, we also show that DC function and allergic airway sensitization in response to HDM were independent of signaling by type I interferons, the main target genes of IRF3. Conclusion: Through its role in DC function, IRF3, mainly known as a central activator of antiviral immunity, is essential for the development of T(H)2-type responses to airway allergens. (J Allergy Clin Immunol 2010;126:836-44.)	[Marichal, Thomas; Bedoret, Denis; Mesnil, Claire; Lekeux, Pierre; Bureau, Fabrice; Desmet, Christophe J.] Univ Liege, Lab Mol & Cellular Physiol, GIGA Res, B-4000 Liege, Belgium; [Marichal, Thomas; Bedoret, Denis; Mesnil, Claire; Lekeux, Pierre; Bureau, Fabrice; Desmet, Christophe J.] Univ Liege, Fac Med Vet, B-4000 Liege, Belgium; [Pichavant, Muriel; Trottein, Francois] Ctr Infect & Immun Lille, Team 8, Lille, France; [Goriely, Stanislas; Goldman, Michel] Univ Libre Bruxelles, Inst Med Immunol, Brussels, Belgium; [Cataldo, Didier] Univ Liege, Lab Biol Tumors & Dev, GIGA Res, B-4000 Liege, Belgium; [Cataldo, Didier] CHU Liege, Liege, Belgium	University of Liege; University of Liege; Universite Libre de Bruxelles; University of Liege; University of Liege	Desmet, CJ (corresponding author), Univ Liege, Lab Mol & Cellular Physiol, GIGA Res, B-4000 Liege, Belgium.	fabrice.bureau@ulg.ac.be; christophe.desmet@ulg.ac.be	Pichavant, Muriel/B-9036-2018; TROTTEIN, Francois/C-2405-2018; Cataldo, Didier/GPG-3453-2022	Pichavant, Muriel/0000-0002-1315-4397; TROTTEIN, Francois/0000-0003-3373-1814; Goriely, Stanislas/0000-0002-7005-6195; Cataldo, Didier/0000-0002-3079-7941	Fonds National de la Recherche Scientifique (FNRS; Belgium); Fonds de la Recherche Scientifique Medicale (FRSM; Belgium); Belgian Programme on Interuniversity Attraction Poles (IUAP); Belgian State (Belgian Science Policy); National Fund for Scientific Research Belgium (FRS-FNRS, Belgium); Fonds National de la Recherche Scientifique (FNRS); Walloon Regional Government (Belgium)	Fonds National de la Recherche Scientifique (FNRS; Belgium)(Fonds de la Recherche Scientifique - FNRS); Fonds de la Recherche Scientifique Medicale (FRSM; Belgium)(Fonds de la Recherche Scientifique - FNRS); Belgian Programme on Interuniversity Attraction Poles (IUAP)(Belgian Federal Science Policy Office); Belgian State (Belgian Science Policy)(Belgian Federal Science Policy Office); National Fund for Scientific Research Belgium (FRS-FNRS, Belgium)(Fonds de la Recherche Scientifique - FNRS); Fonds National de la Recherche Scientifique (FNRS)(Fonds de la Recherche Scientifique - FNRS); Walloon Regional Government (Belgium)	The Laboratory of Cellular and Molecular Physiology is supported by grants of the Fonds National de la Recherche Scientifique (FNRS; Belgium; Mandat d'Impulsion Scientifique), by the Fonds de la Recherche Scientifique Medicale (FRSM; Belgium), and by the Belgian Programme on Interuniversity Attraction Poles (IUAP; FEDIM-MUNE) initiated by the Belgian State (Belgian Science Policy). T.M., D.B., and C.M. are research fellows, C.J.D. is a postdoctoral researcher, and S.G. is research associate of the National Fund for Scientific Research Belgium (FRS-FNRS, Belgium).; Disclosure of potential conflict of interest: D. Cataldo has received grants from Fonds National de la Recherche Scientifique (FNRS) and Walloon Regional Government (Belgium).	Asselin-Paturel C, 2005, J EXP MED, V201, P1157, DOI 10.1084/jem.20041930; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Bedoret D, 2009, J CLIN INVEST, V119, P3723, DOI 10.1172/JCI39717; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cataldo DD, 2002, AM J PATHOL, V161, P491, DOI 10.1016/S0002-9440(10)64205-8; Cates EC, 2004, J IMMUNOL, V173, P6384, DOI 10.4049/jimmunol.173.10.6384; Cates Elizabeth C., 2007, V14, P42, DOI 10.1159/000107054; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348, DOI 10.1164/ajrccm.162.4.9909118; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fonseca DE, 2009, ADV DRUG DELIVER REV, V61, P256, DOI 10.1016/j.addr.2008.12.007; Goriely S, 2006, BLOOD, V107, P1078, DOI 10.1182/blood-2005-06-2416; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hiscott J, 2007, J BIOL CHEM, V282, P15325, DOI 10.1074/jbc.R700002200; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Lacaze P, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-372; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847; Locksley RM, 2010, CELL, V140, P777, DOI 10.1016/j.cell.2010.03.004; Martinez Fernando D, 2008, Novartis Found Symp, V293, P184; Matsukura S, 2006, CLIN EXP ALLERGY, V36, P1049, DOI 10.1111/j.1365-2222.2006.02530.x; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Phipps S, 2007, IMMUNOL CELL BIOL, V85, P463, DOI 10.1038/sj.icb.7100104; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Raymond M, 2009, J ALLERGY CLIN IMMUN, V124, P1333, DOI 10.1016/j.jaci.2009.07.021; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Schroeder NWJ, 2007, J ENDOTOXIN RES, V13, P305, DOI 10.1177/0968051907084652; Shen H, 2008, J IMMUNOL, V181, P1849, DOI 10.4049/jimmunol.181.3.1849; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Thomson SJP, 2009, P NATL ACAD SCI USA, V106, P11564, DOI 10.1073/pnas.0904477106; Thorn J, 1998, AM J RESP CRIT CARE, V157, P1798, DOI 10.1164/ajrccm.157.6.9706081; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Wang Q, 2009, J IMMUNOL, V183, P6989, DOI 10.4049/jimmunol.0901386; Wark PAB, 2006, THORAX, V61, P909, DOI 10.1136/thx.2005.045187; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262	52	34	35	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					836	U262		10.1016/j.jaci.2010.06.009	http://dx.doi.org/10.1016/j.jaci.2010.06.009			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20673978				2022-12-18	WOS:000282510000023
J	Wegienka, G; Johnson, CC; Havstad, S; Ownby, DR; Zoratti, EM				Wegienka, Ganesa; Johnson, Christine Cole; Havstad, Suzanne; Ownby, Dennis R.; Zoratti, Edward M.			Indoor pet exposure and the outcomes of total IgE and sensitization at age 18 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pets; allergy; epidemiology	DOG OWNERSHIP; ATOPIC SENSITIZATION; IMMUNE DEVELOPMENT; EARLY-CHILDHOOD; ASTHMA; CHILDREN; ALLERGY; RISK; CAT; INFANCY	Background: Early-life exposure to household pets has been shown to be protective against allergic sensitization in childhood. Objective: We sought to evaluate the association between early-life pet exposure and allergic sensitization at age 18 years. Methods: Teenagers who had been enrolled in the Detroit Childhood Allergy Study birth cohort in 1987-1989 were contacted at age 18 years. Serum total and allergen-specific IgE levels to 7 common allergens (dust mite, cat, dog, ragweed, Timothy grass, Alternaria species, and peanut; atopy was defined as any specific IgE level >= 0.35 kU/L) were measured at age 18 years. Annual interview data from childhood were used to determine indoor dog and cat (>= 50% of their time in the home) exposure during early life. Exposure was considered in various ways: first year, cumulative lifetime, and age groups, as well as multiple pets. Results: Dog or cat exposure in the first year of life was not associated with atopy (relative risk, 0.97; 95% CI, 0.83-1.12). Those living with pets in the first year and atopic at 18 years had lower total IgE levels. Neither cumulative exposure nor exposure at a particular age was strongly and consistently associated with either outcome. Although not statistically significant, there was a pattern of decreased odds of sensitization among those with 2 or more pets versus no pets in the first year of life. Conclusions: Early-life pet exposure can be associated with lower total IgE levels among atopic subjects but is not strongly associated with decreased likelihood of sensitization to common allergens at age 18 years. (J Allergy Clin Immunol 2010;126:274-9.)	[Wegienka, Ganesa; Johnson, Christine Cole; Havstad, Suzanne] Henry Ford Hosp, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; [Zoratti, Edward M.] Henry Ford Hosp, Dept Internal Med, Detroit, MI 48202 USA; [Ownby, Dennis R.] Med Coll Georgia, Augusta, GA 30912 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University System of Georgia; Augusta University	Wegienka, G (corresponding author), 1 Ford Pl,3E, Detroit, MI 48202 USA.	gwegien1@hfhs.org		Johnson, Christine Cole/0000-0002-6864-6604	Fund for Henry Ford Hospital; National Institutes of Allergy and Infectious Diseases [R01AI051598]; National Institutes of Health (NIH); Feldstein Medical Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051598] Funding Source: NIH RePORTER	Fund for Henry Ford Hospital; National Institutes of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Feldstein Medical Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Fund for Henry Ford Hospital and the National Institutes of Allergy and Infectious Diseases (R01AI051598).; G. Wegienka receives research support from the National Institutes of Health (NIH) and the Feldstein Medical Foundation. C. Cole Johnson receives research support from the NIH. D. R. Ownby receives research support from the NIH and is a reviewer for the NIH. E. M. Zoratti receives research support from the National Institute of Allergy and Infectious Diseases and is a Councilor for the Association of Specialty Professors. S. Havstad has declared that she had no conflict of interest.	Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Bornehag CG, 2003, ALLERGY, V58, P939, DOI 10.1034/j.1398-9995.2003.00050.x; Braback L, 2001, PEDIAT ALLERG IMM-UK, V12, P4, DOI 10.1034/j.1399-3038.2001.012001004.x; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Campo P, 2006, J ALLERGY CLIN IMMUN, V118, P1271, DOI 10.1016/j.jaci.2006.08.008; Cohen J., 1977, STAT POWER ANAL BEHA, P215, DOI [10.1016/B978-0-12-179060-8.50012-8, DOI 10.1016/B978-0-12-179060-8.50012-8]; Eller E, 2008, ALLERGY, V63, P1491, DOI 10.1111/j.1398-9995.2008.01790.x; Gergen PJ, 2009, J ALLERGY CLIN IMMUN, V124, P447, DOI 10.1016/j.jaci.2009.06.011; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Hesselmar B, 2003, CLIN EXP ALLERGY, V33, P1681, DOI 10.1111/j.1365-2222.2003.01821.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holscher B, 2002, PEDIAT ALLERG IMM-UK, V13, P334, DOI 10.1034/j.1399-3038.2002.02063.x; Johnson CC, 2005, J ALLERGY CLIN IMMUN, V115, P1218, DOI 10.1016/j.jaci.2005.04.020; Mandhane PJ, 2009, J ALLERGY CLIN IMMUN, V124, P745, DOI 10.1016/j.jaci.2009.06.038; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Nicholas C, 2009, AM J EPIDEMIOL, V170, P388, DOI 10.1093/aje/kwp139; Oryszczyn MP, 2003, ALLERGY, V58, P1136, DOI 10.1046/j.1398-9995.2003.00314.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; OWNBY DR, 1991, J ALLERGY CLIN IMMUN, V88, P555, DOI 10.1016/0091-6749(91)90148-H; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Strachan D. P., 2004, LIFE COURSE APPROACH, P240, DOI 10.1093/acprof; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Vercelli D, 2010, CURR OPIN ALLERGY CL, V10, P145, DOI 10.1097/ACI.0b013e32833653d7; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x; Williams LK, 2005, J ALLERGY CLIN IMMUN, V116, P102, DOI 10.1016/j.jaci.2005.04.021	30	34	34	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					274	U20		10.1016/j.jaci.2010.05.001	http://dx.doi.org/10.1016/j.jaci.2010.05.001			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20579718	Green Accepted, Bronze			2022-12-18	WOS:000281203800012
J	Bock, SA				Bock, S. Allan			AAAAI support of the EAACI Position Paper on IgG(4)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Boulder Valley Asthma & Allergy Clin, Boulder, CO USA		Bock, SA (corresponding author), Boulder Valley Asthma & Allergy Clin, Boulder, CO USA.	bockdoc@aol.com						Stapel SO, 2008, ALLERGY, V63, P793, DOI 10.1111/j.1398-9995.2008.01705.x	1	34	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1410	1410		10.1016/j.jaci.2010.03.013	http://dx.doi.org/10.1016/j.jaci.2010.03.013			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20451986				2022-12-18	WOS:000278831000038
J	Cramer, C; Link, E; Horster, M; Koletzko, S; Bauer, CP; Berdel, D; von Berg, A; Lehmann, I; Herbarth, O; Borte, M; Schaaf, B; Behrendt, H; Chen, CM; Sausenthaler, S; Illig, T; Wichmann, HE; Heinrich, J; Kramer, U				Cramer, Claudia; Link, Elke; Horster, Maike; Koletzko, Sibylle; Bauer, Carl-P.; Berdel, Dietrich; von Berg, Andrea; Lehmann, Irina; Herbarth, Olf; Borte, Michael; Schaaf, Beate; Behrendt, Heidrun; Chen, Chih-Mei; Sausenthaler, Stefanie; Illig, Thomas; Wichmann, H. -Erich; Heinrich, Joachim; Kraemer, Ursula		LISAplus Study Grp; GINIplus Study Grp	Elder siblings enhance the effect of filaggrin mutations on childhood eczema: Results from the 2 birth cohort studies LISAplus and GINIplus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eczema; siblings; hygiene-hypothesis; filaggrin; barrier function	OF-FUNCTION MUTATIONS; SKIN BARRIER FUNCTION; ATOPIC-DERMATITIS; ALLERGIC SENSITIZATION; RISK-FACTORS; HAY-FEVER; DAY-CARE; ASTHMA; CHILDREN; DISEASE	Background: Several studies showed a protective effect of elder siblings on eczema development, which is in line with the hygiene hypothesis. However, findings are not consistent, and there might exist different causal pathways for the development of eczema. Especially barrier disturbances as found in children with mutations in the filaggrin gene (FLG) seem to play an important role. Objectives: To investigate the interaction between FLG mutations and the presence of elder siblings on the development of eczema in 2 independent birth cohorts. Methods: We used data from 2 German birth cohorts (LISAplus, GINIplus) up to the age of 6 years. Genotyping for FLG mutations (R501X, 2282del4) was performed in 1039 (LISAplus) and 1828 (GINIplus) children. Data on eczema (diagnosis and symptoms) and elder siblings were obtained by parental questionnaires. The association among eczema, FLG mutations, and elder siblings was analyzed longitudinally by using generalized estimating equations. Results: We found no protective effect of elder siblings on eczema development. On the contrary, children with FLG mutations had a significantly higher risk for eczema if they had elder siblings. Attending day care centers lessened this effect. After excluding 303 children who attended early day care, the odds ratio for interaction between FLG mutations and elder siblings was 3.27 (95% CI, 1.14-9.36) in LISAplus and 2.41 (95% Cl, 1.06-5.48) in GINIplus. Conclusion: Our findings did not confirm a protective sibling effect. The prevalence of eczema in children with filaggrin deficiency was higher if elder siblings were present. Our results give evidence for complex skin-driven pathogenic mechanisms that might be different depending on children's genetic backgrounds. (J Allergy Clin Immunol 2010;125:1254-60.)	[Cramer, Claudia] Heinrich Heine Univ gGmbH, Inst Umweltmed Forsch, Dept Epidemiol, D-40225 Dusseldorf, Germany; [Wichmann, H. -Erich] Univ Munich, Inst Med Data Management Biometr & Epidemiol, Munich, Germany; [Bauer, Carl-P.] Tech Univ Munich, Dept Pediat, Munich, Germany; [Bauer, Carl-P.] LVA Oberbayern, Munich, Germany; [Lehmann, Irina] UFZ Helmholtz Ctr Environm Res, Leipzig, Germany; [Chen, Chih-Mei; Sausenthaler, Stefanie; Illig, Thomas; Wichmann, H. -Erich; Heinrich, Joachim] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Munich, Germany; [Herbarth, Olf] Univ Leipzig, Fac Med Environm Med & Environm Hyg, Leipzig, Germany; [Borte, Michael] Univ Leipzig, Dept Pediat, Leipzig, Germany; [Borte, Michael] Municipal Hosp St Georg, Leipzig, Germany; [Behrendt, Heidrun] Tech Univ Munich, Dept Environm Dermatol & Allergy, ZAUM Ctr Allergy & Environm, Munich, Germany	Heinrich Heine University Dusseldorf; University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Leipzig University; Leipzig University; Technical University of Munich	Cramer, C (corresponding author), Heinrich Heine Univ gGmbH, Inst Umweltmed Forsch, Dept Epidemiol, Aufm Hennekamp 50, D-40225 Dusseldorf, Germany.	claudia.cramer@uni-duesseldorf.de	Wichmann, Heinz Erich/AAA-5695-2022; Heinrich, Joachim/N-1720-2013	Heinrich, Joachim/0000-0002-9620-1629; Lehmann, Irina/0000-0001-8875-5587	Federal Ministry for Education, Science, Research and Technology [01 EE 9401-4, 01 EG 9732, 01 EG 9705/2]; Federal Ministry for Environment (IUF) [FKZ 20462296]; GSF National Research Center for the Environment and Health	Federal Ministry for Education, Science, Research and Technology; Federal Ministry for Environment (IUF); GSF National Research Center for the Environment and Health	The German Infant Nutritional Intervention study was supported for the first 3 years by grants of the Federal Ministry for Education, Science, Research and Technology (grant no. 01 EE 9401-4). The 6-year follow-up was partly funded by the Federal Ministry for Environment (IUF, FKZ 20462296) and by the GSF National Research Center for the Environment and Health. The LISAplus study was supported by grants 01 EG 9732 and 01 EG 9705/2 from the Federal Ministry for Education, Science, Research and Technology and funded by the Federal Ministry for Environment (IUF, FKZ 20462296).	Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; BENN CS, 2004, BRIT MED J, V328, P1226; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2008, J INVEST DERMATOL, V128, P1067, DOI 10.1038/jid.2008.88; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Flohr C, 2009, BRIT J DERMATOL, V161, P846, DOI 10.1111/j.1365-2133.2009.09261.x; FLOHR C, 2009, ATOPIC DERMATITIS, P11; Foliaki S, 2008, INT J TUBERC LUNG D, V12, P799; GOLDING J, 1986, BIRTH 5 STUDY HLTH B, P171; Harrop J, 2007, CLIN EXP ALLERGY, V37, P526, DOI 10.1111/j.1365-2222.2007.02679.x; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; Karmaus W, 2005, AM J EPIDEMIOL, V162, P133, DOI 10.1093/aje/kwi170; Kramer U, 1998, BRIT J DERMATOL, V139, P1040; Kulig M, 2000, J ALLERGY CLIN IMMUN, V105, P274, DOI 10.1016/S0091-6749(00)90076-9; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; Nicolaou NC, 2008, J ALLERGY CLIN IMMUN, V122, P500, DOI 10.1016/j.jaci.2008.06.033; Ohfuji S, 2009, PEDIAT ALLERG IMM-UK, V20, P377, DOI 10.1111/j.1399-3038.2008.00804.x; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Perzanowski MS, 2008, CLIN EXP ALLERGY, V38, P968, DOI 10.1111/j.1365-2222.2008.02967.x; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Purvis DJ, 2005, BRIT J DERMATOL, V152, P742, DOI 10.1111/j.1365-2133.2005.06540.x; Rodriguez E, 2008, PHARMACOGENOMICS, V9, P399, DOI 10.2217/14622416.9.4.399; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Zirngibl A, 2002, PEDIAT ALLERG IMM-UK, V13, P394, DOI 10.1034/j.1399-3038.2002.01110.x; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521; Zutavern A, 2005, CLIN EXP ALLERGY, V35, P1301, DOI 10.1111/j.1365-2222.2005.02350.x; Zutavern A, 2007, ACTA PAEDIATR, V96, P1494, DOI 10.1111/j.1651-2227.2007.00412.x	43	34	36	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1254	1260		10.1016/j.jaci.2010.03.036	http://dx.doi.org/10.1016/j.jaci.2010.03.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20513523				2022-12-18	WOS:000278831000012
J	Soeria-Atmadja, D; Onell, A; Borga, A				Soeria-Atmadja, Daniel; Onell, Annica; Borga, Ase			IgE sensitization to fungi mirrors fungal phylogenetic systematics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hierarchical clustering; fungal allergy; IgE sensitization; fungal systematics	ALLERGIC DISEASES; FOOD ALLERGY; MOLD ALLERGY; ALTERNARIA; DIAGNOSIS; ASTHMA; CLASSIFICATION; CLADOSPORIUM; REACTIVITY; ANTIBODIES	Background: Fungal allergy is an elusive disease, and little progress has been made in this field during recent years. Moreover, because of the complexity of the organisms, it is difficult to categorize fungi systematically on the basis of morphologic characterization. However, recent molecular phylogenetics studies have substantially improved fungal categorization. In parallel, new approaches to analyze large IgE antibody datasets enable identification and visualization of IgE sensitization patterns. Objective: To study whether molecular phylogenetic relationships of fungal species, commonly used in allergy diagnosis, also are reflected in IgE sensitization profiles of individuals sensitized to fungi. Methods: A dataset was compiled of recorded serum IgE antibody levels to 17 different fungal species from 668 individuals sensitized to at least I of the 17 species. By applying a clustering method to this dataset, the fungal species were grouped into a hierarchical organization. Finally, the resulting organization was compared with recently published fungal systematics. Results: The hierarchical structure of fungi, based on the presence of IgE antibodies in sensitized individuals, very well reflected phylogenetic relationships. Examples include the distinct separation of basal fungi from the subkingdom Dikarya as well as individual cluster formations of fungi belonging to the subphylum Saccharomycotina and order Pleosporales. Conclusion: To our knowledge, this is the first in-depth study that demonstrates a close relationship between molecular fungal systematics and IgE sensitization to fungal species. Because close evolutionary organisms typically have a higher degree of protein similarity, IgE cross-reactivity is likely the main reason for obtained organization. (J Allergy Clin Immunol 2010;125:1379-86.)	[Soeria-Atmadja, Daniel] Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden	Uppsala University	Soeria-Atmadja, D (corresponding author), Uppsala Univ, Dept Med Sci, Akad Sjukhuset, SE-75185 Uppsala, Sweden.	daniel.soeria-atmadja@medsci.uu.se			Bror Hjerpstedt Foundation (Sweden); Cancer and Allergy Fund (Sweden); Bror Hjerpstedt Foundation; Cancer and Allergy Fund	Bror Hjerpstedt Foundation (Sweden); Cancer and Allergy Fund (Sweden); Bror Hjerpstedt Foundation; Cancer and Allergy Fund	Supported by the Bror Hjerpstedt Foundation (Sweden) and the Cancer and Allergy Fund (Sweden). D. Soeria-Atmadja receives research support from the Bror Hjerpstedt Foundation and the Cancer and Allergy Fund and has provided consulting M data analysis for Phadia. A. Onell and A. Borga are employed by Phadia.	Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Ballmer-Weber BK, 2005, CLIN EXP ALLERGY, V35, P970, DOI 10.1111/j.1365-2222.2005.02294.x; Breitenbach M, 2002, CHEM IMMUNOL, V81, P48; Breitenbach M, 2008, INT ARCH ALLERGY IMM, V145, P58, DOI 10.1159/000107578; Bush RK, 2006, J ALLERGY CLIN IMMUN, V117, P326, DOI 10.1016/j.jaci.2005.12.001; Crameri R, 2009, MYCOSES, V52, P99, DOI 10.1111/j.1439-0507.2008.01644.x; DAMATO G, 1995, ALLERGY, V50, P870, DOI 10.1111/j.1398-9995.1995.tb02492.x; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; Ferrer M, 2009, J INVEST ALLERG CLIN, V19, P19; Gonzalez-Buitrago JM, 2007, CLIN CHIM ACTA, V385, P21, DOI 10.1016/j.cca.2007.07.010; HARWANEGG C, 2006, ALLERG IMMUNOL PARIS, V38, P232; Hastie T., 2009, ELEMENTS STAT LEARNI, V2nd, DOI DOI 10.1007/978-0-387-21606-5; Helm RM, 2000, CURR OPIN IMMUNOL, V12, P647, DOI 10.1016/S0952-7915(00)00157-6; Hibbett DS, 2007, MYCOL RES, V111, P509, DOI 10.1016/j.mycres.2007.03.004; Hong SG, 2005, FUNGAL GENET BIOL, V42, P119, DOI 10.1016/j.fgb.2004.10.009; James TY, 2006, NATURE, V443, P818, DOI 10.1038/nature05110; KARLSSONBORGA A, 1989, ANN ALLERGY, V63, P521; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; Kurup VP, 2000, MICROBES INFECT, V2, P1101, DOI 10.1016/S1286-4579(00)01264-8; Lacey L, 1981, BIOL CONIDIAL FUNGI, P123; LAMROUS S, 2006, INT C COMP INT MOD C; Lidholm J, 2006, CURR OPIN ALLERGY CL, V6, P234, DOI 10.1097/01.all.0000225166.90768.d6; MALANDAIN H, 2005, ALLERG IMMUNOL PARIS, V37, P122; Mari A, 2003, CLIN EXP ALLERGY, V33, P1429, DOI 10.1046/j.1365-2222.2003.01783.x; Miadlikowska J, 2006, MYCOLOGIA, V98, P1088, DOI 10.3852/mycologia.98.6.1088; Niedoszytko M, 2007, ANN ALLERG ASTHMA IM, V98, P153, DOI 10.1016/S1081-1206(10)60688-6; PASTORELLO EA, 1991, ANN ALLERGY, V67, P365; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Poll V, 2009, MOL IMMUNOL, V46, P1360, DOI 10.1016/j.molimm.2008.11.017; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Saenz-de-Santamaria M, 2006, MYCOSES, V49, P91, DOI 10.1111/j.1439-0507.2006.01195.x; Schneider PB, 2006, CLIN EXP ALLERGY, V36, P1513, DOI 10.1111/j.1365-2222.2006.02582.x; Shen HD, 1999, INT ARCH ALLERGY IMM, V119, P259, DOI 10.1159/000024202; Simon-Nobbe B, 2000, J ALLERGY CLIN IMMUN, V106, P887, DOI 10.1067/mai.2000.110799; Soeria-Atmadja D, 2007, J ALLERGY CLIN IMMUN, V120, P1433, DOI 10.1016/j.jaci.2007.07.021; Tariq SM, 1996, CLIN EXP ALLERGY, V26, P794, DOI 10.1111/j.1365-2222.1996.tb00610.x; Yman L, 2001, ALLERGY, V56, P70, DOI 10.1111/j.1398-9995.2001.00921.x; 2004, IMMUNOCAP SPECIFIC I	39	34	36	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1379	1386		10.1016/j.jaci.2010.02.028	http://dx.doi.org/10.1016/j.jaci.2010.02.028			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20466417				2022-12-18	WOS:000278831000028
J	Thalhamer, T; Dobias, H; Stepanoska, T; Proll, M; Stutz, H; Dissertori, O; Lackner, P; Ferreira, F; Wallner, M; Thalhamer, J; Hartl, A				Thalhamer, Theresa; Dobias, Heidi; Stepanoska, Tatjana; Proell, Martina; Stutz, Hanno; Dissertori, Oliver; Lackner, Peter; Ferreira, Fatima; Wallner, Michael; Thalhamer, Josef; Hartl, Arnulf			Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Specific immunotherapy; recombinant allergen; hypoallergen; type I allergy; in silico mutation; knowledge-based potential; z score; Bet v 1; Phl p 5; DNA vaccines	BIRCH POLLEN ALLERGEN; BET V 1; POTENTIAL USE; DNA VACCINES; IGE-BINDING; T-CELLS; IMMUNOTHERAPY; PROTEIN; INDUCTION; FRAGMENTS	Background: The incidence of allergic diseases in developed countries has been increasing constantly in the last 2 decades. The only curative treatment available thus far is specific immunotherapy (SIT). The problematic side effects that can occur during SIT with allergen extracts led to the search for safer alternatives, such as recombinant hypoallergenic proteins with reduced allergenic potential and preserved T-cell immunogenicity. Objective: We created hypoallergenic variants of the allergens Bet v la and Phl p 5b by using in silico mutation and screening and characterized the biochemical and immunologic properties of selected mutant proteins. Methods: Knowledge-based potentials were used to estimate structural changes of the protein structures under sequence variation. IgE antibodies and their cross-linking capacity were determined by using a basophil release assay, binding of human birch pollen specific IgE was investigated by means of ELISA, and ELISPOT assays were performed to examine the T-cell immunogenicity. Results: Selected mutated proteins showed significantly reduced IgE-binding and cross-linking ability but retained their T cell stimulating properties. Immunization with the hypoallergenic mutants induced blocking antibodies against murine and human IgE epitopes. Conclusion: In silica calculation and selection of mutations that render a protein hypoallergenic represents a novel and rapid tool to create candidate molecules for SIT with recombinant allergens. (J Allergy Clin Immunol 2010;125:926-34.)	[Dobias, Heidi; Hartl, Arnulf] Paracelsus Med Univ, Inst Physiol & Pathophysiol, A-5020 Salzburg, Austria; [Thalhamer, Theresa; Stepanoska, Tatjana; Proell, Martina; Dissertori, Oliver; Lackner, Peter] Salzburg Univ, Dept Mol Biol, Div Allergy & Immunol, A-5020 Salzburg, Austria; [Ferreira, Fatima; Wallner, Michael; Thalhamer, Josef] Salzburg Univ, Dept Mol Biol, Christian Doppler Lab Allergy Diag & Therapy, A-5020 Salzburg, Austria; [Stutz, Hanno] Salzburg Univ, Dept Mol Biol, Div Chem & Bioanalyt, A-5020 Salzburg, Austria	Paracelsus Private Medical University; Salzburg University; Salzburg University; Salzburg University	Hartl, A (corresponding author), Paracelsus Med Univ, Inst Physiol & Pathophysiol, A-5020 Salzburg, Austria.	arnulf.hartl@pmu.ac.at	Stutz, Hanno/L-4152-2015; Thalhamer, Josef/E-5787-2011; Lackner, Peter/L-2900-2015; Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019; Wallner, Michael/L-5437-2015	Stutz, Hanno/0000-0001-8456-4943; Thalhamer, Josef/0000-0003-2285-6400; Lackner, Peter/0000-0003-4681-6307; Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Wallner, Michael/0000-0001-6568-7892; Hartl, Arnulf/0000-0001-9626-6425	Austrian Science Fund [S8811]; Christian Doppler Research Association; PMU; Biomay AG; Austrian National Bank; Biomay AG, Vienna	Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Association; PMU; Biomay AG; Austrian National Bank; Biomay AG, Vienna	Supported by the Austrian Science Fund, project S8811: the Christian Doppler Research Association; and the PMU Science Fund.; Disclosure of potential conflict of interest: F. Ferreira has received research support from Biomay AG, the Austrian Science Fund, and the Christian Doppler Research Association and has served as an expert witness on the topic of the AllergenOnline Database. M. Wallner has received research support from the Austrian National Bank. J. Thalhamer has received consulting fees from Biomay AG, Vienna, and has received research support from Biomay AG, Vienna, the Christian Doppler Research Association, and the Austrian Science Fund. The rest of the authors have declared that they have no conflict of interest.	ADKINSON NF, 1979, J IMMUNOL, V122, P965; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Ball T, 2009, ALLERGY, V64, P569, DOI 10.1111/j.1398-9995.2008.01910.x; Bauer R, 2006, J ALLERGY CLIN IMMUN, V118, P269, DOI 10.1016/j.jaci.2006.03.033; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; Buhot C, 2004, PROTEIN SCI, V13, P2970, DOI 10.1110/ps.04885404; Carra JH, 2003, CLIN IMMUNOL, V108, P60, DOI 10.1016/S1521-6616(03)00058-5; Ferreira F, 2004, ADV IMMUNOL, V84, P79, DOI 10.1016/S0065-2776(04)84003-3; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Ferreira Fatima, 2006, Inflammation & Allergy Drug Targets, V5, P5, DOI 10.2174/187152806775269295; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Hartl A, 2004, METHODS, V32, P328, DOI 10.1016/j.ymeth.2003.08.014; Hochreiter R, 2003, EUR J IMMUNOL, V33, P1667, DOI 10.1002/eji.200323377; Holm J, 2004, J IMMUNOL, V173, P5258, DOI 10.4049/jimmunol.173.8.5258; JUTEL M, 1995, J IMMUNOL, V154, P4187; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; King TP, 2001, J IMMUNOL, V166, P6057, DOI 10.4049/jimmunol.166.10.6057; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Linhart B, 2002, FASEB J, V16, P1301, DOI 10.1096/fj.01-1012fje; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Rajashankar K, 2002, ACTA CRYSTALLOGR D, V58, P1175, DOI 10.1107/S0907444902007254; Rolland JM, 2009, PHARMACOL THERAPEUT, V121, P273, DOI 10.1016/j.pharmthera.2008.11.007; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Spangfort MD, 2003, J IMMUNOL, V171, P3084, DOI 10.4049/jimmunol.171.6.3084; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Stutz H, 2005, ELECTROPHORESIS, V26, P1089, DOI 10.1002/elps.200406195; Takai T, 1999, MOL IMMUNOL, V36, P1055, DOI 10.1016/S0161-5890(99)00098-X; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969, DOI 10.1016/S0091-6749(99)70077-1; VIDARD L, 1992, J IMMUNOL, V149, P498; Vrtala S, 1999, INT ARCH ALLERGY IMM, V118, P218, DOI 10.1159/000024075; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2007, J IMMUNOL, V179, P1730, DOI 10.4049/jimmunol.179.3.1730; Wagner S, 2008, J ALLERGY CLIN IMMUN, V121, P246, DOI 10.1016/j.jaci.2007.08.006; Wallner M, 2007, J ALLERGY CLIN IMMUN, V120, P374, DOI 10.1016/j.jaci.2007.05.021; Weiss Richard, 2005, Current Drug Targets - Inflammation and Allergy, V4, P585, DOI 10.2174/156801005774322171; Westritschnig K, 2004, J IMMUNOL, V172, P5684, DOI 10.4049/jimmunol.172.9.5684; Westritschnig K, 2007, J IMMUNOL, V179, P7624, DOI 10.4049/jimmunol.179.11.7624; Wiederstein M, 2005, J MOL BIOL, V345, P1199, DOI 10.1016/j.jmb.2004.11.012; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579	44	34	41	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					926	934		10.1016/j.jaci.2010.01.031	http://dx.doi.org/10.1016/j.jaci.2010.01.031			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20371399				2022-12-18	WOS:000276787900020
J	Finkelman, FD; Boyce, JA; Vercelli, D; Rothenberg, ME				Finkelman, Fred D.; Boyce, Joshua A.; Vercelli, Donata; Rothenberg, Marc E.			Key advances in mechanisms of asthma, allergy, and immunology in 2009	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic conjunctivitis; allergic inflammation; anaphylaxis; asthma; asthma genetics; atopic dermatitis; eosinophils; food allergy; immediate hypersensitivity; mast cells; nasal polyposis; polymorphisms	AIRWAY INFLAMMATION; ATOPIC-DERMATITIS; LUNG-FUNCTION; SENSITIZATION; RISK; POLYMORPHISMS; DISEASE; MODELS; ECZEMA; CELLS	The year 2009 was marked by rapid progress in understanding cellular and chemical mechanisms in the pathogenesis of asthma and other allergic disorders. Studies published in the Journal of Allergy and Clinical Immunology described advances in our knowledge of signaling molecules and pathways, cytokines, and activation and tolerance in asthma and murine models of this disease; food allergy; anaphylaxis and immediate hypersensitivity; mast cells and their disorders; atopic dermatitis; allergic conjunctivitis; nasal polyposis, and hypereosinophilic syndromes. Additional studies provided novel information about the induction and regulation of allergic inflammation and the genetic determinants of asthma and responsiveness to asthma therapy. Critical features of these studies and their potential effect on human atopic disorders are summarized here. (J Allergy Clin Immunol 2010;125:312-8.)	[Finkelman, Fred D.] Univ Cincinnati, Coll Med, Div Immunol, Dept Med, Cincinnati, OH 45267 USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Cincinnati Vet Affairs Med Ctr, Cincinnati, OH 45267 USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH USA; [Rothenberg, Marc E.] Cincinnati Childrens Hosp, Med Ctr, Div Clin Immunol & Allergy, Cincinnati, OH USA; [Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Med, Div Rheumatol Allergy & Immunol,Brigham & Womens, Boston, MA USA; [Vercelli, Donata] Univ Arizona, Funct Genom Lab, Arizona Resp Ctr, Tucson, AZ USA; [Vercelli, Donata] Univ Arizona, Coll Med, Dept Cell Biol, Tucson, AZ USA; [Vercelli, Donata] Univ Arizona, Arizona Ctr Biol Complex Dis, Tucson, AZ USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Arizona; University of Arizona; University of Arizona	Finkelman, FD (corresponding author), Univ Cincinnati, Coll Med, Div Immunol, Dept Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	ffinkelman@pol.net			Abbott Pharmaceuticals; National Institutes of Health; Food Allergy and Anaphylaxis Network	Abbott Pharmaceuticals(Abbott Laboratories); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy and Anaphylaxis Network	F.D. Finkelman has received research support from Abbott Pharmaceuticals and is treasurer-elect for the Federation of American Societies for Experimental Biology. J. A. Boyce is a consultant for Merck. D. Vercelli has received research support from the National Institutes of Health and the Food Allergy and Anaphylaxis Network.	Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Bacharier LB, 2009, J ALLERGY CLIN IMMUN, V123, P1077, DOI 10.1016/j.jaci.2008.12.1120; Barton SJ, 2009, J ALLERGY CLIN IMMUN, V123, P1391, DOI 10.1016/j.jaci.2009.03.014; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Cortes JR, 2009, J ALLERGY CLIN IMMUN, V124, P607, DOI 10.1016/j.jaci.2009.06.023; Dakhama A, 2009, J ALLERGY CLIN IMMUN, V123, P138, DOI 10.1016/j.jaci.2008.10.012; Detoraki A, 2009, J ALLERGY CLIN IMMUN, V123, P1142, DOI 10.1016/j.jaci.2009.01.044; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Finkelman FD, 2008, J ALLERGY CLIN IMMUN, V121, P603, DOI 10.1016/j.jaci.2008.01.008; Fukuda K, 2009, J ALLERGY CLIN IMMUN, V124, P827, DOI 10.1016/j.jaci.2009.06.012; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Goplen N, 2009, J ALLERGY CLIN IMMUN, V123, P925, DOI 10.1016/j.jaci.2009.02.009; Haberberger RV, 2009, J ALLERGY CLIN IMMUN, V124, P933, DOI 10.1016/j.jaci.2009.06.034; Hamasaka A, 2009, J ALLERGY CLIN IMMUN, V124, P90, DOI 10.1016/j.jaci.2009.04.025; Hawkins GA, 2009, J ALLERGY CLIN IMMUN, V123, P1376, DOI 10.1016/j.jaci.2009.01.049; He R, 2009, J ALLERGY CLIN IMMUN, V124, P761, DOI 10.1016/j.jaci.2009.07.040; Janke M, 2009, J ALLERGY CLIN IMMUN, V123, P1026, DOI 10.1016/j.jaci.2009.02.015; Jin HL, 2009, J ALLERGY CLIN IMMUN, V123, P875, DOI 10.1016/j.jaci.2009.02.007; Kanda A, 2009, J ALLERGY CLIN IMMUN, V124, P573, DOI 10.1016/j.jaci.2009.04.031; Le T, 2009, J ALLERGY CLIN IMMUN, V123, P217, DOI 10.1016/j.jaci.2008.09.013; Lenox LE, 2009, J ALLERGY CLIN IMMUN, V124, P1088, DOI 10.1016/j.jaci.2009.08.038; LEWIS CC, 2009, J ALLERGY CLIN IMMUN, V123, pE798; Lewis Christina C, 2009, J Allergy Clin Immunol, V123, P795, DOI 10.1016/j.jaci.2009.01.003; Lopez-Exposito I, 2009, J ALLERGY CLIN IMMUN, V124, P1039, DOI 10.1016/j.jaci.2009.08.024; Mikhak Z, 2009, J ALLERGY CLIN IMMUN, V123, P67, DOI 10.1016/j.jaci.2008.09.049; Nakano N, 2009, J ALLERGY CLIN IMMUN, V123, P74, DOI 10.1016/j.jaci.2008.10.040; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Ohnishi H, 2009, J ALLERGY CLIN IMMUN, V123, P249, DOI 10.1016/j.jaci.2008.10.054; Okano M, 2009, J ALLERGY CLIN IMMUN, V123, P868, DOI 10.1016/j.jaci.2009.01.047; Park JW, 2009, J ALLERGY CLIN IMMUN, V123, P479, DOI 10.1016/j.jaci.2008.10.035; PRUSSIN C, 2009, J ALLERGY C IN PRESS; Raymond M, 2009, J ALLERGY CLIN IMMUN, V124, P1333, DOI 10.1016/j.jaci.2009.07.021; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Setkowicz M, 2009, J ALLERGY CLIN IMMUN, V123, P174, DOI 10.1016/j.jaci.2008.09.005; Shao ZF, 2009, J ALLERGY CLIN IMMUN, V123, P917, DOI 10.1016/j.jaci.2009.01.052; Shiraishi Y, 2009, J ALLERGY CLIN IMMUN, V123, pS56, DOI 10.1016/j.jaci.2008.11.047; SUTTNER K, 2009, J ALLERGY CLIN IMMUN, V123, pE86; Suttner K, 2009, J ALLERGY CLIN IMMUN, V123, P82, DOI 10.1016/j.jaci.2008.09.047; Suttner K, 2009, J ALLERGY CLIN IMMUN, V123, P1062, DOI 10.1016/j.jaci.2009.02.025; Tamagawa-Mineoka R, 2009, J ALLERGY CLIN IMMUN, V123, P581, DOI 10.1016/j.jaci.2008.12.1114; Triggiani M, 2009, J ALLERGY CLIN IMMUN, V124, P558, DOI 10.1016/j.jaci.2009.04.035; Trivedi NN, 2009, J ALLERGY CLIN IMMUN, V124, P1099, DOI 10.1016/j.jaci.2009.07.026; Wagner LA, 2009, J ALLERGY CLIN IMMUN, V123, P1407, DOI 10.1016/j.jaci.2009.01.069; Yamada A, 2009, J ALLERGY CLIN IMMUN, V123, P889, DOI 10.1016/j.jaci.2008.12.1115	45	34	35	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					312	318		10.1016/j.jaci.2009.12.936	http://dx.doi.org/10.1016/j.jaci.2009.12.936			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159240	Bronze			2022-12-18	WOS:000274764000005
J	Langford, CA				Langford, Carol A.			Vasculitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vasculitis; arteritis; antineutrophil cytoplasmic antibody; granuloma; glucocorticoid; cyclophosphamide	GIANT-CELL ARTERITIS; CHURG-STRAUSS-SYNDROME; TERM-FOLLOW-UP; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; NERVOUS-SYSTEM VASCULITIS; PLACEBO-CONTROLLED TRIAL; C VIRUS-INFECTION; RANDOMIZED-TRIAL; TAKAYASU-ARTERITIS; WEGENERS-GRANULOMATOSIS	Vasculitis is defined by the presence of blood vessel inflammation. It can be observed in a wide variety of settings, which can be broadly grouped as secondary vasculitides, which occur in association with an underlying disease or trigger, or primary vasculitides, in which vasculitis is occurring for as-yet unknown causes. The primary systemic vasculitides comprise a range of disease entities that are uniquely identified by their clinical, histopathologic, and therapeutic characteristics. Individual diseases predominantly affect blood vessels of a particular size, which influences their clinical manifestations and has been used in their classification. The vasculitides can also differ in their severity, extending from self-limited illnesses to those that can be life-threatening in the absence of prompt initiation of treatment. Immunosuppressive agents are used to treat many vasculitic diseases. Although such approaches can be effective, the patient's long-term course can be influenced by organ damage from their initial presentation, disease relapses, and medication toxicity. Recent investigations have focused on understanding disease pathophysiology and the exploration of novel therapeutic approaches. (J Allergy Clin Immunol 2010;125:S216-25.)	Cleveland Clin, Dept Rheumat & Immunol Dis, Ctr Vasculitis Care & Res, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Langford, CA (corresponding author), Cleveland Clin, Dept Rheumat & Immunol Dis, Ctr Vasculitis Care & Res, 9500 Euclid Ave,A50, Cleveland, OH 44195 USA.	langfoc@ccf.org			Genentech; Bristol-Myers Squibb	Genentech(Roche HoldingGenentech); Bristol-Myers Squibb(Bristol-Myers Squibb)	Disclosure of potential conflict of interest: C. A. Langford has received research support from Genentech and Bristol-Myers Squibb and is on the Professional Meetings Subcommittee for the American College of Rheumatology.	AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; Barron Karyl S., 1999, Journal of Rheumatology, V26, P170; Bosch X, 2006, LANCET, V368, P404, DOI 10.1016/S0140-6736(06)69114-9; Cacoub P, 2008, CLIN REV ALLERG IMMU, V35, P30, DOI 10.1007/s12016-007-8070-x; Calabrese LH, 2007, ANN INTERN MED, V146, P34, DOI 10.7326/0003-4819-146-1-200701020-00007; Calamia Kenneth T, 2008, Curr Rheumatol Rep, V10, P349, DOI 10.1007/s11926-008-0057-y; CALAMIA KT, 1980, CLIN RHEUM DIS, V6, P389; Chen KR, 2008, AM J CLIN DERMATOL, V9, P71, DOI 10.2165/00128071-200809020-00001; de Groot K, 2005, ARTHRITIS RHEUM-US, V52, P2461, DOI 10.1002/art.21142; Finkielman JD, 2007, ANN INTERN MED, V147, P611, DOI 10.7326/0003-4819-147-9-200711060-00005; Gayraud M, 2001, ARTHRITIS RHEUM, V44, P666, DOI 10.1002/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A; Gibson LE, 2001, DERMATOL CLIN, V19, P603, DOI 10.1016/S0733-8635(05)70303-X; Guillevin L, 1999, ARTHRITIS RHEUM-US, V42, P421, DOI 10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6; Guillevin L, 2005, MEDICINE, V84, P313, DOI 10.1097/01.md.0000180792.80212.5e; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Hajj-Ali RA, 2009, CURR OPIN RHEUMATOL, V21, P10, DOI 10.1097/BOR.0b013e32831cf5e6; Hoffman GS, 2007, ANN INTERN MED, V146, P621, DOI 10.7326/0003-4819-146-9-200705010-00004; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Hoffman GS, 2002, ARTHRITIS RHEUM, V46, P1309, DOI 10.1002/art.10262; HOFFMAN GS, 1994, ARTHRITIS RHEUM, V37, P578, DOI 10.1002/art.1780370420; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1065; Jayne D, 2003, NEW ENGL J MED, V349, P36, DOI 10.1056/NEJMoa020286; Jayne DRW, 2007, J AM SOC NEPHROL, V18, P2180, DOI 10.1681/ASN.2007010090; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Jover JA, 2001, ANN INTERN MED, V134, P106, DOI 10.7326/0003-4819-134-2-200101160-00010; Kallenberg CGM, 2008, J AUTOIMMUN, V30, P29, DOI 10.1016/j.jaut.2007.11.005; Keogh KA, 2006, SEMIN RESP CRIT CARE, V27, P148, DOI 10.1055/s-2006-939518; Keogh KA, 2005, ARTHRITIS RHEUM-US, V52, P262, DOI 10.1002/art.20718; KERR GS, 1994, ANN INTERN MED, V120, P919, DOI 10.7326/0003-4819-120-11-199406010-00004; Lamprecht P, 1999, ARTHRITIS RHEUM, V42, P2507, DOI 10.1002/1529-0131(199912)42:12<2507::AID-ANR2>3.0.CO;2-#; Langford CA, 2003, AM J MED, V114, P463, DOI 10.1016/S0002-9343(03)00077-9; Langford CA, 1998, CLEV CLIN J MED, V65, P135; Lee MS, 2006, ARTHRITIS RHEUM, V54, P3306, DOI 10.1002/art.22141; Mahr AD, 2007, ARTHRITIS RHEUM, V56, P2789, DOI 10.1002/art.22754; Maksimowicz-McKinnon K, 2007, ARTHRITIS RHEUM, V56, P1000, DOI 10.1002/art.22404; MEADOW SR, 1972, Q J MED, V41, P241; Molloy ES, 2008, ANN RHEUM DIS, V67, P1567, DOI 10.1136/ard.2008.093260; Mouthon L, 2002, MEDICINE, V81, P27, DOI 10.1097/00005792-200201000-00002; Nataraja A, 2007, BEST PRACT RES CL RH, V21, P713, DOI 10.1016/j.berh.2007.01.004; Nesher G, 2004, ARTHRITIS RHEUM, V50, P1332, DOI 10.1002/art.20171; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; Nuenninghoff DM, 2003, ARTHRITIS RHEUM-US, V48, P3532, DOI 10.1002/art.11480; Pagnoux C, 2008, NEW ENGL J MED, V359, P2790, DOI 10.1056/NEJMoa0802311; Proven A, 2003, ARTHRIT RHEUM-ARTHR, V49, P703, DOI 10.1002/art.11388; Ribi C, 2008, ARTHRITIS RHEUM-US, V58, P586, DOI 10.1002/art.23198; Saadoun D, 2008, CURR OPIN RHEUMATOL, V20, P23, DOI 10.1097/BOR.0b013e3282f1330c; Salvarani C, 2002, NEW ENGL J MED, V347, P261, DOI 10.1056/NEJMra011913; Salvarani C, 2007, ANN NEUROL, V62, P442, DOI 10.1002/ana.21226; Salvarani C, 2007, ANN INTERN MED, V146, P631, DOI 10.7326/0003-4819-146-9-200705010-00005; Saulsbury FT, 1999, MEDICINE, V78, P395, DOI 10.1097/00005792-199911000-00005; SILMAN AJ, 1990, LANCET, V335, P1078; Stone JH, 2005, NEW ENGL J MED, V352, P351; Vassilopoulos D, 2002, ARTHRITIS RHEUM-US, V46, P585, DOI 10.1002/art.10107; Weyand CM, 2003, NEW ENGL J MED, V349, P160, DOI 10.1056/NEJMra022694; Yurdakul S, 2008, BEST PRACT RES CL RH, V22, P793, DOI 10.1016/j.berh.2008.08.005	55	34	40	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S216	S225		10.1016/j.jaci.2009.07.002	http://dx.doi.org/10.1016/j.jaci.2009.07.002			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	19932919				2022-12-18	WOS:000280170600019
J	Haller, G; Torgerson, DG; Ober, C; Thompson, EE				Haller, Gabe; Torgerson, Dara G.; Ober, Carole; Thompson, Emma E.			Sequencing the IL4 locus in African Americans implicates rare noncoding variants in asthma susceptibility	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rare variants; private alleles; asthma; IL4; IgE; African Americans	GENOME-WIDE ASSOCIATION; GENE POLYMORPHISMS; PLASMA-LEVELS; POPULATIONS; IGE; CHOLESTEROL; CONTRIBUTE; SELECTION; DISEASES; PCSK9	Background: Common genetic variations in the IL4 gene have been associated with asthma and atopy in European and Asian populations, but not in African Americans. Objective: Because populations of African descent have increased levels of genetic variation compared with other populations, particularly with respect to low frequency or rare variants, we hypothesized that rare variants in the IL4 gene contribute to the development of asthma in African Americans. Methods: To test this hypothesis, we sequenced the IL4 locus in 72 African Americans with asthma and 70 African American controls without asthma to identify novel and rare polymorphisms in the IL4 gene that may be contributing to asthma susceptibility. Results: We report an excess of private noncoding single nucleotide polymorphisms (SNPs) in the subjects with asthma compared with control subjects without asthma (P = .031). Tajima's D is significantly more negative in subjects with asthma (-0.375) than controls (-0.073; P = .04), reflecting an excess of rare variants in the subjects with asthma. Conclusion: Our findings indicate that SNPs at the IL4 locus that are potentially exclusive to African Americans are associated with susceptibility to asthma. Only 3 of the 26 private SNPs (ie, SNPs present only in the subjects with asthma or only in the controls) are tagged by single SNPs on one of the common genotyping platforms used in genome-wide association studies. We also find that most of the private SNPs cannot be reliably imputed, highlighting the importance of sequencing to identify genetic variants contributing to common diseases in African Americans. (J Allergy Clin Immunol 2009;124:1204-9.)	[Haller, Gabe; Torgerson, Dara G.; Ober, Carole; Thompson, Emma E.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago	Thompson, EE (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St, Chicago, IL 60637 USA.	eethomps@uchicago.edu		Haller, Gabriel/0000-0002-3884-5776; Ober, Carole/0000-0003-4626-9809	 [R01 HL72414];  [U01 HL049596];  [M01 RR00055];  [R01 HL087665];  [U10 HL064313];  [T32 HL007605]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000055] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064313, R01HL072414, R01HL087665, U01HL049596, T32HL007605] Funding Source: NIH RePORTER	; ; ; ; ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by R01 HL72414, U01 HL049596, and M01 RR00055. D.G.T. is supported by R01 HL087665 and U10 HL064313. E.E.T. is supported by T32 HL007605.	Ahituv N, 2007, AM J HUM GENET, V80, P779, DOI 10.1086/513471; Azzopardi D, 2008, CANCER RES, V68, P358, DOI 10.1158/0008-5472.CAN-07-5733; Barnes Kathleen C, 2007, Proc Am Thorac Soc, V4, P58, DOI 10.1513/pats.200607-146JG; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Basehore MJ, 2004, J ALLERGY CLIN IMMUN, V114, P80, DOI 10.1016/j.jaci.2004.05.035; Blackwell JM, 2004, TRENDS PARASITOL, V20, P268, DOI 10.1016/j.pt.2004.04.003; Bodmer W, 2008, NAT GENET, V40, P695, DOI 10.1038/ng.f.136; Carlson CS, 2005, GENOME RES, V15, P1553, DOI 10.1101/gr.4326505; Chouchane L, 1999, INT ARCH ALLERGY IMM, V120, P50, DOI 10.1159/000024219; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; Cohen JC, 2006, P NATL ACAD SCI USA, V103, P1810, DOI 10.1073/pnas.0508483103; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Donfack J, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-145; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; Gatlin MR, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000375; Gudbjartsson DF, 2008, NAT GENET, V40, P609, DOI 10.1038/ng.122; Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Iyengar Sudha K, 2007, Methods Mol Biol, V376, P71; Ji WZ, 2008, NAT GENET, V40, P592, DOI 10.1038/ng.118; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V112, P893, DOI 10.1016/j.jaci.2003.08.033; Kotowski IK, 2006, AM J HUM GENET, V78, P410, DOI 10.1086/500615; LI Y, 2009, ANNU REV GENOM HUM G, V10, P397; Lohmueller KE, 2008, NATURE, V451, P994, DOI 10.1038/nature06611; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217, DOI 10.1016/S0091-6749(98)70386-0; Ma X, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001318; Madsen BE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000384; Mardis ER, 2008, TRENDS GENET, V24, P133, DOI 10.1016/j.tig.2007.12.007; Marini NJ, 2008, P NATL ACAD SCI USA, V105, P8055, DOI 10.1073/pnas.0802813105; Masson E, 2008, HUM GENET, V123, P83, DOI 10.1007/s00439-007-0459-3; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nagarkatti R, 2004, INT ARCH ALLERGY IMM, V134, P206, DOI 10.1159/000078767; Nejentsev S, 2009, SCIENCE, V324, P387, DOI 10.1126/science.1167728; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Pritchard JK, 2001, AM J HUM GENET, V69, P124, DOI 10.1086/321272; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Romeo S, 2007, NAT GENET, V39, P513, DOI 10.1038/ng1984; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Sankararaman S, 2008, AM J HUM GENET, V82, P290, DOI 10.1016/j.ajhg.2007.09.022; *SEATTLESNPS, NHLBI HL66682 PROGR; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; TAJIMA F, 1989, GENETICS, V123, P585; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thorleifsson G, 2009, NAT GENET, V41, P18, DOI 10.1038/ng.274; Tishkoff SA, 2002, NAT REV GENET, V3, P611, DOI 10.1038/nrg865; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; Xu X, 2001, AM J HUM GENET, V69, P1271, DOI 10.1086/324650; Zuchner S, 2009, MOL PSYCHIATR, V14, P6, DOI 10.1038/mp.2008.83	51	34	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1204	1209		10.1016/j.jaci.2009.09.013	http://dx.doi.org/10.1016/j.jaci.2009.09.013			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19910025	Green Accepted			2022-12-18	WOS:000273071500010
J	Steinke, JW; Culp, JA; Kropf, E; Borish, L				Steinke, John W.; Culp, Jeffrey A.; Kropf, Elizabeth; Borish, Larry			Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; cysteinyl leukotrienes; signal transduction; IL-4	LEUKOTRIENE-RECEPTOR EXPRESSION; CYSTEINYL-LEUKOTRIENES; C-4 SYNTHASE; MAST-CELL; ASTHMA; INHIBITION; IL-4; RHINOSINUSITIS; SINUSITIS; DIAGNOSIS	Background: Aspirin-exacerbated respiratory disease is characterized by asthma, nasal polyps, and intolerance to aspirin with overexpression of leukotriene (LT) C-4 synthase and cysteinyl leukotriene receptors. Through an unknown mechanism, aspirin desensitization is an effective treatment. Objective: We hypothesized that aspirin desensitization blocks IL-4-induced expression of these LT activities through inhibition of signal transducer and activator of transcription 6 (STAT6)-mediated transcription. Methods: Nuclear extracts were derived from THP-1 and normal human monocytes resting and cocultured with aspirin before IL-4 stimulation. Quantitative PCRs were conducted. Electrophoretic mobility shift assays were performed by using oligomers for STAT6 sites within the LT receptor and synthase promoters. Western blots of nuclear extracts were probed by using anti-phospho-STAT6 antibodies. Results: Upregulation of LT receptor mRNA by IL-4 was negated by aspirin and ketorolac but not by sodium salicylate. The STAT6 site in the LT receptor and synthase promoters was confirmed by using mobility shift assays by competing with unlabeled STAT6 consensus probes and supershifts with anti-STAT6 antibodies. Aspirin and ketorolac decreased the IL-4-inducible expression of nuclear STAT6 observed in mobility shift assays and Western hybridization. Conclusion: The LT receptor and synthase promoters have STAT6-binding sites that are engaged by IL-4-induced nuclear extracts and inhibited by aspirin. Assuming that normal monocytes behave like monocytes from patients with aspirin-exacerbated respiratory disease, inhibition of IL-4-STAT6 might explain a mechanism in aspirin desensitization daily treatment, resulting in downregulation of production and responsiveness to cysteinyl leukotrienes. This biologic activity of aspirin likely reflects COX inhibition because it was shared with ketorolac but not sodium salicylate. (J Allergy Clin Immunol 2009; 124:724-30)			Borish, L (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	lb4m@virginia.edu			National Institutes of Health [AI01793]; POI [AI50989]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001793, P01AI050989] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); POI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health AI01793 and POI AI50989.	Aceves M, 2004, J IMMUNOL, V173, P5721, DOI 10.4049/jimmunol.173.9.5721; Antczak A, 2002, AM J RESP CRIT CARE, V166, P301, DOI 10.1164/rccm.2101021; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Boyce JA, 2008, CURR MOL MED, V8, P335, DOI 10.2174/156652408785160989; Chen XH, 1997, J BIOL CHEM, V272, P6556, DOI 10.1074/jbc.272.10.6556; Cianferoni A, 2001, BLOOD, V97, P1742, DOI 10.1182/blood.V97.6.1742; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; Early SB, 2007, AM J RESP CELL MOL, V36, P715, DOI 10.1165/rcmb.2006-0252OC; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; JUERGENS UR, 1995, J ALLERGY CLIN IMMUN, V96, P148, DOI 10.1016/S0091-6749(95)70002-1; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kurth T, 2008, THORAX, V63, P514, DOI 10.1136/thx.2007.091447; Lynch KR, 1999, NATURE, V399, P789; Mascia K, 2005, ANN ALLERG ASTHMA IM, V94, P652, DOI 10.1016/S1081-1206(10)61323-3; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Negri J, 2008, J ALLERGY CLIN IMMUN, V121, P1232, DOI 10.1016/j.jaci.2008.02.007; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; Perez-G M, 2002, J IMMUNOL, V168, P1428, DOI 10.4049/jimmunol.168.3.1428; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; SLADEK K, 1993, EUR RESPIR J, V6, P391; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; SZCZEKLIK A, 1983, BRIT J DIS CHEST, V77, P153, DOI 10.1016/0007-0971(83)90021-9; Szczeklik A, 2000, THORAX, V55, pS42, DOI 10.1136/thorax.55.suppl_2.S42; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; White A, 2006, ANN ALLERG ASTHMA IM, V97, P688, DOI 10.1016/S1081-1206(10)61101-5; White A, 2006, ANN ALLERG ASTHMA IM, V97, P190, DOI 10.1016/S1081-1206(10)60012-9; Woszczek G, 2005, J IMMUNOL, V175, P5152, DOI 10.4049/jimmunol.175.8.5152	40	34	35	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					724	730		10.1016/j.jaci.2009.07.031	http://dx.doi.org/10.1016/j.jaci.2009.07.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767084				2022-12-18	WOS:000270802800016
J	Khasnis, A; Langford, CA				Khasnis, Atul; Langford, Carol A.			Update on vasculitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vasculitis; antineutrophil cytoplasmic antibodies; diagnosis; treatment	CHURG-STRAUSS-SYNDROME; HENOCH-SCHONLEIN PURPURA; GIANT-CELL ARTERITIS; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; TERM-FOLLOW-UP; WEGENERS-GRANULOMATOSIS; POLYARTERITIS-NODOSA; MICROSCOPIC POLYANGIITIS; KAWASAKI-DISEASE; RANDOMIZED-TRIAL	The primary systemic vasculitides comprise a broad group of diseases identified by their clinical, histopathologic, and therapeutic characteristics. These unique entities have a broad spectrum of organ involvement and severity, which influences the approach to diagnosis and treatment. Immunosuppressive and cytotoxic agents are used to manage most vasculitic diseases. Long-term outcome is influenced by chronic sequelae from organ damage, disease relapses, and medication side effects. Further research is needed to understand these diseases and discover more efficacious yet less toxic therapeutic options. This review will focus on vasculitic syndromes more likely to be presented to an allergist/immunologist in an outpatient setting. (J Allergy Clin Immunol 2009;123:1226-36.)	[Khasnis, Atul; Langford, Carol A.] Cleveland Clin, Dept Rheumat & Immunol Dis, Cleveland, OH 44195 USA; [Langford, Carol A.] Cleveland Clin, Ctr Vasculitis Care & Res, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Langford, CA (corresponding author), Cleveland Clin, Dept Rheumat & Immunol Dis, 9500 Euclid Ave,A50, Cleveland, OH 44195 USA.	langfoc@ccf.org						ACHKAR AA, 1994, ANN INTERN MED, V120, P987, DOI 10.7326/0003-4819-120-12-199406150-00003; Agard C, 2003, ARTHRIT RHEUM-ARTHR, V49, P709, DOI 10.1002/art.11387; AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; Boomsma MM, 2000, ARTHRITIS RHEUM-US, V43, P2025, DOI 10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O; Booth A, 2004, J AM SOC NEPHROL, V15, P717, DOI 10.1097/01.ASN.0000114554.67106.28; Bourgarit A, 2005, MEDICINE, V84, P323, DOI 10.1097/01.md.0000180793.80212.17; Carlson JA, 2005, AM J DERMATOPATH, V27, P504, DOI 10.1097/01.dad.0000181109.54532.c5; Cid MC, 2001, BEST PRACT RES CL RH, V15, P259, DOI 10.1053/berh.2001.0143; Cotch MF, 1996, ARTHRITIS RHEUM, V39, P87, DOI 10.1002/art.1780390112; CREAM J J, 1970, QJM, V39, P461; DAJANI AS, 1993, CIRCULATION, V87, P1776, DOI 10.1161/01.CIR.87.5.1776; Davies DJ, 2005, CARDIOVASC PATHOL, V14, P335, DOI 10.1016/j.carpath.2005.08.001; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; de Groot K, 2005, ARTHRITIS RHEUM-US, V52, P2461, DOI 10.1002/art.21142; DURONGPISITKUL K, 1995, PEDIATRICS, V96, P1057; EVANS JM, 1994, ARTHRITIS RHEUM-US, V37, P1539, DOI 10.1002/art.1780371020; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; Finkielman JD, 2007, ANN INTERN MED, V147, P611, DOI 10.7326/0003-4819-147-9-200711060-00005; Finkielman JD, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.08.016; Girard T, 2001, RHEUMATOLOGY, V40, P147, DOI 10.1093/rheumatology/40.2.147; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; GUILLEVIN L, 1995, ARTHRITIS RHEUM, V38, P1638, DOI 10.1002/art.1780381116; Guillevin L, 1999, ARTHRITIS RHEUM-US, V42, P421, DOI 10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6; Guillevin L, 2005, MEDICINE, V84, P313, DOI 10.1097/01.md.0000180792.80212.5e; Guillevin L, 1996, MEDICINE, V75, P17, DOI 10.1097/00005792-199601000-00003; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Hoffman GS, 2007, ANN INTERN MED, V146, P621, DOI 10.7326/0003-4819-146-9-200705010-00004; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Hoffman GS, 2002, ARTHRITIS RHEUM, V46, P1309, DOI 10.1002/art.10262; HOFFMAN GS, 1994, ARTHRITIS RHEUM, V37, P578, DOI 10.1002/art.1780370420; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; Jayne D, 2003, NEW ENGL J MED, V349, P36, DOI 10.1056/NEJMoa020286; Jayne DRW, 2007, J AM SOC NEPHROL, V18, P2180, DOI 10.1681/ASN.2007010090; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Jeong YJ, 2007, RADIOGRAPHICS, V27, P617, DOI 10.1148/rg.273065051; Jover JA, 2001, ANN INTERN MED, V134, P106, DOI 10.7326/0003-4819-134-2-200101160-00010; Kallenberg CGM, 2008, J AUTOIMMUN, V30, P29, DOI 10.1016/j.jaut.2007.11.005; Karassa FB, 2005, ANN INTERN MED, V142, P359, DOI 10.7326/0003-4819-142-5-200503010-00011; Keogh KA, 2006, SEMIN RESP CRIT CARE, V27, P148, DOI 10.1055/s-2006-939518; Keogh KA, 2006, AM J RESP CRIT CARE, V173, P180, DOI 10.1164/rccm.200507-1144OC; Keogh KA, 2005, ARTHRITIS RHEUM-US, V52, P262, DOI 10.1002/art.20718; KERR GS, 1993, ARTHRITIS RHEUM, V36, P365, DOI 10.1002/art.1780360312; KERR GS, 1994, ANN INTERN MED, V120, P919, DOI 10.7326/0003-4819-120-11-199406010-00004; KLEIN RG, 1975, ANN INTERN MED, V83, P806, DOI 10.7326/0003-4819-83-6-806; Knight A, 2008, ARTHRITIS RHEUM-US, V58, P302, DOI 10.1002/art.23157; Langford CA, 1999, ARTHRITIS RHEUM, V42, P2666, DOI 10.1002/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E; Langford CA, 1996, ARTHRITIS RHEUM, V39, P1754, DOI 10.1002/art.1780391020; Langford CA, 2004, ARTHRIT RHEUM-ARTHR, V51, P278, DOI 10.1002/art.20240; Langford CA, 1998, CLEV CLIN J MED, V65, P135; LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001; Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176; Lee MS, 2006, ARTHRITIS RHEUM, V54, P3306, DOI 10.1002/art.22141; Lhote F, 1996, ANN MED INTERNE, V147, P165; Mahr A, 2004, ARTHRIT RHEUM-ARTHR, V51, P92, DOI 10.1002/art.20077; MEADOW SR, 1972, Q J MED, V41, P241; Merkel PA, 2005, ANN INTERN MED, V142, P620, DOI 10.7326/0003-4819-142-8-200505030-00011; Metzler C, 2004, RHEUMATOLOGY, V43, P315, DOI 10.1093/rheumatology/keh009; Molloy ES, 2008, NAT CLIN PRACT RHEUM, V4, P12, DOI 10.1038/ncprheum0675; Nakamura Y, 2008, CIRC J, V72, P134, DOI 10.1253/circj.72.134; Narchi H, 2005, ARCH DIS CHILD, V90, P916, DOI 10.1136/adc.2005.074641; Nathani N, 2008, THORAX, V63, P883, DOI 10.1136/thx.2007.093955; Nesher G, 2004, ARTHRITIS RHEUM, V50, P1332, DOI 10.1002/art.20171; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; Newburger JW, 2004, PEDIATRICS, V114, P1708, DOI 10.1542/peds.2004-2182; Saadoun D, 2008, CURR OPIN RHEUMATOL, V20, P23, DOI 10.1097/BOR.0b013e3282f1330c; Salvarani C, 2002, ANN INTERN MED, V137, P232, DOI 10.7326/0003-4819-137-4-200208200-00006; Saulsbury FT, 1999, MEDICINE, V78, P395, DOI 10.1097/00005792-199911000-00005; SCHWARTZ HR, 1982, MAYO CLIN PROC, V57, P231; Sebastian JK, 2007, J RHEUMATOL, V34, P2446; Shrestha S, 2006, QJM-INT J MED, V99, P253, DOI 10.1093/qjmed/hcl034; SNELLER MC, 1995, ARTHRITIS RHEUM, V38, P608, DOI 10.1002/art.1780380505; Sneller MC, 1997, MED CLIN N AM, V81, P221, DOI 10.1016/S0025-7125(05)70512-5; Stang M., 2001, ENG LIFE SCI, V1, P151, DOI DOI 10.1002/1618-2863(200110)1:4<151::AID-ELSC151>3.0.CO;2-D; Stegeman CA, 1996, NEW ENGL J MED, V335, P16, DOI 10.1056/NEJM199607043350103; Stone JH, 2005, NEW ENGL J MED, V352, P351; Stone JH, 2002, JAMA-J AM MED ASSOC, V288, P1632, DOI 10.1001/jama.288.13.1632; TancredeBohin E, 1997, ARCH DERMATOL, V133, P438, DOI 10.1001/archderm.133.4.438; TAUBERT KA, 1991, J PEDIATR-US, V119, P279, DOI 10.1016/S0022-3476(05)80742-5; Tosoni C, 2009, CLIN EXP DERMATOL, V34, P166, DOI 10.1111/j.1365-2230.2008.02891.x; Tuohy AMM, 2001, AM J CARDIOL, V88, P328; VANDERWOUDE FJ, 1985, LANCET, V1, P425	83	34	41	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1226	1236		10.1016/j.jaci.2009.04.024	http://dx.doi.org/10.1016/j.jaci.2009.04.024			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19501230				2022-12-18	WOS:000266799100010
J	Marcon, A; Corsico, A; Cazzoletti, L; Bugiani, M; Accordini, S; Almar, E; Cerveri, I; Gislason, D; Gulsvik, A; Janson, C; Jarvis, D; Martinez-Moratalia, J; Pin, I; de Marco, R				Marcon, Alessandro; Corsico, Angelo; Cazzoletti, Lucia; Bugiani, Massimiliano; Accordini, Simone; Almar, Enrique; Cerveri, Isa; Gislason, David; Gulsvik, Amund; Janson, Christer; Jarvis, Deborah; Martinez-Moratalia, Jesus; Pin, Isabelle; de Marco, Roberto		European Community Resp Hlth; Therapy Hlth Economics Grp	Body mass index, weight gain, and other determinants of lung function decline in adult asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; lung function decline; airflow obstruction; body mass index; weight gain; obesity; FEV1; allergen sensitization; prospective cohort study; predictors	FOLLOW-UP; INHALED CORTICOSTEROIDS; PULMONARY-FUNCTION; SMOKING-CESSATION; FLOW LIMITATION; RISK-FACTORS; OBESITY; HEALTH; MORTALITY; VOLUME	Background: Little is known about factors associated with lung function decline in asthma. Objective: To identify the determinants of FEV1 decline in adults with asthma with and without airflow obstruction at baseline. Methods: An international cohort of 638 subjects with asthma (20-44 years old) was identified in the European Community Respiratory Health Survey (1991-1993) and followed up from 1998 to 2002. Spirometry was performed on both occasions. FEV1 decline was related to potential determinants evaluated at baseline and during the follow-up by random intercept linear regression models. The analyses were stratified by the presence of airflow obstruction (FEV1/forced vital capacity < 0.70) at baseline. Results: In the group of individuals without airflow obstruction (n = 544), a faster FEV1 decline was observed for subjects with intermediate body mass index (BMI) than for lean and obese subjects. FEV1 decline was associated with weight gain independently of baseline BMI, and this association was stronger in men (20; 95% CI, 10-30, mL/y/kg gained) than in women (6; 95% CI, 1-1.1, mL/y). In the group of individuals with airflow obstruction (n = 94), the absence of allergen sensitization and a low BMI at baseline were associated with a faster FEV1 decline, whereas weight gain was not associated with decline. Conclusions: The detrimental effect of weight gain on FEV1 decline is particularly relevant in subjects with asthma who still do not have an established airflow obstruction. Our findings support the importance of weight management in asthma and recommend weight loss in overweight or obese individuals with asthma. (J Allergy Clin Immunol 2009;123:1069-74.)	[Marcon, Alessandro] Univ Verona, Unit Epidemiol & Med Stat, Dept Med & Publ Hlth, Ist Biol 2, I-37134 Verona, Italy; [Corsico, Angelo; Cerveri, Isa] Univ Pavia, Fdn Ist Ricovero & Cura Carattere Sci San Matteo, Div Resp Dis, I-27100 Pavia, Italy; [Bugiani, Massimiliano] Azienda Sanitaria Locale 4 Torino 2 Piemonte, Unit Pneumol, Turin, Italy; [Almar, Enrique] Junta Comunidades Castilla La Mancha, Dept Publ Hlth, Epidemiol Unit, Albacete, Spain; [Gislason, David] Landspitali Univ Hosp, Dept Allergy Resp Med & Sleep, Reykjavik, Iceland; [Gulsvik, Amund] Univ Bergen, Dept Thorac Med, Haukeland Univ Hosp, Bergen, Norway; [Janson, Christer] Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; [Jarvis, Deborah] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Resp Epidemiol & Publ Hlth Grp, London, England; [Martinez-Moratalia, Jesus] Univ Albacete, Gen Hosp, Ser Neumol, Albacete, Spain; [Pin, Isabelle] CHU Grenoble, F-38043 Grenoble, France; [Pin, Isabelle] Inst Albert Bonniot, INSERM, U823, Grenoble, France	University of Verona; University of Pavia; Landspitali National University Hospital; University of Bergen; Haukeland University Hospital; Uppsala University; Imperial College London; Universidad de Castilla-La Mancha; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Marcon, A (corresponding author), Univ Verona, Unit Epidemiol & Med Stat, Dept Med & Publ Hlth, Ist Biol 2, Str Grazie 8, I-37134 Verona, Italy.	alessandro.marcon@univr.it	PIN, Isabelle/N-3020-2013; Jarvis, Deborah/E-6494-2011; Marcon, Alessandro/C-3349-2012; de Marco, Roberto/A-5470-2008; Corsico, Angelo Guido/AAC-8138-2019	Marcon, Alessandro/0000-0002-2778-658X; Corsico, Angelo Guido/0000-0002-8716-4694; Cerveri, Isa/0000-0003-0337-043X; Jarvis, Deborah/0000-0002-1753-3896	European Commission	European Commission(European CommissionEuropean Commission Joint Research Centre)	The coordination of the European Community Respiratory Health Survey II was supported by the European Commission as part of their Quality of Life program.	Agusti AGN, 2003, EUR RESPIR J, V21, P347, DOI 10.1183/09031936.03.00405703; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; CAMILLI AE, 1987, AM REV RESPIR DIS, V135, P794, DOI 10.1164/arrd.1987.135.4.794; Chinn S, 2005, AM J RESP CRIT CARE, V172, P956, DOI 10.1164/rccm.200503-323OC; Chinn S, 2005, LANCET, V365, P1629, DOI 10.1016/S0140-6736(05)66511-7; de Marco R, 2007, J ALLERGY CLIN IMMUN, V119, P611, DOI 10.1016/j.jaci.2006.11.696; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; DING DJ, 1987, J APPL PHYSIOL, V62, P1324, DOI 10.1152/jappl.1987.62.3.1324; Ferretti A, 2001, CHEST, V119, P1401, DOI 10.1378/chest.119.5.1401; *GOLD, 2006, GLOB STRAT DIAGN MAN; Goldstein H., 2011, MULTILEVEL STAT MODE; Gump A, 2001, J APPL PHYSIOL, V90, P2306, DOI 10.1152/jappl.2001.90.6.2306; Hegewald MJ, 2007, CHEST, V132, P1608, DOI 10.1378/chest.07-1405; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Janson C, 2006, EUR RESPIR J, V27, P517, DOI 10.1183/09031936.06.00106605; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Johannessen A, 2005, THORAX, V60, P842, DOI 10.1136/thx.2005.043943; Jones RL, 2006, CHEST, V130, P827, DOI 10.1378/chest.130.3.827; Lange P, 2006, THORAX, V61, P100, DOI 10.1136/thx.2004.037978; LANGE P, 1989, EUR RESPIR J, V2, P811; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lee JH, 2007, CHEST, V132, P1882, DOI 10.1378/chest.07-0713; Panizza JA, 2006, INTERN MED J, V36, P773, DOI 10.1111/j.1445-5994.2006.01214.x; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Schunemann HJ, 2000, CHEST, V118, P656, DOI 10.1378/chest.118.3.656; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Sin DD, 2002, ARCH INTERN MED, V162, P1477, DOI 10.1001/archinte.162.13.1477; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; Wise RA, 1998, AM J RESP CRIT CARE, V157, P866, DOI 10.1164/ajrccm.157.3.9706076; ZERAH F, 1993, CHEST, V103, P1470, DOI 10.1378/chest.103.5.1470	35	34	35	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1069	1074		10.1016/j.jaci.2009.01.040	http://dx.doi.org/10.1016/j.jaci.2009.01.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19321196				2022-12-18	WOS:000266309400013
J	Okano, M; Fujiwara, T; Haruna, T; Kariya, S; Makihara, S; Higaki, T; Nishizaki, K				Okano, Mitsuhiro; Fujiwara, Tazuko; Haruna, Takenori; Kariya, Shin; Makihara, Seiichiro; Higaki, Takaya; Nishizaki, Kazunori			Prostaglandin E-2 suppresses staphylococcal enterotoxin-induced eosinophilia-associated cellular responses dominantly through an E-prostanoid 2-mediated pathway in nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Enterotoxin; COX; prostaglandin E-2; E-prostanoid receptor; IL-5; IL-13; RANTES; nasal polyps; chronic rhinosinusitis	CHRONIC RHINOSINUSITIS; T-CELLS; CYCLOOXYGENASE-2 EXPRESSION; CHRONIC SINUSITIS; EPITHELIAL-CELLS; IMMUNOGLOBULIN-E; HUMAN AIRWAY; ASTHMA; MUCOSA; RANTES	Background: Recent investigations have revealed that staphylococcal enterotoxins (SEs), COX metabolism, or both might participate in the pathogenesis of eosinophilic airway diseases, such as chronic rhinosinusitis with nasal polyposis. Objective: We sought to determine whether COX metabolism, especially prostaglandin (PG) E-2, plays a significant role in SE-induced cellular responses in nasal polyps. Methods: Dispersed nasal polyp cells (DNPCs) were prepared from nasal polyps by means of enzymatic digestion. DNPCs were cultured with SEB in the presence or absence of COX inhibitors (diclofenac and indomethacin) for 72 hours; then the levels of IL-5, IL-13, RANTES, and eotaxin in the supernatants were measured. The effect of PGE(2) on SEB-induced responses by diclofenac-treated DNPCs was examined, especially in terms of receptor specificity. Results: DNPCs produced significant amounts of IL-5, IL-13, and RANTES in response to SEB. COX inhibitors significantly increased the production of these cytokines. The degree of local eosinophilia was significantly and positively correlated with the changes in IL-5 production induced by diclofenac treatment. PGE2 significantly and dose-dependently inhibited SEB-induced IL-5, IL-13, and RANTES production by diclofenac-treated DNPCs. E-prostanoid (EP) 2 receptor-selective agonist strongly inhibited the production of all 3 cytokines. EP3 and EP4 receptor-selective agonists partially suppressed these responses, whereas EP1 receptor-selective agonist did not. Interestingly, all of the combined treatments with 2 of the 4 EP receptor-selective agonists significantly inhibited the SEB-induced responses by diclofenac-treated DNPCs. Conclusions: These results suggest that PGE2 inhibits the pathogenesis of SEB-induced eosinophilic inflammation primarily through the EP2-mediated pathway in patients with chronic rhinosinusitis with nasal polyposis. (J Allergy Clin Immunol 2009;123:868-74.)	[Okano, Mitsuhiro; Fujiwara, Tazuko; Haruna, Takenori; Kariya, Shin; Makihara, Seiichiro; Higaki, Takaya; Nishizaki, Kazunori] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Otolaryngol Head & Neck Surg, Okayama 7008558, Japan	Okayama University	Okano, M (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Otolaryngol Head & Neck Surg, 2-5-1 Shikatacho, Okayama 7008558, Japan.	mokano@cc.okayama-u.ac.jp			Ministry of Education, Culture. Sports, Science, and Technology, Japan [19591971]	Ministry of Education, Culture. Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Supported in part by grants from the Ministry of Education, Culture. Sports, Science, and Technology, Japan (19591971).	Bachert C, 2007, Chem Immunol Allergy, V93, P214, DOI 10.1159/000100897; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4; Borish L, 2002, J ALLERGY CLIN IMMUN, V109, P606, DOI 10.1067/mai.2002.123024; Burgess JK, 2004, J ALLERGY CLIN IMMUN, V113, P876, DOI 10.1016/j.jaci.2004.02.029; Carayol N, 2002, ALLERGY, V57, P1067, DOI 10.1034/j.1398-9995.2002.23452.x; Cho KN, 2005, J BIOL CHEM, V280, P6676, DOI 10.1074/jbc.M412722200; Conley DB, 2006, AM J RHINOL, V20, P534, DOI 10.2500/ajr.2006.20.2941; Draheim R, 2004, J PHARMACOL EXP THER, V308, P555, DOI 10.1124/jpet.103.059097; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; Kimura N, 1997, ACTA MED OKAYAMA, V51, P33; Krakauer T, 2002, CLIN DIAGN LAB IMMUN, V9, P126, DOI 10.1128/CDLI.9.1.126-131.2002; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Lee CH, 1999, ANN OTO RHINOL LARYN, V108, P594, DOI 10.1177/000348949910800612; Liu LY, 2006, ALLERGY, V61, P589, DOI 10.1111/j.1398-9995.2006.01060.x; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; Matsuwaki Y, 2008, INT ARCH ALLERGY IMM, V146, P77, DOI 10.1159/000126066; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Meyer JE, 2005, AM J RHINOL, V19, P15, DOI 10.1177/194589240501900103; Mullol J, 2002, J ALLERGY CLIN IMMUN, V109, P824, DOI 10.1067/mai.2002.123534; O'Brien GJ, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-115; Okano M, 2006, CLIN EXP ALLERGY, V36, P1028, DOI 10.1111/j.1365-2222.2006.02528.x; Okano M, 2005, CLIN EXP ALLERGY, V35, P506, DOI 10.1111/j.1365-2222.2005.02195.x; Okano M, 2006, IMMUNOLOGY, V118, P343, DOI 10.1111/j.1365-2567.2006.02376.x; Patou J, 2008, J ALLERGY CLIN IMMUN, V121, P110, DOI 10.1016/j.jaci.2007.08.059; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Perez-Novo CA, 2008, J INFECT DIS, V197, P1036, DOI 10.1086/528989; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; Profita M, 2003, J ALLERGY CLIN IMMUN, V112, P709, DOI 10.1016/S0091-6749(03)01889-X; Pujols L, 2004, J ALLERGY CLIN IMMUN, V114, P814, DOI 10.1016/j.jaci.2004.07.050; Rosenberg HF, 2007, J ALLERGY CLIN IMMUN, V119, P1303, DOI 10.1016/j.jaci.2007.03.048; Rostkowska Nadolska B, 2005, AURIS NASUS LARYNX, V32, P225, DOI 10.1016/j.anl.2005.03.001; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; Seiberling KA, 2005, LARYNGOSCOPE, V115, P1580, DOI 10.1097/01.mlg.0000168111.11802.9c; Suh YJ, 2004, CLIN EXP ALLERGY, V34, P1270, DOI 10.1111/j.1365-2222.2004.02051.x; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Takahashi HK, 2002, J IMMUNOL, V168, P4446, DOI 10.4049/jimmunol.168.9.4446; Takishita T, 2005, ALLERGY, V60, P211, DOI 10.1111/j.1398-9995.2005.00660.x; Tripathi A, 2004, LARYNGOSCOPE, V114, P1822, DOI 10.1097/00005537-200410000-00027; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Yamada T, 2001, J IMMUNOL, V166, P538, DOI 10.4049/jimmunol.166.1.538; Yamamoto H, 2007, ALLERGY, V62, P1451, DOI 10.1111/j.1398-9995.2007.01464.x; Yamamoto M, 2009, INT ARCH ALLERGY IMM, V148, P127, DOI 10.1159/000155743; Ying S, 2006, J ALLERGY CLIN IMMUN, V117, P312, DOI 10.1016/j.jaci.2005.10.037	46	34	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					868	874		10.1016/j.jaci.2009.01.047	http://dx.doi.org/10.1016/j.jaci.2009.01.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19254809				2022-12-18	WOS:000265058600013
J	Castro, M; Schweiger, T; Yin-DeClue, H; Ramkumar, TP; Christie, C; Zheng, J; Cohen, R; Schechtman, KB; Strunk, R; Bacharier, LB				Castro, Mario; Schweiger, Toni; Yin-DeClue, Huiquing; Ramkumar, Thiruvamoor P.; Christie, Chandrika; Zheng, Jie; Cohen, Rebecca; Schechtman, Kenneth B.; Strunk, Robert; Bacharier, Leonard B.			Cytokine response after severe respiratory syncytial virus bronchiolitis in early life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RSV bronchiolitis; asthma; eczema; allergic sensitization; cytokines	T-CELL MEMORY; ENVIRONMENTAL ALLERGENS; GAMMA PRODUCTION; FLOW-CYTOMETRY; IFN-GAMMA; AGE; ASTHMA; CHILDREN; INFECTION; INFANCY	Background: Immune response after viral infection usually involves T(H)1-mediated response; however, severe respiratory syncytial virus (RSV) infection appears to be associated with the development of asthma, a T(H)2-predominant phenotype. Objective: To understand the early and subsequent immunologic response to a serious RSV infection in children over time. Methods: A total of 206 previously healthy infants hospitalized with severe RSV bronchiolitis were enrolled in a prospective cohort called the RSV Bronchiolitis in Early Life study. Peripheral blood T cells were obtained immediately after RSV infection and at 2, 4, and 6 years of age, stimulated with phorbol 12-myristate 13-acetate and ionomycin, and analyzed for IL-2, IL-4, IL-13, and IFN-gamma by flow cytometry and real-time PCR. Results: Of the children, 48% (n = 97) developed asthma (physician-diagnosed), and 48% (n = 97) had eczema by age 6 years; 32% (n = 48 of 150) developed allergic sensitization by 3 years of age. Children with asthma had lower IL-13 expression at 6 years of age than those without (P = .001). IFN-gamma, IL-2, and IL-4 levels did not differ by asthma or eczema status during follow-up (all P > .05). Allergic sensitization was not associated with differences in cytokine levels during follow-up (all P > .05). Conclusion: Severe RSV infection early in life is associated with a high incidence of asthma and eczema. Contrary to expectations, subsequent immunologic development in those who developed asthma, eczema, or allergic sensitization was not associated with a T(H)2 phenotype in the peripheral blood.	[Castro, Mario; Schweiger, Toni; Yin-DeClue, Huiquing; Ramkumar, Thiruvamoor P.; Christie, Chandrika; Cohen, Rebecca] Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; [Strunk, Robert; Bacharier, Leonard B.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Zheng, Jie; Schechtman, Kenneth B.] Washington Univ, Sch Med, Dept Biostat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Castro, M (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Campus Box 8052,660 S Euclid, St Louis, MO 63110 USA.	castrom@wustl.edu		Bacharier, Leonard/0000-0003-0432-2704; ZHENG, JIE/0000-0003-4958-2091	National Institutes of Health [HL 61895]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, UL1RR024992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061895] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant no. HL 61895.	Boyce TG, 2000, J PEDIATR-US, V137, P865, DOI 10.1067/mpd.2000.110531; Bradley JP, 2005, PEDIATRICS, V115, pE7, DOI 10.1542/peds.2004-0059; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Chipeta J, 1998, CELL IMMUNOL, V183, P149, DOI 10.1006/cimm.1998.1244; Chung HL, 2007, PEDIAT ALLERG IMM-UK, V18, P94, DOI 10.1111/j.1399-3038.2006.00501.x; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Cooper AC, 2003, J AM SOC NEPHROL, V14, P1776, DOI 10.1097/01.ASN.0000071514.36428.61; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; DELPRETE G, 1988, J IMMUNOL, V140, P4193; Gasparoni A, 2003, BIOL NEONATE, V84, P297, DOI 10.1159/000073638; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Hartel C, 2005, CLIN EXP IMMUNOL, V142, P446, DOI 10.1111/j.1365-2249.2005.02928.x; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P1117, DOI 10.1067/mai.2000.105804; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Ichinohe S, 2003, EUR RESPIR J, V22, P317, DOI 10.1183/09031936.03.00087902; Kristjansson S, 2005, J ALLERGY CLIN IMMUN, V116, P805, DOI 10.1016/j.jaci.2005.07.012; Leader S, 2003, J PEDIATR-US, V143, pS127, DOI 10.1067/S0022-3476(03)00510-9; Leader S, 2002, PEDIATR INFECT DIS J, V21, P629, DOI 10.1097/00006454-200207000-00005; Legg JP, 2003, AM J RESP CRIT CARE, V168, P633, DOI 10.1164/rccm.200210-1148OC; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Moorman JERR, 2007, MMWR-MORBID MORTAL W, V56, P8; Overbergh L, 2003, J Biomol Tech, V14, P33; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Pala P, 2000, J IMMUNOL METHODS, V243, P107, DOI 10.1016/S0022-1759(00)00230-1; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1997, INT ARCH ALLERGY IMM, V113, P75, DOI 10.1159/000237512; Prescott SL, 1998, J IMMUNOL, V160, P4730; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; Rostaing L, 1999, CYTOMETRY, V35, P318, DOI 10.1002/(SICI)1097-0320(19990401)35:4<318::AID-CYTO4>3.0.CO;2-4; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sigurs N, 2001, AM J RESP CRIT CARE, V163, pS2, DOI 10.1164/ajrccm.163.supplement_1.2011109; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; SILVER E, 2008, PEDIAT ALLE IN PRESS; Tassignon J, 2005, J IMMUNOL METHODS, V305, P188, DOI 10.1016/j.jim.2005.07.014; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Upham JW, 2006, P AM THORAC SOC, V3, pA827	40	34	42	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					726	733		10.1016/j.jaci.2008.07.010	http://dx.doi.org/10.1016/j.jaci.2008.07.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	18760461	Green Accepted			2022-12-18	WOS:000259989000016
J	Perzanowski, MS; Chew, GL; Divjan, A; Johnson, A; Goldstein, IF; Garfinkel, RS; Hoepner, LA; Platts-Mills, TAE; Perera, FP; Miller, RL				Perzanowski, Matthew S.; Chew, Ginger L.; Divjan, Adnan; Johnson, Alina; Goldstein, Inge F.; Garfinkel, Robin S.; Hoepner, Lori A.; Platts-Mills, Thomas A. E.; Perera, Frederica P.; Miller, Rachel L.			Cat ownership is a risk factor for the development of anti-cat IgE but not current wheeze at age 5 years in an inner-city cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cat; asthma; allergy; wheeze.; inner-city; rhinitis; IgE; IgG; fel d 1	HOUSE-DUST MITE; MODIFIED TH2 RESPONSE; ALLERGEN EXPOSURE; BIRTH COHORT; CHILDHOOD ASTHMA; INDOOR ALLERGENS; SENSITIZATION; CHILDREN; LIFE; ENDOTOXIN	Background: Cat ownership is inversely associated with atopy and asthma in some areas of the world, but the relevance of cat ownership to allergic disease in the inner city is less known. Objective: We sought to evaluate the relationship between cat ownership and the development of early sensitization and wheeze. Methods: By using a prospective birth cohort study, Dominican and African American mothers living in New York City underwent repeated questionnaires about their child from birth to, age 5 years. Sera collected from children at ages 2 (n = 323), 3 (n = 336), and 5 (n = 242) years were assayed for anti-cat IgE and anti-Fel d 1 IgG antibodies. Results: Cat ownership was a significant risk factor for the development of anti-cat IgE by age 2 years (risk ratio [RR], 6.4; 95% CI, 1.9-22) but not for anti-cat IgE development between the ages of 2 and 5 years (RR, 0.88; 95% Cl, 0.24-2.3). Current wheeze was significantly more common among those children with anti-cat IgE at ages 3 (RR, 3.5; 95% CI, 2.1-6.0) and 5 (RR, 3.4; 95% CI, 2.3-4.9) years. Cat ownership was inversely associated with current wheeze at age 5 years among children without anti-cat IgE (RR, 0.26; 95% CI, 0.083-0.81). Among children with anti-cat IgE, a similar trend was observed (RR, 0.57; P =.044, Fisher exact test), although one with borderline statistical significance. Conclusions: Despite a positive association with sensitization, cat ownership in this inner-city cohort was inversely associated with wheeze, potentially suggesting an IgE-independent protective mechanism in this community.	[Perzanowski, Matthew S.; Chew, Ginger L.; Divjan, Adnan; Hoepner, Lori A.; Perera, Frederica P.; Miller, Rachel L.] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Perzanowski, Matthew S.; Chew, Ginger L.; Divjan, Adnan; Johnson, Alina; Goldstein, Inge F.; Garfinkel, Robin S.; Hoepner, Lori A.; Perera, Frederica P.; Miller, Rachel L.] Columbia Univ, Columbia Ctr Childrens Environm Hlth, New York, NY 10032 USA; [Goldstein, Inge F.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Garfinkel, Robin S.] Columbia Univ, Data Coordinating Ctr, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Johnson, Alina; Miller, Rachel L.] Columbia Univ Coll Phys & Surg, Dept Med, Div Pulm Allergy Crit Care Med, New York, NY 10032 USA; [Platts-Mills, Thomas A. E.] Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; University of Virginia	Perzanowski, MS (corresponding author), Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, 60 Haven Ave,B-1, New York, NY 10032 USA.	mp2217@columbia.edu		Platts-Mills, Thomas/0000-0002-1263-329X; Hoepner, Lori/0000-0002-4404-8140; Divjan, Adnan/0000-0002-8895-5965	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, R03ES013308, R01ES008977, P01ES009600] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00645, M01 RR000645] Funding Source: Medline; NIEHS NIH HHS [R03 ES013308-02, P01 ES009600-11, R03 ES013308, R03ES013308, R01 ES008977, P01 ES09600, R01 ES008977-13, P30 ES009089-04S3, P01 ES009600, 5 R01 ES08977, P30 ES009089] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Al-Mousawi MSH, 2004, J ALLERGY CLIN IMMUN, V114, P1389, DOI 10.1016/j.jaci.2004.09.005; Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Goldstein IF, 2005, INT ARCH ALLERGY IMM, V137, P249, DOI 10.1159/000086338; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LIN RY, 1993, ANN ALLERGY, V71, P33; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; TePas EC, 2006, CHEST, V129, P1500, DOI 10.1378/chest.129.6.1500; Torrent M, 2006, J ALLERGY CLIN IMMUN, V118, P742, DOI 10.1016/j.jaci.2006.04.059; von Bubnoff D, 2004, CLIN EXP ALLERGY, V34, P1056, DOI 10.1111/j.1365-2222.2004.01984.x; 2003, ASTHMA FACTS	34	34	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1047	1052		10.1016/j.jaci.2008.02.005	http://dx.doi.org/10.1016/j.jaci.2008.02.005			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18395554	Green Accepted			2022-12-18	WOS:000254884000035
J	Salt, BH; Niemela, JE; Pandey, R; Hanson, EP; Deering, RP; Quinones, R; Jain, A; Orange, JS; Gelfand, EW				Salt, Bryn H.; Niemela, Julie E.; Pandey, Rahul; Hanson, Eric P.; Deering, Raquel P.; Quinones, Ralph; Jain, Ashish; Orange, Jordan S.; Gelfand, Erwin W.			IKBKG (nuclear factor-kappa B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEMO; Toll-like receptors	ANHIDROTIC ECTODERMAL DYSPLASIA; HYPER-IGM SYNDROME; IKK-GAMMA GENE; INCONTINENTIA PIGMENTI; T-CELL; IMMUNE-DEFICIENCY; HUMAN-DISEASE; NEMO; IMMUNODEFICIENCY; ACTIVATION	Background: Patients with hypomorphic nuclear factor-kappa B essential modulator (NEMO) mutations have extensive phenotypic variability that can include atypical infectious susceptibility. Objective: This study may provide important insight into immunologic mechanisms of host defense. Methods: Immunologic evaluation, including studies of Toll-like receptor (TLR) function, was performed in a 6-month-old boy with normal ectodermal development who was diagnosed with Pneumocystis pneumonia and cytomegalovirus sepsis. Results: Genomic and cDNA sequencing demonstrated a novel NEMO missense mutation, 337G->A, predicted to cause a D113N (aspartic acid to asparagine) substitution in the first coiled-coil region of the NEMO protein. Quantitative serum immunoglobulins, lymphocyte subset numbers, and mitogen-induced lymphocyte proliferation were essentially normal. The PBMC responses to TLR ligands were also surprisingly normal, whereas natural killer cell cytolytic activity, T-cell proliferative responses to specific antigens, and T-cell receptor-induced NF-kappa B activation were diminished. Conclusion: Unlike the unique NEMO mutation described here, the most commonly reported mutations are clustered at the 3' end in the tenth exon, which encodes a zinc finger domain. Because specific hypomorphic variants of NEMO are associated with distinctive phenotypes, this particular NEMO mutation highlights a dispensability of the region including amino acid 113 for TLR signaling and ectodysplasin A receptor function. This region is required for certain immunoreceptor functions as demonstrated by his susceptibility to infections as well as natural killer cell and T-cell defects.	[Pandey, Rahul; Hanson, Eric P.; Deering, Raquel P.; Orange, Jordan S.] Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; [Salt, Bryn H.; Gelfand, Erwin W.] Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; [Niemela, Julie E.; Jain, Ashish] NIH, Bethesda, MD 20892 USA; [Quinones, Ralph] Childrens Hosp, Denver, CO 80218 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Jewish Health; National Institutes of Health (NIH) - USA; Children's Hospital Colorado	Orange, JS (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, 3615 Civ Ctr Blvd,ARC 1016H, Philadelphia, PA 19104 USA.	orange@mail.med.upenn.edu; gelfande@njc.org	Orange, Jordan S/D-5239-2009; Hanson, Eric/AAE-5511-2022	Hanson, Eric/0000-0002-0318-4779; Niemela, Julie/0000-0003-4197-3792; orange, jordan/0000-0001-7117-7725	NATIONAL CANCER INSTITUTE [T32CA009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000924, ZIAAI001078] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009140-34, T32 CA009140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Aradhya S, 2001, HUM MOL GENET, V10, P2171, DOI 10.1093/hmg/10.19.2171; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Deering RP, 2006, CLIN VACCINE IMMUNOL, V13, P68, DOI 10.1128/CVI.13.1.68-76.2006; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dupuis-Girod S, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e97; Fusco F, 2004, HUM MOL GENET, V13, P1763, DOI 10.1093/hmg/ddh192; HARBECK RJ, 1991, MANUAL METHODS PROCE, P211; Jain A, 2004, J CLIN INVEST, V114, P1593, DOI 10.1172/JCI200421345; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Niehues T, 2004, J ALLERGY CLIN IMMUN, V114, P1456, DOI 10.1016/j.jaci.2004.08.047; Orange JS, 2005, IMMUNOL REV, V203, P21, DOI 10.1111/j.0105-2896.2005.00221.x; Orange JS, 2002, MICROBES INFECT, V4, P1545, DOI 10.1016/S1286-4579(02)00038-2; Orange JS, 2004, J ALLERGY CLIN IMMUN, V114, P650, DOI 10.1016/j.jaci.2004.06.052; Orange JS, 2004, J ALLERGY CLIN IMMUN, V113, P725, DOI 10.1016/j.jaci.2004.01.762; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Orstavik KH, 2006, AM J MED GENET A, V140A, P31, DOI 10.1002/ajmg.a.31026; Schmid JMP, 2006, PEDIATRICS, V117, pE1049, DOI 10.1542/peds.2005-2062; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Stilo R, 2004, J BIOL CHEM, V279, P34323, DOI 10.1074/jbc.M402244200; Tang ED, 2003, J BIOL CHEM, V278, P38566, DOI 10.1074/jbc.M304374200; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WELSH RM, 1991, J EXP MED, V173, P1053, DOI 10.1084/jem.173.5.1053; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	30	34	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					976	982		10.1016/j.jaci.2007.11.014	http://dx.doi.org/10.1016/j.jaci.2007.11.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18179816	Green Accepted			2022-12-18	WOS:000254884000024
J	Shaker, M; Lobb, A; Jenkins, P; O'Rourke, D; Takemoto, SK; Sheth, S; Burroughs, T; Dykewicz, MS				Shaker, Marcus; Lobb, Ano; Jenkins, Pamela; O'Rourke, Daniel; Takemoto, Steve K.; Sheth, Salil; Burroughs, Thomas; Dykewicz, Mark S.			An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cost-effectiveness analysis; quality-adjusted life year; aspirin desensitization; aspirin-exacerbated respiratory disease	WILLINGNESS-TO-PAY; HIGH-RISK PATIENTS; QUALITY-OF-LIFE; MYOCARDIAL-INFARCTION; ASTHMATIC-PATIENTS; ORAL CHALLENGE; SENSITIVITY; HEALTH; CLOPIDOGREL; TRIAL	Background: Aspirin desensitization is an effective therapy for moderate-to-severe aspirin-exacerbated respiratory disease (AERD). Desensitization also allows the use of aspirin for secondary cardiovascular prevention. Objective: We sought to investigate the cost-effectiveness of aspirin desensitization with subsequent aspirin therapy in patients with AERD. Methods: The Healthcare Cost and Utilization Project was used, together with average reimbursements from a large Midwestern health care plan, to model the costs of aspirin desensitization for therapeutic and prophylactic use in patients with AERD. Event probabilities were based on the published literature. Results: Ambulatory desensitization for AERD cost $6768 per quality-adjusted life year (QALY) saved ($18.54 per additional symptom-free day). Aspirin desensitization for AERD remained cost-effective (<$50,000 per QALY saved) across a wide range of assumptions. When secondary cardiovascular prophylaxis was considered, ambulatory aspirin desensitization was less expensive than an alternative antiplatelet agent, clopidogrel. Clopidogrel cost $106,453 per incremental QALY saved when compared with desensitization. Conclusions: Aspirin desensitization is a cost-effective therapeutic intervention in patients with moderate-to-severe AERD. Although the incremental cost-effectiveness of clopidogrel in individuals with aspirin allergy is marginal, if available, ambulatory desensitization remains a less-expensive option for secondary cardiovascular prophylaxis.	[Shaker, Marcus] Dartmouth Coll, Hitchcock Med Ctr, Allergy & Clin Immunol Sect, Dept Pediat & Commun & Family Med, Lebanon, NH 03756 USA; [Shaker, Marcus] Dartmouth Coll, Hitchcock Med Ctr, Allergy & Clin Immunol Sect, Lebanon, NH 03756 USA; [Jenkins, Pamela] Dartmouth Coll, Hitchcock Med Ctr, Dept Pediat, Lebanon, NH 03756 USA; [O'Rourke, Daniel] Dartmouth Coll, Hitchcock Med Ctr, Cardiol Sect, Dept Internal Med, Lebanon, NH 03756 USA; [Shaker, Marcus; Lobb, Ano] St Louis Univ, Sch Med, Ctr Evaluat Clin Sci Hanover, St Louis, MO USA; [Takemoto, Steve K.; Sheth, Salil; Burroughs, Thomas] St Louis Univ, Sch Med, Ctr Outcomes Res, St Louis, MO USA; [Dykewicz, Mark S.] St Louis Univ, Sch Med, Dept Internal Med, Div Immunol, St Louis, MO USA	Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; Saint Louis University; Saint Louis University; Saint Louis University	Shaker, M (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Allergy & Clin Immunol Sect, Dept Pediat & Commun & Family Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Marcus.Shaker@dartmouth.edu						*AG HEALTHC RES QU, 2005, HCUPNET HEALTHC COST; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Berges-Gimeno MP, 2003, ANN ALLERG ASTHMA IM, V90, P338, DOI 10.1016/S1081-1206(10)61803-0; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Blumenschein K, 1998, ANN ALLERG ASTHMA IM, V80, P189, DOI 10.1016/S1081-1206(10)62954-7; Boudreaux ED, 2003, CHEST, V124, P803, DOI 10.1378/chest.124.3.803; Bradley CJ, 2000, J CLIN EPIDEMIOL, V53, P555, DOI 10.1016/S0895-4356(99)00219-X; Centers for Disease Control and Prevention, 2007, BEH RISK FACT SURV S; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Gaspoz J, 2002, NEW ENGL J MED, V346, P1800, DOI 10.1056/NEJM200206063462309; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gollapudi RR, 2004, JAMA-J AM MED ASSOC, V292, P3017, DOI 10.1001/jama.292.24.3017; Gosepath J, 2002, LARYNGO RHINO OTOL, V81, P732, DOI 10.1055/s-2002-35002; Hunink M., 2004, DECISION MAKING HLTH; Jenkins C, 2004, BMJ-BRIT MED J, V328, P434, DOI 10.1136/bmj.328.7437.434; Jenkins C, 2000, Am J Ther, V7, P55, DOI 10.1097/00045391-200007020-00003; Kasper L, 2003, ALLERGY, V58, P1064, DOI 10.1034/j.1398-9995.2003.00267.x; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; Mittmann N, 1999, PHARMACOECONOMICS, V15, P369, DOI 10.2165/00019053-199915040-00004; Murphy MP, 2002, OTOLARYNG HEAD NECK, V127, P367, DOI 10.1067/mhn.2002.129815; *NAT CTR HLTH STAT, 2006, NAT CTR HLTH STAT LI; Popma JJ, 2004, CHEST, V126, p576S, DOI 10.1378/chest.126.3_suppl.576S; Ramanuja S, 2004, CIRCULATION, V110, pE1, DOI 10.1161/01.CIR.0000134306.28561.2A; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P401, DOI 10.1016/S0091-6749(99)70463-X; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P408, DOI 10.1016/S0091-6749(99)70464-1; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Schaefer OP, 1999, CARDIOLOGY, V91, P8, DOI 10.1159/000006871; SETTIPANE RA, 1989, J ALLERGY CLIN IMMUN, V84, P26, DOI 10.1016/0091-6749(89)90174-7; Silberman S, 2005, AM J CARDIOL, V95, P509, DOI 10.1016/j.amjcard.2004.10.022; SPECTOR SL, 1998, J ALLERGY CLIN IMMUN, V102, P107; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019; TAN K, 1995, J AM COLL CARDIOL, V25, P855, DOI 10.1016/0735-1097(94)00462-Y; White AA, 2005, ANN ALLERG ASTHMA IM, V95, P330, DOI 10.1016/S1081-1206(10)61150-7; Winkelmayer WC, 2002, MED DECIS MAKING, V22, P417, DOI 10.1177/027298902236927; Wong JT, 2000, J ALLERGY CLIN IMMUN, V105, P997, DOI 10.1067/mai.2000.104571; Yusuf S, 2001, NEW ENGL J MED, V345, P494; YUVAL R, 2007, EUR J CARDIOVASC NUR; Zillich AJ, 2002, PHARMACOECONOMICS, V20, P257, DOI 10.2165/00019053-200220040-00004	40	34	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					81	87		10.1016/j.jaci.2007.06.047	http://dx.doi.org/10.1016/j.jaci.2007.06.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17716716				2022-12-18	WOS:000252372000012
J	Land, MH; Garcia-Lloret, MI; Borzy, MS; Rao, PN; Aziz, N; McGhee, SA; Chen, K; Gorski, J; Stiehm, ER				Land, Michael H.; Garcia-Lloret, Maria I.; Borzy, Michael S.; Rao, P. Nagesh; Aziz, Najib; McGhee, Sean A.; Chen, Karin; Gorski, Jack; Stiehm, E. Richard			Long-term results of bone marrow transplantation in complete DiGeorge syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DiGeorge syndrome; hematopoietic cell transplantation; bone marrow; transplantation; immune deficiency; long-term outcome; treatment	STEM-CELL TRANSPLANTATION; T-CELL; THYMUS TRANSPLANTATION; IMMUNE CONSTITUTION; IMMUNODEFICIENCY; PATIENT	Background: Therapeutic options for DiGeorge syndrome (DGS) with profound T-cell deficiency are very limited. Thymic transplantation has shown promising results but is not easily available. Hematopoietic cell transplantation (HCT) has been successful in restoring immune competence in the short term. Objective: Present the long-term follow-up of 2 patients with complete DGS who received bone marrow transplants in the neonatal period from HLA-matched siblings, and perform a multicenter survey to document the status of other patients with DGS who have undergone HCT. Methods: Immune function assessment by immunophenotyping, lymphocyte proliferation, T-cell receptor excision circles, single nucleotide polymorphism mapping arrays, spectratyping, cytogenetics, and fluorescence in situ hybridization were used. Results: Among reported patients with DGS receiving HCT, survival is greater than 75%. Our patients are in their 20s and in good health. Their hematopoietic compartment shows continuous engraftment with mixed chimerism, normal T-cell function, and Immoral immunity. Circulating T cells exhibit a memory phenotype with a restricted repertoire and are devoid of T-cell receptor excision circles. Conclusion: These features suggest that T-cell reconstitution has occurred predominantly through expansion of the donors' mature T-cell pool. Although restricted, their immune systems are capable of providing substantial protection to infection and respond to vaccines. We conclude that bone marrow transplant achieves long-lived reconstitution of immune function in complete DGS and is a good alternative to thymic transplantation in patients with a suitable donor. Clinical implications: Bone marrow transplant in complete DGS using an HLA-matched sibling donor provides long-lasting immunity and is a suitable and more available alternative to thymic transplantation.	Univ Calif Los Angeles, Med Ctr, Dept Pediat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Med Ctr, Dept Pathol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Med Ctr, Dept Lab Med, Los Angeles, CA 90024 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA; Blood Ctr SE Wisconsin Inc, Milwaukee, WI 53233 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Oregon Health & Science University; Versiti Blood Center of Wisconsin	Garcia-Lloret, MI (corresponding author), Univ Calif Los Angeles, Med Ctr, Mattel Childrens Hosp, 10833 Le Conte Ave,MDCC 12-430, Los Angeles, CA 90095 USA.	MiGarcia@mednet.ucla.edu		Land, Michael/0000-0001-8016-5419				Al-Tamemi S, 2005, PEDIATRICS, V116, pE457, DOI 10.1542/peds.2005-0371; Auletta JJ, 2005, BONE MARROW TRANSPL, V35, P835, DOI 10.1038/sj.bmt.1704966; Bensoussan D, 2002, BRIT J HAEMATOL, V117, P899, DOI 10.1046/j.1365-2141.2002.03496.x; BORZY MS, 1989, J CLIN IMMUNOL, V9, P386, DOI 10.1007/BF00917103; Bowers DC, 1998, LANCET, V352, P1983, DOI 10.1016/S0140-6736(98)00094-4; Clark RA, 2005, J CLIN INVEST, V115, P3239, DOI 10.1172/JCI24731; Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5; GOLDSOBEL AB, 1987, J PEDIATR-US, V111, P40, DOI 10.1016/S0022-3476(87)80339-6; HOENIG M, 2004, AM SOC HEM 46 ANN M; Janda A, 2007, PEDIATR TRANSPLANT, V11, P441, DOI 10.1111/j.1399-3046.2007.00702.x; Knutsen AP, 2000, J CLIN IMMUNOL, V20, P466, DOI 10.1023/A:1026463900925; KOMANDURI K, 2007, BLOOD; Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003; Markert ML, 2007, BLOOD, V109, P4539, DOI 10.1182/blood-2006-10-048652; Markert ML, 1998, J PEDIATR-US, V132, P15, DOI 10.1016/S0022-3476(98)70478-0; Markert ML, 2004, BLOOD, V104, P2574, DOI 10.1182/blood-2003-08-2984; Markert ML, 1999, NEW ENGL J MED, V341, P1180, DOI 10.1056/NEJM199910143411603; Matsumoto T, 1998, BONE MARROW TRANSPL, V22, P927, DOI 10.1038/sj.bmt.1701475; Ohtsuka Y, 2004, EUR J PEDIATR, V163, P747, DOI 10.1007/s00431-004-1524-8; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Rufer N, 2001, TRENDS IMMUNOL, V22, P136, DOI 10.1016/S1471-4906(00)01849-4; STANCZK C, 2007, HUM MUTAT; Sullivan KE, 2004, CURR OPIN ALLERGY CL, V4, P505, DOI 10.1097/00130832-200412000-00006; Wucherpfennig KW, 2007, SEMIN IMMUNOL, V19, P216, DOI 10.1016/j.smim.2007.02.012; YASSAI M, 1997, ANTIGEN T CELL RECEP, P326	25	34	37	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					908	915		10.1016/j.jaci.2007.08.048	http://dx.doi.org/10.1016/j.jaci.2007.08.048			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17931564				2022-12-18	WOS:000250157700027
J	Johansson, S; Wennergren, G; Aberg, N; Rudin, A				Johansson, Sofi; Wennergren, Goran; Aberg, Nils; Rudin, Anna			Clara cell 16-kd protein downregulates T-H(2) differentiation of human naive neonatal T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; children; CC16; CC10; uteroglobin; T-H(2)	DENDRITIC CELLS; 10-KDA PROTEIN; ASTHMA; INFLAMMATION; RESPONSES; SERUM; UTEROGLOBIN; EXPRESSION; DEFICIENT; RHINITIS	Background: Levels of the Clara cell 16-kd protein (CC16) are lower in plasma and bronchoalveolar lavage fluid from adults with asthma relative to those seen in healthy control subjects, and CC16 inhibits the T(H)2 cytokine production from marine T cells. Objective: We sought to determine the plasma levels of CC16 in infants and to investigate whether CC16 might inhibit the T(H)2 cytokine production from neonatal T cells. Methods: Cord blood and blood samples at 4, 18, and 36 months of age were taken from 64 children prospectively, and CC16 levels were analyzed in plasma. Cord monocyte-derived dendritic cells (DCs) were pulsed with birch allergen extract alone or together with CC16 or prostaglandin D-2 receptor inhibitors, after which autologous naive CD4(+) T cells were added to the DCs. The production of IL-5, IL-13, and IFN-gamma was measured by means of ELISA and flow cytometry. Results: The plasma levels of CC16 in children peaked at 4 months. CC16 did not directly affect the cytokine production from human T(H)2 cells. However, CC16 inhibited birch pollen extract-stimulated T(H)2 differentiation of naive T cells through the DC. Inhibition of the prostaglandin D-2 receptors did not consistently result in suppressed T(H)2 differentiation. Conclusion: The production of CC16 seems to peak early in life, and CC16 has an inhibitory effect on T(H)2 cell differentiation from human infants by affecting DCs. Clinical implications: CC16 is an immunoregulatory protein, and its inhibitory effect on T(H)2 cell differentiation might be of importance in the pathogenesis of allergy in infants.	Univ Gothenburg, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, SE-41346 Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Dept Pediat, SE-41346 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Johansson, S (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Guldhedsgatan 10A, SE-41346 Gothenburg, Sweden.	sofi.johansson@rheuma.gu.se		Rudin, Anna/0000-0002-4137-1276				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Broeckaert F, 2000, ENVIRON HEALTH PERSP, V108, P533, DOI 10.2307/3454615; Chen LC, 2001, J IMMUNOL, V167, P3025, DOI 10.4049/jimmunol.167.6.3025; Goriely S, 2001, J IMMUNOL, V166, P2141, DOI 10.4049/jimmunol.166.3.2141; Gosset P, 2005, EUR J IMMUNOL, V35, P1491, DOI 10.1002/eji.200425319; Gosset P, 2003, J IMMUNOL, V170, P4943, DOI 10.4049/jimmunol.170.10.4943; Hammad H, 2003, J IMMUNOL, V171, P3936, DOI 10.4049/jimmunol.171.8.3936; Hung CH, 2004, J ALLERGY CLIN IMMUN, V114, P664, DOI 10.1016/j.jaci.2004.05.042; Johansson S, 2005, ALLERGY, V60, P638, DOI 10.1111/j.1398-9995.2005.00775.x; Karlsson H, 2002, INFECT IMMUN, V70, P6688, DOI 10.1128/IAI.70.12.6688-6696.2002; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; Luster AD, 2004, NAT REV IMMUNOL, V4, P711, DOI 10.1038/nri1438; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; PERI A, 1993, J CLIN INVEST, V92, P2099, DOI 10.1172/JCI116810; Shijubo N, 1997, EUR RESPIR J, V10, P1108, DOI 10.1183/09031936.97.10051108; Shijubo N, 1999, LUNG, V177, P45, DOI 10.1007/PL00007626; Sohn J, 2003, J CLIN INVEST, V111, P121, DOI 10.1172/JCI200315937; VANVYVE T, 1995, J ALLERGY CLIN IMMUN, V95, P60, DOI 10.1016/S0091-6749(95)70153-2; Wang SZ, 2001, AM J PHYSIOL-LUNG C, V281, pL1303, DOI 10.1152/ajplung.2001.281.5.L1303	21	34	37	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					308	314		10.1016/j.jaci.2007.03.021	http://dx.doi.org/10.1016/j.jaci.2007.03.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17481711				2022-12-18	WOS:000248654900014
J	Munitz, A; Levi-Schaffer, F				Munitz, Ariel; Levi-Schaffer, Francesca			Inhibitory receptors on eosinophils: A direct hit to a possible Achilles heel?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						eosinophil; inhibitory receptors; IRp60/CD300a; ITIM	LEUKEMIC MYELOID CELLS; ADVANCED BREAST-CANCER; BISPECIFIC ANTIBODY; 2B4 CD244; GM-CSF; ACTIVATION; IDENTIFICATION; INFLAMMATION; EXPRESSION; MECHANISM	Since their discovery, much data have been accumulated on cosinophil differentiation, morphology, trafficking, and anatomical location(s) in health and disease. Although "classic" activation pathways (such as cytokines, chemokines, proinflammatory components, and adhesion molecules) regulating eosinophil activation have been widely explored, the presence of other activation molecules that might be disease specific is limited. Furthermore, the expression and function of inhibitory receptors on eosinophils have received scant attention. The need to identify new pathways that regulate eosinophil activation is a crucial goal as it can expand our knowledge on this peculiar cell and provide insights into important queries regarding the physiologic function of eosinophils. Over the past several years, it has become increasingly apparent that eosinophils express several receptors belonging to the immunoglobulin superfamily. In this review, we summarize the current knowledge on the expression and function of new pathways that govern eosinophil activation. In addition, we will propose some hypotheses regarding the ability to use these pathways as a future therapeutic approach. In conclusion, we assume that targeting inhibitory receptors on eosinophils may provide opportunities for immunoregulatory therapy in the near future.	Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Munitz, A (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	fls@cc-huji.ac.il		Levi-Schaffer, Francesca/0000-0003-0620-2810				Barrow AD, 2004, J IMMUNOL, V172, P5838, DOI 10.4049/jimmunol.172.10.5838; Barrow AD, 2006, EUR J IMMUNOL, V36, P1646, DOI 10.1002/eji.200636195; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; Eissmann P, 2005, BLOOD, V105, P4722, DOI 10.1182/blood-2004-09-3796; Elsner J, 1996, BLOOD, V88, P4684, DOI 10.1182/blood.V88.12.4684.bloodjournal88124684; Fulkerson PC, 2005, BLOOD, V106, P436, DOI 10.1182/blood-2005-02-0489; Fulkerson PC, 2004, P NATL ACAD SCI USA, V101, P1987, DOI 10.1073/pnas.0308544100; James ND, 2001, BRIT J CANCER, V85, P152, DOI 10.1054/bjoc.2001.1878; Katz HR, 2002, CURR OPIN IMMUNOL, V14, P698, DOI 10.1016/S0952-7915(02)00400-4; Kim CH, 1999, J EXP MED, V190, P681, DOI 10.1084/jem.190.5.681; Kumar V, 2005, NAT REV IMMUNOL, V5, P363, DOI 10.1038/nri1603; Mingari MC, 2001, IMMUNOL REV, V181, P260, DOI 10.1034/j.1600-065X.2001.1810122.x; Munday J, 2001, BIOCHEM J, V355, P489, DOI 10.1042/0264-6021:3550489; Munitz A, 2006, BLOOD, V107, P1996, DOI 10.1182/blood-2005-07-2926; Munitz A, 2005, J IMMUNOL, V174, P110, DOI 10.4049/jimmunol.174.1.110; Munitz A, 2006, J ALLERGY CLIN IMMUN, V118, P1082, DOI 10.1016/j.jaci.2006.07.041; Nutku E, 2005, BIOCHEM BIOPH RES CO, V336, P918, DOI 10.1016/j.bbrc.2005.08.202; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; O'Keefe TL, 1999, J EXP MED, V189, P1307, DOI 10.1084/jem.189.8.1307; Pasquier B, 2005, IMMUNITY, V22, P31, DOI 10.1016/j.immuni.2004.11.017; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Repp R, 2003, BRIT J CANCER, V89, P2234, DOI 10.1038/sj.bjc.6601367; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Sanz L, 2004, TRENDS IMMUNOL, V25, P85, DOI 10.1016/j.it.2003.12.001; Tam SW, 2004, ALLERGY, V59, P772, DOI 10.1111/j.1398-9995.2004.00332.x; Tedla N, 2003, P NATL ACAD SCI USA, V100, P1174, DOI 10.1073/pnas.0337567100; vanOjik HH, 1997, CANCER IMMUNOL IMMUN, V45, P207, DOI 10.1007/s002620050434; Vitale C, 1999, P NATL ACAD SCI USA, V96, P15091, DOI 10.1073/pnas.96.26.15091; Weiner L M, 1995, J Hematother, V4, P453, DOI 10.1089/scd.1.1995.4.453; WEINER LM, 1995, CANCER RES, V55, P4586; Yoshida S, 2003, BLOOD, V101, P2300, DOI 10.1182/blood-2002-03-0831; Zhang H, 2005, IMMUNITY, V22, P235, DOI 10.1016/j.immuni.2005.01.004; Zhang SL, 2006, J LEUKOCYTE BIOL, V79, P363, DOI 10.1189/jlb.0705398; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	37	34	35	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1382	1387		10.1016/j.jaci.2007.01.031	http://dx.doi.org/10.1016/j.jaci.2007.01.031			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17337299				2022-12-18	WOS:000247232800013
J	Mutalithas, K; Croudace, J; Guillen, C; Siddiqui, S; Thickett, D; Wardlaw, A; Lammas, D; Brightling, C				Mutalithas, Kugathasan; Croudace, Joanne; Guillen, Cristina; Siddiqui, Salmon; Thickett, David; Wardlaw, Andrew; Lammas, David; Brightling, Chris			Bronchoalveolar lavage invariant natural killer T cells are not increased in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Leicester, Inst Lung Hlth, Dept Infect Inflammat & Immun, Leicester, Leics, England; Univ Birmingham, MRC, Ctr Infect & Immun, Birmingham, W Midlands, England	University of Leicester; University of Birmingham	Mutalithas, K (corresponding author), Univ Leicester, Inst Lung Hlth, Dept Infect Inflammat & Immun, Leicester, Leics, England.	ceb17@le.ac.uk	thickett, david/I-4770-2012	Wardlaw, Andrew/0000-0001-6583-0791; thickett, david/0000-0002-5456-6080; brightling, chris/0000-0002-9345-4903	Medical Research Council [G9818340] Funding Source: Medline; MRC [G9818340] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; CHANEZ P, 2007, J ALLERGY CLIN  0413; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Pham-Thi N, 2006, NEW ENGL J MED, V354, P2615; Thomas SY, 2006, NEW ENGL J MED, V354, P2613; Umetsu DT, 2006, NAT REV IMMUNOL, V6, P953, DOI 10.1038/nri1968; WARDLAW AJ, 2001, BR MED B, V56, P985	9	34	36	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1274	1276		10.1016/j.jaci.2007.02.021	http://dx.doi.org/10.1016/j.jaci.2007.02.021			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17399777				2022-12-18	WOS:000246427200035
J	Lee, TTT; Morisset, M; Astier, C; Moneret-Vautrin, DA; Cordebar, V; Beaudouin, E; Codreanu, F; Bihain, BE; Kanny, G				Lee, Tzu-Tai Tiger; Morisset, Martine; Astier, Catherine; Moneret-Vautrin, Denise-Anne; Cordebar, Vanina; Beaudouin, Etienne; Codreanu, Fanny; Bihain, Bernard E.; Kanny, Gisele			Contamination of probiotic preparations with milk allergens can cause anaphylaxis in children with cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PLACEBO-CONTROLLED TRIAL; ATOPIC-DERMATITIS; FOOD ALLERGY; INFANTS		Lab Mol Med & Therapeut, EA 3999 Allerg Dis, Vandoeuvre Les Nancy, France; Univ Hosp, Dept Internal Med Clin Immunol & Allergol, Nancy, France; MTM, JE2482 Lipidomix, Vandoeuvre Les Nancy, France	CHU de Nancy	Lee, TTT (corresponding author), Lab Mol Med & Therapeut, EA 3999 Allerg Dis, Vandoeuvre Les Nancy, France.	gisele.kanny@mtm.nancy.inserm.fr	Kanny, Gisèle/AHA-8910-2022; Morisset, Martine/A-3084-2017	Morisset, Martine/0000-0002-4028-703X				Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; FAO/WHO  Codex Alimentarius Commission, 2001, 1012A FAOWHO ALINORM; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Moneret-Vautrin DA, 2006, ALLERGY, V61, P507, DOI 10.1111/j.1398-9995.2006.01050.x; Prescott SL, 2005, CLIN EXP ALLERGY, V35, P1557, DOI 10.1111/j.1365-2222.2005.02376.x; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Sistek D, 2006, CLIN EXP ALLERGY, V36, P629, DOI 10.1111/j.1365-2222.2006.02485.x; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x	9	34	35	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					746	747		10.1016/j.jaci.2006.11.011	http://dx.doi.org/10.1016/j.jaci.2006.11.011			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17270264				2022-12-18	WOS:000244925000032
J	Duong, M; Gauvreau, G; Watson, R; Obminski, G; Strinich, T; Evans, M; Howie, K; Killian, K; O'Byrne, PM				Duong, MyLinh; Gauvreau, Gail; Watson, Richard; Obminski, George; Strinich, Tara; Evans, Michelle; Howie, Karen; Killian, Kieran; O'Byrne, Paul M.			The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	102nd International Conference of the American-Thoracic-Society	MAY 19-24, 2006	San Diego, CA	Amer Thorac Soc		budesonidelformoterol; allergic asthma; reliever combination therapy use	LATE ASTHMATIC RESPONSE; AIRWAY RESPONSIVENESS; MAST-CELLS; SALMETEROL; THERAPY; INFLAMMATION; RELEASE; BECLOMETHASONE; DEXAMETHASONE; EOSINOPHILS	Background: The use of combination inhaled budesonide and formoterol as maintenance and reliever therapy significantly improves the risk and the time to exacerbations in asthma. Objectives: To explore the mechanisms underlying the effect of the reliever dose on exacerbations by examining the effect of combination therapy on the allergen challenge model when given after allergen exposure. Methods: In a randomized, double-blind crossover study, single doses of budesonide/formoterol (400/12 mu g), formoterol (12 mu g), budesonide (400 mu g), or placebo were administered during the acute bronchoconstriction response (early airway response) immediately after allergen inhalation in 15 patients with mild asthma. Allergen-induced late airway response (LAR), sputum inflammatory markers, airway hyperresponsiveness, and exhaled nitric oxide were measured. Results: All active treatments significantly attenuated the LAR, with budesonide/formoterol significantly better than its monocomponents (maximum FEV1 fall:placebo, [mean SEM] 21.2% +/- 3.1%; budesonide/formoterol, 4.2% +/- 1.4%; formoterol, 7.5% +/- 1.7%; budesonide, 10.4% +/- 1.6%). Allergen-induced change in methacholine PGO was significantly attenuated by budesonide/formoterol, but not by its monocomponents. Sputum cell counts and exhaled nitric oxide increased significantly after all allergen challenges, with no significant attenuation by any of the treatments. Therapy with combination and formoterol alone, but not budesonide, significantly reduced the early airway response. Conclusion: A single dose of budesonide/formoterol was superior to its monocomponents in attenuating the allergen-induced LAR and airway hyperresponsiveness. These effects may represent the contribution of the reliever dose to the budesonide/formoterol maintenance and reliever regimen. Clinical implications: The protective effect against allergic airway responses with a single reliever dose of budesonide/formoterol is predominantly related to greater functional antagonism of airway smooth muscles.	McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada	McMaster University	Duong, M (corresponding author), McMaster Univ, Med Ctr, 1200 Main St W,Room 3U-24, Hamilton, ON L8N 3Z5, Canada.	duongmy@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1999, Am J Respir Crit Care Med, V160, P2104; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Brusasco V, 2002, PULM PHARMACOL THER, V15, P399, DOI 10.1006/pupt.2002.0366; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1993, J ALLERGY CLIN IMMUN, V91, P1163, DOI 10.1016/0091-6749(93)90319-B; COHAN VL, 1989, AM REV RESPIR DIS, V140, P951, DOI 10.1164/ajrccm/140.4.951; Dente FL, 1999, THORAX, V54, P622, DOI 10.1136/thx.54.7.622; Gauvreau GM, 2000, CLIN EXP ALLERGY, V30, P1235; Gauvreau GM, 1999, J ALLERGY CLIN IMMUN, V104, P66, DOI 10.1016/S0091-6749(99)70115-6; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; Horvath G, 2006, EUR RESPIR J, V27, P172, DOI 10.1183/09031936.06.00048605; Juniper E, 1994, HISTAMINE METHACHOLI; Kay LJ, 2005, CHEM IMMUNOL ALLERGY, V87, P145, DOI 10.1159/000087641; Ketchell RI, 2002, EUR RESPIR J, V19, P611, DOI 10.1183/09031936.02.00332001; Kidney JC, 1997, J ALLERGY CLIN IMMUN, V100, P65, DOI 10.1016/S0091-6749(97)70196-9; Koopmans JG, 2005, J ALLERGY CLIN IMMUN, V116, P1007, DOI 10.1016/j.jaci.2005.08.016; Liu MC, 2001, J ALLERGY CLIN IMMUN, V108, P29; Lotvall J, 2004, CURR MED RES OPIN, V20, P1711, DOI 10.1185/030079904X3104; Nightingale JA, 1999, AM J RESP CRIT CARE, V159, P1786, DOI 10.1164/ajrccm.159.6.9809090; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PAGGIARO PL, 1994, AM J RESP CRIT CARE, V149, P1447, DOI 10.1164/ajrccm.149.6.8004297; PALMQVIST M, 1992, J ALLERGY CLIN IMMUN, V89, P844, DOI 10.1016/0091-6749(92)90440-D; PEDERSEN B, 1993, ALLERGY, V48, P377, DOI 10.1111/j.1398-9995.1993.tb02410.x; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Pizzichini MMM, 1996, EUR RESPIR J, V9, P449, DOI 10.1183/09031936.96.09030449; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; Scicchitano R, 2004, CURR MED RES OPIN, V20, P1403, DOI 10.1185/030079904X2051; Vogelmeier C, 2005, EUR RESPIR J, V26, P819, DOI 10.1183/09031936.05.00028305; WEERSINK EJM, 1994, AM J RESP CRIT CARE, V150, P1262, DOI 10.1164/ajrccm.150.5.7952550; WONG BJ, 1992, AM REV RESPIR DIS, V146, P1156, DOI 10.1164/ajrccm/146.5_Pt_1.1156	33	34	37	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					322	327		10.1016/j.jaci.2006.10.018	http://dx.doi.org/10.1016/j.jaci.2006.10.018			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	137YB	17141859	Bronze			2022-12-18	WOS:000244327900008
J	Langlois, A; Ferland, C; Tremblay, GM; Laviolette, M				Langlois, Anick; Ferland, Claudine; Tremblay, Guy M.; Laviolette, Michel			Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eosinophil; leukotrienes; matrix metalloproteinase 9; migration; montelukast; MK-0591; plasminogen activator inhibitor; urokinase plasminogen activator; urokinase plasminogen activator receptor	BASEMENT-MEMBRANE COMPONENTS; RECEPTOR ANTAGONIST; 5-OXO-6,8,11,14-EICOSATETRAENOIC ACID; CYSTEINYL LEUKOTRIENES; BONE-MARROW; TRANSMIGRATION; EXPRESSION; MIGRATION; GROWTH; BLOOD	Background: Migration of eosinophils into bronchial mucosa requires proteolysis. Montelukast, a cysteinyl leukotriene (CysLT) 1 receptor antagonist used in asthma treatment, decreases eosinophil infiltration into the asthmatic airways, suggesting that CysLTs modulate eosinophil protease activity. Objective: We sought to determine whether CysLTs and montelukast regulate eosinophil protease activity. Methods: Purified blood eosinophils were treated with or without montelukast; MK-0591, a 5-lipoxygenase-activating protein inhibitor; or leukotriene (LT) D-4. Migration assays through Matrigel were performed in the presence of 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE), a potent eosinophil chemotactic factor, or LTD4. Expression of molecules implicated in plasmin generation and matrix metalloproteinase (MMP) 9 release were also evaluated. Results: Montelukast and MK-0591 decreased eosinophil migration promoted by 5-oxo-ETE, whereas LTD4 failed to induce eosinophil migration. However, LTD4 significantly boosted the migration rate obtained with a suboptimal concentration of 5-oxo-ETE and partially reversed the inhibition obtained with MK-0591. Montelukast significantly reduced the maximal rate of activation of plasminogen into plasmin by eosinophils obtained with 5-oxo-ETE. 5-Oxo-ETE increased the number of eosinophils expressing urokinase plasminogen activator receptor and stimulated secretion of MMP-9. Montelukast, but neither MK-0591 nor LTD4, reduced the expression of urokinase plasminogen activator receptor and the secretion of MMP-9 and increased total cellular activity of urokinase plasminogen activator and the expression of plasminogen activator inhibitor 2 mRNA. C onclusion: Montelukast inhibits eosinophil protease activity in vitro through a mechanism that might be independent of its antagonist effect on CysLT 1 receptor. Clinical implications: This could partially explain montelukast's anti-inflammatory effect in asthma and eventually amplify to improve its therapeutic efficacy.	Univ Laval, Inst Univ Cardiol & Pneumol, Hop Laval, Ctr Rech,Unite Rech Pneumol, Ste Foy, PQ G1V 4G5, Canada	Laval University	Laviolette, M (corresponding author), Univ Laval, Inst Univ Cardiol & Pneumol, Hop Laval, Ctr Rech,Unite Rech Pneumol, 2725 Chemin St Foy, Ste Foy, PQ G1V 4G5, Canada.	Michel.Laviolette@med.ulaval.ca						Al-Ejeh F, 2004, EXP CELL RES, V297, P259, DOI 10.1016/j.yexcr.2004.03.030; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bandeira-Melo C, 2002, J EXP MED, V196, P841, DOI 10.1084/jem.20020516; Barnes N, 2005, J ALLERGY CLIN IMMUN, V115, P47, DOI 10.1016/j.jaci.2004.10.011; Bautz F, 2001, BLOOD, V97, P3433, DOI 10.1182/blood.V97.11.3433; Braccioni F, 2002, J ALLERGY CLIN IMMUN, V110, P96, DOI 10.1067/mai.2002.125000; Dallaire MJ, 2002, CLIN EXP ALLERGY, V32, P898, DOI 10.1046/j.1365-2222.2002.01377.x; Dreval V, 2005, CELL PHYSIOL BIOCHEM, V16, P119, DOI 10.1159/000087738; Dupre DJ, 2004, J PHARMACOL EXP THER, V309, P102, DOI 10.1124/jpet.103.059824; Ferland C, 2004, J IMMUNOL, V173, P4417, DOI 10.4049/jimmunol.173.7.4417; Ferland C, 2001, J LEUKOCYTE BIOL, V69, P772; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Fukushima C, 2005, INT ARCH ALLERGY IMM, V136, P165, DOI 10.1159/000083325; Guilbert M, 1999, AM J RESP CELL MOL, V21, P97, DOI 10.1165/ajrcmb.21.1.3517; Knorr B, 2000, J ALLERGY CLIN IMMUN, V106, pS171, DOI 10.1067/mai.2000.109424; LAVIOLETTE M, 1993, J IMMUNOL METHODS, V165, P253, DOI 10.1016/0022-1759(93)90351-7; Lee KS, 2004, J ALLERGY CLIN IMMUN, V114, P1093, DOI 10.1016/j.jaci.2004.07.039; Liu LX, 1999, J IMMUNOL, V163, P5649; Minoguchi K, 2002, CHEST, V121, P732, DOI 10.1378/chest.121.3.732; Mondino A, 2004, TRENDS IMMUNOL, V25, P450, DOI 10.1016/j.it.2004.06.004; Muro S, 2003, J ALLERGY CLIN IMMUN, V112, P768, DOI 10.1016/S0091-6749(03)01888-8; Nagata M, 2002, J ALLERGY CLIN IMMUN, V109, P676, DOI 10.1067/mai.2002.122841; Nakamura Y, 1998, THORAX, V53, P835, DOI 10.1136/thx.53.10.835; Nicosia S, 2001, PULM PHARMACOL THER, V14, P3, DOI 10.1006/pupt.2000.0262; Okada S, 1997, AM J RESP CELL MOL, V16, P455, DOI 10.1165/ajrcmb.16.4.9115757; Plesner T, 1997, STEM CELLS, V15, P398, DOI 10.1002/stem.150398; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; Powell WS, 2005, PROG LIPID RES, V44, P154, DOI 10.1016/j.plipres.2005.04.002; STAHLEBACKDAHL M, 1993, AM J PATHOL, V142, P995; Suzuki M, 2003, J ASTHMA, V40, P395, DOI 10.1081/JAS-120018709; Swartz JM, 2004, J LEUKOCYTE BIOL, V76, P812, DOI 10.1189/jlb.0304182; Virchow JC, 2001, CLIN EXP ALLERGY, V31, P836, DOI 10.1046/j.1365-2222.2001.01051.x; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wiehler S, 2004, BIOCHEM BIOPH RES CO, V315, P463, DOI 10.1016/j.bbrc.2004.01.078; Yang SY, 2005, J BIOL CHEM, V280, P27130, DOI 10.1074/jbc.M501625200	35	34	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					113	119		10.1016/j.jaci.2006.03.010	http://dx.doi.org/10.1016/j.jaci.2006.03.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815146	Bronze			2022-12-18	WOS:000239184800014
J	Cruz, AA; Naclerio, RM; Proud, D; Togias, A				Cruz, Alvaro A.; Naclerio, Robert M.; Proud, David; Togias, Alkis			Epithelial shedding is associated with nasal reactions to cold, dry air	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hyperosmolarity; hypertonicity; nasal allergen provocation; nasal lavage; nasal challenge	CROSS-COUNTRY SKIERS; INDUCED BRONCHOCONSTRICTION; INFLAMMATORY MEDIATORS; HYPEROSMOLAR SOLUTIONS; ALLERGIC INDIVIDUALS; ANTIGEN CHALLENGE; CELL INVOLVEMENT; RHINITIS; RELEASE; ACTIVATION	Background: Cold, dry air (CDA) can cause symptoms of rhinitis and obstructive airway responses. The pathophysiology of these reactions is not understood. One hypothesis is that the respiratory mucosa of individuals with CDA sensitivity cannot compensate for the loss of water that occurs on exposure to the stimulus, leading to epithelial damage. Objective: To test for an association between nasal reactions to CDA and the number of epithelial cells recovered in nasal fluids. Methods: Ten CDA-sensitive subjects received nasal provocations with CDA and warm, moist air; 10 CDA-insensitive subjects received CDA; and 10 subjects with allergic rhinitis received allergen and diluent challenges. Nasal lavage cytology was performed at baseline and after the challenge. Symptoms were recorded and histamine, [H-3]-N-alpha-tosyl-L-arginine methyl ester-esterase activity, tryptase, and albumin were assayed in nasal lavages. Results: A 6-fold increase in nasal lavage epithelial cells was found in the CDA-sensitive group after CDA (P <.01), but not after warm, moist air. No changes were observed in the CDA-insensitive group, or after allergen or diluent in allergic rhinitis. Conclusion: Epithelial cell shedding accompanies clinical responses to CDA in the human nose. This supports the hypothesis that the airway mucosa of CDA-sensitive individuals cannot compensate for the water loss that occurs under extreme conditions leading to epithelial damage. Clinical implications: A defect in mucosal water homeostasis may need to be considered in individuals who get excessive nasal symptoms when exposed to cold and dry, windy environment.	Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Univ Fed Bahia, Sch Med, Dept Med, Div Pulm, BR-41170290 Salvador, BA, Brazil; Univ Fed Bahia, Sch Med, Dept Med, Div Immunol, BR-41170290 Salvador, BA, Brazil; Univ Chicago, Dept Surg, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA; Univ Calgary, Dept Physiol & Biophys, Calgary, AB, Canada; Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Universidade Federal da Bahia; Universidade Federal da Bahia; University of Chicago; University of Calgary; Johns Hopkins University; Johns Hopkins University	Togias, A (corresponding author), Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Unit Off 7, Baltimore, MD 21224 USA.	atogias@jhmi.edu	Cruz, Alvaro A/I-1676-2012	Cruz, Alvaro A/0000-0002-7403-3871	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037163, R01AI008270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002714] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI37163, R01AI08270] Funding Source: Medline; NIDCD NIH HHS [R01DC02714] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ahern GP, 2005, J NEUROSCI, V25, P5109, DOI 10.1523/JNEUROSCI.0237-05.2005; Anderson SD, 2000, ASTHMA RHINITIS, P1449; Assanasen P, 2000, AM J RESP CRIT CARE, V162, P1031, DOI 10.1164/ajrccm.162.3.9912055; Assanasen P, 2001, AM J RESP CRIT CARE, V164, P1640, DOI 10.1164/ajrccm.164.9.2103086; Baraniuk JN, 1999, AM J RESP CRIT CARE, V160, P655, DOI 10.1164/ajrccm.160.2.9805081; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; Braat JPM, 1998, AM J RESP CRIT CARE, V157, P1748, DOI 10.1164/ajrccm.157.6.9701016; CRUZ AA, 1992, AM REV RESPIR DIS, V146, P340, DOI 10.1164/ajrccm/146.2.340; Davis MS, 2003, MED SCI SPORT EXER, V35, P608, DOI 10.1249/01.MSS.0000058660.88987.A0; EGGLESTON PA, 1987, AM REV RESPIR DIS, V135, P1043; Freed AN, 1999, J APPL PHYSIOL, V87, P1724, DOI 10.1152/jappl.1999.87.5.1724; FREED AN, 1987, J APPL PHYSIOL, V62, P574, DOI 10.1152/jappl.1987.62.2.574; FREED AN, 1994, AM J RESP CELL MOL, V11, P724, DOI 10.1165/ajrcmb.11.6.7946400; Hanes LS, 2006, CLIN EXP ALLERGY, V36, P26, DOI 10.1111/j.1365-2222.2006.02364.x; Heir T., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P134; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; IMANARI T, 1976, DHEW NIH76791 PUBL, P205; INGENITO EP, 1990, AM REV RESPIR DIS, V141, P1162, DOI 10.1164/ajrccm/141.5_Pt_1.1162; Koskela H, 2000, CLIN EXP ALLERGY, V30, P1627; Larsson L., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P124; LINDER A, 1988, CLIN ALLERGY, V18, P29, DOI 10.1111/j.1365-2222.1988.tb02840.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; Philip G, 1996, AM J RESP CRIT CARE, V153, P1222, DOI 10.1164/ajrccm.153.4.8616545; PHILIP G, 1993, AM REV RESPIR DIS, V148, P1616, DOI 10.1164/ajrccm/148.6_Pt_1.1616; PLISS LB, 1990, AM REV RESPIR DIS, V142, P73, DOI 10.1164/ajrccm/142.1.73; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; PROUD D, 1992, J ALLERGY CLIN IMMUN, V89, P1098, DOI 10.1016/0091-6749(92)90293-B; Sanico AM, 1999, J APPL PHYSIOL, V86, P1202, DOI 10.1152/jappl.1999.86.4.1202; Sanico AM, 2000, AM J RESP CRIT CARE, V161, P1631, DOI 10.1164/ajrccm.161.5.9908028; SILBER G, 1988, AM REV RESPIR DIS, V137, P606, DOI 10.1164/ajrccm/137.3.606; SILVERS WS, 1991, ANN ALLERGY, V67, P32; SIRAGANIAN R, 1974, ANAL BIOCHEM, V57, P283; Souques F, 1995, J ALLERGY CLIN IMMUN, V96, P980, DOI 10.1016/S0091-6749(95)70236-9; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; TOGIAS A, 1990, American Review of Respiratory Disease, V141, pA758; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; TOGIAS A, 1990, AM REV RESPIR DIS, V141, P1428, DOI 10.1164/ajrccm/141.6.1428; TOGIAS A, 1998, RHINITIS, P383; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; TOGIAS AG, 1986, AM REV RESPIR DIS, V133, P1133; TOGIAS AG, 1988, AM REV RESPIR DIS, V137, P625, DOI 10.1164/ajrccm/137.3.625; Weller PF, 1997, J ALLERGY CLIN IMMUN, V100, P283, DOI 10.1016/S0091-6749(97)70237-9	43	34	37	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1351	1358		10.1016/j.jaci.2006.01.054	http://dx.doi.org/10.1016/j.jaci.2006.01.054			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750997	Green Published			2022-12-18	WOS:000238332300022
J	Dahlke, I; Nott, DJ; Ruhno, J; Sewell, WA; Collins, AM				Dahlke, Isabell; Nott, David J.; Ruhno, John; Sewell, William A.; Collins, Andrew M.			Antigen selection in the IgE response of allergic and nonallergic individuals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; B cells; IgE antibodies; allergy; repertoire development; antigen selection	CLASS-SWITCH RECOMBINATION; SOMATIC HYPERMUTATION; ATOPIC-DERMATITIS; RHINITIS PATIENTS; GRASS-POLLEN; NASAL-MUCOSA; GENE USAGE; B-CELLS; IMMUNOGLOBULIN; PATIENT	Background: Affinity maturation within germinal centers should usually lead to an accumulation of replacement mutations in complementarity-determining regions (CDRs) of Ig genes as a result of antigen selection. A number of studies have suggested, but not statistically demonstrated, that antigen selection might not guide such an accumulation of replacement mutations in allergic IgE sequences. This has been suggested to reflect the nature of allergens themselves or of the allergic response. Objective: We sought to investigate the role of antigen selection in the evolution of the IgE response by mean of analysis of Ig sequences derived from both allergic and nonallergic individuals. Methods: IgE sequences were amplified from peripheral blood of allergic and nonallergic individuals by using seminested RTPCR. Additional IgE and IgG sequences were obtained from public databases. Analysis considered replacement mutations in the CDRs as a proportion of total mutations and compared IgE sequences with IgG sequences. Results: The nonallergic IgE sequences were significantly less mutated than both the allergic IgE (P < .001) and IgG (P < .01) sequences. There was a low proportion of replacement mutations in the CDRs of both nonallergic and allergic TgE sequences and a significantly increased proportion of such mutations in IgG sequences (P < .001). Conclusions: IgE antibodies in both nonallergic and allergic individuals appear to accumulate few somatic point mutations as a consequence of antigen selection. Clinical implications: Allergic and nonallergic IgE responses might often develop along a common pathway that is distinct from the conventional germinal center reaction through which the IgG response develops.	Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia; Univ New S Wales, Sch Math, Sydney, NSW 2052, Australia; Univ New S Wales, Garvan Inst Med Res, Sydney, NSW 2052, Australia; Univ New S Wales, St Vincents Clin Sch, Sydney, NSW 2052, Australia; Royal N Shore Hosp, Sydney, NSW, Australia	University of New South Wales Sydney; University of New South Wales Sydney; Garvan Institute of Medical Research; University of New South Wales Sydney; University of New South Wales Sydney; Royal North Shore Hospital; University of Sydney	Collins, AM (corresponding author), Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia.	a.collins@unsw.edu.au		Nott, David/0000-0002-5416-0005				Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; Brezinschek HP, 1997, J CLIN INVEST, V99, P2488, DOI 10.1172/JCI119433; CHANG B, 1994, IMMUNOL TODAY, V15, P367, DOI 10.1016/0167-5699(94)90175-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coker HA, 2005, J ALLERGY CLIN IMMUN, V116, P445, DOI 10.1016/j.jaci.2005.04.032; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; Collins AM, 2004, J IMMUNOL, V172, P340, DOI 10.4049/jimmunol.172.1.340; Collins AM, 1996, CLIN EXP ALLERGY, V26, P964, DOI 10.1111/j.1365-2222.1996.tb00634.x; Davies JM, 2004, CLIN EXP ALLERGY, V34, P429, DOI 10.1111/j.1365-2222.2004.01900.x; Diaz M, 2002, CURR OPIN IMMUNOL, V14, P235, DOI 10.1016/S0952-7915(02)00327-8; Dunn-Walters DK, 1998, IMMUNOLOGY, V95, P339; Edwards MR, 2002, J IMMUNOL, V168, P6305, DOI 10.4049/jimmunol.168.12.6305; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Hodgkin PD, 1997, IMMUNOL CELL BIOL, V75, P604, DOI 10.1038/icb.1997.95; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Jakobsen CG, 2004, MOL IMMUNOL, V41, P941, DOI 10.1016/j.molimm.2004.05.009; Janezic A, 1998, J ALLERGY CLIN IMMUN, V101, P391, DOI 10.1016/S0091-6749(98)70253-2; Kabat EA, 1991, SEQUENCES PROTEINS I; Lefranc MP, 2003, NUCLEIC ACIDS RES, V31, P307, DOI 10.1093/nar/gkg085; Lefranc MP, 2003, DEV COMP IMMUNOL, V27, P55, DOI 10.1016/S0145-305X(02)00039-3; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; SNOW RE, 1995, J IMMUNOL, V154, P5576; Snow RE, 1998, EUR J IMMUNOL, V28, P3354, DOI 10.1002/(SICI)1521-4141(199810)28:10<3354::AID-IMMU3354>3.0.CO;2-Z; Snow RE, 1997, EUR J IMMUNOL, V27, P162, DOI 10.1002/eji.1830270124; Snow RE, 1999, IMMUNOLOGY, V98, P646, DOI 10.1046/j.1365-2567.1999.00910.x; Steinberger P, 1996, J BIOL CHEM, V271, P10967, DOI 10.1074/jbc.271.18.10967; Svenson M, 2003, MOL IMMUNOL, V39, P603, DOI 10.1016/S0161-5890(02)00198-0; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99; Varade WS, 1998, IMMUNOLOGY, V93, P171	30	34	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1477	1483		10.1016/j.jaci.2005.12.1359	http://dx.doi.org/10.1016/j.jaci.2005.12.1359			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751016				2022-12-18	WOS:000238332300042
J	Scarupa, MD; Economides, A				Scarupa, MD; Economides, A			Bedbug bites masquerading as urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COMMON BEDBUG; ENVIRONMENT		Inst Asthma & Allergy, Chevy Chase, MD 20815 USA; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Scarupa, MD (corresponding author), Inst Asthma & Allergy, Chevy Chase, MD 20815 USA.							BURNETT JW, 1986, CUTIS, V38, P20; Fletcher CL, 2002, CLIN EXP DERMATOL, V27, P74, DOI 10.1046/j.0307-6938.2001.00967.x; Hwang SW, 2005, EMERG INFECT DIS, V11, P533, DOI 10.3201/eid1104.041126; KUMAR S, 1995, INDIAN J MED RES, V102, P20; PARSONS D J, 1955, Ohio State Med J, V51, P669; Paul J, 2000, BRIT MED J, V320, P1141, DOI 10.1136/bmj.320.7242.1141; Ryan Nathan, 2004, N S W Public Health Bull, V15, P215; Silverman AL, 2001, AM J GASTROENTEROL, V96, P2194, DOI 10.1111/j.1572-0241.2001.03955.x; Ter Poorten MC, 2005, PEDIATR DERMATOL, V22, P183, DOI 10.1111/j.1525-1470.2005.22301.x; Thomas I, 2004, INT J DERMATOL, V43, P430, DOI 10.1111/j.1365-4632.2004.02115.x	10	34	37	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1508	1509		10.1016/j.jaci.2006.03.034	http://dx.doi.org/10.1016/j.jaci.2006.03.034			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751024				2022-12-18	WOS:000238332300051
J	Yalcindag, A; He, R; Laouini, D; Alenius, H; Carroll, M; Oettgen, HC; Geha, RS				Yalcindag, Ali; He, Rui; Laouini, Dhafer; Alenius, Harri; Carroll, Michael; Oettgen, Hans C.; Geha, Raif S.			The complement component C3 plays a critical role in both T(H)1 and T(H)2 responses to antigen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; complement; mouse; T(H)1; T(H)2	T-CELLS EXPRESS; MURINE MODEL; AIRWAY HYPERRESPONSIVENESS; PERITONEAL-MACROPHAGES; ALLERGIC DERMATITIS; ADAPTIVE IMMUNITY; TH2 RESPONSE; ACTIVATION; RECEPTOR; C5A	Background: Complement component C3 is synthesized by keratinocytes and is activated after skin injury. C3 is also synthesized by peritoneal macrophages, which are activated by the adjyvant alum. Objective: We sought to investigate the role of C3 in inciting allergic skin Inflammation and systemic immune responses after epicutaneous sensitization or intraperitoneal sensitization with antigen. Methods: C3-deficient (C3(-/-)) mice and wild-type (WT) control animals were subjected to epicutaneous sensitization with the antigen ovalbumin (OVA) on shaved and tape-stripped skin or intraperitoneal immunization with OVA in alum. Results: Skin Infiltration by eosinophils and expression of mRNA encoding the T(H)2 cytokines IL-4 and IL-5 in OVA-sensitized skin sites was impaired in C3(-/-) mice. Splenocytes from epicutaneously sensitized C3(-/-) mice secreted less IL-4, IL-5, IL-13, and IFN-gamma in response to OVA stimulation than splenocytes from WT control animals. The defect in cytokine secretion by splenocytes was also observed after intraperitoneal immunization of C3(-/-) mice. C3(-/-) mice had impaired IgG1, IgG2a, and IgE antibody responses after both epicutaneous and intraperitoneal immunization. The defect in cytokine secretion of C3(-/-) mice was not due to defective proliferation to antigen, was not observed after anti-CD3 stimulation, and was corrected by the addition of purified C3 protein. Conclusion: These results suggest that C3 plays an important role in both the T(H)1 and T(H)2 response to antigen in vivo. Clinical implications: The complement pathway might be a potential target in the therapy of allergic diseases.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Laouini, Dhafer/Q-6535-2019; Yalcindag, Ali/GLU-9728-2022; He, Rui/P-7302-2019	Laouini, Dhafer/0000-0003-1222-4880; Yalcindag, Ali/0000-0002-5752-0360; He, Rui/0000-0001-5288-9786; Alenius, Harri/0000-0003-0106-8923	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053570, R01AI039246, R01AI054471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417] Funding Source: NIH RePORTER; NIAID NIH HHS [AI054471, AI039246, AI053570] Funding Source: Medline; NIAMS NIH HHS [AR47417] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Applequist SE, 2000, J IMMUNOL, V165, P2398, DOI 10.4049/jimmunol.165.5.2398; BEUSCHER HU, 1986, IMMUNOLOGY, V58, P545; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CHEN A, 1994, J IMMUNOL, V153, P1430; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Drouin SM, 2001, J IMMUNOL, V167, P4141, DOI 10.4049/jimmunol.167.8.4141; Fischer MB, 1996, J IMMUNOL, V157, P549; Fischer WH, 1997, J IMMUNOL, V159, P4279; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hammerberg C, 1998, J EXP MED, V187, P1133, DOI 10.1084/jem.187.7.1133; Hasegawa K, 2004, HUM GENET, V115, P295, DOI 10.1007/s00439-004-1157-z; HETLAND G, 1987, ACTA PATH MICRO IM C, V95, P15; Horie S, 1997, INTERNAL MED, V36, P179, DOI 10.2169/internalmedicine.36.179; Kawamoto S, 2004, J CLIN INVEST, V114, P399, DOI 10.1172/jci200419082; Kerekes K, 1998, INT IMMUNOL, V10, P1923, DOI 10.1093/intimm/10.12.1923; Kim AHJ, 2004, J IMMUNOL, V173, P2524, DOI 10.4049/jimmunol.173.4.2524; Kopf M, 2002, NAT MED, V8, P373, DOI 10.1038/nm0402-373; La Flamme AC, 2003, J IMMUNOL, V170, P470, DOI 10.4049/jimmunol.170.1.470; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Liew FY, 2002, NAT REV IMMUNOL, V2, P55, DOI 10.1038/nri705; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Mochizuki M, 1999, INT ARCH ALLERGY IMM, V120, P19, DOI 10.1159/000053587; Morgan BP, 2005, IMMUNOL LETT, V97, P171, DOI 10.1016/j.imlet.2004.11.010; Nataf S, 1999, J IMMUNOL, V162, P4018; OHKOHCHI K, 1986, J INVEST DERMATOL, V87, P65, DOI 10.1111/1523-1747.ep12523572; Park JW, 2004, AM J RESP CRIT CARE, V169, P726, DOI 10.1164/rccm.200307-1042OC; REYMILLET CA, 1994, MOL IMMUNOL, V31, P1321, DOI 10.1016/0161-5890(94)90050-7; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Tengvall P, 1998, BIOMATERIALS, V19, P935, DOI 10.1016/S0142-9612(98)00005-2; Thornton BP, 1996, CLIN EXP IMMUNOL, V104, P531, DOI 10.1046/j.1365-2249.1996.57761.x; Tsuji RF, 2000, J IMMUNOL, V165, P1588, DOI 10.4049/jimmunol.165.3.1588; Wills-Karp M, 2005, CURR ALLERGY ASTHM R, V5, P362, DOI 10.1007/s11882-005-0007-y; Yoshida Y, 1998, J IMMUNOL, V161, P5873; ZIMMER B, 1982, EUR J IMMUNOL, V12, P426, DOI 10.1002/eji.1830120513	38	34	34	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1455	1461		10.1016/j.jaci.2006.01.048	http://dx.doi.org/10.1016/j.jaci.2006.01.048			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751013				2022-12-18	WOS:000238332300039
J	Lamoureux, J; Stankova, J; Rola-Pleszczynski, M				Lamoureux, J; Stankova, J; Rola-Pleszczynski, M			Leukotriene D-4 enhances immunoglobulin production in CD40-activated human B lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cells; lipid mediators; antibodies; cell surface molecules; receptor; IL-4	NF-KAPPA-B; MOLECULAR-CLONING; CYSTEINYL LEUKOTRIENES; RECEPTOR EXPRESSION; CELL PROLIFERATION; CYSLT(2) RECEPTOR; CD40 RECEPTOR; SMOOTH-MUSCLE; MAST-CELLS; INDUCTION	Background: Cysteinyl-leukotrienes (cysLTs) are lipid mediators recognized for their role in asthma and allergic inflammation. CysLT(1), one of the receptors for cysLTs, is expressed, among others, in bronchial smooth muscle cells, phagocytes, and B lymphocytes. The potential role of CysLT(1) in B lymphocytes remains unexplored. Objective: We examined the modulation of expression and function of CysLT(1) in human B lymphocytes. Methods: Human B lymphocytes were purified from peripheral blood and analyzed by means of RT-PCR and flow cytometry, after culture with IL-4 and anti-CD40 antibody or CD154-transfected fibroblasts. Functional responses to leukotriene (LT) D-4 in terms of cytosolic calcium flux, proliferation, and immunoglobulin production were also examined. Results: B lymphocytes expressed CysLT1 at both the mRNA and protein levels. Two-fold to 3-fold enhancement of CysLT(1) expression was observed after B-cell exposure to a combination of activating anti-CD40 antibody and IL-4. The expression of CysLT1 was also enhanced when B lymphocytes were cocultured with CD154-transfected fibroblasts in the presence of IL-4. Moreover, IL-4 and CD40-activated B lymphocytes showed an increased responsiveness to LTD4 in terms of cytosolic calcium flux, which was totally prevented by the selective CysLT(1) antagonist montelukast. Stimulation of IL-4 and CD40-activated B lymphocytes with picomolar concentrations of LTD4 induced mature epsilon transcripts and upregulated IgE and IgG production 2-fold to 3-fold. Conclusion: We have demonstrated that expression of CysLT(1), can be upregulated in B lymphocytes after stimulation with CD154, with consequent increased responsiveness of the cells to LTD4 in terms of immunoglobulin production. Clinical implications: This study provides evidence that cysLTs generated during allergic reactions can affect B-cell function and enhance IgE and IgG production, which may further contribute to the allergic process.	Univ Sherbrooke, Fac Med, Dept Pediat, Div Immunol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Rola-Pleszczynski, M (corresponding author), Univ Sherbrooke, Fac Med, Dept Pediat, Div Immunol, Sherbrooke, PQ J1H 5N4, Canada.	marek.rola-pleszczynski@usherbrooke.ca						Amrani Y, 2001, AM J RESP CRIT CARE, V164, P2098, DOI 10.1164/ajrccm.164.11.2108005; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Bishop GA, 2003, CYTOKINE GROWTH F R, V14, P297, DOI 10.1016/S1359-6101(03)00024-8; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Cerutti A, 1998, J IMMUNOL, V160, P2145; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Dabak DO, 2004, ANAT HISTOL EMBRYOL, V33, P5, DOI 10.1111/j.1439-0264.2004.00500.x; DUGAS B, 1990, J IMMUNOL, V145, P3406; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; Figueroa DJ, 2003, CLIN EXP ALLERGY, V33, P1380, DOI 10.1046/j.1365-2222.2003.01786.x; FLORESROMO L, 1989, IMMUNOLOGY, V66, P228; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; GRONERT K, 2001, AM J RESP CRIT CARE, V164, P2098; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; Hui YQ, 2001, J BIOL CHEM, V276, P47489, DOI 10.1074/jbc.M107556200; HUO L, 1995, J IMMUNOL, V154, P3300; Jabara HH, 1998, BLOOD, V92, P2435, DOI 10.1182/blood.V92.7.2435.2435_2435_2440; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Karras JG, 1997, J IMMUNOL, V159, P4350; LABAT C, 1992, J PHARMACOL EXP THER, V263, P800; LAW CL, 1994, CURR OPIN IMMUNOL, V6, P238, DOI 10.1016/0952-7915(94)90097-3; LEE TH, 1984, P NATL ACAD SCI-BIOL, V81, P4922, DOI 10.1073/pnas.81.15.4922; Lemiere C, 2004, CLIN EXP ALLERGY, V34, P1684, DOI 10.1111/j.1365-2222.2004.02102.x; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2001, P NATL ACAD SCI USA, V98, P2256, DOI 10.1073/pnas.041624398; Martin V, 2001, BIOCHEM PHARMACOL, V62, P1193, DOI 10.1016/S0006-2952(01)00774-2; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; Neron S, 1996, IMMUNOL INVEST, V25, P79; Nicosia S, 2001, PULM PHARMACOL THER, V14, P3, DOI 10.1006/pupt.2000.0262; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; Okunishi K, 2004, J IMMUNOL, V173, P6393, DOI 10.4049/jimmunol.173.10.6393; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; ROLFMAN CM, 1987, EUR J IMMUNOL, V17, P701; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; SMINIA T, 1989, CRIT REV IMMUNOL, V9, P119; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140; Takeda K, 1997, J MOL MED-JMM, V75, P317, DOI 10.1007/s001090050117; Thivierge M, 2000, J IMMUNOL, V165, P5221, DOI 10.4049/jimmunol.165.9.5221; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; YAMAOKA KA, 1989, J IMMUNOL, V143, P1996; YAMAOKA KA, 1994, CELL IMMUNOL, V156, P124, DOI 10.1006/cimm.1994.1158; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101	52	34	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					924	930		10.1016/j.jaci.2005.12.1329	http://dx.doi.org/10.1016/j.jaci.2005.12.1329			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630953				2022-12-18	WOS:000236862800031
J	Bergeron, C; Fukakusa, M; Olivenstein, R; Lemiere, C; Shannon, J; Ernst, P; Martin, JG; Hamid, Q				Bergeron, C; Fukakusa, M; Olivenstein, R; Lemiere, C; Shannon, J; Ernst, P; Martin, JG; Hamid, Q			Increased glucocorticoid receptor-beta expression, but not decreased histone deacetylase 2, in severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CORTICOSTEROIDS; AIRWAYS; CELLS		McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Div Resp, Montreal, PQ H3A 2T5, Canada; Univ Montreal, Hop Sacre Coeur, Montreal, PQ, Canada	McGill University; McGill University; Universite de Montreal	Bergeron, C (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.			Martin, James/0000-0001-7574-5363				[Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V106, P479; Fukakusa M, 2005, J ALLERGY CLIN IMMUN, V115, P280, DOI 10.1016/j.jaci.2004.10.036; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; Strickland I, 2001, J EXP MED, V193, P585, DOI 10.1084/jem.193.5.585; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; 1987, AM REV RESP DIS, V136, P225	10	34	36	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					703	705		10.1016/j.jaci.2005.12.1344	http://dx.doi.org/10.1016/j.jaci.2005.12.1344			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522474	Bronze			2022-12-18	WOS:000236263100030
J	Su, YC; Rolph, MS; Cooley, MA; Sewell, WA				Su, YC; Rolph, MS; Cooley, MA; Sewell, WA			Cyclophosphamide augments inflammation by reducing immunosuppression in a mouse model of allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cyclophosphamide; eosinophils; IgE; IL-5; regulatory T cells; cytotoxic T lymphocyte-associated antigen 4; FoxP3; IL-10; TGF-beta	REGULATORY T-CELLS; ESTABLISHED TUMORS; ASTHMA; EOSINOPHILIA; MICE; HYPERREACTIVITY; LYMPHOCYTES; SUPPRESSION; MECHANISM; RESPONSES	Background: Allergic asthma is a T(H)2 cell-driven immunological disease, characterized by eosinophilic inflammation. The cytotoxic agent cyclophosphamide paradoxically augments several immune responses. Objective: We studied the proposal that cyclophosphamide may aggravate airway inflammation in allergic mice, and these features might result from the loss of regulatory T cells. Methods: BALB/c mice were immunized with ovalbumin on days 0 and 14 and challenged with aerosolized ovalbumin from days 21 to 27. Some mice also received cyclophosphamide on days -2 and 12. Results: In the lungs of cyclophosphamide-treated animals, pronounced worsening of inflammatory features was noted, including increased eosinophil infiltration, epithelial thickness, mucus occlusion, and eosinophil numbers in bronchoalveolar lavage fluid. There was also increased total and ovalbumin-specific serum IgE, increased IL-4 and IL-5 secretion by peritracheal lymph node cells, and reduced lung mRNA expression of IL-10 and TGF-beta in animals treated with cyclophosphamide. The expression of FoxP3, a marker of regulatory T cells, was significantly reduced in lymphoid organs after the second injection of cyclophosphamide, and in the lung tissue after allergen challenge in cyclophosphamide-treated mice. Lung IL-10(+)CD4(+) T cells and cytotoxic T lymphocyte-associated antigen 4(+)CD4(+) T cells were reduced after allergen challenge in cyclophosphamide-treated mice. Conclusion: Cyclophosphamide worsened features of allergic pulmonary inflammation in this model, in association with increased production of IgE and T(H)2 cytokines. The reduced expression of FoxP3 and immunosuppressive cytokines by cyclophosphamide is consistent with the possibility that toxicity to regulatory T cells may contribute to the increased inflammation.	St Vincents Hosp, Garvan Inst Med Res, Arthrit & Inflammat Res Program, Darlinghurst, NSW 2010, Australia; Cooperat Res Ctr Asthma, Sydney, NSW, Australia; Univ New S Wales, Fac Sci, Sch Biotechnol & Biomol Sci, Kensington, NSW 2033, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Sewell, WA (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Arthrit & Inflammat Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	w.sewell@garvan.org.au						Ablamunits V, 1998, J AUTOIMMUN, V11, P73, DOI 10.1006/jaut.1997.0177; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; CHIORAZZI N, 1976, J IMMUNOL, V117, P1629; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Denzler KL, 2000, J IMMUNOL, V165, P5509, DOI 10.4049/jimmunol.165.10.5509; Fehervari Z, 2004, J CLIN INVEST, V114, P1209, DOI 10.1172/JCI200434495; Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jaffar Z, 2004, J IMMUNOL, V172, P3842, DOI 10.4049/jimmunol.172.6.3842; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Le HN, 2001, J IMMUNOL, V167, P6765, DOI 10.4049/jimmunol.167.12.6765; Levings MK, 2005, BLOOD, V105, P1162, DOI 10.1182/blood-2004-03-1211; Lutsiak MEC, 2005, BLOOD, V105, P2862, DOI 10.1182/blood-2004-06-2410; MU HH, 1993, IMMUNOLOGY, V79, P452; Overbergh L, 2003, J Biomol Tech, V14, P33; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SCHWARTZ A, 1978, J IMMUNOL, V121, P1573; THOMSON AW, 1987, IMMUNOLOGY, V60, P383; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; Weigel S, 2000, PEDIATR HEMAT ONCOL, V17, P659, DOI 10.1080/08880010050211367; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Yang M, 2003, J ALLERGY CLIN IMMUN, V112, P935, DOI 10.1016/j.jaci.2003.08.010; YASUNAMI R, 1988, EUR J IMMUNOL, V18, P481, DOI 10.1002/eji.1830180325; ZHANG ZL, 1993, AUTOIMMUNITY, V15, P1, DOI 10.3109/08916939309004833; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	33	34	41	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					635	641		10.1016/j.jaci.2005.10.042	http://dx.doi.org/10.1016/j.jaci.2005.10.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522464				2022-12-18	WOS:000236263100020
J	Weidinger, S; Mayerhofer, A; Raemsch, R; Ring, J; Kohn, FM				Weidinger, S; Mayerhofer, A; Raemsch, R; Ring, J; Kohn, FM			Prostate-specific antigen as allergen in human seminal plasma allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FLUID		Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-80802 Munich, Germany; GSF Natl Res Ctr Environm, Div Environm Dermatol & Allergy, Munich, Germany; Hlth Tech Univ, Munich, Germany; Univ Munich, Anat Inst, Munich, Germany	Technical University of Munich; Technical University of Munich; University of Munich	Weidinger, S (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.		Weidinger, Stephan/C-8461-2011; Ring, Johannes/GLN-4341-2022	Weidinger, Stephan/0000-0003-3944-252X; Ring, Johannes/0000-0001-8236-3152; Mayerhofer, Artur/0000-0002-9388-4639				Balk SP, 2003, J CLIN ONCOL, V21, P383, DOI 10.1200/JCO.2003.02.083; Eberlein-Konig B, 2004, J INVEST ALLERG CLIN, V14, P10; Frungieri MB, 2002, P NATL ACAD SCI USA, V99, P15072, DOI 10.1073/pnas.232422999; *JOINT TASK FORC P, 2005, J ALLERGY CLIN IM S2, V0115, pS 483; MATLOFF SM, 1993, J ALLERGY CLIN IMMUN, V91, P1230, DOI 10.1016/0091-6749(93)90328-D; OHMAN JL, 1990, J ALLERGY CLIN IMMUN, V85, P103, DOI 10.1016/0091-6749(90)90230-2; Resnick DJ, 2004, AM J REPROD IMMUNOL, V52, P42, DOI 10.1111/j.1600-0897.2004.00180.x; SIRAGANIAN RP, 1975, CLIN IMMUNOL IMMUNOP, V4, P59, DOI 10.1016/0090-1229(75)90040-9; Tomitaka A, 2002, ALLERGY, V57, P1081, DOI 10.1034/j.1398-9995.2002.23836_2.x; Weidinger S, 2005, CHEM IMMUNOL ALLERGY, V88, P128, DOI 10.1159/000087830	10	34	35	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					213	215		10.1016/j.jaci.2005.09.040	http://dx.doi.org/10.1016/j.jaci.2005.09.040			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387609				2022-12-18	WOS:000235687100035
J	Norris, V; Choong, L; Tran, D; Corden, Z; Boyce, M; Arshad, H; Holgate, S; O'Connor, B; Millet, S; Miller, B; Rohatagi, S; Kirkesseli, S				Norris, V; Choong, L; Tran, D; Corden, Z; Boyce, M; Arshad, H; Holgate, S; O'Connor, B; Millet, S; Miller, B; Rohatagi, S; Kirkesseli, S			Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						very late antigen (VLA-4, alpha 4 beta 1) antagonist; inhaled allergen challenge; late asthmatic response; eosinophil	AIRWAY HYPERRESPONSIVENESS; SMALL-MOLECULE; INDUCED SPUTUM; EOSINOPHILS; CHALLENGE; INFLAMMATION; RESPONSES; ADHESION; ANTIGEN; CELL	Background: Very late antigen (VLA-4) antagonists have been proposed as potential therapies for diseases in which cell recruitment and accumulation are causative. Asthma, which is characterized by airway inflammation involving the accumulation of eosinophils and mononuclear cells, is one such disease. Objective: We sought to assess the effect of IVL745, a VLA-4 antagonist, on the early and late asthmatic response (LAR) and on markers of airway inflammation after allergen inhalation. Methods: The study was of a placebo-controlled, double-blind, randomized, 2-way crossover design. Sixteen subjects with mild-to-moderate asthma controlled with short-acting P2-agonists only and with a LAR to inhaled allergen participated in the study. At one treatment period they took 20 mg of IVL745 and one treatment period placebo. Both treatments were taken twice daily for 7 days, with a single dose on day 8. Treatments were separated by a washout period of at least 2 weeks. On day 7 of each treatment period, sputum was induced and collected, and exhaled nitric oxide (NO) was measured. On day 8, an inhaled bolus allergen challenge was performed, and blood was taken for pharmacokinetics. On day 9, exhaled NO was measured, and a methacholine challenge was done. On day 10, sputum was induced and collected. Adverse events, peak expiratory flow (PEF), use of short-acting beta(2)-agonists, and asthma symptoms were recorded daily throughout the study. Results: There was no statistically significant difference between IVL745 and placebo in the effect on the LAR after allergen challenge, as measured by the area under the curve of the percentage change in FEV1 from the prechallenge baseline (mean [SEM], -81.99 [18.80] after IVL745 and -72.58 [21.29] after placebo; 95% CI of difference, -36 to 16.8; P =.46) or by the maximum percentage change from the prechallenge baseline (mean [SEM], -23.44 [4.73] after IVL745 and -21.30 [5.17] after placebo; 95% Cl of difference, -11 to 6.29; P = .60). There was a statistically significant decrease in the percentage of eosinophils in sputum on day 7 of treatment with IVL745 (mean [SEM], 7.32 [1.46]) compared with placebo (mean [SEM], 15.00 [1.92]; 95% CI of difference, -13 to -1.2; P = .02). There was no statistically significant difference between IVL745 and placebo with respect to the early asthmatic response, methacholine hyperresponsiveness, exhaled NO, postallergen sputum, symptoms, inhaled beta(2)-agonist use, or PEF. Conclusion: In patients with mild-to-moderate atopic asthma, IVL745 did not affect the early and late response to inhaled allergen or markers of airway inflammation, except for a modest reduction in sputum eosinophils.	Cent Middlesex Hosp, London NW10 7NS, England; Southampton Gen Hosp, Southampton SO9 4XY, Hants, England; Guys Kings & St Thomas Sch Med, London, England; Aventis Pharmaceut, Bridgewater, MA USA	Imperial College London; University of Southampton; University of London; King's College London; Sanofi-Aventis	Norris, V (corresponding author), Cent Middlesex Hosp, Acton Lane, London NW10 7NS, England.	vnorris@hmrlondon.com		Boyce, Malcolm/0000-0001-8807-612X				Abraham WM, 1997, AM J RESP CRIT CARE, V156, P696, DOI 10.1164/ajrccm.156.3.9609039; ANWAR ARE, 1994, IMMUNOLOGY, V82, P222; ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P3, DOI 10.1016/j.jaci.2003.09.046; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CRIMI E, 1989, J ALLERGY CLIN IMMUN, V83, P985, DOI 10.1016/0091-6749(89)90116-4; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; ELIAS MJ, 2003, CURR OPIN INVESTIG D, V4, P1354; FAHY JV, 1994, J ALLERGY CLIN IMMUN, V93, P1031, DOI 10.1016/S0091-6749(94)70052-4; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P883; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; Koo GC, 2003, AM J RESP CRIT CARE, V167, P1400, DOI 10.1164/rccm.200207-696OC; KUMFIL T, 2002, NERVENZRZT, V73, P552; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lin KC, 1998, CURR OPIN CHEM BIOL, V2, P453, DOI 10.1016/S1367-5931(98)80120-8; Lobb R R, 1999, Expert Opin Investig Drugs, V8, P935, DOI 10.1517/13543784.8.7.935; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; Rohatagi S, 2004, J CLIN PHARMACOL, V44, P348, DOI 10.1177/0091270004263465; Rohatagi Shashank, 2004, Am J Ther, V11, P103, DOI 10.1097/00045391-200403000-00005; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; Taylor DA, 2000, CLIN EXP ALLERGY, V30, P56; TWENTYMAN OP, 1990, LANCET, V336, P338; Ulbrich H, 2003, TRENDS PHARMACOL SCI, V24, P640, DOI 10.1016/j.tips.2003.10.004	29	34	37	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					761	767		10.1016/j.jaci.2005.04.045	http://dx.doi.org/10.1016/j.jaci.2005.04.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210048				2022-12-18	WOS:000235686600007
J	Iikura, M; Suzukawa, M; Yamaguchi, M; Sekiya, T; Komiya, A; Yoshimura-Uchiyama, C; Nagase, H; Matsushima, K; Yamamoto, K; Hirai, K				Iikura, M; Suzukawa, M; Yamaguchi, M; Sekiya, T; Komiya, A; Yoshimura-Uchiyama, C; Nagase, H; Matsushima, K; Yamamoto, K; Hirai, K			5-Lipoxygenase products regulate basophil functions: 5-Oxo-ETE elicits migration, and leukotriene B-4 induces degranulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; leukotriene D-4; leukotriene B-4; 5-oxo-6,8,11,14-eicosatetraenoic acid; receptor; CD11b; chemotaxis; degranulation; Ca2+ influx; human	COLONY-STIMULATING FACTOR; LATE-PHASE RESPONSE; HUMAN MAST-CELLS; 5-OXO-6,8,11,14-EICOSATETRAENOIC ACID; CYSTEINYL-LEUKOTRIENES; HISTAMINE-RELEASE; HUMAN EOSINOPHILS; INTERNATIONAL UNION; POTENT STIMULATOR; MEDIATOR RELEASE	Background: 5-Lipoxygenase (5-LO) products have been strongly implicated in the pathogenesis of allergic diseases. In addition to their physiologic effects on residential cells, 5-LO products are capable of stimulating various eosinophil functions. However, little is known regarding the effects of 5-LO products on basophil functions. Objective: This study was designed to elucidate the effects of the main 5-LO products (ie, leukotriene [LT] B-4, LTD4, and 5-oxo-6,8,11,14-eicosatetraenoic acid [5-oxo-ETE]), as well as their receptor expression on human basophils. Methods: We studied the effects of 5-LO products on Ca2+ mobilization, migration, CD11b expression, and degranulation of human basophils. Expression of the receptors for LTC4/D-4/ E-4 (cysteinyl leukotriene 1 [CysLT(1)] and CysLT(2)), LTB4 (BLT1 and BLT2), and 5-oxo-ETE (oxoeicosanoid [OXE]) was assessed by means of real-time PCR and flow cytometry. Results: At the mRNA level, basophils strongly expressed OXE and predominantly expressed CysLT(1) and BLT2. The expression level of OXE mRNA in basophils was approximately 20-fold higher than in neutrophils and similar to that in eosinophils. At the protein level, basopbils expressed CysLT(1), CysLT(2), BLT1, and OXE, but not BLT2. All products elicited a transient increase of cytosolic calcium, with the order of magnitude being LTB4 > 5-oxo-ETE > LTD4. 5-Oxo-ETE induced a strong basophil migratory response that was almost equivalent to that of prostaglandin D-2. LTB4 elicited significant degranulation of IL-3-primed basophils. In contrast, no functional significance was observed for LTD4. Conclusion: Among 5-LO products, 5-oxo-FTE induces a potent basophil migratory response, and LTB4 elicits degranulation under certain conditions. Our results strongly suggest that 5-oxo-ETE might afford opportunities for therapeutic targeting in allergic inflammation.	Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Hirai, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	hiraiko-tky@umin.ac.jp	Nagase, Hiroyuki/Y-4367-2019	Nagase, Hiroyuki/0000-0002-0296-5901; Suzukawa, Maho/0000-0002-2265-1950; IIKURA, MOTOYASU/0000-0001-5148-0612				BISCHOFF SC, 1990, P NATL ACAD SCI USA, V87, P6813, DOI 10.1073/pnas.87.17.6813; BOCHNER BS, 1990, J IMMUNOL, V145, P1832; BOCHNER BS, 1988, J CLIN INVEST, V81, P1355, DOI 10.1172/JCI113463; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Brink C, 2004, PHARMACOL REV, V56, P149, DOI 10.1124/pr.56.1.4; BRUNNER T, 1991, J IMMUNOL, V147, P237; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; Eum SY, 2003, AM J RESP CELL MOL, V28, P25, DOI 10.1165/rcmb.4532; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hirai K, 1997, CRIT REV IMMUNOL, V17, P325, DOI 10.1615/CritRevImmunol.v17.i3-4.40; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Iikura M, 1998, J IMMUNOL, V161, P1510; Iikura M, 2001, J LEUKOCYTE BIOL, V70, P113; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; Jones CE, 2003, MOL PHARMACOL, V63, P471, DOI 10.1124/mol.63.3.471; Lindsay MA, 1998, J LEUKOCYTE BIOL, V64, P555, DOI 10.1002/jlb.64.4.555; MARONE G, 1979, J IMMUNOL, V123, P1669; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; Minoguchi K, 2002, CHEST, V121, P732, DOI 10.1378/chest.121.3.732; Muro S, 2003, J ALLERGY CLIN IMMUN, V112, P768, DOI 10.1016/S0091-6749(03)01888-8; Nagase H, 2003, J IMMUNOL, V171, P3977, DOI 10.4049/jimmunol.171.8.3977; Nagata M, 2002, J ALLERGY CLIN IMMUN, V109, P676, DOI 10.1067/mai.2002.122841; OFLaherty JT, 1996, J IMMUNOL, V157, P336; Ohshima N, 2002, INT ARCH ALLERGY IMM, V129, P67, DOI 10.1159/000065175; PETERS SP, 1981, NATURE, V292, P455, DOI 10.1038/292455a0; PETERS SP, 1984, J PHARMACOL EXP THER, V228, P400; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; POWELL WS, 1995, J IMMUNOL, V154, P4123; SCHROEDER JT, 1995, ALLERGY, V50, P463, DOI 10.1111/j.1398-9995.1995.tb01180.x; SCHWENK U, 1995, J BIOL CHEM, V270, P15029, DOI 10.1074/jbc.270.25.15029; Stamatiou P, 1998, J CLIN INVEST, V102, P2165, DOI 10.1172/JCI1995; Stamatiou PB, 2004, J BIOL CHEM, V279, P28159, DOI 10.1074/jbc.M401537200; TANIMOTO Y, 1992, CLIN EXP ALLERGY, V22, P1020, DOI 10.1111/j.1365-2222.1992.tb03031.x; Ying S, 1999, J IMMUNOL, V163, P3976; Yoshimura-Uchiyama C, 2004, CLIN EXP ALLERGY, V34, P1283, DOI 10.1111/j.1365-2222.2004.02027.x; Yoshimura-Uchiyama C, 2003, BIOCHEM BIOPH RES CO, V302, P201, DOI 10.1016/S0006-291X(03)00153-0	40	34	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					578	585		10.1016/j.jaci.2005.04.029	http://dx.doi.org/10.1016/j.jaci.2005.04.029			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159627				2022-12-18	WOS:000235686500017
J	Pott, GB; Palmer, BE; Sullivan, AK; Silviera, L; Maier, LA; Newman, LS; Kotzin, BL; Fontenot, AP				Pott, GB; Palmer, BE; Sullivan, AK; Silviera, L; Maier, LA; Newman, LS; Kotzin, BL; Fontenot, AP			Frequency of beryllium-specific, T(H)1-type cytokine-expressing CD4(+) T cells in patients with beryllium-induced disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; lung; CD4-positive T lymphocyte; beryllium; autoimmunity	NATURAL-HISTORY; BLOOD; SENSITIZATION; SUSCEPTIBILITY; LYMPHOCYTES; EXPOSURE; EFFECTOR; SUBSETS	Background: Beryllium sensitization is caused by exposure to beryllium in the workplace. A subset of beryllium-sensitized (BeS) subjects progress to chronic beryllium disease (CBD), a disorder characterized by a CD4(+) T-cell alveolitis and granulomatous inflammation. Whether biomarkers are present in blood that would allow separation of CBD from beryllium sensitization without invasive pulmonary procedures is unknown. Objective: The aim of this study was to determine whether the quantity of beryllium-specific T cells in blood of patients with CBD differs from that found in BeS subjects. Methods: Beryllium-induced T-cell proliferation and Till-type cytokine secretion were determined in blood cells from 33 patients with CBD and 18 BeS subjects. Results: We demonstrate here that patients with CBD have a significantly elevated number of IFN-gamma-producing and IL-2-producing beryllium-specific CD4(+) T cells in blood compared with both BeS and normal control subjects. In contrast, no difference in beryllium-induced proliferation of blood T cells was seen between BeS patients and patients with CBD. Compared with the blood beryllium lymphocyte proliferation test, which detected beryllium-induced proliferation in 65% of BeS patients and patients with CBD, ELISPOT analysis detected IFN-gamma secretion in 80% of these subjects. Higher numbers of beryllium-specific cells in blood were also associated with the extent of alveolar inflammation, as measured by both bronchoalveolar lavage white blood cell and lymphocyte counts. Conclusion: The frequency of beryllium-specific T cells in the blood of beryllium-exposed subjects may be a useful biomarker that helps discriminate between beryllium sensitization and progression to CBD.	Univ Colorado, Hlth Sci Ctr, Dept Med, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Fontenot, AP (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Clin Immunol, 4200 E 9th Ave, Denver, CO 80262 USA.	andrew.fontenot@uchsc.edu	Maier, Lisa/AAA-4378-2020		NCRR NIH HHS [M01-RR-0051] Funding Source: Medline; NHLBI NIH HHS [R01 HL062410, R01 HL62410] Funding Source: Medline; NIEHS NIH HHS [R01 ES06358, P01 ES011810] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011810] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Fontenot AP, 1999, J IMMUNOL, V163, P1019; Fontenot AP, 2000, P NATL ACAD SCI USA, V97, P12717, DOI 10.1073/pnas.220430797; Fontenot AP, 1998, AM J RESP CELL MOL, V18, P581, DOI 10.1165/ajrcmb.18.4.2981; Fontenot AP, 2003, TISSUE ANTIGENS, V62, P449, DOI 10.1046/j.1399-0039.2003.00160.x; Fontenot AP, 2002, J CLIN INVEST, V110, P1473, DOI 10.1172/JCI200215846; Infante PF, 2004, LANCET, V363, P415, DOI 10.1016/S0140-6736(04)15523-2; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Karulin AY, 2000, J IMMUNOL, V164, P1862, DOI 10.4049/jimmunol.164.4.1862; KREISS K, 1993, AM REV RESPIR DIS, V148, P985, DOI 10.1164/ajrccm/148.4_Pt_1.985; Kreiss K, 1996, AM J IND MED, V30, P16, DOI 10.1002/(SICI)1097-0274(199607)30:1<16::AID-AJIM3>3.0.CO;2-Q; KREISS K, 1993, J OCCUP ENVIRON MED, V35, P267; Lombardi G, 2001, J IMMUNOL, V166, P3549, DOI 10.4049/jimmunol.166.5.3549; Maier LA, 2003, AM J IND MED, V43, P592, DOI 10.1002/ajim.10227; MROZ MM, 1991, J ALLERGY CLIN IMMUN, V88, P54, DOI 10.1016/0091-6749(91)90300-D; Newman LS, 1996, ENVIRON HEALTH PERSP, V104, P953, DOI 10.2307/3433017; Newman LS, 1996, ENVIRON HEALTH PERSP, V104, P937, DOI 10.2307/3433014; NEWMAN LS, 1989, AM REV RESPIR DIS, V139, P1479, DOI 10.1164/ajrccm/139.6.1479; NEWMAN LS, 2003, INTERSTITIAL LUNG DI, P435; PAPPAS GP, 1993, AM REV RESPIR DIS, V148, P661, DOI 10.1164/ajrccm/148.3.661; Pathan AA, 2001, J IMMUNOL, V167, P5217, DOI 10.4049/jimmunol.167.9.5217; Pepe MS, 1998, BIOMETRICS, V54, P124, DOI 10.2307/2534001; Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009; RICHELDI L, 1993, SCIENCE, V262, P242, DOI 10.1126/science.8105536; ROSSMAN MD, 1988, ANN INTERN MED, V108, P687, DOI 10.7326/0003-4819-108-5-687; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Tinkle SS, 1997, AM J RESP CRIT CARE, V156, P1884, DOI 10.1164/ajrccm.156.6.9610040; Trudeau JD, 2003, J CLIN INVEST, V111, P217, DOI 10.1172/JCI200316409; 1999, FED REG, V65, P68854	28	34	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1036	1042		10.1016/j.jaci.2005.01.019	http://dx.doi.org/10.1016/j.jaci.2005.01.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867863				2022-12-18	WOS:000229055100021
J	Zuyderduyn, S; Hiemstra, PS; Rabe, KF				Zuyderduyn, S; Hiemstra, PS; Rabe, KF			TGF-beta differentially regulates T(H)2 cytokine-induced eotaxin and eotaxin-3 release by human airway smooth muscle cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human airway smooth muscle cells; T(H)2 cytokines; TGF-beta; chemokines; allergy; asthma	CC-CHEMOKINE RECEPTOR-3; MONOCYTE CHEMOATTRACTANT PROTEIN-3; BRONCHIAL EPITHELIAL-CELLS; HUMAN DERMAL FIBROBLASTS; MESSENGER-RNA; GENE-EXPRESSION; TNF-ALPHA; TRANSFORMING GROWTH-FACTOR-BETA-1; EOSINOPHIL RECRUITMENT; T-CELLS	Background: Human airway smooth muscle cells (HASMs) are involved in the pathogenesis of asthma. By producing chemokines, HASMs play a role in the inflammatory processes observed in this disease. Eotaxin, eotaxin-2, and eotaxin-3 are important chemoattractants for eosinophils, and these chemokines are expressed during different phases of the allergic reaction. T(H)2 cytokines and TGF-beta can be found in increased levels in patients with asthma, and these cytokines may be involved in the regulation of chemokine expression. Objective: The aim of this study was to determine the effect of T(H)2 cytokines and TGF-beta on the regulation of expression of eotaxin, eotaxin-2, and eotaxin-3 by HASMs. Methods: HASMs were incubated for 24 hours with IL-4, IL-13, TGF-beta1, or combinations of these cytokines. Protein and mRNA levels of eotaxin and eotaxin-3 were evaluated by sandwich ELISA and reverse transcriptase-PCR. Results: IL-4 and IL-13 induced mRNA and protein for both eotaxin and eotaxin-3. Eotaxin-2 mRNA and protein were not detected in HASMs. TGF-beta alone did not induce expression of the eotaxins. However, in combination with IL-4 or IL-13, TGF-beta enhanced eotaxin production and inhibited T(H)2 cytokine-induced eotaxin-3 production. Conclusion: TGF-beta differentially regulates T(H)2 cytokine-induced eotaxin and eotaxin-3 release.	Leiden Univ, Med Ctr, Dept Pulmonol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Zuyderduyn, S (corresponding author), Leiden Univ, Med Ctr, Dept Pulmonol, C3-P,POB 9600, NL-2300 RC Leiden, Netherlands.	s.zuyderduyn@lumc.nl	Rabe, Klaus F./AAW-6296-2021; Hiemstra, Pieter/K-8587-2018	Rabe, Klaus F./0000-0002-7020-1401; Hiemstra, Pieter/0000-0002-0238-5982				Atasoy U, 2003, J IMMUNOL, V171, P4369, DOI 10.4049/jimmunol.171.8.4369; Bandeira-Melo C, 2001, AM J RESP CELL MOL, V24, P653, DOI 10.1165/ajrcmb.24.6.f209; Banwell ME, 2002, CYTOKINE, V17, P317, DOI 10.1006/cyto.2002.1021; Beaulieu S, 2002, J IMMUNOL, V169, P2925, DOI 10.4049/jimmunol.169.6.2925; Berkman N, 2001, AM J RESP CELL MOL, V24, P682, DOI 10.1165/ajrcmb.24.6.4301; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; Chung KF, 1999, BRIT J PHARMACOL, V127, P1145, DOI 10.1038/sj.bjp.0702660; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; Cosmi L, 2001, INT ARCH ALLERGY IMM, V125, P273, DOI 10.1159/000053827; Cui CH, 2002, AM J RESP CELL MOL, V27, P329, DOI 10.1165/rcmb.4762; Dulkys Y, 2001, J IMMUNOL, V167, P3443, DOI 10.4049/jimmunol.167.6.3443; Dulkys Y, 2001, J INVEST DERMATOL, V116, P498, DOI 10.1046/j.1523-1747.2001.01299.x; Erjefalt JS, 2003, AM J RESP CELL MOL, V29, P439, DOI 10.1165/rcmb.2003-0015OC; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; GarciaZepeda EA, 1997, GENOMICS, V41, P471, DOI 10.1006/geno.1997.4656; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; Hoeck J, 2001, J IMMUNOL, V167, P3216, DOI 10.4049/jimmunol.167.6.3216; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; Kucich U, 2002, AM J RESP CELL MOL, V26, P183, DOI 10.1165/ajrcmb.26.2.4666; Lanone S, 2002, J CLIN INVEST, V110, P463, DOI 10.1172/JCI200214136; Matsukura S, 1999, J IMMUNOL, V163, P6876; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; Mochizuki M, 1998, J IMMUNOL, V160, P60; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; Nakao A, 2001, TRENDS IMMUNOL, V22, P115, DOI 10.1016/S1471-4906(00)01827-5; Papadopoulos NG, 2001, CLIN EXP ALLERGY, V31, P1060, DOI 10.1046/j.1365-2222.2001.01112.x; Petering H, 2001, J INVEST DERMATOL, V116, P549, DOI 10.1046/j.1523-1747.2001.01302.x; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160; Santibanez JF, 2002, BIOCHEM BIOPH RES CO, V296, P267; Scotet E, 2001, BLOOD, V98, P2568, DOI 10.1182/blood.V98.8.2568; Sheppard D, 2002, NAT IMMUNOL, V3, P337, DOI 10.1038/ni0402-337; Shinkai A, 1999, J IMMUNOL, V163, P1602; Stellato C, 2001, J IMMUNOL, V166, P1457, DOI 10.4049/jimmunol.166.3.1457; Teran LM, 1999, AM J RESP CELL MOL, V20, P777, DOI 10.1165/ajrcmb.20.4.3508; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Wenzel SE, 2002, J IMMUNOL, V169, P4613, DOI 10.4049/jimmunol.169.8.4613; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Ying S, 1999, J IMMUNOL, V163, P6321; Ying S, 1999, J IMMUNOL, V163, P3976; ZUYDERDUYN S, 2002, EUR RESP J S38, V20, pS2	44	34	38	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					791	798		10.1016/j.jaci.2004.06.037	http://dx.doi.org/10.1016/j.jaci.2004.06.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480317	Bronze			2022-12-18	WOS:000224439100011
J	Radinger, M; Johansson, AK; Sitkauskiene, B; Sjostrand, M; Lotvall, J				Radinger, M; Johansson, AK; Sitkauskiene, B; Sjostrand, M; Lotvall, J			Eotaxin-2 regulates newly produced and CD34(+) airway eosinophils after allergen exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eotaxin-1; eotaxin-2; eosinophils; BrdU; CD34(+) progenitors; airway; allergy	MONOCYTE CHEMOATTRACTANT PROTEIN-3; CHEMOKINE RECEPTOR-3 EXPRESSION; HEMATOPOIETIC PROGENITOR CELLS; GUINEA-PIG MODEL; BONE-MARROW; ATOPIC SUBJECTS; IN-VIVO; TISSUE EOSINOPHILIA; IL-5 RECEPTOR; CC-CHEMOKINE	Background: Eosinophils develop from CD34(+) bone marrow progenitors, and evidence increasingly suggests that these progenitors are recruited to the airways in atopic asthmatics after allergen challenge. Moreover, it has been shown that the number of CD34(+) progenitors in bronchial tissue correlates with asthma severity. To date, however, little is known about how these cells are recruited into the airways. Objective: Our aim was to evaluate the role of 2 chemokines, eotaxin-1 and/or eotaxin-2, in the recruitment of newly produced and CD34(+) eosinophils to the airways after allergen exposure. Methods: BALB/c mice sensitized and exposed to ovalbumin were pretreated intraperitoneally or intranasally with a neutralizing anti-eotaxin-1 and/or anti-eotaxin-2 antibody. A thymidine analogue, 5-bromo-2'-deoxyuridine (BrdU), was used to mark newly produced cells. Bronchoalveolar lavage (BAL), blood, and bone marrow were collected 24 hours after the final exposure. Results: Anti-eotaxin-1 and/or anti-eotaxin-2 given intranasally (ie, locally to airways) significantly decreased BAL eosinophils. This decrease was paralleled with a decrease in both BrdU(+) and CD34+ eosinophils. In contrast, systemically administered (ie, intraperitoneally) anti-eotaxin-1 and/or anti-eotaxin-2 resulted in a significant decrease in BAL eosinophils only when the combined treatment was of a sufficiently high dosage to produce measurable concentrations in the airways. Furthermore, neither of the treated groups showed any significant decrease in blood or bone marrow eosinophils. Conclusion: Both eotaxin-1 and eotaxin-2 are involved locally within the airways in the regulation of the recruitment of newly produced and CD34(+) eosinophils after allergen exposure.	Univ Gothenburg, Dept Resp Med & Allergol, Lung Pharmacol Grp, Inst Internal Med, SE-41346 Gothenburg, Sweden; Kaunas Univ Med, Dept Pulm & Immunol, Kaunas, Lithuania	University of Gothenburg; Lithuanian University of Health Sciences	Lotvall, J (corresponding author), Univ Gothenburg, Dept Resp Med & Allergol, Lung Pharmacol Grp, Inst Internal Med, Guldhedsgatan 10A, SE-41346 Gothenburg, Sweden.	jan.lotvall@mednet.gu.se		Lotvall, Jan/0000-0001-9195-9249				BICKNELL S, 1994, AM J RESP CELL MOL, V10, P16, DOI 10.1165/ajrcmb.10.1.8292377; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Denburg JA, 1999, IMMUNOL TODAY, V20, P111, DOI 10.1016/S0167-5699(98)01423-6; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Justice JP, 2003, AM J PHYSIOL-LUNG C, V284, pL169, DOI 10.1152/ajplung.00260.2002; Nakamura H, 1999, AM J RESP CRIT CARE, V160, P1952, DOI 10.1164/ajrccm.160.6.9811089; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Robinson DS, 1999, INT ARCH ALLERGY IMM, V118, P98, DOI 10.1159/000024039; ROTHENBERG ME, 1995, J EXP MED, V181, P1211, DOI 10.1084/jem.181.3.1211; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R, 2003, IMMUNOLOGY, V109, P536, DOI 10.1046/j.1365-2567.2003.01686.x; SEHMI R, 1997, J CLIN INVEST, V100, P466; Sergejeva S, 2004, BLOOD, V103, P1270, DOI 10.1182/blood-2003-05-1618; Tomaki M, 2000, J IMMUNOL, V165, P4040, DOI 10.4049/jimmunol.165.7.4040; Wood LJ, 1998, AM J RESP CELL MOL, V18, P759, DOI 10.1165/ajrcmb.18.6.3006; Yang M, 2003, J ALLERGY CLIN IMMUN, V112, P935, DOI 10.1016/j.jaci.2003.08.010; Ying S, 1999, J IMMUNOL, V163, P6321; Ying S, 1999, J IMMUNOL, V163, P3976; Zeibecoglou K, 1999, J ALLERGY CLIN IMMUN, V103, P99, DOI 10.1016/S0091-6749(99)70532-4; Zimmermann N, 2000, J IMMUNOL, V165, P5839, DOI 10.4049/jimmunol.165.10.5839	30	34	40	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1109	1116		10.1016/j.jaci.2004.03.022	http://dx.doi.org/10.1016/j.jaci.2004.03.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208592				2022-12-18	WOS:000222091000016
J	Davis, MDP; Plager, DA; George, TJ; Weiss, EA; Gleich, GJ; Leiferman, KM				Davis, MDP; Plager, DA; George, TJ; Weiss, EA; Gleich, GJ; Leiferman, KM			Interactions of eosinophil granule proteins with skin: Limits of detection, persistence, and vasopermeabilization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; skin; eosinophil cationic protein; eosinophil-derived neurotoxin; eosinophil peroxidase; major basic protein; detection; persistence; vasopermeability	MAJOR BASIC-PROTEIN; CELL HISTAMINE-RELEASE; ATOPIC-DERMATITIS; DERMAL DEPOSITION; IMAGE-ANALYSIS; MAST-CELLS; ACTIVATION; LOCALIZATION; NEUROTOXIN; BASOPHIL	Background: Eosinophil granule proteins, including eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), eosinophil peroxidase (EPO), and major basic protein (MBP), are prominently deposited in skin in several cutaneous disorders and likely contribute to disease pathology. Objective: We sought to determine the limit of detection, persistence, and vasopermeabilization activity of the eosinophil granule proteins in skin. Methods: The eosinophil granule proteins were injected intradermally. Their minimum detectable concentrations in human surgical waste skin and their persistence in guinea pig skin were determined by indirect immunofluorescence. Vasopermeabilization activity in the guinea pig without and with H-1 antihistamine (pyrilamine maleate) pretreatment was assessed by extrusion of Evans blue dye-treated plasma. Results: The lowest detectable cutaneous concentrations were 0.05 mumol/L EPO, 0.1 mumol/L MBP, 0.25 mumol/L ECP, and 1 mumol/L EDN. Granule proteins persisted in guinea pig skin in vivo for 1 week (EPO), 2 weeks (ECP), 2.5 weeks (EDN), and 6 weeks (MBP). Each of the eosinophil granule proteins increased cutaneous vasopermeability in a concentration-dependent manner. The potency of vasopermeabilization induced by each granule protein was comparable with that of histamine. Pyrilamine maleate pretreatment of guinea pigs did not alter increased vasopermeability induced by ECP and EDN but significantly inhibited that induced by EPO and MBP. Conclusions: Micromolar concentrations of eosinophil granule proteins are often deposited in skin in eosinophil-associated cutaneous disorders such as atopic dermatitis. These patho-physiologically relevant concentrations of eosinophil granule proteins cause increased cutaneous vasopermeability (both by means of histamine-independent and histamine-dependent mechanisms) and might alter cutaneous function for days to weeks.	Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol & Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Leiferman, KM (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Dermatol, 4B454 Sch Med,30 N 1900 E, Salt Lake City, UT 84132 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034577, R37AI009728, P50AI011483, U01AI034577, R01AI009728] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 07047, AI 09728, AI 11483, AI 34577] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; Aractingi S, 1996, ARCH DERMATOL, V132, P535; Bernardini N, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-12-j0002.2002; Buchli R, 1999, J CELL BIOCHEM, V74, P264, DOI 10.1002/(SICI)1097-4644(19990801)74:2<264::AID-JCB11>3.0.CO;2-Z; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; CAVANAH DK, 1991, J ALLERGY CLIN IMMUN, V87, P971, DOI 10.1016/0091-6749(91)90419-O; CHEN KR, 1994, ARCH DERMATOL, V130, P1159, DOI 10.1001/archderm.130.9.1159; Cheng JF, 1997, J ALLERGY CLIN IMMUN, V99, P683, DOI 10.1016/S0091-6749(97)70031-9; Costello RW, 1998, THORAX, V53, P613, DOI 10.1136/thx.53.7.613; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; GLEICH GJ, 2000, ASTHMA RHINITIS, P429; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; JOHNSTON NW, 1974, J IMMUNOL METHODS, V4, P189, DOI 10.1016/0022-1759(74)90060-X; Kiehl P, 2001, BRIT J DERMATOL, V145, P720, DOI 10.1046/j.1365-2133.2001.04456.x; Kiehl P, 1999, ANAL CELL PATHOL, V19, P153, DOI 10.1155/1999/735075; Kondo N, 2000, J INVEST ALLERG CLIN, V10, P11; KRENIK KD, 1989, J IMMUNOL METHODS, V117, P91, DOI 10.1016/0022-1759(89)90122-1; Leiferman KM, 2002, ATOPIC DERMATITIS, P327; LEIFERMAN KM, 1989, J AM ACAD DERMATOL, V21, P75, DOI 10.1016/S0190-9622(89)70151-1; LEIFERMAN KM, 1984, J INVEST DERMATOL, V82, P414; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEIFERMAN KM, 1986, J AM ACAD DERMATOL, V15, P513, DOI 10.1016/S0190-9622(86)70203-X; LEIFERMAN KM, 2003, FITZPATRICKS DERMATO, P959; LEVINE BB, 1964, IMMUNOLOGY, V7, P527; Lischetzki G, 2001, EUR J PAIN, V5, P49, DOI 10.1053/eujp.2000.0214; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; MINNICOZZI M, 1994, J IMMUNOL, V153, P2664; MINNICOZZI M, 1995, MICROVASC RES, V50, P56, DOI 10.1006/mvre.1995.1038; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; OKAYAMA Y, 1994, J ALLERGY CLIN IMMUN, V93, P900, DOI 10.1016/0091-6749(94)90384-0; Omoto M, 2000, ARCH DERMATOL RES, V292, P51, DOI 10.1007/PL00013776; OTT NL, 1994, J ALLERGY CLIN IMMUN, V94, P120, DOI 10.1016/0091-6749(94)90078-7; Patella V, 1996, J IMMUNOL, V157, P1219; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; Piliponsky AM, 2003, BLOOD, V101, P1898, DOI 10.1182/blood-2002-05-1488; Piliponsky AM, 2001, J ALLERGY CLIN IMMUN, V107, P993, DOI 10.1067/mai.2001.114656; PINEDA AA, 1977, TRANSFUSION, V17, P407, DOI 10.1046/j.1537-2995.1977.17578014576.x; Plager DA, 1999, J BIOL CHEM, V274, P14464, DOI 10.1074/jbc.274.20.14464; Raab Y, 1998, DIGEST DIS SCI, V43, P1061, DOI 10.1023/A:1018843104511; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; Swaminathan GJ, 2001, J BIOL CHEM, V276, P26197, DOI 10.1074/jbc.M100848200; TAI PC, 1987, LANCET, V1, P643; TALLEY NJ, 1992, GASTROENTEROLOGY, V103, P137, DOI 10.1016/0016-5085(92)91106-E; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	51	34	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					988	994		10.1016/j.jaci.2003.08.028	http://dx.doi.org/10.1016/j.jaci.2003.08.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610493				2022-12-18	WOS:000186553300024
J	Asero, R				Asero, R			Sex differences in the pathogenesis of chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC IDIOPATHIC URTICARIA; THYROID AUTOIMMUNITY; AUTOLOGOUS SERUM; ANTI-IGE; AUTOANTIBODIES; ANGIOEDEMA; ASSOCIATION		Ambulatorio Allergol Clin San carlo, I-20037 Paderno Dugnano, MI, Italy		Asero, R (corresponding author), Ambulatorio Allergol Clin San carlo, Via Osped 21, I-20037 Paderno Dugnano, MI, Italy.							Asero R, 2001, CLIN EXP ALLERGY, V31, P1105, DOI 10.1046/j.1365-2222.2001.01131.x; COLLET E, 1995, ANN DERMATOL VENER, V122, P413; COOPER KD, 1991, J AM ACAD DERMATOL, V25, P166, DOI 10.1016/0190-9622(91)70184-4; Fagiolo U, 2000, J ALLERGY CLIN IMMUN, V106, P567, DOI 10.1067/mai.2000.108913; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Kaplan AP, 1999, CAN J ALLERGY CLIN I, V4, P286; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; LANIGAN SW, 1987, CLIN EXP DERMATOL, V12, P335, DOI 10.1111/j.1365-2230.1987.tb02503.x; LEUNG DYM, 2001, CLIN IMMUNOLOGY PRIN; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636; MONROE EW, 1977, ARCH DERMATOL, V113, P80, DOI 10.1001/archderm.113.1.80; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Turktas I, 1997, INT J DERMATOL, V36, P187, DOI 10.1046/j.1365-4362.1997.00187.x	20	34	36	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					425	426		10.1067/mai.2003.15	http://dx.doi.org/10.1067/mai.2003.15			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589367	Bronze			2022-12-18	WOS:000180942700031
J	Tiemessen, MM; Van Hoffen, E; Knulst, AC; Van der Zee, JA; Knol, EF; Taams, LS				Tiemessen, MM; Van Hoffen, E; Knulst, AC; Van der Zee, JA; Knol, EF; Taams, LS			CD4(+)CD25(+) regulatory T cells are not functionally impaired in adult patients with IgE-mediated cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ORAL ANTIGEN; TOLERANCE		Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3508 TC Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Rheumatol & Clin Immunol, NL-3508 TC Utrecht, Netherlands	Utrecht University; Utrecht University	Tiemessen, MM (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3508 TC Utrecht, Netherlands.			Knol, Edward/0000-0001-7368-9820; Taams, Leonie/0000-0002-9337-7194				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Annacker O, 2001, J IMMUNOL, V166, P3008, DOI 10.4049/jimmunol.166.5.3008; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P; Taams LS, 2002, EUR J IMMUNOL, V32, P1621, DOI 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q; Thorstenson KM, 2001, J IMMUNOL, V167, P188, DOI 10.4049/jimmunol.167.1.188; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245	10	34	39	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					934	936		10.1067/mai.2002.128856	http://dx.doi.org/10.1067/mai.2002.128856			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464962				2022-12-18	WOS:000179777400018
J	Simons, FER; Silver, NA; Gu, XC; Simons, KJ				Simons, FER; Silver, NA; Gu, XC; Simons, KJ			Clinical pharmacology of H-1-antihistamines in the skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine; H-1-antihistamine; fexofenadine; loratadine chlorpheniramine; skin punch biopsy; wheal; flare; antihistaminic activity; adults; urticaria	HISTAMINE H-1-RECEPTOR OCCUPANCY; CHRONIC IDIOPATHIC URTICARIA; LORATADINE; PLACEBO; EFFICACY; SAFETY	Background: The extent of the distribution of H-1-antibistamines into the skin and H-1-antihistamine activity in the skin are clinically relevant in the treatment of allergic skin disorders. Methods: In a prospective, randomized, double-blind, parallel-group, multiple-dose study, we gave fexofenadine 180 mg, loratadine 10 mg, or chlorpheniramine 8 mg to 21 men (7 in each group). Before dosing and at 1, 3, 6, 9, and 24 hours after the first antihistamine dose as well as at 168, 192, and 216 hours after the first dose (ie, 12, 36, and 60 hours after the seventh and last consecutive daily H-1-antihistamine dose), we measured fexofenadine, loratadine, or chlorpheniramine concentrations in plasma and in skin tissue samples obtained through use of punch biopsies, along with suppression of histamine-induced skin wheals and flares. Loratadine metabolites, including desloratadine and its metabolites, were not measured, and chlorpheniramine metabolites were not measured. Results: All 21 participants completed the study. Skin/plasma fexofenadine ratios ranged from 1.2 +/- 0.5 at 1 hour to 110 +/- 74 at 24 hours, and skin fexofenadine concentrations exceeded loratadine and chlorpheniramine skin concentrations at each test time. This was reflected in significant wheal and flare suppression by fexofenadine in comparison with loratadine at 3 hours and in comparison with chlorpheniramine at 6 and 9 hours (wheal) and from 3 to 24 hours and at 192 hours (flare). Compared with fexofenadine, loratadine significantly suppressed the wheal at 192 hours, and compared with chlorpheniramine, it significantly suppressed the wheal at 9 hours and the flare at 24 and 192 hours. At no time did chlorpheniramine suppress the wheal or flare significantly more than fexofenadine or loratadine. Conclusions: In skin disorders for which H-1-antihistamines are recommended, these results support the use of fexofenadine or loratadine, and they indicate the need for reexamination of the use of chlorpheniramine.	Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; University of Manitoba	Simons, FER (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.							BELAICH S, 1990, ANN ALLERGY, V64, P191; Bisson R., 2002, COMPENDIUM PHARM SPE; DOGAN A, 2000, ANN ALLERG ASTHMA IM, V86, P108; Dubertret L, 1999, J EUR ACAD DERMATOL, V12, P16, DOI 10.1111/j.1468-3083.1999.tb00802.x; Finn AF, 1999, J ALLERGY CLIN IMMUN, V104, P1071, DOI 10.1016/S0091-6749(99)70091-6; GRANT JA, 1988, J ALLERGY CLIN IMMUN, V81, P563, DOI 10.1016/0091-6749(88)90197-2; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x; MONROE EW, 1992, ARZNEIMITTEL-FORSCH, V42-2, P1119; Nelson HS, 2000, ANN ALLERG ASTHMA IM, V84, P517, DOI 10.1016/S1081-1206(10)62515-X; Paul E, 1998, J DERMATOL TREAT, V9, P143, DOI 10.3109/09546639809160545; Petersen LJ, 1997, CLIN EXP ALLERGY, V27, P284; Schmelz M, 1997, J NEUROSCI, V17, P8003; SCHWINGHAMMER TL, 1988, J CLIN PHARMACOL, V28, P388, DOI 10.1002/j.1552-4604.1988.tb05745.x; SIMONS FER, 1995, J ALLERGY CLIN IMMUN, V95, P759, DOI 10.1016/S0091-6749(95)70183-4; Simons FER, 1999, J ALLERGY CLIN IMMUN, V103, P223, DOI 10.1016/S0091-6749(99)70494-X; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; Simons FER, 2001, J ALLERGY CLIN IMMUN, V107, P526, DOI 10.1067/mai.2001.113080; SIMONS FER, 2002, HISTAMINE H1 ANTIHIS, P141; SIMONS FER, 2000, ALLERGIC SKIN DIS, P477; Sutherland FCW, 2001, J CHROMATOGR A, V914, P37, DOI 10.1016/S0021-9673(01)00646-X; Tagawa M, 2001, BRIT J CLIN PHARMACO, V52, P501, DOI 10.1046/j.1365-2125.2001.01471.x; Welch Michael J, 2002, Clin Allergy Immunol, V17, P337; Yanai K, 1995, METHOD FIND EXP CLIN, V17, P64	26	34	36	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					777	783		10.1067/mai.2002.129123	http://dx.doi.org/10.1067/mai.2002.129123			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417888				2022-12-18	WOS:000179082500014
J	Grunstein, MM; Hakonarson, H; Whelan, R; Yu, ZY; Grunstein, JS; Chuang, S				Grunstein, MM; Hakonarson, H; Whelan, R; Yu, ZY; Grunstein, JS; Chuang, S			Rhinovirus elicits proasthmatic changes in airway responsiveness independently of viral infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; transmembrane signaling; airway reactivity; common cold; asthma; intercellular adhesion molecule 1	SMOOTH-MUSCLE RESPONSIVENESS; HYPERREACTIVITY; ASTHMA; ICAM-1; INFLAMMATION; INDUCTION; COLDS; LFA-1; HYBRIDIZATION; PATHOGENESIS	Background: Rhinovirus (RV), the principal pathogen responsible for the common cold, is importantly implicated in triggering attacks of asthma secondary to changes in airway responsiveness. Objective: Because the airway histopathologic features of RV infection are relatively modest, we tested the hypothesis that RV can directly elicit proasthmatic-like changes in airway smooth muscle (ASM) responsiveness independently of actual viral infection and its associated cytopathic effects. Methods: Isolated ASM tissues and cultured ASM cells were inoculated with either infectious or noninfectious (UV-Irradiated) RV16 and RV2, the latter serotypes belonging to the "major" and "minor" groups of RV subtypes, respectively. ASM constrictor and relaxant responsiveness, G(i) protein expression, and proinflammatory cytokine release were subsequently compared under the different treatment conditions. Results: In contrast to RV2, which had no effect, RV16 inoculation elicited enhanced ASM contractility and impaired relaxation to cholinergic and beta -adrenergic agonists, respectively, in association with increased ASM membrane G(i) protein expression and induced release of the proinflammatory cytokines IL-5 and IL-1 beta. These proasthmatic-like effects were also observed in ASM exposed to UV-irradiated RV16, wherein viral replication was completely inhibited. In contrast, pretreatment of ASM with a neutralizing antibody directed against ICAM-1, the host receptor for the "major" group of RVs, completely abrogated the proasthmatic effects of RV16. Conclusions: The results demonstrate that (1) RV16 elicits proasthmatic changes in ASM responsiveness that can occur independently of actual viral infection of the ASM and (2) the effects of RV16 are attributed solely to binding of the virus to its host receptor (ICAM-1) on the ASM cell surface. Collectively, these findings support the notion that RV-induced exacerbation of wheezing in asthmatic individuals can occur even in the absence of any cytopathology associated with viral infection.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Div Pulm Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Grunstein, MM (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Div Pulm Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL-31467, HL-59906, HL-58245, HL-61038] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031467, R01HL058245, R01HL059906, R01HL061038] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARDIN PG, 1994, AM J RESP CELL MOL, V10, P207, DOI 10.1165/ajrcmb.10.2.8110476; BERGELSON JM, 1993, J VIROL, V67, P6847, DOI 10.1128/JVI.67.11.6847-6852.1993; BLAIR HT, 1976, AM REV RESPIR DIS, V114, P95; Bloemen PGM, 1996, AM J RESP CRIT CARE, V153, P521, DOI 10.1164/ajrccm.153.2.8564091; Buckley TL, 1996, ANN NY ACAD SCI, V796, P149, DOI 10.1111/j.1749-6632.1996.tb32576.x; BUSSE WW, 1990, J ALLERGY CLIN IMMUN, V85, P671, DOI 10.1016/0091-6749(90)90181-3; DEARRUDA E, 1991, J MED VIROL, V34, P38, DOI 10.1002/jmv.1890340107; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gern JE, 1996, J IMMUNOL, V156, P621; GERN JE, 1995, AM J RESP CRIT CARE, V152, P40; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Grunberg K, 1999, CLIN EXP ALLERGY, V29, P65; Grunstein MM, 2001, AM J PHYSIOL-LUNG C, V280, pL229, DOI 10.1152/ajplung.2001.280.2.L229; Grunstein MM, 2000, AM J PHYSIOL-LUNG C, V278, pL1146, DOI 10.1152/ajplung.2000.278.6.L1146; Hakonarson H, 1999, AM J PHYSIOL-LUNG C, V277, pL13, DOI 10.1152/ajplung.1999.277.1.L13; Hakonarson H, 1999, J CLIN INVEST, V103, P1077, DOI 10.1172/JCI5809; Hakonarson H, 1998, J CLIN INVEST, V102, P1732, DOI 10.1172/JCI4141; JOHNSTON SL, 1995, AM J RESP CRIT CARE, V152, pS46, DOI 10.1164/ajrccm/152.4_Pt_2.S46; LABERGE S, 1995, AM J RESP CRIT CARE, V151, P822; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133; NAGESE T, 1995, AM J RESP CRIT CARE, V151, P1244; PROUD D, 1994, J INFECT DIS, V169, P1007, DOI 10.1093/infdis/169.5.1007; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749, DOI 10.1152/ajplung.1997.273.4.L749; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WINTHER B, 1986, JAMA-J AM MED ASSOC, V256, P1763, DOI 10.1001/jama.256.13.1763; Wolyniec WW, 1998, AM J RESP CELL MOL, V18, P777, DOI 10.1165/ajrcmb.18.6.3056; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	31	34	35	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					997	1004		10.1067/mai.2001.120276	http://dx.doi.org/10.1067/mai.2001.120276			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742279				2022-12-18	WOS:000172938400017
J	Alexis, NE; Peden, DB				Alexis, NE; Peden, DB			Blunting airway eosinophilic inflammation results in a decreased airway neutrophil response to inhaled LPS in patients with atopic asthma: A role for CD14	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD14; LPS; eosinophilic inflammation; inhaled steroid	BRONCHOALVEOLAR LAVAGE; ENDOTOXIN; CELLS	Recent data demonstrate that atopic inflammation might enhance airway responses to inhaled LPS in individuals with atopic asthma by increasing CD14 expression on airway macrophages. We sought to determine whether blunting airway eosinophilic inflammation decreases CD14 expression and the subsequent airway polymorphonuclear neutrophil (PMN) response to inhaled LPS in subjects with atopic asthma. Twelve such subjects underwent a 2-week, placebo-controlled trial of inhaled steroid (440 mug fluticasone propionate [FP] twice per day); this was followed 48 hours later by an inhaled LPS (5 mug) challenge. A comparison of LPS-induced inflammatory cells in sputum, CD14 expression, and methacholine responsiveness with FP or placebo was conducted. Flow cytometry was used to analyze membrane-bound CD14 expression (mean fluorescence intensity) on sputum macrophages. We report that 48 hours before inhaled LPS challenge (baseline), Fl? significantly blunted airway eosinophils (cells per milligram; P =.04) and mCD14 expression (mean fluorescence intensity; P =.03) but did not decrease the number of PMNs (cells per milligram). Six hours after LPS challenge, airway PMNs and mCD14 expression were significantly decreased for FP in comparison with placebo (P =.04). Our data suggest that decreasing airway allergic inflammation with corticosteroids results in both decreased expression of CD14 on airway monocytic cells and a decreased PMN response to inhaled LPS.	Univ N Carolina, Ctr Environm Med & Lung Biol, Dept Pediat & Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Alexis, NE (corresponding author), Univ N Carolina, Ctr Environm Med & Lung Biol, Dept Pediat & Med, 104 Mason Farm Rd,5th Floor, Chapel Hill, NC 27599 USA.			Peden, David/0000-0003-4526-4627	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062624] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62624] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexis N, 2000, CLIN IMMUNOL, V97, P21, DOI 10.1006/clim.2000.4911; Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Doerschug KC, 1999, AM J RESP CRIT CARE, V159, P1735, DOI 10.1164/ajrccm.159.6.9809051; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; LITCHFIELD TM, 1992, J ASTHMA, V29, P181, DOI 10.3109/02770909209099026; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; MICHEL O, 1994, AM J IND MED, V25, P129, DOI 10.1002/ajim.4700250135; WASSERMAN SI, 1994, AM J RESP CRIT CARE, V150, pS39, DOI 10.1164/ajrccm/150.5_Pt_2.S39; WENZEL SE, 1991, J ALLERGY CLIN IMMUN, V87, P540, DOI 10.1016/0091-6749(91)90013-E	11	34	34	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					577	580						4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590384				2022-12-18	WOS:000171760300017
J	Elliott, K; Fitzpatrick, E; Hill, D; Brown, J; Adams, S; Chee, P; Stewart, G; Fulcher, D; Tang, MM; Kemp, A; King, E; Varigos, G; Bahlo, M; Forrest, S				Elliott, K; Fitzpatrick, E; Hill, D; Brown, J; Adams, S; Chee, P; Stewart, G; Fulcher, D; Tang, MM; Kemp, A; King, E; Varigos, G; Bahlo, M; Forrest, S			The-590C/T and-34C/T interleukin-4 promoter polymorphisms are not associated with atopic eczema in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; eczema; dermatitis; asthma; genetic; IL-4; promoter; polymorphism; association; linkage disequilibrium	GENE; ASTHMA; DERMATITIS; JAPANESE; LINKAGE; GAMMA; IL-4; IGE	Susceptibility to the development of asthma and other atopic diseases is known to have a genetic component. To date, several studies have linked chromosome 5q31 to asthma and atopy in human beings. This region harbors a cluster of cytokine and growth factor genes, IL-4 presenting as a prime atopy candidate gene, inasmuch as it plays a pivotal role in the atopy pathway. Our approach was to identify polymorphisms within the promoter regions of IL-4 and test their association with atopic eczema. Polymorphisms were typed in a cohort of 76 small nuclear families and 25 triads with childhood atopic eczema. The genotypes were used to test for linkage in the presence of association with atopic eczema. A new polymorphism, -34C/T, was identified and studied with a known polymorphism, -590C/T. On its own, each polymorphism showed no association with atopic eczema. The 2 polymorphisms were used to generate haplotypes, and a significant result was found for the -590C/-34C haplotype. However, after Bonferroni correction for multiple testing, the association became nonsignificant. Neither polymorphism predisposes to early-onset atopic eczema by itself, but suggestive linkage was found for the -590C/-34C haplotype in this study.	Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Cooperat Res Ctr Discovery Genes Common Human Dis, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Allergy Ctr, Parkville, Vic 3052, Australia; Westmead Hosp, Dept Clin Immunol & Allergy, Sydney, NSW, Australia; Royal Childrens Hosp, Dept Dermatol, Parkville, Vic 3052, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Sydney; Royal Children's Hospital Melbourne; Walter & Eliza Hall Institute	Forrest, S (corresponding author), Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.			Tang, Mimi/0000-0002-3839-5293				Dizier MH, 1999, GENET EPIDEMIOL, V16, P84, DOI 10.1002/(SICI)1098-2272(1999)16:1<84::AID-GEPI7>3.0.CO;2-D; ELLIOTT KS, 2001, ATOPIC DERMATITIS; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Kawashima T, 1998, J MED GENET, V35, P502, DOI 10.1136/jmg.35.6.502; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Takabayashi A, 1999, J HUM GENET, V44, P352, DOI 10.1007/s100380050176; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; VERCELLI D, 1990, J IMMUNOL, V144, P570; Walley AJ, 1996, J MED GENET, V33, P689, DOI 10.1136/jmg.33.8.689; [No title captured]	11	34	37	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					285	287		10.1067/mai.2001.117180	http://dx.doi.org/10.1067/mai.2001.117180			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496248				2022-12-18	WOS:000170584600020
J	Scadding, GK				Scadding, GK			Corticosteroids in the treatment of pediatric allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; corticosteroids; intranasal corticosteroids; hypothalamic pituitary adrenal axis	AQUEOUS NASAL SPRAY; DOUBLE-BLIND; INTRANASAL CORTICOSTEROIDS; CLINICAL-EVALUATION; CONTROLLED TRIAL; AVOIDANCE; CHILDREN; PLACEBO; ANTIHISTAMINES; DERMATITIS	The goal of treatment in pediatric allergic rhinitis is to provide effective prevention of or relief front allergic rhinitis symptoms as safely and effectively as possible. Removing or avoiding allergens is always advised; however, pharmacotherapy is often necessity. Pharmacologic options include systemic decongestants, which are associated with irritability and insomnia, particularly in children. Antihistamines are widely used; however, first-generation antihistamines are known to cause dry mouth and sedation. Oral corticosteroids are very effective but can have unwanted systemic effects. Over the past decade, intranasal corticosteroids have been shown to be the most effective form of pharmacologic treatment for allergic rhinitis. Data support the use of intranasal corticosteroids as first-line therapy over oral antihistamines; nonetheless, some clinicians have been reluctant to prescribe these agents, particularly for children, because of concerns for systemic effects. Overall, the newer corticosteroids, including mometasone furoate (NIF), beclomethasone dipropionate, and budesonide have an Improved risk-benefit ratio compared with older corticosteroids and are now considered the drug of choice for pediatric allergic rhinitis. A good deal of evidence exists that confirms the lack of systemic effects from intranasal corticosteroids. However, reports of decreased bone growth in children receiving intranasal budesonide short-term and beelomethasone dipropionate long-term have heightened concerns that some of these drugs may have systemic effects. A new intranasal corticosteroid, MF nasal spray, has been studied in children 3 to 12 years of age and has been shown to be effective. Intranasal NIF is available with once-daily dosing, which has the potential to decrease systemic side effects.	Royal Natl Throat Nose & Ear Hosp, London WC1X 8DA, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Scadding, GK (corresponding author), Royal Natl Throat Nose & Ear Hosp, Grays Inn Rd, London WC1X 8DA, England.							AUBIER M, 1992, AM REV RESPIR DIS, V146, P122, DOI 10.1164/ajrccm/146.1.122; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; BORUM P, 1987, ALLERGY, V42, P26, DOI 10.1111/j.1398-9995.1987.tb02183.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Brannan MD, 1997, CLIN THER, V19, P1330, DOI 10.1016/S0149-2918(97)80008-2; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; DICKER ID, 1995, ALLERGY, V50, pS69; DURHAM SR, 1998, DIS HEAD NECK THROAT, P609; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Grob JJ, 1998, ACTA DERM-VENEREOL, V78, P194; HOWARTH PH, 1992, J ALLERGY CLIN IMMUN, V89, P305; KNIEST FM, 1991, CLIN EXP ALLERGY, V21, P39, DOI 10.1111/j.1365-2222.1991.tb00802.x; Mygind N., 1996, ESSENTIAL ALLERGY; Nayak AS, 1998, J ALLERGY CLIN IMMUN, V101, P157, DOI 10.1016/S0091-6749(98)70379-3; *NIH NAT HEART LUN, 1995, GLOB IN ASTHM GLOB S; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; PARIKH A, IN PRESS J AUDIOLOGI; Passali D, 1999, ALLERGY, V54, P5, DOI 10.1111/j.1398-9995.1999.tb04420.x; Pearson MG, 1997, THORAX, V52, pS1; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Scadding GK, 2000, ALLERGY, V55, P19, DOI 10.1034/j.1398-9995.2000.055suppl 62019.x; SCADDING GK, 1997, RHINITIS MANAGEMENT; Schenkel EJ, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e22; SCHULLER DE, 1990, J ALLERGY CLIN IMMUN, V86, P554, DOI 10.1016/S0091-6749(05)80212-X; Skoner DP, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e23; Storms WW, 1997, ALLERGY ASTHMA PROC, V18, P59, DOI 10.2500/108854197778605473; Taccariello Michelle, 1999, Rhinology (Utrecht), V37, P29; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; TOOGOOD JH, 1982, CLIN ALLERGY, V12, P95, DOI 10.1111/j.1365-2222.1982.tb03131.x; Vermeulen J, 1994, Pediatr Allergy Immunol, V5, P209, DOI 10.1111/j.1399-3038.1994.tb00241.x; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V102, P598, DOI 10.1016/S0091-6749(98)70275-1; WOLTHERS OD, 1993, ACTA PAEDIATR, V82, P635, DOI 10.1111/j.1651-2227.1993.tb12780.x	34	34	38	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1		S			S59	S64		10.1067/mai.2001.115568	http://dx.doi.org/10.1067/mai.2001.115568			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	459BU	11449208				2022-12-18	WOS:000170230600010
J	Binkley, K; King, N; Poonai, N; Seeman, P; Ulpian, C; Kennedy, J				Binkley, K; King, N; Poonai, N; Seeman, P; Ulpian, C; Kennedy, J			Idiopathic environmental intolerance: Increased prevalence of panic disorder-associated cholecystokinin B receptor allele 7	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						idiopathic environmental intolerance; panic disorder; cholecystokinin; cholecystokinin B receptor; dopamine D4; dopamine D4 receptor gene; genetic association study	MULTIPLE CHEMICAL-SENSITIVITY; POLYMORPHISMS; CHALLENGES; PATIENT; GENES; DRD4	Background: A growing body of evidence suggests that idiopathic environmental intolerance (IEI) is a psychophysiologic disorder with prominent features of anxiety/panic and somatization, although proponents of a toxicogenic explanation claim, despite a lack of convincing evidence, that symptoms arise from exposure to otherwise nonnoxious environmental agents. Patient behaviour is characterized by strenuous avoidance of perceived triggers to the point of severe impairment of normal social and vocational functioning. IEI proponents claim that previous studies showing a high prevalence of psychopathology in patients with IEI and studies showing panic responses to known panicogenic challenges merely reflect the anxiety-producing result of living with IEI, Objective: We explored whether IEI and panic disorder, personality traits, or both shared an underlying neurogenetic basis that would predate the anxiety of IEI symptomatology. The DNA of patients with IEI was examined for the presence of known panic disorder-associated cholecystokinin B (CCK-B) receptor alleles and for personality trait-associated dopamine D4 receptor polymorphisms. Methods: Eleven patients with typical IEI symptoms were recruited and were individually matched to normal control subjects from an existing bank for age, sex, and ethnic background. Genomic DNA was extracted from peripheral blood samples. CCK-B and dopamine D4 receptor polymorphisms were examined by using standard PCR-based techniques, Results: There was a significantly higher prevalence of the panic disorder-associated CCK-B receptor allele 7 in subjects with IEI (9/22 [40.9%) compared with control subjects (2/22 [9,1%, P = ,037), There was no difference in personality trait-associated polymorphisms of the gene encoding dopamine D4 receptor between patients and control subjects. Conclusions: These findings provide preliminary evidence that IEI and panic disorder share a common neurogenetic basis, which would predate the anxiety-producing effects of IEI symptoms, Further studies with larger samples are warranted, but these results support previous studies that suggest that panic disorder may account for much of the symptomatology in at Least some cases of IEI and provide a basis for rational treatment strategies.	Univ Toronto, Gage Occupat & Environm Hlth Unit, Toronto, ON, Canada; Univ Toronto, Div Clin Immunol & Allergy, Dept Med, St Michaels Hosp, Toronto, ON, Canada; Univ Toronto, Neurogenet Sect, Clarke Div, Ctr Addict & Mental Hlth, Toronto, ON, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON, Canada; Univ Toronto, Dept Psychiat, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto	Binkley, K (corresponding author), 201-30 St Clair Ave W, Toronto, ON M4V 3A1, Canada.							AAAAI Board Directors, 1999, J ALLERGY CLIN IMMUN, V103, P36; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; Binkley KE, 1997, J ALLERGY CLIN IMMUN, V99, P570, DOI 10.1016/S0091-6749(97)70086-1; Binkley KE, 1998, J ALLERGY CLIN IMMUN, V101, pS87; BLACK DW, 1990, JAMA-J AM MED ASSOC, V264, P3166, DOI 10.1001/jama.264.24.3166; Black DW, 1996, PSYCHOSOMATICS, V37, P390, DOI 10.1016/S0033-3182(96)71554-2; Blum K, 1997, MOL PSYCHIATR, V2, P239, DOI 10.1038/sj.mp.4000261; BRADWEJN J, 1991, ARCH GEN PSYCHIAT, V48, P603; BRADWEJN J, 1994, ANN NY ACAD SCI, V713, P273, DOI 10.1111/j.1749-6632.1994.tb44075.x; BRODER I, 1994, MIN PUBL; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; GUGLIELMI RS, 1994, J BEHAV THER EXP PSY, V25, P197; Hamilton SP, 2000, AM J MED GENET, V96, P324, DOI 10.1002/1096-8628(20000612)96:3<324::AID-AJMG18>3.0.CO;2-W; HOWARD LM, 1993, BRIT MED J, V307, P747, DOI 10.1136/bmj.307.6907.747; Kennedy JL, 1999, MOL PSYCHIATR, V4, P284, DOI 10.1038/sj.mp.4000507; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; Leznoff A, 1997, J ALLERGY CLIN IMMUN, V99, P438, DOI 10.1016/S0091-6749(97)70067-8; LICHTER JB, 1993, HUM MOL GENET, V2, P767, DOI 10.1093/hmg/2.6.767; PEARSON DJ, 1988, J ALLERGY CLIN IMMUN, V81, P351, DOI 10.1016/0091-6749(88)90900-1; Poonai N, 2000, J ALLERGY CLIN IMMUN, V105, P358, DOI 10.1016/S0091-6749(00)90088-5; ROSENBERG SJ, 1991, J OCCUP MED, V33, P737; SELNER JC, 1992, TOXICOL IND HEALTH, V8, P145; SIMON GE, 1990, AM J PSYCHIAT, V147, P901; SIMON GE, 1993, ANN INTERN MED, V119, P97, DOI 10.7326/0003-4819-119-2-199307150-00001; STAUDENMAYER H, 1993, REGUL TOXICOL PHARM, V18, P44, DOI 10.1006/rtph.1993.1043; Staudenmayer H, 1997, J ALLERGY CLIN IMMUN, V99, P434; Staudenmayer H., 1999, ENV ILLNESS MYTH REA; Stenn P, 1998, PSYCHOSOMATICS, V39, P547, DOI 10.1016/S0033-3182(98)71289-7; Stenn PG, 1998, PSYCHOSOMATICS, V39, P212; Stenn PG, 1998, PSYCHOSOMATICS, V39, P393, DOI 10.1016/S0033-3182(98)71335-0; Tiihonen J, 1997, AM J PSYCHIAT, V154, P239	31	34	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					887	890		10.1067/mai.2001.114798	http://dx.doi.org/10.1067/mai.2001.114798			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344357	Bronze			2022-12-18	WOS:000168812300018
J	Weiss, ST; Horner, A; Shapiro, G; Sternberg, AL				Weiss, ST; Horner, A; Shapiro, G; Sternberg, AL		Childhood Asthma Management Progra	The prevalence of environmental exposure to perceived asthma triggers in children with mild-to-moderate asthma: Data from the Childhood Asthma Management Program (CAMP)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen exposure; asthma symptoms; childhood asthma; Childhood Asthma Management Program; environmental allergen sensitization; skin prick tests		Background: The Childhood Asthma Management Program, a 5-year randomized clinical trial of treatments for childhood asthma, has enrolled and characterized a cohort of 1041 children with mild-to-moderate asthma, Objective: We sought to describe self-reported sensitivities and environmental exposures and investigate the relationships between self-report of these exposures as asthma triggers and their prevalence in the home. Methods: Self-reports of sensitivities and home exposures were obtained by interview with the child or parent. Sensitivities were further assessed by using allergy skin testing (prick or puncture) against a core battery of allergens. Home exposures were further assessed by using analysis of a home dust sample. Results: Environmental exposures were surprisingly common despite self-reported sensitivities to environmental factors. Of patients reporting that cigarette smoking frequently causes asthma symptoms, 26% reported having at least one parent who smokes cigarettes, Thirty-nine percent of patients reporting that exposure to animals frequently causes asthma symptoms live with a furry pet in their home, We found a smaller proportion of homes with a high level of cat allergen (P < .001) among the children who reported that animals frequently or always trigger asthma symptoms compared with those who reported that animals never or occasionally trigger asthma symptoms, suggesting modification of the home environment. No such results were seen for dog exposure. However, clinical symptoms did not reduce exposure to parental cigarette smoking (P = .15), house dust (P = .31), or damp and musty areas (P = .51).	Johns Hopkins Ctr Clin Trials, CAMP Coordinating Ctr, Baltimore, MD 21205 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; ASTHMA Inc, Seattle, WA USA	Johns Hopkins University; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Diego	Sternberg, AL (corresponding author), Johns Hopkins Ctr Clin Trials, CAMP Coordinating Ctr, 615 N Wolfe St,Room 5010, Baltimore, MD 21205 USA.				DIVISION OF LUNG DISEASES [N01HR016049, N01HR016045, N01HR016050, N01HR016051, N01HR016048, N01HR016052, N01HR016044, N01HR016046, N01HR016047] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719, M01RR000051] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR02719-24, RR00036, M01RR00051, M01RR0099718-24] Funding Source: Medline; NHLBI NIH HHS [N01-HR16049, N01-HR16047, N01-HR16052, N01-HR16045, N01-HR16044, N01-HR16051, N01-HR16048, N01-HR16050, N01-HR16046] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARR LW, 1964, PEDIATRICS, V343, P856; BUFFUM WP, 1966, AM J DIS CHILD, V112, P214, DOI 10.1001/archpedi.1966.02090120082007; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; KRAEPELIEN S, 1963, Acta Paediatr Suppl, V140, P92; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; MCNICHOL KN, 1973, BRIT MED J, V4, P16, DOI 10.1136/bmj.4.5883.16; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; OGILVIE A. G., 1962, THORAX, V17, P183, DOI 10.1136/thx.17.3.183; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Platts-Mills TAE, 1998, J ALLERGY CLIN IMMUN, V101, pS364, DOI 10.1016/S0091-6749(98)70221-0; PLATTSMILLS TAE, 1990, ALLERGY PROC, V11, P269, DOI 10.2500/108854190778879729; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; RYSSING E, 1963, ACTA PAEDIATR, V52, P97, DOI 10.1111/j.1651-2227.1963.tb04083.x; SAS Institute Inc, 1989, SAS STAT US GUID VER; Snedecor GW, 1980, STAT METHODS, V7th; STRACHAN DP, 1995, CHILDHOOD ASTHMA OTH, P2; Tager IB, 1998, AM J RESP CRIT CARE, V158, P349, DOI 10.1164/ajrccm.158.2.ed05-98; vonMutius E, 1996, THORAX, V51, pS3, DOI 10.1136/thx.51.Suppl_1.S3; WEISS ST, 1995, BRONCHIAL ASTHMA MEC; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352, DOI 10.1164/ajrccm.158.2.9705079; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	24	34	34	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					634	640		10.1067/mai.2001.113869	http://dx.doi.org/10.1067/mai.2001.113869			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295651	Bronze			2022-12-18	WOS:000168190100014
J	Stempel, DA; Meyer, JW; Stanford, RH; Yancey, SW				Stempel, DA; Meyer, JW; Stanford, RH; Yancey, SW			One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-College-of-Allergy-Asthma-and-Immunology	NOV 12, 1999	CHICAGO, IL	Amer Coll Allergy, Asthma & Immunol		fluticasone propionate; zafirlukast; retrospective analysis; leukotriene modifiers; inhaled corticosteroids; asthma; claims data; asthma costs	ECONOMIC-EVALUATION; ORAL ZAFIRLUKAST; GUIDELINES; TRIALS; COST	Background: Randomized clinical trials have demonstrated that fluticasone propionate (FP) has better objective as well as subjective clinical outcomes than zafirlukast (ZA) in the treatment of asthma, Objective: The goal of this study was to determine whether the superiority of FP over ZA observed in clinical trials is supported under actual practice conditions. Methods: A retrospective cohort analysis of pharmacy and medical claims for asthma was performed. Patients were identified who had at least 1 ICD-9 (493.XX) claim for asthma and were recently prescribed inhaled FP or ZA, Subjects could not have had a claim for any inhaled corticosteroid or oral leukotriene modifier in the 9 months before initiation of FP or ZA, They were subsequently observed for 12 months. Results: A total of 725 persons were new users of FP and 309 of ZA, FP was associated with a 70% reduced risk for hospitalization (P =.0232), a 49% lower risk for an emergency department event (P =.0546), and a 51% reduction in combined emergency department events and hospitalizations (P =.0268) when compared with ZA. Adjusted annual asthma care costs declined significantly for FP and increased for ZA, The adjusted mean difference in annual asthma costs was $215 less per patient for FP (P <,0001), Conclusion: Asthma care costs decreased for patients treated with FP and increased fur patients treated with ZA, Furthermore, FP-treated patients had significantly lower risks of asthma-related hospitalization than ZA patients. This study supports results seen in clinical trials comparing these two medications.	Virginia Mason Med Ctr, Seattle, WA 98101 USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	Virginia Mason Medical Center; GlaxoSmithKline	Stempel, DA (corresponding author), Virginia Mason Med Ctr, 1100 9th Ave,C4-ALL, Seattle, WA 98101 USA.							*ASS PHARM OUTC RE, 1997, DRUG BENEFIT TRENDS, V9, P51; BALKRISHNAN R, 1998, DRUG BENEFIT TRENDS, V10, P37; Blais L, 1998, THORAX, V53, P1025, DOI 10.1136/thx.53.12.1025; Blaiss MS, 1997, JAMA-J AM MED ASSOC, V278, P1874, DOI 10.1001/jama.278.22.1874; Bleecker ER, 2000, J ALLERGY CLIN IMMUN, V105, P1123, DOI 10.1067/mai.2000.106043; Busse W, 1999, AM J RESP CRIT CARE, V159, pA628; Busse WW, 1998, J ALLERGY CLIN IMMUN, V102, pS17, DOI 10.1016/S0091-6749(98)70002-8; *CDCP, 1998, CDC SURV SUMM, V47; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; GOLDBERGARNOLD R, 1999, VALUE HEALTH, V2, P82; Goldman M, 2000, J ALLERGY CLIN IMMUN, V105, P71, DOI 10.1016/S0091-6749(00)90180-5; Grana J, 1997, Am J Med Qual, V12, P113, DOI 10.1177/0885713X9701200205; GUYATT G, 1986, SOC SCI MED, V22, P393, DOI 10.1016/0277-9536(86)90046-8; HIGGINS G, 1997, INPHARMA, V1077, P9; Ishihara K, 1998, Respirology, V3, P193, DOI 10.1111/j.1440-1843.1998.tb00120.x; JONES AJ, 1995, DRUG BENEFIT TRENDS, V7, P32; JONES AJ, 1995, DRUG BENEFIT TRENDS, V7, P12; JONES AJ, 1995, DRUG BENEFIT TRENDS, V7, P19; JONES AJ, 1995, DRUG BENEFIT TRENDS, V7, P15; Keeley D, 1997, BMJ-BRIT MED J, V314, P315, DOI 10.1136/bmj.314.7077.315; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Minshall ME, 1999, MED CARE, V37, pAS12, DOI 10.1097/00005650-199904001-00003; Mullen B, 1998, J ALLERGY CLIN IMMUN, V101, pS232; *NIH, 1997, NIH PUBL, P1; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Stanford R, 1999, AM J RESP CRIT CARE, V160, P211, DOI 10.1164/ajrccm.160.1.9811040; Stempel DA, 1996, ARCH FAM MED, V5, P36, DOI 10.1001/archfami.5.1.36; Storms W, 1999, AM J RESP CRIT CARE, V159, pA628; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; Westbroek J., 1997, European Respiratory Journal Supplement, V10, p243S; Westbroek J, 1998, AM J RESP CRIT CARE, V157, pA416	33	34	34	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					94	98		10.1067/mai.2001.112029	http://dx.doi.org/10.1067/mai.2001.112029			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	394PW	11149997				2022-12-18	WOS:000166533300017
J	Platts-Mills, TAE; Woodfolk, JA				Platts-Mills, TAE; Woodfolk, JA			Cord blood proliferative responses to inhaled allergens: Is there a phenomenon?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							T-CELL RESPONSES; HOUSE-DUST MITE; SERUM-FREE MEDIUM; PERIPHERAL-BLOOD; ASTHMA; IGE; LYMPHOCYTES; CHILDHOOD; EXPOSURE; RHINITIS		Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X				BEHRMAN RE, 2000, NELSON TXB PEDIAT, P538; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Bjorksten B, 1996, CLIN EXP ALLERGY, V26, P775, DOI 10.1111/j.1365-2222.1996.tb00607.x; Chan-Yeung M, 1999, J ALLERGY CLIN IMMUN, V104, P317, DOI 10.1016/S0091-6749(99)70373-8; D'Arena G, 1998, HAEMATOLOGICA, V83, P197; DELESPESSE G, 1983, MONOGR ALLERGY, V18, P83; Dunbar PR, 1998, CURR BIOL, V8, P413, DOI 10.1016/S0960-9822(98)70161-7; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Holt PG, 1999, NATURE, V402, pB12; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; KOBAYASHI Y, 1994, J ALLERGY CLIN IMMUN, V94, P907, DOI 10.1016/0091-6749(94)90159-7; Kopp MV, 2000, PEDIATR ALLERGY IMMU, V11, P4, DOI 10.1034/j.1399-3038.2000.00053.x; MARSH DG, 1975, ANTIGENS, V3, P271; MILES EA, 1995, J ALLERGY CLIN IMMUN, V95, P381; Platts-Mills TAE, 1984, ASTHMA PHYSL IMMUNOP, P297; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; Prescott SL, 1998, J IMMUNOL, V160, P4730; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; Slunt JB, 1997, CLIN EXP ALLERGY, V27, P1184, DOI 10.1111/j.1365-2222.1997.tb01156.x; Smillie FI, 1999, J ALLERGY CLIN IMMUN, V103, pS109; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Szepfalusi Z, 2000, J ALLERGY CLIN IMMUN, V106, P530; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; VANDURENSCHMIDT K, 1997, PEDIATR RES, V41, P1; Warner JA, 1998, CLIN EXP ALLERGY, V28, P35; Warner JO, 1999, ASTHMA - A LINK BETWEEN ENVIRONMENT, IMMUNOLOGY, AND THE AIRWAYS, P22; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; WOODFOLK JA, 2000, THESIS U VIRGINIA CH; WOODFOLK JA, IN PRESS J IMMUNOL; ZEIGER RS, 1988, ALLERGY PRINCIPLES P, V2, P930	32	34	36	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					441	443						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984361				2022-12-18	WOS:000089471900004
J	Tachimoto, H; Ebisawa, M; Hasegawa, T; Kashiwabara, T; Ra, C; Bochner, BS; Miura, K; Saito, H				Tachimoto, H; Ebisawa, M; Hasegawa, T; Kashiwabara, T; Ra, C; Bochner, BS; Miura, K; Saito, H			Reciprocal regulation of cultured human mast cell cytokine production by IL-4 and IFN-gamma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; mast cell; cellular activation; cytokines; chemokines; IgE; allergy	FC-EPSILON-RI; PERENNIAL ALLERGIC RHINITICS; TUMOR-NECROSIS-FACTOR; IN-VITRO; HISTAMINE-RELEASE; MEDIATOR RELEASE; NASAL-MUCOSA; IGE; EXPRESSION; INTERLEUKIN-4	Background: T(H)1 and T(H)2 cytokines are thought to regulate allergic inflammation. Objective: Two key regulatory cytokines, IL-4 and IFN-gamma, were examined for their effects on cytokine production by cultured human mast cells (CHMCs). Methods: CHMCs were obtained by culturing cord blood-derived CD34(+) cells in the presence of stem cell factor and IL-6 for 14 to 16 weeks. CHMCs were passively sensitized with human myeloma IgE and supplemented with or without IL-4 or IFN-gamma. After the sensitization, CHMCs were stimulated with anti-Fc epsilon RI alpha mAb. Concentrations of secreted cytokines were measured by using ELISA, and cytokine messenger RNA was analyzed by using quantitative competitive RT-PCR. Results: IL-4 profoundly enhanced Fc epsilon RI-mediated production of macrophage inflammatory protein (MIP) 1 alpha, IL-8, and CM-CSF For example, the enhancement by IL-4 (10 ng/mL) of the production of MIP-1 alpha IL-8, and GM-CSF was 25-, 7-, and 90-fold, respectively, after 6 hours. IL-4 also enhanced levels of Fc epsilon RI-induced cytokine messenger RNA but to a Lesser degree. in contrast, IFN-gamma inhibited Fc epsilon RI-induced production of MIP-1 alpha l IL-8, and GM-CSF. For example, the inhibition by IFN-gamma (10 ng/mL) of Fc epsilon RI-mediated production of MIP-1 alpha, IL-8, and GM-CSF was 80%, 75%, and 95%, respectively. IFN-gamma also suppressed Fc epsilon RI-induced messenger RNA expression of these cytokines. Neither IL-4 nor IFN-gamma affected the kinetics of cytokine production by CHMCs. Conclusion: These data suggest that IL-4 and IFN-gamma may influence allergic reactions by modulating human mast cell cytokine production.	Natl Childrens Med Res Ctr, Dept Allergy, Setagaya Ku, Tokyo 1548509, Japan; Natl Sagamihara HOsp, Dept Pediat, Kanagawa, Japan; Genox Res Inc, Tokyo, Japan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	National Center for Child Health & Development - Japan; Juntendo University; Johns Hopkins University; Johns Hopkins Medicine	Ebisawa, M (corresponding author), Natl Childrens Med Res Ctr, Dept Allergy, Setagaya Ku, 3-35-31 Taishido, Tokyo 1548509, Japan.			Ebisawa, Motohiro/0000-0003-4117-558X; Saito, Hirohisa/0000-0002-6630-8337				Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; Bonder CS, 1999, IMMUNOLOGY, V96, P529; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; EBISAWA M, 1995, J ALLERGY CLIN IMMUN, V95, P219; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Igarashi Y, 1996, CLIN EXP ALLERGY, V26, P597; Kluth DC, 1996, SEMIN NEPHROL, V16, P576; Lorentz A, 2000, J IMMUNOL, V164, P43, DOI 10.4049/jimmunol.164.1.43; MOLLER A, 1993, J IMMUNOL, V151, P3261; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; Saito H, 1996, J IMMUNOL, V157, P343; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; STEFFEN M, 1989, IMMUNOLOGY, V66, P445; Sur S, 1999, J IMMUNOL, V162, P6284; Tachimoto H, 1997, INT ARCH ALLERGY IMM, V113, P293, DOI 10.1159/000237578; Toru H, 1998, J ALLERGY CLIN IMMUN, V102, P491, DOI 10.1016/S0091-6749(98)70140-X; Toru H, 1996, INT IMMUNOL, V8, P1367; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; Yanagida M, 1996, IMMUNOLOGY, V89, P547, DOI 10.1046/j.1365-2567.1996.d01-768.x; Yano K, 1997, LAB INVEST, V77, P185	27	34	35	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				141	149		10.1067/mai.2000.107043	http://dx.doi.org/10.1067/mai.2000.107043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887317	Bronze			2022-12-18	WOS:000088393300019
J	Casas, R; Bottcher, MF; Duchen, K; Bjorksten, B				Casas, R; Bottcher, MF; Duchen, K; Bjorksten, B			Detection of IgA antibodies to cat, beta-lactoglobulin, and ovalbumin allergens in human milk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human milk; breast-feeding; antibodies; IgA; cat; beta-lactoglobulin; ovalbumin; ELISA; allergens	GROWTH-FACTOR-BETA; HUMAN B-CELLS; COWS MILK; IMMUNOGLOBULIN-A; RISK; INTERLEUKIN-6; ENVIRONMENT; RESPONSES; CHILDREN	Background: The relationship between the development of allergy during infancy and breast-feeding remains controversial. This controversy may be due to individual variations in the composition of human milk. Antibodies to food antigene to which the mother is commonly exposed are present in the milk, but their relationship to allergy is still unknown. IgA antibodies to inhalant allergens have not been previously detected. Objective: Our purpose was to analyze secretory IgA antibody levels to cat, beta-lactoglobulin, and ovalbumin allergens in colostrum and mature milk in relation to maternal allergy, Methods: Colostrum and samples of mature milk were obtained after 1 and 3 months of lactation from 53 nursing mothers (17 allergic and 36 nonallergic mothers) and were analyzed for total secretory IgA levels by ELISA and secretory IgA antibodies to cat, beta-lactoglobuIin, and ovalbumin by an enzyme-amplified ELISA, The specificity of the assays was confirmed by inhibition experiments. Results: Secretory IgA to cat, beta-lactoglobulin, and ovalbumin allergens were detected in colostrum as well as mature milk. The levels of secretory IgA to ovalbumin were lower in colostrum from allergic mothers with P = .016, whereas the levels to beta-lactoglobulin and cat were similar in the 2 groups. IgA antibodies to ovalbumin were detected in 94% of the colostrum samples from allergic and in all samples from nonallergic mothers, in 82% and 96%, respectively at 1 month, and 53% and 65% at 3 months. Fewer samples had detectable secretory IgA antibodies to beta-lactoglobulin than to ovalbumin and cat, and only 33% and 10% of the samples from the allergic and nonallergic mothers, respectively, remained positive at 3 months. All the allergic mothers had detectable IgA to cat in colostrum, whereas 83% and 73% of the samples were positive at 1 and 3 months, The corresponding numbers mere 93%, 81% and 81% in the nonallergic mothers (not significant). Conclusion: Even a low level of exposure of the mucosa (eg, by inhalant allergens) can induce antibody secretion into the milk, both in allergic and nonallergic mothers.	Fac Hlth Sci, Dept Hlth & Environm, Div Pediat, S-58185 Linkoping, Sweden		Casas, R (corresponding author), Fac Hlth Sci, Dept Hlth & Environm, Div Pediat, S-58185 Linkoping, Sweden.			Duchen, Karel/0000-0002-0570-8898				Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; Bjorksten B, 1997, INT ARCH ALLERGY IMM, V113, P80, DOI 10.1159/000237513; BJORKSTEN B, 1997, ENV RISK FACTORS ATO, V4; Brown MA, 1997, CLIN EXP ALLERGY, V27, P4, DOI 10.1046/j.1365-2222.1997.d01-430.x; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; DUCHEN K, 2000, PEDIATR ALLERGY IMMU, P11; FAGERASBOTTCHER M, 2000, PEDIATR RES, V47, P157; FALTHMAGNUSSON K, 1989, INT ARCH ALLER A IMM, V90, P297, DOI 10.1159/000235041; FALTHMAGNUSSON K, 1987, ALLERGY, V42, P64, DOI 10.1111/j.1398-9995.1987.tb02189.x; FUJIHASHI K, 1991, J CLIN INVEST, V88, P248, DOI 10.1172/JCI115284; Goldman A.S., 1995, HDB MILK COMPOSITION, V1st ed., P727; Hanson L A, 1991, Adv Exp Med Biol, V310, P1; HANSON LA, 1977, INT ARCH ALLER A IMM, V54, P457, DOI 10.1159/000231862; HATTEVIG G, 1990, J ALLERGY CLIN IMMUN, V85, P108, DOI 10.1016/0091-6749(90)90231-R; Jenmalm MC, 1999, PEDIATR ALLERGY IMMU, V10, P112, DOI 10.1034/j.1399-3038.1999.00015.x; Jones CA, 1998, CLIN EXP ALLERGY, V28, P655; LADJEVA I, 1989, CLIN EXP IMMUNOL, V78, P85; LILJA G, 1988, CLIN ALLERGY, V18, P131, DOI 10.1111/j.1365-2222.1988.tb02852.x; MACHTINGER S, 1986, J ALLERGY CLIN IMMUN, V77, P341, DOI 10.1016/S0091-6749(86)80115-4; MUNIR AKM, 1994, ALLERGY, V49, P508, DOI 10.1111/j.1398-9995.1994.tb01121.x; NILSSON L, 1998, RISK FACTORS ATOPIC; Prescott SL, 1998, J IMMUNOL, V160, P4730; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RENZ H, 1990, INT ARCH ALLER A IMM, V92, P247, DOI 10.1159/000235185; SAVILAHTI E, 1991, ACTA PAEDIATR SCAND, V80, P1207, DOI 10.1111/j.1651-2227.1991.tb11810.x; Savilahti E, 1991, Adv Exp Med Biol, V310, P417; VANVLASSELAER P, 1992, J IMMUNOL, V148, P2062; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; WU CY, 1992, CLIN IMMUNOL IMMUNOP, V62, P277, DOI 10.1016/0090-1229(92)90103-U	30	34	38	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1236	1240		10.1067/mai.2000.105805	http://dx.doi.org/10.1067/mai.2000.105805			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856160				2022-12-18	WOS:000087781800027
J	Donfack, J; Tsalenko, A; Hoki, DM; Parry, R; Solway, J; Lester, LA; Ober, C				Donfack, J; Tsalenko, A; Hoki, DM; Parry, R; Solway, J; Lester, LA; Ober, C			HLA-DRB1*01 alleles are associated with sensitization to cockroach allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HLA; cockroach allergens; asthma; Hutterites; African Americans	HUMAN IMMUNE-RESPONSE; LINKAGE DISEQUILIBRIUM; VIRAL-INFECTIONS; ASTHMA; HLA; CHILDREN; EXPOSURE; POLLEN; RESPONSIVENESS; POPULATION	Background: Sensitization to cockroach allergens is an important epidemiologic risk factor for asthma, particularly among African Americans living in urban environments. A recent genome screen in the Hutterites, a white founder population, identified a linkage between an HLA-Linked marker and sensitization to cockroach allergens. Objective: Our purpose was to determine whether alleles at one or more HLA loci are associated with sensitization to cockroach allergens in ethnically diverse populations. Methods: Alleles at 14 HLA region loci were studied in the Hutterites. On the basis of these results, selected loci were examined in 54 African Americans with cockroach sensitization (cases) and 65 African Americans without cockroach sensitization (controls). Sensitivity to cockroach allergens was assessed in both samples by skin prick test to purified cockroach allergens (Periplaneta americana and Blatella germanica). Results: Significant associations between cockroach allergies and DRB1*0101 (P-corrected=.0066), DQA1*0101 (P-corrected =.0012), and DQB1*0501 (P-corrected = .00096) were detected in the Hutterites. In the African American sample, the most significant association was with the DRB1*0102 allele (P-corrected = .0088, odds ratio 16.4, 95% confidence interval 2.0, 131). The DRB1*0101 allele was infrequent in the African American sample (frequency 0.06) and the DRB1*0102 allele was absent in the Hutterites, DRB1*0101 and DRB1*0102 are closely related alleles that differ from nearly all other DRB1 alleles at 3 amino acids in the 1 peptide binding domain of the HLA-DR molecule. Conclusions: The DRB1*0101 allele in the Hutterites and the DRB1*0101 allele in African Americans confer risk for cockroach sensitization. Elucidating this interaction at the molecular level may allow for more targeted treatment and prevention of atopic asthma in inner-city populations.	Univ Chicago, Dept Human Genet, Chicago, IL 60636 USA; Univ Chicago, Dept Med, Chicago, IL 60636 USA; Univ Chicago, Dept Pediat, Chicago, IL 60636 USA; Univ S Dakota, Dept Med, Sioux Falls, SD USA	University of Chicago; University of Chicago; University of Chicago; University of South Dakota	Ober, C (corresponding author), Univ Chicago, Dept Human Genet, 924 E 57th St, Chicago, IL 60636 USA.		Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530	NHLBI NIH HHS [UO1 HL49596, P50 HL56399] Funding Source: Medline; NICHD NIH HHS [R01 HD21244] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021244] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399, U01HL049596] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRESLOW NE, 1980, PUBLICATION IARC SCI, V32; Burge H, 1993, INDOOR ALLERGENS ASS; BUSSE WW, 1989, CLIN EXP ALLERGY, V19, P1, DOI 10.1111/j.1365-2222.1989.tb02336.x; FISCHER GF, 1992, HUM IMMUNOL, V33, P259, DOI 10.1016/0198-8859(92)90333-I; FREIDHOFF LR, 1988, TISSUE ANTIGENS, V31, P211, DOI 10.1111/j.1399-0039.1988.tb02083.x; JARDETZKY T, 1996, HLA MHC GENES MOL FU, P249; Jorde LB, 1998, BIOESSAYS, V20, P126, DOI 10.1002/(SICI)1521-1878(199802)20:2<126::AID-BIES5>3.0.CO;2-R; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P393; Lara-Marquez ML, 1999, CLIN EXP ALLERGY, V29, P60, DOI 10.1046/j.1365-2222.1999.00461.x; MANGE AP, 1964, HUM BIOL, V36, P104; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1987, IMMUNOGENETICS, V26, P230, DOI 10.1007/BF00346517; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; MARTIN AO, 1970, AM J PHYS ANTHROPOL, V32, P351, DOI 10.1002/ajpa.1330320305; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1995, AM J RESP CRIT CARE, V151, P1644, DOI 10.1164/ajrccm.151.5.7735627; NEUSPIEL DR, 1989, AM J PUBLIC HEALTH, V79, P168, DOI 10.2105/AJPH.79.2.168; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Ober C, 1997, AM J HUM GENET, V61, P497, DOI 10.1086/515511; OBER C, 1994, CLIN EXP ALLERGY, V4, P11; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Schlenker E H, 1985, S D J Med, V38, P5; Spielman RS, 1996, AM J HUM GENET, V59, P983; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; SRIRAMARAO P, 1990, CLIN EXP ALLERGY, V20, P555, DOI 10.1111/j.1365-2222.1990.tb03149.x; Togias A, 1997, INT ARCH ALLERGY IMM, V113, P87, DOI 10.1159/000237515; WARNER JA, 1997, CIBA FDN S, V206; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573; Weitkamp LR, 1999, IMMUNOGENETICS, V49, P491, DOI 10.1007/s002510050525; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x	32	34	38	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					960	966		10.1067/mai.2000.106926	http://dx.doi.org/10.1067/mai.2000.106926			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808177				2022-12-18	WOS:000087185000015
J	Sakaguchi, M; Hori, H; Hattori, S; Irie, S; Imai, A; Yanagida, M; Miyazawa, H; Toda, M; Inouye, S				Sakaguchi, M; Hori, H; Hattori, S; Irie, S; Imai, A; Yanagida, M; Miyazawa, H; Toda, M; Inouye, S			IgE reactivity to alpha 1 and alpha 2 chains of bovine type I collagen in children with bovine gelatin allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; anaphylaxis; cross-reactivity; IgE; gelatin; vaccine	IMMEDIATE-TYPE REACTIONS; HUMAN MAST-CELLS; MEASLES-VACCINE; MUMPS; ANAPHYLAXIS; SEQUENCE; ANTIBODY; SURVIVAL	Background: Anaphylactic reactions to measles, mumps, and rubella vaccines, including gelatin as a stabilizer, have been reported. It had been found that most of these reactions to live vaccines are caused by the bovine gelatin included in these vaccines. Gelatin mainly includes denatured type I collagen, which consists of alpha 1 and alpha 2 chains. Objective: The current study was designed to investigate the IgE reactivity to alpha 1 and alpha 2 chains of bovine type I collagen in gelatin-sensitive children. Methods: Serum samples were taken from 10 children who had anaphylaxis to the vaccines and high levels of specific IgE to bovine gelatin. Bovine type I collagen was isolated from bovine skin and then separated to alpha 1 and alpha 2 chains by column chromatography, IgE reactivity to denatured type I collagen and its alpha 1 and alpha 2 chains was analyzed by immunoblotting, ELISA, and histamine release from the mast cells passive sensitized with IgE antibodies in pooled serum of the children. Results: All children had specific IgE to bovine type I collagen. Furthermore, IgE antibodies in their sera reacted with the alpha 2 chain but not with the alpha 1 chain. Similarly, the mast cells sensitized with pooled sera in the children showed alpha 2 chain-specific histamine release but not a1 chain-specific histamine release. Conclusion: In gelatin allergy denatured bovine type I collagen is a major allergen and IgE-binding sites exist in the alpha 2 chain of type I collagen.	Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 162, Japan; Natl Inst Infect Dis, Dis Surveilance Ctr, Shinjuku Ku, Tokyo 162, Japan; Tokyo Med & Dent Univ, Med Res Inst, Div Adult Dis, Tokyo 162, Japan; Nippi Res Inst Biomatrix, Tokyo 162, Japan; Kyorin Univ, Dept Med Technol, Tokyo 162, Japan; Kirwin Brewery, Pharmaceut Dev Lab, Gunma, Japan	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); Tokyo Medical & Dental University (TMDU); Kyorin University	Sakaguchi, M (corresponding author), Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Toyama 1-23-1, Tokyo 162, Japan.		Toda, Masako/S-9810-2019; Inouye, Sharon/R-7216-2019					AUKRUST L, 1980, ALLERGY, V35, P581, DOI 10.1111/j.1398-9995.1980.tb01808.x; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P213; BIRK D, 1994, CELL JUNCTIONS CELL, P978; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; Budavari S., 1996, MERCK INDEX, P742; BUSINCO L, 1994, ANN ALLERGY, V72, P1; HASHIZUME S, 1994, CLIN VIROL, V22, P140; HORI H, 1992, MOL IMMUNOL, V29, P759; JANTUNENBACKMAN K, 1987, AM J DIS CHILD, V141, P1103; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; Miyazawa H, 1996, J ALLERGY CLIN IMMUN, V98, P948, DOI 10.1016/S0091-6749(96)80011-X; PIEZ KA, 1963, BIOCHEMISTRY-US, V2, P58, DOI 10.1021/bi00901a012; POLLOCK TM, 1983, LANCET, V1, P753; Sakaguchi M, 1999, IMMUNOLOGY, V96, P286, DOI 10.1046/j.1365-2567.1999.00696.x; Sakaguchi M, 1999, J ALLERGY CLIN IMMUN, V103, P349, DOI 10.1016/S0091-6749(99)70512-9; Sakaguchi M, 1997, VACCINE, V15, P121, DOI 10.1016/S0264-410X(96)00170-3; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P263, DOI 10.1016/S0091-6749(97)70108-8; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P720, DOI 10.1016/S0091-6749(97)70038-1; Shirai T, 1998, MATRIX BIOL, V17, P85, DOI 10.1016/S0945-053X(98)90076-2; THURSTON A, 1987, J ROY COLL GEN PRACT, V37, P41; WET WD, 1987, J BIOL CHEM, V262, P32; Yanagida M, 1996, IMMUNOLOGY, V89, P547, DOI 10.1046/j.1365-2567.1996.d01-768.x; YANAGIDA M, 1995, BLOOD, V86, P3705, DOI 10.1182/blood.V86.10.3705.bloodjournal86103705; ZIMMERMAN B, 1993, ALLERGY PRINCIPLES P, P469	28	34	36	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				695	699		10.1016/S0091-6749(99)70344-1	http://dx.doi.org/10.1016/S0091-6749(99)70344-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482848	Bronze			2022-12-18	WOS:000082870000036
J	Wickens, K; Crane, J; Pearce, N; Beasley, R				Wickens, K; Crane, J; Pearce, N; Beasley, R			The magnitude of the effect of smaller family sizes on the increase in the prevalence of asthma and hay fever in the United Kingdom and New Zealand	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma prevalence; hay fever prevalence; family size; birth order; England; Wales; New Zealand	BRITISH BIRTH COHORTS; ALLERGIC SENSITIZATION; RESPIRATORY SYMPTOMS; CHILDHOOD INFECTION; ATOPIC DISORDER; AGE 16; CHILDREN; SCHOOLCHILDREN; POPULATION; DISEASE	Background: Declining family size is one factor that has been proposed to contribute to increasing asthma and hay fever prevalence, but its relative importance has not been quantified. Objective: Our purpose was to determine the change in asthma and hay fever prevalence that would be expected from the reduction in family size that has occurred in England/Wales and New Zealand over recent decades, Methods: The relative change in family size between 1961 and 1991 in England/Wales and New Zealand was determined from census data for these years. Summary weighted odds ratios were calculated for the associations among birth order, family size, and asthma and hay fever prevalence. The expected increase in the prevalence of asthma and hay fever between 1961 and 1991 resulting from changes in family size was then calculated. Results: The expected relative increase in the prevalence of asthma between 1961 and 1991 as a result of the smaller family size was 1% and 5% for England/Wales and New Zealand, respectively; smaller family size mould be expected to increase the prevalence of hay fever prevalence in England/Wales by 4%. Conclusions: Changes in family size over the last 30 years do not appear to explain much of the reported increase in asthma or hay fever prevalence. The contribution that other risk factors have made to these increases could be assessed with use of a similar approach.	Wellington Sch Med, Wellington Asthma Res Grp, Dept Med, Wellington S, New Zealand	University of Otago	Wickens, K (corresponding author), Wellington Sch Med, Wellington Asthma Res Grp, Dept Med, POB 7343, Wellington S, New Zealand.			Beasley, Richard/0000-0003-0337-406X; Pearce, Neil/0000-0002-9938-7852				ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; BURR M, 1989, ARCH DIS CHILD, V6, P1452; Butland BK, 1997, THORAX, V52, P618, DOI 10.1136/thx.52.7.618; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; DAVIS JB, 1981, THORAX, V36, P185, DOI 10.1136/thx.36.3.185; *DEP STAT, 1993, 1991 CENS NZ HOM; *DEP STAT, 1965, NZ PEOPL 1961 GEN RE, V10; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HALKEN S, 1995, ALLERGY, V50, P97; HAMMAN RF, 1975, BRIT J PREV SOC MED, V29, P228; Holgate ST, 1998, QJM-MON J ASSOC PHYS, V91, P171, DOI 10.1093/qjmed/91.3.171; Hopkin JM, 1997, CURR OPIN IMMUNOL, V9, P788, DOI 10.1016/S0952-7915(97)80179-3; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; KLJAKOVIC M, 1991, NEW ZEAL MED J, V104, P378; LEADBITTER P, 1999, IN PRESS THORAX; Lewis S, 1996, THORAX, V51, P670, DOI 10.1136/thx.51.7.670; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; MOYES CD, 1995, NEW ZEAL MED J, V108, P358; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; Nicolai T, 1997, Arch Toxicol Suppl, V19, P201; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Office of Population Censuses and Surveys, 1994, POP TRENDS; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; PECKHAM C, 1978, J EPIDEMIOL COMMUN H, V32, P79, DOI 10.1136/jech.32.2.79; PlattsMills TAE, 1997, NEW ENGL J MED, V336, P1382, DOI 10.1056/NEJM199705083361909; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; SHAHEEN SO, 1995, CLIN EXP ALLERGY, V25, P1034; SHAW R, 1994, NEW ZEAL MED J, V107, P387; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; WICKENS K, 1999, IN PRESS EPIDEMIOLOG	40	34	35	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				554	558		10.1016/S0091-6749(99)70323-4	http://dx.doi.org/10.1016/S0091-6749(99)70323-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482827				2022-12-18	WOS:000082870000015
J	Molet, S; Ramos-Barbon, D; Martin, JG; Hamid, Q				Molet, S; Ramos-Barbon, D; Martin, JG; Hamid, Q			Adoptively transferred late allergic response is inhibited by IL-4, but not IL-5, antisense oligonucleotide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; T-H2-type lymphocytes; lung resistance; eosinophils; cytokines; rats	COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; LATE AIRWAY RESPONSES; BROWN-NORWAY RATS; ANTIGEN CHALLENGE; T-CELLS; MURINE MODEL; EOSINOPHIL FUNCTION; INTERFERON-GAMMA; LUNG DAMAGE	Background: We have shown previously that the late airways response (LAR) can be transferred by ovalbumin-primed CD4(+) T lymphocytes in Brown Norway rats. This response is associated with an increase of eosinophils and high expression of T-H2 cytokines (IL-4 and IL-5) in bronchoalveolar lavage (BAL) fluid. Objective: In this study we hypothesized that the inhibition of IL-4 or IL-5 production in the CD4(+) cells transferred to a naive animal could decrease the LAR and prevent airway eosinophilia in response to antigen challenge. Methods: CD4(+) cells, purified from the cervical lymph nodes of ovalbumin-sensitized rats, were maintained in culture for 6 hours with medium alone or with 10 mu g/mL IL-4 antisense (AS), IL-5 AS, or control AS oligodeoxynucleotide. Then the cells were administrated intraperitoneally to naive rats, which were challenged 2 days later by a 5% ovalbumin aerosol, The lung resistance was measured for 8 hours, and then BAL was performed. Cytospin preparations from BAL cells were assessed for the presence of eosinophils by immunocytochemistry for major basic protein and for IL-4, IL-5, and IFN-gamma expression. Results: In rats injected with IL-4 AS-treated T cells, LAR, eosinophils, and IL-4 and IL-5 expression were significantly decreased compared with the other groups. Only IL-5 expression in BAL fluid was slightly decreased consequent to the transfer of IL-5 AS-treated T cells. Conclusion: This study demonstrates that, in the CD4(+) T cell-driven LAR, the early production of IL-4, but not IL-5, by the transferred CD4(+) cells is essential for the development of the LAR.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada	McGill University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		RAMOS-BARBON, DAVID/C-6624-2009	RAMOS-BARBON, DAVID/0000-0002-9615-6557; Martin, James/0000-0001-7574-5363				BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; Coyle AJ, 1998, EUR J IMMUNOL, V28, P2640, DOI 10.1002/(SICI)1521-4141(199809)28:09&lt;2640::AID-IMMU2640&gt;3.0.CO;2-X; DEL PG, 1988, J IMMUNOL, V140, P4193; EIDELMAN DH, 1988, AM REV RESPIR DIS, V137, P1033, DOI 10.1164/ajrccm/137.5.1033; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210, DOI 10.1164/ajrccm.157.1.9702074; Kaminuma O, 1997, AM J RESP CELL MOL, V16, P448, DOI 10.1165/ajrcmb.16.4.9115756; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUNG TT, 1995, AM J RESP CELL MOL, V13, P360, DOI 10.1165/ajrcmb.13.3.7654390; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Nakamura T, 1997, J IMMUNOL, V158, P2648; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; RENZI PM, 1993, AM REV RESPIR DIS, V147, P967, DOI 10.1164/ajrccm/147.4.967; Renzi PM, 1996, AM J RESP CELL MOL, V15, P367, DOI 10.1165/ajrcmb.15.3.8810641; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SAPIENZA S, 1990, AM REV RESPIR DIS, V142, P353, DOI 10.1164/ajrccm/142.2.353; SAPIENZA S, 1991, AM REV RESPIR DIS, V144, P423, DOI 10.1164/ajrccm/144.2.423; SWAIN SL, 1990, J IMMUNOL, V145, P3796; THORNHILL MH, 1991, J IMMUNOL, V146, P592; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALSH GM, 1991, INT ARCH ALLER A IMM, V94, P174, DOI 10.1159/000235355; Watanabe A, 1997, AM J RESP CELL MOL, V16, P69, DOI 10.1165/ajrcmb.16.1.8998081; WATANABE A, 1995, J CLIN INVEST, V96, P1303, DOI 10.1172/JCI118165; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	38	34	37	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					205	214		10.1016/S0091-6749(99)70137-5	http://dx.doi.org/10.1016/S0091-6749(99)70137-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400863	Bronze			2022-12-18	WOS:000081738900033
J	Dastych, J; Walczak-Drzewiecka, A; Wyczolkowska, J; Metcalfe, DD				Dastych, J; Walczak-Drzewiecka, A; Wyczolkowska, J; Metcalfe, DD			Murine mast cells exposed to mercuric chloride release granule-associated N-acetyl-beta-D-hexosaminidase and secrete IL-4 and TNF-alpha	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cell; mercuric chloride; IL-4; TNF-alpha	FC-EPSILON-RI; TUMOR-NECROSIS-FACTOR; BROWN-NORWAY RAT; T-CELLS; TYROSINE PHOSPHORYLATION; AMALGAM FILLINGS; DENTAL AMALGAM; IGE ANTIBODY; INTERLEUKIN-4; CHILDREN	Background: Mast cells, by virtue of their location within the skin, respiratory tract, and gastrointestinal system, are considered as potential targets for environmental agents with immunotoxic effects, Mercuric chloride (HgCl2), is a xenobiotic, which induces autoimmune glomerulonephritis and stimulates polyclonal IgE production. Objective: We sought to determine the ability of HgCl2 to degranulate murine mast cells and promote cytokine secretion and whether this was an active biologic process. Methods: Bone marrow-derived murine mast cells were exposed to HgCl2, and the release of N-acetyl-beta-D-hexosaminidase and secretion of IL-4 and TNF-alpha were measured. Results: HgCl2 was found to directly activate murine mast cells to release the granule-associated enzyme N-acetyl-beta-D-hexosaminidase and to secrete the proinflammatory cytokines IL-4 and TNF-alpha. Cytokine secretion occurred hours after exposure to HgCl2 and required transcription and protein synthesis. The secretion of cytokines mediated by HgCl2 was additive to that which followed Fc epsilon RI-induced mast cell activation. The IL-4 secretion by mast cells occurred at concentrations of HgCl2 (10(-6) mol/L to 10(-5) mol/L) comparable with those required to induce upregulation of IgE production in experimental animals. Conclusion: These findings demonstrate that HgCl2 will directly activate mast cells, which is followed by degranulation and IL-4 and TNF-alpha synthesis and secretion. These findings are consistent with recognition of HgCl2 as a biologically important environmentally derived immunotoxic agent for mast cells.	Polish Acad Sci, Dept Biogen Amines, PL-90950 Lodz, Poland; NIAID, Lab Allerg Dis, NIH, Bethesda, MD USA	Polish Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Dastych, J (corresponding author), Polish Acad Sci, Dept Biogen Amines, POB 225, PL-90950 Lodz, Poland.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000513, Z01AI000513] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; Casale TB, 1996, AM J RESP CELL MOL, V15, P35, DOI 10.1165/ajrcmb.15.1.8679220; Dastych J, 1997, J IMMUNOL, V158, P1803; Eley BM, 1997, BRIT DENT J, V182, P413, DOI 10.1038/sj.bdj.4809401; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; *INT STUD ASTHM AL, 1988, LANCET, V351, P1225; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; Kiely PDW, 1997, J IMMUNOL, V159, P5100; LIU FT, 1980, J IMMUNOL, V124, P2728; MacDougal KC, 1996, ENVIRON HEALTH PERSP, V104, P1102, DOI 10.1289/ehp.961041102; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Neurath MF, 1997, EUR J IMMUNOL, V27, P1743, DOI 10.1002/eji.1830270722; OCHEL M, 1991, J IMMUNOL, V146, P3006; OLIVEIRA DBG, 1995, EUR J IMMUNOL, V25, P2259, DOI 10.1002/eji.1830250822; PELLETIER L, 1988, J IMMUNOL, V140, P750; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PRIGENT P, 1995, CELL IMMUNOL, V161, P107, DOI 10.1006/cimm.1995.1014; PROUVOSTDANON A, 1981, J IMMUNOL, V126, P699; ROELS H, 1987, ANN OCCUP HYG, V31, P135, DOI 10.1093/annhyg/31.2.135; SUZUKI T, 1993, SCI TOTAL ENVIRON, V136, P213, DOI 10.1016/0048-9697(93)90310-3; Trepka MJ, 1997, ARCH ENVIRON HEALTH, V52, P134, DOI 10.1080/00039899709602877; TSAI M, 1996, FASEB J, V10, pA1218; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Warbrick EV, 1995, TOXICOLOGY, V104, P179, DOI 10.1016/0300-483X(95)03146-7; YOSHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P11931, DOI 10.1073/pnas.92.25.11931; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	26	34	37	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1108	1114		10.1016/S0091-6749(99)70186-7	http://dx.doi.org/10.1016/S0091-6749(99)70186-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359893	Bronze			2022-12-18	WOS:000080929500020
J	Mordvinov, VA; Schwenger, GTF; Fournier, R; De Boer, ML; Peroni, SE; Singh, AD; Karlen, S; Holland, JW; Sanderson, CJ				Mordvinov, VA; Schwenger, GTF; Fournier, R; De Boer, ML; Peroni, SE; Singh, AD; Karlen, S; Holland, JW; Sanderson, CJ			Binding of YY1 and Oct1 to a novel element that downregulates expression of IL-5 in human T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-5; promoter; transcription; nuclear factors; T cells; gene expression	HUMAN INTERLEUKIN-5 GENE; HUMAN PAPILLOMAVIRUS TYPE-18; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; PROMOTER; IDENTIFICATION; PROTEINS; SITES; LYMPHOKINES; REPRESSION	Background: IL-5 controls development of eosinophilia and has been shown to be involved in the pathogenesis of allergic diseases. In both atopic and nonatopic asthma, elevated IL-5 has been detected in peripheral blood and the airways. IL-5 is produced mainly by activated T cells, and its expression is regulated at the transcriptional level. Objective: This study focuses on the functional analysis of the human IL-5 (hIL-5) promoter and characterization of eis-regulatory elements and transcription factors involved in the suppression of IL-5 transcription in T cells. Methods: Methods used in this study include DNase I footprint assays, electrophoretic mobility shift assays, and functional analysis by mammalian cell transfection involving deletion analysis and site-directed mutagenesis. Results: We identified 5 protein binding regions (BRs) located within the proximal hIL-5 promoter. Functional analysis indicates that the BRs are involved in control of hIL-5 promoter activity. Two of these regions, BR3 and BR4 located at positions -102 to -73, have not previously been described as regulators of IL-5 expression in T cells. We show that the BR3 sequence contains a novel negative regulatory element located at positions -90 to -79 of the hIL-5 promoter, which binds Oct1, octamer-like, and YY1 nuclear factors. Substitution mutations, which abolished binding of these proteins to the BR3 sequence, significantly increased hIL-5 promoter activity in activated T cells. Conclusion: We suggest that Oct1, YY1, and octamer-like factors binding to the -90/-79 sequence within the proximal IL-5 promoter are involved in suppression of IL-5 transcription in T cells.	TVW Telethon Inst Child Hlth Res, W Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia	Mordvinov, VA (corresponding author), TVW Telethon Inst Child Hlth Res, POB 855, W Perth, WA 6872, Australia.		Holland, John W/B-5485-2010; Mordvinov, Viatcheslav A/S-8277-2017	Mordvinov, Viatcheslav A/0000-0002-6173-0774				CAMPBELL HD, 1988, EUR J BIOCHEM, V174, P345, DOI 10.1111/j.1432-1033.1988.tb14104.x; Delhase M, 1996, J BIOL CHEM, V271, P32349, DOI 10.1074/jbc.271.50.32349; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Karlen S, 1996, BLOOD, V88, P211; KARLEN S, 1993, J VIROL, V67, P4296, DOI 10.1128/JVI.67.7.4296-4306.1993; KEES UR, 1994, J IMMUNOL METHODS, V168, P1, DOI 10.1016/0022-1759(94)90202-X; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Maniatis T., 1989, MOL CLONING LAB MANU; Mori A, 1997, INT ARCH ALLERGY IMM, V113, P272, DOI 10.1159/000237570; NAORA H, 1994, J IMMUNOL, V153, P3466; NAORA H, 1994, BLOOD, V83, P3620; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P189; Stranick KS, 1997, J BIOL CHEM, V272, P16453, DOI 10.1074/jbc.272.26.16453; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Ye JP, 1996, MOL CELL BIOL, V16, P157; Ye JP, 1996, MOL CELL BIOL, V16, P4744	29	34	36	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1125	1135		10.1016/S0091-6749(99)70188-0	http://dx.doi.org/10.1016/S0091-6749(99)70188-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359895				2022-12-18	WOS:000080929500022
J	Wantke, F; MacGlashan, DW; Langdon, JM; MacDonald, SM				Wantke, F; MacGlashan, DW; Langdon, JM; MacDonald, SM			The human recombinant histamine releasing factor: Functional evidence that it does not bind to the IgE molecule	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rat basophilic leukemia cells (RBL-SX38, RBL-2H3); basophils; IgE heterogeneity; Fc epsilon RI	HUMAN BASOPHILS; RECEPTOR; HETEROGENEITY; PURIFICATION; EOSINOPHILS; EXPRESSION; SECRETION; ANTIBODY; IL-3	Background: We have previously shown that the human recombinant histamine releasing Factor (HrHRF) caused histamine release From a subset of basophils from donors with allergy, and this release seemed to be dependent on the presence of a certain type of IgE, termed IgE+. IgE molecules that did not support HrHRF-induced histamine release were termed IgE-. However, subsequently we demonstrated that HrHRF primes anti-IgE-antibody-induced histamine release from all basophils, irrespective of the type of IgE on the cell surface. Objective: Because these data suggested that HrHRF does not exert its biologic effects by binding to IgE, but rather that it interacted with a surface receptor on the basophil, me wanted to obtain functional evidence that HrHRF did or did not bind to the IgE molecule. Methods: The rat basophilic leukemia cell fine (RBL-SX38), which has been transfected to express a functional human Fc epsilon RI (alpha-, beta-, and gamma-chains of the receptor) in addition to the normal rat FceRI, was used. The presence of the human Fc epsilon RI receptor enables these cells to be sensitized with human IgE, Cells were passively sensitized with 1000 ng/mL human IgE+ or 1000 ng/mL human Ige for 60 minutes at 37 degrees C. Unsensitized cells served as a control. After the cells were washed, 1 x 10(5) cells were stimulated in the presence of 1 mmol/L Ca2+ with 0.1 mu g/mL anti-IgE, 40 mu g/mL HrHRF, or 40 mu g/mL mouse recombinant HRP (MrHRF), which has 96% homology to HrHRF, Results: Mean anti-IgE-induced histamine release was 33% +/- 15%, and there was no difference between IgE+ sensitization (32% +/- 12%) and IgE- sensitization (34% +/- 18%). However, in contrast to human basophil experiments, neither HrHRF (0% +/- 0%) nor MrHRF (3% +/- 5%) caused histamine release in RBL cells sensitized with IgE+, In addition, priming the transfected RBL-SX38 cells or the parental cell line, RBL-2H3 cells, with HrHRF or MrHRF did not increase anti-IgE-induced histamine release. Conclusion: The results indicate that HrHRF does not bind to IgE, either IgE+ or IgG. Therefore it appears likely that rHRF signals through its own specific receptor, which is not expressed or functional on RBL-SX38 or RBL-2H3 cells, but which seems to be expressed on basophils of atopic and nonatopic donors.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	MacDonald, SM (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NIAID NIH HHS [AI 20253, AI 32651] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032651, R01AI020253, R01AI032651] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEZA ML, 1989, J CLIN INVEST, V83, P1204, DOI 10.1172/JCI114002; Bheekha-Escura R, 1998, J ALLERGY CLIN IMMUN, V101, pS230; BheekhaEscura R, 1997, J ALLERGY CLIN IMMUN, V99, P368; BOHM H, 1989, BIOCHEM INT, V19, P277; Burch Gross, 1989, NUCLEIC ACIDS RES, V17, P8367; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; KLEINETEBBE J, 1995, J IMMUNOL METHODS, V179, P153, DOI 10.1016/0022-1759(94)00279-6; KULCZYCKI A, 1974, J EXP MED, V139, P600, DOI 10.1084/jem.139.3.600; KUNA P, 1993, J IMMUNOL, V150, P1932; LEVY DA, 1966, J IMMUNOL, V97, P203; LIU FT, 1980, J IMMUNOL, V124, P2728; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MACDONALD SM, 1991, CLIN EXP ALLERGY, V21, P133, DOI 10.1111/j.1365-2222.1991.tb00815.x; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Rajakulasingam K, 1998, AM J RESP CRIT CARE, V158, P233, DOI 10.1164/ajrccm.158.1.9708106; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; Sanchez JC, 1997, ELECTROPHORESIS, V18, P150, DOI 10.1002/elps.1150180127; Schroeder JT, 1997, J IMMUNOL, V159, P447; Schroeder JT, 1996, J EXP MED, V183, P1265, DOI 10.1084/jem.183.3.1265; Seminario MC, 1998, J ALLERGY CLIN IMMUN, V101, pS175; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Wiegand TW, 1996, J IMMUNOL, V157, P221; Yamaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1279, DOI 10.1016/S0091-6749(96)70196-3	26	34	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					642	648		10.1016/S0091-6749(99)70237-X	http://dx.doi.org/10.1016/S0091-6749(99)70237-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200014				2022-12-18	WOS:000079723900018
J	Garraud, O; Mollis, SN; Holland, SM; Sneller, MC; Malech, HL; Gallin, JI; Nutman, TB				Garraud, O; Mollis, SN; Holland, SM; Sneller, MC; Malech, HL; Gallin, JI; Nutman, TB			Regulation of immunoglobulin production in hyper-IgE (Job's) syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; hyper-IgE; IFN-gamma; IgE; IgG4; IL-4; IL-12; IL-13; Job's syndrome	HUMAN B-CELLS; NECROSIS-FACTOR-ALPHA; HUMAN HELMINTH INFECTIONS; INTERFERON-GAMMA; HYPERIMMUNOGLOBULIN-E; T-CELLS; MONONUCLEAR-CELLS; INTERLEUKIN-12 SUPPRESSES; HUMAN-LYMPHOCYTES; IGG4 PRODUCTION	Background: The hyper-IgE (HIE), or Job's, syndrome is a rare, complex disorder characterized by high levels of serum IgE in childhood and chronic dermatitis with recurrent, often severe sinopulmonary and skin infections. Although the etiology of HIE syndrome is unknown, there is evidence that patients with HIE have abnormalities in cellular immune responses, as well as in the production of polyclonal and antigen-specific antibodies, Furthermore, there appears to be a common (but still undefined) mechanism underlying the regulation of IgE and IgG4 in this condition. Objective: We sought to assess the role of cytokines or cytokine receptor blockade in regulating IgE and IgG4 production in HIE. Methods: PBMCs were isolated from patients with HIE (n = 9) and normal individuals (n = 8), and IgE and IgG4 production was assessed spontaneously, in the presence of recombinant IL-4, IL-13, IL-6, IL-8, IL-12, and IFN-gamma, under conditions in which the n-4R was blocked or when these cytokines were neutralized by specific monoclonal or polyclonal antibodies. Results: In PBMCs from patients with HIE, a significant (P <.01) reduction in the spontaneously produced IgE (and IgG4) was induced by either IFN-gamma or IL-12, although neither cytokine could totally abrogate the immunoglobulin production, Whereas spontaneous IgE land IgG4) production was not affected by exogenous IL-4 and IL-13, neutralizing antibodies to IL-4 and IL-13 also significantly (P < .01) reduced the production of IgE and IgG4, a finding supported by the observation of increased expression of IgE germline transcripts in these patients. In contrast to the neutralization of IL-4 and IL-13 protein, anti-IL-4R antibodies or soluble n-4R completely suppressed IgE and IgG4 production in HIE. Similarly, IL-8 or antibodies to IL-6 and TNF-alpha, cytokines known to affect IL-4-dependent IgE production, completely inhibited both IgE and IgG4 production. Conclusion: These data show that overproduction of IgE and IgG4 can be regulated by a number of cytokines affecting the IL-4-dependent pathway of IgE/IgG4 production in HIE and suggest new targets for therapeutic intervention.	NIAID, Helminth Immunol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; NIAID, Immunol Dis Sect, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; NIH, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	Nutman, TB (corresponding author), NIAID, Helminth Immunol Sect, Parasit Dis Lab, NIH, Bldg 4,Room 126, Bethesda, MD 20892 USA.			Malech, Harry/0000-0001-5874-5775	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000646, ZIAAI000805, Z01AI000805, ZIAAI000644, Z01AI000644, ZIAAI000646] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERSE RC, 1993, ALLERGY, V48, P559, DOI 10.1111/j.1398-9995.1993.tb00749.x; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Blaser K, 1996, ADV EXP MED BIOL, V409, P295; CHRETIEN I, 1990, EUR J IMMUNOL, V20, P243, DOI 10.1002/eji.1830200203; CLAASSEN JJ, 1991, J ALLERGY CLIN IMMUN, V88, P713, DOI 10.1016/0091-6749(91)90177-P; CLAASSEN JL, 1990, J IMMUNOL, V144, P2123; deBoer BA, 1997, INFECT IMMUN, V65, P1122, DOI 10.1128/IAI.65.3.1122-1125.1997; DELPRETE G, 1989, J CLIN INVEST, V84, P1830, DOI 10.1172/JCI114368; DEVRIES JE, 1994, J INVEST DERMATOL, V102, P141, DOI 10.1111/1523-1747.ep12371750; DONABEDIAN H, 1983, MEDICINE, V62, P195, DOI 10.1097/00005792-198307000-00001; DRESKIN SC, 1985, J CLIN INVEST, V75, P26, DOI 10.1172/JCI111683; ELSON LH, 1994, INT IMMUNOL, V6, P1003, DOI 10.1093/intimm/6.7.1003; FIOR R, 1994, EUR CYTOKINE NETW, V5, P593; GARRAUD O, 1995, J IMMUNOL, V155, P1316; Garraud O, 1996, INT IMMUNOL, V8, P1841, DOI 10.1093/intimm/8.12.1841; Garraud O, 1996, B I PASTEUR, V94, P285, DOI 10.1016/S0020-2452(97)87084-4; GAUCHAT JF, 1992, INT IMMUNOL, V4, P397, DOI 10.1093/intimm/4.3.397; Grimbacher B, 1998, NEW ENGL J MED, V338, P1073; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; JABARA HH, 1993, J IMMUNOL, V151, P4528; JEPPSON JD, 1991, J PEDIATR-US, V118, P383, DOI 10.1016/S0022-3476(05)82151-1; KIMATA H, 1992, J EXP MED, V176, P1227, DOI 10.1084/jem.176.4.1227; KIMATA H, 1995, EUR J IMMUNOL, V25, P1497, DOI 10.1002/eji.1830250604; KIMATA H, 1995, BLOOD, V85, P3191, DOI 10.1182/blood.V85.11.3191.bloodjournal85113191; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; KING CL, 1993, J IMMUNOL, V151, P458; KINIWA M, 1992, J CLIN INVEST, V90, P262, DOI 10.1172/JCI115846; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LEUNG DYM, 1988, J ALLERGY CLIN IMMUN, V81, P1082, DOI 10.1016/0091-6749(88)90873-1; LEUNG DYM, 1988, HEMATOL ONCOL CLIN N, V2, P81; LEUNG DYM, 1992, PEDIATR RES, V33, pS56; LOH RKS, 1990, INT ARCH ALLER A IMM, V93, P285, DOI 10.1159/000235255; MAGGI E, 1989, IMMUNOLOGY, V68, P300; MAHANTY S, 1992, J IMMUNOL, V148, P3567; PAGANELLI R, 1995, J ALLERGY CLIN IMMUN, V95, P995, DOI 10.1016/S0091-6749(95)70100-1; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Pistoia V, 1997, IMMUNOL TODAY, V18, P343, DOI 10.1016/S0167-5699(97)01080-3; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RIECKMANN P, 1991, J IMMUNOL, V146, P3462; Ring J, 1989, Curr Probl Dermatol, V18, P79; SCHANDENE L, 1993, EUR J IMMUNOL, V23, P56, DOI 10.1002/eji.1830230110; SONDERGAARD I, 1992, ALLERGY, V47, P467, DOI 10.1111/j.1398-9995.1992.tb00666.x; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; TANG HY, 1993, EUR J IMMUNOL, V23, P899, DOI 10.1002/eji.1830230420; VANOMMEN R, 1994, EUR J IMMUNOL, V24, P1396, DOI 10.1002/eji.1830240624; VERCELLI D, 1991, J ALLERGY CLIN IMMUN, V88, P285, DOI 10.1016/0091-6749(91)90087-5; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; VERCELLI D, 1993, ALLERGY PROC, V14, P413, DOI 10.2500/108854193778792795; WHITE CJ, 1986, CLIN IMMUNOL IMMUNOP, V40, P50, DOI 10.1016/0090-1229(86)90068-1; YSSEL H, 1994, INT IMMUNOL, V6, P1091, DOI 10.1093/intimm/6.7.1091; ZHANG XH, 1992, EUR J IMMUNOL, V22, P829, DOI 10.1002/eji.1830220330	54	34	39	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				333	340		10.1016/S0091-6749(99)70510-5	http://dx.doi.org/10.1016/S0091-6749(99)70510-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949327	Bronze			2022-12-18	WOS:000078630100023
J	Norman, PS				Norman, PS			Immunotherapy: Past and present	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							RAGWEED HAY-FEVER; NATURALLY-OCCURRING ALLERGENS; ALGINATE-CONJUGATED EXTRACT; DECREASES SKIN SENSITIVITY; GRASS-POLLEN EXTRACTS; HOUSE DUST MITE; DOUBLE-BLIND; DERMATOPHAGOIDES-PTERONYSSINUS; IGE ANTIBODIES; PERENNIAL RHINITIS		Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Norman, PS (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							AAS K, 1963, ACTA PAEDIATR, V52, P338, DOI 10.1111/j.1651-2227.1963.tb03789.x; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; AHLSTEDT S, 1977, INT ARCH ALLER A IMM, V55, P400, DOI 10.1159/000231951; ARBESMAN CE, 1960, J ALLERGY, V31, P342, DOI 10.1016/0021-8707(60)90070-8; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BARR SE, 1965, J ALLERGY, V36, P47, DOI 10.1016/0021-8707(65)90032-8; Besredka A, 1907, ANN I PASTEUR, V21, P384; BLAINEY AD, 1984, ALLERGY, V39, P521, DOI 10.1111/j.1398-9995.1984.tb00873.x; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; CONNELL JT, 1964, J ALLERGY, V35, P169, DOI 10.1016/0021-8707(64)90031-0; CONNELL JT, 1962, J ALLERGY, V33, P365, DOI 10.1016/0021-8707(62)90036-9; Cooke R. A, 1918, NY MED J, V107, P577; Cooke RA, 1937, J EXP MED, V66, P689, DOI 10.1084/jem.66.6.689; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; COOKE RA, 1933, J ALLERGY, V4, P87; CORRADO OJ, 1989, ALLERGY, V44, P108, DOI 10.1111/j.1398-9995.1989.tb02233.x; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; CRETICOS PS, 1993, J ALLERGY CLIN IMMUN, V91, P226; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DAMATO G, 1995, CLIN EXP ALLERGY, V25, P149, DOI 10.1111/j.1365-2222.1995.tb01020.x; De Besche A, 1923, AM J MED SCI, V166, P265, DOI 10.1097/00000441-192308000-00015; DEUSCHL H, 1977, ACTA ALLERGOL, V32, P248, DOI 10.1111/j.1398-9995.1977.tb01357.x; DEUSCHL H, 1977, CLIN ALLERGY, V7, P315, DOI 10.1111/j.1365-2222.1977.tb01459.x; DIEGES PH, 1976, ACTA ALLERGOL, V31, P130, DOI 10.1111/j.1398-9995.1976.tb01487.x; DOLOVICH J, 1970, J ALLERGY, V45, P286, DOI 10.1016/0021-8707(70)90034-1; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; *EX COMM AAAI, 1994, J ALLERGY CLIN IMMUN, V93, P811; FEINBERG SM, 1952, J ALLERGY, V23, P387, DOI 10.1016/0021-8707(52)90001-4; FONTANA VJ, 1966, J AMER MED ASSOC, V195, P985, DOI 10.1001/jama.195.12.985; FONTANA VJ, 1965, JAMA-J AM MED ASSOC, V193, P985; FORGACS P, 1968, BRIT MED J, V3, P774; FOUCARD T, 1972, INT ARCH ALLER A IMM, V43, P360, DOI 10.1159/000230851; FRANKLAND AW, 1954, LANCET, V1, P1055; FRANKLAND AW, 1966, PRACTITIONER, V196, P766; FRANKLAND AW, 1955, BRIT MED J, V2, P941, DOI 10.1136/bmj.2.4945.941; Freeman J, 1911, LANCET, V2, P814; FUCHS AM, 1959, J ALLERGY, V30, P66, DOI 10.1016/0021-8707(59)90060-7; Gay LN, 1927, B JOHNS HOPKINS HOSP, V40, P270; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; Harley D, 1937, J PATHOL BACTERIOL, V44, P589, DOI 10.1002/path.1700440307; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Hedlin G, 1995, J ALLERGY CLIN IMMUN, V96, P879, DOI 10.1016/S0091-6749(95)70223-7; HELANDER E., 1959, ACTA ALLERGOL, V13, P47, DOI 10.1111/j.1398-9995.1959.tb02750.x; HUHTI E, 1974, ANN ALLERGY, V33, P145; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA K, 1967, J IMMUNOL, V99, P849; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; Jacobsen L, 1996, J ALLERGY CLIN IMMUN, V97, P198; JOHANSSO.SG, 1974, CLIN ALLERGY, V4, P57, DOI 10.1111/j.1365-2222.1974.tb01363.x; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; JOHNSTONE DE, 1959, J PEDIAT, V24, P427; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V85, P606, DOI 10.1016/0091-6749(90)90100-I; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; Levine P, 1926, J IMMUNOL, V11, P449; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1968, J ALLERGY, V41, P49, DOI 10.1016/0021-8707(68)90007-5; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Loveless MH, 1943, J IMMUNOL, V47, P165; Loveless MH, 1940, J IMMUNOL, V38, P25; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MARKIN L. E., 1931, JOUR ALLERGY, V2, P285, DOI 10.1016/S0021-8707(31)90076-2; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MARSH DG, 1972, IMMUNOLOGY, V22, P1013; MATHEWS KP, 1981, INT ARCH ALLER A IMM, V66, P218, DOI 10.1159/000232821; MAY CD, 1970, J ALLERGY, V46, P73, DOI 10.1016/0021-8707(70)90075-4; MEHTA S B, 1975, Clinical Allergy, V5, P279; Melillo G, 1997, ALLERGY, V52, P5, DOI 10.1111/j.1398-9995.1997.tb04814.x; MILLER ACML, 1974, CLIN ALLERGY, V4, P49, DOI 10.1111/j.1365-2222.1974.tb01362.x; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MOSBECH H, 1989, ALLERGY, V44, P487, DOI 10.1111/j.1398-9995.1989.tb04188.x; MOSS RB, 1987, J ALLERGY CLIN IMMUN, V79, P387, DOI 10.1016/0091-6749(87)90160-6; MULLER U, 1993, ALLERGY, V48, P37; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P384, DOI 10.1016/0091-6749(78)90118-5; NORMAN PS, 1994, ARB PEI GSH, V87, P59; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; NORMAN PS, 1966, CLIN PHARM, P639; ORTOLANI C, 1994, ALLERGY, V49, P13, DOI 10.1111/j.1398-9995.1994.tb00767.x; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; PEGELOW KO, 1984, ALLERGY, V39, P275, DOI 10.1111/j.1398-9995.1984.tb00864.x; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; PIENKOWSKI MM, 1988, J ALLERGY CLIN IMMUN, V82, P95, DOI 10.1016/0091-6749(88)90057-7; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SCULLY MARGARET A., 1941, JOUR ALLERGY, V12, P549, DOI 10.1016/S0021-8707(41)90202-2; Sherman WB, 1941, J IMMUNOL, V40, P289; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; STEIN MR, 1978, J ALLERGY CLIN IMMUN, V62, P211, DOI 10.1016/0091-6749(78)90209-9; STULL ARTHUR, 1940, JOUR ALLERGY, V11, P439, DOI 10.1016/S0021-8707(40)90456-7; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TURK A, 1970, IMMUNOLOGY, V19, P85; TURKELTAUB PC, 1991, ALLERGEN IMMUNOTHERA, P171; van Halteren HK, 1997, J ALLERGY CLIN IMMUN, V100, P767, DOI 10.1016/S0091-6749(97)70271-9; VANARSDEL P, 1961, J ALLERGY, V32, P348, DOI 10.1016/0021-8707(61)90103-4; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VANMETRE TE, 1989, J ALLERGY CLIN IMMUN, V83, P888, DOI 10.1016/0091-6749(89)90102-4; VANMETRE TE, 1990, J ALLERGY CLIN IMMUN, V86, P587, DOI 10.1016/S0091-6749(05)80217-9; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; WAHN U, 1988, J ALLERGY CLIN IMMUN, V82, P360, DOI 10.1016/0091-6749(88)90007-3; WELSH PW, 1981, J ALLERGY CLIN IMMUN, V67, P237, DOI 10.1016/0091-6749(81)90067-1; WIDE L, 1967, LANCET, V2, P1105; YANG WH, 1979, J ALLERGY CLIN IMMUN, V63, P300, DOI 10.1016/0091-6749(79)90123-4; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	136	34	39	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					1	10		10.1016/S0091-6749(98)70046-6	http://dx.doi.org/10.1016/S0091-6749(98)70046-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679840	hybrid			2022-12-18	WOS:000074909500001
J	Zimmerman, B; Gold, M; Wherrett, D; Hanna, AK				Zimmerman, B; Gold, M; Wherrett, D; Hanna, AK			Adrenal suppression in two patients with asthma treated with low doses of the inhaled steroid fluticasone propionate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MILD ASTHMA		St Michaels Hosp, Gage Occupat & Environm Hlth Unit, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Hlth Sci Res Ctr, Toronto, ON M5B 1W8, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Toronto, Wellesley Hosp, Toronto, ON M4Y 1J3, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Zimmerman, B (corresponding author), 45A Alvin Ave, Toronto, ON M4T 2A7, Canada.							DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; DOULL IJM, 1995, ARCH DIS CHILD, V72, P321, DOI 10.1136/adc.72.4.321; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; *NAT ASTHM ED PREV, 1997, 974051 NAT ASTHM ED	4	34	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					425	426		10.1016/S0091-6749(98)70260-X	http://dx.doi.org/10.1016/S0091-6749(98)70260-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525464	Bronze			2022-12-18	WOS:000072593900025
J	Cottin, V; Deviller, P; Tardy, F; Cordier, JF				Cottin, V; Deviller, P; Tardy, F; Cordier, JF			Urinary eosinophil-derived neurotoxin/protein X: A simple method for assessing eosinophil degranulation in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; degranulation; cationic protein; eosinophil-derived neurotoxin; chronic eosinophilic pneumonia	PULMONARY IMMUNE CELLS; CHURG-STRAUSS-SYNDROME; MAJOR BASIC-PROTEIN; CATIONIC PROTEIN; HYPEREOSINOPHILIC SYNDROME; BRONCHIAL-ASTHMA; MYALGIA SYNDROME; PNEUMONIA; DISEASE; TRYPTOPHAN	Background: Eosinophil-derived neurotoxin/protein X (EDN/EPX), one of the cationic granule proteins released by polymorphonuclear eosinophils, can be detected in human urine. Objective: We sought to evaluate whether the urinary release of EDN/EPX was dependent on the blood eosinophil cell count, the bronchoalveolar eosinophil cell count, or both and on the clinical diagnosis, We also attempted to determine the precise kinetics of decrease of EDN excretion and eosinophil counts after the onset of corticosteroid treatment. Methods: Daily urinary release of EDN/EPX was measured by radioimmunoassay in 28 patients with high hypereosinophilia (group 1), 32 patients with moderate hypereosinophilia (group 2), 26 patients without hypereosinophilia at the time of the study but with a known pulmonary disease involving eosinophils (group 3), and 13 control patients (group 4). Results: The urinary excretion of EDN/EPX was significantly higher in patients from groups 1 or 2 than in patients from groups 3 or 4. Particularly high levels of EDN/EPX excretion were observed in patients from groups 1 or 2 with chronic eosinophilic pneumonia (chronic eosinophilic pneumonia: 4.7 +/- 8.1 mg/day, control subjects: 0.39 +/- 0.33 mg/day, p < 0.001), Urinary excretion of EDN/EPX was significantly correlated with blood (r = 0.66, p < 0.001) and differential bronchoalveolar (r = 0.62, p = 0.04) eosinophil cell counts in patients from group 1 but not from the other groups, Corticosteroid treatment was followed by a significant decrease in EDN/EPX excretion. The kinetics of decrease in EDN/EPX were delayed as compared with the dramatic drop in peripheral eosinophil counts, Distinct kinetics between urinary EDN/EPX and eosinophil counts differentiated the recurrence of chronic eosinophilic pneumonia from an asthma attack in one patient. Conclusion: Measurement of urinary EDN/EPX excretion may be a useful indicator of eosinophil degranulation in vivo.	Univ Lyon 1, Hop Cardiovasc & Pneumol Louis Pradel, Serv Pneumol, F-69394 Lyon 03, France; Univ Lyon 1, Hop Cardiovasc & Pneumol Louis Pradel, Biochim Lab, F-69394 Lyon, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Cordier, JF (corresponding author), Univ Lyon 1, Hop Cardiovasc & Pneumol Louis Pradel, Serv Pneumol, F-69394 Lyon 03, France.							ALLEN JN, 1994, AM J RESP CRIT CARE, V150, P1423, DOI 10.1164/ajrccm.150.5.7952571; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BOUSQUET J, 1994, AM J RESP CRIT CARE, V150, P533; CAPRON M, 1990, EOSINOPHILS ALLERGY, P11; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; CORDIER JF, 1990, EUR RESPIR J, V3, P115; COTTIN V, 1995, J ALLERGY CLIN IMMUN, V96, P261, DOI 10.1016/S0091-6749(95)70018-8; COTTIN V, 1996, AM J RESP CRIT CARE, V153, pA201; DEVILLER P, 1991, CLIN CHIM ACTA, V201, P105, DOI 10.1016/0009-8981(91)90031-7; FILLEY WV, 1982, LANCET, V2, P11; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GLEICH GJ, 1991, LUNG, P581; GONZALEZ EB, 1986, J ALLERGY CLIN IMMUN, V79, P755; GRANTHAM JG, 1986, AM J MED, V80, P89, DOI 10.1016/0002-9343(86)90053-7; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; JANIN A, 1993, THORAX, V48, P57, DOI 10.1136/thx.48.1.57; KANEKO M, 1995, J CLIN INVEST, V95, P2813, DOI 10.1172/JCI117986; KITA H, 1992, J IMMUNOL, P692; Kristjansson S, 1996, J ALLERGY CLIN IMMUN, V97, P1179, DOI 10.1016/S0091-6749(96)70182-3; KROEGEL C, 1994, EUR RESPIR J, V7, P743, DOI 10.1183/09031936.94.07040743; KROEGEL C, 1994, EUR RESPIR J, V7, P519, DOI 10.1183/09031936.94.07030519; KROEGEL C, 1992, CLIN INVESTIGATOR, V70, P447; MARTIN RW, 1990, ANN INTERN MED, V113, P124, DOI 10.7326/0003-4819-113-2-124; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; PETERS MS, 1988, BLOOD, V71, P780; PETERSON C, 1996, AM J RESP CRIT CARE, V153, pA201; PETERSON CGB, 1987, BIOCHEM J, V245, P781, DOI 10.1042/bj2450781; PRIN L, 1986, CLIN EXP IMMUNOL, V63, P249; QUINONEZ GE, 1986, CLIN INVEST MED, V9, P238; REIMERT CM, 1991, J IMMUNOL METHODS, V141, P97, DOI 10.1016/0022-1759(91)90214-Z; REIMERT CM, 1993, J IMMUNOL METHODS, V166, P183, DOI 10.1016/0022-1759(93)90359-F; TAI PC, 1984, BRIT MED J, V289, P400, DOI 10.1136/bmj.289.6442.400; TARDY F, 1993, CLIN CHEM, V39, P919; WALLEN N, 1991, J IMMUNOL, V147, P3490; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; ZIMMERMAN B, 1994, CLIN EXP ALLERGY, V24, P149, DOI 10.1111/j.1365-2222.1994.tb00212.x	37	34	34	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				116	123		10.1016/S0091-6749(98)70202-7	http://dx.doi.org/10.1016/S0091-6749(98)70202-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449510				2022-12-18	WOS:000071539800018
J	Suda, T; Nagata, S				Suda, T; Nagata, S			Why do defects in the Fas-Fas ligand system cause autoimmunity?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology	JUL   06, 1996	TOKYO, JAPAN	Novartis Pharma KK, Tokyo, Japan			ACTIVATED B-CELLS; LUPUS-PRONE MICE; NEGATIVE T-CELLS; COMPLEX CLASS-I; LPR-LPR MICE; LPR/LPR MICE; AUTOANTIBODY PRODUCTION; LYMPHOPROLIFERATIVE SYNDROME; MEDIATED CYTOTOXICITY; INDUCED APOPTOSIS	We have previously isolated genes that encode Fas and Fas ligand, a receptor-ligand pair that mediates an apoptotic signal. We also have demonstrated that lpr and gld mice, well-known animal models of autoimmune disease are loss-of-function mutants of the Fas and Fas ligand genes, respectively. Patients with autoimmune lymphoproliferative disorders have been found to bear mutations of the Fas gene. These findings indicate that the Fas-Fas ligand system plays an important role in the maintenance of self-tolerance among both humans and mice. During T-cell development, mouse T cells initially express Fas in the thymus and maintain their expression thereafter. Peripheral B cells usually express Fas at much lower levels than do T cells, but various stimuli enhance Fas expression on B cells. In contrast, among the lymphocyte subsets, only activated T cells and natural killer cells express readily detectable levels of Fas ligand. Reactivation of previously activated T cells through T-cell receptors induces apoptosis. This phenomenon (activation-induced cell death) is mediated by means of the Fas-Fas ligand interaction. We recently discovered that peripheral naive T cells in mice are susceptible to Fas ligand but not to agonistic anti-Fas antibodies. To our surprise, engagement of T-cell receptors on naive T cells was shown to induce Fas ligand resistance. On the basis of these findings and other reports, we discuss how the breakdown of self-tolerance occurs as the result of defects in the Fas-Fas ligand system.	Osaka Biosci Inst, Dept Mol Biol, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Genet, Osaka, Japan	Osaka University	Suda, T (corresponding author), Osaka Biosci Inst, Dept Mol Biol, 6-2-4 Furuedai, Osaka 565, Japan.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				Adachi M, 1996, P NATL ACAD SCI USA, V93, P2131, DOI 10.1073/pnas.93.5.2131; ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ARASE H, 1994, J EXP MED, V180, P423, DOI 10.1084/jem.180.2.423; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Christianson GJ, 1996, J IMMUNOL, V156, P4932; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Eisenberg R A, 1994, Semin Immunol, V6, P49, DOI 10.1006/smim.1994.1008; ETTINGER R, 1995, J IMMUNOL, V154, P4302; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GIESE T, 1994, J IMMUNOL, V152, P2000; GIESE T, 1995, J IMMUNOL, V154, P4986; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, EUR J IMMUNOL, V26, P721, DOI 10.1002/eji.1830260332; HANG LM, 1984, J IMMUNOL, V132, P1809; HERRON LR, 1993, J IMMUNOL, V151, P3450; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JEVNIKAR AM, 1994, J EXP MED, V179, P1137, DOI 10.1084/jem.179.4.1137; KOH DR, 1995, EUR J IMMUNOL, V25, P2558, DOI 10.1002/eji.1830250923; MALDONADO MA, 1995, J EXP MED, V181, P641, DOI 10.1084/jem.181.2.641; MARIANI SM, 1994, EUR J IMMUNOL, V24, P3119, DOI 10.1002/eji.1830241231; MIXTER PF, 1995, J IMMUNOL, V154, P2063; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NISHIMURA Y, 1995, J IMMUNOL, V154, P4395; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; OHTEKI T, 1995, EUR J IMMUNOL, V25, P37, DOI 10.1002/eji.1830250108; PERKINS DL, 1990, J IMMUNOL, V145, P549; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; Renno T, 1996, J EXP MED, V183, P431, DOI 10.1084/jem.183.2.431; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SANTORO TJ, 1988, J EXP MED, V167, P1713, DOI 10.1084/jem.167.5.1713; SCOTT DE, 1993, J IMMUNOL, V150, P664; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; STEINBERG AD, 1980, J IMMUNOL, V125, P871; Suda T, 1996, J IMMUNOL, V157, P3918; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; Watanabe D, 1995, INT IMMUNOL, V7, P1949, DOI 10.1093/intimm/7.12.1949; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WOFSY D, 1985, J IMMUNOL, V134, P852	46	34	43	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	2	S			S97	S101		10.1016/S0091-6749(97)70013-7	http://dx.doi.org/10.1016/S0091-6749(97)70013-7			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR026	9440553	Bronze			2022-12-18	WOS:000071449600013
J	Bengtsson, U; Knutson, TW; Knutson, L; Dannaeus, A; Hallgren, R; Ahlstedt, S				Bengtsson, U; Knutson, TW; Knutson, L; Dannaeus, A; Hallgren, R; Ahlstedt, S			Eosinophil cationic protein and histamine after intestinal challenge in patients with cow's milk intolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						albumin; allergy; eosinophils; eosinophil cationic protein; food intolerance; gastrointestinal; histamine; mast cells	MAJOR BASIC-PROTEIN; ALLERGIC INFLAMMATION; CHEMOTACTIC FACTOR; ASTHMA; FOOD; LEUKOCYTES; ACTIVATION; DISEASES; MARKERS; IGE	Background: Mast cells and eosinophils are key cells in the development of active symptoms in allergic diseases and other inflammatory conditions, and they mediate their action through the release of very potent granule constituents. Methods: Five patients with milk-related gastrointestinal symptoms diagnosed by double-blind placebo-controlled milk challenges, but with negative responses to skin prick tests and RASTs with milk, and eight healthy control subjects were investigated. Repeated perfusion studies were performed with a two-balloon, six-channel tube by using milk, casein, and whey as antigens. Luminal eosinophil cationic protein, histamine, and albumin were measured by radioimmunoassay. Results: Luminal cow's milk induced a pronounced increase in intestinal secretion of histamine and eosinophil cationic protein in patients, but not control subjects, during the first 20 minutes after challenge (histamine from 123 +/- 12 to 543 +/- 175 ng/cm, hr; eosinophil cationic protein from 80 +/- 23 to 686 +/- 262 ng/cm, hr). Albumin, as a marker of plasma leakage, was also significantly increased. Conclusion: These data indicate that mast cells and eosinophils are effector cells not only in patients with allergic disease but also in patients intolerant to foods and lacking circulating antibodies. The underlying mechanisms may be a reaction mediated by locally appearing antibodies or an immunologic activation resembling that found in intestinal disorders such as celiac disease.	UNIV HOSP, DEPT ANAESTHESIOL, GOTHENBURG, SWEDEN; UNIV HOSP, DEPT SURG, GOTHENBURG, SWEDEN; UNIV HOSP, DEPT INTERNAL MED, GOTHENBURG, SWEDEN; UNIV GOTHENBURG, DEPT CLIN IMMUNOL, GOTHENBURG, SWEDEN; PHARMACIA DIAGNOST AB, S-75182 UPPSALA, SWEDEN	University of Gothenburg; Pfizer; Pharmacia Corporation	Bengtsson, U (corresponding author), SAHLGRENS UNIV HOSP, ASTHMA & ALLERGY RES CTR, S-41345 GOTHENBURG, SWEDEN.							BACHERT C, 1990, Rhinology (Utrecht), V28, P149; BIGNOLD LP, 1995, EXPERIENTIA, V51, P317, DOI 10.1007/BF01928887; BONINI S, 1993, ALLERGY, V48, P133, DOI 10.1111/j.1398-9995.1993.tb04716.x; BRANDTZAEG P, 1991, BIBL NUTR DIET, V48, P30; BRUIJNZEEL P, 1993, J ALLERGY CLIN IMMUN, V91, P634, DOI 10.1016/0091-6749(93)90269-L; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; COYLE AJ, 1995, J CLIN INVEST, V95, P1735, DOI 10.1172/JCI117850; Durham S R, 1993, Pediatr Allergy Immunol, V4, P7; ENGSTROMLAURENT A, 1985, ANN RHEUM DIS, V44, P83, DOI 10.1136/ard.44.2.83; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; HALLGREN R, 1991, EOSINOPHIL INFLAMMAT, P119; HERNNAS J, 1992, EUR J CELL BIOL, V59, P352; HOHMANN A, 1983, J IMMUNOL METHODS, V64, P199, DOI 10.1016/0022-1759(83)90398-8; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; KNUTSON L, 1989, AM J GASTROENTEROL, V84, P1278; KOLMANNSKOG S, 1985, INT ARCH ALLER A IMM, V76, P133, DOI 10.1159/000233679; LAVO B, 1989, AM J MED, V87, P655, DOI 10.1016/0002-9343(89)90726-2; LUNDGREN JD, 1991, J ALLERGY CLIN IMMUN, V87, P689, DOI 10.1016/0091-6749(91)90390-A; MAKINO S, 1995, ALLERGY PROC, V16, P13, DOI 10.2500/108854195778690110; MALUENDA C, 1984, J PEDIATR GASTR NUTR, V3, P349, DOI 10.1097/00005176-198406000-00008; Mehta Hemalini, 1994, Comprehensive Therapy, V20, P651; Mensinga Tjeert T., 1994, Annals of Epidemiology, V4, P382; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; MOQBEL R, 1986, IMMUNOLOGY, V59, P87; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; RAIBLE DG, 1992, J IMMUNOL, V148, P3536; REED CE, 1994, ANN ALLERGY, V72, P376; SAAVEDRADELGADO AM, 1985, ANN ALLERGY, V55, P694; SMART HL, 1986, HEPATO-GASTROENTEROL, V33, P47; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; VENGE P, 1983, IMMUNOBIOLOGY EOSINO, P163; VRIES J, 1994, CURR OPIN IMMUNOL, V6, P835; WARDLAW AJ, 1994, J ALLERGY CLIN IMMUN, V94, P1163, DOI 10.1016/0091-6749(94)90327-1; WASSERMAN SI, 1980, ENVIRON HEALTH PERSP, V35, P153, DOI 10.2307/3428985; WELLER PF, 1992, CURR OPIN IMMUNOL, V4, P782, DOI 10.1016/0952-7915(92)90062-J; WINQVIST I, 1981, ALLERGY, V36, P419, DOI 10.1111/j.1398-9995.1981.tb01848.x	39	34	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					216	221		10.1016/S0091-6749(97)70227-6	http://dx.doi.org/10.1016/S0091-6749(97)70227-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275143				2022-12-18	WOS:A1997XR35100012
J	Walsh, GM; Wardlaw, AJ				Walsh, GM; Wardlaw, AJ			Dexamethasone inhibits prolonged survival and autocrine granulocyte-macrophage colony-stimulating factor production by human eosinophils cultured on laminin or tissue fibronectin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; dexamethasone; laminin; fibronectin; extracellular matrix; cytokines; integrins; prolonged survival	ADHESION; DEGRANULATION; ACTIVATION; EXPRESSION; MIGRATION; RECEPTOR; CYTOKINE; ASTHMA; VLA-4; CELLS	Background: Eosinophil autocrine generation of viability-promoting cytokines resulting from interaction with extracellular matrix (ECM) proteins may be important in promoting their persistence in allergic inflammation. Objective: We examined eosinophil interaction with fibronectin, laminin, collagen, fibrinogen, hyaluronate, or vitronectin in terms of adhesion and for their ability to promote prolonged eosinophil survival by autocrine generation of IL-3, IL-5, or granulocyte-macrophage colony-stimulating factor (GM-CSF). The effect of dexamethasone was examined because it may inhibit integrin-dependent autocrine generation of viability-enhancing cytokines. Methods: Microtiter wells were coated with different ECM proteins, and assays were performed to determine their levels of eosinophil adhesion, and tests were performed to determine their prolonged survival in culture, The receptors involved in these processes, the cytokines generated, and the effect of a dose range of dexamethasone were all examined. Results: Eosinophils cultured for 3 days on laminin or tissue fibronectin exhibited dose-dependent prolonged survival, which was not seen with any other ECM protein. Unstimulated eosinophils adhered to wells coated with laminin or fibronectin but not to wells coated with any of the other ECM proteins that were tested, Laminin-dependent eosinophil adhesion and prolonged survival were inhibited by specific monoclonal antibodies to beta 1 and alpha 6 beta 1. Laminin-dependent survival was inhibited by a neutralizing antibody to GM-CSF, an anti-IL-5 antibody achieved a measurable hut insignificant inhibition of survival, and an antibody to IL-3 had no effect, Increasing concentrations of dexamethasone (maximal at 10(-7) mol/L) inhibited both laminin-and fibronectin-dependent enhanced eosinophil viability at 3 days, Eosinophils cultured on either laminin or fibronectin for 24 or 72 hours generated picogram quantities of GM-CSF, which were inhibited by the addition of dexamethasone (10(-7) mol/L). Conclusion: We have confirmed that eosinophils adhere to laminin in an alpha 6 beta 1-dependent manner, and this interaction results in the autocrine generation of GM-CSF, which enhances eosinophil survival in culture. Both laminin and tissue fibronectin-dependent autocrine GM-CSF generation were inhibited by physiologically relevant concentrations of dexamethasone. This may represent an important mechanism by which glucocorticoids reduce the tissue eosinophilia in allergic disease.	UNIV LEICESTER,DEPT RESP MED,SCH MED,LEICESTER LE1 7RH,LEICS,ENGLAND	University of Leicester			Walsh, Garry/D-4869-2013	Walsh, Garry/0000-0002-7138-4078; Wardlaw, Andrew/0000-0001-6583-0791	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1991, CELL BIOL EXTRACELLU; ANWAR ARE, 1994, IMMUNOLOGY, V82, P222; ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839; BOCHNER B, 1995, J ALLERGY CLIN IMMUN, V94, P427; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DRI P, 1991, J IMMUNOL, V147, P613; GEORAS SN, 1993, BLOOD, V82, P2872; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HERSHBERGER RP, 1990, MOL CELL BIOL, V10, P662, DOI 10.1128/MCB.10.2.662; HORIE S, 1994, J IMMUNOL, V152, P5457; KAWABORI S, 1991, LAB INVEST, V64, P224; Kita H, 1996, J IMMUNOL, V156, P1174; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LAMAS AM, 1991, J IMMUNOL, V147, P254; Meagher LC, 1996, J IMMUNOL, V156, P4422; MOULD AP, 1990, J BIOL CHEM, V265, P4020; NEELEY SP, 1994, AM J RESP CELL MOL, V11, P206, DOI 10.1165/ajrcmb.11.2.8049081; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRY CJF, 1993, IMMUNOPHARMACOLOGY E, P1; TOURKIN A, 1993, CELL ADHES COMMUN, V1, P161, DOI 10.3109/15419069309095692; WALLEN N, 1991, J IMMUNOL, V147, P3490; WALSH GM, 1995, CLIN EXP ALLERGY, V25, P1128, DOI 10.1111/j.1365-2222.1995.tb03260.x; Walsh GM, 1996, IMMUNOLOGY, V89, P112, DOI 10.1046/j.1365-2567.1996.d01-713.x; WARDLAW AJ, 1994, ALLERGY, V49, P797, DOI 10.1111/j.1398-9995.1994.tb00778.x; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62	29	34	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					208	215		10.1016/S0091-6749(97)70226-4	http://dx.doi.org/10.1016/S0091-6749(97)70226-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275142				2022-12-18	WOS:A1997XR35100011
J	Beezhold, D; Pugh, B; Liss, G; Sussman, G				Beezhold, D; Pugh, B; Liss, G; Sussman, G			Correlation of protein levels with skin prick test reactions in patients allergic to latex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; latex proteins; Lowry assay; immunoassay; skin prick tests	DISPOSABLE MEDICAL GLOVES; NATURAL-RUBBER; DIAGNOSIS; EXTRACTS; AEROALLERGENS; PREVALENCE; ANTIGENS	Background: Natural rubber later (NRL) gloves are the major source of proteins that cause latex allergic reactions in sensitized health care workers and patients. Objective: This study evaluated the effect of manufacturing changes on reducing protein, antigen, and allergen levels of latex medical gloves. Methods: Three types of NRL gloves were manufactured with a common batch of compounded later. The NRL gloves were analyzed for total protein by using the American Society for Testing and Materials D5712-95 Lowry method, and specifically for latex proteins by immunoassay. Allergen levels in the extracts were determined by end-point titration skin prick tests (SPTs) on patients allergic to NRL. Results: Extracts from regular powdered gloves had detectable levels of latex proteins and allergens (62% SPT positive), whereas the powder-free gloves were bw in protein content and allergenicity (5% to 8% SPT positive). No significant difference in SPT reactivity was observed between the chlorinated powder-free gloves and the polymer-coated gloves. Although the protein levels determined by the Lowly assay correlated with SPT reactivity (r = 0.95), the test was restricted by a high detection limit (9.3 mu g/ml). Fifty-eight percent of patients allergic to latex reacted at the 50 mu g/gm detection limit allowed by the Food and Drug Administration. The ELISA had a good correlation with SPT reactivity (r = 0.93), and because of the greater sensitivity, gloves testing below the ELISA reporting limit (0.06 mu g/ml) have a significantly lower potential for. eliciting reactions in patients allergic to latex. Conclusions: Results of protein assays are acceptable criteria with which to rate the potential allergenicity of gloves; however; the American Society for Testing and Materials D5712-95 assay may lack the sensitivity to provide clinically relevant data.	ALADAN CORP, DOTHAN, AL USA; ONTARIO MINIST LABOR, TORONTO, ON, CANADA; UNIV TORONTO, TORONTO, ON, CANADA	University of Toronto	Beezhold, D (corresponding author), GUTHRIE RES INST, LAB MACROPHAGE BIOL, 1 GUTHRIE SQ, SAYRE, PA 18840 USA.			Beezhold, Donald/0000-0001-5543-5747				ALENIUS H, 1994, ANN ALLERGY, V73, P315; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; Beezhold D, 1996, ANN ALLERG ASTHMA IM, V76, P520, DOI 10.1016/S1081-1206(10)63271-1; BEEZHOLD D, 1993, P INT C AMST, P25; BEEZHOLD D, 1992, GUTHRIE J, V61, P77; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; HAMILTON RG, 1994, J LAB CLIN MED, V123, P594; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; JONES RT, 1994, ANN ALLERGY, V73, P321; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; MAKINENKILJUNEN S, 1992, J ALLERGY CLIN IMMUN, V90, P230, DOI 10.1016/0091-6749(92)90076-E; MELTON AL, 1992, INT LATEX C, P26; OWNBY DR, 1994, J ALLERGY CLIN IMMUN, V93, P282; PATTERSON P, 1995, OR MANAGER, V11, P1; SCHWARTZ HJ, 1995, J ALLERGY CLIN IMMUN, V95, P139, DOI 10.1016/S0091-6749(95)70165-6; SUBRAMANIAM A, 1992, INT LATEX C SENS LAT, P63; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; SUSSMAN GL, 1995, ANN ALLERG ASTHMA IM, V75, P133; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; SWANSON MC, 1995, J ALLERGY CLIN IMMUN, V95, P153; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; TAYLOR JK, 1987, QUALITY ASSURANCE CH, P57; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; VASSALLO SA, 1995, ANESTH ANALG, V80, P1057, DOI 10.1097/00000539-199505000-00039; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3; Zehr Bradley D., 1995, Biomedical Instrumentation and Technology, V29, P434	31	34	34	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1097	1102		10.1016/S0091-6749(96)80197-7	http://dx.doi.org/10.1016/S0091-6749(96)80197-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977511				2022-12-18	WOS:A1996WB37800015
J	Kolmer, HL; Taketomi, EA; Hazen, KC; Hughs, E; Wilson, BB; PlattsMills, TAE				Kolmer, HL; Taketomi, EA; Hazen, KC; Hughs, E; Wilson, BB; PlattsMills, TAE			Effect of combined antibacterial and antifungal treatment in severe atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV VIRGINIA, HLTH SCI CTR, ASTHAMA & ALLERG DIS CTR, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT DERMATOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia				Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R37AI020565, R01AI030840] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, AI-30840] Funding Source: Medline; PHS HHS [R RO-847] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BESNIER E, 1892, ANN DERMATOL SYPHIL, V3, P634; CLEMMENSEN OJ, 1983, SEMIN DERMATOL, V2, P26; Cohen MB, 1930, J IMMUNOL, V18, P419; Hopkins JG, 1930, P SOC EXP BIOL MED, V27, P342; JENSENJAROLIM E, 1992, J ALLERGY CLIN IMMUN, V89, P44, DOI 10.1016/S0091-6749(05)80039-9; KAPP A, 1993, ALLERGY, V48, P1, DOI 10.1111/j.1398-9995.1993.tb02167.x; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; MASENGA J, 1990, INT J DERMATOL, V29, P579, DOI 10.1111/j.1365-4362.1990.tb03473.x; MIDDLETON E, 1993, ALLERGY PRINCIPLES P; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; QUEILLEROUSSEL C, 1985, ACTA DERM-VENEREOL, V114, P89; ROST GA, 1932, ARCH DERMATOL SYPHIL, V155, P297; Rostenberg A, 1937, ARCH DERMATOL SYPH, V35, P433, DOI 10.1001/archderm.1937.01470210059006; RYSTEDT I, 1989, ALLERGY, V44, P79, DOI 10.1111/j.1398-9995.1989.tb04321.x; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SONENTHAL KR, 1993, J ALLERGY CLIN IMMUN, V91, P971, DOI 10.1016/0091-6749(93)90208-W; SVEJGAARD E, 1989, ACTA DERM-VENEREOL, P140; SVEJGAARD E, 1990, SEMIN DERMATOL, V9, P255; WAERSTED A, 1985, ACTA DERM-VENEREOL, P146; Walker IC, 1918, J AMER MED ASSOC, V70, P897; [No title captured]	21	34	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					702	707		10.1016/S0091-6749(96)70106-9	http://dx.doi.org/10.1016/S0091-6749(96)70106-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828550				2022-12-18	WOS:A1996VJ42800029
J	Chanez, P; Vignola, AM; Albat, B; Springall, DR; Polak, JM; Godard, P; Bousquet, J				Chanez, P; Vignola, AM; Albat, B; Springall, DR; Polak, JM; Godard, P; Bousquet, J			Involvement of endothelin in mononuclear phagocyte inflammation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endothelin; monocytes; alveolar macrophages; cytokines; asthma	BRONCHIAL EPITHELIAL-CELLS; BRONCHOALVEOLAR LAVAGE FLUID; HUMAN ALVEOLAR MACROPHAGES; AIRWAY INFLAMMATION; CHEMI-LUMINESCENCE; NOCTURNAL ASTHMA; LUNG; DISEASE; RELEASE; IMMUNOREACTIVITY	Background and aim: Endothelin has bronchoconstrictive, vasoactive, and inflammatory properties and may be involved in the pathogenesis of asthma. We have studied the involvement of endothelin in asthma by examining its expression and release by mononuclear phagocytes obtained from 56 patients with asthma and 32 control subjects and the activation of mononuclear phagocytes by endothelin. Methods: Endothelin immunoreactivity was studied by using immunocytochemistry on monocytes and alveolar macrophages. Spontaneous and lipopolysaccharide-induced endothelin release from monocytes and alveolar macrophages was studied by radioimmunoassay. The proportion of intracellular endothelin was assessed after cell disruption by Triton (Union Carbide Corp., Bound Brook, N.J.). The release of fibronectin and tumor necrosis factor-alpha induced by endothelin was studied in alveolar macrophages by enzyme immunoassay. Results: Endothelin immunoreactivity was significantly increased in cells from patients with asthma in comparison with those from the control group, but its release by alveolar macrophages was similar in both groups. Levels in the cell lysates and supernatants were similar for patients with asthma and normal subjects. Endothelin significantly increased the release of tumor necrosis factor-alpha and fibronectin by alveolar macrophages from normal subjects and patients with stable asthma, but it significantly decreased their release in patients with unstable asthma. Conclusion: This study suggests a role for endothelin in airway inflammation in asthma. Endothelin may act in a different fashion on alveolar macrophages, depending on the degree of stability of the disease.	CHU MONTPELLIER,HOP ARNAUD VILLENEUVE,CLIN MALAD RESP,MONTPELLIER,FRANCE; CHU MONTPELLIER,HOP ARNAUD VILLENEUVE,CJF INSERM 9210,MONTPELLIER,FRANCE; CHU MONTPELLIER,HOP ARNAUD VILLENEUVE,SERV CHIRURG CARDIAQUE,MONTPELLIER,FRANCE; CNR,IST FISIOPATOL RESP,PALERMO,ITALY; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0HS,ENGLAND	Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Consiglio Nazionale delle Ricerche (CNR); Imperial College London			Bousquet, Jean/O-4221-2019	chanez, pascal/0000-0003-4059-0917				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; BLACK PN, 1989, FEBS LETT, V255, P129, DOI 10.1016/0014-5793(89)81075-0; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317, DOI 10.1164/ajrccm/145.2_Pt_1.317; CAMPBELL AM, 1993, AM REV RESPIR DIS, V147, P529, DOI 10.1164/ajrccm/147.3.529; CHANEZ P, 1994, J ALLERGY CLIN IMMUN, V94, P997, DOI 10.1016/0091-6749(94)90118-X; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DAMON M, 1989, J BIOLUM CHEMILUM, V4, P279, DOI 10.1002/bio.1170040140; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; FILEP JG, 1993, LIFE SCI, V52, P119, DOI 10.1016/0024-3205(93)90131-L; GIAID A, 1991, AM J RESP CELL MOL, V4, P50, DOI 10.1165/ajrcmb/4.1.50; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768, DOI 10.1164/ajrccm/146.3.768; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HALLER H, 1991, AM J PHYSIOL, V261, pL478, DOI 10.1152/ajplung.1991.261.6.L478; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KISHINO J, 1991, FEBS LETT, V280, P103, DOI 10.1016/0014-5793(91)80214-N; LAGENTE V, 1990, CLIN EXP ALLERGY, V20, P343, DOI 10.1111/j.1365-2222.1990.tb02792.x; LUSCHER TF, 1992, AM REV RESPIR DIS, V146, pS56; MARTINNIZARD F, 1991, FEBS LETT, V293, P127, DOI 10.1016/0014-5793(91)81167-7; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V88, P376, DOI 10.1016/0091-6749(91)90100-3; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; MURCH SH, 1992, LANCET, V339, P381, DOI 10.1016/0140-6736(92)90077-G; NAGASE T, 1990, BIOCHEM BIOPH RES CO, V168, P485, DOI 10.1016/0006-291X(90)92347-3; NOMURA A, 1989, LANCET, V2, P747; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918, DOI 10.1164/ajrccm/145.4_Pt_1.918; POULTER LW, 1994, IMMUNOL TODAY, V15, P258, DOI 10.1016/0167-5699(94)90004-3; ROBINSON DS, 1993, THORAX, V48, P26, DOI 10.1136/thx.48.1.26; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TENCE M, 1992, EUR J NEUROSCI, V4, P993, DOI 10.1111/j.1460-9568.1992.tb00125.x; TURNERWARWICK M, 1988, AM J MED, V85, P6, DOI 10.1016/0002-9343(88)90231-8; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; VANVYVE T, 1993, EUR RESPIR J, V6, P1116; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689; VITTORI E, 1992, AM REV RESPIR DIS, V146, P1320, DOI 10.1164/ajrccm/146.5_Pt_1.1320; *WHO NHLBI, 1995, 953659 WHO NHLBI; 1991, AM REV RESPIR DIS, V144, P1202	41	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					412	420		10.1016/S0091-6749(96)70166-5	http://dx.doi.org/10.1016/S0091-6749(96)70166-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757219	Bronze			2022-12-18	WOS:A1996VC99500021
J	Warrington, RJ; McPhillips, S				Warrington, RJ; McPhillips, S			Independent anaphylaxis to cefazolin without allergy to other beta-lactam antibiotics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PENICILLIN		UNIV MANITOBA,DEPT MED,WINNIPEG,MB,CANADA; DEPT IMMUNOL,WINNIPEG,MB,CANADA	University of Manitoba	Warrington, RJ (corresponding author), HLTH SCI CTR,ALLERGY & CLIN IMMUNOL SECT,820 SHERBROOK ST,WINNIPEG,MB R3A 1R9,CANADA.							BLANCA M, 1990, CLIN EXP ALLERGY, V20, P475, DOI 10.1111/j.1365-2222.1990.tb03139.x; IGEA JM, 1992, ANN ALLERGY, V68, P515; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SILVIUDAN F, 1993, J ALLERGY CLIN IMMUN, V91, P694, DOI 10.1016/0091-6749(93)90188-L; THOBURN R, 1966, J AMER MED ASSOC, V198, P345, DOI 10.1001/jama.198.4.345	5	34	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					460	462		10.1016/S0091-6749(96)70171-9	http://dx.doi.org/10.1016/S0091-6749(96)70171-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757224	Bronze			2022-12-18	WOS:A1996VC99500026
J	Lishner, M; ConfinoCohen, R; Mekori, YA; Feigin, M; Manor, Y; Goldberg, A; Ravid, M; Amiel, A				Lishner, M; ConfinoCohen, R; Mekori, YA; Feigin, M; Manor, Y; Goldberg, A; Ravid, M; Amiel, A			Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						systemic mastocytosis; myeloproliferative disorders; fluorescent in situ hybridization; trisomy 9; trisomy 8	MAST-CELL DISEASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; C-KIT LIGAND; POLYCYTHEMIA-VERA; BONE-MARROW; GROWTH-FACTOR; CHROMOSOME; PROGENITOR; NEOPLASIA; DISORDERS	Background: Systemic mastocytosis is a rare disease characterized by proliferation of mast cells in one or more organs. The origin of the mast cells is still debated although it has been recently shown that they derive from CD34(+) hematopoietic progenitors. Some clinical and in vitro studies have suggested a possible link between myeloproliferative disorders and systemic mast cell disease. Objective: This study was designed to further evaluate the association between systemic mast cell disease and other hematologic disorders by, means of conventional cytogenetic analysis and fluorescent in situ hybridization. Methods: We used cytogenetic analysis and fluorescent in situ hybridization with probes to chromosomes 8 and 9 in situ patients with systemic mast cell disease. Results: Fluorescent in situ hybridization helped to identify, five patients with trisomy 9 and one with trisomy 8. In contrast, chromosomal analysis demonstrated an abnormal karyotype (45,XO/46,XY) in only one patient. Conclusion: The association between myeloproliferative disorders and systemic mast cell disease may be explained by the finding that trisomy 9 and trisomy 8 are common in both disorders. A trisomy was detected in all of the patients in our small group compared with nearly 40% of previously reported patients with nearly 40% previously reported patients with myeloproliferative disorders. FISH is more sensitive than conventional cytogenetics in detecting these aberrations.	MEIR HOSP,DEPT MED,SECT ALLERGY IMMUNOL,IL-44281 KEFAR SAVA,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL; MEIR HOSP,GENET UNIT,IL-44281 KEFAR SAVA,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Lishner, M (corresponding author), MEIR HOSP,DEPT MED,SECT HEMATOL,IL-44281 KEFAR SAVA,ISRAEL.							AGIS H, 1993, J IMMUNOL, V151, P4221; AMIEL A, 1995, CANCER GENET CYTOGEN, V79, P153, DOI 10.1016/0165-4608(94)00139-3; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; AUTIO K, 1990, EUR J HEMATOL, V39, P289; BAGBY GC, 1988, BLOOD REV, V2, P194, DOI 10.1016/0268-960X(88)90025-2; BIRD ML, 1989, LEUKEMIA, V3, P182; CAINS L J, 1972, Australasian Journal of Dermatology, V13, P111, DOI 10.1111/j.1440-0960.1972.tb00502.x; COOPER AJ, 1982, J AM ACAD DERMATOL, V7, P125; DENBURG JA, 1983, BLOOD, V61, P775; DIEZMARTIN JL, 1991, MAYO CLIN PROC, V66, P287, DOI 10.1016/S0025-6196(12)61011-8; GISSLINGER H, 1989, LANCET, V1, P634, DOI 10.1016/S0140-6736(89)92142-9; HAGEMEIJER A, 1987, CHRONIC MYELOID LEUK, P963; HORNY HP, 1985, HUM PATHOL, V16, P808, DOI 10.1016/S0046-8177(85)80252-5; HORNY HP, 1990, BRIT J HAEMATOL, V76, P186, DOI 10.1111/j.1365-2141.1990.tb07870.x; HORTON MA, 1983, BLOOD, V62, P1251; JANKINS RB, 1992, BLOOD, V79, P3307; KIBBELAAR RE, 1993, BLOOD, V82, P904; KIRSHENBAUM AS, 1989, J IMMUNOL, V142, P2424; KIRSHENBAUM AS, 1991, J IMMUNOL, V146, P1410; KIRSHENBAUM AS, 1993, MAST CELL HLTH DIS, P203; KLOKE O, 1993, BRIT J HAEMATOL, V83, P399, DOI 10.1111/j.1365-2141.1993.tb04663.x; KLUINNELEMANS HC, 1992, NEW ENGL J MED, V326, P619, DOI 10.1056/NEJM199202273260907; LALKIN A, 1993, CANCER GENET CYTOGEN, V70, P21, DOI 10.1016/0165-4608(93)90126-7; LENNERT K, 1979, HISTOPATHOLOGY, V3, P349, DOI 10.1111/j.1365-2559.1979.tb03017.x; LEWIS JP, 1987, LEUKEMIA RES, V11, P769, DOI 10.1016/0145-2126(87)90060-9; LIDOR C, 1990, J BONE MINER RES, V5, P871; MEKORI YA, 1993, J IMMUNOL, V151, P3775; METCALFE DD, 1992, CECIL TXB MED, P1483; NAGATA H, 1995, J ALLERGY CLIN IMMUN, V95, P176; NEDERLOF PM, 1989, CANCER GENET CYTOGEN, V42, P87, DOI 10.1016/0165-4608(89)90011-3; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; PARKER RI, 1991, J INVEST DERMATOL, V96, pS52, DOI 10.1111/1523-1747.ep12469045; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RAZIN E, 1984, J IMMUNOL, V132, P1479; REGECAMBRIN G, 1987, CANCER GENET CYTOGEN, V25, P233, DOI 10.1016/0165-4608(87)90183-X; SAGHER F, 1956, J INVEST DERMATOL, V27, P355, DOI 10.1038/jid.1956.108; SMITH RE, 1988, AM J HEMATOL, V29, P174, DOI 10.1002/ajh.2830290311; STRIFE A, 1988, SEMIN HEMATOL, V235, P1; SWOLIN B, 1987, BLOOD, V70, P1928; SWOLIN B, 1988, BLOOD, V72, P386; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; TRAVIS WD, 1988, CANCER, V62, P965, DOI 10.1002/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; WESTIN J, 1976, SCAND J HAEMATOL, V17, P183; YAM LT, 1980, AM J CLIN PATHOL, V73, P48	45	34	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					199	204		10.1016/S0091-6749(96)70243-9	http://dx.doi.org/10.1016/S0091-6749(96)70243-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765835				2022-12-18	WOS:A1996VA69200024
J	Chevailler, A; Arlaud, G; Ponard, D; Pernollet, M; Carrere, F; Renier, G; Drouet, M; Hurez, D; Gardais, J				Chevailler, A; Arlaud, G; Ponard, D; Pernollet, M; Carrere, F; Renier, G; Drouet, M; Hurez, D; Gardais, J			C1-inhibitor binding monoclonal immunoglobulins in three patients with acquired angioneurotic edema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						C1-inhibitor deficiency; acquired angioneurotic edema	C1 ESTERASE INHIBITOR; CHRONIC LYMPHOCYTIC-LEUKEMIA; II AAE-II; HEREDITARY ANGIOEDEMA; LYMPHOPROLIFERATIVE DISORDER; C1-ESTERASE INHIBITOR; REPLACEMENT THERAPY; MALIGNANT-LYMPHOMA; DANAZOL THERAPY; CL INHIBITOR	The syndrome of acquired angioneurotic edema (AAE) is characterized by the adult onset of angioedema, the lack of evidence for inheritance of the disorder, and the frequent association of the C1-inhibitor (C1-INH) deficiency with lymphoproliferative or other malignant diseases. Recently, a new type of AAE (type II AAE) has been described. The two major biologic differences of this new syndrome compared with all other previously reported AAE cases (type I AAE) are the presence in patients' sera of both anti-C1-INH autoantibodies, often monoclonal, and a circulating low molecular weight (95 kd) Ci-INH protein. From the clinical point of view, the absence of underlying lymphoproliferative disease is the hallmark of type II AAE compared with type I AAE. However, the distinction between type I and type II AAE may not be so clear-cut. We report three patients with monoclonal gammopathies and AAE for whom the initial diagnosis was type I AAE. The demonstration by ELISA of the C1-INH binding ability of their monoclonal immunoglobulins in addition to the presence of 95 kd C1-INH protein enables us to change the diagnosis to type II AAE. From the therapeutic point of view, it is crucial to detect the anti-C1-INH antibody and to analyze the C1-INH size to distinguish type I and type II AAE, especially if patients have a monoclonal gammopathy, to give the appropriate treatment (attenuated androgens vs immunosuppressive regimen, respectively) to prevent a fatal outcome.	INST BIOL STRUCT,LAB ENZYMOL MOLEC,GRENOBLE,FRANCE; CTR HOSP REG UNIV,HOP SUD,IMMUNOL LAB,GRENOBLE,FRANCE; CHU ANGERS,LAB ALLERGOL,ANGERS,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Chevailler, A (corresponding author), CHU ANGERS,IMMUNOPATHOL LAB,F-49033 ANGERS 01,FRANCE.							AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; ALSENZ J, 1989, J CLIN INVEST, V83, P1794, DOI 10.1172/JCI114084; ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; ALSENZ J, 1988, NEW ENGL J MED, V318, P122; ALSENZ J, 1989, BEHRING I MITT, V84, P165; ARLAUD GJ, 1977, BIOCHIM BIOPHYS ACTA, V485, P215, DOI 10.1016/0005-2744(77)90208-X; BAIN BJ, 1993, CANCER, V72, P3318, DOI 10.1002/1097-0142(19931201)72:11<3318::AID-CNCR2820721130>3.0.CO;2-N; BORK K, 1988, J ALLERGY CLIN IMMUN, V83, P677; BRECY H, 1975, BIOMED EXPRESS, V23, P328; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; CARREER FMJ, 1992, EUR J CLIN CHEM CLIN, V30, P793; CASALI P, 1978, ACTA HAEMATOL-BASEL, V59, P277, DOI 10.1159/000207773; CHEESBROUGH MJ, 1978, BRIT J DERMATOL, V99, P39, DOI 10.1111/j.1365-2133.1978.tb15236.x; CICARDI M, 1985, Complement, V2, P133; CICARDI M, 1993, AM J MED, V95, P169, DOI 10.1016/0002-9343(93)90257-P; CICARDI M, 1988, CLIN IMMUNOL ALLERGY, V2, P405; COHEN SH, 1978, J ALLERGY CLIN IMMUN, V62, P217, DOI 10.1016/0091-6749(78)90210-5; COHEN SH, 1978, ANN INTERN MED, V88, P429, DOI 10.7326/0003-4819-88-3-429_1; COSTANZI JJ, 1969, J LAB CLIN MED, V74, P902; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DAY NK, 1976, CLIN EXP IMMUNOL, V26, P189; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1985, J CLIN INVEST, V75, P124, DOI 10.1172/JCI111664; DONALDSON VH, 1992, J LAB CLIN MED, V119, P330; DONALDSON VH, 1992, J LAB CLIN MED, V119, P397; FIECHTNER JJ, 1980, CLIN IMMUNOL IMMUNOP, V15, P642; FINE RM, 1985, INT J DERMATOL, V24, P560; FRANK M, 1989, BEHRING I MITT, V84, P161; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FRANK MM, 1987, CLIN RES, V35, pA641; FRIGAS E, 1989, MAYO CLIN PROC, V64, P1269, DOI 10.1016/S0025-6196(12)61290-7; FUST G, 1985, CLIN EXP IMMUNOL, V60, P489; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; GADEK JE, 1979, J CLIN INVEST, V64, P280, DOI 10.1172/JCI109449; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; GELFAND JA, 1979, MEDICINE, V58, P321, DOI 10.1097/00005792-197907000-00004; GRACE RJ, 1990, LANCET, V336, P118, DOI 10.1016/0140-6736(90)91634-M; HARRISON RA, 1983, BIOCHEMISTRY-US, V22, P5001, DOI 10.1021/bi00290a019; HAUPTMANN G, 1977, ANN INTERN MED, V87, P577, DOI 10.7326/0003-4819-87-5-577; HAUPTMANN G, 1979, CLIN EXP IMMUNOL, V37, P523; HAUPTMANN G, 1975, SCAND J HAEMATOL, V15, P22; HAUPTMANN G, 1976, BLUT, V32, P195, DOI 10.1007/BF00995913; HENTGES F, 1986, J ALLERGY CLIN IMMUN, V78, P860, DOI 10.1016/0091-6749(86)90231-9; JACKSON J, 1986, NATURE, V323, P722, DOI 10.1038/323722a0; JACKSON J, 1989, J CLIN INVEST, V83, P698, DOI 10.1172/JCI113934; JACKSON J, 1988, NEW ENGL J MED, V318, P122; JONES L, 1985, CLIN LAB HAEMATOL, V7, P279, DOI 10.1111/j.1365-2257.1985.tb00037.x; JORDON RE, 1974, CLIN EXP IMMUNOL, V18, P407; LEPORRIER M, 1981, NOUV REV FR HEMATOL, V23, P243; LOOS M, 1993, ACTIVATORS INHIBITOR, P181; MALBRAN A, 1988, J ALLERGY CLIN IMMUN, V81, P1199, DOI 10.1016/0091-6749(88)90891-3; MALBRAN A, 1987, CLIN RES, V35, pA255; MANDLE R, 1994, J IMMUNOL, V152, P4680; Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133; MELAMED J, 1986, J ALLERGY CLIN IMMUN, V77, P322; MULLER S, 1976, CLIN EXP IMMUNOL, V23, P233; NAKAMURA S, 1991, ANN RHEUM DIS, V50, P713, DOI 10.1136/ard.50.10.713; NILSEN A, 1980, ACTA MED SCAND, V207, P123; OBERLING F, 1975, NOUV PRESSE MED, V4, P2705; OLTVAI ZN, 1991, LAB INVEST, V65, P381; Osler W, 1888, AM J MED SCI, V95, P362; QASEEM T, 1991, J ROY SOC MED, V84, P628; QUASTEL M, 1983, J CLIN INVEST, V71, P1041, DOI 10.1172/JCI110831; REBOUL A, 1977, FEBS LETT, V79, P45, DOI 10.1016/0014-5793(77)80347-5; RODRIGUEZ M, 1988, ANN ALLERGY, V61, P348; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; ROSENFELD SI, 1975, J ALLERGY CLIN IMMUN, V55, P104; SCHEIDEGGER JJ, 1955, INT ARCH ALLER A IMM, V7, P103, DOI 10.1159/000228215; SCHREIBER AD, 1976, BLOOD, V48, P567; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P640, DOI 10.1016/0091-6749(85)90087-9; SPATH PJ, 1989, ARCH INTERN MED, V149, P1215; WALLINGTON TB, 1978, BRIT J DERMATOL, V99, P39, DOI 10.1111/j.1365-2133.1978.tb15237.x; ZURAW B L, 1990, Journal of Allergy and Clinical Immunology, V85, P208; ZURAW BL, 1993, IMMUNOL ALLERGY CLIN, V13, P441; ZURAW BL, 1991, J ALLERGY CLIN IMMUN, V88, P908, DOI 10.1016/0091-6749(91)90248-M	75	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					998	1008		10.1016/S0091-6749(96)80076-5	http://dx.doi.org/10.1016/S0091-6749(96)80076-5			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655897				2022-12-18	WOS:A1996UG08600016
J	Popescu, MA; Sheehan, MG; Kouides, PA; Loughner, JE; Condemi, JJ; Looney, RJ; Leddy, JP				Popescu, MA; Sheehan, MG; Kouides, PA; Loughner, JE; Condemi, JJ; Looney, RJ; Leddy, JP			Allergic reactions to cyclophosphamide: Delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						drug allergy; cyclophosphamide; allergy to drug metabolites; IgE antibody; anaphylaxis	INTRAVENOUS CYCLOPHOSPHAMIDE; HYPERSENSITIVITY REACTION; CROSS-SENSITIVITY; HUMAN ANAPHYLAXIS; 4-HYDROXYCYCLOPHOSPHAMIDE; PHARMACOKINETICS; MECHLORETHAMINE; URTICARIA	Background: Cyclophosphamide (CP) is one of the relatively few drugs implicated in systemic allergic reactions for which the metabolites are well known. Formation of CP metabolites is a multistep, time-dependent process (hours) with significant interindividual differences. Although allergic reactions to CP have been recorded in 17 previous reports, skin testing with CP or its metabolites has been included in only five. We now describe five patients receiving monthly cycles of intravenous Cp whose allergic reactions included clinical features of type I hypersensitivity but were atypical in their markedly delayed onset (i.e., 8 to 16 hours in patients 1 to 4 and 10 days in patient 5). Objective: The objective was to investigate these late-developing clinical reactions by skin resting with CP and two of its major metabolites. Methods: The five patients and a control group receiving intravenous CP uneventfully were studied by the same skin rest protocol. Results: The four individuals in the control group were unreactive to CP or its metabolites. All five patients with late-onset allergic reactions had positive immediate skin test results to CP metabolites but not to CP itself. We propose that the allergic reactions in patients 1 to 4 were mediated, wholly or in major part, by IgE antibodies reactive with allergens derived from time-dependent drug metabolites. The 10-day lag time in patient 5 is unexplained. Immunomodulation by the underlying malignancies or by the immunosuppressive drugs could have contributed. Conclusion: IgE-mediated allergic drug reactions may have a delayed onset if the allergen is a time-dependent drug metabolite, illustrated in this study by CP.	UNIV ROCHESTER,SCH MED & DENT,CLIN IMMUNOL ALLERGY RHEUMATOL UNIT,ROCHESTER,NY; UNIV ROCHESTER,SCH MED & DENT,DEPT MED,HEMATOL UNIT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester								ANKU V, 1982, CANCER TREAT REP, V66, P2106; AULBERT E, 1983, ONKOLOGIE, V6, P82, DOI 10.1159/000215206; BOOTH BH, 1970, J AMER MED ASSOC, V211, P627, DOI 10.1001/jama.211.4.627; BORCH RF, 1987, J MED CHEM, V30, P427, DOI 10.1021/jm00385a029; CROMAR BW, 1991, J ALLERGY CLIN IMMUN, V88, P965, DOI 10.1016/0091-6749(91)90256-N; DELAGE C, 1973, ARCH PATHOL, V95, P185; GREEN RM, 1989, AUST NZ J MED, V19, P55, DOI 10.1111/j.1445-5994.1989.tb01677.x; GROSBOIS B, 1987, REV MED INTERNE, V8, P208, DOI 10.1016/S0248-8663(87)80174-1; JAMES LP, 1964, NEW ENGL J MED, V270, P597, DOI 10.1056/NEJM196403192701202; JONES JB, 1989, DICP ANN PHARMAC, V23, P88, DOI 10.1177/106002808902300125; KARCHMER RK, 1977, JAMA-J AM MED ASSOC, V237, P475, DOI 10.1001/jama.237.5.475; KATH R, 1986, DEUT MED WOCHENSCHR, V11, P1622; KELLY JW, 1992, CLIN INFECT DIS, V14, P1034, DOI 10.1093/clinids/14.5.1034; KIM HC, 1985, J ALLERGY CLIN IMMUN, V76, P591, DOI 10.1016/0091-6749(85)90780-8; KNYSAK DJ, 1994, ARTHRITIS RHEUM, V37, P1101, DOI 10.1002/art.1780370717; KRITHARIDES L, 1987, CANCER TREAT REP, V71, P1323; KRUTCHIK AN, 1978, ARCH INTERN MED, V138, P1725, DOI 10.1001/archinte.138.11.1725; LAKIN JD, 1975, J ALLERGY CLIN IMMUN, V58, P160; LEGHA SS, 1978, CANCER TREAT REP, V62, P180; Lemanske RF, 1993, ALLERGY PRINCIPLES P, P320; LOW JE, 1982, CANCER RES, V42, P830; MOORE MJ, 1991, CLIN PHARMACOKINET, V20, P194, DOI 10.2165/00003088-199120030-00002; MURTI L, 1979, J PEDIATR-US, V94, P844, DOI 10.1016/S0022-3476(79)80178-X; ROSS WE, 1977, CANCER TREAT REP, V61, P495; SALLES G, 1991, ANN HEMATOL, V62, P74, DOI 10.1007/BF01714904; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P227, DOI 10.1016/0091-6749(85)90048-X; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; Sullivan TJ, 1993, ALLERGY PRINCIPLES P, P1726; TANNENBAUM H, 1975, J ALLERGY CLIN IMMUN, V56, P276; TASSO MJ, 1992, CANCER CHEMOTH PHARM, V30, P207, DOI 10.1007/BF00686313; [No title captured]	32	34	35	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				26	33		10.1016/S0091-6749(96)70279-8	http://dx.doi.org/10.1016/S0091-6749(96)70279-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568134	hybrid			2022-12-18	WOS:A1996TR94700004
J	Yamada, N; Wakugawa, M; Kuwata, S; Yoshida, T; Nakagawa, H				Yamada, N; Wakugawa, M; Kuwata, S; Yoshida, T; Nakagawa, H			Chronologic analysis of in situ cytokine expression in mite allergen-induced dermatitis in atopic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL   23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd		atopic dermatitis; mite allergen patch test; cytokines; RT-PCR	COLONY-STIMULATING FACTOR; INTERFERON-GAMMA; MESSENGER-RNA; INTERLEUKIN-4; EOSINOPHILS	Patch testing with crude dust mite extracts, after removal of horny epidermal layers, was performed on normal-appearing skin of nine adult patients with atopic dermatitis who had high mite-specific IgE antibody levels Positive skin reactions were observed in seven subjects. Skin biopsy specimens were obtained from positive reaction sites at 2, 6, 12, 24, and 48 hours after allergen challenge and subjected to histologic and immunohistochemical studies and extraction of RNA. Perivascular infiltration of small mononuclear cells began at 2 hours, followed by eosinophilic infiltration at 6 hours, which peaked at 24 and 48 hours. increased expression of IL-4 messenger RNA was detected with reverse-transcription polymerase chain reaction at 12 and 24 hours, whereas immunohistochemical staining with anti-IL-4 antibody showed positive reactions in connective tissue around infiltrating cells after 2 hours. Expression of IL-5 and tumor necrosis factor-alpha mRNA was upregulated 2 hours after an application of allergen. Interferon-gamma mRNA was not detected. These findings suggest the crucial role of T-H2-type cytokines in initiating eosinophil infiltration of mite allergen-induced dermatitis in patients with atopic dermatitis.	UNIV TOKYO,FAC MED,DEPT DERMATOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT IMMUNOHEMATOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo								BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BRUYNZEELKOOMEN CAFM, 1988, BRIT J DERMATOL, V118, P229, DOI 10.1111/j.1365-2133.1988.tb01779.x; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HORSMANHEIMO L, 1994, BRIT J DERMATOL, V131, P348, DOI 10.1111/j.1365-2133.1994.tb08522.x; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; MITCHELL EB, 1982, LANCET, V1, P127; MIYAMOTO J, 1975, JPN J EXP MED, V45, P133; MIZOGUCHI M, 1992, LANCET, V339, P1120, DOI 10.1016/0140-6736(92)90719-J; NAKAGAWA H, 1994, LANCET, V344, P883, DOI 10.1016/S0140-6736(94)92855-X; OKAMOTO Y, 1993, J IMMUNOL, V151, P4391; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; SATO Y, 1986, AM J PATHOL, V125, P431; SWAIN SL, 1990, J IMMUNOL, V144, P4110; TANAKA Y, 1990, Journal of Dermatological Science, V1, P361, DOI 10.1016/0923-1811(90)90593-3; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; WAKITA H, 1994, J CUTAN PATHOL, V21, P33, DOI 10.1111/j.1600-0560.1994.tb00688.x	22	34	34	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1069	1075		10.1016/S0091-6749(95)70192-3	http://dx.doi.org/10.1016/S0091-6749(95)70192-3			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ509	8543764				2022-12-18	WOS:A1995TQ50900003
J	GROSSMAN, J; BANOV, C; BOGGS, P; BRONSKY, EA; DOCKHORN, RJ; DRUCE, H; FINDLAY, SR; GEORGITIS, JW; HAMPEL, FC; KAISER, H; RATNER, P; TINKELMAN, DG; VALENTINE, MD; ROSZKO, P; ZEGARELLI, E; WOOD, C				GROSSMAN, J; BANOV, C; BOGGS, P; BRONSKY, EA; DOCKHORN, RJ; DRUCE, H; FINDLAY, SR; GEORGITIS, JW; HAMPEL, FC; KAISER, H; RATNER, P; TINKELMAN, DG; VALENTINE, MD; ROSZKO, P; ZEGARELLI, E; WOOD, C			USE OF IPRATROPIUM BROMIDE NASAL SPRAY IN CHRONIC TREATMENT OF NONALLERGIC PERENNIAL RHINITIS, ALONE AND IN COMBINATION WITH OTHER PERENNIAL RHINITIS MEDICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NONALLERGIC RHINITIS; IPRATROPIUM; NASAL SPRAY; SAFETY; EFFICACY CHRONIC		To study the long-term safety and effectiveness of ipratropium bromide nasal spray 0.03% in the treatment of nonallergic perennial rhinitis, we administered this medication for 1 year in an open-label trial involving 285 patients. Our intention was to maintain the highest protocol dose possible to gain a clearer picture of the long-term side effect profile of the compound. Ipratropium bromide was well tolerated with no serious side effects in this patient population. It provided a significant improvement in rhinorrhea throughout the year-long trial; only 17 of 285 patients (6%) were considered treatment failures. There was an improvement in patient quality of life, as well as a substantial reduction in the need for other medications(antihistamines, decongestants, and nasal steroids) used to treat perennial rhinitis symptoms.										BORUM P, 1979, CLIN OTOLARYNGOL, V4, P407, DOI 10.1111/j.1365-2273.1979.tb01773.x; DRUCE HM, 1992, ANN ALLERGY, V69, P53; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MYGIND N, 1985, ALLERGIC VASOMOTOR R, P17; 1994, SCOTT LEVIN PHYSICIA	5	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	2				1123	1127		10.1016/S0091-6749(95)70216-4	http://dx.doi.org/10.1016/S0091-6749(95)70216-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY918	7538520				2022-12-18	WOS:A1995QY91800008
J	NACLERIO, RM; BAROODY, FM; KAGEYSOBOTKA, A; LICHTENSTEIN, LM				NACLERIO, RM; BAROODY, FM; KAGEYSOBOTKA, A; LICHTENSTEIN, LM			BASOPHILS AND EOSINOPHILS IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							VASCULAR ENDOTHELIAL-CELLS; ANTIGEN CHALLENGE; ADHESION MOLECULES; MAST-CELLS; INFLUX; PRETREATMENT; NEUTROPHILS; EXPRESSION; RELEASE; SURFACE		JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University								BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DRISCOLL PV, 1994, J ALLERGY CLIN IMMUN, V93, P216; EBISAWA M, 1992, J IMMUNOL, V149, P4021; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V93, P183; LIM M, 1993, J ALLERGY CLIN IMMUN, V91, P181; LIM MC, IN PRESS AM J RESPIR; LOZEWICZ S, 1992, J ALLERGY CLIN IMMUN, V89, P951, DOI 10.1016/0091-6749(92)90217-P; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MARONE G, 1981, INT ARCH ALLER A IMM, V65, P339, DOI 10.1159/000232773; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NACLERIO RM, IN PRESS J ALLERGY C; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; POBER JS, 1986, J IMMUNOL, V136, P1680; RIMMER EF, 1988, LEUKOCYTE TYPING, V3, P729; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; VALENT P, 1989, BLOOD, V73, P1778; WACHS M, 1989, J ALLERGY CLIN IMMUN, V84, P492, DOI 10.1016/0091-6749(89)90362-X; WALDEN SM, 1991, AM REV RESPIR DIS, V144, P642, DOI 10.1164/ajrccm/144.3_Pt_1.642; WILLIAMS TJ, 1992, AM REV RESPIR DIS, V146, pS45, DOI 10.1164/ajrccm/146.5_Pt_2.S45	28	34	34	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1303	1309		10.1016/0091-6749(94)90346-8	http://dx.doi.org/10.1016/0091-6749(94)90346-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7528236	hybrid			2022-12-18	WOS:A1994QA02000026
J	ABELSON, MB; GEORGE, MA; SCHAEFER, K; SMITH, LM				ABELSON, MB; GEORGE, MA; SCHAEFER, K; SMITH, LM			EVALUATION OF THE NEW OPHTHALMIC ANTIHISTAMINE, 0.05-PERCENT LEVOCABASTINE, IN THE CLINICAL ALLERGEN CHALLENGE MODEL OF ALLERGIC CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LEVOCABASTINE; ALLERGEN CHALLENGE; ALLERGIC CONJUNCTIVITIS; TYPE 1 HYPERSENSITIVITY; CLINICAL STUDY	TOPICAL LEVOCABASTINE; PROVOCATION TEST; H-1 ANTAGONIST; IMMUNOTHERAPY; PRECISION; HISTAMINE	The objective of this study was to evaluate the efficacy of 0.05% levocabastine, a new antihistamine formulated for ophthalmic use, compared with the placebo vehicle for the treatment of allergic conjunctivitis induced by ocular allergen challenge. Subjects who reacted positively in both eyes on two separate occasions to ocular allergen challenge with grass, ragweed, or cat dander (N = 47) received one dose of 1 to 2 drops of 0.05% levocabastine in one eye and its vehicle in the other eye. After 10 minutes, the predetermined dose of allergen was instilled in both eyes. Signs and symptoms of allergic conjunctivitis were evaluated with biomicroscopy and subjective evaluation of itching after 3, 5, and 10 minutes. Four hours after drug administration subjects were rechallenged and reevaluated to determine levocabastine's duration of action. Results showed that levocabastine was significantly more effective than placebo in inhibiting itching, hyperemia, eyelid swelling, chemosis, and tearing after the initial challenge and in inhibiting all parameters except eyelid swelling after the rechallenge 4 hours later (p < 0.05). These results demonstrate that levocabastine, currently the only ophthalmic antihistamine available that is not combined with a vasoconstrictor, is efficacious in the inhibition of itching, as well as all of the allergic signs of a vascular origin, with a duration of action of at least 4 hours. Because of its strong effects on itching and hyperemia, chemosis, lid swelling, and tearing. levocabastine would be a valuable therapeutic agent to add to the heterogeneous family of antiallergic compounds presently available for the treatment of seasonal allergic conjunctivitis.	HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA; PHARMACEUT DEV CONSULTING,PADUA,ITALY	Harvard University; Harvard Medical School	ABELSON, MB (corresponding author), SCHEPENS EYE RES INST,20 STANIFORD ST,BOSTON,MA 02114, USA.							ABELSON M, 1991, J OCUL PHARMACOL, V7, P313; ABELSON MB, 1980, OPHTHALMOLOGY, V87, P812; ABELSON MB, 1981, ARCH OPHTHALMOL-CHIC, V99, P302; ABELSON MB, 1988, OPHTHALMOLOGY, V95, P1494; ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P84, DOI 10.1001/archopht.1990.01070030090035; ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P520, DOI 10.1001/archopht.1990.01070060068051; ABELSON MB, 1991, OPHTHALMOLOGY S, V98, P157; AICHANE A, 1993, J ALLERGY CLIN IMMUN, V92, P49, DOI 10.1016/0091-6749(93)90036-F; ALLANSMITH MR, 1983, CORNEA, P231; AWOUTERS F, 1986, DRUG DEVELOP RES, V8, P95, DOI 10.1002/ddr.430080112; AWOUTERS F, 1984, AUG IUPHAR INT C PHA; BENDE M, 1987, ALLERGY, V42, P512, DOI 10.1111/j.1398-9995.1987.tb00374.x; BERDY G J, 1990, Investigative Ophthalmology and Visual Science, V31, P65; BERDY G J, 1989, Investigative Ophthalmology and Visual Science, V30, P503; BISGAARD H, 1985, ALLERGY, V40, P417, DOI 10.1111/j.1398-9995.1985.tb02680.x; BRINK FVD, 1978, HDB EXPT PHARM, V18, P251; FRIEDLAENDER MH, 1988, INT OPHTHALMOL CLIN, V28, P338, DOI 10.1097/00004397-198802840-00018; GANELLIN CR, 1978, HDB EXP PHARM, V18, P251; GARRISON J C, 1990, P575; JANSSENS M, 1990, JUL ANN M EUR AC ALL; LEONARDI A, 1992, INVEST OPHTH VIS SCI, V33, P851; MOLLER C, 1986, CLIN ALLERGY, V16, P135, DOI 10.1111/j.1365-2222.1986.tb00757.x; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; ODELRAM H, 1989, ALLERGY, V44, P432, DOI 10.1111/j.1398-9995.1989.tb04175.x; PECOUD A, 1987, INT ARCH ALLER A IMM, V82, P541, DOI 10.1159/000234274; PIPKORN U, 1985, ALLERGY, V40, P491, DOI 10.1111/j.1398-9995.1985.tb00255.x; TANI D, 1978, INVEST OPHTHALMOL  S, V17, P227; WALSH J, 1992, PHYSICIANS DESK REFE, P270; WELSH PW, 1979, J ALLERGY CLIN IMMUN, V64, P209, DOI 10.1016/0091-6749(79)90097-6; WESTON J H, 1981, Investigative Ophthalmology and Visual Science, V20, P32	30	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				458	464		10.1016/0091-6749(94)90201-1	http://dx.doi.org/10.1016/0091-6749(94)90201-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	7916020				2022-12-18	WOS:A1994PG90700004
J	BEIL, WJ; LOGIN, GR; GALLI, SJ; DVORAK, AM				BEIL, WJ; LOGIN, GR; GALLI, SJ; DVORAK, AM			ULTRASTRUCTURAL IMMUNOGOLD LOCALIZATION OF TUMOR-NECROSIS-FACTOR-ALPHA TO THE CYTOPLASMIC GRANULES OF RAT PERITONEAL MAST-CELLS WITH RAPID MICROWAVE FIXATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CYTOKINE; SECRETION; CACHECTIN; INFLAMMATION	ELECTRON-MICROSCOPY; LEUKOCYTE ADHESION; DE-GRANULATION; TNF-ALPHA; CACHECTIN; BASOPHILS; RELEASE; MACROPHAGES	Tumor necrosis factor-alpha (TNF-alpha) is a multifunctional, proinflammatory cytokine, which can be produced by mast cells and several other cell types. We used a newly developed microwave energy-assisted aldehyde fixation method to perpare purified rat peritoneal mast cells for the postembedding immunogold ultrastructural localization of TNF-alpha. These fixation methods were superior to chemical fixation alone in presenting both the ultrastructural morphology and immunoreactive TNF-alpha in rat mast cells. The percent of TNF-alpha-positive mast cells in samples prepared with microwave-assisted fixation in low (84%) and standard (81%) glutaraldehyde concentrations exceeded that for low (56%) and standard (15%) glutaraldehyde concentrations without the assistance of microwave energy. TNF-alpha was identified in the large storage granules of rat mast cells. The percent of positive granules in microwave-assisted standard (44%) and low (40%) glutaraldehyde samples was considerably higher than the percent of positive granules in standard (5%) and low (10%) glutaraldehyde-fixed samples without microwave assistance. This location of TNF-alpha in rat peritoneal mast cells suggests that this cytokine can use the regulated secretory route(s) for release from appropriately stimulated rat mast cells into the microenvironment.	BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033372, R01AI022674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE010059] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33372, AI22674] Funding Source: Medline; NIDCR NIH HHS [DE-10059] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AFFRES H, 1991, KIDNEY INT, V39, P822, DOI 10.1038/ki.1991.103; BEIL WJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1611, DOI 10.1177/41.11.8409368; BENDAYAN M, 1983, J HISTOCHEM CYTOCHEM, V31, P101, DOI 10.1177/31.1.6187796; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BISSONNETTE EY, 1991, J IMMUNOL, V147, P3060; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; COSTA JJ, 1993, J CLIN INVEST, V91, P2673, DOI 10.1172/JCI116506; CUTURI MC, 1987, J EXP MED, V165, P1581, DOI 10.1084/jem.165.6.1581; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; DVORAK AM, 1980, LAB INVEST, V43, P126; DVORAK AM, 1992, DIAGNOSTIC ULTRASTRU, V1; FARQUHAR MG, 1965, J CELL BIOL, V26, P263, DOI 10.1083/jcb.26.1.263; GALLI SJ, 1991, CURR OPIN IMMUNOL, V3, P865, DOI 10.1016/S0952-7915(05)80005-6; GALLI SJ, 1984, PROG ALLERGY, V34, P1; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GURISH MF, 1991, J IMMUNOL, V146, P1527; HARUNA N, 1990, ACTA HISTOCHEM CYTOC, V23, P563, DOI 10.1267/ahc.23.563; HIGUCHI M, 1990, J IMMUNOL, V144, P1425; KARNOVASKY MORRIS J., 1967, J CELL BIOL, V35, P213, DOI 10.1083/jcb.35.1.213; KAWAKAMI M, 1981, J EXP MED, V154, P631, DOI 10.1084/jem.154.3.631; KLEIN LM, 1989, P NATL ACAD SCI USA, V86, P8972, DOI 10.1073/pnas.86.22.8972; LOGIN G, 1992, Journal of Dental Research, V71, P304; LOGIN GR, 1988, HISTOCHEM J, V20, P373, DOI 10.1007/BF01002732; LOGIN GR, 1994, PROG HISTOCHEM CYTOC, V27, P1; LOGIN GR, 1992, J HISTOCHEM CYTOCHEM, V40, P1247, DOI 10.1177/40.9.1506663; LOGIN GR, 1985, AM J PATHOL, V120, P230; LOGIN GR, 1987, LAB INVEST, V57, P592; MANNEL DN, 1980, INFECT IMMUN, V30, P523; MURPHY M, 1992, J IMMUNOL, V149, P2506; PHEND KD, 1992, J HISTOCHEM CYTOCHEM, V40, P1011, DOI 10.1177/40.7.1376741; ROTH J, 1990, HISTOCHEMISTRY, V95, P123; ROUZER CA, 1980, MOL BIOCHEM PARASIT, V2, P31, DOI 10.1016/0166-6851(80)90046-8; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; YOUNG JDE, 1987, P NATL ACAD SCI USA, V84, P9175, DOI 10.1073/pnas.84.24.9175	36	34	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				531	536		10.1016/0091-6749(94)90210-0	http://dx.doi.org/10.1016/0091-6749(94)90210-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083459				2022-12-18	WOS:A1994PG90700013
J	GERN, JE; EGGLESTON, PA; SCHUBERTH, KC; ENEY, ND; GOLDSTEIN, EO; WEISS, ME; ADKINSON, NF				GERN, JE; EGGLESTON, PA; SCHUBERTH, KC; ENEY, ND; GOLDSTEIN, EO; WEISS, ME; ADKINSON, NF			PEAK FLOW VARIATION IN CHILDHOOD ASTHMA - A 3-YEAR ANALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PEAK EXPIRATORY FLOW; VARIABILITY; METHACHOLINE; BRONCHIAL HYPERREACTIVITY; ASTHMA; CHILDREN,; PULMONARY FUNCTION TESTS	EXPIRATORY FLOW; DIURNAL-VARIATION; BRONCHIAL RESPONSIVENESS; CHILDREN; VARIABILITY; MANAGEMENT; SYMPTOMS; HYPERRESPONSIVENESS; DIAGNOSIS; DISEASE	Measuring peak expiratory flow (PEF) variation has been suggested as a indicator of asthma disease severity and also of nonspecific bronchial hyperreactivity. To test these assumptions, we examined the relationships between PEF variation, methacholine reactivity, symptom scores, and medication requirements in 74 children with tightly controlled allergic asthma. The level of mean diurnal variation (MDV) for the group was 7.1%, which is generally regarded as normal. We found statistically significant correlations between MDV and both methacholine reactivity (r = 0.43, p = 0.0001) and symptom scores (r = 0.28, p = 0.016). These asthma variables were analyzed longitudinally in 33 children who were followed up at 6-month intervals for at least 36 months. Visit-to-visit changes in MDV were generally not reflective of changes in other variables. However, group levels of MDV gradually decreased over time, especially in children with initial MDV of more than 8%. This reduction in group MDV coincided with similar reductions in group medication requirements and methacholine reactivity. We conclude that children with moderately severe asthma that is tightly controlled may have normal levels of PEF variation. The correlation between PEF variation and other asthma variables is statistically significant but too weak to be useful in the treatment of individual patients. In contrast, measurement of MDV may be a useful indicator of disease severity in group studies of asthma.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV CLIN IMMUNOL & ALLERGY,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021073] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00035] Funding Source: Medline; NIAID NIH HHS [AI21073, AI07007] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTINI M, 1989, PEDIATR PULM, V7, P140, DOI 10.1002/ppul.1950070305; BELLIA V, 1985, CHEST, V88, P89, DOI 10.1378/chest.88.1.89; BELLIA V, 1984, RESPIRATION, V46, P328, DOI 10.1159/000194707; BRAND PLP, 1991, AM REV RESPIR DIS, V143, P916, DOI 10.1164/ajrccm/143.5_Pt_1.916; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; CROSS D, 1991, J ALLERGY CLIN IMMUN, V87, P120, DOI 10.1016/0091-6749(91)90223-B; GIBSON P G, 1988, Clinical and Investigative Medicine, V11, pC105; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; JOHNSTON IDA, 1984, THORAX, V39, P583, DOI 10.1136/thx.39.8.583; JOSEPHS LK, 1989, AM REV RESPIR DIS, V140, P350, DOI 10.1164/ajrccm/140.2.350; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LEE HS, 1991, BRIT J IND MED, V48, P275; PRIOR JG, 1980, J ROY SOC MED, V73, P731, DOI 10.1177/014107688007301009; QUACKENBOSS JJ, 1991, AM REV RESPIR DIS, V143, P323, DOI 10.1164/ajrccm/143.2.323; REINHARDT D, 1980, INT J CLIN PHARM TH, V9, P399; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SLY PD, 1986, PEDIATR PULM, V2, P141, DOI 10.1002/ppul.1950020305; SLY PD, 1986, PEDIATR PULM, V2, P344, DOI 10.1002/ppul.1950020606; SOUTAR CA, 1975, THORAX, V30, P436, DOI 10.1136/thx.30.4.436; VANAALDEREN WMC, 1988, ACTA PAEDIATR SCAND, V77, P269; VATHENEN AS, 1991, BRIT MED J, V302, P738, DOI 10.1136/bmj.302.6779.738; WEISS M, 1988, American Review of Respiratory Disease, V137, P332; WEISS ME, 1989, AM REV RESPIR DIS, V139, P67, DOI 10.1164/ajrccm/139.1.67; WOOLCOCK AJ, 1988, CLIN ALLERGY, V18, P165, DOI 10.1111/j.1365-2222.1988.tb02856.x; 1991, GUIDELINES DIAGNOSIS	28	34	34	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					706	716		10.1016/0091-6749(94)90250-X	http://dx.doi.org/10.1016/0091-6749(94)90250-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	8163780				2022-12-18	WOS:A1994NH49700003
J	SOHOEL, P; FRENG, BA; KRAMER, J; POPPE, S; REBO, R; KORSRUD, FR; GARUD, O; WOXEN, OJ; OLSEN, AK				SOHOEL, P; FRENG, BA; KRAMER, J; POPPE, S; REBO, R; KORSRUD, FR; GARUD, O; WOXEN, OJ; OLSEN, AK			TOPICAL LEVOCABASTINE COMPARED WITH ORALLY-ADMINISTERED TERFENADINE FOR THE PROPHYLAXIS AND TREATMENT OF SEASONAL RHINOCONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINOCONJUNCTIVITIS; LEVOCABASTINE; TOPICAL ANTIHISTAMINE; H-1-RECEPTOR ANTAGONIST	SODIUM CROMOGLYCATE; ALLERGIC RHINITIS; NASAL SPRAY; EYE DROPS; CONJUNCTIVITIS; ANTIHISTAMINE; PLACEBO	Background: This study was designed to compare the efficacy and tolerability of a new topical (nasal spray and eye drops) H-1-receptor antagonist, levocabastine, with that of orally administered terfenadine for the prophylaxis and treatment of seasonal allergic rhinoconjunctivitis. Methods: A total of 115 patients with documented birch pollen allergy were enrolled in this randomized, double-blind, double-dummy, parallel-group trial. Treatment was initiated immediately before the birch pollen season started and continued for a total of 8 weeks. Xylometrazoline (Otrivin) nasal spray was permitted as rescue medication. Results: The investigator's evaluation of symptoms showed similar effects for levocabastine and terfenadine. Both the patients' and the investigator's global evaluations of ocular and nasal symptoms disclosed a somewhat higher percentage of good or excellent results for levocabastine, but the differences were not statistically significant. Visual analog scale ratings from the patients' diaries showed better results for levocabastine. Levocabastine was significantly more effective than terfenadine in relieving sneezing, rhinorrhea, lacrimation, itch, and burning sensation (p < 0.05). For some symptoms, levocabastine was significantly more effective than terfenadine on days when the pollen count was high. There were no statistically significant differences in the use of rescue medication or in the incidence of adverse reactions reported in each treatment group. Conclusions: In the present study topical levocabastine was frequently more effective than orally administered terfenadine for the treatment of seasonal allergic rhinoconjunctivitis. Both drugs were well-tolerated.	SENTRUM ORENESEHALS AS,SANDVIKA,NORWAY; STROMMEN HORESENTER,SKARER,NORWAY; JANSSEN PHARMA,OSLO,NORWAY; ULLEVAL HOSP,OSLO 1,NORWAY; RADMANN HALMRASTV,SANDVIKA,NORWAY; BRAGERNES TORG,DRAMMEN,NORWAY	Johnson & Johnson; Janssen Pharmaceuticals; University of Oslo	SOHOEL, P (corresponding author), BOGSTADVEIEN ONH KLINIKK,BOGSTADVEIEN 34,N-0366 OSLO 3,NORWAY.							ARMALY MF, 1980, CURRENT OCULAR THERA, P444; AZEVEDO M, 1991, CLIN EXP ALLERGY, V21, P689, DOI 10.1111/j.1365-2222.1991.tb03197.x; BENDE M, 1987, ALLERGY, V42, P512, DOI 10.1111/j.1398-9995.1987.tb00374.x; BUSSE W, 1988, J ALLERGY CLIN IMMUN, V82, P890, DOI 10.1016/0091-6749(88)90031-0; CIPRANDI G, 1990, ANN ALLERGY, V65, P156; CRONIN TP, 1964, ARCH OPHTHALMOL-CHIC, V72, P198; DECHANT KL, 1991, DRUGS, V41, P202, DOI 10.2165/00003495-199141020-00006; DELAFUENTE JC, 1989, CLIN PHARMACY, V8, P474; JANSSENS MML, 1991, CLIN EXP ALLERGY, V21, P29, DOI 10.1111/j.1365-2222.1991.tb01755.x; KIRKEGAARD J, 1982, ALLERGY, V37, P203, DOI 10.1111/j.1398-9995.1982.tb01897.x; ODELRAM H, 1989, ALLERGY, V44, P432, DOI 10.1111/j.1398-9995.1989.tb04175.x; PALMACARLOS AG, 1991, ANN ALLERGY, V67, P394; SCHATA M, 1991, J ALLERGY CLIN IMMUN, V87, P873, DOI 10.1016/0091-6749(91)90136-C; STOKBROEKX RA, 1986, DRUG DEVELOP RES, V8, P87, DOI 10.1002/ddr.430080111; WIHL JA, 1991, CLIN EXP ALLERGY, V21, P37, DOI 10.1111/j.1365-2222.1991.tb01756.x	15	34	34	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				73	81		10.1016/0091-6749(93)90040-M	http://dx.doi.org/10.1016/0091-6749(93)90040-M			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	8101534	Bronze			2022-12-18	WOS:A1993LQ35300012
J	WASSERFALLEN, JB; LEUENBERGER, P; PECOUD, A				WASSERFALLEN, JB; LEUENBERGER, P; PECOUD, A			EFFECT OF CETIRIZINE, A NEW H1-ANTIHISTAMINE, ON THE EARLY AND LATE ALLERGIC REACTIONS IN A BRONCHIAL PROVOCATION TEST WITH ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CETIRIZINE; ANTIHISTAMINE; BRONCHIAL PROVOCATION TEST; LATE ALLERGIC REACTION; EXPERIMENTAL ASTHMA	IMMEDIATE ASTHMATIC RESPONSE; CHRONIC IDIOPATHIC URTICARIA; POLLEN-INDUCED ASTHMA; ATOPIC ASTHMA; DOUBLE-BLIND; ORAL CETIRIZINE; TERFENADINE; HISTAMINE; RHINITIS; ASTEMIZOLE	Background: Cetirizine is a highly sensitive H-1 antihistamine with particular antiallergic properties, which has been shown to be effective in the treatment of allergic rhinitis, urticaria, and hay-fever-associated asthma. Methods: To assess the effect of cetirizine on the late allergic reaction to a specific bronchial provocation test (BPT) with allergen, we selected 25 patients with allergic asthma as determined by history skin tests, and specific IgE levels. They were challenged with increasing doses of a cat or mite extract until a 20% drop in forced expiratory volume in 1 second (FEV1) was recorded. Sixteen patients (11 men and 5 women with a mean age of 22 years; range, 18 to 48 years) exhibited a dual response (early and late allergic reactions). These 16 patients underwent a second BPT 2 weeks later, and each again showed a dual response. They were then randomized to receive either a placebo (8 patients) or cetirizine, 15 mg twice daily (8 patients) in a double-blind fashion. After 7 days of treatment, they underwent a third BPT with the same allergen dose as given in the second BPT. Results: The intensity and duration of early allergic reaction were not affected by cetirizine, whereas all parameters of late allergic reaction were statistically significantly improved in the cetrizine group when compared with those of the placebo group (maximum FEV1 decrease, p = 0.046, FEV1 [area above the curve], p = 0.027; maximum airway resistance increase, p = 0.021; airway resistance [area under the curve], p = 0.036). Conclusions: Cetirizine produced a significant protective effect against an allergen-induced late allergic reaction in a BPT Cetirizine might therefore be effective in the treatment of asthma.	CHU VAUDOIS,DEPT INTERNAL MED,DIV PNEUMOL,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	WASSERFALLEN, JB (corresponding author), CHU VAUDOIS,DIV ALLERGY & CLIN IMMUNOL,CH-1011 LAUSANNE,SWITZERLAND.							ALOMAR A, 1990, J INT MED RES, V18, P358, DOI 10.1177/030006059001800503; BERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P177, DOI 10.1016/0091-6749(88)90273-4; BOUSQUET J, 1990, ANN ALLERGY, V65, P504; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; BRUTTMANN G, 1990, ANN ALLERGY, V64, P224; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CROPP GJA, 1980, ATS NEWS         SPR, P11; DIJKMAN JH, 1990, CLIN EXP ALLERGY, V20, P483, DOI 10.1111/j.1365-2222.1990.tb03140.x; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FALLIERS CJ, 1991, ANN ALLERGY, V66, P257; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; GHOSH SK, 1991, THORAX, V46, P242, DOI 10.1136/thx.46.4.242; GHOSH SK, 1991, J ALLERGY CLIN IMMUN, V87, P1010, DOI 10.1016/0091-6749(91)90424-M; HAMID M, 1990, CLIN EXP ALLERGY, V20, P261, DOI 10.1111/j.1365-2222.1990.tb02681.x; HOLGATE ST, 1989, J ALLERGY CLIN IMMUN, V83, P537, DOI 10.1016/0091-6749(89)90035-3; HOWARTH PH, 1987, J ALLERGY CLIN IMMUN, V75, P166; JUHLIN L, 1988, BRIT J DERMATOL, V119, P67, DOI 10.1111/j.1365-2133.1988.tb07103.x; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P893, DOI 10.1016/0091-6749(87)90238-7; KIETZMANN H, 1990, ANN ALLERGY, V65, P498; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KOPFERSCHMITTKUBLER MC, 1990, ANN ALLERGY, V65, P501; KURZEJA A, 1989, LANCET, V1, P556; LEPREVOST C, 1988, INT ARCH ALLER A IMM, V87, P9, DOI 10.1159/000234641; LOBATON P, 1990, ANN ALLERGY, V65, P401; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; NORGRADY SG, 1978, THORAX, V33, P700; OLLIER S, 1986, J ALLERGY CLIN IMMUN, V78, P358, DOI 10.1016/S0091-6749(86)80090-2; RAFFERTY P, 1989, J ALLERGY CLIN IMMUN, V84, P649, DOI 10.1016/0091-6749(89)90292-3; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; REDIER H, 1992, J ALLERGY CLIN IMMUN, V90, P215, DOI 10.1016/0091-6749(92)90074-C; RIJNTJES E, 1990, J INT MED RES, V18, P219, DOI 10.1177/030006059001800306; TAYTARD A, 1987, BRIT J CLIN PHARMACO, V24, P743, DOI 10.1111/j.1365-2125.1987.tb03240.x	33	34	36	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1189	1197		10.1016/0091-6749(93)90322-7	http://dx.doi.org/10.1016/0091-6749(93)90322-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8099593				2022-12-18	WOS:A1993LG74000011
J	OLDAEUS, G; BRADLEY, CK; BJORKSTEN, B; KJELLMAN, NIM				OLDAEUS, G; BRADLEY, CK; BJORKSTEN, B; KJELLMAN, NIM			ALLERGENICITY SCREENING OF HYPOALLERGENIC MILK-BASED FORMULAS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									LINKOPING UNIV,FAC HLTH SCI,DEPT PEDIAT,S-58185 LINKOPING,SWEDEN; MEAD JOHNSON & CO,RES CTR,EVANSVILLE,IN 47721	Linkoping University								BUSINCO L, 1989, ANN ALLERGY, V62, P333; DREBORG S, 1987, THESIS U LINKOPING; JARRETT EEE, 1977, LANCET, V2, P223	3	34	34	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					133	135						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JE255	1629502				2022-12-18	WOS:A1992JE25500019
J	GREEN, WF; MARKS, GB; TOVEY, ER; TOELLE, BG; WOOLCOCK, AJ				GREEN, WF; MARKS, GB; TOVEY, ER; TOELLE, BG; WOOLCOCK, AJ			HOUSE DUST MITES AND MITE ALLERGENS IN PUBLIC PLACES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note											GREEN, WF (corresponding author), UNIV SYDNEY,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA.		Tovey, Euan R/G-8604-2017; Marks, Guy B./F-5058-2013; Toelle, Brett G/B-1531-2008	Tovey, Euan R/0000-0002-1802-7266; Marks, Guy B./0000-0002-8976-8053; Toelle, Brett G/0000-0002-7375-0019				COLLOFF MJ, 1987, EPIDEMIOL INFECT, V98, P127, DOI 10.1017/S095026880006180X; KALRA S, 1990, LANCET, V336, P449, DOI 10.1016/0140-6736(90)92004-2; MARKS GB, UNPUB J ALLERGY CLIN; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; WARNER JO, 1990, CLIN EXP ALLERGY S3, V29, P15	5	34	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1196	1197		10.1016/0091-6749(92)90305-L	http://dx.doi.org/10.1016/0091-6749(92)90305-L			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1607553	Bronze			2022-12-18	WOS:A1992HZ74800016
J	COCKCROFT, DW				COCKCROFT, DW			THERAPY FOR AIRWAY INFLAMMATION IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											COCKCROFT, DW (corresponding author), ROYAL UNIV HOSP, DEPT MED, DIV RESPIR MED, ELLIS HALL, 5TH FLOOR, SASKATOON S7N 0X0, SASKATCHEWAN, CANADA.							BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BEL EH, 1989, AM REV RESPIR DIS, V139, P427, DOI 10.1164/ajrccm/139.2.427; BERNSTEIN DI, 1988, J ALLERGY CLIN IMMUN, V81, P6, DOI 10.1016/0091-6749(88)90213-8; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHAROUS BL, 1990, ANN ALLERGY, V65, P53; COCKCROFT DW, 1989, CLIN EXP ALLERGY, V19, P225, DOI 10.1111/j.1365-2222.1989.tb02368.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1989, J ALLERGY CLIN IMMUN, V83, P913, DOI 10.1016/0091-6749(89)90105-X; Cockcroft DW, 1988, BRONCHITIS, P23; CUSS FM, 1986, LANCET, V2, P189; DAHL R, 1990, EUR RESPIR J, V3, P1087; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DOLOVICH J, 1983, ASTHMA, P132; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FERGUSON AC, 1989, CHEST, V96, P988, DOI 10.1378/chest.96.5.988; FUJIMURA M, 1986, THORAX, V41, P955, DOI 10.1136/thx.41.12.955; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; GIBSON PG, 1989, LANCET, V1, P1346; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HARRIS R, 1989, ANN ALLERGY, V63, P110; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; KERREBIJN KF, 1986, EUR J RESPIR DIS, V69, P98; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; KIRBY JG, 1989, J APPL PHYSIOL, V66, P578, DOI 10.1152/jappl.1989.66.2.578; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P343, DOI 10.1016/0091-6749(85)90070-3; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MANNING P J, 1990, American Review of Respiratory Disease, V141, pA395; MAPP CE, 1986, EUR J RESPIR DIS, V69, P276; MAPP CE, 1988, AM REV RESPIR DIS, V137, P1326, DOI 10.1164/ajrccm/137.6.1326; MITCHELL EA, 1989, THORAX, V44, P81, DOI 10.1136/thx.44.2.81; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; MURANAKA M, 1978, ANN ALLERGY, V40, P132; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P350, DOI 10.1016/0091-6749(81)90079-8; MURPHY S, 1987, DRUG INTEL CLIN PHAR, V21, P22, DOI 10.1177/10600280870211P102; MURRAY AB, 1983, PEDIATRICS, V71, P418; MURRAY AB, 1985, ANN ALLERGY, V54, P541; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, pS35, DOI 10.1164/ajrccm/136.4_Pt_2.S35; PAUWELS R, 1987, CHEST, V92, pS32, DOI 10.1378/chest.92.1_Supplement.32S; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RAES M, 1989, J ALLERGY CLIN IMMUN, V84, P874, DOI 10.1016/0091-6749(89)90382-5; SEARS MR, 1988, J ALLERGY CLIN IMMUN, V82, P957, DOI 10.1016/0091-6749(88)90130-3; SIMONS FER, 1982, ANN ALLERGY, V48, P145; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; THOMSON NC, 1989, RESP MED, V83, P269, DOI 10.1016/S0954-6111(89)80195-7; TWENTYMAN OP, 1990, EUR RESPIR J S10, V3, P225; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WARNER JO, 1978, LANCET, V2, P912; WOOLCOCK AJ, 1988, CLIN ALLERGY, V18, P165, DOI 10.1111/j.1365-2222.1988.tb02856.x	60	34	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1991	87	5					914	919		10.1016/0091-6749(91)90412-H	http://dx.doi.org/10.1016/0091-6749(91)90412-H			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FM095	2026844	Bronze			2022-12-18	WOS:A1991FM09500002
J	ABRAHAM, WM; AHMED, A; CORTES, A; SOLER, M; FARMER, SG; BAUGH, LE; HARBESON, SL				ABRAHAM, WM; AHMED, A; CORTES, A; SOLER, M; FARMER, SG; BAUGH, LE; HARBESON, SL			AIRWAY EFFECTS OF INHALED BRADYKININ, SUBSTANCE-P, AND NEUROKININ-A IN SHEEP	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IRIS SPHINCTER MUSCLE; INDUCED BRONCHOCONSTRICTION; GUINEA-PIG; MULTIPLE TACHYKININS; SODIUM CROMOGLYCATE; ASTHMATIC SUBJECTS; ANTIGEN CHALLENGE; NEDOCROMIL SODIUM; CONSCIOUS SHEEP; ALLERGIC SHEEP	The effects of inhaled bradykinin (BK), substance P (SP), and neurokinin A (NKA) on pulmonary resistance and airway responsiveness to carbachol were studied in conscious allergic sheep. Inhaled BK (20 breaths, 0.1 to 5.0 mg . ml-1) caused dose-dependent increases in pulmonary resistance. Neither inhaled SP nor NKA (20 breaths, 0.1 to 1.0 mg . ml-1) produced significant bronchoconstriction in allergic sheep. However, the response to SP could be enhanced (p < 0.05) by pretreatment with the neutral endopeptidase inhibitor, thiorphan (40 breaths, 1 mg . ml-1). Sheep that were allergic to Ascaris suum antigen were 5.9 times (p < 0.05) more sensitive to the constrictor effects of BK than nonallergic sheep. BK-induced bronchoconstriction was blocked in a dose-dependent fashion by the BK beta-2-receptor antagonist, NPC 567 (D-arginine{hydroxyproline3, D-phenylalanine7}BK). Atropine (0.2 mg . kg-1, intravenously) and nedocromil sodium (1 mg . kg-1 in 3 ml of saline, aerosolized) significantly inhibited the BK-induced bronchoconstriction by 97% and 43%, respectively. Chlorpheniramine (2 mg . kg-1, intravenously) had no effect. NKA caused a transient increase in airway responsiveness in allergic sheep, producing a mean 1.9-fold leftward shift in dose-response curves to aerosolized carbachol (p < 0.05). This hyperresponsiveness was not evident 24 hours after NKA challenge. Neither SP nor BK changed airway responsiveness. Thus, in allergic sheep, inhaled BK caused a more pronounced bronchoconstriction than that observed in nonallergic sheep. The bronchoconstriction was blocked by a BK-receptor antagonist and appeared to be partially mediated via cholinergic reflexes. The sensory neuropeptides, unlike BK, were not potent bronchoconstrictors when they were administered by inhalation, but NKA may play a role in modulating airway responsiveness.	NOVA PHARMACEUT CORP,BALTIMORE,MD; MERRELL DOW PHARMACEUT INC,RES INST,CINCINNATI,OH 45215; UNIV BASEL,MED KLIN,CH-4051 BASEL,SWITZERLAND	Novartis; Dow Chemical Company; University of Basel	ABRAHAM, WM (corresponding author), MT SINAI MED CTR,DEPT RES,4300 ALTON RD,MIAMI BEACH,FL 33140, USA.				NHLBI NIH HHS [HLBI-33897] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033897] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE K, 1967, EXPERIENTIA, V23, P626, DOI 10.1007/BF02144161; ABRAHAM WM, 1983, AM REV RESPIR DIS, V128, P839; ABRAHAM WM, 1988, J APPL PHYSIOL, V65, P1062, DOI 10.1152/jappl.1988.65.3.1062; AHMED T, 1980, J APPL PHYSIOL, V49, P826, DOI 10.1152/jappl.1980.49.5.826; ALLEGRA L, 1983, J APPL PHYSIOL, V55, P726, DOI 10.1152/jappl.1983.55.3.726; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; COOK CD, 1957, J CLIN INVEST, V36, P440, DOI 10.1172/JCI103441; CRIMI N, 1988, RESPIRATION, V54, P95; DIXON CMS, 1989, BRIT J CLIN PHARMACO, V27, P831, DOI 10.1111/j.1365-2125.1989.tb03446.x; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; DIXON M, 1979, BRIT J PHARMACOL, V67, P569, DOI 10.1111/j.1476-5381.1979.tb08703.x; FARMER SG, 1989, MOL PHARMACOL, V36, P1; FARMER SG, 1989, J PHARMACOL EXP THER, V248, P667; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; FULLER RW, 1984, THORAX, V29, P766; GRIESBACHER T, 1987, BRIT J PHARMACOL, V92, P333, DOI 10.1111/j.1476-5381.1987.tb11328.x; HERXHEIMER H, 1961, J PHYSIOL-LONDON, V158, pP38; HUA XY, 1985, REGUL PEPTIDES, V13, P1, DOI 10.1016/0167-0115(85)90082-5; JIN LS, 1989, BRIT J PHARMACOL, V97, P598, DOI 10.1111/j.1476-5381.1989.tb11991.x; JOOS G, 1987, THORAX, V42, P779, DOI 10.1136/thx.42.10.779; MARCEAU F, 1983, GEN PHARMACOL, V14, P209, DOI 10.1016/0306-3623(83)90001-0; OMINI C, 1989, EUR J PHARMACOL, V163, P195, DOI 10.1016/0014-2999(89)90419-6; ROCCHICCIOLI KMS, 1989, PULM PHARM, V1, P123; RUSSI EW, 1983, AM REV RESPIR DIS, V127, P675; RUSSI EW, 1984, J APPL PHYSIOL, V57, P1182, DOI 10.1152/jappl.1984.57.4.1182; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330, DOI 10.1164/ajrccm/137.6.1330; SHEPPARD D, 1988, J CLIN INVEST, V81, P1111, DOI 10.1172/JCI113424; SHEPPARD D, 1988, AM REV RESPIR DIS, V138, P547, DOI 10.1164/ajrccm/138.3.547; SHEPPARD D, 1981, AM REV RESPIR DIS, V24, P257; SIMONSSON BG, 1973, RESPIRATION, V30, P378, DOI 10.1159/000193051; SOLER M, 1990, Pulmonary Pharmacology, V3, P9, DOI 10.1016/0952-0600(90)90003-2; SOLER M, 1989, J APPL PHYSIOL, V67, P406, DOI 10.1152/jappl.1989.67.1.406; STERANKA LR, 1988, P NATL ACAD SCI USA, V85, P3245, DOI 10.1073/pnas.85.9.3245; STERANKA LR, 1989, FASEB J, V3, P2019, DOI 10.1096/fasebj.3.9.2545496; UEDA N, 1984, J PHARMACOL EXP THER, V230, P469; VARONIER HS, 1968, INT ARCH ALLER A IMM, V34, P293, DOI 10.1159/000230120; WANNER A, 1978, J APPL PHYSIOL, V44, P479, DOI 10.1152/jappl.1978.44.3.479	37	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					557	564		10.1016/0091-6749(91)90015-G	http://dx.doi.org/10.1016/0091-6749(91)90015-G			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1704388	Bronze			2022-12-18	WOS:A1991EX98700014
J	ADELMAN, DC; MATSUDA, T; HIRANO, T; KISHIMOTO, T; SAXON, A				ADELMAN, DC; MATSUDA, T; HIRANO, T; KISHIMOTO, T; SAXON, A			ELEVATED SERUM INTERLEUKIN-6 ASSOCIATED WITH A FAILURE IN B-CELL DIFFERENTIATION IN COMMON VARIABLE IMMUNODEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OSAKA UNIV,INST MOLEC & CELLULAR BIOL,DIV IMMUNOL,OSAKA,JAPAN; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,LOS ANGELES,CA 90024	Osaka University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	ADELMAN, DC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,DIV ALLERGY & IMMUNOL,SAN FRANCISCO,CA 94143, USA.		Hirano, Toshio/C-8194-2009; Kishimoto, Tadamitsu/C-8470-2009; Matsuda, Tadashi/A-3835-2012	Matsuda, Tadashi/0000-0002-3089-3757	NCI NIH HHS [CA-23175, CA-12800] Funding Source: Medline; NIAID NIH HHS [AI-15251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA012800, P01CA023175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015251, R21AI015251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CASTEL JV, 1988, DEC NEW YORK AC SC C; CONLEY ME, 1986, J PEDIATR-US, V108, P915, DOI 10.1016/S0022-3476(86)80927-1; CUNNINGHAMRUNDLES C, 1987, J CLIN IMMUNOL, V7, P294, DOI 10.1007/BF00915550; DAWSON J, 1979, AM J MED, V67, P540, DOI 10.1016/0002-9343(79)90808-8; GARMAN RD, 1987, P NATL ACAD SCI USA, V84, P7629, DOI 10.1073/pnas.84.21.7629; HARADA N, 1987, P NATL ACAD SCI USA, V84, P4581, DOI 10.1073/pnas.84.13.4581; HERMANS PE, 1976, AM J MED, V61, P221, DOI 10.1016/0002-9343(76)90173-X; HINZ CF, 1963, NEW ENGL J MED, V269, P1329, DOI 10.1056/NEJM196312192692501; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; HIRANO T, 1988, IMMUNOL LETT, V17, P41, DOI 10.1016/0165-2478(88)90099-5; HIRANO T, 1987, P NATL ACAD SCI USA, V84, P228, DOI 10.1073/pnas.84.1.228; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KINLEN LJ, 1985, LANCET, V1, P263; KISHIMOTO T, 1987, J CLIN IMMUNOL, V7, P343, DOI 10.1007/BF00917012; KISHIMOTO T, 1985, ANNU REV IMMUNOL, V3, P133, DOI 10.1146/annurev.iy.03.040185.001025; KOHASE M, 1986, CELL, V45, P659, DOI 10.1016/0092-8674(86)90780-4; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; MATSUDA T, 1989, J IMMUNOL, V142, P148; MATSUDA T, 1988, EUR J IMMUNOL, V18, P951, DOI 10.1002/eji.1830180618; MINGARI MC, 1984, NATURE, V312, P641, DOI 10.1038/312641a0; MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332; RALPH P, 1984, J IMMUNOL, V133, P2442; SAXON A, 1989, J ALLERGY CLIN IMMUN, V84, P44, DOI 10.1016/0091-6749(89)90177-2; SUTTON MGSJ, 1980, MAYO CLIN PROC, V55, P371; TANAKA Y, 1988, J IMMUNOL, V141, P3043; TOHYAMA N, 1990, J EXP MED, V171, P389, DOI 10.1084/jem.171.2.389; TOSATO G, 1988, J IMMUNOL, V140, P4329; TWOMEY JJ, 1969, AM J MED, V47, P340, DOI 10.1016/0002-9343(69)90218-6; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; WEBSTER ADB, 1981, J CLIN IMMUNOL, V1, P113, DOI 10.1007/BF00915388; WOLF JK, 1962, NEW ENGL J MED, V266, P473, DOI 10.1056/NEJM196203082661001	34	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				512	521		10.1016/S0091-6749(05)80207-6	http://dx.doi.org/10.1016/S0091-6749(05)80207-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2229813				2022-12-18	WOS:A1990EG45400011
J	GRAMMER, LC; HARRIS, KE; MALO, JL; CARTIER, A; PATTERSON, R				GRAMMER, LC; HARRIS, KE; MALO, JL; CARTIER, A; PATTERSON, R			THE USE OF AN IMMUNOASSAY INDEX FOR ANTIBODIES AGAINST ISOCYANATE HUMAN PROTEIN CONJUGATES AND APPLICATION TO HUMAN ISOCYANATE DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV, SCH MED, DEPT MED, ALLERGY IMMUNOL SECT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT MED, OCCUPAT MED SECT, CHICAGO, IL 60611 USA; HOP SACRE COEUR, SERV PNEUMOL, MONTREAL H4J 1C5, QUEBEC, CANADA	Northwestern University; Northwestern University; Universite de Montreal				Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA K, 1984, J IMMUNOL, V133, P3286; BANKS DE, 1986, ANN ALLERGY, V57, P389; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; BUTCHER B T, 1982, Journal of Allergy and Clinical Immunology, V69, P123; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; GRAMMER LC, 1988, J ALLERGY CLIN IMMUN, V82, P627, DOI 10.1016/0091-6749(88)90975-X; LISS GM, 1988, J ALLERGY CLIN IMMUN, V82, P55, DOI 10.1016/0091-6749(88)90051-6; MALO JL, 1983, J ALLERGY CLIN IMMUN, V72, P413, DOI 10.1016/0091-6749(83)90508-0; NORUSIS MJ, 1988, SPSS PC PLUS VERSION; PAGGIARO PL, 1983, CLIN ALLERGY, V13, P75, DOI 10.1111/j.1365-2222.1983.tb02570.x; PATTERSON R, 1983, J ALLERGY CLIN IMMUN, V71, P604, DOI 10.1016/0091-6749(83)90443-8; PATTERSON R, 1987, INT ARCH ALLER A IMM, V84, P93, DOI 10.1159/000234404; PEZZINI A, 1984, CLIN ALLERGY, V14, P453, DOI 10.1111/j.1365-2222.1984.tb02229.x; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WASS U, 1989, J ALLERGY CLIN IMMUN, V83, P126, DOI 10.1016/0091-6749(89)90487-9; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	22	34	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					94	98		10.1016/S0091-6749(05)80128-9	http://dx.doi.org/10.1016/S0091-6749(05)80128-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2164544				2022-12-18	WOS:A1990DQ68800014
J	BURKS, AW; WILLIAMS, LW; CASTEEL, HB; FIEDOREK, SC; CONNAUGHTON, CA				BURKS, AW; WILLIAMS, LW; CASTEEL, HB; FIEDOREK, SC; CONNAUGHTON, CA			ANTIBODY-RESPONSE TO MILK-PROTEINS IN PATIENTS WITH MILK-PROTEIN INTOLERANCE DOCUMENTED BY CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ARKANSAS MED SCI HOSP, LITTLE ROCK, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	BURKS, AW (corresponding author), ARKANSAS CHILDRENS HOSP, 800 MARSHALL ST, LITTLE ROCK, AR 72202 USA.							ANDERSON JA, 1984, NIH842442 PUBL; ASHKENAZI A, 1980, PEDIATRICS, V66, P399; BAHN SL, 1980, ALLERGIES MILK, P202; BALDO BA, 1984, AUST J DAIRY TECHNOL, V39, P120; BOCK SA, 1980, AM J DIS CHILD, V134, P973, DOI 10.1001/archpedi.1980.02130220049015; BURKS AW, 1989, J PEDIATR GASTR NUTR, V8, P195, DOI 10.1097/00005176-198902000-00012; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; BURKS AW, 1987, J PEDIATR-US, V110, P500; CONOVER WJ, 1971, PRACTICAL NONPARAMET, P101; DANNAEUS A, 1977, ACTA PAEDIATR SCAND, V66, P31, DOI 10.1111/j.1651-2227.1977.tb07803.x; DANNAEUS A, 1978, ACTA PAEDIATR SCAND, V67, P497, DOI 10.1111/j.1651-2227.1978.tb16360.x; DAVIDSON M, 1965, J PEDIATR-US, V66, P545, DOI 10.1016/S0022-3476(65)80119-6; EASTHAM EJ, 1978, J PEDIATR-US, V93, P561, DOI 10.1016/S0022-3476(78)80888-9; FOUCARD T, 1985, PEDIATRICS, V75, P177; FRIER S, 1972, AUST PEDIATR J, V8, P140; FRIERI M, 1988, IMMUNOL ALLERGY PRAC, V10, P9; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; HADDAD ZH, 1983, ANN ALLERGY, V51, P255; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; KUITUNEN P, 1975, ARCH DIS CHILD, V50, P351, DOI 10.1136/adc.50.5.351; MAY CD, 1980, ALLERGY, V35, P301, DOI 10.1111/j.1398-9995.1980.tb01771.x; MCDONALD PJ, 1984, PEDIATR RES, V18, P751, DOI 10.1203/00006450-198408000-00016; PAGANELLI R, 1983, ARCH DIS CHILD, V58, P201, DOI 10.1136/adc.58.3.201; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SAPERSTEIN S, 1963, PEDIATRICS, V32, P580; TAYLOR SL, 1986, J FOOD PROTECT, V49, P239, DOI 10.4315/0362-028X-49.3.239; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915, DOI 10.1016/0016-5085(85)90019-8; WALKER WA, 1974, GASTROENTEROLOGY, V67, P531; WEIL S, 1982, PEDIATR RES, V16, P1040; WOSTMANN BS, 1971, FED PROC, V30, P1779	31	34	36	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					921	927		10.1016/0091-6749(90)90078-I	http://dx.doi.org/10.1016/0091-6749(90)90078-I			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	1692051				2022-12-18	WOS:A1990DD95900016
J	LOPEZ, AF; LYONS, AB; EGLINTON, JM; PARK, LS; TO, LB; CLARK, SC; VADAS, MA				LOPEZ, AF; LYONS, AB; EGLINTON, JM; PARK, LS; TO, LB; CLARK, SC; VADAS, MA			SPECIFIC BINDING OF HUMAN INTERLEUKIN-3 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HUMAN BASOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									IMMUNEX CORP,SEATTLE,WA; GENET INST,CAMBRIDGE,MA	Immunex Corporation	LOPEZ, AF (corresponding author), INST MED & VET SCI,DIV HUMAN IMMUNOL,BOX 14,RUNDLE MALL,ADELAIDE,SA 5000,AUSTRALIA.		Lopez, Angel F/E-2260-2011; Vadas, Mathew/R-1378-2019	Lyons, Alan/0000-0002-8508-5853; Lopez, Angel F/0000-0001-7430-0135				ALAM R, 1989, J IMMUNOL, V142, P3431; Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; ELLIOTT ME, IN PRESS BLOOD; FREW AJ, 1988, J IMMUNOL, V141, P4158; GASSON JC, 1984, SCIENCE, V226, P1339, DOI 10.1126/science.6390681; HAAKFRENDSCHO M, 1988, J CLIN INVEST, V82, P17, DOI 10.1172/JCI113567; HIRAI K, 1988, J IMMUNOL, V141, P3958; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LOPEZ AF, 1983, J IMMUNOL, V131, P2983; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1986, J EXP MED, V163, P1085, DOI 10.1084/jem.163.5.1085; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; OHNISHI M, 1988, J ALLERGY CLIN IMMUN, V81, P1149, DOI 10.1016/0091-6749(88)90883-4; PARK LS, 1986, J EXP MED, V164, P251, DOI 10.1084/jem.164.1.251; PARK LS, 1989, J BIOL CHEM, V264, P5420; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; VADAS MA, 1983, J IMMUNOL, V130, P795; VADAS MA, 1979, J IMMUNOL, V122, P1228; YANG YC, 1988, BLOOD, V71, P958	29	34	34	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				99	102		10.1016/0091-6749(90)90229-W	http://dx.doi.org/10.1016/0091-6749(90)90229-W			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2153721	Bronze			2022-12-18	WOS:A1990CM37800017
J	ROBUSCHI, M; PIERONI, M; REFINI, M; BIANCO, S; ROSSONI, G; MAGNI, F; BERTI, F				ROBUSCHI, M; PIERONI, M; REFINI, M; BIANCO, S; ROSSONI, G; MAGNI, F; BERTI, F			PREVENTION OF ANTIGEN-INDUCED EARLY OBSTRUCTIVE REACTION BY INHALED FUROSEMIDE IN (ATOPIC) SUBJECTS WITH ASTHMA AND (ACTIVELY SENSITIZED) GUINEA-PIGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SIENA,INST LUNG DIS,I-53100 SIENA,ITALY; UNIV MILAN,INST PHARMACOL SCI,I-20122 MILAN,ITALY	University of Siena; University of Milan	ROBUSCHI, M (corresponding author), UNIV MILAN,INST LUNG DIS,VIA COMMENDA 16,I-20122 MILAN,ITALY.		Saido, Takaomi/N-5472-2015; Magni, Fulvio/A-7340-2014	Saido, Takaomi/0000-0003-1970-6903; Magni, Fulvio/0000-0002-8663-0374				BIANCO S, 1988, LANCET, V2, P252; FLINT KC, 1986, RESPIRATION, V50, P31, DOI 10.1159/000195099; HOLGATE ST, 1986, J ALLERGY CLIN IMMUN, V77, P274, DOI 10.1016/S0091-6749(86)80104-X; KONZETT H, 1940, N-S ARCH PHARMACOL, V195, P556; LAGUNOFF D, 1980, HDB INFLAMMATION, V2, P217; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAMB D, 1982, THORAX, V37, P334, DOI 10.1136/thx.37.5.334; LAZARUS SC, 1987, AM REV RESPIR DIS, V135, pS35; PHIPPS RJ, 1983, J APPL PHYSIOL, V55, P1593, DOI 10.1152/jappl.1983.55.5.1593; PIPER PJ, 1969, NATURE, V223, P29, DOI 10.1038/223029a0; RANGA V, 1983, AM REV RESPIR DIS, V128, P1065; ROBUSCHI M, 1988, AM REV RESPIR DIS, V137, P341; ROSSONI G, 1980, PROSTAGLANDINS, V20, P547, DOI 10.1016/0090-6980(80)90042-8; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; SIMMONS PM, 1983, BIOCHEM PHARMACOL, V32, P1353, DOI 10.1016/0006-2952(83)90446-X; SOUHRADA M, 1988, BRIT J PHARMACOL, V93, P884, DOI 10.1111/j.1476-5381.1988.tb11476.x; WELSH MJ, 1983, J CLIN INVEST, V71, P1392, DOI 10.1172/JCI110892; WIDDICOMBE JH, 1983, AM J PHYSIOL, V245, pC388, DOI 10.1152/ajpcell.1983.245.5.C388	18	34	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				10	16		10.1016/0091-6749(90)90215-P	http://dx.doi.org/10.1016/0091-6749(90)90215-P			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2405040				2022-12-18	WOS:A1990CM37800003
J	DEVEY, ME; LEE, SR; RICHARDS, D; KEMENY, DM				DEVEY, ME; LEE, SR; RICHARDS, D; KEMENY, DM			SERIAL STUDIES ON THE FUNCTIONAL AFFINITY AND HETEROGENEITY OF ANTIBODIES OF DIFFERENT IGG SUBCLASSES TO PHOSPHOLIPASE-A2 PRODUCED IN RESPONSE TO BEE-VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT ALLERGY & ALLIED RESP DIS,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	DEVEY, ME (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AALBERSE RC, 1983, J IMMUNOL, V130, P722; BIRD P, 1988, EUR J IMMUNOL, V18, P1217, DOI 10.1002/eji.1830180811; DEVEY M E, 1975, Clinical Allergy, V5, P353, DOI 10.1111/j.1365-2222.1975.tb01874.x; DEVEY ME, 1988, J IMMUNOL METHODS, V106, P119, DOI 10.1016/0022-1759(88)90279-7; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; KEMENY DM, 1986, CLIN ALLERGY, V16, P571, DOI 10.1111/j.1365-2222.1986.tb01996.x; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; PERSSON MAA, 1988, J IMMUNOL, V140, P3875; RATH S, 1988, J IMMUNOL METHODS, V106, P245, DOI 10.1016/0022-1759(88)90204-9; SARVAS HO, 1983, MOL IMMUNOL, V20, P239, DOI 10.1016/0161-5890(83)90062-7; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; STEWARD MW, 1981, IMMUNOL TODAY, V2, P134, DOI 10.1016/0167-5699(81)90079-7; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; VANDAM GJ, 1989, MOL IMMUNOL, V26, P269, DOI 10.1016/0161-5890(89)90080-1; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566	17	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					326	330		10.1016/0091-6749(89)90416-8	http://dx.doi.org/10.1016/0091-6749(89)90416-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2778238				2022-12-18	WOS:A1989AR19900009
J	SVENDSEN, UG; FROLUND, L; MADSEN, F; NIELSEN, NH				SVENDSEN, UG; FROLUND, L; MADSEN, F; NIELSEN, NH			A COMPARISON OF THE EFFECTS OF NEDOCROMIL SODIUM AND BECLOMETHASONE DIPROPIONATE ON PULMONARY-FUNCTION, SYMPTOMS, AND BRONCHIAL RESPONSIVENESS IN PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV HOSP,DEPT MED TTA,ALLERGY UNIT,COPENHAGEN,DENMARK; BISPEBJERG HOSP,DEPT MED P,DK-2400 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen; Bispebjerg Hospital				Madsen, Flemming/0000-0002-9911-0175				BERGLUND E, 1963, ACTA MED SCAND, V173, P185; CHUNG KF, 1988, BRIT MED J, V296, P29, DOI 10.1136/bmj.296.6614.29; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTT GR, 1988, NEW ENGL J MED, V318, P634, DOI 10.1056/NEJM198803103181010; CUALIM F, 1985, PHIL J INT MED, V23, P181; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; FYANS PG, 1986, CLIN ALLERGY, V16, P505, DOI 10.1111/j.1365-2222.1986.tb01988.x; GONZALEZ JP, 1987, DRUGS, V34, P560, DOI 10.2165/00003495-198734050-00004; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; LAL S, 1984, THORAX, V39, P809, DOI 10.1136/thx.39.11.809; MADSEN F, 1987, B EUR PHYSIOPATH RES, V23, P67; REID DM, 1986, BMJ-BRIT MED J, V293, P1463, DOI 10.1136/bmj.293.6560.1463; SCADDING JG, 1977, ASTHMA, P1; SVENDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68; WELLS E, 1986, J IMMUNOL, V137, P3941	15	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					224	231		10.1016/0091-6749(89)90329-1	http://dx.doi.org/10.1016/0091-6749(89)90329-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2547858	Bronze			2022-12-18	WOS:A1989AL83600014
J	STORMS, WW; BODMAN, SF; NATHAN, RA; CHERVINSKY, P; BANOV, CH; DOCKHORN, RJ; JARMOSZUK, I; ZEITZ, HJ; MCGEADY, SJ; PINNAS, JL; GREENSTEIN, S				STORMS, WW; BODMAN, SF; NATHAN, RA; CHERVINSKY, P; BANOV, CH; DOCKHORN, RJ; JARMOSZUK, I; ZEITZ, HJ; MCGEADY, SJ; PINNAS, JL; GREENSTEIN, S			SCH 434 - A NEW ANTIHISTAMINE DECONGESTANT FOR SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WC SERV ALLERGY & ASTHMA RES FDN,COLORADO SPRINGS,CO									AHN HS, 1986, EUR J PHARMACOL, V127, P153, DOI 10.1016/0014-2999(86)90219-0; BARNETT A, 1984, AGENTS ACTIONS, V14, P590, DOI 10.1007/BF01978891; BATENHORST RL, 1986, EUR J CLIN PHARMACOL, V31, P247, DOI 10.1007/BF00606669; BEDARD PM, 1985, ANN ALLERGY, V55, P233; BRADLEY CM, 1987, EUR J CLIN PHARMACOL, V32, P419, DOI 10.1007/BF00543979; BRUTTMANN G, 1985, ANN ALLERGY, V55, P233; BRUTTMANN G, 1987, J INT MED RES, V15, P63, DOI 10.1177/030006058701500201; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; HILBERT J, 1987, J CLIN PHARMACOL, V27, P694, DOI 10.1002/j.1552-4604.1987.tb03090.x; KATCHEN B, 1985, ANN ALLERGY, V55, P393; KEMP JP, 1985, ANN ALLERGY, V54, P502; KEMP JP, 1987, AM J RHINOL, V1, P151; KREUTNER W, 1987, ALLERGY, V42, P57, DOI 10.1111/j.1398-9995.1987.tb02188.x; RADWANSKI E, 1987, J CLIN PHARMACOL, V27, P530, DOI 10.1002/j.1552-4604.1987.tb03061.x; ROMAN IJ, 1986, ANN ALLERGY, V57, P253; ROTH T, 1987, J ALLERGY CLIN IMMUN, V80, P94, DOI 10.1016/S0091-6749(87)80197-5	16	34	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1083	1090		10.1016/0091-6749(89)90450-8	http://dx.doi.org/10.1016/0091-6749(89)90450-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2471718				2022-12-18	WOS:A1989AC23500012
J	LINDGREN, S; BELIN, L; DREBORG, S; EINARSSON, R; PAHLMAN, I				LINDGREN, S; BELIN, L; DREBORG, S; EINARSSON, R; PAHLMAN, I			BREED-SPECIFIC DOG-DANDRUFF ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PHARMACIA AB,UPPSALA,SWEDEN; LINKOPING UNIV,DEPT PEDIAT,S-58185 LINKOPING,SWEDEN	Pfizer; Pharmacia Corporation; Linkoping University	LINDGREN, S (corresponding author), GOTHENBURG UNIV,SAHLGRENS HOSP,ASTHMA & ALLERGY RES CTR,DEPT MED 1,S-41345 GOTHENBURG,SWEDEN.							BLANDS J, 1977, ACTA ALLERGOL, V32, P147, DOI 10.1111/j.1398-9995.1977.tb01346.x; BRANDT R, 1980, INT ARCH ALLER A IMM, V61, P361, DOI 10.1159/000232463; BROWN HM, 1981, ALLERGOLOGIE, V4, P256; DREBORG S, 1987, THESIS U VTT GRAFISK; FAGERBERG E, 1970, INT ARCH ALLER A IMM, V39, P301, DOI 10.1159/000230356; Hooker S. B., 1944, ANN ALLERGY, V2, P281; MCLEAN AC, 1980, ANN ALLERGY, V45, P199; MERINEY DK, 1979, INT ARCH ALLER A IMM, V58, P453, DOI 10.1159/000232226; MOORE BS, 1980, J ALLERGY CLIN IMMUN, V66, P198, DOI 10.1016/0091-6749(80)90039-1; PEPYS J, 1972, P ROY SOC MED, V65, P271, DOI 10.1177/003591577206500320; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; UHLIN T, 1984, ALLERGY, V39, P125, DOI 10.1111/j.1398-9995.1984.tb01944.x; VANTO T, 1982, ALLERGY, V37, P75, DOI 10.1111/j.1398-9995.1982.tb01880.x; VANTO T, 1980, CLIN ALLERGY, V10, P121, DOI 10.1111/j.1365-2222.1980.tb02089.x; VANTO T, 1982, INT ARCH ALLER A IMM, V69, P311, DOI 10.1159/000233192; VANTO T, 1982, ANN ALLERGY, V49, P340; VANTO T, 1980, ALLERGOL IMMUNOPATH, V8, P405; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624; WUTRICH B, 1985, CLIN ALLERGY, V15, P87; YMAN L, 1973, INT ARCH ALLER A IMM, V44, P358, DOI 10.1159/000230944	20	34	35	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					196	204		10.1016/0091-6749(88)90999-2	http://dx.doi.org/10.1016/0091-6749(88)90999-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	2457041				2022-12-18	WOS:A1988P874100009
J	PIENKOWSKI, MM; ADKINSON, NF; PLAUT, M; NORMAN, PS; LICHTENSTEIN, LM				PIENKOWSKI, MM; ADKINSON, NF; PLAUT, M; NORMAN, PS; LICHTENSTEIN, LM			PROSTAGLANDIN-D2 AND HISTAMINE DURING THE IMMEDIATE AND THE LATE-PHASE COMPONENTS OF ALLERGIC CUTANEOUS RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL, 5601 LOCH RAVEN BLVD, BALTIMORE, MD 21239 USA; UNIV TENNESSEE, KNOXVILLE, TN 37996 USA	Johns Hopkins University; University of Tennessee System; University of Tennessee Knoxville					NIAID NIH HHS [AI21073, AI04866, AI08270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R01AI021073, R37AI008270, R37AI004866, R01AI004866] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1977, J LAB CLIN MED, V90, P1043; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS PC, 1987, J ALLERGY CLIN IMMUN, V79, P12, DOI 10.1016/S0091-6749(87)80008-8; BUSH RK, 1977, CLIN ALLERGY, V7, P369, DOI 10.1111/j.1365-2222.1977.tb01465.x; DAVIES RJ, 1976, AM REV RESPIR DIS, V114, P1011; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DOR PJ, 1983, J ALLERGY CLIN IMMUN, V71, P363, DOI 10.1016/0091-6749(83)90063-5; DORSCH W, 1981, J ALLERGY CLIN IMMUN, V67, P117, DOI 10.1016/0091-6749(81)90006-3; DORSCH W, 1980, ALLERGY, V35, P503, DOI 10.1111/j.1398-9995.1980.tb01797.x; FLOWER RJ, 1976, BRIT J PHARMACOL, V56, P229, DOI 10.1111/j.1476-5381.1976.tb07446.x; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; KIISTALA U, 1964, LANCET, V1, P1444; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; LAWRENCE ID, 1987, J ALLERGY CLIN IMMUN, V79, P179; Lemanske R F Jr, 1981, Clin Immunol Rev, V1, P547; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; PIOTROWSKI W, 1986, BRIT J DERMATOL, V114, P37, DOI 10.1111/j.1365-2133.1986.tb02777.x; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; RUZICKA T, 1987, J IMMUNOL, V138, P539; SCHULMAN ES, 1983, EUR J RESPIR DIS, V64, P53; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; TALBOT S, 1984, Journal of Allergy and Clinical Immunology, V73, P147; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TAYLOR G, 1971, Clinical Allergy, V1, P407, DOI 10.1111/j.1365-2222.1971.tb00792.x; TING S, 1981, J ALLERGY CLIN IMMUN, V68, P65, DOI 10.1016/0091-6749(81)90125-1; WILLEBRAND EV, 1978, CLIN IMMUNOL IMMUNOP, V11, P445; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x	33	34	34	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					95	100		10.1016/0091-6749(88)90057-7	http://dx.doi.org/10.1016/0091-6749(88)90057-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3292634				2022-12-18	WOS:A1988P400400016
J	HANSBROUGH, JR; WEDNER, HJ; CHAPLIN, DD				HANSBROUGH, JR; WEDNER, HJ; CHAPLIN, DD			ANAPHYLAXIS TO INTRAVENOUS FUROSEMIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WASHINGTON UNIV,SCH MED,DEPT MED,DIV ALLERGY & IMMUNOL,4566 SCOTT AVE,BOX 8045,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES INST LABS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)				Chaplin, David/0000-0002-1354-3069				BEERMANN B, 1980, CLIN PHARMACOKINET, V5, P221, DOI 10.2165/00003088-198005030-00003; BELL RT, 1979, ARCH INTERN MED, V139, P817, DOI 10.1001/archinte.139.7.817; BOTTIGER LE, 1972, ACTA MED SCAND, V191, P541; CARRINGTON DM, 1986, J ALLERGY CLIN IMMUN, V77, P224; DESWARTE RD, 1985, ALLERGIC DISEASES, P505; DORN MR, 1981, CHEST, V79, P482, DOI 10.1378/chest.79.4.482; DUNCAN A, 1981, LANCET, V1, P1210; FRISCH JM, 1973, J INFECT DIS       S, V128, P607; GOULD L, 1980, NEW YORK STATE J MED, V80, P1975; HALSTENSON CE, 1983, DRUG INTEL CLIN PHAR, V17, P786, DOI 10.1177/106002808301701101; Kleinknecht D, 1978, Contrib Nephrol, V10, P42; LOWELL FC, 1955, ANN INTERN MED, V43, P333, DOI 10.7326/0003-4819-43-2-333; MACHTEY I, 1968, LANCET, V2, P1301; MANDELL GL, 1985, GOODMAN GILMANS PHAR, P1095; MITCHELL JR, 1974, NATURE, V251, P508, DOI 10.1038/251508a0; NEUFELD R, 1980, CUTIS, V26, P290; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P295; RIEDER J, 1973, J INFECT DIS S, V128, P567; SCHERR MS, 1971, ANN ALLERGY, V29, P30; SPINO M, 1978, CAN MED ASSOC J, V118, P1513; TUZEL IH, 1981, J CLIN PHARMACOL, V21, P615, DOI 10.1002/j.1552-4604.1981.tb05673.x; VONARSDEL PP, 1983, ALLERGY PRINCIPLES P, P1392; VONGOERZ G, 1964, DEUT MED WOCHENSCHR, V89, P1301; WAUTERS JP, 1975, BRIT MED J, V4, P624, DOI 10.1136/bmj.4.5997.624; WILSON AE, 1967, LANCET, V1, P105; [No title captured]	26	34	36	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					538	541		10.1016/0091-6749(87)90004-2	http://dx.doi.org/10.1016/0091-6749(87)90004-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	3668117				2022-12-18	WOS:A1987K522400004
J	ESCH, RE; KLAPPER, DG				ESCH, RE; KLAPPER, DG			CROSS-REACTIVE AND UNIQUE GRASS GROUP-I ANTIGENIC DETERMINANTS DEFINED BY MONOCLONAL-ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,804 FAC LAB,OFF BLDG 231-H,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014908] Funding Source: NIH RePORTER; NIAID NIH HHS [AI14908] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BALDO BA, 1983, ALLERGY, V38, P535, DOI 10.1111/j.1398-9995.1983.tb04137.x; BERZOFSKY JA, 1981, MOL IMMUNOL, V18, P751, DOI 10.1016/0161-5890(81)90067-5; CHAKRABARTY S, 1981, INT ARCH ALLER A IMM, V66, P142, DOI 10.1159/000232813; DIAMOND AG, 1984, EUR J IMMUNOL, V14, P405, DOI 10.1002/eji.1830140505; DOWARD AJ, 1984, CLIN ALLERGY, V14, P561; GERHARD W, 1981, NATURE, V290, P713, DOI 10.1038/290713a0; HULL WM, 1979, J ALLERGY CLIN IMMUN, V63, P193; KAHN CR, 1983, J ALLERGY CLIN IMMUN, V71, P95, DOI 10.1016/0091-6749(83)90149-5; KRILIS S, 1983, J ALLERGY CLIN IMMUN, V71, P261, DOI 10.1016/0091-6749(83)90079-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN H, 1978, INT ARCH ALLER A IMM, V57, P379, DOI 10.1159/000232128; MARSH DG, 1975, ANTIGENS, V3, P271; Voller A., 1980, MANUAL CLIN IMMUNOLO, P359; WHITE TJ, 1978, NATURE, V274, P92, DOI 10.1038/274092a0	15	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					489	495		10.1016/0091-6749(87)90367-8	http://dx.doi.org/10.1016/0091-6749(87)90367-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	2434551				2022-12-18	WOS:A1987G479500012
J	GERBLICH, AA; SCHWARTZ, HJ; CHESTER, EH				GERBLICH, AA; SCHWARTZ, HJ; CHESTER, EH			SEASONAL-VARIATION OF AIRWAY FUNCTION IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106	Case Western Reserve University	GERBLICH, AA (corresponding author), VET ADM MED CTR,DEPT MED,DIV PULM,RES BLDG K207,10701 E BLVD,CLEVELAND,OH 44106, USA.							BRISCOE WA, 1958, J CLIN INVEST, V37, P1279, DOI 10.1172/JCI103715; CADE JF, 1971, LANCET, P186; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEBOIS AB, 1956, J CLIN INVEST, V35, P327; DOERSHUK CF, 1974, AM REV RESPIR DIS, V109, P452; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; FAIRSHTER RD, 1979, J ALLERGY CLIN IMMUN, V63, P39, DOI 10.1016/0091-6749(79)90160-X; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; KALINER M, 1973, NEW ENGL J MED, V289, P277, DOI 10.1056/NEJM197308092890601; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KAWABORI S, 1983, CLIN ALLERGY, V13, P181, DOI 10.1111/j.1365-2222.1983.tb02586.x; LLOYD CT, 1963, J APPL PHYSIOL, V18, P114; MORGAN EJ, 1976, THORAX, V31, P80, DOI 10.1136/thx.31.1.80; MYGIND N, 1982, J ALLERGY CLIN IMMUN, V70, P149, DOI 10.1016/0091-6749(82)90036-7; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; ROSENTHAL RR, 1979, CHEST, V75, P228, DOI 10.1378/chest.75.2.228; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SAMTER M, 1955, REGIONAL ALLERGY US, P65; SCHOFIELD NM, 1980, BRIT J DIS CHEST, V74, P155, DOI 10.1016/0007-0971(80)90027-3; Sokal RR, 1969, BIOMETRY, P526; SOLOMON ER, 1967, MANUAL CLIN ALLERGY, P340	24	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					676	681		10.1016/0091-6749(86)90408-2	http://dx.doi.org/10.1016/0091-6749(86)90408-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3700890				2022-12-18	WOS:A1986C390300006
J	IMBUS, HR				IMBUS, HR			CLINICAL-EVALUATION OF PATIENTS WITH COMPLAINTS RELATED TO FORMALDEHYDE EXPOSURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review																		ACHESON ED, 1984, LANCET, V1, P611; ALARIE Y, 1981, TOXICOLOGY PRINCIPLE, P48; ALEXANDERSSON R, 1982, ARCH ENVIRON HEALTH, V37, P279, DOI 10.1080/00039896.1982.10667579; AMDUR MO, 1960, INT J AIR WATER POLL, V3, P201; ANDERSEN I, 1975, ATMOS ENVIRON, V9, P1121, DOI 10.1016/0004-6981(75)90188-2; ANDERSEN KE, 1984, CONTACT DERMATITIS, V10, P227, DOI 10.1111/j.1600-0536.1984.tb00105.x; ANDERSON I, 1979, FORMALDEHYDE INDOOR, P77; AYER HE, 1982, AM J PUBLIC HEALTH, V72, P1283, DOI 10.2105/AJPH.72.11.1283; BAUMANN K, 1979, INT ARCH OCC ENV HEA, V42, P241, DOI 10.1007/BF00377778; BENDER JR, 1983, AM IND HYG ASSOC J, V44, P463, DOI 10.1080/15298668391405139; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; BERNSTEIN RS, 1983, AM IND HYG ASS J, V44, P16; BOUHUYS A, 1960, BRIT MED J, V2, P324; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BREYSSE PA, 1981, JAMA-J AM MED ASSOC, V245, P267; BREYSSE PA, 1977, ENV HLTH SAFETY NEWS, P26; Brusick DJ, 1983, FORMALDEHYDE TOXICIT, P72; CALLAHAN HJ, 1978, IMMUNOLOGICAL DISEAS; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHANG JCF, 1983, TOXICOL APPL PHARM, V68, P161, DOI 10.1016/0041-008X(83)90001-7; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; CROMWELL O, 1979, CLIN ALLERGY, V9, P109, DOI 10.1111/j.1365-2222.1979.tb01529.x; DALBEY WE, 1982, TOXICOLOGY, V24, P9, DOI 10.1016/0300-483X(82)90058-0; DALLY KA, 1981, ARCH ENVIRON HEALTH, V36, P277, DOI 10.1080/00039896.1981.10667638; DEAN JH, TOXICOL APPL PHARM; EGLE JL, 1972, ARCH ENVIRON HEALTH, V25, P119, DOI 10.1080/00039896.1972.10666147; EINBRODT HJ, 1976, ZENTRALBL ARBEITSMED, V8, P54; ENGLE HO, 1966, BR J IND MED, V23, P62; EPSTEIN E, 1966, ARCH DERMATOL, V94, P186, DOI 10.1001/archderm.94.2.186; FISH JE, 1982, J OCCUP ENVIRON MED, V24, P379, DOI 10.1097/00043764-198205000-00009; FOUSSEREAU J, 1982, OCCUPATIONAL CONTACT, P225; FRIGAS E, 1984, MAYO CLIN PROC, V59, P295, DOI 10.1016/S0025-6196(12)61423-2; FRIGAS E, 1981, CHEST, V79, P706, DOI 10.1378/chest.79.6.706; FRIGAS E, 1982, CHEST, V82, P511, DOI 10.1378/chest.82.4.511-b; GAMBLE JF, 1976, AM IND HYG ASSOC J, V37, P499, DOI 10.1080/0002889768507508; GARRY VF, 1980, MINN MED, V63, P107; GODISH T, 1981, J ENVIRON HEALTH, V44, P116; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GOODMAN LS, 1980, PHARMACOL BASIS THER, P955; GOSELIN HC, 1977, FORMALDEHYDE CLIN TO, P165; GOTTSCHLING LM, 1984, AM IND HYG ASSOC J, V45, P19, DOI 10.1080/15298668491399299; HARRINGTON JM, 1975, BRIT MED J, V4, P329, DOI 10.1136/bmj.4.5992.329; HARRIS JC, 1981, JAMA, V245, P267; HECK HD, 1982, BIOMED MASS SPECTROM, V9, P347; HECK HD, 1982, CHEM IND I TOXICOL, V3, P3; HELANDER I, 1977, ARCH DERMATOL, V113, P1443, DOI 10.1001/archderm.113.10.1443; HENDRICK DJ, 1975, BRIT MED J, V1, P607, DOI 10.1136/bmj.1.5958.607; HENDRICK DJ, 1982, J OCCUP ENVIRON MED, V24, P893; HENDRICK DJ, 1977, BRIT J IND MED, V34, P11; HIGENBOTTAM T, 1980, THORAX, V35, P246, DOI 10.1136/thx.35.4.246; HOLLIES NRS, 1982, TEXT RES J, V52, P370, DOI 10.1177/004051758205200603; HOLLOWELL CD, 1981, B NEW YORK ACAD MED, V57, P962; Horsfall FL, 1934, J IMMUNOL, V27, P569; JEFFCOAT RA, 1983, FORMALDEHYDE TOXICIT, P38; JORDAN WP, 1979, J AM ACAD DERMATOL, V1, P44, DOI 10.1016/S0190-9622(79)70003-X; KENSLER CJ, 1963, NEW ENGL J MED, V269, P1161, DOI 10.1056/NEJM196311282692202; KERNS WD, 1983, CANCER RES, V43, P4382; KEY MM, 1961, ARCH DERMATOL, V83, P3, DOI 10.1001/archderm.1961.01580070009002; KONOPINSKI VJ, 1983, AM IND HYG ASSOC J, V44, P205, DOI 10.1080/15298668391404644; LAZAR P, 1966, ARCH DERMATOL, V94, P446; LEVINE RJ, 1984, J OCCUP ENVIRON MED, V26, P91; LINDSKOV R, 1982, CONTACT DERMATITIS, V8, P333, DOI 10.1111/j.1600-0536.1982.tb04240.x; LYNEN R, 1983, VOX SANG, V44, P81, DOI 10.1111/j.1423-0410.1983.tb04106.x; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; Maibach H., 1983, FORMALDEHYDE TOXICIT, P166; MAIBACH HI, 1983, ALLERGY PRINCIPLES P, P1335; MALORNY G, 1965, N-S ARCH EX PATH PH, V250, P419; MARSH GM, 1982, BRIT J IND MED, V39, P313; MCCAMMON CS, 1982, AM IND HYG ASSOC J, V43, P18, DOI 10.1080/15298668291409307; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P21, DOI 10.1016/0091-6749(83)90542-0; NADEL JA, 1961, J APPL PHYSIOL, V16, P713, DOI 10.1152/jappl.1961.16.4.713; NICHOLLS PJ, 1975, BR J IND MED, V33, P127; NORDMAN H, 1985, J ALLERGY CLIN IMMUN, V75, P91, DOI 10.1016/0091-6749(85)90018-1; OLSEN JH, 1982, AM IND HYG ASSOC J, V43, P336; OQUINN SE, 1965, J AMER MED ASSOC, V194, P593, DOI 10.1001/jama.194.6.593; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; ORRINGER EP, 1976, NEW ENGL J MED, V294, P1416, DOI 10.1056/NEJM197606242942602; PATTERSON R, 1982, J ALLERGY CLIN IMMUN, V70, P19, DOI 10.1016/0091-6749(82)90196-8; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; POPA V, 1969, DIS CHEST, V56, P395, DOI 10.1378/chest.56.5.395; PORTER JAH, 1975, LANCET, V2, P603; SAKULA A, 1975, LANCET, V2, P816; SCHOENBERG JB, 1975, ARCH ENVIRON HEALTH, V30, P574, DOI 10.1080/00039896.1975.10666782; SCHUCK EA, 1966, ARCH ENVIRON HEALTH, V13, P570, DOI 10.1080/00039896.1966.10664620; SHELLEY WB, 1982, ARCH DERMATOL, V118, P117, DOI 10.1001/archderm.118.2.117; SHELLEY WB, 1977, ARCH DERMATOL, V113, P187, DOI 10.1001/archderm.113.2.187; SHEPPARD D, 1984, ENVIRON RES, V35, P133, DOI 10.1016/0013-9351(84)90120-8; SLAVIN RG, 1980, ALLERGIC DISEASES DI, P584; SNEDDON IB, 1968, BRIT MED J, V1, P183, DOI 10.1136/bmj.1.5585.183-c; SOTER NA, 1983, INTERNAL MED, P976; STAPLES RE, 1983, FORMALDEHYDE TOXICIT, P51; SWENBERG JA, 1983, CARCINOGENESIS, V4, P945, DOI 10.1093/carcin/4.8.945; TORREY ER, 1981, AM REV RESPIR DIS, V124, P630; WALRATH J, 1983, INT J CANCER, V31, P407, DOI 10.1002/ijc.2910310403; WEBERTSCHOPP A, 1977, INT ARCH OCC ENV HEA, V39, P207, DOI 10.1007/BF00409367; WIDDICOMBE JG, 1962, J APPL PHYSIOL, V17, P613, DOI 10.1152/jappl.1962.17.4.613; Wong O, 1983, FORMALDEHYDE TOXICIT, P256; WOODBURY MA, 1983, FORMALDEHYDE TOXICIT; ZEISS CR, 1982, J ALLERGY CLIN IMMUN, V70, P15, DOI 10.1016/0091-6749(82)90195-6; 1982, IARC MONOGRAPHS EVAL, V29, P357; 1983, OCCUPATIONAL SA 1910; 1984, FED REG, V49, P1883; 1982, CIIT ACTIVITIES, V2, P3; 1976, US DHEW77126 NAT I O; 1976, US EPA560276009; 1977, NIOSH MANUAL ANAL ME, P4; 1979, SMOKING HLTH REPORT; 1980, AM C GOVT IND HYGIEN, P197; 1981, FED REG, V46, P1188; 1981, DORLANS ILLUSTRATED; 1984, ENV HLTH PERSPECT, V58, P323; 1981, FORMALDEHYDE OTHER A	112	34	35	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1985	76	6					831	840		10.1016/0091-6749(85)90757-2	http://dx.doi.org/10.1016/0091-6749(85)90757-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AWX93	3905920	Bronze			2022-12-18	WOS:A1985AWX9300013
J	KAPLAN, AP				KAPLAN, AP			UNUSUAL COLD-INDUCED DISORDERS - COLD-DEPENDENT DERMATOGRAPHISM AND SYSTEMIC COLD URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KAPLAN, AP (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,DEPT MED,DIV ALLERGY RHEUMATOL & CLIN IMMUNOL,STONY BROOK,NY 11794, USA.							BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; COSTANZI JJ, 1969, J LAB CLIN MED, V74, P902; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; GAROFALO J, 1981, J ALLERGY CLIN IMMUN, V68, P103; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; KAPLAN AP, 1981, NEW ENGL J MED, V305, P1074, DOI 10.1056/NEJM198110293051808; KAPLAN AP, 1983, J ALLERGY CLIN IMMUN, V71, P129, DOI 10.1016/0091-6749(83)90287-7; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P438; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; MATTHEWS CN, 1970, BRIT J DERMATOL, V82, P91; SARKANY I, 1971, BRIT J DERMATOL, V85, P46; SIGLER RW, 1978, J ALLERGY CLIN IMMUN, V63, P35; SOTER NA, 1977, J ALLERGY CLIN IMMUN, V59, P294, DOI 10.1016/0091-6749(77)90050-1; TINDALL JP, 1969, ARCH INTERN MED, V124, P129, DOI 10.1001/archinte.124.2.129	15	34	34	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	4					453	456		10.1016/0091-6749(84)90354-3	http://dx.doi.org/10.1016/0091-6749(84)90354-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM089	6200525				2022-12-18	WOS:A1984SM08900005
J	LISS, GM; KOMINSKY, JR; GALLAGHER, JS; MELIUS, J; BROOKS, SM; BERNSTEIN, IL				LISS, GM; KOMINSKY, JR; GALLAGHER, JS; MELIUS, J; BROOKS, SM; BERNSTEIN, IL			FAILURE OF ENZYME ENCAPSULATION TO PREVENT SENSITIZATION OF WORKERS IN THE DRY BLEACH INDUSTRY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267; NIOSH,CINCINNATI,OH 45226	University of Cincinnati; University of Cincinnati; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)								[Anonymous], 1980, AM C GOVT IND HYGIEN; BELIN L, 1970, LANCET, V2, P1153; BENATZEN K, 1976, ACTA PATHOL MICROBIO, V84, P471; BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V49, P219; FARHRNEY D, 1963, J AM CHEM SOC, V85, P997; FLINDT MLH, 1969, LANCET, V1, P1177; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; GILSON JC, 1976, THORAX, V31, P621; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; JUNIPER CP, 1977, J SOC OCCUP MED, V27, P3; KOMINSKY JR, 1980, 8065780 NAT I OCC SA; NEWHOUSE ML, 1970, LANCET, V1, P689; PEPYS J, 1969, LANCET, V1, P1181; PEPYS J, 1973, Clinical Allergy, V3, P143, DOI 10.1111/j.1365-2222.1973.tb01318.x; WEILL H, 1971, J AMER MED ASSOC, V217, P425, DOI 10.1001/jama.217.4.425; WEILL H, 1974, ANN NY ACAD SCI, V221, P76, DOI 10.1111/j.1749-6632.1974.tb28201.x; 1981, MORBID MORTAL WEEKLY, V30, P127; AF1622GB NOV IND INC	20	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					348	355		10.1016/0091-6749(84)90407-X	http://dx.doi.org/10.1016/0091-6749(84)90407-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6366032				2022-12-18	WOS:A1984SK15500008
J	GRAMMER, LC; CHEN, PY; PATTERSON, R				GRAMMER, LC; CHEN, PY; PATTERSON, R			EVALUATION AND MANAGEMENT OF INSULIN ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University				Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARKINS JA, 1962, J ALLERGY, V33, P69, DOI 10.1016/0021-8707(62)90065-5; DAVIDSON JA, 1974, DIABETES, V23, P352; DESHAZO RD, 1977, J ALLERGY CLIN IMMUN, V59, P161, DOI 10.1016/0091-6749(77)90219-6; DESHAZO RD, 1982, J ALLERGY CLIN IMMUN, V69, P229, DOI 10.1016/0091-6749(82)90104-X; DESHAZO RD, 1979, J IMMUNOL, V122, P692; FEINGLOS MN, 1979, LANCET, V1, P122; GALLOWAY JA, 1978, MED CLIN N AM, V62, P663, DOI 10.1016/S0025-7125(16)31764-3; GOLDMAN RA, 1976, JAMA-J AM MED ASSOC, V236, P1148; KUMAR D, 1977, J CLIN ENDOCR METAB, V45, P1159, DOI 10.1210/jcem-45-6-1159; LAMKIN N, 1976, J ALLERGY CLIN IMMUN, V58, P213, DOI 10.1016/0091-6749(76)90157-3; Lawrence RD, 1925, LANCET, V1, P1125; LIEBERMAN P, 1971, J AMER MED ASSOC, V215, P1106; MATTSON JR, 1975, ARCH INTERN MED, V135, P818, DOI 10.1001/archinte.135.6.818; PATTERSON R, 1969, J IMMUNOL, V103, P1061; PATTERSON R, 1973, Journal of Immunology, V110, P1135; PATTERSON R, 1973, J IMMUNOL, V190, P1126; SKYLAR JS, 1980, DIABETES CARE, V3, P638; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Wilder RM, 1922, J METAB RES, V2, P701; Williams JR., 1922, J METAB RES, V2, P729; YUE DK, 1975, DIABETES, V24, P625, DOI 10.2337/diabetes.24.7.625	21	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	2					250	254		10.1016/0091-6749(83)90107-0	http://dx.doi.org/10.1016/0091-6749(83)90107-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC188	6337201				2022-12-18	WOS:A1983QC18800012
J	ATKINS, PC; VALENZANO, M; ZWEIMAN, B				ATKINS, PC; VALENZANO, M; ZWEIMAN, B			PLASMA-CONCENTRATIONS OF HISTAMINE MEASURED BY RADIOENZYMATIC ASSAY - EFFECTS OF HISTAMINASE INCUBATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ATKINS, PC (corresponding author), UNIV PENN, SCH MED, DEPT MED, ALLERGY & IMMUNOL SECT, PHILADELPHIA, PA 19104 USA.				NIAID NIH HHS [AI 14332-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1980, J ALLERGY CLIN IMMUN, V66, P478, DOI 10.1016/0091-6749(80)90009-3; BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BRUCE C, 1979, ANN CLIN BIOCHEM, V16, P259, DOI 10.1177/000456327901600166; DENT C, 1979, AGENTS ACTIONS, V9, P34, DOI 10.1007/BF02024097; DUNSKY EH, 1979, J ALLERGY CLIN IMMUN, V63, P426, DOI 10.1016/0091-6749(79)90217-3; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V66, P295, DOI 10.1016/0091-6749(80)90024-X; LEVY DA, 1973, J LAB CLIN MED, V81, P291; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544	13	34	34	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	1					39	45		10.1016/0091-6749(82)90085-9	http://dx.doi.org/10.1016/0091-6749(82)90085-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ377	6172456				2022-12-18	WOS:A1982MZ37700007
J	SCUDAMORE, HH; PHILLIPS, SF; SWEDLUND, HA; GLEICH, GJ				SCUDAMORE, HH; PHILLIPS, SF; SWEDLUND, HA; GLEICH, GJ			FOOD ALLERGY MANIFESTED BY EOSINOPHILIA, ELEVATED IMMUNOGLOBULIN-E LEVEL, AND PROTEIN-LOSING ENTEROPATHY - THE SYNDROME OF ALLERGIC GASTROENTEROPATHY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO FDN,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic					NCRR NIH HHS [RR 00585] Funding Source: Medline; NIAID NIH HHS [AI 11483] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BROWN WR, 1975, CLIN EXP IMMUNOL, V20, P227; BURHENNE HJ, 1966, AMER J ROENTGENOL RA, V96, P332, DOI 10.2214/ajr.96.2.332; DANNAEUS A, 1977, CLIN ALLERGY, V7, P109, DOI 10.1111/j.1365-2222.1977.tb01431.x; GLEICH GJ, 1981, CLIN RES, V29, P170; GOLBERT TM, 1969, J ALLERGY, V44, P96, DOI 10.1016/0021-8707(69)90005-7; GREENBERGER NJ, 1967, AM J MED, V43, P777, DOI 10.1016/0002-9343(67)90120-9; HUNTLEY CC, 1970, SOUTHERN MED J, V63, P917, DOI 10.1097/00007611-197008000-00009; INGELFINGER FJ, 1949, NEW ENGL J MED, V241, P337, DOI 10.1056/NEJM194909012410905; INGELFINGER FJ, 1949, NEW ENGL J MED, V241, P303, DOI 10.1056/NEJM194908252410805; KLEIN NC, 1970, MEDICINE, V49, P299, DOI 10.1097/00005792-197007000-00003; LEINBACH GE, 1970, GASTROENTEROLOGY, V59, P874; URELES AL, 1961, AM J MED, V30, P899, DOI 10.1016/0002-9343(61)90178-4; VAZ GA, 1978, LANCET, V1, P1066; WALDMANN TA, 1967, NEW ENGL J MED, V276, P761, DOI 10.1056/NEJM196704062761401	15	34	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	2					129	138		10.1016/0091-6749(82)90241-X	http://dx.doi.org/10.1016/0091-6749(82)90241-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PB591	7096820				2022-12-18	WOS:A1982PB59100010
J	KAGEN, SL; FINK, JN; SCHLUETER, DP; KURUP, VP; FRUCHTMAN, RB				KAGEN, SL; FINK, JN; SCHLUETER, DP; KURUP, VP; FRUCHTMAN, RB			STREPTOMYCES-ALBUS - A NEW CAUSE OF HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WOOD VET ADM MED CTR, RES SERV, MILWAUKEE, WI 53193 USA; MED COLL WISCONSIN, DEPT MED, ALLERGY IMMUNOL SECT, MILWAUKEE, WI 53233 USA; MED COLL WISCONSIN, DEPT MED, MED CHEST SECT, MILWAUKEE, WI 53233 USA	Medical College of Wisconsin; Medical College of Wisconsin					NCRR NIH HHS [RR88] Funding Source: Medline; NHLBI NIH HHS [HL 15389] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT P., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P11, DOI 10.1016/0035-9203(56)90004-9; BERRENS L, 1974, ANN NY ACAD SCI, V221, P153, DOI 10.1111/j.1749-6632.1974.tb28213.x; BLACKBUR.CR, 1974, CLIN ALLERGY, V4, P87, DOI 10.1111/j.1365-2222.1974.tb01366.x; Campbell JM, 1932, BRIT MED J, V1932, P1143; COMROE JH, 1978, AM REV RESPIR DIS, V117, P773; EDWARDS C, 1974, BRIT J DIS CHEST, V68, P57, DOI 10.1016/0007-0971(74)90010-2; EDWARDS JH, 1976, CLIN ALLERGY, V6, P19, DOI 10.1111/j.1365-2222.1976.tb01408.x; FINK JN, 1969, J IMMUNOL, V103, P244; FINK JN, 1976, ANN INTERN MED, V84, P406, DOI 10.7326/0003-4819-84-4-406; FINK JN, 1973, J ALLERGY CLIN IMMUN, V52, P309, DOI 10.1016/0091-6749(73)90051-1; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; FINK JN, 1978, AM REV RESPIR DIS, V118, P955; FINK JN, 1971, APPL MICROBIOL, V22, P730, DOI 10.1128/AEM.22.4.730-731.1971; FINK JN, 1978, ALLERGY PRINCIPLES P, P855; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; JOHNSON CL, 1980, AM REV RESPIR DIS, V122, P339; KELLER RH, 1980, CLIN RES, V28, P102; KURUP VP, 1975, INT J SYST BACTERIOL, V25, P150, DOI 10.1099/00207713-25-2-150; Lennette E. H., 1974, MANUAL CLIN MICROBIO; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; OLENCHOCK SA, 1976, J ALLERGY CLIN IMMUN, V58, P76, DOI 10.1016/0091-6749(76)90109-3; PEPYS J, 1969, MONOGR ALLERGY, V4, P69; RAMAZZINI B, 1940, MORBUS ARTIFICUM DIA, P1713; SALVAGGIO JE, 1980, HOSP PRACT, V15, P93, DOI 10.1080/21548331.1980.11946685; SCHLUETER DP, 1969, ANN INTERN MED, V70, P457, DOI 10.7326/0003-4819-70-3-457; SHANLEY JD, 1979, AM J CLIN PATHOL, V72, P107; SPECTOR WG, 1969, J PATHOL, V98, P31, DOI 10.1002/path.1710980105; TARALAKSHMI VV, 1978, ARCH DERMATOL, V114, P204, DOI 10.1001/archderm.114.2.204; WENZEL FJ, 1971, J ALLERGY CLIN IMMUN, V48, P224, DOI 10.1016/0091-6749(71)90069-8; 1978, OSHA 29CFR19101000, P545	30	34	34	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					295	299		10.1016/0091-6749(81)90155-X	http://dx.doi.org/10.1016/0091-6749(81)90155-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	6793652				2022-12-18	WOS:A1981ML52500009
J	KARR, RM; WILSON, MR; ANICETTI, VR; LEHRER, SB; BUTCHER, BT; SALVAGGIO, JE				KARR, RM; WILSON, MR; ANICETTI, VR; LEHRER, SB; BUTCHER, BT; SALVAGGIO, JE			AN APPROACH TO FUNGAL ANTIGEN RELATIONSHIPS BY RADIOALLERGOSORBENT TEST INHIBITION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,DEPT MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70118	Tulane University					NIAID NIH HHS [AI 13401] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARDANA EJ, 1978, J ALLERGY CLIN IMMUN, V61, P255; BIGUET J, 1964, ANN I PASTEUR PARIS, V107, P72; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; DIXON WJ, 1969, INTRO STATISTICAL AN, P222; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HOFFMAN DR, 1979, J ALLERGY CLIN IMMUN, V63, P213; KARR RM, 1978, J ALLERGY CLIN IMMUN, V62, P143, DOI 10.1016/0091-6749(78)90098-2; KARR RM, 1980, CLIN IMMUNOLOGY; KIM SJ, 1978, AM REV RESPIR DIS, V118, P547; KIM SJ, 1978, AM REV RESPIR DIS, V118, P553; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; LOWENSTEIN H, 1977, INT ARCH ALLER A IMM, V55, P1, DOI 10.1159/000231900; Pepys J, 1969, HYPERSENSITIVITY DIS; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4	15	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	3					194	198		10.1016/0091-6749(81)90061-0	http://dx.doi.org/10.1016/0091-6749(81)90061-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG778	6161952	Bronze			2022-12-18	WOS:A1981LG77800006
J	BAGENSTOSE, AH; MATHEWS, KP; HOMBURGER, HA; SAAVEARDDELGADO, AP				BAGENSTOSE, AH; MATHEWS, KP; HOMBURGER, HA; SAAVEARDDELGADO, AP			INHALANT ALLERGY DUE TO CRICKETS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; MAYO CLIN & MAYO FDN,DEPT LAB MED,ROCHESTER,MN 55901	University of Michigan System; University of Michigan; Mayo Clinic								AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; CAZORT A, 1955, LETT INT CORRESPONDE, V18, P55; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CRAWFORD LV, 1978, APR AM COLL ALL M; FEINBERG AR, 1956, J ALLERGY, V27, P437, DOI 10.1016/0021-8707(56)90103-4; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MATHEWS KP, 1978, ALLERGY PRINCIPLES P, P951; PERLMAN F, 1958, J ALLERGY, V29, P302, DOI 10.1016/0021-8707(58)90037-6; SALBERG DJ, 1977, LIFE SCI, V21, P1439, DOI 10.1016/0024-3205(77)90198-9; SHELDON JM, 1967, MANUAL CLIN ALLERGY, P507; WISEMAN RD, 1959, J ALLERGY, V30, P191, DOI 10.1016/0021-8707(59)90067-X	11	34	34	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	1					71	74		10.1016/0091-6749(80)90180-3	http://dx.doi.org/10.1016/0091-6749(80)90180-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB459	6153085				2022-12-18	WOS:A1980JB45900012
J	GERSHON, RK				GERSHON, RK			IMMUNOREGULATION CIRCA 1980 - SOME COMMENTS ON THE STATE OF THE ART	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GERSHON, RK (corresponding author), YALE NEW HAVEN HOSP,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,DIV CELLULAR IMMUNOL,NEW HAVEN,CT 06510, USA.							CANTOR H, 1979, FED PROC, V38, P2058; CANTOR H, 1970, J EXP MED, V131, P235, DOI 10.1084/jem.131.2.235; Cantor H., 1977, COLD SPRING HARB SYM, V41, P23; CHASE MW, 1953, NATURE SIGNIFICANCE, P156; COWING C, 1978, J IMMUNOL, V121, P1680; EARDLEY DD, 1979, J EXP MED, V150, P44, DOI 10.1084/jem.150.1.44; EARDLEY DD, IMMUNOGENETICS; GERSHON RK, 1970, IMMUNOLOGY, V18, P723; GERSHON RK, 1971, IMMUNOLOGY, V21, P903; GERSHON RK, 1980, MACROPHAGE REGULATIO, P431; GLICK B, 1956, POULTRY SCI, V35, P224, DOI 10.3382/ps.0350224; GOWANS JL, 1965, PROG ALLERGY, V9, P1; HABU S, UNPUBLISHED; HODES RJ, 1978, J IMMUNOL, V121, P1501; HUMPHREY JH, 1970, IMMUNOLOGY STUDENTS, pCH1; JANEWAY CA, 1977, P NATL ACAD SCI USA, V74, P4582, DOI 10.1073/pnas.74.10.4582; LAGESTEHR J, 1980, EUR J IMMUNOL, V10, P21, DOI 10.1002/eji.1830100105; MARCHESI VT, 1964, PROC R SOC SER B-BIO, V159, P283, DOI 10.1098/rspb.1964.0002; MOLLER G, 1969, TRANSPLANT REV, V1, P1; PTAK W, 1980, J EXP MED, V151, P362, DOI 10.1084/jem.151.2.362; RAFF MC, 1969, NATURE, V224, P378, DOI 10.1038/224378a0; RAO SV, J IMMUNOL; SCHOEFL GI, 1972, J EXP MED, V136, P568, DOI 10.1084/jem.136.3.568; TROWELL OA, 1958, INT REV CYTOL, V7, P235, DOI 10.1016/S0074-7696(08)62689-3; YAMAUCHI K, UNPUBLISHED	25	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	1					18	24		10.1016/0091-6749(80)90133-5	http://dx.doi.org/10.1016/0091-6749(80)90133-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ541	6991584	Bronze			2022-12-18	WOS:A1980JZ54100003
J	KINO, T; OSHIMA, S				KINO, T; OSHIMA, S			ALLERGY TO INSECTS IN JAPAN .1. REAGINIC SENSITIVITY TO MOTH AND BUTTERFLY IN PATIENTS WITH BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KINO, T (corresponding author), KYOTO UNIV, CHEST DIS RES INST, SAKYO KU, KYOTO 606, JAPAN.							BALYEAT RAY M., 1932, JOUR ALLERGY, V3, P227, DOI 10.1016/S0021-8707(32)90338-4; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; PARLATO SALVATORE J., 1932, JOUR ALLERGY, V3, P459, DOI 10.1016/S0021-8707(32)90181-6; Parlato SJ, 1932, J ALLERGY, V3, P125; PERLMAN F, 1958, J ALLERGY, V29, P302, DOI 10.1016/0021-8707(58)90037-6; PHANICHYA.P, 1969, J ALLERGY, V44, P51, DOI 10.1016/0021-8707(69)90047-1; PHILLIPS GL, 1967, MANUAL CLIN ALLERGY, P507; STEVENSON DD, 1967, J ALLERGY, V39, P274, DOI 10.1016/0021-8707(67)90091-3; URBACH ERIC, 1941, JOUR ALLERGY, V12, P485, DOI 10.1016/S0021-8707(41)90227-7	10	34	35	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	1					10	16		10.1016/0091-6749(78)90467-0	http://dx.doi.org/10.1016/0091-6749(78)90467-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH112	618942				2022-12-18	WOS:A1978EH11200002
J	TSAO, CH; PATTERSON, R; MCKENNA, JM; SUSZKO, IM				TSAO, CH; PATTERSON, R; MCKENNA, JM; SUSZKO, IM			ULTRASTRUCTURAL IDENTIFICATION OF MAST-CELLS OBTAINED FROM HUMAN BRONCHIAL LUMENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611; MCGAW MED CTR,CHICAGO,IL	Northwestern University; Northwestern University								DVORAK HF, 1972, HUM PATHOL, V3, P454, DOI 10.1016/S0046-8177(72)80004-2; FENNESSY JJ, 1968, DIS CHEST, V53, P377, DOI 10.1378/chest.53.4.377; HASTIE R, 1974, LAB INVEST, V31, P223; LAPIN JH, 1958, BLOOD, V13, P1001, DOI 10.1182/blood.V13.10.1001.1001; Orr T S, 1973, Br J Dis Chest, V67, P87, DOI 10.1016/0007-0971(73)90037-5; PATTERSON R, 1976, J LAB CLIN MED, V87, P1016; PATTERSON R, 1977, J CLIN INVEST, V59, P217, DOI 10.1172/JCI108631; PATTERSON R, 1972, SCIENCE, V175, P1012, DOI 10.1126/science.175.4025.1012; PATTERSON R, 1971, J IMMUNOL, V106, P1274; PATTERSON R, 1974, CLIN EXP IMMUNOL, V16, P233; TAICHMAN NS, 1970, J ULTRA MOL STRUCT R, V32, P284, DOI 10.1016/S0022-5320(70)80009-0; TOMITA Y, 1974, INT ARCH ALLER A IMM, V47, P261, DOI 10.1159/000231219; TROTTER CM, 1973, CLIN ALLERGY, V3, P411, DOI 10.1111/j.1365-2222.1973.tb01349.x; TSAO C, 1976, TRANSFUSION, V16, P336; TSAO C, IN PRESS; ZUCKERFRANKLIN D, 1967, BLOOD-J HEMATOL, V29, P878, DOI 10.1182/blood.V29.6.878.878	16	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	4					320	326		10.1016/0091-6749(77)90054-9	http://dx.doi.org/10.1016/0091-6749(77)90054-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DB886	850021				2022-12-18	WOS:A1977DB88600008
J	VERHAEGEN, H; DECOCK, W; DECREE, J				VERHAEGEN, H; DECOCK, W; DECREE, J			HISTAMINE RECEPTOR - BEARING PERIPHERAL T-LYMPHOCYTES IN PATIENTS WITH ALLERGIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									ST BARTHOLOMEUS HOSP,CLIN RES UNIT,B-2060 MERKSEM,BELGIUM									BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; CHISARI FV, 1974, J EXP MED, V140, P1122, DOI 10.1084/jem.140.4.1122; GALANT SP, 1975, J IMMUNOL, V114, P512; JONDAL M, 1972, J EXP MED, V136, P207, DOI 10.1084/jem.136.2.207; MELMON KL, 1974, J CLIN INVEST, V53, P13, DOI 10.1172/JCI107530; PLAUT M, 1975, J CLIN INVEST, V55, P856, DOI 10.1172/JCI107997; PLAUT M, 1973, NATURE, V244, P284, DOI 10.1038/244284a0	7	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	3					266	268		10.1016/0091-6749(77)90161-0	http://dx.doi.org/10.1016/0091-6749(77)90161-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CZ249	300084				2022-12-18	WOS:A1977CZ24900014
J	DAVIES, R; PEPYS, J				DAVIES, R; PEPYS, J			EGG ALLERGY, INFLUENZA VACCINE, AND IMMUNOGLOBULIN-E ANTIBODY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,INST CARDIOTHORAC,DEPT CLIN IMMUNOL,LONDON,ENGLAND; ST THOMAS HOSP,DEPT MED,LONDON SE1,ENGLAND	Royal Brompton Hospital								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; AAS K, 1973, Clinical Allergy, V3, P255, DOI 10.1111/j.1365-2222.1973.tb01331.x; BLEUMINK E, 1969, INT ARCH ALLER A IMM, V35, P1; Bleumink E, 1970, World Rev Nutr Diet, V12, P505; Coombs, 1968, CLIN ASPECTS IMMUNOL, P575; FAUX J A, 1971, Clinical Allergy, V1, P149, DOI 10.1111/j.1365-2222.1971.tb03014.x; FREIER S, 1973, CLIN ALLERGY, V3, P597, DOI 10.1111/j.1365-2222.1973.tb03064.x; MALKIEL S, 1968, INT ARCH ALLER A IMM, V34, P75, DOI 10.1159/000230096; MATSUMURA T, 1967, INT ARCH ALLER A IMM, V31, P217, DOI 10.1159/000229871; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MILLER JR, 1972, J ALLERGY CLIN IMMUN, V49, P109; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; PARISH WE, 1970, LANCET, V2, P591; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; RATNER B, 1946, JAMA-J AM MED ASSOC, V132, P899, DOI 10.1001/jama.1946.02870500005002; RATNER B, 1952, AMA AM J DIS CHILD, V83, P309, DOI 10.1001/archpedi.1952.02040070055006; STENIUS B, 1971, Clinical Allergy, V1, P37, DOI 10.1111/j.1365-2222.1971.tb02446.x; STENIUS B, 1969, LANCET, V2, P455; VAUGHAN JH, 1954, J ALLERGY, V25, P387, DOI 10.1016/0021-8707(54)90001-5; WIDE L, 1969, ACTA ENDOCRINOL-COP, VS 63, P207	20	34	35	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	4					373	383		10.1016/0091-6749(76)90095-6	http://dx.doi.org/10.1016/0091-6749(76)90095-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BM689	1262611				2022-12-18	WOS:A1976BM68900012
J	KAPLAN, MS; BYERS, VS; LEVIN, AS; GERMAN, DF; FUDENBERG, HH; LECAM, LN				KAPLAN, MS; BYERS, VS; LEVIN, AS; GERMAN, DF; FUDENBERG, HH; LECAM, LN			CIRCADIAN-RHYTHM OF STIMULATED LYMPHOCYTE BLASTOGENESIS - 24 HOUR CYCLE IN MIXED LEUKOCYTE-CULTURE REACTION AND WITH SKSD STIMULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KAISER PERMANENTE MED CTR,DEPT ALLERGY,OAKLAND,CA 94611; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT DERMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,DEPT STATISTICS,BERKELEY,CA 94720	Kaiser Permanente; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley								Aschoff J, 1965, CIRCADIAN CLOCKS, P214; BACH FH, 1973, SCIENCE, V180, P403, DOI 10.1126/science.180.4084.403; Bloom B R, 1971, Adv Immunol, V13, P101, DOI 10.1016/S0065-2776(08)60184-4; BRAEMAN J, 1974, LANCET, V1, P28; CALDWELL JR, 1973, J ALLERGY CLIN IMMUN, V52, P225, DOI 10.1016/0091-6749(73)90060-2; CARTER JB, 1975, J ALLERGY CLIN IMMUN, V56, P191, DOI 10.1016/0091-6749(75)90090-1; CONROY RWT, 1970, HUMAN CIRCADIAN RHYT, P72; Garrey WE, 1935, PHYSIOL REV, V15, P597, DOI 10.1152/physrev.1935.15.4.597; GLENN EM, 1963, RECENT PROG HORM RES, V19, P107; HALBERG F, 1969, ANNU REV PHYSIOL, V31, P675, DOI 10.1146/annurev.ph.31.030169.003331; Hellstrom K E, 1974, Adv Immunol, V18, P209, DOI 10.1016/S0065-2776(08)60311-9; KINSELLA TD, 1973, CLIN EXP IMMUNOL, V14, P187; LEVIN AS, 1975, IMMUNODEFICIENCY MAN, P445; LONG JB, 1950, B JOHNS HOPKINS HOSP, V87, P186; MAUER AM, 1965, BLOOD-J HEMATOL, V26, P1; MIGEON CJ, 1956, J CLIN ENDOCR METAB, V16, P622, DOI 10.1210/jcem-16-5-622; MILLS JN, 1966, PHYSIOL REV, V46, P128, DOI 10.1152/physrev.1966.46.1.128; MOORE MC, 1973, CLIN PHARMACOL THER, V14, P925; PERKOFF GT, 1959, J CLIN ENDOCR METAB, V19, P432, DOI 10.1210/jcem-19-4-432; RAFF MC, 1972, 1 INT C IMM PROGR IM, P83; RATTE J, 1973, SURGERY, V73, P102; READ SE, 1974, J CLIN INVEST, V54, P439, DOI 10.1172/JCI107780; REINHARDT WO, 1945, SCIENCE, V101, P360, DOI 10.1126/science.101.2623.360; ROMAGNANI S, 1973, Clinical Allergy, V3, P51, DOI 10.1111/j.1365-2222.1973.tb01309.x; SAMUELS AJ, 1951, J CLIN INVEST, V30, P941, DOI 10.1172/JCI102515; Scheffe H., 1999, ANAL VARIANCE, V72; SEGAL S, 1972, SCIENCE, V175, P1126, DOI 10.1126/science.175.4026.1126; Shaw AFB, 1927, J PATHOL BACTERIOL, V30, P1, DOI 10.1002/path.1700300102; STEEL CM, 1974, NATURE, V247, P387, DOI 10.1038/247387a0; STOBO JD, 1973, J IMMUNOL, V110, P652; TOH BH, 1973, CLIN EXP IMMUNOL, V14, P193; Wilson D. B., 1967, Advances in Immunology, V7, P189, DOI 10.1016/S0065-2776(08)60129-7	32	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					180	189		10.1016/0091-6749(76)90153-6	http://dx.doi.org/10.1016/0091-6749(76)90153-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX744	134051				2022-12-18	WOS:A1976BX74400007
J	SOLOMON, WR				SOLOMON, WR			FUNGUS AEROSOLS ARISING FROM COLD-MIST VAPORIZERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN, MED CTR, SECT ALLERGY, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan								ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; COVELLI HD, 1973, AM REV RESPIR DIS, V108, P698; PIERCE AK, 1970, NEW ENGL J MED, V282, P528, DOI 10.1056/NEJM197003052821002; SOLOMON WR, 1970, J ALLERGY, V45, P1, DOI 10.1016/0021-8707(70)90012-2; SOLOMON WR, 1970, EXCERPTA MED     211, P67; SWEET LC, 1971, J ALLERGY CLIN IMMUN, V48, P171, DOI 10.1016/0091-6749(71)90013-3; TOURVILLE DR, 1972, J ALLERGY CLIN IMMUN, V49, P245, DOI 10.1016/0091-6749(72)90087-5	7	34	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	4					222	228		10.1016/0091-6749(74)90064-5	http://dx.doi.org/10.1016/0091-6749(74)90064-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3236	4413523				2022-12-18	WOS:A1974U323600004
J	ISHIKAWA, T; REISMAN, RE; BERNSTEIN, J; ARBESMAN, CE				ISHIKAWA, T; REISMAN, RE; BERNSTEIN, J; ARBESMAN, CE			SECRETORY OTITIS MEDIA - IMMUNOLOGICAL STUDIES OF MIDDLE-EAR SECRETIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ARBESMAN CE, 1972, J ALLERGY CLIN IMMUN, V49, P72, DOI 10.1016/0091-6749(72)90058-9; BERNSTEIN J, IN PRESS; BEUTNER EH, 1968, B WORLD HEALTH ORGAN, V39, P587; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; ISHIZAKA K, 1970, J ALLERGY, V46, P197, DOI 10.1016/0021-8707(70)90023-7; ITO K, 1971, INT ARCH ALLER A IMM, V41, P477, DOI 10.1159/000230543; MACDEVITT HO, 1963, J IMMUNOL, V90, P634; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; THOMPSON RA, 1969, LANCET, V2, P517; Tomasi T B Jr, 1968, Adv Immunol, V9, P1, DOI 10.1016/S0065-2776(08)60441-1; TONDER O, 1971, ARCHIV OTOLARYNGOL, V93, P473; TSE KS, 1970, J ALLERGY, V46, P352, DOI 10.1016/0021-8707(70)90086-9; VANDECALSEYDE P, 1971, ACTA OTO-LARYNGOL, V71, P153, DOI 10.3109/00016487109125344	13	34	34	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	6					319	+		10.1016/0091-6749(72)90035-8	http://dx.doi.org/10.1016/0091-6749(72)90035-8			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O2043	4628904				2022-12-18	WOS:A1972O204300001
J	ISHIKAWA, T; ARBESMAN, CE; DALTON, AC				ISHIKAWA, T; ARBESMAN, CE; DALTON, AC			PHAGOCYTOSIS OF CANDIDA-ALBICANS BY EOSINOPHILIC LEUKOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		ARCHER GT, 1969, IMMUNOLOGY, V17, P177; BEUTNER EH, 1968, B WORLD HEALTH ORGAN, V39, P587; COHEN SG, 1969, J ALLERGY, V44, P113, DOI 10.1016/0021-8707(69)90007-0; ESTERLY NB, 1968, AM J CLIN PATHOL, V50, P291; ISHIKAWA T, 1971, J ALLERGY, V47, P101; ISHIKAWA T, 1971, FED P, V30, P2694; ITO K, 1971, J ALLERG CL, V41, P477; LEHRER RI, 1971, INFECT IMMUN, V3, P800, DOI 10.1128/IAI.3.6.800-802.1971; LITT M, 1964, ANN NY ACAD SCI, V116, P964, DOI 10.1111/j.1749-6632.1964.tb52562.x; PANUSH RS, 1971, ANN INTERN MED, V75, P199, DOI 10.7326/0003-4819-75-2-199; SABESIN SM, 1963, P SOC EXP BIOL MED, V112, P667, DOI 10.3181/00379727-112-28134; STRUMIA MAX M., 1937, AMER JOUR PATH, V13, P335; ZUCKERFRANKLIN D, 1966, J EXP MED, V124, P521, DOI 10.1084/jem.124.3.521	13	34	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	5					311	&		10.1016/0091-6749(72)90099-1	http://dx.doi.org/10.1016/0091-6749(72)90099-1			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M4215	4553436	Bronze			2022-12-18	WOS:A1972M421500007
J	FINK, JN; SOSMAN, AJ; SALVAGGIO, JE; BARBORIAK, JJ				FINK, JN; SOSMAN, AJ; SALVAGGIO, JE; BARBORIAK, JJ			PRECIPITINS AND DIAGNOSIS OF A HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material																		BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BUECHNER HA, 1958, AM J MED, V25, P234, DOI 10.1016/0002-9343(58)90030-5; DICKIE HA, 1958, JAMA-J AM MED ASSOC, V167, P1069, DOI 10.1001/jama.1958.02990260011004; FAUX J A, 1970, Clinical and Experimental Immunology, V7, P897; FINK JN, 1968, J LAB CLIN MED, V71, P20; FINK JN, 1969, J IMMUNOL, V103, P244; Pepys J, 1969, HYPERSENSITIVITY DIS; REED CE, 1965, J AMER MED ASSOC, V193, P261, DOI 10.1001/jama.1965.03090040005001; SALVAGGIO J, 1969, AM J MED, V46, P538, DOI 10.1016/0002-9343(69)90073-4; SALVAGGIO JE, 1966, ANN INTERN MED, V64, P748, DOI 10.7326/0003-4819-64-4-748; WENZEL F, 1970, CLIN RES, V17, P553	11	34	34	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	3					179	+		10.1016/0091-6749(71)90014-5	http://dx.doi.org/10.1016/0091-6749(71)90014-5			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K3234	4998686				2022-12-18	WOS:A1971K323400008
J	Borowczyk, J; Shutova, M; Brembilla, NC; Boehncke, WH				Borowczyk, Julia; Shutova, Maria; Brembilla, Nicolo Costantino; Boehncke, Wolf-Henning			IL-25 (IL-17E) in epithelial immunology and pathophysiology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						IL-25; IL-17E; keratinocytes; epithelial cells; tuft cells; atopic dermatitis; psoriasis; contact dermatitis; inflammatory bowel disease; ulcerative colitis; Crohn disease; chronic rhinosinusitis; asthma; idiopathic pulmonary fibrosis	INNATE LYMPHOID-CELLS; INFLAMMATORY-BOWEL-DISEASE; NF-KAPPA-B; TUFT CELLS; ATOPIC-DERMATITIS; BARRIER FUNCTION; T-CELLS; CHRONIC RHINOSINUSITIS; ULCERATIVE-COLITIS; CHEMOSENSORY CELLS	IL-25, also known as IL-17E, is a unique cytokine of the IL-17 family. Indeed, IL-25 exclusively was shown to strongly induce expression of the cytokines associated with type 2 immunity. Although produced by several types of immune cells, such as T cells, dendritic cells, or group 2 innate lymphoid cells, a vast amount of IL-25 derives from epithelial cells. The functions of IL-25 have been actively studied in the context of physiology and pathology of various organs including skin, airways and lungs, gastrointestinal tract, and thymus. Accumulating evidence suggests that IL-25 is a "barrier surface"cytokine whose expression depends on extrinsic environmental factors and when upregulated may lead to inflammatory disorders such as atopic dermatitis, psoriasis, or asthma. This review summarizes the progress of the recent years regarding the effects of IL-25 on the regulation of immune response and the balance between its homeostatic and pathogenic role in various epithelia. We revisit IL-25's general and tissue-specific mechanisms of action, mediated signaling pathways, and transcription factors activated in immune and resident cells. Finally, we discuss perspectives of the IL-25-based therapies for inflammatory disorders and compare them with the mainstream ones that target IL-17A. (J Allergy Clin Immunol 2021;148:40-52.)	[Borowczyk, Julia; Shutova, Maria; Brembilla, Nicolo Costantino; Boehncke, Wolf-Henning] Univ Geneva, Dept Pathol & Immunol, Geneva, Switzerland; [Boehncke, Wolf-Henning] Univ Hosp Geneva, Div Dermatol & Venereol, Geneva, Switzerland	University of Geneva; University of Geneva	Boehncke, WH (corresponding author), Geneva Univ Hosp HUG, Div Dermatol & Venerol, Dept Internal Med Specialties, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland.	wolf-henning.boehncke@hcuge.ch		Shutova, Maria/0000-0003-2340-6102	Swiss National Science Foundation, Switzerland [310030_175470/1]; Ernest Boninchi Foundation, Switzerland	Swiss National Science Foundation, Switzerland(Swiss National Science Foundation (SNSF)); Ernest Boninchi Foundation, Switzerland	This work was supported by the Swiss National Science Foundation, Switzerland (grant no. 310030_175470/1) and the Ernest Boninchi Foundation, Switzerland.	Aktar MK, 2015, ALLERGY, V70, P846, DOI 10.1111/all.12633; Amatya N, 2017, TRENDS IMMUNOL, V38, P310, DOI 10.1016/j.it.2017.01.006; An G, 2020, RESPIROLOGY, V25, P603, DOI 10.1111/resp.13711; Andreakos E, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010273; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Angkasekwinai P, 2010, NAT IMMUNOL, V11, P250, DOI 10.1038/ni.1846; Avitabile S, 2015, J INVEST DERMATOL, V135, P2862, DOI 10.1038/jid.2015.278; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Banerjee A, 2018, J CLIN INVEST, V128, P1711, DOI 10.1172/JCI120330; Batalla A, 2015, J DERMATOL SCI, V80, P111, DOI 10.1016/j.jdermsci.2015.06.011; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Berga-Bolanos R, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0121-0; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bezencon C, 2008, J COMP NEUROL, V509, P514, DOI 10.1002/cne.21768; Biancheri P, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-13; Blauvelt A, 2018, CLIN REV ALLERG IMMU, V55, P379, DOI 10.1007/s12016-018-8702-3; Boirivant M, 1998, J EXP MED, V188, P1929, DOI 10.1084/jem.188.10.1929; Bornstein C, 2018, NATURE, V559, P622, DOI 10.1038/s41586-018-0346-1; Borowczyk J, 2020, J INVEST DERMATOL, V140, P1379, DOI 10.1016/j.jid.2019.12.013; Bredo G, 2015, IMMUN INFLAMM DIS, V3, P455, DOI 10.1002/iid3.87; Brembilla NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01682; Bulek K, 2011, NAT IMMUNOL, V12, P844, DOI 10.1038/ni.2080; Buning C, 2003, EUR J IMMUNOGENET, V30, P329, DOI 10.1046/j.1365-2370.2003.00411.x; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Camelo A, 2012, J GASTROENTEROL, V47, P1198, DOI 10.1007/s00535-012-0591-2; Carey RM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092017; Caruso R, 2009, GASTROENTEROLOGY, V136, P2270, DOI 10.1053/j.gastro.2009.02.049; Chang SH, 2006, J BIOL CHEM, V281, P35603, DOI 10.1074/jbc.C600256200; Chang SH, 2011, CELL SIGNAL, V23, P1069, DOI 10.1016/j.cellsig.2010.11.022; Chen X, 2019, J EXP MED, V216, P195, DOI 10.1084/jem.20171849; Cheng D, 2014, AM J RESP CRIT CARE, V190, P639, DOI 10.1164/rccm.201403-0505OC; Cheung PFY, 2006, ALLERGY, V61, P878, DOI 10.1111/j.1398-9995.2006.01102.x; Chiricozzi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090284; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Claudio E, 2009, J IMMUNOL, V182, P1617, DOI 10.4049/jimmunol.182.3.1617; Corrigan CJ, 2011, P NATL ACAD SCI USA, V108, P1579, DOI 10.1073/pnas.1014241108; Dolgachev V, 2009, J IMMUNOL, V183, P5705, DOI 10.4049/jimmunol.0901666; Ely LK, 2009, NAT IMMUNOL, V10, P1245, DOI 10.1038/ni.1813; Emamaullee JA, 2009, DIABETES, V58, P1302, DOI 10.2337/db08-1113; Eyerich K, 2017, EUR J IMMUNOL, V47, P607, DOI 10.1002/eji.201646723; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Fuss IJ, 2004, J CLIN INVEST, V113, P1490, DOI 10.1172/JCI200419836; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Gaffen SL, 2011, CURR OPIN IMMUNOL, V23, P613, DOI 10.1016/j.coi.2011.07.006; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Gauvreau GM, 2020, CURR OPIN PULM MED, V26, P69, DOI 10.1097/MCP.0000000000000615; Gerbe F, 2016, NATURE, V529, P226, DOI 10.1038/nature16527; Gieseck RL, 2018, NAT REV IMMUNOL, V18, P62, DOI 10.1038/nri.2017.90; Girolomoni G, 2017, J EUR ACAD DERMATOL, V31, P1616, DOI 10.1111/jdv.14433; Gooderham MJ, 2019, EXPERT REV CLIN IMMU, V15, P907, DOI 10.1080/1744666X.2019.1648209; Goswami S, 2009, NAT IMMUNOL, V10, P496, DOI 10.1038/ni.1719; Gracz AD, 2018, GASTROENTEROLOGY, V155, P1508, DOI 10.1053/j.gastro.2018.07.023; Gregory LG, 2013, THORAX, V68, P82, DOI 10.1136/thoraxjnl-2012-202003; Grencis RK, 2016, TRENDS PARASITOL, V32, P583, DOI 10.1016/j.pt.2016.04.016; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Ha HL, 2014, P NATL ACAD SCI USA, V111, pE3422, DOI 10.1073/pnas.1400513111; Haber AL, 2017, NATURE, V551, P333, DOI 10.1038/nature24489; Hams E, 2014, P NATL ACAD SCI USA, V111, P367, DOI 10.1073/pnas.1315854111; Hartupee J, 2009, J IMMUNOL, V182, P1660, DOI 10.4049/jimmunol.182.3.1660; Hayakawa Y, 2018, CELL, V174, P251, DOI 10.1016/j.cell.2018.06.037; He F, 2021, ENT-EAR NOSE THROAT, V100, pNP43, DOI 10.1177/0145561319857697; Heller F, 2005, GASTROENTEROLOGY, V129, P550, DOI 10.1053/j.gastro.2005.05.002; Hellings PW, 2020, J ALLERGY CLIN IMMUN, V145, P1499, DOI 10.1016/j.jaci.2020.04.010; Hong HY, 2018, ALLERGY, V73, P459, DOI 10.1111/all.13267; Howitt Michael R, 2020, Immunohorizons, V4, P23, DOI 10.4049/immunohorizons.1900099; Howitt MR, 2016, SCIENCE, V351, P1329, DOI 10.1126/science.aaf1648; Huang CK, 2014, ONCOGENE, V33, P2968, DOI 10.1038/onc.2013.268; Huang YF, 2018, SCIENCE, V359, P114, DOI 10.1126/science.aam5809; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Isailovic N, 2015, J AUTOIMMUN, V60, P1, DOI 10.1016/j.jaut.2015.04.006; Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012; Jabeen R, 2013, J CLIN INVEST, V123, P4641, DOI 10.1172/JCI69489; Jang YH, 2017, J INVEST DERMATOL, V137, P2354, DOI 10.1016/j.jid.2017.03.042; Jiang L, 2018, BIOMED PHARMACOTHER, V107, P24, DOI 10.1016/j.biopha.2018.07.142; Johansson MEV, 2013, NAT REV GASTRO HEPAT, V10, P352, DOI 10.1038/nrgastro.2013.35; Kaiko GE, 2010, J IMMUNOL, V185, P4681, DOI 10.4049/jimmunol.1001758; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kim BE, 2013, J INVEST DERMATOL, V133, P2678, DOI 10.1038/jid.2013.223; Kim MR, 2002, BLOOD, V100, P2330, DOI 10.1182/blood-2002-01-0012; Kleinschek MA, 2007, J EXP MED, V204, P161, DOI 10.1084/jem.20061738; Kohanski MA, 2018, J ALLERGY CLIN IMMUN, V142, P460, DOI 10.1016/j.jaci.2018.03.019; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Kouzaki H, 2013, AM J RESP CELL MOL, V49, P741, DOI 10.1165/rcmb.2012-0304OC; Krasteva G, 2012, HISTOCHEM CELL BIOL, V138, P365, DOI 10.1007/s00418-012-0993-5; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lavocat F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00647; Lawrence MG, 2018, ANN ALLERG ASTHMA IM, V120, P376, DOI 10.1016/j.anai.2018.01.009; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Lee M, 2017, CURR OPIN ALLERGY CL, V17, P17, DOI 10.1097/ACI.0000000000000332; Lee Woo Ho, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276-019-0348-6; Letuve S, 2006, J ALLERGY CLIN IMMUN, V117, P590, DOI 10.1016/j.jaci.2005.10.025; Leyva-Castillo JM, 2020, J ALLERGY CLIN IMMUN, V145, P1606, DOI 10.1016/j.jaci.2020.02.026; Liao S, 2019, CURR TREATMENT OPTIO, P6; Lloyd CM, 2015, CURR OPIN IMMUNOL, V34, P52, DOI 10.1016/j.coi.2015.02.001; Loke P, 2018, IMMUNITY, V49, P16, DOI 10.1016/j.immuni.2018.07.002; Lonati PA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105008; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Luo YL, 2016, CANCER LETT, V375, P390, DOI 10.1016/j.canlet.2016.03.012; MacLeod AS, 2013, J CLIN INVEST, V123, P4364, DOI 10.1172/JCI70064; Maezawa Y, 2006, J IMMUNOL, V176, P1013, DOI 10.4049/jimmunol.176.2.1013; Martin DA, 2013, J INVEST DERMATOL, V133, P17, DOI 10.1038/jid.2012.194; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Martinez-Gonzalez I, 2016, IMMUNITY, V45, P198, DOI 10.1016/j.immuni.2016.06.017; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; Matsumoto Yuri, 2011, Allergology International, V60, P87, DOI 10.2332/allergolint.10-OA-0230; McGinty JW, 2020, CURR OPIN IMMUNOL, V62, P15, DOI 10.1016/j.coi.2019.11.005; Mchenga SSS, 2008, CELL MOL IMMUNOL, V5, P425, DOI 10.1038/cmi.2008.53; McKenzie GJ, 1998, CURR BIOL, V8, P339, DOI 10.1016/S0960-9822(98)70134-4; McKinley ET, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93487; Middelhoff M, 2017, AM J PHYSIOL-GASTR L, V313, pG285, DOI 10.1152/ajpgi.00073.2017; Miller AM, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-22; Miller CN, 2018, NATURE, V559, P627, DOI 10.1038/s41586-018-0345-2; Miller MM, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay3994; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Monin L, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028522; Montoro DT, 2018, NATURE, V560, P319, DOI 10.1038/s41586-018-0393-7; Nadjsombati MS, 2018, IMMUNITY, V49, P33, DOI 10.1016/j.immuni.2018.06.016; Nakanishi Y, 2013, NAT GENET, V45, P98, DOI 10.1038/ng.2481; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Otsuka A, 2012, J EUR ACAD DERMATOL, V26, P1455, DOI 10.1111/j.1468-3083.2011.04345.x; Owyang AM, 2006, J EXP MED, V203, P843, DOI 10.1084/jem.20051496; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pan GH, 2001, J IMMUNOL, V167, P6559, DOI 10.4049/jimmunol.167.11.6559; Papp KA, 2018, J AM ACAD DERMATOL, V79, P277, DOI 10.1016/j.jaad.2018.03.037; Park SK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181806; Parronchi P, 1997, AM J PATHOL, V150, P823; Patel NN, 2018, INT FORUM ALLERGY RH, V8, P900, DOI 10.1002/alr.22142; Petersen BC, 2014, J LEUKOCYTE BIOL, V95, P809, DOI 10.1189/jlb.0913482; Petersen BC, 2012, FUTURE MED CHEM, V4, P833, DOI [10.4155/fmc.12.39, 10.4155/FMC.12.39]; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Popova A, 2012, IMMUNOBIOLOGY, V217, P321, DOI 10.1016/j.imbio.2011.10.004; Qian YC, 2007, NAT IMMUNOL, V8, P247, DOI 10.1038/ni1439; Rankin LC, 2016, NAT IMMUNOL, V17, P179, DOI 10.1038/ni.3332; Reynolds JM, 2015, IMMUNITY, V42, P692, DOI 10.1016/j.immuni.2015.03.008; Rickel EA, 2008, J IMMUNOL, V181, P4299, DOI 10.4049/jimmunol.181.6.4299; Roan F, 2019, J CLIN INVEST, V129, P1441, DOI 10.1172/JCI124606; Roediger B, 2015, ADV IMMUNOL, V125, P111, DOI 10.1016/bs.ai.2014.09.004; Saadoun D, 2011, CURR PHARM DESIGN, V17, P3781, DOI 10.2174/138161211798357872; Saenz SA, 2013, J EXP MED, V210, P1823, DOI 10.1084/jem.20122332; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; Schmidt C, 2005, INFLAMM BOWEL DIS, V11, P16, DOI 10.1097/00054725-200501000-00003; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Senra L, 2019, J INVEST DERMATOL, V139, P1732, DOI 10.1016/j.jid.2019.01.021; Senra L, 2016, J INVEST DERMATOL, V136, P1970, DOI 10.1016/j.jid.2016.06.009; Seys SF, 2013, CLIN EXP ALLERGY, V43, P1009, DOI 10.1111/cea.12125; Sharkhuu T, 2006, CLIN EXP ALLERGY, V36, P1575, DOI 10.1111/j.1365-2222.2006.02595.x; Shin HW, 2015, J ALLERGY CLIN IMMUN, V135, P1476, DOI 10.1016/j.jaci.2015.01.003; Sonobe Y, 2009, J BIOL CHEM, V284, P31834, DOI 10.1074/jbc.M109.025940; Sun DX, 2011, NAT IMMUNOL, V12, P853, DOI 10.1038/ni.2081; Sundrud MS, 2019, MUCOSAL IMMUNOL, V12, P583, DOI 10.1038/s41385-019-0155-3; Suto H, 2018, J ALLERGY CLIN IMMUN, V142, P1500, DOI 10.1016/j.jaci.2017.12.1007; Swaidani S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01293; Swaidani S, 2011, J IMMUNOL, V187, P3155, DOI 10.4049/jimmunol.1002790; Swaidani S, 2009, J IMMUNOL, V182, P1631, DOI 10.4049/jimmunol.182.3.1631; Takahashi K, 2011, J ALLERGY CLIN IMMUN, V128, P1067, DOI 10.1016/j.jaci.2011.06.018; Tamachi T, 2006, J ALLERGY CLIN IMMUN, V118, P606, DOI 10.1016/j.jaci.2006.04.051; Teng YS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1312-z; Terashima A, 2008, J EXP MED, V205, P2727, DOI 10.1084/jem.20080698; Thelen TD, 2016, SCI REP-UK, V6, DOI 10.1038/srep25643; Ting HA, 2019, J IMMUNOL, V202, P1321, DOI 10.4049/jimmunol.1801069; Tortola L, 2012, J CLIN INVEST, V122, P3965, DOI 10.1172/JCI63451; Tworek D, 2016, AM J RESP CRIT CARE, V193, P957, DOI 10.1164/rccm.201509-1751OC; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; Wang AJ, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-72; Wang W, 2018, J IMMUNOL, V201, P2221, DOI 10.4049/jimmunol.1800709; Wang Y, 2014, FERTIL STERIL, V102, P257, DOI 10.1016/j.fertnstert.2014.03.025; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wang YH, 2008, CURR OPIN IMMUNOL, V20, P697, DOI 10.1016/j.coi.2008.09.004; Watarai H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001255; Watt FM, 2006, CURR OPIN GENET DEV, V16, P518, DOI 10.1016/j.gde.2006.08.006; Weathington NM, 2017, AM J RESP CELL MOL, V57, P346, DOI 10.1165/rcmb.2016-0316OC; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Wong CK, 2005, AM J RESP CELL MOL, V33, P186, DOI 10.1165/rcmb.2005-0034OC; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu HH, 2015, J EXP MED, V212, P333, DOI 10.1084/jem.20141702; Wu L, 2015, J EXP MED, V212, P1571, DOI 10.1084/jem.20150204; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Xu G, 2010, ALLERGY, V65, P581, DOI 10.1111/j.1398-9995.2009.02252.x; Xu M, 2018, IMMUNITY, V48, P787, DOI 10.1016/j.immuni.2018.03.019; Xu M, 2017, IMMUNOL REV, V278, P185, DOI 10.1111/imr.12558; Xu XF, 2019, EXP BIOL MED, V244, P770, DOI 10.1177/1535370219843827; Yao XJ, 2014, CLIN EXP ALLERGY, V44, P765, DOI 10.1111/cea.12298; Yao XJ, 2016, RESPIROLOGY, V21, P638, DOI 10.1111/resp.12707; Yasmeen N, 2022, J DERMATOL TREAT, V33, P204, DOI 10.1080/09546634.2020.1743811; Yi L, 2017, MUCOSAL IMMUNOL, V10, P1491, DOI 10.1038/mi.2017.10; YUKAWA K, 1993, GENE, V133, P163; Zaph C, 2008, J EXP MED, V205, P2191, DOI 10.1084/jem.20080720; Zepp JA, 2015, J IMMUNOL, V194, P2826, DOI 10.4049/jimmunol.1402647; Zepp JA, 2012, J IMMUNOL, V189, P33, DOI 10.4049/jimmunol.1200470; Zhao AP, 2010, J IMMUNOL, V185, P6921, DOI 10.4049/jimmunol.1000450; Zhu S, 2010, J EXP MED, V207, P2647, DOI 10.1084/jem.20100703	199	33	34	5	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2021	148	1					40	52		10.1016/j.jaci.2020.12.628	http://dx.doi.org/10.1016/j.jaci.2020.12.628		JUL 2021	13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE3IE	33485651				2022-12-18	WOS:000669906700004
J	Kuhn, H; Kolkhir, P; Babina, M; Dull, M; Frischbutter, S; Fok, JS; Jiao, QQ; Metz, M; Scheffel, J; Wolf, K; Kremer, AE; Maurer, M				Kuehn, Helen; Kolkhir, Pavel; Babina, Magda; Duell, Miriam; Frischbutter, Stefan; Fok, Jie Shen; Jiao, Qingqing; Metz, Martin; Scheffel, Jorg; Wolf, Katharina; Kremer, Andreas E.; Maurer, Marcus			Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						MRGPRX2; MRGX2; agonists; chronic spontaneous urticaria; atopic dermatitis; substance P; neuropeptides; eosinophil granule proteins; antimicrobial peptides; pruritus; itch	EOSINOPHIL CATIONIC PROTEIN; MAJOR BASIC-PROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE; ANTIMICROBIAL PEPTIDE LL-37; N-TERMINAL 20-PEPTIDE; GENE-RELATED PEPTIDE; SUBSTANCE-P; ATOPIC-DERMATITIS; HISTAMINE-RELEASE; CELL ACTIVATION	The Mas-related G protein-coupled receptor X2 (MRGPRX2) is a multiligand receptor responding to various exogenous and endogenous stimuli. Being highly expressed on skin mast cells, MRGPRX2 triggers their degranulation and release of proinflammatory mediators, and it promotes multicellular signaling cascades, such as itch induction and transmission in sensory neurons. The expression of MRGPRX2 by skin mast cells and the levels of the MRGPRX2 agonists (eg, substance P, major basic protein, eosinophil peroxidase) are upregulated in the serum and/or skin of patients with inflammatory and pruritic skin diseases, such as chronic spontaneous urticaria or atopic dermatitis. Therefore, MRGPRX2 and its agonists might be potential biomarkers for the progression of cutaneous inflammatory diseases and the response to treatment. In addition, they may represent promising targets for prevention and treatment of signs and symptoms in patients with skin diseases or drug reactions. To assess this possibility, this review explores the role and relevance of MRGPRX2 and its activators in cutaneous inflammatory disorders and chronic pruritus.	[Kuehn, Helen; Duell, Miriam; Wolf, Katharina; Kremer, Andreas E.] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany; [Kolkhir, Pavel; Babina, Magda; Frischbutter, Stefan; Fok, Jie Shen; Jiao, Qingqing; Metz, Martin; Scheffel, Jorg; Maurer, Marcus] Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Dermatol Allergol, Berlin, Germany; [Kolkhir, Pavel; Babina, Magda; Frischbutter, Stefan; Fok, Jie Shen; Jiao, Qingqing; Metz, Martin; Scheffel, Jorg; Maurer, Marcus] Free Univ Berlin, Berlin, Germany; [Kolkhir, Pavel; Babina, Magda; Frischbutter, Stefan; Fok, Jie Shen; Jiao, Qingqing; Metz, Martin; Scheffel, Jorg; Maurer, Marcus] Humboldt Univ, Berlin, Germany; [Kolkhir, Pavel; Babina, Magda; Frischbutter, Stefan; Fok, Jie Shen; Jiao, Qingqing; Metz, Martin; Scheffel, Jorg; Maurer, Marcus] Berlin Inst Hlth, Berlin, Germany; [Kolkhir, Pavel] IM Sechenov First Moscow State Med Univ, Sechenov Univ, Div Immune Mediated Skin Dis, Moscow, Russia; [Fok, Jie Shen] Box Hill Hosp, Dept Resp Med, Melbourne, Vic, Australia; [Fok, Jie Shen] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia; [Jiao, Qingqing] Soochow Univ, Affiliated Hosp 1, Dept Dermatol, Suzhou, Peoples R China	University of Erlangen Nuremberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Sechenov First Moscow State Medical University; Box Hill Hospital; Monash University; Soochow University - China	Maurer, M (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Maurer, Marcus/ABG-2174-2020; Metz, Martin/B-8799-2009; Frischbutter, Stefan/AAM-9487-2021	Maurer, Marcus/0000-0002-4121-481X; Metz, Martin/0000-0002-4070-9976; Frischbutter, Stefan/0000-0003-3971-7343; Kolkhir, Pavel/0000-0001-5380-8132; Babina, Magda/0000-0002-4500-7615	Russian Academic Excellence Project 5-100; German Research Foundation [KR3618/3-1 [2690], KR3618/5-1, BA3769/4-1]; Interdisciplinary Center for Clinical Research at the Friedrich Alexander University of Erlangen-Nurnberg [E20, E27]; GA2LEN network of Urticaria Centers of Reference and Excellence (UCARE); Bavarian Equal Opportunities Sponsorship (Realisierung von Chancengleichheit von Frauen in Forschung und Lehre-Realization Equal Opportunities for Women in Research and Teaching); GA2LEN fellowship	Russian Academic Excellence Project 5-100(Ministry of Education and Science, Russian FederationProject 5-100, Ministry of Education and Science, Russian Federation); German Research Foundation(German Research Foundation (DFG)); Interdisciplinary Center for Clinical Research at the Friedrich Alexander University of Erlangen-Nurnberg; GA2LEN network of Urticaria Centers of Reference and Excellence (UCARE); Bavarian Equal Opportunities Sponsorship (Realisierung von Chancengleichheit von Frauen in Forschung und Lehre-Realization Equal Opportunities for Women in Research and Teaching); GA2LEN fellowship	This work was supported by the Russian Academic Excellence Project 5-100. A.E.K. was supported by the German Research Foundation (grants KR3618/3-1 [for 2690] and KR3618/5-1) and the Interdisciplinary Center for Clinical Research at the Friedrich Alexander University of Erlangen-Nurnberg (grants E20 and E27). M.B. was likewise supported by the German Research Foundation (grant BA3769/4-1). This work also benefitted from support of the GA<SUP>2</SUP>LEN network of Urticaria Centers of Reference and Excellence (UCARE, www.ga2len-ucare.com). K.W.was supported by a Bavarian Equal Opportunities Sponsorship (Realisierung von Chancengleichheit von Frauen in Forschung und Lehre-Realization Equal Opportunities for Women in Research and Teaching). P.K. was supported by a GA<SUP>2</SUP>LEN fellowship.	ABUGHAZALEH RI, 1992, J MEMBRANE BIOL, V128, P153; Alkanfari I, 2018, J IMMUNOL, V201, P343, DOI 10.4049/jimmunol.1701793; Amatya B, 2010, SKIN PHARMACOL PHYS, V23, P133, DOI 10.1159/000270385; An Jing, 2021, Appl Neuropsychol Adult, V28, P124, DOI 10.1080/23279095.2019.1603151; ANAND P, 1991, BRIT J DERMATOL, V124, P547, DOI 10.1111/j.1365-2133.1991.tb04948.x; Andersen HH, 2017, PAIN, V158, P1780, DOI 10.1097/j.pain.0000000000000980; Angelova-Fischer I, 2006, BRIT J DERMATOL, V154, P1112, DOI 10.1111/j.1365-2133.2006.07201.x; Asano S, 2008, BRIT J DERMATOL, V159, P97, DOI 10.1111/j.1365-2133.2008.08613.x; Ayudhya CCN, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215247; Azimi E, 2017, J ALLERGY CLIN IMMUN, V140, P447, DOI 10.1016/j.jaci.2016.12.980; Babina M, 2018, ALLERGY, V73, P256, DOI 10.1111/all.13301; Babina M, 2019, J INVEST DERMATOL, V139, P1516, DOI 10.1016/j.jid.2019.01.013; Babina M, 2018, EXP DERMATOL, V27, P1298, DOI 10.1111/exd.13762; Babina M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030525; Bader M, 2014, PHARMACOL REV, V66, P1080, DOI 10.1124/pr.113.008136; Ballardini N, 2009, BRIT J DERMATOL, V161, P40, DOI 10.1111/j.1365-2133.2009.09095.x; Bals R, 2003, CELL MOL LIFE SCI, V60, P711, DOI 10.1007/s00018-003-2186-9; Basak PY, 2014, INDIAN J DERMATOL VE, V80, P483, DOI 10.4103/0378-6323.140345; Berroa F, 2015, ANESTH ANALG, V121, P117, DOI 10.1213/ANE.0000000000000776; Borici-Mazi R, 1999, ALLERGY, V54, P46, DOI 10.1034/j.1398-9995.1999.00726.x; BOST K L, 1992, Regional Immunology, V4, P105; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; Cato ACB, 2019, J ALLERGY CLIN IMMUN, P1; Che DL, 2018, CELL IMMUNOL, V332, P121, DOI 10.1016/j.cellimm.2018.08.005; Che DL, 2018, INT IMMUNOPHARMACOL, V62, P244, DOI 10.1016/j.intimp.2018.07.020; Chen XJ, 2006, J DERMATOL SCI, V43, P63, DOI 10.1016/j.jdermsci.2006.03.001; Cheng F L, 2016, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V51, P675, DOI 10.3760/cma.j.issn.1673-0860.2016.09.008; Chieosilapatham P, 2017, CLIN EXP IMMUNOL, V190, P155, DOI 10.1111/cei.13013; Chung Keshi, 2019, Neurobiol Pain, V6, P100032, DOI 10.1016/j.ynpai.2019.100032; CHURCH MK, 1991, INT ARCH ALLER A IMM, V94, P310, DOI 10.1159/000235393; Clausen ML, 2013, BRIT J DERMATOL, V169, P587, DOI 10.1111/bjd.12419; Clausen ML, 2018, SCI REP-UK; COULSON IH, 1990, BRIT J DERMATOL, V122, P343, DOI 10.1111/j.1365-2133.1990.tb08282.x; Demir S, 2017, ALLERGY ASTHMA IMMUN, V9, P347, DOI 10.4168/aair.2017.9.4.347; Dhonneur G, 2004, ANESTH ANALG, V98, P986, DOI [10.1213/01.ANE.0000111206.50145.47, 10.1213/01.ANE.0000111206]; DiLorenzo G, 1996, MEDIAT INFLAMM, V5, P113, DOI 10.1155/S0962935196000191; Ding YY, 2019, INT IMMUNOPHARMACOL, V66, P185, DOI 10.1016/j.intimp.2018.11.025; Domachowske JB, 1998, NUCLEIC ACIDS RES, V26, P3358, DOI 10.1093/nar/26.14.3358; Dong XZ, 2001, CELL, V106, P619, DOI 10.1016/S0092-8674(01)00483-4; DUTHIE DJR, 1987, BRIT J ANAESTH, V59, P61, DOI 10.1093/bja/59.1.61; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Fantini F, 1992, Exp Dermatol, V1, P127; FARDE L, 1988, ARCH GEN PSYCHIAT, V45, P71; Ferry X, 2002, PEPTIDES, V23, P1507, DOI 10.1016/S0196-9781(02)00090-6; Ferry X, 2001, J IMMUNOL, V167, P4805, DOI 10.4049/jimmunol.167.9.4805; Fujisawa D, 2014, J ALLERGY CLIN IMMUN, V134, P622, DOI 10.1016/j.jaci.2014.05.004; Furuta GT, 2000, CLIN EXP IMMUNOL, V122, P35, DOI 10.1046/j.1365-2249.2000.01337.x; Gambichler T, 2008, INT ARCH ALLERGY IMM, V147, P17, DOI 10.1159/000128582; Gaudenzio N, 2016, J CLIN INVEST, V126, P3981, DOI 10.1172/JCI85538; Georgala Sophia, 1994, Journal of Dermatological Science, V8, P125, DOI 10.1016/0923-1811(94)90006-X; GIANNETTI A, 1989, BRIT J DERMATOL, V121, P681, DOI 10.1111/j.1365-2133.1989.tb08209.x; Giavina-Bianchi P, 2019, J ALLER CL IMM-PRACT, V7, P2089, DOI 10.1016/j.jaip.2019.01.059; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Glattard E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008791; Green DP, 2019, NEURON, V101, P412, DOI 10.1016/j.neuron.2019.01.012; Grimes J, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.547; Gupta K, 2018, IMMUNOL REV, V282, P168, DOI 10.1111/imr.12622; Gupta K, 2016, INNATE IMMUN-LONDON, V22, P21, DOI 10.1177/1753425915610643; Guzey C, 2007, EUR J CLIN PHARMACOL, V63, P233, DOI 10.1007/s00228-006-0234-8; Haas S, 2010, J DERMATOL SCI, V58, P193, DOI 10.1016/j.jdermsci.2010.03.020; Han SL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14224-z; Hasbak P, 2006, BASIC CLIN PHARMACOL, V99, P162, DOI 10.1111/j.1742-7843.2006.pto_465.x; Hashimoto T, 2020, J AM ACAD DERMATOL, V83, P53, DOI 10.1016/j.jaad.2019.07.060; Hawro T, 2019, J EUR ACAD DERMATOL, V33, P1755, DOI 10.1111/jdv.15743; Hawro T, 2016, ALLERGY, V71, P1745, DOI 10.1111/all.12995; HERNANZ A, 1989, INT ARCH ALLER A IMM, V90, P198, DOI 10.1159/000235024; Hou YJ, 2019, MOL IMMUNOL, V111, P118, DOI 10.1016/j.molimm.2019.04.008; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; IRANI AMA, 1989, ALLERGY, V44, P31; Jarvikallio A, 2003, ARCH DERMATOL RES, V295, P2, DOI 10.1007/s00403-002-0378-z; JOHANSSON O, 1987, NEUROSCI LETT, V73, P225, DOI 10.1016/0304-3940(87)90249-7; JOHANSSON O, 1984, VIRCHOWS ARCH B, V46, P155, DOI 10.1007/BF02890305; Kajiwara N, 2010, J ALLERGY CLIN IMMUN, V125, P1137, DOI 10.1016/j.jaci.2010.01.056; Kamohara M, 2005, BIOCHEM BIOPH RES CO, V330, P1146, DOI 10.1016/j.bbrc.2005.03.088; Kanbe T, 2001, BRIT J DERMATOL, V144, P1148, DOI 10.1046/j.1365-2133.2001.04224.x; Kanda N, 2012, IMMUNOBIOLOGY, V217, P436, DOI 10.1016/j.imbio.2011.10.010; Karhu T, 2017, BBA-GEN SUBJECTS, V1861, P2530, DOI 10.1016/j.bbagen.2017.08.013; Kashem SW, 2011, EUR J PHARMACOL, V668, P299, DOI 10.1016/j.ejphar.2011.06.027; Kay AB, 2014, BRIT J DERMATOL, V171, P505, DOI 10.1111/bjd.12991; Kenneth M, 2017, JANEWAYS IMMUNOBIOLO, V9th, P613; Kiatsurayanon C, 2016, J DERMATOL SCI, V83, P190, DOI 10.1016/j.jdermsci.2016.05.006; Kiatsurayanon C, 2014, J INVEST DERMATOL, V134, P2163, DOI 10.1038/jid.2014.143; Kim KH, 2003, J DERMATOL SCI, V32, P115, DOI 10.1016/S0923-1811(03)00070-7; Kim N, 2012, J INVEST DERMATOL, V132, P1169, DOI 10.1038/jid.2011.404; Kolkhir P, 2020, J ALLER CL IMM-PRACT, V8, P318, DOI 10.1016/j.jaip.2019.08.025; Kosteletzky F, 2009, ACTA DERM-VENEREOL, V89, P271, DOI 10.2340/00015555-0624; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; Lansu K, 2017, NAT CHEM BIOL, V13, P529, DOI [10.1038/NCHEMBIO.2334, 10.1038/nchembio.2334]; Lee CH, 2006, BRIT J DERMATOL, V154, P1100, DOI 10.1111/j.1365-2133.2006.07191.x; Lee CH, 2012, BRIT J DERMATOL, V167, P794, DOI 10.1111/j.1365-2133.2012.11047.x; Lee SW, 2013, J DERMATOL, V40, P182, DOI 10.1111/1346-8138.12036; Leslie TA, 2015, HANDB EXP PHARMACOL, V226, P337, DOI 10.1007/978-3-662-44605-8_18; Leucht S, 2013, LANCET, V382, P951, DOI 10.1016/S0140-6736(13)60733-3; Leung TF, 2012, J EUR ACAD DERMATOL, V26, P518, DOI 10.1111/j.1468-3083.2011.04083.x; Levy JH, 2000, BRIT J ANAESTH, V85, P844, DOI 10.1093/bja/85.6.844; Li D, 2015, INT J DERMATOL, V54, pE309, DOI 10.1111/ijd.12836; LIN RY, 1990, ANN ALLERGY, V65, P222; Lin YY, 2018, J PHARMACEUT BIOMED, V159, P483, DOI 10.1016/j.jpba.2018.07.027; Liu R, 2017, BIOCHEM PHARMACOL, V146, P214, DOI 10.1016/j.bcp.2017.09.017; LOWMAN MA, 1988, J ALLERGY CLIN IMMUN, V81, P574, DOI 10.1016/0091-6749(88)90199-6; Lu L, 2018, ACS APPL MATER INTER, V10, P6107, DOI 10.1021/acsami.7b14560; Lumry WR, 2011, ANN ALLERG ASTHMA IM, V107, P529, DOI 10.1016/j.anai.2011.08.015; Maurer M, 2012, EXP DERMATOL, V21, P154, DOI 10.1111/j.1600-0625.2011.01410.x; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Meixiong J, 2019, IMMUNITY, V50, P1163, DOI 10.1016/j.immuni.2019.03.013; Metz M, 2014, J INVEST DERMATOL, V134, P2833, DOI 10.1038/jid.2014.226; MOLINA FA, 1992, BRIT J DERMATOL, V127, P344, DOI 10.1111/j.1365-2133.1992.tb00452.x; Motakis E, 2014, BLOOD, V123, pE58, DOI 10.1182/blood-2013-02-483792; Murakami T, 2018, MOL MED REP, V18, P4951, DOI 10.3892/mmr.2018.9532; Nair P, 2013, ALLERGY, V68, P1177, DOI 10.1111/all.12206; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; Nasser SMS, 2001, CLIN EXP ALLERGY, V31, P1014, DOI 10.1046/j.1365-2222.2001.01090.x; Nattkemper LA, 2018, J INVEST DERMATOL, V138, P1311, DOI 10.1016/j.jid.2017.12.029; Navines-Ferrer A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29965-8; Niyonsaba F, 2002, IMMUNOLOGY, V106, P20, DOI 10.1046/j.1365-2567.2002.01398.x; Niyonsaba F, 2010, J IMMUNOL, V184, P3526, DOI 10.4049/jimmunol.0900712; O'Connell AE, 2011, INFECT IMMUN, V79, P2770, DOI 10.1128/IAI.00931-10; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; Ogasawara H, 2019, J LEUKOCYTE BIOL, P1; Ogasawara H, 2020, BIOCHEM BIOPHYS REP, V21, DOI 10.1016/j.bbrep.2019.100719; Ohanyan T, 2018, ACTA DERM-VENEREOL, V98, P26, DOI 10.2340/00015555-2780; Ohnishi K, 2000, INTERNAL MED, V39, P1044, DOI 10.2169/internalmedicine.39.1044; Okamura Y, 2017, ALLERGOL INT, V66, pS9, DOI 10.1016/j.alit.2017.03.002; Oreagba IA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.297; Oskeritzian CA, 2005, J ALLERGY CLIN IMMUN, V115, P1162, DOI 10.1016/j.jaci.2005.02.022; OTT NL, 1994, J ALLERGY CLIN IMMUN, V94, P120, DOI 10.1016/0091-6749(94)90078-7; Otvos L, 2016, ACTA MICROBIOL IMM H, V63, P257, DOI 10.1556/030.63.2016.005; Panahi Y, 2013, CUTAN OCUL TOXICOL, V32, P4, DOI 10.3109/15569527.2012.686077; Patella V, 1996, J IMMUNOL, V157, P1219; Piliponsky AM, 2003, BLOOD, V101, P1898, DOI 10.1182/blood-2002-05-1488; PINCELLI C, 1990, BRIT J DERMATOL, V122, P745, DOI 10.1111/j.1365-2133.1990.tb06261.x; PINCELLI C, 1991, ARCH DERMATOL RES, V283, P230, DOI 10.1007/BF01106107; PIOTROWSKI W, 1985, N-S ARCH PHARMACOL, V331, P364, DOI 10.1007/BF00500821; Plager DA, 1999, J BIOL CHEM, V274, P14464, DOI 10.1074/jbc.274.20.14464; Plum T, 2020, IMMUNITY, V52, P404, DOI 10.1016/j.immuni.2020.01.012; De Oliveira PCR, 2015, CANCER GENOM PROTEOM, V12, P397; Rahman A, 2007, CLIN THER, V29, P1950, DOI 10.1016/j.clinthera.2007.09.005; Reddy VB, 2008, J NEUROSCI, V28, P4331, DOI 10.1523/JNEUROSCI.0716-08.2008; Reddy VB, 2018, J INVEST DERMATOL, V138, P461, DOI 10.1016/j.jid.2017.05.042; Reddy VB, 2017, J ALLERGY CLIN IMMUN, V140, P1726, DOI 10.1016/j.jaci.2017.05.046; Reddy VB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8864; Reddy VB, 2010, J INVEST DERMATOL, V130, P1468, DOI 10.1038/jid.2009.430; Ribas D, 2018, J PERIODONTOL, V89, P228, DOI 10.1902/jop.2017.160679; Robas N, 2003, J BIOL CHEM, V278, P44400, DOI 10.1074/jbc.M302456200; ROTHSCHILD AM, 1970, BRIT J PHARMACOL, V38, P253, DOI 10.1111/j.1476-5381.1970.tb10354.x; Roy S, 2019, J IMMUNOL, V202, P1229, DOI 10.4049/jimmunol.1801227; Rukwied R, 2000, BRIT J DERMATOL, V142, P1114, DOI 10.1046/j.1365-2133.2000.03535.x; RUZICKA T, 1983, ARCH DERMATOL RES, V275, P41, DOI 10.1007/BF00516553; Sage J, 2014, MATRIX BIOL, V33, P41, DOI 10.1016/j.matbio.2013.07.002; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Schonefuss A, 2010, EXP DERMATOL, V19, pE80, DOI 10.1111/j.1600-0625.2009.00990.x; Schulze E, 1997, ACTA HISTOCHEM, V99, P301, DOI 10.1016/S0065-1281(97)80024-4; Selim K, 1999, HEPATOLOGY, V29, P1347, DOI 10.1002/hep.510290535; Serhan N, 2019, NAT IMMUNOL, V20, P1435, DOI 10.1038/s41590-019-0493-z; SHANAHAN F, 1984, J ALLERGY CLIN IMMUN, V74, P499, DOI 10.1016/0091-6749(84)90385-3; Sheen CH, 2007, ALLERGY, V62, P532, DOI 10.1111/j.1398-9995.2007.01345.x; Shichmanter Renata, 2004, Eur J Intern Med, V15, P441, DOI 10.1016/j.ejim.2004.08.006; Siehler S, 2008, MOL CELL ENDOCRINOL, V286, P26, DOI 10.1016/j.mce.2007.12.007; SMITH CH, 1992, LANCET, V339, P91, DOI 10.1016/0140-6736(92)91000-X; Steinhoff M, 2003, J NEUROSCI, V23, P6176; STUTTGEN G, 1980, ARCH DERMATOL RES, V268, P113, DOI 10.1007/BF00403796; Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051; Subramanian H, 2013, J IMMUNOL, V191, P345, DOI 10.4049/jimmunol.1300023; Subramanian H, 2011, J BIOL CHEM, V286, P44739, DOI 10.1074/jbc.M111.277152; Subramanian H, 2011, MOL PHARMACOL, V79, P1005, DOI 10.1124/mol.111.071472; Tatemoto K, 2018, SCAND J IMMUNOL, V87, DOI 10.1111/sji.12655; Tatemoto K, 2006, BIOCHEM BIOPH RES CO, V349, P1322, DOI 10.1016/j.bbrc.2006.08.177; Tedeschi A, 2005, CLIN EXP DERMATOL, V30, P171, DOI 10.1111/j.1365-2230.2005.01732.x; Teresiak-Mikolajczak E, 2013, POSTEP DERM ALERGOL, V30, P286, DOI 10.5114/pdia.2013.38357; Tore F, 2009, CURR PHARM DESIGN, V15, P3433, DOI 10.2174/138161209789105036; Toyoda M, 2002, BRIT J DERMATOL, V147, P71, DOI 10.1046/j.1365-2133.2002.04803.x; TRAVERS JB, 1995, J INVEST DERMATOL, V105, P816, DOI 10.1111/1523-1747.ep12326581; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; Ulambayar B, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0275-6; Umemoto N, 2003, J DERMATOL SCI, V31, P161, DOI 10.1016/S0923-1811(03)00004-5; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; van Hagen PM, 2008, MOL CELL ENDOCRINOL, V286, P141, DOI 10.1016/j.mce.2008.03.007; Van Neste D., 1992, Journal of Dermatological Science, V4, P172, DOI 10.1016/0923-1811(92)90016-5; Varricchi G, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00299; Verma AK, 2017, CYTOKINE GROWTH F R, V38, P37, DOI 10.1016/j.cytogfr.2017.09.002; Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x; Viode C, 2014, EXP DERMATOL, V23, P274, DOI 10.1111/exd.12357; Voisin T, 2019, IMMUNITY, V50, P1117, DOI 10.1016/j.immuni.2019.04.007; WAHLGREN CF, 1991, ACTA DERM-VENEREOL, V71, P488; WALLENGREN J, 1987, ARCH DERMATOL RES, V279, P512, DOI 10.1007/BF00413281; Wang JL, 2020, PHYTOTHER RES, V34, P401, DOI 10.1002/ptr.6531; Wang N, 2018, BIOCHEM PHARMACOL, V148, P147, DOI 10.1016/j.bcp.2017.12.017; Wang Z, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040341; Wedi B, 2020, ALLERGY, V75, P2229, DOI 10.1111/all.14213; WEINSTOCK JV, 1990, CELL IMMUNOL, V125, P380, DOI 10.1016/0008-8749(90)90092-6; Wu KG, 2011, INT J IMMUNOPATH PH, V24, P15, DOI 10.1177/039463201102400103; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Yoshida M, 2001, REGUL PEPTIDES, V101, P163, DOI 10.1016/S0167-0115(01)00283-X; Yu YY, 2016, EUR J PHARMACOL, V780, P115, DOI 10.1016/j.ejphar.2016.03.038; Zhang L, 2005, MOL BRAIN RES, V133, P187, DOI 10.1016/j.molbrainres.2004.10.007; Zheng WJ, 2016, CELL BIOL TOXICOL, V32, P217, DOI 10.1007/s10565-016-9330-4; Zirbs M, 2013, EUR J DERMATOL, V23, P812, DOI 10.1684/ejd.2013.2191	198	33	33	6	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					456	469		10.1016/j.jaci.2020.08.027	http://dx.doi.org/10.1016/j.jaci.2020.08.027		FEB 2021	14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	33071069	Bronze			2022-12-18	WOS:000616665800004
J	Leyva-Castillo, JM; Galand, C; Mashiko, S; Bissonnette, R; McGurk, A; Ziegler, SF; Dong, C; McKenzie, ANJ; Sarfati, M; Geha, RS				Leyva-Castillo, Juan Manuel; Galand, Claire; Mashiko, Shunya; Bissonnette, Robert; McGurk, Alex; Ziegler, Steven F.; Dong, Chen; McKenzie, Andrew N. J.; Sarfati, Marika; Geha, Raif S.			ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; IL-25; IL-13; ILC2	INNATE LYMPHOID-CELLS; ATOPIC-DERMATITIS; T-CELLS; IMMUNE-RESPONSES; TH2 CYTOKINES; TUFT CELLS; EXPRESSION; INTERLEUKIN-13; EXPOSURE; ANTIGEN	Background: Atopic dermatitis skin lesions demonstrate increased expression of IL-25 by keratinocytes and increased numbers of type 2 innate lymphoid cells (ILC2s) that express high levels of IL-25 receptor (IL-25R). IL-13 is expressed in atopic dermatitis skin lesions and plays an important role in pathogenesis of the disease. Objective: Our aim was to determine the role of IL-25 and ILC2s in a mouse model of antigen-driven allergic skin inflammation. Methods: Wild-type mice; mice that express an Il13-driven enhanced green fluorescent protein; and mice that lack IL-25R, IL-25 in keratinocytes, or IL-13 or IL-25R in ILC2s were subjected to acute or chronic epicutaneous sensitization with ovalbumin. Sensitized skin was examined by histology for epidermal thickening. Cellular infiltrates were analyzed for surface markers and intracellular expression of enhanced green fluorescent protein by flow cytometry. Gene expression was quantitated by RT quantitative PCR. Result: In both acute and chronic antigen-driven allergic skin inflammation, signaling by keratinocyte-derived IL-25 in ILC2s is important for epidermal hyperplasia, dermal infiltration by CD4(+) T cells, and cutaneous expression of Il13 and the IL-13 dependent T(H)2-cell attracting chemokines Cc17 and Ccl22. ILCs are the major source of IL-13 in acutely sensitized mouse skin, whereas T cells are its major source in chronically sensitized mouse skin. Conclusion: ILC2 activation by IL-25 is essential for IL-13 expression at sites of allergic skin inflammation.	[Leyva-Castillo, Juan Manuel; Galand, Claire; McGurk, Alex; Geha, Raif S.] Harvard Med Sch, Div Immunol, Boston Childrens Hosp, Boston, MA 02115 USA; [Mashiko, Shunya; Sarfati, Marika] Univ Montreal, Immunoregulat Lab, Ctr Rech Ctr Hosp, Montreal, PQ, Canada; [Bissonnette, Robert] Innovaderm Res, Montreal, PQ, Canada; [Ziegler, Steven F.] Benaroya Res Inst, Immunol Program, Seattle, WA USA; [Ziegler, Steven F.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; [Dong, Chen] Tsinghua Univ, Inst Immunol, Beijing, Peoples R China; [Dong, Chen] Tsinghua Univ, Sch Med, Beijing, Peoples R China; [Dong, Chen] Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China; [McKenzie, Andrew N. J.] MRC, Lab Mol Biol, Cambridge, England; [Galand, Claire] Agenus Inc, Lexington, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Universite de Montreal; Innovaderm Research Inc.; Benaroya Research Institute; University of Washington; University of Washington Seattle; Tsinghua University; Tsinghua University; MRC Laboratory Molecular Biology; Agenus Inc	Leyva-Castillo, JM; Geha, RS (corresponding author), Boston Childrens Hosp, Div Immunol, One Blackfan Circle, Boston, MA 02115 USA.	Manuel.LeyvaCastillo@childrens.harvard.edu; raif.geha@childrens.harvard.edu	dong, chen/B-3181-2009	dong, chen/0000-0002-0084-9130; Leyva Castillo, Juan Manuel/0000-0001-7394-4457	National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis Research Network [U19AI117673]; National Institutes of Health [AI113294-01A1]; National Institute of Allergy and Infectious Diseases [5T32AI007512-32]; MRC [MC_U105178805] Funding Source: UKRI	National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis Research Network; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funded by the National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis Research Network (grant U19AI117673); the National Institutes of Health (grant AI113294-01A1); and the National Institute of Allergy and Infectious Diseases (T32 training grant 5T32AI007512-32).	Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Angkasekwinai P, 2010, NAT IMMUNOL, V11, P250, DOI 10.1038/ni.1846; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Chou SJ, 2013, SCIENCE, V340, P1239, DOI 10.1126/science.1232806; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Vuyst E, 2018, EXP DERMATOL, V27, P435, DOI 10.1111/exd.13113; Deleuran M, 2012, CHEM IMMUNOL ALLERGY, V96, P45, DOI 10.1159/000331871; Gerbe F, 2016, NATURE, V529, P226, DOI 10.1038/nature16527; Gruber R, 2015, AM J PATHOL, V185, P2777, DOI 10.1016/j.ajpath.2015.06.021; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Honzke S, 2016, J INVEST DERMATOL, V136, P631, DOI 10.1016/j.jid.2015.11.007; Howitt MR, 2016, SCIENCE, V351, P1329, DOI 10.1126/science.aaf1648; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Imai Y, 2019, J INVEST DERMATOL, V139, P2185, DOI 10.1016/j.jid.2019.04.016; Jang YH, 2017, J INVEST DERMATOL, V137, P2354, DOI 10.1016/j.jid.2017.03.042; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kim BE, 2013, J INVEST DERMATOL, V133, P2678, DOI 10.1038/jid.2013.223; Leisten S, 2013, J ALLERGY CLIN IMMUN, V131, P1247, DOI 10.1016/j.jaci.2012.12.1576; Leyva-Castillo JM, 2013, J INVEST DERMATOL, V133, P154, DOI 10.1038/jid.2012.239; Malhotra N, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao6923; Matsuo K, 2018, J INVEST DERMATOL, V138, P1764, DOI 10.1016/j.jid.2018.02.027; McKenzie GJ, 1998, CURR BIOL, V8, P339, DOI 10.1016/S0960-9822(98)70134-4; Mearns H, 2014, EUR J IMMUNOL, V44, P1976, DOI 10.1002/eji.201344400; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Mochizuki M, 1998, J IMMUNOL, V160, P60; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Obara W, 2002, DERMATOLOGY, V205, P11, DOI 10.1159/000063145; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Purwar R, 2006, J INVEST DERMATOL, V126, P1043, DOI 10.1038/sj.jid.5700085; Reynolds JM, 2010, CYTOKINE GROWTH F R, V21, P413, DOI 10.1016/j.cytogfr.2010.10.002; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Savinko T, 2012, J INVEST DERMATOL, V132, P1392, DOI 10.1038/jid.2011.446; Simpson EL, 2018, J AM ACAD DERMATOL, V78, P863, DOI 10.1016/j.jaad.2018.01.017; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Tsoi LC, 2019, J INVEST DERMATOL, V139, P1480, DOI 10.1016/j.jid.2018.12.018; Van Dyken SJ, 2016, NAT IMMUNOL, V17, P1381, DOI 10.1038/ni.3582; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Xu M, 2018, IMMUNITY, V48, P787, DOI 10.1016/j.immuni.2018.03.019; Xu M, 2017, IMMUNOL REV, V278, P185, DOI 10.1111/imr.12558; Yoon J, 2016, J EXP MED, V213, P2147, DOI 10.1084/jem.20150376; Zheng T, 2009, J INVEST DERMATOL, V129, P742, DOI 10.1038/jid.2008.295	49	33	33	4	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1606	+		10.1016/j.jaci.2020.02.026	http://dx.doi.org/10.1016/j.jaci.2020.02.026			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32179159	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000539157800016
J	Chinn, IK; Chan, AY; Chen, K; Chou, J; Dorsey, MJ; Hajjar, J; Jongco, AM; Keller, MD; Kobrynski, LJ; Kumanovics, A; Lawrence, MG; Leiding, JW; Lugar, PL; Orange, JS; Patel, K; Platt, CD; Puck, JM; Raje, N; Romberg, N; Slack, MA; Sullivan, KE; Tarrant, TK; Torgerson, TR; Walter, JE				Chinn, Ivan K.; Chan, Alice Y.; Chen, Karin; Chou, Janet; Dorsey, Morna J.; Hajjar, Joud; Jongco, Artemio M., III; Keller, Michael D.; Kobrynski, Lisa J.; Kumanovics, Attila; Lawrence, Monica G.; Leiding, Jennifer W.; Lugar, Patricia L.; Orange, Jordan S.; Patel, Kiran; Platt, Craig D.; Puck, Jennifer M.; Raje, Nikita; Romberg, Neil; Slack, Maria A.; Sullivan, Kathleen E.; Tarrant, Teresa K.; Torgerson, Troy R.; Walter, Jolan E.			Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: A working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma & Immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chromosomal microarray; exome sequencing; gene panel; genetic testing; genome sequencing; Mendelian; primary immunodeficiency; Sanger sequencing; tools; variant interpretation	COPY-NUMBER VARIATION; LOSS-OF-FUNCTION; LYMPHOPROLIFERATIVE SYNDROME ALPS; WHOLE-EXOME CAPTURE; CHROMOSOMAL MICROARRAY; SOMATIC MOSAICISM; INBORN-ERRORS; INTRONIC MUTATION; SEQUENCE VARIANTS; SINGLE NUCLEOTIDE	Genetic testing has become an integral component of the diagnostic evaluation of patients with suspected primary immunodeficiency diseases. Results of genetic testing can have a profound effect on clinical management decisions. Therefore clinical providers must demonstrate proficiency in interpreting genetic data. Because of the need for increased knowledge regarding this practice, the American Academy of Allergy, Asthma & Immunology Primary Immunodeficiency Diseases Committee established a work group that reviewed and summarized information concerning appropriate methods, tools, and resources for evaluating variants identified by genetic testing. Strengths and limitations of tests frequently ordered by clinicians were examined. Summary statements and tables were then developed to guide the interpretation process. Finally, the need for research and collaboration was emphasized. Greater understanding of these important concepts will improve the diagnosis and management of patients with suspected primary immunodeficiency diseases.	[Chinn, Ivan K.; Hajjar, Joud] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Chinn, Ivan K.; Hajjar, Joud] Texas Childrens Hosp, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA; [Chan, Alice Y.; Dorsey, Morna J.; Puck, Jennifer M.] Univ Calif San Francisco, Dept Pediat, Div Allergy Immunol & Bone Marrow Transplantat, San Francisco, CA 94143 USA; [Chen, Karin] Univ Utah, Sch Med, Dept Pediat, Div Allergy & Immunol, Salt Lake City, UT USA; [Chou, Janet; Platt, Craig D.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Chou, Janet; Platt, Craig D.] Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA; [Jongco, Artemio M., III] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Med & Pediat, Great Neck, NY USA; [Jongco, Artemio M., III] Feinstein Inst Med Res, Ctr Hlth Innovat & Outcomes Res, Great Neck, NY USA; [Jongco, Artemio M., III] Cohen Childrens Med Ctr New York, Div Allergy & Immunol, Great Neck, NY USA; [Keller, Michael D.] Childrens Natl Hosp, Dept Allergy & Immunol, Washington, DC USA; [Kobrynski, Lisa J.; Patel, Kiran] Emory Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Atlanta, GA USA; [Kumanovics, Attila] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Lawrence, Monica G.] Univ Virginia Hlth Syst, Dept Med, Div Asthma Allergy & Immunol, Charlottesville, VA USA; [Leiding, Jennifer W.; Walter, Jolan E.] Univ S Florida, Dept Pediat & Med, St Petersburg, FL USA; [Leiding, Jennifer W.; Walter, Jolan E.] Johns Hopkins All Childrens Hosp, Div Pediat Allergy Immunol, St Petersburg, FL USA; [Leiding, Jennifer W.] Johns Hopkins All Childrens Hosp, Canc & Blood Disorders Inst, St Petersburg, FL USA; [Lugar, Patricia L.] Duke Univ, Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA; [Tarrant, Teresa K.] Duke Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Durham, NC 27710 USA; [Orange, Jordan S.] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; [Orange, Jordan S.] New York Presbyterian Morgan Stanley Childrens Ho, New York, NY USA; [Raje, Nikita] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA; [Raje, Nikita] Childrens Mercy Hosp, Div Allergy Asthma Immunol, Kansas City, MO 64108 USA; [Romberg, Neil; Sullivan, Kathleen E.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Romberg, Neil; Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Div Allergy Immunol, Philadelphia, PA 19104 USA; [Slack, Maria A.] Univ Rochester, Med Ctr, Dept Med, Div Allergy Immunol, Rochester, NY 14642 USA; [Slack, Maria A.] Univ Rochester, Med Ctr, Dept Pediat, Div Pediat Allergy & Immunol, Rochester, NY 14642 USA; [Torgerson, Troy R.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Torgerson, Troy R.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA; [Walter, Jolan E.] Massachusetts Gen Hosp, Div Pediat Allergy Immunol, Boston, MA 02114 USA	Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Northwell Health; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Children's National Health System; Emory University; Mayo Clinic; University of Virginia; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Duke University; Duke University; Columbia University; NewYork-Presbyterian Hospital; Morgan Stanley Children's Hospital; University of Missouri System; University of Missouri Kansas City; Children's Mercy Hospital; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Rochester; University of Rochester; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Harvard University; Massachusetts General Hospital	Chinn, IK (corresponding author), 1102 Bates Ave,Suite 330, Houston, TX 77030 USA.	chinn@bcm.edu	Jongco, Artemio/AAB-2168-2021; Dorsey, Morna/V-7270-2018; Hajjar, Joud/H-7482-2017	Dorsey, Morna/0000-0002-9432-3542; Hajjar, Joud/0000-0003-4633-1043; Chinn, Ivan/0000-0001-5684-5457; orange, jordan/0000-0001-7117-7725; Tarrant, Teresa/0000-0003-4067-5363				Acedo A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3202; Adzhubei II, 2013, CURR PROTOC HUM S76; Altimari A, 2013, ONCOTARGETS THER, V6, P1057, DOI 10.2147/OTT.S42369; Apweiler R, 2010, NUCLEIC ACIDS RES, V38, pD142, DOI 10.1093/nar/gkp846; Aradhya S, 2001, HUM MOL GENET, V10, P2557, DOI 10.1093/hmg/10.22.2557; Asgari S, 2017, P NATL ACAD SCI USA, V114, P8342, DOI 10.1073/pnas.1704259114; Bayrak-Toydemir P, 2008, EXP MOL PATHOL, V85, P45, DOI 10.1016/j.yexmp.2008.03.006; Belkadi A, 2015, P NATL ACAD SCI USA, V112, P5473, DOI 10.1073/pnas.1418631112; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Bi WM, 2013, GENET MED, V15, P450, DOI 10.1038/gim.2012.152; Boisson B, 2019, J CLIN INVEST, V129, P583, DOI 10.1172/JCI124011; Boisson B, 2015, CURR OPIN IMMUNOL, V32, P90, DOI 10.1016/j.coi.2015.01.005; Boisson-Dupuis S, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau8714; Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Bomba L, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1212-4; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, pe1; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Booty MG, 2009, ARTHRITIS RHEUM-US, V60, P1851, DOI 10.1002/art.24569; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Brehm A, 2015, J CLIN INVEST, V125, P4196, DOI 10.1172/JCI81260; Butte MJ, 2007, CLIN IMMUNOL, V125, P159, DOI 10.1016/j.clim.2007.06.007; Cacheiro P, 2017, MOL DIAGN THER, V21, P303, DOI 10.1007/s40291-017-0268-x; Carter H, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-S3-S3; Casanova JL, 2015, P NATL ACAD SCI USA, V112, pE7128, DOI 10.1073/pnas.1521651112; Casanova JL, 2014, J EXP MED, V211, P2137, DOI 10.1084/jem.20140520; Chinen J, 2017, J ALLERGY CLIN IMMUN, V140, P959, DOI 10.1016/j.jaci.2017.07.023; Chinn IK, 2019, PEDIATR REV, V40, P229, DOI 10.1542/pir.2017-0308; Choi J, 2017, J ALLERGY CLIN IMMUN, V140, P881, DOI 10.1016/j.jaci.2017.03.025; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; Chou J, 2012, CURR OPIN ALLERGY CL, V12, P623, DOI 10.1097/ACI.0b013e3283588ca6; Clarke J, 2009, NAT NANOTECHNOL, V4, P265, DOI [10.1038/NNANO.2009.12, 10.1038/nnano.2009.12]; Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516; Crestani E, 2014, J CLIN IMMUNOL, V34, P551, DOI 10.1007/s10875-014-0051-2; de Beaucoudrey L, 2010, MEDICINE, V89, P381, DOI 10.1097/MD.0b013e3181fdd832; Dong CL, 2015, HUM MOL GENET, V24, P2125, DOI 10.1093/hmg/ddu733; Dorjbal B, 2019, J ALLERGY CLIN IMMUN, V143, P1482, DOI 10.1016/j.jaci.2018.08.013; Eid J, 2009, SCIENCE, V323, P133, DOI 10.1126/science.1162986; Eilbeck K, 2017, NAT REV GENET, V18, P599, DOI 10.1038/nrg.2017.52; Eldomery MK, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0412-6; Ellis NA, 2001, HUM GENET, V108, P167, DOI 10.1007/s004390000447; Ellison JW, 2012, PEDIATRICS, V130, pE1085, DOI 10.1542/peds.2012-0568; Felgentreff K, 2015, J ALLERGY CLIN IMMUN, V136, P140, DOI 10.1016/j.jaci.2015.03.005; Fieschi C, 2003, J EXP MED, V197, P527, DOI 10.1084/jem.20021769; Fowler A, 2016, WELLCOME OPEN RES, P1; Fresard L, 2019, NAT MED, V25, P911, DOI 10.1038/s41591-019-0457-8; Fromer M, 2012, AM J HUM GENET, V91, P597, DOI 10.1016/j.ajhg.2012.08.005; Ghosh R, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1353-5; Ghosh S, 2012, SCAND J IMMUNOL, V75, P350, DOI 10.1111/j.1365-3083.2011.02658.x; Gonzaga-Jauregui C, 2012, ANNU REV MED, V63, P35, DOI 10.1146/annurev-med-051010-162644; Hagl B, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34953-z; Hambleton S, 2011, NEW ENGL J MED, V365, P127, DOI 10.1056/NEJMoa1100066; Heimall JR, 2018, J CLIN IMMUNOL, V38, P320, DOI 10.1007/s10875-018-0489-8; Herper M, ILLUMINA PROMISES SE; Heyworth PG, 2002, BLOOD, V100, P1845, DOI 10.1182/blood-2002-03-0861; Hirschhorn R, 2003, J MED GENET, V40, P721, DOI 10.1136/jmg.40.10.721; Hoppman-Chaney N, 2010, CLIN CHEM, V56, P1297, DOI 10.1373/clinchem.2010.145441; Hoskinson DC, 2017, CURR OPIN GENET DEV, V42, P33, DOI 10.1016/j.gde.2017.01.001; Houdayer C, 2012, HUM MUTAT, V33, P1228, DOI 10.1002/humu.22101; Hsu AP, 2015, J CLIN IMMUNOL, V35, P449, DOI 10.1007/s10875-015-0174-0; Hsu AP, 2013, J ALLERGY CLIN IMMUN, V131, P1586, DOI 10.1016/j.jaci.2013.02.038; Hsu AP, 2013, BLOOD, V121, P3830, DOI 10.1182/blood-2012-08-452763; Illumina, 1000 GEN IS HER; Ioannidis NM, 2016, AM J HUM GENET, V99, P877, DOI 10.1016/j.ajhg.2016.08.016; Isidoro-Garcia M, 2007, ALLERGOL IMMUNOPATH, V35, P254, DOI 10.1157/13112992; Israel L, 2017, CELL, V168, P789, DOI 10.1016/j.cell.2017.01.039; Itan Y, 2016, NAT METHODS, V13, P109, DOI 10.1038/nmeth.3739; Itan Y, 2015, P NATL ACAD SCI USA, V112, P13615, DOI 10.1073/pnas.1518646112; Itan Y, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-256; Itan Y, 2013, P NATL ACAD SCI USA, V110, P5558, DOI [10.1073/pnas.1218167110, 10.1073/PNAS.1218167110]; Jabara HH, 2016, NAT GENET, V48, P74, DOI 10.1038/ng.3465; Jagadeesh KA, 2016, NAT GENET, V48, P1581, DOI 10.1038/ng.3703; Jensen JM, 2017, GENOME RES, V27, P1597, DOI 10.1101/gr.218891.116; Jian XQ, 2014, NUCLEIC ACIDS RES, V42, P13534, DOI 10.1093/nar/gku1206; Jing H, 2014, J ALLERGY CLIN IMMUN, V133, P1667, DOI 10.1016/j.jaci.2014.03.025; Kanegane H, 2018, ALLERGOL INT, V67, P43, DOI 10.1016/j.alit.2017.06.003; Kang SHL, 2010, AM J MED GENET A, V152A, P1111, DOI 10.1002/ajmg.a.33278; Kawai T, 2012, J CLIN IMMUNOL, V32, P690, DOI 10.1007/s10875-012-9684-1; Kebschull JM, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv717; Kerkhof J, 2017, J MOL DIAGN, V19, P905, DOI 10.1016/j.jmoldx.2017.07.004; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Kircher M, 2010, BIOESSAYS, V32, P524, DOI 10.1002/bies.200900181; Kobayashi Y, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0403-7; Kohler S, 2017, NUCLEIC ACIDS RES, V45, pD865, DOI 10.1093/nar/gkw1039; Kuehn HS, 2016, NEW ENGL J MED, V374, P1032, DOI 10.1056/NEJMoa1512234; Kuhlen M, 2016, CLIN IMMUNOL, V162, P27, DOI 10.1016/j.clim.2015.10.008; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lam HYK, 2012, NAT BIOTECHNOL, V30, P78, DOI 10.1038/nbt.2065; Laurie S, 2016, HUM MUTAT, V37, P1263, DOI 10.1002/humu.23114; Lelieveld SH, 2015, HUM MUTAT, V36, P815, DOI 10.1002/humu.22813; Locke BA, 2014, CLIN REV ALLERG IMMU, V46, P154, DOI 10.1007/s12016-014-8412-4; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Lopez-Bigas N, 2005, FEBS LETT, V579, P1900, DOI 10.1016/j.febslet.2005.02.047; Lutskiy MI, 2005, BLOOD, V106, P2815, DOI 10.1182/blood-2004-12-4724; Maffucci P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00220; Magerus-Chatinet A, 2011, J CLIN INVEST, V121, P106, DOI 10.1172/JCI43752; Mamanova L, 2010, NAT METHODS, V7, P111, DOI 10.1038/nmeth.1419; Manning M, 2010, GENET MED, V12, P742, DOI 10.1097/GIM.0b013e3181f8baad; Martinez-Gallo M, 2013, J ALLERGY CLIN IMMUN, V131, P468, DOI 10.1016/j.jaci.2012.10.029; McDermott DH, 2015, CELL, V160, P686, DOI 10.1016/j.cell.2015.01.014; Meeths M, 2011, BLOOD, V118, P5783, DOI 10.1182/blood-2011-07-369090; Meienberg J, 2015, NUCLEIC ACIDS RES, V43, pE76, DOI 10.1093/nar/gkv216; Meynert AM, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-247; Meyts I, 2016, J ALLERGY CLIN IMMUN, V138, P957, DOI 10.1016/j.jaci.2016.08.003; Miller DT, 2010, AM J HUM GENET, V86, P749, DOI 10.1016/j.ajhg.2010.04.006; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Moens LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114901; Moncada-Velez M, 2011, SCAND J IMMUNOL, V74, P471, DOI 10.1111/j.1365-3083.2011.02593.x; Mousallem T, 2015, J ALLERGY CLIN IMMUN, V136, P476, DOI 10.1016/j.jaci.2015.02.040; Mu WB, 2016, J MOL DIAGN, V18, P923, DOI 10.1016/j.jmoldx.2016.07.006; Mullaney JM, 2010, HUM MOL GENET, V19, pR131, DOI 10.1093/hmg/ddq400; Nijman IJ, 2014, J ALLERGY CLIN IMMUN, V133, P529, DOI 10.1016/j.jaci.2013.08.032; Nussbaum R, 2016, THOMPSON THOMPSON GE; O'Shea JJ, 2004, MOL IMMUNOL, V41, P727, DOI 10.1016/j.molimm.2004.04.014; Oliveira JB, 2010, BLOOD, V116, pE35, DOI 10.1182/blood-2010-04-280347; Olsson LM, 2012, ANTIOXID REDOX SIGN, V16, P71, DOI 10.1089/ars.2011.4013; Ombrello MJ, 2012, NEW ENGL J MED, V366, P330, DOI 10.1056/NEJMoa1102140; Palendira U, 2012, J EXP MED, V209, P911, DOI 10.1084/jem.20112391; Petersheim D, 2018, J ALLERGY CLIN IMMUN, V141, P1060, DOI 10.1016/j.jaci.2017.05.030; Peterson TA, 2013, J MOL BIOL, V425, P4047, DOI 10.1016/j.jmb.2013.08.008; Philippakis AA, 2015, HUM MUTAT, V36, P915, DOI 10.1002/humu.22858; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Picard C, 2009, EUR J IMMUNOL, V39, P1966, DOI 10.1002/eji.200939385; Platt C, 2014, J ALLERGY CLIN IMMUN, V134, P262, DOI 10.1016/j.jaci.2013.08.021; Platt CD, 2017, J ALLERGY CLIN IMMUN, V140, P268, DOI 10.1016/j.jaci.2016.09.057; Pundir Sangya, 2016, Curr Protoc Bioinformatics, V53, DOI 10.1002/0471250953.bi0129s53; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Ritchie GRS, 2014, NAT METHODS, V11, P294, DOI 10.1038/nmeth.2832; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; Schenkel LC, 2016, J MOL DIAGN, V18, P657, DOI 10.1016/j.jmoldx.2016.04.002; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schwab C, 2018, J ALLERGY CLIN IMMUN, V142, P1932, DOI 10.1016/j.jaci.2018.02.055; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Seidel MG, 2014, J MED GENET, V51, P254, DOI 10.1136/jmedgenet-2013-102122; Seleman M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00847; Sharfe N, 2018, J ALLERGY CLIN IMMUN, V142, P618, DOI 10.1016/j.jaci.2017.10.033; Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486; Shendure Jay A, 2011, Curr Protoc Mol Biol, VChapter 7, DOI 10.1002/0471142727.mb0701s96; Shigemizu D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12742; Sims D, 2014, NAT REV GENET, V15, P121, DOI 10.1038/nrg3642; Smith SA, 2014, METHODS MOL BIOL, V1126, P243, DOI 10.1007/978-1-62703-980-2_18; Sobreira Nara, 2015, Hum Mutat, V36, P928, DOI 10.1002/humu.22844; Soemedi R, 2017, NAT GENET, V49, P848, DOI 10.1038/ng.3837; Spinner NB, 2014, AM J MED GENET C, V166, P397, DOI 10.1002/ajmg.c.31421; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Stevens AJ, 2017, G3-GENES GENOM GENET, V7, P1019, DOI 10.1534/g3.116.038687; Stray-Pedersen A, 2017, J ALLERGY CLIN IMMUN, V139, P232, DOI 10.1016/j.jaci.2016.05.042; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; TASSARA C, 1995, HUM MOL GENET, V4, P1693, DOI 10.1093/hmg/4.9.1693; Tavtigian SV, 2018, GENET MED, V20, P1054, DOI 10.1038/gim.2017.210; Thompson D, 2003, AM J HUM GENET, V73, P652, DOI 10.1086/378100; Thul PJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal3321; Uzel G, 2008, BLOOD, V111, P209, DOI 10.1182/blood-2007-04-082552; van Ninnwegen KJM, 2016, CLIN CHEM, V62, P1458, DOI 10.1373/clinchem.2016.258632; van Schouwenburg PA, 2015, CLIN IMMUNOL, V160, P301, DOI 10.1016/j.clim.2015.05.020; Veritas, GEN BREAKS 1000 WHOL; von Bernuth H, 2012, EUR J IMMUNOL, V42, P3126, DOI 10.1002/eji.201242683; Vos J, 2009, GENET MED, V11, P742, DOI 10.1097/GIM.0b013e3181b2e608; Vreeswijk MPG, 2009, HUM MUTAT, V30, P107, DOI 10.1002/humu.20811; Wada T, 2008, CURR OPIN ALLERGY CL, V8, P510, DOI 10.1097/ACI.0b013e328314b651; Wang HY, 2010, HUM MUTAT, V31, P1080, DOI 10.1002/humu.21322; Watkin LB, 2015, NAT GENET, V47, P654, DOI 10.1038/ng.3279; Wortmann SB, 2015, J INHERIT METAB DIS, V38, P437, DOI 10.1007/s10545-015-9823-y; Wu N, 2015, NEW ENGL J MED, V372, P341, DOI 10.1056/NEJMoa1406829; Yamada M, 2012, GENE, V497, P110, DOI 10.1016/j.gene.2012.01.019; Yang YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/jama.2014.14601; Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555; Yee CS, 2016, J ALLERGY CLIN IMMUN, V137, P879, DOI 10.1016/j.jaci.2015.08.020; Zarrei M, 2015, NAT REV GENET, V16, P172, DOI 10.1038/nrg3871; Zhang F, 2015, HUM MOL GENET, V24, pR102, DOI 10.1093/hmg/ddv259; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	170	33	33	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					46	69		10.1016/j.jaci.2019.09.009	http://dx.doi.org/10.1016/j.jaci.2019.09.009			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31568798	Bronze			2022-12-18	WOS:000505590800006
J	Gevaert, E; Delemarre, T; De Volder, J; Zhang, N; Holtappels, G; De Ruyck, N; Persson, E; Heyndrickx, I; Verstraete, K; Aegerter, H; Nauwynck, H; Savvides, SN; Lambrecht, BN; Bachert, C				Gevaert, Elien; Delemarre, Tim; De Volder, Joyceline; Zhang, Nan; Holtappels, Gabriele; De Ruyck, Natalie; Persson, Emma; Heyndrickx, Ines; Verstraete, Kenneth; Aegerter, Helena; Nauwynck, Hans; Savvides, Savvas N.; Lambrecht, Bart N.; Bachert, Claus			Charcot-Leyden crystals promote neutrophilic inflammation in patients with nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EXTRACELLULAR TRAPS		[Gevaert, Elien; Delemarre, Tim; De Volder, Joyceline; Zhang, Nan; Holtappels, Gabriele; De Ruyck, Natalie; Bachert, Claus] Univ Ghent, Fac Med, Upper Airways Res Lab, Ghent, Belgium; [Persson, Emma; Heyndrickx, Ines; Aegerter, Helena; Lambrecht, Bart N.] Univ Ghent, Dept Internal Med & Pediat, Fac Vet Med, Ghent, Belgium; [Verstraete, Kenneth; Savvides, Savvas N.] Univ Ghent, Dept Biochem & Microbiol, Fac Vet Med, Ghent, Belgium; [Nauwynck, Hans] Univ Ghent, Fac Vet Med, Virol Lab, Ghent, Belgium; [Lambrecht, Bart N.] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands; [Bachert, Claus] Karolinska Inst, Div ENT Dis, CLINTEC, Stockholm, Sweden	Ghent University; Ghent University; Ghent University; Ghent University; Erasmus University Rotterdam; Erasmus MC; Karolinska Institutet	Bachert, C (corresponding author), Univ Ghent, Fac Med, Upper Airways Res Lab, Ghent, Belgium.; Bachert, C (corresponding author), Karolinska Inst, Div ENT Dis, CLINTEC, Stockholm, Sweden.	Claus.Bachert@ugent.be	Bachert, Claus/J-8825-2012; Lambrecht, Bart N/K-2484-2014	Lambrecht, Bart N/0000-0003-4376-6834; Gevaert, Elien/0000-0002-0992-3085; Heyndrickx, Ines/0000-0001-8091-6390; Nauwynck, Hans/0000-0001-5470-0713	FWO [FWO/PDO/108, FWO-12A5517N]; Ghent University [BOF/DOC2017005501]; FWO Flanders [1515516N]; Interuniversity Attraction Poles Grant [P7/30]; ERC Advanced grant; Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO Flanders) under EOS project [GOG2318N]; Concerted Research Action (GOA) grant from Ghent University; VIB; Swedish Research Council [2014-6852]; Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO Flanders) [FWO/OPR2017004401]	FWO(FWO); Ghent University(Ghent University); FWO Flanders(FWO); Interuniversity Attraction Poles Grant; ERC Advanced grant(European Research Council (ERC)); Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO Flanders) under EOS project(FWO); Concerted Research Action (GOA) grant from Ghent University; VIB; Swedish Research Council(Swedish Research CouncilEuropean Commission); Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO Flanders)(FWO)	E.G and K.V. were supported by a postdoctoral research fellowship from the FWO (FWO/PDO/108 and FWO-12A5517N). I.H. was supported by a predoctoral grant from Ghent University (BOF/DOC2017005501). C.B. and E.G. were supported by grants from FWO Flanders (1515516N) and the Interuniversity Attraction Poles Grant P7/30. B.N.L. is supported by an ERC Advanced grant. This work was supported by Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO Flanders) under EOS project no. GOG2318N and grant FWO/OPR2017004401 (to B.N.L.), and by a Concerted Research Action (GOA) grant from Ghent University (to B.N.L. and S.N.S.), and the VIB. E.P. was supported by a grant from the Swedish Research Council (2014-6852).	Branzk N, 2014, NAT IMMUNOL, V15, P1017, DOI 10.1038/ni.2987; Charcot CR, 1853, C R MEM SOC BIOL, V5; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Persson EK, 2019, SCIENCE, V364, P751, DOI 10.1126/science.aaw4295; Rodriguez-Alcazar JF, 2019, J IMMUNOL, V202, P550, DOI 10.4049/jimmunol.1800107; Sil P, 2017, INFLAMM RES, V66, P227, DOI 10.1007/s00011-016-1008-0; Ueki S, 2018, BLOOD, V132, P2183, DOI 10.1182/blood-2018-04-842260	8	33	34	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					427	430		10.1016/j.jaci.2019.08.027	http://dx.doi.org/10.1016/j.jaci.2019.08.027			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31493418				2022-12-18	WOS:000505590800045
J	Sereni, L; Castiello, MC; Di Silvestre, D; Della Valle, P; Brombin, C; Ferrua, F; Cicalese, MP; Pozzi, L; Migliavacca, M; Bernardo, ME; Pignata, C; Farah, R; Notarangelo, LD; Marcus, N; Cattaneo, L; Spinelli, M; Giannelli, S; Bosticardo, M; van Rossem, K; D'Angelo, A; Aiuti, A; Mauri, P; Villa, A				Sereni, Lucia; Castiello, Maria Carmina; Di Silvestre, Dario; Della Valle, Patrizia; Brombin, Chiara; Ferrua, Francesca; Cicalese, Maria Pia; Pozzi, Loris; Migliavacca, Maddalena; Bernardo, Maria Ester; Pignata, Claudio; Farah, Roula; Notarangelo, Lucia Dora; Marcus, Nufar; Cattaneo, Lorella; Spinelli, Marco; Giannelli, Stefania; Bosticardo, Marita; van Rossem, Koen; D'Angelo, Armando; Aiuti, Alessandro; Mauri, Pierluigi; Villa, Anna			Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wiskott-Aldrich syndrome; X-linked thrombocytopenia; gene therapy; platelets	X-LINKED THROMBOCYTOPENIA; ACTIVATED PLATELETS; CD40 LIGAND; CELL TRANSPLANTATION; SYNDROME PROTEIN; MUTATIONS; CLEARANCE; SPLENECTOMY; NEUTROPHILS; EXPRESSION	Background: Thrombocytopenia is a serious issue for all patients with classical Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT) because it causes severe and life-threatening bleeding. Lentiviral gene therapy (GT) for WAS has shown promising results in terms of immune reconstitution. However, despite the reduced severity and frequency of bleeding events, platelet counts remain low in GT-treated patients. Objective: We carefully investigated platelet defects in terms of phenotype and function in untreated patients with WAS and assessed the effect of GT treatment on platelet dysfunction. Methods: We analyzed a cohort of 20 patients with WAS/XLT, 15 of them receiving GT. Platelet phenotype and function were analyzed by using electron microscopy, flow cytometry, and an aggregation assay. Platelet protein composition was assessed before and after GT by means of proteomic profile analysis. Results: We show that platelets from untreated patients with WAS have reduced size, abnormal ultrastructure, and a hyperactivated phenotype at steady state, whereas activation and aggregation responses to agonists are decreased. GT restores platelet size and function early after treatment and reduces the hyperactivated phenotype proportionally to WAS protein expression and length of follow-up. Conclusions: Our study highlights the coexistence of morphologic and multiple functional defects in platelets lacking WAS protein and demonstrates that GT normalizes the platelet proteomic profile with consequent restoration of platelet ultrastructure and phenotype, which might explain the observed reduction of bleeding episodes after GT. These results are instrumental also from the perspective of a future clinical trial in patients with XLT only presenting with microthrombocytopenia.	[Sereni, Lucia; Castiello, Maria Carmina; Ferrua, Francesca; Cicalese, Maria Pia; Migliavacca, Maddalena; Bernardo, Maria Ester; Giannelli, Stefania; Bosticardo, Marita; Aiuti, Alessandro; Villa, Anna] IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy SR Tiget, Div Regenerat Med Stem Cells & Gene Therapy, Milan, Italy; [Della Valle, Patrizia; Pozzi, Loris; D'Angelo, Armando] IRCCS San Raffaele Sci Inst, Coagulat Serv, Milan, Italy; [Della Valle, Patrizia; Pozzi, Loris; D'Angelo, Armando] IRCCS San Raffaele Sci Inst, Thrombosis Res Unit, Milan, Italy; [Ferrua, Francesca; Cicalese, Maria Pia; Migliavacca, Maddalena; Bernardo, Maria Ester; Aiuti, Alessandro] IRCCS San Raffaele Sci Inst, Pediat Immunohematol Unit, Milan, Italy; [Di Silvestre, Dario; Mauri, Pierluigi] CNR, ITB, Natl Res Council, Prote & Metabol Lab,Inst Biomed Technol, Segrate, Italy; [Brombin, Chiara] Univ Vita Salute San Raffaele, Univ Ctr Stat Biomed Sci CUSSB, Milan, Italy; [Ferrua, Francesca; Aiuti, Alessandro] Univ Vita Salute San Raffaele, Milan, Italy; [Pignata, Claudio] Univ Naples Federico II, Dept Translat Med Sci, Pediat Sect, Naples, Italy; [Farah, Roula] St George Hosp Univ Med Ctr, Dept Pediat, Div Hematol Oncol, Beirut, Lebanon; [Notarangelo, Lucia Dora] Childrens Hosp, ASST Spedali Civili Brescia, Pediat Oncohaematol & BMT Unit, Brescia, Italy; [Marcus, Nufar] Schneider Childrens Med Ctr Israel, Dept Pediat, Petah Tiqwa, Israel; [Marcus, Nufar] Schneider Childrens Med Ctr Israel, Kipper Inst Immunol, Petah Tiqwa, Israel; [Marcus, Nufar] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Cattaneo, Lorella] Osped Infantile C Arrigo, SC Pediat, Alessandria, Italy; [Spinelli, Marco] MBBM Fdn, Maria Letizia Verga Ctr, Pediat Clin, Monza, Italy; [van Rossem, Koen] GlaxoSmithKline, Rare Dis Unit, Brentford, England; [Villa, Anna] CNR, Ist Ric Genet & Biomed, Milan Unit, Milan, Italy; [Bosticardo, Marita] Natl Inst Allergy & Infect Dis, Lab Clin Immunol & Microbiol, IDGS, Div Intramural Res,NIH,Dept Hlth & Human Serv, Bethesda, MD USA	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; University of Naples Federico II; American University of Beirut; Hospital Spedali Civili Brescia; Tel Aviv University; Sackler Faculty of Medicine; GlaxoSmithKline; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Villa, A (corresponding author), IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy SR Tiget, Div Regenerat Med Stem Cells & Gene Therapy, Milan, Italy.	villa.anna@hst.it	Brombin, Chiara/AAB-9926-2019; FARAH, Roula/AAL-8893-2021; Bosticardo, Marita/ABA-2688-2021; Ferrua, Francesca/K-4340-2016; D'Angelo, Armando/K-2583-2018; Giannelli, Stefania/AAR-2316-2020; di silvestre, dario/AAB-5037-2022; Castiello, Maria Carmina/K-9767-2016; Valle, Patrizia Della/AAA-4089-2019; Mauri, Pietro Luigi/AAC-3095-2019	Brombin, Chiara/0000-0002-8215-6206; FARAH, Roula/0000-0002-6392-1590; Bosticardo, Marita/0000-0002-1771-4523; Ferrua, Francesca/0000-0002-5695-4490; D'Angelo, Armando/0000-0002-9857-4509; di silvestre, dario/0000-0002-7143-6229; Castiello, Maria Carmina/0000-0003-2581-9648; Valle, Patrizia Della/0000-0002-2790-3088; Mauri, Pietro Luigi/0000-0003-4364-0393; Pozzi, Loris/0000-0003-3861-3470; SERENI, LUCIA/0000-0002-8234-3490	Fondazione Telethon; GlaxoSmithKline; Italian CNR InterOmics Project; National Program of CNR Aging Project; Regione Lombardia; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001222] Funding Source: NIH RePORTER	Fondazione Telethon(Fondazione TelethonEuropean Commission); GlaxoSmithKline(GlaxoSmithKline); Italian CNR InterOmics Project; National Program of CNR Aging Project; Regione Lombardia(Regione Lombardia); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was mainly supported by Fondazione Telethon (SR-Tiget core grant, to A.V. and A.A.) and GlaxoSmithKline (A.V.), by the Italian CNR InterOmics Project and Amanda Project by Regione Lombardia (to P.M.), and partially by National Program of CNR Aging Project (to A.V.).	Abina SHB, 2015, JAMA-J AM MED ASSOC, V313, P1550, DOI 10.1001/jama.2015.3253; Recalde MJA, 2017, TOXINS, V9, DOI 10.3390/toxins9110331; Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151; Albert MH, 2010, BLOOD, V115, P3231, DOI 10.1182/blood-2009-09-239087; ALDRICH RA, 1954, PEDIATRICS, V13, P133; Aloui C, 2014, INT J MOL SCI, V15, P22342, DOI 10.3390/ijms151222342; Arkwright PD, 2002, BLOOD, V99, P2694, DOI 10.1182/blood.V99.8.2694; Astrakhan A, 2012, BLOOD, V119, P4395, DOI 10.1182/blood-2011-03-340711; Bennett JS, 2005, J CLIN INVEST, V115, P3363, DOI 10.1172/JCI26989; Boilard E, 2017, KELLEY FIRESTEINS TX; Carestia A, 2016, J LEUKOCYTE BIOL, V99, P153, DOI 10.1189/jlb.3A0415-161R; Castiello MC, 2014, J AUTOIMMUN, V50, P42, DOI 10.1016/j.jaut.2013.10.006; Danese S, 2003, GUT, V52, P1435, DOI 10.1136/gut.52.10.1435; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Elfeky RA, 2018, J ALLERGY CLIN IMMUN, V142, P1654, DOI 10.1016/j.jaci.2018.06.042; Fang WF, 2010, CARCINOGENESIS, V31, P1360, DOI 10.1093/carcin/bgq114; Gabelli M, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26692; Galy A, 2011, CURR OPIN ALLERGY CL, V11, P545, DOI 10.1097/ACI.0b013e32834c230c; Gerrits AJ, 2015, BLOOD, V126, P1367, DOI 10.1182/blood-2014-09-602573; Grgurevich S, 2003, J THROMB HAEMOST, V1, P576, DOI 10.1046/j.1538-7836.2003.00087.x; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Imai K, 2004, BLOOD, V103, P456, DOI 10.1182/blood-2003-05-1480; Joo SJ, 2012, KOREAN CIRC J, V42, P295, DOI 10.4070/kcj.2012.42.5.295; Klinger MHF, 2002, J INTERF CYTOK RES, V22, P913, DOI 10.1089/10799900260286623; Krotz F, 2004, ARTERIOSCL THROM VAS, V24, P1988, DOI 10.1161/01.ATV.0000145574.90840.7d; Litzman J, 1996, ARCH DIS CHILD, V75, P436, DOI 10.1136/adc.75.5.436; Mahlaoui N, 2013, BLOOD, V121, P1510, DOI 10.1182/blood-2012-08-448118; Manfredi AA, 2010, CURR OPIN HEMATOL, V17, P3, DOI 10.1097/MOH.0b013e3283324f97; Mantovani A, 2013, NAT IMMUNOL, V14, P768, DOI 10.1038/ni.2666; Maugeri N, 2011, BLOOD, V118, P3359, DOI 10.1182/blood-2011-02-337337; Maugeri N, 2009, BLOOD, V113, P5254, DOI 10.1182/blood-2008-09-180794; Moal V, 2003, NEPHROL DIAL TRANSPL, V18, P1834, DOI 10.1093/ndt/gfg185; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182/blood-2010-11-319376; MULLEN CA, 1993, BLOOD, V82, P2961; Neumuller J, 2015, TRANSMISSION ELECT M; Nording H, 2018, SEMIN IMMUNOL, V37, P43, DOI 10.1016/j.smim.2018.01.003; Notarangelo LD, 2002, BLOOD, V99, P2268, DOI 10.1182/blood.V99.6.2268; Ochs HD, 2009, BIOL BLOOD MARROW TR, V15, P84, DOI 10.1016/j.bbmt.2008.10.007; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Ochs HD, 2002, ISR MED ASSOC J, V4, P379; Oshima K, 2015, J CLIN IMMUNOL, V35, P15, DOI 10.1007/s10875-014-0105-5; Pawlinski R, 2016, BLOOD, V128, P2376, DOI 10.1182/blood-2016-09-738740; Rivers E, 2019, J ALLER CL IMM-PRACT, V7, P1042, DOI 10.1016/j.jaip.2018.07.009; Semple JW, 1997, BRIT J HAEMATOL, V97, P747, DOI 10.1046/j.1365-2141.1997.1132938.x; Sereni L, 2018, J ALLERGY CLIN IMMUN, V142, P1272, DOI 10.1016/j.jaci.2017.12.1000; Sereni L, 2018, J LEUKOCYTE BIOL, V103, P577, DOI 10.1189/jlb.5MR0617-257R; Shcherbina A, 1999, BRIT J HAEMATOL, V106, P875, DOI 10.1046/j.1365-2141.1999.01637.x; Shcherbina A, 2010, BRIT J HAEMATOL, V148, P416, DOI 10.1111/j.1365-2141.2009.07959.x; Shin CR, 2012, BONE MARROW TRANSPL, V47, P1428, DOI 10.1038/bmt.2012.31; Solanilla A, 2005, BLOOD, V105, P215, DOI 10.1182/blood-2003-07-2367; Sowa JM, 2009, ARCH IMMUNOL THER EX, V57, P235, DOI 10.1007/s00005-009-0032-y; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Vella D, 2017, EURASIP J BIOINFORM, DOI 10.1186/s13637-017-0059-z; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; WISKOTT A, 1937, MONATSSCHR KINDERH, V68, P212; Yang XY, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0348-3; Yin H, 2008, BLOOD, V112, P1139, DOI 10.1182/blood-2008-02-140970; Zhou Z, 2013, CIRCULATION, V127, P476, DOI 10.1161/CIRCULATIONAHA.112.132126	58	33	35	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					825	838		10.1016/j.jaci.2019.03.012	http://dx.doi.org/10.1016/j.jaci.2019.03.012			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	30926529	Green Published, hybrid			2022-12-18	WOS:000485222300026
J	Schofield, JPR; Burg, D; Nicholas, B; Strazzeri, F; Brandsma, J; Staykova, D; Folisi, C; Bansal, AT; Xian, Y; Guo, YK; Rowe, A; Corfield, J; Wilson, S; Ward, J; Lutter, R; Shaw, DE; Bakke, PS; Caruso, M; Dahlen, SE; Fowler, SJ; Horvath, I; Howarth, P; Krug, N; Montuschi, P; Sanak, M; Sandstrom, T; Sun, K; Pandis, I; Riley, J; Auffray, C; De Meulder, B; Lefaudeux, D; Sousa, AR; Adcock, IM; Chung, KF; Sterk, PJ; Skipp, PJ; Djukanovic, R; Ahmed, H; Allen, D; Badorrek, P; Ballereau, S; Baribaud, F; Batuwitage, MK; Bedding, A; Behndig, AF; Berglind, A; Berton, A; Bigler, J; Boedigheimer, MJ; Bonnelykke, K; Brinkman, P; Bush, A; Campagna, D; Casaulta, C; Chaiboonchoe, A; Davison, T; De Meulder, B; Delin, I; Dennison, P; Dodson, P; El Hadjam, L; Erzen, D; Faulenbach, C; Fichtner, K; Fitch, N; Formaggio, E; Gahlemann, M; Galffy, G; Garissi, D; Garret, T; Gent, J; Guillmant-Farry, E; Henriksson, E; Hoda, U; Hohlfeld, JM; Hu, X; James, A; Johnson, K; Jullian, N; Kerry, G; Kluglich, M; Knowles, R; Konradsen, JR; Kretsos, K; Krueger, L; Lantz, AS; Larminie, C; Latzin, P; Lefaudeux, D; Lemonnier, N; Lowe, LA; Lutter, R; Manta, A; Mazein, A; McEvoy, L; Menzies-Gow, A; Mores, N; Murray, CS; Nething, K; Nihlen, U; Niven, R; Nordlund, B; Nsubuga, S; Pellet, J; Pison, C; Pratico, G; Valls, MP; Riemann, K; Rocha, JP; Rossios, C; Santini, G; Saqi, M; Scott, S; Sehgal, N; Selby, A; Soderman, P; Sogbesan, A; Spycher, F; Stephan, S; Stokholm, J; Sunther, M; Szentkereszty, M; Tamasi, L; Tariq, K; Valente, S; van Aalderen, WM; van Drunen, CM; Van Eyll, J; Vyas, A; Yu, W; Zetterquist, W; Zolkipli, Z; Zwinderman, AH; Adriaens, N; Aliprantis, A; Alving, K; Bakke, P; Balgoma, D; Barber, C; Baribaud, F; Bates, S; Bautmans, A; Beleta, J; Bochenek, G; Brandsma, J; Braun, A; Burg, D; Carayannopoulos, L; Rocha, JPCD; Chaleckis, R; D'Amico, A; De Alba, J; De Lepeleire, I; Dekker, T; Dijkhuis, A; Draper, A; Edwards, J; Emma, R; Ericsson, M; Flood, B; Gallart, H; Gomez, C; Gove, K; Gozzard, N; Haughney, J; Hewitt, L; Hohlfeld, J; Holweg, C; Hu, R; Hu, SL; Kamphuis, J; Kennington, EJ; Kerry, D; Knobel, H; Kolmert, J; Kots, M; Kuo, S; Kupczyk, M; Lambrecht, B; Lone-Latif, S; Loza, MJ; Marouzet, L; Martin, J; Masefield, S; Mathon, C; Meah, S; Meiser, A; Metcalf, L; Mikus, M; Miralpeix, M; Monk, P; Naz, S; Nicholas, B; Nilsson, P; Ostling, J; Pacino, A; Palkonen, S; Pavlidis, S; Pennazza, G; Petren, A; Pink, S; Postle, A; Powell, P; Rahman-Amin, M; Rao, N; Ravanetti, L; Ray, E; Reinke, S; Reynolds, L; Riley, J; Robberechts, M; Roberts, A; Russell, K; Rutgers, M; Santoninco, M; Schoelch, C; Schofield, JPR; Sjodin, M; Skipp, PJ; Smids, B; Smith, C; Smith, J; Smith, KM; Staykova, D; Sun, K; Thorngren, JO; Thornton, B; Thorsen, J; van de Pol, M; van Geest, M; Versnel, J; Vink, A; Wald, F; Walker, S; Ward, J; Weiszhart, Z; Wetzel, K; Wheelock, CE; Wiegman, C; Williams, S; Wilson, SJ; Woodcock, A; Yang, X; Yeyasingham, E; Prins, JB; Gahlemann, M; Visintin, L; Evans, H; Puhl, M; Buzermaniene, L; Hudson, V; Bond, L; de Boer, P; Widdershoven, G; Sigmund, R; Roberts, A; Supple, D; Hamerlijnck, D; Negus, J; Kamphuis, J; Sergison, L; Visintin, L; de Boer, P; Onstein, S; MacNee, W; Bernardini, R; Bont, L; Wecksell, PA; de Boer, P; Gahlemann, M; Sigmund, R				Schofield, James P. R.; Burg, Dominic; Nicholas, Ben; Strazzeri, Fabio; Brandsma, Joost; Staykova, Doroteya; Folisi, Caterina; Bansal, Aruna T.; Xian, Yang; Guo, Yike; Rowe, Anthony; Corfield, Julie; Wilson, Susan; Ward, Jonathan; Lutter, Rene; Shaw, Dominick E.; Bakke, Per S.; Caruso, Massimo; Dahlen, Sven-Erik; Fowler, Stephen J.; Horvath, Ildiko; Howarth, Peter; Krug, Norbert; Montuschi, Paolo; Sanak, Marek; Sandstrom, Thomas; Sun, Kai; Pandis, Ioannis; Riley, John; Auffray, Charles; De Meulder, Bertrand; Lefaudeux, Diane; Sousa, Ana R.; Adcock, Ian M.; Chung, Kian Fan; Sterk, Peter J.; Skipp, Paul J.; Djukanovic, Ratko; Ahmed, H.; Allen, D.; Badorrek, P.; Ballereau, S.; Baribaud, F.; Batuwitage, M. K.; Bedding, A.; Behndig, A. F.; Berglind, A.; Berton, A.; Bigler, J.; Boedigheimer, M. J.; Bonnelykke, K.; Brinkman, P.; Bush, A.; Campagna, D.; Casaulta, C.; Chaiboonchoe, A.; Davison, T.; De Meulder, B.; Delin, I.; Dennison, P.; Dodson, P.; El Hadjam, L.; Erzen, D.; Faulenbach, C.; Fichtner, K.; Fitch, N.; Formaggio, E.; Gahlemann, M.; Galffy, G.; Garissi, D.; Garret, T.; Gent, J.; Guillmant-Farry, E.; Henriksson, E.; Hoda, U.; Hohlfeld, J. M.; Hu, X.; James, A.; Johnson, K.; Jullian, N.; Kerry, G.; Klueglich, M.; Knowles, R.; Konradsen, J. R.; Kretsos, K.; Krueger, L.; Lantz, A. -S.; Larminie, C.; Latzin, P.; Lefaudeux, D.; Lemonnier, N.; Lowe, L. A.; Lutter, R.; Manta, A.; Mazein, A.; McEvoy, L.; Menzies-Gow, A.; Mores, N.; Murray, C. S.; Nething, K.; Nihlen, U.; Niven, R.; Nordlund, B.; Nsubuga, S.; Pellet, J.; Pison, C.; Pratico, G.; Puig Valls, M.; Riemann, K.; Rocha, J. P.; Rossios, C.; Santini, G.; Saqi, M.; Scott, S.; Sehgal, N.; Selby, A.; Soderman, P.; Sogbesan, A.; Spycher, F.; Stephan, S.; Stokholm, J.; Sunther, M.; Szentkereszty, M.; Tamasi, L.; Tariq, K.; Valente, S.; van Aalderen, W. M.; van Drunen, C. M.; Van Eyll, J.; Vyas, A.; Yu, W.; Zetterquist, W.; Zolkipli, Z.; Zwinderman, A. H.; Adriaens, Nora; Aliprantis, Antonios; Alving, Kjell; Bakke, Per; Balgoma, David; Barber, Clair; Baribaud, Frederic; Bates, Stewart; Bautmans, An; Beleta, Jorge; Bochenek, Grazyna; Brandsma, Joost; Braun, Armin; Burg, Dominic; Carayannopoulos, Leon; Rocha, Joao Pedro Carvalho da Purificacao; Chaleckis, Romanas; D'Amico, Arnaldo; De Alba, Jorge; De Lepeleire, Inge; Dekker, Tamara; Dijkhuis, Annemiek; Draper, Aleksandra; Edwards, Jessica; Emma, Rosalia; Ericsson, Magnus; Flood, Breda; Gallart, Hector; Gomez, Cristina; Gove, Kerry; Gozzard, Neil; Haughney, John; Hewitt, Lorraine; Hohlfeld, Jens; Holweg, Cecile; Hu, Richard; Hu, Sile; Kamphuis, Juliette; Kennington, Erika J.; Kerry, Dyson; Knobel, Hugo; Kolmert, Johan; Kots, Maxim; Kuo, Scott; Kupczyk, Maciej; Lambrecht, Bart; Lone-Latif, Saeeda; Loza, Matthew J.; Marouzet, Lisa; Martin, Jane; Masefield, Sarah; Mathon, Caroline; Meah, Sally; Meiser, Andrea; Metcalf, Leanne; Mikus, Maria; Miralpeix, Montse; Monk, Philip; Naz, Shama; Nicholas, Ben; Nilsson, Peter; Ostling, Jorgen; Pacino, Antonio; Palkonen, Susanna; Pavlidis, Stelios; Pennazza, Giorgio; Petren, Anne; Pink, Sandy; Postle, Anthony; Powell, Pippa; Rahman-Amin, Malayka; Rao, Navin; Ravanetti, Lara; Ray, Emma; Reinke, Stacey; Reynolds, Leanne; Riley, John; Robberechts, Martine; Roberts, Amanda; Russell, Kirsty; Rutgers, Michael; Santoninco, Marco; Schoelch, Corinna; Schofield, James P. R.; Sjodin, Marcus; Skipp, Paul J.; Smids, Barbara; Smith, Caroline; Smith, Jessica; Smith, Katherine M.; Staykova, Doroteya; Sun, Kai; Thorngren, John-Olof; Thornton, Bob; Thorsen, Jonathan; van de Pol, Marianne; van Geest, Marleen; Versnel, Jenny; Vink, Anton; Wald, Frans; Walker, Samantha; Ward, Jonathan; Weiszhart, Zsoka; Wetzel, Kristiane; Wheelock, Craig E.; Wiegman, Coen; Williams, Sian; Wilson, Susan J.; Woodcock, Ashley; Yang, Xian; Yeyasingham, Elizabeth; Prins, Jan-Bas; Gahlemann, Martina; Visintin, Luigi; Evans, Hazel; Puhl, Martine; Buzermaniene, Lina; Hudson, Val; Bond, Laura; de Boer, Pim; Widdershoven, Guy; Sigmund, Ralf; Roberts, Amanda; Supple, David; Hamerlijnck, Dominique; Negus, Jenny; Kamphuis, Julitte; Sergison, Lehanne; Visintin, Luigi; de Boer, Pim; Onstein, Susanne; MacNee, William; Bernardini, Renato; Bont, Louis; Wecksell, Per-Ake; de Boer, Pim; Gahlemann, Martina; Sigmund, Ralf		U-BIOPRED Study Grp	Stratification of asthma phenotypes by airway proteomic signatures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; proteomics; biomarkers; eosinophils; neutrophils	EXACERBATIONS; DEGRADATION; CD44	Background: Stratification by eosinophil and neutrophil counts increases our understanding of asthma and helps target therapy, but there is room for improvement in our accuracy in prediction of treatment responses and a need for better understanding of the underlying mechanisms. Objective: We sought to identify molecular subphenotypes of asthma defined by proteomic signatures for improved stratification. Methods: Unbiased label-free quantitative mass spectrometry and topological data analysis were used to analyze the proteomes of sputum supernatants from 246 participants (206 asthmatic patients) as a novel means of asthma stratification. Microarray analysis of sputum cells provided transcriptomics data additionally to inform on underlying mechanisms. Results: Analysis of the sputum proteome resulted in 10 clusters (ie, proteotypes) based on similarity in proteomic features, representing discrete molecular subphenotypes of asthma. Overlaying granulocyte counts onto the 10 clusters as metadata further defined 3 of these as highly eosinophilic, 3 as highly neutrophilic, and 2 as highly atopic with relatively low granulocytic inflammation. For each of these 3 phenotypes, logistic regression analysis identified candidate protein biomarkers, and matched transcriptomic data pointed to differentially activated underlying mechanisms. Conclusion: This study provides further stratification of asthma currently classified based on quantification of granulocytic inflammation and provided additional insight into their underlying mechanisms, which could become targets for novel therapies.	[Schofield, James P. R.; Burg, Dominic; Strazzeri, Fabio; Staykova, Doroteya; Folisi, Caterina; Skipp, Paul J.] Ctr Prote Res, Biol Sci, Southampton, Hants, England; [Schofield, James P. R.; Burg, Dominic; Nicholas, Ben; Brandsma, Joost; Wilson, Susan; Ward, Jonathan; Howarth, Peter; Djukanovic, Ratko] NIHR Southampton Biomed Res Ctr, Clin & Expt Sci, Fac Med, Southampton, Hants, England; [Strazzeri, Fabio] Univ Southampton, Math Sci, Southampton, Hants, England; [Bansal, Aruna T.] Acclarogen, Cambridge, England; [Xian, Yang; Guo, Yike; Sun, Kai; Pandis, Ioannis] Imperial Coll, Data Sci Inst, London, England; [Rowe, Anthony] Janssen Res & Dev, High Wycombe, Bucks, England; [Corfield, Julie] Areteva, Nottingham, England; [Lutter, Rene] AMC, Dept Expt Immunol, Amsterdam, Netherlands; [Lutter, Rene; Sterk, Peter J.] Univ Amsterdam, Amsterdam UMC, Amsterdam, Netherlands; [Shaw, Dominick E.] Univ Nottingham, Resp Res Unit, Nottingham, England; [Bakke, Per S.] Univ Bergen, Inst Med, Bergen, Norway; [Caruso, Massimo] Univ Catania, Univ Hosp, Dept Clin & Expt Med, Catania, Italy; [Dahlen, Sven-Erik] Karolinska Inst, Inst Environm Med, Ctr Allergy Res, Stockholm, Sweden; [Fowler, Stephen J.] Univ Manchester, Resp & Allergy Res Grp, Manchester, Lancs, England; [Horvath, Ildiko] Semmelweis Univ, Dept Pulmonol, Budapest, Hungary; [Krug, Norbert] Fraunhofer Inst Toxicol & Expt Med Hannover, Hannover, Germany; [Montuschi, Paolo] Univ Cattolica Sacro Cuore, Fac Med, Rome, Italy; [Sanak, Marek] Jagiellonian Univ, Coll Med, Lab Mol Biol & Clin Genet, Krakow, Poland; [Sandstrom, Thomas] Umea Univ, Dept Med, Umea, Sweden; [Sandstrom, Thomas] Umea Univ, Dept Publ Hlth, Umea, Sweden; [Sandstrom, Thomas] Umea Univ, Clin Med Resp Med Unit, Umea, Sweden; [Auffray, Charles; De Meulder, Bertrand; Lefaudeux, Diane] Univ Lyon, European Inst Syst Biol & Med, CNRS, ENS,UCBL,INSERM, Lyon, France; [Riley, John; Sousa, Ana R.] GlaxoSmithKline, Resp Therapeut Unit, Stockley Pk, England; [Adcock, Ian M.; Chung, Kian Fan] Imperial Coll London, Natl Heart & Lung Inst, Cell & Mol Biol Grp, Airways Dis Sect, London, England; [Ahmed, H.] Univ Lyon, European Inst Syst Biol & Med, Lyon, France; [Allen, D.] North West Severe Asthma Network, Manchester, Lancs, England; [Allen, D.] Pennine Acute Hosp NHS Trust, Manchester, Lancs, England; [Badorrek, P.] Fraunhofer ITEM, Hannover, Germany; [Ballereau, S.] Univ Lyon, European Inst Syst Biol & Med, Lyon, France; [Baribaud, F.] Janssen R&D, Beerse, Belgium; [Batuwitage, M. K.] Imperial Coll, London, England; [Bedding, A.] Roche Diagnost GmbH, Mannheim, Germany; [Behndig, A. F.] Umea Univ, Umea, Sweden; [Berglind, A.] Karolinska Univ Hosp, Stockholm, Sweden; [Berglind, A.] Karolinska Inst, Stockholm, Sweden; [Berton, A.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Bigler, J.; Boedigheimer, M. J.] Amgen Inc, Thousand Oaks, CA USA; [Bonnelykke, K.] Univ Copenhagen, Copenhagen, Denmark; [Bonnelykke, K.] Univ Copenhagen, Gentofte Hosp, Danish Pediat Asthma Ctr, Copenhagen, Denmark; [Brinkman, P.] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Bush, A.] Imperial Coll, Dept Paediat, London, England; [Bush, A.] Imperial Coll, Natl Heart & Lung Inst, London, England; [Bush, A.] Royal Brompton Hosp, Dept Resp Paediat, London, England; [Campagna, D.] Univ Catania, Catania, Italy; [Casaulta, C.] Univ Childrens Hosp Bern, Bern, Switzerland; [Chaiboonchoe, A.] Univ Lyon, European Inst Syst Biol & Med, Lyon, France; [Davison, T.] Janssen R&D, Beerse, Belgium; [De Meulder, B.] Univ Lyon, European Inst Syst Biol & Med, Lyon, France; [Delin, I.] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Dennison, P.] NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Dennison, P.] Univ Southampton, Southampton, Hants, England; [Dodson, P.] AstraZeneca, Molndal, Sweden; [El Hadjam, L.] Univ Lyon, European Inst Syst Biol & Med, Lyon, France; [Erzen, D.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Faulenbach, C.] Fraunhofer ITEM, Hannover, Germany; [Fichtner, K.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Fitch, N.] BioSci Consulting, Maasmechelen, Belgium; [Gahlemann, M.] Boehringer Ingelheim Schweiz GmbH, Basel, Switzerland; [Galffy, G.] Semmelweis Univ, Budapest, Hungary; [Garissi, D.] CROMSOURCE, Global Head Clin Res Div, Verona, Italy; [Garret, T.] BioSci Consulting, Maasmechelen, Belgium; [Gent, J.] Royal Brompton & Harefield NHS Fdn Trust, London, England; [Guillmant-Farry, E.] Royal Brompton Hosp, London, England; [Henriksson, E.] Karolinska Inst, Stockholm, Sweden; [Hoda, U.] Imperial Coll, London, England; [Hohlfeld, J. M.] Fraunhofer ITEM, Hannover, Germany; [Hu, X.] Amgen Inc, Thousand Oaks, CA USA; [James, A.] Karolinska Inst, Stockholm, Sweden; [Johnson, K.] Univ Hosp South Manchester NHS Fdn Trust, Ctr Resp Med & Allergy, Inst Inflammat & Repair, Manchester, Lancs, England; [Jullian, N.] Univ Lyon, European Inst Syst Biol & Med, Lyon, France; [Kerry, G.] Univ Hosp South Manchester NHS Fdn Trust, Ctr Resp Med & Allergy, Inst Inflammat & Repair, Manchester, Lancs, England; [Klueglich, M.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Knowles, R.] Arachos Pharma, Stevenage, Herts, England; [Konradsen, J. R.] Karolinska Univ Hosp, Stockholm, Sweden; [Konradsen, J. R.] Karolinska Inst, Stockholm, Sweden; [Kretsos, K.] UCB, Slough, Berks, England; [Krueger, L.] Univ Childrens Hosp Bern, Bern, Switzerland; [Lantz, A. -S.] Karolinska Univ Hosp, Stockholm, Sweden; [Lantz, A. -S.] Karolinska Inst, Stockholm, Sweden; [Larminie, C.] GSK, London, England; [Latzin, P.] Univ Childrens Hosp Bern, Bern, Switzerland; [Lefaudeux, D.; Lemonnier, N.] Univ Lyon, European Inst Syst Biol & Med, Lyon, France; [Lowe, L. A.] Univ Hosp South Manchester NHS Fdn Trust, Ctr Resp Med & Allergy, Inst Inflammat & Repair, Manchester, Lancs, England; [Lutter, R.] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Manta, A.] Roche Diagnost GmbH, Mannheim, Germany; [Mazein, A.] Univ Lyon, European Inst Syst Biol & Med, Lyon, France; [McEvoy, L.] Univ Hosp, Dept Pulm Med, Bern, Switzerland; [Menzies-Gow, A.] Royal Brompton & Harefield NHS Fdn Trust, Harefield, Middx, England; [Mores, N.] Univ Cattolica Sacro Cuore, Rome, Italy; [Murray, C. S.] Univ Manchester, Univ Hosp South Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Ctr Resp Med & Allergy, Manchester, Lancs, England; [Nething, K.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Nihlen, U.] Skane Univ Hosp, Dept Resp Med & Allergol, Lund, Sweden; [Nihlen, U.] AstraZeneca R&D, Molndal, Sweden; [Niven, R.] Univ Hosp South Manchester NHS Trust, North West Severe Asthma Network, Manchester, Lancs, England; [Nordlund, B.] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Nordlund, B.] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Nsubuga, S.] Royal Brompton Hosp, London, England; [Pellet, J.; Pison, C.] Univ Lyon, European Inst Syst Biol & Med, Lyon, France; [Pratico, G.] CROMSOURCE, Verona, Italy; [Puig Valls, M.] CROMSOURCE, Barcelona, Spain; [Riemann, K.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Rocha, J. P.] Royal Brompton & Harefield NHS Fdn Trust, Harefield, Middx, England; [Rossios, C.] Imperial Coll, London, England; [Santini, G.] Univ Cattolica Sacro Cuore, Rome, Italy; [Saqi, M.] Univ Lyon, European Inst Syst Biol & Med, Lyon, France; [Scott, S.; Sehgal, N.] North West Severe Asthma Network, Manchester, Lancs, England; [Scott, S.] Countess Chester NHS Trust, Chester, Cheshire, England; [Sehgal, N.] Pennine Acute Hosp NHS Trust, Manchester, Lancs, England; [Selby, A.] NIHR Southampton Resp Biomed Res Unit, Clin & Expt Sci & Human Dev & Hlth, Southampton, Hants, England; [Soderman, P.] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Soderman, P.] Dept Womens & Childrens Hlth, Stockholm, Sweden; [Sogbesan, A.] Royal Brompton & Harefield NHS Fdn Trust, Harefield, Middx, England; [Spycher, F.] Univ Hosp, Dept Pulm Med, Bern, Switzerland; [Stephan, S.] Univ Hosp South Manchester NHS Fdn Trust, Inst Inflammat & repair, Ctr Resp Med & Allergy, Manchester, Lancs, England; [Stokholm, J.] Univ Copenhagen, Copenhagen, Denmark; [Stokholm, J.] Univ Copenhagen, Gentofte Hosp, Danish Pediat Asthma Ctr, Copenhagen, Denmark; [Sunther, M.] Univ Hosp South Manchester NHS Fdn Trust, Inst Inflammat & Repair, Ctr Resp Med & Allergy, Manchester, Lancs, England; [Szentkereszty, M.; Tamasi, L.] Semmelweis Univ, Budapest, Hungary; [Tariq, K.] NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Tariq, K.] Univ Southampton, Southampton, Hants, England; [Valente, S.] Univ Cattolica Sacro Cuore, Rome, Italy; [van Aalderen, W. M.; van Drunen, C. M.] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Van Eyll, J.] UCB, Slough, Berks, England; [Vyas, A.] North West Severe Asthma Network, Manchester, Lancs, England; [Vyas, A.] Lancashire Teaching Hosp NHS Trust, Manchester, Lancs, England; [Yu, W.] Amgen Inc, Thousand Oaks, CA USA; [Zetterquist, W.] Karolinska Inst, Dept Woman & Child Hlth, Stockholm, Sweden; [Zolkipli, Z.] Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Zolkipli, Z.] Univ Southampton, Fac Med, Clin & Expt Sci & Human Dev Hlth Acad Unit, Southampton, Hants, England; [Zolkipli, Z.] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Wight, England; [Zwinderman, A. H.; Adriaens, Nora] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Aliprantis, Antonios] Merck Res Labs, Boston, MA USA; [Alving, Kjell] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden; [Bakke, Per] Univ Bergen, Dept Clin Sci, Bergen, Norway; [Balgoma, David] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Barber, Clair] NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Baribaud, Frederic] Janssen R&D, Beerse, Belgium; [Bates, Stewart] GSK, Resp Therapeut Unit, London, England; [Bautmans, An] MSD, Brussels, Belgium; [Beleta, Jorge] Almirall SA, Barcelona, Spain; [Bochenek, Grazyna] Jagiellonian Univ, Coll Med, Dept Internal Med 2, Krakow, Poland; [Brandsma, Joost] Univ Southampton, Southampton, Hants, England; [Braun, Armin] Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany; [Burg, Dominic] Univ Southampton, Ctr Prote Res, Inst Life Sci, Southampton, Hants, England; [Carayannopoulos, Leon] MSD, Brussels, Belgium; [Rocha, Joao Pedro Carvalho da Purificacao] Royal Brompton & Harefield NHS Fdn Trust, London, England; [Chaleckis, Romanas] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [D'Amico, Arnaldo] Univ Roma Tor Vergata, Rome, Italy; [De Alba, Jorge] Almirall SA, Barcelona, Spain; [De Lepeleire, Inge] MSD, Brussels, Belgium; [Dekker, Tamara; Dijkhuis, Annemiek] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Draper, Aleksandra] BioSci Consulting, Maasmechelen, Belgium; [Edwards, Jessica] Asthma UK, London, England; [Emma, Rosalia] Univ Catania, Dept Clin & Expt Med, Catania, Italy; [Ericsson, Magnus] Karolinska Univ Hosp, Stockholm, Sweden; [Flood, Breda] European Federat Allergy & Airways Dis Patients A, Brussels, Belgium; [Gallart, Hector] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Gomez, Cristina] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Gove, Kerry] NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Gozzard, Neil] UCB, Slough, Berks, England; [Haughney, John] Int Primary Care Resp Grp, Aberdeen, Scotland; [Hewitt, Lorraine] NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Hohlfeld, Jens] Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany; [Holweg, Cecile] Genentech Inc, Resp & Allergy Dis, San Francisco, CA USA; [Hu, Richard] Amgen Inc, Thousand Oaks, CA USA; [Hu, Sile] Imperial Coll, Natl Heart & Lung Inst, London, England; [Kamphuis, Juliette] Longfonds, Amersfoort, Netherlands; [Kennington, Erika J.] Asthma UK, London, England; [Kerry, Dyson] CromSource, Stirling, Scotland; [Knobel, Hugo] Philips Res Labs, Eindhoven, Netherlands; [Kolmert, Johan] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Kots, Maxim] Chiesi Pharmaceut SPA, Parma, Italy; [Kuo, Scott] Imperial Coll, Natl Heart & Lung Inst, London, England; [Kupczyk, Maciej] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Lambrecht, Bart] Univ Ghent, Ghent, Belgium; [Lone-Latif, Saeeda] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Loza, Matthew J.] Janssen R&D, Beerse, Belgium; [Marouzet, Lisa; Martin, Jane] NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Masefield, Sarah] European Lung Fdn, Sheffield, S Yorkshire, England; [Mathon, Caroline] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Meah, Sally] Imperial Coll, Natl Heart & Lung Inst, London, England; [Meiser, Andrea] Imperial Coll, Data Sci Inst, London, England; [Metcalf, Leanne] Asthma UK, London, England; [Mikus, Maria] Sci Life Lab, Stockholm, Sweden; [Mikus, Maria] Royal Inst Technol, Stockholm, Sweden; [Miralpeix, Montse] Almirall, Barcelona, Spain; [Monk, Philip] Synairgen Res, Southampton, Hants, England; [Naz, Shama] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Nicholas, Ben] Univ Southampton, Southampton, Hants, England; [Nilsson, Peter] Sci Life Lab, Stockholm, Sweden; [Nilsson, Peter] Royal Inst Technol, Stockholm, Sweden; [Ostling, Jorgen] AstraZeneca, Molndal, Sweden; [Pacino, Antonio] Lega Italiano Anti Fumo, Catania, Italy; [Palkonen, Susanna] European Federat Allergy & Airways Dis Patients A, Brussels, Belgium; [Pavlidis, Stelios] Imperial Coll, Natl Heart & Lung Inst, London, England; [Pennazza, Giorgio] Univ Roma Tor Vergata, Rome, Italy; [Petren, Anne] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Pink, Sandy] NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Postle, Anthony] Univ Southampton, Southampton, Hants, England; [Powell, Pippa] European Lung Fdn, Sheffield, S Yorkshire, England; [Rahman-Amin, Malayka] Asthma UK, London, England; [Rao, Navin] Janssen R&D, Beerse, Belgium; [Ravanetti, Lara] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Ray, Emma] NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Reinke, Stacey] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Reynolds, Leanne] Asthma UK, London, England; [Riley, John] GSK, Resp Therapeut Unit, London, England; [Robberechts, Martine] MSD, Brussels, Belgium; [Roberts, Amanda] Asthma UK, London, England; [Russell, Kirsty] Imperial Coll, Natl Heart & Lung Inst, London, England; [Rutgers, Michael] Longfonds, Amersfoort, Netherlands; [Santoninco, Marco] Univ Roma Tor Vergata, Rome, Italy; [Schoelch, Corinna] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Schofield, James P. R.] Univ Southampton, Inst Life Sci, Ctr Prote Res, Southampton, Hants, England; [Sjodin, Marcus] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Skipp, Paul J.] Univ Southampton, Inst Life Sci, Ctr Prote Res, Southampton, Hants, England; [Smids, Barbara] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Smith, Caroline] NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Smith, Jessica] Asthma UK, London, England; [Smith, Katherine M.] Univ Nottingham, Nottingham, England; [Staykova, Doroteya] Univ Southampton, Southampton, Hants, England; [Sun, Kai] Imperial Coll, Data Sci Inst, London, England; [Thorngren, John-Olof] Karolinska Univ Hosp, Stockholm, Sweden; [Thornton, Bob] MSD, Brussels, Belgium; [Thorsen, Jonathan] Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood, Herlev & Gentofte Hosp, COPSAC, Copenhagen, Denmark; [van de Pol, Marianne] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [van Geest, Marleen] AstraZeneca, Molndal, Sweden; [Versnel, Jenny] Asthma UK, London, England; [Vink, Anton] Philips Res Labs, Eindhoven, Netherlands; [Wald, Frans] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Walker, Samantha] Asthma UK, London, England; [Ward, Jonathan] Univ Southampton, Fac Med, Histochem Res Unit, Southampton, Hants, England; [Weiszhart, Zsoka] Semmelweis Univ, Budapest, Hungary; [Wetzel, Kristiane] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Wheelock, Craig E.] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Wiegman, Coen] Imperial Coll, Natl Heart & Lung Inst, London, England; [Williams, Sian] Int Primary Care Resp Grp, Aberdeen, Scotland; [Wilson, Susan J.] Univ Southampton, Fac Med, Histochem Res Unit, Southampton, Hants, England; [Woodcock, Ashley] Univ Manchester, Inst Inflammat & Repair, Ctr Resp Med & Allergy, Manchester, Lancs, England; [Woodcock, Ashley] Univ Hosp South Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Yang, Xian] Imperial Coll, Data Sci Inst, London, England; [Yeyasingham, Elizabeth] GSK, UK Clin Operat, Stockley Pk, England; [Prins, Jan-Bas] LUMC, Biomed Res, Leiden, Netherlands; [Gahlemann, Martina] BI, Clin Care, Ingelheim, Germany; [Visintin, Luigi] LIAF, Legal Affairs, Catania, Italy; [Puhl, Martine] NAF, Nijmegen, Netherlands; [Buzermaniene, Lina] EFA, Patient Representat, Vilnius, Lithuania; [Hudson, Val; Bond, Laura] Asthma UK, Patient Representat, London, England; [Widdershoven, Guy] Vrije Univ Amsterdam Med Ctr, Res Eth, Amsterdam, Netherlands; [Sigmund, Ralf] BI, Res Methodol & Biostat, Ingelheim, Germany	University of Southampton; Imperial College London; Johnson & Johnson; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; University of Nottingham; University of Bergen; University of Catania; Karolinska Institutet; University of Manchester; Semmelweis University; Fraunhofer Gesellschaft; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Jagiellonian University; Collegium Medicum Jagiellonian University; Umea University; Umea University; Umea University; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; GlaxoSmithKline; Imperial College London; Imperial College London; Roche Holding; Umea University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Boehringer Ingelheim; Amgen; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Imperial College London; Imperial College London; Royal Brompton Hospital; University of Catania; University of Bern; University Hospital of Bern; Karolinska Institutet; University of Southampton; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Semmelweis University; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Karolinska Institutet; Imperial College London; Amgen; Karolinska Institutet; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital NHS Foundation Trust; Boehringer Ingelheim; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; UCB Pharma SA; University of Bern; University Hospital of Bern; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; GlaxoSmithKline; University of Bern; University Hospital of Bern; Wythenshawe Hospital NHS Foundation Trust; University of Amsterdam; Academic Medical Center Amsterdam; Roche Holding; University of Bern; University Hospital of Bern; Royal Brompton & Harefield NHS Foundation Trust; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Boehringer Ingelheim; Lund University; Skane University Hospital; AstraZeneca; Wythenshawe Hospital NHS Foundation Trust; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Royal Brompton Hospital; Boehringer Ingelheim; Royal Brompton & Harefield NHS Foundation Trust; Imperial College London; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Karolinska Institutet; Karolinska University Hospital; Royal Brompton & Harefield NHS Foundation Trust; University of Bern; University Hospital of Bern; Wythenshawe Hospital NHS Foundation Trust; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; Wythenshawe Hospital NHS Foundation Trust; Semmelweis University; University of Southampton; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Amsterdam; Academic Medical Center Amsterdam; UCB Pharma SA; Amgen; Karolinska Institutet; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton; University of Amsterdam; Academic Medical Center Amsterdam; Merck & Company; Uppsala University; University of Bergen; Karolinska Institutet; GlaxoSmithKline; Merck & Company; Almirall; Jagiellonian University; Collegium Medicum Jagiellonian University; University of Southampton; Fraunhofer Gesellschaft; University of Southampton; Merck & Company; Royal Brompton & Harefield NHS Foundation Trust; Karolinska Institutet; University of Rome Tor Vergata; Almirall; Merck & Company; University of Amsterdam; Academic Medical Center Amsterdam; University of Catania; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; UCB Pharma SA; Fraunhofer Gesellschaft; Roche Holding; Genentech; Amgen; Imperial College London; Philips; Philips Research; Karolinska Institutet; Chiesi Pharmaceuticals Inc; Imperial College London; Karolinska Institutet; Ghent University; University of Amsterdam; Academic Medical Center Amsterdam; Karolinska Institutet; Imperial College London; Imperial College London; Royal Institute of Technology; Almirall; Karolinska Institutet; University of Southampton; Royal Institute of Technology; AstraZeneca; Imperial College London; University of Rome Tor Vergata; Karolinska Institutet; University of Southampton; University of Amsterdam; Academic Medical Center Amsterdam; Karolinska Institutet; GlaxoSmithKline; Merck & Company; Imperial College London; University of Rome Tor Vergata; Boehringer Ingelheim; University of Southampton; Karolinska Institutet; University of Southampton; University of Amsterdam; Academic Medical Center Amsterdam; University of Nottingham; University of Southampton; Imperial College London; Karolinska Institutet; Karolinska University Hospital; Merck & Company; University of Copenhagen; University of Amsterdam; Academic Medical Center Amsterdam; AstraZeneca; Philips; Philips Research; Boehringer Ingelheim; University of Southampton; Semmelweis University; Boehringer Ingelheim; Karolinska Institutet; Imperial College London; University of Southampton; University of Manchester; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Imperial College London; GlaxoSmithKline; Leiden University; Leiden University Medical Center (LUMC); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Djukanovic, R (corresponding author), NIHR Southampton Biomed Res Ctr, Clin & Expt Sci, Fac Med, Southampton, Hants, England.; Djukanovic, R (corresponding author), Univ Hosp Southampton, Sir Henry Wellcome Labs, Clin & Expt Sci, Mailpoint 810,Level F,South Block,Tremona Rd, Southampton SO16 6YD, Hants, England.	R.Djukanovic@soton.ac.uk	Brinkman, Paul/AAV-5110-2021; Horváth, Ildikó/GPP-6088-2022; Szentkereszty, Márton/S-2825-2018; Braun, Armin/B-8750-2009; James, Anna/AAY-9937-2021; Balgoma, David/ABG-9548-2020; Caruso, Massimo/P-4161-2016; Nordlund, Björn/AAF-6037-2019; Staykova, Doroteya Kancheva/ABD-3998-2021; 郭, 伊可/GYD-3212-2022; Sterk, P.J./AAK-8175-2020; Masefield, Sarah/AAJ-4425-2021; Thorsen, Jonathan/AAQ-9269-2021; Bernardini, Renato/AAF-6680-2021; Emma, Rosalia/HDO-5255-2022; Sanak, Marek/AAV-1628-2021; Konradsen, Jon/AAD-5620-2021; Chung, Kian Fan/B-1872-2012; Gómez Castellà, Cristina/B-2726-2017; Lemonnier, Nathanael/K-5393-2016; Naz, Shama/AAH-2176-2019; Ravanetti, Lara/AAW-9314-2021	Szentkereszty, Márton/0000-0001-8891-8657; Braun, Armin/0000-0002-1142-1463; Caruso, Massimo/0000-0002-4412-2080; Nordlund, Björn/0000-0001-9888-1659; Masefield, Sarah/0000-0002-3286-0721; Thorsen, Jonathan/0000-0003-0200-0461; Sanak, Marek/0000-0001-7635-8103; Konradsen, Jon/0000-0001-7745-8624; Chung, Kian Fan/0000-0001-7101-1426; Gómez Castellà, Cristina/0000-0001-8518-0095; Lemonnier, Nathanael/0000-0002-3994-8697; Mikus, Maria/0000-0001-6560-6124; Strazzeri, Fabio/0000-0001-7664-1304; MONTUSCHI, Paolo/0000-0001-5589-1750; Djukanovic, Ratko/0000-0001-6039-5612; Rossios, Christos/0000-0003-3470-3233; Fowler, Stephen/0000-0002-4524-1663; Rowe, Anthony/0000-0003-1829-1179; van Drunen, Cornelis M/0000-0001-5503-066X; Stokholm, Jakob/0000-0003-4989-9769; Adcock, Ian/0000-0003-2101-8843; Nicholas, Benjamin/0000-0003-1467-9643; Murray, Clare/0000-0002-8961-8055; Brinkman, Paul/0000-0003-4546-8478; Howarth, Peter/0000-0003-0619-7927; Yang, Xian/0000-0002-1496-8923; Ward, Jon/0000-0002-9278-0002	Innovative Medicines Initiative Joint Undertaking [115010]; European Union; IMI-funded eTRIKS project (EU) [115446]; Engineering and Physical Sciences Research Council, United Kingdom [EP/N014189]; BBSRC [BM/M012387/1]; Wessex Medical Trust; BBSRC [BB/M012387/1] Funding Source: UKRI	Innovative Medicines Initiative Joint Undertaking; European Union(European Commission); IMI-funded eTRIKS project (EU); Engineering and Physical Sciences Research Council, United Kingdom(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wessex Medical Trust; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	U-BIOPRED is supported through an Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115010, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution (www.imi.europa.eu).We would also like to acknowledge help from the IMI-funded eTRIKS project (EU Grant Code no. 115446).r This work was partially funded by the Engineering and Physical Sciences Research Council, United Kingdom (EP/N014189: Joining the Dots, From Data to Insight). Instrumentation in the Centre for Proteomic Research is supported by the BBSRC (BM/M012387/1) and the Wessex Medical Trust. We thank Ayasdi for use of, and support with, the Ayasdi TDA software.	Azevedo EPC, 2012, J BIOL CHEM, V287, P37206, DOI 10.1074/jbc.M112.369942; BEZKOROVAINY A, 1982, ADV EXP MED BIOL, V135, P139; Burg D, 2018, J PROTEOME RES, V17, P2072, DOI 10.1021/acs.jproteome.8b00018; Castro-Giner F, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-128; Chapple RH, 2018, ELIFE, V7, DOI 10.7554/eLife.31159; Dent J, 2005, GUT, V54, P710, DOI 10.1136/gut.2004.051821; Farne HA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010834.pub3; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Guan HB, 2009, J IMMUNOL, V183, P172, DOI 10.4049/jimmunol.0802325; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; Kuo Chih-Hsi Scott, 2017, Eur Respir J, V49, DOI 10.1183/13993003.02135-2016; Li H., 2011, THESIS; Martinho A, 2012, J MOL NEUROSCI, V48, P1, DOI 10.1007/s12031-012-9715-7; McNicholl DM, 2012, AM J RESP CRIT CARE, V186, P1102, DOI 10.1164/rccm.201204-0587OC; Pazdrak K, 2011, J IMMUNOL, V186, P6485, DOI 10.4049/jimmunol.1001868; Pelaia G, 2012, NAT REV DRUG DISCOV, V11, P958, DOI 10.1038/nrd3792; PEREIRA HA, 1995, J LEUKOCYTE BIOL, V57, P805, DOI 10.1002/jlb.57.6.805; Price D, 2016, J ASTHMA ALLERGY, V9, P1, DOI 10.2147/JAA.S97973; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Sun SY, 2015, NAT CELL BIOL, V17, P1546, DOI 10.1038/ncb3266; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; Wang T, 2017, J MOL MED, V95, P1117, DOI 10.1007/s00109-017-1576-7; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Zoubeidi A, 2010, MOL CANCER RES, V8, P119, DOI 10.1158/1541-7786.MCR-09-0277	27	33	35	3	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					70	82		10.1016/j.jaci.2019.03.013	http://dx.doi.org/10.1016/j.jaci.2019.03.013			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30928653	Green Submitted, Bronze, Green Accepted, Green Published			2022-12-18	WOS:000473432800011
J	Grozdanovic, M; Laffey, KG; Abdelkarim, H; Hitchinson, B; Harijith, A; Moon, HG; Park, GY; Rousslang, LK; Masterson, JC; Furuta, GT; Tarasova, NI; Gaponenko, V; Ackerman, SJ				Grozdanovic, Milica; Laffey, Kimberly G.; Abdelkarim, Hazem; Hitchinson, Ben; Harijith, Anantha; Moon, Hyung-Geon; Park, Gye Young; Rousslang, Lee K.; Masterson, Joanne C.; Furuta, Glenn T.; Tarasova, Nadya I.; Gaponenko, Vadim; Ackerman, Steven J.			Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CCR3; eosinophil; allergic inflammation; asthma; biased antagonist; peptide nanoparticles; airway hyperresponsiveness	CHEMOKINE RECEPTOR CCR3; BETA-ARRESTIN; CXCR4 ANTAGONIST; UP-REGULATION; CELL-SURFACE; PROTEIN; EOTAXIN; ACTIVATION; DEGRANULATION; EXPRESSION	Background: Chemokine signaling through CCR3 is a key regulatory pathway for eosinophil recruitment into tissues associated with allergic inflammation and asthma. To date, none of the CCR3 antagonists have shown efficacy in clinical trials. One reason might be their unbiased mode of inhibition that prevents receptor internalization, leading to drug tolerance. Objective: We sought to develop a novel peptide nanoparticle CCR3 inhibitor (R321) with a biased mode of inhibition that would block G protein signaling but enable or promote receptor internalization. Methods: Self-assembly of R321 peptide into nanoparticles and peptide binding to CCR3 were analyzed by means of dynamic light scattering and nuclear magnetic resonance. Inhibitory activity on CCR3 signaling was assessed in vitro by using flow cytometry, confocal microscopy, andWestern blot analysis in a CCR3(+) eosinophil cell line and blood eosinophils. In vivo effects of R321 were assessed by using a triple-allergen mouse asthma model. Results: R321 self-assembles into nanoparticles and binds directly to CCR3, altering receptor function. Half-maximal inhibitory concentration values for eotaxin-induced chemotaxis of blood eosinophils are in the low nanomolar range. R321 inhibits only the early phase of extracellular signal-regulated kinase 1/2 activation and not the late phase generally associated with beta-arrestin recruitment and receptor endocytosis, promoting CCR3 internalization and degradation. In vivo R321 effectively blocks eosinophil recruitment into the blood, lungs, and airways and prevents airway hyperresponsiveness in a mouse eosinophilic asthma model. Conclusions: R321 is a potent and selective antagonist of the CCR3 signaling cascade. Inhibition through a biased mode of antagonism might hold significant therapeutic promise by eluding the formation of drug tolerance.	[Grozdanovic, Milica; Laffey, Kimberly G.; Abdelkarim, Hazem; Hitchinson, Ben; Rousslang, Lee K.; Gaponenko, Vadim; Ackerman, Steven J.] Univ Illinois, Coll Med, Dept Biochem & Mol Genet, MBRB 2074,MC669,900 S Ashland Ave, Chicago, IL 60607 USA; [Harijith, Anantha] Univ Illinois, Coll Med, Dept Pediat, Chicago, IL USA; [Moon, Hyung-Geon; Park, Gye Young] Univ Illinois, Coll Med, Dept Med, Div Pulm Crit Care Sleep & Allergy, Chicago, IL USA; [Masterson, Joanne C.; Furuta, Glenn T.] Univ Colorado, Sch Med, Dept Pediat, Gastrointestinal Eosinophil Dis Program, Aurora, CO USA; [Masterson, Joanne C.; Furuta, Glenn T.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Digest Hlth Inst,Mucosal Inflammat Program, Aurora, CO USA; [Tarasova, Nadya I.] NCI, Ctr Canc Res, Frederick, MD 21701 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ackerman, SJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, MBRB 2074,MC669,900 S Ashland Ave, Chicago, IL 60607 USA.	sackerma@uic.edu	Harijith, Anantha/AAA-5708-2021	Gaponenko, Vadim/0000-0002-7891-9223; Tarasova, Nadya/0000-0002-4949-0069	National Institutes of Health [R21HL118588, R01HL126852, K01DK106315, K24DK100303]; LaCache Chair for GI Allergic and Immunologic Diseases; University of Illinois at Chicago Chancellors Innovation Fund-Proof of Concept program; Intramural Research Program of the National Cancer Institute, National Institutes of Health; American Parkinson Disease Association (APDA); NATIONAL CANCER INSTITUTE [ZIABC011307] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL126852, R21HL118588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK100303, K01DK106315] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); LaCache Chair for GI Allergic and Immunologic Diseases; University of Illinois at Chicago Chancellors Innovation Fund-Proof of Concept program; Intramural Research Program of the National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Parkinson Disease Association (APDA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by National Institutes of Health grants R21HL118588 (to S.J.A./V.G.), R01HL126852 (to G.Y.P.), K01DK106315 (to J.C.M.), and K24DK100303 (to G.T.F.); the LaCache Chair for GI Allergic and Immunologic Diseases (to G.T.F.); a grant from the University of Illinois at Chicago Chancellors Innovation Fund-Proof of Concept program (to S.J.A./V.G.); and the Intramural Research Program of the National Cancer Institute, National Institutes of Health (to N.I.T.). H.A. was supported in part by a postdoctoral fellowship from the American Parkinson Disease Association (APDA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Abraham SJ, 2008, J BIOMOL NMR, V42, P143, DOI 10.1007/s10858-008-9274-y; Abraham SJ, 2009, J BIOMOL NMR, V43, P239, DOI 10.1007/s10858-009-9306-2; Agarwal M, 2013, PROSTATE, V73, P573, DOI 10.1002/pros.22597; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Allouche S, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00280; Bokoch MP, 2010, NATURE, V463, P108, DOI 10.1038/nature08650; BUSSE WW, 1992, ANN ALLERGY, V68, P286; Chavan TS, 2013, MOLECULES, V18, P7103, DOI 10.3390/molecules18067103; Corbisier J, 2017, J BIOL CHEM, V292, P575, DOI 10.1074/jbc.M116.757559; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Denzler KL, 2001, J IMMUNOL, V167, P1672, DOI 10.4049/jimmunol.167.3.1672; Diny NL, 2016, EUR J IMMUNOL, V46, P2749, DOI 10.1002/eji.201646557; Fujisawa T, 2000, J ALLERGY CLIN IMMUN, V106, P507; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; Goplen N, 2009, J ALLERGY CLIN IMMUN, V123, P925, DOI 10.1016/j.jaci.2009.02.009; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; Holden Paul, 2009, BMC Res Notes, V2, P243, DOI 10.1186/1756-0500-2-243; Huber AK, 2018, CLIN IMMUNOL, V189, P29, DOI 10.1016/j.clim.2016.09.010; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Johrer K, 2005, CLIN CANCER RES, V11, P2459, DOI 10.1158/1078-0432.CCR-04-0405; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kumari P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13416; Lamkhioued B, 2003, J IMMUNOL, V170, P537, DOI 10.4049/jimmunol.170.1.537; Lee Y, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/50/505101; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Long HX, 2012, STEM CELLS, V30, P2309, DOI 10.1002/stem.1194; Markowitz JE, 2003, GASTROENTEROL CLIN N, V32, P949, DOI 10.1016/S0889-8553(03)00047-5; Masterson JC, 2011, AM J PATHOL, V179, P2302, DOI 10.1016/j.ajpath.2011.07.039; Meiser A, 2008, J IMMUNOL, V180, P6713, DOI 10.4049/jimmunol.180.10.6713; MIYAGAWA H, 1992, AGENTS ACTIONS, V37, P39, DOI 10.1007/BF01987888; Mori A, 2007, INT IMMUNOL, V19, P913, DOI 10.1093/intimm/dxm049; Neighbour H, 2014, CLIN EXP ALLERGY, V44, P508, DOI 10.1111/cea.12244; Paradis JS, 2015, P NATL ACAD SCI USA, V112, pE5160, DOI 10.1073/pnas.1508836112; Pease JE, 2014, EXPERT OPIN DRUG DIS, V9, P467, DOI 10.1517/17460441.2014.897324; Pinto LH, 2008, MAMM GENOME, V19, P2, DOI 10.1007/s00335-007-9082-9; Provost V, 2013, J LEUKOCYTE BIOL, V94, P213, DOI 10.1189/jlb.0212074; Rajagopal S, 2010, P NATL ACAD SCI USA, V107, P628, DOI 10.1073/pnas.0912852107; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Schmid CL, 2017, CELL, V171, P1165, DOI 10.1016/j.cell.2017.10.035; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Sison EAR, 2015, ONCOTARGET, V6, P30902, DOI 10.18632/oncotarget.5094; Sounier R, 2015, NATURE, V524, P375, DOI 10.1038/nature14680; Stellato C, 2001, J IMMUNOL, V166, P1457, DOI 10.4049/jimmunol.166.3.1457; Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151; Tarasov SG, 2011, P NATL ACAD SCI USA, V108, P9798, DOI 10.1073/pnas.1014598108; Thomson NC, 2014, CLIN EXP ALLERGY, V44, P462, DOI 10.1111/cea.12268; Tian M, 2016, ONCOTARGET, V7, P32617, DOI 10.18632/oncotarget.8958; Tripathi A, 2015, P NATL ACAD SCI USA, V112, pE1659, DOI 10.1073/pnas.1417564112; Uy GL, 2012, BLOOD, V119, P3917, DOI 10.1182/blood-2011-10-383406; White JR, 2000, J BIOL CHEM, V275, P36626, DOI 10.1074/jbc.M006613200; Willems LI, 2010, MED RES REV, V30, P778, DOI 10.1002/med.20181; Wise EL, 2010, J ALLERGY CLIN IMMUN, V126, P150, DOI 10.1016/j.jaci.2010.04.015; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zhu F, 2014, ONCOL REP, V31, P2049, DOI 10.3892/or.2014.3060; Zhu YM, 2011, J IMMUNOL, V186, P516, DOI 10.4049/jimmunol.1000955; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P97, DOI 10.1067/mai.2003.3; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611	58	33	38	2	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					669	+		10.1016/j.jaci.2018.05.003	http://dx.doi.org/10.1016/j.jaci.2018.05.003			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29778505	Green Accepted, Bronze			2022-12-18	WOS:000457718700026
J	Dvorak, CC; Haddad, E; Buckley, RH; Cowan, MJ; Logan, B; Griffith, LM; Kohn, DB; Pai, SY; Notarangelo, L; Shearer, W; Prockop, S; Kapoor, N; Heimall, J; Chaudhury, S; Shyr, D; Chandra, S; Cuvelier, G; Moore, T; Shenoy, S; Goldman, F; Smith, AR; Sunkersett, G; Vander Lugt, M; Caywood, E; Quigg, T; Torgerson, T; Chandrakasan, S; Craddock, J; Saldana, BJD; Gillio, A; Shereck, E; Aquino, V; DeSantes, K; Knutsen, A; Thakar, M; Yu, LL; Puck, JM				Dvorak, Christopher C.; Haddad, Elie; Buckley, Rebecca H.; Cowan, Morton J.; Logan, Brent; Griffith, Linda M.; Kohn, Donald B.; Pai, Sung-Yun; Notarangelo, Luigi; Shearer, William; Prockop, Susan; Kapoor, Neena; Heimall, Jennifer; Chaudhury, Sonali; Shyr, David; Chandra, Sharat; Cuvelier, Geoff; Moore, Theodore; Shenoy, Shalini; Goldman, Fred; Smith, Angela R.; Sunkersett, Gauri; Vander Lugt, Mark; Caywood, Emi; Quigg, Troy; Torgerson, Troy; Chandrakasan, Shanmuganathan; Craddock, John; Saldana, Blachy J. Davila; Gillio, Alfred; Shereck, Evan; Aquino, Victor; DeSantes, Kenneth; Knutsen, Alan; Thakar, Monica; Yu, Lolie; Puck, Jennifer M.			The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Dvorak, Christopher C.; Cowan, Morton J.; Puck, Jennifer M.] Univ Calif San Francisco, Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Haddad, Elie] Univ Montreal, CHU St Justine, Montreal, PQ, Canada; [Buckley, Rebecca H.] Duke Univ, Durham, NC USA; [Logan, Brent] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Griffith, Linda M.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Kohn, Donald B.; Moore, Theodore] Univ Calif Los Angeles, Los Angeles, CA USA; [Pai, Sung-Yun] Boston Childrens Hosp, Boston, MA USA; [Notarangelo, Luigi] NIAID, Lab Clin Immunol & Microbiol, Div Intramural Res, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Shearer, William] Texas Childrens Hosp, Houston, TX 77030 USA; [Prockop, Susan] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Kapoor, Neena] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; [Heimall, Jennifer] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Chaudhury, Sonali] Lurie Childrens Hosp Chicago, Chicago, IL USA; [Shyr, David] Primary Childrens Med Ctr, Salt Lake City, UT USA; [Chandra, Sharat] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Cuvelier, Geoff] CancerCare Manitoba, Winnipeg, MB, Canada; [Shenoy, Shalini] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Goldman, Fred] Childrens Hosp Alabama, Birmingham, AL USA; [Smith, Angela R.] Univ Minnesota, Masonic Childrens Hosp, Minneapolis, MN USA; [Sunkersett, Gauri] Johns Hopkins All Childrens Hosp, St Petersburg, FL USA; [Vander Lugt, Mark] Univ Michigan Hlth Syst, Ann Arbor, MI USA; [Caywood, Emi] Alfred I duPont Hosp Children, Wilmington, DE USA; [Quigg, Troy] Methodist Childrens Hosp South Texas, San Antonio, TX USA; [Torgerson, Troy] Seattle Childrens Hosp, Seattle, WA USA; [Chandrakasan, Shanmuganathan] Childrens Healthcare Atlanta, Atlanta, GA USA; [Craddock, John] Childrens Hosp Colorado, Aurora, CO USA; [Saldana, Blachy J. Davila] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Gillio, Alfred] Hackensack Univ Med Ctr, Hackensack, NJ USA; [Shereck, Evan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Aquino, Victor] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [DeSantes, Kenneth] Univ Wisconsin, Amer Family Childrens Hosp, Madison, WI USA; [Knutsen, Alan] Cardinal Glennon Childrens Hosp, St Louis, MO USA; [Thakar, Monica] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA; [Yu, Lolie] Louisiana State Univ, Hlth Sci Ctr, Childrens Hosp, Shreveport, LA 71105 USA	University of California System; University of California San Francisco; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Duke University; Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California Los Angeles; Harvard University; Boston Children's Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine; Memorial Sloan Kettering Cancer Center; Children's Hospital Los Angeles; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Ann & Robert H. Lurie Children's Hospital of Chicago; Cincinnati Children's Hospital Medical Center; CancerCare Manitoba Foundation; St. Louis Children's Hospital; Washington University (WUSTL); University of Minnesota System; University of Minnesota Twin Cities; Johns Hopkins University; Johns Hopkins Medicine; University of Michigan System; University of Michigan; Nemours Alfred I. duPont Hospital for Children; Seattle Children's Hospital; Children's Healthcare of Atlanta (CHOA); Children's Hospital Colorado; Children's National Health System; Hackensack University Medical Center; Oregon Health & Science University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Wisconsin System; University of Wisconsin Madison; Children's Hospital of Wisconsin; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Dvorak, CC (corresponding author), Univ Calif San Francisco, Benioff Childrens Hosp, San Francisco, CA 94143 USA.	Christopher.dvorak@ucsf.edu	Pai, Sung-Yun/AAH-7762-2019; Dvorak, Christopher C/AAX-1630-2020; Buckley, Rebecca/AAB-1578-2019; Haddad, Elie/AAQ-4971-2020; Chandrakasan, Shanmuganathan/AAM-3430-2020	Pai, Sung-Yun/0000-0002-0158-8147; Dvorak, Christopher C/0000-0002-6146-3952; Davila Saldana, Blachy/0000-0001-8281-3627; Haddad, Elie/0000-0003-2446-6879	Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, Public Health Service grant [U54-AI082973, U54-NS064808, U01-TR001263, R13-AI094943]; Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, MD, Public Health Service grant [U54-AI082973, U54-NS064808, U01-TR001263, R13-AI094943]; Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIAID, NIH; PBMTC Operations Center by the St Baldrick's Foundation; National Heart, Lung and Blood Institute (NHLBI), NIH [U10-HL069254]; National Cancer Institute (NCI), NIH [U10-HL069254]; NCI [U24-CA76518, HHSH250201200016C, HHSH234200637015C]; NHLBI [U24-CA76518, U01-HL069294]; NIAID [U24-CA76518]; Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services; Office of Naval Research [N00014-13-1-0039, N00014-14-1-0028]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD072245] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U24CA076518] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [U01TR001263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R13AI094943, U54AI082973] Funding Source: NIH RePORTER	Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, Public Health Service grant; Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, MD, Public Health Service grant; Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIAID, NIH; PBMTC Operations Center by the St Baldrick's Foundation; National Heart, Lung and Blood Institute (NHLBI), NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Cancer Institute (NCI), NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); Office of Naval Research(Office of Naval Research); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), and the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, MD, Public Health Service grant/cooperative agreements U54-AI082973 (PI: M.J.C.), and U54-NS064808 and U01-TR001263 (PI: J.P. Krischer) and R13-AI094943 (PI: M.J.C.), and the Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIAID, NIH. The Primary Immune Deficiency Treatment Consortium (PIDTC) is a part of the Rare Diseases Clinical Research Network of ORDR, NCATS. The collaborative work of the PIDTC with the Pediatric Blood and Marrow Transplant Consortium (PBMTC) is supported by the U54 grants mentioned above along with support from the PBMTC Operations Center by the St Baldrick's Foundation and grant/cooperative agreement U10-HL069254 (PI: M.A. Pulsipher) from both the National Heart, Lung and Blood Institute (NHLBI) and the National Cancer Institute (NCI), NIH. The collaborative work of the PIDTC with the Center for International Blood and Marrow Transplant Research (CIBMTR) is supported by grant/cooperative agreement U24-CA76518 (PI: M.M. Horowitz) from the NCI, the NHLBI, and the NIAID; grant/cooperative agreement U01-HL069294 from the NHLBI; NCI contracts HHSH250201200016C and HHSH234200637015C with the Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services; and grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research. The content and opinions expressed are solely the responsibility of the authors and do not represent the official policy or position of the NIAID, ORDR, NCATS, NIH, HRSA, or any other agency of the US government.	Haddad E, 2018, BLOOD, V132, P1737, DOI 10.1182/blood-2018-03-840702; Heimall J, 2017, BLOOD, V130, P2718, DOI 10.1182/blood-2017-05-781849; Ktuan A, 2015, SEMIN PERINATOL, V39, P194, DOI 10.1053/j.semperi.2015.03.004; Kwan A, 2015, CLIN IMMUNOL, V158, P29, DOI 10.1016/j.clim.2015.02.015; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Punwani D, 2016, NEW ENGL J MED, V375, P2165, DOI 10.1056/NEJMoa1509164; Richardson AM, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0770-1; Schuetz C, 2014, BLOOD, V123, P281, DOI 10.1182/blood-2013-01-476432; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044	9	33	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					405	+		10.1016/j.jaci.2018.08.027	http://dx.doi.org/10.1016/j.jaci.2018.08.027			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30193840	Green Accepted, Bronze			2022-12-18	WOS:000454918300045
J	Eyerich, K; Brown, SJ; White, BEP; Tanaka, RJ; Bissonette, R; Dhar, S; Bieber, T; Hijnen, DJ; Guttman-Yassky, E; Irvine, A; Thyssen, JP; Vestergaard, C; Werfel, T; Wollenberg, A; Paller, AS; Reynolds, NJ				Eyerich, Kilian; Brown, Sara J.; White, Bethany E. Perez; Tanaka, Reiko J.; Bissonette, Robert; Dhar, Sandipan; Bieber, Thomas; Hijnen, Dirk J.; Guttman-Yassky, Emma; Irvine, Alan; Thyssen, Jacob P.; Vestergaard, Christian; Werfel, Thomas; Wollenberg, Andreas; Paller, Amy S.; Reynolds, Nick J.			Human and computational models of atopic dermatitis: A review and perspectives by an expert panel of the International Eczema Council	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; atopic eczema; endotype; human models; machine learning; mechanistic models; precision medicine; tissue culture models; skin equivalents; systems biology	IN-VITRO MODEL; PATCH TEST REACTIONS; TH2 RESPONSES; SKIN BARRIER; T-CELLS; SENSITIZATION; CYTOKINES; PROTEINS; ASSOCIATION; ACTIVATION	Atopic dermatitis (AD) is a prevalent disease worldwide and is associated with systemic comorbidities representing a significant burden on patients, their families, and society. Therapeutic options for AD remain limited, in part because of a lack of well-characterized animal models. There has been increasing interest in developing experimental approaches to study the pathogenesis of human AD in vivo, in vitro, and in silico to better define pathophysiologic mechanisms and identify novel therapeutic targets and biomarkers that predict therapeutic response. This review critically appraises a range of models, including genetic mutations relevant to AD, experimental challenge of human skin in vivo, tissue culture models, integration of "omics" data sets, and development of predictive computational models. Although no one individual model recapitulates the complex AD pathophysiology, our review highlights insights gained into key elements of cutaneous biology, molecular pathways, and therapeutic target identification through each approach. Recent developments in computational analysis, including application of machine learning and a systems approach to data integration and predictive modeling, highlight the applicability of these methods to AD subclassification (endotyping), therapy development, and precision medicine. Such predictive modeling will highlight knowledge gaps, further inform refinement of biological models, and support new experimental and systems approaches to AD.	[Eyerich, Kilian] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Eyerich, Kilian] HMGU, Ctr Allergy & Environm ZAUM, Munich, Germany; [Eyerich, Kilian] Tech Univ Munich, Munich, Germany; [Brown, Sara J.] Univ Dundee, Sch Med, Skin Res Grp, Dundee, Scotland; [Brown, Sara J.] Ninewells Hosp & Med Sch, Dept Dermatol, Dundee, Scotland; [White, Bethany E. Perez; Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; [White, Bethany E. Perez] Northwestern Univ, Feinberg Sch Med, Skin Tissue Engn Core, Chicago, IL 60611 USA; [Tanaka, Reiko J.] Imperial Coll London, Dept Bioengn, London, England; [Bissonette, Robert] Innovaderm Res, Montreal, PQ, Canada; [Dhar, Sandipan] Inst Child Hlth, Dept Pediat Dermatol, Kolkata, India; [Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany; [Bieber, Thomas] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Hijnen, Dirk J.] Erasmus Univ Med Ctr Erasmus MC, Dept Dermatol, Rotterdam, Netherlands; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Med Ctr, New York, NY 10029 USA; [Irvine, Alan] Trinity Coll Dublin, Natl Childrens Res Ctr, Our Ladys Childrens Hosp, Paediat Dermatol, Dublin, Ireland; [Thyssen, Jacob P.] Univ Copenhagen, Herlev & Gentofte Hosp, Natl Allergy Res Ctr, Dept Dermatol & Allergy, Copenhagen, Denmark; [Vestergaard, Christian] Aalborg Univ Hosp, Dept Dermatol, Aalborg, Denmark; [Werfel, Thomas] Hannover Med Sch, Hannover, Germany; [Wollenberg, Andreas] Ludwig Maximilians Univ Munchen, Dept Dermatol & Allergy, Munich, Germany; [Paller, Amy S.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Paller, Amy S.] Northwestern Univ, Skin Dis Res Ctr, Feinberg Sch Med, Chicago, IL 60611 USA; [Reynolds, Nick J.] Newcastle Univ, Inst Cellular Med, Dermatol Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Reynolds, Nick J.] Newcastle Hosp NHS Fdn Trust, Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne, Tyne & Wear, England	Technical University of Munich; Technical University of Munich; University of Dundee; University of Dundee; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Imperial College London; Innovaderm Research Inc.; University of Bonn; Erasmus University Rotterdam; Erasmus MC; Icahn School of Medicine at Mount Sinai; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; University of Copenhagen; Aalborg University; Aalborg University Hospital; Hannover Medical School; University of Munich; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust	Reynolds, NJ (corresponding author), Newcastle Univ, Inst Cellular Med, Dermatol Sci, Newcastle Upon Tyne, Tyne & Wear, England.; Reynolds, NJ (corresponding author), Newcastle Hosp NHS Fdn Trust, Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne, Tyne & Wear, England.; Eyerich, K (corresponding author), Biedersteiner Str 29, D-80802 Munich, Germany.	kilian.eyerich@tum.de; nick.reynolds@ncl.ac.uk	Thyssen, Jacob/ABD-8517-2020; Irvine, Alan D/A-3982-2008; Hijnen, DirkJan/L-1387-2015; White, Bethany E. Perez/AAF-7256-2020; Werfel, Thomas/B-6921-2012	Irvine, Alan D/0000-0002-9048-2044; Hijnen, DirkJan/0000-0003-3379-3425; Perez White, Bethany/0000-0002-5594-0599; Tanaka, Reiko/0000-0002-0769-9382; Vestergaard, Christian/0000-0001-6485-3158; Dhar, Sandipan/0000-0002-9304-2212; Reynolds, Nick/0000-0002-6484-825X	ERC grant (IMCIS) [676858]; German Research Foundation [EY97/3-1]; Wellcome Trust Senior Research Fellowship in Clinical Science [106865/Z/15/Z]; Dermatology Foundation; National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [P30AR057216, 1K01AR072773-01A1]; Newcastle National Institute of Health Research (NIHR) Biomedical Research Centre; Newcastle NIHR Medtech and In vitro diagnostic Co-operative; Newcastle MRC/EPSRC Molecular Pathology Node; Lundbeck Foundation; EPSRC [EP/G007446/1] Funding Source: UKRI; MRC [MR/N005872/1] Funding Source: UKRI; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057216, K01AR072773] Funding Source: NIH RePORTER	ERC grant (IMCIS); German Research Foundation(German Research Foundation (DFG)); Wellcome Trust Senior Research Fellowship in Clinical Science(Wellcome Trust); Dermatology Foundation; National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Newcastle National Institute of Health Research (NIHR) Biomedical Research Centre; Newcastle NIHR Medtech and In vitro diagnostic Co-operative; Newcastle MRC/EPSRC Molecular Pathology Node; Lundbeck Foundation(Lundbeckfonden); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	K.E. is funded by an ERC grant (IMCIS, 676858) and the German Research Foundation (EY97/3-1). S.J.B. holds a Wellcome Trust Senior Research Fellowship in Clinical Science (106865/Z/15/Z). B.E.P.W. is supported by the Dermatology Foundation and the National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; P30AR057216 and 1K01AR072773-01A1). N.J.R.'s research/laboratory is funded in part by the Newcastle National Institute of Health Research (NIHR) Biomedical Research Centre, the Newcastle NIHR Medtech and In vitro diagnostic Co-operative, and the Newcastle MRC/EPSRC Molecular Pathology Node. J.P.T. is funded by an unrestricted grant from the Lundbeck Foundation.	Abaci HE, 2017, EXP BIOL MED, V242, P1657, DOI 10.1177/1535370217712690; Abolhassani H, 2018, J ALLERGY CLIN IMMUN, V141, P1450, DOI 10.1016/j.jaci.2017.06.049; Barzaghi F, 2018, J ALLERGY CLIN IMMUN, V141, P1036, DOI 10.1016/j.jaci.2017.10.041; Berroth A, 2013, J ALLERGY CLIN IMMUN, V131, P1547, DOI 10.1016/j.jaci.2013.02.029; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Boos AC, 2014, ALLERGY, V69, P943, DOI 10.1111/all.12416; Brunner PM, 2017, J INVEST DERMATOL, V137, P18, DOI 10.1016/j.jid.2016.08.022; Castex-Rizzi N, 2014, BRIT J DERMATOL, V170, P12, DOI 10.1111/bjd.13106; Christodoulides P, 2017, PHILOS T R SOC A, V375, DOI 10.1098/rsta.2016.0285; da Rosa JC, 2015, J ALLERGY CLIN IMMUN, V135, P712, DOI 10.1016/j.jaci.2014.11.017; Danso MO, 2014, J INVEST DERMATOL, V134, P1941, DOI 10.1038/jid.2014.83; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; Darsow U, 1999, J AM ACAD DERMATOL, V40, P187, DOI 10.1016/S0190-9622(99)70186-6; De Vuyst E, 2018, EXP DERMATOL, V27, P435, DOI 10.1111/exd.13113; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Dominguez-Huttinger E, 2017, J ALLERGY CLIN IMMUN, V139, P1861, DOI 10.1016/j.jaci.2016.10.026; Dudeck J, 2017, J EXP MED, V214, P3791, DOI 10.1084/jem.20160783; Elias MS, 2017, J ALLERGY CLIN IMMUN, V140, P1299, DOI 10.1016/j.jaci.2017.01.039; Engebretsen KA, 2018, BRIT J DERMATOL, V179, P679, DOI 10.1111/bjd.16487; Engebretsen KA, 2017, J ALLERGY CLIN IMMUN, V139, P1568, DOI 10.1016/j.jaci.2016.11.021; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Ewald DA, 2017, J ALLERGY CLIN IMMUN, V139, P562, DOI 10.1016/j.jaci.2016.08.029; Eyerich K, 2018, J EUR ACAD DERMATOL, V32, P692, DOI 10.1111/jdv.14673; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Eyerich S, 2011, NEW ENGL J MED, V365, P231, DOI 10.1056/NEJMoa1104200; Fatehullah A, 2016, NAT CELL BIOL, V18, P246, DOI 10.1038/ncb3312; Garzorz-Stark N, 2018, J ALLERGY CLIN IMMUN, V141, P1320, DOI 10.1016/j.jaci.2017.07.045; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Guttman-Yassky E, 2017, J ALLERGY CLIN IMMUN, V140, P1032, DOI 10.1016/j.jaci.2017.01.027; Guttman-Yassky E, 2017, CURR OPIN IMMUNOL, V48, P68, DOI 10.1016/j.coi.2017.08.008; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Hanel KH, 2016, J IMMUNOL, V196, P3233, DOI 10.4049/jimmunol.1402943; Hamann CR, 2017, J AM ACAD DERMATOL, V77, P70, DOI 10.1016/j.jaad.2017.02.001; Honzke S, 2016, J INVEST DERMATOL, V136, P631, DOI 10.1016/j.jid.2015.11.007; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jin HL, 2009, J INVEST DERMATOL, V129, P31, DOI 10.1038/jid.2008.106; Kamsteeg M, 2011, AM J PATHOL, V178, P2091, DOI 10.1016/j.ajpath.2011.01.037; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kiiski V, 2015, ACTA DERM-VENEREOL, V95, P943, DOI 10.2340/00015555-2126; Kim BS, 2018, BIOMATERIALS, V168, P38, DOI 10.1016/j.biomaterials.2018.03.040; Kovalenko P, 2016, CPT-PHARMACOMET SYST, V5, P617, DOI 10.1002/psp4.12136; Krause L, 2016, J ALLERGY CLIN IMMUN, V138, P1207, DOI 10.1016/j.jaci.2016.04.018; Langer K, 2007, EXP DERMATOL, V16, P124, DOI 10.1111/j.1600-0625.2006.00523.x; Lecas S, 2016, TOXICOL LETT, V259, P60, DOI 10.1016/j.toxlet.2016.07.026; Maboni G, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00404; Marionnet C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012059; Newell L, 2013, J INVEST DERMATOL, V133, P2372, DOI 10.1038/jid.2013.148; Niebuhr M, 2010, J ALLERGY CLIN IMMUN, V126, P1176, DOI 10.1016/j.jaci.2010.07.041; Niehues H, 2018, EXP DERMATOL, V27, P501, DOI 10.1111/exd.13531; Nygaard U, 2017, ACTA DERM-VENEREOL, V97, P305, DOI 10.2340/00015555-2552; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, P139, DOI 10.1016/j.jaci.2013.07.027; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Paternoster L, 2018, J ALLERGY CLIN IMMUN, V141, P964, DOI 10.1016/j.jaci.2017.09.044; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Polak ME, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00651-5; Pourchet LJ, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601101; Quaranta M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008946; Reber LL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92900; Rouaud-Tinguely P, 2015, BRIT J DERMATOL, V173, P1006, DOI 10.1111/bjd.14012; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; Saito T, 2017, J CLIN PHARMACOL, V57, P1564, DOI 10.1002/jcph.969; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Schmitt J, 2011, BRIT J DERMATOL, V164, P415, DOI 10.1111/j.1365-2133.2010.10030.x; Strickland I, 2017, J ALLERGY CLIN IMMUN, V140, P1703, DOI 10.1016/j.jaci.2017.06.046; Subramanian I, 2018, BMC DERMATOL, V18, DOI 10.1186/s12895-018-0070-4; Turjanmaa K, 2006, ALLERGY, V61, P1377, DOI 10.1111/j.1398-9995.2006.01136.x; Ungar B, 2017, EXP DERMATOL, V26, P272, DOI 10.1111/exd.13148; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; van Drongelen V, 2015, CELL TISSUE RES, V361, P789, DOI 10.1007/s00441-015-2162-3; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Wallmeyer L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00670-2; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Werfel T, 2015, J ALLERGY CLIN IMMUN, V136, P96, DOI 10.1016/j.jaci.2015.04.015; Yuki T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161759	77	33	33	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					36	45		10.1016/j.jaci.2018.10.033	http://dx.doi.org/10.1016/j.jaci.2018.10.033			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30414395	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000454918300004
J	Stadhouders, R; Li, BWS; de Bruijn, MJW; Gomez, A; Nageswara, T; Fehling, HJ; van IJcken, WFJ; Lim, AI; Di Santo, JP; Graf, T; Hendriks, RW				Stadhouders, Ralph; Li, Bobby W. S.; de Bruijn, Marjolein J. W.; Gomez, Antonio; Nageswara, Tata; Fehling, Hans Joerg; van IJcken, Wilfred F. J.; Lim, Ai Ing; Di Santo, James P.; Graf, Thomas; Hendriks, Rudi W.			Epigenome analysis links gene regulatory elements in group 2 innate lymphocytes to asthma susceptibility	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group 2 innate lymphoid cell; epigenetics; epigenome; asthma; airway inflammation; genome-wide association study; superenhancer; transcription factor; T(H)2 cell; GATA-3	TYPE-2 IMMUNE-RESPONSE; LYMPHOID-CELLS; T-CELLS; TRANSCRIPTION FACTOR; AIRWAY INFLAMMATION; IMMUNOGLOBULIN-E; ASSOCIATION; PLASTICITY; ENHANCERS; CYTOKINE	Background: Group 2 innate lymphoid cells (ILC2s) are major producers of the cytokines driving allergic asthma, and increased ILC2 numbers have been detected in blood and sputum of asthmatic patients. Asthma susceptibility has a strong genetic component, but the underlying mechanisms and whether asthma genetics affect ILC2 biology remain unclear. Objective: We sought to study the ILC2 transcriptome and epigenome during airway inflammation (AI) to couple these to genes and genetic variants associated with asthma pathogenesis. Methods: Mice harboring a reporter for the key ILC2 transcription factor GATA-3 were subjected to IL-33-driven AI, and ILC2s were isolated from bronchoalveolar lavage fluid and mediastinal lymph nodes. Human ILC2s were purified from peripheral blood and activated in vitro. We used RNA sequencing, genome-wide identification of histone-3 lysine-4 dimethylation-marked chromatin, and computational approaches to study the ILC2 transcriptome and epigenome. Results: Activated ILC2s in mice displayed a tissue-specific gene expression signature that emerged from remarkably similar epigenomes. We identified superenhancers implicated in controlling ILC2 identity and asthma-associated genes. More than 300 asthma-associated genetic polymorphisms identified in genome-wide association studies localized to H3K4Me2(+) gene regulatory elements in ILC2s. A refined set of candidate causal asthma-associated variants was uniquely enriched in ILC2, but not T(H)2 cell, regulatory regions. Conclusions: ILC2s in AI use a flexible epigenome that couples adaptation to new microenvironments with functional plasticity. Importantly, we reveal strong correlations between gene regulatory mechanisms in ILC2s and the genetic basis of asthma, supporting a pathogenic role for ILC2s in patients with allergic asthma.	[Stadhouders, Ralph; Li, Bobby W. S.; de Bruijn, Marjolein J. W.; Hendriks, Rudi W.] Erasmus MC, Dept Pulm Med, Room Ee2251a, NL-3000 CA Rotterdam, Netherlands; [van IJcken, Wilfred F. J.] Erasmus MC, Ctr Biom, Rotterdam, Netherlands; [Stadhouders, Ralph; Gomez, Antonio; Graf, Thomas] BIST, CRG, Barcelona, Spain; [Stadhouders, Ralph; Gomez, Antonio; Graf, Thomas] Univ Pompeu Fabra, Barcelona, Spain; [Nageswara, Tata; Fehling, Hans Joerg] Univ Clin, Inst Immunol, Ulm, Germany; [Lim, Ai Ing; Di Santo, James P.] Inst Pasteur, Innate Immun Unit, Paris, France; [Lim, Ai Ing; Di Santo, James P.] INSERM, U1223, Paris, France; [Nageswara, Tata] Univ Hosp Basel, Dept Biomed, Expt Hematol, Basel, Switzerland	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Ulm University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Basel	Stadhouders, R; Hendriks, RW (corresponding author), Erasmus MC, Dept Pulm Med, Room Ee2251a, NL-3000 CA Rotterdam, Netherlands.	r.stadhouders@erasmusmc.nl; r.hendriks@erasmusmc.nl	Di Santo, James P/M-4298-2014; Stadhouders, Ralph/J-8663-2015; van ijcken, willem/N-9805-2018; Gomez Moruno, Antonio/H-7574-2015	Di Santo, James P/0000-0002-7146-1862; Stadhouders, Ralph/0000-0002-1060-5607; van ijcken, willem/0000-0002-0421-8301; Tata, Nageswara Rao/0000-0002-9928-5944; Gomez Moruno, Antonio/0000-0001-5308-981X; Hendriks, Rudi/0000-0003-2291-0382	EMBO Long-term Fellowship [ALTF 1201-2014]; Marie Curie Individual Fellowship [H2020-MSCA-IF-2014]; NWO Veni Fellowship [91617114]; Lung Foundation Netherlands [3.2.12.067]; European Research Council (ERC) Synergy Grant (4DGenome); European Union [317057]; Institut Pasteur; Inserm	EMBO Long-term Fellowship(European Molecular Biology Organization (EMBO)); Marie Curie Individual Fellowship(European Commission); NWO Veni Fellowship(Netherlands Organization for Scientific Research (NWO)); Lung Foundation Netherlands; European Research Council (ERC) Synergy Grant (4DGenome)(European Research Council (ERC)); European Union(European Commission); Institut Pasteur(European Commission); Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	R.S. was supported by an EMBO Long-term Fellowship (ALTF 1201-2014), a Marie Curie Individual Fellowship (H2020-MSCA-IF-2014), and an NWO Veni Fellowship (grant no. 91617114). B.W.S.L. was supported by the Lung Foundation Netherlands (3.2.12.067). T.G. was supported by a European Research Council (ERC) Synergy Grant (4DGenome). A.I.L. is a scholar in the Pasteur-Paris University (PPU) International PhD program and supported by a PhD International Training Network grant from European Union's 7 th Framework Programme under grant agreement no317057 (HOMIN). J.P.D.S. received grant support from the Institut Pasteur and Inserm.	Al-Alwan LA, 2013, J IMMUNOL, V191, P2731, DOI 10.4049/jimmunol.1203421; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Buck MD, 2015, J EXP MED, V212, P1345, DOI 10.1084/jem.20151159; Chen RC, 2017, AM J RESP CRIT CARE, V196, P700, DOI 10.1164/rccm.201612-2427OC; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Denney L, 2015, IMMUNITY, V43, P945, DOI 10.1016/j.immuni.2015.10.012; DeVries A, 2016, ANN AM THORAC SOC, V13, pS48, DOI 10.1513/AnnalsATS.201507-420MG; DeVries A, 2015, CURR OPIN PEDIATR, V27, P719, DOI 10.1097/MOP.0000000000000285; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Drake LY, 2014, ALLERGY, V69, P1300, DOI 10.1111/all.12446; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Eberl G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6566; Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835; Fritz JH, 2007, IMMUNITY, V26, P445, DOI 10.1016/j.immuni.2007.03.009; Gury-BenAri M, 2016, CELL, V166, P1231, DOI 10.1016/j.cell.2016.07.043; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Heinz S, 2015, NAT REV MOL CELL BIO, V16, P144, DOI 10.1038/nrm3949; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Himes BE, 2011, CHEST, V140, P667, DOI 10.1378/chest.10-2973; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Hysi P, 2005, HUM MOL GENET, V14, P935, DOI 10.1093/hmg/ddi087; Jia Y, 2016, AM J RESP CELL MOL, V55, P675, DOI 10.1165/rcmb.2016-0099OC; Karagiannidis C, 2006, J ALLERGY CLIN IMMUN, V117, P111, DOI 10.1016/j.jaci.2005.09.017; Kibbe WA, 2015, NUCLEIC ACIDS RES, V43, pD1071, DOI 10.1093/nar/gku1011; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lauer Mark E, 2015, Int J Cell Biol, V2015, P712507, DOI 10.1155/2015/712507; Li BWS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01684; Li BWS, 2016, EUR J IMMUNOL, V46, P1392, DOI 10.1002/eji.201546119; Li BWS, 2013, IMMUNOLOGY, V140, P281, DOI 10.1111/imm.12153; Liang LM, 2015, NATURE, V520, P670, DOI 10.1038/nature14125; Lim AI, 2017, CELL, V168, P1086, DOI 10.1016/j.cell.2017.02.021; Lim AI, 2016, J EXP MED, V213, P569, DOI 10.1084/jem.20151750; Liu T, 2012, P NATL ACAD SCI USA, V109, P12692, DOI 10.1073/pnas.1207816109; Lombardi V, 2016, J ALLERGY CLIN IMMUN, V138, P305, DOI 10.1016/j.jaci.2015.12.1325; Luyten A, 2014, GENE DEV, V28, P1827, DOI 10.1101/gad.240101.114; Martinez-Gonzalez I, 2015, TRENDS IMMUNOL, V36, P189, DOI 10.1016/j.it.2015.01.005; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; McCormack N, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-36; Mele DA, 2013, J EXP MED, V210, P2181, DOI 10.1084/jem.20130376; Meyers DA, 2014, LANCET RESP MED, V2, P405, DOI 10.1016/S2213-2600(14)70012-8; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Monticelli LA, 2016, NAT IMMUNOL, V17, P656, DOI 10.1038/ni.3421; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Parker SCJ, 2013, P NATL ACAD SCI USA, V110, P17921, DOI 10.1073/pnas.1317023110; Picelli S, 2013, NAT METHODS, V10, P1096, DOI [10.1038/nmeth.2639, 10.1038/NMETH.2639]; Poluektov YO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071228; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Salvi SS, 2001, CHEST, V119, P1533, DOI 10.1378/chest.119.5.1533; Schauberger E, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0628-3; Schmidt C, 2015, NAT METHODS, V12, P963, DOI [10.1038/NMETH.3542, 10.1038/nmeth.3542]; Seumois G, 2014, NAT IMMUNOL, V15, P777, DOI 10.1038/ni.2937; Shih HY, 2016, CELL, V165, P1120, DOI 10.1016/j.cell.2016.04.029; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Spooner CJ, 2013, NAT IMMUNOL, V14, P1229, DOI 10.1038/ni.2743; Springer J, 2003, PULM PHARMACOL THER, V16, P121, DOI 10.1016/S1094-5539(03)00049-X; Stadhouders R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9893; Stadhouders R, 2014, J CLIN INVEST, V124, P1699, DOI 10.1172/JCI71520; Stadhouders R, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001791; Tindemans I, 2014, IMMUNITY, V41, P191, DOI 10.1016/j.immuni.2014.06.006; Ubel C, 2014, J ALLERGY CLIN IMMUN, V133, P198, DOI 10.1016/j.jaci.2013.09.049; Van Dyken SJ, 2016, NAT IMMUNOL, V17, P1381, DOI 10.1038/ni.3582; van Rijt L, 2016, SEMIN IMMUNOPATHOL, V38, P483, DOI 10.1007/s00281-016-0556-2; von Moltke J, 2017, J EXP MED, V214, P27, DOI 10.1084/jem.20161274; Wallrapp A, 2017, NATURE, V549, P351, DOI 10.1038/nature24029; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Wilhelm C, 2016, J EXP MED, V213, P1409, DOI 10.1084/jem.20151448; Winter DR, 2015, NAT REV IMMUNOL, V15, P585, DOI 10.1038/nri3884; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025; Zhang JLA, 2012, CELL, V149, P467, DOI 10.1016/j.cell.2012.01.056; Zhang KN, 2017, J IMMUNOL, V198, P1798, DOI 10.4049/jimmunol.1601421; Zhong C, 2016, NAT IMMUNOL, V17, P169, DOI 10.1038/ni.3318	80	33	33	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1793	1807		10.1016/j.jaci.2017.12.1006	http://dx.doi.org/10.1016/j.jaci.2017.12.1006			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	29486229	Bronze			2022-12-18	WOS:000452315800015
J	Spergel, J; Aceves, SS				Spergel, Jonathan; Aceves, Seema S.			Allergic components of eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Esophagitis; food allergy; allergic rhinitis; antigens; allergy testing	6-FOOD ELIMINATION DIET; COWS MILK ELIMINATION; FOOD ALLERGY; SKIN PRICK; GENE-EXPRESSION; SEASONAL-VARIATION; PEDIATRIC-PATIENTS; CAUSATIVE FOODS; ELEMENTAL DIET; IGE ANTIBODIES	Eosinophilic esophagitis (EoE) is a disorder of increasing prevalence worldwide, causing clinical symptoms of vomiting, failure to thrive, and dysphagia and complications of esophageal remodeling with strictures and food impactions. Molecular profiling demonstrates EoE to be an eosinophil-predominant disorder with a T(H)2 cytokine profile reminiscent of other allergic diseases, such as asthma, allergic rhinitis, and atopic dermatitis. Environmental antigens in the form of foods and aeroallergens induce eosinophil, basophil, mast cell, and T-cell infiltration. Pathogenesis depends on local epithelial immune activation with production of thymic stromal lymphopoietin and eotaxin-3. Complications mirror asthmatic airway pathogenesis, with increases in subepithelial collagen deposition, angiogenesis, and smooth muscle hypertrophy. The removal of instigating antigens, especially foods, causes disease resolution in more than 50% of adults and children. The prevalence of concurrent atopic disorders in patients with EoE and the need to control antigen-specific T(H)2 inflammation underscore the importance of testing for allergens and treating the entire atopic subject to control the potential interplay between organ-specific allergic responses.	[Spergel, Jonathan] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Spergel, Jonathan] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Aceves, Seema S.] Univ Calif San Diego, Dept Pediat, Rady Childrens Hosp San Diego, Div Allergy Immunol, La Jolla, CA 92093 USA; [Aceves, Seema S.] Univ Calif San Diego, Dept Med, Rady Childrens Hosp San Diego, Div Allergy Immunol, La Jolla, CA 92093 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego	Aceves, SS (corresponding author), Univ Calif San Diego, Div Allergy & Immunol, 9500 Gilman Dr,MC 0760, La Jolla, CA 92093 USA.	saceves@ucsd.edu			Stuart Starr Endowed Chair; Children's Hospital Food Allergy Fund; National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID) [AI 092135, K24AI135034]; Consortium for Gastrointestinal Eosinophilic Researchers (CEGIR) [U54 AI117804]; NIAID; National Institute of Diabetes and Digestive and Kidney Diseases; NCATS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI117804, R01AI092135, K24AI135034] Funding Source: NIH RePORTER	Stuart Starr Endowed Chair; Children's Hospital Food Allergy Fund; National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Consortium for Gastrointestinal Eosinophilic Researchers (CEGIR); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	J.S. has received funds from the Stuart Starr Endowed Chair and the Children's Hospital Food Allergy Fund. Support was also provided from National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID) grants AI 092135 (to S.S.A.) and K24AI135034 (to S.S.A.). Both J.S. and S.S.A. have received funding from the Consortium for Gastrointestinal Eosinophilic Researchers (CEGIR). CEGIR (U54 AI117804) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), and is funded through collaboration between NIAID, National Institute of Diabetes and Digestive and Kidney Diseases, and NCATS.	Aalberse RC, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0621-x; Abonia JP, 2013, J ALLERGY CLIN IMMUN, V132, P378, DOI 10.1016/j.jaci.2013.02.030; Aceves SS, 2010, ALLERGY, V65, P109, DOI 10.1111/j.1398-9995.2009.02142.x; Akei HS, 2005, GASTROENTEROLOGY, V129, P985, DOI 10.1053/j.gastro.2005.06.027; Almansa C, 2009, AM J GASTROENTEROL, V104, P828, DOI 10.1038/ajg.2008.169; Armentia A, 2018, ALLERGOL IMMUNOPATH, V46, P181, DOI 10.1016/j.aller.2017.11.001; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Boyce JA, 2011, NUTRITION, V27, P253, DOI 10.1016/j.nut.2010.12.001; Cianferoni A, 2018, ANN ALLERG ASTHMA IM, V120; Clayton F, 2014, GASTROENTEROLOGY, V147, P602, DOI 10.1053/j.gastro.2014.05.036; Dellon ES, 2014, GASTROENTEROL CLIN N, V43, P201, DOI 10.1016/j.gtc.2014.02.002; Doherty TA, 2015, J ALLERGY CLIN IMMUN, V136, P792, DOI 10.1016/j.jaci.2015.05.048; Erwin EA, 2017, J PEDIATR GASTR NUTR, V65, P520, DOI 10.1097/MPG.0000000000001553; Erwin EA, 2016, J ALLERGY CLIN IMMUN, V138, P625, DOI 10.1016/j.jaci.2016.01.048; Erwin EA, 2015, J ALLER CL IMM-PRACT, V3, P896, DOI 10.1016/j.jaip.2015.05.015; Erwin EA, 2010, ANN ALLERG ASTHMA IM, V104, P496, DOI 10.1016/j.anai.2010.03.018; Fahey LM, 2018, CLIN TRANSL GASTROEN, V9, DOI 10.1038/s41424-018-0003-x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Frischmeyer-Guerrerio PA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006448; Gonsalves N, 2009, GASTROENTEROLOGY S, V136, pS1861; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Greenhawt M, 2013, J ALLER CL IMM-PRACT, V1, P332, DOI 10.1016/j.jaip.2013.05.009; Greuter T, 2017, AM J GASTROENTEROL, V112, P1527, DOI 10.1038/ajg.2017.202; Henderson CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1570, DOI 10.1016/j.jaci.2012.03.023; Hill DA, 2017, J ALLER CL IMM-PRACT, V5, P369, DOI 10.1016/j.jaip.2016.11.020; Hirano I, 2014, GASTROENTEROL CLIN N, V43, P297, DOI 10.1016/j.gtc.2014.02.015; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Jensen ET, 2015, ALIMENT PHARM THER, V42, P461, DOI 10.1111/apt.13273; Jyonouchi S, 2011, J ALLERGY CLIN IMMUN, V128, P102, DOI 10.1016/j.jaci.2011.02.026; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kagalwalla AF, 2017, CLIN GASTROENTEROL H, V15, P1698, DOI 10.1016/j.cgh.2017.05.048; Kagalwalla AF, 2012, J PEDIATR GASTR NUTR, V55, P711, DOI 10.1097/MPG.0b013e318268da40; Kagalwalla AF, 2011, J PEDIATR GASTR NUTR, V53, P145, DOI 10.1097/MPG.0b013e31821cf503; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Kliewer KL, 2016, J ALLERGY CLIN IMMUN, V137, P1011, DOI 10.1016/j.jaci.2015.10.040; Kruszewski PG, 2016, DIS ESOPHAGUS, V29, P377, DOI 10.1111/dote.12339; Kuchen T, 2014, ALLERGY, V69, P1248, DOI 10.1111/all.12455; LANDRES RT, 1978, GASTROENTEROLOGY, V74, P1298; Lieberman JA, 2012, ALLERGY, V67, P1299, DOI 10.1111/j.1398-9995.2012.02881.x; Lucendo AJ, 2013, J ALLERGY CLIN IMMUN, V131, P797, DOI 10.1016/j.jaci.2012.12.664; Maggadottir SM, 2014, J ALLERGY CLIN IMMUN, V133, P1487, DOI 10.1016/j.jaci.2014.02.004; Mahdavinia M, 2017, ANN ALLERG ASTHMA IM, V118, P116, DOI 10.1016/j.anai.2016.10.012; Marietta EV, 2017, ALIMENT PHARM THER, V45, P427, DOI 10.1111/apt.13877; Markowitz JE, 2003, AM J GASTROENTEROL, V98, P777, DOI 10.1111/j.1572-0241.2003.07390.x; Merves J, 2014, ANN ALLERG ASTHMA IM, V112, P397, DOI 10.1016/j.anai.2014.01.023; Miehlke Stephan, 2013, Case Rep Gastroenterol, V7, P363, DOI 10.1159/000355161; Moawad FJ, 2010, ALIMENT PHARM THER, V31, P509, DOI 10.1111/j.1365-2036.2009.04199.x; Molina-Infante J, 2018, J ALLERGY CLIN IMMUN, V141, P1365, DOI 10.1016/j.jaci.2017.08.038; Molina-Infante J, 2015, AM J GASTROENTEROL, V110, P1567, DOI 10.1038/ajg.2015.314; Molina-Infante J, 2014, J ALLERGY CLIN IMMUN, V134, P1093, DOI 10.1016/j.jaci.2014.07.023; Niranjan R, 2013, IMMUNOL CELL BIOL, V91, P408, DOI 10.1038/icb.2013.21; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Patel C, 2016, J ALLERGY CLIN IMMUN, V137, pAB62, DOI 10.1016/j.jaci.2015.12.206; Pesek RD, 2017, ANN ALLERG ASTHMA IM, V119, P177, DOI 10.1016/j.anai.2017.06.006; Peterson KA, 2013, AM J GASTROENTEROL, V108, P759, DOI 10.1038/ajg.2012.468; Philpott H, 2016, ALIMENT PHARM THER, V44, P223, DOI 10.1111/apt.13676; Philpott HL, 2015, INTERN MED J, V45, P939, DOI 10.1111/imj.12790; PICUS D, 1981, AM J ROENTGENOL, V136, P1001, DOI 10.2214/ajr.136.5.1001; Prasad GA, 2009, CLIN GASTROENTEROL H, V7, P1055, DOI 10.1016/j.cgh.2009.06.023; Rajan J, 2016, J ALLERGY CLIN IMMUN, V137, P147, DOI 10.1016/j.jaci.2015.05.045; Rajavelu P, 2012, AM J PHYSIOL-GASTR L, V302, pG645, DOI 10.1152/ajpgi.00223.2011; Ram G, 2015, ANN ALLERG ASTHMA IM, V115, P224, DOI 10.1016/j.anai.2015.07.004; Ramirez RM, 2013, J ALLERGY CLIN IMMUN, V132, P503, DOI 10.1016/j.jaci.2013.04.053; Rawson R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144651; Ridolo E, 2011, ANN ALLERG ASTHMA IM, V106, P73, DOI 10.1016/j.anai.2010.10.010; Rodriguez-Sanchez J, 2014, ALLERGY, V69, P936, DOI 10.1111/all.12420; Rothenberg ME, 2015, J ALLERGY CLIN IMMUN, V135, P500, DOI 10.1016/j.jaci.2014.07.049; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Ruffner MA, 2018, J ALLER CL IMM-PRACT, V6, P661, DOI 10.1016/j.jaip.2017.06.035; Sanchez-Garcia S, 2012, J ALLERGY CLIN IMMUN, V129, P1155, DOI 10.1016/j.jaci.2011.11.042; Sherrill JD, 2014, GENES IMMUN, V15, P361, DOI 10.1038/gene.2014.27; Simon D, 2018, ALLERGY, V73, P239, DOI 10.1111/all.13244; Simon D, 2016, ALLERGY, V71, P611, DOI 10.1111/all.12846; Simon D, 2013, ALLERGY, V68, P945, DOI 10.1111/all.12157; Sleiman PMA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6593; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336, DOI 10.1016/S1081-1206(10)61151-9; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Spergel JM, 2007, J ALLERGY CLIN IMMUN, V119, P509, DOI 10.1016/j.jaci.2006.11.016; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282; Stone KD, 2008, CLIN EXP ALLERGY, V38, P1858, DOI 10.1111/j.1365-2222.2008.03122.x; Upadhyaya B, 2011, J IMMUNOL, V187, P3111, DOI 10.4049/jimmunol.1101283; van Rhijn BD, 2013, ALLERGY, V68, P1475, DOI 10.1111/all.12257; van Rhijn BD, 2015, J ALLERGY CLIN IMMUN, V136, P1095, DOI 10.1016/j.jaci.2015.02.038; Wang FY, 2007, J CLIN GASTROENTEROL, V41, P451, DOI 10.1097/01.mcg.0000248019.16139.67; Warners MJ, 2018, GASTROENTEROLOGY, V154, P57, DOI 10.1053/j.gastro.2017.08.062; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Wilson JM, 2016, J ALLERGY CLIN IMMUN, V137, pAB199, DOI 10.1016/j.jaci.2015.12.780; Wolf WA, 2014, CLIN GASTROENTEROL H, V12, P1272, DOI 10.1016/j.cgh.2013.12.034; Wolf WA, 2013, J GASTROINTEST LIVER, V22, P205; Wright BL, 2016, J ALLERGY CLIN IMMUN, V138, P1190, DOI 10.1016/j.jaci.2016.02.024; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	94	33	33	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					1	8		10.1016/j.jaci.2018.05.001	http://dx.doi.org/10.1016/j.jaci.2018.05.001			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29980277	Bronze, Green Accepted			2022-12-18	WOS:000437837500001
J	Deza, G; Bertolin-Colilla, M; Sanchez, S; Soto, D; Pujol, RM; Gimeno, R; Gimenez-Arnau, AM				Deza, Gustavo; Bertolin-Colilla, Marta; Sanchez, Silvia; Soto, Dulce; Pujol, Ramon M.; Gimeno, Ramon; Gimenez-Arnau, Ana M.			Basophil Fc epsilon RI expression is linked to time to omalizumab response in chronic spontaneous urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IGE; THERAPY		[Deza, Gustavo; Bertolin-Colilla, Marta; Sanchez, Silvia; Pujol, Ramon M.; Gimenez-Arnau, Ana M.] Univ Autonoma Barcelona, Hosp del Mar, Inst Invest Med, Dept Dermatol, Barcelona, Spain; [Soto, Dulce; Gimeno, Ramon] Univ Autonoma Barcelona, Hosp del Mar, Inst Invest Med, Dept Immunol, Barcelona, Spain	Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Gimenez-Arnau, AM (corresponding author), Univ Autonoma Barcelona, Hosp del Mar, Inst Invest Med, Dept Dermatol, Barcelona, Spain.	anamariagimenezarnau@gmail.com	Gimeno, Ramon/P-7911-2015	Gimeno, Ramon/0000-0002-8758-121X; PUJOL, RAMON M/0000-0002-5622-6055	Uriach Pharma; Novartis; Genentech; Menarini; Glaxo Smith Kline; Merck MSD; Almirall; Leo Pharma; Intendis-Bayer	Uriach Pharma(Dexcel Pharma); Novartis(Novartis); Genentech(Roche HoldingGenentech); Menarini(Menarini Group); Glaxo Smith Kline(GlaxoSmithKline); Merck MSD(Merck & Company); Almirall(Almirall); Leo Pharma(LEO Pharma); Intendis-Bayer	A. M. Gimenez-Arnau is a medical Advisor for Uriach Pharma, Genentech, and Novartis; has participated in educational activities sponsored by Uriach Pharma, Novartis, Genentech, Menarini, Glaxo Smith & Kline, Merck MSD, Almirall, and Leo Pharma; has consultant arrangements with Novartis, Uriach Pharma, Bayer, and Sanofi; has received grants from Intendis-Bayer, Novartis, and Uriach Pharma; and has received travel support from Novartis. The rest of the authors declare that they have no relevant conflicts of interest.	Deza G, 2017, ACTA DERM-VENEREOL, V97, P698, DOI 10.2340/00015555-2654; Ertas R, 2018, ALLERGY, V73, P705, DOI 10.1111/all.13345; Gericke J, 2017, J ALLERGY CLIN IMMUN, V139, P1059, DOI 10.1016/j.jaci.2016.07.047; Gimenez-Arnau AM, 2016, J EUR ACAD DERMATOL, V30, P25, DOI 10.1111/jdv.13697; Kaplan A, 2016, J ALLERGY CLIN IMMUN, V137, P474, DOI 10.1016/j.jaci.2015.08.023; Metz M, 2017, THERANOSTICS, V7, P1266, DOI 10.7150/thno.18304; Saini SS, 2012, J IMMUNOL METHODS, V383, P60, DOI 10.1016/j.jim.2012.05.016; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Zhao ZT, 2016, J ALLERGY CLIN IMMUN, V137, P1742, DOI 10.1016/j.jaci.2015.12.1342	9	33	37	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2313	2316		10.1016/j.jaci.2018.02.021	http://dx.doi.org/10.1016/j.jaci.2018.02.021			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29518420	Green Accepted, Bronze			2022-12-18	WOS:000434701600047
J	Martin, LJ; He, H; Collins, MH; Abonia, JP; Myers, JMB; Eby, M; Johansson, H; Kottyan, LC; Hershey, GKK; Rothenberg, ME				Martin, Lisa J.; He, Hua; Collins, Margaret H.; Abonia, J. Pablo; Myers, Joceyln M. Biagini; Eby, Michael; Johansson, Hanna; Kottyan, Leah C.; Hershey, Gurjit K. Khurana; Rothenberg, Marc E.			Eosinophilic esophagitis (EoE) genetic susceptibility is mediated by synergistic interactions between EoE-specific and general atopic disease loci	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Genetic association; atopy; eosinophilic esophagitis	THYMIC STROMAL LYMPHOPOIETIN; GENOME-WIDE ASSOCIATION; NICKEL ALLERGY SYNDROME; INNATE LYMPHOID-CELLS; CD4(+) T-CELLS; SWALLOWED FLUTICASONE; CHILDHOOD ASTHMA; TOPICAL FLUTICASONE; EPITHELIAL-CELLS; IL-4 PRODUCTION	Background: Eosinophilic esophagitis (EoE) is an esophageal inflammatory disease associated with atopic diseases. Thymic stromal lymphopoietin (TSLP) and calpain 14 (CAPN14) genetic variations contribute to EoE, but how this relates to atopy is unclear. Objective: The purpose of this study was to explore the relationship between EoE, atopy, and genetic risk. Methods: EoE-atopy enrichment was tested by using 700 patients with EoE and 801 community control subjects. Probing 372 single nucleotide polymorphisms (SNPs) in 63 atopy genes, we evaluated EoE associations using 412 nonatopic and 868 atopic disease control subjects. Interaction and stratified analyses of EoE-specific and atopy-related SNPs were performed. Results: Atopic disease was enriched in patients with EoE (P<.0001). Comparing patients with EoE and nonatopic control subjects, EoE associated strongly with IL-4/kinesin family member 3A (IL4/KIF3A) (P = 2.8 x 10(-6); odds ratio [OR], 1.87), moderately with TSLP (P = 1.5 x 10(-4); OR, 1.43), and nominally with CAPN14 (P = .029; OR, 1.35). Comparing patients with EoE with atopic disease control subjects, EoE associated strongly with ST2 (P = 3.5 x 10(-6); OR, 1.77) and nominally with IL4/KIF3A (P = .019; OR, 1.25); TSLP's association persisted (P = 4.7 x 10(-5); OR, 1.37), and CAPN14's association strengthened (P = .0001; OR, 1.71). Notably, there was gene-gene interaction between TSLP and IL4 SNPs (P = .0074). Children with risk alleles for both genes were at higher risk for EoE (P = 2.0 x 10(-10); OR, 3.67). Conclusions: EoE genetic susceptibility is mediated by EoE-specific and general atopic disease loci, which can have synergistic effects. These results might aid in identifying potential therapeutics and predicting EoE susceptibility.	[Martin, Lisa J.; He, Hua] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; [Collins, Margaret H.] Cincinnati Childrens Hosp Med Ctr, Div Pathol, Cincinnati, OH 45229 USA; [Abonia, J. Pablo; Eby, Michael; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Myers, Joceyln M. Biagini; Johansson, Hanna; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA; [Kottyan, Leah C.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA; [Martin, Lisa J.; Collins, Margaret H.; Abonia, J. Pablo; Myers, Joceyln M. Biagini; Kottyan, Leah C.; Hershey, Gurjit K. Khurana; Rothenberg, Marc E.] Univ Cincinnati, Dept Pediat, Sch Med, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA.	marc.rothenberg@cchmc.org	Kottyan, Leah C./H-3050-2019; Martin, Lisa/E-2425-2016	Kottyan, Leah C./0000-0003-3979-2220; Martin, Lisa/0000-0001-8702-9946; Biagini, Jocelyn/0000-0002-4378-6133	National Institutes of Health [U19 AI70235, R01 AI124355, R01 DK107502, P30 AR070549]; Sunshine Charitable Foundation; American Partnership for Eosinophilic Disorders (APFED); Buckeye Foundation; Campaign Urging Research for Eosinophilic Diseases (CURED) Foundation; Cincinnati Children's Research Foundation; Cincinnati Genomic Control Cohort; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066738, R01AI124355, U54AI117804, U19AI070235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR070549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392, R01DK107502] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sunshine Charitable Foundation; American Partnership for Eosinophilic Disorders (APFED); Buckeye Foundation; Campaign Urging Research for Eosinophilic Diseases (CURED) Foundation; Cincinnati Children's Research Foundation; Cincinnati Genomic Control Cohort; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by National Institutes of Health grants U19 AI70235, R01 AI124355, R01 DK107502, and P30 AR070549; the Sunshine Charitable Foundation and its supporters, Denise A. Bunning and David G. Bunning; the American Partnership for Eosinophilic Disorders (APFED); the Buckeye Foundation; the Campaign Urging Research for Eosinophilic Diseases (CURED) Foundation; and the Cincinnati Children's Research Foundation and its Cincinnati Genomic Control Cohort.	Adams NP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003135.pub4; Alexander ES, 2014, J ALLERGY CLIN IMMUN, V134, P1084, DOI 10.1016/j.jaci.2014.07.021; Alexander JA, 2012, CLIN GASTROENTEROL H, V10, P742, DOI 10.1016/j.cgh.2012.03.018; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Antico A, 2015, ALLERGY RHINOL, V6, pE56, DOI 10.2500/ar.2015.6.0109; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Baye TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016522; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Black S, 2009, ALLERGY, V64, P1172, DOI 10.1111/j.1398-9995.2009.01988.x; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2010, J IMMUNOL, V184, P4033, DOI 10.4049/jimmunol.0903069; Boldorini R, 2013, J CLIN PATHOL, V66, P399, DOI 10.1136/jclinpath-2012-201253; Bouffi C, 2013, J IMMUNOL, V191, P4317, DOI 10.4049/jimmunol.1301465; Butz BK, 2014, GASTROENTEROLOGY, V147, P324, DOI 10.1053/j.gastro.2014.04.019; Jimenez AC, 2014, ALLERGOL IMMUNOPATH, V42, P407, DOI 10.1016/j.aller.2013.04.004; Chadha SN, 2014, ANN ALLERG ASTHMA IM, V113, P445, DOI 10.1016/j.anai.2014.07.020; Collins MH, 2008, CLIN GASTROENTEROL H, V6, P621, DOI 10.1016/j.cgh.2008.01.004; Collins MH, 2014, DIGEST DIS, V32, P68, DOI 10.1159/000357012; da Rosa JC, 2015, J ALLERGY CLIN IMMUN, V135, P712, DOI 10.1016/j.jaci.2014.11.017; Davis BP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86355; de Guia RM, 2015, INT J IMMUNOGENET, V42, P182, DOI 10.1111/iji.12200; de Guia RM, 2010, INT J MOL EPIDEMIOL, V1, P67; DeBrosse CW, 2011, J ALLERGY CLIN IMMUN, V128, P132, DOI 10.1016/j.jaci.2011.05.006; Dellon ES, 2014, CLIN GASTROENTEROL H, V12, P589, DOI 10.1016/j.cgh.2013.09.008; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Dewas C, 2015, J IMMUNOL, V194, P1372, DOI 10.4049/jimmunol.1400519; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Di Gioacchino M, 2014, ANN MED, V46, P31, DOI 10.3109/07853890.2013.861158; Dmitrieva-Zdorova EV, 2012, J INVEST ALLERG CLIN, V22, P126; Doherty TA, 2015, J ALLERGY CLIN IMMUN, V136, P792, DOI 10.1016/j.jaci.2015.05.048; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Harada M, 2011, AM J RESP CELL MOL, V44, P787, DOI 10.1165/rcmb.2009-0418OC; He JQ, 2003, GENES IMMUN, V4, P385, DOI 10.1038/sj.gene.6363985; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; Hunninghake GM, 2010, ALLERGY, V65, P1566, DOI 10.1111/j.1398-9995.2010.02415.x; Hussein YM, 2014, GENE, V545, P276, DOI 10.1016/j.gene.2014.04.024; Jang S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056433; Jiang H, 2012, ALLERGY, V67, P1078, DOI 10.1111/j.1398-9995.2012.02857.x; Kawashima T, 1998, J MED GENET, V35, P502, DOI 10.1136/jmg.35.6.502; Korting HC, 2012, J EUR ACAD DERMATOL, V26, P133, DOI 10.1111/j.1468-3083.2011.04195.x; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Kovacic MB, 2012, PEDIAT ALLER IMM PUL, V25, P104, DOI 10.1089/ped.2011.0116; Kovacic MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023714; Lee DU, 2004, P NATL ACAD SCI USA, V101, P16010, DOI 10.1073/pnas.0407031101; Leyva-Castillo JM, 2013, J INVEST DERMATOL, V133, P154, DOI 10.1038/jid.2012.239; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Litosh VA, 2017, J ALLERGY CLIN IMMUN, V139, P1762, DOI 10.1016/j.jaci.2016.09.027; Liu MX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014706; Lu MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027363; Marenholz I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9804; Martin LJ, 2015, J ALLERGY CLIN IMMUN, V135, P1519, DOI 10.1016/j.jaci.2015.03.004; Meltzer EO, 2014, ALLERGY ASTHMA PROC, V35, pS11, DOI 10.2500/aap.2014.35.3756; Miyake Y, 2013, J INVEST ALLERG CLIN, V23, P242; Moawad FJ, 2013, AM J GASTROENTEROL, V108, P366, DOI 10.1038/ajg.2012.443; Myers JMB, 2014, J ALLERGY CLIN IMMUN, V134, P891, DOI 10.1016/j.jaci.2014.03.037; Namjou B, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00401; Noel RJ, 2004, CLIN GASTROENTEROL H, V2, P568, DOI 10.1016/S1542-3565(04)00240-X; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Omori M, 2007, J IMMUNOL, V178, P1396, DOI 10.4049/jimmunol.178.3.1396; Peden DB, 1998, J ALLERGY CLIN IMMUN, V102, P32, DOI 10.1016/S0091-6749(98)70052-1; Perkins C, 2006, J ALLERGY CLIN IMMUN, V118, P410, DOI 10.1016/j.jaci.2006.06.004; Pinto LA, 2008, J PEDIAT, V84, pS68, DOI [10.1590/S0021-75572008000500010, 10.2223/JPED.1781]; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Reijmerink NE, 2008, J ALLERGY CLIN IMMUN, V122, P651, DOI 10.1016/j.jaci.2008.06.030; Ricciardi L, 2014, INT J IMMUNOPATH PH, V27, P131, DOI 10.1177/039463201402700118; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Rothenberg ME, 2015, GASTROENTEROLOGY, V148, P1143, DOI 10.1053/j.gastro.2015.02.002; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Roy-Ghanta S, 2008, CLIN GASTROENTEROL H, V6, P531, DOI 10.1016/j.cgh.2007.12.045; Santangelo S, 2002, J IMMUNOL, V169, P1893, DOI 10.4049/jimmunol.169.4.1893; Schaefer ET, 2008, CLIN GASTROENTEROL H, V6, P165, DOI 10.1016/j.cgh.2007.11.008; Schmidt-Weber CB, 2012, CHEM IMMUNOL ALLERGY, V96, P120, DOI 10.1159/000332235; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Sleiman PMA, 2015, BEST PRACT RES CL GA, V29, P701, DOI 10.1016/j.bpg.2015.09.003; Sleiman PMA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6593; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336, DOI 10.1016/S1081-1206(10)61151-9; Tatsuno K, 2015, J INVEST DERMATOL, V135, P3017, DOI 10.1038/jid.2015.318; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Travers J, 2016, J ALLERGY CLIN IMMUN, V138, P1381, DOI 10.1016/j.jaci.2016.09.001; Ueta M, 2010, BRIT J OPHTHALMOL, V94, P1239, DOI 10.1136/bjo.2009.173419; Venturelli N, 2016, J ALLERGY CLIN IMMUN, V138, P1367, DOI 10.1016/j.jaci.2016.02.034; Vernon N, 2014, ALLERGY ASTHMA PROC, V35, P409, DOI 10.2500/aap.2014.35.3768; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Wu H, 2010, J ALLERGY CLIN IMMUN, V125, P321, DOI 10.1016/j.jaci.2009.09.007; Zhang Z, 2009, P NATL ACAD SCI USA, V106, P1536, DOI 10.1073/pnas.0812668106; Zhu N, 2013, CHINESE MED J-PEKING, V126, P2943, DOI 10.3760/cma.j.issn.0366-6999.20123060; Zhu SK, 2000, AM J RESP CRIT CARE, V161, P1655, DOI 10.1164/ajrccm.161.5.9906086	96	33	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1690	1698		10.1016/j.jaci.2017.09.046	http://dx.doi.org/10.1016/j.jaci.2017.09.046			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29129581	Green Accepted, Bronze			2022-12-18	WOS:000432148200016
J	Schubert, D; Klein, MC; Hassdenteufel, S; Caballero-Oteyza, A; Yang, LL; Proietti, M; Bulashevska, A; Kemming, J; Kuhn, J; Winzer, S; Rusch, S; Fliegauf, M; Schaffer, AA; Pfeffer, S; Geiger, R; Cavalie, A; Cao, HZ; Yang, F; Li, Y; Rizzi, M; Eibel, H; Kobbe, R; Marks, AL; Peppers, BP; Hostoffer, RW; Puck, JM; Zimmermann, R; Grimbacher, B				Schubert, Desiree; Klein, Marie-Christine; Hassdenteufel, Sarah; Caballero-Oteyza, Andres; Yang, Linlin; Proietti, Michele; Bulashevska, Alla; Kemming, Janine; Kuehn, Johannes; Winzer, Sandra; Rusch, Stephan; Fliegauf, Manfred; Schaffer, Alejandro A.; Pfeffer, Stefan; Geiger, Roger; Cavalie, Adolfo; Cao, Hongzhi; Yang, Fang; Li, Yong; Rizzi, Marta; Eibel, Hermann; Kobbe, Robin; Marks, Amy L.; Peppers, Brian P.; Hostoffer, Robert W.; Puck, Jennifer M.; Zimmermann, Richard; Grimbacher, Bodo			Plasma cell deficiency in human subjects with heterozygous mutations in Sec61 translocon alpha 1 subunit (SEC61A1)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SEC61A1; translocon; protein translocation; antibody deficiency; plasma cell; multiple myeloma; calcium homeostasis; endoplasmic reticulum stress	ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; ER STRESS; PROTEIN; DIFFERENTIATION; RENIN; HYPERURICEMIA; DIAGNOSIS; ANEMIA; GENES	Background: Primary antibody deficiencies (PADs) are the most frequent primary immunodeficiencies in human subjects. The genetic causes of PADs are largely unknown. Sec61 translocon alpha 1 subunit (SEC61A1) is the major subunit of the Sec61 complex, which is the main polypeptide-conducting channel in the endoplasmic reticulum membrane. SEC61A1 is a target gene of spliced X-box binding protein 1 and strongly induced during plasma cell (PC) differentiation. Objective: We identified a novel genetic defect and studied its pathologic mechanism in 11 patients from 2 unrelated families with PADs. Methods: Whole-exome and targeted sequencing were conducted to identify novel genetic mutations. Functional studies were carried out ex vivo in primary cells of patients and in vitro in different cell lines to assess the effect of SEC61A1 mutations on B-cell differentiation and survival. Results: We investigated 2 families with patients with hypogammaglobulinemia, severe recurrent respiratory tract infections, and normal peripheral B-and T-cell subpopulations. On in vitro stimulation, B cells showed an intrinsic deficiency to develop into PCs. Genetic analysis and targeted sequencing identified novel heterozygous missense (c.254T>A, p.V85D) and nonsense (c.1325G>T, p.E381*) mutations in SEC61A1, segregating with the disease phenotype. SEC61A1-V85D was deficient in cotranslational protein translocation, and it disturbed the cellular calcium homeostasis in HeLa cells. Moreover, SEC61A1-V85D triggered the terminal unfolded protein response in multiple myeloma cell lines. Conclusion: We describe a monogenic defect leading to a specific PC deficiency in human subjects, expanding our knowledge about the pathogenesis of antibody deficiencies.	[Schubert, Desiree; Caballero-Oteyza, Andres; Yang, Linlin; Proietti, Michele; Bulashevska, Alla; Kemming, Janine; Kuehn, Johannes; Winzer, Sandra; Rusch, Stephan; Fliegauf, Manfred; Eibel, Hermann; Grimbacher, Bodo] Univ Freiburg, Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Rizzi, Marta] Univ Freiburg, Med Ctr, Dept Rheumatol & Clin Immunol, Freiburg, Germany; [Li, Yong] Univ Freiburg, Med Ctr, Dept Med, Div Nephrol, Freiburg, Germany; [Schubert, Desiree] Univ Freiburg, Fac Med, Spemann Grad Sch Biol & Med SGBM, Freiburg, Germany; [Schubert, Desiree; Zimmermann, Richard] Univ Freiburg, Fac Biol, Freiburg, Germany; [Klein, Marie-Christine; Hassdenteufel, Sarah] Saarland Univ, Med Biochem & Mol Biol, Homburg, Germany; [Schaffer, Alejandro A.] Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; [Pfeffer, Stefan] Max Planck Inst Biochem, Dept Mol Struct Biol, Martinsried, Germany; [Geiger, Roger] Univ Svizzera Italiana, Inst Res Biomed, Bellinzona, Switzerland; [Geiger, Roger] Swiss Fed Inst Technol, Inst Microbiol, Zurich, Switzerland; [Cavalie, Adolfo] Saarland Univ, Expt & Clin Pharmacol & Toxicol, Homburg, Germany; [Cao, Hongzhi; Yang, Fang] BGI Shenzhen, Shenzhen, Peoples R China; [Kobbe, Robin] Univ Med Ctr, Dept Pediat, Hamburg, Germany; [Marks, Amy L.] Beaumont Childrens Hosp, Troy, NY USA; [Peppers, Brian P.; Hostoffer, Robert W.] Univ Hosp Cleveland, Med Ctr, Allergy Immunol Fellowship Program, Cleveland, OH 44106 USA; [Hostoffer, Robert W.] Allergy & Immunol Associates, Mayfield Hts, OH USA; [Puck, Jennifer M.] Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA USA; [Puck, Jennifer M.] UCSF Benioff Childrens Hosp, San Francisco, CA USA; [Grimbacher, Bodo] UCL, Inst Immun & Transplantat, London, England	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Universitatsklinikum des Saarlandes; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Max Planck Society; Universita della Svizzera Italiana; Swiss Federal Institutes of Technology Domain; ETH Zurich; Universitatsklinikum des Saarlandes; Beijing Genomics Institute (BGI); University of Hamburg; University Medical Center Hamburg-Eppendorf; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; University of California System; University of California San Francisco; University of London; University College London	Grimbacher, B (corresponding author), Univ Klinikum Freiburg, CCI, Breisacherstr 115, D-79106 Freiburg, Germany.	bodo.grimbacher@uniklinik-freiburg.de	Schaffer, Alejandro A/F-2902-2012; Hassdenteufel, Sarah/AAE-8915-2022; Rizzi, Marta/ABE-7264-2020; Schaffer, Alejandro/N-1222-2019; Bulashevska, Alla/C-4910-2019; Pfeffer, Stefan/AAF-9790-2019	Hassdenteufel, Sarah/0000-0001-7243-6602; Pfeffer, Stefan/0000-0001-5843-2795; Geiger, Roger/0000-0002-8016-1669; Rizzi, Marta/0000-0002-5153-6089; Hostoffer, Robert/0000-0001-8296-3588; Caballero Garcia de Oteyza, Andres/0000-0002-8892-1255; Kemming, Janine/0000-0002-7967-9313	Bundesministerium fur Bildung und Forschung (BMBF) [IFB/CCI: 01EO1303, E:med/SysInflame: 01ZX1306F, DZIF: 8000805-3]; Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School); National Institutes of Health, NLM; Deutsche Forschungsgemeinschaft [SFB894, IRTG1830]; NATIONAL LIBRARY OF MEDICINE [ZIALM000097] Funding Source: NIH RePORTER	Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School); National Institutes of Health, NLM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	Supported by the Bundesministerium fur Bildung und Forschung (BMBF) with grant nos. IFB/CCI: 01EO1303; E:med/SysInflame: 01ZX1306F, and DZIF: 8000805-3 (to B.G.) and supported in part by the Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School; to D.S.). This work was also supported in part by the Intramural Research Program of the National Institutes of Health, NLM (to A.A.S) and by grants from the Deutsche Forschungsgemeinschaft (to A.C. [SFB894] and R.Z. [IRTG1830, SFB894]).	Beck BB, 2011, AM J KIDNEY DIS, V58, P821, DOI 10.1053/j.ajkd.2011.06.029; Bleyer AJ, 2010, CLIN NEPHROL, V74, P411; Bogaert DJA, 2016, J MED GENET, V53, P575, DOI 10.1136/jmedgenet-2015-103690; Bolar NA, 2016, AM J HUM GENET, V99, P174, DOI 10.1016/j.ajhg.2016.05.028; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Cenci S, 2007, FEBS LETT, V581, P3652, DOI 10.1016/j.febslet.2007.04.031; Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Davila S, 2004, NAT GENET, V36, P575, DOI 10.1038/ng1357; ENOCH HG, 1979, J BIOL CHEM, V254, P6483; Fried AJ, 2009, CLIN MICROBIOL REV, V22, P396, DOI 10.1128/CMR.00001-09; JACKSON RC, 1977, P NATL ACAD SCI USA, V74, P5598, DOI 10.1073/pnas.74.12.5598; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Junne T, 2010, MOL BIOL CELL, V21, P1662, DOI 10.1091/mbc.E10-01-0060; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lang S, 2012, J CELL SCI, V125, P1958, DOI 10.1242/jcs.096727; Lang S, 2011, JOVE-J VIS EXP, DOI 10.3791/2730; Lang S, 2011, CHANNELS, V5, P228, DOI 10.4161/chan.5.3.15314; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Li YM, 2014, ACTA BIOCH BIOPH SIN, V46, P629, DOI 10.1093/abbs/gmu048; Lloyd DJ, 2010, DIABETES, V59, P460, DOI 10.2337/db08-1362; Losfeld ME, 2014, HUM MOL GENET, V23, P1602, DOI 10.1093/hmg/ddt550; Ma YJ, 2010, CELL STRESS CHAPERON, V15, P281, DOI 10.1007/s12192-009-0142-9; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; Park E, 2011, NATURE, V473, P239, DOI 10.1038/nature10014; Pelletier N, 2006, J IMMUNOL, V176, P1340, DOI 10.4049/jimmunol.176.3.1340; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Rieckmann JC, 2017, NAT IMMUNOL, V18, P583, DOI 10.1038/ni.3693; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shi W, 2015, NAT IMMUNOL, V16, P663, DOI 10.1038/ni.3154; Synofzik M, 2014, AM J HUM GENET, V95, P689, DOI 10.1016/j.ajhg.2014.10.013; TAURA T, 1993, J BACTERIOL, V175, P7771, DOI 10.1128/JB.175.24.7771-7775.1993; Todd DJ, 2009, J EXP MED, V206, P2151, DOI 10.1084/jem.20090738; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501; Wilkinson BM, 2000, J BIOL CHEM, V275, P521, DOI 10.1074/jbc.275.1.521; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zivna M, 2009, AM J HUM GENET, V85, P204, DOI 10.1016/j.ajhg.2009.07.010	42	33	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1427	1438		10.1016/j.jaci.2017.06.042	http://dx.doi.org/10.1016/j.jaci.2017.06.042			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28782633	Green Accepted, Bronze			2022-12-18	WOS:000429197800028
J	Seidel, MG; Bohm, K; Dogu, F; Worth, A; Thrasher, A; Florkin, B; Ikinciogullari, A; Peters, A; Bakhtiar, S; Meeths, M; Stepensky, P; Meyts, I; Sharapova, SO; Gamez-Diaz, L; Hammarstrom, L; Ehl, S; Grimbacher, B; Gennery, AR				Seidel, Markus G.; Boehm, Katrin; Dogu, Figen; Worth, Austen; Thrasher, Adrian; Florkin, Benoit; Ikinciogullari, Aydan; Peters, Anke; Bakhtiar, Shahrzad; Meeths, Marie; Stepensky, Polina; Meyts, Isabelle; Sharapova, Svetlana O.; Gamez-Diaz, Laura; Hammarstroem, Lennart; Ehl, Stephan; Grimbacher, Bodo; Gennery, Andrew R.		Inborn Errors Working Party	Treatment of severe forms of LPS-responsive beige-like anchor protein deficiency with allogeneic hematopoietic stem cell transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LRBA; MUTATIONS		[Seidel, Markus G.; Boehm, Katrin] Med Univ Gwraz, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Res Unit Pediat Hematol & Immunol, Graz, Austria; [Dogu, Figen; Ikinciogullari, Aydan] Ankara Univ, Sch Med, Dept Pediat Immunol & Allergy, Ankara, Turkey; [Worth, Austen; Thrasher, Adrian] UCL, Inst Child Hlth, London, England; [Florkin, Benoit] CHR Citadelle, Serv Pediat, Immunohematorhumatol Pediat, Liege, Belgium; [Peters, Anke; Ehl, Stephan] Univ Freiburg, Dept Pediat & Adolescent Med, Freiburg, Germany; [Gamez-Diaz, Laura; Ehl, Stephan; Grimbacher, Bodo] Univ Freiburg, Med Ctr, Ctr Chron Immunodeficiency CCI, Freiburg, Germany; [Bakhtiar, Shahrzad] Univ Hosp Frankfurt, Div Pediat Stem Cell Transplantat & Immunol, Frankfurt, Germany; [Meeths, Marie] Karolinska Univ Hosp Solna, Childhood Canc Res Unit, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Meeths, Marie] Karolinska Univ Hosp Solna, Clin Genet Unit, Dept Mol Med & Surg, Stockholm, Sweden; [Meeths, Marie] Karolinska Univ Hosp Solna, Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; [Stepensky, Polina] Hadassah Hebrew Univ, Med Ctr, Dept Bone Marrow Transplantat, Jerusalem, Israel; [Meyts, Isabelle] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Pediat Immunol Microbiol & Immunol, Leuven, Belgium; [Sharapova, Svetlana O.] Belarusian Res Ctr Pediat Oncol Hematol & Immunol, Res Dept, Minsk, Minsk Region, BELARUS; [Hammarstroem, Lennart] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Immunol, Stockholm, Sweden; [Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England	Ankara University; University of London; University College London; University of Freiburg; University of Freiburg; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Hebrew University of Jerusalem; Hadassah University Medical Center; KU Leuven; University Hospital Leuven; Karolinska Institutet; Karolinska University Hospital; Newcastle University - UK	Seidel, MG (corresponding author), Med Univ Gwraz, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Res Unit Pediat Hematol & Immunol, Graz, Austria.	markus.seidel@medunigraz.at	Sharapova, Svetlana/ABF-3330-2020; Ehl, Stephan/AAM-6006-2020; Ba, Sha/HGB-9711-2022; Dogu, Figen/AAI-1316-2020; Meyts, Isabelle/Z-3295-2019; İkinciogullari, Aydan/AAQ-3841-2020; Seidel, Markus G/N-9951-2017	Dogu, Figen/0000-0002-7869-4941; İkinciogullari, Aydan/0000-0003-1145-0843; Ehl, Stephan/0000-0002-9265-2721; Seidel, Markus G/0000-0003-0981-8661; Florkin, Benoit/0000-0001-7318-8348	Styrian Children's Cancer Aid (Steirische Kinderkrebshilfe); BMBF [01EO1303]	Styrian Children's Cancer Aid (Steirische Kinderkrebshilfe); BMBF(Federal Ministry of Education & Research (BMBF))	M.G.S. was funded in part by the Styrian Children's Cancer Aid (Steirische Kinderkrebshilfe). The work was also supported by the BMBF (grant 01EO1303 to S.E. and B.G.).	Alkhairy OK, 2016, J CLIN IMMUNOL, V36, P33, DOI 10.1007/s10875-015-0224-7; Bakhtiar S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00052; Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; Gamez-Diaz L, 2016, J ALLERGY CLIN IMMUN, V137, P223, DOI 10.1016/j.jaci.2015.09.025; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Sari S, 2016, J CLIN IMMUNOL, V36, P8, DOI 10.1007/s10875-015-0220-y; Seidel MG, 2015, J ALLERGY CLIN IMMUN, V135, P1384, DOI 10.1016/j.jaci.2014.10.048; Tesi B, 2016, J CLIN IMMUNOL, V36, P480, DOI 10.1007/s10875-016-0289-y	9	33	34	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					770	775		10.1016/j.jaci.2017.04.023	http://dx.doi.org/10.1016/j.jaci.2017.04.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28502825	Bronze, Green Published			2022-12-18	WOS:000424410800034
J	Robb, CT; McSorley, HJ; Lee, J; Aoki, T; Yu, CJ; Crittenden, S; Astier, A; Felton, JM; Parkinson, N; Ayele, A; Breyer, RM; Anderton, SM; Narumiya, S; Rossi, AG; Howie, SE; Guttman-Yassky, E; Weller, RB; Yao, CC				Robb, Calum T.; McSorley, Henry J.; Lee, Jinju; Aoki, Tomohiro; Yu, Cunjing; Crittenden, Siobhan; Astier, Anne; Felton, Jennifer M.; Parkinson, Nicholas; Ayele, Adane; Breyer, Richard M.; Anderton, Stephen M.; Narumiya, Shuh; Rossi, Adriano G.; Howie, Sarah E.; Guttman-Yassky, Emma; Weller, Richard B.; Yao, Chengcan			Prostaglandin E-2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic contact dermatitis; atopic dermatitis; prostaglandin E-2; CD4(+) T cells; T(H)22 cells; T(H)17 cells; IL-22	ATOPIC-DERMATITIS; GENE-EXPRESSION; CELL-DIFFERENTIATION; IMMUNE-RESPONSES; MURINE MODELS; SKIN BARRIER; TH17 CELLS; T-CELLS; INFLAMMATION; BETAMETHASONE	Background: Atopic dermatitis (AD) and allergic contact dermatitis (ACD) are both forms of eczema and are common inflammatory skin diseases with a central role of T cell-derived IL-22 in their pathogenesis. Although prostaglandin (PG) E-2 is known to promote inflammation, little is known about its role in processes related to AD and ACD development, including IL-22 upregulation. Objectives: We sought to investigate whether PGE(2) has a role in IL-22 induction and development of ACD, which has increased prevalence in patients with AD. Methods: T-cell cultures and in vivo sensitization of mice with haptens were used to assess the role of PGE(2) in IL-22 production. The involvement of PGE(2) receptors and their downstream signals was also examined. The effects of PGE(2) were evaluated by using the oxazolone-induced ACD mouse model. The relationship of PGE(2) and IL-22 signaling pathways in skin inflammation were also investigated by using genomic profiling in human lesional AD skin. Results: PGE(2) induces IL-22 from T cells through its receptors, E prostanoid receptor (EP) 2 and EP4, and involves cyclic AMP signaling. Selective deletion of EP4 in T cells prevents hapten-induced IL-22 production in vivo, and limits atopic-like skin inflammation in the oxazolone-induced ACD model. Moreover, both PGE(2) and IL-22 pathway genes were coordinately upregulated in human AD lesional skin but were at less than significant detection levels after corticosteroid or UVB treatments. Conclusions: Our results define a crucial role for PGE(2) in promoting ACD by facilitating IL-22 production from T cells.	[Robb, Calum T.; McSorley, Henry J.; Yu, Cunjing; Crittenden, Siobhan; Astier, Anne; Felton, Jennifer M.; Parkinson, Nicholas; Anderton, Stephen M.; Rossi, Adriano G.; Howie, Sarah E.; Weller, Richard B.; Yao, Chengcan] Univ Edinburgh, MRC, Ctr Inflammat Res, Queens Med Res Inst, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland; [Lee, Jinju; Aoki, Tomohiro; Narumiya, Shuh] Kyoto Univ, Grad Sch Med, Ctr Innovat Immunoregulat Technol & Therapeut AK, Kyoto, Japan; [Lee, Jinju; Aoki, Tomohiro; Narumiya, Shuh] Kyoto Univ, Grad Sch Med, Core Res Evolut Sci & Technol, Med Innovat Ctr, Kyoto, Japan; [Ayele, Adane] Univ Addis Ababa, Sch Med, Dept Dermatovenereol, Coll Hlth Sci, Addis Ababa, Ethiopia; [Breyer, Richard M.] Tennessee Valley Hlth Author, Dept Vet Affairs, Nashville, TN USA; [Breyer, Richard M.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY 10029 USA; [Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA	University of Edinburgh; Kyoto University; Japan Science & Technology Agency (JST); Kyoto University; Addis Ababa University; Vanderbilt University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University	Yao, CC (corresponding author), Univ Edinburgh, MRC, Ctr Inflammat Res, Queens Med Res Inst, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	Chengcan.Yao@ed.ac.uk	Astier, Anne L/A-1641-2008; Weller, Richard/B-4954-2010	Astier, Anne L/0000-0002-0144-3431; Weller, Richard/0000-0003-2550-9586; Yao, Chengcan/0000-0003-3754-2842; McSorley, Henry/0000-0003-1300-7407; Parkinson, Nicholas/0000-0001-6336-5654; Aoki, Tomohiro/0000-0002-1578-1394; Felton, Jennifer/0000-0002-5004-0794	University of Edinburgh; Wellcome Trust; Asthma UK; Psoriasis Association UK; Medical Research Council (MRC) UK [MR/K013386/1]; National Institutes of Health [DK37097, R56HL127218]; VA Merit [1BX000616]; Core Research for Evolutional Science and Technology (CREST) of Japan Science and Technology Agency; Chinese Scholarship Council; Grants-in-Aid for Scientific Research [17H01531] Funding Source: KAKEN; MRC [G0901697, MR/K013386/1, G0601481, G0801924] Funding Source: UKRI; Medical Research Council [G0801924, G0901697, MR/K013386/1, 1586877, G0601481] Funding Source: researchfish; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL127218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037097] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000616] Funding Source: NIH RePORTER	University of Edinburgh; Wellcome Trust(Wellcome Trust); Asthma UK; Psoriasis Association UK; Medical Research Council (MRC) UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit(US Department of Veterans Affairs); Core Research for Evolutional Science and Technology (CREST) of Japan Science and Technology Agency(Core Research for Evolutional Science and Technology (CREST)); Chinese Scholarship Council(China Scholarship Council); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	Supported in part by the University of Edinburgh start-up funding and Wellcome Trust Institutional Strategic Support Fund (to C. Yao and H.J.M.), Asthma UK (to H.J.M.), Psoriasis Association UK (to R.B.W.), Medical Research Council (MRC) UK (A.G.R. C.T.R., and J.M.F. were supported by MR/K013386/1 and to S.M.A., R.B.W. and H.J.M.), National Institutes of Health grants DK37097 and R56HL127218 and a VA Merit 1BX000616 (to R.M.B.), and Core Research for Evolutional Science and Technology (CREST) of Japan Science and Technology Agency (to S.N.). C. Yu and C.S. receive scholarship supports from the Chinese Scholarship Council and the University of Edinburgh, respectively.	Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Boniface K, 2009, J EXP MED, V206, P535, DOI 10.1084/jem.20082293; Cella M, 2015, SEMIN IMMUNOL, V27, P310, DOI 10.1016/j.smim.2015.10.002; Chan S, 1996, J ALLERGY CLIN IMMUN, V97, P85, DOI 10.1016/S0091-6749(96)70286-5; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Czarnowicki T, 2014, J ALLER CL IMM-PRACT, V2, P371, DOI 10.1016/j.jaip.2014.03.006; Dhingra N, 2014, J INVEST DERMATOL, V134, P2071, DOI 10.1038/jid.2014.141; Duffin R, 2016, SCIENCE, V351, P1333, DOI 10.1126/science.aad9903; Dyring-Andersen B, 2013, CONTACT DERMATITIS, V68, P339, DOI 10.1111/cod.12043; Egawa G, 2016, J ALLERGY CLIN IMMUN, V138, P350, DOI 10.1016/j.jaci.2016.06.002; Ewald DA, 2017, J ALLERGY CLIN IMMUN, V139, P562, DOI 10.1016/j.jaci.2016.08.029; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Fedyk ER, 1996, P NATL ACAD SCI USA, V93, P10978, DOI 10.1073/pnas.93.20.10978; FOGH K, 1989, J ALLERGY CLIN IMMUN, V83, P450, DOI 10.1016/0091-6749(89)90132-2; Gittler JK, 2013, J ALLERGY CLIN IMMUN, V131, P300, DOI 10.1016/j.jaci.2012.06.048; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2016, J ALLERGY CLIN IMMUN, V137, P301, DOI 10.1016/j.jaci.2015.11.001; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hayashida S, 2011, J DERMATOL SCI, V61, P78, DOI 10.1016/j.jdermsci.2010.08.013; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Hirata T, 2012, ADV IMMUNOL, V116, P143, DOI 10.1016/B978-0-12-394300-2.00005-3; Honda T, 2015, ALLERGOL INT, V64, P11, DOI 10.1016/j.alit.2014.08.002; Honda T, 2013, J INVEST DERMATOL, V133, P303, DOI 10.1038/jid.2012.284; Inada T, 2007, ACTA ANAESTH SCAND, V51, P490, DOI 10.1111/j.1399-6576.2007.01272.x; Jensen JM, 2012, ALLERGY, V67, P413, DOI 10.1111/j.1398-9995.2011.02747.x; Jin HL, 2009, J INVEST DERMATOL, V129, P31, DOI 10.1038/jid.2008.106; Kabashima K, 2003, NAT MED, V9, P744, DOI 10.1038/nm872; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kurz T, 2006, J ALLERGY CLIN IMMUN, V118, P396, DOI 10.1016/j.jaci.2006.04.036; Laouini D, 2005, J ALLERGY CLIN IMMUN, V116, P390, DOI 10.1016/j.jaci.2005.03.042; Malajian D, 2015, CYTOKINE, V73, P311, DOI 10.1016/j.cyto.2014.11.023; Man MQ, 2008, J INVEST DERMATOL, V128, P79, DOI 10.1038/sj.jid.5701011; Nakajima S, 2014, J INVEST DERMATOL, V134, P2122, DOI 10.1038/jid.2014.51; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Nograles KE, 2010, J ALLERGY CLIN IMMUN, V125, P744, DOI 10.1016/j.jaci.2009.12.934; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Peiser M, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/261037; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Rutz S, 2011, NAT IMMUNOL, V12, P1238, DOI 10.1038/ni.2134; Schneider A, 2004, GENESIS, V40, P7, DOI 10.1002/gene.20048; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Simon D, 2014, ALLERGY, V69, P125, DOI 10.1111/all.12351; Souwer Y, 2010, CURR OPIN IMMUNOL, V22, P821, DOI 10.1016/j.coi.2010.10.013; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Yao CC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2684; Yao CC, 2009, NAT MED, V15, P633, DOI 10.1038/nm.1968; Zhao Y, 2009, BRIT J DERMATOL, V161, P1301, DOI 10.1111/j.1365-2133.2009.09400.x; Zulfakar MH, 2010, INFLAMM RES, V59, P23, DOI 10.1007/s00011-009-0065-z	55	33	33	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					152	162		10.1016/j.jaci.2017.04.045	http://dx.doi.org/10.1016/j.jaci.2017.04.045			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28583370	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000419312200021
J	Battersby, AC; Braggins, H; Pearce, MS; Cale, CM; Burns, SO; Hackett, S; Hughes, S; Barge, D; Goldblatt, D; Gennery, AR				Battersby, Alexandra C.; Braggins, Helen; Pearce, Mark S.; Cale, Catherine M.; Burns, Siobhan O.; Hackett, Scott; Hughes, Stephen; Barge, Dawn; Goldblatt, David; Gennery, Andrew R.			Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SYSTEMIC-LUPUS-ERYTHEMATOSUS; REGISTRY		[Battersby, Alexandra C.; Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Battersby, Alexandra C.; Gennery, Andrew R.] Great North Childrens Hosp, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Braggins, Helen; Cale, Catherine M.] Great Ormond St Hosp Sick Children, Dept Immunol, London, England; [Pearce, Mark S.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England; [Burns, Siobhan O.] Royal Free Hosp, Dept Immunol, London, England; [Burns, Siobhan O.] UCL Inst Immun & Transplantat, London, England; [Hackett, Scott] Heartlands Hosp, Dept Paediat Immunol, Birmingham, W Midlands, England; [Hughes, Stephen] Manchester Childrens Hosp, Dept Paediat Immunol, Manchester, Lancs, England; [Barge, Dawn] Royal Victoria Infirm, Dept Clin Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Goldblatt, David] UCL, Inst Child Hlth, London, England	Newcastle University - UK; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Newcastle University - UK; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Heart of England NHS Foundation Trust; Royal Manchester Children's Hospital; Newcastle University - UK; University of London; University College London	Battersby, AC (corresponding author), Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.; Battersby, AC (corresponding author), Great North Childrens Hosp, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England.	Alexandra.Battersby@nuth.nhs.uk	Goldblatt, David/C-5972-2008	Goldblatt, David/0000-0002-0769-5242; Pearce, Mark/0000-0002-0583-3779; Burns, Siobhan/0000-0002-3356-9506; Battersby, Alexandra/0000-0002-5244-424X	Bubble Foundation UK; Sick Childrens Trust; National Institute for Health Research [NF-SI-0611-10066, NF-SI-0515-10065, PB-PG-0909-19060] Funding Source: researchfish	Bubble Foundation UK; Sick Childrens Trust; National Institute for Health Research(National Institute for Health Research (NIHR))	The Bubble Foundation UK and Sick Childrens Trust funded the study.	Agmon-Levin N, 2012, AUTOIMMUN REV, V11, P593, DOI 10.1016/j.autrev.2011.10.020; [Anonymous], 2010, J EUR ACAD DERMATOL; Cale CM, 2007, CLIN EXP IMMUNOL, V148, P79, DOI 10.1111/j.1365-2249.2007.03321.x; Hauck F, 2016, J CROHNS COLITIS, V10, P112, DOI 10.1093/ecco-jcc/jjv186; Jones LBKR, 2008, CLIN EXP IMMUNOL, V152, P211, DOI 10.1111/j.1365-2249.2008.03644.x; Liang MH, 1999, ARTHRITIS RHEUM-US, V42, P599; Magnani A, 2014, J ALLERGY CLIN IMMUN, V134, P655, DOI 10.1016/j.jaci.2014.04.014; O'Neill S, 2010, BEST PRACT RES CL RH, V24, P841, DOI 10.1016/j.berh.2010.10.006; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	9	33	33	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					628	+		10.1016/j.jaci.2017.02.029	http://dx.doi.org/10.1016/j.jaci.2017.02.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28343844	Green Published, Bronze			2022-12-18	WOS:000406855500049
J	Di Candia, L; Gomez, E; Venereau, E; Chachi, L; Kaur, D; Bianchi, ME; Challiss, RAJ; Brightling, CE; Saunders, RM				Di Candia, Leonarda; Gomez, Edith; Venereau, Emilie; Chachi, Latifa; Kaur, Davinder; Bianchi, Marco E.; Challiss, R. A. John; Brightling, Christopher E.; Saunders, Ruth M.			HMGB1 is upregulated in the airways in asthma and potentiates airway smooth muscle contraction via TLR4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MOBILITY GROUP BOX-1; RECEPTOR; INFLAMMATION; CELLS		[Di Candia, Leonarda; Gomez, Edith; Chachi, Latifa; Kaur, Davinder; Brightling, Christopher E.; Saunders, Ruth M.] Univ Leicester, Glenfield Hosp, Dept Infect Immun & Inflammat, Inst Lung Hlth, Leicester, Leics, England; [Venereau, Emilie; Bianchi, Marco E.] San Raffaele Univ & Sci Inst, Milan, Italy; [Venereau, Emilie; Bianchi, Marco E.] HMGBiotech Srl, Milan, Italy; [Challiss, R. A. John] Univ Leicester, Dept Mol & Cell Biol, Leicester, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Vita-Salute San Raffaele University; University of Leicester	Saunders, RM (corresponding author), Univ Leicester, Glenfield Hosp, Dept Infect Immun & Inflammat, Inst Lung Hlth, Leicester, Leics, England.	rms4@le.ac.uk	Venereau, Emilie/AAN-4856-2020; Bianchi, Marco Emilio/K-3417-2018; Challiss, R.A. John/A-9412-2008	Bianchi, Marco Emilio/0000-0002-5329-6445; brightling, chris/0000-0002-9345-4903; Venereau, Emilie/0000-0002-6590-7434; Challiss, John/0000-0001-5506-2848; Saunders, Ruth Mary/0000-0001-8893-6687	GSK; AstraZeneca; BI; Chiesi; Novartis; Roche	GSK(GlaxoSmithKline); AstraZeneca(AstraZeneca); BI; Chiesi(Chiesi Pharmaceuticals Inc); Novartis(Novartis); Roche(Roche Holding)	E. Venereau is an employee of HMBBiotech. M. E. Bianchi serves as a consultant for HMGBiotech, holds a patent application with Ospedale San Raffaele, and has stock options with HMGBiotech. C. E. Brightling serves as a consultant for GSK, AstraZeneca, BI, Chiesi, Novartis, and Roche and receives grant support from GSK, AstraZeneca, BI, Chiesi, Novartis, and Roche. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2014, GLOB STRAT ASTHM MAN; [Anonymous], 2015, CELL MOL IMMUNOL; Doeing DC, 2013, J APPL PHYSIOL, V114, P834, DOI 10.1152/japplphysiol.00950.2012; Hou CC, 2011, MOL MED, V17, P807, DOI 10.2119/molmed.2010.00173; Ito I, 2007, J BIOL CHEM, V282, P16336, DOI 10.1074/jbc.M608467200; Lee CC, 2013, BIOCHEM PHARMACOL, V86, P940, DOI 10.1016/j.bcp.2013.08.003; Liu R, 2009, ACTA MED OKAYAMA, V63, P203; Magna M, 2014, MOL MED, V20, P138, DOI 10.2119/molmed.2013.00164; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Schlueter C, 2003, BBA-GENE STRUCT EXPR, V1630, P1, DOI 10.1016/j.bbaexp.2003.08.008; Shim EJ, 2015, ALLERGY ASTHMA IMMUN, V7, P190, DOI 10.4168/aair.2015.7.2.190; Sutcliffe A, 2012, AM J RESP CRIT CARE, V185, P267, DOI 10.1164/rccm.201107-1281OC; Watanabe T, 2011, RESP MED, V105, P519, DOI 10.1016/j.rmed.2010.10.016; Woodman L, 2008, J IMMUNOL, V181, P5001, DOI 10.4049/jimmunol.181.7.5001; Yang S, 2015, INT IMMUNOPHARMACOL, V28, P450, DOI 10.1016/j.intimp.2015.07.013; Zeng S, 2009, J HEPATOL, V50, P929, DOI 10.1016/j.jhep.2008.11.022; Zhang CC, 2014, J MOL CELL CARDIOL, V74, P260, DOI 10.1016/j.yjmcc.2014.06.003; Zou J, 2015, AIMS MOL SCI, V2, P77, DOI 10.3934/molsci.2015.2.77	18	33	35	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					584	+		10.1016/j.jaci.2016.11.049	http://dx.doi.org/10.1016/j.jaci.2016.11.049			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28259445	Green Published, hybrid			2022-12-18	WOS:000406855500032
J	Freidl, R; Gstoettner, A; Baranyi, U; Swoboda, I; Stolz, F; Focke-Tejkl, M; Wekerle, T; van Ree, R; Valenta, R; Linhart, B				Freidl, Raphaela; Gstoettner, Antonia; Baranyi, Ulrike; Swoboda, Ines; Stolz, Frank; Focke-Tejkl, Margarete; Wekerle, Thomas; van Ree, Ronald; Valenta, Rudolf; Linhart, Birgit			Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Blocking antibodies; fish allergy; hypoallergenic parvalbumin mutant; specific immunotherapy	MURINE MODEL; ORAL IMMUNOTHERAPY; CARP PARVALBUMIN; CELL RESPONSES; POLLEN ALLERGY; FOOD ALLERGEN; HAY-FEVER; SENSITIZATION; PROTEINS; IGE	Background: Fish is a frequent elicitor of severe IgE-mediated allergic reactions. Beside avoidance, there is currently no allergen-specific therapy available. Hypoallergenic variants of the major fish allergen, parvalbumin, for specific immunotherapy based on mutation of the 2 calcium-binding sites have been developed. Objectives: This study sought to establish a mouse model of fish allergy resembling human disease and to investigate whether mouse and rabbit IgG antibodies induced by immunization with a hypoallergenic mutant of the major carp allergen protect against allergic symptoms in sensitized mice. Methods: C3H/HeJ mice were sensitized with recombinant wildtype Cyp c 1 or carp extract by intragastric gavage. Antibody, cellular immune responses, and epitope specificity in sensitized mice were investigated by ELISA, rat basophil leukemia assay, T-cell proliferation experiments using recombinant wildtype Cyp c 1, and overlapping peptides spanning the Cyp c 1 sequence. Anti-hypoallergenic Cyp c 1 mutant mouse and rabbit sera were tested for their ability to inhibit IgE recognition of Cyp c 1, Cyp c 1-specific basophil degranulation, and Cyp c 1-induced allergic symptoms in the mouse model. Results: A mouse model of fish allergy mimicking human disease regarding IgE epitope recognition and symptoms as close as possible was established. Administration of antisera generated in mice and rabbits by immunization with a hypoallergenic Cyp c 1 mutant inhibited IgE binding to Cyp c 1, Cyp c 1-induced basophil degranulation, and allergic symptoms caused by allergen challenge in sensitized mice. Conclusions: Antibodies induced by immunization with a hypoallergenic Cyp c 1 mutant protect against allergic reactions in a murine model of fish allergy.	[Freidl, Raphaela; Gstoettner, Antonia; Swoboda, Ines; Focke-Tejkl, Margarete; Valenta, Rudolf; Linhart, Birgit] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria; [Baranyi, Ulrike; Wekerle, Thomas] Med Univ Vienna, Dept Surg, Sect Transplantat Immunol, Vienna, Austria; [Stolz, Frank] Biomay AG, Vienna, Austria; [van Ree, Ronald] Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands; [van Ree, Ronald] Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands	Medical University of Vienna; Medical University of Vienna; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Linhart, B (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	birgit.linhart@meduniwien.ac.at		Swoboda, Ines/0000-0002-9164-1721; Linhart, Birgit/0000-0001-6857-3049; Valenta, Rudolf/0000-0001-5944-3365; Baranyi, Ulrike/0000-0002-6327-3052	FAST (Food Allergy Specific Immunotherapy) project of the Seventh Framework Program for Research of the European Union [201871]; Austrian Science Fund [P23350-B11, F4605]; Austrian Science Fund (FWF) [P 23350] Funding Source: researchfish	FAST (Food Allergy Specific Immunotherapy) project of the Seventh Framework Program for Research of the European Union; Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by the FAST (Food Allergy Specific Immunotherapy) project 201871 of the Seventh Framework Program for Research of the European Union and by the Austrian Science Fund, Projects P23350-B11 and F4605.	Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bugajska-Schretter A, 2000, GUT, V46, P661, DOI 10.1136/gut.46.5.661; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; Burney PGJ, 2014, ALLERGY, V69, P365, DOI 10.1111/all.12341; Chiang WC, 2007, CLIN EXP ALLERGY, V37, P1055, DOI 10.1111/j.1365-2222.2007.02752.x; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Douladiris N, 2015, J ALLERGY CLIN IMMUN, V136, P493, DOI 10.1016/j.jaci.2015.01.015; Dunbar WP, 1903, HEILUNG HEUFIEBERS; Flicker S, 2013, IMMUNOBIOLOGY, V218, P884, DOI 10.1016/j.imbio.2012.10.008; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Linhart B, 2014, CLIN EXP ALLERGY, V44, P278, DOI 10.1111/cea.12216; Linhart B, 2008, BIOL CHEM, V389, P925, DOI 10.1515/BC.2008.105; Linhart B, 2007, J IMMUNOL, V178, P3924, DOI 10.4049/jimmunol.178.6.3924; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Noon L, 1911, LANCET, V1, P1572; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; Sato S, 2014, INT ARCH ALLERGY IMM, V164, P1, DOI 10.1159/000361025; Sharp MF, 2014, CLIN REV ALLERG IMMU, V46, P258, DOI 10.1007/s12016-013-8363-1; Swoboda I, 2002, J IMMUNOL, V168, P4576, DOI 10.4049/jimmunol.168.9.4576; Swoboda I, 2007, J IMMUNOL, V178, P6290, DOI 10.4049/jimmunol.178.10.6290; Swoboda I, 2013, J ALLERGY CLIN IMMUN, V132, P979, DOI 10.1016/j.jaci.2013.04.027; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; Zuidmeer-Jongejan Laurian, 2012, Clin Transl Allergy, V2, P5, DOI 10.1186/2045-7022-2-5	30	33	33	5	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1897	+		10.1016/j.jaci.2016.10.018	http://dx.doi.org/10.1016/j.jaci.2016.10.018			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27876628	hybrid, Green Accepted			2022-12-18	WOS:000402724600020
J	Martinez-Bravo, MJ; Wahlund, CJE; Qazi, KR; Moulder, R; Lukic, A; Radmark, O; Lahesmaa, R; Grunewald, J; Eklund, A; Gabrielsson, S				Martinez-Bravo, Maria-Jose; Wahlund, Casper J. E.; Qazi, Khaleda Rahman; Moulder, Robert; Lukic, Ana; Radmark, Olof; Lahesmaa, Riitta; Grunewald, Johan; Eklund, Anders; Gabrielsson, Susanne			Pulmonary sarcoidosis is associated with exosomal vitamin D-binding protein and inflammatory molecules	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exosomes; extracellular vesicles; sarcoidosis; leukotrienes; vitamin D-binding protein; proteome; biomarkers; complement	BRONCHOALVEOLAR LAVAGE FLUID; CELLS; VESICLES; IDENTIFICATION; MACROPHAGES; ACTIVATION; PROTEOMICS; IMMUNITY; PROGRESS	Background: Sarcoidosis is an inflammatory granulomatous disorder characterized by accumulation of T(H)1-type CD4(+) T cells and immune effector cells within affected organs, most frequently the lungs. Exosomes are extracellular vesicles conveying intercellular communication with possible diagnostic and therapeutic applications. Objectives: We aimed to provide an understanding of the proinflammatory role of bronchoalveolar lavage fluid (BALF) exosomes in patients with sarcoidosis and to find candidates for disease biomarkers. Methods: We performed a mass spectrometric proteomics characterization of BALF exosomes from 15 patients with sarcoidosis and 5 healthy control subjects and verified the most interesting results with flow cytometry, ELISA, and Western blot analyses in an additional 39 patients and 22 control subjects. Results: More than 690 proteins were identified in the BALF exosomes, several of which displayed significant upregulation in patients, including inflammation-associated proteins, such as leukotriene A(4) hydrolase. Most of the complement-activating factors were upregulated, whereas the complement regulator CD55 was seen less in patients compared with healthy control subjects. In addition, for the first time, we detected vitamin D-binding protein in BALF exosomes, which was more abundant in patients. To evaluate exosome-associated vitamin D-binding protein as a biomarker for sarcoidosis, we investigated plasma exosomes from 23 patients and 11 healthy control subjects and found significantly higher expression in patients. Conclusion: Together, these data contribute to understanding the role of exosomes in lung disease and provide suggestions for highly warranted sarcoidosis biomarkers. Furthermore, the validation of an exosome-associated biomarker in the blood of patients provides novel, and less invasive, opportunities for disease diagnosis.	[Martinez-Bravo, Maria-Jose; Wahlund, Casper J. E.; Qazi, Khaleda Rahman; Gabrielsson, Susanne] Karolinska Inst, Unit Immunol & Allergy, Stockholm, Sweden; [Martinez-Bravo, Maria-Jose; Wahlund, Casper J. E.; Qazi, Khaleda Rahman; Gabrielsson, Susanne] Karolinska Univ Hosp, L2 04, SE-17176 Stockholm, Sweden; [Moulder, Robert; Lahesmaa, Riitta] Univ Turku, Turku Ctr Biotechnol, SF-20500 Turku, Finland; [Lukic, Ana; Radmark, Olof] Univ Hosp, Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, Solna, Sweden; [Grunewald, Johan; Eklund, Anders] Karolinska Inst, Resp Unit, Stockholm, Sweden; [Grunewald, Johan; Eklund, Anders] Univ Hosp, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Turku; Karolinska Institutet; Karolinska Institutet	Gabrielsson, S (corresponding author), Karolinska Univ Hosp, L2 04, SE-17176 Stockholm, Sweden.; Gabrielsson, S (corresponding author), Karolinska Inst, Dept Med Solna, Unit Immunol & Allergy, L2 04, SE-17176 Stockholm, Sweden.	Susanne.Gabrielsson@ki.se	Grunewald, Johan/GQZ-8122-2022; Gabrielsson, S./E-4145-2014	Gabrielsson, S./0000-0003-1771-1346; Ullsten-Wahlund, Casper/0000-0002-5399-1421; Martinez-Bravo, Maria-Jose/0000-0003-1566-8727; Grunewald, Johan/0000-0003-0473-3984; Moulder, Robert/0000-0003-4742-0566	Swedish Medical Research Council [K2013-67x-15242-10-5]; Swedish Heart-Lung Foundation [20140497]; Hesselman's Foundation; Stockholm County Council; Cancer and Allergy Research Foundation; Oscar II Jubilee Foundation; Mats Kleberg Foundation; Center for Allergy Research at the Karolinska Institutet; Karolinska Institutet; Academy of Finland; Centre of Excellence in Molecular Systems Immunology and Physiology Research [250114]; European Commission [FP7-SYBILLA-201106]; Sigrid Juselius Foundation	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Hesselman's Foundation; Stockholm County Council(Stockholm County Council); Cancer and Allergy Research Foundation; Oscar II Jubilee Foundation; Mats Kleberg Foundation; Center for Allergy Research at the Karolinska Institutet(Karolinska Institutet); Karolinska Institutet(Karolinska Institutet); Academy of Finland(Academy of Finland); Centre of Excellence in Molecular Systems Immunology and Physiology Research; European Commission(European CommissionEuropean Commission Joint Research Centre); Sigrid Juselius Foundation(Sigrid Juselius Foundation)	Supported by the Swedish Medical Research Council (grant no. K2013-67x-15242-10-5), the Swedish Heart-Lung Foundation (grant no. 20140497), Hesselman's Foundation, the Stockholm County Council, the Cancer and Allergy Research Foundation, the Oscar II Jubilee Foundation, the Mats Kleberg Foundation, the Center for Allergy Research at the Karolinska Institutet, and the Karolinska Institutet. It was also funded by the Academy of Finland, the Centre of Excellence in Molecular Systems Immunology and Physiology Research, 2012-2017, grant 250114, the Seventh Framework Programme of the European Commission (RL; FP7-SYBILLA-201106), and the Sigrid Juselius Foundation.	Admyre C, 2003, EUR RESPIR J, V22, P578, DOI 10.1183/09031936.03.00041703; Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969; [Anonymous], 1999, Am J Respir Crit Care Med, V160, P736; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Chen ES, 2011, NAT REV RHEUMATOL, V7, P457, DOI 10.1038/nrrheum.2011.93; Chun RF, 2012, CELL BIOCHEM FUNCT, V30, P445, DOI 10.1002/cbf.2835; Elo LL, 2009, BRIEF BIOINFORM, V10, P547, DOI 10.1093/bib/bbp033; Escudier B, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-10; Esser J, 2010, J ALLERGY CLIN IMMUN, V126, P1032, DOI 10.1016/j.jaci.2010.06.039; Foster MW, 2015, J PROTEOME RES, V14, P1238, DOI 10.1021/pr501149m; Fourie AM, 2009, CURR OPIN INVEST DR, V10, P1173; Gabrielsson S, 2014, SEMIN CANCER BIOL, V28, P1, DOI 10.1016/j.semcancer.2014.06.007; Haggmark A, 2015, AM J RESP CRIT CARE, V191, P574, DOI 10.1164/rccm.201407-1341OC; Kalra H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001450; Kamphuis LS, 2014, J BONE MINER RES, V29, P2498, DOI 10.1002/jbmr.2262; Kavathia D, 2010, RESP MED, V104, P564, DOI 10.1016/j.rmed.2009.12.004; KEW RR, 1988, J CLIN INVEST, V82, P364, DOI 10.1172/JCI113596; Lakkaraju A, 2014, ADV EXP MED BIOL, V801, P267, DOI 10.1007/978-1-4614-3209-8_34; Landi C, 2015, J PROTEOMICS, V128, P375, DOI 10.1016/j.jprot.2015.08.012; Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018; Lo Cicero A, 2015, CURR OPIN CELL BIOL, V35, P69, DOI 10.1016/j.ceb.2015.04.013; Magi B, 2002, ELECTROPHORESIS, V23, P3434, DOI 10.1002/1522-2683(200210)23:19<3434::AID-ELPS3434>3.0.CO;2-R; Majumdar R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002336; Milman N, 2002, SARCOIDOSIS VASC DIF, V19, P97; Morse MA, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-9; Muller-Quernheim J, 1998, EUR RESPIR J, V12, P716, DOI 10.1183/09031936.98.12030716; MUNAFO DA, 1994, J CLIN INVEST, V93, P1042, DOI 10.1172/JCI117053; Nagasawa H, 2005, ANTICANCER RES, V25, P3689; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; Olsen HH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043644; Papp K, 2008, MOL IMMUNOL, V45, P2343, DOI 10.1016/j.molimm.2007.11.021; Paredes PT, 2012, ALLERGY, V67, P911, DOI 10.1111/j.1398-9995.2012.02835.x; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Pilzer D, 2005, SPRINGER SEMIN IMMUN, V27, P375, DOI 10.1007/s00281-005-0004-1; PIQUETTE CA, 1994, J LEUKOCYTE BIOL, V55, P349, DOI 10.1002/jlb.55.3.349; Qazi KR, 2010, THORAX, V65, P1016, DOI 10.1136/thx.2009.132027; Radmark O, 2015, BBA-MOL CELL BIOL L, V1851, P331, DOI 10.1016/j.bbalip.2014.08.012; Sabounchi-Schutt F, 2001, ELECTROPHORESIS, V22, P1851, DOI 10.1002/1522-2683(200105)22:9<1851::AID-ELPS1851>3.0.CO;2-8; Smythies LE, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00104; Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854; Wahlstom J, 2007, J CLIN INVEST, V117, P3576, DOI 10.1172/JCI32401; Wahlstrom J, 2009, CLIN IMMUNOL, V133, P353, DOI 10.1016/j.clim.2009.08.008; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	43	33	33	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1186	1194		10.1016/j.jaci.2016.05.051	http://dx.doi.org/10.1016/j.jaci.2016.05.051			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27566455	Bronze			2022-12-18	WOS:000398771800014
J	Driessen, GJ; IJspeert, H; Wentink, M; Yntema, HG; van Hagen, PM; van Strien, A; Bucciol, G; Cogulu, O; Trip, M; Nillesen, W; Peeters, EA; Pico-Knijnenburg, I; Barendregt, BH; Rizzi, M; van Dongen, JJ; Kutukculer, N; van der Burg, M				Driessen, Gertjan J.; IJspeert, Hanna; Wentink, Marjolein; Yntema, Helger G.; van Hagen, P. Martin; van Strien, Arthur; Bucciol, Giorgia; Cogulu, Ozgur; Trip, Margreet; Nillesen, Willy; Peeters, Els A.; Pico-Knijnenburg, Ingrid; Barendregt, Barbara H.; Rizzi, Marta; van Dongen, Jacques J.; Kutukculer, Necil; van der Burg, Mirjam			Increased PI3K/Akt activity and deregulated humoral immune response in human PTEN deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							B-CELLS; IMMUNODEFICIENCY; MUTATION		[Driessen, Gertjan J.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Pediat Infect Dis & Immunol, Rotterdam, Netherlands; [Driessen, Gertjan J.; IJspeert, Hanna; Wentink, Marjolein; van Hagen, P. Martin; van Strien, Arthur; Trip, Margreet; Pico-Knijnenburg, Ingrid; Barendregt, Barbara H.; van Dongen, Jacques J.; van der Burg, Mirjam] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Yntema, Helger G.; Nillesen, Willy] Radboud Univ Nijmegen, Med Ctr, Deparment Human Genet, Nijmegen, Netherlands; [Bucciol, Giorgia] Univ Padua, Dept Women & Children Hlth, Div Pediat, Padua, Italy; [Cogulu, Ozgur] Ege Univ, Dept Pediat, Fac Med, Div Genet, Izmir, Turkey; [Peeters, Els A.] Juliana Childrens Hosp, The Hague, Netherlands; [Rizzi, Marta] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Rizzi, Marta] Univ Freiburg, Freiburg, Germany; [Kutukculer, Necil] Ege Univ, Fac Med, Dept Pediat, Div Pediat Immunol, Izmir, Turkey	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen; University of Padua; Ege University; University of Freiburg; University of Freiburg; Ege University	van der Burg, M (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands.	m.vanderburg@erasmusmc.nl	Rizzi, Marta/ABE-7264-2020; Yntema, H.G./L-4771-2015; Driessen, Gertjan/AAI-9711-2020; IJspeert, Hanna/U-9479-2019	Bucciol, Giorgia/0000-0001-5004-0738; Rizzi, Marta/0000-0002-5153-6089; van Dongen, Jacques J.M./0000-0002-3650-7087				Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Browning MJ, 2015, J MED GENET, V52, P856, DOI 10.1136/jmedgenet-2015-103266; Cogulu O, 2007, CLIN DYSMORPHOL, V16, P81, DOI 10.1097/MCD.0b013e3280464ee6; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Driessen GJ, 2011, BLOOD, V118, P6814, DOI 10.1182/blood-2011-06-361881; IJspeert H, 2011, GENES IMMUN, V12, P434, DOI 10.1038/gene.2011.16; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Omori SA, 2007, CELL CYCLE, V6, P397, DOI 10.4161/cc.6.4.3837; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Werner M, 2010, IMMUNOL REV, V237, P55, DOI 10.1111/j.1600-065X.2010.00934.x	12	33	35	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1744	+		10.1016/j.jaci.2016.07.010	http://dx.doi.org/10.1016/j.jaci.2016.07.010			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27531073	Bronze			2022-12-18	WOS:000390019300042
J	Tkacova, R; Dai, DLY; Vonk, JM; Leung, JM; Hiemstra, PS; van den Berge, M; Kunz, L; Hollander, Z; Tashkin, D; Wise, R; Connett, J; Ng, R; McManus, B; Man, SFP; Postma, DS; Sin, DD				Tkacova, Ruzena; Dai, Darlene L. Y.; Vonk, Judith M.; Leung, Janice M.; Hiemstra, Pieter S.; van den Berge, Maarten; Kunz, Lisette; Hollander, Zsuzsanna; Tashkin, Donald; Wise, Robert; Connett, John; Ng, Raymond; McManus, Bruce; Man, S. F. Paul; Postma, Dirkje S.; Sin, Don D.			Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory hypersensitivity; airway obstruction; lung function tests; death rate	BRONCHIAL HYPERRESPONSIVENESS; METHACHOLINE CHALLENGE; LUNG-FUNCTION; COPD; RESPONSIVENESS; MORTALITY; ADULTS; INTERVENTION; REACTIVITY; SYMPTOMS	Background: The impact of airway hyperreactivity (AHR) on respiratory mortality and systemic inflammation among patients with chronic obstructive pulmonary disease (COPD) is largely unknown. We used data from 2 large studies to determine the relationship between AHR and FEV1 decline, respiratory mortality, and systemic inflammation. Objectives: We sought to determine the relationship of AHR with FEV1 decline, respiratory mortality, and systemic inflammatory burden in patients with COPD in the Lung Health Study (LHS) and the Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study. Methods: The LHS enrolled current smokers with mild-to-moderate COPD (n = 5887), and the GLUCOLD study enrolled former and current smokers with moderate-to-severe COPD (n = 51). For the primary analysis, we defined AHR by a methacholine provocation concentration of 4 mg/mL or less, which led to a 20% reduction in FEV1 (PC20). Results: The primary outcomes were FEV1 decline, respiratory mortality, and biomarkers of systemic inflammation. Approximately 24% of LHS participants had AHR. Compared with patients without AHR, patients with AHR had a 2-fold increased risk of respiratory mortality (hazard ratio, 2.38; 95% CI, 1.38-4.11; P = .002) and experienced an accelerated FEV1 decline by 13.2 mL/y in the LHS (P = .007) and by 12.4 mL/y in the much smaller GLUCOLD study (P = .079). Patients with AHR had generally reduced burden of systemic inflammatory biomarkers than did those without AHR. Conclusions: AHR is common in patients with mild-to-moderate COPD, affecting 1 in 4 patients and identifies a distinct subset of patients who have increased risk of disease progression and mortality. AHR may represent a spectrum of the asthma-COPD overlap phenotype that urgently requires disease modification.	[Tkacova, Ruzena; Dai, Darlene L. Y.; Leung, Janice M.; Hollander, Zsuzsanna; Ng, Raymond; McManus, Bruce; Man, S. F. Paul; Sin, Don D.] Univ British Columbia, James Hogg Res Ctr, Vancouver, BC, Canada; [Tkacova, Ruzena; Dai, Darlene L. Y.; Leung, Janice M.; Hollander, Zsuzsanna; Ng, Raymond; McManus, Bruce; Man, S. F. Paul; Sin, Don D.] St Pauls Hosp, Inst Heart & Lung Hlth, Vancouver, BC, Canada; [Tkacova, Ruzena] Safarik Univ, Fac Med, Dept Resp Med & TB, Kosice, Slovakia; [Dai, Darlene L. Y.; Hollander, Zsuzsanna; Ng, Raymond; McManus, Bruce] St Pauls Hosp, PROOF Ctr Excellence, Vancouver, BC, Canada; [Vonk, Judith M.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Vonk, Judith M.; van den Berge, Maarten; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Groningen, Netherlands; [Leung, Janice M.; Man, S. F. Paul; Sin, Don D.] Univ British Columbia, Div Pulm, Dept Med, Vancouver, BC, Canada; [Hiemstra, Pieter S.; Kunz, Lisette] Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands; [van den Berge, Maarten; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, Groningen, Netherlands; [Tashkin, Donald] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Wise, Robert] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Connett, John] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; [Ng, Raymond] Univ British Columbia, Dept Comp Sci, Vancouver, BC, Canada; [McManus, Bruce] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada	University of British Columbia; St. Paul's Hospital; University of Saskatchewan; University of Pavol Jozef Safarik Kosice; St. Paul's Hospital; University of Saskatchewan; University of Groningen; University of Groningen; University of British Columbia; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Groningen; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; University of Minnesota System; University of Minnesota Twin Cities; University of British Columbia; University of British Columbia	Sin, DD (corresponding author), St Pauls Hosp, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	don.sin@hli.ubc.ca	Vonk, Judith M/ABA-3009-2020; Sin, Don/AAC-2219-2021; Vonk, Judith/K-8477-2019; Hiemstra, Pieter S/K-8587-2018; /V-8478-2019	Vonk, Judith M/0000-0001-7531-4547; Vonk, Judith/0000-0001-7531-4547; Hiemstra, Pieter S/0000-0002-0238-5982; Hollander, Zsuzsanna/0000-0003-4889-996X; van den Berge, Maarten/0000-0002-9336-7340; Wise, Robert/0000-0002-8353-2349	Canadian Institutes of Health Research (CIHR); Canadian Respiratory Research Network; US National Heart, Lung, and Blood Institute [NHLBI-1U10-HL59275]; Netherlands Organization for Scientific Research; GlaxoSmithKline; Leiden University Medical Center; Tier 1 Canada Research Chair in chronic obstructive pulmonary disease; University Medical Center Groningen; Netherlands Asthma Foundation; Genome Canada [144COP]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Respiratory Research Network; US National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); GlaxoSmithKline(GlaxoSmithKline); Leiden University Medical Center; Tier 1 Canada Research Chair in chronic obstructive pulmonary disease; University Medical Center Groningen; Netherlands Asthma Foundation; Genome Canada(Genome Canada)	The Lung Health Study (LHS) Biomarker Study was funded by the Canadian Institutes of Health Research (CIHR) & Genome Canada (grant no. 144COP) and the Canadian Respiratory Research Network. The original LHS was funded by the US National Heart, Lung, and Blood Institute (NHLBI-1U10-HL59275). The Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease study was originally funded by the Netherlands Organization for Scientific Research, the Netherlands Asthma Foundation, GlaxoSmithKline, University Medical Center Groningen, and Leiden University Medical Center. D.D.S. is supported by a Tier 1 Canada Research Chair in chronic obstructive pulmonary disease.	ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Anthonisen NR, 2005, ANN INTERN MED, V142, P233, DOI 10.7326/0003-4819-142-4-200502150-00005; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; Brutsche MH, 2006, THORAX, V61, P671, DOI 10.1136/thx.2005.052241; Cockcroft DW, 2010, CHEST, V138, p18S, DOI 10.1378/chest.10-0088; Cockcroft DW, 2005, CHEST, V127, P839, DOI 10.1378/chest.127.3.839; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; deJong JW, 1997, CLIN EXP ALLERGY, V27, P1114, DOI 10.1046/j.1365-2222.1997.1440948.x; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; From the Global Strategy for Asthma Management and Prevention, 2015, GLOB STRAT ASTHM MAN; Fu JJ, 2014, ALLERGY ASTHMA IMMUN, V6, P316, DOI 10.4168/aair.2014.6.4.316; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Hospers JJ, 2000, LANCET, V356, P1313, DOI 10.1016/S0140-6736(00)02815-4; Iwamoto H, 2014, EUR RESPIR J, V43, P421, DOI 10.1183/09031936.00024313; Soler-Cataluna JJ, 2012, ARCH BRONCONEUMOL, V48, P331, DOI 10.1016/j.arbres.2011.12.009; Lapperre TS, 2009, ANN INTERN MED, V151, P517, DOI 10.7326/0003-4819-151-8-200910200-00004; Man SFP, 2006, THORAX, V61, P849, DOI 10.1136/thx.2006.059808; OCONNOR GT, 1995, AM J RESP CRIT CARE, V152, P87, DOI 10.1164/ajrccm.152.1.7599868; Papaiwannou A, 2014, J THORAC DIS, V6, pS146, DOI 10.3978/j.issn.2072-1439.2014.03.04; Park HY, 2013, AM J RESP CRIT CARE, V188, P1413, DOI 10.1164/rccm.201305-0892OC; Postma DS, 2015, LANCET, V385, P899, DOI 10.1016/S0140-6736(14)60446-3; Postma DS, 1998, AM J RESP CRIT CARE, V158, pS187, DOI 10.1164/ajrccm.158.supplement_2.13tac170; POSTMA DS, 1986, AM REV RESPIR DIS, V134, P276; Prieto L, 2006, ANN ALLERG ASTHMA IM, V97, P175, DOI 10.1016/S1081-1206(10)60009-9; Siersted HC, 2000, EUR RESPIR J, V15, P181, DOI 10.1183/09031936.00.15118100; Suzuki T, 1996, AM J RESP CRIT CARE, V153, P1405, DOI 10.1164/ajrccm.153.4.8616573; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802, DOI 10.1164/ajrccm.153.6.8665038; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; van den Berge M, 2012, EUR RESPIR J, V40, P1098, DOI 10.1183/09031936.00169711; van der Wiel E, 2014, ALLERGY, V69, P1681, DOI 10.1111/all.12510; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Vestbo J, 2011, NEW ENGL J MED, V365, P1184, DOI 10.1056/NEJMoa1105482; Wubbel C, 2004, CHEST, V125, P453, DOI 10.1378/chest.125.2.453; Xu XP, 1997, LANCET, V350, P1431, DOI 10.1016/S0140-6736(97)10041-1	35	33	33	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1571	+		10.1016/j.jaci.2016.04.022	http://dx.doi.org/10.1016/j.jaci.2016.04.022			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27345171	Bronze			2022-12-18	WOS:000390019300011
J	Spahn, JD; Malka, J; Szefler, SJ				Spahn, Joseph D.; Malka, Jonathan; Szefler, Stanley J.			Current application of exhaled nitric oxide in clinical practice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; childhood asthma; dupilumab; inhaled corticosteroids; lebrikizumab; nitric oxide; mepolizumab; omalizumab; severe asthma	ASTHMA		[Spahn, Joseph D.] Childrens Hosp Colorado, Allergy & Immunol Dept, Aurora, CO USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Breathing Inst, Dept Pulm, Aurora, CO USA; [Malka, Jonathan] Pediat Associates, Lauderdale Lakes, FL USA	Children's Hospital Colorado; Children's Hospital Colorado	Szefler, SJ (corresponding author), Childrens Hosp Colorado, 13123 E 16th Ave, Aurora, CO 80045 USA.	stanley.szefler@childrenscolorado.org		Szefler, Stanley/0000-0002-6911-3199				Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Covar RA, 2004, J ALLERGY CLIN IMMUN, V114, P575, DOI 10.1016/j.jaci.2004.06.036; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Piacentini GL, 2009, ALLERGY, V64, P1753, DOI 10.1111/j.1398-9995.2009.02068.x; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Zeiger RS, 2011, J ALLERGY CLIN IMMUN, V128, P412, DOI 10.1016/j.jaci.2011.06.008	10	33	34	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1296	1298		10.1016/j.jaci.2016.09.002	http://dx.doi.org/10.1016/j.jaci.2016.09.002			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27664377	Bronze			2022-12-18	WOS:000389542700007
J	Feng, X; Ramsden, MK; Negri, J; Baker, MG; Payne, SC; Borish, L; Steinke, JW				Feng, Xin; Ramsden, Madison K.; Negri, Julie; Baker, Mary Grace; Payne, Spencer C.; Borish, Larry; Steinke, John W.			Eosinophil production of prostaglandin D-2 in patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; aspirin-tolerant asthma; chronic sinusitis; cytokines; eosinophils; prostaglandin D-2; nasal polyps	INNATE LYMPHOID-CELLS; CHRONIC RHINOSINUSITIS; NASAL POLYPOSIS; MAST-CELL; ASTHMATIC-PATIENTS; ALLERGIC INFLAMMATION; SENSITIVE ASTHMA; T(H)2 CELLS; IFN-GAMMA; EXPRESSION	Background: Aspirin-exacerbated respiratory disease (AERD) differs from aspirin-tolerant disease in part because of eosinophilic tissue infiltration and overexpression of arachidonic acid metabolic pathway components that lead to enhanced secretion of cysteinyl leukotrienes and prostaglandin (PG) D-2 observed constitutively and paradoxically in response to aspirin and other COX inhibitors. We have previously demonstrated the capacity of IFN-gamma to drive cysteinyl leukotriene expression and response. Objective: We investigated eosinophils as a source of PGD(2) production in patients with AERD. Methods: Eosinophils were enriched from tissue and peripheral blood obtained from control subjects, patients with aspirin-tolerant disease, and patients with AERD. mRNA was extracted and evaluated for expression of hematopoietic prostaglandin D synthase (hPGDS). Expression of hPGDS protein was confirmed with Western hybridization and immunofluorescence staining. Cells were stimulated with aspirin, and secretion of PGD(2) was quantified. CD34(+) progenitor cells were isolated and matured into eosinophils in the presence or absence of IFN-gamma and hPGDS mRNA, and PGD(2) release was measured. Results: Gene expression analysis revealed that eosinophils from tissue and blood of patients with AERD display increased levels of hPGDS compared with asthmatic and control samples. Western hybridization confirmed the increase in hPGDS mRNA translated to increased protein expression. Immunofluorescence confirmed mast cells and eosinophils from tissue of patients with AERD and asthma demonstrated hPGDS expression, with higher levels in eosinophils from patients with AERD. Incubation of eosinophils from blood and tissue with aspirin stimulated PGD(2) release. IFN-gamma-matured eosinophil progenitors showed enhanced hPGDS expression and increased levels of PGD(2) release at baseline and after aspirin stimulation. Conclusions: In addition to mast cells, eosinophils represent an important source of PGD(2) in patients with AERD and identify a new target for therapeutic intervention.	[Feng, Xin] Shandong Univ, QiLu Hosp, Dept Otolaryngol, Jinan, Peoples R China; [Ramsden, Madison K.; Negri, Julie; Baker, Mary Grace; Payne, Spencer C.; Borish, Larry; Steinke, John W.] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Borish, Larry; Steinke, John W.] Univ Virginia Hlth Syst, Carter Immunol Ctr, Charlottesville, VA USA; [Payne, Spencer C.; Steinke, John W.] Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA USA; [Borish, Larry] Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA USA; [Payne, Spencer C.] Univ Virginia Hlth Syst, Dept Otolaryngol Head & Neck Surg, Charlottesville, VA USA	Shandong University; University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Steinke, JW (corresponding author), Asthma & Allerg Dis Ctr, Box 801355, Charlottesville, VA 22903 USA.	js3ch@virginia.edu	Feng, Xin/AAY-4922-2021	Feng, Xin/0000-0001-8089-4005; Baker, Mary Grace/0000-0001-7121-3271; Payne, Spencer/0000-0001-9736-4561	National Institutes of Health [R01-AI057438, R56-AI120055, U01-AI100799]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057438, U01AI100799, R56AI120055] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants R01-AI057438, R56-AI120055, and U01-AI100799.	ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Denburg JA, 2000, THORAX, V55, pS24, DOI 10.1136/thorax.55.suppl_2.S24; Denburg JA, 2008, CHEST, V134, P1037, DOI 10.1378/chest.08-0485; Early SB, 2007, AM J RESP CELL MOL, V36, P715, DOI 10.1165/rcmb.2006-0252OC; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1067/MAI.2002.130051; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Higashi N, 2010, J ALLERGY CLIN IMMUN, V125, P1084, DOI 10.1016/j.jaci.2009.12.977; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Ho J, 2015, CLIN EXP ALLERGY, V45, P394, DOI 10.1111/cea.12462; Hudson SA, 2011, J CLIN IMMUNOL, V31, P1045, DOI 10.1007/s10875-011-9589-4; Hyo S, 2007, ARCH OTOLARYNGOL, V133, P693, DOI 10.1001/archotol.133.7.693; Kim YK, 1999, AM J RESP CELL MOL, V20, P388, DOI 10.1165/ajrcmb.20.3.3060; Laidlaw TM, 2014, J ALLERGY CLIN IMMUN, V133, P1692, DOI 10.1016/j.jaci.2013.12.1034; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Liu T, 2015, J IMMUNOL, V195, P3537, DOI 10.4049/jimmunol.1500905; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Luna-Gomes T, 2011, J IMMUNOL, V187, P6518, DOI 10.4049/jimmunol.1101806; Mastalerz L, 2014, ALLERGY, V69, P1550, DOI 10.1111/all.12512; Mattos JL, 2011, INT FORUM ALLERGY RH, V1, P3, DOI 10.1002/alr.20003; Mesquita-Santos FP, 2006, J IMMUNOL, V176, P1326, DOI 10.4049/jimmunol.176.3.1326; Miljkovic D, 2014, ALLERGY, V69, P1154, DOI 10.1111/all.12440; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monneret G, 2005, J PHARMACOL EXP THER, V312, P627, DOI 10.1124/jpet.104.074823; Nantel F, 2004, PROSTAG OTH LIPID M, V73, P87, DOI 10.1016/j.prostaglandins.2003.12.002; Okano M, 2006, CLIN EXP ALLERGY, V36, P1028, DOI 10.1111/j.1365-2222.2006.02528.x; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Payne SC, 2011, LARYNGOSCOPE, V121, P2262, DOI 10.1002/lary.21969; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; Sanak M, 2010, J CHROMATOGR B, V878, P1796, DOI 10.1016/j.jchromb.2010.05.012; Schratl P, 2007, J IMMUNOL, V179, P4792, DOI 10.4049/jimmunol.179.7.4792; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; SLADEK K, 1993, EUR RESPIR J, V6, P391; Steinke JW, 2016, J ASTHMA ALLERGY, V9, P37, DOI 10.2147/JAA.S88739; Steinke JW, 2014, J IMMUNOL, V193, P41, DOI 10.4049/jimmunol.1301753; Steinke JW, 2013, J ALLERGY CLIN IMMUN, V132, P856, DOI 10.1016/j.jaci.2013.05.008; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P159, DOI 10.1385/CRIAI:24:2:159; Stinson SE, 2015, J ALLERGY CLIN IMMUN, V135, P395, DOI 10.1016/j.jaci.2014.08.027; Ta V, 2015, J ALLER CL IMM-PRACT, V3, P711, DOI 10.1016/j.jaip.2015.03.001; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056	53	33	33	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1089	U479		10.1016/j.jaci.2016.04.042	http://dx.doi.org/10.1016/j.jaci.2016.04.042			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27423494	Green Accepted, Bronze			2022-12-18	WOS:000385499400014
J	Kuo, HC; Hsieh, KS; Guo, MMH; Weng, KP; Ger, LP; Chan, WC; Li, SC				Kuo, Ho-Chang; Hsieh, Kai-Sheng; Guo, Mindy Ming-Huey; Weng, Ken-Pen; Ger, Luo-Ping; Chan, Wen-Ching; Li, Sung-Chou			Next-generation sequencing identifies micro-RNA-based biomarker panel for Kawasaki disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GAMMA-GLOBULIN		[Kuo, Ho-Chang; Hsieh, Kai-Sheng; Guo, Mindy Ming-Huey] Kaohsiung Chang Gung Mem Hosp, Dept Pediat, Kaohsiung, Taiwan; [Kuo, Ho-Chang; Hsieh, Kai-Sheng; Guo, Mindy Ming-Huey] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Kuo, Ho-Chang; Hsieh, Kai-Sheng; Guo, Mindy Ming-Huey] Kaohsiung Chang Gung Mem Hosp, Kawasaki Dis Ctr, Kaohsiung, Taiwan; [Weng, Ken-Pen] Kaohsiung Vet Gen Hosp, Dept Pediat, Taipei, Taiwan; [Weng, Ken-Pen] Natl Yang Ming Univ, Taipei, Taiwan; [Ger, Luo-Ping] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung, Taiwan; [Chan, Wen-Ching; Li, Sung-Chou] Kaohsiung Chang Gung Mem Hosp, Dept Med Res, Genom & Prote Core Lab, Kaohsiung, Taiwan; [Chan, Wen-Ching; Li, Sung-Chou] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Chan, Wen-Ching] Univ Chicago, Ctr Res Informat, Chicago, IL USA	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University; Kaohsiung Veterans General Hospital; Chang Gung Memorial Hospital; Chang Gung University; University of Chicago	Kuo, HC (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Pediat, Kaohsiung, Taiwan.; Kuo, HC (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.; Kuo, HC (corresponding author), Kaohsiung Chang Gung Mem Hosp, Kawasaki Dis Ctr, Kaohsiung, Taiwan.	raymond.pinus@gmail.com; wenching.chan@gmail.com	Li, Sung-Chou/AGZ-8626-2022; Kuo, Ho-Chang/AAQ-6644-2020	Li, Sung-Chou/0000-0002-3016-9718; Kuo, Ho-Chang/0000-0002-3295-2984; Hsieh, Kai-Sheng/0000-0002-0294-9872				Burns JC, 2004, LANCET, V364, P533, DOI 10.1016/S0140-6736(04)16814-1; Ko TM, 2015, CIRC RES, V116, P876, DOI 10.1161/CIRCRESAHA.116.305834; Kvon EZ, 2014, NATURE, V512, P91, DOI 10.1038/nature13395; Leidinger P, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-r78; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; Pan CT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/462135; Rowley AH, 2014, PEDIATR INFECT DIS J, V33, P1296, DOI 10.1097/INF.0000000000000449; Shimizu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058159	9	33	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1227	1230		10.1016/j.jaci.2016.04.050	http://dx.doi.org/10.1016/j.jaci.2016.04.050			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27450727	hybrid			2022-12-18	WOS:000385499400039
J	Al-Herz, W; Chu, JI; van der Spek, J; Raghupathy, R; Massaad, MJ; Keles, S; Biggs, CM; Cockerton, L; Chou, J; Dbaibo, G; Elisofon, SA; Hanna-Wakim, R; Kim, HB; Lehmann, LE; McDonald, DR; Notarangelo, LD; Veys, P; Chatila, TA; Geha, RS; Gaspar, HB; Pai, SY				Al-Herz, Waleed; Chu, Julia I.; van der Spek, Jet; Raghupathy, Raj; Massaad, Michel J.; Keles, Sevgi; Biggs, Catherine M.; Cockerton, Lucinda; Chou, Janet; Dbaibo, Ghassan; Elisofon, Scott A.; Hanna-Wakim, Rima; Kim, Heung Bae; Lehmann, Leslie E.; McDonald, Douglas R.; Notarangelo, Luigi D.; Veys, Paul; Chatila, Talal A.; Geha, Raif S.; Gaspar, H. Bobby; Pai, Sung-Yun			Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of cytokinesis 8 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; dedicator of cytokinesis 8 deficiency; hematopoietic stem cell transplantation; conditioning mixed chimerism	HYPER-IGE SYNDROME; DOCK8 DEFICIENCY; MUTATIONS; PHENOTYPE; SURVIVAL	Background: Dedicator of cytokinesis 8 (DOCK8) deficiency can be cured by allogeneic hematopoietic stem cell transplantation (HSCT). Reports of outcomes are still limited. Objective: We sought to analyze the results of HSCT in patients with DOCK8 deficiency and report whether approaches resulting in mixed chimerism result in clinically relevant immune reconstitution. Methods: We performed a retrospective chart review of 11 patients with DOCK8 deficiency and measured DOCK8 expression and cytokine production. Results: Of 11 patients, 7 received HSCT from related and 4 from unrelated donors; 9 patients received busulfan-based conditioning regimens. Survival was excellent (10 [91%] of 11 patients alive), including a patient who had undergone liver transplantation. Patients showed significant improvements in the frequency and severity of infections. Although eczema resolved in all, food allergies and high IgE levels persisted in some patients. Lymphopenia, eosinophilia, low numbers of naive CD8(+) T cells and switched memory B cells, and T(H)1/T(H)2 cytokine imbalance improved in most patients. Although the 8 matched related or unrelated donor recipients had full donor chimerism, all 3 recipients of mismatched unrelated donor HSCT had high levels of donor T-cell chimerism and low B-cell and myeloid cell chimerism (0% to 46%). Almost all switched memory B cells were of donor origin. All patients, including those with mixed chimerism, mounted robust antibody responses to vaccination. Conclusion: Allogeneic HSCT ameliorated the infectious and atopic symptoms of patients with DOCK8 deficiency. In patients with mixed chimerism, selective advantage for donor-derived T cells and switched memory B cells promoted restoration of cellular and humoral immunity and protection against opportunistic infection.	[Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Kuwait, Kuwait; [Raghupathy, Raj] Kuwait Univ, Fac Med, Dept Microbiol, Kuwait, Kuwait; [Al-Herz, Waleed] Al Sabah Hosp, Dept Pediat, Kuwait, Kuwait; [Chu, Julia I.; van der Spek, Jet; Lehmann, Leslie E.; Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA; [Elisofon, Scott A.] Boston Childrens Hosp, Div Gastroenterol Hepatol & Nutr, Boston, MA USA; [Kim, Heung Bae] Boston Childrens Hosp, Dept Surg, Boston, MA USA; [Chu, Julia I.; Lehmann, Leslie E.; Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Massaad, Michel J.; Keles, Sevgi; Biggs, Catherine M.; Chou, Janet; McDonald, Douglas R.; Notarangelo, Luigi D.; Chatila, Talal A.; Geha, Raif S.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Cockerton, Lucinda; Veys, Paul; Gaspar, H. Bobby] NHS Fdn Trust, Great Ormond St Hosp Children, London, England; [Dbaibo, Ghassan; Hanna-Wakim, Rima] Amer Univ Beirut, Div Pediat Infect Dis, Beirut, Lebanon; [Gaspar, H. Bobby] UCL Inst Child Hlth, London, England	Kuwait University; Kuwait University; Al Sabah Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Oxford University Hospitals NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; American University of Beirut; University of London; University College London	Pai, SY (corresponding author), Boston Childrens Hosp, Karp Family Res Labs, Room 08214,One Blackfan Circle, Boston, MA 02115 USA.	sung-yun.pai@childrens.harvard.edu	Kim, Heung Bae/AAG-5323-2019; Dbaibo, Ghassan S./X-2978-2019; Coenen-van der Spek, Jet/ABE-8031-2020; Pai, Sung-Yun/AAH-7762-2019	Kim, Heung Bae/0000-0002-8955-8662; Coenen-van der Spek, Jet/0000-0002-4470-0864; Pai, Sung-Yun/0000-0002-0158-8147; Chatila, Talal/0000-0001-7439-2762; Biggs, Catherine/0000-0002-4363-2660	Translational Investigator Service Award; National Institutes of Health [R01 AI100315, R01 AI085090]; National Heart, Lung, and Blood Institute [5T32HL007574-33]; Ter Meulen Grant of the Royal Netherlands Academy of Arts and Sciences; Ruth L. Kirschstein National Research Service Award; National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital; University College London; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI100315, R01AI085090] Funding Source: NIH RePORTER	Translational Investigator Service Award; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Ter Meulen Grant of the Royal Netherlands Academy of Arts and Sciences; Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital; University College London(General Electric); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a Translational Investigator Service Award (to S.-Y.P.) and the National Institutes of Health (R01 AI100315 to R.S.G. and R01 AI085090 to T.A.C). J.I.C. was supported by a training award from National Heart, Lung, and Blood Institute (5T32HL007574-33). J.v.d.S. was supported by a Ter Meulen Grant of the Royal Netherlands Academy of Arts and Sciences. C.M.B was supported by the Ruth L. Kirschstein National Research Service Award. H.B.G. received support from the National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital and University College London.	Al-Herz W, 2012, CLIN IMMUNOL, V143, P266, DOI 10.1016/j.clim.2012.03.002; Al-Mousa H, 2013, J ALLERGY CLIN IMMUN, V131, P1244, DOI 10.1016/j.jaci.2012.12.663; Aydin SE, 2015, J CLIN IMMUNOL, V35, P189, DOI 10.1007/s10875-014-0126-0; Barlogis V, 2011, J ALLERGY CLIN IMMUN, V128, P420, DOI 10.1016/j.jaci.2011.03.025; Bittner TC, 2010, KLIN PADIATR, V222, P351, DOI 10.1055/s-0030-1265135; Boztug H, 2012, PEDIATR HEMAT ONCOL, V29, P585, DOI 10.3109/08880018.2012.714844; Cuellar-Rodriguez J, 2015, BIOL BLOOD MARROW TR, V21, P1037, DOI 10.1016/j.bbmt.2015.01.022; Engelhardt KR, 2015, J ALLERGY CLIN IMMUN, V136, P402, DOI 10.1016/j.jaci.2014.12.1945; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Gatz SA, 2011, BONE MARROW TRANSPL, V46, P552, DOI 10.1038/bmt.2010.169; Jing H, 2014, J ALLERGY CLIN IMMUN, V133, P1667, DOI 10.1016/j.jaci.2014.03.025; Lambe T, 2011, EUR J IMMUNOL, V41, P3423, DOI 10.1002/eji.201141759; Lebel MJ, 2014, PEDIATR TRANSPLANT, V18, P733, DOI 10.1111/petr.12342; McDonald DR, 2010, J ALLERGY CLIN IMMUN, V126, P1304, DOI 10.1016/j.jaci.2010.07.034; Metin A, 2012, PEDIATR TRANSPLANT, V16, P398, DOI 10.1111/j.1399-3046.2011.01641.x; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Pai SY, 2014, J ALLERGY CLIN IMMUN, V134, P221, DOI 10.1016/j.jaci.2014.02.023; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Randall KL, 2009, NAT IMMUNOL, V10, P1283, DOI 10.1038/ni.1820; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	22	33	35	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					852	+		10.1016/j.jaci.2016.02.022	http://dx.doi.org/10.1016/j.jaci.2016.02.022			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27130861	Bronze, Green Accepted			2022-12-18	WOS:000385496000021
J	Schwerd, T; Frivolt, K; Clavel, T; Lagkouvardos, I; Katona, G; Mayr, D; Uhlig, HH; Haller, D; Koletzko, S; Bufler, P				Schwerd, Tobias; Frivolt, Klara; Clavel, Thomas; Lagkouvardos, Ilias; Katona, Gabor; Mayr, Doris; Uhlig, Holm H.; Haller, Dirk; Koletzko, Sibylle; Bufler, Philip			Exclusive enteral nutrition in active pediatric Crohn disease: Effects on intestinal microbiota and immune regulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLAMMATORY BOWEL DISEASES; T-CELLS; METABOLITES; MODULATION; CHILDREN; COLITIS; CURE		[Schwerd, Tobias; Frivolt, Klara; Katona, Gabor; Koletzko, Sibylle; Bufler, Philip] Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; [Frivolt, Klara] Comenius Univ, Sch Med, Dept Pediat 2, Bratislava, Slovakia; [Clavel, Thomas; Lagkouvardos, Ilias; Uhlig, Holm H.; Haller, Dirk] Tech Univ Munich, ZIEL Inst Food & Hlth, Freising Weihenstephan, Germany; [Mayr, Doris] Univ Munich, Dept Pathol, Munich, Germany; [Uhlig, Holm H.] Univ Oxford, Translat Gastroenterol Unit, Oxford, England; [Uhlig, Holm H.] Univ Oxford, Dept Paediat, Oxford, England; [Haller, Dirk] Tech Univ Munich, Chair Nutr & Immunol, Freising Weihenstephan, Germany	University of Munich; Comenius University Bratislava; Technical University of Munich; University of Munich; University of Oxford; University of Oxford; Technical University of Munich	Schwerd, T (corresponding author), Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany.	tobias.schwerd@ndm.ox.ac.uk	Lagkouvardos, Ilias/AAV-1857-2020	Lagkouvardos, Ilias/0000-0001-9337-4033; Uhlig, Holm/0000-0002-6111-7355; Clavel, Thomas/0000-0002-7229-5595; Haller, Dirk/0000-0002-6977-4085; Bufler, Philip/0000-0002-5742-8273				Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Boschetti G, 2011, INFLAMM BOWEL DIS, V17, P160, DOI 10.1002/ibd.21308; Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052; Chen X, 2013, J IMMUNOL, V190, P1076, DOI 10.4049/jimmunol.1202659; Dalal SR, 2014, J CLIN INVEST, V124, P4190, DOI 10.1172/JCI72330; Dixon AE, 2009, CHEST, V136, P1324, DOI 10.1378/chest.08-1983; Gerasimidis K, 2014, INFLAMM BOWEL DIS, V20, P861, DOI 10.1097/MIB.0000000000000023; Kaakoush NO, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2014.21; Lagkouvardos I, 2015, MOL NUTR FOOD RES, V59, P1614, DOI 10.1002/mnfr.201500125; Leach ST, 2008, ALIMENT PHARM THER, V28, P724, DOI 10.1111/j.1365-2036.2008.03796.x; Lewis JD, 2015, CELL HOST MICROBE, V18, P489, DOI 10.1016/j.chom.2015.09.008; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Manichanh C, 2006, GUT, V55, P205, DOI 10.1136/gut.2005.073817; Mottet C, 2003, J IMMUNOL, V170, P3939, DOI 10.4049/jimmunol.170.8.3939; Quince C, 2015, AM J GASTROENTEROL, V110, P1718, DOI 10.1038/ajg.2015.357; Ruemmele FM, 2014, J CROHNS COLITIS, V8, P1179, DOI 10.1016/j.crohns.2014.04.005; Uhlig HH, 2006, J IMMUNOL, V177, P5852, DOI 10.4049/jimmunol.177.9.5852	17	33	33	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					592	596		10.1016/j.jaci.2015.12.1331	http://dx.doi.org/10.1016/j.jaci.2015.12.1331			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	26987574	Bronze			2022-12-18	WOS:000380835800034
J	Humblet-Baron, S; Franckaert, D; Dooley, J; Bornschein, S; Cauwe, B; Schonefeldt, S; Bossuyt, X; Matthys, P; Baron, F; Wouters, C; Liston, A				Humblet-Baron, Stephanie; Franckaert, Dean; Dooley, James; Bornschein, Simon; Cauwe, Benedicte; Schonefeldt, Susann; Bossuyt, Xavier; Matthys, Patrick; Baron, Frederic; Wouters, Carine; Liston, Adrian			IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cells; familial hemophagocytic lymphohistiocytosis; IL-2; immune homeostasis; perforin; lymphocytic choriomeningitis virus	PATHOGENESIS; TOLERANCE; EXPANSION; SUBSETS; MCL-1; HLH	Background: Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory condition driven by excessive CD8(+) T-cell activation. HLH occurs as both acquired and familial hemophagocytic lymphohistiocytosis (FHL) forms. In both conditions, a sterile or infectious trigger is required for disease initiation, which then becomes self-sustaining and life-threatening. Recent studies have attributed the key distal event to excessive IFN-gamma production; however, the proximal events driving immune dysregulation have remained undefined. Objective: We sought to investigate the role of regulatory T (Treg) cells in the pathophysiology of experimental FHL. Methods: Because mutation in perforin is a common cause of FHL, we used an experimental FHL mouse model in which disease in perforin-deficient mice is triggered by lymphocytic choriomeningitis virus (LCMV). We assessed Treg and CD8(+) T-cell homeostasis and activation during the changing systemic conditions in the mice. In addition, human blood samples were collected and analyzed during the HLH episode. Results: We found no primary Treg cell defects in perforin-deficient mice. However, Treg cell numbers collapsed after LCMV inoculation. The collapse of Treg cell numbers in LCMV-triggered perforin-deficient, but not wild-type, mice was accompanied by the combination of lower IL-2 secretion by conventional CD4(+) T cells, increased IL-2 consumption by activated CD8(+) T cells, and secretion of competitive soluble CD25. Moreover low Treg cell numbers were observed in untreated patients experiencing HLH flares. Conclusion: These results demonstrate that excessive CD8(+) T-cell activation rewires the IL-2 homeostatic network away from Treg cell maintenance and toward feed-forward inflammation. These results also provide a potential mechanistic pathway for the progression of infectious inflammation to persistent inflammation in patients with HLH.	[Humblet-Baron, Stephanie; Franckaert, Dean; Dooley, James; Bornschein, Simon; Cauwe, Benedicte; Schonefeldt, Susann; Liston, Adrian] VIB, Translat Immunol Lab, Leuven, Belgium; [Humblet-Baron, Stephanie; Franckaert, Dean; Dooley, James; Bornschein, Simon; Cauwe, Benedicte; Schonefeldt, Susann; Bossuyt, Xavier; Liston, Adrian] KUL Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium; [Matthys, Patrick] KUL Univ Leuven, Rega Inst, Leuven, Belgium; [Bossuyt, Xavier; Wouters, Carine] Univ Hosp Leuven, Leuven, Belgium; [Wouters, Carine] KUL Univ Leuven, Pediat Immunol, Leuven, Belgium; [Baron, Frederic] Univ Liege, GIGA I3, Liege, Belgium; [Baron, Frederic] Univ Liege, Dept Hematol, Liege, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; University Hospital Leuven; University of Liege; University of Liege	Liston, A (corresponding author), VIB, Autoimmune Genet Lab, Leuven, Belgium.; Liston, A (corresponding author), Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium.	adrian.liston@vib.be	Bossuyt, Xavier/B-2085-2019; Matthys, Patrick/B-4813-2018; Liston, Adrian/G-8606-2013	Bossuyt, Xavier/0000-0001-6856-8485; Matthys, Patrick/0000-0002-9685-6836; Liston, Adrian/0000-0002-6272-4085; Dooley, James/0000-0003-3154-4708; Wouters, Carine/0000-0002-6426-8845; Humblet-Baron, Stephanie/0000-0003-4684-069X	VIB; ERC (-IMMUNO); FWO [G051912N]; IUAP (T-TIME); FWO postdoctoral fellowships	VIB; ERC (-IMMUNO); FWO(FWO); IUAP (T-TIME); FWO postdoctoral fellowships	Supported by the VIB, ERC (-IMMUNO), FWO (G051912N) and IUAP (T-TIME). S.H.-B. and B.C. were supported by FWO postdoctoral fellowships.	Amado IF, 2013, J EXP MED, V210, P2707, DOI 10.1084/jem.20122759; Baud O, 2001, NEW ENGL J MED, V344, P1758, DOI 10.1056/NEJM200106073442304; Benson A, 2012, J IMMUNOL, V188, P800, DOI 10.4049/jimmunol.1100769; Boyman O, 2006, SCIENCE, V311, P1924, DOI 10.1126/science.1122927; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Humblet-Baron S, 2007, J CLIN INVEST, V117, P407, DOI 10.1172/JCI29539; Janka GE, 2014, BLOOD REV, V28, P135, DOI 10.1016/j.blre.2014.03.002; Janka GE, 2013, HEMATOL-AM SOC HEMAT, P605, DOI 10.1182/asheducation-2013.1.605; Jordan MB, 2004, BLOOD, V104, P735, DOI 10.1182/blood-2003-10-3413; Jordan MB, 2011, BLOOD, V118, P4041, DOI 10.1182/blood-2011-03-278127; Kastenmuller W, 2011, J IMMUNOL, V187, P3186, DOI 10.4049/jimmunol.1101649; Lackner H, 2008, HAEMATOLOGICA, V93, P291, DOI 10.3324/haematol.11704; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Malek TR, 2010, IMMUNITY, V33, P153, DOI 10.1016/j.immuni.2010.08.004; Malloy Colleen Ann, 2004, J Perinatol, V24, P458, DOI 10.1038/sj.jp.7211121; Miyara M, 2011, AUTOIMMUN REV, V10, P744, DOI 10.1016/j.autrev.2011.05.004; Nitta A, 2007, J PEDIATR-US, V151, P98, DOI 10.1016/j.jpeds.2007.04.037; Oldenhove G, 2009, IMMUNITY, V31, P772, DOI 10.1016/j.immuni.2009.10.001; Olin RL, 2008, AM J HEMATOL, V83, P747, DOI 10.1002/ajh.21236; Pierson W, 2013, NAT IMMUNOL, V14, P959, DOI 10.1038/ni.2649; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Russell SE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047748; Schlenner SM, 2010, IMMUNITY, V32, P426, DOI 10.1016/j.immuni.2010.03.005; Sepulveda FE, 2013, BLOOD, V121, P595, DOI 10.1182/blood-2012-07-440339; Sharma R, 2009, J IMMUNOL, V183, P1065, DOI 10.4049/jimmunol.0804354; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; Srivastava S, 2014, J EXP MED, V211, P961, DOI 10.1084/jem.20131556; Terrell CE, 2013, BLOOD, V121, P5184, DOI 10.1182/blood-2013-04-495309; Tian L, 2012, BIOESSAYS, V34, P569, DOI 10.1002/bies.201100180; Tomaske M, 2002, MED PEDIATR ONCOL, V38, P141, DOI 10.1002/mpo.1294; Usmani GN, 2013, BRIT J HAEMATOL, V161, P609, DOI 10.1111/bjh.12293; Utzschneider DT, 2013, NAT IMMUNOL, V14, P603, DOI 10.1038/ni.2606; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Vikstrom I, 2010, SCIENCE, V330, P1095, DOI 10.1126/science.1191793	36	33	37	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					200	+		10.1016/j.jaci.2015.12.1314	http://dx.doi.org/10.1016/j.jaci.2015.12.1314			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26947179	Green Accepted, Bronze, Green Submitted			2022-12-18	WOS:000379659100022
J	Li, JT; Bernstein, DI; Calderon, MA; Casale, TB; Cox, L; Passalacqua, G; Pfaar, O; Papadopoulos, NG				Li, James T.; Bernstein, David I.; Calderon, Moises A.; Casale, Thomas B.; Cox, Linda; Passalacqua, Giovanni; Pfaar, Oliver; Papadopoulos, Nikolaos G.			Sublingual grass and ragweed immunotherapy: Clinical considerations-a PRACTALL consensus report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sublingual; immunotherapy; ragweed; sublingual immunotherapy	HOUSE-DUST MITE; ALLERGEN-SPECIFIC IMMUNOTHERAPY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; SUBCUTANEOUS IMMUNOTHERAPY; EFFICACY; CHILDREN; TABLET; ASTHMA; SAFETY	Sublingual allergen immunotherapy provides a new option for patients with allergic rhinitis in the United States. The efficacy of these sublingual immunotherapy tablets in the treatment of allergic rhinitis has been firmly established in large multicenter clinical trials. In addition, the clinical benefits of sublingual immunotherapy might persist after treatment is discontinued. Local reactions, such as gastrointestinal or oropharyngeal symptoms, are common. However, severe anaphylaxis is rare, and therefore the immunotherapy tablets can be administered at home. Sublingual immunotherapy for allergic rhinitis has been used successfully for years in Europe, and these products might be appropriate for patients who do not do well with standard drug therapy or for those who prefer a disease-modifying approach.	[Li, James T.] Mayo Clin, Div Allerg Dis, Rochester, MN 55905 USA; [Bernstein, David I.] Univ Cincinnati, Cincinnati, OH 45221 USA; [Calderon, Moises A.] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; [Casale, Thomas B.] Univ S Florida, Tampa, FL USA; [Cox, Linda] Nova SE Univ, Ft Lauderdale, FL 33314 USA; [Passalacqua, Giovanni] Univ Genoa, Allergy & Resp Dis, I-16126 Genoa, Italy; [Pfaar, Oliver] Ctr Rhinol & Allergol, Wiesbaden, Germany; [Pfaar, Oliver] Heidelberg Univ, Med Fac Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Univ Med Mannheim, Mannheim, Germany; [Papadopoulos, Nikolaos G.] Allergy Res Ctr, Athens, Greece	Mayo Clinic; University System of Ohio; University of Cincinnati; Imperial College London; State University System of Florida; University of South Florida; Nova Southeastern University; University of Genoa; Ruprecht Karls University Heidelberg	Li, JT (corresponding author), Mayo Clin, 200 First St, Rochester, MN 55905 USA.	li.james@mayo.edu	N.G., Papadopoulos/L-8670-2013; Cox, Linda/AAP-1697-2021	N.G., Papadopoulos/0000-0002-4448-3468; Cox, Linda/0000-0002-5258-6870	Merck; Stallergenes; Greer; Amgen; Novartis; GlaxoSmithKline; Circassia; Johnson Johnson; TEVA; Pfizer; Genentech; Boehringer Ingelheim; Astra Zeneca; Stalleregenes; ALK-Abello (Germany/Denmark); Allergopharma (Germany); Stallergenes (Germany/France); HAL Allergy (Germany/The Netherlands); Artu Biologicals (The Netherlands); Allergy Therapeutics/Bencard (United Kingdom/Germany); Hartington (Spain); Lofarma (Italy); Novartis (Germany); LETI-Pharma/Laboratorios LETI (Germany/Spain); GlaxoSmithKline (United Kingdom/Germany); Essex Pharma (Germany); Cytos (Switzerland); Curalogic (Denmark); Roxall (Germany); Biomay (Austria); Thermo Fisher (Germany); Circassia (United Kingdom); European Union; Biotech Tools s.a. (Belgium); MEDA Pharma (Germany); HAL Allergy (The Netherlands/Germany); European Academy of Allergy and Clinical Immunology (EAACI); German Society for Allergology and Clinical Immunology (DGAKI); German Respiratory Society (DGP); DGAKI; GlaxoSmithKline (Germany); Bencard (Germany); Nestle; Abbvie; Sanofi; Menarini; Meda; ALK-Abello; Allergopharma; Uriach; MSD	Merck(Merck & Company); Stallergenes; Greer; Amgen(Amgen); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); Circassia; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); TEVA(Teva Pharmaceutical Industries); Pfizer(Pfizer); Genentech(Roche HoldingGenentech); Boehringer Ingelheim(Boehringer Ingelheim); Astra Zeneca(AstraZeneca); Stalleregenes; ALK-Abello (Germany/Denmark); Allergopharma (Germany); Stallergenes (Germany/France); HAL Allergy (Germany/The Netherlands); Artu Biologicals (The Netherlands)(Netherlands Government); Allergy Therapeutics/Bencard (United Kingdom/Germany); Hartington (Spain); Lofarma (Italy); Novartis (Germany)(Novartis); LETI-Pharma/Laboratorios LETI (Germany/Spain); GlaxoSmithKline (United Kingdom/Germany); Essex Pharma (Germany); Cytos (Switzerland); Curalogic (Denmark); Roxall (Germany); Biomay (Austria); Thermo Fisher (Germany); Circassia (United Kingdom); European Union(European Commission); Biotech Tools s.a. (Belgium); MEDA Pharma (Germany); HAL Allergy (The Netherlands/Germany); European Academy of Allergy and Clinical Immunology (EAACI); German Society for Allergology and Clinical Immunology (DGAKI); German Respiratory Society (DGP); DGAKI; GlaxoSmithKline (Germany)(GlaxoSmithKline); Bencard (Germany); Nestle(Nestle SA); Abbvie(AbbVie); Sanofi; Menarini(Menarini Group); Meda; ALK-Abello; Allergopharma; Uriach; MSD	D. I. Bernstein has received research support from Merck, Stallergenes, Greer, Amgen, Novartis, GlaxoSmithKline, Circassia, Johnson & Johnson, TEVA, Pfizer, Genentech, Boehringer Ingelheim, Astra Zeneca, and Novartis; has consultant arrangements with Merck, BVA, and Circassia; has received payment for service on the Scientific Advisory Committee for Merck; is a board member for the American Board of Allergy and Immunology and the Joint Task Force on Practice Parameters; and has received payment for lectures from Merck. M. A. Calderon has consultant agreements with ALK-Abello (Germany/Denmark), HAL Allergy (The Netherlands/Germany), and Stallergenes (Germany/France). T. B. Casale has received grants from Stalleregenes and Merck and grants and personal fees from Circassia outside the submitted work and serves as Executive Vice President of the American Academy of Allergy, Asthma & Immunology. O. Pfaar has received research grants for his institution from ALK-Abello (Germany/Denmark), Allergopharma (Germany), Stallergenes (Germany/France), HAL Allergy (Germany/The Netherlands), Artu Biologicals (The Netherlands), Allergy Therapeutics/Bencard (United Kingdom/Germany), Hartington (Spain), Lofarma (Italy), Novartis (Germany), LETI-Pharma/Laboratorios LETI (Germany/Spain), GlaxoSmithKline (United Kingdom/Germany), Essex Pharma (Germany), Cytos (Switzerland), Curalogic (Denmark), Roxall (Germany), Biomay (Austria), Thermo Fisher (Germany), Circassia (United Kingdom), European Union (FP-7 Health-2013 Innovation 1), Biotech Tools s.a. (Belgium), and MEDA Pharma (Germany); has served as an advisor and on speakers' bureaus for some of the aforementioned companies; has received travel grants from HAL Allergy (The Netherlands/Germany), Allergopharma (Germany), the European Academy of Allergy and Clinical Immunology (EAACI), the German Society for Allergology and Clinical Immunology (DGAKI), and the German Respiratory Society (DGP); is a consultant for Allergy Therapeutics/Bencard (United Kingdom/Germany), HAL Allergy (Germany/The Netherlands), Novartis (Germany), LETI Pharma/Laboratorios LETI (Germany/Spain), MEDA Pharma (Germany), ALK-Abello (Germany/Denmark), Allergopharma (Germany), Biotech Tools s.a. (Belgium), GfK Bridgehead (UK), Navigant Consulting (United States), Sanofi (United States), Guidepoint Global Advisors (United States), Thermo Fisher (Germany), Pohl-Boskamp (Germany), Stallergenes (Germany/France), and Mobile Chamber Experts (MCX, a GA2LEN Partner); has been Coordinating Investigator in clinical trials of some of the aforementioned companies; is the current chairman of the Immunotherapy Interest Group (IT IG) of the EAACI and is the secretary of the ENT section of the DGAKI; has received grants for the "Spezifische Immuntherapie'' award 2014 and the "Nachwuchsforderpreis'' award 2010 of the DGAKI; is coeditor and author of different chapters of the textbook Allergien bei Kindern und Jugendlichen (publisher: Schattauer, Germany), author of one chapter in Allergologie (publisher: Springer, Germany), and author of different chapters in Allergologie (publisher: Schattauer, Germany); has received payment for development of educational presentations from GlaxoSmithKline (Germany), Bencard (Germany), ALK-Abello (Germany/Denmark), Stallergenes (Germany/France), and Novartis (Germany); and is an editorial board member of Allergo Journal International. N. G.; Papadopoulos has received research support from GlaxoSmithKline, Nestle, and Merck; has received payment for development of educational presentations from Abbvie, Sanofi, Menarini, and Meda; has received consultant fees from GlaxoSmithKline, Abbvie, Novartis, Menarini, Meda, and ALK-Abello; and has received payment for lectures from Novartis, Allergopharma, Uriach, GlaxoSmithKline, Stallergenes, and MSD. The rest of the authors declare that they have no relevant conflicts of interest.	Aasbjerg K, 2014, CLIN EXP ALLERGY, V44, P417, DOI 10.1111/cea.12241; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Antico A, 2014, J ALLERGY CLIN IMMUN, V133, P1482, DOI 10.1016/j.jaci.2014.01.030; Antunez C, 2008, PEDIAT ALLERG IMM-UK, V19, P210, DOI 10.1111/j.1399-3038.2007.00604.x; Aydogan M, 2013, RESP MED, V107, P1322, DOI 10.1016/j.rmed.2013.06.021; Bender BG, 2014, J ALLER CL IMM-PRACT, V2, P152, DOI 10.1016/j.jaip.2014.01.003; Bergmann KC, 2014, J ALLERGY CLIN IMMUN, V133, P1608, DOI 10.1016/j.jaci.2013.11.012; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Canonica GW, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-6; Chelladurai Y, 2014, CURR OPIN OTOLARYNGO, V22, P211, DOI 10.1097/MOO.0000000000000045; Chelladurai Y, 2013, J ALLER CL IMM-PRACT, V1, P361, DOI 10.1016/j.jaip.2013.04.005; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Cox LS, 2014, J ALLER CL IMM-PRACT, V2, P156, DOI 10.1016/j.jaip.2014.01.010; Creticos PS, 2014, J ALLERGY CLIN IMMUN, V133, P751, DOI 10.1016/j.jaci.2013.10.041; Devillier P, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-71; Di Bona D, 2012, J ALLERGY CLIN IMMUN, V130, P1097, DOI 10.1016/j.jaci.2012.08.012; Didier A, 2013, CLIN EXP ALLERGY, V43, P568, DOI 10.1111/cea.12100; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Didier A, 2011, J ALLERGY CLIN IMMUN, V128, P559, DOI 10.1016/j.jaci.2011.06.022; Dretzke J, 2013, J ALLERGY CLIN IMMUN, V131, P1361, DOI 10.1016/j.jaci.2013.02.013; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Eifan AO, 2010, CLIN EXP ALLERGY, V40, P922, DOI 10.1111/j.1365-2222.2009.03448.x; Halken S, 2010, PEDIAT ALLERG IMM-UK, V21, P970, DOI 10.1111/j.1399-3038.2010.01050.x; Incorvaia C, 2010, ALLERGY, V65, P1341, DOI 10.1111/j.1398-9995.2010.02347.x; Keles S, 2011, J ALLERGY CLIN IMMUN, V128, P808, DOI 10.1016/j.jaci.2011.04.033; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kim JM, 2013, PEDIATRICS, V131, P1155, DOI 10.1542/peds.2013-0343; Lin SY, 2013, JAMA-J AM MED ASSOC, V309, P1278, DOI 10.1001/jama.2013.2049; Makatsori M, 2014, ALLERGY, V69, P571, DOI 10.1111/all.12385; Maloney J, 2015, ALLERGY, V70, P302, DOI 10.1111/all.12560; Maloney J, 2014, ANN ALLERG ASTHMA IM, V112, P146, DOI 10.1016/j.anai.2013.11.018; Marogna M, 2008, ANN ALLERG ASTHMA IM, V101, P206, DOI 10.1016/S1081-1206(10)60211-6; Marogna M, 2010, J ALLERGY CLIN IMMUN, V126, P969, DOI 10.1016/j.jaci.2010.08.030; Mauro M, 2007, Eur Ann Allergy Clin Immunol, V39, P119; Meadows A, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17270; Miehlke Stephan, 2013, Case Rep Gastroenterol, V7, P363, DOI 10.1159/000355161; Mosbech H, 2015, ANN ALLERG ASTHMA IM, V114, P134, DOI 10.1016/j.anai.2014.11.015; Mosbech H, 2014, J ALLERGY CLIN IMMUN, V134, P568, DOI 10.1016/j.jaci.2014.03.019; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Nolte H, 2015, J ALLERGY CLIN IMMUN, V135, P1494, DOI 10.1016/j.jaci.2014.12.1911; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Passalacqua G, 2013, J ALLERGY CLIN IMMUN, V132, P93, DOI 10.1016/j.jaci.2013.03.039; PIAZZA I, 1993, ANN ALLERGY, V71, P461; Potter PC, 2015, ANN ALLERG ASTHMA IM, V114, P327, DOI 10.1016/j.anai.2014.12.015; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Radulovic S, 2011, ALLERGY, V66, P740, DOI 10.1111/j.1398-9995.2011.02583.x; Reich K, 2011, CLIN THER, V33, P828, DOI 10.1016/j.clinthera.2011.06.006; Savi E, 2013, ALLERGY, V68, P1193, DOI 10.1111/all.12198; Schwab JA, 2013, CLIN DRUG INVEST, V33, P719, DOI 10.1007/s40261-013-0115-8; Strunk RC, 2009, J PEDIATR-US, V154, P682, DOI 10.1016/j.jpeds.2008.11.036; Tahamiler R, 2008, ORL-J OTO-RHIN-LARYN, V70, P144, DOI 10.1159/000124286; Valovirta E, 2011, CLIN THER, V33, P1537, DOI 10.1016/j.clinthera.2011.09.013; Ventura MT, 2009, INT J IMMUNOPATH PH, V22, P403, DOI 10.1177/039463200902200217; Vita D, 2010, ALLERGY, V65, P668, DOI 10.1111/j.1398-9995.2009.02223.x; Wahn U, 2012, J ALLERGY CLIN IMMUN, V130, P886, DOI 10.1016/j.jaci.2012.06.047; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Wang W, 2010, CHINESE MED J-PEKING, V123, P2099, DOI 10.3760/cma.j.issn.0366-6999.2010.15.026; Yukselen A, 2012, INT ARCH ALLERGY IMM, V157, P288, DOI 10.1159/000327566	65	33	34	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					369	376		10.1016/j.jaci.2015.06.046	http://dx.doi.org/10.1016/j.jaci.2015.06.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26371843	Bronze			2022-12-18	WOS:000369235500004
J	Kondeti, V; Al-Azzam, N; Duah, E; Thodeti, CK; Boyce, JA; Paruchuri, S				Kondeti, Vinay; Al-Azzam, Nosayba; Duah, Ernest; Thodeti, Charles K.; Boyce, Joshua A.; Paruchuri, Sailaja			Leukotriene D-4 and prostaglandin E-2 signals synergize and potentiate vascular inflammation in a mast cell-dependent manner through cysteinyl leukotriene receptor 1 and E-prostanoid receptor 3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; prostaglandin E-2; leukotriene D-4; CysLT(1)R; E-prostanoid receptor 3; prostaglandin D-2; c-fos; protein kinase G; extracellular signal-regulated kinase; macrophage inflammatory protein 1 beta	CYSLT(1) RECEPTORS; RESPONSES; ACTIVATION; ASTHMA; INDUCTION; SUBTYPE; IMMUNE; GPR17; GAMMA; EP3	Background: Although arachidonic acid metabolites, cysteinyl leukotrienes (cys-LTs; leukotriene [LT] C-4, LTD4, and LTE4), and prostaglandin (PG) E-2 are generated at the site of inflammation, it is not known whether crosstalk exists between these 2 classes of inflammatory mediators. Objective: We sought to determine the role of LTD4-PGE(2) crosstalk in inducing vascular inflammation in vivo, identify effector cells, and ascertain specific receptors and pathways involved in vitro. Methods: Vascular (ear) inflammation was assessed by injecting agonists into mouse ears, followed by measuring ear thickness and histology, calcium influx with Fura-2, phosphorylation and expression of signaling molecules by means of immunoblotting, PGD(2) and macrophage inflammatory protein 1 beta generation by using ELISA, and expression of transcripts by using RT-PCR. Candidate receptors and signaling molecules were identified by using antagonists and inhibitors and confirmed by using small interfering RNA. Results: LTD4 plus PGE(2) potentiated vascular permeability and edema, gearing the system toward proinflammation in wild-type mice but not in Kit(W-sh) mice. Furthermore, LTD4 plus PGE(2), through cysteinyl leukotriene receptor 1 (CysLT(1)R) and E-prostanoid receptor (EP) 3, enhanced extracellular signal-regulated kinase (Erk) and c-fos phosphorylation, inflammatory gene expression, macrophage inflammatory protein 1 beta secretion, COX-2 upregulation, and PGD(2) generation in mast cells. Additionally, we uncovered that this synergism is mediated through Gi, protein kinase G, and Erk signaling. LTD4 plus PGE(2)-potentiated effects are partially sensitive to CysLT(1)R or EP3 antagonists but completely abolished by simultaneous treatment both in vitro and in vivo. Conclusions: Our results unravel a unique LTD4-PGE(2) interaction affecting mast cells through CysLT(1)R and EP3 involving Gi, protein kinase G, and Erk and contributing to vascular inflammation in vivo. Furthermore, current results also suggest an advantage of targeting both CysLT(1)R and EP3 in attenuating inflammation.	[Kondeti, Vinay; Al-Azzam, Nosayba; Duah, Ernest; Paruchuri, Sailaja] Univ Akron, Dept Chem, Akron, OH 44325 USA; [Thodeti, Charles K.] Northeast Ohio Med Univ, Dept Integrat Med Sci, Rootstown, OH USA; [Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Boyce, Joshua A.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	University System of Ohio; University of Akron; Northeast Ohio Medical University (NEOMED); Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Paruchuri, S (corresponding author), Univ Akron, Dept Chem, KNCL 406,185 E Mill St, Akron, OH 44325 USA.	sp97@uakron.edu	Duah, Ernest/I-5985-2019	Duah, Ernest/0000-0002-5125-0830	National Institutes of Health [HL098953]; James Foght Assistant Professor endowed professorship grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117945, R00HL098953, R01HL136209, K99HL098953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI052353, R01AI136041, U19AI095219, R01AI052353, R21AI115137, R01AI078908] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James Foght Assistant Professor endowed professorship grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant HL098953 and by James Foght Assistant Professor endowed professorship grant (to S.P.).	Al-Azzam N, 2015, J CELL PHYSIOL, V230, P595, DOI 10.1002/jcp.24777; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Duah E, 2013, SCI REP-UK, V3, DOI 10.1038/srep03274; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Feng CL, 2006, BLOOD, V107, P3243, DOI 10.1182/blood-2005-07-2772; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Hart PH, 2001, IMMUNOL CELL BIOL, V79, P149, DOI 10.1046/j.1440-1711.2001.00983.x; Jiang Y, 2007, BLOOD, V110, P3263, DOI 10.1182/blood-2007-07-100453; KALINER M, 1974, J IMMUNOL, V112, P664; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Kaplan DH, 2012, NAT REV IMMUNOL, V12, P114, DOI 10.1038/nri3150; Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440; Kimple ME, 2013, DIABETES, V62, P1904, DOI 10.2337/db12-0769; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Kondeti V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071536; Laidlaw TM, 2012, CLIN EXP ALLERGY, V42, P1313, DOI 10.1111/j.1365-2222.2012.03982.x; Leclerc JL, 2015, EUR J NEUROSCI, V41, P1381, DOI 10.1111/ejn.12909; Maekawa A, 2009, P NATL ACAD SCI USA, V106, P11685, DOI 10.1073/pnas.0905364106; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Morimoto K, 2014, J IMMUNOL, V192, P1130, DOI 10.4049/jimmunol.1300290; Nguyen MT, 2002, J IMMUNOL, V169, P4586, DOI 10.4049/jimmunol.169.8.4586; Paruchuri S, 2003, J BIOL CHEM, V278, P45577, DOI 10.1074/jbc.M302881200; Paruchuri S, 2002, J CELL SCI, V115, P1883; Paruchuri S, 2008, J BIOL CHEM, V283, P16477, DOI 10.1074/jbc.M705822200; PEACHELL PT, 1988, J IMMUNOL, V140, P571; Sakanaka M, 2008, AM J PHYSIOL-CELL PH, V295, pC1427, DOI 10.1152/ajpcell.00218.2008; St John AL, 2013, J IMMUNOL, V190, P4458, DOI 10.4049/jimmunol.1203420; Stables MJ, 2011, PROG LIPID RES, V50, P35, DOI 10.1016/j.plipres.2010.07.005; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; URADE Y, 1990, J BIOL CHEM, V265, P371; Weller CL, 2007, P NATL ACAD SCI USA, V104, P11712, DOI 10.1073/pnas.0701700104; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690; Woodward DF, 2011, PHARMACOL REV, V63, P471, DOI 10.1124/pr.110.003517; Xue L, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Xue LZ, 2015, J ALLERGY CLIN IMMUN, V135, P1358, DOI 10.1016/j.jaci.2014.09.006; Xue LZ, 2005, J IMMUNOL, V175, P6531, DOI 10.4049/jimmunol.175.10.6531; Ying S, 2006, J ALLERGY CLIN IMMUN, V117, P312, DOI 10.1016/j.jaci.2005.10.037	40	33	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					289	298		10.1016/j.jaci.2015.06.030	http://dx.doi.org/10.1016/j.jaci.2015.06.030			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26255103	Green Accepted			2022-12-18	WOS:000367724300021
J	Gao, L; Bin, LH; Rafaels, NM; Huang, LL; Potee, J; Ruczinski, I; Beaty, TH; Paller, AS; Schneider, LC; Gallo, R; Hanifin, JM; Beck, LA; Geha, RS; Mathias, RA; Barnes, KC; Leung, DYM				Gao, Li; Bin, Lianghua; Rafaels, Nicholas M.; Huang, Lili; Potee, Joseph; Ruczinski, Ingo; Beaty, Terri H.; Paller, Amy S.; Schneider, Lynda C.; Gallo, Rich; Hanifin, Jon M.; Beck, Lisa A.; Geha, Raif S.; Mathias, Rasika A.; Barnes, Kathleen C.; Leung, Donald Y. M.			Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IFNGR1; genetic variants; atopic dermatitis; eczema herpeticum	GAMMA RECEPTOR-1 GENE; INTERFERON-GAMMA; 1 DEFICIENCY; POLYMORPHISM; SUSCEPTIBILITY; TUBERCULOSIS; POPULATION; ANNOTATION; EVOLUTION; CYTOKINES	Background: A subset of atopic dermatitis is associated with increased susceptibility to eczema herpeticum (ADEH+). We previously reported that common single nucleotide polymorphisms (SNPs) in the IFN-gamma (IFNG) and IFN-gamma receptor 1 (IFNGR1) genes were associated with the ADEH+ phenotype. Objective: We sought to interrogate the role of rare variants in interferon pathway genes for the risk of ADEH+. Methods: We performed targeted sequencing of interferon pathway genes (IFNG, IFNGR1, IFNAR1, and IL12RB1) in 228 European American patients with AD selected according to their eczema herpeticum status, and severity was measured by using the Eczema Area and Severity Index. Replication genotyping was performed in independent samples of 219 European American and 333 African American subjects. Functional investigation of loss-of-function variants was conducted by using site-directed mutagenesis. Results: We identified 494 single nucleotide variants encompassing 105 kb of sequence, including 145 common, 349 (70.6%) rare (minor allele frequency <5%), and 86 (17.4%) novel variants, of which 2.8% were coding synonymous, 93.3% were noncoding (64.6% intronic), and 3.8% were missense. We identified 6 rare IFNGR1 missense variants, including 3 damaging variants (Val14Met [V14M], Val61Ile, and Tyr397Cys [Y397C]) conferring a higher risk for ADEH1 (P = .031). Variants V14M and Y397C were confirmed to be deleterious, leading to partial IFNGR1 deficiency. Seven common IFNGR1 SNPs, along with common protective haplotypes (2-7 SNPs), conferred a reduced risk of ADEH1 (P = .015-.002 and P = .0015-.0004, respectively), and both SNP and haplotype associations were replicated in an independent African American sample (P = .004-.0001 and P =.001-.0001, respectively). Conclusion: Our results provide evidence that both genetic variants in the gene encoding IFNGR1 are implicated in susceptibility to the ADEH+ phenotype.	[Gao, Li; Rafaels, Nicholas M.; Huang, Lili; Potee, Joseph; Mathias, Rasika A.; Barnes, Kathleen C.] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA; [Ruczinski, Ingo] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Beaty, Terri H.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Paller, Amy S.] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA; [Paller, Amy S.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Paller, Amy S.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Schneider, Lynda C.] Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA; [Gallo, Rich] Univ Calif San Diego, Div Dermatol, La Jolla, CA 92093 USA; [Hanifin, Jon M.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; [Beck, Lisa A.] Univ Rochester, Med Ctr, Dept Dermatol, Rochester, NY 14627 USA; [Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Bin, Lianghua; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Harvard University; Boston Children's Hospital; University of California System; University of California San Diego; Oregon Health & Science University; University of Rochester; Harvard University; Harvard Medical School; National Jewish Health	Barnes, KC (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Rm 3A-62, Baltimore, MD 21224 USA.	kbarnes@jhmi.edu		Paller, Amy/0000-0001-6187-6549	Atopic Dermatitis Research Network National Institutes of Health/National Institute of Allergy and Infectious Diseases [HHSN272201000020C, HHSN272201000017C]; Mary Beryl Patch Turnbull Scholar Program; Edelstein Family Chair in Pediatric Allergy-Immunology; NIH/NCATS Colorado CTSI grant [UL1 TR000154]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082, UL1TR001422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI117673] Funding Source: NIH RePORTER	Atopic Dermatitis Research Network National Institutes of Health/National Institute of Allergy and Infectious Diseases; Mary Beryl Patch Turnbull Scholar Program; Edelstein Family Chair in Pediatric Allergy-Immunology; NIH/NCATS Colorado CTSI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Atopic Dermatitis Research Network National Institutes of Health/National Institute of Allergy and Infectious Diseases contracts HHSN272201000020C and HHSN272201000017C. K.C.B. was supported in part by the Mary Beryl Patch Turnbull Scholar Program. D.Y.M.L. was supported in part by the Edelstein Family Chair in Pediatric Allergy-Immunology. The CTRC is supported in part by NIH/NCATS Colorado CTSI grant no. UL1 TR000154.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Akhtar MM, 2013, BMC EVOL BIOL, V13, DOI 10.1186/1471-2148-13-145; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Aoki M, 2003, INT J MOL MED, V12, P185; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Biedermann T, 2004, J INVEST DERM SYMP P, V9, P5, DOI 10.1111/j.1087-0024.2004.00829.x; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112; Eichenfield LF, 2003, PEDIATRICS, V111, P608, DOI 10.1542/peds.111.3.608; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Fraser DA, 2003, SCAND J IMMUNOL, V57, P480, DOI 10.1046/j.1365-3083.2003.01253.x; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gao PS, 2012, J INVEST DERMATOL, V132, P650, DOI 10.1038/jid.2011.374; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Gariboldi S, 2009, PULM PHARMACOL THER, V22, P497, DOI 10.1016/j.pupt.2009.05.002; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Gough DJ, 2008, CYTOKINE GROWTH F R, V19, P383, DOI 10.1016/j.cytogfr.2008.08.004; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; He J, 2010, SCAND J IMMUNOL, V71, P452, DOI 10.1111/j.1365-3083.2010.02393.x; Herberth G, 2010, PEDIAT ALLERG IMM-UK, V21, P5, DOI 10.1111/j.1399-3038.2009.00890.x; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Jouanguy E, 2000, J CLIN INVEST, V105, P1429, DOI 10.1172/JCI9166; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Koch O, 2002, J INFECT DIS, V185, P1684, DOI 10.1086/340516; Kumar V, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003201; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Leung DYM, 2013, ANTIVIR RES, V98, P153, DOI 10.1016/j.antiviral.2013.02.010; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Lohmueller KE, 2013, AM J HUM GENET, V93, P1072, DOI 10.1016/j.ajhg.2013.11.005; Newport MJ, 2003, SCAND J IMMUNOL, V58, P383, DOI 10.1046/j.1365-3083.2003.01328.x; Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Tennessen JA, 2012, SCIENCE, V337, P64, DOI 10.1126/science.1219240; Thye T, 2003, AM J HUM GENET, V72, P448, DOI 10.1086/367714; van de Wetering D, 2010, MOL IMMUNOL, V47, P1023, DOI 10.1016/j.molimm.2009.11.016; Velez DR, 2009, HUM GENET, V126, P643, DOI 10.1007/s00439-009-0713-y; Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274; Walters RG, 2010, NATURE, V463, P671, DOI 10.1038/nature08727; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Wild JS, 2000, J IMMUNOL, V164, P2701, DOI 10.4049/jimmunol.164.5.2701; Xu FJ, 2006, JAMA-J AM MED ASSOC, V296, P964, DOI 10.1001/jama.296.8.964	52	33	34	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1591	1600		10.1016/j.jaci.2015.06.047	http://dx.doi.org/10.1016/j.jaci.2015.06.047			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26343451	Green Accepted			2022-12-18	WOS:000366044300021
J	Wiechers, T; Rabenhorst, A; Schick, T; Preussner, LM; Forster, A; Valent, P; Horny, HP; Sotlar, K; Hartmann, K				Wiechers, Tim; Rabenhorst, Anja; Schick, Tina; Preussner, Liane M.; Foerster, Anja; Valent, Peter; Horny, Hans-Peter; Sotlar, Karl; Hartmann, Karin			Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood-onset mastocytosis; cutaneous mastocytosis; KIT mutation; mast cell; mastocytosis; pediatric mastocytosis; prognosis; skin; tryptase; urticaria pigmentosa	KIT D816V MUTATION; PEDIATRIC MASTOCYTOSIS; C-KIT; TRYPTASE LEVELS; URTICARIA-PIGMENTOSA; DIAGNOSTIC-CRITERIA; GERMLINE MUTATION; ALLELE BURDEN; BASE-LINE; CHILDREN	Background: Mastocytosis, characterized by pathologic accumulation of mast cells, can manifest itself in adulthood or childhood. Pediatric patients usually have cutaneous mastocytosis (CM) with mast cell infiltrates limited to the skin and spontaneous improvement of skin lesions after several years. However, there are some patients with persistent disease resembling adulthood-onset mastocytosis. Objective: The current classification of CM differentiates between 3 subforms. In clinical practice we noticed that different variants of these subforms might exist, particularly in patients with childhood-onset mastocytosis. Therefore, in the present study, we aimed to investigate whether specific cutaneous lesions in patients with childhood-onset mastocytosis are associated with other disease parameters. Methods: We analyzed 144 patients with a disease onset of less than age 17 years using a systematic dermatologic approach. Results: One hundred twenty-two patients presented with maculopapular cutaneous mastocytosis (MPCM), 12 patients presented with diffuse CM, and 10 patients presented with solitary mastocytoma of the skin. Patients with MPCM showed particularly heterogeneous cutaneous lesions and were therefore grouped into 3 variants presenting either with small lesions (MPCM-small, skin lesions < 1 cm in diameter; n = 19), large lesions (MPCM-large, skin lesions >= 1 cm in diameter; n = 89), or atypical lesions (MPCM-other, n = 14). Patients with MPCM-large lesions, compared with those with MPCM-small lesions, were characterized by significantly lower tryptase levels, shorter disease duration, and earlier disease onset. In addition, more patients with MPCM-large lesions exhibited spontaneous regression of cutaneous lesions. Conclusion: Our data show that patients with MPCM-large lesions compared with those with MPCM-small lesions have a more favorable disease course and suggest exploring the size of cutaneous lesions as a prognostic parameter in childhood-onset MPCM.	[Wiechers, Tim; Rabenhorst, Anja; Schick, Tina; Preussner, Liane M.; Foerster, Anja; Hartmann, Karin] Univ Cologne, Dept Dermatol, Cologne, Germany; [Schick, Tina] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany; [Valent, Peter] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria; [Horny, Hans-Peter; Sotlar, Karl] Univ Munich, Inst Pathol, D-80539 Munich, Germany; [Hartmann, Karin] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany	University of Cologne; University of Cologne; Medical University of Vienna; University of Munich; University of Lubeck	Hartmann, K (corresponding author), Med Univ Lubeck, Dept Dermatol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	karin.hartmann@uksh.de	Test, Test/Y-7921-2019; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019; Rabenhorst, Anja/J-3217-2016; Hartmann, Karin/N-4865-2015	Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Hartmann, Karin/0000-0002-4595-8226	German Research Council [HA 2393/6-1]	German Research Council(German Research Foundation (DFG))	Supported by a research grant from the German Research Council (HA 2393/6-1; to K.H.).	Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822; Akin C, 2014, IMMUNOL ALLERGY CLIN, V34, P207, DOI 10.1016/j.iac.2014.02.003; Alvarez-Twose I, 2012, ALLERGY, V67, P813, DOI 10.1111/j.1398-9995.2012.02812.x; AZANA JM, 1994, PEDIATR DERMATOL, V11, P102, DOI 10.1111/j.1525-1470.1994.tb00560.x; Ben-Amitai D, 2005, ISR MED ASSOC J, V7, P320; Berezowska S, 2014, MODERN PATHOL, V27, P19, DOI 10.1038/modpathol.2013.117; Bibi S, 2014, IMMUNOL ALLERGY CLIN, V34, P239, DOI 10.1016/j.iac.2014.01.009; Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brockow K, 2003, J AM ACAD DERMATOL, V48, P508, DOI 10.1067/mjd.2003.98; CAPLAN RM, 1963, ARCH DERMATOL, V87, P146, DOI 10.1001/archderm.1963.01590140008002; Carter MC, 2002, ARCH DIS CHILD, V86, P315, DOI 10.1136/adc.86.5.315; Carter MC, 2015, BRIT J HAEMATOL, V168, P865, DOI 10.1111/bjh.13231; Castells M, 2011, AM J CLIN DERMATOL, V12, P259, DOI 10.2165/11588890-000000000-00000; Chatzipetrou A, 2014, CLIN TRANSL ALLERGY, V28, P34; Erben P, 2014, ANN HEMATOL, V93, P81, DOI 10.1007/s00277-013-1964-1; Frieri M, 2013, PEDIAT ALLER IMM PUL, V26, P175, DOI 10.1089/ped.2013.0275; Hannaford R, 2001, Australas J Dermatol, V42, P15, DOI 10.1046/j.1440-0960.2001.00466.x; Hartmann K, 2000, HEMATOL ONCOL CLIN N, V14, P625, DOI 10.1016/S0889-8588(05)70299-9; Hartmann K, 2005, GASTROENTEROLOGY, V129, P1042, DOI 10.1053/j.gastro.2005.06.060; Hartmann K, 2002, INT ARCH ALLERGY IMM, V127, P143, DOI 10.1159/000048187; Hartmann K, 2001, BRIT J DERMATOL, V144, P682, DOI 10.1046/j.1365-2133.2001.04123.x; Heide R, 2009, DERMATOLOGY, V219, P309, DOI 10.1159/000243808; Hoermann G, 2014, ALLERGY, V69, P810, DOI 10.1111/all.12409; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Hup MMA, 2002, J EUR ACAD DERMATOL, V16, P115, DOI 10.1046/j.1468-3083.2002.00370.x; KETTELHUT BV, 1991, J INVEST DERMATOL, V96, pS15, DOI 10.1111/1523-1747.ep12468942; Kiszewski AE, 2004, J EUR ACAD DERMATOL, V18, P285, DOI 10.1111/j.1468-3083.2004.00830.x; Koga H, 2011, PEDIATR DERMATOL, V28, P542, DOI 10.1111/j.1525-1470.2010.01212.x; Kristensen T, 2013, EUR J HAEMATOL, V91, P106, DOI 10.1111/ejh.12128; Kristensen T, 2011, J MOL DIAGN, V13, P180, DOI 10.1016/j.jmoldx.2010.10.004; Lange M, 2013, J EUR ACAD DERMATOL, V27, P97, DOI 10.1111/j.1468-3083.2011.04365.x; Lange M, 2012, J EUR ACAD DERMATOL, V26, P1565, DOI 10.1111/j.1468-3083.2011.04350.x; Lange M, 2012, ARCH MED SCI, V8, P533, DOI 10.5114/aoms.2012.29409; Lanternier F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001906; Meni C, 2015, BRIT J DERMATOL, V172, P642, DOI 10.1111/bjd.13567; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Orfao A, 2007, BRIT J HAEMATOL, V138, P12, DOI 10.1111/j.1365-2141.2007.06619.x; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; Soter NA, 2000, HEMATOL ONCOL CLIN N, V14, P537, DOI 10.1016/S0889-8588(05)70295-1; Sotlar K, 2003, AM J PATHOL, V162, P737, DOI 10.1016/S0002-9440(10)63870-9; Sperr WR, 2002, INT ARCH ALLERGY IMM, V128, P136, DOI 10.1159/000059404; Tang X, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015156; Torrelo A, 2012, CURR OPIN PEDIATR, V24, P480, DOI 10.1097/MOP.0b013e328355b248; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2001, WHO CLASSIFICATION T, P291; Valent P, 2013, AM J CANCER RES, V3, P159; Wolff K, 2001, LEUKEMIA RES, V25, P519, DOI 10.1016/S0145-2126(01)00044-3; Yanagihori H, 2005, J MOL DIAGN, V7, P252, DOI 10.1016/S1525-1578(10)60552-1; Yang Y, 2010, BLOOD, V116, P1114, DOI 10.1182/blood-2009-06-226027	52	33	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1581	U236		10.1016/j.jaci.2015.05.034	http://dx.doi.org/10.1016/j.jaci.2015.05.034			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26152315	Bronze			2022-12-18	WOS:000366044300020
J	Christmann, BS; Abrahamsson, TR; Bernstein, CN; Duck, LW; Mannon, PJ; Berg, G; Bjorksten, B; Jenmalm, MC; Elson, CO				Christmann, Benjamin S.; Abrahamsson, Thomas R.; Bernstein, Charles N.; Duck, L. Wayne; Mannon, Peter J.; Berg, Goran; Bjorksten, Bengt; Jenmalm, Maria C.; Elson, Charles O.			Human seroreactivity to gut microbiota antigens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adaptive; atopy; allergy; childhood; IgG; microarray; microbiota; bacterial antigens; bacterial antibodies	INTESTINAL MICROBIOTA; REDUCED DIVERSITY; FECAL MICROBIOTA; EARLY-LIFE; INFANTS; ANTIBIOTICS; PROBIOTICS; PREGNANCY; DISEASE; HEALTH	Background: Although immune responses directed against antigens from the intestinal microbiota are observed in certain diseases, the normal human adaptive immune response to intestinal microbiota is poorly defined. Objective: Our goal was to assess the adaptive immune response to the intestinal microbiota present in 143 healthy adults and compare this response with the response observed in 52 children and their mothers at risk of having allergic disease. Methods: Human serum was collected from adults and children followed from birth to 7 years of age, and the serum IgG response to a panel of intestinal microbiota antigens was assessed by using a novel protein microarray. Results: Nearly every subject tested, regardless of health status, had serum IgG that recognized a common set of antigens. Seroreactivity to the panel of antigens was significantly lower in atopic adults. Healthy infants expressed the highest level of IgG seroreactivity to intestinal microbiota antigens. This adaptive response developed between 6 and 12 months of age and peaked around 2 years of age. Low IgG responses to certain clusters of microbiota antigens during infancy were associated with allergy development during childhood. Conclusions: There is an observed perturbation of the adaptive response to antigens from the microbiota in allergic subjects. These perturbations are observable even in childhood, suggesting that optimal stimulation of the adaptive immune system by the microbiota might be needed to prevent certain immune-mediated diseases.	[Christmann, Benjamin S.; Duck, L. Wayne; Mannon, Peter J.; Elson, Charles O.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Abrahamsson, Thomas R.; Berg, Goran; Jenmalm, Maria C.] Linkoping Univ, Dept Clin & Expt Med, S-58183 Linkoping, Sweden; [Bernstein, Charles N.] Univ Manitoba, Dept Med, Winnipeg, MB, Canada; [Bjorksten, Bengt] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Bjorksten, Bengt] Univ Orebro, Stockholm, Sweden	University of Alabama System; University of Alabama Birmingham; Linkoping University; University of Manitoba; Karolinska Institutet; Orebro University	Elson, CO (corresponding author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.	coelson@uab.edu	Jenmalm, Maria C/C-9679-2009	Jenmalm, Maria C/0000-0002-2117-5366	National Institutes of Health [DK071176]; Swedish Research Council [K2011-56X-21854-01-06]; Swedish Heart-Lung Foundation [20050514]; Ekhaga Foundation [210-53]; Research Council for the South-East Sweden; Olle Engqvist Foundation; Swedish Asthma and Allergy Association; Vardal Foundation for Health Care Science and Allergy Research, Sweden [B2007 042]; University Hospital of Linkoping, Sweden; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK071176] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Ekhaga Foundation; Research Council for the South-East Sweden; Olle Engqvist Foundation; Swedish Asthma and Allergy Association; Vardal Foundation for Health Care Science and Allergy Research, Sweden; University Hospital of Linkoping, Sweden; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health grant DK071176; the Swedish Research Council (K2011-56X-21854-01-06); the Swedish Heart-Lung Foundation (20050514); the Ekhaga Foundation (210-53); the Research Council for the South-East Sweden; the Olle Engqvist Foundation; the Swedish Asthma and Allergy Association; the Vardal Foundation for Health Care Science and Allergy Research, Sweden (B2007 042); and the University Hospital of Linkoping, Sweden.	Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Bouskra D, 2008, NATURE, V456, P507, DOI 10.1038/nature07450; Caporaso JG, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-5-r50; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Cotter PD, 2012, DISCOV MED, V13, P193; Faith JJ, 2013, SCIENCE, V341, P44, DOI 10.1126/science.1237439; Forno Erick, 2008, Clin Mol Allergy, V6, P11, DOI 10.1186/1476-7961-6-11; Giongo A, 2011, ISME J, V5, P82, DOI 10.1038/ismej.2010.92; GUILBERT B, 1982, J IMMUNOL, V128, P2779; Harmsen HJM, 2000, J PEDIATR GASTR NUTR, V30, P61, DOI 10.1097/00005176-200001000-00019; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Ismail IH, 2012, PEDIAT ALLERG IMM-UK, V23, P674, DOI 10.1111/j.1399-3038.2012.01328.x; Ivanov II, 2008, CELL HOST MICROBE, V4, P337, DOI 10.1016/j.chom.2008.09.009; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Konrad A, 2006, GASTROENTEROLOGY, V130, P2050, DOI 10.1053/j.gastro.2006.02.055; Koren O, 2012, CELL, V150, P470, DOI 10.1016/j.cell.2012.07.008; Le Huerou-Luron I, 2010, NUTR RES REV, V23, P23, DOI 10.1017/S0954422410000065; Lodes MJ, 2004, J CLIN INVEST, V113, P1296, DOI 10.1172/JCI200420295; LUTZ HU, 1982, J IMMUNOL, V128, P1695; Macia L, 2012, IMMUNOL REV, V245, P164, DOI 10.1111/j.1600-065X.2011.01080.x; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Manichanh C, 2006, GUT, V55, P205, DOI 10.1136/gut.2005.073817; Maynard CL, 2012, NATURE, V489, P231, DOI 10.1038/nature11551; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Persson M, 2012, J REPROD IMMUNOL, V95, P50, DOI 10.1016/j.jri.2012.05.003; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Salminen S, 1996, ANTON LEEUW INT J G, V70, P347, DOI 10.1007/BF00395941; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; Schwartz S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-4-r32; Sonnenberg GF, 2012, IMMUNITY, V37, P601, DOI 10.1016/j.immuni.2012.10.003; Stensballe LG, 2013, J PEDIATR-US, V162, P832, DOI 10.1016/j.jpeds.2012.09.049; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; West CE, 2015, CLIN EXP ALLERGY, V45, P43, DOI 10.1111/cea.12332; Wu HJ, 2012, GUT MICROBES, V3, P4, DOI 10.4161/gmic.19320; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053	42	33	55	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1378	+		10.1016/j.jaci.2015.03.036	http://dx.doi.org/10.1016/j.jaci.2015.03.036			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26014812	Green Accepted, Green Submitted			2022-12-18	WOS:000364787200028
J	Guo, CW; Nakazawa, Y; Woodbine, L; Bjorkman, A; Shimada, M; Fawcett, H; Jia, N; Ohyama, K; Li, TS; Nagayama, Y; Mitsutake, N; Pan-Hammarstrom, Q; Gennery, AR; Lehmann, AR; Jeggo, PA; Ogi, T				Guo, Chaowan; Nakazawa, Yuka; Woodbine, Lisa; Bjorkman, Andrea; Shimada, Mayuko; Fawcett, Heather; Jia, Nan; Ohyama, Kaname; Li, Tao-Sheng; Nagayama, Yuji; Mitsutake, Norisato; Pan-Hammarstrom, Qiang; Gennery, Andrew R.; Lehmann, Alan R.; Jeggo, Penny A.; Ogi, Tomoo			XRCC4 deficiency in human subjects causes a marked neurological phenotype but no overt immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DNA double-strand break repair; nonhomologous end-joining; double-strand break repair deficiency; XRCC4/LIG4; immunodeficiency; microcephaly	DNA-LIGASE-IV; STRAND BREAK REPAIR; CLASS SWITCH RECOMBINATION; END-JOINING PATHWAYS; V(D)J RECOMBINATION; GENOMIC INSTABILITY; EMBRYONIC LETHALITY; PRIMORDIAL DWARFISM; COCKAYNE-SYNDROME; PROTEIN XRCC4	Background: Nonhomologous end-joining (NHEJ) is the major DNA double-strand break (DSB) repair mechanism in human cells. The final rejoining step requires DNA ligase IV (LIG4) together with the partner proteins X-ray repair cross-complementing protein 4 (XRCC4) and XRCC4-like factor. Patients with mutations in genes encoding LIG4, XRCC4-like factor, or the other NHEJ proteins DNA-dependent protein kinase catalytic subunit and Artemis are DSB repair defective and immunodeficient because of the requirement for NHEJ during V(D)J recombination. Objective: We found a patient displaying microcephaly and progressive ataxia but a normal immune response. We sought to determine pathogenic mutations and to describe the molecular pathogenesis of the patient. Methods: We performed next-generation exome sequencing. We evaluated the DSB repair activities and V(D) J recombination capacity of the patient's cells, as well as performing a standard blood immunologic characterization. Results: We identified causal mutations in the XRCC4 gene. The patient's cells are radiosensitive and display the most severe DSB repair defect we have encountered using patient-derived cell lines. In marked contrast, a V(D) J recombination plasmid assay revealed that the patient's cells did not display the junction abnormalities that are characteristic of other NHEJ-defective cell lines. The mutant protein can interact efficiently with LIG4 and functions normally in in vitro assays and when transiently expressed in vivo. However, the mutation makes the protein unstable, and it undergoes proteasome-mediated degradation. Conclusion: Our findings reveal a novel separation of impact phenotype: there is a pronounced DSB repair defect and marked clinical neurological manifestation but no clinical immunodeficiency.	[Guo, Chaowan; Nakazawa, Yuka; Jia, Nan; Ogi, Tomoo] Nagoya Univ, Res Inst Environm Med RIeM, Dept Genet, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Guo, Chaowan; Nakazawa, Yuka; Shimada, Mayuko; Jia, Nan; Ohyama, Kaname; Mitsutake, Norisato; Ogi, Tomoo] Nagasaki Univ, Res Ctr Genom Instabil & Carcinogenesis NRGIC, Nagasaki, Japan; [Guo, Chaowan; Nakazawa, Yuka; Shimada, Mayuko; Jia, Nan; Nagayama, Yuji; Ogi, Tomoo] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Mol Med, Nagasaki, Japan; [Li, Tao-Sheng] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Stem Cell Biol, Nagasaki, Japan; [Mitsutake, Norisato] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Radiat Med Sci, Nagasaki, Japan; [Ohyama, Kaname] Nagasaki Univ, Grad Sch Biomed Sci, Course Pharmaceut Sci, Nagasaki, Japan; [Woodbine, Lisa; Fawcett, Heather; Lehmann, Alan R.; Jeggo, Penny A.] Univ Sussex, Genome Damage & Stabil Ctr, Brighton, E Sussex, England; [Bjorkman, Andrea; Pan-Hammarstrom, Qiang] Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Stockholm, Sweden; [Gennery, Andrew R.] Newcastle Univ, Newcastle Upon Tyne Hosp NHS Fdn Trust, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Ogi, Tomoo] Natl Inst Genet, Microbial Genet Lab, Genet Strains Res Ctr, Mishima, Shizuoka 411, Japan	Nagoya University; Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; University of Sussex; Karolinska Institutet; Karolinska University Hospital; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Ogi, T (corresponding author), Nagoya Univ, Res Inst Environm Med RIeM, Dept Genet, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	p.a.jeggo@sussex.ac.uk; togi@riem.nagoya-u.ac.jp	Mitsutake, Norisato/U-9626-2018; hammarstrom, qiang pan/ABA-4589-2021; Guo, Chaowan/AFI-6708-2022; Guo, Chaowan/AAF-3876-2022	Mitsutake, Norisato/0000-0002-2744-8046; Fawcett, Heather/0000-0002-4292-3140; Li, Tao-Sheng/0000-0002-7653-8873; Nakazawa, Yuka/0000-0002-3835-3093; Bjorkman, Andrea/0000-0003-1551-623X; Ogi, Tomoo/0000-0002-5492-9072; pan-hammarstrom, qiang/0000-0003-1990-8804	MRC [G1000050] Funding Source: UKRI; European Research Council [242551] Funding Source: Medline; Medical Research Council [G1000050] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Research Council(European Research Council (ERC)European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alt FW, 2013, CELL, V152, P417, DOI 10.1016/j.cell.2013.01.007; Andres SN, 2012, NUCLEIC ACIDS RES, V40, P1868, DOI 10.1093/nar/gks022; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Bee L, 2015, EMBO MOL MED; Boboila C, 2012, ADV IMMUNOL, V116, P1, DOI 10.1016/B978-0-12-394300-2.00001-6; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; de Bruin C, 2015, J CLIN ENDOCR METAB, V100, pE789, DOI 10.1210/jc.2015-1098; Deriano L, 2013, ANNU REV GENET, V47, P433, DOI 10.1146/annurev-genet-110711-155540; Du LK, 2012, J EXP MED, V209, P291, DOI 10.1084/jem.20110325; Enervald E, 2013, J EXP MED, V210, P2503, DOI 10.1084/jem.20130168; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Ghezraoui H, 2014, MOL CELL, V55, P829, DOI 10.1016/j.molcel.2014.08.002; Gigi V, 2014, NUCLEIC ACIDS RES, V42, P6352, DOI 10.1093/nar/gku295; Girard PM, 2004, HUM MOL GENET, V13, P2369, DOI 10.1093/hmg/ddh274; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Hammel M, 2011, J BIOL CHEM, V286, P32638, DOI 10.1074/jbc.M111.272641; Jia N, 2015, NAT PROTOC, V10, P12, DOI 10.1038/nprot.2014.194; Kashiyama K, 2013, AM J HUM GENET, V92, P807, DOI 10.1016/j.ajhg.2013.04.007; Li G, 2008, MOL CELL, V31, P631, DOI 10.1016/j.molcel.2008.07.017; Liu SQ, 2012, NUCLEIC ACIDS RES, V40, P10780, DOI 10.1093/nar/gks849; Mahaney BL, 2013, BIOCHEM CELL BIOL, V91, P31, DOI 10.1139/bcb-2012-0058; Mani RS, 2010, J BIOL CHEM, V285, P37619, DOI 10.1074/jbc.M109.058719; Modesti M, 2003, J MOL BIOL, V334, P215, DOI 10.1016/j.jmb.2003.09.031; Murray JE, 2015, AM J HUM GENET, V96, P412, DOI 10.1016/j.ajhg.2015.01.013; Murray JE, 2014, HUM MUTAT, V35, P76, DOI 10.1002/humu.22461; Neilan EG, 2008, ARCH NEUROL-CHICAGO, V65, P1117, DOI 10.1001/archneur.65.8.1117; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Ochi T, 2015, SCIENCE, V347, P185, DOI 10.1126/science.1261971; Oh S, 2014, DNA REPAIR, V21, P97, DOI 10.1016/j.dnarep.2014.04.015; Pan Q, 2001, EUR J IMMUNOL, V31, P3622, DOI 10.1002/1521-4141(200112)31:12<3622::AID-IMMU3622>3.0.CO;2-H; Pan-Hammarstrom Q, 2005, J EXP MED, V201, P189, DOI 10.1084/jem.20040772; Radhakrishnan SK, 2014, DNA REPAIR, V17, P2, DOI 10.1016/j.dnarep.2014.01.009; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Riballo E, 2001, J BIOL CHEM, V276, P31124, DOI 10.1074/jbc.M103866200; Riballo E, 2009, NUCLEIC ACIDS RES, V37, P482, DOI 10.1093/nar/gkn957; Rosin N, 2015, HUM MOL GENET, V24, P3708, DOI 10.1093/hmg/ddv115; Shaheen R, 2014, GENOME RES, V24, P291, DOI 10.1101/gr.160572.113; Stavnezer J, 2010, ADV IMMUNOL, V108, P45, DOI 10.1016/S0065-2776(10)08003_X; Verkaik NS, 2002, EUR J IMMUNOL, V32, P701, DOI 10.1002/1521-4141(200203)32:3<701::AID-IMMU701>3.0.CO;2-T; Williams GJ, 2014, DNA REPAIR, V17, P110, DOI 10.1016/j.dnarep.2014.02.009; Windhofer F, 2007, J CELL PHYSIOL, V213, P475, DOI 10.1002/jcp.21120; Woodbine L, 2014, DNA REPAIR, V16, P84, DOI 10.1016/j.dnarep.2014.02.011; Woodbine L, 2013, J CLIN INVEST, V123, P2969, DOI 10.1172/JCI67349; Wu PY, 2009, MOL CELL BIOL, V29, P3163, DOI 10.1128/MCB.01895-08; Wu Q, 2011, BIOCHEM SOC T, V39, P1387, DOI 10.1042/BST0391387; Zha S, 2011, NATURE, V469, P250, DOI 10.1038/nature09604	50	33	35	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1007	1017		10.1016/j.jaci.2015.06.007	http://dx.doi.org/10.1016/j.jaci.2015.06.007			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26255102	Bronze, Green Accepted			2022-12-18	WOS:000362976300019
J	Holt, PG				Holt, Patrick G.			The mechanism or mechanisms driving atopic asthma initiation: The infant respiratory microbiome moves to center stage	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; infancy; viral infections; nasopharyngeal microbiome	FC-EPSILON-RI; LUNG DENDRITIC CELLS; T-REGULATORY CELLS; ANTIGEN-PRESENTING CELLS; HOUSE-DUST MITE; CORD BLOOD; PERIPHERAL-BLOOD; IMMUNOGLOBULIN-E; SYNCYTIAL VIRUS; BRONCHIAL HYPERRESPONSIVENESS	Developments over the last 5 to 10 years, principally from studies on comprehensively phenotyped prospective birth cohorts, have highlighted the important role of viral respiratory tract infections during infancy and early childhood, particularly those occurring against a background of pre-existing sensitization to perennial aeroallergens, in driving the development of early-onset atopic asthma. Although debate surrounding the mechanism or mechanisms governing this causal pathway remains intense, demonstration of the capacity of pretreatment with anti-IgE antibody to blunt seasonal virus-associated asthma exacerbations in children provides strong support for the underlying concept. However, emerging data appear set to further complicate this picture. Notably, a combination of culture-based studies and complementary population-wide bacterial metagenomic data suggests that parallel host-bacteria interactions during infancy might play an additional role in modulating this causal pathway, as well as contributing independently to pathogenesis. These and related issues surrounding development of immune competence during the crucial early postnatal period, when these pathways are maximally active, are discussed below.	[Holt, Patrick G.] Univ Western Australia, Telethon Kids Inst, Perth, WA 6009, Australia; [Holt, Patrick G.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia	Telethon Kids Institute; University of Western Australia; University of Queensland	Holt, PG (corresponding author), Telethon Kids Inst, Div Cell Biol, POB 855, Perth, WA 6872, Australia.	Patrick.Holt@telethonkids.org.au	Holt, Patrick G/H-1548-2011	Holt, Patrick G/0000-0003-1193-0935	National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	The author is funded by the National Health and Medical Research Council of Australia.	Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Al-Garawi A, 2012, J IMMUNOL, V188, P832, DOI 10.4049/jimmunol.1102349; Arkwright PD, 2000, CLIN EXP IMMUNOL, V122, P16, DOI 10.1046/j.1365-2249.2000.01338.x; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Blanco-Quiros A, 1999, PEDIATR PULM, V28, P175, DOI 10.1002/(SICI)1099-0496(199909)28:3<175::AID-PPUL3>3.0.CO;2-U; Bochkov YA, 2011, NAT MED, V17, P627, DOI 10.1038/nm.2358; Bont L, 2000, J INFECT DIS, V181, P1772, DOI 10.1086/315433; Bosco A, 2012, J ALLERGY CLIN IMMUN, V129, P88, DOI 10.1016/j.jaci.2011.10.038; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Cheung DS, 2010, J IMMUNOL, V185, P4983, DOI 10.4049/jimmunol.1002456; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; CRONER S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI DOI 10.1111/J.1399-3038.1990.TB00003.X; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gill MA, 2005, J INFECT DIS, V191, P1105, DOI 10.1086/428589; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Hagendorens MM, 2003, CLIN EXP ALLERGY, V33, P633, DOI 10.1046/j.1365-2222.2003.01649.x; Hales BJ, 2008, THORAX, V63, P221, DOI 10.1136/thx.2006.069492; Hales BJ, 2012, THORAX, V67, P321, DOI 10.1136/thoraxjnl-2011-200650; Havstad S, 2014, J ALLERGY CLIN IMMUN, V134, P722, DOI 10.1016/j.jaci.2014.01.022; Heier I, 2008, THORAX, V63, P703, DOI 10.1136/thx.2007.082974; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hollams EM, 2010, EUR RESPIR J, V36, P509, DOI 10.1183/09031936.00184109; Hollams EM, 2009, J ALLERGY CLIN IMMUN, V124, P463, DOI 10.1016/j.jaci.2009.06.019; Holt PG, 2008, NAT REV IMMUNOL, V8, P142, DOI 10.1038/nri2236; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P597, DOI 10.1111/j.1365-2222.1989.tb02752.x; HOLT PG, 1990, INT ARCH ALLER A IMM, V91, P155, DOI 10.1159/000235107; Huang YJ, 2014, J CLIN MICROBIOL, V52, P2813, DOI 10.1128/JCM.00035-14; Huang YJ, 2011, EXPERT REV RESP MED, V5, P809, DOI [10.1586/ERS.11.76, 10.1586/ers.11.76]; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Koraka P, 2003, J MED VIROL, V70, P91, DOI 10.1002/jmv.10358; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; NELSON DJ, 1995, J IMMUNOL, V155, P3517; NELSON DJ, 1994, J EXP MED, V179, P203, DOI 10.1084/jem.179.1.203; Nilsson C, 2004, CLIN EXP ALLERGY, V34, P373, DOI 10.1111/j.1365-2222.2004.01896.x; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; Prescott SL, 2003, CLIN EXP ALLERGY, V33, P566, DOI 10.1046/j.1365-2222.2003.01659.x; Prescott SL, 1998, J IMMUNOL, V160, P4730; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Robays LJ, 2009, J IMMUNOL, V183, P2758, DOI 10.4049/jimmunol.0802204; Rowe J., 2001, Journal of Infectious Diseases, V184, P80, DOI 10.1086/320996; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Schoos AMM, 2015, ALLERGY, V70, P41, DOI 10.1111/all.12523; Semper AE, 2003, J ALLERGY CLIN IMMUN, V112, P411, DOI 10.1067/mai.2003.1626; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Silver E, 2009, PEDIAT ALLERG IMM-UK, V20, P471, DOI 10.1111/j.1399-3038.2008.00818.x; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Stein RT, 2010, THORAX, V65, P1033, DOI 10.1136/thx.2009.133967; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Strickland DH, 2012, MUCOSAL IMMUNOL, V5, P332, DOI 10.1038/mi.2012.13; Strickland DH, 2011, TRENDS IMMUNOL, V32, P420, DOI 10.1016/j.it.2011.06.010; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Thornton CA, 2004, J IMMUNOL, V173, P3084, DOI 10.4049/jimmunol.173.5.3084; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1046/j.1365-2222.1996.1095481.x; Upham JW, 2009, J ALLERGY CLIN IMMUN, V124, P707, DOI 10.1016/j.jaci.2009.07.009; Upham JW, 2004, J ALLERGY CLIN IMMUN, V114, P1202, DOI 10.1016/j.jaci.2004.06.051; Walker ML, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00447; Weber KSC, 2001, EUR J IMMUNOL, V31, P2458, DOI 10.1002/1521-4141(200108)31:8<2458::AID-IMMU2458>3.3.CO;2-C; Wood LJ, 2002, AM J RESP CRIT CARE, V166, P883, DOI 10.1164/rccm.2108015; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x; Zhang GC, 2009, AM J RESP CRIT CARE, V179, P205, DOI 10.1164/rccm.200803-438OC	87	33	33	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					15	22		10.1016/j.jaci.2015.05.011	http://dx.doi.org/10.1016/j.jaci.2015.05.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	26145983				2022-12-18	WOS:000357542200002
J	Lo, CY; Michaeloudes, C; Bhavsar, PK; Huang, CD; Wang, CH; Kuo, HP; Chung, KF				Lo, Chun-Yu; Michaeloudes, Charalambos; Bhavsar, Pankaj K.; Huang, Chien-Da; Wang, Chun-Hua; Kuo, Han-Pin; Chung, Kian Fan			Increased phenotypic differentiation and reduced corticosteroid sensitivity of fibrocytes in severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fibrocytes; asthma; corticosteroids; remodeling; myofibroblasts; glucocorticoid receptor; CCR7; nonadherent non-T cells; PBMCs	AIRWAY SMOOTH-MUSCLE; PERIPHERAL-BLOOD FIBROCYTES; GLUCOCORTICOID-RECEPTOR; CIRCULATING FIBROCYTES; MONONUCLEAR-CELLS; INSENSITIVE ASTHMA; FLOW OBSTRUCTION; NASAL POLYPS; ACTIVATION; BETA	Background: Patients with severe asthma are less responsive to corticosteroid therapy and show increased airway remodeling. The mesenchymal progenitors, fibrocytes, may be involved in the remodeling of asthmatic airways. We propose that fibrocytes in severe asthma are different from those in nonsevere asthma. Objectives: To examine the survival, myofibroblastic differentiation, and C-C chemokine receptor 7 (CCR7) expression in blood fibrocytes from patients with severe and nonsevere asthma and study the effect of corticosteroids on fibrocyte function. Methods: The nonadherent non-T-cell fraction of blood mononuclear cells was isolated from healthy subjects and patients with nonsevere and severe asthma. Total and differentiating fibrocytes were identified by their expression of CD45, collagen I, and alpha-smooth muscle actin using flow cytometry. The expression of CCR7 and of the glucocorticoid receptor was measured by using flow cytometry. Results: Increased numbers of circulating fibrocytes, with greater myofibroblastic differentiation potential, were observed in patients with severe asthma. Dexamethasone induced apoptosis, leading to reduction in the number of cultured fibrocytes and total nonadherent non-T cells from healthy subjects and patients with nonsevere asthma but not from patients with severe asthma. Dexamethasone reduced CCR7 expression in fibrocytes from patients with nonsevere asthma but not from patients with severe asthma. Glucocorticoid receptor expression was attenuated in fibrocytes from patients with severe asthma. Conclusions: Patients with severe asthma have elevated numbers of circulating fibrocytes that show enhanced myofibroblastic differentiation and that are less responsive to the effects of corticosteroids.	[Lo, Chun-Yu; Michaeloudes, Charalambos; Bhavsar, Pankaj K.; Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London, England; [Lo, Chun-Yu; Michaeloudes, Charalambos; Bhavsar, Pankaj K.; Chung, Kian Fan] Royal Brompton NHS Fdn Trust, NIHR Resp Biomed Res Unit, London, England; [Lo, Chun-Yu; Huang, Chien-Da; Wang, Chun-Hua; Kuo, Han-Pin] Chang Gung Univ, Coll Med, Chang Gung Med Fdn, Dept Thorac Med, Taipei, Taiwan	Imperial College London; Royal Brompton Hospital; Chang Gung Memorial Hospital; Chang Gung University	Chung, KF (corresponding author), Natl Heart & Lung Inst, Airway Dis Sect, Guy Scadding Bldg,Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk	Chung, Kian Fan/B-1872-2012; Chung, Kian Fan/I-8456-2019; Wang, Chun-Hua/C-1488-2016; Wang, Chun-Hua/V-9861-2019; Huang, Chien-Da/AAY-3771-2021	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Wang, Chun-Hua/0000-0002-3514-9353; Michaeloudes, Charalambos/0000-0002-4107-4028; Huang, Chien-Da/0000-0002-4999-6019	Chang Gung Medical Research Project [G3A0872]; National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton Hospital; Imperial College London; National Institute of Health Research Respiratory Disease Biomedical Research Unit at Harefield Foundation NHS Trust	Chang Gung Medical Research Project; National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton Hospital; Imperial College London(General Electric); National Institute of Health Research Respiratory Disease Biomedical Research Unit at Harefield Foundation NHS Trust	This work was supported by the Chang Gung Medical Research Project (grant no. G3A0872) and the National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton Hospital and Harefield Foundation NHS Trust and Imperial College London.	[Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Begueret H, 2007, THORAX, V62, P8, DOI 10.1136/thx.2006.062141; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Chang PJ, 2012, J ALLERGY CLIN IMMUN, V130, P877, DOI 10.1016/j.jaci.2012.07.017; Chesney J, 1998, J IMMUNOL, V160, P419; Choi BR, 2006, EXP MOL MED, V38, P466, DOI 10.1038/emm.2006.55; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1026, DOI 10.1164/ajrccm/144.5.page; Gagliardo R, 2000, AM J RESP CRIT CARE, V162, P7, DOI 10.1164/ajrccm.162.1.9911032; Gibeon D, 2012, CLIN EXP ALLERGY, V42, P678, DOI 10.1111/j.1365-2222.2012.03959.x; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Goleva E, 2006, AM J RESP CRIT CARE, V173, P607, DOI 10.1164/rccm.200507-1046OC; Gomperts BN, 2007, J LEUKOCYTE BIOL, V82, P449, DOI 10.1189/jlb.0906587; Hayashi H, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/738625; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; James AL, 2012, AM J RESP CRIT CARE, V185, P1058, DOI 10.1164/rccm.201110-1849OC; Jeffery Peter K, 2004, Proc Am Thorac Soc, V1, P176, DOI 10.1513/pats.200402-009MS; Kaur D, 2006, AM J RESP CRIT CARE, V174, P1179, DOI 10.1164/rccm.200603-394OC; Larange A, 2012, J LEUKOCYTE BIOL, V91, P105, DOI 10.1189/jlb.1110615; Macedo P, 2009, CLIN EXP ALLERGY, V39, P1668, DOI 10.1111/j.1365-2222.2009.03319.x; Mercado N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041582; Peng H, 2012, CURR OPIN PHARMACOL, V12, P491, DOI 10.1016/j.coph.2012.03.002; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Pujols L, 2008, ALLERGY, V63, P1377, DOI 10.1111/j.1398-9995.2008.01745.x; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Saunders R, 2009, J ALLERGY CLIN IMMUN, V123, P376, DOI 10.1016/j.jaci.2008.10.048; Schmidt M, 2003, J IMMUNOL, V171, P380, DOI 10.4049/jimmunol.171.1.380; Sugiura H, 2009, AM J RESP CELL MOL, V40, P654, DOI 10.1165/rcmb.2008-0371OC; Torrego A, 2004, AM J RESP CRIT CARE, V170, P420, DOI 10.1164/rccm.200308-1143OC; Vazquez-Tello A, 2013, J CLIN IMMUNOL, V33, P466, DOI 10.1007/s10875-012-9828-3; Vizzardelli C, 2006, EUR J IMMUNOL, V36, P1504, DOI 10.1002/eji.200535488; Wang CH, 2008, AM J RESP CRIT CARE, V178, P583, DOI 10.1164/rccm.200710-1557OC; Wang CH, 2012, J ALLERGY CLIN IMMUN, V129, P1367, DOI 10.1016/j.jaci.2012.01.038; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Yang LJ, 2002, LAB INVEST, V82, P1183, DOI 10.1097/01.LAB.0000027841.50269.61	38	33	38	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1186	U570		10.1016/j.jaci.2014.10.031	http://dx.doi.org/10.1016/j.jaci.2014.10.031			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25488691	Green Submitted			2022-12-18	WOS:000353980700011
J	Cotugno, N; Finocchi, A; Cagigi, A; Di Matteo, G; Chiriaco, M; Di Cesare, S; Rossi, P; Aiuti, A; Palma, P; Douagi, I				Cotugno, Nicola; Finocchi, Andrea; Cagigi, Alberto; Di Matteo, Gigliola; Chiriaco, Maria; Di Cesare, Silvia; Rossi, Paolo; Aiuti, Alessandro; Palma, Paolo; Douagi, Iyadh			Defective B-cell proliferation and maintenance of long-term memory in patients with chronic granulomatous disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic granulomatous disease; B cell; proliferation; long-term memory; measles; memory B-cell compartment; reactive oxygen species deficiency	NADPH OXIDASE; IMMUNOLOGICAL MEMORY; IDENTIFICATION; LYMPHOCYTES; ACTIVATION; MECHANISMS; GENERATION; RESPONSES; STRENGTH; DURATION	Background: Chronic granulomatous disease (CGD) is a primary immune deficiency characterized by a defect in reactive oxygen species production. Although the effect of CGD mainly reflects on the phagocytic compartment, B-cell responses are also impaired in patients with CGD. Objective: We sought to investigate how defective gp91(phox) expression in patients with CGD and CGD carriers might affect the B-cell compartment and maintenance of long-term memory. Methods: We studied the B-cell compartment of patients with CGD in terms of phenotype and ability to produce reactive oxygen species and proliferate on stimuli differently directed to the B-cell receptor and Toll-like receptor 9. We further studied their capacity to maintain long-term memory by measuring cellular and serologic responses to measles. Results: We show that the memory B-cell compartment is impaired among patients with CGD, as indicated by reduced total (CD19(+)CD27(+)) and resting (CD19(+)CD27(+)CD21(+)) memory B cells in parallel to increased naive (CD19(+)CD27(-)IgD(+)) B-cell frequencies. Data on CGD carriers reveal that such alterations are related to gp91(phox) expression. Moreover, proliferative capabilities of B cells on selective in vitro stimulation of B-cell receptor or Toll-like receptor 9 pathways were reduced in patients with CGD compared with those seen in age-matched healthy control subjects. Significantly lower measles-specific antibody levels and antibody-secreting cell numbers were also observed, indicating a poor ability to maintain long-term memory in these patients. Conclusion: Altogether, our data suggest that patients with CGD present a defective B-cell compartment in terms of frequencies of memory B cells, response to in vitro stimulation, and maintenance of long-term antigen-specific memory.	[Cotugno, Nicola; Finocchi, Andrea; Cagigi, Alberto; Di Matteo, Gigliola; Chiriaco, Maria; Di Cesare, Silvia; Rossi, Paolo; Aiuti, Alessandro; Palma, Paolo] Childrens Hosp Bambino Gesu, Univ Dept Pediat, Unit Immune & Infect Dis, Rome, Italy; [Cotugno, Nicola; Finocchi, Andrea; Di Matteo, Gigliola; Chiriaco, Maria; Di Cesare, Silvia; Rossi, Paolo; Aiuti, Alessandro] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy; [Aiuti, Alessandro] Ist Sci San Raffaele, TIGET, I-20132 Milan, Italy; [Douagi, Iyadh] Karolinska Inst, Dept Med Huddinge, Ctr Hematol & Regenerat Med HERM, Stockholm, Sweden	IRCCS Bambino Gesu; University of Rome Tor Vergata; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Karolinska Institutet	Aiuti, A (corresponding author), Children Hosp Bambino Gesu, Univ Dept Pediat, Dept Publ Hlth & Cellular Biol, Rome, Italy.	aaiuti@gmail.com; paolo.palma@opbg.net; iyadh.douagi@ki.se	DI MATTEO, GIGLIOLA/AAB-5968-2020; AIUTI, ALESSANDRO/K-3918-2016; Palma, Paolo/AAK-9275-2020; Chiriaco, Maria/K-5332-2018; Rossi, Paolo/K-5746-2016; Cagigi, Alberto/K-4824-2016; Finocchi, Andrea/K-5926-2016; Cotugno, Nicola/AAB-9462-2019; DI CESARE, SILVIA/AAB-5754-2020; Palma, Paolo/K-3379-2016	AIUTI, ALESSANDRO/0000-0002-5398-1717; Palma, Paolo/0000-0002-3066-4719; Chiriaco, Maria/0000-0002-1793-8703; Rossi, Paolo/0000-0003-2620-7918; Cagigi, Alberto/0000-0002-3567-9514; Finocchi, Andrea/0000-0003-0958-8536; Cotugno, Nicola/0000-0002-7748-1581; DI CESARE, SILVIA/0000-0002-9912-7997; DI MATTEO, GIGLIOLA/0000-0001-8344-5635	Bambino Gesu Children's Hospital; Karolinska Institutet; Cell-PID HEALTH [F5-2010-261387]; Italian Ministry of Health [GR-2008-57]	Bambino Gesu Children's Hospital; Karolinska Institutet(Karolinska Institutet); Cell-PID HEALTH; Italian Ministry of Health(Ministry of Health, Italy)	Supported by grants obtained from the Bambino Gesu Children's Hospital and the Karolinska Institutet. Also supported by Cell-PID HEALTH F5-2010-261387, EUROCGD project (ERA-NET E-Rare: "European research projects on rare diseases''), Italian Ministry of Health (Progetto Giovani Ricercatori GR-2008-57 to A.F.).	Abzug MJ, 2013, VACCINE, V31, P4782, DOI 10.1016/j.vaccine.2013.08.002; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Amanna IJ, 2010, IMMUNOL REV, V236, P125, DOI 10.1111/j.1600-065X.2010.00912.x; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Battersby AC, 2013, J CLIN IMMUNOL, V33, P1276, DOI 10.1007/s10875-013-9939-5; Bekeredjian-Ding I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029806; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569; Bleesing JJ, 2006, J IMMUNOL, V176, P7096, DOI 10.4049/jimmunol.176.11.7096; Cagigi A, 2013, CLIN EXP IMMUNOL, V174, P274, DOI 10.1111/cei.12173; Cagigi A, 2014, PEDIATR INFECT DIS J, V33, pE126, DOI 10.1097/INF.0000000000000144; Cagigi A, 2012, HUM VACC IMMUNOTHER, V8, P1784, DOI 10.4161/hv.21827; Capasso M, 2010, NAT IMMUNOL, V11, P265, DOI 10.1038/ni.1843; Chen RT, 1990, P NATL ACAD SCI USA, V162, P1036; Colonna-Romano G, 2009, MECH AGEING DEV, V130, P681, DOI 10.1016/j.mad.2009.08.003; Cotugno N, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/805151; Crotty S, 2004, J IMMUNOL METHODS, V286, P111, DOI 10.1016/j.jim.2003.12.015; Di Matteo G, 2009, MOL IMMUNOL, V46, P1935, DOI 10.1016/j.molimm.2009.03.016; DINAUER MC, 1992, ANNU REV MED, V43, P117, DOI 10.1146/annurev.med.43.1.117; Douagi I, 2009, J IMMUNOL, V182, P1991, DOI 10.4049/jimmunol.0802257; Ha YJ, 2004, J IMMUNOL, V172, P231, DOI 10.4049/jimmunol.172.1.231; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Moir S, 2012, BLOOD, V120, P4850, DOI 10.1182/blood-2012-05-430959; MOREL F, 1993, BIOCHIM BIOPHYS ACTA, V1182, P101, DOI 10.1016/0925-4439(93)90159-X; Paclet MH, 2001, EUR J BIOCHEM, V268, P5197, DOI 10.1046/j.0014-2956.2001.02455.x; Peng SL, 2005, CURR OPIN IMMUNOL, V17, P230, DOI 10.1016/j.coi.2005.03.003; Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106; Pierce SK, 2010, NAT REV IMMUNOL, V10, P767, DOI 10.1038/nri2853; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Richards SM, 2009, EUR J IMMUNOL, V39, P3395, DOI 10.1002/eji.200939587; Rieber N, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/252460; ROOS D, 1994, IMMUNOL REV, V138, P121, DOI 10.1111/j.1600-065X.1994.tb00850.x; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Singh DK, 2005, CELL, V121, P281, DOI 10.1016/j.cell.2005.02.036; Traggiai E, 2003, VACCINE, V21, pS35, DOI 10.1016/S0264-410X(03)00198-1; Tran H, 2008, BLOOD REV, V22, P261, DOI 10.1016/j.blre.2008.03.009; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006; Wheeler ML, 2012, J IMMUNOL, V189, P4405, DOI 10.4049/jimmunol.1201433; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	41	33	35	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					753	U272		10.1016/j.jaci.2014.07.012	http://dx.doi.org/10.1016/j.jaci.2014.07.012			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25175493				2022-12-18	WOS:000351065000023
J	Xie, M; Mustovich, AT; Jiang, Y; Trudeau, JB; Ray, A; Ray, P; Hu, HZ; Holguin, F; Freeman, B; Wenzel, SE				Xie, Min; Mustovich, Anthony T.; Jiang, Yi; Trudeau, John B.; Ray, Anuradha; Ray, Prabir; Hu, Haizhen; Holguin, Fernando; Freeman, Bruce; Wenzel, Sally E.			IL-27 and type 2 immunity in asthmatic patients: Association with severity, CXCL9, and signal transducer and activator of transcription signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; IL-27; IL-13; CXCL9; epithelial cells; signal transducer and activator of transcription 1; signal transducer and activator of transcription 3	BRONCHIAL EPITHELIAL-CELLS; CD4(+) T-CELLS; EOTAXIN-3 EXPRESSION; IL-13 EXPRESSION; NITRIC-OXIDE; TNF-ALPHA; STAT3; RECEPTOR; INTERFERON; INFLAMMATION	Background: Severe asthma (SA) can involve both innate and type 2 cytokine-associated adaptive immunity. Although IL-27 has been reported to potentiate T(H)1 responses (including the chemokine CXCL9) and suppress T(H)2 responses, its function in asthmatic patients is unknown. Objective: We sought to evaluate IL-27 expression in human asthma alone and in combination with type 2 immunity to determine the relationship to disease severity and CXCL9 expression. We also sought to model these interactions in vitro in human bronchial epithelial cells. Methods: Bronchoalveolar lavage cells from 87 participants were evaluated for IL-27 mRNA and protein alone and in association with epithelial CCL26 (a marker of type 2 activation) in relation to asthma severity and CXCL9 mRNA. Human bronchial epithelial cells cultured at the air-liquid interface and stimulated with IL-27 (1-100 ng/mL) with or without IL-13 (1 ng/mL) were evaluated for CXCL9 expression by using quantitative real-time PCR and ELISA. Phosphorylated and total signal transducer and activator of transcription (STAT) 1/3 were detected by means of Western blotting. Small interfering RNA knockdown of STAT1 or STAT3 was performed. Results: Bronchoalveolar lavage cell IL-27 mRNA and protein levels were increased in asthmatic patients. Patients with evidence for type 2 pathway activation had higher IL-27 expression (P = .02). Combined IL-27 and CCL26 expression associated with more SA and higher CXCL9 expression (P = .004 and P = .007 respectively), whereas IL-27 alone was associated with milder disease. In vitro IL-13 augmented IL-27-induced CXCL9 expression, which appeared to be due to augmented STAT1 activation and reduced STAT3 activation. Conclusions: IL-27, in combination with a type 2/CCL26 signature, identifies a more SA phenotype, perhaps through combined effects of IL-27 and IL-13 on STAT signaling. Understanding these interactions could lead to new targets for asthma therapy.	[Xie, Min] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Resp & Crit Care Med, Wuhan 430074, Peoples R China; [Xie, Min; Mustovich, Anthony T.; Jiang, Yi; Trudeau, John B.; Ray, Anuradha; Ray, Prabir; Hu, Haizhen; Holguin, Fernando; Freeman, Bruce; Wenzel, Sally E.] Univ Pittsburgh, Asthma Inst UPMC UPSOM, Dept Med, Pulm Allergy Crit Care Med Div, Pittsburgh, PA 15213 USA	Huazhong University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wenzel, SE (corresponding author), Univ Pittsburgh, Asthma Inst UPMC UPSOM, Montefiore Hosp NW628, Pulm Allergy Crit Care Med Div, 3459 Fifth Ave, Pittsburgh, PA 15213 USA.	wenzelse@upmc.edu		Wenzel, Sally/0000-0002-4242-0164; xie, min/0000-0003-4052-1647	National Institutes of Health [HL069174, HL064937, AI-40600, RR024153]; National Natural Science Foundation of China [81470002]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL058115, U10HL109152, R01HL069174, R01HL064937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040600, P01AI106684, R01AI067780] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (HL069174, HL064937, AI-40600, and RR024153) and the National Natural Science Foundation of China (No. 81470002).	[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032; Bisset LR, 2005, CURR OPIN PULM MED, V11, P35, DOI 10.1097/01.mcp.0000144502.50149.e0; Cao J, 2012, CHEST, V141, P121, DOI 10.1378/chest.10-3297; Cao J, 2010, J CELL PHYSIOL, V223, P788, DOI 10.1002/jcp.22094; Cao YX, 2008, J IMMUNOL, V180, P922, DOI 10.4049/jimmunol.180.2.922; Cardinale F, 2013, ALLERGY ASTHMA PROC, V34, P143, DOI 10.2500/aap.2013.34.3631; Chae SC, 2007, J HUM GENET, V52, P355, DOI 10.1007/s10038-007-0123-8; Chen ZH, 2013, J ALLERGY CLIN IMMUN, V132, P912, DOI 10.1016/j.jaci.2013.06.035; Chibana K, 2008, CLIN EXP ALLERGY, V38, P936, DOI 10.1111/j.1365-2222.2008.02969.x; Coleman JM, 2012, THORAX, V67, P1061, DOI 10.1136/thoraxjnl-2012-201634; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Diegelmann J, 2012, J BIOL CHEM, V287, P286, DOI 10.1074/jbc.M111.294355; do Rosario APF, 2012, J IMMUNOL, V188, P1178, DOI 10.4049/jimmunol.1102755; Dong SS, 2013, AM J RESP CELL MOL, V48, P518, DOI 10.1165/rcmb.2012-0340OC; Fajt ML, 2013, J ALLERGY CLIN IMMUN, V131, P1504, DOI 10.1016/j.jaci.2013.01.035; Fujita H, 2009, J IMMUNOL, V183, P254, DOI 10.4049/jimmunol.0800520; Hibbert L, 2003, J INTERF CYTOK RES, V23, P513, DOI 10.1089/10799900360708632; Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200; Holgate ST, 2003, EUR RESPIR J, V22, p24S, DOI 10.1183/09031936.03.00000803; Hong F, 2002, J CLIN INVEST, V110, P1503, DOI 10.1172/JCI200215841; Hunter CA, 2005, NAT REV IMMUNOL, V5, P521, DOI 10.1038/nri1648; Hunter CA, 2004, IMMUNOL REV, V202, P106, DOI 10.1111/j.0105-2896.2004.00213.x; Kalliolias GD, 2008, J IMMUNOL, V180, P6325, DOI 10.4049/jimmunol.180.9.6325; Lai ST, 2008, PEDIATR INT, V50, P99, DOI 10.1111/j.1442-200X.2007.02533.x; Larousserie F, 2004, J PATHOL, V202, P164, DOI 10.1002/path.1508; Li JJ, 2010, J IMMUNOL, V185, P4401, DOI 10.4049/jimmunol.1001039; Liu LY, 2004, AM J RESP CRIT CARE, V169, P1118, DOI 10.1164/rccm.200312-1659OC; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Neufert C, 2007, EUR J IMMUNOL, V37, P1809, DOI 10.1002/eji.200636896; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043; Nieminen K, 2010, PEDIAT ALLERG IMM-UK, V21, pE174, DOI 10.1111/j.1399-3038.2009.00920.x; Owaki T, 2005, J IMMUNOL, V175, P2191, DOI 10.4049/jimmunol.175.4.2191; Peters AT, 2010, J ALLERGY CLIN IMMUN, V125, P397, DOI 10.1016/j.jaci.2009.10.072; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Ravensberg AJ, 2005, J ALLERGY CLIN IMMUN, V115, P779, DOI 10.1016/j.jaci.2004.11.045; Regis G, 2008, SEMIN CELL DEV BIOL, V19, P351, DOI 10.1016/j.semcdb.2008.06.004; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; Shahabuddin S, 2006, AM J PHYSIOL-CELL PH, V291, pC34, DOI 10.1152/ajpcell.00441.2005; Shibata S, 2013, J INVEST DERMATOL, V133, P479, DOI 10.1038/jid.2012.313; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Summers SA, 2011, AM J PATHOL, V178, P580, DOI 10.1016/j.ajpath.2010.10.013; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Trudeau J, 2006, J ALLERGY CLIN IMMUN, V117, P1446, DOI 10.1016/j.jaci.2006.01.049; Umeshita-Suyama R, 2000, INT IMMUNOL, V12, P1499, DOI 10.1093/intimm/12.11.1499; van Wetering S, 2007, MOL IMMUNOL, V44, P803, DOI 10.1016/j.molimm.2006.04.008; Voraphani N, 2014, MUCOSAL IMMUNOL, V7, P1175, DOI 10.1038/mi.2014.6; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; Wittmann M, 2009, J ALLERGY CLIN IMMUN, V124, P81, DOI 10.1016/j.jaci.2009.04.026; Wong CK, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3067; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042; Xu B, 2003, MOL CELL BIOL, V23, P3918, DOI 10.1128/MCB.23.11.3918-3928.2003; Yamamoto M, 2012, CLIN EXP ALLERGY, V42, P760, DOI 10.1111/j.1365-2222.2011.03860.x; Yoshimoto T, 2007, J IMMUNOL, V179, P4415, DOI 10.4049/jimmunol.179.7.4415; Zhao JM, 2009, AM J RESP CRIT CARE, V179, P782, DOI 10.1164/rccm.200811-1744OC; 1986, AM REV RESP DIS, V136, P225	62	33	34	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					386	U517		10.1016/j.jaci.2014.08.023	http://dx.doi.org/10.1016/j.jaci.2014.08.023			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25312760	Green Accepted			2022-12-18	WOS:000349372300010
J	Menard, L; Cantaert, T; Chamberlain, N; Tangye, SG; Riminton, S; Church, JA; Klion, A; Cunningham-Rundles, C; Nichols, KE; Meffre, E				Menard, Laurence; Cantaert, Tineke; Chamberlain, Nicolas; Tangye, Stuart G.; Riminton, Sean; Church, Joseph A.; Klion, Amy; Cunningham-Rundles, Charlotte; Nichols, Kim E.; Meffre, Eric			Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SLAM-associated protein; signaling lymphocytic activation molecule; B-cell tolerance; regulatory T cells	LINKED LYMPHOPROLIFERATIVE-DISEASE; INVARIANT NKT CELLS; T-CELLS; HUMORAL IMMUNITY; ENCODING GENE; SAP; SLAM; ASSOCIATION; DEFICIENCY; MICE	Background: Signaling lymphocytic activation molecule (SLAM)-associated protein (SAP) can mediate the function of SLAM molecules, which have been proposed to be involved in the development of autoimmunity in mice. Objective: We sought to determine whether the SLAM/SAP pathway regulates the establishment of human B-cell tolerance and what mechanisms of B-cell tolerance could be affected by SAP deficiency. Methods: We tested the reactivity of antibodies isolated from single B cells from SAP-deficient patients with X-linked lymphoproliferative disease (XLP). The expressions of SAP and SLAM family members were assessed in human bone marrow-developing B cells. We also analyzed regulatory T (Treg) cell function in patients with XLP and healthy control subjects. Results: We found that new emigrant/transitional B cells from patients with XLP were enriched in autoreactive clones, revealing a defective central B-cell tolerance checkpoint in the absence of functional SAP. In agreement with a B cell-intrinsic regulation of central tolerance, we identified SAP expression in a discrete subset of bone marrow immature B cells. SAP colocalized with SLAMF6 only in association with clustered B-cell receptors likely recognizing self-antigens, suggesting that SLAM/SAP regulate B-cell receptor-mediated central tolerance. In addition, patients with XLP displayed defective peripheral B-cell tolerance, which is normally controlled by Treg cells. Treg cells in patients with XLP seem functional, but SAP-deficient T cells were resistant to Treg cell-mediated suppression. Indeed, SAP-deficient T cells were hyperresponsive to T-cell receptor stimulation, which resulted in increased secretion of IL-2, IFN-gamma, and TNF-alpha. Conclusions: SAP expression is required for the counterselection of developing autoreactive B cells and prevents their T cell-dependent accumulation in the periphery.	[Menard, Laurence; Cantaert, Tineke; Chamberlain, Nicolas; Meffre, Eric] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06511 USA; [Tangye, Stuart G.] Univ New S Wales, Garvan Inst Med Res, Program Immunol, Darlinghurst, NSW, Australia; [Tangye, Stuart G.] Univ New S Wales, St Vincents Clin Sch, Darlinghurst, NSW, Australia; [Riminton, Sean] Concord Hosp, Dept Immunol, Sydney, NSW, Australia; [Church, Joseph A.] Univ So Calif, Childrens Hosp Los Angeles, Div Clin Immunol & Allergy, Los Angeles, CA USA; [Church, Joseph A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Klion, Amy] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Inst Immunol, Dept Med, New York, NY USA; [Nichols, Kim E.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA	Yale University; Garvan Institute of Medical Research; University of New South Wales Sydney; University of New South Wales Sydney; Concord Repatriation General Hospital; Children's Hospital Los Angeles; University of Southern California; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Icahn School of Medicine at Mount Sinai; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Meffre, E (corresponding author), Yale Univ, Sch Med, 300 George St, New Haven, CT 06511 USA.	eric.meffre@yale.edu	cantaert, tineke/HGB-2648-2022; Nichols, Kim/E-9353-2016; Nichols, Kim/AAP-8592-2020; Tangye, Stuart G/H-4023-2014	cantaert, tineke/0000-0002-8911-1502; Nichols, Kim/0000-0002-5581-6555; Nichols, Kim/0000-0002-5581-6555; Tangye, Stuart G/0000-0002-5360-5180; Riminton, Sean/0000-0002-9953-9959; Klion, Amy/0000-0002-4986-5326	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NAID) [AI061093, AI071087, AI082713, AI095848, T32 AI089704]; Division of Intramural Research, NIH/NIAID; Rubicon grant from The Netherlands Organization for Scientific Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001130, U19AI082713, R21AI095848, R01AI071087, P01AI061093, T32AI089704] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NAID); Division of Intramural Research, NIH/NIAID; Rubicon grant from The Netherlands Organization for Scientific Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NAID) grants AI061093, AI071087, AI082713, AI095848 (to E. M.), and T32 AI089704 (to L. M.); the Division of Intramural Research, NIH/NIAID (to A. K.); and a Rubicon grant from The Netherlands Organization for Scientific Research (to T.C.).	Baev DV, 2008, J IMMUNOL, V181, P869, DOI 10.4049/jimmunol.181.2.869; Baldanzi G, 2011, J IMMUNOL, V187, P5941, DOI 10.4049/jimmunol.1002476; Cannons JL, 2011, ANNU REV IMMUNOL, V29, P665, DOI 10.1146/annurev-immunol-030409-101302; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Coraglia A, 2011, CLIN IMMUNOL, V141, P357, DOI 10.1016/j.clim.2011.09.007; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; Deenick EK, 2010, IMMUNITY, V33, P241, DOI 10.1016/j.immuni.2010.07.015; Dominguez-Villar M, 2011, NAT MED, V17, P673, DOI 10.1038/nm.2389; Graham DSC, 2008, GENES IMMUN, V9, P93, DOI 10.1038/sj.gene.6364453; Herve M, 2007, J EXP MED, V204, P1583, DOI 10.1084/jem.20062287; Isnardi I, 2008, IMMUNITY, V29, P746, DOI 10.1016/j.immuni.2008.09.015; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Kageyama R, 2012, IMMUNITY, V36, P986, DOI 10.1016/j.immuni.2012.05.016; Kinnunen T, 2013, J CLIN INVEST, V123, P2737, DOI 10.1172/JCI68775; Kinnunen T, 2013, BLOOD, V121, P1595, DOI 10.1182/blood-2012-09-457465; Kumar KR, 2006, SCIENCE, V312, P1665, DOI 10.1126/science.1125893; Ma CS, 2006, J CLIN INVEST, V116, P322, DOI 10.1172/JCI25720; Meffre E, 2004, J EXP MED, V199, P145, DOI 10.1084/jem.20031550; Meffre E, 2011, ANN NY ACAD SCI, V1246, P1, DOI 10.1111/j.1749-6632.2011.06347.x; Menard L, 2011, J CLIN INVEST, V121, P3635, DOI 10.1172/JCI45790; Meyers G, 2011, P NATL ACAD SCI USA, V108, P11554, DOI 10.1073/pnas.1102600108; Nagy N, 2009, P NATL ACAD SCI USA, V106, P11966, DOI 10.1073/pnas.0905691106; Ng YS, 2004, J EXP MED, V200, P927, DOI 10.1084/jem.20040920; Nichols KE, 2005, IMMUNOL REV, V203, P180, DOI 10.1111/j.0105-2896.2005.00230.x; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Nichols KE, 2005, NAT MED, V11, P340, DOI 10.1038/nm1189; Palendira U, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001187; Pasquier B, 2005, J EXP MED, V201, P695, DOI 10.1084/jem.20042432; Peluso I, 2007, J IMMUNOL, V178, P732, DOI 10.4049/jimmunol.178.2.732; Qi H, 2008, NATURE, V455, P764, DOI 10.1038/nature07345; Ruprecht CR, 2005, J EXP MED, V201, P1793, DOI 10.1084/jem.20050085; Sanzone S, 2003, J BIOL CHEM, V278, P29593, DOI 10.1074/jbc.M300565200; Sauer AV, 2012, J CLIN INVEST, V122, P2141, DOI 10.1172/JCI61788; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schneider A, 2008, J IMMUNOL, V181, P7350, DOI 10.4049/jimmunol.181.10.7350; Shlapatska LM, 2001, J IMMUNOL, V166, P5480, DOI 10.4049/jimmunol.166.9.5480; Snow AL, 2009, J CLIN INVEST, V119, P2976, DOI 10.1172/JCI39518; Suzuki A, 2008, NAT GENET, V40, P1224, DOI 10.1038/ng.205; Valencia X, 2006, BLOOD, V108, P253, DOI 10.1182/blood-2005-11-4567; van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964; Veillette A, 2008, P NATL ACAD SCI USA, V105, P1273, DOI 10.1073/pnas.0710698105; Wandstrat AE, 2004, IMMUNITY, V21, P769, DOI 10.1016/j.immuni.2004.10.009; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Wermeling F, 2010, J EXP MED, V207, P943, DOI 10.1084/jem.20091314; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713; Zhao DM, 2006, BLOOD, V107, P3925, DOI 10.1182/blood-2005-11-4502; Zhao F, 2012, IMMUNITY, V36, P1003, DOI 10.1016/j.immuni.2012.05.017	49	33	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1149	1161		10.1016/j.jaci.2013.10.051	http://dx.doi.org/10.1016/j.jaci.2013.10.051			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24373350	Green Accepted			2022-12-18	WOS:000333531700027
J	Kundig, TM; Johansen, P; Bachmann, MF; Cardell, LO; Senti, G				Kuendig, Thomas M.; Johansen, Pal; Bachmann, Martin F.; Cardell, Lars O.; Senti, Gabriela			Intralymphatic immunotherapy: Time interval between injections is essential	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Kuendig, Thomas M.; Johansen, Pal; Bachmann, Martin F.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; [Cardell, Lars O.] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div ENT Dis, Stockholm, Sweden; [Senti, Gabriela] Univ Zurich Hosp, Clin Trials Ctr, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; Karolinska Institutet; University of Zurich; University Zurich Hospital	Kundig, TM (corresponding author), Univ Zurich Hosp, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland.	thomas.kuendig@usz.ch	Johansen, Pål/A-1403-2013; Senti, Gabriela/Y-1019-2019	Johansen, Pål/0000-0002-5055-6299; Senti, Gabriela/0000-0002-9066-8383				[Anonymous], 2011, REC ADV COMM IMM PRA; Guery JC, 1996, J EXP MED, V183, P485, DOI 10.1084/jem.183.2.485; Hylander T, 2013, J ALLERGY CLIN IMMUN, V131, P412, DOI 10.1016/j.jaci.2012.10.056; Kedl RM, 2003, CURR OPIN IMMUNOL, V15, P120, DOI 10.1016/S0952-7915(02)00009-2; Lovgren T, 2012, CANCER IMMUNOL IMMUN, V61, P817, DOI 10.1007/s00262-011-1140-1; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P1290, DOI 10.1016/j.jaci.2012.02.026; Senti G, 2011, CURR TOP MICROBIOL, V352, P71, DOI 10.1007/82_2011_133; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Siegrist C-A., 2013, VACCINES-BASEL, V6th, DOI [DOI 10.1016/B978-1-4557-0090-5.00004-5, 10.1016/B978-1-4557-0090-5.00004-5]; Witten M, 2013, J ALLERGY CLIN IMMUN, V132, P1248, DOI 10.1016/j.jaci.2013.07.033	11	33	36	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					930	931		10.1016/j.jaci.2013.11.036	http://dx.doi.org/10.1016/j.jaci.2013.11.036			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24439076				2022-12-18	WOS:000332397600052
J	Figueiredo, CA; Barreto, ML; Alcantara-Neves, NM; Rodrigues, LC; Cooper, PJ; Cruz, AA; Pontes-de-Carvalho, LC; Lemaire, DC; Costa, RD; Amorim, LD; Vergara, C; Rafaels, N; Gao, L; Foster, C; Campbell, M; Mathias, RA; Barnes, KC				Figueiredo, Camila Alexandrina; Barreto, Mauricio Lima; Alcantara-Neves, Neuza Maria; Rodrigues, Laura Cunha; Cooper, Philip John; Cruz, Alvaro A.; Pontes-de-Carvalho, Lain Carlos; Lemaire, Denise C.; Costa, Ryan dos Santos; Amorim, Leila D.; Vergara, Candelaria; Rafaels, Nicholas; Gao, Li; Foster, Cassandra; Campbell, Monica; Mathias, Rasika A.; Barnes, Kathleen C.			Coassociations between IL10 polymorphisms, IL-10 production, helminth infection, and asthma/wheeze in an urban tropical population in Brazil	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL10; polymorphisms; helminth infection; immune modulation; allergy; asthma; Social Changes Asthma and Allergy in Latin America	CYTOKINE PRODUCTION; HYGIENE HYPOTHESIS; MECHANISMS; PARASITES; SUPPRESSION; DISEASE	Background: Helminth infections are associated with protection against allergies. It is postulated that IL-10 production after helminth infection suppresses skin hypersensitivity and increases IgG(4) production, protecting against allergies. Objective: We aimed to determine whether IL10 polymorphisms are associated with helminth infection and the risk of wheeze and allergy. Methods: Twelve IL10 single nucleotide polymorphisms were genotyped in 1353 children aged 4 to 11 years living in a poor urban area in Salvador, Brazil. Wheezing status, Ascaris lumbricoides and Trichuris trichiura infection, IL-10 production by peripheral blood leukocytes stimulated with A lumbricoides extract, serum total IgE levels, specific IgE levels, skin prick test responses to common aeroallergens, and IgG(4) and IgE anti-A lumbricoides antibody levels were measured in all children. Association tests were performed by using logistic or linear regression when appropriate, including sex, age, helminth infection, and principal components for ancestry informative markers as covariates by using PLINK. Results: Allele G of marker rs3024496 was associated with the decreased production of IL-10 by peripheral blood leukocytes in response to A lumbricoides stimulation. Allele C of marker rs3024498 was negatively associated with helminth infection or its markers. Marker rs3024492 was positively associated with the risk of atopic wheeze, total IgE levels, and skin prick test responses to cockroach. Conclusions: Our findings suggest that IL10 polymorphisms might play a role in the production of IL-10, helminth infection, and allergy. We hypothesize that polymorphisms related to protection against helminths, which would offer an evolutionary advantage to subjects in the past, might be associated with increased risk of allergic diseases.	[Figueiredo, Camila Alexandrina; Vergara, Candelaria; Rafaels, Nicholas; Gao, Li; Foster, Cassandra; Campbell, Monica; Mathias, Rasika A.; Barnes, Kathleen C.] Johns Hopkins Univ, Div Allergy & Clin Immunol, Baltimore, MD 21218 USA; [Figueiredo, Camila Alexandrina; Alcantara-Neves, Neuza Maria; Lemaire, Denise C.; Costa, Ryan dos Santos] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil; [Barreto, Mauricio Lima] Univ Fed Bahia, Inst Saude Colet, Salvador, BA, Brazil; [Cruz, Alvaro A.] Univ Fed Bahia, ProAR Nucl Excelencia Asma, Salvador, BA, Brazil; [Amorim, Leila D.] Univ Fed Bahia, Inst Matemat, Salvador, BA, Brazil; [Rodrigues, Laura Cunha] London Sch Hyg & Trop Med, London, England; [Cooper, Philip John] Univ San Francisco Quito, San Francisco, CA USA; [Cooper, Philip John] Univ London, Ctr Infect, London WC1E 7HU, England; [Pontes-de-Carvalho, Lain Carlos] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil; [Lemaire, Denise C.] Univ Estado Bahia, Dept Ciencias Vida, Salvador, BA, Brazil	Johns Hopkins University; Universidade Federal da Bahia; Universidade Federal da Bahia; Universidade Federal da Bahia; Universidade Federal da Bahia; University of London; London School of Hygiene & Tropical Medicine; University of San Francisco; University of London; Fundacao Oswaldo Cruz; Universidade do Estado Bahia	Barnes, KC (corresponding author), Johns Hopkins Univ, Div Allergy & Clin Immunol, Baltimore, MD 21218 USA.	kbarnes@jhmi.edu	RODRIGUES, LAURA CUNHA/AAO-4130-2021; Costa, Ryan S/G-4294-2016; Figueiredo, Camila Alexandrina/H-3525-2015; Barreto, Mauricio L/B-1752-2008; Amorim, Leila/B-4508-2015; Amorim, Leila/ABG-9480-2021; Cruz, Alvaro A/I-1676-2012; Costa, Ryan/AAV-8643-2021	Costa, Ryan S/0000-0003-3075-0729; Figueiredo, Camila Alexandrina/0000-0003-1356-6188; Barreto, Mauricio L/0000-0002-0215-4930; Amorim, Leila/0000-0002-1112-2332; Amorim, Leila/0000-0002-1112-2332; Cruz, Alvaro A/0000-0002-7403-3871; Alcantara-Neves, Neuza Maria/0000-0002-2102-260X	Wellcome Trust, UK; HCPC Latin America Excellence Centre Programme [072405/Z/03/Z]; Brazilian agency Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq; David G. Marsh Award; Mary Beryl Patch Turnbull Scholar Program; Wellcome Trust; National Research Council-Brazil; GlaxoSmithKline; Merck Sharp Dohme; Novartis; National Institutes of Health; National Institutes of Health/National Heart, Lung, and Blood Institute; "Evolution and Diseases of Modern Environments" Symposium; Cincinnati Children's Hospital Medical Center Allergy Conference; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL112088] Funding Source: NIH RePORTER	Wellcome Trust, UK(Wellcome Trust); HCPC Latin America Excellence Centre Programme; Brazilian agency Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); David G. Marsh Award; Mary Beryl Patch Turnbull Scholar Program; Wellcome Trust(Wellcome TrustEuropean Commission); National Research Council-Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); GlaxoSmithKline(GlaxoSmithKline); Merck Sharp Dohme(Merck & Company); Novartis(Novartis); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); "Evolution and Diseases of Modern Environments" Symposium; Cincinnati Children's Hospital Medical Center Allergy Conference; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the Wellcome Trust, UK; the HCPC Latin America Excellence Centre Programme, Ref 072405/Z/03/Z; the Brazilian agency Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq; and the David G. Marsh Award. K. C. B. was supported in part by the Mary Beryl Patch Turnbull Scholar Program.; M. L. Barreto has received grants from the Wellcome Trust and the National Research Council-Brazil and is employed by the Federal University of Bahia. P. J. Cooper has received grants from the Wellcome Trust and is employed by the Liverpool School of Tropical Medicine. A. A. Cruz serves on boards for Merck Sharp & Dohme and Roche; has consultant arrangements with Mantecorp; receives grants from GlaxoSmithKline; receives payment for lectures from Merck Sharp & Dohme; has received travel/accommodations/meeting expenses from Merck Sharp & Dohme and Novartis; and has conducted clinical trials for AstraZeneca, Novartis, TAKEDA, Eurofarma, GlaxoSmithKline, and Genentech. L. C. Pontes-de-Carvalho is employed by the Ministry of Health, Brazil. C. Vergara, C. Foster, M. Campbell, and R. A. Mathias are employed by Johns Hopkins University and have received grants from the National Institutes of Health. K. C. Barnes serves on boards for Genentech; has consultant arrangements with Sanofi-Aventis and Sirius Genomics; is employed by Johns Hopkins University; has received grants from the National Institutes of Health/National Heart, Lung, and Blood Institute; has received payment for lectures from the "Evolution and Diseases of Modern Environments" Symposium, the Cincinnati Children's Hospital Medical Center Allergy Conference, the 50th Annual Swineford Allergy Conference, and the American Academy of Allergy, Asthma & Immunology; and receives royalties from Up-To-Date. The rest of the authors declare that they have no relevant conflicts of interest.	Abhimanyu, 2011, INFECT GENET EVOL, V11, P1015, DOI 10.1016/j.meegid.2011.03.017; Akdis M, 2008, EXPERT OPIN BIOL TH, V8, P769, DOI 10.1517/14712598.8.6.769 ; Alcantara-Neves NM, 2012, J ALLERGY CLIN IMMUN, V129, P359, DOI 10.1016/j.jaci.2011.09.015; Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barreto Mauricio L, 2006, BMC Pulm Med, V6, P15, DOI 10.1186/1471-2466-6-15; Barreto ML, 2010, ENVIRON HEALTH PERSP, V118, P1637, DOI 10.1289/ehp.1002058; Cooper PJ, 2009, CURR OPIN ALLERGY CL, V9, P29, DOI 10.1097/ACI.0b013e32831f44a6; Fallon PG, 2007, NAT REV IMMUNOL, V7, P220, DOI 10.1038/nri2039; Figueiredo CA, 2011, CLIN IMMUNOL, V139, P57, DOI 10.1016/j.clim.2010.12.019; Figueiredo CA, 2010, INFECT IMMUN, V78, P3160, DOI 10.1128/IAI.01228-09; Figueiredo CA, 2009, ENVIRON HEALTH PERSP, V117, P845, DOI 10.1289/ehp.0800366; Fumagalli M, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-264; Garn H, 2007, IMMUNOBIOLOGY, V212, P441, DOI 10.1016/j.imbio.2007.03.006; Grant AV, 2011, GENES IMMUN, V12, P46, DOI 10.1038/gene.2010.50; Guarner F, 2006, NAT CLIN PRACT GASTR, V3, P275, DOI 10.1038/ncpgasthep0471; Hoffman W. A., 1934, PUERTO RICO J PUBLIC, V9, P281, DOI DOI 10.1590/S0037-86822012000300024; Hunninghake GM, 2008, J ALLERGY CLIN IMMUN, V122, P93, DOI 10.1016/j.jaci.2008.03.015; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rodrigues LC, 2008, CLIN EXP ALLERGY, V38, P1769, DOI 10.1111/j.1365-2222.2008.03027.x; Rook GAW, 2007, T ROY SOC TROP MED H, V101, P1072, DOI 10.1016/j.trstmh.2007.05.014; Shrier I, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-70; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572	26	33	33	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1683	1690		10.1016/j.jaci.2012.10.043	http://dx.doi.org/10.1016/j.jaci.2012.10.043			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23273955	Green Published, Green Accepted			2022-12-18	WOS:000320532800029
J	Pinczower, GD; Bertalli, NA; Bussmann, N; Hamidon, M; Allen, KJ; DunnGalvin, A; Hourihane, JO; Gurrin, LC; Tang, MLK				Pinczower, Gideon D.; Bertalli, Nadine A.; Bussmann, Neiden; Hamidon, Melisa; Allen, Katrina J.; DunnGalvin, Audrey; Hourihane, Jonathan O'B.; Gurrin, Lyle C.; Tang, Mimi L. K.			The effect of provision of an adrenaline autoinjector on quality of life in children with food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Pinczower, Gideon D.; Bussmann, Neiden; Hamidon, Melisa; Allen, Katrina J.; Tang, Mimi L. K.] Univ Melbourne, Dept Allergy & Immunol, Royal Childrens Hosp, Melbourne, Vic, Australia; [Pinczower, Gideon D.; Tang, Mimi L. K.] Univ Melbourne, Dept Pediat, Melbourne, Vic, Australia; [Bertalli, Nadine A.; Allen, Katrina J.; Gurrin, Lyle C.; Tang, Mimi L. K.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Bertalli, Nadine A.; Gurrin, Lyle C.] Ctr Mol Environm Genet & Analyt MEGA Epidemiol, Sch Populat Hlth, Melbourne, Vic, Australia; [DunnGalvin, Audrey; Hourihane, Jonathan O'B.] Natl Univ Ireland Univ Coll Cork, Dept Paediat & Child Hlth, Cork, Ireland	Royal Children's Hospital Melbourne; University of Melbourne; University of Melbourne; Murdoch Children's Research Institute; University College Cork	Pinczower, GD (corresponding author), Univ Melbourne, Dept Allergy & Immunol, Royal Childrens Hosp, Melbourne, Vic, Australia.	mimi.tang@rch.org.au	Allen, Katrina/I-4361-2018; Bertalli, Nadine A/B-5440-2015; Tang, Mimi/ABD-8350-2020; DunnGalvin, Audrey/G-1741-2012	Allen, Katrina/0000-0002-1921-4493; Tang, Mimi/0000-0002-3839-5293; Gurrin, Lyle/0000-0001-7052-1969				Australian Society of Clinical Immunology and Allergy (ASCIA), 2012, AUSTR SOC CLIN IMM A; Burks AW, 2011, PEDIATRICS, V128, P955, DOI 10.1542/peds.2011-0539; Cummings AJ, 2010, ALLERGY, V65, P933, DOI 10.1111/j.1398-9995.2010.02342.x; DunnGalvin A, 2008, CLIN EXP ALLERGY, V38, P977, DOI 10.1111/j.1365-2222.2008.02978.x; Lieberman JA, 2011, CURR OPIN ALLERGY CL, V11, P236, DOI 10.1097/ACI.0b013e3283464cf0; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Tang MLK, 2008, J PAEDIATR CHILD H, V18, P309	8	33	33	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					238	U349		10.1016/j.jaci.2012.09.038	http://dx.doi.org/10.1016/j.jaci.2012.09.038			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23199601	Bronze			2022-12-18	WOS:000312961200039
J	Chiang, WC; Huang, CH; Llanora, GV; Gerez, I; Goh, SH; Shek, LPC; Nauta, AJ; Van Doorn, WA; Bindels, J; Ulfman, LH; Knipping, K; Delsing, DJ; Knol, EF; Lee, BW				Chiang, Wen Chin; Huang, Chiung-Hui; Llanora, Genevieve V.; Gerez, Irvin; Goh, Si Hui; Shek, Lynette P. C.; Nauta, Alma J.; Van Doorn, Wilhelmina A.; Bindels, Jacques; Ulfman, Laurien H.; Knipping, Karen; Delsing, Dianne J.; Knol, Edward F.; Lee, Bee Wah			Anaphylaxis to cow's milk formula containing short-chain galacto-oligosaccharide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Galacto-oligosaccharide allergy; Asia; children; basophil activation test; skin prick test	FRUCTO-OLIGOSACCHARIDES; ALLERGIC REACTIONS; IGE; RELEVANCE; MIXTURE; INULIN	Background: On the basis of the proven prebiotic effects of oligosaccharides in cow's milk formula (CMF) in infants, CMFs are supplemented with oligosaccharides. Objective: We present a series of 5 cases of cow's milk-tolerant but atopic patients with a history of respiratory allergies. All had anaphylaxis after the ingestion of CMF supplemented with short-chain galacto-oligosaccharide (scGOS). The allergen trigger was investigated. Methods: Clinical histories were collated. Skin prick tests (SPTs) and basophil activation tests (BATs) were carried out with the eliciting CMF that triggered anaphylaxis, with or without supplemented prebiotics (scGOS) and with scGOS fractions containing oligosaccharides of different chain lengths. Results: The median age of presentation was 6 years (range, 5-38 years). Anaphylaxis occurred within 30 minutes of the first known exposure to CMF supplemented with prebiotics in all patients. Only 1 patient was subjected to oral challenge, which resulted in an anaphylactic reaction. All patients demonstrated IgE sensitization through SPTs and BATs to scGOS and fractions of scGOS containing 3 sugar units or greater but not to cow's milk or long-chain fructo-oligosaccharide. Eight child control subjects tolerant to regular ingestion of scGOS-supplemented CMF and 1 adult volunteer were found to have negative results to scGOS through SPTs and BATs. In addition, in vitro BATs with donor basophils sensitized with sera from 2 of the 3 reported cases showed reactions to scGOS. The scGOS-induced basophil activation was inhibited in the presence of wortmannin, a phosphatidylinositol 3-kinase inhibitor. Conclusions: This study describes an unusual form of IgE-mediated anaphylaxis triggered by low-molecular-weight oligosaccharides in scGOS. The primary sensitizer for this phenomenon requires further investigation. (J Allergy Clin Immunol 2012;130:1361-7.)	[Chiang, Wen Chin; Goh, Si Hui] KK Womans & Childrens Hosp, Dept Paediat, Singapore 229899, Singapore; [Huang, Chiung-Hui; Llanora, Genevieve V.; Gerez, Irvin; Shek, Lynette P. C.; Lee, Bee Wah] Natl Univ Hlth Syst, Dept Paediat, Singapore, Singapore; [Nauta, Alma J.; Bindels, Jacques] Danone Res Ctr Specialised Nutr, Singapore, Singapore; [Knipping, Karen] Danone Res Ctr Specialised Nutr, Wageningen, Netherlands; [Nauta, Alma J.] Univ Utrecht, Dept Pharmacol, UIPS, Utrecht, Netherlands; [Ulfman, Laurien H.; Delsing, Dianne J.] FrieslandCampina, Amersfoort, Netherlands; [Van Doorn, Wilhelmina A.; Knol, Edward F.] Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands	KK Women's & Children's Hospital; National University of Singapore; Danone Nutricia; Danone Nutricia; Utrecht University; Utrecht University; Utrecht University Medical Center	Chiang, WC (corresponding author), KK Womans & Childrens Hosp, Dept Paediat Med, 100 Bukit Timah Rd, Singapore 229899, Singapore.	Chiang.Wen.Chin@kkh.com.sg	Shek, Lynette/D-8016-2015	Shek, Lynette/0000-0001-9064-8983; Knol, Edward/0000-0001-7368-9820	National Medical Research Council (Singapore) [NMRC/EDG/0039/2008]	National Medical Research Council (Singapore)(National Medical Research Council, Singapore)	Supported in part by the National Medical Research Council (Singapore NMRC/EDG/0039/2008).	Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Barboza M, 2009, APPL ENVIRON MICROB, V75, P7319, DOI 10.1128/AEM.00842-09; Boehm G, 2003, ACTA PAEDIATR, V92, P64; Boehm G, 2007, J NUTR, V137, p847S, DOI 10.1093/jn/137.3.847S; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V124, P652, DOI 10.1016/j.jaci.2009.08.026; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Coulier L, 2009, J AGR FOOD CHEM, V57, P8488, DOI 10.1021/jf902549e; Ebo DG, 2012, EXPERT REV CLIN IMMU, V8, P9, DOI [10.1586/eci.11.73, 10.1586/ECI.11.73]; Fanaro S, 2005, ACTA PAEDIATR, V94, P22, DOI 10.1080/08035320510043538; Franck P, 2005, INT ARCH ALLERGY IMM, V136, P155, DOI 10.1159/000083323; Gay-Crosier F, 2000, NEW ENGL J MED, V342, P1372, DOI 10.1056/NEJM200005043421814; GIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/jn/125.6.1401; Jyo T, 1993, J HIROSMIMA MED ASS, V25, P19; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Moro G, 2006, ARCH DIS CHILD, V91, P814, DOI 10.1136/adc.2006.098251; OHTA M, 1991, ARCH BIOCHEM BIOPHYS, V290, P474, DOI 10.1016/0003-9861(91)90569-5; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Starling S, 2008, PREBIOTIC WINS GRAS; Vo TH, 2012, FOODBORNE PATHOG DIS, V9, P156, DOI 10.1089/fpd.2011.1059; Urashima T., 2007, COMPREHENSIVE GLYCOS, P693, DOI [10.1016/B978-044451967-2/00128-8, DOI 10.1016/B978-044451967-2/00128-8]; van Hoffen E, 2009, ALLERGY, V64, P484, DOI 10.1111/j.1398-9995.2008.01765.x; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Yunginger JW, 2001, J ALLERGY CLIN IMMUN, V108, P650, DOI 10.1067/mai.2001.118131	27	33	34	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1361	1367		10.1016/j.jaci.2012.08.048	http://dx.doi.org/10.1016/j.jaci.2012.08.048			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23102546				2022-12-18	WOS:000311641100017
J	Mansbach, JM; Piedra, PA; Borregaard, N; Martineau, AR; Neuman, MI; Espinola, JA; Camargo, CA				Mansbach, Jonathan M.; Piedra, Pedro A.; Borregaard, Niels; Martineau, Adrian R.; Neuman, Mark I.; Espinola, Janice A.; Camargo, Carlos A., Jr.			Serum cathelicidin level is associated with viral etiology and severity of bronchiolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VITAMIN-D; INNATE IMMUNITY; PLASMA		[Mansbach, Jonathan M.; Neuman, Mark I.] Boston Childrens Hosp, Dept Med, Boston, MA USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Borregaard, Niels] Rigshosp, Dept Hematol, DK-2100 Copenhagen, Denmark; [Martineau, Adrian R.] Barts & London Queen Marys Sch Med & Dent, Ctr Primary Care & Publ Hlth, London, England; [Espinola, Janice A.; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Harvard University; Boston Children's Hospital; Baylor College of Medicine; Rigshospitalet; University of Copenhagen; University of London; Queen Mary University London; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Mansbach, JM (corresponding author), Boston Childrens Hosp, Dept Med, Boston, MA USA.	jonathan.mansbach@childrens.harvard.edu	Camargo, Carlos A./C-2145-2008; Martineau, Adrian R/A-3083-2010	Camargo, Carlos A./0000-0002-5071-7654; 	NCRR NIH HHS [UL1 RR025758, UL1 RR-025758] Funding Source: Medline; NIAID NIH HHS [U01 AI-67693, U01 AI067693, K23 AI-77801, K23 AI077801] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI067693, K23AI077801] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams JS, 2008, NAT CLIN PRACT ENDOC, V4, P80, DOI 10.1038/ncpendmet0716; Bartley J, 2010, J LARYNGOL OTOL, V124, P465, DOI 10.1017/S0022215109992684; Bhan I, 2011, J ALLERGY CLIN IMMUN, V127, P1302, DOI 10.1016/j.jaci.2010.12.1097; Gombart AF, 2009, CLIN INFECT DIS, V48, P418, DOI 10.1086/596314; Leow L, 2011, RESPIROLOGY, V16, P611, DOI 10.1111/j.1440-1843.2011.01924.x; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Mansbach JM, 2012, VITAMIN D LUNG MECH, P181; Mansbach JM, 2012, ARCH PEDIAT ADOL MED, V166, P700, DOI 10.1001/archpediatrics.2011.1669; Sorensen O, 1997, J IMMUNOL METHODS, V206, P53, DOI 10.1016/S0022-1759(97)00084-7	10	33	34	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					1007	+		10.1016/j.jaci.2012.07.044	http://dx.doi.org/10.1016/j.jaci.2012.07.044			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22944482	Green Accepted			2022-12-18	WOS:000309594800031
J	Jakob, T; Kohler, J; Blank, S; Magnusson, U; Huss-Marp, J; Spillner, E; Lidholm, J				Jakob, Thilo; Koehler, Julian; Blank, Simon; Magnusson, Ulrika; Huss-Marp, Johannes; Spillner, Edzard; Lidholm, Jonas			Comparable IgE reactivity to natural and recombinant Api m 1 in cross-reactive carbohydrate determinant-negative patients with bee venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RVES V 5; DISTINGUISH BEE; SUFFICIENT; DIAGNOSIS		[Jakob, Thilo; Koehler, Julian] Univ Med Ctr, Dept Dermatol, Allergy Res Grp, Freiburg, Germany; [Blank, Simon; Spillner, Edzard] Univ Hamburg, Dept Chem, Inst Biochem & Mol Biol, Hamburg, Germany; [Magnusson, Ulrika; Lidholm, Jonas] Thermo Fisher Sci, Uppsala, Sweden; [Huss-Marp, Johannes] Thermo Fisher Sci, Freiburg, Germany	University of Freiburg; University of Hamburg; Thermo Fisher Scientific; Thermo Fisher Scientific	Jakob, T (corresponding author), Univ Med Ctr, Dept Dermatol, Allergy Res Grp, Freiburg, Germany.	thilo.jakob@uniklinik-freiburg.de	Blank, Simon/M-7708-2013; Jakob, Thilo/J-1621-2012	spillner, edzard/0000-0003-0999-5254; Lidholm, Jonas/0000-0002-7779-3411				Blank S, 2011, PROTEIN PEPTIDE LETT, V18, P415, DOI 10.2174/092986611794653923; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V128, P248, DOI 10.1016/j.jaci.2011.02.020; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V127, P265, DOI 10.1016/j.jaci.2010.06.042; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Korosec P, 2011, J ALLERGY CLIN IMMUN, V128, P671, DOI 10.1016/j.jaci.2011.03.012; Seismann H, 2010, MOL IMMUNOL, V47, P799, DOI 10.1016/j.molimm.2009.10.005; Sturm GJ, 2011, J ALLERGY CLIN IMMUN, V128, P247, DOI 10.1016/j.jaci.2011.02.021	7	33	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					276	278		10.1016/j.jaci.2012.03.048	http://dx.doi.org/10.1016/j.jaci.2012.03.048			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22633321	Bronze			2022-12-18	WOS:000306644800043
J	Chinuki, Y; Kaneko, S; Dekio, I; Takahashi, H; Tokuda, R; Nagao, M; Fujisawa, T; Morita, E				Chinuki, Yuko; Kaneko, Sakae; Dekio, Itaru; Takahashi, Hitoshi; Tokuda, Reiko; Nagao, Mizuho; Fujisawa, Takao; Morita, Eishin			CD203c expression-based basophil activation test for diagnosis of wheat-dependent exercise-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PEPTIDES		[Chinuki, Yuko; Kaneko, Sakae; Dekio, Itaru; Takahashi, Hitoshi; Morita, Eishin] Shimane Univ, Dept Dermatol, Fac Med, Izumo, Shimane, Japan; [Tokuda, Reiko; Nagao, Mizuho; Fujisawa, Takao] Mie Natl Hosp, Inst Clin Res, Tsu, Mie, Japan	Shimane University	Chinuki, Y (corresponding author), Shimane Univ, Dept Dermatol, Fac Med, Izumo, Shimane, Japan.	ychinuki@med.shimane-u.ac.jp	Dekio, Itaru/X-2371-2019	Dekio, Itaru/0000-0001-9428-0098				Chinuki Y, 2011, CONTACT DERMATITIS, V65, P55, DOI 10.1111/j.1600-0536.2011.01917.x; Fukutomi Y, 2011, J ALLERGY CLIN IMMUN, V127, P531, DOI 10.1016/j.jaci.2010.09.035; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Leduc V, 2003, J ALLERGY CLIN IMMUN, V111, P897, DOI 10.1067/mai.2003.1345; Matsuo H, 2008, ALLERGY, V63, P233, DOI 10.1111/j.1398-9995.2007.01504.x; Matsuo H, 2005, J IMMUNOL, V175, P8116, DOI 10.4049/jimmunol.175.12.8116; Matsuo H, 2005, CLIN EXP ALLERGY, V35, P461, DOI 10.1111/j.1365-2222.2005.02213.x; Nagao M, 2008, INT ARCH ALLERGY IMM, V146, P47, DOI 10.1159/000126061; Tokuda Reiko, 2009, Allergology International, V58, P193, DOI 10.2332/allergolint.08-OA-0023	9	33	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1404	1406		10.1016/j.jaci.2012.02.049	http://dx.doi.org/10.1016/j.jaci.2012.02.049			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22464646				2022-12-18	WOS:000303418000034
J	Kellberger, J; Dressel, H; Vogelberg, C; Leupold, W; Windstetter, D; Weinmayr, G; Genuneit, J; Heumann, C; Nowak, D; von Mutius, E; Radon, K				Kellberger, Jessica; Dressel, Holger; Vogelberg, Christian; Leupold, Wolfgang; Windstetter, Doris; Weinmayr, Gudrun; Genuneit, Jon; Heumann, Christian; Nowak, Dennis; von Mutius, Erika; Radon, Katja			Prediction of the incidence and persistence of allergic rhinitis in adolescence: A prospective cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; disease prediction; adolescence; cohort study	SYMPTOM QUESTIONNAIRE; CHILDHOOD ISAAC; ASTHMA; CHILDREN; PREVALENCE; IMPACT; RHINOCONJUNCTIVITIS; SENSITIZATION; POPULATION; VALIDATION	Background: Predictive models have rarely been used in allergy research and practice. However, they might support physicians in advising patients. Objective: The aim of this study was to create predictive models for the incidence and persistence of allergic rhinitis (AR) during adolescence. Methods: A prospective population-based cohort study was conducted starting at age 9 to 11 years. Potential risk factors for atopic diseases obtained at baseline in 2810 subjects were used to create predictive logistic regression models for the incidence and persistence of physician-diagnosed AR with current symptoms at age 15 to 18 years. Results: Positive skin prick test responses to outdoor allergens at baseline were the most important determinant for both the incidence and persistence of AR until follow-up. For the incidence of AR, positive skin prick test responses to indoor allergens, parental history of asthma, female sex, and not having been breast-fed exclusively for 2 or more months were additional statistically significant independent risk factors. Depending on the number of risk factors present, the probability of the incidence of AR increased from 2% (no risk factors present) to 72% (full model; 95% CI, 58% to 85%). The probability of persistence of AR ranged from 33% (no risk factors present) to 83% (full model; 95% CI, 70% to 97%). Conclusion: The course of AR over puberty can be predicted using risk factors that are easy to determine in childhood. Sensitization to outdoor allergens seems to play a much greater role for disease development than sensitization to indoor allergens. This might help pediatricians in advising patients. (J Allergy Clin Immunol 2012;129:397-402.)	[Kellberger, Jessica; Dressel, Holger; Windstetter, Doris; Nowak, Dennis; Radon, Katja] Univ Hosp Munich LMU, Occupat & Environm Epidemiol & Net Teaching Unit, Inst & Outpatient Clic Occupat Social & Environm, D-80336 Munich, Germany; [Weinmayr, Gudrun; Genuneit, Jon] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Vogelberg, Christian; Leupold, Wolfgang] Univ Childrens Hosp, Dresden, Germany; [Heumann, Christian] Ludwig Maximilians Univ Munchen, Dept Stat, Munich, Germany; [von Mutius, Erika] Univ Hosp Munich LMU, Dr V Haunersches Kinderspital, D-80336 Munich, Germany	University of Munich; Ulm University; Technische Universitat Dresden; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Munich	Kellberger, J (corresponding author), Univ Hosp Munich LMU, Occupat & Environm Epidemiol & Net Teaching Unit, Inst & Outpatient Clic Occupat Social & Environm, Ziemssenstr 1, D-80336 Munich, Germany.	jessica.kellberger@med.lmu.de	Genuneit, Jon/I-9323-2012; Gerlich, Jessica/L-2590-2016	Genuneit, Jon/0000-0001-5764-1528; Gerlich, Jessica/0000-0002-0737-9506; Dressel, Holger/0000-0002-1268-0416; von Mutius, Erika/0000-0002-8893-4515	Federal Office for Occupational Safety and Occupational Medicine; Federal Ministry of Labor and Social Affairs (Germany); InfectoPharm; Airsonett AB	Federal Office for Occupational Safety and Occupational Medicine; Federal Ministry of Labor and Social Affairs (Germany); InfectoPharm; Airsonett AB(HOGANAS ABStatisticon AB)	Supported by the Federal Office for Occupational Safety and Occupational Medicine and the Federal Ministry of Labor and Social Affairs (Germany).; E. von Mutius has consulted for Novartis, GlaxoSmithKline, ALK Abello, and Protectimmun; has received a speaker's fee from InfectoPharm; has received research support from Airsonett AB; and is a member of the expert panel for the UK Research Excellence Framework. The rest of the authors declare that they have no relevant conflicts of interest.	Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Baena-Cagnani CE, 2009, CURR OPIN ALLERGY CL, V9, P136, DOI 10.1097/ACI.0b013e3283294038; Bertelsen RJ, 2010, CLIN EXP ALLERGY, V40, P1388, DOI 10.1111/j.1365-2222.2010.03543.x; Bjorksten B, 2008, PEDIAT ALLERG IMM-UK, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x; Blaiss MS, 2007, ALLERGY ASTHMA PROC, V28, P393, DOI 10.2500/aap.2007.28.3013; Borges Wellington G., 2006, J. Pediatr. (Rio J.), V82, P137, DOI [10.2223/JPED.1461, 10.1590/S0021-75572006000200011]; Bousquet PJ, 2008, ALLERGY, V63, P1301, DOI 10.1111/j.1398-9995.2008.01824.x; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; Burney P, 1998, REV EPIDEMIOL SANTE, V46, P491; Codispoti CD, 2010, J ALLERGY CLIN IMMUN, V125, P1054, DOI 10.1016/j.jaci.2010.02.004; de Bot CMA, 2009, PEDIAT ALLERG IMM-UK, V20, P571, DOI 10.1111/j.1399-3038.2008.00829.x; de Meer G, 2010, PEDIAT ALLERG IMM-UK, V21, P823, DOI 10.1111/j.1399-3038.2009.00971.x; Di Lorenzo G, 2011, INT ARCH ALLERGY IMM, V155, P263, DOI 10.1159/000320050; Genuneit J, 2006, THORAX, V61, P572, DOI 10.1136/thx.2005.051227; Horton NJ, 2001, AM STAT, V55, P244, DOI 10.1198/000313001317098266; Karakaya G, 2006, Allergol Immunopathol (Madr), V34, P257; Keil T, 2010, PEDIAT ALLERG IMM-UK, V21, P962, DOI 10.1111/j.1399-3038.2010.01046.x; Kramer U, 2010, CLIN EXP ALLERGY, V40, P289, DOI 10.1111/j.1365-2222.2009.03435.x; Matheson MC, 2009, CLIN EXP ALLERGY, V39, P370, DOI 10.1111/j.1365-2222.2008.03175.x; Matheson MC, 2007, J ALLERGY CLIN IMMUN, V120, P1051, DOI 10.1016/j.jaci.2007.06.030; Meltzer EO, 2011, ANN ALLERG ASTHMA IM, V106, pS12, DOI 10.1016/j.anai.2010.10.014; Mosges R, 2007, ALLERGY, V62, P969, DOI 10.1111/j.1398-9995.2007.01440.x; Muche-Borowski C, 2010, J DTSCH DERMATOL GES, V8, P718, DOI 10.1111/j.1610-0387.2009.07313.x; Omenaas E, 2008, CLIN RESPIR J, V2, P45, DOI 10.1111/j.1752-699X.2008.00083.x; Papadopoulou A, 2011, ALLERGOL IMMUNOPATH; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Peters AS, 2010, J ALLERGY CLIN IMMUN, V126, P590, DOI 10.1016/j.jaci.2010.06.020; Radon K, 2006, EUR RESPIR J, V27, P774, DOI 10.1183/09031936.06.00093005; Radon K, 2006, SCAND J WORK ENV HEA, V32, P132, DOI 10.5271/sjweh.988; Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008; Rondon C, 2009, J ALLERGY CLIN IMMUN, V123, P1098, DOI 10.1016/j.jaci.2009.02.018; Schafer T, 2007, ALLERGY, V62, P1282, DOI 10.1111/j.1398-9995.2007.01453.x; Schafer T, 2003, PEDIATR ALLERGY IMMU, V14, P120, DOI 10.1034/j.1399-3038.2003.00024.x; Schlaud M, 2007, BUNDESGESUNDHEITSBLA, V50, P701, DOI 10.1007/s00103-007-0231-9; Schoefer Y, 2008, ALLERGY, V63, P81, DOI 10.1111/j.1398-9995.2007.01517.x; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064; Settipane Russell A, 2007, Clin Allergy Immunol, V19, P23; Sherrill DL, 2005, RESP MED, V99, P1377, DOI 10.1016/j.rmed.2005.03.025; Sinescu Crina, 2010, J Med Life, V3, P421; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Tanaka Keiko, 2007, Allergol Int, V56, P363, DOI 10.2332/allergolint.R-07-143; The ISAAC Steering Committee, 1998, PHAS 2 MOD INT STUD; Ulrik CS, 2000, ALLERGY, V55, P1019, DOI 10.1034/j.1398-9995.2000.00630.x; Vanna AT, 2001, PEDIAT ALLERG IMM-UK, V12, P95, DOI 10.1034/j.1399-3038.2001.012002095.x; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Yuan YC., 2000, MULTIPLE IMPUTATION	50	33	34	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					397	U189		10.1016/j.jaci.2011.08.016	http://dx.doi.org/10.1016/j.jaci.2011.08.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	21924762				2022-12-18	WOS:000299951700015
J	Sastre, J; Manso, L; Sanchez-Garcia, S; Fernandez-Nieto, M				Sastre, Joaquin; Manso, Luis; Sanchez-Garcia, Silvia; Fernandez-Nieto, Mar			Medical and economic impact of misdiagnosis of drug hypersensitivity in hospitalized patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGIES		[Sastre, Joaquin; Manso, Luis; Sanchez-Garcia, Silvia; Fernandez-Nieto, Mar] Fdn Jimenez Diaz, Dept Allergy, E-28040 Madrid, Spain		Sastre, J (corresponding author), Fdn Jimenez Diaz, Dept Allergy, E-28040 Madrid, Spain.	jsastre@fjd.es	Silvia, Sanchez-Garcia/B-5206-2017	Silvia, Sanchez-Garcia/0000-0002-0808-0645; Luis, Manso/0000-0002-1683-550X				Gomes ER, 2005, CURR OPIN ALLERGY CL, V5, P309, DOI 10.1097/01.all.0000173785.81024.33; Lee CE, 2000, ARCH INTERN MED, V160, P2819, DOI 10.1001/archinte.160.18.2819; Lutomski DM, 2008, PHARMACOTHERAPY, V28, P1348, DOI 10.1592/phco.28.11.1348; Thong BYH, 2003, ANN ALLERG ASTHMA IM, V90, P342, DOI 10.1016/S1081-1206(10)61804-2	4	33	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					566	567		10.1016/j.jaci.2011.09.028	http://dx.doi.org/10.1016/j.jaci.2011.09.028			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22035657				2022-12-18	WOS:000299951700042
J	Cruse, G; Singh, SR; Duffy, SM; Doe, C; Saunders, R; Brightling, CE; Bradding, P				Cruse, Glenn; Singh, Shailendra R.; Duffy, S. Mark; Doe, Camille; Saunders, Ruth; Brightling, Chris E.; Bradding, Peter			Functional K(Ca)3.1 K+ channels are required for human fibrocyte migration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pulmonary fibrosis; asthma; fibrocyte; cell migration; ion channel; K(Ca)3.1; patch clamp electrophysiology	PERIPHERAL-BLOOD FIBROCYTES; INTERMEDIATE-CONDUCTANCE; CIRCULATING FIBROCYTES; ASTHMA; ACTIVATION; MYOFIBROBLASTS; FIBROBLASTS; PROGENITOR; ICA-17043; PATHWAY	Background: Fibrocytes are bone marrow-derived CD34(+) collagen I-positive cells present in peripheral blood that develop alpha-smooth muscle actin expression and contractile activity in tissue culture. They are implicated in the pathogenesis of tissue remodeling and fibrosis in both patients with asthma and those with idiopathic pulmonary fibrosis. Targeting fibrocyte migration might therefore offer a new approach for the treatment of these diseases. Ion channels play key roles in cell function, but the ion-channel repertoire of human fibrocytes is unknown. Objective: We sought to examine whether human fibrocytes express the K(Ca)3.1 K+ channel and to determine its role in cell differentiation, survival, and migration. Methods: Fibrocytes were cultured from the peripheral blood of healthy subjects and patients with asthma. Whole-cell patch-lamp electrophysiology was used for the measurement of ion currents, whereas mRNA and protein were examined to confirm channel expression. Fibrocyte migration and proliferation assays were performed in the presence of K(Ca)3.1 ion-channel blockers. Results: Human fibrocytes cultured from the peripheral blood of both healthy control subjects and asthmatic patients expressed robust K(Ca)3.1 ion currents together with K(Ca)3.1 mRNA and protein. Two specific and distinct K(Ca)3.1 blockers (TRAM-34 and ICA-17043) markedly inhibited fibrocyte migration in transwell migration assays. Channel blockers had no effect on fibrocyte growth, apoptosis, or differentiation in cell culture. Conclusions: The K+ channel K(Ca)3.1 plays a key role in human fibrocyte migration. Currently available K(Ca)3.1-channel blockers might therefore attenuate tissue fibrosis and remodeling in patients with diseases such as idiopathic pulmonary fibrosis and asthma through the inhibition of fibrocyte recruitment. (J Allergy Clin Immunol 2011;128:1303-9.)	[Cruse, Glenn; Singh, Shailendra R.; Duffy, S. Mark; Doe, Camille; Saunders, Ruth; Brightling, Chris E.; Bradding, Peter] Univ Leicester, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester, Leics, England	University of Leicester	Bradding, P (corresponding author), Glenfield Hosp, Dept Resp Med, Groby Rd, Leicester LE3 9QP, Leics, England.	pbradding@hotmail.com	Cruse, Glenn/B-4597-2012; Cruse, Glenn/AAZ-1093-2021	Saunders, Ruth Mary/0000-0001-8893-6687; Bradding, Peter/0000-0001-8403-0319; brightling, chris/0000-0002-9345-4903; Cruse, Glenn/0000-0002-7511-0082	Wellcome Trust [082265]; Asthma UK [07/007]; ERDF [05567]; GlaxoSmithKline; Novartis; Chiesi; MedImmune; AstraZeneca	Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK; ERDF(European Commission); GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Chiesi(Chiesi Pharmaceuticals Inc); MedImmune(AstraZenecaMedimmune); AstraZeneca(AstraZeneca)	Supported by a Wellcome Trust Senior Clinical Fellowship (grant 082265) and Asthma UK (grant 07/007). This research was conducted in laboratories part-funded by ERDF no. 05567.; R. Saunders receives research support from Asthma UK. C. E. Brightling has consultant arrangements with GlaxoSmithKline, Novartis, Genentech, Roche, Chiesi, MedImmune, and AstraZeneca and receives research support from GlaxoSmithKline, Novartis, Chiesi, MedImmune, and AstraZeneca. P. Bradding has had consultant arrangements with Icagen, Inc. The rest of the authors have declared that they have no conflict of interest.	Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; Andersson-Sjoland A, 2008, INT J BIOCHEM CELL B, V40, P2129, DOI 10.1016/j.biocel.2008.02.012; Ataga KI, 2008, BLOOD, V111, P3991, DOI 10.1182/blood-2007-08-110098; Begenisich T, 2004, J BIOL CHEM, V279, P47681, DOI 10.1074/jbc.M409627200; Bellini A, 2007, LAB INVEST, V87, P858, DOI 10.1038/labinvest.3700654; Bradding P, 2009, BRIT J PHARMACOL, V157, P1330, DOI 10.1111/j.1476-5381.2009.00362.x; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; Chandy KG, 2004, TRENDS PHARMACOL SCI, V25, P280, DOI 10.1016/j.tips.2004.03.010; Chen MX, 2004, N-S ARCH PHARMACOL, V369, P602, DOI 10.1007/s00210-004-0934-5; Cruse G, 2006, THORAX, V61, P880, DOI 10.1136/thx.2006.060319; Duffy SM, 2005, FASEB J, V19, P1006, DOI 10.1096/fj.04-3439fje; Duffy SM, 2004, J ALLERGY CLIN IMMUN, V114, P66, DOI 10.1016/j.jaci.2004.04.005; Duffy SM, 2003, J ALLERGY CLIN IMMUN, V112, P965, DOI 10.1016/j.jaci.2003.07.004; Duffy SM, 2001, J IMMUNOL, V167, P4261, DOI 10.4049/jimmunol.167.8.4261; Epperly MW, 2003, AM J RESP CELL MOL, V29, P213, DOI 10.1165/rcmb.2002-0069OC; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Grgic I, 2009, PFLUG ARCH EUR J PHY, V458, P291, DOI 10.1007/s00424-008-0619-x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hashimoto N, 2004, J CLIN INVEST, V113, P243, DOI 10.1172/JCI200418847; Hollins F, 2008, J IMMUNOL, V181, P2772, DOI 10.4049/jimmunol.181.4.2772; Horuk R, 2009, NAT REV DRUG DISCOV, V8, P23, DOI 10.1038/nrd2734; Mehrad B, 2007, BIOCHEM BIOPH RES CO, V353, P104, DOI 10.1016/j.bbrc.2006.11.149; Muessel MJ, 2008, J IMMUNOL, V180, P8354, DOI 10.4049/jimmunol.180.12.8354; Nihlberg K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-50; Pedersen KA, 1999, BBA-BIOMEMBRANES, V1420, P231, DOI 10.1016/S0005-2736(99)00110-8; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Saunders R, 2009, J ALLERGY CLIN IMMUN, V123, P376, DOI 10.1016/j.jaci.2008.10.048; Schilling T, 2004, EUR J NEUROSCI, V19, P1469, DOI 10.1111/j.1460-9568.2004.03265.x; Schmidt M, 2003, J IMMUNOL, V171, P380, DOI 10.4049/jimmunol.171.1.380; SCHWAB A, 1995, PFLUG ARCH EUR J PHY, V430, P802, DOI 10.1007/BF00386179; Schwab A, 1999, CELL PHYSIOL BIOCHEM, V9, P126, DOI 10.1159/000016309; Shepherd MC, 2007, AM J RESP CELL MOL, V37, P525, DOI 10.1165/rcmb.2006-0358OC; Si H, 2006, CIRC RES, V99, P537, DOI 10.1161/01.RES.0000238377.08219.0c; Stocker JW, 2003, BLOOD, V101, P2412, DOI 10.1182/blood-2002-05-1433; Su LT, 2006, J BIOL CHEM, V281, P11260, DOI 10.1074/jbc.M512885200; Tharp DL, 2006, AM J PHYSIOL-HEART C, V291, pH2493, DOI 10.1152/ajpheart.01254.2005; Toyama K, 2008, J CLIN INVEST, V118, P3025, DOI 10.1172/JCI30836; Wang CH, 2008, AM J RESP CRIT CARE, V178, P583, DOI 10.1164/rccm.200710-1557OC; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Wykes RCE, 2007, J IMMUNOL, V179, P4045, DOI 10.4049/jimmunol.179.6.4045	41	33	37	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1303	U664		10.1016/j.jaci.2011.07.047	http://dx.doi.org/10.1016/j.jaci.2011.07.047			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21872912	Green Published, hybrid			2022-12-18	WOS:000298342700021
J	Zhang, Z; Linkin, DR; Finkelman, BS; O'Malley, BW; Thaler, ER; Doghramji, L; Kennedy, DW; Cohen, NA; Palmer, JN				Zhang, Zi; Linkin, Darren R.; Finkelman, Brian S.; O'Malley, Bert W., Jr.; Thaler, Erica R.; Doghramji, Laurel; Kennedy, David W.; Cohen, Noam A.; Palmer, James N.			Asthma and biofilm-forming bacteria are independently associated with revision sinus surgeries for chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Zhang, Zi; Finkelman, Brian S.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Linkin, Darren R.] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA; [O'Malley, Bert W., Jr.; Thaler, Erica R.; Doghramji, Laurel; Kennedy, David W.; Cohen, Noam A.; Palmer, James N.] Univ Penn, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Zhang, Z (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.	james.palmer@uphs.upenn.edu		Linkin, Darren R./0000-0002-2408-0987; Finkelman, Brian/0000-0002-4348-8208; Cohen, Noam/0000-0002-9462-3932				Banerji A, 2007, AM J RHINOL, V21, P19, DOI 10.2500/ajr.2007.21.2979; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Fokkens W, 2007, RHINOLOGY, V45, P97; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; Prince AA, 2008, AM J RHINOL, V22, P239, DOI 10.2500/ajr.2008.22.3180; Psaltis AJ, 2008, AM J RHINOL, V22, P1, DOI 10.2500/ajr.2008.22.3119; Richtsmeier WJ, 2001, LARYNGOSCOPE, V111, P1952, DOI 10.1097/00005537-200111000-00015	9	33	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					221	223		10.1016/j.jaci.2011.02.022	http://dx.doi.org/10.1016/j.jaci.2011.02.022			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21439623				2022-12-18	WOS:000292245600033
J	Rosenlund, H; Kull, I; Pershagen, G; Wolk, A; Wickman, M; Bergstrom, A				Rosenlund, Helen; Kull, Inger; Pershagen, Goran; Wolk, Alicja; Wickman, Magnus; Bergstrom, Anna			Fruit and vegetable consumption in relation to allergy: Disease-related modification of consumption?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; rhinitis; asthma; eczema; atopy; reverse causation; FFQ; fruit; vegetables	SCHOOL-CHILDREN; BIRTH COHORT; FOOD HYPERSENSITIVITY; MEDITERRANEAN DIET; CHILDHOOD ASTHMA; POLLEN ALLERGY; SYMPTOMS; HEALTH; AGE; SENSITIZATION	Background: Previous largely cross-sectional studies suggest that fruit and vegetable consumption reduces the risk of allergic disease in children, but results are conflicting. Objective: To investigate the association between current fruit or vegetable intake and allergic disease in 8-year-old Swedish children, and to evaluate the potential effect of disease-related modification of consumption. Methods: Cross-sectional data were obtained from a Swedish birth cohort study. Information on fruit and vegetable consumption as well as symptoms and diagnoses of allergic diseases was obtained by parental questionnaires at the 8-year follow-up. Allergen-specific IgE levels against food and inhalant allergens were obtained from blood samples collected at age 8 years. In total, 2447 children were included. Data were analyzed with logistic regression. Results: An inverse relation was observed between total fruit consumption and rhinitis (odds ratio, highest vs lowest quartile, 0.62; 95% CI, 0.45-0.86; P for trend,.002), whereas no association was observed for total vegetable intake. In analyses of individual foods, intake of apples/pears and carrots was inversely associated with rhinitis, asthma, and atopic sensitization. Fifty percent of the children with rhinitis were sensitized against birch pollen, which may cross-react with apples and carrots. After exclusion of children who reported food-related allergic symptoms, most of the observed inverse associations moved toward the null and became nonsignificant. Conclusion: We confirm the inverse associations between fruit intake and allergic disease in children observed in earlier studies. However, our data also indicate that disease-related modification of consumption contributed to this association. (J Allergy Clin Immunol 2011;127:1219-25.)	[Rosenlund, Helen] Karolinska Inst, Environm Epidemiol Unit, Inst Environm Med, SE-17177 Stockholm, Sweden; [Rosenlund, Helen; Kull, Inger] Karolinska Inst, Ctr Allergy Res, SE-17177 Stockholm, Sweden; [Wickman, Magnus] Soder Sjukhuset, Sachs Childrens Hosp, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital	Rosenlund, H (corresponding author), Karolinska Inst, Environm Epidemiol Unit, Inst Environm Med, Box 210, SE-17177 Stockholm, Sweden.	helen.rosenlund@ki.se		Kull, Inger/0000-0001-6096-3771; Pershagen, Goran/0000-0002-9701-1130	Stockholm County Council; Heart and Lung Foundation; Swedish Asthma and Allergy Association; Swedish Foundation for Health Care Science and Allergy Research; Swedish Research Council; MSD	Stockholm County Council(Stockholm County Council); Heart and Lung Foundation(Swedish Heart-Lung Foundation); Swedish Asthma and Allergy Association; Swedish Foundation for Health Care Science and Allergy Research; Swedish Research Council(Swedish Research CouncilEuropean Commission); MSD	Supported by the Stockholm County Council, the Heart and Lung Foundation, the Swedish Asthma and Allergy Association, the Swedish Foundation for Health Care Science and Allergy Research, and the Swedish Research Council.; Disclosure of potential conflict of interest: M. Wickman has received lecture fees from MSD and is a consultant for AstraZeneca. The rest of the authors have declared that they have no conflict of interest.	ANDERSEN MB, 2009, CLIN REV ALLERG 1023; Antova T, 2003, THORAX, V58, P231, DOI 10.1136/thorax.58.3.231; Asarnoj A, 2008, CLIN EXP ALLERGY, V38, P1507, DOI 10.1111/j.1365-2222.2008.03046.x; Bohle B, 2007, ALLERGY, V62, P3, DOI 10.1111/j.1398-9995.2006.01258.x; Brugman E, 1998, EUR J CLIN NUTR, V52, P577, DOI 10.1038/sj.ejcn.1600609; Chatzi L, 2007, THORAX, V62, P677, DOI 10.1136/thx.2006.069419; Chatzi L, 2007, PEDIAT ALLERG IMM-UK, V18, P480, DOI 10.1111/j.1399-3038.2007.00596.x; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Farchi S, 2003, EUR RESPIR J, V22, P772, DOI 10.1183/09031936.03.00006703; Forastiere F, 2000, THORAX, V55, P283, DOI 10.1136/thorax.55.4.283; Garcia-Marcos L, 2007, THORAX, V62, P503, DOI 10.1136/thx.2006.060020; Greene LS, 1999, NUTRITION, V15, P899, DOI 10.1016/S0899-9007(99)00209-9; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; Kim JL, 2005, INDOOR AIR, V15, P170, DOI 10.1111/j.1600-0668.2005.00334.x; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Mai XM, 2008, ALLERGY, V63, P1499, DOI 10.1111/j.1398-9995.2008.01792.x; Marmsjo K, 2009, AM J CLIN NUTR, V90, P1693, DOI 10.3945/ajcn.2009.27963; Murray CS, 2006, ALLERGY, V61, P438, DOI 10.1111/j.1398-9995.2005.00927.x; Nja F, 2005, ACTA PAEDIATR, V94, P147, DOI 10.1080/08035250410023638; Okoko BJ, 2007, EUR RESPIR J, V29, P1161, DOI 10.1183/09031936.00097806; Ostblom E, 2008, CLIN EXP ALLERGY, V38, P1325, DOI 10.1111/j.1365-2222.2008.03010.x; Romieu I, 2005, INT J TUBERC LUNG D, V9, P362; RONA RJ, 1987, BRIT MED J, V294, P863, DOI 10.1136/bmj.294.6576.863; Roumelioti M, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-8; Tabak C, 2006, THORAX, V61, P1048, DOI 10.1136/thx.2005.043034; Vereecken CA, 2003, PUBLIC HEALTH NUTR, V6, P581, DOI 10.1079/PHN2003466; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567	30	33	36	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1219	1225		10.1016/j.jaci.2010.11.019	http://dx.doi.org/10.1016/j.jaci.2010.11.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21215999				2022-12-18	WOS:000290018600017
J	Schnabel, E; Heinrich, J				Schnabel, Eva; Heinrich, Joachim		LISA Study Grp	Respiratory tract infections and not paracetamol medication during infancy are associated with asthma development in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RHINOVIRUS ILLNESSES; POLLEN ALLERGEN; RAGWEED-POLLEN; CHILDREN; ACETAMINOPHEN; IBUPROFEN; RISK		[Schnabel, Eva; Heinrich, Joachim] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol, Neuherberg, Germany; [Schnabel, Eva] Univ Munich, Childrens Hosp, Dr Von Haunerschen Kinderspital, D-8000 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Schnabel, E (corresponding author), Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol, Neuherberg, Germany.	Schnabel@helmholtz-muenchen.de	Heinrich, Joachim/N-1720-2013	Heinrich, Joachim/0000-0002-9620-1629				Beasley R, 2008, LANCET, V372, P1039, DOI 10.1016/S0140-6736(08)61445-2; Farquhar H, 2009, J ALLERGY CLIN IMMUN, V124, P649, DOI 10.1016/j.jaci.2009.07.037; GRAHAM NMH, 1990, J INFECT DIS, V162, P1277, DOI 10.1093/infdis/162.6.1277; Heinrich J, 2002, EUR RESPIR J, V20, P617, DOI 10.1183/09031936.02.02322001; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jahn-Schmid B, 2002, J IMMUNOL, V169, P6005, DOI 10.4049/jimmunol.169.10.6005; Kang EM, 2009, OBSTET GYNECOL, V114, P1295, DOI 10.1097/AOG.0b013e3181c225c0; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lesko SM, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e20; Tapiainen T, 2010, J ALLERGY CLIN IMMUN, V125, P751, DOI 10.1016/j.jaci.2009.11.039; Wopfner N, 2009, MOL IMMUNOL, V46, P2090, DOI 10.1016/j.molimm.2009.02.005	12	33	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					1071	1073		10.1016/j.jaci.2010.08.023	http://dx.doi.org/10.1016/j.jaci.2010.08.023			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20888627				2022-12-18	WOS:000283727100026
J	Freudenberg, F; Wintergerst, U; Roesen-Wolff, A; Albert, MH; Prell, C; Strahm, B; Koletzko, S; Ehl, S; Roos, D; Tommasini, A; Ventura, A; Belohradsky, BH; Seger, R; Roesler, J; Gungor, T				Freudenberg, Folke; Wintergerst, Uwe; Roesen-Wolff, Angela; Albert, Michael H.; Prell, Christine; Strahm, Brigitte; Koletzko, Sibylle; Ehl, Stephan; Roos, Dirk; Tommasini, Alberto; Ventura, Alessandro; Belohradsky, Bernd H.; Seger, Reinhard; Roesler, Joachim; Guengoer, Tayfun			Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EUROPEAN EXPERIENCE; COLITIS		[Freudenberg, Folke; Prell, Christine; Koletzko, Sibylle] Univ Munich, Dr v Haunersches Kinderspital, Div Gastroenterol, Munich, Germany; [Roesen-Wolff, Angela; Roesler, Joachim] Univ Hosp Dresden, Dept Pediat, Dresden, Germany; [Roos, Dirk] Univ Amsterdam, Acad Med Ctr, Sanquin Res & Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands; [Wintergerst, Uwe] St Joseph Hosp, Braunau, Austria; [Seger, Reinhard; Guengoer, Tayfun] Univ Childrens Hosp, Div Immunol Hematol BMT, Zurich, Switzerland; [Strahm, Brigitte; Ehl, Stephan] Univ Freiburg, Dept Pediat Hematol & Oncol, Ctr Pediat & Adolescent Med, Freiburg, Germany; [Tommasini, Alberto; Ventura, Alessandro] Childrens Hosp IRCCS Burlo Garofolo, Dept Pediat, Inst Child Hlth, Trieste, Italy; [Wintergerst, Uwe; Belohradsky, Bernd H.] Univ Munich, Dr v Haunersches Kinderspital, Div Immunol, Munich, Germany; [Albert, Michael H.] Univ Munich, Dr v Haunersches Kinderspital, Div Hematol Oncol Stem Cell Transplantat, Munich, Germany	University of Munich; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University Children's Hospital Zurich; University of Freiburg; IRCCS Burlo Garofolo; University of Munich; University of Munich	Freudenberg, F (corresponding author), Univ Munich, Dr v Haunersches Kinderspital, Div Gastroenterol, Munich, Germany.	roeslerj@rcs.urz.tu-dresden.de	Ehl, Stephan/AAM-6006-2020; Güngör, Tayfun/ABF-4256-2020; Tommasini, Alberto/AAE-3882-2020	Güngör, Tayfun/0000-0002-3261-1186; Tommasini, Alberto/0000-0002-6943-7927; Ehl, Stephan/0000-0002-9265-2721; Wintergerst, Uwe/0000-0002-0785-0337; Ventura, Alessandro/0000-0002-4657-1760				Gungor T, 2005, TRANSPLANTATION, V79, P1596, DOI 10.1097/01.TP.0000163466.73485.5E; Marciano BE, 2004, PEDIATRICS, V114, P462, DOI 10.1542/peds.114.2.462; Mauch L, 2007, CLIN CHEM, V53, P890, DOI 10.1373/clinchem.2006.083444; Roesler J, 2000, BLOOD, V95, P2150, DOI 10.1182/blood.V95.6.2150; Schappi MG, 2003, J PEDIATR GASTR NUTR, V36, P623, DOI 10.1097/00005176-200305000-00006; Schappi MG, 2001, ARCH DIS CHILD, V84, P147, DOI 10.1136/adc.84.2.147; Seger RA, 2002, BLOOD, V100, P4344, DOI 10.1182/blood-2002-02-0583; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234	8	33	35	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					943	946		10.1016/j.jaci.2010.01.035	http://dx.doi.org/10.1016/j.jaci.2010.01.035			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20371400				2022-12-18	WOS:000276787900025
J	Busse, WW				Busse, William W.			The National Institutes of Allergy and Infectious Diseases networks on asthma in inner-city children: An approach to improved care	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; inner city; cockroach sensitivity; asthma treatment	IMMUNOTHERAPY; EXACERBATIONS; HEALTH; RISK; PAT	Asthma in inner-city children is prevalent, has increased severity, and for many patients poses difficulty in achieving control. Although some of the limitations to asthma control in inner-city children include socioeconomic burdens, other factors, such as environmental allergens, pollutants, infections, and stress, contribute significantly to the disease burden found in these children. As a consequence of these unmet needs for asthma control in inner-city children, the National Institute of Allergy and Infectious Diseases established research networks with an ultimate goal of improving care for this at-risk population. The Inner-City Asthma Network Program began in 1991 and has, over the ensuing years, funded 3 distinct networks that have a common goal: to improve care for the child with asthma. Each of these networks has expanded our knowledge about asthma in the inner cities and asthma in general. The National Institute of Allergy and Infectious Diseases' efforts continue with the current inner-city network, the Inner City Asthma Consortium 2. The following article will discuss the application of these inner-city networks to the study of asthma, the contributions of each of the individual networks, and how newly proposed efforts under the Inner City Asthma Consortium 2 propose to improve our understanding and eventual control of asthma in inner-city children. (J Allergy Clin Immunol 2010;125:529-37.)	Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, J5-219 CSC,Box 2454,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu			National Institutes of Health; National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Novartis; AstraZeneca; GlaxoSmithKline; MedImmune; Ception	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Novartis(Novartis); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Ception	W.W. Busse is on advisory boards for Altair, GlaxoSmithKline, Merck, Wyeth, Pfizer, Centocor, Amgen, and Johnson & Johnson; is a speaker for Merck; is a consultant for Novartis, AstraZeneca, TEVA, and Boehringer Ingelheim; and has received research support from the National Institutes of Health, National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, Novartis, AstraZeneca, GlaxoSmithKline, MedImmune, and Ception.; Supported by the National Institutes of Health Inner City Asthma Consortium, contract HHSN272200900052C.	Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; [Anonymous], 2006, LANCET, V368, P705; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Busse WW, 2007, J ALLERGY CLIN IMMUN, V119, P43, DOI 10.1016/j.jaci.2006.10.021; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Esch RE, 2008, CURR OPIN OTOLARYNGO, V16, P260, DOI 10.1097/MOO.0b013e3282fc706f; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Frew AJ, 2008, NEW ENGL J MED, V358, P2259, DOI 10.1056/NEJMct0708337; Galea S, 2005, ANNU REV PUBL HEALTH, V26, P341, DOI 10.1146/annurev.publhealth.26.021304.144708; Gern JE, 2010, J ALLERGY CLIN IMMUN, V125, P545, DOI 10.1016/j.jaci.2010.01.037; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Gruchalla RS, 2009, J ALLERGY CLIN IMMUN, V124, P213, DOI 10.1016/j.jaci.2009.05.036; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KANG BC, 1988, J ASTHMA, V25, P205, DOI 10.3109/02770908809071367; Kelly JT, 2008, J ALLERGY CLIN IMMUN, V122, P671, DOI 10.1016/j.jaci.2008.08.013; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sears MR, 2008, J ALLERGY CLIN IMMUN, V122, P662, DOI 10.1016/j.jaci.2008.08.003; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Smith LA, 2005, PUBLIC HEALTH REP, V120, P109, DOI 10.1177/003335490512000203; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P521, DOI 10.1016/j.jaci.2010.01.025; VAN VI, 2008, ALLERGY, V63, P570; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; WILSON DR, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD002893, 10.1002/14651858]	37	33	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					529	537		10.1016/j.jaci.2010.01.036	http://dx.doi.org/10.1016/j.jaci.2010.01.036			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226289	Green Accepted			2022-12-18	WOS:000275883200004
J	Lee, SJ; Chinen, J; Kavanaugh, A				Lee, Susan J.; Chinen, Javier; Kavanaugh, Arthur			Immunomodulator therapy: Monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Monoclonal antibodies; fusion proteins; immunoglobulins; cytokines; autoimmunity	PLACEBO-CONTROLLED TRIAL; ACTIVE RHEUMATOID-ARTHRITIS; INTERLEUKIN-6 RECEPTOR INHIBITION; MODIFYING ANTIRHEUMATIC DRUGS; CHRONIC PLAQUE PSORIASIS; NECROSIS FACTOR THERAPY; LONG-TERM EFFICACY; PHASE-III TRIAL; DOUBLE-BLIND; ANKYLOSING-SPONDYLITIS	The immune system consists of a diverse array of immunocompetent cells and inflammatory mediators that exist in complex networks. These components interact through cascades and feedback circuits, maintaining physiologic inflammation (eg, tissue repair) and immunosurveillance. In various autoimmune and allergic diseases, a foreign antigen or autoantigen might upset this fine balance, leading to dysregulated immunity, persistent inflammation, and ultimately pathologic sequelae. In recent years, there has been tremendous progress delineating the specific components of the immune system that contribute to various aspects of normal immunity and specific disease states. With this greater understanding of pathogenesis coupled with advances in biotechnology, many immunomodulatory agents commonly called "biologic agents'' have been introduced into the clinic for the treatment of various conditions, including immune globulins and cytokines. The 2 most common classes of approved biologic agents are mAbs and fusion proteins with exquisite specificity. These agents have the potential both to optimize outcomes through more thorough modulation of specific parts of the dysregulated immune response and to minimize toxicity compared with less specific methods of immunosuppression. (J Allergy Clin Immunol 2010;125:S314-23.)	[Lee, Susan J.; Kavanaugh, Arthur] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA; [Lee, Susan J.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Chinen, Javier] Baylor Coll Med, Dept Pediat, Allergy & Immunol Sect, Houston, TX 77030 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Baylor College of Medicine	Kavanaugh, A (corresponding author), Univ Calif San Diego, Div Rheumatol Allergy & Immunol, 9500 Gilman Dr,Mail Code 0943, La Jolla, CA 92093 USA.	akavanaugh@ucsd.edu			Amgen; UCB; Abbott; Centocor; Roche; BMS; Genentech; Biogen Idec	Amgen(Amgen); UCB(UCB Pharma SA); Abbott(Abbott Laboratories); Centocor; Roche(Roche Holding); BMS(Bristol-Myers Squibb); Genentech(Roche HoldingGenentech); Biogen Idec(Biogen)	A. Kavanaugh has received research support from Amgen, UCB, Abbott, Centocor, Roche, BMS, Genentech, and Biogen Idec. S. J. Lee and J. Chinen have declared that they have no conflict of interest.	Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315; Antoni CE, 2008, J RHEUMATOL, V35, P869; Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; Ballow M, 2008, J ALLERGY CLIN IMMUN, V122, P1038, DOI 10.1016/j.jaci.2008.08.012; Baraliakos X, 2005, ARTHRIT RHEUM-ARTHR, V53, P856, DOI 10.1002/art.21588; Breedveld FC, 2006, ARTHRITIS RHEUM-US, V54, P26, DOI 10.1002/art.21519; Calabrese LH, 2008, ANN RHEUM DIS, V67, P64, DOI 10.1136/ard.2008.097972; Clair EWS, 2004, ARTHRITIS RHEUM-US, V50, P3432, DOI 10.1002/art.20568; Cohen SB, 2006, ARTHRITIS RHEUM-US, V54, P2793, DOI 10.1002/art.22025; Coppin C, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006017.pub2; Durelli L, 2009, ANN NEUROL, V65, P499, DOI 10.1002/ana.21652; Emery P, 2008, ANN RHEUM DIS, V67, P1516, DOI 10.1136/ard.2008.092932; Emery P, 2006, ARTHRITIS RHEUM, V54, P1390, DOI 10.1002/art.21778; Furst DE, 2003, J RHEUMATOL, V30, P2563; Genovese MC, 2008, ANN RHEUM DIS, V67, P547, DOI 10.1136/ard.2007.074773; Genovese MC, 2008, ARTHRITIS RHEUM-US, V58, P2968, DOI 10.1002/art.23940; Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308; Gottlieb A, 2009, LANCET, V373, P633, DOI 10.1016/S0140-6736(09)60140-9; Hanauer SB, 2006, GASTROENTEROLOGY, V130, P323, DOI 10.1053/j.gastro.2005.11.030; Hoffman HM, 2008, ARTHRITIS RHEUM, V58, P2443, DOI 10.1002/art.23687; HOLLAND SM, 2009, CLIN REV ALLERGY IMM; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Hutchinson M, 2009, J NEUROL, V256, P405, DOI 10.1007/s00415-009-0093-1; Hyrich KL, 2007, ARTHRITIS RHEUM-US, V56, P13, DOI 10.1002/art.22331; Inman RD, 2008, ARTHRITIS RHEUM-US, V58, P3402, DOI 10.1002/art.23969; KAPOOR D, 2007, RHEUM DIS CLIN UPDAT, V2, P1; Kay J, 2008, ARTHRITIS RHEUM-US, V58, P964, DOI 10.1002/art.23383; Keystone E, 2008, ARTHRITIS RHEUM, V58, P3319, DOI 10.1002/art.23964; Keystone E, 2007, ARTHRITIS RHEUM-US, V56, P3896, DOI 10.1002/art.23059; Kremer JM, 2008, ARTHRITIS RHEUM, V58, P953, DOI 10.1002/art.23397; Krueger GG, 2008, J DERMATOL TREAT, V19, P146, DOI 10.1080/09546630701846103; Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382; Landewe R, 2006, ARTHRITIS RHEUM-US, V54, P3119, DOI 10.1002/art.22143; Lee SJ, 2005, J ALLERGY CLIN IMMUN, V116, P900, DOI 10.1016/j.jaci.2005.03.028; Levy Y, 2009, J CLIN INVEST, V119, P997, DOI 10.1172/JCI38052; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Lovell DJ, 2008, NEW ENGL J MED, V359, P810, DOI 10.1056/NEJMoa0706290; Maini RN, 2004, ARTHRITIS RHEUM-US, V50, P1051, DOI 10.1002/art.20159; Mease PJ, 2006, ARTHRITIS RHEUM-US, V54, P1638, DOI 10.1002/art.21870; Mease PJ, 2004, ARTHRITIS RHEUM-US, V50, P2264, DOI 10.1002/art.20335; Mease PJ, 2005, ARTHRITIS RHEUM-US, V52, P3279, DOI 10.1002/art.21306; Mitsuyasu R, 2007, ARCH INTERN MED, V167, P597, DOI 10.1001/archinte.167.6.597; Moreland LW, 2006, J RHEUMATOL, V33, P854; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Nishimoto N, 2007, ANN RHEUM DIS, V66, P1162, DOI 10.1136/ard.2006.068064; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; Ross JB, 2008, J CUTAN MED SURG, V12, P8, DOI 10.2310/7750.2008.07050; Rozenblit M, 2009, DERMATOL THER, V22, P56, DOI 10.1111/j.1529-8019.2008.01216.x; Ruperto N, 2007, ARTHRITIS RHEUM-US, V56, P3096, DOI 10.1002/art.22838; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; Sandborn WJ, 2007, NEW ENGL J MED, V357, P228, DOI 10.1056/NEJMoa067594; Sandborn WJ, 2001, GASTROENTEROLOGY, V121, P1088, DOI 10.1053/gast.2001.28674; Schiff M, 2008, ANN RHEUM DIS, V67, P1096, DOI 10.1136/ard.2007.080002; Schreiber S, 2007, NEW ENGL J MED, V357, P239, DOI 10.1056/NEJMoa062897; Sieper J, 2005, RHEUMATOLOGY, V44, P1525, DOI 10.1093/rheumatology/kei046; Slavin RG, 2009, J ALLERGY CLIN IMMUN, V123, P107, DOI 10.1016/j.jaci.2008.09.050; Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140-6736(08)60453-5; Sugiyama H, 2008, CLIN DERMATOL, V26, P503, DOI 10.1016/j.clindermatol.2007.10.028; Tarhini AA, 2008, CANCER, V113, P1632, DOI 10.1002/cncr.23791; Toth DP, 2008, DERMATOL THER, V21, pS6, DOI 10.1111/j.1529-8019.2008.00235.x; van der Heijde D, 2008, ANN RHEUM DIS, V67, P1218, DOI 10.1136/ard.2007.082529; van der Heijde D, 2005, ARTHRITIS RHEUM-US, V52, P582, DOI 10.1002/art.20852; van der Heijde D, 2008, ARTHRITIS RHEUM-US, V58, P3063, DOI 10.1002/art.23901; VANDERHEIJDE D, 2006, ARTHRITIS RHEUM, V54, P76; Waldmann TA, 2007, J CLIN IMMUNOL, V27, P1, DOI 10.1007/s10875-006-9060-0; Weinblatt M, 2006, ARTHRITIS RHEUM, V54, P2807, DOI 10.1002/art.22070; Weinblatt ME, 2003, ARTHRITIS RHEUM, V48, P855, DOI 10.1002/art.546; Welzel TM, 2009, HEPATOLOGY, V49, P1847, DOI 10.1002/hep.22877	69	33	38	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S314	S323		10.1016/j.jaci.2009.08.018	http://dx.doi.org/10.1016/j.jaci.2009.08.018			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20036416				2022-12-18	WOS:000280170600029
J	Takeda, N; Maghni, K; Daigle, S; L'Archeveque, J; Castellanos, L; Al-Ramli, W; Malo, JL; Hamid, Q				Takeda, Naoya; Maghni, Karim; Daigle, Sylvie; L'Archeveque, Jocelyne; Castellanos, Lucero; Al-Ramli, Wisam; Malo, Jean-Luc; Hamid, Qutayba			Long-term pathologic consequences of acute irritant-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway hyperresponsiveness (AHR); basement membrane thickness; eosinophil; inflammation; irritant-induced asthma	BRONCHIAL SUBEPITHELIAL FIBROSIS; AIRWAYS DYSFUNCTION SYNDROME; PERSISTENT ASTHMA; ACCIDENTAL EXPOSURE; TISSUE INHIBITOR; EXPRESSION; RESPONSIVENESS; MATRIX-METALLOPROTEINASE-9; INFLAMMATION; INHALATION	Background: Acute irritant-induced asthma (IrIa) or reactive airways dysfunction syndrome is caused by exposure to a high concentration of an agent. The long-term pathologic consequences of IrIa remain thus far unknown. Objective: The aim of our study was to investigate the chronic airway inflammation and remodeling that occur in association with IrIa. Methods: Ten subjects with a history of IrIa (mean interval of 10.9 years, minimum of 4 years, since the inhalational accident) underwent bronchoscopy followed by bronchoalveolar lavage and bronchial biopsies. Immunologic and morphologic data from patients with IrIa were compared with those of patients with mild to moderate asthma as well as healthy controls. Results: Bronchoalveolar lavage fluid analysis showed increased eosinophil and neutrophil counts in 30% and 60% of subjects with IrIa, respectively. In the supernatant of bronchoalveolar lavage, we found a significant increase in the majority of mediators compared with healthy subjects and a significant increase in eosinophilic cationic protein, IL-8, basic fibroblast growth factor, and matrix metalloproteinase 1 compared with control patients with asthma. Evaluation of basement membrane thickness (subepithelial fibrosis) demonstrated a significant increase in patients with IrIa compared with healthy subjects and subjects with asthma. Basement membrane thickness also significantly correlated with the PC20 value. The epithelial cell detachment showed an elevated although not significant trend compared with subjects with asthma and control subjects. Immunocytochemical analysis demonstrated increases in the number of eosinophil cationic protein and TGF-beta 1-positive cells compared with healthy controls. Conclusion: This study provides evidence of a significant eosinophilic and neutrophilic inflammation as well as remodeling in IrIa many years after an inhalational accident. (J Allergy Clin Immunol 2009;124:975-81.)	[Takeda, Naoya; Al-Ramli, Wisam; Hamid, Qutayba] McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; [Maghni, Karim; Daigle, Sylvie; L'Archeveque, Jocelyne; Castellanos, Lucero; Malo, Jean-Luc] Hop Sacre Coeur Montreal, Montreal, PQ, Canada	McGill University; Universite de Montreal	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca			Center for Asthma in the Workplace; Canadian Institutes for Health Research; Canadian and Quebec Lung Associations; Institut de recherche Robert-Sauve en sante et securite du travail du Quebec	Center for Asthma in the Workplace(Canadian Institutes of Health Research (CIHR)); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian and Quebec Lung Associations; Institut de recherche Robert-Sauve en sante et securite du travail du Quebec	Supported by the Center for Asthma in the Workplace, Canadian Institutes for Health Research, the Canadian and Quebec Lung Associations, and the Institut de recherche Robert-Sauve en sante et securite du travail du Quebec.	Aghanouri R, 2004, AM J PHYSIOL-LUNG C, V287, pL1160, DOI 10.1152/ajplung.00169.2003; Alberts WM, 1996, CHEST, V109, P1618, DOI 10.1378/chest.109.6.1618; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; Bernstein I. L., 2006, ASTHMA WORKPLACE, V3, P1; BERSNTEIN IL, 2006, ASTHMA WORKPLACE, P319; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676, DOI 10.1164/ajrccm.149.6.8004329; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Demnati R, 1998, EUR RESPIR J, V11, P922, DOI 10.1183/09031936.98.11040922; DESCHAMPS D, 1994, CHEST, V105, P1895, DOI 10.1378/chest.105.6.1895; DESCHAMPS D, 1992, BRIT J IND MED, V49, P523; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P12, DOI 10.1016/0091-6749(94)90228-3; Gautrin D, 1999, AM J RESP CRIT CARE, V160, P1232, DOI 10.1164/ajrccm.160.4.9811074; Gautrin D, 2006, ASTHMA WORKPLACE, P579; Ghanei M, 2008, RESP MED, V102, P825, DOI 10.1016/j.rmed.2008.01.016; Han Z, 2003, RESP MED, V97, P563, DOI 10.1053/rmed.2001.1162; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Little SA, 2002, THORAX, V57, P247, DOI 10.1136/thorax.57.3.247; Malo JL, 2009, AM J RESP CRIT CARE, V179, P923, DOI 10.1164/rccm.200810-1550OC; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; Martin JG, 2003, AM J RESP CRIT CARE, V168, P568, DOI 10.1164/rccm.200201-021OC; Nemery B, 1996, EUR RESPIR J, V9, P1973, DOI 10.1183/09031936.96.09101973; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; Sagara H, 2002, J ALLERGY CLIN IMMUN, V110, P249, DOI 10.1067/mai.2002.126078; Sumi Y, 2007, CLIN EXP ALLERGY, V37, P1781, DOI 10.1111/j.1365-2222.2007.02828.x; TARLO SM, 1989, CHEST, V96, P297, DOI 10.1378/chest.96.2.297; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; WEILL H, 1987, B EUR PHYSIOPATH RES, V23, P587; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110	36	33	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					975	981		10.1016/j.jaci.2009.08.008	http://dx.doi.org/10.1016/j.jaci.2009.08.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895985				2022-12-18	WOS:000272108000015
J	Fukuda, K; Ohbayashi, M; Morohoshi, K; Zhang, L; Liu, FT; Ono, SJ				Fukuda, Ken; Ohbayashi, Masaharu; Morohoshi, Kei; Zhang, Lane; Liu, Fu-Tong; Ono, Santa J.			Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ocular allergy; mast cells; inflammation; IgE; eosinophil; bone marrow-derived mast cells; adoptive transfer; mast cell-deficient mouse	IMMUNE-MEDIATED BLEPHAROCONJUNCTIVITIS; LATE-PHASE REACTION; VERNAL KERATOCONJUNCTIVITIS; AIRWAY HYPERRESPONSIVENESS; DEFICIENT MICE; C57BL/6 MICE; T-CELLS; INFLAMMATION; ASTHMA; HETEROGENEITY	Background: Allergic conjunctivitis is characterized by allergen-specific IgE in the serum and infiltration of eosinophils into the conjunctiva. The role of IgE and mast cells in allergic conjunctivitis is largely unknown, however. Objectives: We investigated the importance of conjunctival mast cells in a murine model of IgE-mediated allergic conjunctivitis. Methods: IgE-mediated allergic conjunctivitis was initiated in C57BL/6-Kit(+/+) wild-type mice, mast cell-deficient Kit(W-sh/W-sh) mice, and Kit(W-sh/W-sh) mice that had been subconjunctivally or systemically engrafted with bone marrow-derived, cultured mast cells (BMCMCs) from Kit(+/+) wild-type mice, and clinical symptoms and infiltration of eosinophil of the eyes were evaluated. Total numbers of mast cells in the conjunctiva were counted, and the phenotypes of these cells were characterized by means of immunostaining and PCR analysis of murine mast cell proteases. Results: No mast cells were detected in the conjunctiva or eyelid dermis of adult Kit(W-sh/W-sh) mice. Subconjunctival injection of BMCMCs resulted in local mast cell reconstitution, with the numbers of reconstituted mast cells in the conjunctiva and eyelid dermis comparable with those observed in wild-type Kit(+/+) littermates. Reconstituted and naive conjunctival mast cells expressed proteases ascribed to connective tissue-type mast cells but not mucosal mast cells. Passive transfer of ragweed-specific IgE followed by antigen challenge resulted in both early-phase clinical symptoms and late-phase eosinophilic inflammation in Kit(+/+) mice. These responses, which were significantly decreased in Kit(W-sh/W-sh) mice, were restored on reconstitution of the conjunctival mast cell population. Conclusions: These results suggest a direct contribution of IgE-activated mast cells to both the early-phase reaction and late-phase inflammation during ocular allergy. (J Allergy Clin Immunol 2009;124:827-33.)	[Fukuda, Ken; Ohbayashi, Masaharu; Morohoshi, Kei; Zhang, Lane; Ono, Santa J.] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA; [Liu, Fu-Tong] Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA	Emory University; University of California System; University of California Davis	Fukuda, K (corresponding author), Emory Univ, Sch Med, Dept Ophthalmol, 1365B Clifton Rd NE, Atlanta, GA 30322 USA.	kfukud2@emory.edu	Fukuda, Ken/A-3076-2011; Liu, FU-TONG/A-5749-2019	Fukuda, Ken/0000-0003-4990-6308; Liu, FU-TONG/0000-0002-3354-1001; Morohoshi, Kei/0000-0002-2891-9073	Japan Eye Bank Association; Bausch & Lomb Japan Overseas Research Fellowship; National Institutes of Health; Genentech	Japan Eye Bank Association; Bausch & Lomb Japan Overseas Research Fellowship; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genentech(Roche HoldingGenentech)	Supported in part by the Japan Eye Bank Association and a Bausch & Lomb Japan Overseas Research Fellowship to K. F.; Disclosure of potential conflict of interest: F.-T. Liu has received research support from the National Institutes of Health and Genentech. S. J. Ono is Chief Scientific Officer of iCo Therapeutics, Inc. The rest of the authors have declared that they have no conflict of interest,	Clair JMS, 2004, J CLIN INVEST, V113, P628, DOI 10.1172/JCI200419062; Fukuda Ken, 2006, Allergol Int, V55, P121, DOI 10.2332/allergolint.55.121; Fukushima A, 2006, EXP EYE RES, V82, P210, DOI 10.1016/j.exer.2005.06.010; Fukushima A, 2005, CURR EYE RES, V30, P241, DOI 10.1080/02713680590927560; Fukushima A, 2003, INVEST OPHTH VIS SCI, V44, P4366, DOI 10.1167/iovs.02-1323; Fukushima A, 2007, CORNEA, V26, pS36, DOI 10.1097/ICO.0b013e31812f6970; Fukushima A, 2006, CLIN EXP OPHTHALMOL, V34, P347, DOI 10.1111/j.1442-9071.2006.01221.x; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; IRANI AMA, 1994, ALLERGY PROC, V15, P303, DOI 10.2500/108854194778816472; Kumagai N, 2006, PROG RETIN EYE RES, V25, P165, DOI 10.1016/j.preteyeres.2005.09.002; Leonardi A, 2002, PROG RETIN EYE RES, V21, P319, DOI 10.1016/S1350-9462(02)00006-X; LIU FT, 1984, HYBRIDOMA, V3, P277, DOI 10.1089/hyb.1984.3.277; Magone MT, 1998, CLIN IMMUNOL IMMUNOP, V87, P75, DOI 10.1006/clin.1997.4507; Mayr SI, 2002, J IMMUNOL, V169, P2061, DOI 10.4049/jimmunol.169.4.2061; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Miyazaki D, 2005, J CLIN INVEST, V115, P434, DOI 10.1172/JCI200518452; Miyazaki D, 2008, MOL VIS, V14, P1525; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; Ono SJ, 2005, J ALLERGY CLIN IMMUN, V115, P118, DOI 10.1016/j.jaci.2004.10.042; Ozaki A, 2005, J IMMUNOL, V175, P5489, DOI 10.4049/jimmunol.175.8.5489; Ozaki A, 2003, GRAEF ARCH CLIN EXP, V241, P394, DOI 10.1007/s00417-003-0641-9; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Ueta M, 2007, J ALLERGY CLIN IMMUN, V120, P476, DOI 10.1016/j.jaci.2007.04.024; Welle M, 1997, J LEUKOCYTE BIOL, V61, P233, DOI 10.1002/jlb.61.3.233; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Wolters PJ, 2005, CLIN EXP ALLERGY, V35, P82, DOI 10.1111/j.1365-2222.2005.02136.x	27	33	35	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					827	833		10.1016/j.jaci.2009.06.012	http://dx.doi.org/10.1016/j.jaci.2009.06.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19660804				2022-12-18	WOS:000270802800030
J	Adams, RJ; Appleton, SL; Hill, CL; Ruffin, RE; Wilson, DH				Adams, Robert J.; Appleton, Sarah L.; Hill, Catherine L.; Ruffin, Richard E.; Wilson, David H.			Inadequate health literacy is associated with increased asthma morbidity in a population sample	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NEWEST VITAL SIGN; CARE		[Adams, Robert J.; Appleton, Sarah L.; Hill, Catherine L.; Ruffin, Richard E.; Wilson, David H.] Univ Adelaide, Hlth Observ, Woodville, SA, Australia; [Hill, Catherine L.] Queen Elizabeth Hosp, Rheumatol Unit, Woodville, SA 5011, Australia	University of Adelaide	Adams, RJ (corresponding author), Univ Adelaide, Hlth Observ, Queen Elizabeth Hosp Campus, Woodville, SA, Australia.	robert.adams@adelaide.edu.au	Appleton, Sarah/Y-5206-2019; Hill, Catherine L/AAE-7152-2019; Adams, Robert/Z-3197-2019; Appleton, Sarah/E-9149-2017	Hill, Catherine L/0000-0001-8289-4922; Appleton, Sarah/0000-0001-7292-9714				Apter AJ, 2006, J ASTHMA, V43, P705, DOI 10.1080/02770900600925585; BERKMAN N, 2004, AHRQ PUBLICATION; DeSalvo KB, 2006, QUAL LIFE RES, V15, P191, DOI 10.1007/s11136-005-0887-2; Mancuso CA, 2006, J GEN INTERN MED, V21, P813, DOI 10.1111/j.1525-1497.2006.00528.x; Osborn CY, 2007, AM J HEALTH BEHAV, V31, pS36; Paasche-Orlow MK, 2005, AM J RESP CRIT CARE, V172, P980, DOI 10.1164/rccm.200409-1291OC; Poureslami Iraj M, 2007, MedGenMed, V9, P40; Weiss BD, 2005, ANN FAM MED, V3, P514, DOI 10.1370/afm.405; Wilson DH., 1992, HLTH PROMOT J AUST, V2, P47	9	33	33	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					601	603		10.1016/j.jaci.2009.05.035	http://dx.doi.org/10.1016/j.jaci.2009.05.035			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19631974				2022-12-18	WOS:000274315900031
J	Schedel, M; Frei, R; Bieli, C; Cameron, L; Adamski, J; Lauener, R; Kabesch, M				Schedel, Michaela; Frei, Remo; Bieli, Christian; Cameron, Lisa; Adamski, Jerzy; Lauener, Roger; Kabesch, Michael			An IgE-associated polymorphism in STAT6 alters NF-kappa B binding, STAT6 promoter activity, and mRNA expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						STAT6; NF-kappa B binding; regulatory element; mRNA gene expression; splice variants	AIRWAY HYPERRESPONSIVENESS; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; SIGNAL TRANSDUCER; UP-REGULATION; CD14 GENE; ASTHMA; ACTIVATION; HAPLOTYPE; PATHWAYS	Background: The IL-4/IL-13 pathway is central for IgE regulation. Signal transducer and activator of transcription 6 (STAT6) is the major transcription factor within this pathway. STAT6 polymorphisms were recently associated with elevated total IgE levels in a genome-wide association study. Objective: This study aimed to assess biological mechanisms by which an IgE-associated genetic variation in STAT6 may potentially influence gene expression. Methods: STAT6 intron 2 carrying either the wild-type C or the polymorphic T allele of the putatively causal single nucleotide polymorphism rs324011 was cloned into STAT6 promoter vectors to investigate their influence on STAT6 promoter activity by in vitro luciferase assays. Transcription factor binding depending on rs324011 was examined by electrophoretic mobility shift assays in Jurkat T cells and primary CD4(+) T cells. Allele-specific STAT6 gene expression of 3 splice variants was studied ex vivo by real-time PCR in 239 individuals. Results: STAT6 intron 2 acts as a silencer regulatory element. The polymorphic T allele at rs324011 (in linkage disequilibrium with the genome-wide association signal and consistently associated with elevated IgE levels in 3 previous studies) increases STAT6 promoter activity significantly in vitro (P < .00001) and gene expression of STAT6 splice variants ex vivo (P < .01) compared with the wild-type C allele. These effects correlate with the creation of a novel, T-allele-specific binding site for the transcription factor nuclear factor-kappa B in T cells. Conclusion: The consistently replicated effects of genetic variance in STAT6 on IgE regulation may be explained in part by allele-specific alterations in nuclear factor-kappa B binding at rs324011 and consecutive changes in STAT6 gene expression. (J Allergy Clin Immunol 2009; 124: 583-9.)	[Schedel, Michaela; Kabesch, Michael] Hannover Med Sch, Clin Paediat Pneumol & Neonatol, Ctr Paediat, D-30625 Hannover, Germany; [Frei, Remo; Bieli, Christian; Lauener, Roger] Univ Zurich, Childrens Hosp, CH-8006 Zurich, Switzerland; [Cameron, Lisa] Univ Alberta, Edmonton, AB T6G 2M7, Canada; [Adamski, Jerzy] Helmholtz Zentrum Munchen, Genome Anal Ctr, Inst Expt Genet, Neuherberg, Germany; [Kabesch, Michael] Hosp Allergy, Hochgebirgsklin Davos Wolfgang, Davos, Switzerland	Hannover Medical School; University Children's Hospital Zurich; University of Zurich; University of Alberta; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Kabesch, M (corresponding author), Hannover Med Sch, Clin Paediat Pneumol & Neonatol, Ctr Paediat, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kabesch.Michael@mh-hannover.de	Kabesch, Michael/GZM-1583-2022; Kabesch, Michael/AAB-5701-2020; Schedel, Michaela/B-3065-2019; Frei, Remo/AAI-9180-2020; Lauener, Roger P/O-8612-2016; Bieli, Christian/F-7209-2014	Schedel, Michaela/0000-0001-8465-2986; Lauener, Roger P/0000-0002-8412-606X; Bieli, Christian/0000-0002-2128-6082; Adamski, Jerzy/0000-0001-9259-0199	German Ministry of Education and Research/National Genome Research Network [NGFN 01GS 0429]; Kuhne Foundation; Swiss National Research Foundation; European Union	German Ministry of Education and Research/National Genome Research Network(Federal Ministry of Education & Research (BMBF)); Kuhne Foundation; Swiss National Research Foundation(Swiss National Science Foundation (SNSF)); European Union(European Commission)	Supported by German Ministry of Education and Research/National Genome Research Network research grant NGFN 01GS 0429, the Kuhne Foundation, and the Swiss National Research Foundation. Funding sources had no influence in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.; Disclosure of potential conflict of interest: R. Lauener receives grant support from the European Union, the Swiss National Research Foundation, and the Kuhne Foundation.	Angelini F, 2007, INT J IMMUNOPATH PH, V20, P59, DOI 10.1177/039463200702000107; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Cameron L, 2006, J IMMUNOL, V177, P8633, DOI 10.4049/jimmunol.177.12.8633; Duetsch G, 2002, HUM MOL GENET, V11, P613, DOI 10.1093/hmg/11.6.613; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Hirschfeld M, 2009, CANCER RES, V69, P2082, DOI 10.1158/0008-5472.CAN-08-1997; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V112, P893, DOI 10.1016/j.jaci.2003.08.033; Kaplan MH, 1999, J IMMUNOL, V163, P6536; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kwan T, 2008, NAT GENET, V40, P225, DOI 10.1038/ng.2007.57; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Li-Weber M, 1998, J BIOL CHEM, V273, P32460, DOI 10.1074/jbc.273.49.32460; Matsukura S, 1999, J IMMUNOL, V163, P6876; Messner B, 1997, J IMMUNOL, V159, P3330; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Patel BKR, 1998, GENOMICS, V52, P192, DOI 10.1006/geno.1998.5436; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Patel BKR, 1998, P NATL ACAD SCI USA, V95, P172, DOI 10.1073/pnas.95.1.172; Pozzoli U, 2005, CELL MOL LIFE SCI, V62, P1579, DOI 10.1007/s00018-005-5030-6; Rosenwasser LJ, 1998, CLIN EXP ALLERGY, V28, P13; ROSENWASSER LJ, 1998, CLIN EXP ALLERGY, V28, P26; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; Schedel M, 2008, AM J RESP CRIT CARE, V177, P613, DOI 10.1164/rccm.200703-373OC; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Stark M, 2009, BLOOD, V113, P4362, DOI 10.1182/blood-2008-08-173799; Stutz AM, 1999, J IMMUNOL, V163, P4383; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Tang XR, 2005, P NATL ACAD SCI USA, V102, P5132, DOI 10.1073/pnas.0501159102; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283, DOI 10.1164/ajrccm.160.4.9809065; Weidinger S, 2004, J MED GENET, V41, P658, DOI 10.1136/jmg.2004.020263; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166	35	33	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					583	U282		10.1016/j.jaci.2009.06.024	http://dx.doi.org/10.1016/j.jaci.2009.06.024			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19665768				2022-12-18	WOS:000274315900026
J	van den Biggelaar, AHJ; Prescott, SL; Roponen, M; Nadal-Sims, MA; Devitt, CJ; Phuanukoonnon, S; Pomat, W; Tulic, MK; Lehmann, D; Siba, PM; Richmond, PC; Holt, PG				van den Biggelaar, Anita H. J.; Prescott, Susan L.; Roponen, Marjut; Nadal-Sims, Marie A.; Devitt, Catherine J.; Phuanukoonnon, Suparat; Pomat, William; Tulic, Meri K.; Lehmann, Deborah; Siba, Peter M.; Richmond, Peter C.; Holt, Patrick G.			Neonatal innate cytokine responses to BCG controlling T-cell development vary between populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BCG; neonatal; allergy; atopy; innate immune system; TLR; IL-10; IFN-gamma; T(H)1; T(H)2; Papua New Guinea	BACILLUS-CALMETTE-GUERIN; NATURAL-KILLER-CELLS; DENDRITIC CELLS; CORD BLOOD; IMMUNE-RESPONSES; IN-VITRO; MYCOBACTERIUM-TUBERCULOSIS; ATOPIC DISEASE; IFN-GAMMA; B-CELLS	Background: The protective effect of Mycobacterium bovis BCG vaccination against infection and atopy varies between populations. Objective: To identify differences in neonatal responses to BCG between diverse populations and study longitudinal associations with memory T-cell responses. Methods: Cord blood mononuclear cells were collected from Papua New Guinean (PNG) and Western Australian (WA) newborns. Toll-like receptor (TLR)-2, TLR4, and TLR9 mRNA expression and in vitro BCG-stimulated (+/- IFN-gamma priming) innate cytokine responses were compared. When PNG infants were 3 months old, PBMCs were stimulated in vitro with Mycobacterium-purified protein derivative (PPD) to determine memory T-cell responses. Results: BCG-induced IL-10 and IFN-gamma responses were significantly higher in cord blood mononuclear cells of PNG newborns, and TLR2 and TLR9 expression was significantly higher and TLR4 expression lower compared with WA newborns. High neonatal IL-10 and low IFN-gamma responses to BCG were found to promote the development of PPD-memory T(H)2 responses in infancy, whereas neonatal BCG-TNF alpha responses inhibited the development of PPD-IL 10 responses. When primed with IFN-gamma, BCG-induced TNF-alpha, IL-12p70, and in particular IFN-gamma responses were enhanced to a significantly higher extent in WA than in PNG newborns. In response to IFN-gamma priming and BCG stimulation, natural killer cells of WA newborns produced IFN-gamma, whereas natural killer cells of PNG newborns contributed only indirectly to this response. Conclusion: Neonatal BCG-related innate immune responses control the differentiation of T-H memory responses and vary between populations. This may explain differences in the effects of BCG vaccination between populations. (J Allergy Clin Immunol 2009;124:544-50.)	[van den Biggelaar, Anita H. J.; Roponen, Marjut; Nadal-Sims, Marie A.; Devitt, Catherine J.; Tulic, Meri K.; Lehmann, Deborah; Holt, Patrick G.] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Prescott, Susan L.] Univ Western Australia, Sch Pediat & Child Hlth, Perth, WA 6009, Australia; [Roponen, Marjut; Tulic, Meri K.; Richmond, Peter C.] Natl Publ Hlth Inst, Dept Environm Hlth, Kuopio, Finland; [Phuanukoonnon, Suparat; Pomat, William; Siba, Peter M.] Papua New Guinea Inst Med Res, Goroka, Papua N Guinea	Telethon Kids Institute; University of Western Australia; University of Western Australia; Finland National Institute for Health & Welfare; PNG Institute Of Medical Research	van den Biggelaar, AHJ (corresponding author), Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.	Anitav@ichr.uwa.edu.au	Holt, Patrick G/H-1548-2011; Tulic, Meri K/ABB-5138-2020; Richmond, Peter C/G-3379-2012; Tulic, Meri/P-6613-2016; Roponen, Marjut/C-2086-2017; Prescott, Susan/H-5665-2014	Holt, Patrick G/0000-0003-1193-0935; Tulic, Meri K/0000-0002-2661-2369; Richmond, Peter C/0000-0001-7562-7228; Tulic, Meri/0000-0002-2661-2369; Roponen, Marjut/0000-0002-4442-9090; 	Australian National Health and Medical Research Council [513836]; Wellcome Trust/National Health and Medical Research Council [071613/Z/03/Z]; University of Western Australia	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Wellcome Trust/National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of AustraliaWellcome Trust); University of Western Australia	Supported by the Australian National Health and Medical Research Council Project Grant (513836), the Wellcome Trust/National Health and Medical Research Council International Collaborative Research Grant Scheme (071613/Z/03/Z), and the University of Western Australia Research Grant Scheme.	Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; Adegnika AA, 2008, J INFECT DIS, V198, P928, DOI 10.1086/591057; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Annus T, 2004, ALLERGY, V59, P1068, DOI 10.1111/j.1398-9995.2004.00557.x; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Dalle JH, 2005, PEDIATR RES, V57, P649, DOI 10.1203/01.PDR.0000156501.55431.20; Dilli D, 2008, J ASTHMA, V45, P155, DOI 10.1080/02770900701840279; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Elias D, 2008, VACCINE, V26, P3897, DOI 10.1016/j.vaccine.2008.04.083; Esin S, 2004, IMMUNOLOGY, V112, P143, DOI 10.1111/j.1365-2567.2004.01858.x; Finan C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003485; FINE PE, 1999, WHO B, V23, P449; Fock RA, 2007, CYTOKINE, V40, P105, DOI 10.1016/j.cyto.2007.08.007; Goriely S, 2004, J EXP MED, V199, P1011, DOI 10.1084/jem.20031272; Gruber C, 2002, PEDIAT ALLERG IMM-UK, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Hwang JH, 2007, RESPIROLOGY, V12, P906, DOI 10.1111/j.1440-1843.2007.01171.x; Jang S, 2004, J IMMUNOL, V173, P3392, DOI 10.4049/jimmunol.173.5.3392; Larsen JM, 2007, IMMUNOLOGY, V121, P276, DOI 10.1111/j.1365-2567.2007.02575.x; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Liu EM, 2003, PEDIATR RES, V54, P105, DOI 10.1203/01.PDR.0000069703.58586.8B; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; Miles DJC, 2008, CLIN VACCINE IMMUNOL, V15, P995, DOI 10.1128/CVI.00037-08; Misch EA, 2008, CLIN SCI, V114, P347, DOI 10.1042/CS20070214; Noakes PS, 2006, EUR RESPIR J, V28, P721, DOI 10.1183/09031936.06.00050206; Omenaas E, 2000, THORAX, V55, P454, DOI 10.1136/thorax.55.6.454; Ota MOC, 2002, J IMMUNOL, V168, P919, DOI 10.4049/jimmunol.168.2.919; Pace E, 2008, IMMUNOLOGY, V124, P401, DOI 10.1111/j.1365-2567.2007.02788.x; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; Pompei L, 2007, J IMMUNOL, V178, P5192, DOI 10.4049/jimmunol.178.8.5192; Prescott SL, 2008, J ALLERGY CLIN IMMUN, V122, P391, DOI 10.1016/j.jaci.2008.04.042; Sahiratmadja E, 2007, INFECT IMMUN, V75, P820, DOI 10.1128/IAI.00602-06; Schroder K, 2006, IMMUNOBIOLOGY, V211, P511, DOI 10.1016/j.imbio.2006.05.007; Semnani RT, 2008, BLOOD, V112, P1290, DOI 10.1182/blood-2008-04-149856; Sharp MJ, 2003, CLIN EXP ALLERGY, V33, P435, DOI 10.1046/j.1365-2222.2003.01627.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Walker WE, 2007, J IMMUNOL, V179, P1700, DOI 10.4049/jimmunol.179.3.1700; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Yerkovich ST, 2007, PEDIATR RES, V62, P547, DOI 10.1203/PDR.0b013e3181568105; Zhang XM, 2007, J EXP MED, V204, P1107, DOI 10.1084/jem.20062013; Zhao J, 2008, P NATL ACAD SCI USA, V105, P7528, DOI 10.1073/pnas.0800152105	43	33	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					544	U222		10.1016/j.jaci.2009.03.040	http://dx.doi.org/10.1016/j.jaci.2009.03.040			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19500827				2022-12-18	WOS:000274315900021
J	Joenvaara, S; Mattila, P; Renkonen, J; Makitie, A; Toppila-Salmi, S; Lehtonen, M; Salmi, P; Lehti, S; Makinen, J; Sormunen, R; Paavonen, T; Renkonen, R				Joenvaara, Sakari; Mattila, Pirkko; Renkonen, Jutta; Makitie, Antti; Toppila-Salmi, Sanna; Lehtonen, Mikko; Salmi, Paula; Lehti, Satu; Makinen, Jarno; Sormunen, Raija; Paavonen, Timo; Renkonen, Risto			Caveolar transport through allergen Bet v 1 in allergic nasal epithelium of birch pollen patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pollen; allergy; epithelium; caveola; lipid raft; cytoskeleton; systems biology; pathway; integration	HUMAN INTESTINAL EPITHELIUM; GENE-EXPRESSION; LIPID RAFTS; IN-VIVO; HUMAN CONJUNCTIVA; VIRUS ENTRY; T-CELLS; ENDOCYTOSIS; PROTEIN; INFECTION	Background: Previous work in type I pollen allergies has focused on aberrant immunoresponses. Objective: Our systems-level analyses explore the role of epithelium in early pathogenesis of type I allergic reactions. Methods: We began top-down analyses of differences in human nasal epithelial cells and biopsy specimens obtained from patients with birch allergy and healthy control subjects in the resting state and after intranasal in vivo birch pollen challenges. Immunohistochemistry, immunotransmission electron microscopy, mass spectrometry, transcriptomics, and integration of data to a pathway were conducted. Results: Bet v 1 allergen bound to epithelium immediately after in vivo birch pollen challenge during winter only in allergic individuals. It also travelled through epithelium with caveolae to mast cells. Sixteen unique proteins were found to bind to the Bet v I column only in lysates from allergic epithelial cells; 6 of these were caveolar and 6 were cytoskeletal proteins. The nasal epithelial transcriptome analysis from allergic and healthy subjects differed during the winter season, and these subjects also responded differentially to birch pollen challenge. Within this pollen-induced response, the gene ontology categories of cytoskeleton and actin cytoskeleton were decreased in allergic patients, whereas the actin-binding category was enriched in healthy subjects. Integration of microscopic, mass spectrometric, and transcriptomic data to a common protein-protein binding network showed how these were connected to each other. Conclusion: We propose a hypothesis of caveolae-dependent uptake and transport of birch pollen allergen in the epithelium of allergic patients only. Application of discovery-driven methodologies can provide new hypotheses worth further analysis of complex multifactorial diseases, such as type I allergy. (J Allergy Clin Immunol 2009;124:135-42.)	[Joenvaara, Sakari; Renkonen, Jutta; Salmi, Paula; Lehti, Satu; Renkonen, Risto] Univ Helsinki, Haartman Inst, Transplantat Lab, FI-00014 Helsinki, Finland; [Joenvaara, Sakari; Renkonen, Jutta; Salmi, Paula; Lehti, Satu; Renkonen, Risto] Univ Helsinki, Haartman Inst, Infect Biol Res Program, FI-00014 Helsinki, Finland; [Joenvaara, Sakari; Mattila, Pirkko; Makinen, Jarno] Medicel Ltd, Helsinki, Finland; [Renkonen, Jutta; Renkonen, Risto] Helsinki Univ Cent Hosp, HUSLAB, Helsinki, Finland; [Makitie, Antti] Helsinki Univ Hosp, Dept Otolaryngol Head & Neck Surg, Helsinki, Finland; [Toppila-Salmi, Sanna; Lehtonen, Mikko] Univ Tampere, FIN-33101 Tampere, Finland; [Toppila-Salmi, Sanna; Lehtonen, Mikko] Tampere Univ Hosp, Dept Eye Ear & Oral Dis, Tampere, Finland; [Sormunen, Raija] Oulu Univ, Dept Pathol, Oulu, Finland; [Paavonen, Timo] Tampere Univ, Dept Pathol, FIN-33101 Tampere, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University Hospital; University of Oulu; Tampere University	Renkonen, R (corresponding author), Univ Helsinki, Haartman Inst, Transplantat Lab, POB 21,Haartmaninkatu 3, FI-00014 Helsinki, Finland.	risto.renkonen@helsinki.fi	Toppila-Salmi, Sanna/ABF-5840-2020	Toppila-Salmi, Sanna/0000-0003-0890-6686	Academy of Finland; Technology Development Centre (TEKES); Sigrid Juselius Foundation; Helsinki University Central Hospital Research Funds, Helsinki, Finland	Academy of Finland(Academy of Finland); Technology Development Centre (TEKES)(Finnish Funding Agency for Technology & Innovation (TEKES)); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Helsinki University Central Hospital Research Funds, Helsinki, Finland	Supported in part by Research Grants from the Academy of Finland, the Technology Development Centre (TEKES), the Sigrid Juselius Foundation, and Helsinki University Central Hospital Research Funds, Helsinki, Finland.	Ashkenazi M, 2008, BIOINFORMATICS, V24, P1465, DOI 10.1093/bioinformatics/btn208; Atshaves BP, 2007, LIPIDS, V42, P871, DOI 10.1007/s11745-007-3091-z; Averbeck Marco, 2007, J Dtsch Dermatol Ges, V5, P1015, DOI 10.1111/j.1610-0387.2007.06538.x; Barrias ES, 2007, BIOCHEM BIOPH RES CO, V363, P828, DOI 10.1016/j.bbrc.2007.09.068; Benson M, 2002, CLIN EXP ALLERGY, V32, P301, DOI 10.1046/j.1365-2222.2002.01300.x; Bohle B, 2007, ALLERGY, V62, P3, DOI 10.1111/j.1398-9995.2006.01258.x; Cantin C, 2007, J GEN VIROL, V88, P559, DOI 10.1099/vir.0.82150-0; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; Damm EM, 2006, CELL MICROBIOL, V8, P1219, DOI 10.1111/j.1462-5822.2006.00745.x; Echarri A, 2007, SEMIN CELL DEV BIOL, V18, P627, DOI 10.1016/j.semcdb.2007.08.004; Fukushima A, 2007, CORNEA, V26, pS36, DOI 10.1097/ICO.0b013e31812f6970; Ghosh D, 2008, MOL IMMUNOL, V45, P456, DOI 10.1016/j.molimm.2007.05.025; Helinto M, 2004, J IMMUNOL, V172, P3235, DOI 10.4049/jimmunol.172.5.3235; JANSEN M, 1920, J BIOL CHEM, V283, P14610; Joenvaara S, 2008, GLYCOBIOLOGY, V18, P339, DOI 10.1093/glycob/cwn013; Kirveskari J, 2002, BLOOD, V100, P2203, DOI 10.1182/blood-2002-04-1017; Kirveskari J, 2001, NAT MED, V7, P376, DOI 10.1038/85538; Kowalski MP, 2007, SCIENCE, V317, P130, DOI 10.1126/science.1142311; Larche M, 2007, CHEST, V132, P1007, DOI 10.1378/chest.06-2434; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lu L, 2008, GASTROENTEROLOGY, V135, P185, DOI 10.1053/j.gastro.2008.03.038; Luo C, 2008, CELL MOL IMMUNOL, V5, P1, DOI 10.1038/cmi.2008.1; Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007; Michel V, 2007, BIOL CELL, V99, P129, DOI 10.1042/BC20060051; Mogensen JE, 2002, J BIOL CHEM, V277, P23684, DOI 10.1074/jbc.M202065200; Moriyama T, 2007, J VIROL, V81, P8552, DOI 10.1128/JVI.00924-07; Oh P, 2007, NAT BIOTECHNOL, V25, P327, DOI 10.1038/nbt1292; Parr RD, 2006, J VIROL, V80, P2842, DOI 10.1128/JVI.80.6.2842-2854.2006; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Pelkmans L, 2003, CURR OPIN CELL BIOL, V15, P414, DOI 10.1016/S0955-0674(03)00081-4; Pilch PF, 2007, J LIPID RES, V48, P2103, DOI 10.1194/jlr.R700009-JLR200; RENKONEN J, ALLERGY; Rivals I, 2007, BIOINFORMATICS, V23, P401, DOI 10.1093/bioinformatics/btl633; Rytkonen AK, 2006, FEBS J, V273, P5535, DOI 10.1111/j.1742-4658.2006.05544.x; Samaj J, 2004, PLANT PHYSIOL, V135, P1150, DOI 10.1104/pp.104.040683; Schelhaas M, 2007, CELL, V131, P516, DOI 10.1016/j.cell.2007.09.038; Smith JL, 2007, J VIROL, V81, P9922, DOI 10.1128/JVI.00988-07; Takizawa Hajime, 2005, Current Drug Targets - Inflammation and Allergy, V4, P305, DOI 10.2174/1568010054022123; Tu Y, 2005, GASTROENTEROLOGY, V129, P928, DOI 10.1053/j.gastro.2005.06.014; Tu YH, 2006, AM J PHYSIOL-GASTR L, V291, pG532, DOI 10.1152/ajpgi.00524.2005; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; van Drunen C, 2005, ALLERGY, V60, P5; Vroling AB, 2007, ALLERGY, V62, P1310, DOI 10.1111/j.1398-9995.2007.01495.x; Vroling AB, 2008, AM J RESP CELL MOL, V38, P293, DOI 10.1165/rcmb.2007-0278OC; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Yang Longlong, 2008, In Silico Biology, V8, P47; Yang PC, 2000, J CLIN INVEST, V106, P879, DOI 10.1172/JCI9258	48	33	34	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					135	142		10.1016/j.jaci.2008.11.048	http://dx.doi.org/10.1016/j.jaci.2008.11.048			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19344938	Green Published			2022-12-18	WOS:000267909700017
J	Kaplan, AP				Kaplan, Allen P.			What the first 10,000 patients with chronic urticaria have taught me: A personal journey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Urticaria; angioedema; histamine; antihistamine; corticosteroids; cyclosporine; anti-IgE receptor	CHRONIC IDIOPATHIC URTICARIA; FC-EPSILON-RI; HISTAMINE-RELEASE; DRIVING PERFORMANCE; DOUBLE-BLIND; DIPHENHYDRAMINE; FOOD; AUTOANTIBODIES; BASOPHILS; PLACEBO		[Kaplan, Allen P.] Med Univ S Carolina, Div Pulm Crit Care Med & Allergy & Clin Immunol, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina	Kaplan, AP (corresponding author), Med Univ S Carolina, Div Pulm Crit Care Med & Allergy & Clin Immunol, Dept Med, Charleston, SC 29425 USA.	kaplana@musc.edu						Aversano M, 2005, ALLERGY, V60, P489, DOI 10.1111/j.1398-9995.2005.00723.x; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P770, DOI 10.1067/mai.2003.1408; Breneman DL, 1996, ANN PHARMACOTHER, V30, P1075, DOI 10.1177/106002809603001001; Cassano N, 2005, ACTA DERM-VENEREOL, V85, P254, DOI 10.1080/00015550510025560; Di Campli C, 1998, DIGEST DIS SCI, V43, P1226, DOI 10.1023/A:1018851623109; Di Lorenzo G, 2005, INT ARCH ALLERGY IMM, V138, P235, DOI 10.1159/000088724; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Finkle WD, 2002, ANN ALLERG ASTHMA IM, V89, P244, DOI 10.1016/S1081-1206(10)61950-3; Gaig P, 2004, J INVEST ALLERG CLIN, V14, P214; Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Greaves M W., 2001, ALLERGY CLIN IMMUNOL, V13, P23; GREAVES MW, 1974, CLIN ALLERGY, V4, P265, DOI 10.1111/j.1365-2222.1974.tb01384.x; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; GUBER L, 2008, J ALLERGY CLIN IMMUN, V5, P147; Guerra L, 2007, J AM ACAD DERMATOL, V56, P88, DOI 10.1016/j.jaad.2006.07.023; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; JAMES J, 1971, BRIT J DERMATOL, V84, P227, DOI 10.1111/j.1365-2133.1971.tb14212.x; James J, 1970, Br J Dermatol, V82, P204, DOI 10.1111/j.1365-2133.1970.tb15015.x; JUHLIN L, 1980, INT J DERMATOL, V19, P548, DOI 10.1111/j.1365-4362.1980.tb00802.x; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V121, pS226, DOI 10.1016/j.jaci.2007.12.895; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Kikuchi Y, 2003, J ALLERGY CLIN IMMUN, V112, P218, DOI 10.1067/mai.2003.1605; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; LANG PG, 1979, J AM ACAD DERMATOL, V1, P479, DOI 10.1016/S0190-9622(79)80088-2; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; Luquin E, 2005, CLIN EXP ALLERGY, V35, P456, DOI 10.1111/j.1365-2222.2005.02212.x; McGirt LY, 2006, ARCH DERMATOL, V142, P1337, DOI 10.1001/archderm.142.10.1337; MICHAELSSON G, 1973, BRIT J DERMATOL, V88, P525, DOI 10.1111/j.1365-2133.1973.tb08014.x; Morgan M, 2008, ANN ALLERG ASTHMA IM, V100, P403, DOI 10.1016/S1081-1206(10)60462-0; Nguyen T, 2001, MOL PHARMACOL, V59, P427, DOI 10.1124/mol.59.3.427; Powell RJ, 2007, CLIN EXP ALLERGY, V37, P631, DOI 10.1111/j.1365-2222.2007.02678.x; RAMAEKERS JG, 1994, EUR J CLIN PHARMACOL, V47, P261, DOI 10.1007/BF02570506; REES L, 1957, J PSYCHOSOM RES, V2, P172, DOI 10.1016/0022-3999(57)90002-8; Reeves GEM, 2004, INTERN MED J, V34, P182, DOI 10.1111/j.1444-0903.2004.00532.x; Schnyder B, 1999, INT ARCH ALLERGY IMM, V119, P60, DOI 10.1159/000024176; SCHWEITZER PK, 1994, J ALLERGY CLIN IMMUN, V94, P716, DOI 10.1016/0091-6749(94)90179-1; SHOEMAKER RJ, 1963, PSYCHOSOMATICS, V4, P125; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Soundararajan S, 2005, J ALLERGY CLIN IMMUN, V115, P815, DOI 10.1016/j.jaci.2004.12.1120; Toubi E, 1997, ALLERGY, V52, P312, DOI 10.1111/j.1398-9995.1997.tb00996.x; Verster JC, 2004, ANN ALLERG ASTHMA IM, V92, P294, DOI 10.1016/S1081-1206(10)61566-9; Verster JC, 2003, PSYCHOPHARMACOLOGY, V169, P84, DOI 10.1007/s00213-003-1462-6; Verster JC, 2003, J ALLERGY CLIN IMMUN, V111, P623, DOI 10.1067/mai.2003.63; Vonakis BM, 2007, J ALLERGY CLIN IMMUN, V119, P441, DOI 10.1016/j.jaci.2006.09.035; Weiler JM, 2000, ANN INTERN MED, V132, P354, DOI 10.7326/0003-4819-132-5-200003070-00004; Zuberbier T, 2006, ALLERGY, V61, P321, DOI 10.1111/j.1398-9995.2006.00962.x; Zuberbier T, 1995, ACTA DERM-VENEREOL, V75, P484; Zuberbier T, 2002, J ALLERGY CLIN IMMUN, V109, P343, DOI 10.1067/mai.2002.121309	51	33	37	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					713	717		10.1016/j.jaci.2008.10.050	http://dx.doi.org/10.1016/j.jaci.2008.10.050			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19081615				2022-12-18	WOS:000264731200043
J	Lebre, MC; van Capel, TMM; Bos, JD; Knol, EF; Kapsenberg, ML; de Jong, EC				Lebre, M. Cristina; van Capel, Toni M. M.; Bos, Jan D.; Knol, Edward F.; Kapsenberg, Martien L.; de Jong, Esther C.			Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; blood; myeloid dendritic cells; plasmacytoid dendritic cells; IL-12; IFN-alpha	DOUBLE-STRANDED-RNA; T-CELLS; CYTOKINE PRODUCTION; CELLULAR-RESPONSES; INTERFERON-ALPHA; IL-12 PRODUCTION; WALL COMPONENTS; HUMAN MONOCYTES; EXPRESSION; SUBSETS	Background: Dendritic cells (DCs) can act both as innate cells in host defense and as antigen-presenting cells for naive T cells in adaptive immunity. These functions, among others, are determined by the level of production of particular cytokines. Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by an initial phase predominated by T(H)2 cytokines that switches into a second, more chronic T(H)1-dominated eczematous phase. Objective: To assess to what extent the AD phenotype is associated with an aberrant phenotype and function of DCs. Methods: Classic CD1c(+)/blood DC antigen (BDCA)-1(+) myeloid (m) DCs and CD304(+)/BDCA4(+) plasmacytoid (p) DCs, the natural IFN-producing cells, were isolated from peripheral blood of patients with AD and healthy controls and analyzed for their phenotype and function. Results: Purified CD1c(+)/BDCA1(+) mDCs from patients with AD showed a selective and dramatic reduction of IL-12p70 and TNF-alpha release. IL-12p70 reduction was attributed to a defective expression of both IL-12p35 and IL-12p40 subunits. Accordingly, mature CD1c(+)/BDCA1(+) mDCs from patients with AD induced considerably less IFN-gamma-producing and more IL-4-producing T(H) cells compared with mDCs from healthy controls. In addition, CD304(+)/BDCA4(+) pDCs from patients with AD produced significantly lower levels of IFN-alpha compared with healthy controls. Conclusion: Myeloid DCs and pDCs from patients with AD show defective IL-12, TNF-alpha, and IFN-alpha production, which may contribute to increased susceptibility to infection and to the maintenance of the T(H)2 cell-mediated allergic state in patients with AD. (J Allergy Clin Immunol 2008;122:969-76.)	[Lebre, M. Cristina; van Capel, Toni M. M.; Kapsenberg, Martien L.; de Jong, Esther C.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1100 DE Amsterdam, Netherlands; [Lebre, M. Cristina; Bos, Jan D.; Kapsenberg, Martien L.; de Jong, Esther C.] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1100 DE Amsterdam, Netherlands; [Knol, Edward F.] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center	de Jong, EC (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, POB 22700, NL-1100 DE Amsterdam, Netherlands.	E.C.deJong@AMC.UvA.NL		Knol, Edward/0000-0001-7368-9820	Fundacao para a Ciencia e a Tecnologia, Lisbon, Portugal [PRAXIS XXI/BD/13678/97]; Haarlems Allergenen Laboratorium (HAL) BV	Fundacao para a Ciencia e a Tecnologia, Lisbon, Portugal(Portuguese Foundation for Science and Technology); Haarlems Allergenen Laboratorium (HAL) BV	Supported by Fundacao para a Ciencia e a Tecnologia, Lisbon, Portugal (grant no. PRAXIS XXI/BD/13678/97 to M.C.L.). E.C.d.J. and T.M.M.v.C. were financially supported by Haarlems Allergenen Laboratorium (HAL) BV.	Akdis M, 1997, J IMMUNOL, V159, P4611; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bos JD, 1998, EXP DERMATOL, V7, P132, DOI 10.1111/j.1600-0625.1998.tb00313.x; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; CHRISTOPHERS E, 1987, ARCH DERMATOL RES, V279, pS48, DOI 10.1007/BF00585919; Clark GJ, 2000, MICROBES INFECT, V2, P257, DOI 10.1016/S1286-4579(00)00302-6; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Fujimura T, 1997, J ALLERGY CLIN IMMUN, V100, P274, DOI 10.1016/S0091-6749(97)70236-7; Goriely S, 2001, J IMMUNOL, V166, P2141, DOI 10.4049/jimmunol.166.3.2141; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Hasannejad H, 2007, J ALLERGY CLIN IMMUN, V120, P69, DOI 10.1016/j.jaci.2007.04.010; Hashizume H, 2005, J IMMUNOL, V174, P2396, DOI 10.4049/jimmunol.174.4.2396; HAYES MP, 1995, BLOOD, V86, P646, DOI 10.1182/blood.V86.2.646.bloodjournal862646; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Kalinski P, 1998, J IMMUNOL, V161, P2804; KOGA C, 2008, J INVEST DERMAT 0424; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; LEUNG DYM, 1998, DERMATOLOGY GEN MED, P1464; Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; Pulendran B, 2000, J IMMUNOL, V165, P566, DOI 10.4049/jimmunol.165.1.566; Reider N, 2002, J ALLERGY CLIN IMMUN, V109, P89, DOI 10.1067/mai.2002.120556; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Snijders A, 1996, J IMMUNOL, V156, P1207; Snijders A, 1998, CLIN EXP IMMUNOL, V111, P472; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Takeuchi O, 2000, INT IMMUNOL, V12, P113, DOI 10.1093/intimm/12.1.113; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x; Uchida Y, 2001, J ALLERGY CLIN IMMUN, V108, P1005, DOI 10.1067/mai.2001.119741; Upham JW, 2002, CLIN EXP ALLERGY, V32, P818, DOI 10.1046/j.1365-2222.2002.01375.x; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001	41	33	33	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					969	976		10.1016/j.jaci.2008.08.028	http://dx.doi.org/10.1016/j.jaci.2008.08.028			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18845325				2022-12-18	WOS:000260940100016
J	Yu, M; Zheng, XM; Peake, J; Joad, JP; Pinkerton, KE				Yu, Mang; Zheng, Xiaomu; Peake, Janice; Joad, Jesse P.; Pinkerton, Kent E.			Perinatal environmental tobacco smoke exposure alters the immune response and airway innervation in infant primates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						environmental tobacco smoke; perinatal exposure; T(H)2 cytokine; brain-derived neurotrophic factor; substance P; asthma susceptibility	HUMAN MAST-CELLS; NECROSIS-FACTOR-ALPHA; FC-EPSILON-RI; CIGARETTE-SMOKE; NEUROTROPHIC FACTOR; DENDRITIC CELLS; EOSINOPHIL RECRUITMENT; SMOOTH-MUSCLE; SUBSTANCE-P; T-CELLS	Background: Epidemiologic studies associate environmental tobacco smoke (ETS) exposure with childhood asthma. Objective: To investigate whether specific pathophysiological alterations that contribute to asthma development in human beings can be induced in infant monkeys after perinatal ETS exposure. Methods: Rhesus macaque fetuses/infants were exposed to ETS at 1 mg/m(3) of total suspended particulate matter from 50 days gestational age to 2.5 months postnatal age. Inflammatory and neural responses to ETS exposure were measured in the infant monkeys. Results: Perinatal ETS exposure could induce systemic and local responses, which include significant elevation of plasma levels of C5a and brain-derived neurotrophic factor, as well as significant increases in pulmonary expression of proinflammatory cytokine TNF-alpha and T(H)2 cytokine IL-5, chemokine monocyte chemoattractant protein 1, and the density of substance P-positive nerves along the bronchial epithelium. Perinatal ETS exposure also significantly increased the numbers of mast cells, eosinophils, monocytes, and lymphocytes in the lungs of infant monkeys. In addition, ex vivo measurements showed significantly increased levels of IL-4 and brain-derived neurotrophic factor in the culture supernatant of PBMCs. Interestingly, as an important component of cigarette smoke, LPS was detected in the plasma of infant monkeys subjected to perinatal exposure to ETS. In contrast, an inhibitory effect of perinatal ETS exposure was also observed, which is associated with decreased phagocytic activity of alveolar macrophages and a significantly decreased level of nerve growth factor in the bronchoalveolar lavage fluid. Conclusion: Perinatal ETS exposure can induce a T(H)2-biased inflammatory response and alter airway innervation in infant monkeys.	[Yu, Mang; Zheng, Xiaomu; Peake, Janice; Pinkerton, Kent E.] Univ Calif Davis, Ctr Hlth & Environm, Davis, CA 95616 USA; [Peake, Janice; Pinkerton, Kent E.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; [Yu, Mang; Zheng, Xiaomu; Peake, Janice; Joad, Jesse P.; Pinkerton, Kent E.] Univ Calif Davis, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA; [Joad, Jesse P.; Pinkerton, Kent E.] Univ Calif Davis, Dept Pediat, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Pinkerton, KE (corresponding author), Univ Calif Davis, Ctr Hlth & Environm, 1 Shields Ave, Davis, CA 95616 USA.	kepinkerton@ucdavis.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011634] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES011634] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARNES PJ, 1986, LANCET, V1, P242; Bergren DR, 2006, J APPL PHYSIOL, V100, P1918, DOI 10.1152/japplphysiol.01276.2005; Bhalla DK, 1999, J TOXICOL ENV HEAL B, V2, P31, DOI 10.1080/109374099281232; Braun A, 1999, INT ARCH ALLERGY IMM, V118, P163, DOI 10.1159/000024056; Braun A, 1999, AM J RESP CELL MOL, V21, P537, DOI 10.1165/ajrcmb.21.4.3670; Brightling CE, 2003, CLIN EXP ALLERGY, V33, P550, DOI 10.1046/j.1365-2222.2003.01636.x; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; *CA ENV PROT AG OF, 2005, HLTH EFF ASS ENV TOB; Carr M J, 2001, Curr Opin Pulm Med, V7, P1, DOI 10.1097/00063198-200101000-00001; Chu HW, 2000, J ALLERGY CLIN IMMUN, V106, P713, DOI 10.1067/mai.2000.109829; Churg A, 2004, AM J RESP CRIT CARE, V170, P492, DOI 10.1164/rccm.200404-511OC; Churg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC; COFFMAN RL, 1986, CURR TOP MICROBIOL, V132, P127; Columbo M, 1996, CLIN IMMUNOL IMMUNOP, V81, P68, DOI 10.1006/clin.1996.0159; Cookson WOC, 2000, HUM MOL GENET, V9, P2359, DOI 10.1093/hmg/9.16.2359; DAHER S, 1995, J INVEST ALLERG CLIN, V5, P251; DELUCCA AJ, 1984, AM IND HYG ASSOC J, V45, P336, DOI 10.1080/15298668491399884; Eisner Mark D, 2005, Environ Health, V4, P7, DOI 10.1186/1476-069X-4-7; Evans MJ, 2000, AM J RESP CELL MOL, V22, P393, DOI 10.1165/ajrcmb.22.4.3913; Fischer A, 1996, J CLIN INVEST, V98, P2284, DOI 10.1172/JCI119039; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gerard NP, 2002, CURR OPIN IMMUNOL, V14, P705, DOI 10.1016/S0952-7915(02)00410-7; Groneberg DA, 2006, CURR DRUG TARGETS, V7, P1005, DOI 10.2174/138945006778019318; Guerin M.R., 1992, CHEM ENV TOBACCO SMO; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hahn C, 2006, J ALLERGY CLIN IMMUN, V117, P787, DOI 10.1016/j.jaci.2005.12.1339; Hammad H, 2002, J IMMUNOL, V169, P1524, DOI 10.4049/jimmunol.169.3.1524; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hodge G, 2007, CLIN EXP IMMUNOL, V150, P22, DOI 10.1111/j.1365-2249.2007.03451.x; Hoshino K, 1999, J IMMUNOL, V162, P3749; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; JOAD JP, 1995, TOXICOL APPL PHARM, V132, P63, DOI 10.1006/taap.1995.1087; Joad JP, 1999, TOXICOL APPL PHARM, V155, P253, DOI 10.1006/taap.1998.8612; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kerr BJ, 1999, J NEUROSCI, V19, P5138; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; Kleeberger SR, 2001, J APPL PHYSIOL, V90, P713, DOI 10.1152/jappl.2001.90.2.713; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; Korea Ministry of Health and Welfare, 2016, DEV NAT BIOM PROGR E; Kubo Y, 2007, INFLAMM RES, V56, P70, DOI 10.1007/s00011-006-6064-4; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; LEONARD C, 1997, AM J RESP CELL MOL B, V17, P68; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Mai SK, 2007, HLTH CONS SMOK REP S, V2, P30; Marone G, 2005, TRENDS IMMUNOL, V26, P25, DOI 10.1016/j.it.2004.10.010; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Mitani H, 2000, BRIT J HAEMATOL, V109, P288, DOI 10.1046/j.1365-2141.2000.02020.x; Moshammer H, 2006, AM J RESP CRIT CARE, V173, P1255, DOI 10.1164/rccm.200510-1552OC; NAGATA S, 1987, J ALLERGY CLIN IMMUN, V80, P24, DOI 10.1016/S0091-6749(87)80186-0; *NAT CANC I, 1999, SMOK TOB CONTR MON, V10; Noga O, 2008, CLIN EXP ALLERGY, V38, P473, DOI 10.1111/j.1365-2222.2007.02907.x; [Office of Research and Development Office of Health Environmental Assessment United States Environmental Protection Agency], 1992, RESP HLTH EFF PASS S; OHNISHI T, 1993, J ALLERGY CLIN IMMUN, V92, P607, DOI 10.1016/0091-6749(93)90085-T; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; Okumura S, 2003, BLOOD, V102, P2547, DOI 10.1182/blood-2002-12-3929; Oskeritzian CA, 2005, J ALLERGY CLIN IMMUN, V115, P1162, DOI 10.1016/j.jaci.2005.02.022; OWNBY DR, 1990, J ALLERGY CLIN IMMUN, V86, P279, DOI 10.1016/S0091-6749(05)80088-0; Palmer LJ, 2000, GENOME RES, V10, P1280, DOI 10.1101/gr.143400; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330, DOI 10.1164/ajrccm/137.6.1330; Schelegle ES, 2001, AM J PATHOL, V158, P333, DOI 10.1016/S0002-9440(10)63973-9; Schulte-Herbruggen O, 2005, J NEUROIMMUNOL, V160, P204, DOI 10.1016/j.jneuroim.2004.10.026; Skadhauge LR, 1999, EUR RESPIR J, V13, P8, DOI 10.1183/09031936.99.13100899; Soruri A, 2003, J IMMUNOL, V171, P2631, DOI 10.4049/jimmunol.171.5.2631; Spina D, 2002, TRENDS PHARMACOL SCI, V23, P311, DOI 10.1016/S0165-6147(02)02022-9; Steinke JW, 2001, RESP RES, V2, P66, DOI 10.1186/rr40; Tam SY, 1997, BLOOD, V90, P1807, DOI 10.1182/blood.V90.5.1807; Thangam EB, 2005, FASEB J, V19, P798, DOI 10.1096/fj.04-2797fje; Thorn J, 2001, INFLAMM RES, V50, P254, DOI 10.1007/s000110050751; US Department of Health and Human Services, 1986, DHHS PUBL, V87-8398; *USEPA, 1992, PUBL US EPA; Varadaradjalou S, 2003, EUR J IMMUNOL, V33, P899, DOI 10.1002/eji.200323830; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; Wang L, 2007, J ALLERGY CLIN IMMUN, V120, P445, DOI 10.1016/j.jaci.2007.03.028; Wang Y, 2006, NAT BIOTECHNOL, V24, P1224, DOI 10.1038/nbt1006-1224; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wu ZX, 1999, J APPL PHYSIOL, V87, P1621, DOI 10.1152/jappl.1999.87.5.1621; Yu M, 2002, TOXICOL SCI, V68, P488, DOI 10.1093/toxsci/68.2.488; YU M, 2001, TOXICOLOGIST, V60, pA197; Zughaier SM, 2005, INFECT IMMUN, V73, P2940, DOI 10.1128/IAI.73.5.2940-2950.2005	90	33	34	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					640	647		10.1016/j.jaci.2008.04.038	http://dx.doi.org/10.1016/j.jaci.2008.04.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18571708				2022-12-18	WOS:000259234000030
J	Levesque, MC; Hauswirth, DW; Mervin-Blake, S; Fernandez, CA; Patch, KB; Alexander, KM; Allgood, S; McNair, PD; Allen, AS; Sundy, JS				Levesque, Marc C.; Hauswirth, David W.; Mervin-Blake, Sabrena; Fernandez, Carolyn A.; Patch, Kistie B.; Alexander, Katie M.; Allgood, Sallie; McNair, Patrice D.; Allen, Andrew S.; Sundy, John S.			Determinants of exhaled nitric oxide levels in healthy, nonsmoking African American adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						african American; human subjects; nitric oxide; respiratory function tests; IgE; respiratory tract infections	POPULATION-SAMPLE; EPITHELIAL-CELLS; T-LYMPHOCYTES; ASTHMA; AIRWAY; SYNTHASE; IGE; PROTECTION; NITRATE; GENDER	Background: Asthma is a significant cause of morbidity and mortality for African Americans. Fraction of exhaled nitric oxide (FeNO) levels are increased in patients with asthma, and airway levels of nitric oxide metabolites regulate airway inflammation and airway diameter. More needs to be known about the factors that regulate FeNO. There is a need for FeNO reference values for African Americans. Objective: We sought to establish reference values and identify factors associated with FeNO levels in healthy African American adults. Methods: FeNO levels were measured in 895 healthy, nonsmoking African Americans between the ages of 18 and 40 years. FeNO measurements were repeated in 84 subjects. Factors potentially associated with FeNO were measured, including blood pressure, height, weight, and serum total IgE, eosinophil cationic protein, C-reactive protein, and nitrate levels. Data on respiratory symptoms, including upper respiratory tract infection (URI) symptoms, were collected. Univariate and multivariate analyses of the relationship between these variables and FeNO levels were performed. Results: In healthy, nonsmoking African Americans FeNO levels were stable during repeated measurements (intraclass correlation coefficient, 0.81). Sex (P < .0001), serum total IgE levels (P < .0001), and current URI symptoms (P = .0002) contributed significantly to FeNO variability but together accounted for less than 50% of the variation in FeNO levels. Conclusion: The high correlation between repeated measurements of FeNO and the low correlation coefficients of known factors associated with FeNO suggest that other factors might contribute substantially to variability of FeNO levels in African Americans.	[Levesque, Marc C.; Mervin-Blake, Sabrena; Fernandez, Carolyn A.; Patch, Kistie B.; Alexander, Katie M.; Allgood, Sallie; McNair, Patrice D.; Sundy, John S.] Duke Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Durham, NC 27710 USA; [Sundy, John S.] Duke Univ, Med Ctr, Div Pulm Allergy & Critical Care Med, Durham, NC 27710 USA; [Hauswirth, David W.] Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA; [Allen, Andrew S.] Duke Univ, Med Ctr, Dept Pediat, Dept Biostat & Bioinformat, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Levesque, MC (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Box 3266, Durham, NC 27710 USA.	marc.levesque@duke.edu		Allen, Andrew/0000-0002-7232-2143; Allgood, Sallie/0000-0002-0329-4572	NCRR NIH HHS [M01-RR-30] Funding Source: Medline; NIEHS NIH HHS [ES011185] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES011185] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALVING K, 1993, EUR RESPIR J, V6, P1368; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Baldacci S, 1996, ALLERGY, V51, P149, DOI 10.1111/j.1398-9995.1996.tb00055.x; Barnes KC, 2006, J ALLERGY CLIN IMMUN, V117, P243, DOI 10.1016/j.jaci.2005.11.030; Bell RG, 1996, IMMUNOL CELL BIOL, V74, P337, DOI 10.1038/icb.1996.60; BENJAMIN N, 1994, NATURE, V368, P502, DOI 10.1038/368502a0; Bjorne H, 2004, J CLIN INVEST, V113, P106, DOI [10.1172/JCI200419019, 10.1172/JCI19019]; Bland JM, 1996, BRIT MED J, V313, P41, DOI 10.1136/bmj.313.7048.41; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Carraro S, 2006, AM J PHYSIOL-LUNG C, V290, pL827, DOI 10.1152/ajplung.00406.2005; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; Donnelly LE, 2004, AM J PHYSIOL-LUNG C, V287, pL774, DOI 10.1152/ajplung.00110.2004; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Esposito E, 2005, ENDOCRINOLOGY, V146, P3301, DOI 10.1210/en.2005-0375; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; Fagan JK, 2001, ANN ALLERG ASTHMA IM, V86, P177, DOI 10.1016/S1081-1206(10)62688-9; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69, DOI 10.1164/ajrccm.159.1.9804134; Franklin PJ, 2004, CHEST, V126, P1540, DOI 10.1378/chest.126.5.1540; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Ho LP, 2000, CHEST, V118, P1327, DOI 10.1378/chest.118.5.1327; Hobbs MR, 2002, LANCET, V360, P1468, DOI 10.1016/S0140-6736(02)11474-7; HUSAIN M, 1994, CIRCULATION, V89, P2498, DOI 10.1161/01.CIR.89.6.2498; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; James SL, 1998, INFECT IMMUN, V66, P3510, DOI 10.1128/IAI.66.8.3510-3518.1998; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609, DOI 10.1164/ajrccm.152.2.7543345; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Kun JF, 2001, J INFECT DIS, V184, P330, DOI 10.1086/322037; Lund MB, 2007, EUR RESPIR J, V29, P292, DOI 10.1183/09031936.00044805; Marczin N, 1997, LANCET, V349, P1742, DOI 10.1016/S0140-6736(05)62953-4; McKnight GM, 1997, GUT, V40, P211, DOI 10.1136/gut.40.2.211; Murphy AW, 1998, CHEST, V114, P452, DOI 10.1378/chest.114.2.452; Ohmori H, 2000, IMMUNOPHARMACOLOGY, V46, P55, DOI 10.1016/S0162-3109(99)00158-7; Olin AC, 2006, CHEST, V130, P1319, DOI 10.1378/chest.130.5.1319; Park EM, 2006, J CEREBR BLOOD F MET, V26, P392, DOI 10.1038/sj.jcbfm.9600194; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rodriguez D, 2003, J IMMUNOL, V171, P1001, DOI 10.4049/jimmunol.171.2.1001; Sacco O, 2003, PEDIAT ALLERG IMM-UK, V14, P475, DOI 10.1046/j.0905-6157.2003.00092.x; Saito J, 2004, J ALLERGY CLIN IMMUN, V114, P512, DOI 10.1016/j.jaci.2004.05.033; Saito S, 1999, J HEART LUNG TRANSPL, V18, P937, DOI 10.1016/S1053-2498(99)00060-1; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911, DOI 10.1164/ajrccm.159.3.9802108; SCHILLING J, 1994, EUR RESPIR J, V7, P467, DOI 10.1183/09031936.94.07030467; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Taylor DR, 2006, THORAX, V61, P817, DOI 10.1136/thx.2005.056093; Travers J, 2007, AM J RESP CRIT CARE, V176, P238, DOI 10.1164/rccm.200609-1346OC; Tsang KW, 2001, LUNG, V179, P83, DOI 10.1007/s004080000050; Wechsler ME, 2000, AM J RESP CRIT CARE, V162, P2043, DOI 10.1164/ajrccm.162.6.2003089; Weinberg JB, 1998, MOL MED, V4, P557, DOI 10.1007/BF03401758; Xu R, 1999, LIFE SCI, V64, P2451, DOI 10.1016/S0024-3205(99)00202-7; Zetterquist W, 1999, EUR RESPIR J, V13, P327, DOI 10.1034/j.1399-3003.1999.13b18.x; Zitter JN, 2002, JAMA-J AM MED ASSOC, V288, P483, DOI 10.1001/jama.288.4.483	58	33	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					396	402		10.1016/j.jaci.2007.09.031	http://dx.doi.org/10.1016/j.jaci.2007.09.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18036642				2022-12-18	WOS:000253337800018
J	Burks, AW; Jones, SM				Burks, A. Wesley; Jones, Stacie M.			Egg oral immunotherapy in nonanaphylactic children with egg allergy: Follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Burks, A. Wesley] Duke Univ, Med Ctr, Dept Pediat Allergy Immunol, Durham, NC USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Jones, Stacie M.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA	Duke University; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital	Burks, AW (corresponding author), Duke Univ, Med Ctr, Dept Pediat Allergy Immunol, Durham, NC USA.	wesley.burks@duke.edu						Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016	1	33	34	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					270	271		10.1016/j.jaci.2007.07.066	http://dx.doi.org/10.1016/j.jaci.2007.07.066			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17889930	Bronze			2022-12-18	WOS:000252372000058
J	Munthe-Kaas, MC; Carlsen, KH; Haland, G; Devulapalli, CS; Gervin, K; Egeland, T; Carlsen, KL; Undlien, D				Munthe-Kaas, Monica Cheng; Carlsen, Kai Hakon; Haland, Geir; Devulapalli, Chandra Sekhar; Gervin, Kristina; Egeland, Thore; Carlsen, Karin Lodrup; Undlien, Dag			T cell-specific T-box transcription factor haplotype is associated with allergic asthma in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; cohort study; genetic analysis; association study; T-bet; TBX21	IFN-GAMMA PRODUCTION; BET EXPRESSION; ENVIRONMENT; POLYMORPHISMS; METHACHOLINE; DISTINCT; TBX21; BIRTH; OSLO	Background: T cell-specific T-box transcription factor (T-bet) is a member of the T-box family of transcription factors regulating lineage commitment of T-H lymphocytes toward a predominant T(H)1 phenotype. Asthma and allergy are common complex diseases characterized by T(H)2-mediated inflammation. Objective: We aimed to assess possible relationships between the T-bet gene (TBX21) and asthma and allergy in children. Method: Twelve single nucleotide polymorphisms (SNPs) in the TBX21 region were genotyped in 948 children from the Environment and Childhood Asthma study. Allele and haplotype frequencies were compared in children with and without asthma (by 10 years) and allergy (>= 1 positive skin prick test response), as well as for the quantitative traits bronchial hyperresponsiveness determined by means of methacholine bronchial challenge testing, lung function determined by means of forced flow volume loops, fractional exhaled nitric oxide measurement, eosinophil count, and serum total IgE level. Results: Allergic asthma was significantly associated with 2 of the tested SNPs (rs11650354 and rs16947078) and further associated with the particular haplotype including these SNPs, with homozygote status resulting in an odds ratio of 8.3 (95% CI, 2.5-26.9) for allergic asthma. Neither nonallergic asthma or '' allergy alone '' nor the remaining quantitative variables were associated with TBX21 SNPs or haplotypes. Conclusion: An association between a specific TBX21 haplotype and allergic asthma in children is demonstrated for the first time and might explain previously detected associations between SNPs within TBX21 and asthma and bronchial hyperresponsiveness.	[Munthe-Kaas, Monica Cheng; Haland, Geir; Devulapalli, Chandra Sekhar; Carlsen, Karin Lodrup] Ullevaal Univ Hosp, Dept Paediat, N-0407 Oslo, Norway; [Munthe-Kaas, Monica Cheng; Undlien, Dag] Univ Oslo, Ullevaal Hosp, Fac Div, Inst Med Genet, N-0407 Oslo, Norway; [Carlsen, Kai Hakon; Devulapalli, Chandra Sekhar; Carlsen, Karin Lodrup] Univ Oslo, Fac Med, N-0316 Oslo, Norway; [Carlsen, Kai Hakon] Ullevaal Univ Hosp, Rikshosp Radiumhosp Med Ctr, Dept Pediat, Oslo, Norway; [Gervin, Kristina; Egeland, Thore; Undlien, Dag] Ullevaal Univ Hosp, Dept Med Genet, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo	Munthe-Kaas, MC (corresponding author), Ullevaal Univ Hosp, Dept Paediat, N-0407 Oslo, Norway.	m.c.inunthe-kaas@llledisin.uio.no	Devulapalli, Chandra Sekhar/B-6170-2008	Gervin, Kristina/0000-0002-9851-1890; Devulapalli, Chandra Sekhar/0000-0001-5473-9642				Akahoshi M, 2005, HUM GENET, V117, P16, DOI 10.1007/s00439-005-1285-0; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Carlsen KCL, 2006, ALLERGY, V61, P454, DOI 10.1111/j.1398-9995.2005.00938.x; Carlsen KCL, 2002, PEDIAT ALLERG IMM-UK, V13, P29, DOI 10.1034/j.1399-3038.13.s.15.2.x; Chung Hun Taek, 2003, Hum Mutat, V22, P257, DOI 10.1002/humu.9169; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Dong L, 2006, CHINESE MED J-PEKING, V119, P1396, DOI 10.1097/00029330-200608020-00013; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Fujiwara M, 2007, J ALLERGY CLIN IMMUN, V119, P662, DOI 10.1016/j.jaci.2006.12.643; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hohler T, 2005, J IMMUNOL, V175, P5457, DOI 10.4049/jimmunol.175.8.5457; Kiwamoto T, 2006, AM J RESP CRIT CARE, V174, P142, DOI 10.1164/rccm.200601-079OC; Ko FWS, 2007, CLIN EXP IMMUNOL, V147, P526, DOI 10.1111/j.1365-2249.2006.03315.x; Larche M, 1998, J IMMUNOL, V161, P6375; Martinez FD, 2005, IMMUNOL ALLERGY CLIN, V25, P709, DOI 10.1016/j.iac.2005.09.001; Munthe-Kaas MC, 2007, ALLERGY, V62, P991, DOI 10.1111/j.1398-9995.2007.01377.x; Munthe-Kaas MC, 2006, RESP MED, V100, P2121, DOI 10.1016/j.rmed.2006.03.026; Nystad W, 1999, PEDIATR ALLERGY IMMU, V10, P58, DOI 10.1034/j.1399-3038.1999.101003.x; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; Raby BA, 2006, AM J RESP CRIT CARE, V173, P64, DOI 10.1164/rccm.200503-505OC; Robinson DS, 2002, CURR BIOL, V12, pR322, DOI 10.1016/S0960-9822(02)00830-8; Salyakina D, 2005, HUM HERED, V60, P19, DOI 10.1159/000087540; Singh AM, 2006, THORAX, V61, P809, DOI 10.1136/thx.2005.045179; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; Ylikoski E, 2004, CLIN EXP ALLERGY, V34, P1049, DOI 10.1111/j.1365-2222.2004.01995.x; Zapletal A, 1987, PROG RESPIR RES, V1987, P113	34	33	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					51	56		10.1016/j.jaci.2007.07.068	http://dx.doi.org/10.1016/j.jaci.2007.07.068			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17949803				2022-12-18	WOS:000252372000008
J	Pegorier, S; Arouche, N; Dombret, MC; Aubier, M; Pretolani, M				Pegorier, Sophie; Arouche, Nassim; Dombret, Marie-Christine; Aubier, Michel; Pretolani, Marina			Augmented epithelial endothelin-1 expression in refractory asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endothelin-1; severe asthma; laser microdissection fibrosis; airway smooth muscle	IDIOPATHIC PULMONARY-FIBROSIS; GROWTH-FACTOR RECEPTOR; NECROSIS-FACTOR-ALPHA; LUNG-DISEASES; BRONCHOALVEOLAR LAVAGE; BRONCHIAL EPITHELIUM; CELLS; INFLAMMATION; PROLIFERATION; AIRWAYS	Background: Airway remodeling in patients with severe steroid-refractory asthma might result from a reduced ability of steroid therapy to limit the transcription of remodeling factors by the bronchial epithelium. Objective: We sought to compare the levels of transcripts encoding remodeling factors in bronchial epithelium of healthy volunteers and of asthmatic patients with either steroid-sensitive or steroid-refractory disease and to correlate these levels with hallmarks of airway remodeling. Methods: By means of real-time quantitative PCR, we assessed the levels of 14 transcripts encoding remodeling factors, matrix metalolproteinases, and extracellular matrix proteins in laser-capture microdissected bronchial epithelium of healthy volunteers, patients with mild steroid-untreated asthma, and patients with steroid-sensitive and steroid-refractory asthma (n = 8-10 in each group). Histologic features of airway remodeling and endothelin-1 (EDN1) immunolocalization were determined by using frozen specimens. Results: Patients with steroid-refractory asthma had greater levels of EDN1 transcripts (4.1-fold increase, P = .026) and protein (P = .0009) in their bronchial epithelium compared with patients with steroid-sensitive asthma. EDN1 mRNA levels and protein expression in asthmatic patients were negatively correlated with prebronchodilator and postbronchodilator FEV1 value (r(2) >= 0.193, P <= .03), and they were positively related to airway smooth muscle areas (r(2) = 0.253, P = .01 and r(2) = 0.281, P = .005 for EDN1 mRNA and protein expression, respectively). Conclusion: Increased EDN1 synthesis by the bronchial epithelium characterizes severe refractory asthma and correlates with airway remodeling and airflow obstruction. Clinical implications: Targeting EDN1 might represent a novel therapeutic strategy for severe steroid-refractory asthma.	[Pegorier, Sophie; Arouche, Nassim; Aubier, Michel; Pretolani, Marina] Univ Paris 07, INSERM, U700, Fac Med Denis Diderot, F-75018 Paris, France; [Dombret, Marie-Christine; Aubier, Michel] Hop Paris, CHU Bichat Claude Bernard, Dept Pneumol A, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Pretolani, M (corresponding author), Univ Paris 07, INSERM, U700, Fac Med Denis Diderot, Site Xavier Bichat,16 Rue Henri Huchard, F-75018 Paris, France.	mpretol@bichat.inserm.fr	Pretolani, Marina/G-6643-2017					ACKERMAN V, 1995, J ALLERGY CLIN IMMUN, V96, P618, DOI 10.1016/S0091-6749(95)70260-1; Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; [Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341; Aubert JD, 1997, BIOCHEM PHARMACOL, V53, P547; Balzar S, 2005, J ALLERGY CLIN IMMUN, V115, P110, DOI 10.1016/j.jaci.2004.09.034; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Cundall M, 2003, J ALLERGY CLIN IMMUN, V112, P1064, DOI 10.1016/j.jaci.2003.08.013; Dawes KE, 1996, INT J BIOCHEM CELL B, V28, P229, DOI 10.1016/1357-2725(95)00124-7; GLASSBERG MK, 1994, AM J RESP CELL MOL, V10, P316, DOI 10.1165/ajrcmb.10.3.7509612; Goldie RG, 1999, PULM PHARMACOL THER, V12, P79, DOI 10.1006/pupt.1999.0190; Govindaraju V, 2006, AM J PHYSIOL-CELL PH, V291, pC957, DOI 10.1152/ajpcell.00451.2005; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Gueders MM, 2006, EUR J PHARMACOL, V533, P133, DOI 10.1016/j.ejphar.2005.12.082; Hamilton LM, 2003, CLIN EXP ALLERGY, V33, P233, DOI 10.1046/j.1365-2222.2003.01593.x; Knight DA, 2004, CURR OPIN PHARMACOL, V4, P251, DOI 10.1016/j.coph.2004.02.002; Marini M, 1996, BIOCHEM BIOPH RES CO, V220, P896, DOI 10.1006/bbrc.1996.0502; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V88, P376, DOI 10.1016/0091-6749(91)90100-3; Minshall E, 2000, J ALLERGY CLIN IMMUN, V105, P232, DOI 10.1016/S0091-6749(00)90070-8; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Miotto D, 2001, J ALLERGY CLIN IMMUN, V107, P664, DOI 10.1067/mai.2001.113524; *NIH NAT HEART LUN, 1997, NIH PUBL; Nocker RET, 1996, INT ARCH ALLERGY IMM, V109, P183, DOI 10.1159/000237218; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324, DOI 10.1164/ajrccm.162.6.2001041; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Redington AE, 1997, J ALLERGY CLIN IMMUN, V100, P544, DOI 10.1016/S0091-6749(97)70148-9; Shahar I, 1999, INT J IMMUNOPHARMACO, V21, P759, DOI 10.1016/S0192-0561(99)00056-9; SMITH RE, 1995, J LEUKOCYTE BIOL, V57, P782, DOI 10.1002/jlb.57.5.782; Sun G, 1997, PEPTIDES, V18, P1449, DOI 10.1016/S0196-9781(97)00194-0; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vignola A M, 1997, Monaldi Arch Chest Dis, V52, P159; Vignola AM, 2001, J ALLERGY CLIN IMMUN, V108, P738, DOI 10.1067/mai.2001.119160; Walter Nicholas, 2006, Proc Am Thorac Soc, V3, P330, DOI 10.1513/pats.200602-016TK; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Xu SW, 2004, J BIOL CHEM, V279, P23098, DOI 10.1074/jbc.M311430200; Zhang SL, 1999, LAB INVEST, V79, P395; 1985, AM REV RESP DIS, V132, P180	43	33	34	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1301	1307		10.1016/j.jaci.2007.09.023	http://dx.doi.org/10.1016/j.jaci.2007.09.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17996929				2022-12-18	WOS:000251653800009
J	Pilette, C; Coppens, N; Houssiau, FA; Rodenstein, DO				Pilette, Charles; Coppens, Nathalie; Houssiau, Frederic A.; Rodenstein, Daniel O.			Severe serum sickness-like syndrome after omalizumab therapy for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTIBODY		Clin Univ St Luc, Dept Pneumol, B-1200 Brussels, Belgium; Clin Univ St Luc, Dept Rheumatol, B-1200 Brussels, Belgium	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Pilette, C (corresponding author), Clin Univ St Luc, Dept Pneumol, Ave Hippocrate 10, B-1200 Brussels, Belgium.	charles.pilette@pneu.ucl.ac.be						Dreyfus DH, 2006, ANN ALLERG ASTHMA IM, V96, P624, DOI 10.1016/S1081-1206(10)63560-0; Feuring-Buske M, 2000, ANN HEMATOL, V79, P493, DOI 10.1007/s002770000163; Forero A, 2006, CANCER BIOTHER RADIO, V21, P561, DOI 10.1089/cbr.2006.21.561; Graham LE, 2001, RHEUMATOL INT, V20, P251, DOI 10.1007/s002960100112; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; *US FDA, 2003, 1039760 US FDA DEP H; FOOD DRUG ADM FDA NE	7	33	34	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					972	973		10.1016/j.jaci.2007.06.038	http://dx.doi.org/10.1016/j.jaci.2007.06.038			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17716723				2022-12-18	WOS:000250157700042
J	Sanchez-Borges, M; Iraola, V; Fernandez-Caldas, E; Capriles-Hulett, A; Caballero-Fonseca, F				Sanchez-Borges, Maric; Iraola, Victor; Fernandez-Caldas, Enrique; Capriles-Hulett, Arnaldo; Caballero-Fonseca, Fernan			Dust mite ingestion-associated, exercise-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Ctr Medicodocente Trinidad, Caracas, Venezuela; Lab Leti SL, Madrid, Spain; Hosp San Juan Dios, Caracas, Venezuela		Sanchez-Borges, M (corresponding author), Ctr Medicodocente Trinidad, Caracas, Venezuela.	malsan@cantv.net						CAPRILESHULETT A, 2006, 25 C EUR AC ALL CLIN; Codina R, 2002, ALLERGY, V57, P260, DOI 10.1034/j.1398-9995.2002.1n3484.x; Fiocchi A, 1997, J ALLERGY CLIN IMMUN, V100, P424, DOI 10.1016/S0091-6749(97)70258-6; LEWIS J, 1981, J ALLERGY CLIN IMMUN, V68, P432, DOI 10.1016/0091-6749(81)90197-4; LIEBERMAN P, 2005, J ALLERGY CLIN IMMUN, V115, pS483, DOI DOI 10.1016/J.JACI.2005.01.010; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; Puerta L, 2005, ALLERGY, V60, P41, DOI 10.1111/j.1398-9995.2004.00636.x; SanchezBorges M, 1997, J ALLERGY CLIN IMMUN, V99, P738, DOI 10.1016/S0091-6749(97)80005-X; SanchezBorges M, 1997, CUTIS, V59, P311	9	33	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					714	716		10.1016/j.jaci.2007.04.017	http://dx.doi.org/10.1016/j.jaci.2007.04.017			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17531300				2022-12-18	WOS:000249505400034
J	Lopez-Torrejon, G; Diaz-Perales, A; Rodriguez, J; Sanchez-Monge, R; Crespo, JF; Salcedo, G; Pacios, LF				Lopez-Torrejon, Gema; Diaz-Perales, Araceli; Rodriguez, Julia; Sanchez-Monge, Rosa; Crespo, Jesus F.; Salcedo, Gabriel; Pacios, Luis F.			An experimental and modeling-based approach to locate IgE epitopes of plant profilin allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						profilin; melon allergy; cross-reactivity; 3-dimensional modeling; solvent exposure; electrostatic potential; allergen surface; IgE epitope	BINDING; REACTIVITY; BIRCH	Background: Plant profilins are actin-binding proteins that form a well-known panallergen family responsible for cross-sensitization between plant foods and pollens. Melon profilin, Cue m 2, is the major allergen of this fruit. Objective: We sought to map IgE epitopes on the 3-dimensional structure of Cue m 2. Methods: IgE binding to synthetic peptides spanning the full Cue m 2 amino acid sequence was assayed by using a serum pool and individual sera from 10 patients with melon allergy with significant specific IgE levels to this allergen. Three-dimensional modeling and potential epitope location were based on analysis of both solvent exposure and electrostatic properties of the Cue m 2 surface. Results: Residues included in synthetic peptides that exerted the strongest IgE-binding capacity defined 2 major epitopes (El, consisting of residues 66-75 and 81-93, and E2, consisting of residues 95-99 and 122-131) that partially overlapped with the actin-binding site of Cue m 2. Two additional epitopes (E3, including residues 2-10, and E4, including residues 35-45) that should show weaker putative antigen-antibody associations and shared most residues with synthetic peptides with low lgE-binding capacity were predicted on theoretical grounds. Conclusions: Strong and weak IgE epitopes have been uncovered in melon profilin, Cue m 2. Clinical implications: The different types of IgE epitopes located in the 3-dimensional structure of melon profilin can constitute the molecular basis to explain the sensitization and cross-reactivity exhibited by this panallergen family.	ETS Ingenieros Montes, Dept Biotecno, Unidad Bioquim, Madrid, Spain; Univ Madrid, Hosp 12 Octubre, Servicio Alergia, Madrid, Spain; ETS Ingenieros Montes, Dept Biotecn, Unidad Quim & Bioquim, Madrid, Spain	Hospital Universitario 12 de Octubre	Pacios, LF (corresponding author), ETS Ingenieros Montes, Unidad Quim & Bioquim, Ciudad Univ, Madrid 28040, Spain.	luis.fpacios@upm.es	Pacios, Luis F/I-5164-2015; Pacios, Luis F./AAL-6124-2021; Díaz-Perales, Araceli/D-8433-2016	Pacios, Luis F/0000-0002-0585-4289; Pacios, Luis F./0000-0002-0585-4289; Díaz-Perales, Araceli/0000-0002-1093-3627; Lopez-Torrejon, Gema/0000-0003-2588-4378				Asturias JA, 2002, INT IMMUNOL, V14, P993, DOI 10.1093/intimm/dxf070; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V111, P628, DOI 10.1067/mai.2003.75; Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HONIG B, 1995, NATURE, V268, P1144; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; Leitner A, 1998, EUR J IMMUNOL, V28, P2921, DOI 10.1002/(SICI)1521-4141(199809)28:09<2921::AID-IMMU2921>3.0.CO;2-D; Lopez-Torrejon G, 2005, ALLERGY, V60, P1424, DOI 10.1111/j.1398-9995.2005.00903.x; Lopez-Torrejon G, 2005, CLIN EXP ALLERGY, V35, P1065, DOI 10.1111/j.1365-2222.2005.02303.x; PACIOS LF, 1994, COMPUT CHEM, V18, P377, DOI 10.1016/0097-8485(94)80030-8; Pacios LF, 2001, J CHEM INF COMP SCI, V41, P1427, DOI 10.1021/ci010369n; PALLAVI T, 2006, J ALLERGY CLIN IMMUN, V118, P915; Radauer C, 2006, CLIN EXP ALLERGY, V36, P920, DOI 10.1111/j.1365-2222.2006.02521.x; Radauer C, 2004, PLANT FOOD ALLERGENS, P105; Rihs HP, 1999, J ALLERGY CLIN IMMUN, V104, P1293, DOI 10.1016/S0091-6749(99)70027-8; Rodriguez J, 2000, J ALLERGY CLIN IMMUN, V106, P968, DOI 10.1067/mai.2000.110467; Rossi RE, 1996, ALLERGY, V51, P940; SANCHEZMADRID F, 1984, J IMMUNOL METHODS, V73, P367, DOI 10.1016/0022-1759(84)90412-5; Sankian Mojtaba, 2005, Clin Mol Allergy, V3, P13, DOI 10.1186/1476-7961-3-13; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Sinha N, 2002, BIOPHYS J, V83, P2946, DOI 10.1016/S0006-3495(02)75302-2; Thomas Robert A., 1997, Herpetological Natural History, V5, P19; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; Vallverdu A, 1998, J ALLERGY CLIN IMMUN, V101, P363, DOI 10.1016/S0091-6749(98)70249-0; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Weber A, 1999, MOL CELL BIOCHEM, V190, P67, DOI 10.1023/A:1006984010267; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003	33	33	36	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1481	1488		10.1016/j.jaci.2007.02.004	http://dx.doi.org/10.1016/j.jaci.2007.02.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17397911				2022-12-18	WOS:000247232800025
J	Ito, I; Laporte, JD; Fiset, PO; Asai, K; Yamauchi, Y; Martin, JG; Hamid, Q				Ito, Isao; Laporte, Johanne D.; Fiset, Pierre O.; Asai, Kazuhisa; Yamauchi, Yasuhiro; Martin, James G.; Hamid, Qutayba			Downregulation of a disintegrin and metalloproteinase 33 by IFN-gamma in human airway smooth muscle cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway remodeling; airway smooth muscle; a disintegrin and metalloproteinase 33; IFN-gamma; extracellular signal-regulated kinase pathway	PROTEIN-KINASE-C; INTERFERON-GAMMA; ADAM33 GENE; SIGNALING PATHWAYS; MESSENGER-RNA; EXPRESSION; ASTHMA; ACTIVATION; ADHESION; INTERLEUKIN-4	Background: A disintegrin and metalloproteinase 33 (ADAM33) has been identified as a susceptibility gene for asthma. ADAM33 is expressed in airway smooth muscle (ASM) cells and is suggested to play a role in the function of these cells. However, there is little information on the regulation of ADAM33. Objective: To investigate whether ADAM33 is more highly expressed in ASM cells of patients with asthma than in those of normal subjects, and whether there is any inflammatory mediator (asthma-related cytokine/chemokine) that could modulate the expression of ADAM33 in ASM cells. Method: smRNA and protein expression of ADAM33 in bronchial biopsy specimens was investigated (in situ hybridization and immunohistochemistry). Effects of cytokines on expression of ADAM33 in cultured human ASM cells were evaluated by measuring mRNA (real-time RT-PCR) and protein (Western blotting). Results: ADAM33 mRNA and protein in biopsied specimens were more highly expressed in ASM cells of patients with asthma than in cells of normal subjects. Cultured ASM cells expressed ADAM33 at both the mRNA and the protein levels. IFN-gamma reduced the mRNA expression dose-dependently and time-dependently, whereas IL-4 and IL-13 or chemokines did not affect the expression. The reduction by IFN-gamma was partially restored by U0126, inhibitor for mitogen-activated protein kinase kinase 1/2, suggesting a role for extracellular signal-regulated kinase pathway. Further studies using cycloheximide and actinomycin-D suggested that the downregulation was at the transcriptional level. Conclusion: The expression of ADAM33 by ASM cells is increased in patients with asthma, and its expression may be regulated by IFN-gamma. Clinical implications: IFN-gamma might have a role in suppressing ADAM33 in ASM cells.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada	McGill University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca		Martin, James/0000-0001-7574-5363; Ito, Isao/0000-0003-3109-898X				Behera AK, 2002, HUM GENE THER, V13, P1697, DOI 10.1089/104303402760293547; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chae SC, 2003, J HUM GENET, V48, P278, DOI 10.1007/s10038-003-0019-1; Chen H, 1998, BIOPOLYMERS, V47, P299, DOI 10.1002/(SICI)1097-0282(1998)47:4<299::AID-BIP5>3.0.CO;2-X; Choudhury GG, 2004, J BIOL CHEM, V279, P27399, DOI 10.1074/jbc.M403530200; Chung HK, 2002, EXP MOL MED, V34, P451, DOI 10.1038/emm.2002.63; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Garlisi CG, 2003, BIOCHEM BIOPH RES CO, V301, P35, DOI 10.1016/S0006-291X(02)02976-5; Gendron FP, 2003, J NEUROCHEM, V87, P344, DOI 10.1046/j.1471-4159.2003.01995.x; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Haque NS, 2004, BLOOD, V103, P1296, DOI 10.1182/blood-2002-05-1480; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Howard TD, 2003, J ALLERGY CLIN IMMUN, V112, P717, DOI 10.1016/S0091-6749(03)01939-0; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Huang J, 2005, MOL BIOL CELL, V16, P4982, DOI 10.1091/mbc.E05-03-0258; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; King NE, 2004, AM J RESP CELL MOL, V31, P257, DOI 10.1165/rcmb.2004-0026OC; Kodali RB, 2004, ARTERIOSCL THROM VAS, V24, P1211, DOI 10.1161/01.ATV.0000131654.90788.f5; Lajoie-Kadoch S, 2006, AM J PHYSIOL-LUNG C, V290, pL1238, DOI 10.1152/ajplung.00301.2005; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Lee JY, 2006, AM J RESP CRIT CARE, V173, P729, DOI 10.1164/rccm.200409-1175OC; Lee YC, 2001, CLIN EXP ALLERGY, V31, P1623, DOI 10.1046/j.1365-2222.2001.01211.x; Leir SH, 2003, AM J PHYSIOL-LUNG C, V285, pL1305, DOI 10.1152/ajplung.00255.2002; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298, DOI 10.1164/ajrccm.159.4.9708080; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; Muro S, 2001, J ALLERGY CLIN IMMUN, V108, P970, DOI 10.1067/mai.2001.119556; Nguyen VAT, 2000, BIOCHEM J, V349, P427, DOI 10.1042/0264-6021:3490427; Powell RM, 2004, AM J RESP CELL MOL, V31, P13, DOI 10.1165/rcmb.2003-0330OC; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sasaguri T, 1998, ATHEROSCLEROSIS, V138, P247, DOI 10.1016/S0021-9150(97)00296-7; Selzman CH, 2002, AM J PHYSIOL-HEART C, V283, pH1455, DOI 10.1152/ajpheart.00188.2002; Sengupta P, 2005, J BIOL CHEM, V280, P21004, DOI 10.1074/jbc.M413191200; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shapiro SD, 2002, NEW ENGL J MED, V347, P936, DOI 10.1056/NEJMcibr022144; Shibuya Y, 2004, LIFE SCI, V75, P435, DOI 10.1016/j.lfs..2003.12.016; Song JH, 2005, J BIOL CHEM, V280, P12896, DOI 10.1074/jbc.M412139200; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Tonnel AB, 2001, INT ARCH ALLERGY IMM, V124, P267, DOI 10.1159/000053729; Trautmann A, 2002, J ALLERGY CLIN IMMUN, V109, P329, DOI 10.1067/mai.2002.121460; Umland SP, 2004, AM J RESP CELL MOL, V30, P530, DOI 10.1165/rcmb.2003-0220OC; Umland SP, 2003, AM J RESP CELL MOL, V29, P571, DOI 10.1165/rcmb.2003-0028OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Wen FQ, 2003, J ALLERGY CLIN IMMUN, V111, P1307, DOI 10.1067/mai.2003.1455; Werner M, 2004, CLIN EXP ALLERGY, V34, P26, DOI 10.1111/j.1365-2222.2004.01846.x; Wu T, 2004, CYTOKINE, V25, P11, DOI 10.1016/j.cyto.2003.08.013; Yoshida M, 2002, AM J RESP CRIT CARE, V166, P451, DOI 10.1164/rccm.200202-095OC; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6; Zou J, 2004, J BIOL CHEM, V279, P9818, DOI 10.1074/jbc.M309696200; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	57	33	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					89	97		10.1016/j.jaci.2006.08.038	http://dx.doi.org/10.1016/j.jaci.2006.08.038			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208589				2022-12-18	WOS:000243622200014
J	Kamchaisatian, W; Wanwatsuntikul, W; Sleasman, JW; Tangsinmankong, N				Kamchaisatian, Wasu; Wanwatsuntikul, Watcharaphong; Sleasman, John W.; Tangsinmankong, Nutthapong			Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pneumococcal antibody; humoral deficiency; children; polysaccharide vaccine; HIV	POLYSACCHARIDE VACCINE; ANTIRETROVIRAL THERAPY; PNEUMONIA; DISEASE; IMPACT; RISK; MEN	Background: Measuring antibody responses to 23-valent pneumococcal polysaccharide vaccines (PPV) is crucial to evaluation of humoral immune function. However, data are limited comparing responses in immunodeficient subjects. Objective: A case-controlled study comparing changes in PPV antibody titer in immunocompetent and immunodeficient children was performed to validate current guidelines. Methods: A cohort of 95 immunocompetent children and 22 HIV-infected children, ages 2 to 15 years, was vaccinated with PPV, and before and after vaccination, IgG titers against capsular polysaccharides for 12 pneumococcal serotypes were measured. Results were used to calculate the receiver operator characteristic curve, sensitivity, and specificity of various interpretation criteria for their accuracy in detecting suboptimal responders. Results: Immunodeficient subjects had lower CD4%, antidiphtheria, antitetanus titers, and mean post-PPV titers (2.5 +/- 1.7 vs 4.5 +/- 2.1 mu g/mL; P < .001) compared with immunocompetent subjects. The interpretation, using individual post-PPV titer of >= 4-fold increase over prevaccination as a positive response, yielded the highest accuracy as measured by area under the curve value (receiver operator characteristic curve = .755). For this criterion, the numbers of serotypes with positive responses of <= 5 of 12 serotypes measured yielded 72.7% sensitivity and 56.8% specificity in detecting antibody-deficient subjects. Conclusion: Current guidelines using >= 4-fold increase in post-PPV titers has sufficient sensitivity and specificity to identify antibody deficiency. The minimal positive responses should be at least 50% of serotypes tested. Clinical implications: Measurement of PPV antibody response based on the current guidelines accurately identify children with humoral immunodeficiency.	Univ S Florida, All Childrens Hosp, Div Allergy & Immunol, Dept Pediat, St Petersburg, FL 33701 USA	State University System of Florida; University of South Florida	Tangsinmankong, N (corresponding author), Univ S Florida, All Childrens Hosp, Div Allergy & Immunol, Dept Pediat, 801 6th St S, St Petersburg, FL 33701 USA.	ntangsin@health.usf.edu			NIAID NIH HHS [R01 AI47723-04A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047723] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramson JS, 2000, PEDIATRICS, V106, P362; [Anonymous], 1999, CLIN EXP IMMUNOL, V118, P1; ARPADI SM, 1994, J PEDIATR-US, V125, P77, DOI 10.1016/S0022-3476(94)70127-X; BERNSTEIN LJ, 1985, J PEDIATR-US, V107, P352, DOI 10.1016/S0022-3476(85)80505-9; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Breiman RF, 2000, ARCH INTERN MED, V160, P2633, DOI 10.1001/archinte.160.17.2633; Chiappini E, 2005, CLIN EXP IMMUNOL, V140, P320, DOI 10.1111/j.1365-2249.2005.02756.x; Concepcion NF, 2001, CLIN DIAGN LAB IMMUN, V8, P266, DOI 10.1128/CDLI.8.2.266-272.2001; Conge AM, 1998, AIDS, V12, P1437, DOI 10.1097/00002030-199812000-00005; Dworkin MS, 2001, CLIN INFECT DIS, V32, P794, DOI 10.1086/319218; Fleisher TA, 2004, J ALLERGY CLIN IMMUN, V114, P227, DOI 10.1016/j.jaci.2004.06.001; French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1; Go ES, 1996, J ALLERGY CLIN IMMUN, V98, P205, DOI 10.1016/S0091-6749(96)70244-0; Hedlund J, 2000, SCAND J INFECT DIS, V32, P281, DOI 10.1080/00365540050165929; LANDESMAN SH, 1981, REV INFECT DIS, V3, pS184; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LAWRENCE EM, 1983, AM J DIS CHILD, V137, P846, DOI 10.1001/archpedi.1983.02140350024007; Lopez-Palomo C, 2004, J MED VIROL, V72, P517, DOI 10.1002/jmv.20045; MacDonald NE, 1998, JAMA-J AM MED ASSOC, V280, P1685, DOI 10.1001/jama.280.19.1685; PAHWA SG, 1984, ANN INTERN MED, V101, P757, DOI 10.7326/0003-4819-101-6-757; Shearer WT, 2000, J ALLERGY CLIN IMMUN, V106, P559, DOI 10.1067/mai.2000.109433; Sleasman John W., 2003, Journal of Allergy and Clinical Immunology, V111, pS582; Sorensen RU, 2000, PEDIATR CLIN N AM, V47, P1225, DOI 10.1016/S0031-3955(05)70269-8; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; Tangsinmankong N, 2004, ANN ALLERG ASTHMA IM, V92, P558, DOI 10.1016/S1081-1206(10)61764-4; Tangsinmankong N, 2001, ANN ALLERG ASTHMA IM, V87, P362, DOI 10.1016/S1081-1206(10)62915-8; Tangsinmankong N, 2001, ANN ALLERG ASTHMA IM, V87, P423; Wasserman RL, 1999, PEDIATR INFECT DIS J, V18, P157, DOI 10.1097/00006454-199902000-00016; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823	30	33	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1336	1341		10.1016/j.jaci.2006.09.036	http://dx.doi.org/10.1016/j.jaci.2006.09.036			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157665				2022-12-18	WOS:000242880300021
J	Buckley, RH				Buckley, RH			Primary immunodeficiency or not? Making the correct diagnosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						severe combined immunodeficiency; intestinal lymphangiectasia; T-cell function; common variable immunodeficiency; specific antibody titers; skin prick test; bacteriophage phi X174		Making a correct diagnosis of a primary immunodeficiency disease is crucial for the selection of proper therapy. Although many cases go undiagnosed, there are also many instances of incorrect diagnosis that result in years of inappropriate treatment and failure to implement beneficial treatment. This article summarizes 2 actual cases in which incorrect diagnoses led to recommendations of unwarranted high-risk or costly treatments. Had the physicians chosen tests of immune function rather than relying on immunoglobulin levels or cell counts, they would have arrived at the true diagnoses.	Duke Univ, Med Ctr, Sch Med, Durham, NC 27710 USA	Duke University	Buckley, RH (corresponding author), Duke Univ, Med Ctr, Sch Med, Box 2898, Durham, NC 27710 USA.	buckL003@mc.duke.edu	Buckley, Rebecca/AAB-1578-2019					Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Durandy A, 2005, INT ARCH ALLERGY IMM, V136, P217, DOI 10.1159/000083948; Fuss IJ, 1998, EUR J IMMUNOL, V28, P4275, DOI 10.1002/(SICI)1521-4141(199812)28:12<4275::AID-IMMU4275>3.0.CO;2-P; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; WALDMANN TA, 1966, GASTROENTEROLOGY, V50, P422	5	33	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					756	758		10.1016/j.jaci.2006.01.008	http://dx.doi.org/10.1016/j.jaci.2006.01.008			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630930				2022-12-18	WOS:000236862800005
J	Park, HW; Lee, JE; Shin, ES; Lee, JY; Bahn, JW; Oh, HB; Oh, SY; Cho, SH; Moon, HB; Min, KU; Elias, JA; Kim, YY; Kim, YK				Park, HW; Lee, JE; Shin, ES; Lee, JY; Bahn, JW; Oh, HB; Oh, SY; Cho, SH; Moon, HB; Min, KU; Elias, JA; Kim, YY; Kim, YK			Association between genetic variations of vascular endothelial growth factor receptor 2 and atopy in the Korean population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						vascular endothelial growth factor; kinase insert domain-containing receptor; single nucleotide polymorphism; Korean population; atopy	TYROSINE KINASE; FACTOR VEGF; ASTHMA; SENSITIZATION; ANGIOGENESIS; EXPRESSION; CHILDREN; PERMEABILITY; INFLAMMATION; EXPOSURE	Background: Vascular endothelial growth factor (VEGF) has been suggested to be a key mediator in the development of atopy and T(H)2 inflammation. Objective: We sought to evaluate the effects of variations in the gene coding VEGF receptor (VEGFR) 2 on intermediate phenotypes of asthma in the Korean population. Methods: A cohort of 2055 children and adolescents responded to a questionnaire concerning asthma symptoms and risk factors and underwent methacholine bronchial challenge and skin tests. The VEGFR2 gene, including the promoter area, was sequenced on 24 healthy subjects to discover informative single nucleotide polymorphisms (SNPs; minor allele frequency >2%). After haplotype reconstruction, 4 tagging SNPs (IVS6+54A>G, +889G>A, +1416T>A, and IVS25-92G>A) were scored. These SNPs were also scored in 480 adult asthmatic patients to verify the above genetic association study. Results: The prevalence of atopy was associated with a single SNP (+889G>A) of VFGFR2 with borderline significance (P =.048; relative risk, 1.13; 95% CI, 1.00-1.28). However, haplotype analysis showed that the atopy prevalence was strongly associated with a haplotype (AGAG) of VEGFR2 (P =.002; relative risk, 1.25; 95% CI, 1.09-1.42). As for airway hyperresponsiveness., neither individual SNPs nor haplotypes were found to be associated. Interestingly, the significant association was also found between atopy and the AGAG haplotype among adult asthmatic patients (P =.008; odds ratio, 1.66; 95% CI, 1.14-2.44). Conclusions: The present study demonstrated that genetic variations of VEGFR2 are significantly associated with atopy in the Korean population.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Inst Allergy & Clin Immunol, Seoul 110744, South Korea; DNA Link Inc, Seoul, South Korea; Hallym Univ, Coll Med, Dept Internal Med, Kyunggido, South Korea; Univ Ulsan, Coll Med, Dept Lab Med, Seoul, South Korea; Univ Ulsan, Coll Med, Dept Internal Med, Seoul, South Korea; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA	Seoul National University (SNU); Seoul National University (SNU); DNA Link, Inc.; Hallym University; University of Ulsan; University of Ulsan; Yale University	Kim, YK (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Yongun Dong 28, Seoul 110744, South Korea.	juinea@snu.ac.kr	Cho, Sang Heon/J-2793-2012; Park, Heung-Woo/AAW-7690-2020; Min, Kyung-Up/J-5468-2012	Park, Heung-Woo/0000-0002-6970-3228; 				Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797; Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Han W, 2004, CLIN CANCER RES, V10, P124, DOI 10.1158/1078-0432.CCR-0834-3; Holgate ST, 2002, MOL BIOTECHNOL, V22, P179, DOI 10.1385/MB:22:2:179; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885; Kim YK, 2002, CLIN EXP ALLERGY, V32, P1305, DOI 10.1046/j.1365-2745.2002.01478.x; Kim YK, 2001, CLIN EXP ALLERGY, V31, P582, DOI 10.1046/j.1365-2222.2001.01056.x; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee YC, 2001, J ALLERGY CLIN IMMUN, V107, P1106, DOI 10.1067/mai.2001.115628; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; Townley RG, 2003, CLIN REV ALLERG IMMU, V24, P85, DOI 10.1385/CRIAI:24:1:85; Wiesch DG, 1999, J ALLERGY CLIN IMMUN, V104, P895, DOI 10.1016/S0091-6749(99)70065-5	21	33	34	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					774	779		10.1016/j.jaci.2005.12.1328	http://dx.doi.org/10.1016/j.jaci.2005.12.1328			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630933				2022-12-18	WOS:000236862800009
J	Ball, TM; Anderson, D; Minto, J; Halonen, M				Ball, TM; Anderson, D; Minto, J; Halonen, M			Cortisol circadian rhythms and stress responses in infants at risk of allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endogenous cortisol; atopy; sibling; childcare; birth order; day care; hypothalamic-pituitary-adrenal axis	PSYCHOSOCIAL STRESS; ASTHMA; CHILDREN; PREVENTION; DISORDERS; ENDOTOXIN; EXPOSURE; CARE; AGE	Background: The cortisol circadian rhythm and response to stressful stimuli are altered in children and adults with allergic disease, including asthma. It is not known whether these alterations precede or follow the onset of allergic disease. Objective: We sought to evaluate the cortisol circadian rhythm and stress response among infants at risk for the development of allergic disease. Methods: Infants with and without risk factors for allergic disease were evaluated at age 6 months. Saliva was obtained at 8 AM, 2 PM, and 8 PM at home (n = 68) by parents when their infants were comfortable and in the clinic (n = 88) before and after their physical examination and vaccinations. Information regarding parental allergy and exposure to other children at home or in child care were obtained by questionnaire. Results: In multivariate analysis the circadian rhythm of cortisol was flattened because of the lack of the expected morning surge of cortisol, resulting in decreased diurnal variation of cortisol in infants of mothers with allergy (P = .035) or asthma (P = .002) or an asthmatic father (P = .022). The cortisol stress response was greater in infants of mothers with allergy (P = .045) or asthma (P = .039), those with fewer siblings (P = .066), and those not entering day care early in life (P = .017). Conclusions: These alterations in both basal and stress levels of endogenous cortisol among infants predisposed to allergic disease might affect the development of allergic immune responses early in life through interactions with inflammatory mediators.	Univ Arizona, Hlth Sci Ctr, Dept Pediat, Tucson, AZ 85724 USA; Univ Arizona, Hlth Sci Ctr, Steele Mem Childrens Res Ctr, Tucson, AZ USA; Univ Arizona, Hlth Sci Ctr, Dept Pharmacol, Tucson, AZ USA; Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	Ball, TM (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Pediat, 1501 N Campbell Ave,POB 245073, Tucson, AZ 85724 USA.	tball@u.arizona.edu		Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [HL67981] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL067981] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brown MA, 1997, CLIN EXP ALLERGY, V27, P4, DOI 10.1046/j.1365-2222.1997.d01-430.x; Buske-Kirschbaum A, 2004, PSYCHONEUROENDOCRINO, V29, P705, DOI 10.1016/S0306-4530(03)00100-8; Buske-Kirschbaum A, 2003, PSYCHOSOM MED, V65, P806, DOI 10.1097/01.PSY.0000095916.25975.4F; BuskeKirschbaum A, 1997, PSYCHOSOM MED, V59, P419, DOI 10.1097/00006842-199707000-00012; Chrousos GP, 2004, J CLIN ENDOCR METAB, V89, P563, DOI 10.1210/jc.2003-032026; Clifton VL, 2004, PLACENTA, V25, pS45, DOI 10.1016/j.placenta.2004.01.004; de Weerth C, 2003, EARLY HUM DEV, V73, P39, DOI 10.1016/S0378-3782(03)00074-4; Fei GH, 2004, ACTA PHARMACOL SIN, V25, P651; Fujitaka M, 2000, CLIN CHIM ACTA, V299, P101, DOI 10.1016/S0009-8981(00)00278-3; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9; Landyshev Iu S, 1994, Ter Arkh, V66, P12; LEWIS M, 1995, CHILD DEV, V66, P657, DOI 10.1111/j.1467-8624.1995.tb00896.x; Mantagos S, 1998, J PEDIATR ENDOCR MET, V11, P549; Martinez FD, 2003, NEW ENGL J MED, V349, P1473, DOI 10.1056/NEJMe030041; PRICE DA, 1983, ARCH DIS CHILD, V58, P454, DOI 10.1136/adc.58.6.454; SELYE H, 1951, AM J MED, V10, P549, DOI 10.1016/0002-9343(51)90327-0; Shanks N, 2000, P NATL ACAD SCI USA, V97, P5645, DOI 10.1073/pnas.090571897; *STAT COLL SAL LLC, EXP RANG HIGH SENS C; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; Tout K, 1998, CHILD DEV, V69, P1247, DOI 10.2307/1132263; Wamboldt MZ, 2003, J ALLERGY CLIN IMMUN, V111, P509, DOI 10.1067/mai.2003.140	25	33	34	1	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					306	311		10.1016/j.jaci.2005.11.009	http://dx.doi.org/10.1016/j.jaci.2005.11.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461131				2022-12-18	WOS:000235687300012
J	Suzaki, Y; Hamada, K; Sho, M; Ito, T; Miyamoto, K; Akashi, S; Kashizuka, H; Ikeda, N; Nakajima, Y; Iwase, M; Homma, I; Kobzik, L; Kimura, H				Suzaki, Y; Hamada, K; Sho, M; Ito, T; Miyamoto, K; Akashi, S; Kashizuka, H; Ikeda, N; Nakajima, Y; Iwase, M; Homma, I; Kobzik, L; Kimura, H			A potent antiangiogenic factor, endostatin prevents the development of asthma in a murine model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endostatin; vascular endothelial growth factor; ovalbumin; asthma	ENDOTHELIAL GROWTH-FACTOR; AIRWAY HYPERRESPONSIVENESS; CELL-ADHESION; FACTOR VEGF; ANGIOGENESIS; NEOVASCULARIZATION; INFLAMMATION; EXPRESSION; VASCULARITY; RECEPTORS	Background: Clinical studies suggest a role for angiogenesis in the development and persistence of chronic asthma, but whether angiogenic mediators contribute to acute asthma has not been fully studied. Objective: The aim of this study was to investigate a role of vascular endothelial growth factor (VEGF), a major angiogenic and proinflammatory mediator, in allergen-induced acute asthma and to determine whether endostatin/Fc, a potent antiangiogenic factor can attenuate allergic airway responses. Methods: We sensitized BALB/c mice with ovalbumin. We measured serum VEGF and examined immunoreactive VEGF around the airways 48 hours after the last challenge with either aerosolized PBS or ovalbumin once per day for 3 days. We also treated ovalbumin-sensitized mice with either endostatin/Fc or control fusion protein at the time of challenge with ovalbumin. We analyzed allergic airway responses 48 hours after the last ovalbumin challenge. Results: Ovalbumin challenge induced immunolocalization of numerous VEGF-positive cells around airways and increased serum VEGF levels. Treatment with endostatin/Fc inhibited the airway hyperresponsiveness, pulmonary allergic inflammation, production of ovalbumin-specific IgE, and lung inflammatory mediators. Both VEGF-dependent and independent mechanisms are indicated by results using antibody blockade of VEGF receptors, which caused decreased allergic pulmonary inflammation but did not alter airway hyperresponsiveness or serum IgE levels. Conclusion: These data demonstrate for the first time that recombinant endostatin can prevent the development of asthma features in a mouse model and suggest that this class of agents merits further study as novel therapeutics for asthma.	Nara Med Univ, Dept Internal Med 2, Kashihara, Nara 6348522, Japan; Nara Med Univ, Dept Surg, Kashihara, Nara 6348522, Japan; Showa Univ, Sch Med, Dept Physiol 2, Tokyo, Japan; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Nara Medical University; Nara Medical University; Showa University; Harvard University; Harvard T.H. Chan School of Public Health	Hamada, K (corresponding author), Nara Med Univ, Dept Internal Med 2, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	khamada@naramed-u.ac.jp						Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9; Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bates J, 2004, AM J RESP CELL MOL, V31, P373, DOI 10.1165/ajrcmb.31.3.1; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Djukanovic R, 2002, J ALLERGY CLIN IMMUN, V109, pS539, DOI 10.1067/mai.2002.124568; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Hamada K, 2003, J IMMUNOL, V170, P1683, DOI 10.4049/jimmunol.170.4.1683; Hamada K, 1999, J TOXICOL ENV HEAL A, V58, P129, DOI 10.1080/009841099157340; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hartert T V, 2000, Curr Opin Pulm Med, V6, P4, DOI 10.1097/00063198-200001000-00002; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kim YM, 2002, J BIOL CHEM, V277, P27872, DOI 10.1074/jbc.M202771200; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; *NAT RES COUNC, 1996, I LAB AN RES COMM LI; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Salvato G, 2001, THORAX, V56, P902, DOI 10.1136/thorax.56.12.902; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje; Tanaka H, 2003, AM J RESP CRIT CARE, V168, P1495, DOI 10.1164/rccm.200306-727OC; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yin GY, 2002, MOL THER, V5, P547, DOI 10.1006/mthe.2002.0590; Yoshiji H, 1998, HEPATOLOGY, V28, P1489, DOI 10.1002/hep.510280607; Yoshiji H, 2004, HEPATOLOGY, V39, P1517, DOI 10.1002/hep.20218; Yoshiji H, 1999, HEPATOLOGY, V30, P1179, DOI 10.1002/hep.510300509	40	33	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1220	1227		10.1016/j.jaci.2005.08.052	http://dx.doi.org/10.1016/j.jaci.2005.08.052			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337449				2022-12-18	WOS:000235687000008
J	Hufnagl, K; Winkler, B; Focke, M; Valenta, R; Scheiner, O; Renz, H; Wiedermann, U				Hufnagl, K; Winkler, B; Focke, M; Valenta, R; Scheiner, O; Renz, H; Wiedermann, U			Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						animal model; type 1 allergy; polysensitization; mucosal tolerance; polypeptides; hybrid; IL-10; TGF-beta	BIRCH POLLEN ALLERGEN; T-CELL EPITOPES; GRASS PHLEUM-PRATENSE; MUCOSAL TOLERANCE; IMMUNE-RESPONSES; AIRWAY INFLAMMATION; MURINE MODEL; IMMUNOTHERAPY; PEPTIDES; BET-V-1	Background: Specific immunotherapy is less effective in patients with multiple allergic sensitizations compared with monosensitized patients. Objective: We therefore established a mouse model of polysensitization to the major birch and timothy grass pollen allergens to test whether allergic polysensitization can be prevented by multiple allergen application via the mucosal route. Methods: Female BALB/c mice were immunized intraperitoneally with recombinant (r) Bet v 1, rPhl p 1, and rPhl p 5. For intranasal tolerance induction, a mixture of the complete allergens was compared with allergen-derived immunodominant peptides applied either as a mixture or as a synthetic hybrid peptide composed of the T-cell epitopes of the 3 allergens. Results: Intranasal application of the mixture of the complete allergen molecules did not prevent polysensitization to the same allergens. In contrast, pretreatment with a mixture of the immunodominant peptides or the hybrid peptide led to significantly reduced allergen-specific IgE responses in sera, IL-4 production in vitro, and suppressed airway inflammation. TGF-beta mRNA levels did not change, and IL-10 production was significantly suppressed after the pretreatment. The fact that the reduction of IL-10 was not abrogated after IL-10 receptor neutralization and that tolerance was not transferable with splenocytes indicates that the suppression of T(H)2 responses in polysensitized mice might not be mediated by immunosuppressive cytokines. Conclusion: Our study demonstrates that it is possible to suppress allergic immune responses simultaneously to several clinical important allergens. Thus, mucosal coapplication of selected peptides/hybrid peptides could be the basis of a mucosal polyvalent vaccine to prevent multiple sensitivities in atopic patients.	Univ Vienna, Dept Specif Prophylaxis & Trop Med, Ctr Physiol & Pathophysiol, A-1095 Vienna, Austria; Hosp Philipps Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany	University of Vienna; Philipps University Marburg	Wiedermann, U (corresponding author), Univ Vienna, Dept Specif Prophylaxis & Trop Med, Ctr Physiol & Pathophysiol, Kinderspitalgasse 15, A-1095 Vienna, Austria.	ursula.wiedermann@meduniwien.ac.at		Valenta, Rudolf/0000-0001-5944-3365; Wiedermann, Ursula/0000-0002-1302-3223				Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; Alexander Clare, 2002, Current Drug Targets - Inflammation and Allergy, V1, P353, DOI 10.2174/1568010023344562; Astori M, 2000, J IMMUNOL, V165, P3497, DOI 10.4049/jimmunol.165.6.3497; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; EBNER C, 1995, J IMMUNOL, V154, P1932; Eriksson NE, 1996, J INVEST ALLERG CLIN, V6, P36; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Fowler S, 2002, EUR J IMMUNOL, V32, P2997, DOI 10.1002/1521-4141(2002010)32:10<2997::AID-IMMU2997>3.0.CO;2-D; Hirahara K, 2001, J ALLERGY CLIN IMMUN, V108, P94, DOI 10.1067/mai.2001.115481; HOLT PG, 1981, IMMUNOLOGY, V42, P409; Hoyne GF, 2000, INT IMMUNOL, V12, P177, DOI 10.1093/intimm/12.2.177; Hoyne GF, 1997, INT IMMUNOL, V9, P1165, DOI 10.1093/intimm/9.8.1165; Hufnagl K, 2003, CLIN EXP IMMUNOL, V133, P170, DOI 10.1046/j.1365-2249.2003.02210.x; Hufnagl K, 2002, ALLERGY, V57, P49; Jarnicki AG, 2001, INT IMMUNOL, V13, P1223, DOI 10.1093/intimm/13.10.1223; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; LoMan R, 1997, HUM IMMUNOL, V54, P180, DOI 10.1016/S0198-8859(97)00076-1; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; Muller WD, 1998, CLIN EXP ALLERGY, V28, P1538; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; Schenk S, 1995, J ALLERGY CLIN IMMUN, V96, P986, DOI 10.1016/S0091-6749(95)70237-7; Shi FD, 1998, J NEUROL SCI, V155, P1, DOI 10.1016/S0022-510X(97)00232-3; Silvestri M, 1999, ANN ALLERG ASTHMA IM, V83, P335, DOI 10.1016/S1081-1206(10)62674-9; Smith TRF, 2004, CYTOKINE, V28, P49, DOI 10.1016/j.cyto.2004.07.001; Southwood S, 1998, J IMMUNOL, V160, P3363; Takabayashi K, 2003, J IMMUNOL, V170, P3898, DOI 10.4049/jimmunol.170.7.3898; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Von Garnier C, 2002, CLIN EXP ALLERGY, V32, P401, DOI 10.1046/j.1365-2222.2002.01304.x; VRTALA S, 1993, J IMMUNOL, V151, P4773; Wiedermann U, 1999, J ALLERGY CLIN IMMUN, V103, P1202, DOI 10.1016/S0091-6749(99)70200-9; Wiedermann U, 2001, INT ARCH ALLERGY IMM, V126, P68, DOI 10.1159/000049496; Winkler B, 2003, IMMUNOLOGY, V110, P376, DOI 10.1046/j.1365-2567.2003.01751.x; Winkler B, 2002, CLIN EXP ALLERGY, V32, P30, DOI 10.1046/j.0022-0477.2001.01214.x	41	33	37	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					370	376		10.1016/j.jaci.2005.04.002	http://dx.doi.org/10.1016/j.jaci.2005.04.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083792				2022-12-18	WOS:000235686400020
J	Kocabas, CN; Yavuz, AS; Lipsky, PE; Metcalfe, DD; Akin, C				Kocabas, CN; Yavuz, AS; Lipsky, PE; Metcalfe, DD; Akin, C			Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	60th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 18-23, 2004	San Francisco, CA	Amer Acad Allergy, Asthma & Immunol		mast cells; basophils; c-kit; mastocytosis; hematopoiesis	BLOOD MONONUCLEAR-CELLS; SYSTEMIC MASTOCYTOSIS; PERIPHERAL-BLOOD; SMOLDERING MASTOCYTOSIS; HEMATOLOGIC DISORDER; PROGENITOR CELLS; STEM-CELLS; INVOLVEMENT; DIFFERENTIATION; EXPRESSION	Background: Mast cells and basophils share similar morphologic and functional properties; however, it is not known whether they are derived from a bilineage (basophil/mast cell)-restricted progenitor. Objective: To assess whether basophils and mast cells are derived from common committed progenitors using the c-kit D816V mutation as a biologic signature. Methods: The D816V c-kit mutation found in mast cells of patients with systemic mastocytosis is used as a trackable genetic marker to assess the lineage relationship between mast cells and basophils. Blood and bone marrow aspirates were collected from 33 consecutive patients with mastocytosis with different disease severity. Peripheral blood basophils, monocytes and neutrophils were sorted by immunomagnetic beads. Presence of the D816V e-kit mutation was analyzed by restriction fragment length polymorphism in the genomic DNA and mRNA from sorted cells in all patients and in the genomic DNA of individual basophils of 1 patient. Results: The c-kit D816V mutation was detectable in basophils of 5 patients (15%). All 5 patients had the c-kit mutation also detectable in monocytes and thus had multilineage involvement. Single cell analysis of the genomic DNA in I patient showed a similar degree of clonal expansion in basophils, monocytes, and neutrophils. Mutated c-kit was expressed at the mRNA level in all 5 patients. There was no difference in surface Kit expression levels in basophils. Conclusion: Basophils carrying the D816V c-kit mutation in mastocytosis were detected only in the context of a multilineage involvement. These results argue against the presence of a bilineage-restricted committed progenitor for mast cells and basophils.	Univ Michigan, Dept Med, Div Allergy & Immunol, Ann Arbor, MI 48109 USA; NIAID, Lab Allerg Dis, Bethesda, MD USA; NIAMSD, Autoimmun Branch, NIH, Bethesda, MD USA; Istanbul Univ, Fac Med, Div Hematol, Istanbul, Turkey	University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Istanbul University	Akin, C (corresponding author), Univ Michigan, Dept Med, Div Allergy & Immunol, 4220D MSRB-3,Box 0638,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	cemakin@umich.edu		Akin, Cem/0000-0001-6301-4520	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000249, Z01AI000249] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Afonja O, 1998, ANN HEMATOL, V77, P183, DOI 10.1007/s002770050439; Agis H, 1996, IMMUNOLOGY, V87, P535, DOI 10.1046/j.1365-2567.1996.493578.x; AGIS H, 1993, J IMMUNOL, V151, P4221; Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822; Akin C, 2000, EXP HEMATOL, V28, P140, DOI 10.1016/S0301-472X(99)00145-9; Akin C, 2003, LEUKEMIA RES, V27, P877, DOI 10.1016/S0145-2126(03)00093-6; Akin C, 2001, LEUKEMIA RES, V25, P635, DOI 10.1016/S0145-2126(01)00023-6; ANDRE C, 1989, ONCOGENE, V4, P1047; Arock M, 2002, J LEUKOCYTE BIOL, V71, P557; BOYCE JA, 1995, J EXP MED, V182, P49, DOI 10.1084/jem.182.1.49; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Buhring HJ, 1999, BLOOD, V94, P2343; CZARNETZKI BM, 1983, INT ARCH ALLER A IMM, V71, P161, DOI 10.1159/000233381; DENBURG JA, 1985, BLOOD, V66, P312; HERMINE O, 1992, BLOOD, V80, P3060; Jordan JH, 2001, LEUKEMIA RES, V25, P627, DOI 10.1016/S0145-2126(01)00019-4; Kempuraj D, 1999, BLOOD, V93, P3338, DOI 10.1182/blood.V93.10.3338.410k05_3338_3346; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; KITAMURA Y, 1993, AM J MED SCI, V306, P185, DOI 10.1097/00000441-199309000-00011; Li LX, 1998, J IMMUNOL, V161, P5079; Metcalfe DD, 2001, LEUKEMIA RES, V25, P577, DOI 10.1016/S0145-2126(01)00046-7; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; Pardanani A, 2003, BLOOD, V102, P3093, DOI 10.1182/blood-2003-05-1627; Pardanani A, 2003, LEUKEMIA RES, V27, P883, DOI 10.1016/S0145-2126(03)00065-1; POCH T, 1973, NEOPLASMA, V20, P413; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Sotlar K, 2000, J CLIN PATHOL-MOL PA, V53, P188, DOI 10.1136/mp.53.4.188; Sundstrom M, 2003, IMMUNOLOGY, V108, P89, DOI 10.1046/j.1365-2567.2003.01559.x; Takahashi N, 1998, BLOOD, V92, P4758, DOI 10.1182/blood.V92.12.4758; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; VALENT P, 1992, BLOOD, V80, P2237; Valent P, 2003, HEMATOL ONCOL CLIN N, V17, P1227, DOI 10.1016/S0889-8588(03)00089-3; Valent P, 2002, INT ARCH ALLERGY IMM, V127, P137, DOI 10.1159/000048185; Valent P, 2001, WHO CLASSIFICATION T, P291; WEIL SC, 1987, AM J CLIN PATHOL, V87, P66, DOI 10.1093/ajcp/87.1.66; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; Yavuz AS, 2002, BLOOD, V100, P661, DOI 10.1182/blood-2002-01-0203	39	33	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1155	1161		10.1016/j.jaci.2005.02.030	http://dx.doi.org/10.1016/j.jaci.2005.02.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	935WZ	15940128	Bronze			2022-12-18	WOS:000229815400008
J	Jabara, HH; Geha, RS				Jabara, HH; Geha, RS			Jun N-terminal kinase is essential for CD40-mediated IgE class switching in B cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD40; B cells; isotype switching; Jun terminal kinase	ACTIVATED PROTEIN-KINASE; CYTIDINE DEAMINASE AID; INTERCELLULAR-ADHESION MOLECULE-1; FACTOR-KAPPA-B; C-JUN; DIFFERENTIAL ACTIVATION; GENE-EXPRESSION; NH2-TERMINAL KINASE; INDUCED APOPTOSIS; CD40 LIGAND	Background: CD40 ligation activates nuclear factor kappa B (NF-kappa B) and the mitogen-activated protein kinases p38 and C-Jun N-terminal kinase (JNK) and causes immunoglobulin class-switch recombination (CSR) in B cells. Both NF-kappa B and p38 are important for CD40-mediated CSR. The role of JNK activation in CD40-mediated isotype switching is unknown. Objective: We sought to determine the role of JNK activation in CD40-mediated isotype switching. Methods: Splenic B cells from BALB/c mice were stimulated with anti-CD40 mAb and IL-4 or with soluble CD40 ligand in the presence or absence of SP600125, an anthrapyrazolone inhibitor of JNK. The following events were examined: IgE production by means of ELISA; S mu-S is an element of deletional switch recombination by means of digestion circularization PCR; C is an element of germline, mature E, and activation-induced deaminase (AID) transcription by means of RT-PCR; and proliferation by tritiated thymidine incorporation and surface expression of CD23, CD54, and CD86 by means of FACS analysis. Results: SP600125 at 10 mu M drastically inhibited JNK phosphorylation but had little effect on CD40-mediated p38 phosphorylation and expression of the NF-kappa B dependent genes c-Myc and bcl-xL. SP600125 inhibited IgE synthesis by approximately 88% but bad no effect on B-cell proliferation and survival in response to anti-CD40 + IL-4 or on upregulation of CD23, CD54, and CD86 in response to CD40 ligation. Analysis of molecular events involved in IgE class switching revealed that SP600125 had no effect on the expression of C is an element of germline and AID transcripts. In contrast, SP600125 severely reduced S mu-S is an element of switch recombination and expression of mature E transcripts. Conclusion: These results demonstrate that JNK activation is essential for CD40-mediated CSR to IgE and suggest that JNK is important for AID activity in B cells.	Harvard Univ, Div Immunol, Childrens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University	Jabara, HH (corresponding author), Harvard Univ, Div Immunol, Childrens Hosp, Sch Med, KARP Bldg 10126,1 Blackfan Circle, Boston, MA 02115 USA.	Haifa.jabara@childrens.harvard.edu			NIAID NIH HHS [AI 31136] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031136] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aicher A, 1999, J IMMUNOL, V163, P5786; Bacharier LB, 1998, INT ARCH ALLERGY IMM, V115, P257, DOI 10.1159/000069456; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Brady K, 2001, BIOCHEM BIOPH RES CO, V289, P276, DOI 10.1006/bbrc.2001.5968; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHU CC, 1992, P NATL ACAD SCI USA, V89, P6978, DOI 10.1073/pnas.89.15.6978; Dadgostar H, 1998, J BIOL CHEM, V273, P24775, DOI 10.1074/jbc.273.38.24775; Dadgostar H, 2002, P NATL ACAD SCI USA, V99, P1497, DOI 10.1073/pnas.032665099; Dedeoglu F, 2004, INT IMMUNOL, V16, P395, DOI 10.1093/intimm/dxh042; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466; Hasbold J, 1998, EUR J IMMUNOL, V28, P1040, DOI 10.1002/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.3.CO;2-0; Hayakawa J, 2003, J BIOL CHEM, V278, P20582, DOI 10.1074/jbc.M210992200; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Honjo T, 2002, NAT IMMUNOL, V3, P800, DOI 10.1038/ni0902-800; Horwitz BH, 1999, J IMMUNOL, V162, P1941; Iciek LA, 1997, J IMMUNOL, V158, P4769; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Li YY, 1996, J IMMUNOL, V157, P1440; Liao HL, 2000, ENDOTHELIUM-NEW YORK, V7, P121, DOI 10.3109/10623320009072207; Lim W, 2002, J IMMUNOL, V168, P1759, DOI 10.4049/jimmunol.168.4.1759; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Muscarella DE, 2002, TOXICOL SCI, V68, P82, DOI 10.1093/toxsci/68.1.82; Park S, 2004, J CELL BIOCHEM, V91, P973, DOI 10.1002/jcb.10768; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Richards ML, 1997, J IMMUNOL, V158, P263; Roebuck KA, 1999, INT J MOL MED, V4, P223; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sakata N, 1999, EUR J IMMUNOL, V29, P2999, DOI 10.1002/(SICI)1521-4141(199909)29:09<2999::AID-IMMU2999>3.0.CO;2-L; Sanchez-Perez I, 2002, MOL BIOL CELL, V13, P2933, DOI 10.1091/mbc.E02-01-0022; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Sutherland CL, 1999, J IMMUNOL, V162, P4720; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Takada E, 2001, J IMMUNOL, V166, P1641, DOI 10.4049/jimmunol.166.3.1641; Wang NP, 1999, ARTERIOSCL THROM VAS, V19, P2078, DOI 10.1161/01.ATV.19.9.2078; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; Zhang K, 2002, J ALLERGY CLIN IMMUN, V110, P421, DOI 10.1067/mai.2002.126382	59	33	33	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					856	863		10.1016/j.jaci.2005.01.020	http://dx.doi.org/10.1016/j.jaci.2005.01.020			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806010				2022-12-18	WOS:000228373400029
J	Sampson, HA				Sampson, HA			Food allergy: When mucosal immunity goes wrong	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							TELEPHONE SURVEY; PEANUT PROTEINS; HYPERSENSITIVITY; CHILDREN; PREVALENCE; IGE; ALLERGENICITY; EPITOPES; FISH		Mt Sinai Sch Med, Dept Pediat & Immunol, Div Pediat Allergy & Immunol, New York, NY 10029 USA; Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Sampson, HA (corresponding author), Mt Sinai Sch Med, Dept Pediat & Immunol, Div Pediat Allergy & Immunol, Box 1198, New York, NY 10029 USA.	hugh.sampson@mssm.edu						AAS K, 1966, INT ARCH ALLER A IMM, V29, P346, DOI 10.1159/000229716; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; BOCK SA, 1987, PEDIATRICS, V79, P683; BRAUNSTAHL GJ, 2005, UNIFIED IMMUNE SYSTE, V115, P142; Breiteneder H, 2005, J ALLERGY CLIN IMMUN, V115, P14, DOI 10.1016/j.jaci.2004.10.022; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; ELSAYED S, 1975, SCAND J IMMUNOL, V4, P203, DOI 10.1111/j.1365-3083.1975.tb02618.x; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; James SP, 2005, J ALLERGY CLIN IMMUN, V115, P25, DOI 10.1016/j.jaci.2004.11.011; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2002, CURR OPIN ALLERGY CL, V2, P273, DOI 10.1097/00130832-200206000-00019; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; Mayer L, 2003, PEDIATRICS, V111, P1595; MCDONALD PJ, 1984, PEDIATR RES, V18, P751, DOI 10.1203/00006450-198408000-00016; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003	31	33	39	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					139	141		10.1016/j.jaci.2004.11.003	http://dx.doi.org/10.1016/j.jaci.2004.11.003			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637560				2022-12-18	WOS:000226267000020
J	Kanda, N; Mitsui, H; Watanabe, S				Kanda, N; Mitsui, H; Watanabe, S			Prostaglandin E-2 suppresses CCL27 production through EP2 and EP3 receptors in human keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CCL27; prostaglandin E-2; EP2; EP3; NF-kappa B; cyclic adenosine monophosphate; Ca2(+)	NF-KAPPA-B; PROTEIN-KINASE-A; ATOPIC-DERMATITIS; TRANSCRIPTIONAL ACTIVITY; HUMAN MONOCYTES; GROWTH-FACTOR; MAST-CELLS; CHEMOKINE; SUBTYPES; ALPHA	Background: The chemokine CCL27 attracts skin-homing T cells. CCL27 production by keratinocytes is enhanced in skin lesions from patients with atopic dermatitis or psoriasis vulgaris. It is suggested that prostaglandin E-2 (PGE(2)) regulates skin inflammation. Objective: We examined the in vitro effects of PGE(2) On CCL27 production in human keratinocytes. Methods: Keratinocytes were incubated with TNF-alpha in the presence or absence of PGE(2)-CCL27 secretion and mRNA level were analyzed by means of ELISA and RT-PCR, respectively. Nuclear factor kappaB (NF-kappaB)-dependent transcriptional activity was analyzed by using luciferase assays. Results: TNF-alpha increased CCL27 secretion and mRNA levels in parallel to NF-kappaB activity in keratinocytes. NF-kappaB p50 or p65 antisense oligonucleotides suppressed TNF-alpha-induced CCL27 production, indicating the requirement of NF-kappaB for CCL27 production. PGE(2), EP2, or EP3 agonists reduced TNF-alpha-induced CCL27 secretion and mRNA levels in parallel to NF-kappaB activity and CCL2, CCL5, CXCL8, and CXCLIO mRNA levels. Either EP3-specific or dual EP1-EP2 antagonist partially blocked the inhibitory effects of PGE(2) on CCL27 production and NF-KB activity, and the addition of both completely abrogated the inhibition, whereas EP1 or EP4 antagonists were ineffective. Intracellular Ca2+ chelator BAPTA/AM or cyclic adenosine monophosphate (cAMP)-dependent protein kinase inhibitor H-89 partially blocked the inhibitory effects of PGE(2) on CCL27 production and NF-KB activity, and the addition of both completely abrogated the inhibition. PGE(2) or EP3 agonist increased intracellular Ca2+ concentrations. PGE(2) or EP2 agonist increased intracellular cAMP concentrations. Conclusion: PGE(2) might suppress CCL27 production by inhibiting NF-KB activity through EP2-mediated cAMP and EP3-mediated Ca2+ signals. PGE(2) might terminate T cellmediated skin inflammation by inhibiting CCL27 production.	Teikyo Univ, Sch Med, Dept Dermatol, Itabashi Ku, Tokyo 1738605, Japan; Univ Tokyo, Dept Dermatol, Tokyo, Japan	Teikyo University; University of Tokyo	Kanda, N (corresponding author), Teikyo Univ, Sch Med, Dept Dermatol, Itabashi Ku, 11-1,Kaga 2, Tokyo 1738605, Japan.	nmk@med.teikyo-u.ac.jp	Kanda, Naoko/AAD-1808-2020	Kanda, Naoko/0000-0003-4389-2312				Abdel-Majid RM, 2004, J IMMUNOL, V172, P1227, DOI 10.4049/jimmunol.172.2.1227; Alexanian AR, 1999, FASEB J, V13, P1611, DOI 10.1096/fasebj.13.12.1611; Anthonsen MW, 2001, J BIOL CHEM, V276, P30527, DOI 10.1074/jbc.M008481200; Asboth G, 1996, ENDOCRINOLOGY, V137, P2572, DOI 10.1210/en.137.6.2572; Cherian PP, 2003, J BIOL CHEM, V278, P43146, DOI 10.1074/jbc.M302993200; Delgado M, 2003, BIOCHEM BIOPH RES CO, V302, P275, DOI 10.1016/S0006-291X(03)00149-9; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; GREAVES MW, 1988, ARCH DERMATOL RES, V280, pS33; IMAYAMA S, 1995, LANCET, V346, P1559, DOI 10.1016/S0140-6736(95)92089-7; Kakinuma T, 2003, J ALLERGY CLIN IMMUN, V111, P592, DOI 10.1067/mai.2003.114; Kanda N, 2003, J INVEST DERMATOL, V121, P570, DOI 10.1046/j.1523-1747.2003.12428.x; Kanda N, 2002, J INVEST DERMATOL, V119, P1290, DOI 10.1046/j.1523-1747.2002.19626.x; KATAYAMA H, 1981, Journal of Dermatology (Tokyo), V8, P323; Kiekens RCM, 2001, BRIT J DERMATOL, V145, P957, DOI 10.1046/j.1365-2133.2001.04508.x; Konger RL, 1998, BBA-MOL CELL RES, V1401, P221, DOI 10.1016/S0167-4889(97)00114-6; Locati M, 2002, J IMMUNOL, V168, P3557, DOI 10.4049/jimmunol.168.7.3557; Miyauchi-Hashimoto H, 2001, J IMMUNOL, V166, P5782, DOI 10.4049/jimmunol.166.9.5782; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; NEGISHI M, 1995, J LIPID MEDIAT CELL, V12, P379, DOI 10.1016/0929-7855(95)00024-K; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Parry GCN, 1997, J IMMUNOL, V159, P5450; Reilly DM, 2000, ACTA DERM-VENEREOL, V80, P171; REMY W, 1986, INT J DERMATOL, V25, P266, DOI 10.1111/j.1365-4362.1986.tb02240.x; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Santamaria LF, 1999, INT ARCH ALLERGY IMM, V118, P351, DOI 10.1159/000024132; Shinomiya S, 2001, BIOCHEM PHARMACOL, V61, P1153, DOI 10.1016/S0006-2952(01)00586-X; Shreedhar V, 1998, J IMMUNOL, V160, P3783; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432-1033.2002.03157.x; Takayama K, 2002, J BIOL CHEM, V277, P44147, DOI 10.1074/jbc.M204810200; VOORHEES JJ, 1983, ARCH DERMATOL, V119, P541, DOI 10.1001/archderm.119.7.541; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x	33	33	36	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1403	1409		10.1016/j.jaci.2004.08.041	http://dx.doi.org/10.1016/j.jaci.2004.08.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577845	Bronze			2022-12-18	WOS:000225577400024
J	Saini, S; Bloom, DC; Bieneman, A; Vasagar, K; Togias, A; Schroeder, J				Saini, S; Bloom, DC; Bieneman, A; Vasagar, K; Togias, A; Schroeder, J			Systemic effects of allergen exposure on blood basophil IL-13 secretion and Fc epsilon RI beta	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE receptors; basophils; IL-13; allergen challenge; Fc epsilon RI beta	NERVE GROWTH-FACTOR; MIXED LEUKOCYTE-CULTURES; HISTAMINE-RELEASE; PERIPHERAL-BLOOD; ACTIVATION; RELEASABILITY; EXPRESSION; CHALLENGE; ASTHMA; INTERLEUKIN-13	Background: Airway allergen challenge studies have shown the upregulation of cytokines in local airway tissues and distal effects on bone marrow precursors for eosinophils and basophils. Objective: We investigated whether local intranasal allergen challenge alters the phenotype of circulating basophils to a primed state. Methods: Ten subjects with allergic rhinitis were challenged with allergen by means of intranasal spray on 3 sequential days. Basophils were isolated from subjects before challenge and 3, 24, and 96 hours after the third allergen challenge. Basophils were compared before challenge and after the last allergen challenge for levels of Fcis an element ofRIbeta protein by means of Western blotting and for Fcis an element ofRIbeta mRNA expression by means of realtime PCR. Basophils were also compared with regard to spontaneous secretion of IL-4 and IL-13. Results: Basophil Fcis an element ofRIbeta protein levels increased in 5 of 6 subjects after allergen challenge relative to before challenge. Likewise, basophil Fcis an element ofRIbeta mRNA levels increased a median of 2-fold after the last challenge relative to before challenge (P = .007, n = 9). IL-13 protein was detected in supernatants of 7 of 9 subjects' basophil-enriched cultures after the last challenge compared with 3 of 9 basophil-enriched cultures before challenge (median, 6.2 vs 0 pg/mL; P = .058). IL-4 was not detected in any culture supernatant. Conclusion: Intranasal allergen challenge transiently activates circulating basophils by increasing expression of the Fcis an element ofRIbeta subunit and spontaneous IL-13 secretion. Because Fcis an element ofRIbeta is an amplifier of Fcis an element ofRI-mediated responses and IL-13 is proinflammatory, these findings support a primed basophil functional state and demonstrate a systemic effect of local allergen challenge that could contribute in exacerbating allergic reactions.	Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Dept Med, Baltimore, MD USA	Johns Hopkins University	Saini, S (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayveiw Circle, Baltimore, MD 21224 USA.	ssaini@jhmi.edu			NIAID NIH HHS [AI01564, K08 AI001564-05, AI42221] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042221, R01AI042221, R29AI042221, K08AI001564] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; CASOLARO V, 1989, AM REV RESPIR DIS, V139, P1375, DOI 10.1164/ajrccm/139.6.1375; Denburg JA, 1998, J ALLERGY CLIN IMMUN, V102, pS74, DOI 10.1016/S0091-6749(98)70034-X; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; Gibbs BF, 1996, EUR J IMMUNOL, V26, P2493, DOI 10.1002/eji.1830261033; GILBERT HS, 1975, BLOOD, V46, P279; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; Li HM, 1996, J IMMUNOL, V156, P4833; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; Lie WJ, 2000, CLIN EXP ALLERGY, V30, P882; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Liu MC, 2001, J ALLERGY CLIN IMMUN, V108, P29; MARONE G, 1994, J ALLERGY CLIN IMMUN, V94, P1293, DOI 10.1016/0091-6749(94)90345-X; Miura K, 2001, J IMMUNOL, V167, P2282, DOI 10.4049/jimmunol.167.4.2282; Nouri-Aria KT, 2001, J ALLERGY CLIN IMMUN, V108, P205, DOI 10.1067/mai.2001.117175; Ochensberger B, 1996, BLOOD, V88, P3028, DOI 10.1182/blood.V88.8.3028.bloodjournal8883028; Redrup AC, 1998, J IMMUNOL, V160, P1957; Saini SS, 2001, J ALLERGY CLIN IMMUN, V107, P832, DOI 10.1067/mai.2001.114653; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; Schleimer RP, 2000, J ALLERGY CLIN IMMUN, V106, pS191; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; Schroeder JT, 2001, J ALLERGY CLIN IMMUN, V107, P265, DOI 10.1067/mai.2001.112846; Sin AZ, 2001, J ALLERGY CLIN IMMUN, V108, P387; TUNG R, 1982, J IMMUNOL, V128, P2067; Yamaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1279, DOI 10.1016/S0091-6749(96)70196-3; Yoshimura C, 2002, J ALLERGY CLIN IMMUN, V109, P817, DOI 10.1067/mai.2002.123532	29	33	35	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					768	774		10.1016/j.jaci.2004.06.015	http://dx.doi.org/10.1016/j.jaci.2004.06.015			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480314				2022-12-18	WOS:000224439100008
J	Kopper, RA; Odum, NJ; Sen, M; Helm, RM; Stanley, JS; Burks, AW				Kopper, RA; Odum, NJ; Sen, M; Helm, RM; Stanley, JS; Burks, AW			Peanut protein allergens: Gastric digestion is carried out exclusively by pepsin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanuts; food allergy; gastric digestion	IGE-BINDING EPITOPES; FOOD ALLERGENS; IN-VITRO; DIGESTIBILITY; STABILITY; BIOLOGY	Background: A major characteristic of many food allergens, including Ara h 1, a major peanut allergen, is their resistance to gastric digestion. One estimate of the allergenic potential of a possible protein allergen is its stability under simulated gastric conditions. Objective: Because the rate and extent of digestion of allergenic proteins will affect the severity of any subsequent allergic response, it is important to correlate protein allergen digestion in simulated gastric fluid with that in actual gastric fluid. Methods: A major peanut allergen, Ara h 1, was digested in vitro by using both pepsin and porcine gastric fluid. Several comparisons between the 2 sets of proteolytic conditions were assessed including pH optima and the effect of temperature, denaturants, and specific enzyme inhibitors. Results: In vitro digestion of Ara h 1 with pepsin and porcine gastric fluid resulted in virtually identical hydrolysis patterns as observed on SDS-PAGE. The protease activity of both pepsin and gastric fluid were inhibited at high pH and in the presence of pepstatin. However, both remained active in 4 mol/L urea and at 60 degreesC. Conclusions: Protein digestion in the porcine stomach is carried out by pepsin. In vivo gastric digestion is modeled accurately by peptic hydrolysis. Digestion conditions in vivo are comparable to experimental conditions in vitro provided that the acidic nature of the stomach contents is optimal for characterization of the allergen under standard pepsin digestion conditions. Additional experimentation using crude food extracts, both in the presence and absence of a complete meal, is needed to elucidate the complete physiologic nature of food allergen digestion.	Univ Arkansas Med Sci, Arkansas Childrens Hosp, Arkansas Childrens Nutr Ctr, Dept Microbiol Immunol, Little Rock, AR 72202 USA; Duke Univ, Ctr Med, Dept Pediat, Div Pediat Allergy & Immunol, Durham, NC 27706 USA; Univ Arkansas Med Sci, Arkansas Childrens Hosp, Res Inst, Chem Dept,Hendrix Coll, Little Rock, AR USA	Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Duke University; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	Helm, RM (corresponding author), Univ Arkansas Med Sci, Arkansas Childrens Hosp, Arkansas Childrens Nutr Ctr, Dept Microbiol Immunol, Slot 512-20B,1120 Marshall St, Little Rock, AR 72202 USA.	HelmRickiM@uams.edu						Aalberse RC, 1997, ENVIRON TOXICOL PHAR, V4, P55, DOI 10.1016/S1382-6689(97)10042-4; Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; *BOARD TRUST, 1995, US PHARM, V23, P2053; DARRAGH AJ, 1995, J PEDIATR GASTR NUTR, V21, P387, DOI 10.1097/00005176-199511000-00004; DESHPANDE SS, 1987, J FOOD SCI, V52, P1326, DOI 10.1111/j.1365-2621.1987.tb14074.x; Hefle SL, 1996, FOOD TECHNOL-CHICAGO, V50, P86; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; MOUGHAN PJ, 1989, P NUT SOC N, V14, P116; MOUGHAN PJ, 1990, J PEDIATR GASTR NUTR, V10, P385, DOI 10.1097/00005176-199004000-00020; ROWAN AM, 1994, BRIT J NUTR, V71, P29, DOI 10.1079/BJN19940108; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Vieths S, 1997, ENVIRON TOXICOL PHAR, V4, P61, DOI 10.1016/S1382-6689(97)10043-6; Vieths S, 1998, ALLERGY, V53, P65, DOI 10.1111/j.1398-9995.1998.tb04965.x; Yagami T, 2000, J ALLERGY CLIN IMMUN, V106, P752, DOI 10.1067/mai.2000.109171; [No title captured]	17	33	35	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					614	618		10.1016/j.jaci.2004.05.012	http://dx.doi.org/10.1016/j.jaci.2004.05.012			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356566				2022-12-18	WOS:000223799600022
J	Leo, HL; Bender, BG; Leung, SB; Tran, ZV; Leung, DYM				Leo, HL; Bender, BG; Leung, SB; Tran, ZV; Leung, DYM			Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Pediat Behav Hlth, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leo, HL (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, 1400 Jackson St, Denver, CO 80206 USA.							Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P598, DOI 10.1067/mai.2003.174; COLE RJ, 1992, SLEEP, V15, P461, DOI 10.1093/sleep/15.5.461; DAHL RE, 1995, ARCH PEDIAT ADOL MED, V149, P856, DOI 10.1001/archpedi.1995.02170210030005; Ebata T, 2001, BRIT J DERMATOL, V144, P305, DOI 10.1046/j.1365-2133.2001.04019.x; Eichenfield LF, 2003, J ALLERGY CLIN IMMUN, V111, P1154, DOI 10.1067/mai.2003.1492; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; LEWISJONES MS, 1995, BRIT J DERMATOL, V132, P942; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, pS128, DOI DOI 10.1016/j.jaci.2003.09.032; Reuveni H, 1999, ARCH PEDIAT ADOL MED, V153, P249	10	33	35	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					691	693		10.1016/j.jaci.2004.05.037	http://dx.doi.org/10.1016/j.jaci.2004.05.037			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15446293				2022-12-18	WOS:000223799600035
J	Mohapatra, SS; Lockey, RF; Vesely, DL; Gower, WR				Mohapatra, SS; Lockey, RF; Vesely, DL; Gower, WR			Natriuretic peptides and genesis of asthma: An emerging paradigm?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atrial natriuretic peptide; kaliuretic peptide; asthma; inflammation; bronchodilation; nuclear factor kappa B	NF-KAPPA-B; HUMAN ENDOTHELIAL-CELLS; PROTEIN-KINASE; KALIURETIC PEPTIDE; GROWTH-FACTOR; CYCLIC-GMP; POTENT BRONCHODILATOR; BRONCHIAL EPITHELIUM; ALPHA PRODUCTION; SMOOTH-MUSCLE	Exposure to allergens and infections contribute to early immune development. However, knowledge of the role of cellular metabolic, physiologic, and endocrinologic factors in controlling immune development and asthma is limited. Immune cells, including macrophages, dendritic cells, and T lymphocytes, express receptors for atrial natriuretic peptide (ANP) both in the fetal and neonatal lymphoid organs. ANP has garnered much attention for its cardiovascular effects, but its apparently significant role in the physiology and immunity of the lung has been underappreciated. Studies indicate that ANP also plays a significant role in shaping the early immune responses to environmental antigens. The C-terminal prohormone natriuretic peptide ANP (or NP99-126), which possesses bronchodilatory properties, is involved in polarizing dendritic cells to produce a T(H)2 response. Also, de novo overexpression of another pro-ANP peptide, NP73-102, provides persistent bronchoprotection and induces significant anti-inflammatory activities in the lung epithelial cells. Thus natriuretic peptides appear to play a pivotal role in the genesis and control of asthma, and they might provide an important target to modulate allergen-induced immune responses in allergic patients.	Univ S Florida, Coll Med, Dept Internal Med, JMC Airway Dis Res Ctr,Div Allergy & Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Div Endocrinol, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; VA Hosp, Tampa, FL USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Mohapatra, SS (corresponding author), Univ S Florida, Coll Med, Dept Internal Med, JMC Airway Dis Res Ctr,Div Allergy & Immunol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	smohapat@hsc.usf.edu	Mohapatra, Shyam/C-2500-2012		NHLBI NIH HHS [R01 HL 071101] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071101] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbey SE, 2003, ENDOCRINOLOGY, V144, P240, DOI 10.1210/en.2002-220702; ABELL TJ, 1989, BIOCHEM BIOPH RES CO, V160, P1392, DOI 10.1016/S0006-291X(89)80158-5; AITON JF, 1987, J PHYSIOL-LONDON, V392, pP97; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; ANGUS RM, 1994, CLIN EXP ALLERGY, V24, P784, DOI 10.1111/j.1365-2222.1994.tb00991.x; ANGUS RM, 1993, AM REV RESPIR DIS, V147, P1122, DOI 10.1164/ajrccm/147.5.1122; APPEL RG, 1988, FEBS LETT, V238, P135, DOI 10.1016/0014-5793(88)80242-4; Beltowski J, 2000, Postepy Hig Med Dosw, V54, P895; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chai OH, 2000, EXP MOL MED, V32, P179, DOI 10.1038/emm.2000.29; CHANEZ P, 1990, J ALLERGY CLIN IMMUN, V86, P321, DOI 10.1016/S0091-6749(05)80094-6; CHIOU S, 1995, ENDOCRINOLOGY, V136, P2033, DOI 10.1210/en.136.5.2033; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200; DESCHEPPER CF, 1994, J NEUROCHEM, V62, P1974; FLUGE T, 1995, EUR J CLIN INVEST, V25, P728, DOI 10.1111/j.1365-2362.1995.tb01951.x; Forssmann WG, 2001, CARDIOVASC RES, V51, P450, DOI 10.1016/S0008-6363(01)00331-5; GERBES AL, 1990, SCAND J CLIN LAB INV, V50, P195, DOI 10.3109/00365519009089153; GUTKOWSKA J, 1989, ENDOCR REV, V10, P519, DOI 10.1210/edrv-10-4-519; Hamad AM, 1999, AM J PHYSIOL-LUNG C, V277, pL910, DOI 10.1152/ajplung.1999.277.5.L910; Hellermann G, 2004, J ALLERGY CLIN IMMUN, V113, P79, DOI 10.1016/j.jaci.2003.10.009; Hofmann F, 2000, J CELL SCI, V113, P1671; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113, DOI 10.1164/ajrccm.162.supplement_2.ras-12; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; HULKS G, 1994, EUR RESPIR J, V7, P1593, DOI 10.1183/09031936.94.07091593; HULKS G, 1990, CLIN SCI, V79, P51, DOI 10.1042/cs0790051; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V264, P696, DOI 10.1006/bbrc.1999.1542; Izumi T, 2001, J CLIN INVEST, V108, P203, DOI 10.1172/JCI200112088; Ji Da, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P459; Kiemer AK, 1998, J BIOL CHEM, V273, P13444, DOI 10.1074/jbc.273.22.13444; Kiemer AK, 2003, ENDOCRINOLOGY, V144, P802, DOI 10.1210/en.2002-220610; Kiemer AK, 2002, BIOCHEM BIOPH RES CO, V295, P1068, DOI 10.1016/S0006-291X(02)00807-0; Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3; Kiemer AK, 2001, IMMUNOL CELL BIOL, V79, P11, DOI 10.1046/j.1440-1711.2001.00969.x; Kiemer AK, 2000, J IMMUNOL, V165, P175, DOI 10.4049/jimmunol.165.1.175; Kiemer AK, 1997, ENDOCRINOLOGY, V138, P4282, DOI 10.1210/en.138.10.4282; Kiemer AK, 2000, J HEPATOL, V33, P236, DOI 10.1016/S0168-8278(00)80364-5; KOMATSU Y, 1992, LANCET, V340, P622, DOI 10.1016/0140-6736(92)92167-E; Kumar M, 2002, J ALLERGY CLIN IMMUN, V110, P879, DOI 10.1067/mai.2002.129699; LEITMAN DC, 1988, J BIOL CHEM, V263, P3720; Levin ER, 1998, NEW ENGL J MED, V339, P321; MANTYH CR, 1986, HYPERTENSION, V8, P712, DOI 10.1161/01.HYP.8.8.712; Matsukawa N, 1999, P NATL ACAD SCI USA, V96, P7403, DOI 10.1073/pnas.96.13.7403; Morita R, 2003, J IMMUNOL, V170, P5869, DOI 10.4049/jimmunol.170.12.5869; MOSS RB, 1991, PEPTIDES, V12, P851, DOI 10.1016/0196-9781(91)90145-F; Ohbayashi H, 1998, EUR J PHARMACOL, V346, P55, DOI 10.1016/S0014-2999(98)00014-4; OHSAKI Y, 1993, CANCER RES, V53, P3165; Overton RM, 1996, PEPTIDES, V17, P1041; Panchenko MP, 1998, BBA-MOL CELL RES, V1403, P115, DOI 10.1016/S0167-4889(98)00023-8; Pedram A, 2000, J BIOL CHEM, V275, P7365, DOI 10.1074/jbc.275.10.7365; Pedram A, 2001, ENDOCRINOLOGY, V142, P1578, DOI 10.1210/en.142.4.1578; PERREAULT T, 1995, AM J RESP CRIT CARE, V151, P226, DOI 10.1164/ajrccm.151.1.7812560; Saetta M, 1989, Eur Respir J Suppl, V6, p477s; SAKAMOTO M, 1986, BIOCHEM BIOPH RES CO, V135, P515, DOI 10.1016/0006-291X(86)90024-0; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; Szukiewicz D, 2001, INFLAMM RES, V50, pS59; TALLERICOMELNYK T, 1992, BIOCHEM BIOPH RES CO, V189, P610, DOI 10.1016/0006-291X(92)92244-R; Thrane EV, 2001, EXP LUNG RES, V27, P387, DOI 10.1080/019021401750193638; Toda M, 2002, J ALLERGY CLIN IMMUN, V109, P246, DOI 10.1067/mai.2002.121555; Tsukagoshi H, 2001, REGUL PEPTIDES, V99, P21, DOI 10.1016/S0167-0115(01)00218-X; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VESELY DL, 1995, AM J MED SCI, V310, P143, DOI 10.1097/00000441-199510000-00003; VESELY DL, 1994, CIRCULATION, V90, P1129, DOI 10.1161/01.CIR.90.3.1129; Vesely DL, 2001, CARDIOVASC RES, V51, P647, DOI 10.1016/S0008-6363(01)00256-5; Vesely DL, 2001, J CLIN ENDOCR METAB, V86, P5438, DOI 10.1210/jc.86.11.5438; Vesely DL, 1998, AM J NEPHROL, V18, P204, DOI 10.1159/000013338; VESELY DL, 1995, J ENDOCRINOL, V146, P373, DOI 10.1677/joe.0.1460373; Vesely DL, 1996, METABOLISM, V45, P315, DOI 10.1016/S0026-0495(96)90284-X; Vollmar AM, 1996, ENDOCRINOLOGY, V137, P1706, DOI 10.1210/en.137.5.1706; VOLLMAR AM, 1990, COMP BIOCHEM PHYS A, V96, P459, DOI 10.1016/0300-9629(90)90661-B; Xu KP, 2002, INVEST OPHTH VIS SCI, V43, P3673	73	33	44	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					520	526		10.1016/j.jaci.2004.05.028	http://dx.doi.org/10.1016/j.jaci.2004.05.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356551	Bronze			2022-12-18	WOS:000223799600008
J	Vonk, JM; Boezen, HM; Postma, DS; Schouten, JP; van Aalderen, WMC; Boersma, ER				Vonk, JM; Boezen, HM; Postma, DS; Schouten, JP; van Aalderen, WMC; Boersma, ER			Perinatal risk factors for bronchial hyperresponsiveness and atopy after a follow-up of 20 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial hyperresponsiveness; atopy; perinatal risk factors; prospective cohort study; children; adults	EUROPEAN-COMMUNITY; LUNG-FUNCTION; AIRWAY RESPONSIVENESS; PULMONARY-FUNCTION; ALLERGIC RHINITIS; MATERNAL SMOKING; BIRTH COHORT; ASTHMA; CHILDHOOD; PREGNANCY	Background: Perinatal risk factors are associated with lung function and respiratory symptoms in adult life. Whether the same holds for distinctive asthma features, such as bronchial hyperresponsiveness (BUR) and atopy, has scarcely been studied. Objective: We sought to identify the perinatal risk factors for the development of BUR and atopy. Methods: BUR and atopy were measured after 20 years' follow-up in 597 of 3162 babies born from 1975 through 1978. Factors directly related to delivery of these children were studied in association with the presence of BUR and atopy. Results: Twenty-five percent had BUR, and 47% had atopy. Delivery duration of longer than 12 hours was associated with the development of atopy (odds ratio [OR], 2.24; 95% CI, 1.30-3.86), and severe respiratory infection in the first year of life was associated with the development of BUR (OR, 2.69; 95% CI, 1.41-5.16). Nonatopic subjects born after induced labor and current smokers were more likely to have BUR (ORs of 2.41 [95% CI, 1.07-5.41] and 2.50 [95% CI, 1.12-5.59], respectively). Prenatal smoke exposure and childhood pet keeping decreased the risk for atopy, especially in BHR-positive subjects (ORs of 0.51 [95% CI, 0.27-0.99] and 0.46 [95% CI, 0.24-0.88], respectively). Conclusions: It has been shown that events before or during birth still have an effect on respiratory health 20 years later. We put forward that an extreme hormonal status during delivery primes the fetal immune system toward atopy development. Furthermore, a severe respiratory infection in the first year of life appears associated with BUR development, and prenatal smoke exposure might be protective for the development of atopy, yet explanatory mechanisms are lacking thus far.	Univ Groningen, Dept Epidemiol & Stat, NL-9700 AD Groningen, Netherlands; Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands; Univ Amsterdam, Acad Med Ctr, NL-1012 WX Amsterdam, Netherlands; Univ Groningen Hosp, Dept Obstet & Gynecol Pediat, Sect Perinatal Nutr & Dev, Groningen, Netherlands	University of Groningen; University of Groningen; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen	Vonk, JM (corresponding author), Univ Groningen, Dept Epidemiol & Stat, POB 196, NL-9700 AD Groningen, Netherlands.	j.m.vonk@med.rug.nl	Vonk, Judith M/ABA-3009-2020; Vonk, Judith/K-8477-2019	Vonk, Judith M/0000-0001-7531-4547; Vonk, Judith/0000-0001-7531-4547				APGAR V, 1953, Curr Res Anesth Analg, V32, P260; Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P51, DOI 10.1067/mai.2003.34; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; Boezen HM, 2002, EUR RESPIR J, V20, P383, DOI 10.1183/09031936.02.00234102; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Castro-Rodriguez JA, 1999, AM J RESP CRIT CARE, V159, P1891, DOI 10.1164/ajrccm.159.6.9811035; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; DeKruyff R, 1998, J IMMUNOL, V160, P2231; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Gitau R, 1998, LANCET, V352, P707, DOI 10.1016/S0140-6736(05)60824-0; GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x; Gregory A, 1999, CLIN EXP ALLERGY, V29, P330; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Hjern A, 2001, CLIN EXP ALLERGY, V31, P908, DOI 10.1046/j.1365-2222.2001.01096.x; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Jaakkola JJK, 2002, J ALLERGY CLIN IMMUN, V109, P784, DOI 10.1067/mai.2002.123870; Koopman LP, 2001, PEDIATRICS, V108, P943, DOI 10.1542/peds.108.4.943; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; LIU AH, 2003, J ALLERGY CLIN IMM S, V1, pS785; Martinez Fernando D, 2002, Paediatr Respir Rev, V3, P193, DOI 10.1016/S1526-0542(02)00188-4; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P800, DOI 10.1067/mai.2002.124046; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Nafstad P, 2000, J ALLERGY CLIN IMMUN, V106, P867, DOI 10.1067/mai.2000.110558; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; Power LL, 2002, J REPROD IMMUNOL, V56, P19, DOI 10.1016/S0165-0378(01)00146-2; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Shaheen SO, 1999, THORAX, V54, P396, DOI 10.1136/thx.54.5.396; SOYSETH V, 1995, CHEST, V107, P389, DOI 10.1378/chest.107.2.389; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1998, THORAX, V53, P117, DOI 10.1136/thx.53.2.117; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; TOUWEN BCL, 1980, EARLY HUM DEV, V4, P207, DOI 10.1016/0378-3782(80)90027-4; Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732	39	33	34	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					270	276		10.1016/j.jaci.2004.03.051	http://dx.doi.org/10.1016/j.jaci.2004.03.051			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316502				2022-12-18	WOS:000223405600009
J	Platts-Mills, TAE				Platts-Mills, TAE			Allergen avoidance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							HOUSE-DUST MITE; BRONCHIAL HYPERREACTIVITY; ASTHMATIC-CHILDREN; PRIMARY PREVENTION; EXPOSURE; CAT; REDUCTION; COVERS; DOG; INTERVENTION		Univ Virginia, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X				ADKINSON NF, 1997, NEW ENGL J MED, V334, P501; *AM AC ALL ATHM IM, 2001, ALL REP 2000; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; BONER AL, 1993, ALLERGY, V48, P119, DOI 10.1111/j.1398-9995.1993.tb04713.x; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; Chowdhury BA, 2003, NEW ENGL J MED, V349, P1668; Custis NJ, 2003, CLIN EXP ALLERGY, V33, P986, DOI 10.1046/j.1365-2222.2003.01706.x; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gore RB, 2002, CLIN EXP ALLERGY, V32, P856, DOI 10.1046/j.1365-2222.2002.01403.x; Gotzsche PC, 1998, BRIT MED J, V317, P1105, DOI 10.1136/bmj.317.7166.1105; Gotzsche PC, 2001, COCHRANE DB SYST REV, V3; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Htut T, 2001, J ALLERGY CLIN IMMUN, V107, P55, DOI 10.1067/mai.2001.111240; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; MURRAY AB, 1983, PEDIATRICS, V71, P418; *NIH, 1997, NIH PUBL; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills TAE, 2003, NEW ENGL J MED, V349, P207, DOI 10.1056/NEJMp030082; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; PLATTSMILLS TAE, 1982, LANCET, V2, P675; Rijssenbeek-Nouwens LHM, 2002, THORAX, V57, P784, DOI 10.1136/thorax.57.9.784; Ronmark E, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e37; Sheikh Aziz, 2002, BMC Fam Pract, V3, P12, DOI 10.1186/1471-2296-3-12; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Terreehorst I, 2002, CLIN EXP ALLERGY, V32, P1160, DOI 10.1046/j.1365-2745.2002.01461.x; Tovey ER, 2003, NEW ENGL J MED, V349, P1669; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; Vanlaar CH, 2000, J ALLERGY CLIN IMMUN, V105, P1130, DOI 10.1067/mai.2000.106213; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; WALSHAW MJ, 1986, Q J MED, V58, P199; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175	42	33	37	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					388	391		10.1016/j.jaci.2003.12.027	http://dx.doi.org/10.1016/j.jaci.2003.12.027			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007333	Bronze			2022-12-18	WOS:000220144200003
J	Herrick, CA; Das, J; Xu, L; Wisnewski, AV; Redlich, CA; Bottomly, K				Herrick, CA; Das, J; Xu, L; Wisnewski, AV; Redlich, CA; Bottomly, K			Differential roles for CD4 and CD8 T cells after diisocyanate sensitization: Genetic control of T(H)2-induced lung inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; diisocyanate; skin; airway; eosinophils; contact hypersensitivity	AIRWAY HYPERRESPONSIVENESS; OCCUPATIONAL ASTHMA; IMMUNE-RESPONSES; DENDRITIC CELLS; EOSINOPHILIA; LYMPHOCYTES; EXPOSURE; WORKERS; MICE; ASSOCIATION	Background: Exposure to diisocyanates is a major cause of occupational asthma. We previously developed a novel mouse model of diisocyanate-induced asthma involving epicutaneous sensitization to hexamethylene diisocyanate (HDI) that demonstrates many features of the human disease, including airway eosinophilia and mucus hypersecretion. Objective: To determine what factors are critical for the development of HDI-induced airway inflammation, we investigated the strain distribution of this response and the roles of CD4(+) and CD8(+) T cells. Methods: Mice were epicutaneously exposed to HDI and then challenged with HDI, either by means of inhalation to induce airway inflammation or on the ear to induce contact hypersensitivity (CHS). Lymph node cytokine production and serum antibodies were also measured. Results: Induction of airway eosinophilia was highly dependent on the mouse strain used, with C57BL/6, A/J, CBA, C3H, and C57BL/10 mice all having significantly fewer eosinophils than BALB/c mice. HDI-specific antibodies and lymph node IL-5 and IL-13 production were also diminished in nonBALB/c strains. In contrast, CHS to HDI developed in all strains tested. Studies in mice deficient in either CD4+ or CD8+ T cells revealed that CD4+ T cells were critical for HDI-induced airway eosinophilia, whereas CD8+ T cells were the major effector cells in CHS. Conclusion: The data suggest that, in contrast to CHS, induction of T(H)2 responses after epicutaneous exposure to diisocyanates is strongly genetically influenced. Furthermore, the lung inflammatory response to inhaled HDI appears to depend primarily on effective generation of these CD4+ TH2 responses, as is the case in atopic asthma.	Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Herrick, CA (corresponding author), Yale Univ, Sch Med, Dept Dermatol, 333 Cedar St,POB 208059, New Haven, CT 06520 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069495, R01HL062622, R01HL065209, P50HL056389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K24ES000355] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL062622, R01 HL062622-03, R01-HL62622, R01 HL062622-02, R01 HL069495, P50-HL56389, R01-HL65209, R01 HL069495-01] Funding Source: Medline; NIEHS NIH HHS [K24-ES00355] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Balboni A, 1996, EUR RESPIR J, V9, P207, DOI 10.1183/09031936.96.09020207; Baur X, 1996, AM J IND MED, V29, P467, DOI 10.1002/(SICI)1097-0274(199605)29:5<467::AID-AJIM5>3.0.CO;2-J; BENTLEY AM, 1994, J INVEST ALLERG CLIN, V4, P222; Bernstein DI, 1999, AM J IND MED, V36, P459, DOI 10.1002/(SICI)1097-0274(199910)36:4<459::AID-AJIM7>3.0.CO;2-W; Bernstein JA, 1996, TOXICOLOGY, V111, P181, DOI 10.1016/0300-483X(96)03375-6; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Cohn L, 2001, J IMMUNOL, V166, P2760, DOI 10.4049/jimmunol.166.4.2760; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Cullinan P, 1998, CLIN EXP ALLERGY, V28, P668; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FINOTTO S, 1991, BRIT J IND MED, V48, P116; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Herrick CA, 2000, J CLIN INVEST, V105, P765, DOI 10.1172/JCI8624; Herrick CA, 2002, J ALLERGY CLIN IMMUN, V109, P873, DOI 10.1067/mai.2002.123533; Hnizdo E, 2001, CLIN EXP ALLERGY, V31, P32, DOI 10.1046/j.1365-2222.2001.00981.x; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Kimber I, 2002, CONTACT DERMATITIS, V46, P1, DOI 10.1034/j.1600-0536.2002.460101.x; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LEVIN D, 1993, J IMMUNOL, V151, P6742; Liu YC, 2000, AM J IND MED, V37, P265, DOI 10.1002/(SICI)1097-0274(200003)37:3<265::AID-AJIM4>3.0.CO;2-O; Lummus ZL, 1998, J ALLERGY CLIN IMMUN, V102, P265, DOI 10.1016/S0091-6749(98)70095-8; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376, DOI 10.5271/sjweh.1383; Mapp C, 1999, ANN ALLERG ASTHMA IM, V83, P645, DOI 10.1016/S1081-1206(10)62888-8; Mapp CE, 2000, CLIN EXP ALLERGY, V30, P651; Morokata T, 1999, IMMUNOLOGY, V98, P345, DOI 10.1046/j.1365-2567.1999.00890.x; Park HS, 1999, CLIN EXP ALLERGY, V29, P1395; Petsonk EL, 2000, CHEST, V118, P1183, DOI 10.1378/chest.118.4.1183; RATTRAY NJ, 1994, TOXICOLOGY, V88, P15, DOI 10.1016/0300-483X(94)90108-2; Redlich CA, 2002, INT IMMUNOPHARMACOL, V2, P213, DOI 10.1016/S1567-5769(01)00174-6; Redlich CA, 2001, AM J IND MED, V39, P587, DOI 10.1002/ajim.1058; Schwarze J, 1999, J IMMUNOL, V162, P4207; Van Rijt LS, 2001, MICROSC RES TECHNIQ, V53, P256, DOI 10.1002/jemt.1092; Wang BH, 2000, J IMMUNOL, V165, P6783, DOI 10.4049/jimmunol.165.12.6783; WillsKarp M, 1997, AM J RESP CRIT CARE, V156, pS89, DOI 10.1164/ajrccm.156.4.12-tac-3; Wisnewski AV, 2001, CURR OPIN ALLERGY CL, V1, P169, DOI 10.1097/01.all.0000011003.36723.d8; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661, DOI 10.1164/ajrccm.155.2.9032210	42	33	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1087	1094		10.1067/mai.2003.1413	http://dx.doi.org/10.1067/mai.2003.1413			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743574				2022-12-18	WOS:000182904500024
J	Meyer, KA; Arduino, JM; Santanello, NC; Knorr, BA; Bisgaard, H				Meyer, KA; Arduino, JM; Santanello, NC; Knorr, BA; Bisgaard, H			Response to montelukast among subgroups of children aged 2 to 14 years with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; montelukast sodium; preschool children	LEUKOTRIENE RECEPTOR ANTAGONIST; DOUBLE-BLIND TRIAL; PRESCHOOL-CHILDREN; PERSISTENT ASTHMA; CHILDHOOD ASTHMA; YOUNG-CHILDREN; VARIABILITY; VALIDATION; SYMPTOMS; THERAPY	Background: Determining who responds to asthma therapies, particularly leukotriene modifiers, continues to be explored. Objective: We sought to identify patient characteristics predictive of response to montelukast. Methods: We used data from 2 clinical trials in which children with asthma received either montelukast or placebo. Symptoms, beta-agonist use, and unanticipated health resource use caused by asthma were recorded in validated daily diaries for children 2 to 5 (n = 689) and 6 to 14 (n = 336) years old. We defined primary end points of days without asthma in 2- to 5-year-old patients (24 hours without symptoms, beta-agonist use, or asthma attack) and change in percent predicted FEV1 in 6- to 14-year-old children. Asthma attack was defined by the use of rescue oral corticosteroids or by an unscheduled visit to a medical provider. Patients were grouped according to baseline characteristics, such as family history of asthma, personal history of allergy, frequency of asthma symptoms, eosinophilia, and concomitant use of inhaled corticosteroids; or cromolyn. We examined the stratum-specific effects of montelukast on the percentage of days without asthma, change in percent predicted FEV1, asthma attack, and a variety of secondary symptom and FEV1 end points. Results: We did not identify characteristics that predicted response to montelukast in either preschool or 6- to 14-year-old children. These findings were consistent across all symptom and FEV1 outcomes. There was also no differential response to montelukast in either age group when asthma attack was the outcome. Conclusion: The patient characteristics studied do not appear to provide an indication of who will benefit most from treatment with montelukast.	Merck & Co Inc, Merck Res Labs, Dept Pulm Immunol, W Point, PA 19486 USA; Merck & Co Inc, Merck Res Labs, Dept Epidemiol, W Point, PA 19486 USA; Merck & Co Inc, Merck Res Labs, Dept Pulm Immunol, Rahway, NJ 07065 USA; Merck & Co Inc, Merck Res Labs, Dept Epidemiol, Rahway, NJ 07065 USA; Copenhagen Univ Hosp, Dept Paediat, Copenhagen, Denmark	Merck & Company; Merck & Company; Merck & Company; Merck & Company; University of Copenhagen	Arduino, JM (corresponding author), Merck & Co Inc, Merck Res Labs, Dept Pulm Immunol, BL1-7,POB 4, W Point, PA 19486 USA.		Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592				Adams RJ, 2001, PEDIATRICS, V107, P706, DOI 10.1542/peds.107.4.706; ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Bisgaard H, 2000, PEDIATR PULM, V29, P221, DOI 10.1002/(SICI)1099-0496(200003)29:3<221::AID-PPUL11>3.3.CO;2-G; BROOKE AM, 1995, AM J RESP CRIT CARE, V152, P1872, DOI 10.1164/ajrccm.152.6.8520749; Brookes S T, 2001, Health Technol Assess, V5, P1; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; CRAPO RO, 1995, AM J RESP CRIT CARE, V152, P1107, DOI DOI 10.1164/AJRCCM.152.3.7663792; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; KALINER M, 1995, ANN ALLERG ASTHMA IM, V75, P169; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Knorr B, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e48; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Martinez FD, 1999, ALLERGY, V54, P24, DOI 10.1111/j.1398-9995.1999.tb04384.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; *NAT ASTHM ED PREV, 1997, NIH PUBL; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Roorda RJ, 2001, J ALLERGY CLIN IMMUN, V108, P540, DOI 10.1067/mai.2001.118789; Rosner B, 2011, FUNDAMENTALS BIOSTAT; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Santanello NC, 2000, J ALLERGY CLIN IMMUN, V106, P861, DOI 10.1067/mai.2000.110478; Santanello NC, 1999, ARCH DIS CHILD, V80, P414, DOI 10.1136/adc.80.5.414; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Zhang J, 2002, CLIN THER, V24, P574, DOI 10.1016/S0149-2918(02)85133-5	27	33	33	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					757	762		10.1067/mai.2003.1391	http://dx.doi.org/10.1067/mai.2003.1391			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704354				2022-12-18	WOS:000182258500014
J	Zimmermann, N; Rothenberg, ME				Zimmermann, N; Rothenberg, ME			Receptor internalization is required for eotaxin-induced responses in human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; chemokines; eosinophils	PROTEIN-COUPLED RECEPTORS; MEDIATED ENDOCYTOSIS; DIFFERENTIAL REGULATION; ACTIN POLYMERIZATION; HUMAN-NEUTROPHILS; BETA-ARRESTINS; CHEMOTAXIS; ACTIVATION; EXPRESSION; CELLS	Background: CC chemokine receptor 3 (CCR3) is a major chemokine receptor involved in regulating eosinophil trafficking, and therefore the elucidation of ligand-induced CCR3 events has important implications in understanding the biologic and pathologic properties of eosinophils. After ligand binding to. CCR3, cellular signals include stimulatory fie, calcium mobilization, actin polymerization, shape change, and chemotaxis) and inhibitory tie, desensitization of the receptor) events. We have previously demonstrated that CCR3 undergoes rapid and prolonged ligand-induced internalization. Objective: Here we explore the role of internalization in downstream cellular processes, including shape change, actin polymerization, calcium mobilization, and desensitization. Methods: Peripheral blood-derived human eosinophils were pretreated with 2 mechanistically distinct inhibitors of internalization, sucrose and phenylarsine oxide, and functional responses were monitored. Results: We first demonstrate that ligand-induced internalization is required for chemokine-induced eosinophil shape change. To define which signaling components upstream of eosinophil shape change required internalization, we next studied the role of internalization in calcium mobilization and actin polymerization. Sucrose and phenylarsine oxide pretreatment inhibited actin polymerization, implicating receptor internalization in this early response. In contrast, calcium mobilization was not inhibited by blockade of internalization. Finally, we were interested in testing the role of internalization in receptor desensitization. We first demonstrated that preincubation with eotaxin induced a dose-dependent desensitization in eotaxin induced eosinophil transepithelial migration. However, this phenomenon was not inhibited by blockade of internalization. Conclusion: These results establish that CCR3 internalization is critically involved in select eosinophil functional responses (ie, cellular shape change and actin polymerization) but not desensitization and calcium mobilization.	Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Childrens Hosp, Med Ctr, Div Allergy & Immunol, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NIAID NIH HHS [R01 AI42242-05, R01 AI45898-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042242, R01AI045898] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; Boehme SA, 1999, J IMMUNOL, V163, P1611; Bohm SK, 1997, BIOCHEM J, V322, P1; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; El-Shazly A, 1999, BIOCHEM BIOPH RES CO, V264, P163, DOI 10.1006/bbrc.1999.1379; Elsner J, 1996, J CELL PHYSIOL, V167, P548, DOI 10.1002/(SICI)1097-4652(199606)167:3<548::AID-JCP18>3.3.CO;2-Y; Elsner J, 2000, J BIOL CHEM, V275, P7787, DOI 10.1074/jbc.275.11.7787; Forster R, 1998, J IMMUNOL, V160, P1522; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HERTEL C, 1985, J BIOL CHEM, V260, P2547; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOWARD TH, 1984, J CELL BIOL, V98, P1265, DOI 10.1083/jcb.98.4.1265; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; LUKACS NW, 1995, AM J RESP CELL MOL, V13, P1; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631; Sabroe I, 1999, J IMMUNOL, V162, P2946; Sambrano GR, 1999, J BIOL CHEM, V274, P20178, DOI 10.1074/jbc.274.29.20178; SKLAR LA, 1985, J CELL BIOL, V101, P1161, DOI 10.1083/jcb.101.3.1161; Sorensen SD, 1998, MOL PHARMACOL, V53, P827; WALLACE PJ, 1984, J CELL BIOL, V99, P1060, DOI 10.1083/jcb.99.3.1060; WYMANN MP, 1990, J BIOL CHEM, V265, P619; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Ying S, 1999, J IMMUNOL, V163, P6321; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zimmermann N, 2000, J IMMUNOL, V165, P5839, DOI 10.4049/jimmunol.165.10.5839; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611; Zimmermann N, 2000, J IMMUNOL, V164, P1055, DOI 10.4049/jimmunol.164.2.1055	44	33	37	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					97	105		10.1067/mai.2003.3	http://dx.doi.org/10.1067/mai.2003.3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532103				2022-12-18	WOS:000180465500015
J	Peng, ZK; Rasic, N; Liu, Y; Simons, FER				Peng, ZK; Rasic, N; Liu, Y; Simons, FER			Mosquito saliva-specific IgE and IgG antibodies in 1059 blood donors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RESPONSES; EXTRACTS; BITES		Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB, Canada; Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba	Peng, ZK (corresponding author), Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB, Canada.							Hassoun S, 1999, Allerg Immunol (Paris), V31, P285; KONISHI E, 1990, J MED ENTOMOL, V27, P519, DOI 10.1093/jmedent/27.4.519; MCCORMACK DR, 1995, ANN ALLERG ASTHMA IM, V74, P39; OKA K, 1989, Journal of Dermatology (Tokyo), V16, P212; Palosuo K, 1997, INT ARCH ALLERGY IMM, V114, P367, DOI 10.1159/000237696; Peng ZK, 1996, ANN ALLERG ASTHMA IM, V77, P238, DOI 10.1016/S1081-1206(10)63262-0; Peng ZK, 1998, J ALLERGY CLIN IMMUN, V101, P284, DOI 10.1016/S0091-6749(98)70395-1; Peng ZK, 1998, J ALLERGY CLIN IMMUN, V101, P498, DOI 10.1016/S0091-6749(98)70357-4; PENG ZK, 1995, ANN ALLERG ASTHMA IM, V74, P259; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P705, DOI 10.1016/S0091-6749(99)70348-9	10	33	34	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					816	817		10.1067/mai.2002.128736	http://dx.doi.org/10.1067/mai.2002.128736			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417897				2022-12-18	WOS:000179082500023
J	Keir, S; Page, C; Spina, D				Keir, S; Page, C; Spina, D			Bronchial hyperresponsiveness induced by chronic treatment with albuterol: Role of sensory nerves	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						albuterol; enantiomers; bronchial hyperresponsiveness; heterogeneity; capsaicin	INDUCED AIRWAY HYPERRESPONSIVENESS; REGULAR INHALED ALBUTEROL; GUINEA-PIGS; BETA-AGONIST; ASTHMA; RESPONSIVENESS; SALBUTAMOL; CAPSAICIN; ISOPRENALINE; RESPONSES	Background: It has recently been suggested that regular treatment with racemic beta(2)-adrenoceptor agonists might result in bronchial hyperresponsiveness (BHR) to a range of spasmogens, and this might be due to adverse effects of the distomer. Objective: We sought to determine whether BIIR induced by means of continuous exposure to racemic and S-albuterol was mediated by sensory nerves. Methods: Naive or ovalbumin-sensitized guinea pigs were treated for 10 days with RS-, R-, or S-albuterol (1 mg.kg(-1).d(-1)) through subcutaneously implanted minipumps. Lung function was then determined in response to a number of spasmogens and assessed on the basis of an increase in total airway resistance. A separate group of animals were chronically treated with capsaicin (80 mg/kg) before the albuterol treatment. Results: Treatment with RS- or S-albuterol increased airway responsiveness to bradykinin, leukotriene C-4, and capsaicin in naive guinea pigs (P<.05) and to histamine and ovalbumin in immunized guinea pigs (P<.05). Chronic treatment with capsaicin prevented the development of RS- and S-albuterol-induced BHR in these models. The bronchodilator efficacy of acute intravenously administered RS-albuterol was unaffected in RS-, R-, or S-albuterol-treated guinea pigs compared with in vehicle-treated animals. Conclusion: We have provided evidence demonstrating that continuous exposure to RS- and S-albuterol increases bronchial responsiveness to a range of stimuli, an effect not attributed to beta-adrenoceptor occupancy or desensitization. Furthermore, capsaicin-sensitive sensory nerves mediate the development of BHR, at least in part.	Kings Coll London, GKT Sch Biomed Sci, Sackler Inst Pulm Pharmacol, Div Pharmacol & Therapeut, London SE1 1UL, England	University of London; King's College London	Spina, D (corresponding author), Kings Coll London, GKT Sch Biomed Sci, Sackler Inst Pulm Pharmacol, Div Pharmacol & Therapeut, 5th Floor Hodgkin Bldg,Guys Campus, London SE1 1UL, England.			Spina, Domenico/0000-0002-6815-1564; Page, Clive Peter/0000-0002-9358-3799				BAI TR, 1997, ASTHMA, P985; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, P838, DOI 10.1164/ajrccm.152.3.7663795; BUCHHEIT KH, 1995, EUR J PHARMACOL, V287, P85, DOI 10.1016/0014-2999(95)00613-3; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; Cockcroft DW, 1995, J ALLERGY CLIN IMMUN, V96, P1013, DOI 10.1016/S0091-6749(95)70245-8; CRANE J, 1989, LANCET, V1, P917; Dhand R, 1999, AM J RESP CRIT CARE, V160, P1136, DOI 10.1164/ajrccm.160.4.9812074; GALLAND BC, 1993, BRIT J PHARMACOL, V108, P1016, DOI 10.1111/j.1476-5381.1993.tb13499.x; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; HERD CM, 1995, EUR J PHARMACOL, V282, P111, DOI 10.1016/0014-2999(95)00291-R; HOLZER P, 1991, ADV EXP MED BIOL, V298, P3; HOSHIKO K, 1993, JPN J PHARMACOL, V63, P159, DOI 10.1254/jjp.63.159; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; JANSON C, 1991, EUR RESPIR J, V4, P544; JARREAU PH, 1994, AM J RESP CRIT CARE, V149, P128, DOI 10.1164/ajrccm.149.1.8111569; JENNE JW, 1987, DRUG THERAPY ASTHMA, P213; Kamachi A, 2001, THORAX, V56, P19, DOI 10.1136/thorax.56.1.19; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KOTO H, 1995, AM J RESP CRIT CARE, V151, P1763, DOI 10.1164/ajrccm.151.6.7767518; LAI CKW, 1989, AM REV RESPIR DIS, V140, P917, DOI 10.1164/ajrccm/140.4.917; MANZINI S, 1993, EUR J PHARMACOL, V249, P251, DOI 10.1016/0014-2999(93)90519-N; MANZINI S, 1987, EUR J PHARMACOL, V138, P307, DOI 10.1016/0014-2999(87)90451-1; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; MURAKI K, 1993, J PHYSIOL-LONDON, V471, P563, DOI 10.1113/jphysiol.1993.sp019916; PAGE CP, 1991, LANCET, V337, P1285, DOI 10.1016/0140-6736(91)92952-X; PAUWELS R, 1988, CLIN ALLERGY, V18, P317, DOI 10.1111/j.1365-2222.1988.tb02878.x; Riccio MM, 1997, BRIT J PHARMACOL, V122, P249, DOI 10.1038/sj.bjp.0701379; SANJAR S, 1990, J PHYSIOL-LONDON, V425, P43, DOI 10.1113/jphysiol.1990.sp018091; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Seeds EAM, 1999, PULM PHARMACOL THER, V12, P27, DOI 10.1006/pupt.1999.0167; SPINA D, 1991, BRIT J PHARMACOL, V103, P1268, DOI 10.1111/j.1476-5381.1991.tb12335.x; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; THOMPSON JE, 1987, AM REV RESPIR DIS, V136, P43, DOI 10.1164/ajrccm/136.1.43; Van Schoor J, 2000, EUR RESPIR J, V16, P514, DOI 10.1034/j.1399-3003.2000.016003514.x; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; VATHENEN AS, 1988, LANCET, V1, P554; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; WALDECK B, 1993, CHIRALITY, V5, P350, DOI 10.1002/chir.530050514	40	33	33	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					388	394		10.1067/mai.2002.126661	http://dx.doi.org/10.1067/mai.2002.126661			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209084				2022-12-18	WOS:000177936900007
J	Kinaciyan, T; Natter, S; Kraft, D; Stingl, G; Valenta, R				Kinaciyan, T; Natter, S; Kraft, D; Stingl, G; Valenta, R			IgE autoantibodies monitored in a patient with atopic dermatitis under cyclosporin A treatment reflect tissue damage	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SERUM IGE		Univ Vienna, Vienna Gen Hosp, Sch Med,Dept Dermatol, Div Immunol Allergy & Infect Dis, Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Sch Med, Dept Pathophysiol,Div Immunopathol, Vienna, Austria	University of Vienna; University of Vienna	Kinaciyan, T (corresponding author), Univ Vienna, Vienna Gen Hosp, Sch Med,Dept Dermatol, Div Immunol Allergy & Infect Dis, Waehringer Guertel 18, Vienna, Austria.			Kinaciyan, Tamar/0000-0002-8238-2561; Valenta, Rudolf/0000-0001-5944-3365				HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; Keller TH, 2001, PROG RESPIR RES, V31, P237; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Natter S, 1998, FASEB J, V12, P1559, DOI 10.1096/fasebj.12.14.1559; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617	8	33	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					717	719		10.1067/mai.2002.123303	http://dx.doi.org/10.1067/mai.2002.123303			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941327				2022-12-18	WOS:000175132600026
J	Ahrens, R; Weinberger, M				Ahrens, R; Weinberger, M			Levalbuterol and racemic albuterol: Are there therapeutic differences?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						levalbuterol; albuterol; salbutamol; B-2-agonist; asthma; bronchodilator; inhaled bronchodilator	METERED-DOSE INHALER; HEALTHY-VOLUNTEERS; S-SALBUTAMOL; ASTHMA; ENANTIOMERS; METHACHOLINE; AGONISTS; PLACEBO; PHARMACOKINETICS; VENTOLIN		Univ Iowa, Coll Med, Pediat Allergy & Pulm Div, Iowa City, IA USA	University of Iowa	Weinberger, M (corresponding author), Univ Iowa Hosp, Dept Pediat, Iowa City, IA 52242 USA.		Weinberger, Miles/H-6743-2019					AHRENS RC, 1991, ANN ALLERGY, V67, P296; Ahrens RC, 1999, AM J RESP CRIT CARE, V160, P1238, DOI 10.1164/ajrccm.160.4.9806101; Asmus MJ, 2000, PHARMACOTHERAPY, V20, P123, DOI 10.1592/phco.20.3.123.34776; ASMUS MJ, IN PRESS AM J RESP C; Cockcroft DW, 1997, THORAX, V52, P845, DOI 10.1136/thx.52.10.845; Cockcroft DW, 1999, J ALLERGY CLIN IMMUN, V103, P1049, DOI 10.1016/S0091-6749(99)70178-8; FINNEY DJ, 1978, STAT METHODS BIOL AS, P105; Gawchik SM, 1999, J ALLERGY CLIN IMMUN, V103, P615, DOI 10.1016/S0091-6749(99)70233-2; Handley D, 1999, J ALLERGY CLIN IMMUN, V104, pS69, DOI 10.1016/S0091-6749(99)70276-9; Handley DA, 2000, J ASTHMA, V37, P319, DOI 10.3109/02770900009055455; Handley DA, 1998, CHIRALITY, V10, P262, DOI 10.1002/(SICI)1520-636X(1998)10:3<262::AID-CHIR9>3.0.CO;2-B; Jenne JW, 1998, J ALLERGY CLIN IMMUN, V102, P893, DOI 10.1016/S0091-6749(98)70324-0; Leff AR, 1997, PULM PHARMACOL THER, V10, P97, DOI 10.1006/pupt.1997.0082; Lipworth BJ, 1997, THORAX, V52, P849, DOI 10.1136/thx.52.10.849; Lotvall J, 2001, J ALLERGY CLIN IMMUN, V108, P726; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, pS77, DOI 10.1016/S0091-6749(99)70277-0; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; PANCU D, 2001, ACAD EMERG MED, V8, P496; Parameswaran KN, 1999, AM J RESP CRIT CARE, V160, P354, DOI 10.1164/ajrccm.160.1.9812035; PERRINFAYOLLE M, 1995, LANCET, V346, P1101, DOI 10.1016/S0140-6736(95)91775-6; Ramsay CM, 1999, EUR J CLIN PHARMACOL, V55, P353, DOI 10.1007/s002280050640; Schmekel B, 1999, EUR RESPIR J, V13, P1230, DOI 10.1034/j.1399-3003.1999.13f04.x; Stewart BA, 2000, CHEST, V117, P714, DOI 10.1378/chest.117.3.714; Waldeck B, 1999, J ALLERGY CLIN IMMUN, V103, P742, DOI 10.1016/S0091-6749(99)70414-8	25	33	34	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					681	684						4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692088				2022-12-18	WOS:000172523800003
J	Quirce, S; Fernandez-Nieto, M; de Miguel, J; Sastre, J; Diaz, FJ				Quirce, S; Fernandez-Nieto, M; de Miguel, J; Sastre, J; Diaz, FJ			Chronic cough due to latex-induced eosinophilic bronchitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Autonoma Madrid, Fdn Jimenez Diaz, Dept Allergy, Madrid, Spain	Autonomous University of Madrid	Quirce, S (corresponding author), Univ Autonoma Madrid, Fdn Jimenez Diaz, Dept Allergy, Madrid, Spain.		s, q/AAD-7171-2020					COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; GIBSON PG, 1989, LANCET, V1, P1346; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; Lemiere C, 1997, J ALLERGY CLIN IMMUN, V100, P852, DOI 10.1016/S0091-6749(97)70286-0; OGAWA H, 1995, RESP MED, V89, P219, DOI 10.1016/0954-6111(95)90251-1; Poley GE, 2000, J ALLERGY CLIN IMMUN, V105, P1054, DOI 10.1067/mai.2000.106925; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6	7	33	35	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					143	143		10.1067/mai.2001.116120	http://dx.doi.org/10.1067/mai.2001.116120			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447398				2022-12-18	WOS:000170171200023
J	Pinsonneault, S; El Bassam, S; Mazer, B; Cruikshank, WW; Laberge, S				Pinsonneault, S; El Bassam, S; Mazer, B; Cruikshank, WW; Laberge, S			11-16 inhibits IL-5 production by antigen-stimulated T cells in atopic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-16; IL-5; lymphocyte; atopy; antigen	LYMPHOCYTE CHEMOATTRACTANT FACTOR; INTERFERON-GAMMA PRODUCTION; TRANSCRIPTION FACTOR GATA-3; ALLERGIC DISEASE; AIRWAY HYPERRESPONSIVENESS; TH2-SPECIFIC EXPRESSION; BRONCHIAL-MUCOSA; PRIMARY CULTURE; CD4 LIGAND; INTERLEUKIN-16	Background: We have previously shown increased expression of the CD4(+) cell chemoattractant IL-16 at sites of airway allergic inflammation. Little is known about the significance of IL-16 in allergic inflammation and its role in allergen-driven T-cell cytokine responses. Because IL-16 interacts specifically with CD4(+) T cells, we hypothesized that IL-16 released at sites of inflammation may modulate the pattern of cytokines produced by CD4(+) T cells. Objective: We investigated the effects of exogenous rhIL-16 on cytokine production of PBMCs from atopic and nonatopic subjects in response to antigen and PHA. Methods: Primary cultures of freshly isolated PBMCs from ragweed-sensitive atopic subjects and nonatopic subjects were stimulated with ragweed or PHA in the presence or absence of rhIL-16, Supernatant levels of IL-4, IL-5, and IFN-gamma were determined by means of ELISA at different time points between 2 and 6 days. Effects of IL-16 on antigen-induced cellular proliferative responses were determined. Results: No IL-4 protein was detected after antigen stimulation of PBMCs from atopic subjects, whereas significant levels of IL-5 were measured on day 6 (median, 534.9 pg/mL). IL-5 secretion was abolished in PBMC cultures depleted of CD4(+) cells. The addition of rhIL-16 in antigen-stimulated PBMC cultures significantly reduced the amount of IL-5 released (median, 99.8 pg/mL; P < .001). Detectable levels of IFN-<gamma> (median, 53.3 pg/mL) were identified after antigen stimulation. The addition of rhIL-16 in antigen-stimulated PBMC cultures significantly increased IFN-gamma levels (median, 255.6 pg/mL; P < .05). Effects of rhIL-16 appear to be specific for antigen-stimulated PBMCs in atopic subjects because rhIL-16 did not alter IL-5 or IFN-<gamma> production in response to PHA nor did rhIL-16 alter cytokine production in nonatopic normal subjects. Conclusion: These studies suggest that IL-16 can play a role in regulating the production of cytokines seen in allergic states in response to antigen.	Univ Montreal, Hop St Justine, Montreal, PQ H3T 1C5, Canada; McGill Univ, Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada; Boston Univ, Sch Med, Boston, MA 02118 USA	Universite de Montreal; McGill University; Boston University	Laberge, S (corresponding author), Univ Montreal, Hop St Justine, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.							Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; CRUIKSHANK WW, 1991, J IMMUNOL, V146, P2928; Cruikshank WW, 1996, J IMMUNOL, V157, P5240; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738, DOI 10.1165/ajrcmb.13.6.7576712; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817; Essayan DM, 1996, J ALLERGY CLIN IMMUN, V98, P1035, DOI 10.1016/S0091-6749(96)80188-6; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gerosa F, 1996, J EXP MED, V183, P2559, DOI 10.1084/jem.183.6.2559; Hessel EM, 1998, J IMMUNOL, V160, P2998; IMADA M, 1995, IMMUNOLOGY, V85, P373; Laberge S, 2000, J ALLERGY CLIN IMMUN, V106, P293; Laberge S, 1997, J ALLERGY CLIN IMMUN, V100, P569, DOI 10.1016/S0091-6749(97)70152-0; Laberge S, 1997, AM J RESP CELL MOL, V17, P193, DOI 10.1165/ajrcmb.17.2.2750; Lee HJ, 1998, J IMMUNOL, V160, P2343; Leonard C, 1997, AM J RESP CELL MOL, V17, P368, DOI 10.1165/ajrcmb.17.3.2797; MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264; MCHUGH SM, 1994, ALLERGY, V49, P751, DOI 10.1111/j.1398-9995.1994.tb02098.x; Parada NA, 1998, J IMMUNOL, V160, P2115; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; RYAN TC, 1995, J BIOL CHEM, V270, P17081, DOI 10.1074/jbc.270.29.17081; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P317; Theodore AC, 1996, J IMMUNOL, V157, P1958; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; Till S, 1997, IMMUNOLOGY, V91, P53, DOI 10.1046/j.1365-2567.1997.00218.x; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Wurtzen PA, 1998, J ALLERGY CLIN IMMUN, V101, P241, DOI 10.1016/S0091-6749(98)70389-6; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597	29	33	35	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					477	482		10.1067/mai.2001.112373	http://dx.doi.org/10.1067/mai.2001.112373			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240948				2022-12-18	WOS:000167793300009
J	Powell, WS; Ahmed, S; Gravel, S; Rokach, J				Powell, WS; Ahmed, S; Gravel, S; Rokach, J			Eotaxin and RANTES enhance 5-oxo-6,8,11,14-eicosatetraenoic acid-induced eosinophil chemotaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eicosanoids; lipid mediators; 5-axo-ETE; 5-lipoxygenase products; RANTES; eotaxin; eosinophils; asthma; chemoattractants; adhesion molecules	PLATELET-ACTIVATING-FACTOR; CHEMOKINE RECEPTOR CCR3; BROWN-NORWAY RATS; HUMAN NEUTROPHILS; 5-LIPOXYGENASE INHIBITOR; ACTIN POLYMERIZATION; CALCIUM MOBILIZATION; AIRWAY INFLAMMATION; POTENT STIMULATOR; GUINEA-PIG	Background: The 5-lipoxygenase product 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is a potent activator of human eosinophils and, among lipid mediators, is the most active chemoattractant for these cells. Studies have demonstrated the importance of 5-lipoxygenase products in allergen-induced pulmonary eosinophilia. Because CC chemokines such as eotaxin and RANTES also play critical roles in this phenomenon, it would seem likely that members of both classes of mediators contribute to this response. Objective: The study was designed to directly compare the effects of 5-oxo-ETE on eosinophils with those of eotaxin and RANTES and to determine whether these chemokines could enhance the chemotactic response to 5-oxo-ETE, Methods: Eosinophil chemotaxis was measured with microchemotaxis chambers. CD11b, L-selectin, and actin polymerization were measured by flow cytometry, Calcium mobilization was measured by fluorescence. Results: 5-Oxo-ETE stimulated eosinophil chemotaxis with a potency between those of eotaxin and RANTES and a maximal response about 50% higher than that of eotaxin, Threshold concentrations of eotaxin and RANTES increased the chemotactic potency of 5-oxo-ETE by more than 4-fold. 5-Oxo-ETE and eotaxin were approximately equipotent in mobilizing cytosolic calcium in eosinophils, Eotaxin was more potent in inducing CD11b expression and actin polymerization, but the maximal responses to 5-oxo-ETE were about 50% higher. 5-Oxo-ETE strongly induced L-selectin shedding, whereas eotaxin elicited only a weak and variable response, Conclusion: 5-Oxo-ETE is a strong activator of human eosinophils with a chemotactic potency comparable to those of eotaxin and RANTES, both of which enhance 5-oxo-ETE-induced chemotaxis. 5-Oxo-ETE and CC chemokines may combine to induce pulmonary eosinophilia in asthma.	McGill Univ, Dept Med, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	McGill University; Florida Institute of Technology; Florida Institute of Technology	Powell, WS (corresponding author), McGill Univ, Dept Med, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Powell, William/AAE-9000-2020	Rokach, Joshu/0000-0003-1814-7505; Powell, William/0000-0002-8507-4038	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44730] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM WM, 1992, EUR J PHARMACOL, V217, P119, DOI 10.1016/0014-2999(92)90829-S; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Elsner J, 1996, J CELL PHYSIOL, V167, P548, DOI 10.1002/(SICI)1097-4652(199606)167:3<548::AID-JCP18>3.3.CO;2-Y; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Guilbert M, 1999, AM J RESP CELL MOL, V21, P97, DOI 10.1165/ajrcmb.21.1.3517; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; HENDEY B, 1993, BLOOD CELLS, V19, P143; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; IRVIN CG, 1997, AM J PHYSL, V272; Kane GC, 1996, J ALLERGY CLIN IMMUN, V97, P646, DOI 10.1016/S0091-6749(96)70310-X; KAY AB, 1970, CLIN EXP IMMUNOL, V6, P75; Khanapure SP, 1998, J ORG CHEM, V63, P337, DOI 10.1021/jo9716993; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LOCATI M, 1994, J BIOL CHEM, V269, P4746; MAGHNI K, 1991, J PHARMACOL EXP THER, V258, P784; MESHULAM T, 1986, J IMMUNOL, V137, P1954; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Namovic MT, 1996, EUR J PHARMACOL, V315, P81, DOI 10.1016/S0014-2999(96)00590-0; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; OFLAHERTY JT, 1994, BBA-GEN SUBJECTS, V1201, P505, DOI 10.1016/0304-4165(94)90083-3; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; POWELL WS, 1993, J BIOL CHEM, V268, P9280; Powell WS, 1996, J IMMUNOL, V156, P336; POWELL WS, 1995, J IMMUNOL, V154, P4123; ROSSI AG, 1991, LIPIDS, V26, P1184, DOI 10.1007/BF02536528; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SCHWENK U, 1992, J BIOL CHEM, V267, P12482; SEEDS EAM, 1995, EUR J PHARM-ENVIRON, V293, P369, DOI 10.1016/0926-6917(95)90057-8; Stamatiou P, 1998, J CLIN INVEST, V102, P2165, DOI 10.1172/JCI1995; STOSSEL TP, 1994, BLOOD, V84, P367; Tenscher K, 1996, BLOOD, V88, P3195, DOI 10.1182/blood.V88.8.3195.bloodjournal8883195; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850, DOI 10.1164/ajrccm.154.4.8887574; Ward SG, 1998, BIOCHEM J, V333, P457, DOI 10.1042/bj3330457; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802	43	33	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					272	278		10.1067/mai.2001.112847	http://dx.doi.org/10.1067/mai.2001.112847			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174193				2022-12-18	WOS:000167071400013
J	Izuhara, K; Yanagihara, Y; Hamasaki, N; Shirakawa, T; Hopkin, JM				Izuhara, K; Yanagihara, Y; Hamasaki, N; Shirakawa, T; Hopkin, JM			Atopy and the human IL-4 receptor alpha chain	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on New Trends in Immunopharmacology 1998	JUL   25, 1998	TOKYO, JAPAN			atopy; IL-4 receptor alpha chain; IgE; Stat6; signal transduction	FC-EPSILON-RI; HUMAN INTERLEUKIN-4 RECEPTOR; IMMUNOGLOBULIN-E RECEPTOR; SIGNAL-TRANSDUCTION; BETA-SUBUNIT; BRONCHIAL HYPERRESPONSIVENESS; IGE SYNTHESIS; ALLELIC ASSOCIATION; JAPANESE POPULATION; CYTOPLASMIC DOMAIN	Background: Atopy is a common inherited disorder characterized by increased IgE responsiveness, but no functional analysis of the candidate genes related to atopy has been performed. IL-4 is important for B-cell production of IgE, and the human IL-4 receptor a chain (hIL-4R alpha) is crucial for the binding and signal transduction of IL-4, so hIL-4R alpha may be a candidate gene related to atopy. Objective: We examined the relationship between the variation at amino acid 50 of hIL-4R alpha and atopic asthma. Methods: We performed a genetic study to investigate the relationship between the variation of amino acid 50 (isoleucine [Ile(50)] or valine [Val(50)]) and atopic asthma in a Japanese population and a functional study with the use of transfectants that expressed hIL4R alpha bearing either Ile(50) or Val(50). Furthermore, we analyzed CD23 expression and IgE synthesis after IL-4 stimulation of peripheral blood mononuclear cells bearing either Ile(50) or Val(50). Results: The prevalence of Ile(50) was higher than that of Val(50) in individuals with atopic asthma, especially during childhood. In transfectants, germline epsilon transcription activity and Stat6 activity were upregulated by the Ile(50) variant, compared with Val(50), but receptor affinity for IL-4 was similar between the two. CD23 expression and IgE synthesis in response to IL-4 were augmented in Ile(50)-expressing peripheral mononuclear blood cells compared to cells expressing Val(50). Conclusion: The ILe(50) variant of hIL-4R alpha may be related to atopic asthma, particularly in children.	Kyushu Univ, Fac Med, Dept Clin Chem & Lab Med, Higashi Ku, Fukuoka 8128582, Japan; Natl Sagamihara Hosp, Clin Res Ctr Allergy, Sagamihara, Kanagawa, Japan; Univ Wales, Dept Expt Med, Swansea, W Glam, Wales	Kyushu University	Izuhara, K (corresponding author), Kyushu Univ, Fac Med, Dept Clin Chem & Lab Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; Cox HE, 1998, BRIT J DERMATOL, V138, P182; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; Fujiwara H, 1997, P NATL ACAD SCI USA, V94, P5866, DOI 10.1073/pnas.94.11.5866; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; Green SL, 1998, AM J RESP CRIT CARE, V158, P1487, DOI 10.1164/ajrccm.158.5.9707099; HARADA N, 1992, J BIOL CHEM, V267, P22752; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hijazi Z, 1998, CLIN GENET, V53, P149; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Izuhara K, 1999, INT J MOL MED, V3, P3; Izuhara K, 1996, J BIOL CHEM, V271, P619, DOI 10.1074/jbc.271.2.619; IZUHARA K, 1993, BIOCHEM BIOPH RES CO, V149, P995; Jenh CH, 1998, J IMMUNOL METHODS, V217, P87, DOI 10.1016/S0022-1759(98)00095-7; Kammer W, 1996, J BIOL CHEM, V271, P23634, DOI 10.1074/jbc.271.39.23634; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lai SY, 1996, EMBO J, V15, P4506, DOI 10.1002/j.1460-2075.1996.tb00828.x; Leonard WJ, 1995, IMMUNOL REV, V148, P97, DOI 10.1111/j.1600-065X.1995.tb00095.x; LIN JX, 1995, IMMUNITY, V2, P1; Mao XQ, 1996, LANCET, V348, P581, DOI 10.1016/S0140-6736(95)10244-2; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; Murata T, 1998, BLOOD, V91, P3884; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Reichel M, 1997, J IMMUNOL, V158, P5860; Rosenwasser LJ, 1997, AM J RESP CRIT CARE, V156, pS152, DOI 10.1164/ajrccm.156.4.12tac-14; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schulte T, 1997, J EXP MED, V186, P1419, DOI 10.1084/jem.186.9.1419; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shirakawa T, 1996, HUM MOL GENET, V5, P1129, DOI 10.1093/hmg/5.8.1129; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Trabetti E, 1998, J MED GENET, V35, P680, DOI 10.1136/jmg.35.8.680; Ulbrecht M, 1997, J ALLERGY CLIN IMMUN, V99, P828, DOI 10.1016/S0091-6749(97)80018-8; YANAGIHARA Y, 1992, INT ARCH ALLERGY IMM, V98, P189, DOI 10.1159/000236184; YANAGIHARA Y, 1987, J ALLERGY CLIN IMMUN, V79, P448, DOI 10.1016/0091-6749(87)90362-9	51	33	34	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	2	S			S65	S71		10.1067/mai.2000.106776	http://dx.doi.org/10.1067/mai.2000.106776			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	339NF	10887336	Bronze			2022-12-18	WOS:000088482600009
J	Kayaba, H; Hirokawa, M; Watanabe, A; Saitoh, N; Changhao, C; Yamada, Y; Honda, K; Kobayashi, Y; Urayama, O; Chihara, J				Kayaba, H; Hirokawa, M; Watanabe, A; Saitoh, N; Changhao, C; Yamada, Y; Honda, K; Kobayashi, Y; Urayama, O; Chihara, J			Serum markers of graft-versus-host disease after bone marrow transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on New Trends in Immunopharmacology 1998	JUL   25, 1998	TOKYO, JAPAN			graft-versus-host disease; bone marrow transplantation; tumor necrosis factor; tumor necrosis factor-receptor; Fas; intercellular adhesion molecule-1; c-kit; growth-related oncogene protein-alpha	RECEPTOR	Background: Graft-versus-host disease is one of the major complications after allogenic bone marrow transplantation, but it is not easy to anticipate the onset. Objectives: The purpose of this study was to determine clinically useful markers of acute graft-versus-host disease. Methods: We measured the serum levels of tumor necrosis factor-alpha, soluble tumor necrosis factor receptor 1, soluble c-kit, soluble Fas, soluble intercellular adhesion molecule-1, growth-related oncogene protein-alpha alpha, thrombomadurin, and interleukin-16 in 13 patients at 1 to 7 weeks after allogenic bone marrow transplantation. Results: The patients with acute graft-versus-host disease showed a significant increase of tumor necrosis factor, soluble tumor necrosis factor receptor 1, soluble Fas, soluble intercellular adhesion molecule-1, and growth-related oncogene protein-alpha, although there was a decrease of soluble c-kit. The increases of serum soluble tumor necrosis factor receptor 1, intercellular adhesion molecule-1, and growth-related oncogene protein-alpha were preceded by the elevation of soluble Fas. Conclusion: The patients with acute graft-versus-host disease had increased serum levels of tumor necrosis factor-alpha, soluble tumor necrosis factor receptor 1, soluble Fas, and soluble intercellular adhesion molecule 1 and a decreased soluble c-kit level. Tumor necrosis facter-alpha and soluble c-kit were shown to be sensitive and specific parameters for graft-versus-host disease after bone marrow transplantation, and soluble Fas mas shown to be a predictor of acute graft-versus-host disease after bone marrow transplantation.	Akita Univ, Sch Med, Dept Clin & Lab Med, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Internal Med 3, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Pediat, Akita 0108543, Japan	Akita University; Akita University; Akita University	Kayaba, H (corresponding author), Akita Univ, Sch Med, Dept Clin & Lab Med, 1-1-1 Hondo, Akita 0108543, Japan.							Cruikshank W W, 1998, Int Rev Immunol, V16, P523, DOI 10.3109/08830189809043007; Facon T, 1997, BONE MARROW TRANSPL, V20, P511, DOI 10.1038/sj.bmt.1700912; GASPERINI S, 1995, J INFLAMM, V45, P143; HASHINO S, 1995, BRIT J HAEMATOL, V89, P897; Hattori K, 1998, BLOOD, V91, P4051, DOI 10.1182/blood.V91.11.4051.411k16_4051_4055; Kanamori H, 1998, BONE MARROW TRANSPL, V21, P705, DOI 10.1038/sj.bmt.1701151; KNIPPING E, 1995, BLOOD, V85, P1562, DOI 10.1182/blood.V85.6.1562.bloodjournal8561562; Liem LM, 1998, BLOOD, V91, P1464, DOI 10.1182/blood.V91.4.1464; Maeda Y, 1997, J ALLERGY CLIN IMMUN, V100, pS77, DOI 10.1016/S0091-6749(97)70010-1; Miyamoto T, 1996, BONE MARROW TRANSPL, V17, P185; Nagler A, 1998, CYTOKINES CELL MOL T, V4, P161; Or R, 1996, CYTOKINES MOL THER, V2, P243; Poritz LS, 1998, J SURG RES, V80, P280, DOI 10.1006/jsre.1998.5422; Speiser DE, 1997, J IMMUNOL, V158, P5185; Toren A, 1997, CYTOKINES CELL MOL T, V3, P153	15	33	35	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	2	S			S40	S44		10.1067/mai.2000.106060	http://dx.doi.org/10.1067/mai.2000.106060			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	339NF	10887332				2022-12-18	WOS:000088482600005
J	Hamilton, RG; Brown, RH				Hamilton, RG; Brown, RH			Impact of personal avoidance practices on health care workers sensitized to natural rubber latex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural rubber latex; natural history; skin rest; serologic test; glove provocation	AEROALLERGENS		Johns Hopkins Univ, Div Clin Immunol & Allergy, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Publ Hlth, Div Physiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Hamilton, RG (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Room 1A20,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; BROWN RH, 1999, ANESTHESIOLOGY, V90, P292; Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, P925, DOI 10.1016/S0091-6749(99)70440-9; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6	5	33	34	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					839	841		10.1067/mai.2000.105224	http://dx.doi.org/10.1067/mai.2000.105224			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756239				2022-12-18	WOS:000086604100027
J	Vaughan, JW; Woodfolk, JA; Platts-Mills, TAE				Vaughan, JW; Woodfolk, JA; Platts-Mills, TAE			Assessment of vacuum cleaners and vacuum cleaner bags recommended for allergic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen avoidance; vacuum cleaners; vacuum cleaner bags	PARTICLE-SIZE DISTRIBUTION; CAT ALLERGEN; AIRBORNE; DUST	Background: High-quality vacuum cleaners and vacuum cleaner bags are often recommended to allergic patients as a means of reducing indoor allergen exposure. A number of vacuum cleaners on the market today claim to capture 99.9% of particles 03 mu m or larger entering the vacuum cleaner, and many vacuum cleaner bags are now being sold as microfiltration bags. Objective: The purpose of this study was to compare the allergen-trapping abilities of vacuum cleaners and to use a new technique for testing vacuum cleaner bags that are recommended for allergic patients. Methods: Vacuum cleaners were tested in an 18-m(3) laboratory room permeated with dust containing high levels of cat allergen by using techniques previously described. Air was sampled with parallel filters in conjunction with a particle counter. The filters were assayed by ELISA for cat allergen (Fel d 1), Vacuum cleaner bags mere tested by using a modified dust trap to pull sieved house dust containing a known amount of Fel d 1 across the material used for the bag. Allergen passing through the bag mas trapped on a filter covering the exit of the trap and analyzed for Fel d 1, Results: In general, vacuum cleaners designed for allergic patients leaked lower amounts of allergen (<0.5-4.04 ng/m(3)) than that found in our previous studies (<0.5-100 ng/m(3)). Single-layer vacuum cleaner bags performed poorly (1250-2640 ng recovered) compared with most of the 2- and 3-layer microfiltration bags (0.53-2450 ng recovered). The range of allergen recovered from the 2-layer bags (0.93-2450 ng recovered) highlighted the variability found between manufacturers. Conclusion: The results suggest that although allergen leakage has been reduced, there is still room for improvement. A method of testing allergen leakage by using Fel d I should be; applied to vacuum cleaners and bags recommended for allergic patients.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, Box 225,Hlth Sci Ctr, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034607, U01AI034607, R37AI020565, R01AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, AI-34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		de Blay F, 1998, ALLERGY, V53, P411, DOI 10.1111/j.1398-9995.1998.tb03914.x; Horak F, 1995, Wien Med Wochenschr, V145, P1; LEFCOE NM, 1975, ARCH ENVIRON HEALTH, V30, P565, DOI 10.1080/00039896.1975.10666780; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MCLAUGHLIN TE, 1998, J ALLERGY CLIN IMMUN, V101, pA690; Munir A K, 1993, Pediatr Allergy Immunol, V4, P136, DOI 10.1111/j.1399-3038.1993.tb00082.x; SLY RM, 1985, ANN ALLERGY, V54, P209; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V103, P227, DOI 10.1016/S0091-6749(99)70495-1; WOODFOLK JA, 1993, J ALLERGY CLIN IMMUN, V91, P829, DOI 10.1016/0091-6749(93)90339-H; 1997, CONSUMER REPORTS, V62, P39	12	33	33	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1079	1083		10.1016/S0091-6749(99)70092-8	http://dx.doi.org/10.1016/S0091-6749(99)70092-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550756				2022-12-18	WOS:000083778400034
J	Niven, RM; Fletcher, AM; Pickering, AC; Custovic, A; Sivour, JB; Preece, AR; Oldham, LA; Francis, HC				Niven, RM; Fletcher, AM; Pickering, AC; Custovic, A; Sivour, JB; Preece, AR; Oldham, LA; Francis, HC			Attempting to control mite allergens with mechanical ventilation and dehumidification in British houses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mites; Der p 1; avoidance; dehumidification; humidity; mechanical ventilation	DUST MITE; BRONCHIAL HYPERREACTIVITY; SEASONAL-VARIATION; REDUCTION; ASTHMA; AVOIDANCE; CHILDREN	Background: Allergen avoidance is of considerable interest in the treatment and even prevention of asthma. Attempts to control house dust mites have included environmental manipulation in homes in an attempt to reduce humidity below a Level that favors mite survival. This appears to have some benefit in Scandinavia, but a previous attempt with mechanical ventilation heat pump recovery (MVHR) units in the UK failed to achieve the desired results. Objective: We report a study using an additional central dehumidification modification of the MVHR (MVHRcd) in an attempt to reduce allergen levels in houses of asthmatic subjects. Methods: Ten houses of asthmatic patients allergic to dust mites and 10 architectural control houses were studied. The active houses were fitted with an MVHRcd unit in November/December 1994 and activated in January 1995. The active and control houses were monitored continuously for internal temperature and humidity by using digital sensors in the asthmatic and control bedrooms. Dust samples were collected to determine allergen levels at baseline (January 1994) and 3, 6, 9, and 15 months after switching on the units. Results: The winter seasonal average humidity fell from 50% relative humidity (RH) in control bedrooms to 37% RH in asthmatic bedrooms compared with 72% RH in the ambient air as measured on the intake of the MVHRcd systems. There was no corresponding change in seasonal mean temperature within the houses. Although the temperature and humidity weekly and seasonal means remained below the study target of 45% RH or 7 g/kg absolute humidity at 21 degrees C, there were transient rises in humidity detected by the sensors in the houses with MVHRcd systems. Allergen levels fell both in active and control houses during the study period, but there was no significant advantage gained from the installation of MVHRcd systems. Conclusion: The MVHRcd system failed to confer a benefit in terms of mite allergen reduction despite apparently adequate control of temperature and humidity.	Wythenshawe Hosp, N W Lung Ctr, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Niven, RM (corresponding author), Wythenshawe Hosp, N W Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Niven, Robert/0000-0003-2249-960X				ARLIAN LG, 1989, IMMUNOL ALLERGY CLIN, V9, P339; BONER AL, 1985, ANN ALLERGY, V54, P42; COLLOFF MJ, 1979, EXP APPL ACAROL, V3, P191; CUSTOVIC A, 1995, CLIN EXP ALLERGY, V25, P312, DOI 10.1111/j.1365-2222.1995.tb01048.x; deBoer R, 1997, ALLERGY, V52, P299; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Fletcher AM, 1996, CLIN EXP ALLERGY, V26, P1051, DOI 10.1111/j.1365-2222.1996.tb00643.x; HARVING H, 1991, ALLERGY, V46, P33, DOI 10.1111/j.1398-9995.1991.tb00647.x; KALRA S, 1992, THORAX, V47, P928, DOI 10.1136/thx.47.11.928; KORSGAARD J, 1991, DUST MITE ALLERGENS, P87; LANG JD, 1978, ENVIRON ENTOMOL, V7, P121, DOI 10.1093/ee/7.1.121; LUTZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442, DOI 10.1164/ajrccm.149.6.8004296; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; RIJEKAERT G, 1981, OCOLOGIA BEL, V48, P183	18	33	34	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				756	762		10.1016/S0091-6749(99)70416-1	http://dx.doi.org/10.1016/S0091-6749(99)70416-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329806				2022-12-18	WOS:000080470200007
J	Sakaguchi, M; Kaneda, H; Inouye, S				Sakaguchi, M; Kaneda, H; Inouye, S			A case of anaphylaxis to gelatin included in erythropoietin products	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IMMEDIATE-TYPE REACTIONS; CHILDREN; MEASLES; MUMPS; VACCINES; IGE		Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 162, Japan; Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Shinjuku Ku, Tokyo 162, Japan; Kamome Clin, Iwaki, Fukushima, Japan	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID)	Sakaguchi, M (corresponding author), Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Toyama 1-23-1, Tokyo 162, Japan.		Inouye, Sharon/R-7216-2019					BUSINCO L, 1994, ANN ALLERGY, V72, P1; GARCIA JE, 1993, NEPHRON, V65, P636, DOI 10.1159/000187578; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6	5	33	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				349	350		10.1016/S0091-6749(99)70512-9	http://dx.doi.org/10.1016/S0091-6749(99)70512-9			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949329	Bronze			2022-12-18	WOS:000078630100025
J	Noertjojo, K; Dimich-Ward, H; Obata, H; Manfreda, J; Chan-Yeung, M				Noertjojo, K; Dimich-Ward, H; Obata, H; Manfreda, J; Chan-Yeung, M			Exposure and sensitization to cat dander: Asthma and asthma-like symptoms among adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pets; cat; adults; asthma; respiratory symptoms; sensitization	FEL-D-I; RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; INDOOR ENVIRONMENT; HOME-ENVIRONMENT; RISK-FACTORS; CHILDREN; PREVALENCE; ALLERGY; DOG	Background: Several pets, such as cats, dogs, and rodents, are known to produce allergens. Despite the clinical and laboratory evidence that exposure to pets can cause bronchoconstriction in sensitized subjects, the results of population studies have been contradictory, Objectives: The purpose of this study mas to investigate the relationship between cat ownership and the prevalence of asthma, asthma-like symptoms, and bronchitic symptoms among subjects 20 to 44 years of age in Vancouver, Canada and to determine whether sensitization is responsible for such an association. Methods: Two thousand nine hundred ninety-nine (88%) randomly selected subjects responded to a mail questionnaire. Of these, 504 participated in laboratory examination, including allergy skin testing, Results: One thousand nineteen study responders (34%) were pet owners at the time of the study (current owners). Current pet owners were found to have a higher prevalence of current asthma, asthma-like symptoms, and bronchitic symptoms compared with those without pets, Cat owners had significantly higher risk of having current asthma and asthma-like symptoms. rn the subset who had allergic skin tests, we found that those who were allergic to cat dander had a significantly higher risk of current asthma than those not allergic to cat dander and not owning a cat. Conclusion: This study provides evidence that sensitization to cat dander is a more important risk factor for current asthma and asthma-like symptoms than cat ownership itself.	Univ British Columbia, Dept Med, Div Resp, Occupat & Environm Res Unit, Vancouver, BC, Canada; Univ Manitoba, Dept Med, Winnipeg, MB, Canada; Univ Manitoba, Dept Community Hlth, Winnipeg, MB, Canada	University of British Columbia; University of Manitoba; University of Manitoba	Chan-Yeung, M (corresponding author), 2775 Heather St, Vancouver, BC V5Z 3J5, Canada.		Noertjojo, Kukuh/H-6806-2019					ABDULRAZZAQ YM, 1995, J ASTHMA, V32, P117, DOI 10.3109/02770909509083232; ALFRAYH AR, 1990, J ROY SOC HEALTH, V110, P98, DOI 10.1177/146642409011000309; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; Austin JB, 1997, ARCH DIS CHILD, V76, P22, DOI 10.1136/adc.76.1.22; BARRY DMJ, 1991, THORAX, V46, P405, DOI 10.1136/thx.46.6.405; Bener A, 1995, Allerg Immunol (Paris), V27, P190; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURR ML, 1994, INT J EPIDEMIOL, V23, P341, DOI 10.1093/ije/23.2.341; Butland BK, 1997, THORAX, V52, P618, DOI 10.1136/thx.52.7.618; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; CUIJPERS CEJ, 1995, ENVIRON RES, V68, P11, DOI 10.1006/enrs.1995.1003; David MMA, 1996, AM J RESP CRIT CARE, V153, P1285, DOI 10.1164/ajrccm.153.4.8616555; DEANDRADE AD, 1995, J ALLERGY CLIN IMMUN, V95, P1158, DOI 10.1016/S0091-6749(95)70071-4; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DEHAMEL F, 1985, NEW ZEAL MED J, V98, P1056; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570, DOI 10.1164/ajrccm.152.2.7633709; HOSEIN HR, 1989, INT J EPIDEMIOL, V18, P390, DOI 10.1093/ije/18.2.390; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834, DOI 10.1093/oxfordjournals.aje.a116745; KJELLMAN B, 1983, ALLERGY, V38, P65, DOI 10.1111/j.1398-9995.1983.tb00858.x; LUYT DK, 1995, EUR RESPIR J, V8, P1736, DOI 10.1183/09031936.95.08101736; MANFREDA J, 1996, AM J RESP CRIT CARE, V153, pA432; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; QUIRCE S, 1995, ANN ALLERG ASTHMA IM, V75, P325; SHAW R, 1994, NEW ZEAL MED J, V107, P387; STRACHAN DP, 1995, BRIT MED J, V311, P1053, DOI 10.1136/bmj.311.7012.1053; TIMONEN KL, 1995, EUR RESPIR J, V8, P1155, DOI 10.1183/09031936.95.08071155; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; Warner JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; WILKIE AT, 1995, NEW ZEAL MED J, V108, P188; 1997, STATA REFERENCE GO	33	33	33	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				60	65		10.1016/S0091-6749(99)70526-9	http://dx.doi.org/10.1016/S0091-6749(99)70526-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893186				2022-12-18	WOS:000078112300010
J	Platts-Mills, TAE; Mueller, GA; Wheatley, LM				Platts-Mills, TAE; Mueller, GA; Wheatley, LM			Future directions for allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						immunotherapy; recombinant allergens; peptides; DNA vaccines	DUST MITE ALLERGEN; IMMUNOSTIMULATORY DNA-SEQUENCES; GRASS-POLLEN IMMUNOTHERAPY; AMINO-ACID-SEQUENCE; ATOPIC-DERMATITIS; MAJOR ALLERGEN; ANTIBODY-RESPONSES; IMMUNE-RESPONSES; INTERFERON-GAMMA; IGE ANTIBODIES	Over the last 30 years several approaches to modify immunotherapy have been tested, including allergoids, alum precipitation, and most recently peptides, However, none of these have replaced the traditional regimens. Over the same period our scientific understanding of allergic disease has been transformed. Today it is possible to identify and monitor changes occurring during treatment and to target many different aspects of the immune system. Recombinant technology provides a powerful technique both for sequencing proteins and producing allergens in commercial quantities. The recombinant proteins can be modified by site-directed mutagenesis so as to decrease their reactivity with IgE antibodies while maintaining reactivity with T cells. Knowledge of the tertiary structure of allergens will make it simpler to identify and change surface epitopes, A completely different approach is to use plasmids to introduce the genes for an allergen. The strength of this technique is that the plasmid can be designed to control expression and also to influence the cytokine profile of the response or the isotype of antibodies produced, Finally, different adjuvants can be used with proteins to alter the response. These include IL-12, immunostimulatory sequences of DNA, and bacterial proteins such as those used in HibVax, It is now possible to identify the cells that control the immune response to allergens and to design treatments that will either downregulate or change the response of T cells. The challenge is to transform this information into an effective treatment for allergic disease.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, UVA Asthma & Allerg Dis Ctr, Box 225 HSC, Charlottesville, VA 22908 USA.		Mueller, Geoffrey A/I-2909-2017	Mueller, Geoffrey A/0000-0001-8361-5323; Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001416, R37AI020565, R01AI030840, R01AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01416, AI20565, AI30840] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERSE RC, 1993, ALLERGY, V48, P559, DOI 10.1111/j.1398-9995.1993.tb00749.x; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Bressler RB, 1997, J ALLERGY CLIN IMMUN, V99, P508, DOI 10.1016/S0091-6749(97)70078-2; BURKS AW, 1995, J ALLERGY CLIN IMMUN, V95, P607, DOI 10.1016/S0091-6749(95)70323-3; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; Chua KY, 1996, CLIN EXP ALLERGY, V26, P829, DOI 10.1111/j.1365-2222.1996.tb00615.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Comoy EE, 1998, J IMMUNOL, V160, P2456; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; Creticos PS, 1997, J ALLERGY CLIN IMMUN, V99, P1631; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Dannemann A, 1996, INT ARCH ALLERGY IMM, V111, P262, DOI 10.1159/000237376; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; ELSAYED S, 1983, ALLERGY, V38, P449, DOI 10.1111/j.1398-9995.1983.tb02353.x; Ferreira F, 1997, INT ARCH ALLERGY IMM, V113, P125, DOI 10.1159/000237524; FRANKLAND AW, 1954, LANCET, V1, P1055; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GodnicCvar J, 1997, J ALLERGY CLIN IMMUN, V99, P354, DOI 10.1016/S0091-6749(97)70053-8; GRAFT DF, 1985, ALLERGY, P679; HAYGLASS KT, 1991, J EXP MED, V173, P279, DOI 10.1084/jem.173.2.279; HENDRIX SG, 1981, J ALLERGY CLIN IMMUN, V67, P124, DOI 10.1016/0091-6749(81)90007-5; HETZEL C, 1994, CLIN IMMUNOL IMMUNOP, V73, P1, DOI 10.1006/clin.1994.1163; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; Hoyne GF, 1995, CURR OPIN IMMUNOL, V7, P757, DOI 10.1016/0952-7915(95)80044-1; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Ichikawa S, 1998, J BIOL CHEM, V273, P356, DOI 10.1074/jbc.273.1.356; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; ISHIZAKA K, 1974, J IMMUNOL, V113, P70; JUNIPER EF, 1986, J ALLERGY CLIN IMMUN, V78, P851, DOI 10.1016/0091-6749(86)90229-0; MARSH DG, 1975, ANTIGENS, V3, P271; MOLE LE, 1975, BIOCHEMISTRY-US, V14, P1216, DOI 10.1021/bi00677a019; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; Mueller GA, 1997, J BIOL CHEM, V272, P26893, DOI 10.1074/jbc.272.43.26893; MUELLER GA, 1998, THESIS U VIRGINIA, P2; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1995, J ALLERGY CLIN IMMUN, V95, P259; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; RAWLE FC, 1984, J IMMUNOL, V133, P195; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; Rempel JD, 1997, J IMMUNOL, V159, P1490; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROMAGNANI S, 1991, INT J CLIN LAB RES, V21, P152; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; SALE SR, 1992, ALLERGY THEORY PRACT, P279; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sitz KV, 1997, J INFECT DIS, V176, P1085, DOI 10.1086/516517; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; Smith AM, 1997, CLIN EXP ALLERGY, V27, P593, DOI 10.1111/j.1365-2222.1997.tb00750.x; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith AM, 1998, J ALLERGY CLIN IMMUN, V101, P423, DOI 10.1016/S0091-6749(98)70259-3; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; SUZUKI G, 1988, J IMMUNOL, V140, P1359; Thomas WR, 1997, INT ARCH ALLERGY IMM, V113, P96, DOI 10.1159/000237516; Till S, 1997, CLIN EXP IMMUNOL, V110, P114, DOI 10.1111/j.1365-2249.1997.494-ce1392.x; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Woodfolk JA, 1996, J IMMUNOL, V156, P1695	71	33	40	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					335	343		10.1016/S0091-6749(98)70117-4	http://dx.doi.org/10.1016/S0091-6749(98)70117-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768570				2022-12-18	WOS:000076212800001
J	Knippels, LMJ; Penninks, AH; Houben, GF				Knippels, LMJ; Penninks, AH; Houben, GF			Continued expression of anti-soy protein antibodies in rats bred on a soy protein-free diet for one generation: The importance of dietary control in oral sensitization research	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; Brown Norway rat; oral; sensitization; soy protein-free diet; IgG	SYSTEMIC IMMUNE-RESPONSES; ANAPHYLACTIC SENSITIZATION; T-CELLS; IGE; MICE; IMMUNIZATION; OVALBUMIN; TOLERANCE; SUPPRESSION; ACTIVATION	Background: One of the major factors that may have negatively affected the results of many oral sensitization studies in animals has been unscheduled dietary preexposure of the test animals or their parental generations to the antigen under investigation. Objective: The influence of dietary preexposure to soy protein on oral sensitization studies with soy protein in Brown Norway rats was investigated. Methods: Brown Norway rats bred on a soy protein-containing diet for several generations (routine bred [RB] animals) were placed on a soy protein-free diet during and for at least 6 months before breeding (F0 group). Four generations of offspring were bred on a soy protein-free diet (F1, F2, F3, and F4 groups). RB and F4 animals were exposed to soy protein either ad libitum through drinking water or parenterally with an adjuvant. Results: In the F0 and F1 animals soy protein-specific IgG antibodies were still detectable, whereas no soy protein-specific Ige was detectable in the other generations tested. In RE animals no significant increase in soy protein-specific IgG titers occurred after exposure to soy protein. Enteral exposure of the F4 animals to soy protein resulted in sensitization to soy protein, with increased soy protein-specific IgG titers. Conclusions: These studies demonstrate that there is a continued expression of anti-soy protein antibodies in rats bred and raised on a soy protein-free diet for one generation. Not only must the test animals be bred and raised on a specified antigen-free diet, but their parental generations must also be bred in the same manner to avoid any problems in oral sensitization studies.	TNO, Nutr & Food Res Inst, Dept Immuno Inhalat & In Vitro Toxicol, NL-3700 AJ Zeist, Netherlands; Univ Utrecht, Toxicol Res Inst, NL-3508 TD Utrecht, Netherlands	Netherlands Organization Applied Science Research; Utrecht University	Knippels, LMJ (corresponding author), TNO, Nutr & Food Res Inst, Dept Immuno Inhalat & In Vitro Toxicol, POB 360, NL-3700 AJ Zeist, Netherlands.			Houben, Geert/0000-0001-7261-3912				Atkinson HAC, 1996, FOOD CHEM TOXICOL, V34, P27, DOI 10.1016/0278-6915(95)00084-4; BAILEY M, 1993, INT ARCH ALLERGY IMM, V101, P266, DOI 10.1159/000236456; BAZIN H, 1976, IMMUNOLOGY, V30, P679; BOZELKA BE, 1987, INT ARCH ALLER A IMM, V83, P271, DOI 10.1159/000234307; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; DEVEY ME, 1976, CLIN EXP IMMUNOL, V26, P542; HEPPELL LMJ, 1982, INT ARCH ALLER A IMM, V68, P54, DOI 10.1159/000233067; HEPPELL LMJ, 1989, RES VET SCI, V47, P257, DOI 10.1016/S0034-5288(18)31216-5; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; JARRETT E, 1979, NATURE, V280, P145, DOI 10.1038/280145a0; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; JARRETT EEE, 1976, IMMUNOLOGY, V30, P671; KOBAYASHI Y, 1994, J ALLERGY CLIN IMMUN, V94, P907, DOI 10.1016/0091-6749(94)90159-7; MELAMED D, 1994, EUR J IMMUNOL, V24, P1974, DOI 10.1002/eji.1830240906; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; NGAN J, 1978, J IMMUNOL, V120, P861; PAHUD JJ, 1985, PRODUCTION REGULATIO, P264; PAUWELS R, 1979, IMMUNOLOGY, V36, P145; PERI BA, 1981, INFECT IMMUN, V32, P1148, DOI 10.1128/IAI.32.3.1148-1154.1981; PIACENTINI GL, 1994, ALLERGY, V49, P361, DOI 10.1111/j.1398-9995.1994.tb02282.x; RUBINSTEIN LJ, 1982, J EXP MED, V156, P506, DOI 10.1084/jem.156.2.506; STEIN KE, 1984, J EXP MED, V160, P1001, DOI 10.1084/jem.160.4.1001; STEINMANN J, 1990, INT ARCH ALLER A IMM, V91, P62, DOI 10.1159/000235091; STOKES CR, 1983, CLIN EXP IMMUNOL, V52, P678; STOKES CR, 1983, CLIN EXP IMMUNOL, V52, P399; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; STROBEL S, 1986, GUT, V27, P829, DOI 10.1136/gut.27.7.829; TURNER MW, 1990, CLIN EXP ALLERGY, V20, P421, DOI 10.1111/j.1365-2222.1990.tb02804.x	30	33	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				815	820		10.1016/S0091-6749(98)70309-4	http://dx.doi.org/10.1016/S0091-6749(98)70309-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648709				2022-12-18	WOS:000074414200016
J	Weiss, ST; O'Connor, GT; DeMolles, D; Platts-Mills, T; Sparrow, D				Weiss, ST; O'Connor, GT; DeMolles, D; Platts-Mills, T; Sparrow, D			Indoor allergens and longitudinal FEV1 decline in older adults: The Normative Aging Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; FEV1 asthma; smoking	RISK-FACTORS; BRONCHIAL RESPONSIVENESS; VENTILATORY IMPAIRMENT; PULMONARY-FUNCTION; INHALED HISTAMINE; LUNG-FUNCTION; SERUM IGE; ASTHMA; METHACHOLINE; REACTIVITY	We investigated the relationship between home allergen exposure and decline in FEV1 in 10 asthmatic and 30 randomly selected, age-matched, nonasthmatic participants in the Normative Aging Study. We defined asthma as subject-reported wheezing apart from colds, with either a physician's diagnosis of asthma or a methacholine PD20 FEV1, of 8.6 mu mol or less. We examined the relationship between the annual decline in FEV, and the concentrations of the cockroach (Blattella germanica) allergens Bla g 1 and Bla g 2, the dust mite (Dermatophagoides pteronyssinus and Dermatophagoides farinae) allergens Der p 1 and Der f 1, and the cat (Felis domesticus) allergen Fel d 1 in house dust specimens. Bla g 1 (-79.8 ml/yr, p = 0.0006) and Bla g 2 (-40.81 ml/yr, p 0.0004) were significant predictors of decline in FEV1. after adjustment for age, smoking, and baseline FEV1. These results were unchanged after elimination of the asthmatic subjects from the analysis. We conclude that cockroach allergen levels in homes is a risk factor for accelerated decline in FEV1 independent of airway responsiveness.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Med, Ctr Pulm, Boston, MA 02118 USA; VA Outpatient Clin, Normat Aging Study, Boston, MA USA; Univ Virginia, Med Ctr, Dept Med, Div Allergy, Charlottesville, VA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Boston University; University of Virginia	Weiss, ST (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.			O'Connor, George/0000-0002-6476-3926; Platts-Mills, Thomas/0000-0002-1263-329X	NHLBI NIH HHS [HL34645] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNESI I, 1987, B EUR PHYSIOPATH RES, V23, P397; [Anonymous], 1979, AM REV RESPIR DIS, V119, P831; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; BELL B, 1972, AGING HUM DEVELOP, V3, P5, DOI 10.2190/GGVP-XLB5-PC3N-EF0G; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1988, AM REV RESPIR DIS, V138, P829, DOI 10.1164/ajrccm/138.4.829; CHATHAM M, 1982, CHEST, V82, P15, DOI 10.1378/chest.82.1.15; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1983, LANCET, V2, P253; DOW L, 1992, AM REV RESPIR DIS, V146, P402, DOI 10.1164/ajrccm/146.2.402; Fletcher CM, 1976, NATURAL HIST CHRONIC; FREW AJ, 1992, AM REV RESPIR DIS, V146, P878, DOI 10.1164/ajrccm/146.4.878; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gottlieb DJ, 1996, AM J RESP CRIT CARE, V153, P561, DOI 10.1164/ajrccm.153.2.8564098; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG BC, 1992, ANN ALLERGY, V68, P237; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LOWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V78, P1035, DOI 10.1016/0091-6749(86)90300-3; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; OCONNOR GT, 1995, AM J RESP CRIT CARE, V152, P87, DOI 10.1164/ajrccm.152.1.7599868; OCONNOR GT, 1993, CHEST, V103, P376, DOI 10.1378/chest.103.2.376; OMENAAS E, 1995, AM J RESP CRIT CARE, V152, P1158, DOI 10.1164/ajrccm.152.4.7551364; Orie NGM, 1961, BRONCHITIS INT S; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; RIESS A, 1961, OCCUPATIONS THEIR SO; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377, DOI 10.1164/ajrccm.151.5.7735588; ROCHE WR, 1989, LANCET, V1, P520; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SCHACHTER EN, 1984, CHEST, V85, P623, DOI 10.1378/chest.85.5.623; SPARROW D, 1987, AM REV RESPIR DIS, V135, P1255; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TAYLOR RG, 1985, THORAX, V40, P9, DOI 10.1136/thx.40.1.9; VILLAR MTA, 1995, AM J RESP CRIT CARE, V151, P656, DOI 10.1164/ajrccm/151.3_Pt_1.656; VOLLMER WM, 1986, CHEST, V90, P416, DOI 10.1378/chest.90.3.416	38	33	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				720	725		10.1016/S0091-6749(98)70300-8	http://dx.doi.org/10.1016/S0091-6749(98)70300-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648697	Bronze			2022-12-18	WOS:000074414200002
J	Takao, A; Shimoda, T; Kohno, S; Asai, S; Harda, S				Takao, A; Shimoda, T; Kohno, S; Asai, S; Harda, S			Correlation between alcohol-induced asthma and acetaldehyde dehydrogenase-2 genotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial asthma; alcohol; Asians; histamine release; ALDH2 genotype	ALDEHYDE DEHYDROGENASE; POLYMORPHISM; METABOLISM	Background: Alcohol-induced asthma, a phenomenon characteristic of Asians, is due to differences in alcohol metabolism, particularly acetaldehyde metabolism. me investigated the effect of polymorphism in acetylaldehyde dehydrogenase 2 (ALDH2) gene on the response to alcohol challenge testing in a group of Japanese asthmatic subjects and normal subjects. Methods: Subjects were 32 asthmatic subjects and 30 healthy individuals. We measured the change in FEV1 after ingestion of 30 gm of ethanol. Blood ethanol, acetylaldehyde, and histamine concentrations were determined. ALDH2 gene type was established by polymerase chain reaction. Results: Ethanol provocation test results were positive in 15 (47% responders) asthmatic subjects. The blood ethanol concentration was similar in responders and nonresponders. The fall in FEV1 was associated with a rise in blood acetaldehyde and histamine concentrations. The response to oral ethanol challenge was positive in three (19%) of 16 patients with normal homozygote ALDH2 genotype, 10 (71%) of 14 patients with type mutant heterozygote, and two (100%) of two patients with type mutant homozygote ALDH2 genotype. Conclusions: Alcohol-induced asthma is probably caused by increased blood acetaldehyde concentration resulting from abnormalities of ALDH2 enzyme activity based on ALDH2 genotype differences.	Nagasaki Univ, Sch Med, Dept Internal Med 2, Nagasaki 852, Japan; Sasebo Municipal Cent Hosp, Sasebo, Japan; Tukuba Univ, Dept Legal Med, Ibaragi, Japan	Nagasaki University; University of Tsukuba	Takao, A (corresponding author), Nagasaki Univ, Sch Med, Dept Internal Med 2, 1-7-1 Sakamoto Machi, Nagasaki 852, Japan.							BRESLIN A B X, 1973, Clinical Allergy, V3, P71, DOI 10.1111/j.1365-2222.1973.tb01311.x; DAHL R, 1986, J ALLERGY CLIN IMMUN, V78, P1126, DOI 10.1016/0091-6749(86)90261-7; EADE NR, 1959, J PHARMACOL EXP THER, V127, P29; ENOMOTO N, 1990, J CLIN EXP MED, V154, P823; GEPPERT EF, 1978, AM REV RESPIR DIS, V118, P135; GOEDDE HW, 1985, ALCOHOL, V2, P383, DOI 10.1016/0741-8329(85)90099-0; GONG H, 1981, CHEST, V80, P167, DOI 10.1378/chest.80.2.167; HARADA S, 1991, J ANTHROPOL SOC NIP, V99, P123; HARADA S, 1985, ALCOHOL, V2, P391, DOI 10.1016/0741-8329(85)90100-4; HARADA S, 1990, J CLIN EXP MED, V154, P817; IJIRI I, 1974, JPN J STUD ALCOHOL, V9, P35; KROSAWA M, 1990, J INT MED RESP, V18, P435; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MIZOI Y, 1979, PHARMACOL BIOCHEM BE, V10, P303, DOI 10.1016/0091-3057(79)90105-9; MIZOI Y, 1985, ALCOHOL, V2, P393, DOI 10.1016/0741-8329(85)90101-6; MORROWBROWN H, 1987, PRACTITIONER, V231, P684; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; REED TE, 1976, CAN MED ASSOC J, V115, P851; Sambrook J, 1989, MOL CLONING LAB MANU; Shimoda T, 1996, J ALLERGY CLIN IMMUN, V97, P74, DOI 10.1016/S0091-6749(96)70285-3; WALLS AF, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb00106.x; WOLFF PH, 1972, SCIENCE, V175, P449, DOI 10.1126/science.175.4020.449; WOLFF PH, 1973, AM J HUM GENET, V25, P193; ZEINER AR, 1979, ALCOHOL CLIN EXP RES, V3, P11, DOI 10.1111/j.1530-0277.1979.tb04759.x	24	33	34	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					576	580		10.1016/S0091-6749(98)70162-9	http://dx.doi.org/10.1016/S0091-6749(98)70162-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600491	Bronze			2022-12-18	WOS:000073697400002
J	Kornfeld, SJ; Haire, RN; Strong, SJ; Brigino, EN; Tang, HY; Sung, SSJ; Fu, SM; Litman, GW				Kornfeld, SJ; Haire, RN; Strong, SJ; Brigino, EN; Tang, HY; Sung, SSJ; Fu, SM; Litman, GW			Extreme variation in X-linked agammaglobulinemia phenotype in a three-generation family	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bruton's tyrosine kinase; DNA sequencing; primary immunodeficiency disease; protein tyrosine kinase; X-linked agammaglobulinemia	BRUTONS TYROSINE KINASE; HYPOGAMMAGLOBULINEMIA; MUTATION; GENE	Background: X-linked agammaglobulinemia is typically a severe life-threatening disease characterized by the failure of B-cell differentiation and antibody production, which manifests in infancy and early childhood. Recently, we reported a novel mutation (Cys(14S-->STOP) in Bruton's tyrosine kinase in a ii-year-old man who was referred for evaluation because of chronic nasal congestion, recurrent sinusitis, sporadic pneumonia, and a family history suggestive of an ii-linked immunodeficiency disease. He had not been treated with gammaglobulin. Objective: This study was performed to investigate the clinical and immunologic phenotypes of this patient's other affected male family members. Methods: A detailed family history and comprehensive review of medical records was carried out. Genetic mutation analysis of the gene encoding Bruton's tyrosine kinase was carried out in the proband's brother and nephew. Results: Clinically affected male family members exhibit marked phenotypic variation with manifestations ranging from extremely mild to severe recurrent infections. Immunologic evaluation revealed extreme variation in immunoglobulin levels, B-cell numbers, and functional antibody titers. Genetic analysis documented a novel mutation in the gene encoding Bruton's tyrosine kinase in the proband. his brother, and his nephew. Conclusions: Despite their sharing the same genetic abnormality , extreme variation was noted in the immunologic findings and phenotypic expression of affected family members. This family study is extraordinary in that clinically affected male members who did not receive aggressive medical treatment died of the disease in childhood or survived into late adulthood.	UNIV S FLORIDA,COLL MED,ALL CHILDRENS HOSP,DEPT PEDIAT,ST PETERSBURG,FL 33701; UNIV VIRGINIA,SCH MED,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908	State University System of Florida; University of South Florida; University of Virginia								BRUTON OC, 1952, PEDIATRICS, V9, P722; Bykowsky MJ, 1996, AM J HUM GENET, V58, P477; CONLEY ME, 1994, IMMUNOL REV, V138, P5, DOI 10.1111/j.1600-065X.1994.tb00844.x; HERMASZEWSKI RA, 1993, Q J MED, V86, P31; KORNFELD SJ, 1995, J ALLERGY CLIN IMMUN, V95, P915, DOI 10.1016/S0091-6749(95)70138-9; Kornfeld SJ, 1996, MOL MED, V2, P619, DOI 10.1007/BF03401645; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; LEICKLEY FE, 1986, CLIN EXP IMMUNOL, V65, P90; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SALTZMAN RL, 1987, REV INFECT DIS, V9, P1127; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0	16	33	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					702	706		10.1016/S0091-6749(97)70176-3	http://dx.doi.org/10.1016/S0091-6749(97)70176-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389302	Bronze			2022-12-18	WOS:A1997YG20200019
J	Vidal, C; Chomon, B; PerezCarral, C; GonzalezQuintela, A				Vidal, C; Chomon, B; PerezCarral, C; GonzalezQuintela, A			Sensitization to Lepidoglyphus destructor, Tyrophagus putrescentiae, and Acarus siro in patients allergic to house dust mites (Dermatophagoides spp.)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							STORAGE MITES; PTERONYSSINUS; REACTIVITY		COMPLEJO HOSP UNIV SANTIAGO,DIV BIOCHEM,SANTIAGO COMPOSTE,SPAIN; COMPLEJO HOSP UNIV SANTIAGO,DIV INTERNAL MED,SANTIAGO COMPOSTE,SPAIN	Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela	Vidal, C (corresponding author), HOSP CONXO,COMPLEJO HOSP UNIV SANTIAGO,UNIDAD ALERGIA,DIV ALLERGY,RUA RAMON BALTAR SN,SANTIAGO COMPOSTE 15706,SPAIN.			Gonzalez-Quintela, Arturo/0000-0002-6909-1807				BLAINEY AD, 1989, J ALLERGY CLIN IMMUN, V84, P296, DOI 10.1016/0091-6749(89)90411-9; BONER AL, 1989, ANN ALLERGY, V63, P82; EBNER C, 1994, CLIN EXP ALLERGY, V24, P347, DOI 10.1111/j.1365-2222.1994.tb00245.x; FORD AW, 1987, CLIN REV ALLERG, V55, P49; GRIFFIN P, 1989, J ALLERGY CLIN IMMUN, V84, P108, DOI 10.1016/0091-6749(89)90184-X; IVERSEN M, 1990, CLIN EXP ALLERGY, V20, P211, DOI 10.1111/j.1365-2222.1990.tb02670.x; IVERSEN M, 1990, ALLERGY, V45, P81, DOI 10.1111/j.1398-9995.1990.tb00462.x; LLERENA LP, 1991, J ALLERGY CLIN IMMUN, V88, P943, DOI 10.1016/0091-6749(91)90252-J; VANHAGEHAMSTEN M, 1989, J ALLERGY CLIN IMMUN, V83, P581, DOI 10.1016/0091-6749(89)90069-9	9	33	34	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					716	718		10.1016/S0091-6749(97)70181-7	http://dx.doi.org/10.1016/S0091-6749(97)70181-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389307	Bronze			2022-12-18	WOS:A1997YG20200024
J	Sicherer, SH; Wood, RA; Eggleston, PA				Sicherer, SH; Wood, RA; Eggleston, PA			Determinants of airway responses to cat allergen: Comparison of environmental challenge to quantitative nasal and bronchial allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						environmental allergen challenge; cat; asthma; rhinitis; bronchoprovocation; airway hyperreactivity	FEL-D-I; BRONCHOALVEOLAR LAVAGE; MAST-CELLS; ASTHMA; HISTAMINE; RHINITIS; RELEASE; RESPONSIVENESS; METHACHOLINE; DOMESTICUS	Background: Why allergic subjects may have asthma or rhinitis on allergen exposure remains unclear, Objective: This study was carried out to compare airway responses during environmental allergen challenge (EAC) with quantitative allergen provocation challenges of the upper and lower airways. Methods: Thirteen subject with allergy to cats underwent EAC to cats. Lower airway responses during EAC were compared with bronchoprovocation with allergen. Nasal mucosal challenge with allergen-soaked disks were compared with EAC nasal responses. Nonspecific bronchial reactivity was assessed with methacholine; allergen sensitivity was assessed by skin prick tests, RAST, and end-point skin titration. Results: During EAC, the maximal fall in FEV1 ranged from 6% to 57% (median, 18%) and correlated closely with allergen bronchoprovocation PD20 (Spearman's correlation coefficient [R-s] = -0.85. p < 0.0002). EAC asthmatic responses and allergen bronchoprovocation correlated with methacholine PD20 (R-s = -0.85, p = 0.0002 and R-s = 0.83, p = 0.0004, respectively). Nasal provocation and EAC nasal responses correlated with each other but not with lower airway responses. On the basis of EAC and allergen bronchoprovocation responses, seven participants with asthma were identified. This group was significantly more sensitive to inhaled methacholine but was similar to the nonasthmatic group in IgE-mediated sensitivity and nasal responses. Conclusions: The lower respiratory tract is less responsive to allergic and nonallergic stimuli in persons with allergic rhinitis. In persons with asthma during EAC, the response to nebulized cat allergen is also abnormal and correlates closely with their abnormal responsiveness to nonimmunologic stimuli.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV IMMUNOL & ALLERGY,BALTIMORE,MD 21205	Johns Hopkins University					NCRR NIH HHS [RR-00052] Funding Source: Medline; NIAID NIH HHS [AI-07007] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAROODY FM, 1994, AM J RESP CRIT CARE, V149, P1457, DOI 10.1164/ajrccm.149.6.7516250; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661, DOI 10.1152/jappl.1993.74.6.2661; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CLARKE SW, 1994, TXB RESP MED, P345; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; EGGLESTON PA, 1995, AM J RESP CRIT CARE, V151, P640; FISH JE, 1980, J ALLERGY CLIN IMMUN, V65, P154, DOI 10.1016/0091-6749(80)90201-8; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; LAM S, 1991, J ALLERGY CLIN IMMUN, V87, P842, DOI 10.1016/0091-6749(91)90131-7; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MULLER BA, 1993, J ALLERGY CLIN IMMUN, V91, P758, DOI 10.1016/0091-6749(93)90196-M; PERMUTT S, 1977, ASTHMA PHYSL IMMUNOP, P265; PLATTSMILLS TAE, 1992, AM REV RESPIR DIS, V145, pS44, DOI 10.1164/ajrccm/145.2_Pt_2.S44; STEVENS WJ, 1980, EUR J RESPIR DIS, V61, P203; STUART BO, 1984, ENVIRON HEALTH PERSP, V55, P369, DOI 10.2307/3429715; SVENSSON C, 1995, J ALLERGY CLIN IMMUN, V96, P239, DOI 10.1016/S0091-6749(95)70013-7; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; WOOD R A, 1992, American Review of Respiratory Disease, V145, pA692; WOOD RA, 1995, AM J RESP CRIT CARE, V151, P315, DOI 10.1164/ajrccm.151.2.7842184; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P542	28	33	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				798	805		10.1016/S0091-6749(97)80014-0	http://dx.doi.org/10.1016/S0091-6749(97)80014-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215248				2022-12-18	WOS:A1997XH19300013
J	Sakaguchi, M; Yoshida, T; Asahi, T; Aoki, T; Miyatani, Y; Inouye, S				Sakaguchi, M; Yoshida, T; Asahi, T; Aoki, T; Miyatani, Y; Inouye, S			Development of IgE antibody to gelatin in children with systemic immediate-type reactions to vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MEASLES; MUMPS		SHIZUOKA CHILDRENS HOSP,SHIZUOKA,JAPAN; MIYATANI CLIN,CHIRYU,JAPAN; FUKUOKA CHILDRENS HOSP,FUKUOKA,JAPAN; MED CTR INFECT DIS,FUKUOKA,JAPAN		Sakaguchi, M (corresponding author), NATL INST HLTH,DEPT EPIDEMIOL,SHINJUKU KU,TOYAMA 1-23-1,TOKYO 162,JAPAN.		Inouye, Sharon/R-7216-2019					BUSINCO L, 1994, ANN ALLERGY, V72, P1; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; MUNOZ JJ, 1981, INFECT IMMUN, V33, P820, DOI 10.1128/IAI.33.3.820-826.1981; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Vogel F. R., 1995, VACCINE DESIGN SUBUN, P141; ZIMMERMAN B, 1993, ALLERGY PRINCIPLES P, P1705	7	33	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					720	721		10.1016/S0091-6749(97)70038-1	http://dx.doi.org/10.1016/S0091-6749(97)70038-1			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155843				2022-12-18	WOS:A1997WY60000024
J	Ciprandi, G; Ricca, V; Passalacqua, G; Truffelli, T; Bertolini, C; Fiorino, N; Riccio, AM; Bagnasco, M; Canonica, GW				Ciprandi, G; Ricca, V; Passalacqua, G; Truffelli, T; Bertolini, C; Fiorino, N; Riccio, AM; Bagnasco, M; Canonica, GW			Seasonal rhinitis and azelastine: Long- or short-term treatment?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						azelastine; allergic inflammation; seasonal rhinitis	NASAL EPITHELIAL-CELLS; PERITONEAL MAST-CELLS; ALLERGIC SUBJECTS; HISTAMINE-RELEASE; CHALLENGE; EXPRESSION; INHIBITION; ICAM-1; CD54	Background: Azelastine is a topical antihistamine, clinically demonstrated to be effective in allergic rhinitis. Objective: We evaluated the clinical efficacy and the antiallergic activity of azelastine nasal spray, administered 0.56 mg per day, 0.28 mg per day, or on demand over a 3-month period during natural allergen exposure, in a double-blind, placebo-controlled fashion. Methods: Thirty patients, sensitized to grass or Parietaria pollen, were allocated to three treatment groups: those receiving the standard dosage (0.14 mg/nostril two times a day), half the dosage (0.07 mg/nostril two times a day), or placebo daily for 3 months. All patients were allowed to take additional doses of azelastine when needed. Evaluation parameters were as follows: clinical symptoms recorded on a diary card, number of additional, on-demand azelastine puffs, nasal inflammatory cell count, intercellular adhesion molecule-1 expression on nasal epithelial cells, and pollen count. Results: This study showed the following: (1) the half dose (0.28 mg/day) and the standard dose (0.56 mg/day) were equally effective in reducing clinical symptoms (p = NS), although the standard dosage required fewer additional puffs during times of peak pollen counts (p < 0.05); (2) both dosages were able to reduce the allergic inflammation (p < 0.05 vs placebo); and (3) on-demand use achieved acceptable clinical control but did not significantly reduce allergic inflammation. Conclusion: Continuous treatment was more effective than on-demand use as assessed by both clinical evaluation and antiinflammatory action.	UNIV GENOA,DIPARTIMENTO MED INTERNA,ALLERGY & CLIN IMMUNOL SERV,I-16132 GENOA,ITALY	University of Genoa			canonica, giorgio walter/ABF-2037-2020; Ciprandi, Giorgio/G-7462-2012	canonica, giorgio walter/0000-0001-8467-2557; Ciprandi, Giorgio/0000-0001-7016-8421; RICCIO, ANNA MARIA/0000-0001-8392-533X				BARATA LT, 1996, CLIN EXP ALLERGY, V26, P68; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; Busse WW, 1996, AM J RESP CRIT CARE, V153, P122, DOI 10.1164/ajrccm.153.1.8542104; CANONICA GW, 1994, ALLERGY, V49, P135, DOI 10.1111/j.1398-9995.1994.tb00815.x; CANONICA GW, 1993, ALLERGY CLIN IMMUNOL, V5, P80; CHAND N, 1985, AGENTS ACTIONS, V16, P318, DOI 10.1007/BF01982866; CIPRANDI G, 1994, AM J RESP CRIT CARE, V150, P1653, DOI 10.1164/ajrccm.150.6.7524984; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P1227, DOI 10.1016/0091-6749(93)90327-C; CIPRANDI G, 1994, INT ARCH ALLERGY IMM, V104, P92, DOI 10.1159/000236713; CIPRANDI G, 1995, ALLERGY, V50, P184; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; CIPRANDI G, 1995, CLIN EXP ALLERGY, V25, P871, DOI 10.1111/j.1365-2222.1995.tb00030.x; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; CIPRANDI G, 1994, J ALLERGY CLIN IMMUN, V94, P738, DOI 10.1016/0091-6749(94)90182-1; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; FIELDS DAS, 1984, J ALLERGY CLIN IMMUN, V73, P400, DOI 10.1016/0091-6749(84)90415-9; FISHER B, 1981, ARZNEIMITTEL-FORSCH, V31, P1193; KATAYAMA S, 1987, INT ARCH ALLER A IMM, V83, P284, DOI 10.1159/000234309; MCTAVISH D, 1989, DRUGS, V38, P778, DOI 10.2165/00003495-198938050-00005; PELUCCHI A, 1995, J ALLERGY CLIN IMMUN, V95, P515, DOI 10.1016/S0091-6749(95)70313-6; SCORDAMAGLIA A, 1995, ALLERGY, V26, P266; SHIN MH, 1992, CLIN EXP ALLERGY, V22, P289, DOI 10.1111/j.1365-2222.1992.tb03085.x	22	33	36	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					301	307		10.1016/S0091-6749(97)70046-0	http://dx.doi.org/10.1016/S0091-6749(97)70046-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058684				2022-12-18	WOS:A1997WM42200005
J	Toogood, JH; White, FA; Baskerville, JC; Fraher, LJ; Jennings, B				Toogood, JH; White, FA; Baskerville, JC; Fraher, LJ; Jennings, B			Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inhaled steroids; budesonide; lung deposition; spacer; Nebuhaler; dry powder inhalers; Turbuhaler	METERED-DOSE INHALER; BECLOMETHASONE DIPROPIONATE; MULTIPLE ACTUATIONS; ORAL PREDNISOLONE; LUNG DEPOSITION; BONE TURNOVER; SEVERE ASTHMA; DEVICE; INHALATION; TERBUTALINE	To determine therapeutically and systemically equivalent dosages of budesonide inhaled through the Turbuhaler dry powder inhalation device (Astra Pharma Production AB, Sodertalje, Sweden) or pressurized metered-dose inhaler (pMDI) plus Nebuhaler spacer (Astra Pharma Production AB), we compared these devices in a randomized, open, parallel-group trial. Adults with moderate to severe asthma inhaled budesonide (0.4, 0.8, 1.6, and 2.4 mg/day), for 2 weeks at each dose level, through the Turbuhaler (n = 30) or pMDI + Nebuhaler (n = 28). Dose-dependent effects were demonstrated on asthma symptoms (p = 0.0001), daily peak expiratory flow (p = 0.02), blood eosinophils (p = 0.0001), urinary cortisol output per day (p = 0.0001), serum cortisol (p = 0.006), serum osteocalcin (p = 0.0001), and the oropharyngeal Candida colony count (p = 0.0007, analysis of covariance). The ratio of the responses to the two inhalation devices approximated 1.0 for each index measured; that is, no significant between-device difference was found (p greater than or equal to 0.29). However, the 95% confidence limits for the ratio of their respective systemic effects on osteocalcin production were 0.83 to 1.48. Thus in adults who use inhalation devices efficiently and have optimally controlled asthma, conversions from the pMDI + Nebuhaler to the Turbuhaler may reasonably be made at milligram equivalent doses of budesonide, then down-titrated to minimize possible systemic effects. Because earlier studies have shown that the Turbuhaler can double intrapulmonary drug delivery in comparison with a pMDI without a spacer, a 50% dose reduction may be indicated when converting from a pMDI to the Turbuhaler.	UNIV WESTERN ONTARIO, DEPT MED, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, DEPT STAT & ACTUARIAL SCI, LONDON, ON, CANADA; ST JOSEPHS HLTH CTR, DEPT MED, LONDON, ON, CANADA; ST JOSEPHS HLTH CTR, LAWSON RES INST, LONDON, ON, CANADA; ASTRA PHARMA INC, DEPT MED, MISSISSAUGA, ON, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Toogood, JH (corresponding author), LONDON HLTH SCI CTR, DEPT MED, VICTORIA CAMPUS, 800 COMMISSIONERS RD E, LONDON, ON N6A 4G5, CANADA.							AGERTOFT L, 1993, ARCH DIS CHILD, V69, P130, DOI 10.1136/adc.69.1.130; AMIRAV I, 1994, J ALLERGY CLIN IMMUN, V94, P669, DOI 10.1016/0091-6749(94)90173-2; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; BARRY PW, 1994, EUR RESPIR J, V7, P1707, DOI 10.1183/09031936.94.07091707; Barry PW, 1994, THORAX, V49, p402P; BOE J, 1989, ALLERGY, V44, P349, DOI 10.1111/j.1398-9995.1989.tb00457.x; BORGSTROM L, 1994, EUR RESPIR J, V7, P69, DOI 10.1183/09031936.94.07010069; ENGEL T, 1989, ALLERGY, V44, P220, DOI 10.1111/j.1398-9995.1989.tb02266.x; FIESE EF, 1988, J PHARM SCI, V77, P90, DOI 10.1002/jps.2600770118; FINNEY DJ, 1964, STATISTICAL METHOD B, P99; HINDLE M, 1995, CHEST, V107, P629, DOI 10.1378/chest.107.3.629; HINDLE M, 1993, THORAX, V48, P607, DOI 10.1136/thx.48.6.607; HODSMAN AB, 1991, J CLIN ENDOCR METAB, V72, P530, DOI 10.1210/jcem-72-3-530; JENNINGS BH, 1991, EUR J CLIN PHARMACOL, V40, P77, DOI 10.1007/BF00315143; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MITCHELL J, 1995, J AEROSOL MED, V8, pB89; NEWMAN SP, 1984, THORAX, V39, P935, DOI 10.1136/thx.39.12.935; NEWMAN SP, 1981, AM REV RESPIR DIS, V124, P317; NEWMAN SP, 1981, EUR J RESPIR DIS, V62, P3; NEWMAN SP, 1981, CHEST, V80, P909; OCALLAGHAN C, 1993, THORAX, V48, P603, DOI 10.1136/thx.48.6.603; OCALLAGHAN C, 1994, THORAX, V49, P961, DOI 10.1136/thx.49.10.961; PEDERSEN S, 1993, BRIT J CLIN PHARMACO, V36, P211, DOI 10.1111/j.1365-2125.1993.tb04219.x; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; SAS Institute Inc, 1989, SAS STAT US GUID VER, P846; SELROOS O, 1994, THORAX, V49, P1228, DOI 10.1136/thx.49.12.1228; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; Toogood J H, 1994, Int J Risk Saf Med, V5, P1, DOI 10.3233/JRS-1994-5102; TOOGOOD JH, 1988, EUR J CLIN PHARMACOL, V34, P113, DOI 10.1007/BF01061431; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1990, J ALLERGY CLIN IMMUN, V85, P872, DOI 10.1016/0091-6749(90)90071-B; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; TOOGOOD JH, 1984, EUR J RESPIR DIS, V65, P35; TOOGOOD JH, 1996, LUNG BIOL HLTH DIS S, P607; TOOGOOD JH, 1995, J AEROSOL MED, V8, P129; VANDENBERG JHM, 1977, CLIN CHIM ACTA, V78, P165, DOI 10.1016/0009-8981(77)90303-5	39	33	34	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					186	193		10.1016/S0091-6749(97)70094-0	http://dx.doi.org/10.1016/S0091-6749(97)70094-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042043	Bronze			2022-12-18	WOS:A1997WH83100006
J	Sanwo, M; Nwadiuko, R; Beall, G				Sanwo, M; Nwadiuko, R; Beall, G			Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intravenous immunoglobulin; adverse drug reactions; Stevens-Johnson syndrome	ERYTHEMA MULTIFORME; THALIDOMIDE; THERAPY	Patients with AIDS have increased frequency of severe cutaneous reactions to certain medications, and these patients often require prolonged hospitalizations because of these reactions. Some reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, appear to involve immune-mediated destruction of cutaneous tissue and therefore respond to antiinflammatory agents. Intravenous immunoglobulin has potent antiinflammatory activity. We have treated two patients with AIDS and severe drug reactions with intravenous immunoglobulin with good outcome. Corticosteroids were avoided because of the potential risk of further immunosuppression in these already immunodeficient patients. Both patients improved rapidly with intravenous immunoglobulin, and hospitalizations for treatment of these reactions were either prevented or shortened because of this treatment. Intravenous immunoglobulin therefore appeals to be an effective alternative treatment for severe cutaneous drug reactions in immunodeficient patients.	UNIV CALIF LOS ANGELES,MED CTR,DIV CLIN IMMUNOL & ALLERGY,TORRANCE,CA 90509	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center								BALLOW M, 1989, J ALLERGY CLIN IMMUN, V84, P595, DOI 10.1016/0091-6749(89)90196-6; BARRY W, 1992, JAMA-J AM MED ASSOC, V267, P3315, DOI 10.1001/jama.267.24.3315; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; CABALLER BD, 1991, J ALLERGY CLIN IMMUN, V88, P137, DOI 10.1016/0091-6749(91)90311-B; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; GRIFFITHS CEM, 1989, BRIT J DERMATOL, V120, P1, DOI 10.1111/j.1365-2133.1989.tb07759.x; HALEBIAN PH, 1986, ANN SURG, V204, P503, DOI 10.1097/00000658-198611000-00001; HUFF JC, 1991, IMMUNOLOGIC DIS SKIN, P463; KAVERI SV, 1992, SEMIN HEMATOL, V29, P64; KAZMIEROWSKI JA, 1978, J INVEST DERMATOL, V71, P366, DOI 10.1111/1523-1747.ep12556746; LEUNG DYM, 1989, LANCET, V2, P1298; LYELL A, 1967, BRIT J DERMATOL, V79, P662, DOI 10.1111/j.1365-2133.1967.tb11434.x; MITSUYASU R, 1983, NEW ENGL J MED, V308, P1535, DOI 10.1056/NEJM198306233082512; MOISSON YF, 1992, BRIT J DERMATOL, V126, P92, DOI 10.1111/j.1365-2133.1992.tb08415.x; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; NORRIS DA, 1990, J INVEST DERMATOL, V95, pS111, DOI 10.1111/1523-1747.ep12874977; SCOTT DF, 1989, REV INFECT DIS, V11, pS214	17	33	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1112	1115		10.1016/S0091-6749(96)80199-0	http://dx.doi.org/10.1016/S0091-6749(96)80199-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977513				2022-12-18	WOS:A1996WB37800017
J	Chang, JH; Chan, H; Quirce, S; Green, T; Noertjojo, K; Lam, S; Frew, A; Keown, P; ChanYeung, M				Chang, JH; Chan, H; Quirce, S; Green, T; Noertjojo, K; Lam, S; Frew, A; Keown, P; ChanYeung, M			In vitro T-lymphocyte response and house dust mite-induced bronchoconstriction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-lymphocyte activation; cytokine release; mite allergen; specific bronchial responsiveness; nonallergic bronchial responsiveness	ASTHMATIC REACTIONS; ATOPIC-DERMATITIS; ALLERGEN; CELLS; RESPONSIVENESS; EOSINOPHILIA; ACTIVATION; FREQUENCY; DISEASE; GAMMA	Background: There is considerable evidence that T cells may play an important role in asthma. The purpose of this study was to determine whether the responsiveness of T lymphocytes to mite allergen stimulation in vitro is a determinant of bronchial response to house dust mite (HDM) allergen challenge in subjects who are allergic to HDM. Methods: Peripheral blood was taken from seven healthy nonatopic subjects and 23 subjects with positive skin test reactions to HDM. Of the subjects in the latter group, 16 had an asthmatic reaction on inhalation challenge with HDM extract (HDM-responders), whereas the remaining seven had a negative reaction (HDM allergic). The proportion of subsets of T lymphocytes and their activation and the amount of IL-2, IL-4, IL-5, and interferon-gamma released in the supernatants with and without stimulation with the HDM extract were determined. Results: Without stimulation, the proportions of subsets of T lymphocytes and their activation were similar between groups. When stimulated with the HDM allergen, the proportion of CD4(+)CD25(+) cells from HDM responders was significantly higher than those in the control group. Comparison within groups of cell cultures with and without stimulation with the mite allergen showed that the proportion of CD4(+), CD4(+)CD25(+), CD4(+)/CD8(+) and CD3(+)HLADR(+) cells were significantly increased in HDM responders with stimulation; there was a trend for CD4(+)CD25(+) cells to be increased in the HDM-allergic subjects; no increase in any T-lymphocyte subsets was found in the control subjects. The release of IL-5 was significantly greater in HDM responders than in the other two groups. The severity of the immediate asthmatic reaction was significantly associated with the degree of nonallergic bronchial hyperresponsiveness and the amount of IL-5 released but not with the level of specific IgE to the mite allergen or subsets of T lymphocytes with and without stimulation. Conclusion: The findings suggest that responsiveness of T lymphocytes to allergen challenge in vitro may play a role in determining the bronchial response to the allergen in vivo.	UNIV BRITISH COLUMBIA,DEPT MED,DIV RESP,VANCOUVER,BC V5Z 3J5,CANADA; UNIV SOUTHAMPTON,DEPT MED,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 1M9,CANADA	University of British Columbia; University of Southampton; University of British Columbia			s, q/AAD-7171-2020; Noertjojo, Kukuh/H-6806-2019; Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392				BURASTERO SE, 1993, J ALLERGY CLIN IMMUN, V91, P1075, DOI 10.1016/0091-6749(93)90222-2; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; CORRIGAN CJ, 1988, LANCET, V1, P1129; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FREW AJ, 1990, AM REV RESPIR DIS, V141, P407, DOI 10.1164/ajrccm/141.2.407; FREW AJ, 1992, J ALLERGY CLIN IMMUN, V89, P783, DOI 10.1016/0091-6749(92)90431-Z; KAY AB, 1991, CLIN EXP ALLERGY S1, V21, P17; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P361; KUS J, 1990, CLIN EXP ALLERGY, V20, P165, DOI 10.1111/j.1365-2222.1990.tb02662.x; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LOONEY RJ, 1994, J ALLERGY CLIN IMMUN, V93, P476, DOI 10.1016/0091-6749(94)90357-3; MAGGI E, 1992, J IMMUNOL, V148, P2142; MCHUGH S, 1992, CLIN EXP ALLERGY, V23, P137; MOSSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145; PAGANO M, 1993, PRINCIPLES BIOSTATIS; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WOOLLEY MJ, AM J RESP CRIT CARE, V152, P1508	24	33	34	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				922	931		10.1016/S0091-6749(96)80008-X	http://dx.doi.org/10.1016/S0091-6749(96)80008-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939155	Bronze			2022-12-18	WOS:A1996VU76400008
J	Vrtala, S; Mayer, P; Ferreira, F; Susani, M; Sehon, AH; Kraft, D; Valenta, R				Vrtala, S; Mayer, P; Ferreira, F; Susani, M; Sehon, AH; Kraft, D; Valenta, R			Induction of IgE antibodies' in mice and rhesus monkeys with recombinant birch pollen allergens: Different allergenicity of Bet v 1 and Bet v 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; recombinant Bet v 1 and Bet v 2; allergenicity; immunization mice; rhesus monkeys	INTERFERON-GAMMA; ESCHERICHIA-COLI; IGG2A RESPONSES; BINDING PROTEIN; MURINE IGE; PROFILIN; ANTIGEN; EXPRESSION; IDENTIFICATION; PURIFICATION	Background: Serologic measurements with recombinant birch pollen allergens, rBet nu 1 and rBet nu 2 (birch profilin), have shown that more than 95% of patients allergic to tree pollen mount high levels of IgE against rBet nu 1, whereas only approximately 10% of the patients display rather low levels of IgE against rBet nu 2. Objective: In this study an attempt was made to determine whether the different allergenicity of the major birch pollen allergen, rBet nu 1, and a minor birch pollen allergen, rBet nu 2, might be related to a different immunogenicity of the proteins as evaluated in experimental animal systems (mice and rhesus monkeys). Methods: Purified recombinant allergens were injected into mice and rhesus monkeys with aluminum hydroxide as adjuvant for elicitation of specific IgE responses. Antibody responses to the allergens were detected by immunoblotting, and time courses of immune responses were measured by ELISA. Results: In both animal models more than the 10-fold dose of rBet nu 2 was required to induce IgE antibodies, and even then, the amount of specific IgE antibodies elicited with rBet nu 1 was substantially higher than that induced by rBet nu 2. It was noted that rBet nu 2 formed stable polymers through disulfide bonds. Conclusion: In two different animal models (mice and rhesus monkeys) the major birch pollen allergen rBet nu 1, induced substantially higher levels of IgE than rBet nu 2. A reduced allergenicity of Bet nu 2 caused by polymer formation would be in agreement with previous studies indicating reduced allergenicity of proteins on chemical polymerization.	UNIV VIENNA,INST GEN & EXPT PATHOL,AKH,A-1090 VIENNA,AUSTRIA; SANDOZ INST MED RES,VIENNA,AUSTRIA; SALZBURG UNIV,INST DEV BIOL & GENET,A-5020 SALZBURG,AUSTRIA; AUSTRIAN ACAD SCI,INST MOL BIOL,A-5020 SALZBURG,AUSTRIA; UNIV MANITOBA,DEPT IMMUNOL,WINNIPEG,MB R3E 0W3,CANADA	University of Vienna; Novartis; Sandoz; Salzburg University; Austrian Academy of Sciences; University of Manitoba			Ferreira, Fatima/AAB-4321-2019; Ferreira, Fatima/E-4889-2011	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243				ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENBACH M, 1990, EPITOPES ATOPIC ALLE, P57; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHER DJ, 1987, J IMMUNOL, V138, P3688; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Ferreira FD, 1996, J ALLERGY CLIN IMMUN, V97, P95, DOI 10.1016/S0091-6749(96)70287-7; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FREUND J, 1956, Bibl Tuberc, P130; HAYGLASS KT, 1991, IMMUNOLOGY, V73, P407; HAYGLASS KT, 1991, J IMMUNOL, V147, P2455; HAYGLASS KT, 1991, J EXP MED, V173, P279, DOI 10.1084/jem.173.2.279; HAYGLASS KT, 1991, IMMUNOLOGY, V73, P24; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SB, 1977, IMMUNOLOGY, V32, P507; LEHRER SB, 1975, INT ARCH ALLER A IMM, V49, P796, DOI 10.1159/000231464; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; LISE LD, 1989, CURR OPIN IMMUNOL, V2, P269, DOI 10.1016/0952-7915(89)90199-4; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SNAPPER CM, 1988, IMMUNOL REV, V102, P51, DOI 10.1111/j.1600-065X.1988.tb00741.x; STEWART GA, 1990, EPITOPES ATOPIC ALLE, P83; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567	40	33	35	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				913	921		10.1016/S0091-6749(96)80007-8	http://dx.doi.org/10.1016/S0091-6749(96)80007-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939154				2022-12-18	WOS:A1996VU76400007
J	Horsmanheimo, L; Harvima, IT; Harvima, RJ; BrummerKorvenkontio, H; Francois, G; Reunala, T				Horsmanheimo, L; Harvima, IT; Harvima, RJ; BrummerKorvenkontio, H; Francois, G; Reunala, T			Histamine and leukotriene C-4 release in cutaneous mosquito-bite reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aedes aegypti mosquito; wheals; bite papules; mediator release	HUMAN SKIN; MICRODIALYSIS; ANTIBODIES; IGE	Background: Mosquito bites are known to sensitize persons, and the most common cutaneous reactions are immediate wheals and delayed bite papules. Anti-saliva IgE and IgG(4) antibodies are common in mosquito-sensitive subjects, but mediator release in bite reactions is not known. Methods: We used the microdialysis technique to measure in vivo histamine and leukotriene C-4 release after bite challenges in six mosquito-sensitive subjects. One individual who was not sensitive to bites volunteered as a control subject. Results: Three of the six mosquito-sensitive subjects had large wheals and showed clearly increased histamine concentrations 30 to 45 minutes after the bites. The histamine levels declined to baseline value within 2 hours; thereafter, one subject showed a second increase in histamine concentration. Four of the six mosquito-sensitive subjects showed increased leukotriene C-4 concentrations, and this mediator seemed to be released somewhat later than histamine. Conclusions: The increased histamine and leukotriene C-4 release observed in this study suggests that both mediators are involved in the early allergic response caused by mosquito bites.	HELSINKI UNIV HOSP,DEPT DERMATOL,FIN-00250 HELSINKI,FINLAND; KUOPIO UNIV HOSP,DEPT DERMATOL,SF-70210 KUOPIO,FINLAND; NATL PUBL HLTH INST,HELSINKI,FINLAND; INST TROP MED PRINCE LEOPOLD,LAB PROTOZOOL,B-2000 ANTWERP,BELGIUM	University of Helsinki; Helsinki University Central Hospital; Kuopio University Hospital; University of Eastern Finland; Finland National Institute for Health & Welfare; Institute of Tropical Medicine (ITM)								ANDERSON C, 1992, SKIN PHARMACOL, V5, P177, DOI 10.1159/000211035; BRUMMERKORVENKONTIO H, 1994, J ALLERGY CLIN IMMUN, V93, P551, DOI 10.1016/S0091-6749(94)70066-4; HARVIMA RJ, 1988, CLIN CHIM ACTA, V171, P247, DOI 10.1016/0009-8981(88)90150-7; KARPPINEN A, 1996, IN PRESS CLIN EXP AL; PETERSEN LJ, 1994, J ALLERGY CLIN IMMUN, V94, P773, DOI 10.1016/0091-6749(94)90186-4; REUNALA T, 1994, J ALLERGY CLIN IMMUN, V94, P902, DOI 10.1016/0091-6749(94)90158-9; REUNALA T, 1994, ANN MED, V26, P301, DOI 10.3109/07853899409147906; REUNALA T, 1993, CLIN EXP ALLERGY, V23, P72, DOI 10.1111/j.1365-2222.1993.tb02487.x; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WILSON AB, 1965, INT ARCH ALLER A IMM, V26, P294, DOI 10.1159/000229580	11	33	33	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					408	411		10.1016/S0091-6749(96)70165-3	http://dx.doi.org/10.1016/S0091-6749(96)70165-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757218				2022-12-18	WOS:A1996VC99500020
J	Blaauw, PJ; Smithuis, OLMJ; Elbers, ARW				Blaauw, PJ; Smithuis, OLMJ; Elbers, ARW			The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						insect sting challenge; hymenoptera allergy; venom immunotherapy; field sting	DIAGNOSTIC METHODS; CROSS-REACTIVITY; YELLOW JACKETS; APIS-MELLIFERA; WASP VENOM; HYPERSENSITIVITY; ANAPHYLAXIS; ALLERGY; SENSITIVITY; SEVERITY	Background: Venom immunotherapy is a generally accepted treatment for serious allergy to bee and yellow jacket venom. However, It is not precisely known to whom venom immunotherapy should be offered. Objective: The purpose of this study was to determine whether an in-hospital insect sting challenge (IHC) can be used as a criterion for application or omission of venom immunotherapy. Methods: An IHC was carried out in a group of 479 patients (136 sensitized to bee venom and 343 sensitized to yellow jacket venom). The patients with a negative IHC response were interviewed about their experience with subsequent stings under natural circumstances. Results: A total of 76 of 136 bee-sensitized patients (56%) and 284 of 343 yellow jacket-sensitized patients (83%) had a negative IHC response. All of the patients who had a systemic reaction after the IHC were advised to receive venom immunotherapy. The success rate of this therapy was 96.4% for patients allergic to bee venom (54 of 56) and 91.4% for patients allergic to yellow jacket venom (53 of 58). Of a total of 76 bee-sensitized patients with negative IHC responses, 41 were subsequently stung in the field; six patients had a mild (Mueller grade I) systemic reaction (14.6%). Of a total of 284 yellow jacket-sensitized with negative IHC responses, 127 were subsequently stung in the field; nine patients had a mild (Mueller grade I) systemic reaction (14.6%). Of a total of 284 yellow jacket-sensitized with negative IHC responses, 127 were subsequently string in the field; nine patients had a mild (Mueller grades I and II) systemic reaction (7.1%), and four patients had a severe (Mueller grades III and IV) systemic reaction (3.1%). Without IHC as a selection criterion for venom immunotherapy, the percentage of patients unnecessarily treated was calculated to be 48% for bee venom-sensitized patients and 74% for yellow jacket-sensitized patients. However, with a negative test IHC response as a selection criterion for the omission of venom immunotherapy, 14.6% of the bee venom-sensitized patients and 10.2% of the yellow jacket-sensitized patients were proven to be at risk for systemic reactions on subsequent field stings. Conclusion: Venom immunotherapy with bee or yellow jacket venom is justifiable only after a positive response to an IHC is observed.	ELKERLIEK HOSP, NL-5707 HA HELMOND, NETHERLANDS; ANIM HLTH SERV, EPIDEMIOL UNIT, BOXTEL, NETHERLANDS									BLAAUW PJ, 1986, ALLERGOLOGIE, V9, pS81; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; CLAYTON WF, 1983, J ALLERGY CLIN IMMUN, V71, P141, DOI 10.1016/0091-6749(83)90335-4; FORSTER J, 1991, Journal of Allergy and Clinical Immunology, V87, P238, DOI 10.1016/0091-6749(91)91676-K; FRANKEN HH, 1994, J ALLERGY CLIN IMMUN, V93, P431, DOI 10.1016/0091-6749(94)90351-4; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; HAUK P, 1990, Clinical and Experimental Allergy, V20, P112; HENOCQ E, 1982, ANN M EAACI 1981 CLE, V2, P886; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; KING TP, 1987, J ALLERGY CLIN IMMUN, V79, P113, DOI 10.1016/S0091-6749(87)80025-8; LICHTENSTEIN LM, 1994, J ALLERGY CLIN IMMUN, V94, P137, DOI 10.1016/0091-6749(94)90030-2; MOSBECH H, 1986, CLIN ALLERGY, V16, P433, DOI 10.1111/j.1365-2222.1986.tb01978.x; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1993, ALLERGY, V48, P37; MULLER U, 1991, CLIN EXP ALLERGY, V21, P281, DOI 10.1111/j.1365-2222.1991.tb01659.x; Muller UR., 1990, INSECT STING ALLERGY; OWEN MD, 1977, J INSECT PHYSIOL, V23, P1031, DOI 10.1016/0022-1910(77)90131-7; OWEN MD, 1979, TOXICON, V17, P94, DOI 10.1016/0041-0101(79)90260-5; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; PUCCI S, 1994, ALLERGY, V49, P894, DOI 10.1111/j.1398-9995.1994.tb00796.x; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; REISMAN RE, 1979, CLIN ALLERGY, V9, P167, DOI 10.1111/j.1365-2222.1979.tb01538.x; SCHUMACHER MJ, 1992, J ALLERGY CLIN IMMUN, V90, P59, DOI 10.1016/S0091-6749(06)80011-4; SCHUMACHER MJ, 1994, J ALLERGY CLIN IMMUN, V93, P831, DOI 10.1016/0091-6749(94)90373-5; Sokal R.R., 1980, BIOMETRY PRINCIPLES; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; VANDERLINDEN PWG, 1993, ANN INTERN MED, V118, P161, DOI 10.7326/0003-4819-118-3-199302010-00001; VANDERLINDEN PWG, 1993, THESIS MED FACULTY U; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0; 1994, STAT ANAL SOFTWARE V	34	33	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					39	47		10.1016/S0091-6749(96)70224-5	http://dx.doi.org/10.1016/S0091-6749(96)70224-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765816				2022-12-18	WOS:A1996VA69200005
J	Knutsson, PU; Bronnegard, M; Marcus, C; Stierna, P				Knutsson, PU; Bronnegard, M; Marcus, C; Stierna, P			Regulation of glucocorticoid receptor mRNA in nasal mucosa by local administration of fluticasone and budesonide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoid receptor; mRNA; topical corticosteroids; allergic rhinitis; fluticasone propionate; budesonide	EXPRESSION; RHINITIS; METALLOTHIONEIN; EFFICACY; GENE; ACID	The glucocorticoid receptor (GR) is downregulated by glucocorticoids (autoregulation). In contrast, the metallothionein gene (MTIIa) is positively regulated by glucocorticoids, which requires a functional receptor protein. We have investigated the expression of GR and MTIIa mRNA in nasal mucosal biopsy specimens, nasal brush-lavage samples, and peripheral blood lymphocytes from 14 healthy volunteers after local treatment with one of two different glucocorticoids: fluticasone propionate or budesonide. In nasal mucosal biopsy specimens, a significant decrease in GR mRNA occurred with increasing doses of both steroids, whereas a significant and parallel increase in MTIIa mRNA was observed. We found nasal brush-lavage less suitable for studies of GR mRNA and MTIIa mRNA regulation by locally administered glucocorticoids. In mucosal biopsy specimens, but not in peripheral blood lymphocytes, we found a correlation between basal GR mRNA and MTIIa mRNA levels, where low GR mRNA levels were associated with low MTIIa mRNA levels, and vice versa. In conclusion, this study shows that locally administered glucocorticoids significantly affect the expression of specific genes and that there is an interindividual and tissue-specific variation in GR mRNA and MTIIa mRNA expression, which may be used in studies of variations in clinical responses to nasal glucocorticoids.	HUDDINGE UNIV HOSP, KAROLINSKA INST, DEPT PEDIAT, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet	Knutsson, PU (corresponding author), HUDDINGE UNIV HOSP, KAROLINSKA INST, DEPT OTORHINOLARYNGOL, S-14186 HUDDINGE, SWEDEN.							BENDE M, 1992, J LARYNGOL OTOL, V106, P810, DOI 10.1017/S0022215100120948; Brattsand R., 1992, NEW DRUGS ASTHMA, V2, P193; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; BRONNEGARD M, 1991, J STEROID BIOCHEM, V39, P693, DOI 10.1016/0960-0760(91)90369-G; BRONNEGARD M, 1988, MOL ENDOCRINOL, V2, P732, DOI 10.1210/mend-2-8-732; BRYSON HM, 1992, DRUGS, V43, P760, DOI 10.2165/00003495-199243050-00009; BURNSTEIN KL, 1992, MOL CELL ENDOCRINOL, V83, pC1, DOI 10.1016/0303-7207(92)90187-B; BURNSTEIN KL, 1991, STEROIDS, V56, P52, DOI 10.1016/0039-128X(91)90124-E; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DONG Y, 1988, MOL ENDOCRINOL, V2, P1256, DOI 10.1210/mend-2-12-1256; DURHAM DM, 1983, ANAL BIOCHEM, V131, P385; GOULDING NJ, 1992, IMMUNOL TODAY, V13, P295, DOI 10.1016/0167-5699(92)90040-E; HALAMA A R, 1990, Rhinology (Utrecht), V28, P25; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KNUTSSON PU, 1995, ENDOCRINOLOGY, V144, P301; LINDQVIST N, 1986, ALLERGY, V41, P179, DOI 10.1111/j.1398-9995.1986.tb00298.x; LOE N, 1987, NATURE, V325, P368; MCINTYRE WR, 1985, J BIOL CHEM, V260, P418; OKRET S, 1991, BIOCHIMIE, V73, P51, DOI 10.1016/0300-9084(91)90074-B; PIPKORN U, 1983, ACTA OTO-LARYNGOL, V95, P167, DOI 10.3109/00016488309130931; PIPKORN U, 1988, EUR RESPIR J, V1, P856; PIPKORN U, 1989, ANTIINFLAMMATORY STE, P469; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SVEC F, 1985, LIFE SCI, V36, P2359, DOI 10.1016/0024-3205(85)90339-X	27	33	35	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					655	661		10.1016/S0091-6749(96)70311-1	http://dx.doi.org/10.1016/S0091-6749(96)70311-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621851				2022-12-18	WOS:A1996TW08700011
J	Koutsonikolis, A; Nelson, RP; FernandezCaldas, E; Brigino, EN; Seleznick, M; Good, RA; Lockey, RF				Koutsonikolis, A; Nelson, RP; FernandezCaldas, E; Brigino, EN; Seleznick, M; Good, RA; Lockey, RF			Serum total and specific IgE levels in children infected with human immunodeficiency virus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; pediatric HIV	IMMUNE-DEFICIENCY SYNDROME; B-CELL ACTIVATION; HIV INFECTION; ANTIBODIES; INDIVIDUALS; ELEVATION; SINUSITIS; DISEASES; ANTIGENS; ATOPY	Background: Human immunodeficiency virus (HIV) infection is associated with polyclonal B-cell activation, and elevated IgE levels are found in infected adults. Chronic nasal symptoms, sinusitis, and otitis media are particularly common in children infected with HIV. The possible allergic cause of nasal symptoms in children infected with HIV has not been explored. Objective: The study was designed to evaluate the relationship between HIV infection and IgE levels in a group of children infected with HIV. Methods: Total serum IgE was measured by enzyme immunoassay and compared with values for age-matched normal subjects. Specific IgE was determined by RAST test to Dermatophagoides pteronyssinus, American cockroach, Bahia grass, short ragweed, cat, and oak. Lymphocyte subpopulations were determined by standard flow cytometry. Results: Fifty-seven total IgE and 342 specific IgE levels were determined from 29 infected children (19 girls and 10 boys; ages 7 to 150 months; mean age, 49 months). Initial IgE levels of 29 subjects ranged from 1.4 to 787.6 IU/ml (mean = 123.4 +/- 34.4 IU/ml). Nine of 29 (31%) subjects had initial IgE levels greater than two standard deviations higher than age-matched normal subjects. No patients had detectable specific IgE to any of the six aeroallergens. There was no correlation, as determined by linear regression analysis, between IgE levels and absolute CD4 number or CD4:CD8. Conclusion: Elevated total but not specific IgE is common in children infected with HIV and does not correlate with absolute CD4 lymphocyte count, suggesting that the elevated IgE level reflects a somewhat independent polyclonal activation of B lymphocytes.	UNIV S FLORIDA,COLL MED,ALL CHILDRENS HOSP,DEPT PEDIAT,ST PETERSBURG,FL 33701; UNIV S FLORIDA,COLL MED,JAMES A HALEY VET ADM HOSP,TAMPA,FL	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital								BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; BRIGINO EN, 1994, J ALLERGY CLIN IMMUN, V93, P237; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; BUCKLEY RH, 1981, CLIN IMMUNOLOGY UPDA, P147; BUCKLEY RH, 1993, ALLERGY PRINCIPLES P, P1059; BUCKLEY RH, 1975, IMMUNODEFICIENCY MAN, P134; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; GOLDFARB AA, 1961, NEW YORK STATE J MED, V61, P2721; GRIFFIN DE, 1985, J ALLERGY CLIN IMMUN, V76, P206, DOI 10.1016/0091-6749(85)90703-1; ISRAELBIET D, 1992, J ALLERGY CLIN IMMUN, V89, P68, DOI 10.1016/S0091-6749(05)80042-9; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LIM DT, 1988, ANN ALLERGY, V61, P175; LIM DT, 1988, ANN ALLERGY, V61, P224; LUCEY DR, 1990, AIDS RES HUM RETROV, V6, P427, DOI 10.1089/aid.1990.6.427; MAGGI E, 1989, RES CLIN LAB, V19, P45; MIZUMA H, 1988, CLIN EXP IMMUNOL, V71, P410; ODONNELL CR, 1988, CHEST, V94, P945, DOI 10.1378/chest.94.5.945; OLESKE J, 1983, JAMA-J AM MED ASSOC, V249, P2345, DOI 10.1001/jama.249.17.2345; Ownby DR, 1993, ALLERGY PRINCIPLES P, P1059; Paganelli R, 1993, Immunodeficiency, V4, P149; PETERSON RD, 1962, J ALLERGY, V33, P406, DOI 10.1016/0021-8707(62)90045-X; POLMAR SH, 1972, AM J PATHOL, V69, P499; RING J, 1986, ACTA DERM-VENEREOL, V66, P530; RUBENSTEIN A, 1983, JAMA-J AM MED ASSOC, V249, P2350; SAMPLE S, 1990, J ALLERGY CLIN IMMUN, V86, P876, DOI 10.1016/S0091-6749(05)80149-6; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SCOTT GB, 1984, NEW ENGL J MED, V310, P76, DOI 10.1056/NEJM198401123100202; SLAVIN RG, 1993, ALLERGY PRINCIPLES P, P1457; SMALL CB, 1993, J INFECT DIS, V167, P283, DOI 10.1093/infdis/167.2.283; STRAKA BF, 1988, J AM ACAD DERMATOL, V18, P1089, DOI 10.1016/S0190-9622(88)70112-7; WALD ER, 1992, NEW ENGL J MED, V326, P319; WALDMANN TA, 1972, J IMMUNOL, V109, P304; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; 1992, KALLESTADTM ALLERCOA, P11; 1991, KALLESTADTM TOTAL IG, P9	36	33	34	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					692	697		10.1016/S0091-6749(96)70316-0	http://dx.doi.org/10.1016/S0091-6749(96)70316-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621856				2022-12-18	WOS:A1996TW08700016
J	Puerta, L; FernandezCaldas, E; Mercado, D; Lockey, RF; Caraballo, LR				Puerta, L; FernandezCaldas, E; Mercado, D; Lockey, RF; Caraballo, LR			Sequential determinations of Blomia tropicalis allergens in mattress and floor dust samples in a tropical city	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mites; Blomia tropicalis; house dust; climate	PREVALENCE; ASTHMA; MITE	Background: The mite species Blomia tropicalis is commonly found in tropical and subtropical regions, and it is an important source of allergen in the city of Cartagena, Columbia. Aim: The study was designed to determine seasonal allergen levels of B. tropicalis in homes of patients with asthma and mite allergy. Methods: Dust samples from mattresses and floors in 20 homes were collected on a monthly basis for 1 year. Outdoor temperature, relative humidity, and rainfall were recorded. RAST inhibition was performed on extracts of dust samples. Allergen levels were compared with variations in climate. Results: B. tropicalis allergens were detected in all mattress samples. More than 50% RAST inhibition was detected in 30% of mattress samples and in 4.3% of floor samples, reflecting a high concentration of allergen. Significant correlations were only found between allergen levels and absolute humidity. Conclusion: Levels of B. tropicalis allergen fluctuated minimally in Cartagena, Colombia.	UNIV CARTAGENA, IMMUNOL RES INST, CARTAGENA, COLOMBIA; UNIV S FLORIDA, COLL MED, TAMPA, FL USA	Universidad de Cartagena; State University System of Florida; University of South Florida								ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; CARABALLO L, 1992, ANN ALLERGY, V68, P525; COLLOFF MJ, 1991, REV MED VET ENTOMOL, V79, P612; FERNANDEZCALDAS E, 1993, CLIN EXP ALLERGY, V23, P292, DOI 10.1111/j.1365-2222.1993.tb00325.x; LLERENA LP, 1991, J ALLERGY CLIN IMMUN, V88, P943, DOI 10.1016/0091-6749(91)90252-J; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9	6	33	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					689	691		10.1016/S0091-6749(96)70315-9	http://dx.doi.org/10.1016/S0091-6749(96)70315-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621855	Bronze			2022-12-18	WOS:A1996TW08700015
J	DIAMOND, L; DOCKHORN, RJ; GROSSMAN, J; KISICKI, JC; POSNER, M; ZINNY, MA; KOKER, P; KORTS, D; WECKER, MT				DIAMOND, L; DOCKHORN, RJ; GROSSMAN, J; KISICKI, JC; POSNER, M; ZINNY, MA; KOKER, P; KORTS, D; WECKER, MT			A DOSE-RESPONSE STUDY OF THE EFFICACY AND SAFETY OF IPRATROPIUM BROMIDE NASAL SPRAY IN THE TREATMENT OF THE COMMON COLD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COMMON COLD; IPRATROPIUM; NASAL SPRAY; RHINORRHEA; ADMINISTRATION		Rhinorrhea is an annoying symptom of the common cold for which effective therapy is not currently available. Ipratropium bromide (IB) is an anticholinergic drug that has been shown to decrease glandular secretion. when applied topically to the nasal mucosa. The purpose of this study was to compare the efficacy and safety of three doses of IB nasal spray versus either vehicle or no treatment in relieving rhinorrhea in patients with naturally acquired colds. Rhinorrhea severity was measured objectively by determining nasal discharge weights and subjectively by means of visual analog scale scores. Compared with either vehicle ol no treatment, IB nasal spray produced a significant decrease in the severity of rhinorrhea. A dose of 84 mu g (two sprays of a 0.06% solution in buffered saline solution) in each nostril was more efficacious than a 42 mu g per nostril dose and only marginally less efficacious than a 168 mu g per nostril dose. The 84 mu g per nostril dose also was associated with fewer adverse events than was the higher dose. None of the adverse events related to intranasal IB therapy was of a serious nature. The use of IB nasal spray appears to be a rational and safe approach to relieving rhinorrhea associated with the common cold.	INT MED TECH CONSULTANTS INC,LENEXA,KS; ALLERGY CARE CONSULTANTS,TUCSON,AZ; HARRIS LAB INC,LINCOLN,NE; MED TECH RES ASSOC,BOSTON,MA; BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877	Boehringer Ingelheim	DIAMOND, L (corresponding author), UNIV COLORADO,HLTH SCI CTR,SCH PHARM,CAMPUS BOX C238,4200 E 9TH AVE,DENVER,CO 80262, USA.							BORUM P, 1978, Rhinology (Utrecht), V16, P225; BORUM P, 1981, AM REV RESPIR DIS, V123, P418; DOCKHORN R, 1992, J ALLERGY CLIN IMMUN, V90, P1076, DOI 10.1016/0091-6749(92)90126-M; GAFFEY MJ, 1987, AM REV RESPIR DIS, V135, P241; GAFFEY MJ, 1988, ANTIMICROB AGENTS CH, V32, P1644, DOI 10.1128/AAC.32.11.1644	5	33	33	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	2				1139	1146		10.1016/S0091-6749(95)70219-9	http://dx.doi.org/10.1016/S0091-6749(95)70219-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY918	7751531				2022-12-18	WOS:A1995QY91800011
J	PERSOONS, JHA; BERKENBOSCH, F; SCHORNAGEL, K; THEPEN, T; KRAAL, G				PERSOONS, JHA; BERKENBOSCH, F; SCHORNAGEL, K; THEPEN, T; KRAAL, G			INCREASED SPECIFIC IGE PRODUCTION IN LUNGS AFTER THE INDUCTION OF ACUTE STRESS IN RATS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LUNGS; FOOT-SHOCK STRESS; ANTIGEN-SPECIFIC IGE; TNP-KLH; RATS	LYMPHOID-TISSUE BALT; T-CELL ACTIVATION; RESPIRATORY-TRACT; ALVEOLAR MACROPHAGES; NEUROPEPTIDES; RESPONSES; INVIVO; INTERLEUKIN-1; ELIMINATION; ALPHA	Under normal conditions, immune responses in the lung are suppressed, resulting in low antigen-specific serum antibody titers after intratracheal immunization of rodents. We attempted to determine whether mild inescapable electric foot-shock stress, immediately followed by intratracheal instillation of trinitrophenyl-conjugated keyhole limpet hemocyanin, could enhance the primary and secondary humoral immune responses in male Wistar rats. This acute emotional stress paradigm and subsequent intratracheal administration of trinitrophenyl-conjugated keyhole limpet hemocyanin resulted in a dramatic increment of trinitrophenyl-specific immunoglobulin isotype concentrations in serum, including IgE. Analysis of paratracheal lymph node and spleen tissue for trinitrophenyl-specific antibody-forming cells revealed that the increased specific antibody concentrations resulted from a local production in the paratracheal lymph nodes. Because the presence of aeroantigen-specific IgE is associated with diseases such as allergic asthma, we advocate the view that acute emotional stress can contribute to the onset or severity of allergic asthma by lowering the threshold of induction of aeroantigen-specific IgE production in the lungs.	VRIJE UNIV AMSTERDAM, DEPT PHARMACOL, 1081 BT AMSTERDAM, NETHERLANDS; ACAD HOSP UTRECHT, DEPT DERMATOL & ALLERGOL, UTRECHT, NETHERLANDS	Vrije Universiteit Amsterdam; Utrecht University; Utrecht University Medical Center	PERSOONS, JHA (corresponding author), VRIJE UNIV AMSTERDAM, FAC MED, DEPT CELL BIOL & IMMUNOL, VAN BOECHORSTSTR 7, 1081 BT AMSTERDAM, NETHERLANDS.							BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; BERKENBOSCH F, 1984, ENDOCRINOLOGY, V115, P1051, DOI 10.1210/endo-115-3-1051; BICE DE, 1988, EXP LUNG RES, V14, P133, DOI 10.3109/01902148809115121; BUIJS J, 1993, TOXOCARA INFECTION A, P141; CLAASSEN E, 1984, J IMMUNOL METHODS, V75, P181, DOI 10.1016/0022-1759(84)90237-0; CORRIGAN CJ, 1992, CURR OPIN IMMUNOL, V4, P798, DOI 10.1016/0952-7915(92)90065-M; DELARMARRE FGA, 1989, ANAT REC, V223, P152; DESOWITZ RS, 1981, INT ARCH ALLER A IMM, V65, P361, DOI 10.1159/000232777; DEVRIES JE, 1991, CURR OPIN IMMUNOL, V3, P851, DOI 10.1016/S0952-7915(05)80003-2; ESTERLING B, 1987, BEHAV NEUROSCI, V101, P115; FLESHNER M, 1989, PHYSIOL BEHAV, V45, P1183, DOI 10.1016/0031-9384(89)90107-8; HERSCOWITZ HB, 1985, ANN ALLERGY, V55, P634; HOLT PG, 1986, CLIN EXP IMMUNOL, V63, P261; HOLT PG, 1985, CLIN EXP IMMUNOL, V62, P586; ISENBERG SA, 1992, PSYCHOSOM MED, V54, P191; KALTREIDER HB, 1976, AM REV RESPIR DIS, V113, P347; KAPSENBERG ML, 1992, CURR OPIN IMMUNOL, V4, P788, DOI 10.1016/0952-7915(92)90063-K; LAUDENSLAGER M L, 1988, Brain Behavior and Immunity, V2, P92, DOI 10.1016/0889-1591(88)90010-4; NOHR D, 1991, BRAIN BEHAV IMMUN, V5, P84, DOI 10.1016/0889-1591(91)90009-Y; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; RICHARDSON JB, 1983, AM REV RESPIR DIS, V128, pS65; ROTTEVEEL FTM, 1991, CELL IMMUNOL, V138, P245, DOI 10.1016/0008-8749(91)90149-6; SAID SI, 1988, ANN NY ACAD SCI, V527, P450; STRICKLAND DH, 1993, IMMUNOLOGY, V80, P266; TAYLOR MRH, 1988, LANCET, V1, P692, DOI 10.1016/S0140-6736(88)91486-9; THEPEN T, 1989, J EXP MED, V170, P499, DOI 10.1084/jem.170.2.499; THEPEN T, 1992, CLIN EXP ALLERGY, V22, P1107, DOI 10.1111/j.1365-2222.1992.tb00137.x; TURNER KJ, 1979, INT ARCH ALLER A IMM, V58, P232, DOI 10.1159/000232197; VANDERBRUGGEGAMELKOORN GJ, 1986, IMMUNOLOGY, V57, P405; WIEDERMANN CJ, 1987, ANN NY ACAD SCI, V496, P205, DOI 10.1111/j.1749-6632.1987.tb35767.x	31	33	35	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					765	770		10.1016/S0091-6749(95)70184-2	http://dx.doi.org/10.1016/S0091-6749(95)70184-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897162				2022-12-18	WOS:A1995QM01700019
J	CABRERA, P; JULIASERDA, G; DECASTRO, FR; CAMINERO, J; BARBER, D; CARRILLO, T				CABRERA, P; JULIASERDA, G; DECASTRO, FR; CAMINERO, J; BARBER, D; CARRILLO, T			REDUCTION OF HOUSE-DUST MITE ALLERGENS AFTER DEHUMIDIFIER USE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									ABELLO SA,ALLERGY & IMMUNOL LAB,MADRID,SPAIN; UNIV LAS PALMAS,HOSP NUESTRA SENORA PINO,ALLERGY SECT,LAS PALMAS,SPAIN	Universidad de Las Palmas de Gran Canaria	CABRERA, P (corresponding author), HOSP NUESTR SENORA PINO,PNEUMOL SECT,ANGEL GUIMERA 93,E-35005 LAS PALMAS,SPAIN.		Barber, Domingo/Y-9516-2019; de Castro, Felipe Rodriguez/R-8416-2019	Barber, Domingo/0000-0002-5488-5700; Rodriguez de Castro, Felipe/0000-0002-6812-2739				ALGUACIL PV, 1990, REV ESP ALERGOL INMU, V5, P71; ALONSO EG, 1992, J INVEST ALLERG CLIN, V2, P19; ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0	5	33	33	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					635	636		10.1016/S0091-6749(95)70328-4	http://dx.doi.org/10.1016/S0091-6749(95)70328-4			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7852676				2022-12-18	WOS:A1995QH69700018
J	MARONE, G; SPADARO, G; PATELLA, V; GENOVESE, A				MARONE, G; SPADARO, G; PATELLA, V; GENOVESE, A			THE CLINICAL RELEVANCE OF BASOPHIL RELEASABILITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MAST-CELL RELEASABILITY; INDUCED HISTAMINE-RELEASE; PERIPHERAL-BLOOD BASOPHILS; KIT RECEPTOR LIGAND; SERUM IGE LEVELS; MEDIATOR RELEASE; ATOPIC-DERMATITIS; CHRONIC URTICARIA; ANTI-IGE; SYSTEMIC-SCLEROSIS				MARONE, G (corresponding author), UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,SCH MED,DIV CLIN IMMUNOL,I-80131 NAPLES,ITALY.		Patella, Vincenzo/AAJ-6232-2020	Patella, Vincenzo/0000-0001-5640-6446; Ziyadullaev, Shukhrat/0000-0002-9309-3933				BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BEDARD PM, 1986, J ALLERGY CLIN IMMUN, V78, P1121, DOI 10.1016/0091-6749(86)90260-5; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; BULL HA, 1993, J INVEST DERMATOL, V100, P305, DOI 10.1111/1523-1747.ep12469895; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BUSSE WW, 1986, J ALLERGY CLIN IMMUN, V78, P90, DOI 10.1016/0091-6749(86)90119-3; CASOLARO V, 1990, AM REV RESPIR DIS, V142, P1108, DOI 10.1164/ajrccm/142.5.1108; CASOLARO V, 1989, AM REV RESPIR DIS, V139, P1375, DOI 10.1164/ajrccm/139.6.1375; CASOLARO V, 1989, J IMMUNOL RES, V1, P67; CASOLARO V, 1993, GENETICS ASTHMA, P291; CHANEZ P, 1993, AM REV RESPIR DIS, V147, P1497, DOI 10.1164/ajrccm/147.6_Pt_1.1497; CIRILLO R, 1990, J IMMUNOL, V144, P3891; CLAMAN HN, 1990, RHEUM DIS CLIN N AM, V16, P141; COLUMBO M, 1990, J IMMUNOL, V145, P3855; COLUMBO M, 1992, J IMMUNOL, V149, P599; CONROY MC, 1977, J IMMUNOL, V118, P1317; CZARNETZKI BM, 1976, J INVEST DERMATOL, V67, P276, DOI 10.1111/1523-1747.ep12514261; DEPAULIS A, 1992, INT ARCH ALLERGY IMM, V99, P326, DOI 10.1159/000236275; DEPAULIS A, 1991, ARTHRITIS RHEUM-US, V34, P1289, DOI 10.1002/art.1780341013; DEPAULIS A, 1992, NEW ADV CYTOKINES, P367; DVORAK AM, 1983, FED PROC, V42, P2510; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GADDY JN, 1986, AM REV RESPIR DIS, V134, P969, DOI 10.1164/arrd.1986.134.5.969; GLOVSKY MM, 1979, J CLIN INVEST, V64, P804, DOI 10.1172/JCI109527; GREAVES MW, 1974, CLIN ALLERGY, V4, P265, DOI 10.1111/j.1365-2222.1974.tb01384.x; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KAUFMAN LD, 1989, ANN RHEUM DIS, V48, P201, DOI 10.1136/ard.48.3.201; KAZIMIERCZAK W, 1984, AM REV RESPIR DIS, V129, P592; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1692; LICHTENSTEIN LM, 1976, ALLERGY CLIN IMMUNOL, P109; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MACGLASHAN DW, 1993, J IMMUNOL, V151, P6358; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MARONE G, 1989, PROGRESS IN ALLERGY AND CLINICAL IMMUNOLOGY, P125; MARONE G, 1986, J ALLERGY CLIN IMMUN, V78, P974, DOI 10.1016/0091-6749(86)90288-5; MARONE G, 1989, CLIN IMMUNOL IMMUNOP, V50, pS24, DOI 10.1016/0090-1229(89)90111-6; MARONE G, 1989, LIFE SCI, V45, P1745, DOI 10.1016/0024-3205(89)90513-4; MARONE G, 1989, J INVEST DERMATOL, V93, P246, DOI 10.1111/1523-1747.ep12277582; MARONE G, 1985, INT ARCH ALLER A IMM, V77, P103, DOI 10.1159/000233761; MARONE G, 1986, J ALLERGY CLIN IMMUN, V77, P377, DOI 10.1016/S0091-6749(86)80121-X; MARONE G, 1986, J IMMUNOL, V137, P3588; MARONE G, 1986, J INVEST DERMATOL, V87, P19, DOI 10.1111/1523-1747.ep12523520; MARONE G, 1984, J IMMUNOL, V133, P1542; MARONE G, 1987, INFECT IMMUN, V55, P803, DOI 10.1128/IAI.55.3.803-809.1987; MARONE G, 1985, PROGR ALLERGY CLIN I, P175; MARONE G, 1992, CLIN EXP IMMUNOL, V50, P661; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MERGET RD, 1990, INT ARCH ALLER A IMM, V92, P366, DOI 10.1159/000235167; MOLLER A, 1993, J IMMUNOL, V151, P3261; NAWATA Y, 1984, CLIN EXP IMMUNOL, V58, P348; PARISI P, 1983, NATURE, V304, P626, DOI 10.1038/304626a0; PATELLA V, 1990, J IMMUNOL, V145, P3054; PEARSON ME, 1988, ARTHRITIS RHEUM, V31, P672, DOI 10.1002/art.1780310514; PLAUT M, 1986, J ALLERGY CLIN IMMUN, V78, P968, DOI 10.1016/0091-6749(86)90287-3; QUINTI I, 1986, J ALLERGY CLIN IMMUN, V77, P586, DOI 10.1016/0091-6749(86)90350-7; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SCHLEIMER RP, 1981, J IMMUNOL, V126, P570; SEIBOLD JR, 1990, ARTHRITIS RHEUM, V33, P1702, DOI 10.1002/art.1780331114; SPARROW D, 1994, AM J RESP CRIT CARE, V149, P376, DOI 10.1164/ajrccm.149.2.8306033; STELLATO C, 1992, J INVEST DERMATOL, V98, P800, DOI 10.1111/1523-1747.ep12499960; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; TUNG R, 1982, J IMMUNOL, V128, P2067; VALENT P, 1992, ADV IMMUNOL, V52, P333, DOI 10.1016/S0065-2776(08)60879-2; WHITE MV, 1992, BLOOD, V76, P1491	71	33	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1293	1303		10.1016/0091-6749(94)90345-X	http://dx.doi.org/10.1016/0091-6749(94)90345-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7528235				2022-12-18	WOS:A1994QA02000025
J	SCHARENBERG, AM; KINET, JP				SCHARENBERG, AM; KINET, JP			INITIAL EVENTS IN FC-EPSILON-RI SIGNAL-TRANSDUCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PROTEIN-TYROSINE KINASE; TUMOR MAST-CELLS; BASOPHILIC LEUKEMIA-CELLS; HIGH-AFFINITY RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; HISTAMINE-RELEASE; ANTIGEN RECEPTOR; IGE RECEPTORS; PHOSPHORYLATION; ACTIVATION		NIAID,MOLEC ALLERGY & IMMUNOL SECT,ROCKVILLE,MD 20852; NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA								ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; ADAMCZEWSKI M, UNPUB REGULATION CD4; ALBER G, 1991, J BIOL CHEM, V266, P22613; ATKINSON TP, 1992, J IMMUNOL, V148, P2194; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CUNHAMELO JR, 1987, J BIOL CHEM, V262, P11455; EISEMAN E, 1992, NATURE, V355, P78; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HOOK WA, 1991, J IMMUNOL, V147, P2670; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KINET JP, 1992, CURR OPIN IMMUNOL, V4, P43, DOI 10.1016/0952-7915(92)90122-U; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; MILLARD PJ, 1988, P NATL ACAD SCI USA, V85, P1854, DOI 10.1073/pnas.85.6.1854; Miller L., 1988, J BIOL CHEM, V205, P7819; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; OLIVER JM, 1994, IN PRESS J BIOL CHEM; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PRENTKI M, 1984, NATURE, V309, P562, DOI 10.1038/309562a0; RANDRIAMAMPITA C, 1993, NATURE, V264, P809; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P1037; SEAGRAVE J, 1991, J CELL PHYSIOL, V148, P139, DOI 10.1002/jcp.1041480117; SEAGRAVE JC, 1987, CYTOMETRY, V8, P287, DOI 10.1002/cyto.990080309; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VALLE A, UNPUB REGULATION CD4; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	33	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1142	1146		10.1016/0091-6749(94)90323-9	http://dx.doi.org/10.1016/0091-6749(94)90323-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798551				2022-12-18	WOS:A1994QA02000003
J	REUNALA, T; BRUMMERKORVENKONTIO, H; RASANEN, L; FRANCOIS, G; PALOSUO, T				REUNALA, T; BRUMMERKORVENKONTIO, H; RASANEN, L; FRANCOIS, G; PALOSUO, T			PASSIVE TRANSFER OF CUTANEOUS MOSQUITO-BITE HYPERSENSITIVITY BY IGE ANTI-SALIVA ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MOSQUITO ALLERGY IGE AND IGG(4) ANTIBODIES; PRAUSNITZ-KUSTNER TEST; BASOPHIL HISTAMINE RELEASE TEST		Background: Mosquito bites frequently cause cutaneous wheal and flare reactions, and recent immunoblotting studies have shown specific anti-saliva IgE antibodies in many persons who have such reactions. Objective: The study was designed to show that human serum containing mosquito saliva-specific IgE antibodies can produce histamine release in vitro and whealing and vivo. Methods: Two mosquito bite-tolerant subjects had bite challenges and Prausnitz-Kustner tests with heated and unheated serum from one patient with Aedes mosquito allergy. Immunoblotting and basophil histamine release tests were performed with the patient's and subjects' sera. Results: Both mosquito bite-tolerant subjects had positive Prausnitz-Kustner reactions, which indicated a successful transfer of cutaneous mosquito hypersensitivity. The ordinary and passive basophil histamine release tests also produced positive results with Aedes communis antigens. Conclusion: The results of the Prausnitz-Kustner test, immunoblotting, and basophil histamine release tests are consistent with the hypothesis that mosquito bite whealing is mediated by specific anti-saliva IgE antibodies.	UNIV TAMPERE,DEPT CLIN MED,SF-33101 TAMPERE,FINLAND; NATL PUBL HLTH INST,HELSINKI,FINLAND; INST TROP MED PRINCE LEOPOLD,B-2000 ANTWERP,BELGIUM	Tampere University; Finland National Institute for Health & Welfare; Institute of Tropical Medicine (ITM)	REUNALA, T (corresponding author), HELSINKI UNIV HOSP,DEPT DERMATOL,MEILAHDENTIE 2,SF-00250 HELSINKI,FINLAND.							ALLEN JR, 1966, EXP PARASITOL, V19, P132, DOI 10.1016/0014-4894(66)90061-0; BRUMMERKORVENKONTIO H, 1994, J ALLERGY CLIN IMMUN, V93, P551, DOI 10.1016/S0091-6749(94)70066-4; DAS MK, 1991, J AM MOSQUITO CONTR, V7, P319; HARVIMA RJ, 1988, CLIN CHIM ACTA, V171, P247, DOI 10.1016/0009-8981(88)90150-7; McKIEL J. A., 1961, Pcdiat. Clin. N. Amer, V8, P795; REUNALA T, 1994, INT ARCH ALLERGY IMM, V104, P366, DOI 10.1159/000236693; REUNALA T, 1990, CLIN EXP ALLERGY, V20, P19, DOI 10.1111/j.1365-2222.1990.tb02472.x; ROCKWELL EM, 1952, J INVEST DERMATOL, V19, P137, DOI 10.1038/jid.1952.78; SHEN HD, 1989, ANN ALLERGY, V63, P143; WILSON AB, 1965, INT ARCH ALLER A IMM, V26, P294, DOI 10.1159/000229580	10	33	34	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					902	906		10.1016/0091-6749(94)90158-9	http://dx.doi.org/10.1016/0091-6749(94)90158-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7525679				2022-12-18	WOS:A1994PR24000015
J	SIRACUSA, A; BETTINI, P; BACOCCOLI, R; SEVERINI, C; VERGA, A; ABBRITTI, G				SIRACUSA, A; BETTINI, P; BACOCCOLI, R; SEVERINI, C; VERGA, A; ABBRITTI, G			ASTHMA CAUSED BY LIVE FISH BAIT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LIVE FISH BAIT; LATE ASTHMATIC REACTION; OCCUPATIONAL ASTHMA	MEALWORM	Background: Larvae of insects and worms are commonly used as live fish bait (LFB) by anglers. Asthma, rhinoconjunctivitis, and urticaria related to various kinds of LFB have been reported. Methods: We studied 14 subjects with respiratory symptoms associated with exposure to LFB. Skin prick tests and RASTs with Lucilia caesar, Galleria mellonella, and Tenebrio molitor extracts were carried out in all subjects. Monitoring of peak expiratory flow rate and evaluation of bronchial responsiveness to methacholine before and after exposure to LFB were performed in seven subjects. Results: Thirteen subjects had asthma, all 14 had rhinoconjunctivitis, and three had contact urticaria. Eleven subjects had respiratory symptoms after fishing with LFB, and the other three subjects had symptoms during their work in a commercial fish bait farm. Positive skin prick test results or significant RAST binding to L. caesar extract were observed in 13 subjects, to G. mellonella extract in four subjects, and to T. molitor extract in three subjects. After exposure to LFB, two subjects had an early asthmatic response, three had a late asthmatic response, and two had no asthmatic response. Late asthmatic response was associated with a long-lasting increase in bronchial responsiveness. Conclusions: This study demonstrates that emanations from LFB are sensitizers, which have the potential to elicit IgE-mediated asthma. Exposure to LFB is common and LFB should be considered as a possible sensitizing agent for asthma.	BAYROPHARM ITALIANA, MILAN, ITALY		SIRACUSA, A (corresponding author), UNIV PERUGIA, INST OCCUPAT MED, VIA E DAL POZZO, I-06100 PERUGIA, ITALY.							BAUR X, 1982, J ALLERGY CLIN IMMUN, V69, P66, DOI 10.1016/0091-6749(82)90090-2; BERNSTEIN DI, 1983, J ALLERGY CLIN IMMUN, V72, P475, DOI 10.1016/0091-6749(83)90584-5; BUISSERET P, 1978, LANCET, V1, P668; CERVERI I, 1989, AM REV RESPIR DIS, V140, P191, DOI 10.1164/ajrccm/140.1.191; FORESI A, 1986, J ALLERGY CLIN IMMUN, V78, P1130, DOI 10.1016/0091-6749(86)90262-9; GOLD BL, 1985, AM REV RESPIR DIS, V131, P949; MACHADO L, 1986, CLIN ALLERGY, V16, P111, DOI 10.1111/j.1365-2222.1986.tb00754.x; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; RAMAZZINI B, 1982, MALATTIE LAVORATORI, P140; RIGO M, 1977, FOLIA ALLERGOL IMMUN, V24, P588; SCHROECKENSTEIN DC, 1990, J ALLERGY CLIN IMMUN, V86, P182, DOI 10.1016/S0091-6749(05)80064-8; SESTINI P, 1987, ALLERGOL IMMUNOPATH, V15, P25; SGAMBATO F, 1987, Bollettino dell'Istituto Sieroterapico Milanese, V66, P411; Siracusa A, 1989, Med Lav, V80, P489; STEVENSON DD, 1967, J ALLERGY, V39, P274, DOI 10.1016/0021-8707(67)90091-3; STOCKLEY RA, 1982, CLIN ALLERGY, V12, P151, DOI 10.1111/j.1365-2222.1982.tb01634.x; VALERO A, 1989, 14TH C EUR AC ALL CL, P149; WIDE L, 1967, LANCET, V2, P1105	18	33	34	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					424	430		10.1016/0091-6749(94)90350-6	http://dx.doi.org/10.1016/0091-6749(94)90350-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	8120269				2022-12-18	WOS:A1994MY58100002
J	CHANYEUNG, M; MCMURREN, T; CATONIOBEGLEY, F; LAM, S				CHANYEUNG, M; MCMURREN, T; CATONIOBEGLEY, F; LAM, S			OCCUPATIONAL ASTHMA IN A TECHNOLOGIST EXPOSED TO GLUTARALDEHYDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						OCCUPATIONAL ASTHMA; WORKPLACE CHALLENGE TEST; GLUTARALDEHYDE		Background: Occupational asthma can be caused by several sterilizing agents, including glutaraldehyde, which has been shown to cause irritation of the eyes and upper respiratory tract and skin rash. We report a case of occupational asthma that was caused by exposure to glutaraldehyde. Methods: To document the diagnosis of occupational asthma in a respiratory technologist, the following tests were performed preshift and postshift spirometry, serial measurements of peak expiratory flow rate and nonspecific bronchial hyperresponsiveness, and workplace challenge test. Results: Monitoring of peak expiratory flow rate showed improvement when the subject was away from the workplace. Improvements in forced expiratory volume in 1 second (FEV1) and provocative concentration causing a 20% fall in FEV1 were also observed. A workplace challenge test showed a progressive fall in FEV1 when the subject was exposed to glutaraldehyde in a sterilizing agent used to clean bronchoscopes at her workplace. After the diagnosis of occupational asthma was confirmed, the subject continued to assist with bronchoscopy but no longer cleaned the bronchoscopes. Conclusions: This case study illustrates the usefulness of a workplace challenge test in confirming the diagnosis of occupational asthma. It also indicates the importance of preventing or reducing exposure to sterilizing agents such as glutaraldehyde by means of effective ventilation and proper storage and enclosure during use.			CHANYEUNG, M (corresponding author), VANCOUVER GEN HOSP,DEPT MED,DIV RESP,OCCUPAT LUNG DIS RES UNIT,VANCOUVER V5Z 1M9,BC,CANADA.							BENSON WG, 1984, J SOC OCCUP MED, V34, P63; BOURNE MS, 1979, BRIT MED J, V2, P10, DOI 10.1136/bmj.2.6181.10; BURGE PS, 1989, BMJ-BRIT MED J, V299, P342, DOI 10.1136/bmj.299.6695.342; CHANYEUNG M, 1990, CHEST, V98, pS148, DOI 10.1378/chest.98.5.148S; CORRADO OJ, 1986, HUM TOXICOL, V5, P325, DOI 10.1177/096032718600500505; HENDRICK DJ, 1975, BRIT MED J, V1, P607, DOI 10.1136/bmj.1.5958.607; JACHUCK SJ, 1989, J SOC OCCUP MED, V39, P69; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; NORBACK D, 1988, SCAND J WORK ENV HEA, V14, P366, DOI 10.5271/sjweh.1910; WACLAWSKI ER, 1989, BRIT MED J, V298, P929, DOI 10.1136/bmj.298.6678.929	10	33	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					974	978		10.1016/0091-6749(93)90209-X	http://dx.doi.org/10.1016/0091-6749(93)90209-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8491947	Bronze			2022-12-18	WOS:A1993LC97800003
J	PARK, CS; LEE, SM; UH, ST; KIM, HT; CHUNG, YT; KIM, YH; CHOI, BW; HUE, SH; LEE, HB				PARK, CS; LEE, SM; UH, ST; KIM, HT; CHUNG, YT; KIM, YH; CHOI, BW; HUE, SH; LEE, HB			SOLUBLE INTERLEUKIN-2 RECEPTOR AND CELLULAR PROFILES IN BRONCHOALVEOLAR LAVAGE FLUID FROM PATIENTS WITH BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SOLUBLE INTERLEUKIN-2 RECEPTOR; BRONCHIAL ASTHMA; EOSINOPHILS; BRONCHOALVEOLAR LAVAGE; BRONCHIAL HYPERREACTIVITY	LYMPHOCYTES-T; ALLERGEN CHALLENGE; MILD ASTHMA; EOSINOPHILS; INVITRO; LYMPHOKINE; EXPRESSION; HYPERREACTIVITY; RESPONSIVENESS; IDENTIFICATION	Background: To elucidate the role of T-cell activation in the physiologic changes and cellular infiltrations in the bronchial tree of patients with symptomatic bronchial asthma, we measured the concentration of soluble interleukin-2 receptor (sIL-2R), cellular compositions and IL-2R expression on cells in bronchoalveolar lavage (BAL) fluid. We also measured physiologic parameters, including a provocation concentration of histamine required to reduce the forced expiratory volume in 1 second by 20% of the prechallenge baseline (PC20). Results: The concentration of sIL-2R and the ratio of IL-2R expression on CD3 positive lymphocytes were significantly higher in BAL fluid from 20 patients with symptomatic bronchial asthma than concentrations influid from nine healthy controls (p < 0.01) and six asymptomatic patients with bronchial asthma (p < 0.05). The concentration of sIL-2R correlated with the percentage of IL-2R expression on CD3 positive lymphocytes (r(s) = 0.709, p < 0.01). There was no difference in sIL-2R concentration of BAL fluid between the healthy control and the patient with asymptomatic bronchial asthma. Among the inflammatory cells recovered in BAL fluid, the percentages of eosinophils showed significant positive correlation with the concentration of sIL-2R in BAL fluid in the patients with bronchial asthma. The concentration of sIL-2R significantly correlated with forced expiratory volume one second, peak expiratory flow rate, and PC20 when observed in all study subjects, but not in the patients with bronchial asthma. Conclusion: We conclude that T-cell activation within the bronchial tree appears to have a role in the infiltration of eosinophils into the bronchial tree, which may lead to enhanced bronchial hyperreactivity in patients with bronchial asthma.	CHUNGANG UNIV HOSP, SEOUL, SOUTH KOREA	Chung Ang University; Chung Ang University Hospital	PARK, CS (corresponding author), SOONCHUNHYANG UNIV HOSP, DEPT INTERNAL MED, SEOUL 140743, SOUTH KOREA.							AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BIENENSTOCK J, 1987, AM REV RESPIR DIS, V135, pS5; BUTTERWORTH AE, 1981, NEW ENGL J MED, V304, P154, DOI 10.1056/NEJM198101153040305; CANTRELL DA, 1983, J EXP MED, V158, P1895, DOI 10.1084/jem.158.6.1895; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COCKCROFT DW, 1985, ANN ALLERGY, V55, P527; CORNABY A, 1988, TRANSPLANT P, V20, P108; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1988, LANCET, V1, P1129; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FREW AJ, 1988, J IMMUNOL, V141, P4158; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GOLDSTEIN RA, 1985, AM REV RESPIR DIS, V132, P180; GREENE WC, 1988, INFLAMMATION BASIC P, P209; Hogg J. C., 1977, Asthma - physiology, immunopharmacology, and treatment. (Proc. 2nd Internat. Conf. on asthma, Augusta, Michigan, Sept. 20-22, 1976)., P1; HOLGATE ST, 1987, AM REV RESPIR DIS, V135, pS57; HUTSON PA, 1988, AM REV RESPIR DIS, V137, P548, DOI 10.1164/ajrccm/137.3.548; ILJIMA H, 1987, AM REV RESPIR DIS, V336, P922; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KAY AB, 1987, AM REV RESPIR DIS, V135, pS63; KURTJONES EA, 1987, J EXP MED, V166, P1774, DOI 10.1084/jem.166.6.1774; LAM S, 1987, J ALLERGY CLIN IMMUN, V80, P44, DOI 10.1016/S0091-6749(87)80189-6; LAWRENCE EC, 1988, AM REV RESPIR DIS, V137, P759, DOI 10.1164/ajrccm/137.4.759; MARCON L, 1988, ANN INTERN MED, V109, P274, DOI 10.7326/0003-4819-109-4-274; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; Park C.S., 1990, ADV ASTHMOLOGY, P445; PRINCE HE, 1988, J CLIN IMMUNOL, V8, P114, DOI 10.1007/BF00917899; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SCHENKEL E, 1982, J ALLERGY CLIN IMMUN, V70, P321, DOI 10.1016/0091-6749(82)90020-3; TREIGER BF, 1986, J IMMUNOL, V136, P4099; WAGNER DK, 1987, J CLIN ONCOL, V5, P1262, DOI 10.1200/JCO.1987.5.8.1262; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; YAMAGUCHI Y, 1990, J IMMUNOL, V145, P873	37	33	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					623	633		10.1016/0091-6749(93)90268-K	http://dx.doi.org/10.1016/0091-6749(93)90268-K			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	7679684	Bronze			2022-12-18	WOS:A1993KN54800010
J	MUILENBERG, ML; BURGE, HA; SWEET, T				MUILENBERG, ML; BURGE, HA; SWEET, T			HYPERSENSITIVITY PNEUMONITIS AND EXPOSURE TO ACID-FAST BACILLI IN COOLANT AEROSOLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	33	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	2				311	311						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK431					2022-12-18	WOS:A1993KK43100683
J	BAROODY, FM; CRUZ, AA; LICHTENSTEIN, LM; KAGEYSOBOTKA, A; PROUD, D; NACLERIO, RM				BAROODY, FM; CRUZ, AA; LICHTENSTEIN, LM; KAGEYSOBOTKA, A; PROUD, D; NACLERIO, RM			INTRANASAL BECLOMETHASONE INHIBITS ANTIGEN-INDUCED NASAL HYPERRESPONSIVENESS TO HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INTRANASAL BECLOMETHASONE DIPROPIONATE; HISTAMINE; ANTIGEN; HYPERRESPONSIVENESS	TOPICAL GLUCOCORTICOSTEROIDS; BUDESONIDE; CHALLENGE	To determine whether intranasal steroid treatment inhibits the increased sensitivity to histamine that occurs 24 hours after nasal antigen challenge, 12 allergic volunteers were entered into a double-blind study comparing placebo or 164 mug of beclomethasone dipropionate twice a day for 7 days. Beclomethasone dipropionate partially reduced the early mediator response to antigen and the influx of eosinophils 24 hours later. Comparing the initial histamine challenge with that done 24 hours after antigen with the subjects on placebo, there was a significant increase in sneezes, TAME-esterase activity, and albumin. Pretreatment with intranasal beclomethasone dipropionate resulted in a reduced response to histamine 24 hours after antigen challenge. A positive correlation occurred between the number of eosinophils in the lavage before histamine challenge and the level of TAME-esterase activity (r(s) = 0.67, p = 0.03) during the histamine challenge that followed antigen with the subjects on placebo. We thus confirmed the increase in nonspecific nasal airway responsiveness 24 hours after antigen challenge, with a concomitant increase in eosinophils, and demonstrate its inhibition by pretreatment with intranasal steroids.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University			Cruz, Alvaro A/I-1676-2012	Cruz, Alvaro A/0000-0002-7403-3871	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, R01AI008270] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32272] Funding Source: Medline; NIAID NIH HHS [AI 33135, AI 08270] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON M, 1989, ACTA OTO-LARYNGOL, V107, P270, DOI 10.3109/00016488909127508; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; KONNO A, 1981, ARCH OTO-RHINO-LARYN, V232, P253, DOI 10.1007/BF00457450; MAJCHEL AM, 1992, J ALLERGY CLIN IMMUN, V90, P85, DOI 10.1016/S0091-6749(06)80014-X; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1982, ALLERGY, V37, P129, DOI 10.1111/j.1398-9995.1982.tb01886.x; PIPKORN U, 1982, ALLERGY, V37, P359, DOI 10.1111/j.1398-9995.1982.tb01922.x; VILSVIK J S, 1975, Clinical Allergy, V5, P291, DOI 10.1111/j.1365-2222.1975.tb01865.x; WALDEN SM, 1991, AM REV RESPIR DIS, V3, P642	9	33	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				373	376		10.1016/S0091-6749(05)80017-X	http://dx.doi.org/10.1016/S0091-6749(05)80017-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527319				2022-12-18	WOS:A1992JP52000015
J	SHAPIRO, GG; SHARPE, M; DEROUEN, TA; PIERSON, WE; FURUKAWA, CT; VIRANT, FS; BIERMAN, CW				SHAPIRO, GG; SHARPE, M; DEROUEN, TA; PIERSON, WE; FURUKAWA, CT; VIRANT, FS; BIERMAN, CW			CROMOLYN VERSUS TRIAMCINOLONE ACETONIDE FOR YOUNGSTERS WITH MODERATE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CROMOLYN; INHALED STEROIDS; TRIAMCINOLONE; CHILDHOOD ASTHMA	DOUBLE-BLIND EVALUATION; SODIUM CROMOGLYCATE; BRONCHIAL HYPERRESPONSIVENESS; BECLOMETHASONE DIPROPIONATE; INHALED CORTICOSTEROIDS; NEBULIZED CROMOLYN; CHILDHOOD ASTHMA; HYPERREACTIVITY; TERBUTALINE; COMBINATION	Although both cromolyn (C) and inhaled corticosteroids are anti-inflammatory therapies for childhood asthma, there are few controlled comparisons of these medications for asthma therapy in children. None were conducted in the United States, and none specifically study triamcinolone acetonide (T) versus C. This 12-week evaluation followed 31 youths, aged 8 to 18 years, with moderate asthma who were assigned to receive C or T according to a prerandomized and blinded code. Patients were instructed to take two inhalations from the study metered-dose inhaler (active T or placebo) and to inhale the contents of one study-provided ampule (C, 20 mg, or placebo) from a compressor-driven home nebulizer three times per day. Patients also used albuterol, two inhalations from a metered-dose inhaler, three times a day (before study medication) and, additionally, if needed. Patients maintained a daily dairy, recording extra medication use, adverse experiences, peak flow rates morning and night, and asthma symptom scores. Laboratory assessment of pulmonary function was done at 1, 4, 8, and 12 weeks. Cosyntropin challenge and methacholine bronchoprovocation challenge were performed at the beginning and end of the study. C and T provided similar, adequate asthma control. Symptoms of wheezing, cough, and chest tightness decreased, and daily peak expiratory flow rate increased with both regimens compared to during a 2-week baseline when patients received medication only as needed. There was no significant change in methacholine sensitivity and no change in endocrine function, as measured with fasting plasma control before and after administration of cosyntropin. Although there were significant intragroup differences in the T- but not C-treated groups, there were no discernible significant differences between C and T at these dosages.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT BIOSTAT, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	SHAPIRO, GG (corresponding author), UNIV WASHINGTON, SCH MED, DEPT PEDIAT, 4540 SAND POINT WAY NE, SEATTLE, WA 98105 USA.							BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; FRANCIS RS, 1984, CLIN ALLERGY, V14, P537, DOI 10.1111/j.1365-2222.1984.tb02241.x; HILLER EJ, 1975, BRIT J DIS CHEST, V69, P103; KONIG P, 1988, J ALLERGY CLIN IMMUN, V82, P297, DOI 10.1016/0091-6749(88)91015-9; KRAEMER R, 1985, PROG RESPIR RES, V19, P406; KUZEMKO JA, 1974, POSTGRAD MED J, V50, P53; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MITCHELL I, 1976, BRIT MED J, V2, P457, DOI 10.1136/bmj.2.6033.457-a; NG SH, 1977, POSTGRAD MED J, V53, P315, DOI 10.1136/pgmj.53.620.315; REED CE, 1988, CHEST, V94, P175, DOI 10.1378/chest.94.1.175; SARSFIELD JK, 1977, PRACTITIONER, V218, P128; SHAPIRO GG, 1988, J ALLERGY CLIN IMMUN, V81, P449, DOI 10.1016/0091-6749(88)90915-3; SVENDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X	19	33	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					742	748		10.1016/0091-6749(91)90181-M	http://dx.doi.org/10.1016/0091-6749(91)90181-M			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1955633	Bronze			2022-12-18	WOS:A1991GQ45200009
J	ANDERSSON, M; NOLTE, H; OLSSON, M; SKOV, PS; PIPKORN, U				ANDERSSON, M; NOLTE, H; OLSSON, M; SKOV, PS; PIPKORN, U			MEASUREMENT OF HISTAMINE IN NASAL LAVAGE FLUID - COMPARISON OF A GLASS-FIBER BASED FLUOROMETRIC METHOD WITH 2 RADIOIMMUNOASSAYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV HOSP COPENHAGEN,DEPT MED,COPENHAGEN,DENMARK; UNIV LUND HOSP,DEPT CLIN IMMUNOL,S-22185 LUND,SWEDEN	University of Copenhagen; Lund University; Skane University Hospital	ANDERSSON, M (corresponding author), UNIV LUND HOSP,DEPT OTORHINOLARYNGOL,S-22185 LUND,SWEDEN.							ANDERSSON M, 1987, ALLERGY, V42, P631, DOI 10.1111/j.1398-9995.1987.tb00395.x; BISGAARD H, 1988, ALLERGY, V43, P219; DAVIES RJ, 1987, ALLERGIC VASOMOTOR R, P178; EGGLESTON PA, 1978, INT ARCH ALLER A IMM, V57, P193, DOI 10.1159/000232103; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; LINDER A, 1988, ALLERGY, V43, P119, DOI 10.1111/j.1398-9995.1988.tb00405.x; MCBRIDE PT, 1989, ACI NEWS, V2, P50; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1984, ARCH OTOLARYNGOL, V110, P25; NOLTE H, 1987, ALLERGY, V42, P366, DOI 10.1111/j.1398-9995.1987.tb02223.x; NOLTE H, 1990, ACTA DERM-VENEREOL, V70, P154; NOLTE H, 1990, ALLERGY, V45, P213, DOI 10.1111/j.1398-9995.1990.tb00486.x; NOLTE H, 1989, ALLERGY, V44, P543, DOI 10.1111/j.1398-9995.1989.tb04199.x; SCHUBELER K, 1989, ALLERGOLOGIE, V12, P322; SKOV PS, 1984, AGENTS ACTIONS, V14, P414, DOI 10.1007/BF01973840	15	33	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					815	820		10.1016/S0091-6749(05)80188-5	http://dx.doi.org/10.1016/S0091-6749(05)80188-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	2229845				2022-12-18	WOS:A1990EJ63100016
J	DEBOER, R				DEBOER, R			THE CONTROL OF HOUSE DUST MITE ALLERGENS IN RUGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DEBOER, R (corresponding author), UNIV AMSTERDAM,DEPT PURE & APPL ECOL,POPULAT BIOL SECT,KRUISLAAM 302,1098 SM AMSTERDAM,NETHERLANDS.							ARLIAN L G, 1977, Journal of Medical Entomology, V14, P484, DOI 10.1093/jmedent/14.4.484; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1982, PHYSIOL ZOOL, V55, P344, DOI 10.1086/physzool.55.4.30155862; ARLIAN LG, 1981, PHYSIOL ZOOL, V54, P393, DOI 10.1086/physzool.54.4.30155831; ARLIAN LG, 1979, COMP BIOCHEM PHYS A, V64, P191, DOI 10.1016/0300-9629(79)90650-9; CARSWELL F, 1982, CLIN ALLERGY, V12, P533, DOI 10.1111/j.1365-2222.1982.tb02552.x; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; DUSBABEK F, 1975, Folia Parasitologica (Ceske Budejovice), V22, P219; GEORGES-GRIDELET D D, 1987, Journal of Medical Entomology, V24, P408; GEORGESGRIDELET DD, 1987, ACAROLOGIA, V28, P345; HUGHES A M, 1973, Clinical Allergy, V3, P127, DOI 10.1111/j.1365-2222.1973.tb01316.x; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; VANBRONS.JE, 1973, J MED ENTOMOL, V10, P63, DOI 10.1093/jmedent/10.1.63; VANBRONSWIJK JEM, 1981, HOUSE DUST BIOL ALLE; VANBRONSWIJK JEM, 1985, AIRWAYS, V4, P10; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VONBISCHOFF E, 1986, ALLERGOLOGIE, V9, P45; WASSENAAR DPJ, 1988, ALLERGOLOGIE, V11, P268; WASSENAAR DPJ, 1988, EXP APPL ACAROL, V4, P53, DOI 10.1007/BF01213841	24	33	33	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					808	814						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	2229844	Bronze			2022-12-18	WOS:A1990EJ63100015
J	WOODWARD, JK				WOODWARD, JK			PHARMACOLOGY OF ANTIHISTAMINES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	MEETING ON HISTAMINE AND DISEASE : A FORUM ON CURRENT AND FUTURE MANAGEMENT	AUG 25-26, 1989	CARLSBAD, CA	MERRELL DOW PHARM							WOODWARD, JK (corresponding author), MERRELL DOW PHARMACEUT INC,RES INST,2110 E GALBRAITH RD,CINCINNATI,OH 45215, USA.							BRUGMANS J, 1982, CURRENT CHEMOTHERAPY; Heykants J, 1984, MED PUBLISHING F S S, V11, P25; HILBERT J, 1987, J CLIN PHARMACOL, V27, P694, DOI 10.1002/j.1552-4604.1987.tb03090.x; KASSEM N, 1988, ANN ALLERGY, V60, P505; SIMONS FER, 1983, PEDIATR CLIN N AM, V30, P899; SIMONS KJ, 1989, CLIN PHARMACOL THER, V45, P9, DOI 10.1038/clpt.1989.2; Staub AM, 1937, CR SOC BIOL, V125, P818; WOODWARD JK, 1988, CUTIS, V42, P5	8	33	34	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			606	612		10.1016/S0091-6749(05)80224-6	http://dx.doi.org/10.1016/S0091-6749(05)80224-6			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	1977782				2022-12-18	WOS:A1990EH09300005
J	OLSON, R; KARPINK, MH; SHELANSKI, S; ATKINS, PC; ZWEIMAN, B				OLSON, R; KARPINK, MH; SHELANSKI, S; ATKINS, PC; ZWEIMAN, B			SKIN REACTIVITY TO CODEINE AND HISTAMINE DURING PROLONGED CORTICOSTEROID-THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-14332] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON M, 1987, J ALLERGY CLIN IMMUN, V79, P345, DOI 10.1016/0091-6749(87)90153-9; ATKINS PC, 1987, J ALLERGY CLIN IMMUN, V79, P12, DOI 10.1016/S0091-6749(87)80008-8; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; CHIPPS BE, 1980, J ALLERGY CLIN IMMUN, V65, P61, DOI 10.1016/0091-6749(80)90178-5; DUNSKY EH, 1979, J ALLERGY CLIN IMMUN, V63, P426, DOI 10.1016/0091-6749(79)90217-3; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; GRONNEBERG R, 1985, ALLERGY, V40, P223; LAVKER RM, 1985, J IMMUNOL, V135, P2368; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; LONG WF, 1985, J ALLERGY CLIN IMMUN, V76, P113, DOI 10.1016/0091-6749(85)90813-9; LOWMAN MA, 1988, J ALLERGY CLIN IMMUN, V81, P574, DOI 10.1016/0091-6749(88)90199-6; MCKENZIE AW, 1962, ARCH DERMATOL, V86, P611, DOI 10.1001/archderm.1962.01590110047006; MEULEMAN J, 1985, MED CLIN N AM, V69, P805, DOI 10.1016/S0025-7125(16)31020-3; NATHAN RA, 1981, J ALLERGY CLIN IMMUN, V67, P171, DOI 10.1016/0091-6749(81)90057-9; NELSON HS, 1983, ANN ALLERGY, V51, P411; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1985, ANNU REV PHARMACOL, V25, P381, DOI 10.1146/annurev.pharmtox.25.1.381; SLOTT RI, 1974, J ALLERGY CLIN IMMUN, V54, P229, DOI 10.1016/0091-6749(74)90065-7; STAHLE M, 1984, ACTA DERM-VENEREOL, V64, P239; TALBOT S, 1987, ANN ALLERGY, V58, P363; THOMAS RHM, 1985, J ALLERGY CLIN IMMUN, V76, P864, DOI 10.1016/0091-6749(85)90761-4; ZHENG P, 1984, J INVEST DERMATOL, V82, P345, DOI 10.1111/1523-1747.ep12260665; ZWEIMAN B, 1976, J ALLERGY CLIN IMMUN, V58, P657, DOI 10.1016/0091-6749(76)90177-9	27	33	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					153	159		10.1016/S0091-6749(05)80060-0	http://dx.doi.org/10.1016/S0091-6749(05)80060-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2384646				2022-12-18	WOS:A1990DV31600003
J	CRIMI, E; VOLTOLINI, S; GIANIORIO, P; ORENGO, G; TROISE, C; BRUSASCO, V; CRIMI, P; NEGRINI, AC				CRIMI, E; VOLTOLINI, S; GIANIORIO, P; ORENGO, G; TROISE, C; BRUSASCO, V; CRIMI, P; NEGRINI, AC			EFFECT OF SEASONAL EXPOSURE TO POLLEN ON SPECIFIC BRONCHIAL SENSITIVITY IN ALLERGIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV GENOA,IST IGIENE,CATTEDRA MED COMUN,I-16126 GENOA,ITALY; OSPED CIVILE,SERV ALLERGOL,GENOA,ITALY	University of Genoa	CRIMI, E (corresponding author), OSPED SAN MARTINO GENOVA,IST MED SPORT,CATTEDRA ALLERGOL RESP,VIALE BENEDETTO XV,I-16132 GENOA,ITALY.							ALTOUNYAN REC, 1969, DISODIUM CROMOGLYCAT, P47; BERG T, 1971, INT ARCH ALLER A IMM, V41, P452, DOI 10.1159/000230539; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; CRIMI E, 1986, J ALLERGY CLIN IMMUN, V78, P908, DOI 10.1016/0091-6749(86)90239-3; DEUSCHL H, 1976, INT ARCH ALLER A IMM, V52, P376, DOI 10.1159/000231704; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; JULIUSSON S, 1988, CLIN ALLERGY, V18, P615, DOI 10.1111/j.1365-2222.1988.tb02913.x; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; ROSENTHAL RR, 1979, CHEST, V75, P228, DOI 10.1378/chest.75.2.228; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5	14	33	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					1014	1019		10.1016/0091-6749(90)90045-6	http://dx.doi.org/10.1016/0091-6749(90)90045-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	2355152				2022-12-18	WOS:A1990DK50900006
J	SEDGWICK, JB; FRICK, WE; SONDEL, PM; HANK, JA; BORDEN, E; BUSSE, WW				SEDGWICK, JB; FRICK, WE; SONDEL, PM; HANK, JA; BORDEN, E; BUSSE, WW			THE APPEARANCE OF HYPODENSE EOSINOPHILS DURING INTERLEUKIN-2 TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN, DEPT MED, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT HUMAN ONCOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIAID NIH HHS [AI 15685, AI 23181, AI 10404] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023181, P50AI010404, R01AI015685] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOSTI JM, 1987, J ALLERGY CLIN IMMUN, V79, P496, DOI 10.1016/0091-6749(87)90368-X; ATKINS MB, 1986, J CLIN ONCOL, V4, P1380, DOI 10.1200/JCO.1986.4.9.1380; BIRCHENALLSPARKS MC, 1986, SCIENCE, V233, P455, DOI 10.1126/science.3088729; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; ETTINGHAUSEN SE, 1987, BLOOD, V69, P1654; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; FRICK WE, 1988, J ALLERGY CLIN IMMUN, V82, P119, DOI 10.1016/0091-6749(88)90061-9; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GILLIS S, 1978, J IMMUNOL, V120, P2027; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; HANK JA, 1988, CANCER RES, V48, P1965; INOUE T, 1983, IMMUNOBIOLOGY EOSINO, P283; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; KOHLER PC, IN PRESS CANCER INVE; KOVACH JS, 1986, J CLIN ONCOL, V4, P815, DOI 10.1200/JCO.1986.4.5.815; LOWE D, 1981, J CLIN PATHOL, V34, P1343, DOI 10.1136/jcp.34.12.1343; NALDINI A, 1987, J IMMUNOL, V139, P1880; NUTMAN TB, 1988, ALLERGY PRINCIPLES P, P861; OLOFSSON T, 1980, SCAND J HAEMATOL, V24, P254; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PASTRNAK A, 1984, NEOPLASMA, V31, P323; PETERS MS, 1988, BLOOD, V71, P780; PRETLOW TP, 1983, CANCER RES, V43, P2997; PRIN L, 1986, CLIN EXP IMMUNOL, V63, P249; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; ROTHENBERG ME, 1988, J BIOL CHEM, V263, P13901; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SEDGWICK JB, IN PRESS AM REV RESP; SHULT PA, 1988, J ALLERGY CLIN IMMUN, V81, P429, DOI 10.1016/0091-6749(88)90912-8; SILBERSTEIN DS, 1989, J IMMUNOL, V142, P2162; SONDEL PM, 1988, CANCER RES, V48, P2561; SONDEL PM, 1986, J IMMUNOL, V137, P502; SOSMAN JA, 1988, J NATL CANCER I, V80, P60, DOI 10.1093/jnci/80.1.60; WINQVIST I, 1982, IMMUNOLOGY, V47, P531; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	38	33	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					557	566		10.1016/0091-6749(90)90093-J	http://dx.doi.org/10.1016/0091-6749(90)90093-J			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2312991				2022-12-18	WOS:A1990CU66800004
J	MCCUSKER, MT; CHUNG, KF; ROBERTS, NM; BARNES, PJ				MCCUSKER, MT; CHUNG, KF; ROBERTS, NM; BARNES, PJ			EFFECT OF TOPICAL CAPSAICIN ON THE CUTANEOUS RESPONSES TO INFLAMMATORY MEDIATORS AND TO ANTIGEN IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL HEART & LUNG INST, DEPT THORAC MED, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND	Imperial College London			Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Barnes, Peter/0000-0002-5122-4018				ANAND P, 1983, BRIT J PHARMACOL, V78, P665, DOI 10.1111/j.1476-5381.1983.tb09418.x; ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; ARCHER CB, 1985, BRIT J PHARMACOL, V85, P109, DOI 10.1111/j.1476-5381.1985.tb08836.x; BERNSTEIN JE, 1981, J INVEST DERMATOL, V76, P394, DOI 10.1111/1523-1747.ep12520912; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; CHUNG KF, 1987, LANCET, V1, P248; CHUNG KF, 1988, J ALLERGY CLIN IMMUN, V81, P1192, DOI 10.1016/0091-6749(88)90890-1; CUELLO AC, 1978, BRAIN RES, V152, P499, DOI 10.1016/0006-8993(78)91105-8; CURZEN N, 1987, THORAX, V42, P946, DOI 10.1136/thx.42.12.946; FOREMAN JC, 1983, J PHYSIOL-LONDON, V335, P449, DOI 10.1113/jphysiol.1983.sp014543; FULLER RW, 1987, BRIT J PHARMACOL, V92, P781, DOI 10.1111/j.1476-5381.1987.tb11381.x; GAMSE R, 1980, BRIT J PHARMACOL, V68, P207, DOI 10.1111/j.1476-5381.1980.tb10409.x; HAGERMARK O, 1978, J INVEST DERMATOL, V71, P233, DOI 10.1111/1523-1747.ep12515092; HOKFELT T, 1975, BRAIN RES, V100, P235, DOI 10.1016/0006-8993(75)90481-3; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; JANCSO N, 1968, BRIT J PHARMACOL, V33, P32, DOI 10.1111/j.1476-5381.1968.tb00471.x; JESSELL TM, 1978, BRAIN RES, V152, P183, DOI 10.1016/0006-8993(78)90146-4; LEWIS T, 1927, BLOOD VESSELS HUMAN, P67; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0; LUNDBERG JM, 1985, EUR J PHARMACOL, V108, P315, DOI 10.1016/0014-2999(85)90456-X; LUNDBLAD L, 1985, EUR J PHARMACOL, V113, P461, DOI 10.1016/0014-2999(85)90098-6; PAYAN DG, 1984, J IMMUNOL, V132, P1601; PHILLIPS MJ, 1983, BRIT J CLIN PHARMACO, V15, P277, DOI 10.1111/j.1365-2125.1983.tb01500.x; ROBERTS NM, 1988, J ALLERGY CLIN IMMUN, V82, P236, DOI 10.1016/0091-6749(88)91005-6; SCIBERRAS DG, 1987, BRIT J CLIN PHARMACO, V24, P753, DOI 10.1111/j.1365-2125.1987.tb03242.x; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; WARREN JB, 1987, CLIN SCI, V73, pP8; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2	28	33	33	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1118	1124		10.1016/0091-6749(89)90455-7	http://dx.doi.org/10.1016/0091-6749(89)90455-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2471719				2022-12-18	WOS:A1989AC23500017
J	DOLOVICH, J; HARGREAVE, FE; JORDANA, M; DENBURG, J				DOLOVICH, J; HARGREAVE, FE; JORDANA, M; DENBURG, J			LATE-PHASE AIRWAY REACTION AND INFLAMMATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,MED CTR,DEPT PATHOL,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University; McMaster University	DOLOVICH, J (corresponding author), MCMASTER UNIV,MED CTR,DEPT PEDIAT,RM 3V41,HAMILTON L8S 4L8,ONTARIO,CANADA.							BOSCHETTO P, 1986, J ALLERGY CLIN IMMUN, V77, pA496; BOULET LP, 1987, J ALLERGY CLIN IMMUN, V80, P655, DOI 10.1016/0091-6749(87)90284-3; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENBURG JA, 1988, J ALLERGY CLIN IMMUN, V81, P281, DOI 10.1016/0091-6749(88)90686-0; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; FABBRI LM, 1985, AM REV RESPIR DIS, V132, P1010; HAAKFRENDSCHO M, 1988, J ALLERGY CLIN IMMUN, V81, P224, DOI 10.1016/0091-6749(88)90460-5; ISHIZAKA T, 1985, INT ARCH ALLER A IMM, V77, P137, DOI 10.1159/000233768; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KIRBY J G, 1987, American Review of Respiratory Disease, V135, pA221; KIRBY J G, 1987, American Review of Respiratory Disease, V135, pA312; KITAMURA Y, 1986, MAST CELL DIFFERENTI, P135; LARCHEVEQUE J, 1986, J ALLERGY CLIN IMMUN, V77, P170; MAPP C, 1987, AM REV RESPIR DIS, V136, P1403, DOI 10.1164/ajrccm/136.6.1403; OHNISI M, 1987, J ALLERGY CLIN IMMUN, V79, P197; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, 1986, AM REV RESPIR DIS, V133, P757; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; OTSUKA H, 1987, AM REV RESPIR DIS, V136, P710, DOI 10.1164/ajrccm/136.3.710; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; ROTHENBERG ME, 1988, J ALLERGY CLIN IMMUN, V81, P209, DOI 10.1016/0091-6749(88)90401-0; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; RUHNO J, 1988, J ALLERGY CLIN IMMUN, V81, P172, DOI 10.1016/0091-6749(88)90253-9; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SLY RM, 1984, ANN ALLERGY, V53, P20; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; VIEGAS M, 1987, INT ARCH ALLER A IMM, V82, P275, DOI 10.1159/000234205; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62	33	33	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	2				521	524		10.1016/0091-6749(89)90032-8	http://dx.doi.org/10.1016/0091-6749(89)90032-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4491	2645348	Bronze			2022-12-18	WOS:A1989T449100003
J	ARNTZEN, FC; WILHELMSEN, TW; LOWENSTEIN, H; GJESING, B; MAASCH, HJ; STROMBERG, R; EINARSSON, R; BACKMAN, A; MAKINENKILJUNEN, S; FORD, A				ARNTZEN, FC; WILHELMSEN, TW; LOWENSTEIN, H; GJESING, B; MAASCH, HJ; STROMBERG, R; EINARSSON, R; BACKMAN, A; MAKINENKILJUNEN, S; FORD, A			THE INTERNATIONAL COLLABORATIVE STUDY ON THE 1ST INTERNATIONAL STANDARD OF BIRCH (BETULA-VERRUCOSA) POLLEN EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COPENHAGEN, PROT LAB, DK-1168 COPENHAGEN, DENMARK; ALLERGOPHARMA JOACHIM GANZER KG, REINBEK, FED REP GER; PHARMACIA AB, DIV ALLERGY & DIAGNOST, UPPSALA, SWEDEN; UNIV HELSINKI, CENT HOSP, DEPT ALLERG DIS, SF-00290 HELSINKI 29, FINLAND; NATL INST BIOL STAND & CONTROL, LONDON NW3 6RB, ENGLAND	University of Copenhagen; Allergopharma; Pfizer; Pharmacia Corporation; University of Helsinki; Helsinki University Central Hospital; National Institute for Biological Standards & Control	ARNTZEN, FC (corresponding author), NORWEGIAN MED CONTROL AUTHOR, DIV BIOL, SVEN OFTEDALSVEI 6, N-0950 OSLO 9, NORWAY.							ANDERSON MC, 1981, RAST INHIBITION PROC; APOLD J, 1981, INT ARCH ALLER A IMM, V64, P439, DOI 10.1159/000232724; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BUTCHER EC, 1976, ANAL BIOCHEM, V76, P502, DOI 10.1016/0003-2697(76)90343-2; CAMPBELL PJ, 1974, J BIOL STAND, V2, P259, DOI 10.1016/0092-1157(74)90034-1; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CLARKE H. G. MINCHIN, 1967, PROTIDES BIOL FLUIDS, V14, P503; DREBORG S, 1986, HDB EXPT IMMUNOLOGY, V1, pCH10; FINNEY DJ, 1978, STATISTICAL METHOD B; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HELM RM, 1984, J ALLERGY CLIN IMMUN, V73, P790, DOI 10.1016/0091-6749(84)90449-4; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; Kirkwood TBL, 1979, BIOMETRICS, V35, P908; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; STAHLSKOV P, 1977, CLIN EXP IMMUNOL, V27, P432; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; WEBER K, 1975, PROTEINS, V1, P180; Yman L, 1975, Dev Biol Stand, V29, P151; 1982, NLN PUBLICATION, V7; 1978, WHO TECHNICAL REPORT, V626	26	33	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					66	82		10.1016/0091-6749(89)90479-X	http://dx.doi.org/10.1016/0091-6749(89)90479-X			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2464016				2022-12-18	WOS:A1989T041900010
J	OWNBY, DR; MCCULLOUGH, J				OWNBY, DR; MCCULLOUGH, J			PASSIVE EXPOSURE TO CIGARETTE-SMOKE DOES NOT INCREASE ALLERGIC SENSITIZATION IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											OWNBY, DR (corresponding author), HENRY FORD HOSP,DEPT PEDIAT,DIV PEDIAT ALLERGY IMMUNOL,2799 W GRAND BLVD,DETROIT,MI 48202, USA.							BAHNA SL, 1983, CLIN EXP IMMUNOL, V51, P624; FERGUSSON DM, 1981, J EPIDEMIOL COMMUN H, V35, P180, DOI 10.1136/jech.35.3.180; FOX DJ, 1976, DOCUMENTATION MIDAS; GORTMAKER SL, 1982, AM J PUBLIC HEALTH, V72, P574, DOI 10.2105/AJPH.72.6.574; GREENBERG RA, 1984, NEW ENGL J MED, V310, P1075, DOI 10.1056/NEJM198404263101703; KJELLMAN NIM, 1981, LANCET, V1, P993; KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; PATTISHALL EN, 1985, AM J DIS CHILD, V139, P1101, DOI 10.1001/archpedi.1985.02140130039026; ROWE MS, 1986, J ALLERGY CLIN IMMUN, V77, P714, DOI 10.1016/0091-6749(86)90416-1; VEDAL S, 1984, AM REV RESPIR DIS, V130, P187; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; WEISS ST, 1980, AM REV RESPIR DIS, V122, P697, DOI 10.1164/arrd.1980.122.5.697; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573; ZETTERSTROM O, 1985, J ALLERGY CLIN IMMUN, V75, P594, DOI 10.1016/0091-6749(85)90035-1; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215	17	33	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					634	638		10.1016/0091-6749(88)90976-1	http://dx.doi.org/10.1016/0091-6749(88)90976-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3171004				2022-12-18	WOS:A1988Q639900016
J	SHIBASAKI, M; TAJIMA, K; MORIKAWA, A; MITSUHASHI, M; SUMAZAKI, R; TOKUYAMA, K				SHIBASAKI, M; TAJIMA, K; MORIKAWA, A; MITSUHASHI, M; SUMAZAKI, R; TOKUYAMA, K			RELATION BETWEEN FREQUENCY OF ASTHMA AND IGE ANTIBODY-LEVELS AGAINST DERMATOPHAGOIDES-FARINAE AND TOTAL SERUM IGE LEVELS IN SCHOOLCHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GUNMA UNIV,SCH MED,DEPT PEDIAT,MAEBASHI,GUNMA 371,JAPAN	Gunma University	SHIBASAKI, M (corresponding author), UNIV TSUKUBA,INST CLIN MED,DEPT PEDIAT,SAKURA,IBARAKI 305,JAPAN.							AAS K, 1970, ARCH DIS CHILD, V45, P221, DOI 10.1136/adc.45.240.221; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CONROY MC, 1977, J IMMUNOL, V118, P1317; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; ELLIS EF, 1983, J ALLERGY CLIN IMMUN, V72, P526, DOI 10.1016/0091-6749(83)90479-7; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FERRIS BG, 1987, AM REV RESPIR DIS, V118, P7; FLINT KC, 1985, CLIN SCI, V68, P33; JOHANSSON SGO, 1978, ALLERGY PRINCIPLES P, V2, P551; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; MIYAMOTO T, 1974, J ALLERGY CLIN IMMUN, V53, P9, DOI 10.1016/0091-6749(74)90094-3; Oshima S., 1970, Jap. J. sanit. Zool., V21, P1; REED CE, 1978, ALLERGY PRINCIPLES P, P659; SHIBASAKI M, 1987, CLIN ALLERGY, V16, P469; STENIUS B, 1969, LANCET, V2, P455; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; WIDE L, 1967, LANCET, V2, P1105; 1982, STUDIES STANDARDIZAT, P1; 1979, SAS USERS GUIDE	23	33	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					86	94		10.1016/0091-6749(88)90056-5	http://dx.doi.org/10.1016/0091-6749(88)90056-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3392374				2022-12-18	WOS:A1988P400400015
J	KOPFERSCHMITTKUBLER, MC; BIGOT, H; PAULI, G				KOPFERSCHMITTKUBLER, MC; BIGOT, H; PAULI, G			ALLERGEN BRONCHIAL CHALLENGE TESTS - VARIABILITY AND REPRODUCIBILITY OF THE EARLY RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU STRASBOURG,SERV PNEUMOL,PAVILLON LAENNEC,F-67091 STRASBOURG,FRANCE; CNRS,CTR CALCUL,UNITE STAT,STRASBOURG,FRANCE	CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1983, THORAX, V38, P523, DOI 10.1136/thx.38.7.523; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; EISER NM, 1981, CLIN RES PROC, V17, P427; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; ELSTON RC, 1962, BIOMETRICS, V18, P148, DOI 10.2307/2527453; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FISH JE, 1979, J ALLERGY CLIN IMMUN, V64, P592, DOI 10.1016/0091-6749(79)90019-8; FROLUND L, 1986, ALLERGY, V41, P30, DOI 10.1111/j.1398-9995.1986.tb00271.x; GEUBELLE F, 1971, Bulletin de Physio-Pathologie Respiratoire, V7, P839; GOLDSTEIN A, 1974, PRINCIPLES DRUG ACTI; HABIB MP, 1979, J APPL PHYSIOL, V47, P51, DOI 10.1152/jappl.1979.47.1.51; HORTON DJ, 1978, AM REV RESPIR DIS, V117, P1029; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; LEMAO J, 1980, J ALLERGY CLIN IMMUN, V65, P381, DOI 10.1016/0091-6749(80)90217-1; LOWHAGEN O, 1983, EUR J RESPIR DIS, V64, P466; LOWHAGEN O, 1980, ALLERGY, V35, P349, DOI 10.1111/j.1398-9995.1980.tb01777.x; MADSEN F, 1985, EUR J RESPIR DIS, V67, P193; NIEJENS HJ, 1979, J ALLERGY CLIN IMMUN, V64, P507; OREHEK J, 1975, J ALLERGY CLIN IMMUN, V55, P164, DOI 10.1016/0091-6749(75)90012-3; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; Orehek J, 1981, Bull Eur Physiopathol Respir, V17, P329; PETERS JE, 1982, J IMMUNOL, V129, P1245; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; RUFIN P, 1984, CLIN ALLERGY, V14, P387, DOI 10.1111/j.1365-2222.1984.tb02220.x; RYAN G, 1981, J ALLERGY CLIN IMMUN, V67, P156, DOI 10.1016/0091-6749(81)90012-9; Siegel S., 1956, NONPARAMETRIC STAT B; SPECTOR S, 1976, AM REV RESPIR DIS, V113, P43; TAMURA G, 1985, J ALLERGY CLIN IMMUN, V75, P47, DOI 10.1016/0091-6749(85)90011-9; Tiffeneau R, 1958, Acta Allergol Suppl (Copenh), V5, P187; TIFFENEAU R, 1957, DEDUCTION DIAGNOSTIQ, P1; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; WANNER A, 1985, AM REV RESPIR DIS, V131, P3; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; 1981, BMDP STATISTICAL SOF; 1971, AIDE MEMOIRE PRATIQU	40	33	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					730	740		10.1016/0091-6749(87)90295-8	http://dx.doi.org/10.1016/0091-6749(87)90295-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K9930	3680817	Bronze			2022-12-18	WOS:A1987K993000015
J	LIND, P; NORMAN, PS; NEWTON, M; LOWENSTEIN, H; SCHWARTZ, B				LIND, P; NORMAN, PS; NEWTON, M; LOWENSTEIN, H; SCHWARTZ, B			THE PREVALENCE OF INDOOR ALLERGENS IN THE BALTIMORE AREA - HOUSE DUST MITE AND ANIMAL-DANDER ANTIGENS MEASURED BY IMMUNOCHEMICAL TECHNIQUES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; ALK,RES GRP,COPENHAGEN,DENMARK; ALK,DIAGNOSELAB,COPENHAGEN,DENMARK	Johns Hopkins University	LIND, P (corresponding author), UNIV COPENHAGEN,PROT LAB,SIGURDSGADE 34,DK-2200 COPENHAGEN N,DENMARK.							ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; BLYTHE ME, 1976, BRIT J DIS CHEST, V70, P3, DOI 10.1016/0007-0971(76)90003-6; BRONSWIJK JEM, 1978, ALLERGOLOGIE, V1, P55; CARSWELL F, 1982, CLIN ALLERGY, V12, P533, DOI 10.1111/j.1365-2222.1982.tb02552.x; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; Dirksen A, 1982, Dan Med Bull, V29, P5; HALL CC, 1971, ANN ALLERGY, V29, P81; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; KORSGAARD J, 1983, ALLERGY, V38, P93, DOI 10.1111/j.1398-9995.1983.tb01592.x; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LIND P, 1986, INT ARCH ALLER A IMM, V79, P60, DOI 10.1159/000233943; LIND P, 1979, ALLERGY, V34, P319; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; LOWENSTEIN H, 1976, INT ARCH ALLER A IMM, V51, P48, DOI 10.1159/000231578; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWENSTEIN H, 1981, ALLERGOLOGIE, V4, P265; MULLA MS, 1975, J MED ENTOMOL, V12, P5, DOI 10.1093/jmedent/12.1.5; OHMAN JL, 1974, J IMMUNOL, V113, P1668; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P716, DOI 10.1136/adc.49.9.716; SCHWARTZ B, 1984, Journal of Allergy and Clinical Immunology, V73, P156; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; [No title captured]	27	33	34	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					541	547		10.1016/0091-6749(87)90005-4	http://dx.doi.org/10.1016/0091-6749(87)90005-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	3668118				2022-12-18	WOS:A1987K522400005
J	OKA, S; SHIGETA, S; ONO, K; JYO, T				OKA, S; SHIGETA, S; ONO, K; JYO, T			AN EPITOPE RESIDING IN CARBOHYDRATE CHAINS OF A SEA SQUIRT ANTIGEN TERMED GI-REP	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HIROSHIMA PREFECT HOSP,DEPT INTERNAL MED 3,HIROSHIMA,JAPAN		OKA, S (corresponding author), HIROSHIMA UNIV,FAC ENGN,DEPT FERMENTAT TECHNOL,HIROSHIMA 724,JAPAN.							ANDERSON B, 1964, J BIOL CHEM, V239, P2716; DAIBO A, 1986, JPN J ALLERGOL, V35, P747; JYO T, UNPUB J ALLERGY CLIN; JYO T, 1985, ALERGIA, V14, P26; JYO T, 1978, JPN J ALLERGOL, V27, P842; NEESER JR, 1984, ANAL BIOCHEM, V142, P58, DOI 10.1016/0003-2697(84)90516-5; OKA S, 1982, J BIOCHEM-TOKYO, V91, P1403, DOI 10.1093/oxfordjournals.jbchem.a133828; OKA S, 1982, J BIOCHEM-TOKYO, V91, P247, DOI 10.1093/oxfordjournals.jbchem.a133681; OKA S, 1979, INT ARCH ALLER A IMM, V59, P408, DOI 10.1159/000232288; OKA S, 1979, ANAL BIOCHEM, V98, P417, DOI 10.1016/0003-2697(79)90161-1; SUZUKI H, 1984, J BIOCHEM-TOKYO, V96, P849, DOI 10.1093/oxfordjournals.jbchem.a134903; TANAKA K, 1965, J BIOL CHEM, V249, pC1487; TANIFUJI K, 1984, Japanese Journal of Allergology, V33, P78	13	33	32	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					57	63		10.1016/S0091-6749(87)80191-4	http://dx.doi.org/10.1016/S0091-6749(87)80191-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	2439561				2022-12-18	WOS:A1987J219400009
J	NORMAN, PS				NORMAN, PS			FATAL MISADVENTURES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											NORMAN, PS (corresponding author), GOOD SAMARITAN HOSP,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239, USA.							Committee on the Safety of Medicines (CSM) in Great Britain, 1986, BR MED J, V293, P948; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CYPRESS BK, 1984, ADV DATA VITAL HLTH, V99; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2	6	33	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					572	573		10.1016/S0091-6749(87)80150-1	http://dx.doi.org/10.1016/S0091-6749(87)80150-1			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	3558995	Bronze			2022-12-18	WOS:A1987G972000003
J	GOLUB, AL; FROST, RW; BETLACH, CJ; GONZALEZ, MA				GOLUB, AL; FROST, RW; BETLACH, CJ; GONZALEZ, MA			PHYSIOLOGICAL CONSIDERATIONS IN DRUG ABSORPTION FROM THE GASTROINTESTINAL-TRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GOLUB, AL (corresponding author), KEY PHARMACEUT INC, 50 NW 176TH ST, MIAMI, FL 33169 USA.							BETLACH C, 1986, 133RD ANN M AM PHARM; BINS M, 1984, HEPATO-GASTROENTEROL, V31, P41; BREIMER DD, 1983, DRUG DELIVERY SYSTEM, P18; CODE CF, 1975, J PHYSIOL-LONDON, V246, P289, DOI 10.1113/jphysiol.1975.sp010891; FELDMAN M, 1984, GASTROENTEROLOGY, V87, P895; GONZALEZ MA, 1983, DRUG DEV IND PHARM, V9, P1379, DOI 10.3109/03639048309046324; GRANGER B, 1950, ANAT REC, V107, P423, DOI 10.1002/ar.1091070409; HENDELES L, 1985, CHEST, V87, P758, DOI 10.1378/chest.87.6.758; HINDER RA, 1977, AM J PHYSIOL, V233, pE335, DOI 10.1152/ajpendo.1977.233.4.E335; HIRTZ J, 1985, BRIT J CLIN PHARMACO, V19, pS77, DOI 10.1111/j.1365-2125.1985.tb02746.x; HOFMANN AF, 1983, DRUG DEV IND PHARM, V9, P1077, DOI 10.3109/03639048309046314; HORTON RE, 1965, BMJ-BRIT MED J, V1, P1537, DOI 10.1136/bmj.1.5449.1537; HUNT JN, 1951, J PHYSIOL-LONDON, V113, P157, DOI 10.1113/jphysiol.1951.sp004562; HUNT JN, 1956, J PHYSIOL-LONDON, V132, P267, DOI 10.1113/jphysiol.1956.sp005524; HUNT JN, 1968, J PHYSIOL-LONDON, V194, P327, DOI 10.1113/jphysiol.1968.sp008411; JONKMAN JHG, 1985, EUR J CLIN PHARMACOL, V28, P225, DOI 10.1007/BF00609697; Karim A, 1985, Am Pharm, VNS25, P4; KELLY KA, 1980, GASTROINTEST LIVER P, V2, pG71; KUNA S., 1964, ARCH INT PHARMACODYN THERAP, V151, P79; LEEDS NH, 1982, J CLIN PHARMACOL, V22, P196, DOI 10.1002/j.1552-4604.1982.tb02162.x; LEVINE RR, 1970, AM J DIG DIS, V15, P171, DOI 10.1007/BF02235648; MEYER JH, 1979, GASTROENTEROLOGY, V76, P804; MEYER JH, 1985, GASTROENTEROLOGY, V88, P1502; MINAMI H, 1984, GASTROENTEROLOGY, V86, P1592; MOORE JG, 1981, DIGEST DIS SCI, V26, P16, DOI 10.1007/BF01307971; PEDERSEN S, 1984, PEDIATRICS, V74, P534; PRESCOTT LF, 1974, MED CLIN N AM, V58, P907, DOI 10.1016/S0025-7125(16)32088-0; RITSCHEL WA, 1980, HDB BASIC PHARMACOKI, P71; SCHANKER LS, 1960, J MED PHARMACEUT CH, V2, P343, DOI 10.1021/jm50011a001; SIPS AP, 1984, EUR J CLIN PHARMACOL, V26, P405, DOI 10.1007/BF00548776; STEPHENS JR, 1975, GASTROENTEROLOGY, V69, P920; WEINBERGER M, 1978, NEW ENGL J MED, V299, P852, DOI 10.1056/NEJM197810192991603; WELLING PG, 1975, CLIN PHARMACOL THER, V17, P475	33	33	36	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				689	694		10.1016/0091-6749(86)90047-3	http://dx.doi.org/10.1016/0091-6749(86)90047-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3534051				2022-12-18	WOS:A1986E568400005
J	WARD, PA				WARD, PA			HOST-DEFENSE MECHANISMS RESPONSIBLE FOR LUNG INJURY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											WARD, PA (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PATHOL,1500 E MED CTR,ANN ARBOR,MI 48104, USA.							AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; BALDWIN SR, 1986, LANCET, V1, P11; BOWERN N, 1984, J EXP MED, V160, P1532, DOI 10.1084/jem.160.5.1532; DOROSHOW JH, 1980, J CLIN INVEST, V65, P128, DOI 10.1172/JCI109642; FANTONE JC, 1985, OXYGEN DERIVED RADIC; FLIGIEL SEG, 1984, AM J PATHOL, V115, P418; HARLAN JM, 1985, LAB INVEST, V52, P141; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; JOHNSON KJ, 1981, J IMMUNOL, V126, P2365; JOHNSON KJ, 1984, J CLIN INVEST, V74, P358, DOI 10.1172/JCI111431; JOHNSON KJ, 1986, LAB INVEST, V54, P499; JOHNSON KJ, 1982, AM J PATHOL, V107, P29; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; Lands W E, 1985, J Free Radic Biol Med, V1, P97, DOI 10.1016/0748-5514(85)90012-1; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; REHAN A, 1984, LAB INVEST, V51, P396; REHAN A, 1985, KIDNEY INT, V27, P503, DOI 10.1038/ki.1985.39; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; SCHRAUFSTATTER IU, 1984, J CLIN INVEST, V73, P1175, DOI 10.1172/JCI111303; SPEER CP, 1984, J IMMUNOL, V133, P2151; TILL GO, 1985, AM J PATHOL, V119, P376; TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548; VARANI J, 1985, LAB INVEST, V53, P656; WARD PA, 1983, J CLIN INVEST, V72, P789, DOI 10.1172/JCI111050; WEISS SJ, 1980, J BIOL CHEM, V255, P9912; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; WEISS SJ, 1983, IMMUNOLOGY INFLAMMAT, P37	27	33	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	1				373	378		10.1016/0091-6749(86)90020-5	http://dx.doi.org/10.1016/0091-6749(86)90020-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1148	3531290				2022-12-18	WOS:A1986E114800001
J	KUHN, JP				KUHN, JP			IMAGING OF THE PARA-NASAL SINUSES - CURRENT STATUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											KUHN, JP (corresponding author), SUNY BUFFALO,CHILDRENS HOSP,SCH MED,DEPT RADIOL,BUFFALO,NY 14203, USA.							BILANIUK LT, 1982, RADIOL CLIN N AM, V20, P51; BOWEN A, 1981, PEDIATR CLIN N AM, V28, P905; CAFFEY J, 1985, PEDIATRIC XRAY DIAGN; Dowd S B, 1984, Appl Radiol, V13, P81; FERNBACH SK, 1981, NEURORADIOLOGY, V22, P7, DOI 10.1007/BF00344603; GOLDBERG F, 1978, PEDIATRICS, V62, P1000; HOSHAW TC, 1974, ARCH OTOLARYNGOL, V100, P194; KOGUTT MS, 1978, RADIOLOGY, V129, P133; Maresh MM, 1940, AM J DIS CHILD, V60, P841, DOI 10.1001/archpedi.1940.02000040060005; Maresh MM, 1940, AM J DIS CHILD, V60, P55, DOI 10.1001/archpedi.1940.02000010064005; PFLEIDERER AG, 1984, CLIN OTOLARYNGOL, V9, P335, DOI 10.1111/j.1365-2273.1984.tb01517.x; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; REVONTA M, 1981, J LARYNGOL OTOL, V95, P133, DOI 10.1017/S0022215100090538; REVONTA M, 1979, LANCET, V1, P320; REVONTA M, 1980, ACTA OTOLARYNGOL S S, V370; ROHR AS, J ALLERGY CLIN IMMUN; SHAPIRO ED, 1982, J INFECT DIS, V146, P589, DOI 10.1093/infdis/146.5.589; SHAPIRO GG, 1986, J ALLERGY CLIN IMMUN, V77, P59, DOI 10.1016/0091-6749(86)90324-6; SHOPFNER CE, 1973, AM J ROENTGENOL, V118, P176, DOI 10.2214/ajr.118.1.176; Swischuk L. E., 1982, RADIOGRAPHICS, V2, P241; Towbin R, 1982, RADIOGRAPHICS, V2, P253; UHARI M, 1977, DUODECIM, V93, P327; VUORINEN P, 1962, J Laryngol Otol, V76, P359, DOI 10.1017/S0022215100059442; WALD ER, 1984, J PEDIATR-US, V104, P297, DOI 10.1016/S0022-3476(84)81018-5; WALD ER, 1981, PEDIATR CLIN N AM, V28, P777; WATTBOOLSEN S, 1977, CLIN OTOLARYNGOL, V2, P41, DOI 10.1111/j.1365-2273.1977.tb01333.x; 1981, NRCP68 REP	27	33	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				6	8		10.1016/0091-6749(86)90314-3	http://dx.doi.org/10.1016/0091-6749(86)90314-3			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3511126				2022-12-18	WOS:A1986AZD3600002
J	SLY, RM				SLY, RM			ADVERSE-EFFECTS AND COMPLICATIONS OF TREATMENT WITH BETA-ADRENERGIC AGONIST DRUGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SLY, RM (corresponding author), CHILDRENS HOSP, NATL MED CTR, 111 MICHIGAN AVE NW, WASHINGTON, DC 20010 USA.							BANNER AS, 1979, ARCH INTERN MED, V139, P434, DOI 10.1001/archinte.139.4.434; BARBERA JM, 1984, ANN ALLERGY, V52, P224; BASS M, 1970, J AMER MED ASSOC, V212, P2075, DOI 10.1001/jama.212.12.2075; BROWN JE, 1983, CLIN PHARMACOL THER, V33, P424, DOI 10.1038/clpt.1983.57; CAPLIN I, 1969, ANN ALLERGY, V27, P65; CHAPMAN KR, 1984, CLIN PHARMACOL THER, V35, P762, DOI 10.1038/clpt.1984.108; CLARK DG, 1972, ANN ALLERGY, V30, P536; CONNOLLY CK, 1975, BRIT MED J, V3, P21, DOI 10.1136/bmj.3.5974.21; DAVIS C, 1977, CLIN SCI MOL MED, V52, pP28; DOLLERY CT, 1974, CLIN PHARMACOL THER, V15, P59; DOLOVICH M, 1981, CHEST, V80, P911; ELLULMICALLEF R, 1975, THORAX, V30, P312, DOI 10.1136/thx.30.3.312; FRIEDMAN R, 1982, AM J DIS CHILD, V136, P1091, DOI 10.1001/archpedi.1982.03970480057013; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GANDEVIA B, 1973, MED J AUSTRALIA, V1, P273, DOI 10.5694/j.1326-5377.1973.tb119742.x; GAZIOGLU K, 1971, AM J MED, V50, P185, DOI 10.1016/0002-9343(71)90147-1; HARRIS L, 1972, J ALLERGY CLIN IMMUN, V49, P63, DOI 10.1016/0091-6749(72)90057-7; HEIMER D, 1980, J ALLERGY CLIN IMMUN, V66, P75, DOI 10.1016/0091-6749(80)90141-4; HEITZ A, 1983, BRIT J PHARMACOL, V80, P711, DOI 10.1111/j.1476-5381.1983.tb10062.x; HIGBEE MD, 1982, J ALLERGY CLIN IMMUN, V70, P377, DOI 10.1016/0091-6749(82)90028-8; HODGES IGC, 1981, ARCH DIS CHILD, V56, P787, DOI 10.1136/adc.56.10.787; INGRAM RH, 1970, AM REV RESPIR DIS, V101, P364; INMAN WHW, 1969, LANCET, V2, P279; JACK D, 1971, BRIT MED J, V2, P708, DOI 10.1136/bmj.2.5763.708-b; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; JOHANSSON LH, 1983, J PHARM PHARMACOL, V35, P804, DOI 10.1111/j.2042-7158.1983.tb02900.x; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; KEMP JP, 1984, J ALLERGY CLIN IMMUN, V73, P32, DOI 10.1016/0091-6749(84)90481-0; KNUDSON RJ, 1967, J APPL PHYSIOL, V22, P402, DOI 10.1152/jappl.1967.22.3.402; KOEPKE JW, 1983, J ALLERGY CLIN IMMUN, V72, P504, DOI 10.1016/0091-6749(83)90588-2; KRAVITZ S, 1982, ANN ALLERGY, V48, P261; KUNG M, 1984, AM REV RESPIR DIS, V129, P329; KURLAND G, 1979, J ALLERGY CLIN IMMUN, V63, P407, DOI 10.1016/0091-6749(79)90214-8; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; MATSON JR, 1978, J PEDIATR-US, V92, P776, DOI 10.1016/S0022-3476(78)80150-4; MURRAY AB, 1974, J ALLERGY CLIN IMMUN, V53, P83; NELSON HS, 1982, CHEST, V82, pS33; NELSON HS, 1977, INT ARCH ALLER A IMM, V55, P362, DOI 10.1159/000231947; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; NEVILLE A, 1977, BRIT MED J, V1, P413, DOI 10.1136/bmj.1.6058.413; NEVILLE E, 1982, BRIT MED J, V285, P796, DOI 10.1136/bmj.285.6344.796; NEWHOUSE MT, 1978, CHEST, V73, P936, DOI 10.1378/chest.73.6.936; NEWMAN SP, 1981, AM REV RESPIR DIS, V124, P317; NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52; NICKLAS RA, 1984, J ALLERGY CLIN IMMUN, V73, P20, DOI 10.1016/0091-6749(84)90479-2; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; REPSHER LH, 1984, CHEST, V85, P34, DOI 10.1378/chest.85.1.34; RIDING W D, 1970, British Journal of Diseases of the Chest, V64, P37, DOI 10.1016/S0007-0971(70)80047-X; ROBBERECHT P, 1983, MOL PHARMACOL, V24, P169; SAUNDERS KB, 1965, BRIT MED J, V1, P1037, DOI 10.1136/bmj.1.5441.1037; SHIM C, 1980, AM J MED, V69, P891, DOI 10.1016/S0002-9343(80)80016-7; SLY RM, 1977, J ALLERGY CLIN IMMUN, V59, P128, DOI 10.1016/0091-6749(77)90214-7; SLY RM, 1984, ANN ALLERGY, V53, P20; SPEIZER FE, 1968, BRIT MED J, V1, P339, DOI 10.1136/bmj.1.5588.339; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STANESCU DC, 1972, RESPIRATION, V29, P532; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; TAGGART P, 1979, BRIT HEART J, V41, P214; TAYLOR GJ, 1970, J AMER MED ASSOC, V214, P81, DOI 10.1001/jama.214.1.81; TRAUTLEIN J, 1976, CHEST, V70, P711, DOI 10.1378/chest.70.6.711; WAELBROECK M, 1983, MOL PHARMACOL, V24, P174; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X; WEINER N, 1980, PHARMACOL BASIS THER, P138; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1; WILSON JD, 1981, LANCET, V1, P1235; WINSOR T, 1975, MICROVASC RES, V9, P261, DOI 10.1016/0026-2862(75)90063-1	68	33	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	4					443	449						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AFY44					2022-12-18	WOS:A1985AFY4400002
J	CASALE, TB; KALINER, M				CASALE, TB; KALINER, M			DEMONSTRATION THAT CIRCULATING HUMAN-BLOOD CELLS HAVE NO DETECTABLE ALPHA-1-ADRENERGIC RECEPTORS BY RADIOLIGAND BINDING ANALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,ROOM 11C-205,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				AARONS RD, 1980, J CLIN INVEST, V65, P949, DOI 10.1172/JCI109781; BERNSTEIN RA, 1972, J LAB CLIN MED, V80, P772; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; CASALE TB, 1982, J IMMUNOL METHODS, V55, P347, DOI 10.1016/0022-1759(82)90094-1; COFFEY RG, 1975, ENDOCR RES COMMUN, V2, P179, DOI 10.1080/07435807509053848; DAVIS PB, 1982, J ALLERGY CLIN IMMUN, V69, P35, DOI 10.1016/0091-6749(82)90084-7; EXTON JH, 1982, TRENDS PHARMACOL SCI, V3, P111, DOI 10.1016/0165-6147(82)91045-8; FERRANTE A, 1978, J IMMUNOL METHODS, V24, P389, DOI 10.1016/0022-1759(78)90143-6; GALANT SP, 1980, J CLIN INVEST, V65, P577, DOI 10.1172/JCI109702; GRIECO MH, 1968, AM J MED, V44, P863, DOI 10.1016/0002-9343(68)90086-7; Hadden J W, 1970, Cell Immunol, V1, P583, DOI 10.1016/0008-8749(70)90024-9; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; HENNEY CS, 1972, J IMMUNOL, V108, P1526; HOFFMAN BB, 1980, NEW ENGL J MED, V302, P1390, DOI 10.1056/NEJM198006193022504; IGNARRO LJ, 1974, SCIENCE, V183, P855, DOI 10.1126/science.183.4127.855; KAFKA MS, 1977, LIFE SCI, V21, P1429, DOI 10.1016/0024-3205(77)90197-7; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KARIMAN K, 1980, LUNG, V158, P41, DOI 10.1007/BF02713701; KIRKPATRICK CH, 1967, AM REV RESPIR DIS, V96, P692; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; MALBON CC, 1978, J BIOL CHEM, V253, P671; MELMON KL, 1974, J CLIN INVEST, V53, P13, DOI 10.1172/JCI107530; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; NELSON MJ, 1979, BIOCHIM BIOPHYS ACTA, V558, P136, DOI 10.1016/0005-2736(79)90323-7; NEWMAN KD, 1978, J CLIN INVEST, V61, P395, DOI 10.1172/JCI108950; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PERTOFT H, 1979, CELL POPULATIONS MET, V9, P67; SANO J, 1981, J ALLERGY CLIN IMMUN, V67, P59; SHEPPARD JR, 1977, NATURE, V269, P693, DOI 10.1038/269693a0; SMITH U, 1977, EUR J CLIN INVEST, V7, P355, DOI 10.1111/j.1365-2362.1977.tb01620.x; SNASHALL PD, 1978, CLIN SCI MOL MED, V54, P283, DOI 10.1042/cs0540283; Szentivanyi A, 1980, ACTA DERM-VENEREOL, VS92, P19; WILLIAMS LT, 1976, J CLIN INVEST, V57, P149, DOI 10.1172/JCI108254; WILLIAMS LT, 1977, J BIOL CHEM, V252, P2787; WINCHURCH RA, 1977, BIOMEDICINE, V26, P36	37	33	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	6					812	818		10.1016/0091-6749(84)90184-2	http://dx.doi.org/10.1016/0091-6749(84)90184-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW418	6094641				2022-12-18	WOS:A1984TW41800009
J	FOREMAN, JC				FOREMAN, JC			MAST-CELLS AND THE ACTIONS OF FLAVONOIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											FOREMAN, JC (corresponding author), UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND.							ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; ASSEM ESK, 1971, BRIT J PHARMACOL, V42, P620, DOI 10.1111/j.1476-5381.1971.tb07146.x; BENNETT JP, 1981, ARZNEIMITTEL-FORSCH, V31-1, P433; BURNET FM, 1965, J PATHOL BACTERIOL, V89, P271, DOI 10.1002/path.1700890128; BUSSE WW, 1984, J ALLERGY CLIN IMMUN, V73, P801, DOI 10.1016/0091-6749(84)90450-0; CARSTAIRS JR, 1973, EXP CELL RES, V81, P156, DOI 10.1016/0014-4827(73)90122-5; COCKROFT S, 1982, MORE RECEPTORS, P162; CZARNETZKI BM, 1982, INT ARCH ALLER A IMM, V67, P44, DOI 10.1159/000232986; ENNERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289; ENNERBACK L, 1966, ACTA PATHOL MICROBIO, V66, P313; ENNERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303; FANNING MJ, 1983, INT ARCH ALLER A IMM, V71, P371, DOI 10.1159/000233423; FELDBERG W, 1954, BRIT J PHARM CHEMOTH, V9, P197, DOI 10.1111/j.1476-5381.1954.tb00841.x; FEWTRELL CMS, 1977, NATURE, V265, P635, DOI 10.1038/265635a0; FEWTRELL CMS, 1977, BIOCHIM BIOPHYS ACTA, V469, P52, DOI 10.1016/0005-2736(77)90325-X; FOREMAN JC, 1973, NATURE, V245, P249, DOI 10.1038/245249a0; FOREMAN JC, 1981, ANNU REV PHARMACOL, V21, P63, DOI 10.1146/annurev.pa.21.040181.000431; GARLAND LG, 1984, TXB IMMUNOPHARMACOLO, P265; GINSBURG H, 1978, IMMUNOLOGY, V35, P485; GUYGRAND D, 1978, J EXP MED, V148, P1661, DOI 10.1084/jem.148.6.1661; HAIG DM, 1982, NATURE, V300, P188, DOI 10.1038/300188a0; HANAHOE THP, 1973, J PHARM PHARMACOL, V25, P429, DOI 10.1111/j.2042-7158.1973.tb10046.x; HARRIS JM, 1963, GENET RES, V4, P346, DOI 10.1017/S0016672300003748; HARRIS JM, 1963, BRIT J PHARM CHEMOTH, V20, P550, DOI 10.1111/j.1476-5381.1963.tb01492.x; HIRATA F, 1979, P NATL ACAD SCI USA, V76, P2640, DOI 10.1073/pnas.76.6.2640; HOPE WC, 1983, BIOCHEM PHARMACOL, V32, P367, DOI 10.1016/0006-2952(83)90569-5; ISHIZAKA T, 1977, J IMMUNOL, V118, P211; JOHANSEN T, 1972, N-S ARCH PHARMACOL, V275, P457, DOI 10.1007/BF00501133; KELLER R, 1976, EXPERIENTIA, V32, P171, DOI 10.1007/BF01937747; KITAMURA Y, 1981, NATURE, V291, P159, DOI 10.1038/291159a0; KITAMURA Y, 1979, BLOOD, V53, P1085; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; LEE TP, 1982, LIFE SCI, V31, P2765, DOI 10.1016/0024-3205(82)90723-8; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LICHTENSTEIN LM, 1971, INT ARCH ALLER A IMM, V41, P56, DOI 10.1159/000230488; LICHTENSTEIN LM, 1980, MAST CELL, P83; MAYRHOFER G, 1979, IMMUNOLOGY, V37, P145; MAYRHOFER G, 1981, INT ARCH ALLER A IMM, V64, P320, DOI 10.1159/000232710; MAYRHOFER G, 1980, HISTOCHEM J, V12, P513, DOI 10.1007/BF01011925; MIDDLETON E, 1982, BIOCHEM PHARMACOL, V31, P1449, DOI 10.1016/0006-2952(82)90044-2; MIDDLETON E, 1981, J IMMUNOL, V127, P546; MONGAR JL, 1952, J PHYSL, V119, P48; PADAWER J, 1969, J CELL BIOL, V40, P747, DOI 10.1083/jcb.40.3.747; PEARCE FL, 1983, TRENDS PHARMACOL SCI, V4, P165, DOI 10.1016/0165-6147(83)90345-0; PEARCE FL, 1984, J ALLERGY CLIN IMMUN, V73, P819, DOI 10.1016/0091-6749(84)90453-6; POYSER RH, 1965, BRIT J PHARM CHEMOTH, V25, P602, DOI 10.1111/j.1476-5381.1965.tb01784.x; RACKER E, 1975, BIOCHEM SOC T, V3, P785, DOI 10.1042/bst0030785; RILEY JF, 1953, J PHYSIOL-LONDON, V120, P528, DOI 10.1113/jphysiol.1953.sp004915; RUCKSTUHL M, 1981, BIOCHEM PHARMACOL, V30, P697, DOI 10.1016/0006-2952(81)90153-2; Schneider C, 1979, Adv Exp Med Biol, V121, P371; SCHRADER J, 1981, P NATL ACAD SCI US, V71, P323; SCHRADER J, 1981, J IMMUNOL, V126, P453; SCHWARTZ A, 1982, IMMUNOPHARMACOLOGY, V4, P125, DOI 10.1016/0162-3109(82)90015-7; SHOWELL HJ, 1981, J RETICULOENDOTH SOC, V30, P167; SIEGHART W, 1978, NATURE, V275, P329, DOI 10.1038/275329a0; SIRAGANIAN RP, 1983, TRENDS PHARMACOL SCI, V4, P432, DOI 10.1016/0165-6147(83)90478-9; SPIEGELBERG HL, 1983, FED PROC, V42, P124; SREDNI B, 1983, J IMMUNOL, V131, P915; WOODBURY RG, 1978, P NATL ACAD SCI USA, V75, P2785, DOI 10.1073/pnas.75.6.2785; WOODBURY RG, 1978, P NATL ACAD SCI USA, V75, P5311, DOI 10.1073/pnas.75.11.5311; WOODBURY RG, 1978, BIOCHEMISTRY-US, V17, P4298, DOI 10.1021/bi00613a029; WOODBURY RG, 1981, METHOD ENZYMOL, V80, P588; WOODBURY RG, 1982, IMMUNOLOGY, V46, P487	63	33	35	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	6					769	774		10.1016/0091-6749(84)90446-9	http://dx.doi.org/10.1016/0091-6749(84)90446-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SV829	6202730				2022-12-18	WOS:A1984SV82900002
J	OSTERBALLE, O; IPSEN, H; WEEKE, B; LOWENSTEIN, H				OSTERBALLE, O; IPSEN, H; WEEKE, B; LOWENSTEIN, H			SPECIFIC IGE RESPONSE TOWARD ALLERGENIC MOLECULES DURING PERENNIAL HYPOSENSITIZATION - A 3-YEAR PROSPECTIVE DOUBLE-BLIND-STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COPENHAGEN HOSP,DEPT MED TA,DK-2100 COPENHAGEN,DENMARK; UNIV COPENHAGEN,PROT LAB,DK-1123 COPENHAGEN K,DENMARK	University of Copenhagen; University of Copenhagen	OSTERBALLE, O (corresponding author), UNIV COPENHAGEN HOSP,DEPT PAEDIAT G,DK-2100 COPENHAGEN,DENMARK.							AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; BERG T, 1980, INT ARCH ALLER A IMM, V63, P266, DOI 10.1159/000232636; FROSTAD AB, 1980, ALLERGY, V35, P81, DOI 10.1111/j.1398-9995.1980.tb01722.x; KJELLMAN NIM, 1980, ALLERGY, V35, P323, DOI 10.1111/j.1398-9995.1980.tb01774.x; LOWENSTEIN H, 1978, ALLERGY, V33, P30, DOI 10.1111/j.1398-9995.1978.tb01504.x; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWENSTEIN H, 1981, CLIN IMMUNOL ALLERGY, P265; MARSH DG, 1975, ANTIGENS, V3, P271; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; OSTERBALLE O, 1982, ALLERGY, V37, P491, DOI 10.1111/j.1398-9995.1982.tb02332.x; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; OSTERBALLE O, 1981, ALLERGY, V36, P183, DOI 10.1111/j.1398-9995.1981.tb01834.x; OSTERBALLE O, 1982, INT ARCH ALLER A IMM, V68, P286, DOI 10.1159/000233114	13	33	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					40	46		10.1016/0091-6749(83)90545-6	http://dx.doi.org/10.1016/0091-6749(83)90545-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ461	6337196	Bronze			2022-12-18	WOS:A1983PZ46100007
J	SCHENKEL, E; ATKINS, PC; YOST, R; ZWEIMAN, B				SCHENKEL, E; ATKINS, PC; YOST, R; ZWEIMAN, B			ANTIGEN-INDUCED NEUTROPHIL CHEMOTACTIC ACTIVITY FROM SENSITIZED LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19104	University of Pennsylvania					NIAID NIH HHS [R0 AI 14332-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS PC, 1979, J ALLERGY CLIN IMMUN, V64, P251, DOI 10.1016/0091-6749(79)90140-4; ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; CZARNETZKI BM, 1976, J IMMUNOL, V117, P229; GOETZL EJ, 1980, NEW ENGL J MED, V303, P822, DOI 10.1056/NEJM198010023031421; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; KONIG W, 1976, J IMMUNOL, V117, P235; KONIG W, 1981, P ANN M AM ACADEMY A, P1; LEVY D, 1973, J LAB CLIN MED, V81, P29; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	13	33	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					321	325		10.1016/0091-6749(82)90020-3	http://dx.doi.org/10.1016/0091-6749(82)90020-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PQ105	6182177				2022-12-18	WOS:A1982PQ10500002
J	HAMILTON, RG; ADKINSON, NF				HAMILTON, RG; ADKINSON, NF			QUANTITATION OF ANTIGEN-SPECIFIC IMMUNOGLOBULIN-G IN HUMAN-SERUM .2. COMPARISON OF RADIOIMMUNOPRECIPITATION AND SOLID-PHASE RADIOIMMUNOASSAY TECHNIQUES FOR MEASUREMENT OF IMMUNOGLOBULIN-G SPECIFIC FOR A COMPLEX ALLERGEN MIXTURE (YELLOW JACKET VENOM)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239	Johns Hopkins University					NIAID NIH HHS [AI 11936-06] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERSE RC, 1971, IMMUNOGLOBULIN E ALL, P89; ADKINSON NF, 1976, MANUAL CLIN IMMUNOLO; BRUNDA MJ, 1978, FED PROC, V37, P1278; CUATRECASAS P, 1971, METHOD ENZYMOL, V22, P351; FORSGREN A, 1968, J IMMUNOL, V100, P921; GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAMILTON RG, 1980, J IMMUNOL, V124, P2966; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HAMILTON RG, J LAB CLIN MED; JOHANSSON SGO, 1978, IMMUNOL REV, V41, P248, DOI 10.1111/j.1600-065X.1978.tb01467.x; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; LIND I, 1970, Acta Pathologica et Microbiologica Scandinavica Section B Microbiology and Immunology, V78, P673; MCDOWELL G, 1971, ACTA PATH MICRO IM A, VB 79, P801; SAXTON EH, 1978, FED P, V37, P1853; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; Schur P H, 1972, Prog Clin Immunol, V1, P71; SHIMIZU M, 1978, J IMMUNOL METHODS, V19, P317, DOI 10.1016/0022-1759(78)90016-9; SJOQUIST J., 1967, NOBEL SYMP, V3, P341; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X	21	33	33	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	1					14	21		10.1016/0091-6749(81)90039-7	http://dx.doi.org/10.1016/0091-6749(81)90039-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KZ173	6161142				2022-12-18	WOS:A1981KZ17300004
J	LEFF, AR; MUNOZ, NM				LEFF, AR; MUNOZ, NM			INTERRELATIONSHIP BETWEEN ALPHA-ADRENERGIC AND BETA-ADRENERGIC AGONISTS AND HISTAMINE IN CANINE AIRWAYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LEFF, AR (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,DEPT MED,PULM SECT,CHICAGO,IL 60637, USA.							BARNETT DB, 1978, AM REV RESPIR DIS, V118, P723, DOI 10.1164/arrd.1978.118.4.723; BEINFIELD WH, 1980, J APPL PHYSIOL, V48, P329, DOI 10.1152/jappl.1980.48.2.329; BERGEN JM, 1980, FED PROC, V39, P1175; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BROWN J K, 1980, American Review of Respiratory Disease, V121, P59; BROWN JK, 1980, J APPL PHYSIOL, V49, P84, DOI 10.1152/jappl.1980.49.1.84; CABEZAS GA, 1971, J APPL PHYSIOL, V31, P651, DOI 10.1152/jappl.1971.31.5.651; CASTRODELAMATA R, 1962, J PHARMACOL EXP THER, V135, P197; DEKOCK MA, 1970, BRONCHITIS, V3, P300; DRAZEN JM, 1978, J APPL PHYSIOL, V44, P340, DOI 10.1152/jappl.1978.44.3.340; DUCKLES SP, 1974, J PHARMACOL EXP THER, V190, P472; EVANS GH, 1973, J PHARMACOL EXP THER, V186, P114; FLEISCH JH, 1970, AM J PHYSIOL, V218, P596, DOI 10.1152/ajplegacy.1970.218.2.596; HIMORI N, 1976, BRIT J PHARMACOL, V56, P293, DOI 10.1111/j.1476-5381.1976.tb07641.x; HOFFMAN BB, 1980, NEW ENGL J MED, V302, P1390, DOI 10.1056/NEJM198006193022504; KESSLER GF, 1973, J APPL PHYSIOL, V35, P703, DOI 10.1152/jappl.1973.35.5.703; KNEUSSL MP, 1978, J APPL PHYSIOL, V45, P307, DOI 10.1152/jappl.1978.45.2.307; KONNO A, 1976, J OTOLARYNGOL JPN, V79, P725; Krebs HA, 1932, Z PHYSIOL CHEM, V210, P33; NADEL JA, 1977, AM REV RESPIR DIS, V115, P117; PATTERSON JW, 1979, AM REV RESPIR DIS, V120, P1145; PHIPPS RJ, 1980, AM REV RESPIR DIS, V121, P359; SOUHRADA JF, 1976, RESP PHYSIOL, V26, P27, DOI 10.1016/0034-5687(76)90049-9; STEPHENS NL, 1969, J APPL PHYSIOL, V26, P685, DOI 10.1152/jappl.1969.26.6.685; STEPHENS NL, 1968, J APPL PHYSIOL, V25, P376, DOI 10.1152/jappl.1968.25.4.376; STEPHENS NL, 1975, METHOD PHARMACOL, V3, P265; STEPHENS NL, 1976, LUNG CELLS DISEASE, P113; UEKI I, 1980, AM REV RESPIR DIS, V121, P351; WINDHOLTZ MS, 1976, MERCK INDEX, P868	29	33	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					300	309		10.1016/0091-6749(81)90156-1	http://dx.doi.org/10.1016/0091-6749(81)90156-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	6116729	Bronze			2022-12-18	WOS:A1981ML52500010
J	FURUKAWA, CT; ALTMAN, LC				FURUKAWA, CT; ALTMAN, LC			DEFECTIVE MONOCYTE AND POLYMORPHONUCLEAR LEUKOCYTE CHEMOTAXIS IN ATOPIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT PEDIAT,DIV ALLERGY & INFECT DIS,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	FURUKAWA, CT (corresponding author), UNIV WASHINGTON,DEPT MED,DIV ALLERGY & INFECT DIS,SEATTLE,WA 98195, USA.							ALTMAN LC, 1977, J IMMUNOL, V119, P199; ALTMAN LC, 1974, J CLIN INVEST, V54, P486, DOI 10.1172/JCI107784; ALTMAN LC, 1975, USE CHEMOTACTIC CHAM; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; Bruning J. L., 1968, COMPUTATIONAL HDB ST; CLARK RA, 1973, ANN INTERN MED, V78, P515, DOI 10.7326/0003-4819-78-4-515; DAHL MV, 1976, ARCH DERMATOL, V112, P1387, DOI 10.1001/archderm.112.10.1387; FISCHER TJ, 1977, ANN ALLERGY, V38, P308; Fisher R. A., 1950, STATISTICAL METHODS; HILL HR, 1974, LANCET, V2, P617; HILL HR, 1974, LANCET, V1, P183; HILL HR, 1976, ANN INTERN MED, V85, P39, DOI 10.7326/0003-4819-85-1-39; PINCUS SH, 1975, J PEDIATR-US, V87, P908, DOI 10.1016/S0022-3476(75)80903-6; PREUDHOM.JL, 1974, J IMMUNOL, V113, P1650; ROGGE JL, 1976, ARCH DERMATOL, V112, P1391, DOI 10.1001/archderm.112.10.1391; SHIN HS, 1968, SCIENCE, V162, P361, DOI 10.1126/science.162.3851.361; SNYDERMAN R, 1972, J IMMUNOL, V108, P857; SNYDERMAN R, 1977, J ALLERGY CLIN IMMUN, V60, P121, DOI 10.1016/0091-6749(77)90037-9; TERRITO MC, 1977, J IMMUNOL, V118, P187; VANSCOY RE, 1975, ANN INTERN MED, V82, P766, DOI 10.7326/0003-4819-82-6-766; WARD PA, 1968, AM J PATHOL, V52, P725	21	33	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	5					288	293		10.1016/0091-6749(78)90049-0	http://dx.doi.org/10.1016/0091-6749(78)90049-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EY714	641264				2022-12-18	WOS:A1978EY71400003
J	COHAN, RH; BLOOM, FL; RHOADES, RB; WITTIG, HJ; HAUGH, LD				COHAN, RH; BLOOM, FL; RHOADES, RB; WITTIG, HJ; HAUGH, LD			TREATMENT OF PERENNIAL ALLERGIC RHINITIS WITH CROMOLYN SODIUM - DOUBLE-BLIND-STUDY ON 34 ADULT PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA,COLL ARTS & SCI,DEPT STATISTICS,GAINESVILLE,FL 32601; UNIV FLORIDA,COLL MED,DEPT PEDIAT,GAINESVILLE,FL 32601	State University System of Florida; University of Florida; State University System of Florida; University of Florida								AAS K, 1973, INT ARCH ALLER A IMM, V45, P57, DOI 10.1159/000231002; BRESLIN ABX, 1973, CLIN ALLERGY, V3, P1; CULLEN KJ, 1973, AUSTR FAMILY PHYSICI, V2, P441; FREIER S, 1973, LANCET, V1, P913; FROST M, 1973, LANCET, V2, P389; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; KINGSLEY PJ, 1974, LANCET, V2, P1011; MELON J, 1973, REV FR ALLERGOL, V13, P241, DOI 10.1016/S0035-2845(73)80039-3; TAYLOR G, 1971, Clinical Allergy, V1, P189, DOI 10.1111/j.1365-2222.1971.tb03018.x; VERSTRAETEN JM, 1974, REV FR ALLERGOL, V14, P145, DOI 10.1016/S0335-7457(74)80028-6; WUETHRICH B, 1974, SCHWEIZ MED WOCHENSC, V104, P1033	11	33	34	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					121	128		10.1016/0091-6749(76)90147-0	http://dx.doi.org/10.1016/0091-6749(76)90147-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX744	821986				2022-12-18	WOS:A1976BX74400001
J	WHITESIDE, TL; RABIN, BS; ZETTERBERG, J; CRIEP, L				WHITESIDE, TL; RABIN, BS; ZETTERBERG, J; CRIEP, L			PRESENCE OF IGE ON SURFACE OF LYMPHOCYTES IN NASAL POLYPS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM HOSP,ALLERGY LAB,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,DEPT PATHOL,DIV CLIN IMMUNOPATHOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,HLTH CTR,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BOYUM A, 1968, SCAND J CLIN LAB S97, V21; BRANDTZAEG P, 1967, IMMUNOCHEMISTRY, V4, P57, DOI 10.1016/0019-2791(67)90197-8; DONOVAN R, 1970, INT ARCH ALLER A IMM, V37, P154, DOI 10.1159/000230229; HOBDAY JD, 1971, CLIN EXP IMMUNOL, V9, P577; ISHIZAKA K, 1970, J ALLERGY, V46, P197, DOI 10.1016/0021-8707(70)90023-7; KALINER M, 1973, NEW ENGL J MED, V289, P277, DOI 10.1056/NEJM197308092890601; LOOR F, 1972, EUR J IMMUNOL, V2, P203, DOI 10.1002/eji.1830020304; SAMTER M, 1961, ARCHIV OTOLARYNGOL, V73, P334; SAMTER M, 1973, HOSP PRACT, V8, P85; SMITH MP, 1971, LARYNGOSCOPE, V81, P636, DOI 10.1288/00005537-197105000-00003; SMITH RW, 1973, J IMMUNOL, V110, P884; TADA T, 1970, Journal of Immunology, V104, P377; TSE KS, 1973, J ALLERGY CLIN IMMUN, V51, P208, DOI 10.1016/0091-6749(73)90140-1; TSE KS, 1970, J ALLERGY, V46, P352, DOI 10.1016/0021-8707(70)90086-9; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5	15	33	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	3					186	194		10.1016/0091-6749(75)90015-9	http://dx.doi.org/10.1016/0091-6749(75)90015-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V8448	1089698				2022-12-18	WOS:A1975V844800006
J	TSE, KS; WICHER, K; ARBESMAN, CE				TSE, KS; WICHER, K; ARBESMAN, CE			EFFECT OF IMMUNOTHERAPY ON APPEARANCE OF ANTIBODIES TO RAGWEED IN EXTERNAL SECRETIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP, ALLERGY RES LAB, BUFFALO, NY 14203 USA; SUNY, DEPT MED, BUFFALO, NY 14214 USA; SUNY, DEPT MICROBIOL, BUFFALO, NY 14214 USA	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; SUNY Maritime College								ARBESMAN CE, 1960, J ALLERGY, V31, P317, DOI 10.1016/0021-8707(60)90068-X; CALLIES QC, 1970, J ALLERGY, V45, P123; CLAMAN HN, 1967, J ALLERGY, V40, P151, DOI 10.1016/0021-8707(67)90004-4; CONNELL JT, 1969, J ALLERGY, V43, P22, DOI 10.1016/0021-8707(69)90017-3; DOLOVICH J, 1970, J ALLERGY, V45, P286, DOI 10.1016/0021-8707(70)90034-1; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; HURLIMANN J, 1968, IMMUNOLOGY, V14, P809; ITO K, 1969, J IMMUNOL, V103, P622; KEIMOWITZ RI, 1964, J LAB CLIN MED, V63, P54; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; NEWCOMB RW, 1969, J IMMUNOL, V103, P215; NEWCOMB RW, 1970, J ALLERGY, V45, P105; OGRA PL, 1968, NEW ENGL J MED, V279, P893, DOI 10.1056/NEJM196810242791701; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; REMINGTON JS, 1964, J CLIN INVEST, V43, P1613, DOI 10.1172/JCI105037; ROSSEN RD, 1966, J CLIN INVEST, V45, P768, DOI 10.1172/JCI105391; ROSSEN RD, 1966, J IMMUNOL, V97, P369; SCHEIDEGGER JJ, 1955, INT ARCH ALLER A IMM, V7, P103, DOI 10.1159/000228215; Tomasi T B Jr, 1968, Adv Immunol, V9, P1, DOI 10.1016/S0065-2776(08)60441-1; TOMASI TB, 1965, J EXP MED, V121, P101, DOI 10.1084/jem.121.1.101; TOMASI TB, 1963, J CLIN INVEST, V42, P1552, DOI 10.1172/JCI104840; TOMASI TB, 1970, ADV INTERNAL MED, V16, P401; TOURVILL.DR, 1969, J EXP MED, V129, P411, DOI 10.1084/jem.129.2.411; TSE KS, 1970, J ALLERGY, V46, P352, DOI 10.1016/0021-8707(70)90086-9; TURK A, 1970, IMMUNOLOGY, V19, P85; WALDMAN RH, 1968, NATURE, V218, P594, DOI 10.1038/218594a0	28	33	33	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	4					208	217		10.1016/0091-6749(73)90140-1	http://dx.doi.org/10.1016/0091-6749(73)90140-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P3010	4631916				2022-12-18	WOS:A1973P301000003
J	REED, CE; MAKINO, S; ENTA, T; BENNER, M; CARR, RH; LOCKEY, SD				REED, CE; MAKINO, S; ENTA, T; BENNER, M; CARR, RH; LOCKEY, SD			MECHANISM OF ADJUVANT EFFECT OF BORDETELLA-PERTUSSIS VACCINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BERGMAN RK, 1969, P SOC EXP BIOL MED, V131, P964; EISEN HN, 1954, J IMMUNOL, V73, P296; ENTA L, 1968, P SOC EXP BIOL MED, V127, P136; FINGER H, 1967, EXPERIENTIA, V23, P591, DOI 10.1007/BF02137991; FISHEL CW, 1963, J ALLERGY, V34, P439, DOI 10.1016/0021-8707(63)90009-1; GULBENKIAN A, 1968, ENDOCRINOLOGY, V83, P885, DOI 10.1210/endo-83-4-885; Hadden J W, 1970, Cell Immunol, V1, P583, DOI 10.1016/0008-8749(70)90024-9; HADDEN JW, 1971, INT ARCH ALLER A IMM, V40, P526, DOI 10.1159/000230436; HERBERT WJ, 1968, IMMUNOLOGY, V14, P301; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; ISHIZUKA M, 1970, P SOC EXP BIOL MED, V134, P963; MAKINO S, 1970, Federation Proceedings, V29, P431; MCMANUS JP, 1969, EXP CELL RES, V58, P188; MIDDLETON E JR, 1969, Clinical Research, V17, P547; MINDEN P, 1967, HDB EXPT IMMUNOLOGY, P463; MUNOZ J, 1968, BACTERIOL REV, V32, P103, DOI 10.1128/MMBR.32.2.103-126.1968; NOWELL PC, 1962, FED P, V21, P72; ORTEZ RA, 1970, J ALLERGY, V45, P111; PEARLMAN DS, 1971, J ALLERGY, V47, P109; SMITH J W, 1969, Clinical Research, V17, P549; SMITH JW, 1969, FED PROC, V28, P566; STIEHM ER, 1966, PEDIATRICS, V37, P715; SZENTIVANYI A, 1963, J INFECT DIS, V113, P86, DOI 10.1093/infdis/113.2.86; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TOWNLEY RG, 1968, J ALLERGY, V41, P122; WHITFIELD JF, 1970, P SOC EXP BIOL MED, V133, P1270	26	33	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	3					174	&		10.1016/0091-6749(72)90111-X	http://dx.doi.org/10.1016/0091-6749(72)90111-X			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L8566	5011091				2022-12-18	WOS:A1972L856600005
J	Chovatiya, R; Paller, AS				Chovatiya, Raj; Paller, Amy S.			JAK inhibitors in the treatment of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; eczema; itch; therapy; JAK inhibitor	JANUS KINASE INHIBITOR; DOUBLE-BLIND; DELGOCITINIB OINTMENT; ADULT PATIENTS; OPEN-LABEL; EFFICACY; SAFETY; ABROCITINIB; DUPILUMAB; CHILDREN	Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous presentation and often immense patient burden. Safe, targeted treatment options are currently limited. This focused review of the published literature, including clinical trial results, case reports, and abstracts, as well as presentations from scientific meetings and data from industry press releases, describes the use of topical and systemic Janus kinase (JAK) inhibitors in the treatment of AD. New topical JAK inhibitors include ruxolitinib (JAK1/2) and delgocitinib (pan-JAK). Ruxolitinib cream met all primary and secondary endpoints in phase 3 clinical trials for mild-to moderate AD with minimal treatment-emergent adverse events. Delgocitinib ointment was recently approved in Japan for pediatric and adult AD. Oral JAK inhibitors include baricitinib (JAK1/2), abrocitinib (JAK1-selective), and upadacitinib (JAK1-selective). All 3 met primary and secondary endpoints across numerous trials for moderate-to-severe AD. Treatment emergent adverse events were mainly mild to moderate and included acne, nausea, headache, upper respiratory tract infection, and to a lesser degree, herpes infection and selected laboratory abnormalities. JAK inhibitors hold great promise as the next generation of targeted AD therapy. While their outstanding efficacy is balanced by a favorable safety profile in clinical trials, real-world data are needed to better understand long-term safety, durability, and treatment success. (J Allergy Clin Immunol 2021;148:927-40.)	[Chovatiya, Raj; Paller, Amy S.] Northwestern Univ, Sch Med, Dept Dermatol, 676 N St Clair St,Suite 1600, Chicago, IL 60611 USA	Northwestern University	Paller, AS (corresponding author), Northwestern Univ, Sch Med, Dept Dermatol, 676 N St Clair St,Suite 1600, Chicago, IL 60611 USA.	apaller@northwestern.edu						Alexis A, 2020, ANN ALLERG ASTHMA IM, V125, pS51; [Anonymous], 2020, JT REC MAN MARK APPR; [Anonymous], 2021, JT REC APPR CORECTIM; Bao Lei, 2013, JAKSTAT, V2, pe24137, DOI 10.4161/jkst.24137; Bhutani T, 2020, ANN ALLERG ASTHMA IM, V125, pS50; Bieber T, 2021, J EUR ACAD DERMATOL, V35, P476, DOI 10.1111/jdv.16948; Bieber T, 2021, NEW ENGL J MED, V384, P1101, DOI 10.1056/NEJMoa2019380; Bin LH, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0158-5; Bissonnette R, 2019, BRIT J DERMATOL, V181, P733, DOI 10.1111/bjd.17932; Bissonnette R, 2016, BRIT J DERMATOL, V175, P902, DOI 10.1111/bjd.14871; Blauvelt A, 2021, J AM ACAD DERMATOL, V85, pAB121; Blauvelt A, 2017, LANCET, V389, P2287, DOI 10.1016/S0140-6736(17)31191-1; Boguniewicz M, 2018, ANN ALLERG ASTHMA IM, V120, P10, DOI 10.1016/j.anai.2017.10.039; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Clark JD, 2014, J MED CHEM, V57, P5023, DOI 10.1021/jm401490p; Czarnowicki T, 2020, J ALLERGY CLIN IMMUN, V145, P215, DOI 10.1016/j.jaci.2019.09.031; Czarnowicki T, 2019, J ALLERGY CLIN IMMUN, V143, P1, DOI 10.1016/j.jaci.2018.10.032; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Damsky W, 2017, J AM ACAD DERMATOL, V76, P736, DOI 10.1016/j.jaad.2016.12.005; Eichenfield L, 2021, J ALLERGY CLIN IMMUN, V147, pAB146; Eichenfield LF, 2021, J AM ACAD DERMATOL, V85, pAB179; Eichenfield LF, 2014, J AM ACAD DERMATOL, V71, P116, DOI 10.1016/j.jaad.2014.03.023; Ferreira SB, 2020, CLIN CASE REP, V8, P3243, DOI 10.1002/ccr3.3325; Fuxench ZCC, 2019, J INVEST DERMATOL, V139, P583, DOI 10.1016/j.jid.2018.08.028; Ghoreschi K, 2011, J IMMUNOL, V186, P4234, DOI 10.4049/jimmunol.1003668; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gooderham MJ, 2021, BRIT J DERMATOL, V184, pE72; Gooderham M, 2021, J AM ACAD DERMATOL, V85, pAB77; Gooderham MJ, 2019, JAMA DERMATOL, V155, P1371, DOI 10.1001/jamadermatol.2019.2855; Guttman-Yassky E, 2021, LANCET, V397, P2151, DOI 10.1016/S0140-6736(21)00588-2; Guttman-Yassky E, 2020, J ALLERGY CLIN IMMUN, V145, P877, DOI 10.1016/j.jaci.2019.11.025; Guttman-Yassky E, 2019, J AM ACAD DERMATOL, V80, P913, DOI 10.1016/j.jaad.2018.01.018; Hua T, 2018, ANN ALLERG ASTHMA IM, V121, P622, DOI 10.1016/j.anai.2018.07.019; Kim BS, 2020, J AM ACAD DERMATOL, V82, P1305, DOI 10.1016/j.jaad.2020.02.009; Kim BS, 2020, J ALLERGY CLIN IMMUN, V145, P572, DOI 10.1016/j.jaci.2019.08.042; King B, 2021, AM J CLIN DERMATOL, V22, P395, DOI 10.1007/s40257-021-00602-x; Landis M., 2020, P EUR AC DERM VEN VI; Leung DYM, 2013, ALLERGOL INT, V62, P151, DOI 10.2332/allergolint.13-RAI-0564; Levy LL, 2015, J AM ACAD DERMATOL, V73, P395, DOI 10.1016/j.jaad.2015.06.045; Lin CPL, 2019, J AM ACAD DERMATOL, V80, P1451, DOI 10.1016/j.jaad.2018.10.054; Lio P, 2021, J AM ACAD DERMATOL, V85, pAB113; Morris Gabriela M, 2018, JAAD Case Rep, V4, P515, DOI 10.1016/j.jdcr.2017.12.016; Nakagawa H, 2018, BRIT J DERMATOL, V178, P424, DOI 10.1111/bjd.16014; Nakagawa H, 2021, J AM ACAD DERMATOL, V85, pAB52; Nakagawa H, 2020, J AM ACAD DERMATOL, V82, P823, DOI 10.1016/j.jaad.2019.12.015; Nakagawa H, 2020, J DERMATOL, V47, P114, DOI 10.1111/1346-8138.15173; Nakagawa H, 2019, J ALLERGY CLIN IMMUN, V144, P1575, DOI 10.1016/j.jaci.2019.08.004; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Paller AS, 2020, J AM ACAD DERMATOL, V83, P375, DOI 10.1016/j.jaad.2020.03.075; Paller AS, 2020, J AM ACAD DERMATOL, V83, P1282, DOI 10.1016/j.jaad.2020.06.054; Paller AS, 2016, J AM ACAD DERMATOL, V75, P494, DOI 10.1016/j.jaad.2016.05.046; Papp K, 2020, BRIT J DERMATOL, V183, pE116; Papp K, EUR AC DERM VEN VIRT; Peterson Danielle M, 2021, JAAD Case Rep, V10, P4, DOI 10.1016/j.jdcr.2021.01.020; Reich K, EUR AC DERM VEN VIRT; Reich K, 2020, JAMA DERMATOL, V156, P1333, DOI 10.1001/jamadermatol.2020.3260; Reitamo S, 2000, ARCH DERMATOL, V136, P999, DOI 10.1001/archderm.136.8.999; Renert-Yuval Y, 2021, J ALLERGY CLIN IMMUN, V148, P148, DOI 10.1016/j.jaci.2021.01.001; Schlessinger J, 2020, AM J CLIN DERMATOL, V21, P275, DOI 10.1007/s40257-020-00510-6; Schwartz DM, 2016, NAT REV RHEUMATOL, V12, P25, DOI 10.1038/nrrheum.2015.167; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P327, DOI 10.1016/j.jaad.2014.03.030; Silverberg JI, 2022, J ALLERGY CLIN IMMUN, V149, P977, DOI 10.1016/j.jaci.2021.07.036; Silverberg JI, 2021, JAMA DERMATOL, V157, P691, DOI 10.1001/jamadermatol.2021.1273; Silverberg JI, 2020, JAMA DERMATOL, V156, P863, DOI 10.1001/jamadermatol.2020.1406; Silverberg JI, 2019, J ALLER CL IMM-PRACT, V7, P2699, DOI 10.1016/j.jaip.2019.05.055; Silverberg JI, 2019, ANN ALLERG ASTHMA IM, V123, P144, DOI 10.1016/j.anai.2019.04.020; Silverberg JI, 2019, J ALLER CL IMM-PRACT, V7, P1246, DOI 10.1016/j.jaip.2018.11.043; Silverberg JI, 2018, ANN ALLERG ASTHMA IM, V121, P604, DOI 10.1016/j.anai.2018.07.042; Silverberg JI, 2018, ANN ALLERG ASTHMA IM, V121, P340, DOI 10.1016/j.anai.2018.07.006; Silverberg JI, 2017, CLIN DERMATOL, V35, P360, DOI 10.1016/j.clindermatol.2017.03.008; Silverberg JI, 2014, DERMATITIS, V25, P107, DOI 10.1097/DER.0000000000000034; Silverberg JI, 2013, PEDIAT ALLERG IMM-UK, V24, P476, DOI 10.1111/pai.12095; Simpson EL, 2020, BRIT J DERMATOL, V183, P242, DOI 10.1111/bjd.18898; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson E, 2020, J AM ACAD DERMATOL, V83, P839, DOI 10.1016/j.jaad.2020.04.104; Simpson EL, 2021, J AM ACAD DERMATOL, V85, pAB121; Simpson EL, 2021, J AM ACAD DERMATOL, V85, pAB178; Simpson EL, 2021, J AM ACAD DERMATOL, V85, P62, DOI 10.1016/j.jaad.2021.02.028; Simpson EL, 2020, LANCET, V396, P255, DOI 10.1016/S0140-6736(20)30732-7; Simpson EL, 2020, JAMA DERMATOL, V156, P44, DOI 10.1001/jamadermatol.2019.3336; Smith S, 2020, J AM ACAD DERMATOL, V83, pAB170; Soerensen P, 2021, J AM ACAD DERMATOL, V85, pAB121; Sofen H, EUR AC DERM VEN VIRT; Tanimoto A, 2018, EXP DERMATOL, V27, P22, DOI 10.1111/exd.13370; US Food and Drug Administration, 2019, JAKAFI RUX HIGHL PRE; US Food and Drug Administration, 2020, XELJANZ TOF HIGHL PR; US Food and Drug Administration, 2020, DUPIXENT DUP HIGHL P; US Food and Drug Administration, 2020, EUCRISA CRIS HIGHL P; US Food and Drug Administration, 2018, OLUMIANT BAR HIGHL P; Wollenberg A, 2021, J EUR ACAD DERMATOL, V35, P1543, DOI 10.1111/jdv.17278; Wollenberg A, 2018, J EUR ACAD DERMATOL, V32, P657, DOI 10.1111/jdv.14891; Wollenberg A, 2021, DERMATITIS, DOI [10.1097/DER.0000000000000725, DOI 10.1097/DER.0000000000000725]; Worm M, 2020, BRIT J DERMATOL, V182, P1103, DOI 10.1111/bjd.18469; Yamamoto Y, 2020, J DERMATOL SCI, V97, P161, DOI 10.1016/j.jdermsci.2019.12.008; Yew YW, 2019, J AM ACAD DERMATOL, V80, P390, DOI 10.1016/j.jaad.2018.09.035; Yosipovitch G, 2019, BRIT J DERMATOL, V181, P761, DOI 10.1111/bjd.17744; Yosipovitch G, 2018, J ALLERGY CLIN IMMUN, V142, P1375, DOI 10.1016/j.jaci.2018.09.005; Yu SH, 2016, DERMATITIS, V27, P50, DOI 10.1097/DER.0000000000000161	99	32	33	4	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2021	148	4					927	940		10.1016/j.jaci.2021.08.009	http://dx.doi.org/10.1016/j.jaci.2021.08.009		OCT 2021	14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD6BK	34437922				2022-12-18	WOS:000705023300002
J	Chou, JE; Platt, CD; Habiballah, S; Nguyen, AA; Elkins, M; Weeks, S; Peters, Z; Day-Lewis, M; Novak, T; Armant, M; Williams, L; Rockowitz, S; Sliz, P; Williams, DA; Randolph, AG; Geha, RS				Chou, Janet; Platt, Craig D.; Habiballah, Saddiq; Nguyen, Alan A.; Elkins, Megan; Weeks, Sabrina; Peters, Zachary; Day-Lewis, Megan; Novak, Tanya; Armant, Myriam; Williams, Lucinda; Rockowitz, Shira; Sliz, Piotr; Williams, David A.; Randolph, Adrienne G.; Geha, Raif S.		Taking COVID-19 Together Study Inv	Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Multisystem inflammatory syndrome in children; MIS-C; COVID-19; SARS-CoV-2; whole exome sequencing	HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; XIAP; IMMUNODEFICIENCY; INFECTION; DISEASE	Background: Multisystem inflammatory syndrome in children (MIS-C) is a pediatric complication of severe acute respiratory syndrome coronavirus 2 infection that is characterized by multiorgan inflammation and frequently by cardiovascular dysfunction. It occurs predominantly in otherwise healthy children. We previously reported haploinsufficiency of suppressor of cytokine signaling 1 (SOCS1), a negative regulator of type I and II interferons, as a genetic risk factor for MIS-C. Objectives: We aimed to identify additional genetic mechanisms underlying susceptibility to severe acute respiratory syndrome coronavirus 2-associated MIS-C. Methods: In a single-center, prospective cohort study, whole exome sequencing was performed on patients with MIS-C. The impact of candidate variants was tested by using patients' PBMCs obtained at least 7 months after recovery. Results: We enrolled 18 patients with MIS-C (median age = 8 years; interquartile range = 5-12.25 years), of whom 89% had no conditions other than obesity. In 2 boys with no significant infection history, we identified and validated hemizygous deleterious defects in XIAP, encoding X-linked inhibitor of apoptosis, and CYBB, encoding cytochrome b-245, beta subunit. Including the previously reported SOCS1 haploinsufficiency, a genetic diagnosis was identified in 3 of 18 patients (17%). In contrast to patients with mild COVID-19, patients with defects in SOCS1, XIAP, or CYBB exhibit an inflammatory immune cell transcriptome with enrichment of differentially expressed genes in pathways downstream of IL-18, oncostatin M, and nuclear factor KB, even after recovery. Conclusions: Although inflammatory disorders are rare in the general population, our cohort of patients with MIS-C was enriched for monogenic susceptibility to inflammation. Our results support the use of next-generation sequencing in previously healthy children who develop MIS-C.	[Chou, Janet; Platt, Craig D.; Habiballah, Saddiq; Nguyen, Alan A.; Elkins, Megan; Weeks, Sabrina; Peters, Zachary; Day-Lewis, Megan; Geha, Raif S.] Harvard Med Sch, Div Immunol, Boston, MA 02115 USA; [Novak, Tanya; Randolph, Adrienne G.] Harvard Med Sch, Div Crit Care Med, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02115 USA; [Armant, Myriam] Harvard Med Sch, TransLab, Boston, MA 02115 USA; [Williams, Lucinda] Harvard Med Sch, Inst Ctr Clin & Translat Res, Boston, MA 02115 USA; [Rockowitz, Shira; Sliz, Piotr] Harvard Med Sch, Computat Hlth Informat Program, Boston, MA 02115 USA; [Rockowitz, Shira; Sliz, Piotr] Harvard Med Sch, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA; [Williams, David A.] Harvard Med Sch, Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; [Williams, David A.] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Williams, David A.] Harvard Med Sch, Boston Childrens Hosp, Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Chou, JE (corresponding author), 1 Blackfan Circle,Karp Bldg,10th Floor, Boston, MA 02115 USA.	Janet.Chou@childrens.harvard.edu	Kahn, Stacy/V-5807-2017	Kahn, Stacy/0000-0002-8001-6955; Randolph, Adrienne/0000-0002-3084-3071; Roberts, Jordan/0000-0002-0976-5697	National Institute of Allergy and Infectious Diseases [R01-AI139633, R01-AI139633-S1, R01-AI154470]; Centers for Disease Control and Prevention [75D30120C07725]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [R21-HD095228]; Per-kin Fund; Samara Jan Turkel Center for Autoimmune Diseases; Institutional Centers for Clinical and Translational Research at Boston Children's Hospital; Children's Rare Disease Cohorts initiative at Boston Children's Hospital	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Per-kin Fund; Samara Jan Turkel Center for Autoimmune Diseases; Institutional Centers for Clinical and Translational Research at Boston Children's Hospital; Children's Rare Disease Cohorts initiative at Boston Children's Hospital	Supported by the National Institute of Allergy and Infectious Diseases (grants R01-AI139633 [to R.S.G.] , R01-AI139633-S1 [to R.S.G., J.C., and A.G.R.] ,R01-AI154470 [to A.G.R.] , the Centers for Disease Control and Prevention (grant 75D30120C07725 [to A.G.R. and J.C.] ) , the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant R21-HD095228 [to A.G.R.] ) , the Per-kin Fund (to R.S.G.) , and the Samara Jan Turkel Center for Autoimmune Diseases (to J.C.) , as well as by the Institutional Centers for Clinical and Translational Research and the Children's Rare Disease Cohorts initiative at Boston Children's Hospital.	Ammann S, 2014, CLIN EXP IMMUNOL, V176, P394, DOI 10.1111/cei.12306; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Bai BC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02985-x; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Hsieh WC, 2014, BLOOD, V124, P2847, DOI 10.1182/blood-2014-03-564609; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Lee PY, 2020, J ALLERGY CLIN IMMUN, V146, P1194, DOI 10.1016/j.jaci.2020.07.033; Marsh RA, 2010, BLOOD, V116, P1079, DOI 10.1182/blood-2010-01-256099; Marsh RA, 2009, CYTOM PART B-CLIN CY, V76B, P334, DOI 10.1002/cyto.b.20473; Meissner F, 2010, BLOOD, V116, P1570, DOI 10.1182/blood-2010-01-264218; Meyts I, 2021, J ALLERGY CLIN IMMUN, V147, P520, DOI 10.1016/j.jaci.2020.09.010; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nakao A, 2004, NUCLEIC ACIDS RES, V32, pD168, DOI 10.1093/nar/gkh004; Network TCHA, 2020, MULT INFL SYNDR CHIL; Philipp J, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a036426; Pothlichet J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003256; Rockowitz S, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-020-0137-0; Sancho-Shimizu V, 2021, J EXP MED, V218, DOI 10.1084/jem.20210446; Spaccamela VM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02236; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sweeny KF, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-027763; Thaventhiran JED, 2020, NATURE, V583, P90, DOI 10.1038/s41586-020-2265-1; van de Geer A, 2018, J CLIN INVEST, V128, P3957, DOI 10.1172/JCI97116; van der Made CI, 2020, JAMA-J AM MED ASSOC, V324, P663, DOI 10.1001/jama.2020.13719; Wada T, 2014, CYTOKINE, V65, P74, DOI 10.1016/j.cyto.2013.09.007; Yabal M, 2014, CELL REP, V7, P1796, DOI 10.1016/j.celrep.2014.05.008; Zhao YC, 2021, CELL RES, V31, P818, DOI 10.1038/s41422-021-00495-9	29	32	34	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2021	148	3					732	+		10.1016/j.jaci.2021.06.024	http://dx.doi.org/10.1016/j.jaci.2021.06.024		SEP 2021	8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UP2VR	34224783	Green Published			2022-12-18	WOS:000695242900021
J	Davis, CM; Apter, AJ; Casillas, A; Foggs, MB; Louisias, M; Morris, EC; Nanda, A; Nelson, MR; Ogbogu, PU; Walker-McGill, CL; Wang, JL; Perry, TT				Davis, Carla M.; Apter, Andrea J.; Casillas, Adrian; Foggs, Michael B.; Louisias, Margee; Morris, Elsie C.; Nanda, Anil; Nelson, Michael R.; Ogbogu, Princess U.; Walker-McGill, Cheryl Lynn; Wang, Julie; Perry, Tamara T.			Health disparities in allergic and immunologic conditions in racial and ethnic underserved populations: A Work Group Report of the AAAAI Committee on the Underserved	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Health disparities; allergic rhinitis; asthma; atopic dermatitis; primary immunodeficiency; drug allergy; food allergy; coronavirus disease 2019	PRIMARY IMMUNODEFICIENCY DISEASES; ASTHMA CARE COORDINATION; UNITED-STATES; ATOPIC-DERMATITIS; FOOD ALLERGY; SOCIOECONOMIC-STATUS; SOCIAL DETERMINANTS; ECZEMA PREVALENCE; CLINICAL-TRIALS; AGED CHILDREN	Health disparities are health differences linked with economic, social, and environmental disadvantage. They adversely affect groups that have systematically experienced greater social or economic obstacles to health. Renewed efforts are needed to reduced health disparities in the United States, highlighted by the disparate impact on racial minorities during the coronavirus pandemic. Institutional or systemic patterns of racism are promoted and legitimated through accepted societal standards, and organizational processes within the field of medicine, and contribute to health disparities. Herein, we review current evidence regarding health disparities in allergic rhinitis, asthma, atopic dermatitis, food allergy, drug allergy, and primary immune deficiency disease in racial and ethnic underserved populations. Best practices to address these disparities involve addressing social determinants of health and adopting policies to improve access to specialty care and treatment for the underserved through telemedicine and community partnerships, cross-cultural provider training to reduce implicit bias, inclusion of underserved patients in research, implementation of culturally competent patient education, and recruitment and training of health care providers from underserved communities. Addressing health disparities requires a multilevel approach involving patients, health providers, local agencies, professional societies, and national governmental agencies. (J Allergy Clin Immunol 2021;147:1579-93.)	[Davis, Carla M.] Baylor Coll Med, Houston, TX USA; [Davis, Carla M.] Texas Childrens Hosp, Food Allergy Program, Houston, TX USA; [Apter, Andrea J.] Univ Penn, Perelman Sch Med, Philadelphia, PA USA; [Casillas, Adrian] Texas Tech Hlth Sci Ctr, Sierra Providence Med Partners, El Paso, TX USA; [Foggs, Michael B.] Advocate Aurora Hlth Clin, Advocate Med Grp, Chicago, IL USA; [Louisias, Margee] Harvard Med Sch, Brig Ham & Womens Hosp, Boston Childrens Hosp, Boston, MA USA; [Morris, Elsie C.] Allergy Asthma & Immunol, Pittsburgh, PA USA; [Nanda, Anil] Asthma & Allergy Ctr, Lewisville, TX USA; [Nanda, Anil] Asthma & Allergy Ctr, Flower Mound, TX USA; [Nanda, Anil] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Nelson, Michael R.] Walter Reed Natl Mil Med Ctr, Allergy Immunol Serv, Bethesda, MD USA; [Ogbogu, Princess U.] Case Western Reserve Univ, Rainbow Babies & Children, UH Cleveland Med Ctr, Cleveland, OH USA; [Walker-McGill, Cheryl Lynn] Carolina Complete Hlth, Charlotte, NC USA; [Walker-McGill, Cheryl Lynn] Wingate Univ, Grad Sch Business, Charlotte, NC USA; [Wang, Julie] Icahn Sch Med Mt Sinai, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY USA; [Perry, Tamara T.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Perry, Tamara T.] Arkansas Childrens Res Inst, Little Rock, AR USA	Baylor College of Medicine; Baylor College of Medicine; University of Pennsylvania; Pennsylvania Medicine; Texas Tech University System; Texas Tech University Health Science Center; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Texas System; University of Texas Southwestern Medical Center Dallas; Walter Reed National Military Medical Center; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Icahn School of Medicine at Mount Sinai; University of Arkansas System; University of Arkansas Medical Sciences	Davis, CM (corresponding author), 1102 Bates Ave,MC 330-01, Houston, TX 77030 USA.	carlad@bcm.edu	Nelson, Michael Shawn/GXF-4934-2022; Ojakorotu, Chukwuamaka/ABF-5973-2021					Abuabara K, 2020, J ALLERGY CLIN IMMUN, V145, P192, DOI 10.1016/j.jaci.2019.06.044; Acevedo MJ, 2019, BIOL BLOOD MARROW TR, V25, P1666, DOI 10.1016/j.bbmt.2019.04.008; Adler NE, 2016, JAMA-J AM MED ASSOC, V316, P1641, DOI 10.1001/jama.2016.14058; Akinbami LJ, TRENDS ASTHMA PREVAL; Ali A, 2019, CAN RESPIR J, V2019, DOI 10.1155/2019/5165189; Anderson WC, 2019, ANN ALLERG ASTHMA IM, V122, P367, DOI 10.1016/j.anai.2019.01.018; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Apter AJ, 2019, J ALLERGY CLIN IMMUN, V144, P846, DOI 10.1016/j.jaci.2019.05.030; Apter AJ, 2009, J ALLERGY CLIN IMMUN, V123, P1237, DOI 10.1016/j.jaci.2009.04.028; Baptist AP, 2020, J ALLER CL IMM-PRACT, V8, P3371, DOI 10.1016/j.jaip.2020.09.015; Baram M, 2013, J ALLER CL IMM-PRACT, V1, P442, DOI 10.1016/j.jaip.2013.07.005; Barker JN, 2019, BLOOD ADV, V3, P939, DOI 10.1182/bloodadvances.2018028662; Barker JN, 2010, BIOL BLOOD MARROW TR, V16, P1541, DOI 10.1016/j.bbmt.2010.08.011; Bergmark RW, 2016, OTOLARYNG HEAD NECK, V155, P790, DOI 10.1177/0194599816658018; Bhattacharya T, 2014, JAMA DERMATOL, V150, P1232, DOI 10.1001/jamadermatol.2014.1674; Bilaver LA, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3678; Bird JA, 2015, J ALLER CL IMM-PRACT, V3, P1, DOI 10.1016/j.jaip.2014.06.008; Blake K, 2013, PULM PHARMACOL THER, V26, P342, DOI 10.1016/j.pupt.2013.01.009; Bloom Barbara, 2006, Vital Health Stat 10, P1; Boguniewicz M, 2017, J ALLER CL IMM-PRACT, V5, P1519, DOI 10.1016/j.jaip.2017.08.005; Bollinger ME, 2019, ANN ALLERG ASTHMA IM, V122, P381, DOI 10.1016/j.anai.2019.02.002; Bonham VL, 2016, NEW ENGL J MED, V374, P2003, DOI 10.1056/NEJMp1511294; Braveman P, 2014, PUBLIC HEALTH REP, V129, P5, DOI 10.1177/00333549141291S203; Bruzzese JM, 2019, J ALLERGY CLIN IMMUN, V143, P550, DOI 10.1016/j.jaci.2018.10.031; Bryant-Stephens T, 2016, J ALLERGY CLIN IMMUN, V138, P1526, DOI 10.1016/j.jaci.2016.10.006; Bryant-Stephens Tyra, 2009, Am J Public Health, V99 Suppl 3, pS657, DOI 10.2105/AJPH.2009.165423; Bryant-Stephens T, 2011, J URBAN HEALTH, V88, pS156, DOI 10.1007/s11524-010-9518-5; Buster KJ, 2012, DERMATOL CLIN, V30, P53, DOI 10.1016/j.det.2011.08.002; CDC.gov, 2019, CDC ASTHM MOST REC A; CDC.gov, 2019, CDC ASTHM DAT SURV A; Centers for Disease Control and Prevention, ASTHM STAT UNC ASTHM; Charrow A, 2017, JAMA DERMATOL, V153, P193, DOI 10.1001/jamadermatol.2016.4129; Chen E, 2016, PSYCHOSOM MED, V78, P1043, DOI 10.1097/PSY.0000000000000392; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Cunningham-Rundles C, 2004, J ALLERGY CLIN IMMUN, V113, P747, DOI 10.1016/j.jaci.2004.01.761; Daya M, 2019, ANN ALLERG ASTHMA IM, V122, P456, DOI 10.1016/j.anai.2019.02.009; Delaigue S, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00233; Dilley MA, 2019, PEDIAT ALLERG IMM-UK, V30, P363, DOI 10.1111/pai.13019; Dunlop JH, 2018, IMMUNOL ALLERGY CLIN, V38, P13, DOI 10.1016/j.iac.2017.09.002; Dykewicz MS, 2017, ANN ALLERG ASTHMA IM, V119, P489, DOI 10.1016/j.anai.2017.08.012; Egan M, 2019, J ALLER CL IMM-PRACT, V7, P655, DOI 10.1016/j.jaip.2018.05.021; Esteban CA, 2014, PEDIAT ALLER IMM PUL, V27, P75, DOI 10.1089/ped.2014.0344; Everhart RO, 2014, ANN ALLERG ASTHMA IM, V112, P365, DOI 10.1016/j.anai.2014.02.002; Fitzpatrick AM, 2019, J ALLERGY CLIN IMMUN, V143, P2052, DOI 10.1016/j.jaci.2018.11.022; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; George M, 2019, J ADV NURS, V75, P876, DOI 10.1111/jan.13916; George M, 2014, J ALLERGY CLIN IMMUN, V134, P1252, DOI 10.1016/j.jaci.2014.07.044; Greenhawt M, 2013, J ALLER CL IMM-PRACT, V1, P378, DOI 10.1016/j.jaip.2013.04.009; Gupta RS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.5630; Gupta RS, 2009, ANN ALLERG ASTHMA IM, V103, P43, DOI 10.1016/S1081-1206(10)60142-1; Halterman JS, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2017.4938; Hankin CS, 2008, J ALLERGY CLIN IMMUN, V121, P227, DOI 10.1016/j.jaci.2007.10.026; Hannaway PJ, 2005, ANN ALLERG ASTHMA IM, V95, P143, DOI 10.1016/S1081-1206(10)61203-3; HANSEN JA, 1994, TRANSPLANT P, V26, P1710; Harris K, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011651.pub2; Hasegawa K, 2015, ANN ALLERG ASTHMA IM, V115, P10, DOI 10.1016/j.anai.2015.05.004; Hirano SA, 2012, PEDIATR DERMATOL, V29, P749, DOI 10.1111/j.1525-1470.2012.01797.x; Hollenbach JP, 2014, J ALLERGY CLIN IMMUN, V134, P1245, DOI 10.1016/j.jaci.2014.10.014; Hui JW, 2017, ANN ALLERG ASTHMA IM, V118, P685, DOI 10.1016/j.anai.2017.03.009; Jacobs TS, 2014, J ALLERGY CLIN IMMUN, V134, P737, DOI 10.1016/j.jaci.2014.03.028; Janevic MR, 2017, J ASTHMA, V54, P514, DOI 10.1080/02770903.2016.1242136; Janevic MR, 2016, AM J PUBLIC HEALTH, V106, P2012, DOI 10.2105/AJPH.2016.303373; Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018; Joseph CLM, 2016, ANN ALLERG ASTHMA IM, V116, P219, DOI 10.1016/j.anai.2015.12.019; Karnick P, 2007, J ASTHMA, V44, P39, DOI 10.1080/02770900601125391; Kaufman BP, 2018, EXP DERMATOL, V27, P340, DOI 10.1111/exd.13514; Keefe KR, 2018, AM J RHINOL ALLERGY, V32, P473, DOI 10.1177/1945892418793518; Keet CA, 2014, ANN ALLERG ASTHMA IM, V112, P222, DOI 10.1016/j.anai.2013.12.007; Keller SF, 2018, ANN RHEUM DIS, V77, P1188, DOI 10.1136/annrheumdis-2017-212905; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Kiechle ES, 2018, J MED TOXICOL, V14, P272, DOI 10.1007/s13181-018-0671-7; Kim CH, 2020, ACAD PEDIATR, V20, P893, DOI 10.1016/j.acap.2020.05.008; King Gary, 1996, Ethnicity and Disease, V6, P30; Kinney PL, 2000, ENVIRON HEALTH PERSP, V108, P213, DOI 10.2307/3454436; Kit BK, 2012, PEDIATRICS, V129, P62, DOI 10.1542/peds.2011-1513; Kobrynski L, 2014, J CLIN IMMUNOL, V34, P954, DOI 10.1007/s10875-014-0102-8; Lagarde M, 2017, SOC SCI MED, V179, P147, DOI 10.1016/j.socscimed.2017.03.002; Landrigan PJ, 2018, LANCET, V391, P462, DOI 10.1016/S0140-6736(17)32345-0; Leung J, 2018, J CLIN IMMUNOL, V38, P717, DOI 10.1007/s10875-018-0534-7; Louisias M, 2019, CLIN PEDIATR, V58, P586, DOI 10.1177/0009922819832087; Lu DG, 2017, J ASTHMA, V54, P504, DOI 10.1080/02770903.2016.1238927; Lu N, 2016, SEMIN ARTHRITIS RHEU, V46, P253, DOI 10.1016/j.semarthrit.2016.03.014; Mahdavinia M, 2017, J ALLER CL IMM-PRACT, V5, P352, DOI 10.1016/j.jaip.2016.10.006; Margolis DJ, 2014, J ALLERGY CLIN IMMUN, V133, P784, DOI 10.1016/j.jaci.2013.09.015; Margolis DJ, 2012, J ALLERGY CLIN IMMUN, V130, P912, DOI 10.1016/j.jaci.2012.07.008; Matsui EC, 2017, JAMA-J AM MED ASSOC, V317, P1027, DOI 10.1001/jama.2016.21048; McGowan EC, 2020, J ALLER CL IMM-PRACT, V8, P2796, DOI 10.1016/j.jaip.2020.04.009; McKenzie C, 2019, ANN ALLERG ASTHMA IM, V123, P173, DOI 10.1016/j.anai.2019.05.014; Melton C, 2014, J ASTHMA, V51, P703, DOI 10.3109/02770903.2014.906605; Meltzer EO, 2007, CLIN THER, V29, P1428, DOI 10.1016/j.clinthera.2007.07.013; Merriman JA, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00295-16; Nolte F, 2006, RESP MED, V100, P354, DOI 10.1016/j.rmed.2005.05.012; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ortega VE, 2014, LANCET RESP MED, V2, P204, DOI 10.1016/S2213-2600(13)70289-3; Parekh TM, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0878-7; Penman-Aguilar A, 2016, J PUBLIC HEALTH MAN, V22, pS33, DOI 10.1097/PHH.0000000000000373; Purnell TS, 2016, HEALTH AFFAIR, V35, P1410, DOI 10.1377/hlthaff.2016.0158; Ramamoorthy A, 2015, CLIN PHARMACOL THER, V97, P263, DOI 10.1002/cpt.61; Reinhart Kurt, 2008, Pharmacy Pract (Granada), V6, P197; Reynolds KC, 2018, J PEDIATR PSYCHOL, V43, P943, DOI 10.1093/jpepsy/jsy027; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Sedaghat AR, 2016, J ALLER CL IMM-PRACT, V4, P82, DOI 10.1016/j.jaip.2015.09.006; Shah SS, 2014, J ALLER CL IMM-PRACT, V2, P288, DOI 10.1016/j.jaip.2013.09.016; Shaw MG, 2009, J NATL MED ASSOC, V101, P900, DOI 10.1016/S0027-9684(15)31037-3; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Silverberg JI, 2013, J ALLERGY CLIN IMMUN, V132, P1132, DOI 10.1016/j.jaci.2013.08.031; Silverberg JI, 2013, PEDIAT ALLERG IMM-UK, V24, P476, DOI 10.1111/pai.12095; Sousa-Pinto B, 2017, ANN ALLERG ASTHMA IM, V119, P362, DOI 10.1016/j.anai.2017.07.009; Stevenson MD, 2007, J PEDIATR-US, V151, P187, DOI 10.1016/j.jpeds.2007.03.001; Su JG, 2017, ENVIRON HEALTH PERSP, V125, P254, DOI 10.1289/EHP266; Szefler SJ, 2016, ALLERGY ASTHMA PROC, V37, P4, DOI 10.2500/aap.2016.37.3906; Szychlinski C, 2015, J ALLER CL IMM-PRACT, V3, P805, DOI 10.1016/j.jaip.2015.04.017; Taylor-Black S, 2012, ANN ALLERG ASTHMA IM, V109, P431, DOI 10.1016/j.anai.2012.09.012; Taylor-Black SA, 2014, ANN ALLERG ASTHMA IM, V112, P554, DOI 10.1016/j.anai.2014.03.020; Togias A, 2019, J ALLERGY CLIN IMMUN, V143, P1003, DOI 10.1016/j.jaci.2018.07.041; Turnbull S, 2020, J MED INTERNET RES, V22, DOI 10.2196/17849; Turner PJ, 2017, J ALLER CL IMM-PRACT, V5, P1169, DOI 10.1016/j.jaip.2017.06.031; U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion, HLTH PEOPL 2030; Unequal treatment, 2003, UN TREATM CONFR RAC, DOI [10.17226/12875, DOI 10.17226/12875]; Vachiramon V, 2012, PEDIATR DERMATOL, V29, P395, DOI 10.1111/j.1525-1470.2012.01740.x; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; Weinstein JN, NATL ACAD SCI ENG ME; Wells KE, 2016, J ALLERGY CLIN IMMUN, V137, P1364, DOI 10.1016/j.jaci.2015.12.1334; Wheatley LM, 2015, NEW ENGL J MED, V372, P456, DOI 10.1056/NEJMcp1412282; Williams DR, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16040606; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; Winkelstein JA, 2006, MEDICINE, V85, P193, DOI 10.1097/01.md.0000229482.27398.ad; Wu CL, 2014, J PEDIATR-US, V164, P827, DOI 10.1016/j.jpeds.2013.11.029; Zahran HS, 2018, MMWR-MORBID MORTAL W, V67, P149, DOI 10.15585/mmwr.mm6705e1; Zimmerman FJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6386	133	32	32	3	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2021	147	5					1579	1593		10.1016/j.jaci.2021.02.034	http://dx.doi.org/10.1016/j.jaci.2021.02.034		MAY 2021	15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	RY1MN	33713767				2022-12-18	WOS:000647680800004
J	Damsky, W; Peterson, D; Ramseier, J; Al-Bawardy, B; Chun, H; Proctor, D; Strand, V; Flavell, RA; King, B				Damsky, William; Peterson, Danielle; Ramseier, Julie; Al-Bawardy, Badr; Chun, Hyung; Proctor, Deborah; Strand, Vibeke; Flavell, Richard A.; King, Brett			The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoimmune disease; baricitinib; inflammatory disease; JAK inhibitor; Janus kinase inhibitor; JAK-STAT; ruxolitinib; tofaci-tinib; upadacitinib; cytokine	RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; JAK-STAT; TOFACITINIB CITRATE; MAINTENANCE THERAPY; TREATED PATIENTS; TYROSINE KINASE; ALOPECIA-AREATA; SAFETY PROFILE; RUXOLITINIB	Autoimmune and inflammatory diseases are common and diverse, and they can affect nearly any organ system. Much of the pathogenesis of these diseases is related to dysregulated cytokine activity. Historically, autoimmune and inflammatory diseases have been treated with medications that nonspecifically suppress the immune system. mAbs that block the action of pathogenic cytokines emerged 2 decades ago and have become widely useful. More recently, agents that simultaneously block multiple pathogenic cytokines via inhibition of the downstream Janus kinase (JAK)? signal transducer and activator of transcription pathway have emerged and are becoming increasingly important. These small molecule inhibitors, collectively termed JAK inhibitors, are US Food and Drug Administration?approved in a few autoimmune/ inflammatory disorders and are being evaluated in many others. Here, we review the biology of the JAK?signal transducer and activator of transcription pathway and the use of JAK inhibitors to treat autoimmune and inflammatory diseases across medical subspecialties. (J Allergy Clin Immunol 2021;147:814-26.)	[Damsky, William; Peterson, Danielle; Ramseier, Julie; King, Brett] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [Al-Bawardy, Badr; Proctor, Deborah] Yale Univ, Sch Med, Div Digest Dis, New Haven, CT USA; [Chun, Hyung] Yale Univ, Sch Med, Div Cardiovasc Med, New Haven, CT USA; [Flavell, Richard A.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA; [Flavell, Richard A.] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; [Strand, Vibeke] Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA	Yale University; Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Yale University; Stanford University	Damsky, W; King, B (corresponding author), Yale Sch Med, Dept Dermatol, 333 Cedar St,LCI 501,POB 208059, New Haven, CT 06510 USA.	william.damsky@yale.edu; brett.king@yale.edu			Dermatology Foundation; Ranjini and Ajay Poddar Fund for Dermatologic Diseases Research	Dermatology Foundation; Ranjini and Ajay Poddar Fund for Dermatologic Diseases Research	W.D. is supported by a Career Development Award form the Dermatology Foundation. B.K. is supported by the Ranjini and Ajay Poddar Fund for Dermatologic Diseases Research. R.A.F. is a Howard Hughes Medical Institute Investigator. The funding sources had no direct involvement in this work.	Bach JF, 2018, NAT REV IMMUNOL, V18, P105, DOI 10.1038/nri.2017.111; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Berekmeri A, 2018, EXPERT REV CLIN IMMU, V14, P719, DOI 10.1080/1744666X.2018.1512404; Broglie L, 2017, BLOOD ADV, V1, P1533, DOI 10.1182/bloodadvances.2017007526; Chakraborty D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01236-6; Chan ES, 2015, J INVEST DERMATOL, V135, P2338, DOI 10.1038/jid.2015.216; Cheng E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157376; Clowse MEB, 2016, DRUG SAFETY, V39, P755, DOI 10.1007/s40264-016-0431-z; Cohen S, 2014, ARTHRITIS RHEUMATOL, V66, P2924, DOI 10.1002/art.38779; Cooper GS, 2003, AUTOIMMUN REV, V2, P119, DOI 10.1016/S1568-9972(03)00006-5; Craiglow BG, 2017, J AM ACAD DERMATOL, V76, P29, DOI 10.1016/j.jaad.2016.09.006; Craiglow BG, 2015, JAMA DERMATOL, V151, P1110, DOI 10.1001/jamadermatol.2015.1520; Craiglow BG, 2014, J INVEST DERMATOL, V134, P2988, DOI 10.1038/jid.2014.260; Crispin MK, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89776; Curtis C, 2016, CLIN REV ALLERG IMMU, V50, P240, DOI 10.1007/s12016-015-8506-7; Curtis JR, 2016, ANN RHEUM DIS, V75, P1843, DOI 10.1136/annrheumdis-2016-209131; Curtis JR, 2016, ANN RHEUM DIS, V75, P831, DOI 10.1136/annrheumdis-2014-205847; Damsky W, 2020, J INVEST DERMATOL, V140, P1446, DOI 10.1016/j.jid.2019.12.019; Damsky W, 2020, J ALLERGY CLIN IMMUN, V145, P1708, DOI 10.1016/j.jaci.2020.01.031; Damsky W, 2020, J AM ACAD DERMATOL, V82, P612, DOI 10.1016/j.jaad.2019.05.098; Damsky W, 2018, NEW ENGL J MED, V379, P2540, DOI 10.1056/NEJMoa1805958; Damsky W, 2017, J AM ACAD DERMATOL, V76, P736, DOI 10.1016/j.jaad.2016.12.005; Damsky William E, 2019, JAAD Case Rep, V5, P1018, DOI 10.1016/j.jdcr.2019.07.004; Das R, 2016, BLOOD, V127, P1666, DOI 10.1182/blood-2015-12-684399; Dengler HS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao2151; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524; Enerback C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25282-2; Esteban YM, 2017, PEDIATR ANN, V46, pE309, DOI 10.3928/19382359-20170717-01; Gadina M, 2019, RHEUMATOLOGY, V58, P4, DOI 10.1093/rheumatology/key432; Gadina M, 2018, J LEUKOCYTE BIOL, V104, P499, DOI 10.1002/JLB.5RI0218-084R; Ghoreschi K, 2011, J IMMUNOL, V186, P4234, DOI 10.4049/jimmunol.1003668; Vicent MG, 2019, AM J HEMATOL, V94, P319, DOI 10.1002/ajh.25376; Guttman-Yassky E, 2020, J ALLERGY CLIN IMMUN, V145, P877, DOI 10.1016/j.jaci.2019.11.025; Hanauer S, 2019, CLIN GASTROENTEROL H, V17, P139, DOI 10.1016/j.cgh.2018.07.009; Harigai M, 2019, RHEUMATOLOGY, V58, P34, DOI 10.1093/rheumatology/key287; HENCH PS, 1950, ARCH INTERN MED, V85, P545, DOI 10.1001/archinte.1950.00230100002001; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Hinchcliff M, 2008, AM FAM PHYSICIAN, V78, P961; Hosking AM, 2018, J AM ACAD DERMATOL, V79, P535, DOI 10.1016/j.jaad.2018.04.018; Hu XY, 2007, J LEUKOCYTE BIOL, V82, P237, DOI 10.1189/jlb.1206763; Hurabielle C, 2017, BRIT J DERMATOL, V177, pE206, DOI 10.1111/bjd.15593; Jagasia M, 2020, BLOOD, V135, P1739, DOI 10.1182/blood.2020004823; Jagpal A, 2018, DRUG SAFETY, V41, P545, DOI 10.1007/s40264-018-0639-1; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kaltenecker D, 2019, CYTOKINE, V124, DOI 10.1016/j.cyto.2018.10.010; Khanna DBE, 2019, AM COLL RHEUMATOLOGY, V71; Kheirkhah A, 2017, CORNEA, V36, P799, DOI 10.1097/ICO.0000000000001206; Kim BS, 2020, J ALLERGY CLIN IMMUN, V145, P572, DOI 10.1016/j.jaci.2019.08.042; Kim D, 2020, NAT MED, V26, P236, DOI 10.1038/s41591-019-0733-7; Kim Sa Rang, 2018, JAAD Case Rep, V4, P443, DOI 10.1016/j.jdcr.2017.12.003; King B, 2017, J INVEST DERMATOL, V137, P951, DOI 10.1016/j.jid.2016.10.044; Kornbluth A, 1998, Inflamm Bowel Dis, V4, P328, DOI 10.1002/ibd.3780040415; Kotyla PJ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7492904; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kurtzman DJB, 2016, JAMA DERMATOL, V152, P944, DOI 10.1001/jamadermatol.2016.0866; Levraut M, 2019, ANN RHEUM DIS, V78, P1606, DOI 10.1136/annrheumdis-2019-215387; Li Jiliang, 2013, JAKSTAT, V2, pe23930, DOI 10.4161/jkst.23930; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Ma C, 2019, ALIMENT PHARM THER, V50, P5, DOI 10.1111/apt.15297; Maschalidi S, 2016, BLOOD, V128, P60, DOI 10.1182/blood-2016-02-700013; MASON JW, 1995, NEW ENGL J MED, V333, P269, DOI 10.1056/NEJM199508033330501; Milara J, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0728-9; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; O'Shea JJ, 2013, NEW ENGL J MED, V368, P161, DOI 10.1056/NEJMra1202117; O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014; Olivera PA, 2020, GASTROENTEROLOGY, V158, P1554, DOI 10.1053/j.gastro.2020.01.001; Panes J, 2017, GUT, V66, P1049, DOI 10.1136/gutjnl-2016-312735; Papp K, 2018, NEW ENGL J MED, V379, P1313, DOI 10.1056/NEJMoa1806382; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Ramstein J, 2016, AM J RESP CRIT CARE, V193, P1281, DOI 10.1164/rccm.201507-1499OC; Rashighi M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007811; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Rosmarin D, 2020, LANCET, V396, P110, DOI 10.1016/S0140-6736(20)30609-7; Rotenberg C, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01482-2018; Ruperto N, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-017-0212-y; Salas A, 2020, NAT REV GASTRO HEPAT, V17, P323, DOI 10.1038/s41575-020-0273-0; Sanchez GAM, 2018, J CLIN INVEST, V128, P3041, DOI 10.1172/JCI98814; Sandborn WJ, 2020, J CROHNS COLITIS, V14, P1202, DOI 10.1093/ecco-jcc/jjaa049; Sandborn WJ, 2020, GASTROENTEROLOGY, V158, P2123, DOI 10.1053/j.gastro.2020.01.047; Sandborn WJ, 2019, ALIMENT PHARM THER, V50, P1068, DOI 10.1111/apt.15514; Sandborn WJ, 2019, CLIN GASTROENTEROL H, V17, P1541, DOI 10.1016/j.cgh.2018.11.035; Sandborn WJ, 2017, NEW ENGL J MED, V376, P1723, DOI 10.1056/NEJMoa1606910; Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201; Scott IC, 2018, DRUG SAFETY, V41, P645, DOI 10.1007/s40264-018-0651-5; Silverberg JI, 2020, JAMA DERMATOL, V156, P863, DOI 10.1001/jamadermatol.2020.1406; Simpson EL, 2020, BRIT J DERMATOL, V183, P242, DOI 10.1111/bjd.18898; Sin Jonathan H, 2019, Hematol Oncol Stem Cell Ther, V12, P166, DOI 10.1016/j.hemonc.2017.07.002; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Strand V, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0880-2; Sutton SA, 2005, CLIN IMMUNOL, V115, P51, DOI 10.1016/j.clim.2005.02.006; Tang LY, 2017, J BIOL CHEM, V292, P4302, DOI 10.1074/jbc.M116.773085; Taylor PC, 2019, ARTHRITIS RHEUMATOL, V71, P1042, DOI 10.1002/art.40841; Thomas SJ, 2015, BRIT J CANCER, V113, P365, DOI 10.1038/bjc.2015.233; U.S. Food and Drug Administration, 2019, FDA NEWS REL; U.S. Food and Drug Administration, 2018, FDA NEWS REL; Vanderver A, 2020, NEW ENGL J MED, V383, P986, DOI 10.1056/NEJMc2001362; Verden A, 2018, DRUG SAFETY, V41, P357, DOI 10.1007/s40264-017-0622-2; Vermeire S, 2017, LANCET, V389, P266, DOI 10.1016/S0140-6736(16)32537-5; Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557; Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028; Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691; von Bubnoff N, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5045-7; Wallace DJ, 2018, LANCET, V392, P222, DOI 10.1016/S0140-6736(18)31363-1; Wang A, 2021, J ALLERGY CLIN IMMUN, V147, P1795, DOI 10.1016/j.jaci.2020.10.012; Wang JS, 2020, HAEMATOLOGICA, V105, pE210, DOI 10.3324/haematol.2019.222471; Wang LF, 2015, J INTERN MED, V278, P369, DOI 10.1111/joim.12395; Wang WX, 2020, J SCLERODERMA RELAT, V5, P40, DOI 10.1177/2397198319865367; Wei Jenny J, 2019, JAAD Case Rep, V5, P360, DOI 10.1016/j.jdcr.2019.02.006; Wenzel J, 2016, J INVEST DERMATOL, V136, P1281, DOI 10.1016/j.jid.2016.02.015; Wheeland RG, 2010, DERMATOL SURG, V36, P1231, DOI 10.1111/j.1524-4725.2010.01614.x; Winthrop KL, 2016, ANN RHEUM DIS, V75, P1133, DOI 10.1136/annrheumdis-2015-207319; Winthrop KL, 2018, J AM ACAD DERMATOL, V78, P1149, DOI 10.1016/j.jaad.2017.09.076; Winthrop KL, 2017, NAT REV RHEUMATOL, V13, P234, DOI 10.1038/nrrheum.2017.23; Xing LZ, 2014, NAT MED, V20, P1043, DOI 10.1038/nm.3645; Xu XJ, 2012, J PEDIATR-US, V160, P984, DOI 10.1016/j.jpeds.2011.11.046; Zandvakili I, 2018, AM J HEMATOL, V93, pE123, DOI 10.1002/ajh.25063; Zeiser R, 2015, LEUKEMIA, V29, P2062, DOI 10.1038/leu.2015.212; Zhang Q, 2011, CURR OPIN PEDIATR, V23, P653, DOI 10.1097/MOP.0b013e32834c7f65	119	32	33	5	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					814	826		10.1016/j.jaci.2020.10.022	http://dx.doi.org/10.1016/j.jaci.2020.10.022		MAR 2021	13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RA9TV	33129886				2022-12-18	WOS:000631762400004
J	Stevens, WW; Jerschow, E; Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Keswani, A; Levy, JM; Nanda, A; Laidlaw, TM; White, AA				Stevens, Whitney W.; Jerschow, Elina; Baptist, Alan P.; Borish, Larry; Bosso, John V.; Buchheit, Kathleen M.; Cahill, Katherine N.; Campo, Paloma; Cho, Seong H.; Keswani, Anjeni; Levy, Joshua M.; Nanda, Anil; Laidlaw, Tanya M.; White, Andrew A.			The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; AERD; NSAID-exacerbated respiratory disease; Samter triad; aspirin desensitization		Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme. Patients with AERD on average have more severe respiratory disease compared with patients with chronic rhinosinusitis with nasal polyps and/or asthma alone. Although patients with AERD traditionally develop significant upper and lower respiratory tract symptoms on ingestion of cycloxgenase-1 inhibitors, most of these same patients report clinical benefit when desensitized to aspirin and maintained on daily aspirin therapy. This Work Group Report provides a comprehensive review of aspirin challenges, aspirin desensitizations, and maintenance aspirin therapy in patients with AERD. Identification of appropriate candidates, indications and contraindications, medical and surgical optimization strategies, protocols, medical management during the desensitization, and recommendations for maintenance aspirin therapy following desensitization are reviewed. Also included is a summary of studies evaluating the clinical efficacy of aspirin therapy after desensitization as well as a discussion on the possible cellular and molecular mechanisms explaining how this therapy provides unique benefit to patients with AERD.	[Stevens, Whitney W.] Northwestern Univ, Dept Med, Div Allergy & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Jerschow, Elina] Montefiore Med Ctr, Albert Einstein Coll Med, Div Allergy & Immunol, Bronx, NY 10467 USA; [Baptist, Alan P.] Univ Michigan, Sch Med, Dept Med, Div Allergy & Clin Immunol, Ann Arbor, MI 48104 USA; [Borish, Larry] Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA USA; [Borish, Larry] Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA USA; [Bosso, John V.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Div Rhinol, Philadelphia, PA 19104 USA; [Buchheit, Kathleen M.; Laidlaw, Tanya M.] Brigham & Womens Hosp, Dept Med, Div Allergy & Clin Immunol, 75 Francis St, Boston, MA 02115 USA; [Cahill, Katherine N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA; [Campo, Paloma] IBIMA Hosp Reg Univ Malaga, Allergy Unit, Malaga, Spain; [Cho, Seong H.] Univ S Florida, Div Allergy & Immunol, Morsani Coll Med, Tampa, FL 33620 USA; [Keswani, Anjeni] George Washington Univ, Sch Med & Hlth Sci, Dept Med, Div Allergy Immunol, Washington, DC 20052 USA; [Levy, Joshua M.] Emory Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Atlanta, GA USA; [Nanda, Anil] Asthma & Allergy Ctr, Lewisville, TX USA; [Nanda, Anil] Asthma & Allergy Ctr, Flower Mound, TX USA; [Nanda, Anil] Univ Texas Southwestern Med Ctr Dallas, Div Allergy & Immunol, Dallas, TX 75390 USA; [White, Andrew A.] Scripps Clin, Div Allergy Asthma & Immunol, San Diego, CA USA	Northwestern University; Feinberg School of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Michigan System; University of Michigan; University of Virginia; University of Virginia; University of Pennsylvania; Harvard University; Brigham & Women's Hospital; Vanderbilt University; State University System of Florida; University of South Florida; George Washington University; Emory University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute	Stevens, WW (corresponding author), Div Allergy Immunol, 211 E Ontario St,Ste 1000, Chicago, IL 60611 USA.	whitney-stevens@northwestern.edu		Stevens, Whitney/0000-0002-2608-6610; Cahill, Katherine/0000-0002-8549-1835				Adappa ND, 2018, INT FORUM ALLERGY RH, V8, P49, DOI 10.1002/alr.22036; Anderson WC, 2019, ANN ALLERG ASTHMA IM, V122, P367, DOI 10.1016/j.anai.2019.01.018; [Anonymous], 1987, J ASTHMA, V24, P297; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; Bachert C, 2019, J ALLER CL IMM-PRACT, V7, P2447, DOI 10.1016/j.jaip.2019.03.023; Baker TW, 2011, ALLERGY ASTHMA PROC, V32, P335, DOI 10.2500/aap.2011.32.3457; Baschat AA, 2018, ULTRASOUND OBST GYN, V52, P728, DOI 10.1002/uog.18992; BASOMBA A, 1976, CLIN ALLERGY, V6, P269, DOI 10.1111/j.1365-2222.1976.tb01907.x; Becker RC, 1998, AM HEART J, V135, P786, DOI 10.1016/S0002-8703(98)70036-5; Belay ED, 1999, NEW ENGL J MED, V340, P1377, DOI 10.1056/NEJM199905063401801; Berges-Gimeno MP, 2003, ANN ALLERG ASTHMA IM, V90, P338, DOI 10.1016/S1081-1206(10)61803-0; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Berges-Gimeno MP, 2002, CLIN EXP ALLERGY, V32, P1491, DOI 10.1046/j.1365-2745.2002.01501.x; Bobolea I, 2018, RESP MED, V143, P39, DOI 10.1016/j.rmed.2018.08.009; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Bochenek G, 2014, J ALLERGY CLIN IMMUN, V133, P98, DOI 10.1016/j.jaci.2013.07.004; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; Cahill KN, 2019, AM J RESP CRIT CARE, V200, P704, DOI 10.1164/rccm.201809-1755OC; Cahill KN, 2019, J ALLERGY CLIN IMMUN, V143, P799, DOI 10.1016/j.jaci.2018.10.007; Cahill KN, 2017, J ALLERGY CLIN IMMUN, V139, P819, DOI 10.1016/j.jaci.2016.05.048; Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; Chen JR, 2015, J ALLER CL IMM-PRACT, V3, P926, DOI 10.1016/j.jaip.2015.06.013; Cho KS, 2014, OTOLARYNG HEAD NECK, V151, P575, DOI 10.1177/0194599814545750; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHRISTIE PE, 1993, EUR RESPIR J, V6, P1468; Chu DK, 2019, INT FORUM ALLERGY RH, V9, P1409, DOI 10.1002/alr.22428; Cianferoni A, 2001, BLOOD, V97, P1742, DOI 10.1182/blood.V97.6.1742; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Comert S, 2013, ALLERGY, V68, P1443, DOI 10.1111/all.12269; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; DeConde AS, 2015, INT FORUM ALLERGY RH, V5, P691, DOI 10.1002/alr.21541; DeGregorio GA, 2019, J ALLER CL IMM-PRACT, V7, P1174, DOI 10.1016/j.jaip.2018.10.032; Do T, 2019, ALLERGY ASTHMA PROC, V40, P311, DOI 10.2500/aap.2019.40.4239; Durrani SR, 2013, J ALLERGY CLIN IMMUN, V131, P244, DOI 10.1016/j.jaci.2012.10.006; Dursun AB, 2008, ANN ALLERG ASTHMA IM, V100, P420, DOI 10.1016/S1081-1206(10)60465-6; Eid RC, 2019, J ALLER CL IMM-PRACT, V7, P1338, DOI 10.1016/j.jaip.2018.09.012; Ekstrom P, 1996, SCAND J GASTROENTERO, V31, P753, DOI 10.3109/00365529609010347; Esmaeilzadeh H, 2015, CLIN IMMUNOL, V160, P349, DOI 10.1016/j.clim.2015.05.012; Feldman JM, 2019, J ASTHMA, V56, P731, DOI 10.1080/02770903.2018.1490754; Feldman M, 1999, AM J CARDIOL, V84, P404, DOI 10.1016/S0002-9149(99)00324-0; Feng X, 2016, J ALLERGY CLIN IMMUN, V138, P1089, DOI 10.1016/j.jaci.2016.04.042; Fruth K, 2013, ALLERGY, V68, P659, DOI 10.1111/all.12131; Garcia-Rodriguez LA, 2013, NEUROLOGY, V81, P566, DOI 10.1212/WNL.0b013e31829e6ffa; GIAMPIERO P, 1991, ANN ALLERGY, V67, P588; Gorelick PB, 2005, STROKE, V36, P1801, DOI 10.1161/01.STR.0000174189.81153.85; Graham DY, 2002, ARCH INTERN MED, V162, P169, DOI 10.1001/archinte.162.2.169; Havel M, 2013, EUR ARCH OTO-RHINO-L, V270, P571, DOI 10.1007/s00405-012-2048-x; Hayashi H, 2016, J ALLERGY CLIN IMMUN, V137, P1585, DOI 10.1016/j.jaci.2015.09.034; HEYMANN MA, 1976, NEW ENGL J MED, V295, P530, DOI 10.1056/NEJM197609022951004; Hope AP, 2009, J ALLERGY CLIN IMMUN, V123, P406, DOI 10.1016/j.jaci.2008.09.048; Hoyte FCL, 2012, J ALLERGY CLIN IMMUN, V129, P1684, DOI 10.1016/j.jaci.2011.12.003; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Huang GX, 2019, J ALLER CL IMM-PRACT, V7, P1647, DOI 10.1016/j.jaip.2019.02.037; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; James AH, 2008, OBSTET GYNECOL SURV, V63, P49, DOI 10.1097/OGX.0b013e31815e8731; Jerschow E, 2019, J ALLER CL IMM-PRACT, V7, P1580, DOI 10.1016/j.jaip.2018.12.014; Jerschow E, 2017, J ALLER CL IMM-PRACT, V5, P998, DOI 10.1016/j.jaip.2016.11.021; Jerschow E, 2016, ANN ALLERG ASTHMA IM, V116, P321, DOI 10.1016/j.anai.2015.12.026; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Katial RK, 2010, J ALLERGY CLIN IMMUN, V126, P738, DOI 10.1016/j.jaci.2010.06.036; Klimek L, 2009, IMMUNOL ALLERGY CLIN, V29, P669, DOI 10.1016/j.iac.2009.07.008; KLION AD, 1993, ALLERGY PROC, V14, P371, DOI 10.2500/108854193778773985; Kowalski ML, 2019, ALLERGY, V74, P28, DOI 10.1111/all.13599; KOWALSKI ML, 1984, ALLERGY, V39, P171, DOI 10.1111/j.1398-9995.1984.tb02621.x; Laidlaw TM, 2019, J ALLERGY CLIN IMMUN, V143, P316, DOI 10.1016/j.jaci.2018.06.001; Laidlaw TM, 2017, J ALLER CL IMM-PRACT, V5, P537, DOI 10.1016/j.jaip.2016.10.021; Laidlaw TM, 2016, NEW ENGL J MED, V374, P484, DOI 10.1056/NEJMcibr1514013; Laidlaw TM, 2014, J ALLERGY CLIN IMMUN, V133, P1692, DOI 10.1016/j.jaci.2013.12.1034; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Laine L, 2010, ALIMENT PHARM THER, V32, P1240, DOI 10.1111/j.1365-2036.2010.04465.x; Laine L, 2012, AM J GASTROENTEROL, V107, P345, DOI 10.1038/ajg.2011.480; Lang DM, 2018, ANN ALLERG ASTHMA IM, V121, P98, DOI 10.1016/j.anai.2018.05.007; Lanza FL, 2009, AM J GASTROENTEROL, V104, P728, DOI 10.1038/ajg.2009.115; Lee DKC, 2004, EUR RESPIR J, V24, P226, DOI 10.1183/09031936.04.00100303; Lee JY, 2007, J ALLERGY CLIN IMMUN, V119, P157, DOI 10.1016/j.jaci.2006.09.011; Lee RU, 2010, ANN ALLERG ASTHMA IM, V105, P130, DOI 10.1016/j.anai.2010.05.020; Lee-Sarwar K, 2015, J ALLER CL IMM-PRACT, V3, P449, DOI 10.1016/j.jaip.2015.01.007; Levy JM, 2016, INT FORUM ALLERGY RH, V6, P1273, DOI 10.1002/alr.21826; Lin KJ, 2011, GASTROENTEROLOGY, V141, P71, DOI 10.1053/j.gastro.2011.03.049; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; Machado-Carvalho L, 2016, RHINOLOGY, V54, P254, DOI 10.4193/Rhino15.207; Machado-Carvalho L, 2016, J ALLERGY CLIN IMMUN, V137, P99, DOI 10.1016/j.jaci.2015.09.028; Macy E, 2007, ANN ALLERG ASTHMA IM, V98, P172, DOI 10.1016/S1081-1206(10)60692-8; McMains KC, 2006, AM J RHINOL, V20, P573, DOI 10.2500/ajr.2006.20.2913; Melillo G, 2001, ALLERGY, V56, P899, DOI 10.1034/j.1398-9995.2001.00025.x; Mendelsohn D, 2011, ANN OTO RHINOL LARYN, V120, P162, DOI 10.1177/000348941112000304; Miller B, 2013, CLIN EXP ALLERGY, V43, P874, DOI 10.1111/cea.12110; Mita H, 2004, CLIN EXP ALLERGY, V34, P1262, DOI 10.1111/j.1365-2222.2004.02034.x; Morrissey DK, 2016, INT FORUM ALLERGY RH, V6, P820, DOI 10.1002/alr.21739; Mortazavi N, 2017, IRAN J PHARM RES, V16, P1639; Naidoo Y, 2013, INT FORUM ALLERGY RH, V3, P412, DOI 10.1002/alr.21109; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; Nassiri M, 2015, J ALLERGY CLIN IMMUN, V135, P491, DOI 10.1016/j.jaci.2014.09.004; Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x; Pauls JD, 2000, ANN ALLERG ASTHMA IM, V85, P40, DOI 10.1016/S1081-1206(10)62432-5; Pelletier T, 2019, J ALLER CL IMM-PRACT, V7, P1319, DOI 10.1016/j.jaip.2018.08.004; Pelletier T, 2017, ANN ALLERG ASTHMA IM, V118, P120, DOI 10.1016/j.anai.2016.10.018; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Peters AT, 2014, ANN ALLERG ASTHMA IM, V113, P347, DOI 10.1016/j.anai.2014.07.025; Phillips-Angles E, 2017, J ALLER CL IMM-PRACT, V5, P842, DOI 10.1016/j.jaip.2016.12.013; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; Roca-Ferrer J, 2011, J ALLERGY CLIN IMMUN, V128, P66, DOI 10.1016/j.jaci.2011.01.065; Rolnik DL, 2017, NEW ENGL J MED, V377, P613, DOI 10.1056/NEJMoa1704559; Rozsasi A, 2008, ALLERGY, V63, P1228, DOI 10.1111/j.1398-9995.2008.01658.x; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Schuler CF, 2017, ANN ALLERG ASTHMA IM, V118, P333, DOI 10.1016/j.anai.2016.11.021; Selak V, 2018, JAMA-J AM MED ASSOC, V319, P2507, DOI 10.1001/jama.2018.8194; Shah NH, 2016, J ALLER CL IMM-PRACT, V4, P1215, DOI 10.1016/j.jaip.2016.04.028; Shah SJ, 2019, INT FORUM ALLERGY RH, V9, P1401, DOI 10.1002/alr.22418; Shaker M, 2008, J ALLERGY CLIN IMMUN, V121, P81, DOI 10.1016/j.jaci.2007.06.047; Sheikh A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006312.pub2; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Steinke John W, 2012, J Allergy (Cairo), V2012, P182090, DOI 10.1155/2012/182090; Steinke JW, 2009, J ALLERGY CLIN IMMUN, V124, P724, DOI 10.1016/j.jaci.2009.07.031; Stevens WW, 2017, J ALLER CL IMM-PRACT, V5, P1061, DOI 10.1016/j.jaip.2016.12.027; Stevenson DD, 2000, ANN ALLERG ASTHMA IM, V85, P477, DOI 10.1016/S1081-1206(10)62575-6; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; Swierczynska-Krepa M, 2014, J ALLERGY CLIN IMMUN, V134, P883, DOI 10.1016/j.jaci.2014.02.041; SZCZEKLIK A, 1979, THORAX, V34, P654, DOI 10.1136/thx.34.5.654; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Szmidt M, 1996, J INVEST ALLERG CLIN, V6, P121; Ta V, 2015, J ALLER CL IMM-PRACT, V3, P711, DOI 10.1016/j.jaip.2015.03.001; Waldram J, 2018, J ALLERGY CLIN IMMUN, V141, P250, DOI 10.1016/j.jaci.2017.05.006; Waldram JD, 2016, IMMUNOL ALLERGY CLIN, V36, P693, DOI 10.1016/j.iac.2016.06.006; Walters KM, 2018, AM J RHINOL ALLERGY, V32, P280, DOI 10.1177/1945892418770260; Walters KM, 2017, ANN ALLERG ASTHMA IM, V119, P71, DOI 10.1016/j.anai.2017.05.003; White AA, 2005, ANN ALLERG ASTHMA IM, V95, P330, DOI 10.1016/S1081-1206(10)61150-7; White A, 2006, ANN ALLERG ASTHMA IM, V97, P688, DOI 10.1016/S1081-1206(10)61101-5; White A, 2006, ANN ALLERG ASTHMA IM, V97, P190, DOI 10.1016/S1081-1206(10)60012-9; White AA, 2018, NEW ENGL J MED, V379, P2281, DOI 10.1056/NEJMc1813469; White AA, 2013, ALLERGY ASTHMA PROC, V34, P378, DOI 10.2500/aap.2013.34.3670; White JL, 2018, J ALLER CL IMM-PRACT, V6, P1553, DOI 10.1016/j.jaip.2017.12.020; Whitlock EP, 2016, ANN INTERN MED, V164, P826, DOI 10.7326/M15-2112; Widal MF, 1922, PRESSE MED, V30, P189; Williams AN, 2007, J ALLERGY CLIN IMMUN, V120, P273, DOI 10.1016/j.jaci.2007.03.020; Yamamoto M, 2009, INT ARCH ALLERGY IMM, V148, P127, DOI 10.1159/000155743; Young J, 2007, AM J RHINOL, V21, P743, DOI 10.2500/ajr.2007.21.3108; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2	144	32	32	3	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					827	844		10.1016/j.jaci.2020.10.043	http://dx.doi.org/10.1016/j.jaci.2020.10.043		MAR 2021	18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RA9TV	33307116	Green Accepted			2022-12-18	WOS:000631762400005
J	Gisondi, P; Piaserico, S; Naldi, L; Dapavo, P; Conti, A; Malagoli, P; Marzano, AV; Bardazzi, F; Gasperini, M; Cazzaniga, S; Costanzo, A				Gisondi, Paolo; Piaserico, Stefano; Naldi, Luigi; Dapavo, Paolo; Conti, Andrea; Malagoli, Piergiorgio; Marzano, Angelo Valerio; Bardazzi, Federico; Gasperini, Massimo; Cazzaniga, Simone; Costanzo, Antonio		Studies COVID-19 Pandemic	Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; biologics; COVID-19; interstitial pneumonia		Introduction: Whether biologic therapies enhance the risk of coronavirus 2019 (COVID-19) or affect the disease outcome in patients with chronic plaque psoriasis remains to be ascertained. Objective: We sought to investigate the incidence of hospitalization and death for COVID-19 in a large sample of patients with plaque psoriasis receiving biologic therapies compared with the general population. Methods: This is a retrospective multicenter cohort study including patients with chronic plaque psoriasis (n 5 6501) being treated with biologic therapy and regularly followed up at the divisions of dermatology of several main hospitals in the Northern Italian cities of Verona, Padua, Vicenza, Modena, Bologna, Piacenza, Turin, and Milan. Incidence rates of hospitalization and death per 10,000 person-months with exact mid-p 95% CIs and standardized incidence ratios were estimated in the patients with psoriasis and compared with those in the general population in the same geographic areas. Results: The incidence rate of hospitalization for COVID-19 was 11.7 (95% CI, 7.2-18.1) per 10,000 person-months in patients with psoriasis and 14.4 (95% CI, 14.3-14.5) in the general population; the incidence rate of death from COVID-19 was 1.3 (95% CI, 0.2-4.3) and 4.7 (95% CI, 4.6-4.7) in patients with psoriasis and the general population, respectively. The standardized incidence ratio of hospitalization and death in patients with psoriasis compared with those in the general population was 0.94 (95% CI, 0.57-1.45; P 5.82) and 0.42 (95% CI, 0.07-1.38; P 5.19), respectively. Conclusions: Our data did not show any adverse impact of biologics on COVID-19 outcome in patients with psoriasis. We would not advise biologic discontinuation in patients on treatment since more than 6 months and not infected with severe acute respiratory syndrome coronavirus 2 to prevent hospitalization and death from COVID-19.	[Gisondi, Paolo] Univ Verona, Dept Med, Sect Dermatol & Venereol, Piazzale A Stefani 1, I-37126 Verona, Italy; [Piaserico, Stefano] Univ Padua, Dept Med, Sect Dermatol, Padua, Italy; [Naldi, Luigi; Cazzaniga, Simone] Ctr GISED, Bergamo, Italy; [Naldi, Luigi; Cazzaniga, Simone] San Bortolo Hosp, Dept Dermatol, Vicenza, Italy; [Dapavo, Paolo; Cazzaniga, Simone] Univ Turin, Dept Biomed Sci & Human Oncol, Dermatol Clin 2, Turin, Italy; [Conti, Andrea; Cazzaniga, Simone] Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci Related Transpla, Dermatol Unit, Modena, Italy; [Malagoli, Piergiorgio; Cazzaniga, Simone] Azienda Osped San Donato Milanese, Dermatol Unit, Milan, Italy; [Marzano, Angelo Valerio; Cazzaniga, Simone] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy; [Marzano, Angelo Valerio; Cazzaniga, Simone] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Bardazzi, Federico; Cazzaniga, Simone] Univ Bologna, Dermatol Unit, Dept Expt Diagnost & Specialty Med, Bologna, Italy; [Gasperini, Massimo; Cazzaniga, Simone] Osped Guglielmo Saliceto, Dermatol Unit, Piacenza, Italy; [Cazzaniga, Simone] Univ Hosp Bern, Dept Dermatol, Inselspital, Bern, Switzerland; [Costanzo, Antonio] Humanitas Univ, Dept Biomed Sci, Dermatol Unit, Pieve Emanuele, Italy; [Costanzo, Antonio] IRCCS, Humanitas Clin & Res Ctr, Rozzano, Italy	University of Verona; University of Padua; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; University of Turin; Universita di Modena e Reggio Emilia; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Bologna; Guglielmo da Saliceto Hospital; University of Bern; University Hospital of Bern; Humanitas University; IRCCS Humanitas Research Hospital	Gisondi, P (corresponding author), Univ Verona, Dept Med, Sect Dermatol & Venereol, Piazzale A Stefani 1, I-37126 Verona, Italy.	paolo.gisondi@univr.it	Costanzo, Antonio/GZG-2433-2022; Gisondi, Paolo/AGI-4840-2022; Pileri, Alessandro/D-7345-2017; Conti, Andrea/K-8793-2013	Costanzo, Antonio/0000-0001-9697-2557; Gisondi, Paolo/0000-0002-1777-9001; Malagoli, Piergiorgio/0000-0002-6181-6922; Pileri, Alessandro/0000-0002-1025-7171; Bardazzi, Federico/0000-0001-6162-2004; Damiani, Giovanni/0000-0002-2390-6505; Conti, Andrea/0000-0003-4848-3817; piaserico, stefano/0000-0002-1091-4733; Cazzaniga, Simone/0000-0001-8161-6138	Fondazione Cariplo; Fondazione Veronesi [1833073, 2020-1363]	Fondazione Cariplo(Fondazione Cariplo); Fondazione Veronesi(Fondazione Umberto Veronesi)	Supported by Fondazione Cariplo, Fondazione Veronesi, Impact of COVID19 infection on patients affected by inflammatory skin diseases on immuno-suppressive therapies (COVISKIN); ID 1833073 rif. 2020-1363.	Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411; Brenner EJ., SECURE IBD DATABASE; Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475; Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8; Gisondi P, 2020, J EUR ACAD DERMATOL, V34, P1196, DOI 10.1111/jdv.16515; Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567; Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031; Liu YX, 2020, NATL SCI REV, V7, P1003, DOI 10.1093/nsr/nwaa037; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433; Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022	11	32	33	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					558	+		10.1016/j.jaci.2020.10.032	http://dx.doi.org/10.1016/j.jaci.2020.10.032		FEB 2021	4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	33160968	Bronze, Green Published			2022-12-18	WOS:000616665800016
J	Woo, A; Lee, SW; Koh, HY; Kim, MA; Han, MY; Yon, DK				Woo, Ala; Lee, Seung Won; Koh, Hyun Yong; Kim, Mi Ae; Han, Man Yong; Yon, Dong Keon			Incidence of cancer after asthma development: 2 independent population-based cohort studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; cancer; chronic inflammation; carcinogenesis; tumor mutation burden		Background: Evidence regarding the risk of cancer development after asthma diagnosis is controversial and inconclusive. Objective: This study sought to determine whether asthma is associated with an increased risk for incident cancer. Methods: Two independent, population-based, longitudinal cohorts were examined, and estimated hazard ratios were determined using Cox regression. One group consisted of an unmatched cohort of 475,197 participants and a propensity score-matched cohort of 75,307 participants from the National Health Insurance Service-National Sample Cohort (NHIS-NSC; claims-based data from 2003 to 2015). The other group consisted of 5,440 participants from the Ansan-Ansung cohort (interview-based data from 2001 to 2014). Results: The NHIS-NSC matched cohort had 572,740 personyears of follow-up, 6,885 people with new asthma diagnoses, and 68,422 people without asthma diagnoses. Adults with asthma had a 75% greater risk of incident cancer overall. The excess risk for incident cancer was greatest during the first 2 years after asthma diagnosis, and this risk remained elevated throughout follow-up. Patients with nonatopic asthma had a greater risk of overall cancer than those with atopic asthma. A high cumulative dose of inhaled corticosteroids among asthma patients was associated with a 56% reduced risk of lung cancer, but had no effect on the risk of overall cancer. The results from the NHIS-NSC unmatched cohort and the Ansan-Ansung cohort were similar to the primary results from the NHIS-NSC matched cohort. Conclusions: Asthma development was associated with an increased risk of subsequent cancer in 2 different Korean cohorts. Our findings provide an improved understanding of the pathogenesis of asthma and its relationship with carcinogenesis and suggest that clinicians should be aware of the higher risk of incident cancer among patients with asthma.	[Woo, Ala] Univ Ulsan, Div Pulm & Crit Care Med, Asan Med Ctr, Coll Med, Seoul, South Korea; [Lee, Seung Won] Sejong Univ, Coll Software Convergence, Dept Data Sci, Seoul, South Korea; [Koh, Hyun Yong] Harvard Med Sch, FM Kirby Neurobiol Ctr, Boston Childrens Hosp, Boston, MA 02115 USA; [Kim, Mi Ae] CHA Univ, Sch Med, Dept Pulmonol Allergy & Crit Care Med, CHA Bundang Med Ctr, Seongnam, South Korea; [Han, Man Yong] CHA Univ, Sch Med, Dept Pediat, CHA Bundang Med Ctr, Seongnam, South Korea; [Yon, Dong Keon] Republ Korea Armed Forces, Armed Force Med Command, Seongnam, South Korea	University of Ulsan; Asan Medical Center; Sejong University; Harvard University; Boston Children's Hospital; Harvard Medical School; Pochon Cha University; Pochon Cha University	Yon, DK (corresponding author), CHA Univ, Dept Pediat, Sch Med, 351 Yatap Dong, Seongnam 463712, Gyeonggi Do, South Korea.	yonkkang@gmail.com	Yon, Dong Keon/M-1264-2017; Koh, Hyun Yong/AAX-4374-2020; Lee, Seung Won/GQQ-7259-2022; Lee, Seung Won/AAK-9460-2021	Yon, Dong Keon/0000-0003-1628-9948; Koh, Hyun Yong/0000-0002-3995-4341; Lee, Seung Won/0000-0001-5632-5208; Lee, Seung Won/0000-0001-5632-5208; WOO, ALA/0000-0002-8818-6115	National Research Foundation of Korea - Korea government [NRF2019R1G1A109977912]	National Research Foundation of Korea - Korea government(National Research Foundation of KoreaKorean Government)	This work was supported by the National Research Foundation of Korea grant funded by the Korea government (NRF2019R1G1A109977912). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.	Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; Chang JS, 2012, AM J EPIDEMIOL, V176, P970, DOI 10.1093/aje/kws263; Chipman J, 2019, JAMA-J AM MED ASSOC; Engels EA, 2008, EXPERT REV ANTICANC, V8, P605, DOI 10.1586/14737140.8.4.605; Fenger RV, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003933; Franklin JM, 2017, STAT MED, V36, P1946, DOI 10.1002/sim.7250; Gomez-Rubio P, 2017, GUT, V66, P314, DOI 10.1136/gutjnl-2015-310442; Ha J., CLIN EXP PEDIAT; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hemminki K, 2014, INT J CANCER, V135, P2397, DOI 10.1002/ijc.28873; Hsiao JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055138; Hughes AM, 2007, INT J CANCER, V121, P819, DOI 10.1002/ijc.22702; Hwang CY, 2012, INT J CANCER, V130, P1160, DOI 10.1002/ijc.26105; Hwangbo Y, 2018, JAMA ONCOL, V4, P1099, DOI 10.1001/jamaoncol.2018.1684; Jacobs EJ, 2013, CANCER EPIDEM BIOMAR, V22, P661, DOI 10.1158/1055-9965.EPI-12-1229; Jeong JS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030713; Ji J, 2009, BRIT J CANCER, V100, P829, DOI 10.1038/sj.bjc.6604890; Josephs DH, 2013, CLIN EXP ALLERGY, V43, P1110, DOI 10.1111/cea.12178; KALLEN B, 1993, EUR RESPIR J, V6, P694; Kankaanranta H, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/3690628; Kantor ED, 2019, CANCER EPIDEM BIOMAR, V28, P1395, DOI [10.1158/1055-9965.epi-18-1330, 10.1158/1055-9965.EPI-18-1330]; Kim HT, 2007, CLIN CANCER RES, V13, P559, DOI 10.1158/1078-0432.CCR-06-1210; Kim HJ, 2019, J ALLERGY CLIN IMMUN, V144, P1004, DOI 10.1016/j.jaci.2019.06.024; Kim Y, 2017, INT J EPIDEMIOL, V46, DOI 10.1093/ije/dyv316; Kozlowska R, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0147-8; Lee CH, 2013, RESP MED, V107, P1222, DOI 10.1016/j.rmed.2012.12.002; Lee SW, 2019, J ALLERGY CLIN IMMUN, V144, P1542, DOI 10.1016/j.jaci.2019.08.037; Liu XD, 2015, ACTA ONCOL, V54, P1120, DOI 10.3109/0284186X.2014.1001497; Lowe KE, 2020, J ALLERGY CLIN IMMUN, V145, P563, DOI 10.1016/j.jaci.2019.09.015; Martincorena I, 2015, SCIENCE, V349, P1483, DOI 10.1126/science.aab4082; Michaud DS, 2012, CANCER CAUSE CONTROL, V23, P1317, DOI 10.1007/s10552-012-0009-8; Multhoff G, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00098; Noh H, 2020, PEDIAT ALLERG IMM-UK, V31, P98, DOI 10.1111/pai.13132; Prizment AE, 2007, CANCER EPIDEM BIOMAR, V16, P2357, DOI 10.1158/1055-9965.EPI-07-0468; Qu YL, 2017, ONCOTARGET, V8, P11614, DOI 10.18632/oncotarget.14595; Raymakers AJN, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01257-2018; Rudant J, 2010, AM J EPIDEMIOL, V172, P1015, DOI 10.1093/aje/kwq233; Shantakumar S, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-017-0571-7; Shin JY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33316-y; Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X; Su YL, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001371; Talbot-Smith A, 2003, AM J EPIDEMIOL, V157, P606, DOI 10.1093/aje/kwg020; Wang H, 2006, BRIT J DERMATOL, V154, P205, DOI 10.1111/j.1365-2133.2005.07077.x; Wang H, 2006, INT J CANCER, V119, P695, DOI 10.1002/ijc.21883; Wang IJ, 2018, ANN THORAC MED, V13, P156, DOI 10.4103/atm.ATM_367_17; Wen WQ, 2000, CANCER CAUSE CONTROL, V11, P303, DOI 10.1023/A:1008958724739; Yang W, 2018, ANN NEUROL, V83, P375, DOI 10.1002/ana.25158; Yon DK, 2019, AM J RESP CRIT CARE, V200, P388, DOI 10.1164/rccm.201810-1980LE	48	32	32	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					135	143		10.1016/j.jaci.2020.04.041	http://dx.doi.org/10.1016/j.jaci.2020.04.041		JAN 2021	9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32417133				2022-12-18	WOS:000613645900018
J	Miethe, S; Karsonova, A; Karaulov, A; Renz, H				Miethe, Sarah; Karsonova, Antonina; Karaulov, Alexander; Renz, Harald			Obesity and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; obesity; metabolism	BODY-MASS INDEX; INNATE LYMPHOID-CELLS; INDUCED AIRWAY INFLAMMATION; WEIGHT-LOSS; ASYMMETRIC DIMETHYLARGININE; LUNG-FUNCTION; SYSTEMIC INFLAMMATION; INSULIN-RESISTANCE; METABOLIC SYNDROME; ADIPOSE-TISSUE	Obesity has been well recognized as an important comorbidity in patients with asthma, representing a unique phenotype and endotype. This association indicates a close relationship between metabolic and inflammatory dysregulation. However, the detailed organ-organ, cellular, and molecular interactions are not completely resolved. Because of that, the relationship between obesity and asthma remains unclear. In this article, clinical and epidemiological studies, as well as data from experimental animal work, are being summarized to provide a state of the art update on this important topic. Much more work is needed, particularly mechanistic, to fully understand the interaction between obesity and asthma and to develop novel preventive and therapeutic strategies.	[Miethe, Sarah; Renz, Harald] Philipps Univ Marburg, Inst Lab Med & Pathobiochem Mol Diagnost, Baldingerstr, D-35043 Marburg, Germany; [Karsonova, Antonina; Karaulov, Alexander] Sechenov Univ, Lab Immunopathol, Dept Clin Immunol & Allergol, Moscow, Russia; [Renz, Harald] German Ctr Lung Res DZL, Marburg, Germany	Philipps University Marburg; Sechenov First Moscow State Medical University	Renz, H (corresponding author), Philipps Univ Marburg, Inst Lab Med & Pathobiochem Mol Diagnost, Baldingerstr, D-35043 Marburg, Germany.	harald.renz@uk-gm.de	Karsonova, Antonina V./U-8600-2017; Karaulov, Alexander V/C-2482-2016	Karsonova, Antonina V./0000-0002-8697-9816; Karaulov, Alexander V/0000-0002-1930-5424	German Lung Centre (DZL)	German Lung Centre (DZL)	H.R. is supported by the German Lung Centre (DZL).	Acosta JR, 2016, DIABETOLOGIA, V59, P560, DOI 10.1007/s00125-015-3810-6; Al Ghobain M, 2012, BMC PULM MED, V12, DOI [10.1186/1471-2466-12-10, 10.1186/1471-2458-12-239]; Assad N, 2013, AM J RESP CRIT CARE, V188, P319, DOI 10.1164/rccm.201303-0457OC; Ather JL, 2016, AM J RESP CELL MOL, V55, P176, DOI 10.1165/rcmb.2016-0070OC; Azambuja RD, 2015, LUNG, V193, P749, DOI 10.1007/s00408-015-9793-8; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Bhatraju NK, 2017, ANN AM THORAC SOC, V14, pS368, DOI 10.1513/AnnalsATS.201701-042AW; Bi PP, 2015, TRENDS ENDOCRIN MET, V26, P248, DOI 10.1016/j.tem.2015.02.006; Bianco A, 2017, PULM PHARMACOL THER, V43, P20, DOI 10.1016/j.pupt.2017.01.004; Biring MS, 1999, AM J MED SCI, V318, P293, DOI 10.1097/00000441-199911000-00002; Brumpton BM, 2013, EUR RESPIR J, V42, P1495, DOI 10.1183/09031936.00046013; Calixto MC, 2010, BRIT J PHARMACOL, V159, P617, DOI 10.1111/j.1476-5381.2009.00560.x; Cardet JC, 2016, EUR RESPIR J, V48, P403, DOI 10.1183/13993003.00246-2016; Carraro S, 2013, CHEST, V144, P405, DOI 10.1378/chest.12-2379; Chen ZH, 2017, AM J RESP CRIT CARE, V195, P1181, DOI 10.1164/rccm.201608-1691OC; Chong L, 2018, INT IMMUNOPHARMACOL, V56, P197, DOI 10.1016/j.intimp.2018.01.033; COLLINS LC, 1995, CHEST, V107, P1298, DOI 10.1378/chest.107.5.1298; Contreras ZA, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00504-2018; Cvejoska-Cholakovska V., 2019, J MED SCI, V7, P1314, DOI DOI 10.3889/0AMJMS.2019.310; Nguyen DV, 2017, LANCET RESP MED, V5, P162, DOI 10.1016/S2213-2600(17)30051-6; Dias SA, 2014, EUR RESPIR J, V43, P1368, DOI 10.1183/09031936.00053413; Dietze J, 2012, ALLERGY, V67, P1519, DOI 10.1111/all.12031; Dinger K, 2016, SCI REP-UK, V6, DOI 10.1038/srep24168; Dixon AE, 2018, EXPERT REV RESP MED, V12, P755, DOI 10.1080/17476348.2018.1506331; Dixon Anne E, 2010, Proc Am Thorac Soc, V7, P325, DOI 10.1513/pats.200903-013ST; Eid HMA, 2004, METABOLISM, V53, P1574, DOI 10.1016/j.metabol.2004.06.026; Everaere L, 2016, J ALLERGY CLIN IMMUN, V138, P1309, DOI 10.1016/j.jaci.2016.03.019; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Forno E, 2015, J ALLERGY CLIN IMMUN, V136, P304, DOI 10.1016/j.jaci.2015.01.010; Forno E, 2014, PEDIATRICS, V134, pE535, DOI 10.1542/peds.2014-0439; Freedman DS, 2017, OBESITY, V25, P739, DOI 10.1002/oby.21782; Freitas PD, 2017, AM J RESP CRIT CARE, V195, P32, DOI [10.1164/rccm.201603-0446OC, 10.1164/rccm.201603-0446oc]; Fukushima A, 2006, EXP EYE RES, V82, P210, DOI 10.1016/j.exer.2005.06.010; Gonzalez-Barcala FJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010221; Granell R, 2014, PLOS MED, V11; Guedes AGP, 2008, AM J PHYSIOL-LUNG C, V294, pL290, DOI 10.1152/ajplung.00367.2007; Hao WM, 2018, EUR REV MED PHARMACO, V22, P1409, DOI 10.26355/eurrev_201803_14487; He QQ, 2009, PEDIATR PULM, V44, P997, DOI 10.1002/ppul.21091; Holguin F, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131733; Holguin F, 2013, AM J RESP CRIT CARE, V187, P153, DOI 10.1164/rccm.201207-1270OC; Holguin F, 2011, J ALLERGY CLIN IMMUN, V127, P1486, DOI 10.1016/j.jaci.2011.03.036; Huang MT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143508; Ito T, 2018, J PHYSIOL BIOCHEM, V74, P9, DOI 10.1007/s13105-017-0597-6; JENKINS SC, 1991, RESP MED, V85, P309, DOI 10.1016/S0954-6111(06)80102-2; Jensen ME, 2013, CLIN EXP ALLERGY, V43, P775, DOI 10.1111/cea.12115; Jones RL, 2006, CHEST, V130, P827, DOI 10.1378/chest.130.3.827; Jovicic N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134089; Karczewski J, 2018, EUR CYTOKINE NETW, V29, P83, DOI 10.1684/ecn.2018.0415; Kim DY, 2009, EUR J PHARMACOL, V612, P98, DOI 10.1016/j.ejphar.2009.03.078; Kim HY, 2014, NAT MED, V20, P54, DOI 10.1038/nm.3423; Kim JY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116540; Kleinert M, 2018, NAT REV ENDOCRINOL, V14, P140, DOI 10.1038/nrendo.2017.161; Kuo NW, 2014, J ALLERGY CLIN IMMUN, V134, P731, DOI 10.1016/j.jaci.2014.03.018; Kuschnir FC, 2018, J ALLERGY CLIN IMMUN, V141, P1947, DOI 10.1016/j.jaci.2018.01.026; Lazarus R, 1997, CHEST, V111, P891, DOI 10.1378/chest.111.4.891; Lee MW, 2015, CELL, V160, P74, DOI 10.1016/j.cell.2014.12.011; Leiria LOS, 2015, METABOLISM, V64, P172, DOI 10.1016/j.metabol.2014.10.002; Ma J, 2015, ANN AM THORAC SOC, V12, P1, DOI 10.1513/AnnalsATS.201406-271OC; Maniscalco M, 2017, J ALLERGY CLIN IMMUN, V139, P1536, DOI 10.1016/j.jaci.2016.08.038; Martinez FD, 2018, AM J RESP CRIT CARE, V197, P573, DOI 10.1164/rccm.201706-1091PP; McLaughlin T, 2014, ARTERIOSCL THROM VAS, V34, P2637, DOI 10.1161/ATVBAHA.114.304636; Melen E, 2013, CLIN EXP ALLERGY, V43, P463, DOI 10.1111/cea.12054; Melen E, 2010, J ALLERGY CLIN IMMUN, V126, P631, DOI 10.1016/j.jaci.2010.06.030; Michalovich D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13751-9; Miethe S, 2018, POL ARCH INTERN MED, V128, P469, DOI 10.20452/pamw.4304; Mizuta K, 2019, JPN DENT SCI REV, V55, P103, DOI 10.1016/j.jdsr.2019.07.002; Molofsky AB, 2013, J EXP MED, V210, P535, DOI 10.1084/jem.20121964; Murphy A, 2009, AM J HUM GENET, V85, P87, DOI 10.1016/j.ajhg.2009.06.011; Nials AT, 2008, DIS MODEL MECH, V1, P213, DOI 10.1242/dmm.000323; Pakhale S, 2015, CHEST, V147, P1582, DOI 10.1378/chest.14-3105; Pelosi P, 1998, ANESTH ANALG, V87, P654, DOI 10.1097/00000539-199809000-00031; Peroni DG, 2010, INT J OBESITY, V34, P599, DOI 10.1038/ijo.2009.273; Rastogi D, 2017, ANN AM THORAC SOC, V14, pS363, DOI [10.1513/AnnalsATS.201703-231AW, 10.1513/annalsats.201703-231aw]; Raviv S, 2011, J ASTHMA, V48, P98, DOI 10.3109/02770903.2010.534220; RAY CS, 1983, AM REV RESPIR DIS, V128, P501, DOI 10.1164/arrd.1983.128.3.501; RUBINSTEIN I, 1990, ANN INTERN MED, V112, P828, DOI 10.7326/0003-4819-112-11-828; Salome CM, 2010, J APPL PHYSIOL, V108, P206, DOI 10.1152/japplphysiol.00694.2009; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; Scott HA, 2013, CLIN EXP ALLERGY, V43, P36, DOI 10.1111/cea.12004; Scott JA, 2011, AM J RESP CRIT CARE, V184, P779, DOI 10.1164/rccm.201011-1810OC; SHARP JT, 1964, J APPL PHYSIOL, V19, P959, DOI 10.1152/jappl.1964.19.5.959; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021; Sin DD, 2002, ARCH INTERN MED, V162, P1477, DOI 10.1001/archinte.162.13.1477; Singh VP, 2018, INT IMMUNOPHARMACOL, V55, P20, DOI 10.1016/j.intimp.2017.11.014; Skaaby T, 2018, ALLERGY, V73, P153, DOI 10.1111/all.13242; Sutherland ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036631; Tan HTT, 2019, ALLERGY, V74, P294, DOI 10.1111/all.13619; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; van Huisstede A, 2015, THORAX, V70, P659, DOI 10.1136/thoraxjnl-2014-206712; Wang LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117939; Wells SM, 2007, AM J RESP CELL MOL, V36, P520, DOI 10.1165/rcmb.2006-0302SM; Wells SM, 2009, AM J RESP CELL MOL, V40, P179, DOI 10.1165/rcmb.2008-0148OC; Williams B, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-40; Winnica D, 2017, CLIN EXP ALLERGY, V47, P190, DOI 10.1111/cea.12802; Yuan YZ, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1943497; Zeng ZY, 2019, LAB INVEST, V99, P1784, DOI 10.1038/s41374-019-0294-x; Zeng ZY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00049; ZERAH F, 1993, CHEST, V103, P1470, DOI 10.1378/chest.103.5.1470; Zhang JH, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20176841, 10.1590/1414-431x20176841]; Zheng HD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27278-4; Zheng HD, 2016, J BIOL CHEM, V291, P22043, DOI 10.1074/jbc.M116.743187; Zhu LL, 2019, INT IMMUNOPHARMACOL, V67, P396, DOI 10.1016/j.intimp.2018.12.030	104	32	35	3	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					685	693		10.1016/j.jaci.2020.08.011	http://dx.doi.org/10.1016/j.jaci.2020.08.011			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	33032723	Bronze			2022-12-18	WOS:000582395800001
J	Liu, P; Zheng, JW; Yang, P; Wang, X; Wei, C; Zhang, SY; Feng, SW; Lan, J; He, BY; Zhao, DC; Li, JF; Zhang, YZ				Liu, Pin; Zheng, Junwen; Yang, Pu; Wang, Xia; Wei, Cong; Zhang, Shiyu; Feng, Shuwen; Lan, Jing; He, Bingyan; Zhao, Dongchi; Li, Jiafu; Zhang, Yuanzhen			The immunologic status of newborns born to SARS-CoV-2-infected mothers in Wuhan, China	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Newborn; pregnant women; COVID-19; third-trimester; lymphocyte subsets and cytokines		Background: Immunologic dysfunction due to coronavirus disease 2019 (COVID-19) is closely related to clinical prognosis, and the inflammatory response of pregnant women may affect the directional differentiation and function of fetal immune cells. Objective: We sought to analyze the immune status of newborns from mothers with COVID-19 in the third trimester. Methods: Along with collecting the clinical data from 51 newborns and their respective mothers, we recorded the immunophenotypes and cytokine and immunoglobulin levels of the newborns. Results: None of the 51 newborns showed fever or respiratory distress during hospitalization. Detection of severe acute respiratory syndrome coronavirus 2 nucleic acid in pharyngeal swabs was negative. Except for the low level of CD16-CD56 cells, the count and proportion of lymphocytes, CD3, CD4, CD8, and CD19 were all in the normal range. Moreover, the serum IgG and IgM levels were within the normal range, whereas IL-6 showed increased levels. There was no correlation between maternal COVID-19 duration and the lymphocyte subsets or cytokine levels (IFN-gamma, IL-2, IL-4, IL-6, IL-10, and TNF-alpha). There was a positive correlation between IL-6 and IL-10 levels and CD16-CD56 cells. One (1.96%) infant with an extremely elevated IL-6 concentration developed necrotizing enterocolitis in the third week after birth, and the remaining 50 infants did not show abnormal symptoms through the end of the follow-up period. Conclusions: COVID-19 in the third trimester did not significantly affect the cellular and humoral immunity of the fetus, and there was no evidence that the differentiation of lymphocyte subsets was seriously unbalanced.	[Liu, Pin; Zheng, Junwen; Yang, Pu; Wang, Xia; Wei, Cong; Zhang, Shiyu; Feng, Shuwen; Lan, Jing; He, Bingyan; Zhao, Dongchi] Wuhan Univ, Zhongnan Hosp, Childrens Digital Hlth & Data Ctr, Dept Pediat, Wuhan 430071, Hubei, Peoples R China; [Li, Jiafu; Zhang, Yuanzhen] Wuhan Univ, Zhongnan Hosp, Clin Med Res Ctr Prenatal Diag & Birth Hlth Hubei, Dept Obstet & Gynecol, Wuhan, Peoples R China	Wuhan University; Wuhan University	Zhao, DC (corresponding author), Wuhan Univ, Zhongnan Hosp, Childrens Digital Hlth & Data Ctr, Dept Pediat, Wuhan 430071, Hubei, Peoples R China.	zhao_wh2004@hotmail.com		Zhang, Yuan zhen/0000-0003-0437-423X; Zhao, Dongchi/0000-0002-9454-6041	Science and Technology Department of Hubei Province [2019-nCoV, 2020FCA011]	Science and Technology Department of Hubei Province	This work was supported by the Science and Technology Department of Hubei Province (grant no. 2019-nCoV. No. 2020FCA011).	Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642; Amatuni GS, 2019, J ALLERGY CLIN IMMUN, V144, P1674, DOI 10.1016/j.jaci.2019.05.038; Bhat BV, 2018, IMMUNITY AND INFLAMMATION IN HEALTH AND DISEASE: EMERGING ROLES OF NUTRACEUTICALS AND FUNCTIONAL FOODS IN IMMUNE SUPPORT, P15, DOI 10.1016/B978-0-12-805417-8.00002-0; Bordi L, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.8.2000170; Cao Q, 2020, J FORMOS MED ASSOC, V119, P670, DOI 10.1016/j.jfma.2020.02.009; Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; China NHCo, 2020, DIAGNOSIS TREATMENT; Chua MSQ, BJOG, DOI [10.1111/1471-0528.16257., DOI 10.1111/1471-0528.16257]; Cruz AT, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0834; Debock I, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00393; Heinonen S, 2019, IMMUNOL ALLERGY CLIN, V39, P361, DOI 10.1016/j.iac.2019.03.005; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jansen JM, 2019, J CLIN VIROL, V119, P44, DOI 10.1016/j.jcv.2019.08.009; Kam KQ, 2020, CLIN INFECT DIS, V71, P847, DOI 10.1093/cid/ciaa201; Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685; Liu X, 2020, ELECTRON J DIFFER EQ; Olin A, 2018, CELL, V174, P1277, DOI 10.1016/j.cell.2018.06.045; Poon LLM, 2020, NAT MED, V26, P317, DOI 10.1038/s41591-020-0796-5; Rasmussen SA, 2020, AM J OBSTET GYNECOL, V222, P415, DOI 10.1016/j.ajog.2020.02.017; Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194; Shek CC, 2003, PEDIATRICS, V112, pE254, DOI 10.1542/peds.112.4.e254; Weitkamp JH, 2018, IMMUNOLOGY FETUS NEW; Wong SF, 2004, AM J OBSTET GYNECOL, V191, P292, DOI 10.1016/j.ajog.2003.11.019; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xiao AT, 2020, J MED VIROL, V92, P1755, DOI 10.1002/jmv.25855; Xu Y, 2020, NAT MED, V26, P502, DOI 10.1038/s41591-020-0817-4; Yang P, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104356; Yang P, 2020, J INFECTION, V80, P684, DOI 10.1016/j.jinf.2020.02.024; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	32	32	33	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					101	+		10.1016/j.jaci.2020.04.038	http://dx.doi.org/10.1016/j.jaci.2020.04.038			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32437740	Green Published, Bronze			2022-12-18	WOS:000579170500019
J	Mullol, J; Marino-Sanchez, F; Valls, M; Alobid, I; Marin, C				Mullol, Joaquim; Marino-Sanchez, Franklin; Valls, Meritxell; Alobid, Isam; Marin, Concepcio			The sense of smell in chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Smell; olfaction; chronic rhinosinusitis; nasal polyps; anosmia			[Mullol, Joaquim; Alobid, Isam] Hosp Clin Barcelona, ENT Dept, Rhinol Unit, Barcelona, Catalonia, Spain; [Mullol, Joaquim; Alobid, Isam] Hosp Clin Barcelona, ENT Dept, Smell Clin, Barcelona, Catalonia, Spain; [Mullol, Joaquim; Marino-Sanchez, Franklin; Alobid, Isam; Marin, Concepcio] IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Catalonia, Spain; [Mullol, Joaquim; Alobid, Isam; Marin, Concepcio] CIBER Resp Dis CIBERES, Barcelona, Catalonia, Spain; [Marino-Sanchez, Franklin] Ramon & Cajal Univ Hosp, Rhinol & Skull Base Surg Unit, ENT Dept, Madrid, Spain; [Valls, Meritxell] Hosp Son Espases, Palma de Mallorca, Illes Balears, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Hospital Universitario Ramon y Cajal; Hospital Universitari Son Espases	Mullol, J (corresponding author), Hosp Clin Barcelona, IDIBAPS, C Villarroel 170, E-08036 Barcelona, Catalonia, Spain.	jmullol@clinic.cat						Alobid I, 2014, LARYNGOSCOPE, V124, P50, DOI 10.1002/lary.24330; Alobid I, 2011, RHINOLOGY, V49, P519, DOI 10.4193/Rhino10.295; Bachert C, 2019, LANCET, V394, P1638, DOI 10.1016/S0140-6736(19)31881-1; Fokkens WJ, 2020, RHINOLOGY, V58, P1, DOI 10.4193/Rhin20.401; Fokkens WJ, 2019, ALLERGY, V74, P2312, DOI 10.1111/all.13875; Haxel BR, 2019, LARYNGOSCOPE, V129, P1053, DOI 10.1002/lary.27764; Hummel T, 2017, RHINOLOGY, V54, P7, DOI 10.4193/Rhino16.248; Mullol J, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001256; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS22, DOI 10.1002/alr.21695; Stevens WW, 2019, J ALLER CL IMM-PRACT, V7, P2812, DOI 10.1016/j.jaip.2019.05.009	10	32	32	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					773	776		10.1016/j.jaci.2020.01.024	http://dx.doi.org/10.1016/j.jaci.2020.01.024			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	32145875	Bronze			2022-12-18	WOS:000518756700011
J	Galle-Treger, L; Hurrell, BP; Lewis, G; Howard, E; Jahani, PS; Banie, H; Razani, B; Soroosh, P; Akbari, O				Galle-Treger, Lauriane; Hurrell, Benjamin P.; Lewis, Gavin; Howard, Emily; Jahani, Pedram Shafiei; Banie, Homayon; Razani, Babak; Soroosh, Pejman; Akbari, Omid			Autophagy is critical for group 2 innate lymphoid cell metabolic homeostasis and effector function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group 2 innate lymphoid cells; immune metabolism; autophagy; airway hyperreactivity	MITOCHONDRIAL FISSION; IMMUNE-RESPONSE; DIFFERENTIATION; INFLAMMATION; SURVIVAL; INDUCTION; FATE; ATG5	Background: Allergic asthma is a chronic inflammatory disorder characterized by airway hyperreactivity (AHR) and driven by T(H)2 cytokine production. Group 2 innate lymphoid cells (ILC2s) secrete high amounts of T(H)2 cytokines and contribute to the development of AHR. Autophagy is a cellular degradation pathway that recycles cytoplasmic content. However, the role of autophagy in ILC2s remains to be fully elucidated. Objective: We characterized the effects of autophagy deficiency on ILC2 effector functions and metabolic balance. Methods: ILC2s from autophagy-deficient mice were isolated to evaluate proliferation, apoptosis, cytokine secretion, gene expression and cell metabolism. Also, autophagy-deficient ILC2s were adoptively transferred into Rag(-/-)GC(-/)-mice, which were then challenged with IL-33 and assessed for AHR and lung inflammation. Results: We demonstrate that autophagy is extensively used by activated ILC2s to maintain their homeostasis and effector functions. Deletion of the critical autophagy gene autophagy-related 5 (Atg5) resulted in decreased cytokine secretion and increased apoptosis. Moreover, lack of autophagy among ILC2s impaired their ability to use fatty acid oxidation and strikingly promoted glycolysis, as evidenced by our transcriptomic and metabolite analyses. This shift of fuel dependency led to impaired homeostasis and T(H)2 cytokine production, thus inhibiting the development of ILC2-mediated AHR. Notably, this metabolic reprogramming was also associated with an accumulation of dysfunctional mitochondria, producing excessive reactive oxygen species. Conclusion: These findings provide new insights into the metabolic profile of ILC2s and suggest that modulation of fuel dependency by autophagy is a potentially new therapeutic approach to target ILC2-dependent inflammation.	[Galle-Treger, Lauriane; Hurrell, Benjamin P.; Howard, Emily; Jahani, Pedram Shafiei; Akbari, Omid] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, NRT 5505,1450 Biggy St, Los Angeles, CA 90033 USA; [Lewis, Gavin; Banie, Homayon; Soroosh, Pejman] Janssen Res & Dev, San Diego, CA USA; [Razani, Babak] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Razani, Babak] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Razani, Babak] John Cochran VA Med Ctr, St Louis, MO USA	University of Southern California; Washington University (WUSTL); Washington University (WUSTL)	Akbari, O (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, NRT 5505,1450 Biggy St, Los Angeles, CA 90033 USA.	akbari@usc.edu	Soroosh, Pejman/AAD-8386-2021		National Institutes of Health Public Health Service [R01 ES025786, R01 ES021801, R01 HL144790, R21 AI109059]; Swiss National Science Foundation [181286]	National Institutes of Health Public Health Service(United States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This article was financially supported by National Institutes of Health Public Health Service grants R01 ES025786, R01 ES021801, R01 HL144790, and R21 AI109059 (to O.A.). B.P.H. is supported by the Swiss National Science Foundation for Early Postdoc.Mobility #181286.	Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Berod L, 2014, NAT MED, V20, P1327, DOI 10.1038/nm.3704; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Cavagnero Kellen, 2017, J Cytokine Biol, V2; Chang JE, 2014, J ALLERGY CLIN IMMUN, V133, P899, DOI 10.1016/j.jaci.2013.09.020; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Clarke AJ, 2018, J EXP MED, V215, P399, DOI 10.1084/jem.20170771; Claudio E, 2006, CELL DEATH DIFFER, V13, P697, DOI 10.1038/sj.cdd.4401894; da Luz FAC, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/342410; Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532; DeVorkin L, 2019, CELL REP, V27, P502, DOI 10.1016/j.celrep.2019.03.037; Doherty TA, 2018, J ALLERGY CLIN IMMUN, V141, P1587, DOI 10.1016/j.jaci.2018.02.034; Doherty TA, 2015, J LEUKOCYTE BIOL, V97, P455, DOI 10.1189/jlb.5BT0814-374R; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Frank M, 2012, BBA-MOL CELL RES, V1823, P2297, DOI 10.1016/j.bbamcr.2012.08.007; Galle-Treger L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08449-x; Galle-Treger L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13202; Geltink RIK, 2017, CELL, V171, P385, DOI 10.1016/j.cell.2017.08.018; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hazenberg MD, 2014, BLOOD, V124, P700, DOI 10.1182/blood-2013-11-427781; Huang P, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1221-1; Hurrell BP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02694; Jia W, 2011, J IMMUNOL, V186, P5313, DOI 10.4049/jimmunol.1002404; Jia W, 2011, J IMMUNOL, V186, P1564, DOI 10.4049/jimmunol.1001822; Kerzerho J, 2013, J ALLERGY CLIN IMMUN, V131, P1048, DOI 10.1016/j.jaci.2012.09.027; Konya V, 2016, IMMUNOL LETT, V179, P36, DOI 10.1016/j.imlet.2016.07.006; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Maazi H, 2018, J ALLERGY CLIN IMMUN, V141, P893, DOI 10.1016/j.jaci.2017.04.043; Maazi H, 2015, IMMUNITY, V42, P538, DOI 10.1016/j.immuni.2015.02.007; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Nagakumar P, 2016, J ALLERGY CLIN IMMUN, V137, P624, DOI 10.1016/j.jaci.2015.06.038; O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570; O'Sullivan TE, 2016, CELL REP, V15, P1910, DOI 10.1016/j.celrep.2016.04.082; Ouimet M, 2011, CELL METAB, V13, P655, DOI 10.1016/j.cmet.2011.03.023; Pearce EJ, 2018, NAT REV IMMUNOL, V18, P81, DOI 10.1038/nri.2017.139; Pearce EL, 2009, NATURE, V460, P103, DOI 10.1038/nature08097; Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303; Riffelmacher T, 2017, IMMUNITY, V47, P466, DOI 10.1016/j.immuni.2017.08.005; Rigas D, 2017, J ALLERGY CLIN IMMUN, V139, P1468, DOI 10.1016/j.jaci.2016.08.034; Ryter SW, 2012, ANNU REV PHYSIOL, V74, P377, DOI 10.1146/annurev-physiol-020911-153348; Schauberger E, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0628-3; Schulze RJ, 2017, BBA-MOL CELL BIOL L, V1862, P1178, DOI 10.1016/j.bbalip.2017.06.008; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; Sergin I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15750; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976; Singh RK, 2012, INT J OPT, V2012, DOI [10.1155/2012/282041, 10.1155/2012/832086]; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Tal MC, 2009, P NATL ACAD SCI USA, V106, P2770, DOI 10.1073/pnas.0807694106; Tornatore L, 2012, TRENDS CELL BIOL, V22, P557, DOI 10.1016/j.tcb.2012.08.001; Toyama EQ, 2016, SCIENCE, V351, P275, DOI 10.1126/science.aab4138; Walker JA, 2013, CURR OPIN IMMUNOL, V25, P148, DOI 10.1016/j.coi.2013.02.010; Wildenberg ME, 2012, GASTROENTEROLOGY, V142, P1493, DOI 10.1053/j.gastro.2012.02.034; Wilhelm C, 2016, J EXP MED, V213, P1409, DOI 10.1084/jem.20151448; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103; Zhang Y, 2007, AUTOPHAGY, V3, P337, DOI 10.4161/auto.4127	68	32	32	2	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					502	+		10.1016/j.jaci.2019.10.035	http://dx.doi.org/10.1016/j.jaci.2019.10.035			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31738991	Bronze, Green Accepted			2022-12-18	WOS:000512887400014
J	Portnoy, JM; Pandya, A; Waller, M; Elliott, T				Portnoy, Jay M.; Pandya, Aarti; Waller, Morgan; Elliott, Tania			Telemedicine and emerging technologies for health care in allergy/immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Telemedicine; store & forward; e-consults; remote patient monitoring; facilitated visit; virtual visit	ELECTRONIC DIARY; ASTHMA; CHILDREN; PROGRAM; PATIENT; ACCESS	Telemedicine (TM) has become a popular method of accessing medical services between providers and patients and is viewed as a cost-effective alternative to more traditional episodic face-to-face encounters. TM overcomes 2 barriers that patients face when seeking health care: distance and time. It is as effective as in-person visits for outpatient treatment of asthma, and it is a convenient way to provide inpatient consultations for patients when the allergist practices outside of the hospital. TM also has been used to manage patients with asthma in schools. Patients tend to be as satisfied with TM or they prefer TM over in-person visits, but infrequently they do prefer in-person visits. In addition to virtual visits using TM, there are several emerging technologies that are relevant to the practice of allergy/immunology including electronic diaries (eg, symptoms and medication use), wearable technology (eg, to monitor activity and vital signs), remote patient monitoring (eg, environmental exposures and medication adherence) as well as electronic medical records augmented with clinical decision support. We believe that the use of TM, particularly when combined with information technologies such as electronic health records, has the potential to cause a transformational change in the way care is delivered by altering the process of interaction between patient and provider. TM addresses the shortage of allergy specialists in rural and underserved urban communities and facilitates patient access to allergy services. As patients take more control of their health care, use of TM is likely to increase because a large part of the move to adopt TM is driven by patient preference.	[Portnoy, Jay M.; Pandya, Aarti; Waller, Morgan] Childrens Mercy Hosp, Kansas City, MO 64108 USA; [Elliott, Tania] NYU, Med Ctr, New York, NY 10016 USA	Children's Mercy Hospital; New York University	Portnoy, JM (corresponding author), Childrens Mercy Hosp, Sect Allergy Asthma & Immunol, 2401 Gillham Rd, Kansas City, MO 64108 USA.	jportnoy@cmh.edu						American College of Allergy Asthma & Immunology, 2019, ALL; American Well, 2019, TEL IND; [Anonymous], 2018, PHYS WEEKLY; [Anonymous], 2018, MEDSCAPE NATL PHYS B; [Anonymous], 2019, TEL; Asthma and Allergy Foundation of America, 2018, TEVA ANN FDA APPR PR; Aungst LA, 2019, J AM ASSOC NURSE PRA, V31, P162, DOI 10.1097/JXX.0000000000000117; Bergman DA, 2008, INT J TELEMED APPL, V2008, DOI 10.1155/2008/159276; Biagio L, 2013, TELEMED E-HEALTH, V19, P252, DOI 10.1089/tmj.2012.0161; Bousquet J, 2019, J ALLER CL IMM-PRACT, V7, P2511, DOI 10.1016/j.jaip.2019.07.044; Bove AA, 2013, AM HEART J, V165, P615, DOI 10.1016/j.ahj.2013.01.004; Broderick Joan E, 2008, Pharmaceut Med, V22, P69; Brown W, 2015, J ALLER CL IMM-PRACT, V3, P300, DOI 10.1016/j.jaip.2014.10.003; Bulik RJ, 2008, J TELEMED TELECARE, V14, P169, DOI 10.1258/jtt.2007.007041; Butz AM, 2005, ANN ALLERG ASTHMA IM, V94, P360, DOI 10.1016/S1081-1206(10)60988-X; Centers for Medicare & Medicaid Services, 2019, EL HLTH REC; Chandra S, 2016, ANN EMERG MED, V68, pS155; Donovan BM, 2019, ANN ALLERG ASTHMA IM, V123, P550, DOI 10.1016/j.anai.2019.08.460; Dowling PJ, 2019, J ALLER CL IMM-PRACT, V7, P2568, DOI 10.1016/j.jaip.2019.06.025; Field MJ, 1997, J DIGIT IMAGING, V10, P28, DOI 10.1007/BF03168648; Findlay S., 2018, YOU SHOULD GO URGENT; Floro JN, 2009, RES Q EXERCISE SPORT, V80, P153; Godschalk I, 1996, RESP MED, V90, P619, DOI 10.1016/S0954-6111(96)90020-7; Gough F, 2015, TELEMED E-HEALTH, V21, P233, DOI 10.1089/tmj.2015.0008; Greiwe J, 2019, J ALLER CL IMM-PRACT, V7, P2560, DOI 10.1016/j.jaip.2019.07.012; Guleria R, 2019, INTERACT J MED RES, V8, DOI 10.2196/13530; Halterman JS, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2017.4938; Himes BE, 2019, J ALLER CL IMM-PRACT, V7, P2535, DOI 10.1016/j.jaip.2019.08.034; HYLAND ME, 1993, BRIT MED J, V306, P487, DOI 10.1136/bmj.306.6876.487; Ireland AM, 2012, J ASTHMA, V49, P952, DOI 10.3109/02770903.2012.724754; Kagen S, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0840-z; Kane CK, 2018, HEALTH AFFAIR, V37, P1923, DOI 10.1377/hlthaff.2018.05077; Kikidis D, 2016, J AEROSOL MED PULM D, V29, P219, DOI 10.1089/jamp.2015.1267; Kruse CS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016242; Kupczyk M, 2013, THORAX, V68, P611, DOI 10.1136/thoraxjnl-2012-201815; Lacktman N, 2017, 2017 TELEMEDICINE DI; Lin JC, 2019, ANN VASC SURG, DOI 10.1016/j.avsg.2019.10.069; Lowe AA, 2016, AM J RESP CRIT CARE, V193; Marcolino MS, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.8873; Martinez KA, 2018, JAMA INTERN MED, V178, P1558, DOI 10.1001/jamainternmed.2018.4318; Martinez KA, 2018, J GEN INTERN MED, V33, P1768, DOI 10.1007/s11606-018-4621-5; Mcree L, 2014, HEART LUNG, V43, P546, DOI 10.1016/j.hrtlng.2014.05.009; OConnor S., 2017, WHAT ROLE DOES EHR S; Ofei-Dodoo Samuel, 2019, Kans J Med, V12, P57; Perry TT, 2019, J ALLER CL IMM-PRACT, V7, P2524, DOI 10.1016/j.jaip.2019.08.009; Perry TT, 2018, ANN ALLERG ASTHMA IM, V120, P401, DOI 10.1016/j.anai.2018.02.013; Phadke NA, 2019, J ALLER CL IMM-PRACT, V7, P2594, DOI 10.1016/j.jaip.2019.05.039; Polinski JM, 2016, J GEN INTERN MED, V31, P269, DOI 10.1007/s11606-015-3489-x; Portnoy JM, 2016, ANN ALLERG ASTHMA IM, V117, P241, DOI 10.1016/j.anai.2016.07.012; Pruthi S, 2013, MAYO CLIN PROC, V88, P68, DOI 10.1016/j.mayocp.2012.10.015; Ramnath VR, 2014, TELEMED E-HEALTH, V20, P962, DOI 10.1089/tmj.2014.0024; Rimsza ME, 2015, PEDIATRICS, V136, P202, DOI 10.1542/peds.2015-1253; Roth M., 2020, EPIC DOMINATES EMR M; Segura-Bedmar I, 2018, J BIOMED INFORM, V87, P50, DOI 10.1016/j.jbi.2018.09.012; Shanafelt TD, 2016, MAYO CLIN PROC, V91, P836, DOI 10.1016/j.mayocp.2016.05.007; Shih J, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0807-5; Sikka Neal, 2014, Virtual Mentor, V16, P976, DOI 10.1001/virtualmentor.2014.16.12.medu1-1412; Spaulding R, 2011, CHILD ADOL PSYCH CL, V20, P29, DOI 10.1016/j.chc.2010.08.010; Staicu ML, 2018, J ALLER CL IMM-PRACT, V6, P2033, DOI 10.1016/j.jaip.2018.04.038; Taylor L, 2019, J ALLER CL IMM-PRACT, V7, P2554, DOI 10.1016/j.jaip.2019.06.012; Taylor L, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0812-8; Tipton B., 2019, 9 STAGES TRANSFORMAT; University of New Mexico School of Medicine ECHO, 2019, PROJ ECHO; US Food and Drug Administration, 2018, DIG HLTH INN ACT PLA; Vierhile A, 2018, J PEDIATR HEALTH CAR, V32, P500, DOI 10.1016/j.pedhc.2018.02.004; Waller M, 2019, PEDIATR ANN, V48, pE243, DOI 10.3928/19382359-20190520-01; Wongpoowarak W, 2002, COMPUT METH PROG BIO, V68, P63, DOI 10.1016/S0169-2607(01)00156-0; Wright MO, 2009, AM J INFECT CONTROL, V37, P364, DOI 10.1016/j.ajic.2008.11.003; Zapata MA, 2017, TELEMED E-HEALTH, V23, P31, DOI 10.1089/tmj.2016.0020	69	32	32	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					445	454		10.1016/j.jaci.2019.12.903	http://dx.doi.org/10.1016/j.jaci.2019.12.903			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	KK6ZG	32035604	Bronze			2022-12-18	WOS:000512887400001
J	Everman, JL; Sajuthi, S; Saef, B; Rios, C; Stoner, AM; Numata, M; Hu, DL; Eng, C; Oh, S; Rodriguez-Santana, J; Vladar, EK; Voelker, DR; Burchard, EG; Seibold, MA				Everman, Jamie L.; Sajuthi, Satria; Saef, Benjamin; Rios, Cydney; Stoner, Ari M.; Numata, Mari; Hu, Donglei; Eng, Celeste; Oh, Sam; Rodriguez-Santana, Jose; Vladar, Eszter K.; Voelker, Dennis R.; Burchard, Esteban G.; Seibold, Max A.			Functional genomics of CDHR3 confirms its role in HRV-C infection and childhood asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway epithelium; CRISPR; rhinovirus; expression quantitative trait loci	HUMAN RHINOVIRUS C; AIR-POLLUTION; GALA II; ASSOCIATION; CHILDREN; RECEPTOR; RISK	Background: Research in transformed immortalized cell lines indicates the cadherin-related family member 3 (CDHR3) protein serves as a receptor for human rhinovirus (HRV)-C. Similar experiments indicate that the CDHR3 coding variant rs6967330 increases CDHR3 protein surface expression. Objective: We sought to determine whether CDHR3 is necessary for HRV-C infection of primary airway epithelial cells (AECs) and to identify molecular mechanisms by which CDHR3 variants confer risk for asthma exacerbations. Methods: CDHR3 function and influence on HRV-C infection were investigated by using single-cell transcriptomics, CRISPR-Cas9 gene knockout, and genotype-specific donor experiments performed in primary AECs. Nasal airway epithelium cis-expression quantitative trait locus (eQTL) analysis of CDHR3 was performed, followed by association testing for asthma hospitalization in minority children. Results: CDHR3 lung expression is exclusive to ciliated AECs and associated with basal bodies during and after motile ciliogenesis. Knockout of CDHR3 in human AECs did not prevent ciliated cell differentiation but was associated with a decrease in transepithelial resistance and an 80% decrease in HRV-C infection of the mucociliary epithelium. AECs from subjects homozygous for the risk-associated rs6967330 single nucleotide polymorphism (SNP) exhibited greater HRV-C infection compared with cells homozygous for the nonrisk allele. AEC cis-eQTL analysis indicated that rs6967330 and other SNPs are eQTLs for CDHR3. Only the eQTL block containing the rs6967330 SNP showed a significant association with childhood asthma hospitalization. Conclusions: Genetic deletion and genotype-specific studies in primary AECs indicate CDHR3 is critical to HRV-C infection of ciliated cells. The rs6967330 SNP confers risk of severe childhood asthma exacerbations, likely through increasing HRV-C infection levels and protein surface localization.	[Everman, Jamie L.; Sajuthi, Satria; Saef, Benjamin; Rios, Cydney; Stoner, Ari M.; Seibold, Max A.] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA; [Numata, Mari; Voelker, Dennis R.] Natl Jewish Hlth, Dept Med, Denver, CO USA; [Seibold, Max A.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Hu, Donglei; Eng, Celeste; Oh, Sam; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Rodriguez-Santana, Jose] Ctr Neumol Pediat, San Juan, PR USA; [Vladar, Eszter K.; Seibold, Max A.] Univ Colorado, Sch Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA; [Vladar, Eszter K.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA; [Vladar, Eszter K.] Univ Colorado, Sch Med, Dept Cell & Dev Biol, Aurora, CO USA	National Jewish Health; National Jewish Health; National Jewish Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Seibold, MA (corresponding author), Ctr Genes Environm & Hlth, 1400 Jackson St A636, Denver, CO 80206 USA.	seiboldm@njhealth.org		Stoner, Ari/0000-0003-3259-8038; Vladar, Eszter/0000-0002-4160-8894; Sajuthi, Satria/0000-0001-9598-7298; Everman, Jamie/0000-0002-1935-4672	 [R01 HL135156];  [R01 MD010443];  [R01 HL128439];  [P01 HL132821];  [P01 HL107202];  [U01 HL138626]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL138626, P01HL132821, P01HL107202, R01HL128439, R01HL135156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI125357] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD010443] Funding Source: NIH RePORTER	; ; ; ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Supported by R01 HL135156, R01 MD010443, R01 HL128439, P01 HL132821, P01 HL107202, and U01 HL138626.	Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Bochkov YA, 2011, NAT MED, V17, P627, DOI 10.1038/nm.2358; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Chang EH, 2017, J ALLERGY CLIN IMMUN, V139, P1990, DOI 10.1016/j.jaci.2016.10.027; Chen WJ, 2015, J CLIN VIROL, V64, P74, DOI 10.1016/j.jcv.2015.01.007; Chu HW, 2015, GENE THER, V22, P822, DOI 10.1038/gt.2015.53; Everman JL, 2018, METHODS MOL BIOL, V1799, P419, DOI 10.1007/978-1-4939-7896-0_30; Everman JL, 2018, METHODS MOL BIOL, V1706, P267, DOI 10.1007/978-1-4939-7471-9_15; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Griggs TF, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0567-0; Hammar KS, 2018, PEDIAT ALLERG IMM-UK, V29, P200, DOI 10.1111/pai.12858; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Husby A, 2017, J ALLERGY CLIN IMMUN, V140, P1469, DOI 10.1016/j.jaci.2017.06.044; Ivanova JI, 2012, J ALLERGY CLIN IMMUN, V129, P1229, DOI 10.1016/j.jaci.2012.01.039; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kanazawa J, 2017, ALLERGOL INT, V66, P563, DOI 10.1016/j.alit.2017.02.012; Khetsuriani N, 2008, EMERG INFECT DIS, V14, P1793, DOI 10.3201/eid1411.080386; Kosmider B, 2018, METHODS MOL BIOL, V1809, P83, DOI 10.1007/978-1-4939-8570-8_7; Miller EK, 2009, J CLIN VIROL, V46, P85, DOI 10.1016/j.jcv.2009.06.007; Neophytou AM, 2016, AM J RESP CRIT CARE, V193, P1271, DOI 10.1164/rccm.201508-1706OC; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; Nurmagambetov T, 2018, ANN AM THORAC SOC, V15, P348, DOI 10.1513/AnnalsATS.201703-259OC; Reynolds SD, 2016, AM J RESP CELL MOL, V55, P323, DOI 10.1165/rcmb.2015-0274MA; Vladar EK, 2007, J CELL BIOL, V178, P31, DOI 10.1083/jcb.200703064; Zacharias WJ, 2018, NATURE, V555, P251, DOI 10.1038/nature25786; Zhaot M, 2016, CHINESE MED J-PEKING, V129, P1513, DOI 10.4103/0366-6999.184463	29	32	37	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					962	971		10.1016/j.jaci.2019.01.052	http://dx.doi.org/10.1016/j.jaci.2019.01.052			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	30930175	Bronze, Green Accepted			2022-12-18	WOS:000488803900012
J	Yan, B; Lou, HF; Wang, Y; Li, Y; Meng, YF; Qi, SH; Wang, M; Xiao, L; Wang, CS; Zhang, L				Yan, Bing; Lou, Hongfei; Wang, Yang; Li, Ying; Meng, Yifan; Qi, Sihan; Wang, Ming; Xiao, Lei; Wang, Chengshuo; Zhang, Luo			Epithelium-derived cystatin SN enhances eosinophil activation and infiltration through IL-5 in patients with chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis with nasal polyps; cystatin SN; eosinophil activation; eosinophil recruitment; epithelial cells; IL-5	EXPRESSION; INFLAMMATION; PROFILES; CELLS	Background: The interaction between epithelial cells and immune cells plays an important role in the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP); however, the mechanism or mechanisms underlying T-H-biased inflammation in this process are largely unknown. Profiling protein expression in patients with CRSwNP by using shotgun proteomics suggested that cystatin SN (CST1), a type 2 cysteine protease inhibitor, might play a role because this was expressed with the greatest difference in patients with eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP) and those with noneosinophilic chronic rhinosinusitis with nasal polyps (nonECRSwNP). Objectives: We sought to investigate the expression and role of CST1 in modulating eosinophilic inflammation in patients with CRSwNP. Methods: Sinonasal tissues were collected from 192 patients with ECRSwNP, 52 patients with nonECRSwNP, and 40 control subjects. CST1 mRNA expression, localization, and concentration in the tissues were measured by using real-time PCR, in situ hybridization, immunohistochemistry, and an ELISA. Recombinant CST1 was used to further explore the function of the molecule in dispersed nasal polyp cells and eosinophils extracted from polyp tissues and peripheral blood. Results: CST1 was mainly expressed by epithelial cells and significantly increased in patients with ECRSwNP but decreased in patients with nonECRSwNP compared with that in control subjects. CST1 expression was further increased in patients with ECRSwNP and comorbid asthma and correlated with eosinophil percentages in tissue samples. CST1 was induced by IL-4 and IL-13 in tissue from both patients with ECRSwNP and those with nonECRSwNP and repressed by IL-17A in patients with nonECRSwNP in the presence of neutrophils. CST1 enhanced eosinophil activation and recruitment through induction of IL-5. Conclusion: Epithelium-derived CST1 modulates eosinophil activation and recruitment, expression of which could be regulated by T(H)2 and T(H)17 cytokines.	[Yan, Bing; Lou, Hongfei; Wang, Yang; Li, Ying; Meng, Yifan; Qi, Sihan; Wang, Ming; Wang, Chengshuo; Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Dept Allergy, Beijing, Peoples R China; [Yan, Bing; Wang, Yang; Li, Ying; Qi, Sihan; Wang, Ming; Wang, Chengshuo; Zhang, Luo] Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China; [Xiao, Lei] Univ Illinois, Dept Med, Chicago, IL USA; [Xiao, Lei] NHLBI, Lung Cell & Vasc Biol Program, NIH, Bldg 10, Bethesda, MD 20892 USA	Capital Medical University; Capital Medical University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wang, CS; Zhang, L (corresponding author), Capital Med Univ, Beijing TongRen Hosp, 1 DongJiaoMinXiang, Beijing 100005, Peoples R China.	wangcs830@126.com; dr.luozhang@139.com		Zhang, Luo/0000-0002-0910-9884	program for Changjiang Scholars and Innovative Research Team [IRT13082]; National Natural Science Foundation of China [81420108009, 81630023, 81400444, 81470678]; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support [ZYLX201310]; Beijing Natural Science Foundation [7131006]; Beijing Health Bureau Program for High Level Talents [2011-3-043]; Beijing Municipal Administration of Hospitals' Mission Plan [SML20150203]; Priming Scientific Research Foundation for the Senior Researcher in Beijing TongRen Hospital [2017-YJJ-GGL-005]; National Institutes of Health [1R01 HL083218]	program for Changjiang Scholars and Innovative Research Team(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support; Beijing Natural Science Foundation(Beijing Natural Science Foundation); Beijing Health Bureau Program for High Level Talents; Beijing Municipal Administration of Hospitals' Mission Plan; Priming Scientific Research Foundation for the Senior Researcher in Beijing TongRen Hospital; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by grants from the program for Changjiang Scholars and Innovative Research Team (IRT13082), the National Natural Science Foundation of China (81420108009, 81630023, 81400444 and 81470678), the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201310), the Beijing Natural Science Foundation (7131006), the Beijing Health Bureau Program for High Level Talents (2011-3-043), the Beijing Municipal Administration of Hospitals' Mission Plan (SML20150203), and the Priming Scientific Research Foundation for the Senior Researcher in Beijing TongRen Hospital (2017-YJJ-GGL-005). This work was supported in part by National Institutes of Health (http://www.nih.gov/) grant 1R01 HL083218 (to L.X.). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acharya KR, 2014, J BIOL CHEM, V289, P17406, DOI 10.1074/jbc.R113.546218; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Binder JX, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau012; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Diny NL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00484; Doyle AD, 2013, BLOOD, V122, P781, DOI 10.1182/blood-2013-01-473405; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Giovannini-Chami L, 2012, EUR RESPIR J, V39, P1197, DOI 10.1183/09031936.00070511; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Ikeda K, 2013, LARYNGOSCOPE, V123, pE1, DOI 10.1002/lary.24154; Imoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067057; Ishitoya Junichi, 2010, Allergol Int, V59, P239, DOI 10.2332/allergolint.10-RAI-0231; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Kato Y, 2018, AM J RESP CELL MOL, V59, P448, DOI 10.1165/rcmb.2017-0325OC; Kim JW, 2007, OTOLARYNG HEAD NECK, V137, P925, DOI 10.1016/j.otohns.2007.07.036; Kopitar-Jerala N, 2006, FEBS LETT, V580, P6295, DOI 10.1016/j.febslet.2006.10.055; Liao B, 2018, ALLERGY, V73, P1459, DOI 10.1111/all.13411; Liu Z, 2004, J ALLERGY CLIN IMMUN, V114, P783, DOI 10.1016/j.jaci.2004.04.052; Lou HF, 2016, RHINOLOGY, V54, P150, DOI [10.4193/Rhin15.271, 10.4193/Rhino15.271]; Lou HF, 2015, AM J RHINOL ALLERGY, V29, P350, DOI 10.2500/ajra.2015.29.4231; Matthews SP, 2016, IMMUNITY, V44, P795, DOI 10.1016/j.immuni.2016.03.003; Melo RCN, 2010, HISTOL HISTOPATHOL, V25, P1341, DOI 10.14670/HH-25.1341; Milara J, 2017, J ALLERGY CLIN IMMUN, V139, P855, DOI 10.1016/j.jaci.2016.06.064; Plager DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011450; Renaux A, 2018, NUCLEIC ACIDS RES, V46, P2699, DOI 10.1093/nar/gky092; Rinia AB, 2007, ALLERGY, V62, P348, DOI 10.1111/j.1398-9995.2007.01323.x; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Sun YX, 2013, IMMUNOLOGY, V138, P370, DOI 10.1111/imm.12049; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Turner JH, 2018, J ALLERGY CLIN IMMUN, V141, P1895, DOI 10.1016/j.jaci.2018.02.002; Van Zele T, 2010, J ALLERGY CLIN IMMUN, V125, P1069, DOI 10.1016/j.jaci.2010.02.020; Wang M, 2015, J ALLERGY CLIN IMMUN, V136, P1700, DOI 10.1016/j.jaci.2015.09.005; Wang WQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26604; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; WILCOX D, 1992, BIOCHEM J, V285, P495, DOI 10.1042/bj2850495; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zi MT, 2018, IMMUNOL LETT, V196, P80, DOI 10.1016/j.imlet.2018.01.006	38	32	34	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					455	469		10.1016/j.jaci.2019.03.026	http://dx.doi.org/10.1016/j.jaci.2019.03.026			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	30974106	Bronze			2022-12-18	WOS:000478789300014
J	Holgado, A; Braun, H; Van Nuffel, E; Detry, S; Schuijs, MJ; Deswarte, K; Vergote, K; Haegman, M; Baudelet, G; Haustraete, J; Hammad, H; Lambrecht, BN; Savvides, SN; Afonina, IS; Beyaert, R				Holgado, Aurora; Braun, Harald; Van Nuffel, Elien; Detry, Sammy; Schuijs, Martijn J.; Deswarte, Kim; Vergote, Karl; Haegman, Mira; Baudelet, Griet; Haustraete, Jurgen; Hammad, Hamida; Lambrecht, Bart N.; Savvides, Savvas N.; Afonina, Inna S.; Beyaert, Rudi			IL-33trap is a novel IL-33-neutralizing biologic that inhibits allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-33; soluble ST2; antagonist; airway inflammation; allergic asthma	INNATE LYMPHOID-CELLS; TYPE-2 INFLAMMATION; SOLUBLE ST2; INTERLEUKIN 33; SEVERE ASTHMA; IDENTIFICATION; RECEPTOR; DISEASE; IMMUNOGENICITY; ASSOCIATION	Background: The emergence of IL-33 as a key molecular player in the development and propagation of widespread inflammatory diseases, including asthma and atopic dermatitis, has established the need for effective IL-33 neutralizing biologics. Objective: Here we describe the development and validation of a new antagonist of IL-33, termed IL-33trap, which combines the extracellular domains of the IL-33 receptor (ST2) and its coreceptor, IL-1 receptor accessory protein, into a single fusion protein. Methods: We produced and purified recombinant IL-33trap from human cells and analyzed its IL-33 binding affinity and IL-33 antagonistic activity in cultured cells and mice. IL-33trap activity was also benchmarked with a recombinant soluble ST2 corresponding to the naturally occurring IL-33 decoy receptor. Finally, we studied the effect of IL-33trap in the Alternaria alternata mouse model of allergic airway inflammation. Results: In vitro IL-33trap binds IL-33 and inhibits IL-33 activity to a much stronger degree than soluble ST2. Furthermore, IL-33trap inhibits eosinophil infiltration, splenomegaly, and production of signature cytokines in splenic lymphocytes and lung tissue on IL-33 injection. Finally, administration of IL-33trap at the time of allergen challenge inhibits inflammatory responses in a preclinical mouse model of acute allergic airway inflammation. Conclusions: IL-33trap is a novel IL-33 antagonist that outperforms the natural IL-33 decoy receptor and shows anti-inflammatory activities in a preclinical mouse model of acute allergic airway inflammation when administered at the time of allergen challenge.	[Holgado, Aurora; Braun, Harald; Van Nuffel, Elien; Haegman, Mira; Baudelet, Griet; Afonina, Inna S.; Beyaert, Rudi] VIB UGent Ctr Inflammat Res, Unit Mol Signal Transduct Inflammat, Ghent, Belgium; [Detry, Sammy; Savvides, Savvas N.] VIB UGent Ctr Inflammat Res, Unit Struct Biol, Ghent, Belgium; [Schuijs, Martijn J.; Deswarte, Kim; Vergote, Karl; Hammad, Hamida; Lambrecht, Bart N.] VIB UGent Ctr Inflammat Res, Lab Immunoregulat & Mucosal Immunol, Ghent, Belgium; [Haustraete, Jurgen] VIB UGent Ctr Inflammat Res, Prot Serv Facil, Ghent, Belgium; [Holgado, Aurora; Braun, Harald; Van Nuffel, Elien; Haegman, Mira; Baudelet, Griet; Haustraete, Jurgen; Afonina, Inna S.; Beyaert, Rudi] Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium; [Detry, Sammy; Savvides, Savvas N.] Univ Ghent, Dept Biochem & Microbiol, Lab Prot Biochem & Biomol Engn, Ghent, Belgium; [Schuijs, Martijn J.; Deswarte, Kim; Vergote, Karl; Hammad, Hamida; Lambrecht, Bart N.] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University; Ghent University; Ghent University Hospital	Beyaert, R (corresponding author), VIB UGent Ctr Inflammat Res, Unit Mol Signal Transduct Inflammat, Ghent, Belgium.	Rudi.Beyaert@irc.vib-ugent.be	Detry, Sammy/AHA-4665-2022; Afonina, Inna/AAM-8978-2020; Lambrecht, Bart N/K-2484-2014; Hammad, Hamida/J-9391-2015	Afonina, Inna/0000-0001-8894-5305; Lambrecht, Bart N/0000-0003-4376-6834; Hammad, Hamida/0000-0003-3762-8603; Holgado, Aurora/0000-0001-6724-2758; Braun, Harald/0000-0002-3491-9504; Deswarte, Kim/0000-0002-9761-6973; Haegman, Mira/0000-0002-4883-312X	VIB (Belgium); Fund for Scientific Research Flanders (FWO; Belgium); Foundation Against Cancer; Ghent University Concerted Research Actions (GOA; Belgium); Ghent University Industrial Research Fund (IOF; Belgium) [F2016/IOF-Advanced/307]; FWO research grant	VIB (Belgium); Fund for Scientific Research Flanders (FWO; Belgium)(FWO); Foundation Against Cancer; Ghent University Concerted Research Actions (GOA; Belgium); Ghent University Industrial Research Fund (IOF; Belgium); FWO research grant(FWO)	Supported by grants from the VIB (Belgium), the Fund for Scientific Research Flanders (FWO; Belgium), the Foundation Against Cancer, the Ghent University Concerted Research Actions (GOA; Belgium), and the Ghent University Industrial Research Fund (IOF; Belgium; F2016/IOF-Advanced/307). I.S.A. is a postdoctoral fellow of the FWO and holds an FWO research grant. E. V. N. is a predoctoral fellow of the FWO. S. D. is a predoctoral fellow of the Flanders Agency for Innovation and Development.	Arshad MI, 2016, CLIN THER, V38, P1000, DOI 10.1016/j.clinthera.2016.02.021; Bartelds GM, 2011, JAMA-J AM MED ASSOC, V305, P1460, DOI 10.1001/jama.2011.406; Bendtzen K, 2006, ARTHRITIS RHEUM-US, V54, P3782, DOI 10.1002/art.22214; Braun H, 2018, BIOCHEM PHARMACOL, V148, P238, DOI 10.1016/j.bcp.2018.01.010; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Chen CC, 2017, J ALLERGY CLIN IMMUN, V140, P1351, DOI 10.1016/j.jaci.2017.01.015; Cohen ES, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9327; Diaz-Jimenez D, 2011, WORLD J GASTROENTERO, V17, P2181, DOI 10.3748/wjg.v17.i17.2181; Elegheert J, 2012, NAT STRUCT MOL BIOL, V19, P938, DOI 10.1038/nsmb.2367; Felix J, 2017, NAT REV IMMUNOL, V17, P112, DOI 10.1038/nri.2016.134; Galli SJ, 2016, J ALLERGY CLIN IMMUN, V137, P1289, DOI 10.1016/j.jaci.2016.03.006; Godar M, 2018, J ALLERGY CLIN IMMUN, V142, P1185, DOI 10.1016/j.jaci.2018.06.002; Gordon ED, 2016, P NATL ACAD SCI USA, V113, P8765, DOI 10.1073/pnas.1601914113; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hong J, 2011, J BIOL CHEM, V286, P20078, DOI 10.1074/jbc.M111.219089; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kontermann RE, 2011, CURR OPIN BIOTECH, V22, P868, DOI 10.1016/j.copbio.2011.06.012; Liu X, 2013, P NATL ACAD SCI USA, V110, P14918, DOI 10.1073/pnas.1308651110; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Martin SJ, 2016, FEBS J, V283, P2599, DOI 10.1111/febs.13775; Moots RJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175207; Nascimento DC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14919; Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120; Potaczek DP, 2016, J ALLERGY CLIN IMMUN, V137, P1334, DOI 10.1016/j.jaci.2015.12.1344; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Ramirez-Carrozzi V, 2017, J ALLERGY CLIN IMMUN, V139, P705, DOI 10.1016/j.jaci.2016.08.026; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Sanada S, 2007, J CLIN INVEST, V117, P1538, DOI 10.1172/JCI30634; Sati SP, 2002, EUR J BIOCHEM, V269, P5259, DOI 10.1046/j.1432-1033.2002.03237.x; Scheuermann TH, 2015, METHODS, V76, P87, DOI 10.1016/j.ymeth.2014.11.024; Schmidt SR, 2009, IDRUGS, V12, P284; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Scott IC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21589-2; Sears MR, 2014, CHEST, V145, P219, DOI 10.1378/chest.13-2059; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P194, DOI 10.1016/0167-4889(93)90009-E; Theoharides TC, 2015, J PHARMACOL EXP THER, V354, P24, DOI 10.1124/jpet.114.222505; van Schouwenburg PA, 2013, NAT REV RHEUMATOL, V9, P164, DOI 10.1038/nrrheum.2013.4; Vannella KM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1938; Velazquez-Campoy A, 2006, NAT PROTOC, V1, P186, DOI 10.1038/nprot.2006.28; Velazquez-Campoys A, 2004, CURR PROT CELL BIOL, V23; Verstraete K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14937; Vocca L, 2015, IMMUNOBIOLOGY, V220, P954, DOI 10.1016/j.imbio.2015.02.005; Weinberg EO, 2003, CIRCULATION, V107, P721, DOI 10.1161/01.CIR.0000047274.66749.FE; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zhao HY, 2015, METHODS, V76, P137, DOI 10.1016/j.ymeth.2014.11.012	50	32	33	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					204	215		10.1016/j.jaci.2019.02.028	http://dx.doi.org/10.1016/j.jaci.2019.02.028			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30876911	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000473432800023
J	Robinson, PFM; Pattaroni, C; Cook, J; Gregory, L; Alonso, AM; Fleming, LJ; Lloyd, CM; Bush, A; Marsland, BJ; Saglani, S				Robinson, Polly F. M.; Pattaroni, Celine; Cook, James; Gregory, Lisa; Alonso, Aldara Martin; Fleming, Louise J.; Lloyd, Clare M.; Bush, Andrew; Marsland, Benjamin J.; Saglani, Sejal			Lower airway microbiota associates with inflammatory phenotype in severe preschool wheeze	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHILDREN; QUALITY		[Robinson, Polly F. M.; Cook, James; Gregory, Lisa; Alonso, Aldara Martin; Fleming, Louise J.; Lloyd, Clare M.; Bush, Andrew; Saglani, Sejal] Imperial Coll, Natl Heart & Lung Inst, London, England; [Robinson, Polly F. M.; Cook, James; Fleming, Louise J.; Bush, Andrew; Saglani, Sejal] Royal Brompton & Harefield NHS Fdn Trust, Paediat Resp Dept, London, England; [Pattaroni, Celine; Marsland, Benjamin J.] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Immunol & Pathol, Melbourne, Vic, Australia	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Monash University	Saglani, S (corresponding author), Imperial Coll, Natl Heart & Lung Inst, London, England.; Saglani, S (corresponding author), Royal Brompton & Harefield NHS Fdn Trust, Paediat Resp Dept, London, England.	s.saglani@imperial.ac.uk	Saglani, Sejal/AAE-5072-2019; Fleming, Louise/ABD-7452-2020; /AAF-4973-2019; /AFN-8948-2022	/0000-0002-9920-1181; /0000-0002-9920-1181; Fleming, Louise/0000-0002-7268-7433; Gregory, Lisa/0000-0003-2199-5417; Lloyd, Clare/0000-0001-8977-6726	British Lung Foundation, UK [RG14-12]	British Lung Foundation, UK	The project was funded by the British Lung Foundation, UK (grant reference RG14-12).	Bernasconi E, 2016, AM J RESP CRIT CARE, V194, P1252, DOI 10.1164/rccm.201512-2424OC; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brand PLP, 2014, EUR RESPIR J, V43, P1172, DOI 10.1183/09031936.00199913; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Friedman J, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002687; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Jochmann A, 2016, PEDIATR PULM, V51, P778, DOI 10.1002/ppul.23366; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Murphy KR, 2009, J ALLERGY CLIN IMMUN, V123, P833, DOI 10.1016/j.jaci.2009.01.058; Rapin Alexis, 2017, Curr Protoc Mouse Biol, V7, P100, DOI 10.1002/cpmo.29; Saglani S, 2005, ARCH DIS CHILD, V90, P961, DOI 10.1136/adc.2004.071134; Saglani S, 2006, EUR RESPIR J, V27, P29, DOI 10.1183/09031936.06.00030605; Saglani S, 2003, THORAX, V58, P1053, DOI 10.1136/thorax.58.12.1053; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Taylor SL, 2018, J ALLERGY CLIN IMMUN, V141, P94, DOI 10.1016/j.jaci.2017.03.044	16	32	32	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1607	+		10.1016/j.jaci.2018.12.985	http://dx.doi.org/10.1016/j.jaci.2018.12.985			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30579850	Green Published, hybrid			2022-12-18	WOS:000463348900034
J	Morse, JC; Li, P; Ely, KA; Shilts, MH; Wannemuehler, TJ; Huang, LC; Sheng, QH; Chowdhury, NI; Chandra, RK; Das, SR; Turner, JH				Morse, Justin C.; Li, Ping; Ely, Kim A.; Shilts, Meghan H.; Wannemuehler, Todd J.; Huang, Li-Ching; Sheng, Quanhu; Chowdhury, Naweed I.; Chandra, Rakesh K.; Das, Suman R.; Turner, Justin H.			Chronic rhinosinusitis in elderly patients is associated with an exaggerated neutrophilic proinflammatory response to pathogenic bacteria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinosinusitis; aging; cytokine; neutrophil; bacteria; endotype; inflammation; IL-1 beta	MUCOCILIARY CLEARANCE; NASAL POLYPS; INFLAMMATION; ASTHMA; RESPONSIVENESS; EPIDEMIOLOGY; RECOGNITION; MICROBIOTA; CELLS; NOD1	Background: Potential effects of aging on chronic rhinosinusitis (CRS) pathophysiology have not been well defined but might have important ramifications given a rapidly aging US and world population. Objective: The goal of the current study was to determine whether advanced age is associated with specific inflammatory CRS endotypes or immune signatures. Methods: Levels of 17 mucus cytokines and inflammatory mediators were measured in 147 patients with CRS. Hierarchical cluster analysis was used to identify and characterize inflammatory CRS endotypes, as well as to determine whether age was associated with specific immune signatures. Results: A CRS endotype with a proinflammatory neutrophilic immune signature was enriched in older patients. In the overall cohort patients 60 years and older had increased mucus levels of IL-1b, IL-6, IL-8, and TNF-alpha when compared with their younger counterparts. Increases in levels of proinflammatory cytokines were associated with both tissue neutrophilia and symptomatic bacterial infection/colonization in aged patients. Conclusions: Aged patients with CRS have a unique inflammatory signature that corresponds to a neutrophilic proinflammatory response. Neutrophil-driven inflammation in aged patients with CRS might be less likely to respond to corticosteroids and might be closely linked to chronic microbial infection or colonization.	[Morse, Justin C.; Li, Ping; Wannemuehler, Todd J.; Chowdhury, Naweed I.; Chandra, Rakesh K.; Turner, Justin H.] Vanderbilt Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, 1215 21st Ave South,Suite 7209, Nashville, TN 37232 USA; [Ely, Kim A.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Shilts, Meghan H.; Das, Suman R.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Huang, Li-Ching; Sheng, Quanhu] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Turner, JH (corresponding author), Vanderbilt Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, 1215 21st Ave South,Suite 7209, Nashville, TN 37232 USA.	justin.h.turner@vanderbilt.edu	Morse, Justin/AAA-8316-2021; Turner, Justin/AAD-8607-2020; Das, Suman/ABB-7273-2020; Sheng, Quanhu/B-9543-2009	Das, Suman/0000-0003-2496-9724; Sheng, Quanhu/0000-0001-8951-9295; Turner, Justin/0000-0002-5501-9900; Chandra, Rakesh/0000-0002-3612-0026; Chowdhury, Naweed/0000-0001-9826-4917	NIH [RO3 DC014809, L30 AI113795]; CTSA award from the National Center for Advancing Translational Sciences [UL1TR000445]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC014809] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CTSA award from the National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This project was supported by NIH RO3 DC014809 (to J.H.T.), L30 AI113795 (J.H.T.), and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.	Agarwal S, 2010, ANN ALLERG ASTHMA IM, V104, P183, DOI 10.1016/j.anai.2009.11.009; Anand VK, 2004, ANN OTO RHINOL LARYN, V113, P3, DOI 10.1177/00034894041130S502; [Anonymous], 1983, FACTOR ANAL; BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; Bhattacharyya N, 2011, ANN OTO RHINOL LARYN, V120, P423, DOI 10.1177/000348941112000701; Blackwell DL, 2014, VITAL HLTH STAT, V10, P1; Brooks CR, 2013, RESPIROLOGY, V18, P857, DOI 10.1111/resp.12079; Bupp MRG, 2015, CELL IMMUNOL, V294, P102, DOI 10.1016/j.cellimm.2015.02.002; Busse PJ, 2017, J ALLERGY CLIN IMMUN, V139, P1808, DOI 10.1016/j.jaci.2016.09.015; Busse PJ, 2010, J ALLERGY CLIN IMMUN, V126, P690, DOI 10.1016/j.jaci.2010.08.011; Chalermwatanachai T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136068; Chen L, 2017, NAT IMMUNOL, V18, P541, DOI 10.1038/ni.3690; Cho SH, 2015, AM J RESP CELL MOL, V53, P601, DOI 10.1165/rcmb.2015-0207RC; Cho SH, 2012, J ALLERGY CLIN IMMUN, V129, P858, DOI 10.1016/j.jaci.2011.12.002; Cisalpino D, 2017, J IMMUNOL, V198, P4096, DOI 10.4049/jimmunol.1600852; Clarke TB, 2010, NAT MED, V16, P228, DOI 10.1038/nm.2087; Davidson JO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096558; de Oliveira-Maul JP, 2013, CHEST, V143, P1091, DOI 10.1378/chest.12-1183; DelGaudio JM, 2016, INT FORUM ALLERGY RH, V6, P1083, DOI 10.1002/alr.21787; DOTY RL, 1984, LARYNGOSCOPE, V94, P176, DOI 10.1288/00005537-198402000-00004; Ducharme ME, 2011, RESP MED, V105, P1284, DOI 10.1016/j.rmed.2011.04.006; Dykewicz Mark S., 2003, Journal of Allergy and Clinical Immunology, V111, pS520; Evans MD, 2018, J ALLERGY CLIN IMMUN, V142, P415, DOI 10.1016/j.jaci.2017.09.035; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Frutuoso MS, 2010, MICROBES INFECT, V12, P819, DOI 10.1016/j.micinf.2010.05.006; Gerassy-Vainberg S, 2018, GUT, V67, P97, DOI 10.1136/gutjnl-2017-313789; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Grubb BR, 2016, AM J PHYSIOL-LUNG C, V310, pL860, DOI 10.1152/ajplung.00015.2016; Gury-BenAri M, 2016, CELL, V166, P1231, DOI 10.1016/j.cell.2016.07.043; Hauser LJ, 2017, INT FORUM ALLERGY RH, V7, P957, DOI 10.1002/alr.21994; Ho JC, 2001, AM J RESP CRIT CARE, V163, P983, DOI 10.1164/ajrccm.163.4.9909121; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Kee VR, 2012, AM J GERIATR PHARMAC, V10, P14, DOI 10.1016/j.amjopharm.2011.12.004; Kim RY, 2017, AM J RESP CRIT CARE, V196, P283, DOI 10.1164/rccm.201609-1830OC; Kim YS, 2011, AM J RHINOL ALLERGY, V25, pE117, DOI 10.2500/ajra.2011.25.3630; Krings JG, 2014, LARYNGOSCOPE, V124, P838, DOI 10.1002/lary.24401; Kuhar HN, 2017, INT FORUM ALLERGY RH, V7, P990, DOI 10.1002/alr.21989; Liu WM, 2017, J ALLERGY CLIN IMMUN, V139, P1548, DOI 10.1016/j.jaci.2016.08.032; Mahdavinia M, 2018, J ALLERGY CLIN IMMUN, V142, P287, DOI 10.1016/j.jaci.2018.01.033; McDonough AK, 2008, CURR OPIN RHEUMATOL, V20, P131, DOI 10.1097/BOR.0b013e3282f51031; Min JY, 2017, J ALLERGY CLIN IMMUN, V140, P1562, DOI 10.1016/j.jaci.2017.05.032; Mitra S, 2018, J LEUKOCYTE BIOL, V103, P643, DOI 10.1002/JLB.2RI0717-278R; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Nyenhuis SM, 2010, J ALLERGY CLIN IMMUN, V125, P1163, DOI 10.1016/j.jaci.2010.02.015; O'Rourke N, 2013, STEP BY STEP APPROAC; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS22, DOI 10.1002/alr.21695; Ortman JM, 2014, AGING NATION OLDER P; Oyer SL, 2013, LARYNGOSCOPE, V123, pE72, DOI 10.1002/lary.24305; Poetker DM, 2015, AM J RHINOL ALLERGY, V29, P339, DOI 10.2500/ajra.2015.29.4223; Poetker DM, 2015, OTOLARYNG CLIN N AM, V48, P817, DOI 10.1016/j.otc.2015.05.009; Ramakrishnan VR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085507; Rammal A, 2017, J OTOLARYNGOL-HEAD N, V46, DOI 10.1186/s40463-016-0183-x; Rea IM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00586; Ross KF, 2001, INFECT IMMUN, V69, P3248, DOI 10.1128/IAI.69.5.3248-3254.2001; Rossios C, 2018, J ALLERGY CLIN IMMUN, V141, P560, DOI 10.1016/j.jaci.2017.02.045; Schiller Jeannine S, 2012, Vital Health Stat 10, P1; Schirmer M, 2016, CELL, V167, P1897, DOI 10.1016/j.cell.2016.11.046; Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547; Snidvongs K, 2012, INT FORUM ALLERGY RH, V2, P376, DOI 10.1002/alr.21032; Turner JH, 2018, INT FORUM ALLERGY RH, V8, P1175, DOI 10.1002/alr.22160; Turner JH, 2018, J ALLERGY CLIN IMMUN, V141, P1895, DOI 10.1016/j.jaci.2018.02.002; van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193; Ventura Maria Teresa, 2017, Clin Mol Allergy, V15, P21, DOI 10.1186/s12948-017-0077-0; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Wise BL, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2012.05.027; Wu J, 2018, LARYNGOSCOPE, V128, pE304, DOI 10.1002/lary.27112	67	32	37	6	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					990	+		10.1016/j.jaci.2018.10.056	http://dx.doi.org/10.1016/j.jaci.2018.10.056			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30468775	Green Accepted, Bronze			2022-12-18	WOS:000460272900019
J	Polak, D; Hafner, C; Briza, P; Kitzmuller, C; Elbe-Burger, A; Samadi, N; Gschwandtner, M; Pfutzner, W; Zlabinger, GJ; Jahn-Schmid, B; Bohle, B				Polak, Dominika; Hafner, Christine; Briza, Peter; Kitzmueller, Claudia; Elbe-Buerger, Adelheid; Samadi, Nazanin; Gschwandtner, Maria; Pfuetzner, Wolfgang; Zlabinger, Gerhard J.; Jahn-Schmid, Beatrice; Bohle, Barbara			A novel role for neutrophils in IgE-mediated allergy: Evidence for antigen presentation in late-phase reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antigen presentation; neutrophils; IgE-mediated allergy; allergic inflammation; allergic late-phase reaction; T cells; T-cell activation	COLONY-STIMULATING FACTOR; BIRCH POLLEN ALLERGEN; SKIN REACTIONS; CLASS-II; POLYMORPHONUCLEAR NEUTROPHILS; IN-VITRO; HLA-DR; CELLS; INFLAMMATION; ASTHMA	Background: Neutrophils and allergen-specific T cells accumulate in patients with allergic late-phase reactions (LPRs). Their presence is associated with severe inflammation. Cytokines, such as GM-CSF, IFN-gamma, and IL-3, which are typically found in patients with allergic LPRs, have been proposed to convert neutrophils into antigen-presenting cells (APCs). Objective: We sought to assess the antigen-processing and antigen-presenting capacities of neutrophils from allergic patients. Methods: Neutrophils were isolated from peripheral blood of donors with birch pollen allergy and stimulated with GM-CSF, IFN-gamma, and IL-3. The viability and expression of HLA-DR, CD80, and CD86 were assessed by using flow cytometry. HLA-DM expression was analyzed by means of immunoblotting. Allergen uptake was studied after fluorescence labeling of the major birch pollen allergen Bet v 1. Bet v 1 was digested with neutrophilic endolysosomal extracts, and the resulting fragments were sequenced by using mass spectrometry. Neutrophils were used as APCs in coculture experiments with autologous HLA-DR-restricted and Bet v 1-specific T-cell clones reactive with epitopes in different regions of the allergen. In all experiments monocytes were used for comparison. Fluids from suction blisters formed on top of LPRs induced by using intradermal allergen injection were assessed for HLA-DR 1 neutrophils by using flow cytometry. Results: The cytokines significantly enhanced the survival, allergen uptake, and expression of HLA-DM and HLA-DR on neutrophils. Neutrophils rapidly degraded Bet v 1 into fragments containing all relevant T-cell epitopes. Cytokine-activated, allergen-pulsed neutrophils induced proliferative and cytokine responses of Bet v 1-specific T cells irrespective of epitope specificity, confirming that they fully processed and presented the allergen. HLA-DR 1 neutrophils were detected in patients with cutaneous allergic LPRs. Conclusion: Neutrophils can serve as APCs for local allergen-specific effector T cells in patients with allergic LPRs.	[Polak, Dominika; Kitzmueller, Claudia; Samadi, Nazanin; Jahn-Schmid, Beatrice; Bohle, Barbara] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Elbe-Buerger, Adelheid] Med Univ Vienna, Dept Dermatol, Vienna, Austria; [Gschwandtner, Maria] Med Univ Vienna, Dept Dermatol, Res Div Biol & Pathobiol Skin, Vienna, Austria; [Zlabinger, Gerhard J.] Med Univ Vienna, Inst Immunol, Vienna, Austria; [Hafner, Christine] Karl Landsteiner Univ Hlth Sci, Univ Hosp St Polten, Dept Dermatol, St Polten, Austria; [Briza, Peter] Univ Salzburg, Dept Mol Biol, Salzburg, Austria; [Pfuetzner, Wolfgang] Philipps Univ Marburg, Dept Dermatol & Allergol, Marburg, Germany	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Salzburg University; Philipps University Marburg	Bohle, B (corresponding author), Univ Vienna, Gen Hosp Vienna, Inst Pathophysiol & Allergy Res, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at	Briza, Peter/D-7309-2012	Briza, Peter/0000-0002-4941-6782; Bohle, Barbara/0000-0002-5105-7985; Kitzmuller, Claudia/0000-0002-3829-8020; Gschwandtner, Maria/0000-0002-7944-7475; Zlabinger, Gerhard/0000-0002-7478-4173	Austrian Science Fund [W1248, SFB F4610]; Medical University of Vienna	Austrian Science Fund(Austrian Science Fund (FWF)); Medical University of Vienna	Supported by the Austrian Science Fund, projects W1248 and SFB F4610 and the Medical University of Vienna.	Akbar AN, 2013, CLIN EXP IMMUNOL, V173, P163, DOI 10.1111/cei.12107; Bloemen K, 2007, IMMUNOL LETT, V113, P6, DOI 10.1016/j.imlet.2007.07.010; Calzetti F, 2017, J ALLERGY CLIN IMMUN, V139, P352, DOI 10.1016/j.jaci.2016.06.025; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291, DOI 10.1164/ajrccm/147.2.291; Deifl S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109075; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; Duffy D, 2012, IMMUNITY, V37, P917, DOI 10.1016/j.immuni.2012.07.015; Durham SR, 1998, CLIN EXP ALLERGY, V28, P11; Eberlein-Konig B, 1999, CLIN EXP ALLERGY, V29, P1641, DOI 10.1046/j.1365-2222.1999.00671.x; Eifan AO, 2016, CLIN EXP ALLERGY, V46, P1139, DOI 10.1111/cea.12780; FREW AJ, 1988, J IMMUNOL, V141, P4158; FREW AJ, 1988, J ALLERGY CLIN IMMUN, V81, P1117, DOI 10.1016/0091-6749(88)90878-0; GAGA M, 1991, J IMMUNOL, V147, P816; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gauvreau Gail M., 2007, V14, P21, DOI 10.1159/000107052; Gauvreau GM, 2015, EUR RESPIR J, V46, DOI [10.1183/13993003.congress-2015.PA5091, 10.1183/13993003.00536-2015]; GOSSELIN EJ, 1993, J IMMUNOL, V151, P1482; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hosoki K, 2016, AM J RESP CELL MOL, V54, P81, DOI 10.1165/rcmb.2015-0044OC; Hosoki K, 2016, CURR OPIN ALLERGY CL, V16, P45, DOI 10.1097/ACI.0000000000000231; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jung CM, 1997, ALLERGY, V52, P717, DOI 10.1111/j.1398-9995.1997.tb01228.x; Kitzmuller C, 2012, ALLERGY, V67, P593, DOI 10.1111/j.1398-9995.2011.02764.x; Kitzmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P151, DOI 10.1016/j.jaci.2014.12.1928; Leaker BR, 2017, MUCOSAL IMMUNOL, V10, P408, DOI 10.1038/mi.2016.74; Lommatzsch M, 2006, J ALLERGY CLIN IMMUN, V118, P91, DOI 10.1016/j.jaci.2006.02.034; Lopuhaa CE, 2002, CLIN EXP ALLERGY, V32, P1720, DOI 10.1046/j.1365-2222.2002.01542.x; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Megiovanni AM, 2006, J LEUKOCYTE BIOL, V79, P977, DOI 10.1189/jlb.0905526; Monteseirin J, 2009, J INVEST ALLERG CLIN, V19, P340; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; MUDZINSKI SP, 1995, BLOOD, V86, P2452, DOI 10.1182/blood.V86.6.2452a.bloodjournal8662452a; Mutschlechner S, 2010, J ALLERGY CLIN IMMUN, V125, P711, DOI 10.1016/j.jaci.2009.10.052; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Pelaia G, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/879783; Pelletier M, 2010, BLOOD, V115, P335, DOI 10.1182/blood-2009-04-216085; Reinisch W, 1996, BLOOD, V87, P3068, DOI 10.1182/blood.V87.7.3068.bloodjournal8773068; Ricciardolo FLM, 2017, J ALLERGY CLIN IMMUN, V140, P395, DOI 10.1016/j.jaci.2016.10.034; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Scapini P, 2014, BLOOD, V124, P710, DOI 10.1182/blood-2014-03-453217; Sharpe AH, 2009, IMMUNOL REV, V229, P5, DOI 10.1111/j.1600-065X.2009.00784.x; SMITH WB, 1995, BLOOD, V86, P3938, DOI 10.1182/blood.V86.10.3938.bloodjournal86103938; Takashima A, 2015, J LEUKOCYTE BIOL, V98, P489, DOI 10.1189/jlb.1MR1014-502R; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; Verstraelen S, 2008, TOXICOL IN VITRO, V22, P1419, DOI 10.1016/j.tiv.2008.05.008; Vono M, 2017, BLOOD, V129, P1991, DOI 10.1182/blood-2016-10-744441; WERFEL S, 1995, J ALLERGY CLIN IMMUN, V96, P57, DOI 10.1016/S0091-6749(95)70033-1; Ying S, 2002, J ALLERGY CLIN IMMUN, V109, P694, DOI 10.1067/mai.2002.123236	49	32	32	2	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1143	+		10.1016/j.jaci.2018.06.005	http://dx.doi.org/10.1016/j.jaci.2018.06.005			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	29920351	Green Accepted, Bronze			2022-12-18	WOS:000460272900034
